<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="0" size="14" family="Times" color="#000000"/>
	<fontspec id="1" size="19" family="Times" color="#000000"/>
	<fontspec id="2" size="19" family="Times" color="#000000"/>
	<fontspec id="3" size="12" family="Times" color="#000000"/>
	<fontspec id="4" size="16" family="Times" color="#000000"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="95" left="176" width="863" height="19" font="1"><b>2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease Data Supplements</b> </text>
<text top="118" left="430" width="354" height="13" font="3"><b>(Section numbers correspond to the full-text guideline) </b></text>
<text top="166" left="537" width="142" height="16" font="4"><b>Table of Contents </b></text>
<text top="189" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#3">Data Supplement 1. RCTs of Patient-Centered Approaches for Providing Comprehensive ASCVD Prevention (Section 2.1) ............................................................. 3 </a></text>
<text top="208" left="66" width="1038" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#33">Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Patient-Centered Approaches for Providing Comprehensive ASCVD </a></text>
<text top="227" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#33">Prevention (Section 2.1) ......................................................................................................................................................................................................................... 33 </a></text>
<text top="246" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#48">Data Supplement 3. Nonrandomized Trials, Observational Studies, and/or Registries of Assessment of Cardiovascular Risk (Section 2.2) ..................................... 48 </a></text>
<text top="265" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#93">Data Supplement 4. RCTs of Nutrition and Diet (Section 3.1.) ............................................................................................................................................................. 93 </a></text>
<text top="284" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#96">Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Nutrition and Diet (Section 3.1.) ................................................................ 96 </a></text>
<text top="303" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#124">Data Supplement 6. RCTs of Exercise and Physical Activity (Section 3.2.) ....................................................................................................................................... 124 </a></text>
<text top="322" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#126">Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries of Exercise and Physical Activity (Section 3.2.) .......................................... 126 </a></text>
<text top="341" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#148">Data Supplement 8. RCTs of Obesity and Being Overweight (Section 4.1.) ...................................................................................................................................... 148 </a></text>
<text top="360" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#153">Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of Obesity and Being Overweight (Section 4.1.).......................................... 153 </a></text>
<text top="379" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#159">Data Supplement 10. RCTs of Type 2 Diabetes Mellitus (Section 4.2.) ............................................................................................................................................. 159 </a></text>
<text top="398" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#189">Data Supplement 11. RCTs of High Blood Cholesterol (Section 4.3.) ................................................................................................................................................ 189 </a></text>
<text top="417" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#210">Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of High Blood Cholesterol (Section 4.3.) ................................................... 210 </a></text>
<text top="436" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#222">Data Supplement 13. RCTs of High Blood Pressure or Hypertension (Section 4.4.) .......................................................................................................................... 222 </a></text>
<text top="455" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#277">Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of High Blood Pressure or Hypertension (Section 4.4.) ............................. 277 </a></text>
<text top="474" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#283">Data Supplement 15. RCTs of Tobacco Use (Section 4.5.) ................................................................................................................................................................. 283 </a></text>
<text top="493" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#286">Data Supplement 16. Nonrandomized Trials, Observational Studies, and/or Registries of Tobacco Use (Section 4.5.) .................................................................... 286 </a></text>
<text top="512" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#292">Data Supplement 17. RCTs of Aspirin Use (Section 4.6.) ................................................................................................................................................................... 292 </a></text>
<text top="531" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#300">Data Supplement 18. Nonrandomized Trials, Observational Studies, and/or Registries of Aspirin Use (Section 4.6) ....................................................................... 300 </a></text>
<text top="550" left="66" width="1082" height="15" font="0"><a href="20190301_Prevention_Data_Supplement_Tables.html#302">References ............................................................................................................................................................................................................................................ 302 </a></text>
<text top="569" left="66" width="4" height="15" font="0"> </text>
<text top="600" left="66" width="4" height="15" font="0"> </text>
<text top="631" left="66" width="4" height="15" font="0"> </text>
<text top="663" left="66" width="4" height="15" font="0"> </text>
<text top="696" left="66" width="4" height="15" font="0"> </text>
<text top="728" left="66" width="4" height="15" font="0"> </text>
<text top="760" left="66" width="4" height="15" font="0"> </text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="94" left="66" width="241" height="15" font="0">Methodology and Evidence Review </text>
<text top="113" left="66" width="1077" height="15" font="0">The recommendations listed in this guideline are, whenever possible, evidence based. An extensive evidence review was conducted from April through July 2018, </text>
<text top="132" left="66" width="1039" height="15" font="0">that included literature published through July 2018. Key search words included but were not limited to the following.Terms may have been used alone or in </text>
<text top="151" left="66" width="91" height="15" font="0">combination. </text>
<text top="170" left="66" width="4" height="15" font="0"> </text>
<text top="190" left="66" width="1055" height="15" font="0">Abbreviations 1 indicates primary; 2, secondary; ACC, American College of Cardiology; ACE, angiotensin-converting-enzyme; ACR, albumin-to-creatinine </text>
<text top="209" left="66" width="1006" height="15" font="0">ratio; AHA, American Heart Association; ALT, alanine aminotransferase; AMI, acute myocardial infarction; ARB, angiotensin-receptor blocker; ART; </text>
<text top="228" left="66" width="1054" height="15" font="0">antiretroviral therapy; AS, ankylosing spondylitis; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm; ASPEN, the Atorvastatin </text>
<text top="247" left="66" width="1062" height="15" font="0">Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus; Atorva, atorvastatin; AURORA, A Study to Evaluate the </text>
<text top="266" left="66" width="1049" height="15" font="0">Use of Rosuvastatin in Subjects on Regular Hemodialysis; BMI, body mass index; BP, blood pressure; CAC, coronary artery calcium; CARDS, Collaborative </text>
<text top="285" left="66" width="1076" height="15" font="0">Atorvastatin Diabetes Study; CHD, coronary heart disease; chol, cholesterol; CI, confidence interval; CIMT, carotid intima-media thickness; CK, Creatine kinase; </text>
<text top="304" left="66" width="1035" height="15" font="0">CKD, chronic kidney disease; cPB, carotid plaque burden score; CPK, creatine phosphokinase; CRP, C-reactive protein; CVD, cardiovascular disease; DM, </text>
<text top="323" left="66" width="1073" height="15" font="0">diabetes mellitus; DR, diabetic retinopathy; EC, extended care; eGFR, estimated glomerular filtration rate; ERD, electronic reminder device; f/u, follow up; FDC, </text>
<text top="342" left="66" width="1065" height="15" font="0">fixed-dose combination; FET, Fisher’s exact test; FOCUS, Fixed Dose Combination Drug [Polypill] for Secondary Cardiovascular Prevention; GFR, glomerular </text>
<text top="361" left="66" width="1075" height="15" font="0">filtration rate; h/o, history of; HbA1c, hemoglobin A1c; HCV, Hepatitis C viral; HF, heart failure; HPS, Heart Protection Study; HPS2-THRIVE, Heart Protection </text>
<text top="380" left="66" width="1073" height="15" font="0">Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events; HR, hazard ratio; ICD, International Classification of Disease; IQR, Inter Quartile range; </text>
<text top="399" left="66" width="1057" height="15" font="0">ITT, intention to treat; JART, Justification for Atherosclerosis Regression Treatment; KDIGO, kidney international guidelines; LDL-C, low density lipoprotein </text>
<text top="418" left="66" width="1032" height="15" font="0">cholesterol; LFT, liver function test; LVH, left ventricular hypertrophy; MACE, Major adverse cardiovascular events; MAQ, Morisky Green questionnaire; </text>
<text top="437" left="66" width="1075" height="15" font="0">MEMS, medication event monitoring system; MESA, Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; N/A, not applicable; NHANES, National </text>
<text top="456" left="66" width="1058" height="15" font="0">Health And Nutrition Education Survey; NNT, number needed to treat; NODM, new onset diabetes mellitus; NP, nurse practitioner; NR, not reported; NRI, net </text>
<text top="475" left="66" width="1063" height="15" font="0">reclassification index; NYHA, New York Heart Association; OR, odds ratio; P01, first co-primary outcome; PAD, peripheral arterial disease; PCI, percutaneous </text>
<text top="494" left="66" width="1035" height="15" font="0">coronary intervention; P02, second co-primary outcome; PCP, primary care provider; PI, pharmacist-delivered intervention; PN, Peripheral neuropathy; pts, </text>
<text top="513" left="66" width="1016" height="15" font="0">patients; RA, rheumatoid arthritis; RAS, renin angiotensin system; revasc, revascularization; RC, routine care; RCT, randomized controlled trial; rhabdo, </text>
<text top="532" left="66" width="1061" height="15" font="0">rhabdomyolysis; rosuva; rosuvastatin; RUTHERFORD, Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder; </text>
<text top="551" left="66" width="1045" height="15" font="0">RR, relative risk; RRF, reduced renal function; RRR, relative risk reduction; SBP, systolic blood pressure; SCr, serum creatinine; SD, standard deviation; SE, </text>
<text top="570" left="66" width="1060" height="15" font="0">standard error; SHARP, Study of Heart and Renal Protection; Simva; simvastatin; SLE, systemic lupus erythematosus; T1DM, type 1 diabetes mellitus; T2DM, </text>
<text top="589" left="66" width="1036" height="15" font="0">type 2 diabetes mellitus; TC, total cholesterol; UC, usual care; UL, upper limit; ULN, Upper limit of normal; UMPIRE, Use of a Multidrug Pill In Reducing </text>
<text top="608" left="66" width="1031" height="15" font="0">Cardiovascular Events; UK, United Kingdom; US, United States; vs., versus; WOSCOPS, West of Scotland Coronary Prevention Study; y, years; yr, year;  </text>
<text top="627" left="66" width="4" height="15" font="0"> </text>
<text top="659" left="66" width="4" height="15" font="0"> </text>
<text top="692" left="66" width="4" height="15" font="0"> </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="5" size="12" family="Times" color="#000000"/>
	<fontspec id="6" size="12" family="Times" color="#6f6363"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="90" left="66" width="852" height="21" font="4"><b>Data Supplement 1. RCTs of Patient-Centered Approaches for Providing Comprehensive ASCVD Prevention (Section 2.1) </b></text>
<text top="114" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="132" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="149" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="114" left="211" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="132" left="216" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="149" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="114" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="114" left="536" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="132" left="554" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="149" left="536" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="166" left="557" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="114" left="727" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="132" left="667" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="149" left="737" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="116" left="935" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="115" left="1000" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="133" left="970" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="150" left="977" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="184" left="75" width="93" height="17" font="5">Carter BL, et al., </text>
<text top="201" left="75" width="49" height="17" font="5">2009 (1) </text>
<text top="218" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19858431">19858431</a></text>
<text top="218" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19858431"> </a></text>
<text top="184" left="193" width="68" height="17" font="3"><b>Study Aim: </b></text>
<text top="201" left="193" width="76" height="17" font="5">To determine </text>
<text top="218" left="193" width="81" height="17" font="5">the potency of </text>
<text top="236" left="193" width="91" height="17" font="5">interventions for </text>
<text top="253" left="193" width="85" height="17" font="5">blood pressure </text>
<text top="270" left="193" width="106" height="17" font="5">involving nurses or </text>
<text top="287" left="193" width="70" height="17" font="5">pharmacists </text>
<text top="305" left="193" width="3" height="17" font="5"> </text>
<text top="322" left="193" width="70" height="17" font="3"><b>Study type: </b></text>
<text top="339" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="356" left="193" width="103" height="17" font="5">and meta analysis </text>
<text top="373" left="193" width="3" height="17" font="5"> </text>
<text top="391" left="193" width="90" height="17" font="5">N=37 controlled </text>
<text top="408" left="193" width="73" height="17" font="5">clinical trials  </text>
<text top="184" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="203" left="324" width="154" height="18" font="5">•  Quasi-randomized trials, </text>
<text top="221" left="325" width="170" height="17" font="5">controlled before-after studies, </text>
<text top="238" left="325" width="171" height="17" font="5">interrupted time-series studies, </text>
<text top="255" left="325" width="181" height="17" font="5">patient-randomized trials, cluster </text>
<text top="272" left="325" width="97" height="17" font="5">randomized trials </text>
<text top="290" left="324" width="166" height="18" font="5">•  Published January 1, 1970 </text>
<text top="308" left="325" width="142" height="17" font="5">through February 5, 2009 </text>
<text top="325" left="324" width="193" height="18" font="5">•  Intervention of team based care </text>
<text top="343" left="325" width="138" height="17" font="5">of hypertension involving </text>
<text top="361" left="325" width="124" height="17" font="5">pharmacists or nurses </text>
<text top="378" left="325" width="3" height="17" font="5"> </text>
<text top="184" left="535" width="113" height="17" font="3"><b>Intervention:</b> Team </text>
<text top="201" left="535" width="78" height="17" font="5">based care of </text>
<text top="218" left="535" width="74" height="17" font="5">hypertension </text>
<text top="236" left="535" width="51" height="17" font="5">involving </text>
<text top="253" left="535" width="84" height="17" font="5">pharmacists or </text>
<text top="270" left="535" width="95" height="17" font="5">nurses. Because </text>
<text top="287" left="535" width="111" height="17" font="5">components varied, </text>
<text top="305" left="535" width="108" height="17" font="5">reviewers assigned </text>
<text top="322" left="535" width="104" height="17" font="5">a potency score of </text>
<text top="339" left="535" width="74" height="17" font="5">the predicted </text>
<text top="356" left="535" width="81" height="17" font="5">potency of the </text>
<text top="373" left="535" width="83" height="17" font="5">combination of </text>
<text top="391" left="535" width="74" height="17" font="5">effects of the </text>
<text top="408" left="535" width="73" height="17" font="5">interventions </text>
<text top="425" left="535" width="3" height="17" font="5"> </text>
<text top="442" left="535" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="459" left="535" width="75" height="17" font="5">Not specified </text>
<text top="185" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="184" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="202" left="662" width="3" height="17" font="5"> </text>
<text top="220" left="662" width="99" height="17" font="5">Net change in BP </text>
<text top="237" left="662" width="232" height="17" font="5">Net change in BP Control (control was BP </text>
<text top="254" left="662" width="162" height="17" font="5">lower than 140/90 mm Hg for </text>
<text top="271" left="662" width="228" height="17" font="5">uncomplicated BP and lower than 130/80 </text>
<text top="288" left="662" width="229" height="17" font="5">mm Hg for those with diabetes mellitus or </text>
<text top="306" left="662" width="132" height="17" font="5">chronic kidney disease) </text>
<text top="323" left="662" width="3" height="17" font="5"> </text>
<text top="340" left="662" width="219" height="17" font="5">A significant predicted reduction in SBP </text>
<text top="357" left="662" width="197" height="17" font="5">was found in interventions including </text>
<text top="375" left="662" width="222" height="17" font="5">pharmacist recommended medication to </text>
<text top="392" left="662" width="199" height="17" font="5">physician (-27.21 mm Hg, p=0.002), </text>
<text top="409" left="662" width="218" height="17" font="5">counseling about lifestyle modification (-</text>
<text top="426" left="662" width="193" height="17" font="5">12.63 mm Hg, p=0.03), pharmacist </text>
<text top="443" left="662" width="215" height="17" font="5">performed intervention (-11.70 mm Hg, </text>
<text top="461" left="662" width="214" height="17" font="5">p=0.03), use of a treatment algorithm (-</text>
<text top="478" left="662" width="216" height="17" font="5">8.46 mm Hg, p&lt;0.001), completion of a </text>
<text top="495" left="662" width="214" height="17" font="5">drug profile and/or medication history (-</text>
<text top="512" left="662" width="183" height="17" font="5">8.28 mm Hg, p-0.01), and overall </text>
<text top="530" left="662" width="216" height="17" font="5">intervention potency score assigned by </text>
<text top="547" left="662" width="123" height="17" font="5">reviewers (p&lt;0.001).   </text>
<text top="564" left="662" width="3" height="17" font="5"> </text>
<text top="581" left="662" width="219" height="17" font="5">A significant predicted reduction in DBP </text>
<text top="598" left="662" width="206" height="17" font="5">was found for interventions including: </text>
<text top="616" left="662" width="221" height="17" font="5">referral made to a specialist (-19.61 mm </text>
<text top="633" left="662" width="215" height="17" font="5">Hg, p0.04), providing patient education </text>
<text top="650" left="662" width="212" height="17" font="5">about BP medications (-17.60 mm Hg, </text>
<text top="667" left="662" width="207" height="17" font="5">p=0.003), completion of a drug profile </text>
<text top="684" left="662" width="223" height="17" font="5">and/or medication history (-7.27 mm Hg, </text>
<text top="702" left="662" width="179" height="17" font="5">p=0.006), pharmacist performed </text>
<text top="719" left="662" width="232" height="17" font="5">intervention (-4.03 mm Hg, p=0.04), nurse </text>
<text top="736" left="662" width="208" height="17" font="5">performed intervention (-3.94 mm Hg, </text>
<text top="753" left="662" width="49" height="17" font="5">p=0.04). </text>
<text top="770" left="662" width="3" height="17" font="5"> </text>
<text top="184" left="910" width="111" height="17" font="3"><b>Study Limitations: </b></text>
<text top="201" left="910" width="189" height="17" font="5">The analysis included studies with </text>
<text top="218" left="910" width="179" height="17" font="5">varying trial designs and varying </text>
<text top="236" left="910" width="73" height="17" font="5">interventions </text>
<text top="253" left="910" width="3" height="17" font="5"> </text>
<text top="270" left="910" width="152" height="17" font="5">There was no formal test of </text>
<text top="287" left="910" width="226" height="17" font="5">heterogeneity, but at least one study had </text>
<text top="305" left="910" width="194" height="17" font="5">an extremely high OR (OR=29.71), </text>
<text top="322" left="910" width="196" height="17" font="5">though sensitivity analysis revealed </text>
<text top="339" left="910" width="196" height="17" font="5">potential for a change to the OR for </text>
<text top="356" left="910" width="222" height="17" font="5">community pharmacy intervention to 1.8 </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="208" height="17" font="5">In a non-parametric analysis, the only </text>
<text top="108" left="662" width="198" height="17" font="5">intervention component significantly </text>
<text top="125" left="662" width="210" height="17" font="5">associated with a reduction in BP was </text>
<text top="142" left="662" width="218" height="17" font="5">education about BP medications, which </text>
<text top="160" left="662" width="218" height="17" font="5">was associated with a median 8.75 mm </text>
<text top="177" left="662" width="235" height="17" font="5">Hg reduction in SBP (IQR: -11.90 to -4.25) </text>
<text top="194" left="662" width="233" height="17" font="5">and a median 3.60 reduction in DBP (IQR: </text>
<text top="211" left="662" width="91" height="17" font="5">-7.03 to -1.00).   </text>
<text top="229" left="662" width="3" height="17" font="5"> </text>
<text top="246" left="662" width="191" height="17" font="5">In meta regressions examining the </text>
<text top="263" left="662" width="206" height="17" font="5">outcome of controlled BP, there were </text>
<text top="280" left="662" width="180" height="17" font="5">significant effects of team-based </text>
<text top="297" left="662" width="221" height="17" font="5">interventions regardless of whether they </text>
<text top="315" left="662" width="225" height="17" font="5">involved nurses, community pharmacies, </text>
<text top="332" left="662" width="231" height="17" font="5">or primary care clinic pharmacists, though </text>
<text top="349" left="662" width="209" height="17" font="5">the strongest effect was in community </text>
<text top="366" left="662" width="185" height="17" font="5">pharmacies.  In trials of nurse-led </text>
<text top="383" left="662" width="230" height="17" font="5">interventions, the overall OR for control of </text>
<text top="401" left="662" width="188" height="17" font="5">SBP in the intervention vs. control </text>
<text top="418" left="662" width="223" height="17" font="5">group=1.69 (95% CI 1.48-1.93).  In trials </text>
<text top="435" left="662" width="220" height="17" font="5">of community pharmacies, the OR=2.89 </text>
<text top="452" left="662" width="230" height="17" font="5">(95% CI 1.83-4.55), and in pharmacists in </text>
<text top="469" left="662" width="209" height="17" font="5">primary care clinics OR=2.17 (95% CI </text>
<text top="487" left="662" width="230" height="17" font="5">1.75-2.68).  In nonparametric analyses, in </text>
<text top="504" left="662" width="211" height="17" font="5">nursing studies, the mean reduction in </text>
<text top="521" left="662" width="214" height="17" font="5">SBP=5.84 mm Hg compared to 7.76 in </text>
<text top="538" left="662" width="215" height="17" font="5">pharmacists in primary care clinics and </text>
<text top="556" left="662" width="181" height="17" font="5">9.31 mm Hg in interventions with </text>
<text top="573" left="662" width="206" height="17" font="5">community pharmacists. Comparable </text>
<text top="590" left="662" width="233" height="17" font="5">reductions in DBP were 3.46 mm Hg, 4.18 </text>
<text top="607" left="662" width="216" height="17" font="5">mm Hg, and 4.59 mm Hg, respectively. </text>
<text top="625" left="75" width="81" height="17" font="5">Chen Z, et al., </text>
<text top="642" left="75" width="49" height="17" font="5">2013 (2) </text>
<text top="660" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23614849">23614849</a></text>
<text top="660" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23614849"> </a></text>
<text top="625" left="193" width="86" height="17" font="3"><b>Study Aim: </b>To </text>
<text top="642" left="193" width="106" height="17" font="5">compare indices of </text>
<text top="660" left="193" width="79" height="17" font="5">24-hour blood </text>
<text top="677" left="193" width="116" height="17" font="5">pressure  following a </text>
<text top="694" left="193" width="119" height="17" font="5">physician-pharmacist </text>
<text top="711" left="193" width="72" height="17" font="5">collaborative </text>
<text top="728" left="193" width="104" height="17" font="5">intervention and to </text>
<text top="746" left="193" width="70" height="17" font="5">describe the </text>
<text top="763" left="193" width="112" height="17" font="5">associated changes </text>
<text top="625" left="325" width="143" height="17" font="3"><b>Clinic Inclusion criteria: </b></text>
<text top="644" left="324" width="156" height="18" font="5">•  Community-based family </text>
<text top="662" left="325" width="157" height="17" font="5">medicine offices with clinical </text>
<text top="679" left="325" width="163" height="17" font="5">pharmacists on staff who had </text>
<text top="696" left="325" width="182" height="17" font="5">worked in offices at least 3 years </text>
<text top="714" left="325" width="3" height="17" font="5"> </text>
<text top="732" left="325" width="151" height="17" font="3"><b>Patient Inclusion criteria: </b></text>
<text top="751" left="324" width="79" height="18" font="5">•  21 or older </text>
<text top="625" left="535" width="104" height="17" font="3"><b>Intervention:</b> N=3 </text>
<text top="642" left="535" width="53" height="17" font="5">practices </text>
<text top="660" left="535" width="57" height="17" font="5">Physician-</text>
<text top="677" left="535" width="63" height="17" font="5">pharmacist </text>
<text top="694" left="535" width="92" height="17" font="5">comanagement. </text>
<text top="711" left="535" width="113" height="17" font="5">Clinical pharmacists </text>
<text top="728" left="535" width="57" height="17" font="5">evaluated </text>
<text top="746" left="535" width="113" height="17" font="5">medications and BP </text>
<text top="763" left="535" width="97" height="17" font="5">at baseline and 1 </text>
<text top="626" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="625" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="643" left="662" width="197" height="17" font="5">Pre-post and intervention vs control </text>
<text top="661" left="662" width="202" height="17" font="5">comparison of Measurement of BMI, </text>
<text top="678" left="662" width="69" height="17" font="5">assessment </text>
<text top="695" left="662" width="213" height="17" font="5">Drug therapy changes (diuretic added, </text>
<text top="712" left="662" width="210" height="17" font="5">nondiuretic added, switch within same </text>
<text top="730" left="662" width="212" height="17" font="5">class, dose increased, dose decrease, </text>
<text top="747" left="662" width="105" height="17" font="5">drug discontinued) </text>
<text top="625" left="910" width="111" height="17" font="3"><b>Study Limitations: </b></text>
<text top="642" left="910" width="197" height="17" font="5">Small number of randomized clinics </text>
<text top="660" left="910" width="3" height="17" font="5"> </text>
<text top="677" left="910" width="206" height="17" font="5">Data analyzed at patient level though </text>
<text top="694" left="910" width="210" height="17" font="5">randomization was done at clinic level </text>
<text top="711" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="106" height="17" font="5">in antihypertensive </text>
<text top="108" left="193" width="69" height="17" font="5">medications<b> </b></text>
<text top="125" left="193" width="3" height="17" font="5"> </text>
<text top="142" left="193" width="71" height="17" font="3"><b>Study type:</b> </text>
<text top="160" left="193" width="108" height="17" font="5">secondary analysis </text>
<text top="177" left="193" width="63" height="17" font="5">of a cluster </text>
<text top="194" left="193" width="108" height="17" font="5">randomized clinical </text>
<text top="211" left="193" width="23" height="17" font="5">trial </text>
<text top="229" left="193" width="3" height="17" font="5"> </text>
<text top="246" left="193" width="105" height="17" font="5">N=6 clinics (n=374 </text>
<text top="263" left="193" width="51" height="17" font="5">patients) </text>
<text top="91" left="324" width="174" height="18" font="5">•  Had a diagnosis of essential </text>
<text top="109" left="325" width="74" height="17" font="5">hypertension </text>
<text top="126" left="324" width="172" height="18" font="5">•  Taking 0-3 antihypertensive </text>
<text top="144" left="325" width="195" height="17" font="5">medications without changes in the </text>
<text top="162" left="325" width="77" height="17" font="5">prior 4 weeks </text>
<text top="179" left="324" width="175" height="18" font="5">•  Uncomplicated hypertension </text>
<text top="197" left="325" width="159" height="17" font="5">with SBP 140-179 mm Hg or </text>
<text top="214" left="325" width="183" height="17" font="5">diastolic BP 90 to 109 mm Hg, or </text>
<text top="232" left="325" width="194" height="17" font="5">hypertension with diabetes mellitus </text>
<text top="249" left="325" width="195" height="17" font="5">or chronic kidney disease with SBP </text>
<text top="266" left="325" width="189" height="17" font="5">130 to 179 mm Hg or DBP 80-109 </text>
<text top="283" left="325" width="43" height="17" font="5">mm Hg </text>
<text top="301" left="326" width="3" height="17" font="5"> </text>
<text top="331" left="326" width="154" height="17" font="3"><b>Patient Exclusion criteria: </b></text>
<text top="362" left="324" width="196" height="18" font="5">•  Serious renal or hepatic disease </text>
<text top="380" left="324" width="136" height="18" font="5">•  Cognitive impairment </text>
<text top="398" left="324" width="192" height="18" font="5">•  Poor prognosis (life expectancy </text>
<text top="416" left="325" width="55" height="17" font="5">&lt;3 years) </text>
<text top="434" left="324" width="190" height="18" font="5">•  Recent myocardial infarction or </text>
<text top="452" left="325" width="37" height="17" font="5">stroke </text>
<text top="91" left="535" width="86" height="17" font="5">month, had a 3-</text>
<text top="108" left="535" width="111" height="17" font="5">month check in with </text>
<text top="125" left="535" width="80" height="17" font="5">more frequent </text>
<text top="142" left="535" width="76" height="17" font="5">contact of BP </text>
<text top="160" left="535" width="92" height="17" font="5">remained poorly </text>
<text top="177" left="535" width="60" height="17" font="5">controlled. </text>
<text top="194" left="535" width="65" height="17" font="5">Pharmacist-</text>
<text top="211" left="535" width="91" height="17" font="5">identified issues </text>
<text top="229" left="535" width="24" height="17" font="5">and </text>
<text top="246" left="535" width="101" height="17" font="5">recommendations </text>
<text top="263" left="535" width="96" height="17" font="5">were shared with </text>
<text top="280" left="535" width="107" height="17" font="5">patient’s physician, </text>
<text top="297" left="535" width="87" height="17" font="5">typically face to </text>
<text top="315" left="535" width="79" height="17" font="5">face. Therapy </text>
<text top="332" left="535" width="105" height="17" font="5">changed had to be </text>
<text top="349" left="535" width="70" height="17" font="5">accepted by </text>
<text top="366" left="535" width="62" height="17" font="5">physician.  </text>
<text top="383" left="535" width="3" height="17" font="5"> </text>
<text top="401" left="535" width="51" height="17" font="3"><b>Control: </b></text>
<text top="418" left="535" width="79" height="17" font="5">N=3 practices </text>
<text top="435" left="535" width="3" height="17" font="5"> </text>
<text top="452" left="535" width="101" height="17" font="5">Usual care. Office </text>
<text top="469" left="535" width="110" height="17" font="5">pharmacists did not </text>
<text top="487" left="535" width="78" height="17" font="5">make therapy </text>
<text top="504" left="535" width="101" height="17" font="5">recommendations </text>
<text top="521" left="535" width="106" height="17" font="5">except typical drug </text>
<text top="538" left="535" width="64" height="17" font="5">information </text>
<text top="556" left="535" width="60" height="17" font="5">questions. </text>
<text top="573" left="535" width="3" height="17" font="5"> </text>
<text top="91" left="662" width="236" height="17" font="5">Compared ambulatory BPs for patients not </text>
<text top="108" left="662" width="197" height="17" font="5">taking diuretic at baseline but had a </text>
<text top="125" left="662" width="234" height="17" font="5">diuretic added with those who never had a </text>
<text top="142" left="662" width="81" height="17" font="5">diuretic added </text>
<text top="160" left="662" width="3" height="17" font="5"> </text>
<text top="177" left="662" width="226" height="17" font="5">At the end of the study (6 months), mean </text>
<text top="194" left="662" width="232" height="17" font="5">24-hour SBP was significantly lower in the </text>
<text top="211" left="662" width="230" height="17" font="5">co-managed group than the control group </text>
<text top="229" left="662" width="226" height="17" font="5">(122.8 vs. 134.4, p&lt;0.001), as was mean </text>
<text top="246" left="662" width="232" height="17" font="5">nighttime SBP (114.8 vs. 123.7, p&lt;0.001), </text>
<text top="263" left="662" width="229" height="17" font="5">and mean overall 24-hour SBP (120.4 vs. </text>
<text top="280" left="662" width="100" height="17" font="5">131.8, p&lt;0.001).   </text>
<text top="297" left="662" width="3" height="17" font="5"> </text>
<text top="315" left="662" width="211" height="17" font="5">The percent of patients with controlled </text>
<text top="332" left="662" width="209" height="17" font="5">SBP was significantly higher in the co-</text>
<text top="349" left="662" width="231" height="17" font="5">managed group than the control group for </text>
<text top="366" left="662" width="206" height="17" font="5">mean daytime SBP (79.6% s. 57.6%, </text>
<text top="383" left="662" width="231" height="17" font="5">p&lt;0.001), for mean nighttime SBP (67.9% </text>
<text top="401" left="662" width="232" height="17" font="5">vs. 48.1%, p&lt;0.001), and mean overall 24-</text>
<text top="418" left="662" width="222" height="17" font="5">hour SBP (75.6% vs. 50.0%, p&lt;0.001).   </text>
<text top="435" left="662" width="3" height="17" font="5"> </text>
<text top="452" left="662" width="210" height="17" font="5">The mean number of antihypertensive </text>
<text top="469" left="662" width="217" height="17" font="5">medications was significantly greater in </text>
<text top="487" left="662" width="233" height="17" font="5">the co-managed than control group (1.3 to </text>
<text top="504" left="662" width="219" height="17" font="5">2.3 vs. 1.9 to 2.2, p&lt;0.01).  Significantly </text>
<text top="521" left="662" width="210" height="17" font="5">greater number of drug changed were </text>
<text top="538" left="662" width="226" height="17" font="5">initiated in the co-managed group than in </text>
<text top="556" left="662" width="201" height="17" font="5">the control group (mean=2.7 vs. 1.1, </text>
<text top="573" left="662" width="63" height="17" font="5">p&lt;0.001).   </text>
<text top="590" left="662" width="3" height="17" font="5"> </text>
<text top="607" left="662" width="224" height="17" font="5">95% of pharmacist recommendations for </text>
<text top="624" left="662" width="221" height="17" font="5">antihypertensive regimen changes were </text>
<text top="642" left="662" width="232" height="17" font="5">accepted and implemented by physicians. </text>
<text top="659" left="662" width="3" height="17" font="5"> </text>
<text top="676" left="662" width="213" height="17" font="5">Significantly greater percentages of co-</text>
<text top="693" left="662" width="203" height="17" font="5">managed than control patients had a </text>
<text top="710" left="662" width="184" height="17" font="5">diuretic added (41.5% vs. 15.2%, </text>
<text top="728" left="662" width="195" height="17" font="5">p&lt;0.001), a nondiuretic drug added </text>
<text top="745" left="662" width="223" height="17" font="5">(64.8% vs. 20.2%, p&lt;0.001), had a dose </text>
<text top="762" left="662" width="216" height="17" font="5">increased (55.7% vs. 30.8%, p&lt;0.001), </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="7" size="12" family="Times" color="#000000"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="221" height="17" font="5">had a dose decreased (15.9% vs. 5.1%, </text>
<text top="108" left="662" width="233" height="17" font="5">p&lt;0.001), had a drug discontinued (18.2% </text>
<text top="125" left="662" width="212" height="17" font="5">vs. 10.1%, p=0.024), and had a switch </text>
<text top="142" left="662" width="219" height="17" font="5">within class (6.8% vs. 2.0%, p=0.022).   </text>
<text top="160" left="662" width="3" height="17" font="5"> </text>
<text top="177" left="662" width="207" height="17" font="5">The specific class of antihypertensive </text>
<text top="194" left="662" width="234" height="17" font="5">medication used in co-managed vs control </text>
<text top="211" left="662" width="232" height="17" font="5">patients were: diuretics (79.6% vs. 62.6%, </text>
<text top="230" left="662" width="56" height="17" font="5">p&lt;0.001), </text>
<text top="229" left="717" width="165" height="18" font="5">-blockers (42.1% vs. 47.0%, </text>
<text top="247" left="662" width="223" height="17" font="5">p≥0.05), angiotensin-converting enzyme </text>
<text top="264" left="662" width="206" height="17" font="5">inhibitors (51.1% vs. 51.5%, p≥0.05), </text>
<text top="281" left="662" width="202" height="17" font="5">calcium channel blockers (33.0% vs. </text>
<text top="300" left="662" width="92" height="17" font="5">29.3%, p≥0.05), </text>
<text top="299" left="753" width="118" height="18" font="5">-Blockers (0.0% vs. </text>
<text top="317" left="662" width="199" height="17" font="5">5.6%, p&lt;0.01), angiotensin receptor </text>
<text top="334" left="662" width="202" height="17" font="5">blockers (11.9% vs. 10.1%, p≥0.05), </text>
<text top="352" left="662" width="85" height="17" font="5">centrally acting </text>
<text top="351" left="747" width="117" height="18" font="5">-blockers (1.1% vs. </text>
<text top="370" left="662" width="215" height="17" font="5">3.0%, , p≥0.05), vasodilators (0.0% vs. </text>
<text top="387" left="662" width="201" height="17" font="5">2.0%, p≥0.05), aldosterone receptor </text>
<text top="404" left="662" width="190" height="17" font="5">blockers (4.0% vs. 1.0%, p≥0.05)) </text>
<text top="421" left="662" width="3" height="17" font="5"> </text>
<text top="439" left="662" width="221" height="17" font="5">Effect of adding a diuretic: baseline vs 6 </text>
<text top="456" left="662" width="44" height="17" font="5">months </text>
<text top="473" left="662" width="3" height="17" font="5"> </text>
<text top="490" left="662" width="198" height="17" font="7"><i>Daytime ambulatory blood pressure </i></text>
<text top="507" left="662" width="234" height="17" font="5">No diuretic added 137.1 vs. 129.6 mm Hg  </text>
<text top="525" left="662" width="3" height="17" font="5"> </text>
<text top="542" left="662" width="213" height="17" font="5">Diuretic added in first month: 138.9 vs. </text>
<text top="559" left="662" width="202" height="17" font="5">122.5 mm Hg (p&lt;0.01 vs. no diuretic </text>
<text top="576" left="662" width="77" height="17" font="5">added group) </text>
<text top="593" left="662" width="3" height="17" font="5"> </text>
<text top="611" left="662" width="235" height="17" font="5">Diuretic added between months 1-3: 151.4 </text>
<text top="628" left="662" width="96" height="17" font="5">vs. 135.5 mm Hg </text>
<text top="645" left="662" width="3" height="17" font="5"> </text>
<text top="662" left="662" width="235" height="17" font="5">Diuretic added between 3-6 months: 150.5 </text>
<text top="679" left="662" width="96" height="17" font="5">vs. 132.3 mm Hg </text>
<text top="697" left="662" width="3" height="17" font="5"> </text>
<text top="714" left="662" width="223" height="17" font="5">Diuretic added any time: 141.4 vs. 124.9 </text>
<text top="731" left="662" width="43" height="17" font="5">mm Hg </text>
<text top="748" left="662" width="3" height="17" font="5"> </text>
<text top="766" left="662" width="204" height="17" font="7"><i>Nighttime ambulatory blood pressure </i></text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="3" height="17" font="5"> </text>
<text top="108" left="662" width="234" height="17" font="5">No diuretic added 126.5 vs. 121.7 mm Hg  </text>
<text top="125" left="662" width="3" height="17" font="5"> </text>
<text top="142" left="662" width="213" height="17" font="5">Diuretic added in first month: 126.7 vs. </text>
<text top="160" left="662" width="218" height="17" font="5">111.8 mm Hg (p&lt;0.001 compared to no </text>
<text top="177" left="662" width="120" height="17" font="5">diuretic added group) </text>
<text top="194" left="662" width="3" height="17" font="5"> </text>
<text top="211" left="662" width="235" height="17" font="5">Diuretic added between months 1-3: 140.0 </text>
<text top="229" left="662" width="96" height="17" font="5">vs. 123.9 mm Hg </text>
<text top="246" left="662" width="3" height="17" font="5"> </text>
<text top="263" left="662" width="235" height="17" font="5">Diuretic added between 3-6 months: 134.4 </text>
<text top="280" left="662" width="96" height="17" font="5">vs. 124.3 mm Hg </text>
<text top="297" left="662" width="3" height="17" font="5"> </text>
<text top="315" left="662" width="223" height="17" font="5">Diuretic added any time: 128.6 vs. 114.2 </text>
<text top="332" left="662" width="220" height="17" font="5">mm Hg (p&lt;0.01 compared to no diuretic </text>
<text top="349" left="662" width="77" height="17" font="5">added group) </text>
<text top="366" left="662" width="3" height="17" font="5"> </text>
<text top="383" left="662" width="186" height="17" font="7"><i>Overall 24-hour ambulatory blood </i></text>
<text top="401" left="662" width="51" height="17" font="7"><i>pressure </i></text>
<text top="418" left="662" width="3" height="17" font="5"> </text>
<text top="435" left="662" width="234" height="17" font="5">No diuretic added 134.2 vs. 127.4 mm Hg  </text>
<text top="452" left="662" width="3" height="17" font="5"> </text>
<text top="469" left="662" width="210" height="17" font="5">Diuretic added in first month: 135.4 vs </text>
<text top="487" left="662" width="81" height="17" font="5">119.2 mm Hg  </text>
<text top="504" left="662" width="3" height="17" font="5"> </text>
<text top="521" left="662" width="235" height="17" font="5">Diuretic added between months 1-3: 148.7 </text>
<text top="538" left="662" width="96" height="17" font="5">vs. 133.3 mm Hg </text>
<text top="556" left="662" width="3" height="17" font="5"> </text>
<text top="573" left="662" width="235" height="17" font="5">Diuretic added between 3-6 months: 145.2 </text>
<text top="590" left="662" width="96" height="17" font="5">vs. 129.4 mm Hg </text>
<text top="607" left="662" width="3" height="17" font="5"> </text>
<text top="624" left="662" width="223" height="17" font="5">Diuretic added any time: 137.8 vs. 121.8 </text>
<text top="642" left="662" width="220" height="17" font="5">mm Hg (p&lt;0.05 compared to no diuretic </text>
<text top="659" left="662" width="77" height="17" font="5">added group) </text>
<text top="676" left="662" width="3" height="17" font="5"> </text>
<text top="694" left="75" width="92" height="17" font="5">Fazel MT, et al., </text>
<text top="711" left="75" width="49" height="17" font="5">2017 (3) </text>
<text top="728" left="75" width="3" height="17" font="5"> </text>
<text top="746" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28573873">28573873</a></text>
<text top="746" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28573873"> </a></text>
<text top="694" left="193" width="68" height="17" font="3"><b>Study Aim: </b></text>
<text top="711" left="193" width="74" height="17" font="5">To conduct a </text>
<text top="728" left="193" width="87" height="17" font="5">comprehensive </text>
<text top="746" left="193" width="100" height="17" font="5">systematic review </text>
<text top="763" left="193" width="107" height="17" font="5">and meta-analyses </text>
<text top="694" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="713" left="324" width="190" height="18" font="5">•  Studies involving patients aged </text>
<text top="731" left="325" width="72" height="17" font="5">18 and older </text>
<text top="748" left="324" width="159" height="18" font="5">•  Type 1 or type 2 diabetes </text>
<text top="767" left="324" width="159" height="18" font="5">•  Pharmacist interventions  </text>
<text top="694" left="533" width="78" height="17" font="3"><b>Intervention:</b> </text>
<text top="713" left="533" width="65" height="17" font="5">Pharmacist </text>
<text top="731" left="533" width="73" height="17" font="5">interventions </text>
<text top="750" left="533" width="87" height="17" font="5">providing direct </text>
<text top="768" left="533" width="113" height="17" font="5">patient care within a </text>
<text top="695" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="694" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="712" left="662" width="96" height="17" font="5">Hemoglobin A1C </text>
<text top="730" left="662" width="3" height="17" font="5"> </text>
<text top="747" left="662" width="228" height="17" font="5">N=7417 from 36 study arms in 35 studies </text>
<text top="764" left="662" width="3" height="17" font="5"> </text>
<text top="695" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="694" left="917" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="712" left="910" width="131" height="17" font="5">Systolic blood pressure </text>
<text top="730" left="910" width="89" height="17" font="5">LDL cholesterol </text>
<text top="747" left="910" width="3" height="17" font="5"> </text>
<text top="764" left="910" width="35" height="17" font="7"><i>SBP</i>:  </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="8" size="7" family="Times" color="#000000"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="119" height="17" font="5">examining the impact </text>
<text top="108" left="193" width="77" height="17" font="5">of pharmacist </text>
<text top="125" left="193" width="114" height="17" font="5">interventions as part </text>
<text top="142" left="193" width="115" height="17" font="5">of health care teams </text>
<text top="160" left="193" width="67" height="17" font="5">on diabetes </text>
<text top="177" left="193" width="64" height="17" font="5">therapeutic </text>
<text top="194" left="193" width="70" height="17" font="5">outcomes in </text>
<text top="211" left="193" width="92" height="17" font="5">ambulatory care </text>
<text top="229" left="193" width="46" height="17" font="5">settings<b> </b></text>
<text top="246" left="193" width="3" height="17" font="5"> </text>
<text top="263" left="193" width="71" height="17" font="3"><b>Study type:</b> </text>
<text top="280" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="297" left="193" width="117" height="17" font="5">and meta-analysis of </text>
<text top="315" left="193" width="67" height="17" font="5">studies with </text>
<text top="332" left="193" width="116" height="17" font="5">comparative designs </text>
<text top="349" left="193" width="109" height="17" font="5">(controlled and non-</text>
<text top="366" left="193" width="110" height="17" font="5">controlled trials and </text>
<text top="383" left="193" width="95" height="17" font="5">pre-post studies) </text>
<text top="401" left="193" width="3" height="17" font="5"> </text>
<text top="418" left="193" width="107" height="17" font="5">N=42 in systematic </text>
<text top="435" left="193" width="119" height="17" font="5">review, N=35 in meta </text>
<text top="452" left="193" width="48" height="17" font="5">analysis </text>
<text top="91" left="324" width="150" height="18" font="5">•  Ambulatory care setting </text>
<text top="109" left="324" width="193" height="18" font="5">•  Usable data on HbA1C, systolic </text>
<text top="127" left="325" width="192" height="17" font="5">blood pressure, or LDL cholesterol </text>
<text top="144" left="324" width="151" height="18" font="5">•  English language article </text>
<text top="163" left="326" width="3" height="17" font="5"> </text>
<text top="193" left="326" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="224" left="324" width="133" height="18" font="5">•  Gestational diabetes </text>
<text top="242" left="324" width="168" height="18" font="5">•  Review articles, systematic </text>
<text top="260" left="325" width="191" height="17" font="5">reviews, meta analyses, abstracts, </text>
<text top="277" left="325" width="162" height="17" font="5">poster/seminar presentations </text>
<text top="91" left="533" width="108" height="17" font="5">health care team in </text>
<text top="109" left="533" width="109" height="17" font="5">an ambulatory care </text>
<text top="128" left="533" width="93" height="17" font="5">setting (could be </text>
<text top="147" left="533" width="113" height="17" font="5">educational, clinical, </text>
<text top="165" left="533" width="46" height="17" font="5">or both) </text>
<text top="196" left="535" width="3" height="17" font="5"> </text>
<text top="213" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="232" left="533" width="107" height="17" font="5">alternative or usual </text>
<text top="250" left="533" width="27" height="17" font="5">care </text>
<text top="281" left="535" width="3" height="17" font="5"> </text>
<text top="91" left="662" width="224" height="17" font="5">Overall SMD=0.57, p&lt;0.01 (difference of </text>
<text top="108" left="662" width="194" height="17" font="5">1.1% in HbA1C, 95% CI 0.88-1.27) </text>
<text top="125" left="662" width="3" height="17" font="5"> </text>
<text top="142" left="662" width="153" height="17" font="5">Evidence of heterogeneity (I</text>
<text top="144" left="815" width="4" height="11" font="8">2</text>
<text top="142" left="819" width="46" height="17" font="5">=92%).  </text>
<text top="160" left="662" width="3" height="17" font="5"> </text>
<text top="177" left="662" width="210" height="17" font="5">No significant differences in results by </text>
<text top="194" left="662" width="188" height="17" font="5">study design (SMD for RCT=0.59, </text>
<text top="211" left="662" width="222" height="17" font="5">retrospective non randomized controlled </text>
<text top="229" left="662" width="214" height="17" font="5">trial=0.48, pre-post=0.73, retrospective </text>
<text top="246" left="662" width="204" height="17" font="5">pre-post=0.61, p for difference=0.48) </text>
<text top="263" left="662" width="3" height="17" font="5"> </text>
<text top="280" left="662" width="204" height="17" font="5">SMD for results stratified by baseline </text>
<text top="297" left="662" width="156" height="17" font="5">HbA1C: Low baseline=0.49, </text>
<text top="315" left="662" width="184" height="17" font="5">medium=0.52, high=1.08, p=0.18 </text>
<text top="332" left="662" width="3" height="17" font="5"> </text>
<text top="349" left="662" width="233" height="17" font="5">Differences in SMD for results stratified by </text>
<text top="366" left="662" width="217" height="17" font="5">age &lt;59 vs &gt;59 not significant (p=0.75) </text>
<text top="383" left="662" width="3" height="17" font="5"> </text>
<text top="401" left="662" width="174" height="17" font="5">No evidence of publication bias </text>
<text top="91" left="910" width="198" height="17" font="5">N=14 studies with 4275 participants </text>
<text top="108" left="910" width="154" height="17" font="5">Overall SMD=0.31 (p&lt;0.01) </text>
<text top="125" left="910" width="222" height="17" font="5">(difference=4.3 mm Hg, 95% CI 4.3-6.2) </text>
<text top="142" left="910" width="3" height="17" font="5"> </text>
<text top="160" left="910" width="153" height="17" font="5">Evidence of heterogeneity (I</text>
<text top="161" left="1063" width="4" height="11" font="8">2</text>
<text top="160" left="1068" width="43" height="17" font="5"> =84%) </text>
<text top="177" left="910" width="174" height="17" font="5">No evidence of publication bias </text>
<text top="194" left="910" width="3" height="17" font="5"> </text>
<text top="211" left="910" width="92" height="17" font="7"><i>LDL cholesterol</i>: </text>
<text top="229" left="910" width="198" height="17" font="5">N=19 studies with 5029 participants </text>
<text top="246" left="910" width="3" height="17" font="5"> </text>
<text top="263" left="910" width="154" height="17" font="5">Overall SMD=0.32 (p&lt;0.01) </text>
<text top="280" left="910" width="227" height="17" font="5">(difference=106 mg/dL, 95% CI 7.1-14.1) </text>
<text top="297" left="910" width="3" height="17" font="5"> </text>
<text top="315" left="910" width="153" height="17" font="5">Evidence of heterogeneity (I</text>
<text top="316" left="1063" width="4" height="11" font="8">2</text>
<text top="315" left="1068" width="43" height="17" font="5"> =83%) </text>
<text top="332" left="910" width="174" height="17" font="5">No evidence of publication bias </text>
<text top="470" left="75" width="93" height="17" font="5">Hirsch JD, et al., </text>
<text top="487" left="75" width="49" height="17" font="5">2014 (4) </text>
<text top="505" left="75" width="3" height="17" font="5"> </text>
<text top="522" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25085406">25085406</a></text>
<text top="522" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25085406"> </a></text>
<text top="470" left="193" width="68" height="17" font="3"><b>Study Aim: </b></text>
<text top="487" left="193" width="101" height="17" font="5">To examine blood </text>
<text top="505" left="193" width="104" height="17" font="5">pressure control in </text>
<text top="522" left="193" width="119" height="17" font="5">hypertensive patients </text>
<text top="539" left="193" width="116" height="17" font="5">managed by a newly </text>
<text top="556" left="193" width="119" height="17" font="5">formed PharmD-PCP </text>
<text top="573" left="193" width="102" height="17" font="5">MTM team versus </text>
<text top="591" left="193" width="83" height="17" font="5">usual care in a </text>
<text top="608" left="193" width="93" height="17" font="5">university-based </text>
<text top="625" left="193" width="103" height="17" font="5">primary care clinic </text>
<text top="642" left="193" width="3" height="17" font="5"> </text>
<text top="660" left="193" width="71" height="17" font="3"><b>Study type:</b> </text>
<text top="677" left="193" width="72" height="17" font="5">Randomized </text>
<text top="694" left="193" width="81" height="17" font="5">pragmatic trial </text>
<text top="711" left="193" width="3" height="17" font="5"> </text>
<text top="728" left="193" width="40" height="17" font="5">N=166 </text>
<text top="470" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="489" left="324" width="67" height="18" font="5">•  Age 18+ </text>
<text top="507" left="324" width="162" height="18" font="5">•  Diagnosis of hypertension </text>
<text top="525" left="324" width="183" height="18" font="5">•  Most recent BP measurement </text>
<text top="544" left="325" width="186" height="17" font="5">≥140/≥90 mm Hg (≥130/≥80 mm </text>
<text top="561" left="325" width="148" height="17" font="5">Hg with comorbid diabetes </text>
<text top="578" left="325" width="49" height="17" font="5">mellitus) </text>
<text top="595" left="324" width="159" height="18" font="5">•  Current treatment with 1+ </text>
<text top="613" left="325" width="156" height="17" font="5">antihypertensive medication </text>
<text top="631" left="324" width="163" height="18" font="5">•  At least 1 visit in 6 months </text>
<text top="649" left="325" width="95" height="17" font="5">before screening </text>
<text top="666" left="324" width="154" height="18" font="5">•  English speaking/able to </text>
<text top="684" left="325" width="154" height="17" font="5">complete a questionnaire in </text>
<text top="701" left="325" width="44" height="17" font="5">English </text>
<text top="719" left="326" width="3" height="17" font="5"> </text>
<text top="749" left="326" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="470" left="533" width="78" height="17" font="3"><b>Intervention:</b> </text>
<text top="489" left="533" width="78" height="17" font="5">PharmD-PCP </text>
<text top="507" left="533" width="103" height="17" font="5">collaborative care  </text>
<text top="526" left="533" width="3" height="17" font="5"> </text>
<text top="545" left="533" width="3" height="17" font="5"> </text>
<text top="563" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="582" left="533" width="62" height="17" font="5">Usual care </text>
<text top="471" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="470" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="489" left="662" width="212" height="17" font="5">Change in systolic blood pressure at 6 </text>
<text top="506" left="662" width="44" height="17" font="5">months </text>
<text top="523" left="662" width="3" height="17" font="5"> </text>
<text top="540" left="662" width="208" height="17" font="7"><i>PharmD-PCP vs. usual care: month 6 </i></text>
<text top="557" left="662" width="121" height="17" font="5">-7.1 vs. 1.6 (p=0.008) </text>
<text top="575" left="662" width="208" height="17" font="7"><i>PharmD-PCP vs. usual care: month 9 </i></text>
<text top="592" left="662" width="113" height="17" font="5">-5.2 vs. -1.7, p=0.22 </text>
<text top="471" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="470" left="917" width="72" height="18" font="5"><b> endpoint:  </b></text>
<text top="489" left="910" width="226" height="17" font="5">Percent of patients at BP goal Change in </text>
<text top="506" left="910" width="68" height="17" font="5">diastolic BP </text>
<text top="523" left="910" width="29" height="17" font="5">LDL  </text>
<text top="540" left="910" width="28" height="17" font="5">HDL </text>
<text top="557" left="910" width="180" height="17" font="5">Number and types of medication </text>
<text top="575" left="910" width="50" height="17" font="5">changes </text>
<text top="592" left="910" width="215" height="17" font="5">Number and types of anti-hypertensive </text>
<text top="609" left="910" width="179" height="17" font="5">drug therapy problems identified </text>
<text top="626" left="910" width="172" height="17" font="5">Patient satisfaction with clinical </text>
<text top="643" left="910" width="206" height="17" font="5">pharmacist using 22-item Pharmacist </text>
<text top="661" left="910" width="124" height="17" font="5">Service Questionnaire </text>
<text top="678" left="910" width="3" height="17" font="5"> </text>
<text top="695" left="910" width="157" height="17" font="5">PharmD-PCP vs. usual care </text>
<text top="712" left="910" width="70" height="17" font="7"><i>Diastolic BP </i></text>
<text top="730" left="910" width="164" height="17" font="5">Month 6: -3.8 vs. 1.7 p=0.006 </text>
<text top="747" left="910" width="165" height="17" font="5">Month 9: -2.5 vs. -0.3, p=0.27 </text>
<text top="764" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="324" width="162" height="18" font="5">•  Did not meet provisions of </text>
<text top="109" left="325" width="160" height="17" font="5">clinical collaborative-practice </text>
<text top="126" left="325" width="158" height="17" font="5">protocol in the opinion of the </text>
<text top="143" left="325" width="150" height="17" font="5">patients PCP or the clinical </text>
<text top="161" left="325" width="64" height="17" font="5">pharmacist </text>
<text top="178" left="326" width="3" height="17" font="5"> </text>
<text top="91" left="910" width="89" height="17" font="7"><i>LDL cholesterol </i></text>
<text top="108" left="910" width="156" height="17" font="5">Month 6: 0.1 vs. 4.6, p=0.21 </text>
<text top="125" left="910" width="165" height="17" font="5">Month 9: -3.5 vs. -3.1, p=0.95 </text>
<text top="142" left="910" width="3" height="17" font="5"> </text>
<text top="160" left="910" width="91" height="17" font="7"><i>HDL cholesterol </i></text>
<text top="177" left="910" width="156" height="17" font="5">Month 6: 2.4 vs. 0.3, p=0.54 </text>
<text top="194" left="910" width="160" height="17" font="5">Month 9: -1.0 vs. 0.4, p=0.67 </text>
<text top="211" left="910" width="3" height="17" font="5"> </text>
<text top="229" left="910" width="166" height="17" font="7"><i>Percent of patients at BP goal </i></text>
<text top="246" left="910" width="178" height="17" font="5">Month 6: 81% vs. 44%, p&lt;0.001 </text>
<text top="263" left="910" width="171" height="17" font="5">Month 9: 70% vs. 52%, p=0.02 </text>
<text top="280" left="910" width="3" height="17" font="5"> </text>
<text top="297" left="910" width="118" height="17" font="5">Number of total visits </text>
<text top="315" left="910" width="219" height="17" font="5">(PCP+pharmacist)=4.4 in PharmD-PCP </text>
<text top="332" left="910" width="182" height="17" font="5">group vs. 4.2 in usual care group </text>
<text top="349" left="910" width="49" height="17" font="5">(p=0.38) </text>
<text top="366" left="910" width="3" height="17" font="5"> </text>
<text top="383" left="910" width="169" height="17" font="5">PharmD-PCP baseline vs post </text>
<text top="401" left="910" width="67" height="17" font="5">intervention </text>
<text top="418" left="910" width="3" height="17" font="7"><i> </i></text>
<text top="435" left="910" width="175" height="17" font="7"><i>Drug therapy problem identified </i></text>
<text top="452" left="910" width="219" height="17" font="5">Baseline: 45.2% (42% of whom needed </text>
<text top="469" left="910" width="217" height="17" font="5">additional therapy, 33.3% needed dose </text>
<text top="487" left="910" width="201" height="17" font="5">increase, 15.2% had nonadherence, </text>
<text top="504" left="910" width="185" height="17" font="5">6.1% had adverse drug reaction)  </text>
<text top="521" left="910" width="3" height="17" font="5"> </text>
<text top="538" left="910" width="226" height="17" font="5">Month 6: 20.0% (58.3% of whom needed </text>
<text top="556" left="910" width="217" height="17" font="5">additional therapy, 25.0% needed dose </text>
<text top="573" left="910" width="194" height="17" font="5">increase, 8.3% had nonadherence, </text>
<text top="590" left="910" width="189" height="17" font="5">16.7% had adverse drug reaction) </text>
<text top="607" left="910" width="3" height="17" font="5"> </text>
<text top="624" left="910" width="219" height="17" font="5">Month 9: 7.8% (25.0% of whom needed </text>
<text top="642" left="910" width="217" height="17" font="5">additional therapy, 25.0% needed dose </text>
<text top="659" left="910" width="222" height="17" font="5">increase, 25.0% had nonadherence, 0% </text>
<text top="676" left="910" width="150" height="17" font="5">had adverse drug reaction) </text>
<text top="693" left="910" width="3" height="17" font="5"> </text>
<text top="710" left="910" width="145" height="17" font="7"><i>Medication change at visit </i></text>
<text top="728" left="910" width="188" height="17" font="5">Baseline: 34.2%  (60.0% of whom </text>
<text top="745" left="910" width="179" height="17" font="5">increased dosage, 32.0% added </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="9" size="12" family="Times" color="#121312"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="910" width="221" height="17" font="5">medication, 12.0% changed medication, </text>
<text top="108" left="910" width="127" height="17" font="5">8.0% decreased dose) </text>
<text top="125" left="910" width="3" height="17" font="5"> </text>
<text top="142" left="910" width="182" height="17" font="5">Month 6: 11.7% (42.9% of whom </text>
<text top="160" left="910" width="179" height="17" font="5">increased dosage, 28.6% added </text>
<text top="177" left="910" width="221" height="17" font="5">medication, 14.3% changed medication, </text>
<text top="194" left="910" width="133" height="17" font="5">14.3% decreased dose) </text>
<text top="211" left="910" width="3" height="17" font="5"> </text>
<text top="229" left="910" width="228" height="17" font="5">Month 9: 3.9%  (3.9% of whom increased </text>
<text top="246" left="910" width="217" height="17" font="5">dosage, 100.0% added medication, 0% </text>
<text top="263" left="910" width="199" height="17" font="5">changed medication, 0% decreased </text>
<text top="280" left="910" width="34" height="17" font="5">dose) </text>
<text top="297" left="910" width="3" height="17" font="7"><i> </i></text>
<text top="315" left="910" width="156" height="17" font="7"><i>Satisfaction with pharmacist </i></text>
<text top="332" left="910" width="79" height="17" font="5">Month 6: 92.4 </text>
<text top="349" left="910" width="79" height="17" font="5">Month 9: 92.7 </text>
<text top="366" left="910" width="3" height="17" font="5"> </text>
<text top="383" left="910" width="3" height="17" font="5"> </text>
<text top="401" left="75" width="84" height="17" font="5">Hunt JS, et al., </text>
<text top="419" left="75" width="49" height="17" font="5">2008 (5) </text>
<text top="436" left="75" width="3" height="17" font="5"> </text>
<text top="453" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18815843">18815843</a></text>
<text top="453" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18815843"> </a></text>
<text top="401" left="193" width="72" height="17" font="3"><b>Study Aim:  </b></text>
<text top="419" left="193" width="119" height="17" font="5">To assess the impact </text>
<text top="436" left="193" width="74" height="17" font="5">of co-located </text>
<text top="453" left="193" width="119" height="17" font="5">physician-pharmacist </text>
<text top="470" left="193" width="113" height="17" font="5">team-based care on </text>
<text top="487" left="193" width="85" height="17" font="5">blood pressure </text>
<text top="505" left="193" width="115" height="17" font="5">control, quality of life </text>
<text top="522" left="193" width="64" height="17" font="5">and patient </text>
<text top="539" left="193" width="78" height="17" font="5">satisfaction in </text>
<text top="556" left="193" width="115" height="17" font="5">patients cared for by </text>
<text top="573" left="193" width="76" height="17" font="5">all physicians </text>
<text top="591" left="193" width="115" height="17" font="5">practicing in multiple </text>
<text top="608" left="193" width="100" height="17" font="5">community-based </text>
<text top="625" left="193" width="113" height="17" font="5">clinics over a 1-year </text>
<text top="642" left="193" width="34" height="17" font="5">period</text>
<text top="642" left="227" width="3" height="17" font="9">.</text>
<text top="642" left="230" width="3" height="17" font="5"> </text>
<text top="660" left="193" width="3" height="17" font="5"> </text>
<text top="677" left="193" width="71" height="17" font="3"><b>Study type:</b> </text>
<text top="694" left="193" width="106" height="17" font="5">prospective, single-</text>
<text top="711" left="193" width="97" height="17" font="5">blind randomized </text>
<text top="728" left="193" width="80" height="17" font="5">controlled trial </text>
<text top="746" left="193" width="3" height="17" font="5"> </text>
<text top="763" left="193" width="40" height="17" font="5">N=463 </text>
<text top="402" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="420" left="324" width="163" height="18" font="5">•  patients with an office visit </text>
<text top="438" left="325" width="126" height="17" font="5">within the past 2 years </text>
<text top="456" left="324" width="189" height="18" font="5">•  diagnosis of hypertension (ICD-</text>
<text top="474" left="325" width="60" height="17" font="5">9 of 410.*) </text>
<text top="491" left="324" width="168" height="18" font="5">•  last systolic blood pressure </text>
<text top="509" left="325" width="191" height="17" font="5">≥160 mmHg and/or a last diastolic </text>
<text top="526" left="325" width="157" height="17" font="5">blood pressure ≥100 mmHg </text>
<text top="544" left="325" width="3" height="17" font="5"> </text>
<text top="562" left="325" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="581" left="324" width="197" height="18" font="5">•  no blood pressure reading in the </text>
<text top="599" left="325" width="158" height="17" font="5">chart in the previous 2 years </text>
<text top="616" left="324" width="196" height="18" font="5">•  attended a visit with a pharmacy </text>
<text top="634" left="325" width="158" height="17" font="5">practitioner in the previous 6 </text>
<text top="652" left="325" width="47" height="17" font="5">months, </text>
<text top="669" left="324" width="186" height="18" font="5">•  had transferred care out of the </text>
<text top="687" left="325" width="49" height="17" font="5">Network </text>
<text top="402" left="533" width="78" height="17" font="3"><b>Intervention:</b> </text>
<text top="420" left="533" width="57" height="17" font="5">Physician-</text>
<text top="439" left="533" width="63" height="17" font="5">pharmacist </text>
<text top="457" left="533" width="109" height="17" font="5">collaborative model </text>
<text top="476" left="533" width="48" height="17" font="5">(N=230) </text>
<text top="494" left="533" width="3" height="17" font="5"> </text>
<text top="513" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="532" left="533" width="110" height="17" font="5">Usual care (N=233) </text>
<text top="550" left="533" width="3" height="17" font="5"> </text>
<text top="403" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="402" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="420" left="662" width="222" height="17" font="5">Difference in mean systolic and diastolic </text>
<text top="437" left="662" width="226" height="17" font="5">blood pressure between intervention and </text>
<text top="454" left="662" width="40" height="17" font="5">control </text>
<text top="471" left="662" width="3" height="17" font="5"> </text>
<text top="489" left="662" width="133" height="17" font="5">Systolic Blood Pressure </text>
<text top="506" left="662" width="161" height="17" font="7"><i>Study exit visit measurement </i></text>
<text top="523" left="662" width="231" height="17" font="5">137 intervention vs. 143 control (p=0.007) </text>
<text top="540" left="662" width="3" height="17" font="7"><i> </i></text>
<text top="557" left="662" width="22" height="17" font="7"><i>ITT </i></text>
<text top="575" left="662" width="231" height="17" font="5">142 intervention vs. 148 control (p=0.002) </text>
<text top="592" left="662" width="3" height="17" font="5"> </text>
<text top="609" left="662" width="137" height="17" font="5">Diastolic Blood Pressure </text>
<text top="626" left="662" width="167" height="17" font="5">Study exist visit measurement </text>
<text top="643" left="662" width="212" height="17" font="5">75 intervention vs. 78 control, p=0.003 </text>
<text top="661" left="662" width="3" height="17" font="5"> </text>
<text top="678" left="662" width="182" height="17" font="5">ITT 77 intervention vs. 80 control </text>
<text top="695" left="662" width="56" height="17" font="5">(p=0.003) </text>
<text top="712" left="662" width="3" height="17" font="5"> </text>
<text top="730" left="662" width="3" height="17" font="5"> </text>
<text top="747" left="662" width="3" height="17" font="5"> </text>
<text top="403" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="402" left="917" width="76" height="18" font="5"><b> endpoints: </b></text>
<text top="420" left="910" width="213" height="17" font="5">Proportion of subjects achieving target </text>
<text top="437" left="910" width="173" height="17" font="5">blood pressure &lt;140/90 mmHg </text>
<text top="454" left="910" width="3" height="17" font="5"> </text>
<text top="471" left="910" width="187" height="17" font="5">Self-management knowledge and </text>
<text top="489" left="910" width="51" height="17" font="5">behavior </text>
<text top="506" left="910" width="124" height="17" font="5">Medication adherence </text>
<text top="523" left="910" width="219" height="17" font="5">Use of home blood pressure monitoring </text>
<text top="540" left="910" width="39" height="17" font="5">device </text>
<text top="557" left="910" width="118" height="17" font="5">Healthcare utilization </text>
<text top="575" left="910" width="44" height="17" font="5">HRQoL </text>
<text top="592" left="910" width="148" height="17" font="5">Satisfaction with treatment </text>
<text top="609" left="910" width="3" height="17" font="5"> </text>
<text top="626" left="910" width="166" height="17" font="5">General healthcare utilization: </text>
<text top="643" left="910" width="127" height="17" font="5">intervention vs. control </text>
<text top="661" left="910" width="141" height="17" font="5">Mean Number PCP visits </text>
<text top="678" left="910" width="119" height="17" font="5">3.2 vs. 4.7, p&lt;0.0001 </text>
<text top="695" left="910" width="213" height="17" font="5">Mean number pharmacist visits 4.0 vs. </text>
<text top="712" left="910" width="79" height="17" font="5">0.2, p&lt;0.0001 </text>
<text top="730" left="910" width="153" height="17" font="5">Mean total visits per patient </text>
<text top="747" left="910" width="119" height="17" font="5">7.2 vs. 4.9, p&lt;0.0001 </text>
<text top="764" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="910" width="178" height="17" font="5">Hypertension-related healthcare </text>
<text top="108" left="910" width="185" height="17" font="5">utilization: intervention vs. control </text>
<text top="125" left="910" width="3" height="17" font="5"> </text>
<text top="142" left="910" width="141" height="17" font="5">Mean Number PCP visits </text>
<text top="160" left="910" width="119" height="17" font="5">1.8 vs. 2.9, p&lt;0.0001 </text>
<text top="177" left="910" width="213" height="17" font="5">Mean number pharmacist visits 4.0 vs. </text>
<text top="194" left="910" width="79" height="17" font="5">0.2, p&lt;0.0001 </text>
<text top="211" left="910" width="153" height="17" font="5">Mean total visits per patient </text>
<text top="229" left="910" width="119" height="17" font="5">5.8 vs. 3.1, p&lt;0.0001 </text>
<text top="246" left="910" width="3" height="17" font="5"> </text>
<text top="263" left="910" width="190" height="17" font="5">Pharmacotherapy: intervention vs. </text>
<text top="280" left="910" width="40" height="17" font="5">control </text>
<text top="297" left="910" width="3" height="17" font="5"> </text>
<text top="315" left="910" width="172" height="17" font="5">Mean number antihypertensive </text>
<text top="332" left="910" width="69" height="17" font="5">medications </text>
<text top="349" left="910" width="105" height="17" font="5">2.7 vs. 2.4, p=0.02 </text>
<text top="366" left="910" width="3" height="17" font="5"> </text>
<text top="383" left="910" width="165" height="17" font="5">Mean pills per patient per day </text>
<text top="401" left="910" width="105" height="17" font="5">2.4 vs. 2.5, p=0.87 </text>
<text top="418" left="910" width="3" height="17" font="5"> </text>
<text top="435" left="910" width="215" height="17" font="5">Percent using generic antihypertensive </text>
<text top="452" left="910" width="34" height="17" font="5">agent </text>
<text top="469" left="910" width="147" height="17" font="5">50.7% vs. 39.7%, p=0.008 </text>
<text top="487" left="910" width="3" height="17" font="5"> </text>
<text top="504" left="910" width="178" height="17" font="5">Goal attainment &lt;140/90 mmHg </text>
<text top="521" left="910" width="161" height="17" font="7"><i>Study exit visit measurement </i></text>
<text top="538" left="910" width="179" height="17" font="5">62% intervention vs 44% control </text>
<text top="556" left="910" width="56" height="17" font="5">(p=0.003) </text>
<text top="573" left="910" width="3" height="17" font="7"><i> </i></text>
<text top="590" left="910" width="25" height="17" font="7"><i>ITT</i>  </text>
<text top="607" left="910" width="182" height="17" font="5">54% intervention vs. 42% control </text>
<text top="624" left="910" width="56" height="17" font="5">(p=0.005) </text>
<text top="642" left="910" width="3" height="17" font="5"> </text>
<text top="659" left="910" width="223" height="17" font="5">HRQOL (SF-36): Intervention vs. control </text>
<text top="676" left="910" width="214" height="17" font="5">Physical functioning: 44 vs. 42, p=0.33 </text>
<text top="693" left="910" width="192" height="17" font="5">Role limitation, physical: 48 vs. 49, </text>
<text top="710" left="910" width="41" height="17" font="5">p=0.49 </text>
<text top="728" left="910" width="165" height="17" font="5">Bodily pain: 32 vs. 33, p=0.43 </text>
<text top="745" left="910" width="186" height="17" font="5">General health: 42 vs. 44, p=0.01 </text>
<text top="762" left="910" width="141" height="17" font="5">Vitality: 48 vs. 49, p=0.20 </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="910" width="201" height="17" font="5">Social functioning: 35 vs. 35, p=0.70 </text>
<text top="108" left="910" width="207" height="17" font="5">Role limitations, emotional: 49 vs. 48, </text>
<text top="125" left="910" width="41" height="17" font="5">p=0.32 </text>
<text top="142" left="910" width="179" height="17" font="5">Mental health: 44 vs. 42, p=0.15 </text>
<text top="160" left="910" width="228" height="17" font="5">Physical component summary: 41 vs. 42, </text>
<text top="177" left="910" width="41" height="17" font="5">p=0.12 </text>
<text top="194" left="910" width="198" height="17" font="5">Mental component score: 45 vs. 44, </text>
<text top="211" left="910" width="41" height="17" font="5">p=0.16 </text>
<text top="229" left="910" width="3" height="17" font="5"> </text>
<text top="246" left="910" width="148" height="17" font="5">Satisfaction with treatment </text>
<text top="263" left="910" width="217" height="17" font="5">Overall: 8.6 intervention vs. 8.5 control, </text>
<text top="280" left="910" width="41" height="17" font="5">p=0.75 </text>
<text top="297" left="910" width="220" height="17" font="5">No significant between-group difference </text>
<text top="315" left="910" width="217" height="17" font="5">on any of the 11 satisfaction measures, </text>
<text top="332" left="910" width="221" height="17" font="5">no association between satisfaction and </text>
<text top="349" left="910" width="215" height="17" font="5">blood pressure goal attainment (p=0.4) </text>
<text top="367" left="75" width="91" height="17" font="5">Chisholm-Burns </text>
<text top="384" left="75" width="100" height="17" font="5">M, et al., 2010 (6) </text>
<text top="401" left="75" width="3" height="17" font="5"> </text>
<text top="419" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20720510">20720510</a></text>
<text top="419" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20720510"> </a></text>
<text top="367" left="193" width="68" height="17" font="3"><b>Study Aim: </b></text>
<text top="384" left="193" width="74" height="17" font="5">To conduct a </text>
<text top="401" left="193" width="87" height="17" font="5">comprehensive </text>
<text top="419" left="193" width="100" height="17" font="5">systematic review </text>
<text top="436" left="193" width="103" height="17" font="5">with focused meta-</text>
<text top="453" left="193" width="115" height="17" font="5">analyses to examine </text>
<text top="470" left="193" width="74" height="17" font="5">the effects of </text>
<text top="487" left="193" width="115" height="17" font="5">pharmacist-provided </text>
<text top="505" left="193" width="118" height="17" font="5">direct patient care on </text>
<text top="522" left="193" width="107" height="17" font="5">therapeutic, safety, </text>
<text top="539" left="193" width="86" height="17" font="5">and humanistic </text>
<text top="556" left="193" width="60" height="17" font="5">outcomes. </text>
<text top="573" left="193" width="3" height="17" font="5"> </text>
<text top="591" left="193" width="86" height="17" font="3"><b>Study Design: </b></text>
<text top="608" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="625" left="193" width="103" height="17" font="5">and meta analysis </text>
<text top="642" left="193" width="3" height="17" font="5"> </text>
<text top="660" left="193" width="82" height="17" font="5">N=298 studies </text>
<text top="367" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="386" left="324" width="198" height="18" font="5">•  Published through January 2009 </text>
<text top="404" left="324" width="148" height="18" font="5">•  Evidence of pharmacist </text>
<text top="422" left="325" width="183" height="17" font="5">involvement in direct patient care </text>
<text top="439" left="324" width="166" height="18" font="5">•  Comparison group present </text>
<text top="458" left="324" width="156" height="18" font="5">•  Patient related outcomes </text>
<text top="476" left="325" width="175" height="17" font="5">reported (therapeutic, safety, or </text>
<text top="493" left="325" width="66" height="17" font="5">humanistic) </text>
<text top="510" left="324" width="160" height="18" font="5">•  No restrictions by age (26 </text>
<text top="528" left="325" width="162" height="17" font="5">studies included patients &lt;18 </text>
<text top="546" left="325" width="38" height="17" font="5">years) </text>
<text top="563" left="325" width="3" height="17" font="5"> </text>
<text top="581" left="325" width="3" height="17" font="5"> </text>
<text top="600" left="325" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="619" left="324" width="107" height="18" font="5">•  Non-US studies </text>
<text top="637" left="324" width="166" height="18" font="5">•  Descriptive studies with no </text>
<text top="655" left="325" width="102" height="17" font="5">comparison group </text>
<text top="672" left="324" width="160" height="18" font="5">•  Systematic reviews, meta </text>
<text top="691" left="325" width="156" height="17" font="5">analyses, clinical drug trials, </text>
<text top="708" left="325" width="180" height="17" font="5">commentaries, letters, editorials, </text>
<text top="725" left="325" width="171" height="17" font="5">books, book chapters, meeting </text>
<text top="742" left="325" width="194" height="17" font="5">abstracts, case studies, guidelines, </text>
<text top="759" left="325" width="162" height="17" font="5">online exams, bibliographies, </text>
<text top="367" left="533" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="386" left="533" width="103" height="17" font="5">Direct patient care </text>
<text top="404" left="533" width="80" height="17" font="5">by pharmacist </text>
<text top="423" left="533" width="3" height="17" font="5"> </text>
<text top="441" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="460" left="533" width="75" height="17" font="5">Not specified </text>
<text top="368" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="367" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="385" left="662" width="94" height="17" font="7"><i>Hemoglobin A1c </i></text>
<text top="403" left="662" width="202" height="17" font="5">SMD=0.6, p=0.005. Mean difference </text>
<text top="420" left="662" width="216" height="17" font="5">between intervention and comparison=-</text>
<text top="437" left="662" width="235" height="17" font="5">1.8% (95% CI -2.7 to -0.9). No evidence of </text>
<text top="454" left="662" width="88" height="17" font="5">publication bias </text>
<text top="471" left="662" width="3" height="17" font="5"> </text>
<text top="489" left="662" width="221" height="17" font="7"><i>LDL</i>: SMD=0.3, p-0.01. Mean difference </text>
<text top="506" left="662" width="216" height="17" font="5">between intervention and comparison=-</text>
<text top="523" left="662" width="195" height="17" font="5">6.3 mg/dL (95% CI -6.5 to -6.0). No </text>
<text top="540" left="662" width="155" height="17" font="5">evidence of publication bias </text>
<text top="557" left="662" width="3" height="17" font="5"> </text>
<text top="575" left="662" width="221" height="17" font="7"><i>Diastolic BP</i>: SMD=0.3, p=0.001.  Mean </text>
<text top="592" left="662" width="198" height="17" font="5">difference between intervention and </text>
<text top="609" left="662" width="229" height="17" font="5">comparison=-2.9 mm Hg (95% CI -3.8 to -</text>
<text top="626" left="662" width="222" height="17" font="5">2.0). Some evidence of publication bias. </text>
<text top="643" left="662" width="3" height="17" font="5"> </text>
<text top="661" left="662" width="217" height="17" font="7"><i>Systolic BP</i>: SMD=0.5, p&lt;0.001.  Mean </text>
<text top="678" left="662" width="198" height="17" font="5">difference between intervention and </text>
<text top="695" left="662" width="229" height="17" font="5">comparison=-7.8 mm Hg (95% CI -9.7 to -</text>
<text top="712" left="662" width="205" height="17" font="5">5.8).  No evidence of publication bias </text>
<text top="730" left="662" width="3" height="17" font="5"> </text>
<text top="747" left="662" width="222" height="17" font="7"><i>Adverse drug events</i>: OR=0.53 (p=0.01) </text>
<text top="764" left="662" width="180" height="17" font="5">indicating significant reduction in </text>
<text top="368" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="367" left="917" width="65" height="18" font="5"><b> endpoint </b></text>
<text top="385" left="910" width="217" height="17" font="5">Summary estimates were not produced </text>
<text top="403" left="910" width="194" height="17" font="5">for other study outcomes, including </text>
<text top="420" left="910" width="205" height="17" font="5">hospitalization/readmission, length of </text>
<text top="437" left="910" width="205" height="17" font="5">hospital stay, emergency department </text>
<text top="454" left="910" width="224" height="17" font="5">visit, INR/PT/aPTT, mortality, BMI, blood </text>
<text top="471" left="910" width="224" height="17" font="5">glucose, appropriate medication use, lab </text>
<text top="489" left="910" width="186" height="17" font="5">monitoring/screening, appropriate </text>
<text top="506" left="910" width="207" height="17" font="5">medication dose, aspirin use, primary </text>
<text top="523" left="910" width="225" height="17" font="5">care/urgent care visit, asthma measures, </text>
<text top="540" left="910" width="192" height="17" font="5">eye exam, adverse drug reactions, </text>
<text top="557" left="910" width="166" height="17" font="5">medication errors, and patient </text>
<text top="575" left="910" width="65" height="17" font="5">satisfaction </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="325" width="169" height="17" font="5">dissertations, lectures, theses, </text>
<text top="108" left="325" width="153" height="17" font="5">book reviews, news articles </text>
<text top="91" left="662" width="203" height="17" font="5">pharmacist-provided care group.  No </text>
<text top="108" left="662" width="221" height="17" font="5">evidence of heterogeneity or publication </text>
<text top="125" left="662" width="26" height="17" font="5">bias </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="186" height="17" font="7"><i>Medication adherence</i>: SMD=0.6, </text>
<text top="177" left="662" width="220" height="17" font="5">p=0.001. Evidence of heterogeneity. No </text>
<text top="194" left="662" width="155" height="17" font="5">evidence of publication bias </text>
<text top="211" left="662" width="3" height="17" font="5"> </text>
<text top="229" left="662" width="217" height="17" font="7"><i>Patient knowledge</i>: SMD=1.1, p=0.001. </text>
<text top="246" left="662" width="234" height="17" font="5">Evidence of heterogeneity. No evidence of </text>
<text top="263" left="662" width="88" height="17" font="5">publication bias </text>
<text top="280" left="662" width="3" height="17" font="5"> </text>
<text top="297" left="662" width="222" height="17" font="7"><i>QoL-general health</i>: SMD=0.1, p=0.003. </text>
<text top="315" left="662" width="202" height="17" font="5">No evidence of heterogeneity. Some </text>
<text top="332" left="662" width="206" height="17" font="5">indication of publication bias, but non-</text>
<text top="349" left="662" width="188" height="17" font="5">significant Kendall’s tau (p=0.327) </text>
<text top="366" left="662" width="3" height="17" font="5"> </text>
<text top="383" left="662" width="3" height="17" font="5"> </text>
<text top="401" left="75" width="48" height="17" font="5">Study of </text>
<text top="419" left="75" width="85" height="17" font="5">Cardiovascular </text>
<text top="436" left="75" width="95" height="17" font="5">Risk Intervention </text>
<text top="453" left="75" width="88" height="17" font="5">by Pharmacists-</text>
<text top="470" left="75" width="76" height="17" font="5">Hypertension </text>
<text top="487" left="75" width="82" height="17" font="5">(SCRIP-HTN)  </text>
<text top="505" left="75" width="3" height="17" font="5"> </text>
<text top="522" left="75" width="103" height="17" font="5">McLean DL, et al., </text>
<text top="539" left="75" width="49" height="17" font="5">2008 (7) </text>
<text top="556" left="75" width="3" height="17" font="5"> </text>
<text top="573" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19029501">19029501</a></text>
<text top="573" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19029501"> </a></text>
<text top="401" left="193" width="68" height="17" font="3"><b>Study Aim: </b></text>
<text top="419" left="193" width="76" height="17" font="5">To determine </text>
<text top="436" left="193" width="89" height="17" font="5">the efficacy of a </text>
<text top="453" left="193" width="100" height="17" font="5">community-based </text>
<text top="470" left="193" width="90" height="17" font="5">multidisciplinary </text>
<text top="487" left="193" width="104" height="17" font="5">intervention on BP </text>
<text top="505" left="193" width="100" height="17" font="5">control in patients </text>
<text top="522" left="193" width="75" height="17" font="5">with diabetes </text>
<text top="539" left="193" width="45" height="17" font="5">mellitus </text>
<text top="556" left="193" width="3" height="17" font="5"> </text>
<text top="573" left="193" width="74" height="17" font="3"><b>Study Type: </b></text>
<text top="591" left="193" width="72" height="17" font="5">Randomized </text>
<text top="608" left="193" width="80" height="17" font="5">controlled trial </text>
<text top="625" left="193" width="3" height="17" font="5"> </text>
<text top="642" left="193" width="40" height="17" font="5">N=227 </text>
<text top="402" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="420" left="325" width="3" height="17" font="5"> </text>
<text top="439" left="324" width="55" height="18" font="5">•  Adults </text>
<text top="457" left="324" width="69" height="18" font="5">•  Diabetes </text>
<text top="475" left="324" width="196" height="18" font="5">•  BP higher than 130/80mmHg on </text>
<text top="493" left="325" width="182" height="17" font="5">2 screening visits separated by 2 </text>
<text top="510" left="325" width="42" height="17" font="5">weeks  </text>
<text top="528" left="325" width="3" height="17" font="5"> </text>
<text top="546" left="325" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="565" left="324" width="174" height="18" font="5">•  institutionalized (or had their </text>
<text top="583" left="325" width="169" height="17" font="5">medications administered by a </text>
<text top="600" left="325" width="128" height="17" font="5">professional caregiver) </text>
<text top="618" left="324" width="108" height="18" font="5">•  refused consent </text>
<text top="636" left="324" width="197" height="18" font="5">•  declined attendance at follow-up </text>
<text top="654" left="325" width="153" height="17" font="5">visits for BP measurements </text>
<text top="402" left="533" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="420" left="533" width="95" height="17" font="5">Pharmacists and </text>
<text top="439" left="533" width="34" height="17" font="5">nurse </text>
<text top="457" left="533" width="3" height="17" font="5"> </text>
<text top="476" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="494" left="533" width="62" height="17" font="5">Usual care </text>
<text top="403" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="402" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="420" left="662" width="3" height="17" font="5"> </text>
<text top="437" left="662" width="193" height="17" font="5">Difference in change in systolic BP </text>
<text top="454" left="662" width="179" height="17" font="5">between baseline and 24 weeks </text>
<text top="471" left="662" width="3" height="17" font="5"> </text>
<text top="489" left="662" width="233" height="17" font="5">Mean change of -10.1 mm Hg intervention </text>
<text top="506" left="662" width="134" height="17" font="5">vs. -5.0 mm Hg control   </text>
<text top="523" left="662" width="3" height="17" font="5"> </text>
<text top="540" left="662" width="212" height="17" font="5">Mean adjusted difference=5.6 mm Hg  </text>
<text top="557" left="662" width="56" height="17" font="5">(p=0.008) </text>
<text top="403" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="402" left="917" width="76" height="18" font="5"><b> endpoints: </b></text>
<text top="420" left="910" width="3" height="17" font="5"> </text>
<text top="437" left="910" width="226" height="17" font="7"><i>achievement of BP targets of 130/80 mm </i></text>
<text top="454" left="910" width="59" height="17" font="7"><i>Hg or less </i></text>
<text top="471" left="910" width="3" height="17" font="5"> </text>
<text top="489" left="910" width="206" height="17" font="5">Significant increases from baseline in </text>
<text top="506" left="910" width="180" height="17" font="5">both groups (2.6% at baseline in </text>
<text top="523" left="910" width="223" height="17" font="5">Intervention group to 47.0% at follow up, </text>
<text top="540" left="910" width="199" height="17" font="5">p&lt;0.001; 3.6% at baseline in control </text>
<text top="557" left="910" width="211" height="17" font="5">group to 33.0% at follow up, p&lt;0.001.  </text>
<text top="575" left="910" width="185" height="17" font="5">14% absolute difference between </text>
<text top="592" left="910" width="180" height="17" font="5">intervention and control, p=0.02) </text>
<text top="609" left="910" width="3" height="17" font="5"> </text>
<text top="626" left="910" width="199" height="17" font="7"><i>The addition, or dosage increase, of </i></text>
<text top="643" left="910" width="165" height="17" font="7"><i>antihypertensive drug therapy </i></text>
<text top="661" left="910" width="3" height="17" font="5"> </text>
<text top="678" left="910" width="220" height="17" font="5">Diuretics: Intervention=8.7% baseline to </text>
<text top="695" left="910" width="221" height="17" font="5">9.6% follow up. Control=12.5% baseline </text>
<text top="712" left="910" width="104" height="17" font="5">to 15.2% follow up </text>
<text top="730" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="910" width="224" height="18" font="5">-blockers: Intervention=21.7% baseline </text>
<text top="109" left="910" width="192" height="17" font="5">to 23.5% follow up. Control=13.4% </text>
<text top="126" left="910" width="153" height="17" font="5">baseline to 13.4% follow up </text>
<text top="144" left="910" width="3" height="17" font="5"> </text>
<text top="161" left="910" width="147" height="17" font="5">Calcium channel blockers: </text>
<text top="178" left="910" width="211" height="17" font="5">Intervention=24.3% baseline to 23.5% </text>
<text top="195" left="910" width="203" height="17" font="5">follow up. Control=22.3% baseline to </text>
<text top="212" left="910" width="90" height="17" font="5">23.2% follow up </text>
<text top="230" left="910" width="3" height="17" font="5"> </text>
<text top="247" left="910" width="194" height="17" font="5">ACE inhibitors: Intervention=40.0% </text>
<text top="264" left="910" width="156" height="17" font="5">baseline to 39.1% follow up. </text>
<text top="281" left="910" width="221" height="17" font="5">Control=42.9% baseline to 42.9% follow </text>
<text top="299" left="910" width="17" height="17" font="5">up </text>
<text top="316" left="910" width="3" height="17" font="5"> </text>
<text top="333" left="910" width="169" height="17" font="5">Angiotensin receptor blockers: </text>
<text top="350" left="910" width="211" height="17" font="5">Intervention=30.4% baseline to 32.2% </text>
<text top="367" left="910" width="203" height="17" font="5">follow up. Control=26.8% baseline to </text>
<text top="385" left="910" width="90" height="17" font="5">29.5% follow up </text>
<text top="402" left="910" width="3" height="17" font="5"> </text>
<text top="419" left="910" width="221" height="17" font="7"><i>The proportion of patients prescribed an </i></text>
<text top="436" left="910" width="220" height="17" font="7"><i>angiotensin-converting enzyme inhibitor </i></text>
<text top="453" left="910" width="189" height="17" font="7"><i>or angiotensin receptor antagonist </i></text>
<text top="471" left="910" width="3" height="17" font="5"> </text>
<text top="488" left="910" width="210" height="17" font="5">Intervention: 61.7% baseline to 59.1% </text>
<text top="505" left="910" width="200" height="17" font="5">follow up. Control:65.2% baseline to </text>
<text top="522" left="910" width="94" height="17" font="5">67.0% follow up. </text>
<text top="539" left="910" width="3" height="17" font="5"> </text>
<text top="557" left="910" width="211" height="17" font="7"><i>the difference in change in systolic BP </i></text>
<text top="574" left="910" width="191" height="17" font="7"><i>between baseline and 24 weeks in </i></text>
<text top="591" left="910" width="227" height="17" font="7"><i>patients with baseline systolic BP greater </i></text>
<text top="608" left="910" width="94" height="17" font="7"><i>than 160 mm Hg </i></text>
<text top="626" left="910" width="3" height="17" font="5"> </text>
<text top="643" left="910" width="229" height="17" font="5">-27.4 mm Hg Intervention vs. -3.3 mm Hg </text>
<text top="660" left="910" width="220" height="17" font="5">Control (adjusted mean difference=24.1 </text>
<text top="677" left="910" width="99" height="17" font="5">mm Hg, p&lt;0.001) </text>
<text top="695" left="75" width="84" height="17" font="5">Mills KT, et al., </text>
<text top="712" left="75" width="49" height="17" font="5">2018 (8) </text>
<text top="730" left="75" width="3" height="17" font="5"> </text>
<text top="747" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29277852">29277852</a></text>
<text top="747" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29277852"> </a></text>
<text top="695" left="193" width="68" height="17" font="3"><b>Study Aim: </b></text>
<text top="712" left="193" width="3" height="17" font="5"> </text>
<text top="730" left="193" width="80" height="17" font="5">To assess the </text>
<text top="747" left="193" width="70" height="17" font="5">comparative </text>
<text top="764" left="193" width="99" height="17" font="5">effectiveness of 8 </text>
<text top="695" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="714" left="324" width="170" height="18" font="5">•  Randomized controlled trial </text>
<text top="732" left="324" width="184" height="18" font="5">•  Study participants were adults </text>
<text top="750" left="325" width="195" height="17" font="5">with hypertension (average systolic </text>
<text top="768" left="325" width="194" height="17" font="5">BP ≥ 140 mmHg, average diastolic </text>
<text top="695" left="533" width="78" height="17" font="3"><b>Intervention:</b> </text>
<text top="714" left="533" width="95" height="17" font="5">Health coaching, </text>
<text top="732" left="533" width="54" height="17" font="5">home BP </text>
<text top="751" left="533" width="112" height="17" font="5">monitoring, provider </text>
<text top="770" left="533" width="101" height="17" font="5">training, audit and </text>
<text top="696" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="695" left="668" width="65" height="18" font="5"><b> endpoint </b></text>
<text top="714" left="662" width="3" height="17" font="5"> </text>
<text top="731" left="662" width="193" height="17" font="5">Difference in change in systolic BP </text>
<text top="748" left="662" width="226" height="17" font="5">between Intervention and Control groups </text>
<text top="765" left="662" width="66" height="17" font="5">at follow up </text>
<text top="696" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="695" left="917" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="714" left="910" width="85" height="17" font="5">None specified </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="87" height="17" font="5">implementation </text>
<text top="108" left="193" width="108" height="17" font="5">strategies for blood </text>
<text top="125" left="193" width="104" height="17" font="5">pressure control in </text>
<text top="142" left="193" width="61" height="17" font="5">adults with </text>
<text top="160" left="193" width="74" height="17" font="5">hypertension </text>
<text top="177" left="193" width="3" height="17" font="5"> </text>
<text top="194" left="193" width="74" height="17" font="3"><b>Study Type: </b></text>
<text top="211" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="229" left="193" width="116" height="17" font="5">and meta analysis of </text>
<text top="246" left="193" width="35" height="17" font="5">RCTs </text>
<text top="263" left="193" width="3" height="17" font="5"> </text>
<text top="280" left="193" width="82" height="17" font="5">N=100 articles </text>
<text top="297" left="193" width="110" height="17" font="5">(n=55,920 patients) </text>
<text top="91" left="325" width="167" height="17" font="5">BP ≥ 90 mmHg, and/or use of </text>
<text top="108" left="325" width="160" height="17" font="5">antihypertensive medication) </text>
<text top="125" left="324" width="178" height="18" font="5">•  A main trial outcome was the </text>
<text top="143" left="325" width="155" height="17" font="5">net change in systolic BP or </text>
<text top="161" left="325" width="68" height="17" font="5">diastolic BP </text>
<text top="178" left="324" width="173" height="18" font="5">•  The trial intervention targets </text>
<text top="196" left="325" width="186" height="17" font="5">barriers to hypertension control at </text>
<text top="213" left="325" width="148" height="17" font="5">one or more of the patient, </text>
<text top="230" left="325" width="178" height="17" font="5">provider, and healthcare system </text>
<text top="248" left="325" width="35" height="17" font="5">levels </text>
<text top="265" left="324" width="167" height="18" font="5">•  The control group received </text>
<text top="283" left="325" width="181" height="17" font="5">usual care or minimal education  </text>
<text top="301" left="324" width="181" height="18" font="5">•  The trial duration was at least </text>
<text top="319" left="325" width="62" height="17" font="5">six months </text>
<text top="336" left="324" width="171" height="18" font="5">•  Variance of BP changes (or </text>
<text top="354" left="325" width="181" height="17" font="5">data to calculate it) was reported </text>
<text top="372" left="324" width="197" height="18" font="5">•  If a trial was cluster-randomized, </text>
<text top="390" left="325" width="194" height="17" font="5">clustering must be accounted for in </text>
<text top="407" left="325" width="72" height="17" font="5">the analysis. </text>
<text top="424" left="325" width="3" height="17" font="5"> </text>
<text top="443" left="325" width="3" height="17" font="5"> </text>
<text top="91" left="533" width="113" height="17" font="5">feedback, electronic </text>
<text top="109" left="533" width="93" height="17" font="5">decision support </text>
<text top="128" left="533" width="107" height="17" font="5">systems, multilevel </text>
<text top="147" left="533" width="99" height="17" font="5">strategies without </text>
<text top="165" left="533" width="98" height="17" font="5">team based care, </text>
<text top="184" left="533" width="95" height="17" font="5">team based care </text>
<text top="202" left="533" width="86" height="17" font="5">with physicians </text>
<text top="221" left="533" width="44" height="17" font="5">titrating </text>
<text top="239" left="533" width="103" height="17" font="5">medications, team </text>
<text top="258" left="533" width="89" height="17" font="5">based care with </text>
<text top="277" left="533" width="79" height="17" font="5">non-physician </text>
<text top="295" left="533" width="98" height="17" font="5">providers titrating </text>
<text top="314" left="533" width="69" height="17" font="5">medications </text>
<text top="332" left="533" width="3" height="17" font="5"> </text>
<text top="351" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="369" left="533" width="76" height="17" font="5">Usual care or </text>
<text top="388" left="533" width="103" height="17" font="5">minimal education </text>
<text top="407" left="533" width="3" height="17" font="5"> </text>
<text top="91" left="662" width="3" height="17" font="5"> </text>
<text top="108" left="662" width="148" height="17" font="7"><i>Net Change in Systolic BP </i></text>
<text top="125" left="660" width="221" height="17" font="5">Health coaching: -3.9 mm HG (95% CI: -</text>
<text top="144" left="660" width="126" height="17" font="5">5.4 TO -2.3, P&lt;0.001)  </text>
<text top="162" left="660" width="3" height="17" font="5"> </text>
<text top="181" left="660" width="220" height="17" font="5">Home BP monitoring: -2.7 mm Hg (95% </text>
<text top="200" left="660" width="148" height="17" font="5">CI: -3.6 to -1.7, p&lt;0.001).   </text>
<text top="218" left="660" width="3" height="17" font="5"> </text>
<text top="237" left="660" width="219" height="17" font="5">Provider training: -1.4 mm Hg (95% CI: -</text>
<text top="255" left="660" width="104" height="17" font="5">3.6 to 0.7, p&gt;0.05) </text>
<text top="274" left="660" width="3" height="17" font="5"> </text>
<text top="292" left="660" width="235" height="17" font="5">Audit and feedback: --0.8 mm Hg (95% CI: </text>
<text top="311" left="660" width="108" height="17" font="5">-2.1 to 0.5, p&gt;0.05) </text>
<text top="330" left="660" width="3" height="17" font="5"> </text>
<text top="348" left="660" width="227" height="17" font="5">Electronic decision support systems: -3.7 </text>
<text top="367" left="660" width="213" height="17" font="5">mm Hg (95% CI: -5.2 to -2.2, p&lt;0.001) </text>
<text top="385" left="660" width="3" height="17" font="5"> </text>
<text top="404" left="660" width="221" height="17" font="5">Multilevel strategies without team based </text>
<text top="422" left="660" width="216" height="17" font="5">care: -5.0 mm Hg (95% CI: -8.0 to -2.0, </text>
<text top="441" left="660" width="52" height="17" font="5">p=0.001) </text>
<text top="460" left="660" width="3" height="17" font="5"> </text>
<text top="478" left="660" width="229" height="17" font="5">Team based care with physicians titrating </text>
<text top="497" left="660" width="230" height="17" font="5">medications: -6.2 mm Hg (95% CI: -8.1 to </text>
<text top="515" left="660" width="87" height="17" font="5">-4.2, p&lt;0.001).  </text>
<text top="534" left="660" width="3" height="17" font="5"> </text>
<text top="553" left="660" width="204" height="17" font="5">Team based care with non-physician </text>
<text top="571" left="660" width="219" height="17" font="5">providers titrating medications: -7.1 mm </text>
<text top="590" left="660" width="189" height="17" font="5">Hg (95% CI: -8.9 to -5.2, p&lt;0.001) </text>
<text top="608" left="660" width="3" height="17" font="5"> </text>
<text top="627" left="660" width="152" height="17" font="7"><i>Net Change in Diastolic BP </i></text>
<text top="645" left="660" width="3" height="17" font="5"> </text>
<text top="664" left="660" width="221" height="17" font="5">Health coaching: -2.1 mm HG (95% CI: -</text>
<text top="683" left="660" width="126" height="17" font="5">2.9 TO -1.3, P&lt;0.001)  </text>
<text top="701" left="660" width="3" height="17" font="5"> </text>
<text top="720" left="660" width="220" height="17" font="5">Home BP monitoring: -1.5 mm Hg (95% </text>
<text top="738" left="660" width="148" height="17" font="5">CI: -2.3 to -0.8, p&lt;0.001).   </text>
<text top="757" left="660" width="3" height="17" font="5"> </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="660" width="219" height="17" font="5">Provider training: -1.0 mm Hg (95% CI: -</text>
<text top="109" left="660" width="104" height="17" font="5">2.2 to 0.1, p&gt;0.05) </text>
<text top="128" left="660" width="3" height="17" font="5"> </text>
<text top="147" left="660" width="235" height="17" font="5">Audit and feedback: --0.6 mm Hg (95% CI: </text>
<text top="165" left="660" width="108" height="17" font="5">-1.3 to 0.1, p&gt;0.05) </text>
<text top="184" left="660" width="3" height="17" font="5"> </text>
<text top="202" left="660" width="206" height="17" font="5">Electronic decision support systems:  </text>
<text top="221" left="660" width="185" height="17" font="5">-1.5 mm Hg (95% CI: -1.9 to -1.1, </text>
<text top="239" left="660" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="258" left="660" width="3" height="17" font="5"> </text>
<text top="277" left="660" width="221" height="17" font="5">Multilevel strategies without team based </text>
<text top="295" left="660" width="216" height="17" font="5">care: -2.9 mm Hg (95% CI: -5.4 to -0.4, </text>
<text top="314" left="660" width="52" height="17" font="5">p=0.025) </text>
<text top="332" left="660" width="3" height="17" font="5"> </text>
<text top="351" left="660" width="229" height="17" font="5">Team based care with physicians titrating </text>
<text top="369" left="660" width="230" height="17" font="5">medications: -2.7 mm Hg (95% CI: -3.8 to </text>
<text top="388" left="660" width="87" height="17" font="5">-1.5, p&lt;0.001).  </text>
<text top="407" left="660" width="3" height="17" font="5"> </text>
<text top="425" left="660" width="204" height="17" font="5">Team based care with non-physician </text>
<text top="444" left="660" width="219" height="17" font="5">providers titrating medications: -3.1 mm </text>
<text top="462" left="660" width="189" height="17" font="5">Hg (95% CI: -4.1 to -2.2, p&lt;0.001) </text>
<text top="493" left="662" width="3" height="17" font="5"> </text>
<text top="510" left="662" width="211" height="17" font="7"><i>Adjusted Difference in Blood Pressure </i></text>
<text top="527" left="662" width="208" height="17" font="7"><i>Reduction with Team based care with </i></text>
<text top="544" left="662" width="211" height="17" font="7"><i>titration by non-physician compared to </i></text>
<text top="562" left="662" width="105" height="17" font="7"><i>other interventions </i></text>
<text top="579" left="662" width="3" height="17" font="5"> </text>
<text top="596" left="662" width="206" height="17" font="5">Vs Team based care with titration by  </text>
<text top="613" left="662" width="216" height="17" font="5">physician: DBP -0.48 mm Hg (95% CI: -</text>
<text top="631" left="662" width="230" height="17" font="5">1.95 to 0.99), SBP -0.88 mm Hg (95% CI -</text>
<text top="648" left="662" width="73" height="17" font="5">3.58 to 1.80) </text>
<text top="665" left="662" width="3" height="17" font="5"> </text>
<text top="682" left="662" width="232" height="17" font="5">vs. Multilevel strategy without team-based </text>
<text top="700" left="662" width="227" height="17" font="5">care: DBP -0.28 mm Hg (95% CI -2.84 to </text>
<text top="717" left="662" width="230" height="17" font="5">2.26); SBP -2.05 mm Hg (95% CI -5.53 to </text>
<text top="734" left="662" width="31" height="17" font="5">1.43) </text>
<text top="751" left="662" width="3" height="17" font="5"> </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="228" height="17" font="5">Vs. Health coaching: DBP -1.08 mm Hg (-</text>
<text top="108" left="662" width="230" height="17" font="5">2.29 to 0.14); SBP -3.22 mm Hg (95% CI -</text>
<text top="125" left="662" width="121" height="17" font="5">5.72 to -0.72, p&lt;0.05) </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="214" height="17" font="5">Vs. Electronic decision support system </text>
<text top="177" left="662" width="231" height="17" font="5">DBP -1.68 mm Hg (95% CI -2.65 to -0.72, </text>
<text top="194" left="662" width="210" height="17" font="5">p&lt;0.001); SBP -3.35 mm Hg (95% CI -</text>
<text top="211" left="662" width="121" height="17" font="5">5.75 to -0.96, p&lt;0.01) </text>
<text top="229" left="662" width="3" height="17" font="5"> </text>
<text top="246" left="662" width="232" height="17" font="5">Vs. Home blood pressure monitoring DBP </text>
<text top="263" left="662" width="202" height="17" font="5">-1.60 mm Hg (95% CI -2.71 to -0.48, </text>
<text top="280" left="662" width="231" height="17" font="5">p&lt;0.01); SBP -4.41 mm Hg (95% CI -6.50 </text>
<text top="297" left="662" width="101" height="17" font="5">to -2.32, p&lt;0.001) </text>
<text top="315" left="662" width="3" height="17" font="5"> </text>
<text top="332" left="662" width="221" height="17" font="5">Vs. Provider training: DBP -2.12 mm Hg </text>
<text top="349" left="662" width="209" height="17" font="5">(95% CI -3.57 to -0.68, p&lt;0.01); SBP -</text>
<text top="366" left="662" width="198" height="17" font="5">5.63 mm Hg (95% CI -8.57 to -2.69, </text>
<text top="383" left="662" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="401" left="662" width="3" height="17" font="5"> </text>
<text top="418" left="662" width="217" height="17" font="5">Vs. Audit and feedback: DBP -2.52 mm </text>
<text top="435" left="662" width="231" height="17" font="5">Hg (95% CI -3.54 to -1.51, p&lt;0.001); SBP </text>
<text top="452" left="662" width="202" height="17" font="5">-6.29 mm Hg (95% CI -8.52 to -4.05, </text>
<text top="469" left="662" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="487" left="75" width="58" height="17" font="5">CAPTION </text>
<text top="505" left="75" width="3" height="17" font="5"> </text>
<text top="522" left="75" width="88" height="17" font="5">Polgreen LA, et </text>
<text top="539" left="75" width="69" height="17" font="5">al., 2015 (9) </text>
<text top="556" left="75" width="3" height="17" font="5"> </text>
<text top="573" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26527048">26527048</a></text>
<text top="573" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26527048"> </a></text>
<text top="487" left="193" width="68" height="17" font="3"><b>Study Aim: </b></text>
<text top="505" left="193" width="3" height="17" font="5"> </text>
<text top="522" left="193" width="110" height="17" font="5">to examine the cost </text>
<text top="539" left="193" width="109" height="17" font="5">effectiveness of the </text>
<text top="556" left="193" width="67" height="17" font="5">intervention </text>
<text top="573" left="193" width="107" height="17" font="5">implemented in the </text>
<text top="591" left="193" width="85" height="17" font="5">CAPTION Trial </text>
<text top="608" left="193" width="3" height="17" font="5"> </text>
<text top="625" left="193" width="70" height="17" font="3"><b>Study type: </b></text>
<text top="642" left="193" width="119" height="17" font="5">Economic analysis of </text>
<text top="660" left="193" width="96" height="17" font="5">RCT intervention </text>
<text top="677" left="193" width="3" height="17" font="5"> </text>
<text top="694" left="193" width="40" height="17" font="5">N=625 </text>
<text top="488" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="506" left="324" width="196" height="18" font="5">•  Spoke either English or Spanish </text>
<text top="524" left="324" width="132" height="18" font="5">•  At least 18 years old </text>
<text top="543" left="324" width="187" height="18" font="5">•  Had uncontrolled hypertension </text>
<text top="561" left="325" width="186" height="17" font="5">(BP ≥ 140 mmHg systolic or ≥ 90 </text>
<text top="578" left="325" width="195" height="17" font="5">mmHg diastolic, or for patients with </text>
<text top="595" left="325" width="195" height="17" font="5">diabetes or chronic kidney disease, </text>
<text top="612" left="325" width="195" height="17" font="5">these cut offs were ≥ 130 and ≥ 80 </text>
<text top="630" left="325" width="44" height="17" font="5">mmHg) </text>
<text top="488" left="533" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="506" left="533" width="57" height="17" font="5">Physician-</text>
<text top="525" left="533" width="65" height="17" font="5">Pharmacist-</text>
<text top="543" left="533" width="109" height="17" font="5">collaborative model </text>
<text top="562" left="533" width="3" height="17" font="5"> </text>
<text top="580" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="599" left="533" width="62" height="17" font="5">Usual care </text>
<text top="618" left="533" width="3" height="17" font="5"> </text>
<text top="489" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="488" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="506" left="662" width="3" height="17" font="5"> </text>
<text top="523" left="662" width="94" height="17" font="5">Intervention cost </text>
<text top="540" left="662" width="197" height="17" font="5">Incremental cost-effectiveness ratio </text>
<text top="557" left="662" width="3" height="17" font="5"> </text>
<text top="575" left="662" width="232" height="17" font="7"><i>Health care costs: Intervention vs. Control </i></text>
<text top="592" left="662" width="3" height="17" font="5"> </text>
<text top="609" left="662" width="196" height="17" font="5">Changed hypertension medications </text>
<text top="626" left="662" width="170" height="17" font="5">$272.45 vs $170.75, p=0.0352 </text>
<text top="643" left="662" width="3" height="17" font="5"> </text>
<text top="661" left="662" width="206" height="17" font="5">Hypertension medication: $951.46 vs </text>
<text top="678" left="662" width="106" height="17" font="5">$972.52, p=0.7848 </text>
<text top="695" left="662" width="3" height="17" font="5"> </text>
<text top="712" left="662" width="220" height="17" font="5">Total drug cost: $1223.91 vs. $1146.27, </text>
<text top="730" left="662" width="55" height="17" font="5">p=0.4715 </text>
<text top="747" left="662" width="3" height="17" font="5"> </text>
<text top="764" left="662" width="230" height="17" font="5">Pharmacist cost: $140.62 vs. $0, p&lt;0.001 </text>
<text top="487" left="910" width="24" height="17" font="5">N/A </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="3" height="17" font="5"> </text>
<text top="108" left="662" width="197" height="17" font="5">Physician cost: $98.34 vs. $113.67, </text>
<text top="125" left="662" width="55" height="17" font="5">p=0.1774 </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="189" height="17" font="5">Total cost: $1462.87vs. $1259.94, </text>
<text top="177" left="662" width="55" height="17" font="5">p=0.0759 </text>
<text top="194" left="662" width="3" height="17" font="5"> </text>
<text top="211" left="662" width="104" height="17" font="7"><i>Cost effectiveness </i></text>
<text top="229" left="662" width="234" height="17" font="5">Compared to the control group, the cost to </text>
<text top="246" left="662" width="232" height="17" font="5">lower systolic BP by 1 mm Hg was $33.27 </text>
<text top="263" left="662" width="233" height="17" font="5">and to lower diastolic BP by 1 mm Hg was </text>
<text top="280" left="662" width="222" height="17" font="5">$69.98.  The cost to increase BP control </text>
<text top="297" left="662" width="212" height="17" font="5">by one percentage point was $22.55.   </text>
<text top="315" left="662" width="3" height="17" font="5"> </text>
<text top="332" left="662" width="179" height="17" font="5">In subgroup completing 9 month </text>
<text top="349" left="662" width="233" height="17" font="5">intervention, cost to lower systolic BP by 1 </text>
<text top="366" left="662" width="206" height="17" font="5">mm Hg was $38.82 and cost to lower </text>
<text top="383" left="662" width="232" height="17" font="5">diastolic BP by 1 mm Hg was $81.66. The </text>
<text top="401" left="662" width="190" height="17" font="5">cost to increase BP control by one </text>
<text top="418" left="662" width="161" height="17" font="5">percentage point was $26.31 </text>
<text top="435" left="662" width="3" height="17" font="5"> </text>
<text top="452" left="662" width="218" height="17" font="5">Using deflated drug costs, cost to lower </text>
<text top="469" left="662" width="233" height="17" font="5">systolic BP 1 mm Hg was $26.54 and cost </text>
<text top="487" left="662" width="193" height="17" font="5">to lower diastolic BP 1 mm Hg was </text>
<text top="504" left="662" width="203" height="17" font="5">$44.82. Deflated cost to increase BP </text>
<text top="521" left="662" width="201" height="17" font="5">control by one percentage point was </text>
<text top="538" left="662" width="41" height="17" font="5">$17.99 </text>
<text top="556" left="75" width="89" height="17" font="5">Proia KK, et al., </text>
<text top="573" left="75" width="56" height="17" font="5">2014 (10) </text>
<text top="591" left="75" width="3" height="17" font="5"> </text>
<text top="608" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24933494">24933494</a></text>
<text top="608" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24933494"> </a></text>
<text top="556" left="193" width="66" height="17" font="3"><b>Study aim: </b></text>
<text top="573" left="193" width="3" height="17" font="5"> </text>
<text top="591" left="193" width="88" height="17" font="5">To examine the </text>
<text top="608" left="193" width="89" height="17" font="5">effectiveness of </text>
<text top="625" left="193" width="109" height="17" font="5">team-based care in </text>
<text top="642" left="193" width="90" height="17" font="5">improving blood </text>
<text top="660" left="193" width="111" height="17" font="5">pressure  outcomes </text>
<text top="677" left="193" width="3" height="17" font="5"> </text>
<text top="694" left="193" width="70" height="17" font="3"><b>Study type: </b></text>
<text top="711" left="193" width="119" height="17" font="5">Systematic review  of </text>
<text top="728" left="193" width="59" height="17" font="5">RCTs and </text>
<text top="746" left="193" width="119" height="17" font="5">observational studies </text>
<text top="763" left="193" width="3" height="17" font="5"> </text>
<text top="556" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="575" left="324" width="196" height="18" font="5">•  Met the definition of team-based </text>
<text top="593" left="325" width="134" height="17" font="5">care as described in the </text>
<text top="610" left="325" width="127" height="17" font="5">conceptual framework; </text>
<text top="628" left="324" width="110" height="18" font="5">•  Were in English; </text>
<text top="646" left="324" width="155" height="18" font="5">•  Were not in the Walsh et </text>
<text top="664" left="325" width="101" height="17" font="5">al.(2006)  review;  </text>
<text top="681" left="324" width="161" height="18" font="5">•  Were conducted in a high-</text>
<text top="700" left="325" width="180" height="17" font="5">income economy consistent with </text>
<text top="717" left="325" width="156" height="17" font="5">Community Guide methods; </text>
<text top="734" left="324" width="158" height="18" font="5">•  Reported at least one BP </text>
<text top="752" left="325" width="194" height="17" font="5">outcome of interest (i.e., proportion </text>
<text top="769" left="325" width="165" height="17" font="5">of patients with controlled BP, </text>
<text top="556" left="533" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="575" left="533" width="99" height="17" font="5">Team based care </text>
<text top="594" left="533" width="111" height="17" font="5">(adding new staff or </text>
<text top="612" left="533" width="104" height="17" font="5">changing the roles </text>
<text top="631" left="533" width="99" height="17" font="5">of existing staff to </text>
<text top="649" left="533" width="109" height="17" font="5">work with a primary </text>
<text top="668" left="533" width="83" height="17" font="5">care provider) <b> </b></text>
<text top="686" left="533" width="3" height="17" font="5"> </text>
<text top="705" left="533" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="724" left="533" width="66" height="17" font="5">Usual care  </text>
<text top="742" left="533" width="3" height="17" font="5"> </text>
<text top="557" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="556" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="575" left="662" width="222" height="17" font="5">Proportion of patients with controlled BP </text>
<text top="592" left="662" width="218" height="17" font="5">(&lt;140/90 mm Hg or &lt;130/80 mm Hg for </text>
<text top="609" left="662" width="113" height="17" font="5">those with diabetes) </text>
<text top="626" left="662" width="3" height="17" font="5"> </text>
<text top="643" left="662" width="152" height="17" font="5">Reduction in SBP and DBP </text>
<text top="661" left="662" width="3" height="17" font="5"> </text>
<text top="678" left="662" width="229" height="17" font="7"><i>Proportion of patients with controlled BP:  </i></text>
<text top="695" left="662" width="213" height="17" font="5">Median effect estimate=12 percentage </text>
<text top="712" left="662" width="225" height="17" font="5">points (IQI=3.2-20.8 percentage points).  </text>
<text top="730" left="662" width="3" height="17" font="5"> </text>
<text top="747" left="662" width="217" height="17" font="5">By location: US=10.0 percentage point, </text>
<text top="764" left="662" width="179" height="17" font="5">Non-US=15.6 percentage points </text>
<text top="557" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="556" left="917" width="76" height="18" font="5"><b> endpoints: </b></text>
<text top="575" left="910" width="124" height="17" font="5">Medication adherence </text>
<text top="592" left="910" width="120" height="17" font="5">Satisfaction with care </text>
<text top="609" left="910" width="228" height="17" font="5">Changes in lipids and diabetes outcomes </text>
<text top="626" left="910" width="3" height="17" font="5"> </text>
<text top="643" left="910" width="124" height="17" font="7"><i>Medication adherence </i></text>
<text top="661" left="910" width="226" height="17" font="5">High medication adherence increased by </text>
<text top="678" left="910" width="186" height="17" font="5">median of 16.3 percentage points </text>
<text top="695" left="910" width="3" height="17" font="5"> </text>
<text top="712" left="910" width="120" height="17" font="7"><i>Satisfaction with care </i></text>
<text top="730" left="910" width="177" height="17" font="5">One of the two studies found an </text>
<text top="747" left="910" width="217" height="17" font="5">improvement of 14.0 percentage points </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="111" height="17" font="5">N=80 studies (n=52 </text>
<text top="108" left="193" width="87" height="17" font="5">newly identified </text>
<text top="125" left="193" width="97" height="17" font="5">studies and n=28 </text>
<text top="142" left="193" width="108" height="17" font="5">studies from Walsh </text>
<text top="160" left="193" width="65" height="17" font="5">et al, 2006) </text>
<text top="91" left="325" width="179" height="17" font="5">reduction in SBP, or reduction in </text>
<text top="108" left="325" width="36" height="17" font="5">DBP); </text>
<text top="125" left="324" width="194" height="18" font="5">•  Included a comparison group or </text>
<text top="143" left="325" width="167" height="17" font="5">had an interrupted time-series </text>
<text top="161" left="325" width="130" height="17" font="5">design with at least two </text>
<text top="178" left="325" width="195" height="17" font="5">measurements before and after the </text>
<text top="195" left="325" width="70" height="17" font="5">intervention; </text>
<text top="212" left="324" width="161" height="18" font="5">•  Targeted populations with </text>
<text top="230" left="325" width="133" height="17" font="5">primary hypertension or </text>
<text top="248" left="325" width="145" height="17" font="5">populations with comorbid </text>
<text top="265" left="325" width="171" height="17" font="5">conditions such as diabetes as </text>
<text top="282" left="325" width="175" height="17" font="5">long as the primary focus of the </text>
<text top="299" left="325" width="159" height="17" font="5">intervention was BP control;  </text>
<text top="317" left="324" width="193" height="18" font="5">•  Did not include populations with </text>
<text top="335" left="325" width="165" height="17" font="5">secondary hypertension (e.g., </text>
<text top="352" left="325" width="168" height="17" font="5">pregnancy) or with a history of </text>
<text top="369" left="325" width="185" height="17" font="5">CVD (e.g., myocardial infarction). </text>
<text top="387" left="325" width="3" height="17" font="5"> </text>
<text top="91" left="662" width="3" height="17" font="5"> </text>
<text top="108" left="662" width="189" height="17" font="5">By setting: Similar improvement in </text>
<text top="125" left="662" width="193" height="17" font="5">healthcare and community settings </text>
<text top="142" left="662" width="240" height="17" font="5">(median=12.0 percentage points for both).   </text>
<text top="160" left="662" width="3" height="17" font="5"> </text>
<text top="177" left="662" width="199" height="17" font="5">By team member added: Nurse=8.5 </text>
<text top="194" left="662" width="193" height="17" font="5">percentage point, pharmacist=22.0 </text>
<text top="211" left="662" width="146" height="17" font="5">percentage points, nurse+ </text>
<text top="229" left="662" width="199" height="17" font="5">pharmacist=16.2 percentage points, </text>
<text top="246" left="662" width="157" height="17" font="5">other=2.6 percentage points </text>
<text top="263" left="662" width="3" height="17" font="5"> </text>
<text top="280" left="662" width="216" height="17" font="5">By type of team member role related to </text>
<text top="297" left="662" width="234" height="17" font="5">medication: Independent=17.4 percentage </text>
<text top="315" left="662" width="215" height="17" font="5">points, PCP approval=15.0 percentage </text>
<text top="332" left="662" width="236" height="17" font="5">points, support only=7.9 percentage points </text>
<text top="349" left="662" width="3" height="17" font="5"> </text>
<text top="366" left="662" width="203" height="17" font="5">By number of team members added: </text>
<text top="383" left="662" width="221" height="17" font="5">PCP+ 1 team member=10.5 percentage </text>
<text top="401" left="662" width="199" height="17" font="5">points, PCP+2 team members=13.5 </text>
<text top="418" left="662" width="224" height="17" font="5">percentage points, PCP+3 or more team </text>
<text top="435" left="662" width="187" height="17" font="5">members=17.0 percentage points </text>
<text top="452" left="662" width="3" height="17" font="5"> </text>
<text top="469" left="662" width="199" height="17" font="5">By baseline level of percentage with </text>
<text top="487" left="662" width="226" height="17" font="5">controlled BP: 0=14.0 percentage points, </text>
<text top="504" left="662" width="209" height="17" font="5">≤50=14.0 percentage points, &gt;50=1.1 </text>
<text top="521" left="662" width="101" height="17" font="5">percentage points </text>
<text top="538" left="662" width="3" height="17" font="5"> </text>
<text top="556" left="662" width="100" height="17" font="7"><i>Reduction in SBP </i></text>
<text top="573" left="662" width="235" height="17" font="5">Median reduction=5.4 mm Hg (IQI=2.0-7.2 </text>
<text top="590" left="662" width="47" height="17" font="5">mm Hg) </text>
<text top="607" left="662" width="3" height="17" font="5"> </text>
<text top="624" left="662" width="216" height="17" font="5">By location: US=5.8 percentage points, </text>
<text top="642" left="662" width="173" height="17" font="5">Non-US=4.9 percentage points </text>
<text top="659" left="662" width="3" height="17" font="5"> </text>
<text top="676" left="662" width="216" height="17" font="5">By setting: Healthcare= 5.7 percentage </text>
<text top="693" left="662" width="232" height="17" font="5">points, Community-based=4.5 percentage </text>
<text top="710" left="662" width="43" height="17" font="5">points   </text>
<text top="728" left="662" width="3" height="17" font="5"> </text>
<text top="745" left="662" width="199" height="17" font="5">By team member added: Nurse=5.4 </text>
<text top="762" left="662" width="186" height="17" font="5">percentage point, pharmacist=5.0 </text>
<text top="91" left="910" width="225" height="17" font="5">(p&lt;0.001), while the other found similarly </text>
<text top="108" left="910" width="173" height="17" font="5">high satisfaction in both groups </text>
<text top="125" left="910" width="3" height="17" font="5"> </text>
<text top="142" left="910" width="206" height="17" font="7"><i>Total cholesterol</i>: -3 mg/dL change in </text>
<text top="160" left="910" width="223" height="17" font="5">mean, 13.0 percentage point increase in </text>
<text top="177" left="910" width="159" height="17" font="5">proportion of patients at goal </text>
<text top="194" left="910" width="3" height="17" font="5"> </text>
<text top="211" left="910" width="211" height="17" font="7"><i>LDL cholesterol</i>: -4.3 mg/dL change in </text>
<text top="229" left="910" width="216" height="17" font="5">mean, 3.2 percentage point increase in </text>
<text top="246" left="910" width="159" height="17" font="5">proportion of patients at goal </text>
<text top="263" left="910" width="3" height="17" font="5"> </text>
<text top="280" left="910" width="209" height="17" font="7"><i>HDL cholesterol</i>: 1.3 mg/dL change in </text>
<text top="297" left="910" width="214" height="17" font="5">mean, -6.0 percentage point change in </text>
<text top="315" left="910" width="159" height="17" font="5">proportion of patients at goal </text>
<text top="332" left="910" width="3" height="17" font="5"> </text>
<text top="349" left="910" width="195" height="17" font="7"><i>Triglycerides</i>: -7.9 mg/dL change in </text>
<text top="366" left="910" width="34" height="17" font="5">mean </text>
<text top="383" left="910" width="3" height="17" font="5"> </text>
<text top="401" left="910" width="217" height="17" font="7"><i>A1C level</i>: -0.3% change in mean, 10.0 </text>
<text top="418" left="910" width="217" height="17" font="5">percentage point increase in proportion </text>
<text top="435" left="910" width="101" height="17" font="5">of patients at goal </text>
<text top="452" left="910" width="3" height="17" font="5"> </text>
<text top="469" left="910" width="203" height="17" font="7"><i>Blood glucose</i>: -7.0 mg/dL change in </text>
<text top="487" left="910" width="34" height="17" font="5">mean </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="234" height="17" font="5">percentage points, nurse+ pharmacist=5.6 </text>
<text top="108" left="662" width="225" height="17" font="5">percentage points, other=3.2 percentage </text>
<text top="125" left="662" width="36" height="17" font="5">points </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="216" height="17" font="5">By type of team member role related to </text>
<text top="177" left="662" width="227" height="17" font="5">medication: Independent=7.2 percentage </text>
<text top="194" left="662" width="208" height="17" font="5">points, PCP approval=5.0 percentage </text>
<text top="211" left="662" width="236" height="17" font="5">points, support only=3.8 percentage points </text>
<text top="229" left="662" width="3" height="17" font="5"> </text>
<text top="246" left="662" width="203" height="17" font="5">By number of team members added: </text>
<text top="263" left="662" width="215" height="17" font="5">PCP+ 1 team member=5.6 percentage </text>
<text top="280" left="662" width="192" height="17" font="5">points, PCP+2 team members=5.3 </text>
<text top="297" left="662" width="224" height="17" font="5">percentage points, PCP+3 or more team </text>
<text top="315" left="662" width="180" height="17" font="5">members=5.9 percentage points </text>
<text top="332" left="662" width="3" height="17" font="5"> </text>
<text top="349" left="662" width="198" height="17" font="5">By baseline SBP: ≥140 mm Hg=5.9 </text>
<text top="366" left="662" width="203" height="17" font="5">percentage points, &lt;140 mm Hg=5.0 </text>
<text top="383" left="662" width="101" height="17" font="5">percentage points </text>
<text top="401" left="662" width="3" height="17" font="5"> </text>
<text top="418" left="662" width="100" height="17" font="7"><i>Reduction in DBP</i> </text>
<text top="435" left="662" width="235" height="17" font="5">Median reduction=1.8 mm Hg (IQI=0.7-3.2 </text>
<text top="452" left="662" width="47" height="17" font="5">mm Hg) </text>
<text top="469" left="662" width="3" height="17" font="5"> </text>
<text top="487" left="662" width="216" height="17" font="5">By location: US=1.8 percentage points, </text>
<text top="504" left="662" width="173" height="17" font="5">Non-US=1.7 percentage points </text>
<text top="521" left="662" width="3" height="17" font="5"> </text>
<text top="538" left="662" width="216" height="17" font="5">By setting: Healthcare= 1.8 percentage </text>
<text top="556" left="662" width="232" height="17" font="5">points, Community-based=0.5 percentage </text>
<text top="573" left="662" width="43" height="17" font="5">points   </text>
<text top="590" left="662" width="3" height="17" font="5"> </text>
<text top="607" left="662" width="199" height="17" font="5">By team member added: Nurse=2.9 </text>
<text top="624" left="662" width="186" height="17" font="5">percentage point, pharmacist=1.7 </text>
<text top="642" left="662" width="234" height="17" font="5">percentage points, nurse+ pharmacist=3.5 </text>
<text top="659" left="662" width="225" height="17" font="5">percentage points, other=0.4 percentage </text>
<text top="676" left="662" width="36" height="17" font="5">points </text>
<text top="693" left="662" width="3" height="17" font="5"> </text>
<text top="710" left="662" width="216" height="17" font="5">By type of team member role related to </text>
<text top="728" left="662" width="227" height="17" font="5">medication: Independent=3.5 percentage </text>
<text top="745" left="662" width="208" height="17" font="5">points, PCP approval=1.7 percentage </text>
<text top="762" left="662" width="236" height="17" font="5">points, support only=1.0 percentage points </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="3" height="17" font="5"> </text>
<text top="108" left="662" width="203" height="17" font="5">By number of team members added: </text>
<text top="125" left="662" width="215" height="17" font="5">PCP+ 1 team member=1.4 percentage </text>
<text top="142" left="662" width="192" height="17" font="5">points, PCP+2 team members=3.2 </text>
<text top="160" left="662" width="224" height="17" font="5">percentage points, PCP+3 or more team </text>
<text top="177" left="662" width="180" height="17" font="5">members=3.0 percentage points </text>
<text top="194" left="662" width="3" height="17" font="5"> </text>
<text top="211" left="662" width="192" height="17" font="5">By baseline DBP: ≥90 mm Hg=3.3 </text>
<text top="229" left="662" width="203" height="17" font="5">percentage points, &lt;140 mm Hg=1.6 </text>
<text top="246" left="662" width="101" height="17" font="5">percentage points </text>
<text top="263" left="662" width="3" height="17" font="5"> </text>
<text top="281" left="75" width="87" height="17" font="5">Buhse S, et al., </text>
<text top="298" left="75" width="31" height="17" font="5">2015 </text>
<text top="315" left="75" width="3" height="17" font="5"> </text>
<text top="333" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26567256">26567256</a></text>
<text top="333" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26567256"> </a></text>
<text top="281" left="193" width="66" height="17" font="3"><b>Study aim: </b></text>
<text top="298" left="193" width="85" height="17" font="5">To evaluate an </text>
<text top="315" left="193" width="92" height="17" font="5">informed shared </text>
<text top="333" left="193" width="88" height="17" font="5">decisionmaking </text>
<text top="350" left="193" width="114" height="17" font="5">programm (ISDM-P) </text>
<text top="367" left="193" width="120" height="17" font="5">for people with type 2 </text>
<text top="384" left="193" width="111" height="17" font="5">diabetes under high </text>
<text top="401" left="193" width="97" height="17" font="5">fidelity conditions </text>
<text top="419" left="193" width="3" height="17" font="5"> </text>
<text top="436" left="193" width="70" height="17" font="3"><b>Study type: </b></text>
<text top="453" left="193" width="96" height="17" font="5">Single blind RCT </text>
<text top="470" left="193" width="3" height="17" font="5"> </text>
<text top="487" left="193" width="43" height="17" font="5">N=154  </text>
<text top="281" left="325" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="300" left="324" width="156" height="18" font="5">•  registered in the German </text>
<text top="318" left="325" width="191" height="17" font="5">Disease Management Programme </text>
<text top="335" left="325" width="144" height="17" font="5">(DMP) for type 2 diabetes </text>
<text top="352" left="324" width="165" height="18" font="5">•  were 40–69 years old, had </text>
<text top="370" left="325" width="171" height="17" font="5">glycated haemoglobin (HbA1c) </text>
<text top="387" left="325" width="155" height="17" font="5">values between 6% and 9% </text>
<text top="405" left="324" width="169" height="18" font="5">•  had no history of ischaemic </text>
<text top="423" left="325" width="152" height="17" font="5">heart disease (International </text>
<text top="440" left="325" width="176" height="17" font="5">Classification of Diseases (ICD) </text>
<text top="458" left="325" width="151" height="17" font="5">I20-I25) or stroke (ICD I63) </text>
<text top="475" left="324" width="180" height="18" font="5">•  had previously participated in </text>
<text top="493" left="325" width="165" height="17" font="5">structured diabetes education </text>
<text top="510" left="325" width="165" height="17" font="5">sessions as typically provided </text>
<text top="527" left="325" width="86" height="17" font="5">within the DMP </text>
<text top="545" left="325" width="3" height="17" font="5"> </text>
<text top="563" left="325" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="582" left="324" width="176" height="18" font="5">•  had proliferative retinopathy, </text>
<text top="600" left="325" width="186" height="17" font="5">chronic kidney disease stage 3 or </text>
<text top="617" left="325" width="38" height="17" font="5">higher </text>
<text top="635" left="324" width="141" height="18" font="5">•  had metastatic cancer </text>
<text top="653" left="324" width="157" height="18" font="5">•  were addicted to alcohol  </text>
<text top="671" left="324" width="155" height="18" font="5">•  were cared for by a legal </text>
<text top="689" left="325" width="51" height="17" font="5">guardian </text>
<text top="706" left="325" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="78" height="17" font="3"><b>Intervention:</b> </text>
<text top="298" left="535" width="91" height="17" font="5">Evidence-based </text>
<text top="315" left="535" width="86" height="17" font="5">decision aid for </text>
<text top="333" left="535" width="84" height="17" font="5">patients on the </text>
<text top="350" left="535" width="106" height="17" font="5">prevention of heart </text>
<text top="367" left="535" width="98" height="17" font="5">attack, structured </text>
<text top="384" left="535" width="90" height="17" font="5">patient teaching </text>
<text top="401" left="535" width="74" height="17" font="5">provideed by </text>
<text top="419" left="535" width="111" height="17" font="5">diabetes educators, </text>
<text top="436" left="535" width="72" height="17" font="5">and provider </text>
<text top="453" left="535" width="83" height="17" font="5">training (n=77) </text>
<text top="470" left="535" width="3" height="17" font="3"><b> </b></text>
<text top="487" left="535" width="79" height="17" font="3"><b>Comparison: </b></text>
<text top="505" left="533" width="60" height="17" font="5">usual care </text>
<text top="523" left="533" width="106" height="17" font="5">supplemented with </text>
<text top="542" left="533" width="107" height="17" font="5">90 minute teaching </text>
<text top="561" left="533" width="101" height="17" font="5">module on sports, </text>
<text top="579" left="533" width="111" height="17" font="5">nutrition, and stress </text>
<text top="598" left="533" width="78" height="17" font="5">issues (n=77) </text>
<text top="282" left="662" width="7" height="17" font="3"><b>1</b></text>
<text top="281" left="668" width="69" height="18" font="5"><b> endpoint: </b></text>
<text top="299" left="662" width="212" height="17" font="5">Patient comprehension of relevant risk </text>
<text top="317" left="662" width="208" height="17" font="5">information after the teaching session </text>
<text top="334" left="662" width="3" height="17" font="5"> </text>
<text top="351" left="662" width="210" height="17" font="7"><i>Risk comprehension</i>: Mean difference </text>
<text top="368" left="662" width="214" height="17" font="5">between ISDM and control group=5.63 </text>
<text top="385" left="662" width="159" height="17" font="5">(95% CI 4.82-6.44, p&lt;0.001) </text>
<text top="403" left="662" width="3" height="17" font="5"> </text>
<text top="420" left="662" width="217" height="17" font="7"><i>Realistic expectations</i>: Mean difference </text>
<text top="437" left="662" width="214" height="17" font="5">between ISDM and control group=3.67 </text>
<text top="454" left="662" width="159" height="17" font="5">(95% CI 3.23-4.11, p&lt;0.001) </text>
<text top="471" left="662" width="3" height="17" font="5"> </text>
<text top="489" left="662" width="234" height="17" font="7"><i>Sufficient risk comprehension</i>: Percentage </text>
<text top="506" left="662" width="208" height="17" font="5">difference between ISDM and Control </text>
<text top="523" left="662" width="224" height="17" font="5">group=48.6% (95% CI 37.0% vs. 60.2%, </text>
<text top="540" left="662" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="282" left="910" width="7" height="17" font="3"><b>2</b></text>
<text top="281" left="917" width="76" height="18" font="5"><b> endpoints: </b></text>
<text top="299" left="910" width="191" height="17" font="5">Comprehension, including realistic </text>
<text top="317" left="910" width="144" height="17" font="5">expectations, at 6 months </text>
<text top="334" left="910" width="3" height="17" font="5"> </text>
<text top="351" left="910" width="219" height="17" font="5">Adherence to individual treatment goals </text>
<text top="368" left="910" width="215" height="17" font="5">related to use of statins, levels of office </text>
<text top="385" left="910" width="223" height="17" font="5">systolic blood pressure, and HbA1c, and </text>
<text top="403" left="910" width="49" height="17" font="5">smoking </text>
<text top="420" left="910" width="3" height="17" font="5"> </text>
<text top="437" left="910" width="221" height="17" font="5">Adherence to prioritized treatment goals </text>
<text top="454" left="910" width="197" height="17" font="5">related to statin uptake, office blood </text>
<text top="471" left="910" width="206" height="17" font="5">pressure values, and HbA1c levels at </text>
<text top="489" left="910" width="206" height="17" font="5">follow up with the treatment goals the </text>
<text top="506" left="910" width="219" height="17" font="5">patients set and prioritized at the end of </text>
<text top="523" left="910" width="116" height="17" font="5">the teaching session </text>
<text top="540" left="910" width="3" height="17" font="5"> </text>
<text top="557" left="910" width="115" height="17" font="7"><i>Risk comprehension </i></text>
<text top="575" left="910" width="199" height="17" font="5">Mean difference=0.98 (95% CI 0.15-</text>
<text top="592" left="910" width="83" height="17" font="5">1.80, p=0.021) </text>
<text top="609" left="910" width="3" height="17" font="5"> </text>
<text top="626" left="910" width="122" height="17" font="7"><i>Realistic expectations </i></text>
<text top="643" left="910" width="199" height="17" font="5">Mean difference=0.51 (95% CI 0.09-</text>
<text top="661" left="910" width="83" height="17" font="5">0.93, p=0.018) </text>
<text top="678" left="910" width="3" height="17" font="5"> </text>
<text top="695" left="910" width="170" height="17" font="7"><i>Treatment goals after teaching </i></text>
<text top="712" left="910" width="216" height="17" font="5">Taking statins: mean difference=28.7% </text>
<text top="730" left="910" width="162" height="17" font="5">(95% CI: 12.9-44.5, p=0.001) </text>
<text top="747" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="910" width="215" height="17" font="5">Stop smoking: mean difference=13.6% </text>
<text top="108" left="910" width="179" height="17" font="5">(95% CI: -31.2 to 58.5, p=0.552) </text>
<text top="125" left="910" width="3" height="17" font="5"> </text>
<text top="142" left="910" width="216" height="17" font="5">Average group systolic blood pressure: </text>
<text top="160" left="910" width="224" height="17" font="5">mean difference= -0.9 %(95% CI: -3.5 to </text>
<text top="177" left="910" width="76" height="17" font="5">1.7, p=0.419) </text>
<text top="194" left="910" width="3" height="17" font="5"> </text>
<text top="211" left="910" width="162" height="17" font="5">Average group HbA1c: mean </text>
<text top="229" left="910" width="221" height="17" font="5">difference=0.07 (-0.11 to 0.25, p=0.492) </text>
<text top="246" left="910" width="3" height="17" font="5"> </text>
<text top="263" left="910" width="200" height="17" font="7"><i>Achievement of treatment goals at 6 </i></text>
<text top="280" left="910" width="223" height="17" font="7"><i>months (mean difference between ISDM </i></text>
<text top="297" left="910" width="110" height="17" font="7"><i>and control group):  </i></text>
<text top="315" left="910" width="3" height="17" font="5"> </text>
<text top="332" left="910" width="212" height="17" font="5">Statin: 7.6% (95% CI: -3.4% to 18.6%, </text>
<text top="349" left="910" width="52" height="17" font="5">p=0.203) </text>
<text top="366" left="910" width="3" height="17" font="5"> </text>
<text top="383" left="910" width="221" height="17" font="5">Blood pressure value between 80-120% </text>
<text top="401" left="910" width="225" height="17" font="5">of defined goal: -2.4% (-17.7% to 12.9%, </text>
<text top="418" left="910" width="52" height="17" font="5">p=0.856) </text>
<text top="435" left="910" width="3" height="17" font="5"> </text>
<text top="452" left="910" width="222" height="17" font="5">HbA1c: 10.1% (95% CI 0.6% vs. 19.5%, </text>
<text top="469" left="910" width="52" height="17" font="5">p=0.046) </text>
<text top="487" left="910" width="3" height="17" font="5"> </text>
<text top="504" left="910" width="188" height="17" font="5">Smoking: -8.3% (95% CI -52.9% - </text>
<text top="521" left="910" width="94" height="17" font="5">36.2%, p=1.000) </text>
<text top="538" left="910" width="3" height="17" font="5"> </text>
<text top="556" left="910" width="214" height="17" font="5">Prioritized goal: -3.4% (95% CI -15.3%-</text>
<text top="573" left="910" width="87" height="17" font="5">8.5%, p=0.627) </text>
<text top="591" left="75" width="99" height="17" font="5">Cooper LA, et al., </text>
<text top="608" left="75" width="31" height="17" font="5">2011 </text>
<text top="625" left="75" width="3" height="17" font="5"> </text>
<text top="642" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21732195">21732195</a></text>
<text top="642" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21732195"> </a></text>
<text top="591" left="193" width="59" height="17" font="5">Study Aim </text>
<text top="608" left="193" width="90" height="17" font="5">To compare the </text>
<text top="625" left="193" width="89" height="17" font="5">effectiveness of </text>
<text top="642" left="193" width="92" height="17" font="5">patient centered </text>
<text top="660" left="193" width="73" height="17" font="5">interventions </text>
<text top="677" left="193" width="98" height="17" font="5">targeting patients </text>
<text top="694" left="193" width="85" height="17" font="5">and physicians </text>
<text top="711" left="193" width="46" height="17" font="5">with the </text>
<text top="728" left="193" width="89" height="17" font="5">effectiveness of </text>
<text top="746" left="193" width="119" height="17" font="5">minimal interventions </text>
<text top="591" left="325" width="62" height="17" font="7"><i>Physicians </i></text>
<text top="609" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="628" left="324" width="173" height="18" font="5">•  general internists and family </text>
<text top="646" left="325" width="172" height="17" font="5">physicians who saw patients at </text>
<text top="663" left="325" width="185" height="17" font="5">least 20 hours per week at one of </text>
<text top="681" left="325" width="155" height="17" font="5">the participating study sites. </text>
<text top="698" left="325" width="3" height="17" font="5"> </text>
<text top="716" left="325" width="99" height="17" font="5">Exclusion Criteria </text>
<text top="735" left="324" width="171" height="18" font="5">•  Physicians were excluded if </text>
<text top="753" left="325" width="191" height="17" font="5">they intended to leave the practice </text>
<text top="770" left="325" width="96" height="17" font="5">within 12 months </text>
<text top="591" left="535" width="62" height="17" font="7"><i>Physicians </i></text>
<text top="608" left="535" width="68" height="17" font="5">Intervention </text>
<text top="625" left="535" width="56" height="17" font="5">Physician </text>
<text top="642" left="535" width="86" height="17" font="5">communication </text>
<text top="660" left="535" width="104" height="17" font="5">skills program with </text>
<text top="677" left="535" width="73" height="17" font="5">personalized </text>
<text top="694" left="535" width="107" height="17" font="5">feedback based on </text>
<text top="711" left="535" width="63" height="17" font="5">videotaped </text>
<text top="728" left="535" width="98" height="17" font="5">performance with </text>
<text top="746" left="535" width="107" height="17" font="5">simulated patient.   </text>
<text top="763" left="535" width="3" height="17" font="5"> </text>
<text top="592" left="662" width="7" height="17" font="5">1</text>
<text top="591" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="609" left="662" width="207" height="17" font="5">-Physician Communication Behaviors </text>
<text top="626" left="662" width="169" height="17" font="5">-Patient Ratings of Physicians’ </text>
<text top="643" left="662" width="197" height="17" font="5">Participatory Decision-Making Style </text>
<text top="661" left="662" width="159" height="17" font="5">-Patient Involvement in Care </text>
<text top="678" left="662" width="206" height="17" font="5">-Systolic and diastolic blood pressure </text>
<text top="695" left="662" width="131" height="17" font="5">-Blood pressure control </text>
<text top="712" left="662" width="3" height="17" font="5"> </text>
<text top="730" left="662" width="203" height="17" font="7"><i>Physician Communication Behaviors </i></text>
<text top="747" left="662" width="3" height="17" font="5"> </text>
<text top="592" left="910" width="7" height="17" font="5">2</text>
<text top="591" left="917" width="60" height="18" font="5"> endpoint </text>
<text top="609" left="910" width="85" height="17" font="5">None specified </text>
<text top="626" left="910" width="3" height="17" font="5"> </text>
<text top="643" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="90" height="17" font="5">for underserved </text>
<text top="108" left="193" width="44" height="17" font="5">groups. </text>
<text top="125" left="193" width="3" height="17" font="5"> </text>
<text top="142" left="193" width="62" height="17" font="5">Study type </text>
<text top="160" left="193" width="29" height="17" font="5">RCT </text>
<text top="177" left="193" width="3" height="17" font="5"> </text>
<text top="194" left="193" width="97" height="17" font="5">N=41 physicians, </text>
<text top="211" left="193" width="87" height="17" font="5">N=279 patients </text>
<text top="91" left="325" width="3" height="17" font="5"> </text>
<text top="109" left="325" width="48" height="17" font="7"><i>Patients </i></text>
<text top="128" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="147" left="324" width="187" height="18" font="5">•  Patients recruited for the study </text>
<text top="165" left="325" width="171" height="17" font="5">were adults aged 18 years and </text>
<text top="182" left="325" width="31" height="17" font="5">older </text>
<text top="199" left="324" width="177" height="18" font="5">•  diagnosis of hypertension (at </text>
<text top="217" left="325" width="167" height="17" font="5">least one claim with the ICD-9 </text>
<text top="235" left="325" width="176" height="17" font="5">code 401 in the preceding year) </text>
<text top="252" left="324" width="144" height="18" font="5">•  able to provide contact </text>
<text top="270" left="325" width="185" height="17" font="5">information for themselves and at </text>
<text top="287" left="325" width="129" height="17" font="5">least one other person. </text>
<text top="305" left="325" width="3" height="17" font="5"> </text>
<text top="323" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="342" left="324" width="176" height="18" font="5">•  too acutely ill, disoriented, or </text>
<text top="360" left="325" width="164" height="17" font="5">unresponsive to complete the </text>
<text top="377" left="325" width="122" height="17" font="5">baseline assessment  </text>
<text top="394" left="325" width="187" height="17" font="5">medical conditions that might limit </text>
<text top="413" left="325" width="167" height="17" font="5">participation in the study (e.g., </text>
<text top="432" left="325" width="182" height="17" font="5">AIDS/HIV, schizophrenia, cancer </text>
<text top="450" left="325" width="189" height="17" font="5">(except skin), Alzheimer’s or other </text>
<text top="469" left="325" width="188" height="17" font="5">form of dementia; end-stage renal </text>
<text top="487" left="325" width="183" height="17" font="5">disease, congestive heart failure, </text>
<text top="506" left="325" width="127" height="17" font="5">or active tuberculosis)  </text>
<text top="91" left="535" width="70" height="17" font="5">Comparison </text>
<text top="108" left="535" width="100" height="17" font="5">No feedback after </text>
<text top="125" left="535" width="63" height="17" font="5">videotaped </text>
<text top="142" left="535" width="98" height="17" font="5">performance with </text>
<text top="160" left="535" width="103" height="17" font="5">simulated patient.  </text>
<text top="177" left="535" width="3" height="17" font="5"> </text>
<text top="207" left="535" width="48" height="17" font="7"><i>Patients </i></text>
<text top="238" left="535" width="68" height="17" font="5">Intervention </text>
<text top="268" left="535" width="108" height="17" font="5">Patient intervention </text>
<text top="286" left="535" width="96" height="17" font="5">included pre-visit </text>
<text top="303" left="535" width="53" height="17" font="5">coaching </text>
<text top="320" left="535" width="3" height="17" font="5"> </text>
<text top="337" left="535" width="70" height="17" font="5">Comparison </text>
<text top="355" left="535" width="35" height="17" font="5">Usual </text>
<text top="372" left="535" width="90" height="17" font="5">care+newsletter </text>
<text top="389" left="535" width="86" height="17" font="5">(received by all </text>
<text top="406" left="535" width="103" height="17" font="5">study participants) </text>
<text top="423" left="535" width="3" height="17" font="5"> </text>
<text top="454" left="590" width="3" height="17" font="5"> </text>
<text top="485" left="590" width="3" height="17" font="5"> </text>
<text top="515" left="535" width="3" height="17" font="5"> </text>
<text top="91" left="662" width="218" height="17" font="5">Verbal dominance: Change in Intensive </text>
<text top="108" left="662" width="229" height="17" font="5">vs. Minimal physician intervention group: -</text>
<text top="125" left="662" width="128" height="17" font="5">1.67 vs. -1.94 (p=0.35) </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="209" height="17" font="5">Patient Centerdness ratio: Change in  </text>
<text top="177" left="662" width="172" height="17" font="5">Intensive vs. Minimal physician </text>
<text top="194" left="662" width="226" height="17" font="5">intervention group -0.52 vs. -0.82, p-0.04 </text>
<text top="211" left="662" width="3" height="17" font="9"> </text>
<text top="229" left="662" width="229" height="17" font="7"><i>Participatory Decision Making: Change at </i></text>
<text top="246" left="662" width="61" height="17" font="7"><i>12 months </i></text>
<text top="263" left="662" width="230" height="17" font="5">Physician+Patient Intensive: 6.2 (95% CI -</text>
<text top="280" left="662" width="233" height="17" font="5">0.5-12.9, p compared to physician+patient </text>
<text top="297" left="662" width="81" height="17" font="5">minimal=0.03) </text>
<text top="315" left="662" width="3" height="17" font="5"> </text>
<text top="332" left="662" width="222" height="17" font="5">Physician minimal/patient intensive: -3.2 </text>
<text top="349" left="662" width="186" height="17" font="5">(95% CI -4.8-11.3, p compared to </text>
<text top="366" left="662" width="183" height="17" font="5">physician+patient minimal =0.13) </text>
<text top="383" left="662" width="3" height="17" font="5"> </text>
<text top="401" left="662" width="222" height="17" font="5">Physician intensive/patient minimal: -3.1 </text>
<text top="418" left="662" width="186" height="17" font="5">(95% CI -3.9-10.2, p compared to </text>
<text top="435" left="662" width="183" height="17" font="5">physician+patient minimal =0.12) </text>
<text top="452" left="662" width="3" height="17" font="5"> </text>
<text top="469" left="662" width="229" height="17" font="5">Physician+patient minimal: -5.2 (95% CI: -</text>
<text top="487" left="662" width="53" height="17" font="5">13.0-2.5) </text>
<text top="504" left="662" width="3" height="17" font="9"> </text>
<text top="521" left="662" width="155" height="17" font="7"><i>Patient Involvement in Care </i></text>
<text top="538" left="662" width="3" height="17" font="7"><i> </i></text>
<text top="556" left="662" width="222" height="17" font="5">Doctor facilitation: Change at 12 months </text>
<text top="573" left="662" width="233" height="17" font="5">Physician+Patient Intensive: 0.22 (95% CI </text>
<text top="590" left="662" width="141" height="17" font="5">0.00-0.43, p compared to </text>
<text top="607" left="662" width="180" height="17" font="5">physician+patient minimal=0.03) </text>
<text top="624" left="662" width="3" height="17" font="5"> </text>
<text top="642" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="659" left="662" width="220" height="17" font="5">0.12 (95% CI -0.15-0.39, p compared to </text>
<text top="676" left="662" width="183" height="17" font="5">physician+patient minimal =0.11) </text>
<text top="693" left="662" width="3" height="17" font="5"> </text>
<text top="710" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="728" left="662" width="220" height="17" font="5">0.09 (95% CI -0.14-0.33, p compared to </text>
<text top="745" left="662" width="183" height="17" font="5">physician+patient minimal =0.14) </text>
<text top="762" left="662" width="3" height="17" font="5"> </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="232" height="17" font="5">Physician+patient minimal: -0.17 (95% CI: </text>
<text top="108" left="662" width="64" height="17" font="5">-0.43-0.09) </text>
<text top="125" left="662" width="3" height="17" font="9"> </text>
<text top="142" left="662" width="200" height="17" font="5">Information exchange: change at 12 </text>
<text top="160" left="662" width="47" height="17" font="5">months  </text>
<text top="177" left="662" width="3" height="17" font="9"> </text>
<text top="194" left="662" width="233" height="17" font="5">Physician+Patient Intensive: 0.32 (95% CI </text>
<text top="211" left="662" width="141" height="17" font="5">0.08-0.56, p compared to </text>
<text top="229" left="662" width="187" height="17" font="5">physician+patient minimal=0.005) </text>
<text top="246" left="662" width="3" height="17" font="5"> </text>
<text top="263" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="280" left="662" width="220" height="17" font="5">0.16 (95% CI -0.14-0.45, p compared to </text>
<text top="297" left="662" width="183" height="17" font="5">physician+patient minimal =0.08) </text>
<text top="315" left="662" width="3" height="17" font="5"> </text>
<text top="332" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="349" left="662" width="220" height="17" font="5">0.13 (95% CI -0.13-0.38, p compared to </text>
<text top="366" left="662" width="183" height="17" font="5">physician+patient minimal =0.08) </text>
<text top="383" left="662" width="3" height="17" font="5"> </text>
<text top="401" left="662" width="232" height="17" font="5">Physician+patient minimal: -0.22 (95% CI: </text>
<text top="418" left="662" width="64" height="17" font="5">-0.51-0.07) </text>
<text top="435" left="662" width="3" height="17" font="9"> </text>
<text top="452" left="662" width="211" height="17" font="5">Patient decision making: change at 12 </text>
<text top="469" left="662" width="47" height="17" font="5">months  </text>
<text top="487" left="662" width="3" height="17" font="9"> </text>
<text top="504" left="662" width="233" height="17" font="5">Physician+Patient Intensive: 0.21 (95% CI </text>
<text top="521" left="662" width="145" height="17" font="5">-0.03-0.44, p compared to </text>
<text top="538" left="662" width="180" height="17" font="5">physician+patient minimal=0.08) </text>
<text top="556" left="662" width="3" height="17" font="5"> </text>
<text top="573" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="590" left="662" width="220" height="17" font="5">0.07 (95% CI -0.23-0.36, p compared to </text>
<text top="607" left="662" width="183" height="17" font="5">physician+patient minimal =0.35) </text>
<text top="624" left="662" width="3" height="17" font="5"> </text>
<text top="642" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="659" left="662" width="220" height="17" font="5">0.16 (95% CI -0.10-0.41, p compared to </text>
<text top="676" left="662" width="183" height="17" font="5">physician+patient minimal =0.14) </text>
<text top="693" left="662" width="3" height="17" font="5"> </text>
<text top="710" left="662" width="232" height="17" font="5">Physician+patient minimal: -0.13 (95% CI: </text>
<text top="728" left="662" width="64" height="17" font="5">-0.42-0.16) </text>
<text top="745" left="662" width="3" height="17" font="5"> </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="233" height="17" font="5">Medication adherence on Morisky scale at </text>
<text top="108" left="662" width="64" height="17" font="5">12 months: </text>
<text top="125" left="662" width="3" height="17" font="5"> </text>
<text top="142" left="662" width="233" height="17" font="5">Physician+Patient Intensive: 0.75 (95% CI </text>
<text top="160" left="662" width="145" height="17" font="5">-0.62-0.84, p compared to </text>
<text top="177" left="662" width="180" height="17" font="5">physician+patient minimal=0.75) </text>
<text top="194" left="662" width="3" height="17" font="5"> </text>
<text top="211" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="229" left="662" width="220" height="17" font="5">0.80 (95% CI -0.65-0.90, p compared to </text>
<text top="246" left="662" width="183" height="17" font="5">physician+patient minimal =0.76) </text>
<text top="263" left="662" width="3" height="17" font="5"> </text>
<text top="280" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="297" left="662" width="220" height="17" font="5">0.66 (95% CI -0.53-0.77, p compared to </text>
<text top="315" left="662" width="183" height="17" font="5">physician+patient minimal =0.22) </text>
<text top="332" left="662" width="3" height="17" font="5"> </text>
<text top="349" left="662" width="232" height="17" font="5">Physician+patient minimal: 0.77 (95% CI: -</text>
<text top="366" left="662" width="60" height="17" font="5">0.63-0.87) </text>
<text top="383" left="662" width="3" height="17" font="5"> </text>
<text top="401" left="662" width="190" height="17" font="7"><i>Systolic BP: Change at 12 months </i></text>
<text top="418" left="662" width="3" height="17" font="5"> </text>
<text top="435" left="662" width="42" height="17" font="5">Overall </text>
<text top="452" left="662" width="3" height="17" font="5"> </text>
<text top="469" left="662" width="230" height="17" font="5">Physician+Patient Intensive: -2.8 (95% CI </text>
<text top="487" left="662" width="230" height="17" font="5">-9.5-3.8, p compared to physician+patient </text>
<text top="504" left="662" width="81" height="17" font="5">minimal=0.58) </text>
<text top="521" left="662" width="3" height="17" font="5"> </text>
<text top="538" left="662" width="222" height="17" font="5">Physician minimal/patient intensive: -6.5 </text>
<text top="556" left="662" width="186" height="17" font="5">(95% CI -14.2-1.2, p compared to </text>
<text top="573" left="662" width="183" height="17" font="5">physician+patient minimal =0.24) </text>
<text top="590" left="662" width="3" height="17" font="5"> </text>
<text top="607" left="662" width="222" height="17" font="5">Physician intensive/patient minimal: -2.3 </text>
<text top="624" left="662" width="175" height="17" font="5">(95% CI 8.7-4.0, p compared to </text>
<text top="642" left="662" width="183" height="17" font="5">physician+patient minimal =0.65) </text>
<text top="659" left="662" width="3" height="17" font="5"> </text>
<text top="676" left="662" width="229" height="17" font="5">Physician+patient minimal: -0.1 (95% CI: -</text>
<text top="693" left="662" width="46" height="17" font="5">7.5-7.4) </text>
<text top="710" left="662" width="3" height="17" font="5"> </text>
<text top="728" left="662" width="135" height="17" font="5">Uncontrolled at baseline </text>
<text top="745" left="662" width="3" height="17" font="5"> </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="221" height="17" font="5">Physician+Patient Intensive: -13.2 (95% </text>
<text top="108" left="662" width="171" height="17" font="5">CI -23.1 to -3.4, p compared to </text>
<text top="125" left="662" width="180" height="17" font="5">physician+patient minimal=0.14) </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="177" left="662" width="235" height="17" font="5">-16.8 (95% CI -28.0 to -5.6, p compared to </text>
<text top="194" left="662" width="183" height="17" font="5">physician+patient minimal =0.07) </text>
<text top="211" left="662" width="3" height="17" font="5"> </text>
<text top="229" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="246" left="662" width="231" height="17" font="5">-10.6 (95% CI -21.5 to 0.3, p compared to </text>
<text top="263" left="662" width="183" height="17" font="5">physician+patient minimal =0.27) </text>
<text top="280" left="662" width="3" height="17" font="5"> </text>
<text top="297" left="662" width="229" height="17" font="5">Physician+patient minimal: -2.0 (95% CI: -</text>
<text top="315" left="662" width="66" height="17" font="5">13.2 to 9.2) </text>
<text top="332" left="662" width="3" height="17" font="5"> </text>
<text top="349" left="662" width="194" height="17" font="7"><i>Diastolic BP: Change at 12 months </i></text>
<text top="366" left="662" width="3" height="17" font="7"><i> </i></text>
<text top="383" left="662" width="42" height="17" font="5">Overall </text>
<text top="401" left="662" width="226" height="17" font="5">Physician+Patient Intensive: 0.2 (95% CI </text>
<text top="418" left="662" width="226" height="17" font="5">3.7-4.1, p compared to physician+patient </text>
<text top="435" left="662" width="74" height="17" font="5">minimal=1.0) </text>
<text top="452" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="469" left="662" width="204" height="17" font="5">-0.9 (95% CI -5.4-3.6, p compared to </text>
<text top="487" left="662" width="183" height="17" font="5">physician+patient minimal =0.72) </text>
<text top="504" left="662" width="3" height="17" font="5"> </text>
<text top="521" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="538" left="662" width="206" height="17" font="5">-1.4 (95% CI –5.1-2.3, p compared to </text>
<text top="556" left="662" width="183" height="17" font="5">physician+patient minimal =0.57) </text>
<text top="573" left="662" width="3" height="17" font="5"> </text>
<text top="590" left="662" width="225" height="17" font="5">Physician+patient minimal: 0.2 (95% CI: -</text>
<text top="607" left="662" width="46" height="17" font="5">4.1-4.6) </text>
<text top="624" left="662" width="3" height="17" font="5"> </text>
<text top="642" left="662" width="135" height="17" font="5">Uncontrolled at baseline </text>
<text top="659" left="662" width="3" height="17" font="5"> </text>
<text top="676" left="662" width="230" height="17" font="5">Physician+Patient Intensive: -5.2 (95% CI </text>
<text top="693" left="662" width="138" height="17" font="5">-11.1-0.7, p compared to </text>
<text top="710" left="662" width="180" height="17" font="5">physician+patient minimal=0.24) </text>
<text top="728" left="662" width="3" height="17" font="5"> </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="108" left="662" width="211" height="17" font="5">-5.4 (95% CI -12.1-1.3, p compared to </text>
<text top="125" left="662" width="183" height="17" font="5">physician+patient minimal =0.26) </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="177" left="662" width="213" height="17" font="5">-5.2 (95% CI –11.7-1.3, p compared to </text>
<text top="194" left="662" width="183" height="17" font="5">physician+patient minimal =0.27) </text>
<text top="211" left="662" width="3" height="17" font="5"> </text>
<text top="229" left="662" width="225" height="17" font="5">Physician+patient minimal: 0.0 (95% CI: -</text>
<text top="246" left="662" width="59" height="17" font="5">6.7 to 6.7) </text>
<text top="263" left="662" width="3" height="17" font="5"> </text>
<text top="280" left="662" width="197" height="17" font="7"><i>% with BP controlled: Change at 12 </i></text>
<text top="297" left="662" width="44" height="17" font="7"><i>months </i></text>
<text top="315" left="662" width="3" height="17" font="5"> </text>
<text top="332" left="662" width="42" height="17" font="5">Overall </text>
<text top="349" left="662" width="233" height="17" font="5">Physician+Patient Intensive: 0.53 (95% CI </text>
<text top="366" left="662" width="141" height="17" font="5">0.38-0.68, p compared to </text>
<text top="383" left="662" width="180" height="17" font="5">physician+patient minimal=0.92) </text>
<text top="401" left="662" width="3" height="17" font="5"> </text>
<text top="418" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="435" left="662" width="216" height="17" font="5">0.61 (95% CI 0.43-0.77, p compared to </text>
<text top="452" left="662" width="183" height="17" font="5">physician+patient minimal =0.58) </text>
<text top="469" left="662" width="3" height="17" font="5"> </text>
<text top="487" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="504" left="662" width="216" height="17" font="5">0.65 (95% CI 0.50-0.78, p compared to </text>
<text top="521" left="662" width="183" height="17" font="5">physician+patient minimal =0.35) </text>
<text top="538" left="662" width="3" height="17" font="5"> </text>
<text top="556" left="662" width="228" height="17" font="5">Physician+patient minimal: 0.55 (95% CI: </text>
<text top="573" left="662" width="60" height="17" font="5">0.37-0.71) </text>
<text top="590" left="662" width="3" height="17" font="5"> </text>
<text top="607" left="662" width="3" height="17" font="5"> </text>
<text top="624" left="662" width="135" height="17" font="5">Uncontrolled at baseline </text>
<text top="642" left="662" width="3" height="17" font="5"> </text>
<text top="659" left="662" width="233" height="17" font="5">Physician+Patient Intensive: 0.44 (95% CI </text>
<text top="676" left="662" width="141" height="17" font="5">0.19-0.73, p compared to </text>
<text top="693" left="662" width="180" height="17" font="5">physician+patient minimal=0.52) </text>
<text top="710" left="662" width="3" height="17" font="5"> </text>
<text top="728" left="662" width="201" height="17" font="5">Physician minimal/patient intensive:  </text>
<text top="745" left="662" width="216" height="17" font="5">0.63 (95% CI 0.28-0.88, p compared to </text>
<text top="762" left="662" width="183" height="17" font="5">physician+patient minimal =0.15) </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="3" height="17" font="5"> </text>
<text top="108" left="662" width="201" height="17" font="5">Physician intensive/patient minimal:  </text>
<text top="125" left="662" width="216" height="17" font="5">0.39 (95% CI 0.17-0.67, p compared to </text>
<text top="142" left="662" width="183" height="17" font="5">physician+patient minimal =0.67) </text>
<text top="160" left="662" width="3" height="17" font="5"> </text>
<text top="177" left="662" width="228" height="17" font="5">Physician+patient minimal: 0.31 (95% CI: </text>
<text top="194" left="662" width="60" height="17" font="5">0.11-0.63) </text>
<text top="212" left="75" width="97" height="17" font="5">Beauchamp, A et </text>
<text top="229" left="75" width="51" height="17" font="5">al., 2010 </text>
<text top="247" left="75" width="3" height="17" font="5"> </text>
<text top="264" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20562629">20562629</a></text>
<text top="264" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20562629"> </a></text>
<text top="212" left="193" width="81" height="17" font="5">Study Aim: To </text>
<text top="229" left="193" width="105" height="17" font="5">determine whether </text>
<text top="247" left="193" width="113" height="17" font="5">key interventions for </text>
<text top="264" left="193" width="114" height="17" font="5">CVD prevention and </text>
<text top="281" left="193" width="77" height="17" font="5">treatment are </text>
<text top="298" left="193" width="90" height="17" font="5">effective among </text>
<text top="315" left="193" width="117" height="17" font="5">lower socioeconomic </text>
<text top="333" left="193" width="108" height="17" font="5">groups, to describe </text>
<text top="350" left="193" width="86" height="17" font="5">barriers to their </text>
<text top="367" left="193" width="119" height="17" font="5">effectiveness and the </text>
<text top="384" left="193" width="100" height="17" font="5">potential or actual </text>
<text top="401" left="193" width="87" height="17" font="5">impact of these </text>
<text top="419" left="193" width="111" height="17" font="5">interventions on the </text>
<text top="436" left="193" width="85" height="17" font="5">socioeconomic </text>
<text top="453" left="193" width="94" height="17" font="5">gradient in CVD. </text>
<text top="470" left="193" width="3" height="17" font="5"> </text>
<text top="487" left="193" width="65" height="17" font="5">Study type: </text>
<text top="505" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="522" left="193" width="114" height="17" font="5">(narrative synthesis) </text>
<text top="539" left="193" width="3" height="17" font="5"> </text>
<text top="556" left="193" width="76" height="17" font="5">N=49 studies </text>
<text top="212" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="231" left="324" width="184" height="18" font="5">•  used quantitative outcomes to </text>
<text top="249" left="325" width="180" height="17" font="5">examine the effectiveness of the </text>
<text top="266" left="325" width="162" height="17" font="5">particular intervention among </text>
<text top="283" left="325" width="187" height="17" font="5">groups or individuals according to </text>
<text top="301" left="325" width="35" height="17" font="5">SES.  </text>
<text top="318" left="324" width="185" height="18" font="5">•  Published between January 1, </text>
<text top="336" left="325" width="153" height="17" font="5">1996 and October 31, 2008 </text>
<text top="353" left="324" width="115" height="18" font="5">•  Adult populations </text>
<text top="371" left="325" width="3" height="17" font="5"> </text>
<text top="390" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="409" left="324" width="187" height="18" font="5">•  studies of interventions among </text>
<text top="427" left="325" width="140" height="17" font="5">children and adolescents </text>
<text top="444" left="325" width="183" height="17" font="5">studies of sex or ethnicity-related </text>
<text top="463" left="325" width="173" height="17" font="5">inequalities, unless participants </text>
<text top="481" left="325" width="166" height="17" font="5">were specifically described as </text>
<text top="500" left="325" width="108" height="17" font="5">being of lower SES<i> </i></text>
<text top="212" left="535" width="68" height="17" font="5">Intervention </text>
<text top="229" left="535" width="105" height="17" font="5">Smoking reduction </text>
<text top="247" left="535" width="98" height="17" font="5">strategies among </text>
<text top="264" left="535" width="105" height="17" font="5">the well population </text>
<text top="281" left="535" width="3" height="17" font="5"> </text>
<text top="298" left="535" width="74" height="17" font="5">Absolute risk </text>
<text top="315" left="535" width="83" height="17" font="5">assessment to </text>
<text top="333" left="535" width="102" height="17" font="5">identify those who </text>
<text top="350" left="535" width="100" height="17" font="5">are asymptomatic </text>
<text top="367" left="535" width="87" height="17" font="5">but at most risk </text>
<text top="384" left="535" width="3" height="17" font="5"> </text>
<text top="401" left="535" width="62" height="17" font="5">Secondary </text>
<text top="419" left="535" width="61" height="17" font="5">prevention </text>
<text top="436" left="535" width="93" height="17" font="5">medications and </text>
<text top="453" left="535" width="43" height="17" font="5">cardiac </text>
<text top="470" left="535" width="73" height="17" font="5">rehabilitation </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="94" height="17" font="5">Heart failure self-</text>
<text top="522" left="535" width="75" height="17" font="5">management </text>
<text top="539" left="535" width="55" height="17" font="5">programs </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="70" height="17" font="5">Comparison </text>
<text top="591" left="535" width="3" height="17" font="5"> </text>
<text top="608" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="213" left="662" width="7" height="17" font="5">1</text>
<text top="212" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="230" left="662" width="234" height="17" font="5">changes in rates of smoking prevalence or </text>
<text top="248" left="662" width="73" height="17" font="5">consumption </text>
<text top="265" left="662" width="234" height="17" font="5">for absolute risk equations, their predictive </text>
<text top="282" left="662" width="229" height="17" font="5">performance or changes in the proportion </text>
<text top="299" left="662" width="233" height="17" font="5">of people assessed at being at high risk of </text>
<text top="317" left="662" width="29" height="17" font="5">CVD </text>
<text top="334" left="662" width="3" height="17" font="5"> </text>
<text top="351" left="662" width="211" height="17" font="5">for secondary prevention medications, </text>
<text top="368" left="662" width="208" height="17" font="5">cardiac rehabilitation and heart failure </text>
<text top="385" left="662" width="228" height="17" font="5">programs, outcomes included changes in </text>
<text top="403" left="662" width="206" height="17" font="5">mortality rates, further CVD events or </text>
<text top="420" left="662" width="188" height="17" font="5">hospital readmissions, changes in </text>
<text top="437" left="662" width="223" height="17" font="5">cardiovascular risk factors, or behavioral </text>
<text top="454" left="662" width="69" height="17" font="5">modification </text>
<text top="471" left="662" width="3" height="17" font="5"> </text>
<text top="489" left="662" width="3" height="17" font="5"> </text>
<text top="506" left="662" width="181" height="17" font="5">NO QUANTITATIVE SUMMARY </text>
<text top="212" left="910" width="223" height="17" font="5">Overall, only limited evidence was found </text>
<text top="229" left="910" width="221" height="17" font="5">for the effectiveness of the interventions </text>
<text top="247" left="910" width="226" height="17" font="5">examined and there was little exploration </text>
<text top="264" left="910" width="220" height="17" font="5">of SES-related barriers to their uptake.   </text>
<text top="281" left="910" width="3" height="17" font="5"> </text>
<text top="298" left="910" width="144" height="17" font="5">Summarized conclusions: </text>
<text top="315" left="910" width="112" height="17" font="7"><i>Potential successes </i></text>
<text top="333" left="910" width="217" height="17" font="5">Combining population-based strategies </text>
<text top="350" left="910" width="182" height="17" font="5">with those specifically directed to </text>
<text top="367" left="910" width="213" height="17" font="5">disadvantaged groups may reduce the </text>
<text top="384" left="910" width="126" height="17" font="5">SES-smoking gradient </text>
<text top="401" left="910" width="3" height="17" font="5"> </text>
<text top="419" left="910" width="224" height="17" font="5">Heart failure self-management programs </text>
<text top="436" left="910" width="213" height="17" font="5">are effective among lower SES groups </text>
<text top="453" left="910" width="191" height="17" font="5">possibly because they allow for an </text>
<text top="470" left="910" width="204" height="17" font="5">intensive and personalized approach </text>
<text top="487" left="910" width="3" height="17" font="5"> </text>
<text top="505" left="910" width="125" height="17" font="7"><i>Potential opportunities </i></text>
<text top="522" left="910" width="213" height="17" font="5">Creative and innovative approaches to </text>
<text top="539" left="910" width="195" height="17" font="5">improve uptake of interventions are </text>
<text top="556" left="910" width="201" height="17" font="5">needed, such as those that increase </text>
<text top="573" left="910" width="160" height="17" font="5">access (home-based cardiac </text>
<text top="591" left="910" width="208" height="17" font="5">rehabilitation programs), or those that </text>
<text top="608" left="910" width="228" height="17" font="5">remove cost (free NRT), or those that are </text>
<text top="625" left="910" width="227" height="17" font="5">tailored towards lower SES groups (heart </text>
<text top="642" left="910" width="195" height="17" font="5">failure self-management programs) </text>
<text top="660" left="910" width="3" height="17" font="5"> </text>
<text top="677" left="910" width="207" height="17" font="5">Lower SES individuals could be more </text>
<text top="694" left="910" width="217" height="17" font="5">appropriately identified as being at high </text>
<text top="711" left="910" width="210" height="17" font="5">risk of CVD either through inclusion of </text>
<text top="728" left="910" width="215" height="17" font="5">SES into absolute risk equations, or by </text>
<text top="746" left="910" width="210" height="17" font="5">lowering their thresholds for treatment </text>
<text top="763" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="910" width="215" height="17" font="7"><i>Future directions for policy makers and </i></text>
<text top="108" left="910" width="68" height="17" font="7"><i>researchers </i></text>
<text top="125" left="910" width="212" height="17" font="5">Many barriers to the effectiveness and </text>
<text top="142" left="910" width="217" height="17" font="5">utilization of CVD interventions in lower </text>
<text top="160" left="910" width="208" height="17" font="5">SES groups are directly related to the </text>
<text top="177" left="910" width="188" height="17" font="5">underlying factors associated with </text>
<text top="194" left="910" width="195" height="17" font="5">disadvantage. More efforts towards </text>
<text top="211" left="910" width="185" height="17" font="5">identification of these barriers are </text>
<text top="229" left="910" width="49" height="17" font="5">required </text>
<text top="246" left="910" width="3" height="17" font="5"> </text>
<text top="263" left="910" width="206" height="17" font="5">Approaches that have been shown to </text>
<text top="280" left="910" width="205" height="17" font="5">work among the disadvantaged need </text>
<text top="297" left="910" width="217" height="17" font="5">further research into the causes of their </text>
<text top="315" left="910" width="197" height="17" font="5">effectiveness, for example, reasons </text>
<text top="332" left="910" width="208" height="17" font="5">underlying the declines in educational </text>
<text top="349" left="910" width="181" height="17" font="5">inequalities in smoking in the UK </text>
<text top="366" left="910" width="3" height="17" font="5"> </text>
<text top="383" left="910" width="228" height="17" font="5">The increased burden of CVD associated </text>
<text top="401" left="910" width="225" height="17" font="5">with lower SES is likely to be cumulative. </text>
<text top="418" left="910" width="202" height="17" font="5">Emphasis must be on intervening as </text>
<text top="435" left="910" width="180" height="17" font="5">early as possible within the CVD </text>
<text top="452" left="910" width="60" height="17" font="5">continuum </text>
<text top="470" left="75" width="93" height="17" font="5">Havranek EP, et </text>
<text top="487" left="75" width="51" height="17" font="5">al., 2015 </text>
<text top="505" left="75" width="3" height="17" font="5"> </text>
<text top="522" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26240271">26240271</a></text>
<text top="522" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26240271"> </a></text>
<text top="470" left="193" width="59" height="17" font="5">Study Aim </text>
<text top="487" left="193" width="68" height="17" font="5">To increase </text>
<text top="505" left="193" width="97" height="17" font="5">awareness of the </text>
<text top="522" left="193" width="101" height="17" font="5">influence of social </text>
<text top="539" left="193" width="78" height="17" font="5">factors on the </text>
<text top="556" left="193" width="117" height="17" font="5">incidence, treatment, </text>
<text top="573" left="193" width="94" height="17" font="5">and outcomes of </text>
<text top="591" left="193" width="110" height="17" font="5">CVD; to summarize </text>
<text top="608" left="193" width="106" height="17" font="5">the current state of </text>
<text top="625" left="193" width="96" height="17" font="5">knowledge about </text>
<text top="642" left="193" width="115" height="17" font="5">these factors; and to </text>
<text top="660" left="193" width="81" height="17" font="5">suggest future </text>
<text top="677" left="193" width="69" height="17" font="5">directions in </text>
<text top="694" left="193" width="117" height="17" font="5">research, particularly </text>
<text top="711" left="193" width="117" height="17" font="5">research on effective </text>
<text top="728" left="193" width="87" height="17" font="5">interventions to </text>
<text top="746" left="193" width="69" height="17" font="5">attenuate or </text>
<text top="763" left="193" width="86" height="17" font="5">eliminate these </text>
<text top="470" left="325" width="95" height="17" font="5">Inclusion Criteria </text>
<text top="489" left="325" width="24" height="17" font="5">N/A<i> </i></text>
<text top="470" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="470" left="662" width="204" height="17" font="5">No primary or quantitative outcomes  </text>
<text top="487" left="662" width="3" height="17" font="5"> </text>
<text top="505" left="662" width="204" height="17" font="5">Recommendations and Conclusions: </text>
<text top="522" left="662" width="3" height="17" font="5"> </text>
<text top="539" left="662" width="134" height="17" font="7"><i>Socioeconomic Position </i></text>
<text top="556" left="662" width="226" height="17" font="5">•No single parameter fully captures SEP; </text>
<text top="573" left="662" width="223" height="17" font="5">income, education, and occupation have </text>
<text top="591" left="662" width="134" height="17" font="5">been used successfully. </text>
<text top="608" left="662" width="233" height="17" font="5">•Measures of socioeconomic position may </text>
<text top="625" left="662" width="208" height="17" font="5">vary by race/ethnic groups, and these </text>
<text top="642" left="662" width="225" height="17" font="5">synergistic effects should be considered. </text>
<text top="660" left="662" width="235" height="17" font="5">•Novel markers of socioeconomic position  </text>
<text top="677" left="662" width="225" height="17" font="5">should be investigated for broader use in </text>
<text top="694" left="662" width="114" height="17" font="5">understanding CVD. </text>
<text top="711" left="662" width="3" height="17" font="5"> </text>
<text top="728" left="662" width="82" height="17" font="7"><i>Race/Ethnicity </i></text>
<text top="746" left="662" width="221" height="17" font="5">•Race/ethnicity is a social construct with </text>
<text top="763" left="662" width="173" height="17" font="5">little biological or genetic basis. </text>
<text top="470" left="910" width="119" height="17" font="5">Author’s Conclusions </text>
<text top="487" left="910" width="217" height="17" font="5">The focus on the causes of CVD has to </text>
<text top="505" left="910" width="213" height="17" font="5">be broadened to incorporate the social </text>
<text top="522" left="910" width="183" height="17" font="5">determinants of health. Failure to </text>
<text top="539" left="910" width="225" height="17" font="5">demonstrate awareness of this will result </text>
<text top="556" left="910" width="228" height="17" font="5">in a growing burden of CVD, especially in </text>
<text top="573" left="910" width="220" height="17" font="5">those with the least means to engage in </text>
<text top="591" left="910" width="124" height="17" font="5">the healthcare system </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="82" height="17" font="5">adverse social </text>
<text top="108" left="193" width="59" height="17" font="5">influences </text>
<text top="125" left="193" width="3" height="17" font="5"> </text>
<text top="142" left="193" width="66" height="17" font="5">Study Type </text>
<text top="160" left="193" width="112" height="17" font="5">Scientific Statement </text>
<text top="177" left="193" width="3" height="17" font="5"> </text>
<text top="194" left="193" width="43" height="17" font="5">N= N/A </text>
<text top="91" left="662" width="186" height="17" font="5">•The concepts of implicit bias and </text>
<text top="108" left="662" width="233" height="17" font="5">stereotype threat are real phenomena that </text>
<text top="125" left="662" width="232" height="17" font="5">affect health and disease and may be root </text>
<text top="142" left="662" width="138" height="17" font="5">causes of disparate care </text>
<text top="160" left="662" width="192" height="17" font="5">• Effective interventions to improve </text>
<text top="177" left="662" width="199" height="17" font="5">patient-provider communication and </text>
<text top="194" left="662" width="234" height="17" font="5">patient satisfaction/trust across racial lines </text>
<text top="211" left="662" width="108" height="17" font="5">are clearly needed. </text>
<text top="229" left="662" width="3" height="17" font="5"> </text>
<text top="246" left="662" width="199" height="17" font="7"><i>Social Support and Social Networks </i></text>
<text top="263" left="662" width="198" height="17" font="5">•Although diminished social support </text>
<text top="280" left="662" width="232" height="17" font="5">contributes to CVD, effective interventions </text>
<text top="297" left="662" width="165" height="17" font="5">for low support have not been </text>
<text top="315" left="662" width="82" height="17" font="5">demonstrated. </text>
<text top="332" left="662" width="215" height="17" font="5">•Mechanisms by which social networks </text>
<text top="349" left="662" width="178" height="17" font="5">affect health are unknown and a </text>
<text top="366" left="662" width="230" height="17" font="5">significant opportunity for future research. </text>
<text top="383" left="662" width="220" height="17" font="5">• Engaging individuals and their support </text>
<text top="401" left="662" width="223" height="17" font="5">networks may be a powerful intervention </text>
<text top="418" left="662" width="203" height="17" font="5">tool and is worth future investigation. </text>
<text top="435" left="662" width="3" height="17" font="5"> </text>
<text top="452" left="662" width="87" height="17" font="7"><i>Access to Care </i></text>
<text top="469" left="662" width="227" height="17" font="5">•Barriers to access are many and include </text>
<text top="487" left="662" width="218" height="17" font="5">issues involving patient beliefs, literacy, </text>
<text top="504" left="662" width="125" height="17" font="5">culture, and language. </text>
<text top="521" left="662" width="234" height="17" font="5">• There is a poor geographic distribution of </text>
<text top="538" left="662" width="95" height="17" font="5">cardiac services. </text>
<text top="556" left="662" width="180" height="17" font="5">• Barriers to improving access to </text>
<text top="573" left="662" width="188" height="17" font="5">subspecialty care for patients with </text>
<text top="590" left="662" width="172" height="17" font="5">Medicaid are a critical issue for </text>
<text top="607" left="662" width="146" height="17" font="5">cardiovascular specialists. </text>
<text top="624" left="662" width="221" height="17" font="5">• Although access to health insurance is </text>
<text top="642" left="662" width="234" height="17" font="5">necessary, it is not a sufficient intervention </text>
<text top="659" left="662" width="198" height="17" font="5">for improving cardiovascular health. </text>
<text top="676" left="662" width="225" height="17" font="5">• Improving access is a multifaceted task </text>
<text top="693" left="662" width="219" height="17" font="5">that will require not only the provision of </text>
<text top="710" left="662" width="202" height="17" font="5">insurance coverage but also a better </text>
<text top="728" left="662" width="129" height="17" font="5">distribution of services. </text>
<text top="745" left="662" width="3" height="17" font="5"> </text>
<text top="762" left="662" width="143" height="17" font="7"><i>Residential Environments </i></text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="223" height="17" font="5">•Residential environments characterized </text>
<text top="108" left="662" width="224" height="17" font="5">by diminished socioeconomic resources, </text>
<text top="125" left="662" width="231" height="17" font="5">access to healthy foods and resources for </text>
<text top="142" left="662" width="230" height="17" font="5">physical activity have a measurable effect </text>
<text top="160" left="662" width="199" height="17" font="5">on CVD and the density of CVD risk </text>
<text top="177" left="662" width="44" height="17" font="5">factors. </text>
<text top="194" left="662" width="200" height="17" font="5">•Proactive efforts to change the built </text>
<text top="211" left="662" width="215" height="17" font="5">environment may reduce the burden of </text>
<text top="229" left="662" width="55" height="17" font="5">CVD risk. </text>
<text top="246" left="662" width="3" height="17" font="5"> </text>
<text top="263" left="662" width="227" height="17" font="7"><i>Psychological, Behavioral, and Biological </i></text>
<text top="280" left="662" width="73" height="17" font="7"><i>Mechanisms </i></text>
<text top="297" left="662" width="233" height="17" font="5">•Psychological factors such as depression </text>
<text top="315" left="662" width="228" height="17" font="5">and a comprehensive set of psychosocial </text>
<text top="332" left="662" width="198" height="17" font="5">stressors may mediate associations </text>
<text top="349" left="662" width="183" height="17" font="5">between social determinants and </text>
<text top="366" left="662" width="220" height="17" font="5">cardiovascular outcomes and should be </text>
<text top="383" left="662" width="194" height="17" font="5">investigated more in future studies. </text>
<text top="401" left="662" width="3" height="17" font="5"> </text>
<text top="418" left="662" width="233" height="17" font="5">•Although cardiovascular health behaviors </text>
<text top="435" left="662" width="235" height="17" font="5">vary across social groups, they do not fully </text>
<text top="452" left="662" width="210" height="17" font="5">account for social group differences in </text>
<text top="469" left="662" width="143" height="17" font="5">cardiovascular outcomes. </text>
<text top="487" left="662" width="219" height="17" font="5">•Physiological and anatomical effects of </text>
<text top="504" left="662" width="223" height="17" font="5">early disadvantage affect risk for CVD in </text>
<text top="521" left="662" width="61" height="17" font="5">adulthood. </text>
<text top="538" left="662" width="207" height="17" font="5">• Effective interventions to reduce the </text>
<text top="556" left="662" width="222" height="17" font="5">impact of early disadvantage will require </text>
<text top="573" left="662" width="226" height="17" font="5">organizational partnerships that currently </text>
<text top="590" left="662" width="89" height="17" font="5">are uncommon. </text>
<text top="608" left="75" width="85" height="17" font="5">Vilhelmsson A, </text>
<text top="625" left="75" width="83" height="17" font="5">Östergren PO, </text>
<text top="642" left="75" width="31" height="17" font="5">2018 </text>
<text top="660" left="75" width="3" height="17" font="5"> </text>
<text top="677" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29659598">29659598</a></text>
<text top="677" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29659598"> </a></text>
<text top="608" left="193" width="66" height="17" font="5">Study Aims </text>
<text top="625" left="193" width="76" height="17" font="5">to assess the </text>
<text top="642" left="193" width="74" height="17" font="5">magnitude of </text>
<text top="660" left="193" width="108" height="17" font="5">evidence regarding </text>
<text top="677" left="193" width="67" height="17" font="5">intervention </text>
<text top="694" left="193" width="91" height="17" font="5">evaluations with </text>
<text top="711" left="193" width="112" height="17" font="5">high-quality designs </text>
<text top="728" left="193" width="101" height="17" font="5">concerning health-</text>
<text top="746" left="193" width="95" height="17" font="5">related behavior, </text>
<text top="763" left="193" width="114" height="17" font="5">which have shown a </text>
<text top="608" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="627" left="324" width="187" height="18" font="5">•  Published between 1990-2015 </text>
<text top="645" left="324" width="143" height="18" font="5">•  published in English in </text>
<text top="663" left="325" width="152" height="17" font="5">international peer-reviewed </text>
<text top="680" left="325" width="100" height="17" font="5">scientific journals  </text>
<text top="698" left="324" width="190" height="18" font="5">•  populations from countries with </text>
<text top="716" left="325" width="179" height="17" font="5">developed welfare systems (i.e., </text>
<text top="733" left="325" width="174" height="17" font="5">from countries in Europe, North </text>
<text top="750" left="325" width="158" height="17" font="5">America, Australia, and New </text>
<text top="767" left="325" width="52" height="17" font="5">Zealand) </text>
<text top="608" left="535" width="68" height="17" font="5">Intervention </text>
<text top="625" left="535" width="100" height="17" font="5">of non-healthcare-</text>
<text top="642" left="535" width="110" height="17" font="5">based interventions </text>
<text top="660" left="535" width="93" height="17" font="5">regarding health-</text>
<text top="677" left="535" width="101" height="17" font="5">related behavioral </text>
<text top="694" left="535" width="81" height="17" font="5">factors among </text>
<text top="711" left="535" width="48" height="17" font="5">different </text>
<text top="728" left="535" width="107" height="17" font="5">educational groups </text>
<text top="746" left="535" width="3" height="17" font="5"> </text>
<text top="763" left="535" width="70" height="17" font="5">Comparison </text>
<text top="609" left="662" width="7" height="17" font="5">1</text>
<text top="608" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="626" left="662" width="227" height="17" font="5">Health related behavior (smoking, dietary </text>
<text top="643" left="662" width="212" height="17" font="5">intake, physical activity, mental health, </text>
<text top="661" left="662" width="232" height="17" font="5">mammography) reductions by educational </text>
<text top="678" left="662" width="29" height="17" font="5">level </text>
<text top="695" left="662" width="3" height="17" font="5"> </text>
<text top="712" left="662" width="181" height="17" font="5">NO QUANTITATIVE SUMMARY </text>
<text top="730" left="662" width="3" height="17" font="5"> </text>
<text top="747" left="662" width="3" height="17" font="5"> </text>
<text top="608" left="910" width="122" height="17" font="5">Author’s Conclusions: </text>
<text top="625" left="910" width="220" height="17" font="5">Smoking cessation:, could not draw any </text>
<text top="642" left="910" width="116" height="17" font="5">decisive conclusions </text>
<text top="660" left="910" width="3" height="17" font="5"> </text>
<text top="677" left="910" width="177" height="17" font="5">Limited evidence for decreasing </text>
<text top="694" left="910" width="229" height="17" font="5">inequality through interventions regarding </text>
<text top="711" left="910" width="196" height="17" font="5">dietary intake, physical activity, and </text>
<text top="728" left="910" width="77" height="17" font="5">mental health </text>
<text top="746" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="118" height="17" font="5">higher impact among </text>
<text top="108" left="193" width="118" height="17" font="5">individuals with a low </text>
<text top="125" left="193" width="115" height="17" font="5">educational level, as </text>
<text top="142" left="193" width="111" height="17" font="5">well as the potential </text>
<text top="160" left="193" width="101" height="17" font="5">of reducing health </text>
<text top="177" left="193" width="55" height="17" font="5">inequality </text>
<text top="194" left="193" width="3" height="17" font="5"> </text>
<text top="211" left="193" width="104" height="17" font="5">Study Type: Rapid </text>
<text top="229" left="193" width="39" height="17" font="5">review </text>
<text top="246" left="193" width="3" height="17" font="5"> </text>
<text top="263" left="193" width="69" height="17" font="5">N=9 studies </text>
<text top="91" left="324" width="183" height="18" font="5">•  evaluations of non-healthcare-</text>
<text top="109" left="325" width="165" height="17" font="5">based interventions regarding </text>
<text top="126" left="325" width="179" height="17" font="5">health-related behavioral factors </text>
<text top="143" left="325" width="196" height="17" font="5">among different educational groups </text>
<text top="161" left="324" width="154" height="18" font="5">•  studies comparing those </text>
<text top="179" left="325" width="175" height="17" font="5">receiving the intervention with a </text>
<text top="196" left="325" width="147" height="17" font="5">control group (randomized </text>
<text top="213" left="325" width="193" height="17" font="5">controlled trials or non-randomized </text>
<text top="230" left="325" width="146" height="17" font="5">trials with a cohort design) </text>
<text top="248" left="324" width="58" height="18" font="5">•  N≥100 </text>
<text top="266" left="326" width="3" height="17" font="5"> </text>
<text top="297" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="327" left="324" width="177" height="18" font="5">•  Did not measure educational </text>
<text top="345" left="325" width="36" height="17" font="5">status </text>
<text top="363" left="324" width="107" height="18" font="5">•  No original data </text>
<text top="381" left="324" width="175" height="18" font="5">•  Lacked data on outcomes of </text>
<text top="399" left="325" width="44" height="17" font="5">interest </text>
<text top="416" left="325" width="3" height="17" font="7"><i> </i></text>
<text top="91" left="535" width="75" height="17" font="5">Not specified<i> </i></text>
<text top="91" left="910" width="231" height="17" font="5">Mammography: only one study identified,  </text>
<text top="108" left="910" width="192" height="17" font="5">concluded that there is not enough </text>
<text top="125" left="910" width="187" height="17" font="5">scientific evidence concerning the </text>
<text top="142" left="910" width="215" height="17" font="5">potential for increased health equity for </text>
<text top="160" left="910" width="77" height="17" font="5">this approach </text>
<text top="448" left="75" width="86" height="17" font="5">Schultz WM, et </text>
<text top="465" left="75" width="51" height="17" font="5">al., 2018 </text>
<text top="482" left="75" width="3" height="17" font="5"> </text>
<text top="499" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29760227">29760227</a></text>
<text top="499" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29760227"> </a></text>
<text top="448" left="193" width="66" height="17" font="5">Study Aims </text>
<text top="465" left="193" width="119" height="17" font="5">To review the current </text>
<text top="482" left="193" width="106" height="17" font="5">state of knowledge </text>
<text top="499" left="193" width="119" height="17" font="5">on the impact of SES </text>
<text top="517" left="193" width="96" height="17" font="5">on the incidence, </text>
<text top="534" left="193" width="83" height="17" font="5">treatment, and </text>
<text top="551" left="193" width="113" height="17" font="5">outcomes of CVD in </text>
<text top="568" left="193" width="70" height="17" font="5">high-income </text>
<text top="585" left="193" width="101" height="17" font="5">societies, suggest </text>
<text top="603" left="193" width="86" height="17" font="5">future research </text>
<text top="620" left="193" width="106" height="17" font="5">directions aimed at </text>
<text top="637" left="193" width="96" height="17" font="5">the elimination of </text>
<text top="654" left="193" width="81" height="17" font="5">these adverse </text>
<text top="671" left="193" width="88" height="17" font="5">factors, and the </text>
<text top="689" left="193" width="74" height="17" font="5">integration of </text>
<text top="706" left="193" width="99" height="17" font="5">measures of SES </text>
<text top="723" left="193" width="44" height="17" font="5">into the </text>
<text top="740" left="193" width="92" height="17" font="5">customization of </text>
<text top="448" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="466" left="325" width="24" height="17" font="5">N/A </text>
<text top="485" left="325" width="3" height="17" font="5"> </text>
<text top="503" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="522" left="325" width="24" height="17" font="5">N/A<i> </i></text>
<text top="448" left="535" width="68" height="17" font="5">Intervention </text>
<text top="465" left="535" width="80" height="17" font="5">Various (none </text>
<text top="482" left="535" width="74" height="17" font="5">prespecified) </text>
<text top="499" left="535" width="3" height="17" font="5"> </text>
<text top="517" left="535" width="70" height="17" font="5">Comparison </text>
<text top="534" left="535" width="80" height="17" font="5">Various (none </text>
<text top="551" left="535" width="74" height="17" font="5">prespecified)<i> </i></text>
<text top="449" left="662" width="7" height="17" font="5">1</text>
<text top="448" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="466" left="662" width="85" height="17" font="5">None specified </text>
<text top="483" left="662" width="3" height="17" font="5"> </text>
<text top="500" left="662" width="181" height="17" font="5">NO QUANTITATIVE SUMMARY </text>
<text top="518" left="662" width="3" height="17" font="5"> </text>
<text top="535" left="662" width="3" height="17" font="5"> </text>
<text top="448" left="910" width="119" height="17" font="5">Author’s Conclusions </text>
<text top="465" left="910" width="211" height="17" font="5">SES has a measurable and significant </text>
<text top="482" left="910" width="183" height="17" font="5">impact on cardiovascular health.  </text>
<text top="499" left="910" width="3" height="17" font="5"> </text>
<text top="517" left="910" width="228" height="17" font="5">Individuals of low SES carry a substantial </text>
<text top="534" left="910" width="206" height="17" font="5">burden of CVD and are more likely to </text>
<text top="551" left="910" width="208" height="17" font="5">experience increased event rates and </text>
<text top="568" left="910" width="103" height="17" font="5">poorer outcomes.  </text>
<text top="585" left="910" width="3" height="17" font="5"> </text>
<text top="603" left="910" width="189" height="17" font="5">Current models do not adequately </text>
<text top="620" left="910" width="201" height="17" font="5">account for the risk conveyed by low </text>
<text top="637" left="910" width="35" height="17" font="5">SES.  </text>
<text top="654" left="910" width="3" height="17" font="5"> </text>
<text top="671" left="910" width="210" height="17" font="5">The independent association between </text>
<text top="689" left="910" width="195" height="17" font="5">SES and mortality is comparable in </text>
<text top="706" left="910" width="211" height="17" font="5">strength and consistency to that of the </text>
<text top="723" left="910" width="157" height="17" font="5">traditional major risk factors. </text>
<text top="740" left="910" width="3" height="17" font="5"> </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="10" size="12" family="Times" color="#ffffff"/>
	<fontspec id="11" size="16" family="Times" color="#00537a"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="193" width="83" height="17" font="5">cardiovascular </text>
<text top="108" left="193" width="55" height="17" font="5">treatment </text>
<text top="125" left="193" width="3" height="17" font="5"> </text>
<text top="142" left="193" width="66" height="17" font="5">Study Type </text>
<text top="160" left="193" width="88" height="17" font="5">Non-systematic </text>
<text top="177" left="193" width="109" height="17" font="5">literature summary  </text>
<text top="194" left="193" width="3" height="17" font="5"> </text>
<text top="211" left="193" width="40" height="17" font="5">N=N/A </text>
<text top="229" left="193" width="3" height="17" font="5"> </text>
<text top="91" left="910" width="213" height="17" font="5">There is a need for increased focus on </text>
<text top="108" left="910" width="212" height="17" font="5">effective and sustainable interventions </text>
<text top="125" left="910" width="192" height="17" font="5">informed by clinical and population </text>
<text top="142" left="910" width="204" height="17" font="5">science insights from SES research.  </text>
<text top="160" left="910" width="3" height="17" font="5"> </text>
<text top="177" left="910" width="204" height="17" font="5">Further research is required to better </text>
<text top="194" left="910" width="218" height="17" font="5">understand the underlying mechanisms </text>
<text top="211" left="910" width="223" height="17" font="5">of CVD risk that disproportionately affect </text>
<text top="229" left="910" width="131" height="17" font="5">individuals of low SES.  </text>
<text top="247" left="66" width="35" height="17" font="10">TEXT </text>
<text top="295" left="66" width="1034" height="21" font="4"><b>Data Supplement 2. Nonrandomized Trials, Observational Studies, and/or Registries of Patient-Centered Approaches for Providing Comprehensive </b></text>
<text top="316" left="66" width="224" height="21" font="4"><b>ASCVD Prevention (Section 2.1)</b></text>
<text top="316" left="290" width="4" height="21" font="11"><b> </b></text>
<text top="340" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="357" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="375" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="340" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="357" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="340" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="340" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="357" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="340" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="357" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="393" left="75" width="90" height="17" font="5">Chen EH, et al., </text>
<text top="410" left="75" width="56" height="17" font="5">2010 (11) </text>
<text top="427" left="75" width="3" height="17" font="5"> </text>
<text top="444" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20737236">20737236</a></text>
<text top="444" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20737236"> </a></text>
<text top="393" left="193" width="59" height="17" font="5">Study Aim </text>
<text top="410" left="193" width="102" height="17" font="5">To implement and </text>
<text top="427" left="193" width="118" height="17" font="5">evaluate the Teamlet </text>
<text top="444" left="193" width="104" height="17" font="5">Model, which uses </text>
<text top="461" left="193" width="86" height="17" font="5">health coaches </text>
<text top="479" left="193" width="115" height="17" font="5">working with primary </text>
<text top="496" left="193" width="102" height="17" font="5">care physicians to </text>
<text top="513" left="193" width="92" height="17" font="5">improve care for </text>
<text top="530" left="193" width="72" height="17" font="5">patients with </text>
<text top="547" left="193" width="88" height="17" font="5">diabetes and/or </text>
<text top="565" left="193" width="104" height="17" font="5">hypertension in an </text>
<text top="582" left="193" width="103" height="17" font="5">academic practice </text>
<text top="599" left="193" width="3" height="17" font="5"> </text>
<text top="616" left="193" width="91" height="17" font="5">Study type: Non-</text>
<text top="633" left="193" width="68" height="17" font="5">randomized </text>
<text top="651" left="193" width="67" height="17" font="5">intervention </text>
<text top="668" left="193" width="3" height="17" font="5"> </text>
<text top="685" left="193" width="43" height="17" font="5">N=541  </text>
<text top="393" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="411" left="324" width="174" height="18" font="5">•  Transferred from graduating </text>
<text top="429" left="325" width="185" height="17" font="5">third year resident to an incoming </text>
<text top="447" left="325" width="177" height="17" font="5">first year resident (control group </text>
<text top="464" left="325" width="187" height="17" font="5">had and kept second or third year </text>
<text top="481" left="325" width="105" height="17" font="5">resident providers) </text>
<text top="498" left="324" width="186" height="18" font="5">•  Had at least one visit in prior 2 </text>
<text top="516" left="325" width="33" height="17" font="5">years </text>
<text top="534" left="324" width="154" height="18" font="5">•  Spoke English, Spanish, </text>
<text top="552" left="325" width="135" height="17" font="5">Cantonese, or Mandarin </text>
<text top="569" left="326" width="176" height="17" font="5">Diagnosed with diabetes and/or </text>
<text top="586" left="326" width="74" height="17" font="5">hypertension </text>
<text top="394" left="535" width="7" height="17" font="5">1</text>
<text top="393" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="411" left="535" width="214" height="17" font="5">Intervention vs. control comparisons of </text>
<text top="428" left="535" width="222" height="17" font="5">mean daytime, nighttime, and overall 24-</text>
<text top="445" left="535" width="215" height="17" font="5">hour ambulatory SBP and control rates </text>
<text top="463" left="535" width="3" height="17" font="5"> </text>
<text top="480" left="535" width="237" height="17" font="7"><i>Change in intervention group from the year </i></text>
<text top="497" left="535" width="160" height="17" font="7"><i>prior to the intervention year</i>: </text>
<text top="514" left="535" width="3" height="17" font="5"> </text>
<text top="531" left="535" width="199" height="17" font="5">BP ≤goal: 48.7% vs. 56.5%, p=0.22 </text>
<text top="549" left="535" width="219" height="17" font="5">HbA1c≤ goal: 26.7% vs. 36.7%, p=0.12 </text>
<text top="566" left="535" width="208" height="17" font="5">LDL ≤ goal: 49.1% vs. 58.6%, p=0.07 </text>
<text top="583" left="535" width="201" height="17" font="5">HbA1c measured: 86.9% vs. 88.9%, </text>
<text top="600" left="535" width="41" height="17" font="5">p=0.82 </text>
<text top="617" left="535" width="228" height="17" font="5">LDL measured: 74.0% vs. 84.9%, p=0.02 </text>
<text top="635" left="535" width="227" height="17" font="5">BMI measured: 3.4% vs. 88.4%, p&lt;0.001 </text>
<text top="652" left="535" width="197" height="17" font="5">Smoking status assessed: 4.1% vs. </text>
<text top="669" left="535" width="90" height="17" font="5">86.9%, p&lt;0.001 </text>
<text top="686" left="535" width="222" height="17" font="5">Self-management plan made: 19.9% vs. </text>
<text top="703" left="535" width="90" height="17" font="5">55.5%, p&lt;0.001 </text>
<text top="721" left="535" width="3" height="17" font="5"> </text>
<text top="738" left="535" width="233" height="17" font="7"><i>Difference in change between intervention </i></text>
<text top="755" left="535" width="226" height="17" font="7"><i>group and control group for year prior vs. </i></text>
<text top="772" left="535" width="111" height="17" font="7"><i>year of intervention</i>: </text>
<text top="393" left="786" width="56" height="17" font="5">Summary </text>
<text top="410" left="786" width="299" height="17" font="5">Teamlet model was implemented without decreases in </text>
<text top="427" left="786" width="55" height="17" font="5">efficiency </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="142" height="17" font="5">BP ≤goal: +3.8%, p=0.06 </text>
<text top="178" left="535" width="162" height="17" font="5">HbA1c≤ goal: +1.8%, p=0.83 </text>
<text top="195" left="535" width="151" height="17" font="5">LDL ≤ goal: +3.2%, p=0.79 </text>
<text top="212" left="535" width="185" height="17" font="5">HbA1c measured: +5.6%, p=0.17 </text>
<text top="229" left="535" width="175" height="17" font="5">LDL measured: -5.8%, p=0.001 </text>
<text top="260" left="535" width="3" height="17" font="5"> </text>
<text top="292" left="535" width="7" height="17" font="5">2</text>
<text top="291" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="309" left="535" width="237" height="17" font="5">First year residents provided an average of </text>
<text top="326" left="535" width="180" height="17" font="5">146 patient visits during the year </text>
<text top="343" left="535" width="199" height="17" font="5">compared to 136 on average for the </text>
<text top="360" left="535" width="138" height="17" font="5">previous residency class </text>
<text top="378" left="535" width="3" height="17" font="5"> </text>
<text top="409" left="75" width="81" height="17" font="5">CAPTION trial </text>
<text top="426" left="75" width="76" height="17" font="5">(subanalysis) </text>
<text top="443" left="75" width="3" height="17" font="5"> </text>
<text top="461" left="75" width="87" height="17" font="5">Isetts BJ, et al., </text>
<text top="478" left="75" width="31" height="17" font="5">2016 </text>
<text top="495" left="75" width="3" height="17" font="5"> </text>
<text top="512" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26893135">26893135</a></text>
<text top="512" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26893135"> </a></text>
<text top="409" left="193" width="58" height="17" font="5">Study aim </text>
<text top="426" left="193" width="84" height="17" font="5">to describe the </text>
<text top="443" left="193" width="84" height="17" font="5">components of </text>
<text top="461" left="193" width="115" height="17" font="5">pharmacists’ work in </text>
<text top="478" left="193" width="109" height="17" font="5">the management of </text>
<text top="495" left="193" width="109" height="17" font="5">hypertension with a </text>
<text top="512" left="193" width="119" height="17" font="5">physician-pharmacist </text>
<text top="530" left="193" width="109" height="17" font="5">collaborative model </text>
<text top="547" left="193" width="3" height="17" font="5"> </text>
<text top="564" left="193" width="62" height="17" font="5">Study type </text>
<text top="581" left="193" width="112" height="17" font="5">Descriptive analysis </text>
<text top="598" left="193" width="98" height="17" font="5">of components of </text>
<text top="616" left="193" width="90" height="17" font="5">intervention in a </text>
<text top="633" left="193" width="107" height="17" font="5">cluster randomized </text>
<text top="650" left="193" width="120" height="17" font="5">trial (present report is </text>
<text top="667" left="193" width="119" height="17" font="5">on pharmacists’ work </text>
<text top="684" left="193" width="119" height="17" font="5">in intervention group) </text>
<text top="702" left="193" width="3" height="17" font="5"> </text>
<text top="719" left="193" width="118" height="17" font="5">N=32 medical offices </text>
<text top="736" left="193" width="93" height="17" font="5">(n=390 patients) </text>
<text top="409" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="426" left="324" width="107" height="18" font="5">•  uncontrolled BP </text>
<text top="410" left="535" width="7" height="17" font="5">1</text>
<text top="409" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="441" left="535" width="215" height="17" font="5">3.44 hours/patient for face-to-face care </text>
<text top="458" left="535" width="31" height="17" font="5">visits </text>
<text top="475" left="535" width="3" height="17" font="5"> </text>
<text top="492" left="535" width="179" height="17" font="5">Pharmacists spent a mean of 33 </text>
<text top="510" left="535" width="208" height="17" font="5">minutes/patient in face-to-face time in </text>
<text top="527" left="535" width="217" height="17" font="5">initial counter and 28 minutes/patient in </text>
<text top="544" left="535" width="191" height="17" font="5">face-to-face time in each follow-up </text>
<text top="561" left="535" width="209" height="17" font="5">encounter. Pharmacists also spent an </text>
<text top="579" left="535" width="224" height="17" font="5">average of 4.05 minutes for pre-visit and </text>
<text top="596" left="535" width="191" height="17" font="5">8.85 minutes for post visit time per </text>
<text top="613" left="535" width="175" height="17" font="5">encounter, representing 31% of </text>
<text top="630" left="535" width="221" height="17" font="5">pharmacists’ work. Total time spent was </text>
<text top="647" left="535" width="194" height="17" font="5">4.99 hours per patient in 9 months. </text>
<text top="665" left="535" width="3" height="17" font="5"> </text>
<text top="682" left="535" width="237" height="17" font="5">12.3% of patients were at BP goal on initial </text>
<text top="699" left="535" width="205" height="17" font="5">assessment, despite uncontrolled BP </text>
<text top="716" left="535" width="199" height="17" font="5">assessed by the study coordinators’ </text>
<text top="734" left="535" width="217" height="17" font="5">structured measurements at the time of </text>
<text top="751" left="535" width="94" height="17" font="5">study enrollment </text>
<text top="768" left="535" width="3" height="17" font="5"> </text>
<text top="409" left="786" width="63" height="17" font="5">Summary:  </text>
<text top="426" left="786" width="346" height="17" font="5">The physician-pharmacist collaborative care model required an </text>
<text top="443" left="786" width="320" height="17" font="5">average of 4.99 hours of pharmacist time per patient per 9 </text>
<text top="461" left="786" width="310" height="17" font="5">months. The intervention resulted in a greater number of </text>
<text top="478" left="786" width="325" height="17" font="5">medication increases or additions than in the control group, </text>
<text top="495" left="786" width="332" height="17" font="5">which were nearly always accepted by the physician, and no </text>
<text top="512" left="786" width="207" height="17" font="5">greater frequency of adverse events.  </text>
<text top="530" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="231" height="17" font="5">0% of patients’ blood pressure goals were </text>
<text top="160" left="535" width="229" height="17" font="5">achieved at baseline compared to 43% at </text>
<text top="178" left="535" width="54" height="17" font="5">9 months </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="236" height="17" font="5">2.6 dose increases or medication additions </text>
<text top="229" left="535" width="220" height="17" font="5">in intervention group compared to 0.8 in </text>
<text top="247" left="535" width="134" height="17" font="5">control group, p=0.0001 </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="228" height="17" font="5">98.6% of recommendations made to alter </text>
<text top="298" left="535" width="233" height="17" font="5">drug therapy were accepted by physicians </text>
<text top="315" left="535" width="3" height="17" font="5"> </text>
<text top="333" left="535" width="195" height="17" font="5">43% of patient encounters involved </text>
<text top="350" left="535" width="206" height="17" font="5">patient-specific drug therapy problem </text>
<text top="367" left="535" width="158" height="17" font="5">resolution recommendations </text>
<text top="384" left="535" width="3" height="17" font="5"> </text>
<text top="401" left="535" width="237" height="17" font="5">Monitoring by medical monitors and a Data </text>
<text top="419" left="535" width="229" height="17" font="5">and Safety Monitoring Board indicated no </text>
<text top="436" left="535" width="228" height="17" font="5">significant difference in adverse events in </text>
<text top="453" left="535" width="215" height="17" font="5">the intervention group compared to the </text>
<text top="470" left="535" width="132" height="17" font="5">control group (p=0.500) </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="230" height="17" font="5">392 adverse events were assessed, 64 of </text>
<text top="522" left="535" width="217" height="17" font="5">which were possibly medication-related </text>
<text top="539" left="535" width="3" height="17" font="5"> </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="574" left="75" width="100" height="17" font="5">Kravetz JD, et al., </text>
<text top="591" left="75" width="31" height="17" font="5">2016 </text>
<text top="609" left="75" width="3" height="17" font="5"> </text>
<text top="626" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27106631">27106631</a></text>
<text top="626" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27106631"> </a></text>
<text top="574" left="193" width="25" height="17" font="5">Aim </text>
<text top="591" left="193" width="119" height="17" font="5">to determine whether </text>
<text top="609" left="193" width="87" height="17" font="5">proactive panel </text>
<text top="626" left="193" width="120" height="17" font="5">management within a </text>
<text top="643" left="193" width="116" height="17" font="5">Patient Aligned Care </text>
<text top="660" left="193" width="112" height="17" font="5">Team (PACT) could </text>
<text top="678" left="193" width="81" height="17" font="5">improve blood </text>
<text top="695" left="193" width="115" height="17" font="5">pressure control in a </text>
<text top="712" left="193" width="72" height="17" font="5">primary care </text>
<text top="729" left="193" width="118" height="17" font="5">population compared </text>
<text top="746" left="193" width="74" height="17" font="5">to usual care </text>
<text top="764" left="193" width="3" height="17" font="5"> </text>
<text top="574" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="592" left="324" width="182" height="18" font="5">•  Blood pressure &gt;160/100 mm </text>
<text top="610" left="325" width="19" height="17" font="5">Hg </text>
<text top="627" left="324" width="195" height="18" font="5">•  Patient at West Haven Veterans </text>
<text top="645" left="325" width="124" height="17" font="5">Affairs Medical Center </text>
<text top="575" left="535" width="7" height="17" font="5">1</text>
<text top="574" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="606" left="535" width="123" height="17" font="5">Change in systolic BP </text>
<text top="623" left="535" width="127" height="17" font="5">Change in diastolic BP </text>
<text top="641" left="535" width="233" height="17" font="5">% with lower systolic BP at 4-month follow </text>
<text top="658" left="535" width="17" height="17" font="5">up </text>
<text top="675" left="535" width="237" height="17" font="5">% with lower diastolic BP at 4-month follow </text>
<text top="692" left="535" width="17" height="17" font="5">up </text>
<text top="709" left="535" width="182" height="17" font="5">% who did not return to follow up </text>
<text top="727" left="535" width="3" height="17" font="5"> </text>
<text top="744" left="535" width="213" height="17" font="7"><i>Change in systolic BP: Intervention vs. </i></text>
<text top="761" left="535" width="43" height="17" font="7"><i>Control </i></text>
<text top="574" left="786" width="56" height="17" font="5">Summary </text>
<text top="591" left="786" width="344" height="17" font="5">The team approach resulted in a significantly greater reduction </text>
<text top="609" left="786" width="230" height="17" font="5">in blood pressure compared to usual care </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="193" width="62" height="17" font="5">Study type </text>
<text top="160" left="193" width="94" height="17" font="5">Non-randomized </text>
<text top="178" left="193" width="90" height="17" font="5">intervention trial </text>
<text top="195" left="193" width="3" height="17" font="5"> </text>
<text top="212" left="193" width="40" height="17" font="5">N=665 </text>
<text top="143" left="535" width="225" height="17" font="5">-15.6 vs. -9.9 mm Hg, p&lt;0.001.  (-15 vs. -</text>
<text top="160" left="535" width="203" height="17" font="5">7.3 mm Hg, p&lt;0.001 when excluding </text>
<text top="178" left="535" width="189" height="17" font="5">patients with medication changes) </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="217" height="17" font="7"><i>Change in diastolic BP: Intervention vs. </i></text>
<text top="229" left="535" width="43" height="17" font="7"><i>Control </i></text>
<text top="247" left="535" width="229" height="17" font="5">-5.4 vs. -4.6 mm Hg, p=0.32 (-5.2 vs. -3.6 </text>
<text top="264" left="535" width="229" height="17" font="5">mm Hg, p=0.079 when excluding patients </text>
<text top="281" left="535" width="142" height="17" font="5">with medication changes) </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="205" height="17" font="7"><i>% with lower systolic BP at follow up: </i></text>
<text top="333" left="535" width="130" height="17" font="7"><i>Intervention vs. Control </i></text>
<text top="350" left="535" width="147" height="17" font="5">61.1% vs. 41.0%, p&lt;0.001 </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="209" height="17" font="7"><i>% with lower diastolic BP at follow up: </i></text>
<text top="401" left="535" width="130" height="17" font="7"><i>Intervention vs. Control </i></text>
<text top="419" left="535" width="147" height="17" font="5">53.7% vs. 37.5%, p&lt;0.001 </text>
<text top="436" left="535" width="3" height="17" font="5"> </text>
<text top="453" left="535" width="189" height="17" font="7"><i>% who did not return for follow up: </i></text>
<text top="470" left="535" width="130" height="17" font="7"><i>Intervention vs. Control </i></text>
<text top="488" left="535" width="151" height="17" font="5">32.0% vs. 48.0%, p&lt;0.001  </text>
<text top="518" left="535" width="189" height="17" font="5">Mean increase in number of blood </text>
<text top="537" left="535" width="210" height="17" font="5">pressure medications from 1.37 to 1.5 </text>
<text top="555" left="535" width="225" height="17" font="5">(p=0.01) in intervention group (change in </text>
<text top="574" left="535" width="149" height="17" font="5">control group not reported) </text>
<text top="604" left="535" width="3" height="17" font="5"> </text>
<text top="622" left="75" width="88" height="17" font="5">Olomu A, et al., </text>
<text top="640" left="75" width="31" height="17" font="5">2016 </text>
<text top="657" left="75" width="3" height="17" font="5"> </text>
<text top="674" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27484348">27484348</a></text>
<text top="674" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27484348"> </a></text>
<text top="622" left="193" width="59" height="17" font="5">Study Aim </text>
<text top="640" left="193" width="81" height="17" font="5">to evaluate: 1) </text>
<text top="657" left="193" width="88" height="17" font="5">feasibility of the </text>
<text top="674" left="193" width="115" height="17" font="5">Office-GAP program </text>
<text top="691" left="193" width="113" height="17" font="5">among patients with </text>
<text top="708" left="193" width="117" height="17" font="5">diabetes and CHD in </text>
<text top="726" left="193" width="116" height="17" font="5">a Federally Qualified </text>
<text top="743" left="193" width="103" height="17" font="5">Healthcare Center </text>
<text top="760" left="193" width="85" height="17" font="5">(FQHC); 2) the </text>
<text top="622" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="641" left="324" width="148" height="18" font="5">•  Adults aged 18 or older </text>
<text top="659" left="324" width="195" height="18" font="5">•  could provide informed consent  </text>
<text top="678" left="324" width="176" height="18" font="5">•  sought care from September </text>
<text top="696" left="325" width="135" height="17" font="5">2009 to December 2011 </text>
<text top="713" left="324" width="152" height="18" font="5">•  diagnosis of 1) Diabetes </text>
<text top="731" left="325" width="148" height="17" font="5">mellitus. 2) Coronary heart </text>
<text top="748" left="325" width="53" height="17" font="5">disease.  </text>
<text top="624" left="535" width="7" height="17" font="5">1</text>
<text top="622" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="641" left="535" width="204" height="17" font="5">Implementation of program elements </text>
<text top="658" left="535" width="218" height="17" font="5">Patient satisfaction with communication </text>
<text top="675" left="535" width="152" height="17" font="5">and confidence in decision  </text>
<text top="692" left="535" width="88" height="17" font="5">Medication Use </text>
<text top="710" left="535" width="3" height="17" font="5"> </text>
<text top="727" left="535" width="87" height="17" font="7"><i>Implementation </i></text>
<text top="744" left="535" width="210" height="17" font="5">All providers and staff attended the 90 </text>
<text top="761" left="535" width="84" height="17" font="5">minute training </text>
<text top="622" left="786" width="56" height="17" font="5">Summary </text>
<text top="640" left="786" width="341" height="17" font="5">The use of Office-GAP program to teach SDM and use of DAs </text>
<text top="657" left="786" width="338" height="17" font="5">in real time was demonstrated to be feasible in FQHCs. It has </text>
<text top="674" left="786" width="276" height="17" font="5">the potential to improve satisfaction with physician </text>
<text top="691" left="786" width="325" height="17" font="5">communication and confidence in decisions and to improve </text>
<text top="708" left="786" width="90" height="17" font="5">medication use. </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="193" width="111" height="17" font="5">impact on a) patient </text>
<text top="160" left="193" width="90" height="17" font="5">satisfaction with </text>
<text top="178" left="193" width="55" height="17" font="5">physician </text>
<text top="195" left="193" width="110" height="17" font="5">communication and </text>
<text top="212" left="193" width="76" height="17" font="5">confidence in </text>
<text top="229" left="193" width="119" height="17" font="5">decisions; and b) use </text>
<text top="247" left="193" width="110" height="17" font="5">of guidelines-based </text>
<text top="264" left="193" width="110" height="17" font="5">medication for CHD </text>
<text top="281" left="193" width="64" height="17" font="5">prevention  </text>
<text top="298" left="193" width="3" height="17" font="5"> </text>
<text top="315" left="193" width="116" height="17" font="5">Study type: Pre-Post </text>
<text top="333" left="193" width="106" height="17" font="5">quasi experimental </text>
<text top="350" left="193" width="40" height="17" font="5">design </text>
<text top="367" left="193" width="3" height="17" font="5"> </text>
<text top="384" left="193" width="33" height="17" font="5">N=95 </text>
<text top="143" left="326" width="3" height="17" font="5"> </text>
<text top="174" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="204" left="326" width="182" height="17" font="5">Adults with cognitive impairment, </text>
<text top="221" left="326" width="151" height="17" font="5">dementia and psychosis as </text>
<text top="239" left="326" width="142" height="17" font="5">determined by ICD codes </text>
<text top="143" left="535" width="216" height="17" font="5">81.1% of patients who attended first 90 </text>
<text top="160" left="535" width="225" height="17" font="5">minute group visit completed Office-GAP </text>
<text top="178" left="535" width="221" height="17" font="5">provider visit and 63.2% completed final </text>
<text top="195" left="535" width="25" height="17" font="5">visit </text>
<text top="212" left="535" width="227" height="17" font="5">Office-GAP checklist completed in 98.7% </text>
<text top="229" left="535" width="104" height="17" font="5">of medical records </text>
<text top="247" left="535" width="3" height="17" font="5"> </text>
<text top="264" left="535" width="218" height="17" font="7"><i>Patient satisfaction with communication </i></text>
<text top="281" left="535" width="218" height="17" font="7"><i>and confidence in decision: hierarchical </i></text>
<text top="298" left="535" width="170" height="17" font="7"><i>model coefficients vs. baseline </i></text>
<text top="315" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="333" left="535" width="67" height="17" font="5">Satisfaction </text>
<text top="350" left="535" width="232" height="17" font="5">3 months: model coefficient=4.55 (95% CI </text>
<text top="367" left="535" width="111" height="17" font="5">2.63-6.46, p&lt;0.001) </text>
<text top="384" left="535" width="232" height="17" font="5">6 months: model coefficient: 5.03 (95% CI </text>
<text top="401" left="535" width="111" height="17" font="5">3.09-6.97, p&lt;0.001) </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="436" left="535" width="66" height="17" font="5">Confidence </text>
<text top="453" left="535" width="232" height="17" font="5">3 months: model coefficient=3.70 (95% CI </text>
<text top="470" left="535" width="104" height="17" font="5">1.33-6.07, p&lt;0.01) </text>
<text top="487" left="535" width="228" height="17" font="5">6 months: model coefficient 5.48 (95% CI </text>
<text top="505" left="535" width="107" height="17" font="5">2.96-8.00, p&lt;0.001 </text>
<text top="522" left="535" width="3" height="17" font="5"> </text>
<text top="539" left="535" width="185" height="17" font="5">Medication use (OR vs. baseline) </text>
<text top="556" left="535" width="61" height="17" font="5">3 months:  </text>
<text top="573" left="535" width="238" height="17" font="5">Aspirin/Plavix OR=1.50 (95% CI 1.05-2.15) </text>
<text top="591" left="535" width="195" height="17" font="5">Statin OR=1.12 (95% CI 1.00-1.25) </text>
<text top="608" left="535" width="218" height="17" font="5">ACB/ABR OR=1.21 (95% CI 0.84-1.75) </text>
<text top="625" left="535" width="232" height="17" font="5">Beta blocker OR=1.31 (95% CI 0.91-1.89) </text>
<text top="642" left="535" width="216" height="17" font="5">Global medication adherence OR=1.19 </text>
<text top="660" left="535" width="107" height="17" font="5">(95% CI 0.85-1.66) </text>
<text top="677" left="535" width="3" height="17" font="5"> </text>
<text top="694" left="535" width="54" height="17" font="5">6 months </text>
<text top="711" left="535" width="3" height="17" font="5"> </text>
<text top="728" left="535" width="238" height="17" font="5">Aspirin/Plavix OR=1.92 (95% CI 1.27-2.92) </text>
<text top="746" left="535" width="195" height="17" font="5">Statin OR=1.34 (95% CI 0.99-1.81) </text>
<text top="763" left="535" width="218" height="17" font="5">ACB/ABR OR=1.38 (95% CI 0.92-2.09) </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="232" height="17" font="5">Beta blocker OR=1.75 (95% CI 1.07-2.85) </text>
<text top="160" left="535" width="216" height="17" font="5">Global medication adherence OR=1.52 </text>
<text top="178" left="535" width="107" height="17" font="5">(95% CI 1.01-2.29) </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="61" height="17" font="5">12 months </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="238" height="17" font="5">Aspirin/Plavix OR=1.81 (95% CI 1.17-2.79) </text>
<text top="264" left="535" width="195" height="17" font="5">Statin OR=1.52 (95% CI 1.07-2.16) </text>
<text top="281" left="535" width="218" height="17" font="5">ACB/ABR OR=1.13 (95% CI 0.72-1.78) </text>
<text top="298" left="535" width="232" height="17" font="5">Beta blocker OR=1.75 (95% CI 1.07-2.85) </text>
<text top="315" left="535" width="216" height="17" font="5">Global medication adherence OR=1.34 </text>
<text top="333" left="535" width="107" height="17" font="5">(95% CI 0.87-2.06) </text>
<text top="350" left="75" width="97" height="17" font="5">Parchman ML, et </text>
<text top="368" left="75" width="51" height="17" font="5">al., 2010 </text>
<text top="385" left="75" width="3" height="17" font="5"> </text>
<text top="402" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20843882">20843882</a></text>
<text top="402" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20843882"> </a></text>
<text top="350" left="193" width="58" height="17" font="5">Study aim </text>
<text top="368" left="193" width="108" height="17" font="5">To assess a causal </text>
<text top="385" left="193" width="111" height="17" font="5">pathway among the </text>
<text top="402" left="193" width="72" height="17" font="5">relationships </text>
<text top="419" left="193" width="113" height="17" font="5">between physicians’ </text>
<text top="437" left="193" width="70" height="17" font="5">participatory </text>
<text top="454" left="193" width="92" height="17" font="5">decision-making </text>
<text top="471" left="193" width="72" height="17" font="5">style, patient </text>
<text top="488" left="193" width="103" height="17" font="5">participation in the </text>
<text top="505" left="193" width="85" height="17" font="5">encounter, and </text>
<text top="523" left="193" width="60" height="17" font="5">outcomes  </text>
<text top="540" left="193" width="3" height="17" font="5"> </text>
<text top="557" left="193" width="62" height="17" font="5">Study type </text>
<text top="574" left="193" width="105" height="17" font="5">Prospective cohort </text>
<text top="591" left="193" width="3" height="17" font="5"> </text>
<text top="609" left="193" width="40" height="17" font="5">N=141 </text>
<text top="351" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="369" left="324" width="197" height="18" font="5">•  Patients at one of 5 independent </text>
<text top="387" left="325" width="124" height="17" font="5">primary care practices </text>
<text top="405" left="326" width="171" height="17" font="5">Diagnosis of type 2 diabetes in </text>
<text top="422" left="326" width="88" height="17" font="5">past 12 months </text>
<text top="352" left="535" width="7" height="17" font="5">1</text>
<text top="351" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="369" left="535" width="238" height="17" font="5">-<i> Effect of medication adherence on clinical </i></text>
<text top="386" left="535" width="57" height="17" font="7"><i>outcomes </i></text>
<text top="403" left="535" width="228" height="17" font="7"><i>-Effect of patient activation on medication </i></text>
<text top="420" left="535" width="65" height="17" font="7"><i>adherence: </i></text>
<text top="438" left="535" width="231" height="17" font="7"><i>-Effect of participatory decision making on </i></text>
<text top="455" left="535" width="161" height="17" font="7"><i>patient activation at follow up </i></text>
<text top="472" left="535" width="3" height="17" font="5"> </text>
<text top="489" left="535" width="3" height="17" font="5"> </text>
<text top="507" left="535" width="230" height="17" font="7"><i>Effect of medication adherence on clinical </i></text>
<text top="524" left="535" width="57" height="17" font="7"><i>outcomes </i></text>
<text top="541" left="535" width="198" height="17" font="5">HbA1c: regression coefficient=0.04, </text>
<text top="558" left="535" width="41" height="17" font="5">p=0.05 </text>
<text top="575" left="535" width="197" height="17" font="5">Systolic Blood Pressure: regression </text>
<text top="593" left="535" width="140" height="17" font="5">coefficient=0.04 (p=0.80) </text>
<text top="610" left="535" width="156" height="17" font="5">LDL Cholesterol: regression </text>
<text top="627" left="535" width="140" height="17" font="5">coefficient=1.08 (p=0.04) </text>
<text top="644" left="535" width="3" height="17" font="5"> </text>
<text top="661" left="535" width="224" height="17" font="7"><i>Effect of patient activation on medication </i></text>
<text top="679" left="535" width="65" height="17" font="7"><i>adherence: </i></text>
<text top="696" left="535" width="236" height="17" font="5">HbA1c model: regression coefficient=-0.04 </text>
<text top="713" left="535" width="49" height="17" font="5">(p=0.02) </text>
<text top="730" left="535" width="234" height="17" font="5">Systolic Blood Pressure model: regression </text>
<text top="748" left="535" width="147" height="17" font="5">coefficient=-0.004 (p-0.02) </text>
<text top="350" left="786" width="353" height="17" font="5">Participatory decision making during primary care encounters by </text>
<text top="368" left="786" width="312" height="17" font="5">patients with type 2 diabetes resulted in improvements in </text>
<text top="385" left="786" width="351" height="17" font="5">hemoglobin A1c levels and LDL cholesterol values by improving </text>
<text top="402" left="786" width="357" height="17" font="5">patient activation, which in turn improved medication adherence.  </text>
<text top="419" left="786" width="343" height="17" font="5">This relationship was not observed for systolic blood pressure. </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="190" height="17" font="5">LDL cholesterol model: regression </text>
<text top="160" left="535" width="144" height="17" font="5">coefficient=-0.04 (p=0.02) </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="228" height="17" font="7"><i>Effect of participatory decision making on </i></text>
<text top="212" left="535" width="161" height="17" font="7"><i>patient activation at follow up </i></text>
<text top="229" left="535" width="231" height="17" font="5">HbA1c model: regression coefficient=0.44 </text>
<text top="247" left="535" width="49" height="17" font="5">(p=0.03) </text>
<text top="264" left="535" width="234" height="17" font="5">Systolic Blood Pressure model: regression </text>
<text top="281" left="535" width="140" height="17" font="5">coefficient=0.43 (p=0.04) </text>
<text top="298" left="535" width="190" height="17" font="5">LDL cholesterol model: regression </text>
<text top="317" left="535" width="140" height="17" font="5">coefficient=0.42 (p=0.04) </text>
<text top="348" left="75" width="90" height="17" font="5">Backholer  K, et </text>
<text top="365" left="75" width="51" height="17" font="5">al., 2017 </text>
<text top="382" left="75" width="3" height="17" font="5"> </text>
<text top="400" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27974445">27974445</a></text>
<text top="400" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27974445"> </a></text>
<text top="348" left="193" width="59" height="17" font="5">Study Aim </text>
<text top="365" left="193" width="117" height="17" font="5">to ascertain the most </text>
<text top="382" left="193" width="93" height="17" font="5">reliable estimate </text>
<text top="400" left="193" width="120" height="17" font="5">of the sex differences </text>
<text top="417" left="193" width="119" height="17" font="5">in the relative risks of </text>
<text top="434" left="193" width="102" height="17" font="5">SES on the risk of </text>
<text top="451" left="193" width="116" height="17" font="5">incident CHD, stroke </text>
<text top="468" left="193" width="87" height="17" font="5">and CVD in the </text>
<text top="486" left="193" width="105" height="17" font="5">general population </text>
<text top="503" left="193" width="3" height="17" font="5"> </text>
<text top="520" left="193" width="69" height="17" font="5">Study Type: </text>
<text top="537" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="555" left="193" width="103" height="17" font="5">and meta-analysis </text>
<text top="572" left="193" width="3" height="17" font="5"> </text>
<text top="589" left="193" width="115" height="17" font="5">N=116 cohorts (over </text>
<text top="606" left="193" width="120" height="17" font="5">22 million individuals) </text>
<text top="348" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="367" left="324" width="103" height="18" font="5">•  Cohort studies  </text>
<text top="385" left="324" width="184" height="18" font="5">•  Reported sex-specific RRs, or </text>
<text top="403" left="325" width="147" height="17" font="5">equivalent, together with a </text>
<text top="420" left="325" width="160" height="17" font="5">measure of variability, on the </text>
<text top="438" left="325" width="189" height="17" font="5">relationship between any indicator </text>
<text top="455" left="325" width="183" height="17" font="5">of SES and CHD, stroke or CVD  </text>
<text top="472" left="324" width="115" height="18" font="5">•  Adult populations </text>
<text top="490" left="326" width="3" height="17" font="5"> </text>
<text top="507" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="526" left="324" width="162" height="18" font="5">•   available results were not </text>
<text top="544" left="325" width="135" height="17" font="5">adjusted for at least age </text>
<text top="561" left="325" width="171" height="17" font="5">selected on the basis of a prior </text>
<text top="580" left="325" width="154" height="17" font="5">CVD event or an underlying </text>
<text top="599" left="325" width="117" height="17" font="5">pathological disorder </text>
<text top="349" left="535" width="7" height="17" font="5">1</text>
<text top="348" left="542" width="58" height="18" font="5">Endpoint </text>
<text top="366" left="535" width="238" height="17" font="5">combined fatal and non-fatal incident CHD, </text>
<text top="384" left="535" width="213" height="17" font="5">stroke or CVD (where studies reported </text>
<text top="401" left="535" width="219" height="17" font="5">results for fatal outcomes only, we used </text>
<text top="418" left="535" width="163" height="17" font="5">this end point in our analyses </text>
<text top="435" left="535" width="3" height="17" font="5"> </text>
<text top="454" left="535" width="7" height="17" font="5">2</text>
<text top="453" left="542" width="64" height="18" font="5">Endpoints </text>
<text top="471" left="535" width="3" height="17" font="5"> </text>
<text top="488" left="535" width="223" height="17" font="5">Pooled RRs (highest vs. lowest SES) for </text>
<text top="505" left="535" width="217" height="17" font="5">each sex both adjusted for age, without </text>
<text top="523" left="535" width="124" height="17" font="5">other CVD risk factors </text>
<text top="540" left="535" width="3" height="17" font="5"> </text>
<text top="557" left="535" width="238" height="17" font="5">Multiple adjusted RRs with adjustment sets </text>
<text top="574" left="535" width="180" height="17" font="5">that most closely matched to the </text>
<text top="591" left="535" width="238" height="17" font="5">conventional CVD risk factors (ie, smoking, </text>
<text top="609" left="535" width="216" height="17" font="5">diabetes, total cholesterol, high-density </text>
<text top="626" left="535" width="224" height="17" font="5">lipoprotein cholesterol and systolic blood </text>
<text top="643" left="535" width="229" height="17" font="5">pressure), while avoiding adjustment sets </text>
<text top="660" left="535" width="204" height="17" font="5">that included other measures of SES </text>
<text top="677" left="535" width="3" height="17" font="5"> </text>
<text top="696" left="535" width="7" height="17" font="5">1</text>
<text top="695" left="542" width="58" height="18" font="5">Endpoint </text>
<text top="713" left="535" width="3" height="17" font="5"> </text>
<text top="730" left="535" width="30" height="17" font="7"><i>CHD </i></text>
<text top="747" left="535" width="58" height="17" font="7"><i>Education </i></text>
<text top="765" left="535" width="208" height="17" font="5">Female: RR=1.66 (95% CI 1.46-1,88) </text>
<text top="348" left="786" width="3" height="17" font="5"> </text>
<text top="365" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="193" height="17" font="5">Male: RR=1.30 (95% CI 1.15-1.48) </text>
<text top="160" left="535" width="3" height="17" font="5"> </text>
<text top="178" left="535" width="95" height="17" font="7"><i>Area Deprivation </i></text>
<text top="195" left="535" width="208" height="17" font="5">Female: RR=1.83 (95% CI 1.61-2.07) </text>
<text top="212" left="535" width="193" height="17" font="5">Male: RR=1.50 (95% CI 1.38-1.63) </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="66" height="17" font="7"><i>Occupation </i></text>
<text top="264" left="535" width="208" height="17" font="5">Female: RR=1.59 (95% CI 1.26-1.97) </text>
<text top="281" left="535" width="193" height="17" font="5">Male: RR=1.50 (95% CI 1.25-1.80) </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="44" height="17" font="7"><i>Income </i></text>
<text top="333" left="535" width="208" height="17" font="5">Female: RR=2.48 (95% CI 1.53-4.00) </text>
<text top="350" left="535" width="193" height="17" font="5">Male: RR=2.01 (95% CI 1.47-2.74) </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="228" height="17" font="5">Age adjusted RRR comparing women vs. </text>
<text top="401" left="535" width="227" height="17" font="5">men: RRR=1.24 (95% CI 1.09-1.41), and </text>
<text top="419" left="535" width="227" height="17" font="5">adjusting for major CVD risk factors RRR </text>
<text top="436" left="535" width="212" height="17" font="5">comparing women vs. men RRR=1.34 </text>
<text top="453" left="535" width="111" height="17" font="5">(95% CI 1.09-1.63). </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="39" height="17" font="7"><i>Stroke </i></text>
<text top="522" left="535" width="58" height="17" font="7"><i>Education </i></text>
<text top="539" left="535" width="208" height="17" font="5">Female: RR=1.34 (95% CI 1.07-1,69) </text>
<text top="556" left="535" width="193" height="17" font="5">Male: RR=1.53 (95% CI 1.27-1.86) </text>
<text top="573" left="535" width="3" height="17" font="5"> </text>
<text top="591" left="535" width="95" height="17" font="7"><i>Area Deprivation </i></text>
<text top="608" left="535" width="208" height="17" font="5">Female: RR=1.60 (95% CI 1.21-2.12) </text>
<text top="625" left="535" width="193" height="17" font="5">Male: RR=1.63 (95% CI 1.35-1.96) </text>
<text top="642" left="535" width="3" height="17" font="5"> </text>
<text top="660" left="535" width="66" height="17" font="7"><i>Occupation </i></text>
<text top="677" left="535" width="208" height="17" font="5">Female: RR=1.81 (95% CI 0.91-3.62) </text>
<text top="694" left="535" width="193" height="17" font="5">Male: RR=1.50 (95% CI 0.96-2.36) </text>
<text top="711" left="535" width="3" height="17" font="5"> </text>
<text top="728" left="535" width="44" height="17" font="7"><i>Income </i></text>
<text top="746" left="535" width="208" height="17" font="5">Female: RR=1.64 (95% CI 1.36-1.96) </text>
<text top="763" left="535" width="193" height="17" font="5">Male: RR=1.73 (95% CI 1.33-2.24) </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="228" height="17" font="5">Age adjusted RRR comparing women vs. </text>
<text top="178" left="535" width="227" height="17" font="5">men: RRR=0.93 (95% CI 0.72-1.18), and </text>
<text top="195" left="535" width="227" height="17" font="5">adjusting for major CVD risk factors RRR </text>
<text top="212" left="535" width="212" height="17" font="5">comparing women vs. men RRR=0.79 </text>
<text top="229" left="535" width="111" height="17" font="5">(95% CI 0.53-1.17). </text>
<text top="247" left="535" width="3" height="17" font="5"> </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="29" height="17" font="7"><i>CVD </i></text>
<text top="298" left="535" width="58" height="17" font="7"><i>Education </i></text>
<text top="315" left="535" width="208" height="17" font="5">Female: RR=1.66 (95% CI 1.43-1,92) </text>
<text top="333" left="535" width="193" height="17" font="5">Male: RR=1.42 (95% CI 1.25-1.63) </text>
<text top="350" left="535" width="3" height="17" font="5"> </text>
<text top="367" left="535" width="95" height="17" font="7"><i>Area Deprivation </i></text>
<text top="384" left="535" width="208" height="17" font="5">Female: RR=1.75 (95% CI 1.55-1.98) </text>
<text top="401" left="535" width="193" height="17" font="5">Male: RR=1.60 (95% CI 1.45-1.76) </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="436" left="535" width="66" height="17" font="7"><i>Occupation </i></text>
<text top="453" left="535" width="208" height="17" font="5">Female: RR=1.80 (95% CI 1.51-2.40) </text>
<text top="470" left="535" width="193" height="17" font="5">Male: RR=1.74 (95% CI 1.38-2.20) </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="44" height="17" font="7"><i>Income </i></text>
<text top="522" left="535" width="208" height="17" font="5">Female: RR=1.46 (95% CI 1.43-1.50) </text>
<text top="539" left="535" width="193" height="17" font="5">Male: RR=1.36 (95% CI 1.34-1.39) </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="228" height="17" font="5">Age adjusted RRR comparing women vs. </text>
<text top="591" left="535" width="227" height="17" font="5">men: RRR=1.18 (95% CI 1.03-1.36), and </text>
<text top="608" left="535" width="227" height="17" font="5">adjusting for major CVD risk factors RRR </text>
<text top="625" left="535" width="212" height="17" font="5">comparing women vs. men RRR=1.21 </text>
<text top="642" left="535" width="111" height="17" font="5">(95% CI 1.04-1.42). </text>
<text top="660" left="535" width="3" height="17" font="5"> </text>
<text top="677" left="535" width="223" height="17" font="5">No evidence of publication bias (p=0.68) </text>
<text top="694" left="535" width="3" height="17" font="5"> </text>
<text top="711" left="535" width="3" height="17" font="5"> </text>
<text top="729" left="75" width="90" height="17" font="5">Khaing W et al., </text>
<text top="746" left="75" width="31" height="17" font="5">2017 </text>
<text top="764" left="75" width="3" height="17" font="5"> </text>
<text top="729" left="193" width="59" height="17" font="5">Study Aim </text>
<text top="746" left="193" width="114" height="17" font="5">to pool the effects of </text>
<text top="764" left="193" width="119" height="17" font="5">low to high education </text>
<text top="729" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="748" left="324" width="193" height="18" font="5">•  assessed associations between </text>
<text top="766" left="325" width="124" height="17" font="5">education/income and </text>
<text top="730" left="535" width="7" height="17" font="5">1</text>
<text top="729" left="542" width="58" height="18" font="5">Endpoint </text>
<text top="748" left="535" width="3" height="17" font="5"> </text>
<text top="729" left="786" width="351" height="17" font="5">Summary: In general, groups with low to medium education and </text>
<text top="746" left="786" width="277" height="17" font="5">income are at higher risk of CAD, CVE, stroke and </text>
<text top="764" left="786" width="354" height="17" font="5">cardiovascular death than those with high education and income </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28406328">28406328</a></text>
<text top="143" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28406328"> </a></text>
<text top="143" left="193" width="84" height="17" font="5">and income on </text>
<text top="160" left="193" width="43" height="17" font="5">various </text>
<text top="178" left="193" width="83" height="17" font="5">cardiovascular </text>
<text top="195" left="193" width="73" height="17" font="5">outcomes by </text>
<text top="212" left="193" width="83" height="17" font="5">including more </text>
<text top="229" left="193" width="115" height="17" font="5">studies conducted in </text>
<text top="247" left="193" width="116" height="17" font="5">developing countries </text>
<text top="264" left="193" width="3" height="17" font="5"> </text>
<text top="281" left="193" width="62" height="17" font="5">Study type </text>
<text top="298" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="315" left="193" width="106" height="17" font="5">and Meta analysis  </text>
<text top="333" left="193" width="3" height="17" font="5"> </text>
<text top="350" left="193" width="76" height="17" font="5">N=72 studies </text>
<text top="143" left="325" width="152" height="17" font="5">cardiovascular outcomes in </text>
<text top="160" left="325" width="192" height="17" font="5">general adults or specific diseases </text>
<text top="178" left="324" width="189" height="18" font="5">•  measured education or income </text>
<text top="196" left="324" width="172" height="18" font="5">•  had at least one outcome of </text>
<text top="214" left="325" width="154" height="17" font="5">interest (i.e. coronary artery </text>
<text top="231" left="325" width="181" height="17" font="5">diseases, cardiovascular events, </text>
<text top="248" left="325" width="194" height="17" font="5">strokes and cardiovascular deaths) </text>
<text top="266" left="324" width="187" height="18" font="5">•  had contingency data between </text>
<text top="284" left="325" width="124" height="17" font="5">education/income and </text>
<text top="301" left="325" width="167" height="17" font="5">cardiovascular outcomes, or a </text>
<text top="318" left="325" width="94" height="17" font="5">beta-coefficient.  </text>
<text top="336" left="324" width="196" height="18" font="5">•  Published 1982 through July 31, </text>
<text top="354" left="325" width="31" height="17" font="5">2016 </text>
<text top="371" left="325" width="3" height="17" font="5"> </text>
<text top="390" left="325" width="100" height="17" font="5">Exclusion criteria  </text>
<text top="408" left="324" width="186" height="18" font="5">•  data for education and income </text>
<text top="426" left="325" width="87" height="17" font="5">were combined </text>
<text top="444" left="325" width="195" height="17" font="5">income was based on ownership of </text>
<text top="462" left="325" width="171" height="17" font="5">car/house/health insurance/zip-</text>
<text top="481" left="325" width="33" height="17" font="5">code. </text>
<text top="143" left="535" width="227" height="17" font="5">CVDs including CAD (e.g. acute MI, IHD, </text>
<text top="160" left="535" width="231" height="17" font="5">coronary heart disease (CHD)), CVE (e.g. </text>
<text top="178" left="535" width="208" height="17" font="5">HF, hospital admission due to cardiac </text>
<text top="195" left="535" width="225" height="17" font="5">causes, revascularization and composite </text>
<text top="212" left="535" width="194" height="17" font="5">CVDs (e.g. IHD or stroke)), strokes </text>
<text top="229" left="535" width="216" height="17" font="5">(ischemic or hemorrhagic strokes), and </text>
<text top="247" left="535" width="130" height="17" font="5">cardiovascular deaths.  </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="223" height="17" font="5">45 out of 72 (62%) had a low risk of bias </text>
<text top="298" left="535" width="226" height="17" font="5">and 27 out of 72 (38%) had a high risk of </text>
<text top="315" left="535" width="26" height="17" font="5">bias </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="350" left="535" width="141" height="17" font="5">Coronary artery diseases </text>
<text top="367" left="535" width="62" height="17" font="7"><i>Education  </i></text>
<text top="384" left="535" width="216" height="17" font="5">Medium vs High RR=1.21 (95%CI 1.06-</text>
<text top="401" left="535" width="31" height="17" font="5">1.40) </text>
<text top="419" left="535" width="234" height="17" font="5">Low vs. High RR=1.36 (95% CI 1.11-1.66) </text>
<text top="436" left="535" width="164" height="17" font="5">Effects were heterogeneous (I</text>
<text top="437" left="699" width="4" height="11" font="8">2</text>
<text top="436" left="703" width="68" height="17" font="5">=94%-96%) </text>
<text top="453" left="535" width="3" height="17" font="5"> </text>
<text top="470" left="535" width="224" height="17" font="5">Medium vs. High USA RR=1.21 (95% CI </text>
<text top="487" left="535" width="60" height="17" font="5">0.97-1.51) </text>
<text top="505" left="535" width="231" height="17" font="5">Low vs. High USA RR=1.51 (95% CI 0.93-</text>
<text top="522" left="535" width="31" height="17" font="5">2.45) </text>
<text top="539" left="535" width="8" height="17" font="5">(I</text>
<text top="540" left="542" width="4" height="11" font="8">2</text>
<text top="539" left="547" width="57" height="17" font="5">=47-75%) </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="44" height="17" font="7"><i>Income </i></text>
<text top="591" left="535" width="218" height="17" font="5">Medium vs high RR=1.27 (95% CI 1.10-</text>
<text top="608" left="535" width="31" height="17" font="5">1.47) </text>
<text top="625" left="535" width="231" height="17" font="5">Low vs. high RR=1.49 (95% CI 1.16-1.91) </text>
<text top="642" left="535" width="3" height="17" font="5"> </text>
<text top="660" left="535" width="164" height="17" font="5">Effects were heterogeneous (I</text>
<text top="661" left="699" width="4" height="11" font="8">2</text>
<text top="660" left="703" width="68" height="17" font="5">=95%-98%) </text>
<text top="677" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="694" left="535" width="125" height="17" font="5">Cardiovascular events </text>
<text top="711" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="728" left="535" width="58" height="17" font="7"><i>Education </i></text>
<text top="746" left="535" width="218" height="17" font="5">Medium vs high RR=1.27 (95% CI 1.09-</text>
<text top="763" left="535" width="31" height="17" font="5">1.48) </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="228" height="17" font="5">Low vs high RR=1.50 (95% CI 1.17-1.92) </text>
<text top="160" left="535" width="164" height="17" font="5">Effects were heterogeneous (I</text>
<text top="161" left="699" width="4" height="11" font="8">2</text>
<text top="160" left="703" width="68" height="17" font="5">=83%-99%) </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="221" height="17" font="5">Medium vs. high USA RR=1.07 (95% CI </text>
<text top="212" left="535" width="67" height="17" font="5">0.69-1.66) (I</text>
<text top="213" left="602" width="4" height="11" font="8">2</text>
<text top="212" left="606" width="39" height="17" font="5">=78%) </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="44" height="17" font="7"><i>Income </i></text>
<text top="264" left="535" width="221" height="17" font="7"><i>Medium vs. high RR=1.05 (95% CI 0.98-</i></text>
<text top="281" left="535" width="31" height="17" font="7"><i>1.13) </i></text>
<text top="298" left="535" width="231" height="17" font="7"><i>Low vs. high RR=1.17 (95% CI 0.96-1.44) </i></text>
<text top="315" left="535" width="164" height="17" font="7"><i>Effects were heterogeneous </i>(I</text>
<text top="316" left="699" width="4" height="11" font="8">2</text>
<text top="315" left="703" width="68" height="17" font="5">=97%-99%)<i> </i></text>
<text top="333" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="350" left="535" width="45" height="17" font="5">Strokes </text>
<text top="367" left="535" width="58" height="17" font="7"><i>Education </i></text>
<text top="384" left="535" width="221" height="17" font="5">Medium vs. high RR=1.17 (95% CI 1.01-</text>
<text top="401" left="535" width="31" height="17" font="5">1.35) </text>
<text top="419" left="535" width="231" height="17" font="5">Low vs. high RR=1.23 (95% CI 1.06-1.43) </text>
<text top="436" left="535" width="164" height="17" font="5">Effects were heterogeneous (I</text>
<text top="437" left="699" width="4" height="11" font="8">2</text>
<text top="436" left="703" width="68" height="17" font="5">=83%-99%) </text>
<text top="453" left="535" width="3" height="17" font="5"> </text>
<text top="470" left="535" width="222" height="17" font="5">Medium vs. high USA RR=0.98 (95% CI </text>
<text top="487" left="535" width="60" height="17" font="5">0.81-1.19) </text>
<text top="505" left="535" width="225" height="17" font="5">Low vs high USA RR=0.99 (95% CI 0.83-</text>
<text top="522" left="535" width="31" height="17" font="5">1.20) </text>
<text top="539" left="535" width="8" height="17" font="5">(I</text>
<text top="540" left="542" width="4" height="11" font="8">2</text>
<text top="539" left="547" width="68" height="17" font="5">=53%-89%) </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="44" height="17" font="7"><i>Income </i></text>
<text top="591" left="535" width="221" height="17" font="5">Medium vs. high RR=1.24 (95% CI 1.00-</text>
<text top="608" left="535" width="31" height="17" font="5">1.53) </text>
<text top="625" left="535" width="228" height="17" font="5">Low vs high RR=1.30 (95% CI 0.99-1.72) </text>
<text top="642" left="535" width="164" height="17" font="5">Effects were heterogeneous (I</text>
<text top="644" left="699" width="4" height="11" font="8">2</text>
<text top="642" left="703" width="68" height="17" font="5">=98%-99%) </text>
<text top="660" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="677" left="535" width="221" height="17" font="5">Medium vs. high USA RR=0.89 (95% CI </text>
<text top="694" left="535" width="60" height="17" font="5">0.62-1.27) </text>
<text top="711" left="535" width="225" height="17" font="5">Low vs. high USA RR=0.91 (95%CI 0.58-</text>
<text top="728" left="535" width="31" height="17" font="5">1.41) </text>
<text top="746" left="535" width="8" height="17" font="5">(I</text>
<text top="747" left="542" width="4" height="11" font="8">2</text>
<text top="746" left="547" width="68" height="17" font="5">=49%-78%) </text>
<text top="763" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="126" height="17" font="5">Cardiovascular deaths </text>
<text top="160" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="178" left="535" width="58" height="17" font="7"><i>Education </i></text>
<text top="195" left="535" width="221" height="17" font="5">Medium vs. high RR=1.21 (95% CI 1.12-</text>
<text top="212" left="535" width="31" height="17" font="5">1.30) </text>
<text top="229" left="535" width="231" height="17" font="5">Low vs. high RR=1.39 (95% CI 1.26-1.54) </text>
<text top="247" left="535" width="164" height="17" font="5">Effects were heterogeneous (I</text>
<text top="248" left="699" width="4" height="11" font="8">2</text>
<text top="247" left="703" width="28" height="17" font="5">=98) </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="222" height="17" font="5">Medium vs. high USA RR=1.30 (95% CI </text>
<text top="298" left="535" width="60" height="17" font="5">1.14-1.49) </text>
<text top="315" left="535" width="229" height="17" font="5">Low vs. high USA RR=1.69 (95% CI 1.28-</text>
<text top="333" left="535" width="31" height="17" font="5">2.22) </text>
<text top="350" left="535" width="8" height="17" font="5">(I</text>
<text top="351" left="542" width="4" height="11" font="8">2</text>
<text top="350" left="547" width="68" height="17" font="5">=72%-95%) </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="44" height="17" font="7"><i>Income </i></text>
<text top="401" left="535" width="221" height="17" font="5">Medium vs. high RR=1.34 (95% CI 1.17-</text>
<text top="419" left="535" width="31" height="17" font="5">1.64) </text>
<text top="436" left="535" width="231" height="17" font="5">Low vs. high RR=1.76 (95% CI 1.45-2.14) </text>
<text top="453" left="535" width="164" height="17" font="5">Effects were heterogeneous (I</text>
<text top="454" left="699" width="4" height="11" font="8">2</text>
<text top="453" left="703" width="68" height="17" font="5">=96%-99%) </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="488" left="75" width="91" height="17" font="5">Pollitt RA, et al., </text>
<text top="505" left="75" width="31" height="17" font="5">2005 </text>
<text top="523" left="75" width="3" height="17" font="5"> </text>
<text top="540" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15661071">15661071</a></text>
<text top="540" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15661071"> </a></text>
<text top="488" left="193" width="63" height="17" font="5">Study Aim: </text>
<text top="505" left="193" width="88" height="17" font="5">To describe the </text>
<text top="523" left="193" width="89" height="17" font="5">major groups of </text>
<text top="540" left="193" width="82" height="17" font="5">conceptual life </text>
<text top="557" left="193" width="115" height="17" font="5">course SES models, </text>
<text top="574" left="193" width="84" height="17" font="5">categorize and </text>
<text top="591" left="193" width="106" height="17" font="5">summarize studies </text>
<text top="609" left="193" width="94" height="17" font="5">that examine the </text>
<text top="626" left="193" width="71" height="17" font="5">associations </text>
<text top="643" left="193" width="109" height="17" font="5">between life course </text>
<text top="660" left="193" width="104" height="17" font="5">SES and CVD risk </text>
<text top="678" left="193" width="3" height="17" font="5"> </text>
<text top="695" left="193" width="65" height="17" font="5">Study type: </text>
<text top="712" left="193" width="103" height="17" font="5">Systematic review </text>
<text top="729" left="193" width="3" height="17" font="5"> </text>
<text top="746" left="193" width="76" height="17" font="5">N=49 studies </text>
<text top="488" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="507" left="324" width="156" height="18" font="5">•  publication date between </text>
<text top="525" left="325" width="158" height="17" font="5">January 1966 and July 2003 </text>
<text top="542" left="324" width="174" height="18" font="5">•  SES or related measures as </text>
<text top="561" left="325" width="124" height="17" font="5">independent variables </text>
<text top="578" left="325" width="193" height="17" font="5">outcomes of subclinical CHD, CVD </text>
<text top="596" left="325" width="159" height="17" font="5">morbidity and/or mortality, or </text>
<text top="615" left="325" width="149" height="17" font="5">traditional CVD risk factors </text>
<text top="488" left="535" width="181" height="17" font="5">NO QUANTITATIVE SUMMARY </text>
<text top="505" left="535" width="3" height="17" font="5"> </text>
<text top="523" left="535" width="202" height="17" font="5">Early SES: All 19 studies conducting </text>
<text top="540" left="535" width="204" height="17" font="5">unadjusted or age adjusted analyses </text>
<text top="557" left="535" width="223" height="17" font="5">reported a point estimate consistent with </text>
<text top="574" left="535" width="225" height="17" font="5">an inverse association between early-life </text>
<text top="591" left="535" width="222" height="17" font="5">SES and risk of one or more of the adult </text>
<text top="609" left="535" width="140" height="17" font="5">cardiovascular outcomes </text>
<text top="626" left="535" width="3" height="17" font="5"> </text>
<text top="643" left="535" width="212" height="17" font="5">Social trajectory studies: Of 10 studies </text>
<text top="660" left="535" width="236" height="17" font="5">carrying out statistical analyses, six did not </text>
<text top="678" left="535" width="215" height="17" font="5">report associations between upward or </text>
<text top="695" left="535" width="212" height="17" font="5">downward mobility and either elevated </text>
<text top="712" left="535" width="212" height="17" font="5">levels of CVD risk factors or increased </text>
<text top="729" left="535" width="238" height="17" font="5">CVD morbidity or mortality when compared </text>
<text top="746" left="535" width="234" height="17" font="5">to stable low-SES or high-SES trajectories </text>
<text top="764" left="535" width="3" height="17" font="5"> </text>
<text top="488" left="786" width="70" height="17" font="5">Conclusions </text>
<text top="505" left="786" width="340" height="17" font="5">The literature identified modestly supports the existence of life </text>
<text top="523" left="786" width="221" height="17" font="5">course SES effects on risk of adult CVD </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="217" height="17" font="5">Cumulative SES: All 7 papers reviewed </text>
<text top="160" left="535" width="223" height="17" font="5">reported that participants' cumulative life </text>
<text top="178" left="535" width="217" height="17" font="5">course exposure to low SES conditions </text>
<text top="195" left="535" width="211" height="17" font="5">was associated with increases in CVD </text>
<text top="212" left="535" width="218" height="17" font="5">outcome. Several studies indicated that </text>
<text top="229" left="535" width="207" height="17" font="5">cumulative SES was a more powerful </text>
<text top="247" left="535" width="236" height="17" font="5">predictor of CVD morbidity and/or mortality </text>
<text top="264" left="535" width="183" height="17" font="5">than adult or early-life SES alone </text>
<text top="281" left="535" width="3" height="17" font="5"> </text>
<text top="299" left="75" width="89" height="17" font="5">Wan EYF et al., </text>
<text top="316" left="75" width="31" height="17" font="5">2018 </text>
<text top="333" left="75" width="3" height="17" font="5"> </text>
<text top="350" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29138274">29138274</a></text>
<text top="350" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29138274"> </a></text>
<text top="299" left="193" width="63" height="17" font="5">Study Aim: </text>
<text top="316" left="193" width="99" height="17" font="5">To evaluate the 5-</text>
<text top="333" left="193" width="116" height="17" font="5">year effectiveness of </text>
<text top="350" left="193" width="100" height="17" font="5">a multidisciplinary </text>
<text top="368" left="193" width="97" height="17" font="5">Risk Assessment </text>
<text top="385" left="193" width="99" height="17" font="5">and Management </text>
<text top="402" left="193" width="71" height="17" font="5">Programme–</text>
<text top="419" left="193" width="97" height="17" font="5">Diabetes Mellitus </text>
<text top="437" left="193" width="83" height="17" font="5">(RAMP-DM) in </text>
<text top="454" left="193" width="118" height="17" font="5">primary care patients </text>
<text top="471" left="193" width="112" height="17" font="5">with type 2 diabetes </text>
<text top="488" left="193" width="3" height="17" font="5"> </text>
<text top="505" left="193" width="66" height="17" font="5">Study Type </text>
<text top="523" left="193" width="105" height="17" font="5">Prospective cohort </text>
<text top="540" left="193" width="33" height="17" font="5">study </text>
<text top="557" left="193" width="3" height="17" font="5"> </text>
<text top="574" left="193" width="57" height="17" font="5">N=53,436 </text>
<text top="299" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="318" left="324" width="135" height="18" font="5">•  age at least 18 years </text>
<text top="336" left="324" width="189" height="18" font="5">•  clinical diagnosis of type 2 DM  </text>
<text top="354" left="324" width="185" height="18" font="5">•  no prior CVD or microvascular </text>
<text top="372" left="325" width="78" height="17" font="5">complications </text>
<text top="389" left="325" width="3" height="17" font="5"> </text>
<text top="408" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="300" left="535" width="7" height="17" font="5">1</text>
<text top="299" left="542" width="58" height="18" font="5">Endpoint </text>
<text top="317" left="535" width="102" height="17" font="5">all cause mortality </text>
<text top="334" left="535" width="3" height="17" font="5"> </text>
<text top="353" left="535" width="7" height="17" font="5">2</text>
<text top="352" left="542" width="64" height="18" font="5">Endpoints </text>
<text top="370" left="535" width="231" height="17" font="5">incidences of CVD events (coronary heart </text>
<text top="387" left="535" width="180" height="17" font="5">disease, heart failure, or stroke), </text>
<text top="404" left="535" width="229" height="17" font="5">microvascular complications (retinopathy, </text>
<text top="422" left="535" width="233" height="17" font="5">nephropathy, neuropathy, end-stage renal </text>
<text top="439" left="535" width="214" height="17" font="5">disease, and sight-threatening diabetic </text>
<text top="456" left="535" width="195" height="17" font="5">retinopathy), and service use rates. </text>
<text top="473" left="535" width="3" height="17" font="5"> </text>
<text top="490" left="535" width="221" height="17" font="5">All cause mortality: 1.68 per 100 person-</text>
<text top="508" left="535" width="235" height="17" font="5">years in RAMP-DM (95% CI 1.61-1.75) vs. </text>
<text top="525" left="535" width="220" height="17" font="5">5.07 per 100 person years in usual care </text>
<text top="542" left="535" width="221" height="17" font="5">(95% CI 4.95-5.20).  HR=0.339 (95% CI </text>
<text top="559" left="535" width="125" height="17" font="5">0.321-0.357), p&lt;0.001 </text>
<text top="577" left="535" width="3" height="17" font="5"> </text>
<text top="594" left="535" width="220" height="17" font="5">Any CV or microvascular complications: </text>
<text top="611" left="535" width="224" height="17" font="5">4.34 per 100 person years (4.22-4.46) in </text>
<text top="628" left="535" width="229" height="17" font="5">RAMP-DM vs. 7.73 (95% CI 7.57-7.90) in </text>
<text top="645" left="535" width="209" height="17" font="5">usual care.  HR=0.594 (95% CI 0.572-</text>
<text top="663" left="535" width="90" height="17" font="5">0.617), p&lt;0.001 </text>
<text top="680" left="535" width="3" height="17" font="5"> </text>
<text top="697" left="535" width="212" height="17" font="5">CVD: 2.47 per 100 person years (2.38-</text>
<text top="714" left="535" width="229" height="17" font="5">2.55) in RAMP-DM vs. 5.58 (95% CI 5.44-</text>
<text top="732" left="535" width="215" height="17" font="5">5.72) in usual care. HR=0.434 (95% CI </text>
<text top="749" left="535" width="125" height="17" font="5">0.414-0.455), p&lt;0.001 </text>
<text top="766" left="535" width="3" height="17" font="5"> </text>
<text top="299" left="786" width="334" height="17" font="5">Summary RAMP-DM led to significantly greater reductions in </text>
<text top="316" left="786" width="346" height="17" font="5">CVD/ microvascular complications and secondary/ tertiary care </text>
<text top="333" left="786" width="215" height="17" font="5">service uses compared with usual care </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="213" height="17" font="5">CHD: 1.11 per 100 person years (1.05-</text>
<text top="160" left="535" width="229" height="17" font="5">1.17) in RAMP-DM vs. 2.79 (95% CI 2.70-</text>
<text top="178" left="535" width="218" height="17" font="5">2.89) in usual care.  HR=0.383 (95% CI </text>
<text top="195" left="535" width="125" height="17" font="5">0.358-0.410), p&lt;0.001 </text>
<text top="212" left="535" width="3" height="17" font="5"> </text>
<text top="229" left="535" width="221" height="17" font="5">Heart failure: 0.71 per 100 person years </text>
<text top="247" left="535" width="229" height="17" font="5">(95% CI 0.67-0.76) in RAMP-DM vs. 1.75 </text>
<text top="264" left="535" width="187" height="17" font="5">(95% CI 1.68-1.83) in usual care.  </text>
<text top="281" left="535" width="232" height="17" font="5">HR=0.401 (95% CI 0.368-0.436), p&lt;0.001 </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="234" height="17" font="5">Stroke:1.00 per 100 person years (95% CI </text>
<text top="333" left="535" width="229" height="17" font="5">0.95-1.06) in RAMP-DM vs. 1.92 (95% CI </text>
<text top="350" left="535" width="231" height="17" font="5">1.84-1.99) in usual care.  HR=0.533 (95% </text>
<text top="367" left="535" width="141" height="17" font="5">CI 0.495-0.574), p&lt;0.001 </text>
<text top="384" left="535" width="3" height="17" font="5"> </text>
<text top="401" left="535" width="230" height="17" font="5">Any microvascular complications:2.23 per </text>
<text top="419" left="535" width="219" height="17" font="5">100 person years (95% CI 2.15-2.31) in </text>
<text top="436" left="535" width="229" height="17" font="5">RAMP-DM vs. 2.95 (95% CI 2.85-3.05) in </text>
<text top="453" left="535" width="209" height="17" font="5">usual care.  HR=0.881 (95% CI 0.834-</text>
<text top="470" left="535" width="90" height="17" font="5">0.930), p&lt;0.001 </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="219" height="17" font="5">Retinopathy: 0.81 per 100 person years </text>
<text top="522" left="535" width="232" height="17" font="5">(95% CI: 0.76-0.86) in RAMP-DM vs. 0.87 </text>
<text top="539" left="535" width="187" height="17" font="5">(95% CI 0.82-0.92) in usual care.  </text>
<text top="556" left="535" width="232" height="17" font="5">HR=1.256 (95% CI 1.144-1.379), p&lt;0.001 </text>
<text top="573" left="535" width="3" height="17" font="5"> </text>
<text top="591" left="535" width="224" height="17" font="5">Nephropathy: 1.50 per 100 person years </text>
<text top="608" left="535" width="229" height="17" font="5">(95% CI 1.44-1.57) in RAMP-DM vs. 2.24 </text>
<text top="625" left="535" width="184" height="17" font="5">(95% CI 2.16-2.33) in usual care. </text>
<text top="642" left="535" width="232" height="17" font="5">HR=0.742 (95% CI 0.696-0.791), p&lt;0.001 </text>
<text top="660" left="535" width="3" height="17" font="5"> </text>
<text top="677" left="535" width="217" height="17" font="5">Neuropathy: 0.10 per 100 person years </text>
<text top="694" left="535" width="229" height="17" font="5">(95% CI 0.08-0.12) in RAMP-DM vs. 0.25 </text>
<text top="711" left="535" width="187" height="17" font="5">(95% CI 0.22-0.28) in usual care.  </text>
<text top="728" left="535" width="230" height="17" font="5">HR=0.391 (95% CI 0.314-0.488), P,0.001 </text>
<text top="746" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="236" height="17" font="5">ESRD: 0.11 per 100 person years (95% CI </text>
<text top="160" left="535" width="229" height="17" font="5">0.09-0.13) in RAMP-DM vs. 0.28 (95% CI </text>
<text top="178" left="535" width="231" height="17" font="5">0.25-0.31) in usual care.  HR=0.384 (95% </text>
<text top="195" left="535" width="141" height="17" font="5">CI 0.311-0.474), p&lt;0.001 </text>
<text top="212" left="535" width="3" height="17" font="5"> </text>
<text top="229" left="535" width="235" height="17" font="5">STDR: 0.11 per 100 person years (95% CI </text>
<text top="247" left="535" width="229" height="17" font="5">0.09-0.13) in RAMP-DM vs. 0.34 (95% CI </text>
<text top="264" left="535" width="231" height="17" font="5">0.31-0.38) in usual care.  HR=0.412 (95% </text>
<text top="281" left="535" width="141" height="17" font="5">CI 0.334-0.509), p&lt;0.001 </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="207" height="17" font="5">Hospitalization: 32.49 per 100 person </text>
<text top="333" left="535" width="238" height="17" font="5">years in RAMP-DM vs.64.35 in usual care.  </text>
<text top="350" left="535" width="232" height="17" font="5">HR=0.415 (95% CI 0.403-0.428), p&lt;0.001 </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="216" height="17" font="5">A&amp;E attendance: 52.41 per 100 person </text>
<text top="401" left="535" width="208" height="17" font="5">years in RAMP-DM vs. 80.43 in usual </text>
<text top="419" left="535" width="218" height="17" font="5">care.  HR=0.588 (95% CI 0.575-0.602), </text>
<text top="436" left="535" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="453" left="535" width="3" height="17" font="5"> </text>
<text top="470" left="535" width="233" height="17" font="5">SOPC attendance: 210.79 per 100 person </text>
<text top="487" left="535" width="211" height="17" font="5">years in RAMP-DM vs.307.47 in usual </text>
<text top="505" left="535" width="218" height="17" font="5">care.  HR=0.650 (95% CI 0.636-0.664), </text>
<text top="522" left="535" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="539" left="535" width="3" height="17" font="5"> </text>
<text top="556" left="535" width="234" height="17" font="5">GOPC attendance: 456.95 per 100 person </text>
<text top="573" left="535" width="214" height="17" font="5">years in RAMP-DM vs. 354.34 in usual </text>
<text top="591" left="535" width="218" height="17" font="5">care.  HR=1.326 (95% CI 1.311-1.340), </text>
<text top="608" left="535" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="625" left="535" width="3" height="17" font="5"> </text>
<text top="642" left="535" width="232" height="17" font="5">HRs were presented for 21 strata for each </text>
<text top="660" left="535" width="213" height="17" font="5">outcome (by age, smoking, duration of </text>
<text top="677" left="535" width="220" height="17" font="5">DM, eGFR level, control of HbA1c, BMI, </text>
<text top="694" left="535" width="216" height="17" font="5">control of BP, control of LDL-C, level of </text>
<text top="711" left="535" width="183" height="17" font="5">CVD risk). In general, RAMP-DM </text>
<text top="728" left="535" width="220" height="17" font="5">participants in all subgroups observed a </text>
<text top="746" left="535" width="190" height="17" font="5">40% greater risk reduction in each </text>
<text top="763" left="535" width="221" height="17" font="5">CVD/microvascular complications and a </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="191" height="17" font="5">55–85% risk reduction in all-cause </text>
<text top="160" left="535" width="234" height="17" font="5">mortality compared to usual care subjects. </text>
<text top="178" left="535" width="218" height="17" font="5">RAMP-DM participants in all subgroups </text>
<text top="195" left="535" width="215" height="17" font="5">had significantly fewer hospitalizations, </text>
<text top="212" left="535" width="235" height="17" font="5">A&amp;E attendances, and SOPC attendances </text>
<text top="229" left="535" width="222" height="17" font="5">but more GOPC attendances than usual </text>
<text top="247" left="535" width="81" height="17" font="5">care patients.  </text>
<text top="264" left="535" width="227" height="17" font="5">RAMP-DM participants ,&lt;65 years of age </text>
<text top="281" left="535" width="213" height="17" font="5">with a DM duration of  &lt;2 years or with </text>
<text top="298" left="535" width="197" height="17" font="5">low/medium CVD risks received the </text>
<text top="315" left="535" width="208" height="17" font="5">greatest benefits from the RAMP-DM. </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="350" left="535" width="238" height="17" font="5">The number needed to treat to prevent one </text>
<text top="367" left="535" width="232" height="17" font="5">CVD event was 8 and the number needed </text>
<text top="384" left="535" width="198" height="17" font="5">to treat for all-cause mortality was 6 </text>
<text top="402" left="66" width="3" height="17" font="5"> </text>
<text top="433" left="66" width="3" height="17" font="5"> </text>
<text top="481" left="66" width="958" height="21" font="4"><b>Data Supplement 3. Nonrandomized Trials, Observational Studies, and/or Registries of Assessment of Cardiovascular Risk (Section 2.2) </b></text>
<text top="506" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="523" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="540" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="506" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="523" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="506" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="506" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="523" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="506" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="523" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="558" left="75" width="103" height="17" font="5">Lloyd-Jones et al., </text>
<text top="577" left="75" width="56" height="17" font="5">2006 (12) </text>
<text top="595" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16461820">16461820</a></text>
<text top="595" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16461820"> </a></text>
<text top="558" left="205" width="31" height="17" font="5">Aim:  </text>
<text top="575" left="205" width="88" height="17" font="5">To estimate the </text>
<text top="593" left="205" width="112" height="17" font="5">lifetime risk for CVD </text>
<text top="610" left="205" width="87" height="17" font="5">and to examine </text>
<text top="627" left="205" width="118" height="17" font="5">overall survival in the </text>
<text top="644" left="205" width="78" height="17" font="5">presence and </text>
<text top="661" left="205" width="63" height="17" font="5">absence of </text>
<text top="679" left="205" width="88" height="17" font="5">established risk </text>
<text top="696" left="205" width="44" height="17" font="5">factors. </text>
<text top="713" left="205" width="3" height="17" font="5"> </text>
<text top="730" left="205" width="65" height="17" font="5">Study type: </text>
<text top="747" left="205" width="107" height="17" font="5">prospective cohort  </text>
<text top="765" left="205" width="3" height="17" font="5"> </text>
<text top="558" left="344" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="589" left="341" width="154" height="18" font="5">•  Free of CVD before their </text>
<text top="607" left="342" width="116" height="17" font="5">earliest examination  </text>
<text top="624" left="341" width="147" height="18" font="5">•  examined at least once </text>
<text top="642" left="342" width="183" height="17" font="5">between 50 and 94 years of age  </text>
<text top="660" left="344" width="175" height="17" font="5">had follow-up after their earliest </text>
<text top="678" left="344" width="111" height="17" font="5">eligible examination </text>
<text top="558" left="546" width="72" height="17" font="5">1° Endpoint: </text>
<text top="589" left="546" width="194" height="17" font="5">All atherosclerotic CVD events (MI, </text>
<text top="607" left="546" width="221" height="17" font="5">coronary insufficiency, death from CHD, </text>
<text top="626" left="546" width="226" height="17" font="5">angina pectoris, atherothrombotic stroke, </text>
<text top="644" left="546" width="182" height="17" font="5">intermittent claudication, or other </text>
<text top="663" left="546" width="121" height="17" font="5">cardiovascular death) </text>
<text top="694" left="546" width="182" height="17" font="5">Hard atherosclerotic CVD events </text>
<text top="712" left="546" width="196" height="17" font="5">(excluding angina and claudication) </text>
<text top="743" left="546" width="31" height="17" font="7"><i>Men: </i></text>
<text top="558" left="791" width="331" height="17" font="5">The absence of established risk factors at 50 years of age is </text>
<text top="577" left="791" width="325" height="17" font="5">associated with very low lifetime risk for CVD and markedly </text>
<text top="595" left="791" width="83" height="17" font="5">longer survival </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="47" height="17" font="5">N=7926 </text>
<text top="143" left="546" width="214" height="17" font="5">In men free of CVD at 50 years of age, </text>
<text top="162" left="546" width="211" height="17" font="5">lifetime risk of all ASCVD events to 95 </text>
<text top="180" left="546" width="224" height="17" font="5">years of age=51.7% (95% CI 49.3-54.2), </text>
<text top="199" left="546" width="210" height="17" font="5">and median overall survival=30 years. </text>
<text top="218" left="546" width="230" height="17" font="5">Lifetime risk of hard CVD=41.2% (95% CI </text>
<text top="236" left="546" width="60" height="17" font="5">38.8-43.7) </text>
<text top="267" left="546" width="206" height="17" font="5">Lifetime risk to age 75 increased with </text>
<text top="285" left="546" width="209" height="17" font="5">increasing total cholesterol (26.2% for </text>
<text top="304" left="546" width="218" height="17" font="5">&lt;180 mg/dL, 29.2% for 180-199 mg/dL, </text>
<text top="323" left="546" width="225" height="17" font="5">34.5% for 200-239 mg/dL, and 45.3% for </text>
<text top="341" left="546" width="194" height="17" font="5">≥240 mg/dL), with decreasing HDL </text>
<text top="360" left="546" width="210" height="17" font="5">cholesterol (23.6% ≥40 mg/dL, 34.0% </text>
<text top="378" left="546" width="212" height="17" font="5">&lt;40 mg/dL), with increasing systolic or </text>
<text top="397" left="546" width="217" height="17" font="5">diastolic blood pressure (26.6%&lt;120 or </text>
<text top="415" left="546" width="205" height="17" font="5">&lt;80, 31.8% 120-139 or 80-89, 46.4% </text>
<text top="434" left="546" width="210" height="17" font="5">140-159 or 90-99, and 51.3% ≥160 or </text>
<text top="452" left="546" width="213" height="17" font="5">≥100 or treated), with diabetes (30.2% </text>
<text top="471" left="546" width="199" height="17" font="5">nondiabetic vs 67.1% diabetic), with </text>
<text top="490" left="546" width="219" height="17" font="5">smoking (27.8% nonsmoking vs. 34.0% </text>
<text top="508" left="546" width="191" height="17" font="5">smoking), and with increasing BMI </text>
<text top="527" left="546" width="219" height="17" font="5">(27.5% &lt;25, 30.4% 25-29.9, and 41.8% </text>
<text top="545" left="546" width="36" height="17" font="5">≥30).  </text>
<text top="576" left="546" width="221" height="17" font="5">Lifetime risk at age 50 years to 95 years </text>
<text top="595" left="546" width="113" height="17" font="5">by risk factor status: </text>
<text top="625" left="546" width="217" height="17" font="5">All optimal risk factors: 5.2% (95% CI 0-</text>
<text top="644" left="546" width="183" height="17" font="5">12.2) (median survival&gt;39 years) </text>
<text top="674" left="546" width="230" height="17" font="5">≥1 Not optimal risk factor: 36.4% (95% CI </text>
<text top="693" left="546" width="211" height="17" font="5">23.1-49.6) (median survival=36 years) </text>
<text top="723" left="546" width="209" height="17" font="5">≥ Elevated risk factor: 45.5% (95% CI </text>
<text top="742" left="546" width="211" height="17" font="5">38.0-53.1) (median survival=35 years) </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="219" height="17" font="5">1 Major risk factor: 50.4% (95% CI 46.2-</text>
<text top="162" left="546" width="183" height="17" font="5">54.5) (median survival=30 years) </text>
<text top="192" left="546" width="205" height="17" font="5">≥2 Major risk factors: 68.9% (95% CI </text>
<text top="211" left="546" width="211" height="17" font="5">61.7-73.2) (median survival=28 years) </text>
<text top="241" left="546" width="46" height="17" font="7"><i>Women </i></text>
<text top="272" left="546" width="229" height="17" font="5">In women free of CVD at 50 years of age, </text>
<text top="291" left="546" width="210" height="17" font="5">lifetime risk of all ASCVD events to 95 </text>
<text top="309" left="546" width="224" height="17" font="5">years of age=39.2% (95% CI 37.0-41.4), </text>
<text top="328" left="546" width="210" height="17" font="5">and median overall survival=36 years. </text>
<text top="346" left="546" width="217" height="17" font="5">Lifetime risk of hard CVD= 28.8% (95% </text>
<text top="365" left="546" width="79" height="17" font="5">CI 26.6-30.8). </text>
<text top="396" left="546" width="206" height="17" font="5">Lifetime risk to age 75 increased with </text>
<text top="414" left="546" width="202" height="17" font="5">increasing total cholesterol (9.1% for </text>
<text top="433" left="546" width="218" height="17" font="5">&lt;180 mg/dL, 11.3% for 180-199 mg/dL, </text>
<text top="451" left="546" width="225" height="17" font="5">16.7% for 200-239 mg/dL, and 30.0% for </text>
<text top="470" left="546" width="194" height="17" font="5">≥240 mg/dL), with decreasing HDL </text>
<text top="489" left="546" width="210" height="17" font="5">cholesterol (11.0% ≥50 mg/dL, 15.9% </text>
<text top="507" left="546" width="212" height="17" font="5">&lt;50 mg/dL), with increasing systolic or </text>
<text top="526" left="546" width="217" height="17" font="5">diastolic blood pressure (10.5%&lt;120 or </text>
<text top="544" left="546" width="205" height="17" font="5">&lt;80, 17.9% 120-139 or 80-89, 28.8% </text>
<text top="563" left="546" width="210" height="17" font="5">140-159 or 90-99, and 35.0% ≥160 or </text>
<text top="581" left="546" width="213" height="17" font="5">≥100 or treated), with diabetes (16.3% </text>
<text top="600" left="546" width="199" height="17" font="5">nondiabetic vs 57.3% diabetic), with </text>
<text top="618" left="546" width="219" height="17" font="5">smoking (14.2% nonsmoking vs. 20.6% </text>
<text top="637" left="546" width="191" height="17" font="5">smoking), and with increasing BMI </text>
<text top="656" left="546" width="219" height="17" font="5">(14.7% &lt;25, 18.1% 25-29.9, and 21.9% </text>
<text top="674" left="546" width="36" height="17" font="5">≥30).  </text>
<text top="705" left="546" width="221" height="17" font="5">Lifetime risk at age 50 years to 95 years </text>
<text top="723" left="546" width="113" height="17" font="5">by risk factor status: </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="217" height="17" font="5">All optimal risk factors: 8.2% (95% CI 0-</text>
<text top="162" left="546" width="183" height="17" font="5">22.3) (median survival&gt;39 years) </text>
<text top="192" left="546" width="230" height="17" font="5">≥1 Not optimal risk factor: 26.9% (95% CI </text>
<text top="211" left="546" width="211" height="17" font="5">18.4-35.5) (median survival=39 years) </text>
<text top="241" left="546" width="219" height="17" font="5">≥ 1 Elevated risk factor: 39.1% (95% CI </text>
<text top="260" left="546" width="211" height="17" font="5">33.0-45.1) (median survival=39 years) </text>
<text top="291" left="546" width="219" height="17" font="5">1 Major risk factor: 38.8% (95% CI 35.0-</text>
<text top="309" left="546" width="183" height="17" font="5">42.6) (median survival=35 years) </text>
<text top="340" left="546" width="205" height="17" font="5">≥2 major risk factors: 50.2% (95% CI </text>
<text top="359" left="546" width="211" height="17" font="5">44.7-55.7) (median survival=31 years) </text>
<text top="378" left="75" width="96" height="17" font="5">Yano et al., 2017 </text>
<text top="396" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28746709">28746709</a></text>
<text top="396" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28746709"> </a></text>
<text top="378" left="205" width="31" height="17" font="5">Aim:  </text>
<text top="395" left="205" width="88" height="17" font="5">To examine the </text>
<text top="412" left="205" width="104" height="17" font="5">predictive ability of </text>
<text top="429" left="205" width="86" height="17" font="5">coronary artery </text>
<text top="447" left="205" width="116" height="17" font="5">calcium (CAC) score </text>
<text top="464" left="205" width="103" height="17" font="5">vs age for incident </text>
<text top="481" left="205" width="118" height="17" font="5">ASCVD and how risk </text>
<text top="498" left="205" width="123" height="17" font="5">prediction changes by </text>
<text top="516" left="205" width="103" height="17" font="5">adding CAC score </text>
<text top="533" left="205" width="104" height="17" font="5">and removing only </text>
<text top="550" left="205" width="109" height="17" font="5">age from prediction </text>
<text top="567" left="205" width="43" height="17" font="5">models </text>
<text top="584" left="205" width="3" height="17" font="5"> </text>
<text top="602" left="205" width="65" height="17" font="5">Study type: </text>
<text top="619" left="205" width="124" height="17" font="5">Pooled analysis of US </text>
<text top="636" left="205" width="97" height="17" font="5">population based </text>
<text top="653" left="205" width="42" height="17" font="5">studies </text>
<text top="670" left="205" width="3" height="17" font="5"> </text>
<text top="688" left="205" width="80" height="17" font="5">N=4778 in US </text>
<text top="705" left="205" width="105" height="17" font="5">studies, N=4990 in </text>
<text top="722" left="205" width="99" height="17" font="5">European studies </text>
<text top="739" left="205" width="3" height="17" font="5"> </text>
<text top="378" left="344" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="408" left="341" width="161" height="18" font="5">•  Framingham Heart Study, </text>
<text top="427" left="342" width="116" height="17" font="5">Multi-Ethnic Study of </text>
<text top="444" left="342" width="137" height="17" font="5">Atherosclerosis (MESA), </text>
<text top="461" left="342" width="159" height="17" font="5">Cardiovascular Health Study </text>
<text top="478" left="342" width="187" height="17" font="5">(CHS) data, as well as Rotterdam </text>
<text top="495" left="342" width="173" height="17" font="5">Study and Heinz Nixdorf Recall </text>
<text top="513" left="342" width="120" height="17" font="5">Study for comparison </text>
<text top="530" left="341" width="76" height="18" font="5">•  ≥60 years </text>
<text top="548" left="341" width="184" height="18" font="5">•  Without known cardiovascular </text>
<text top="566" left="342" width="171" height="17" font="5">diseases at baseline (including </text>
<text top="584" left="342" width="170" height="17" font="5">CHD, stroke, and heart failure) </text>
<text top="601" left="344" width="3" height="17" font="5"> </text>
<text top="631" left="344" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="662" left="341" width="119" height="18" font="5">•  Missing CAC data </text>
<text top="680" left="341" width="122" height="18" font="5">•  Missing covariates </text>
<text top="698" left="344" width="3" height="17" font="5"> </text>
<text top="729" left="344" width="3" height="17" font="5"> </text>
<text top="378" left="546" width="72" height="17" font="5">1° Endpoint: </text>
<text top="408" left="546" width="190" height="17" font="5">Incident ASCVD, CHD, and stroke </text>
<text top="439" left="546" width="160" height="17" font="5">Median follow up=10.7 years </text>
<text top="470" left="546" width="201" height="17" font="5">The probability of remaining ASCVD </text>
<text top="488" left="546" width="193" height="17" font="5">event free during 12-year follow up </text>
<text top="507" left="546" width="225" height="17" font="5">increased with increasing CAC category. </text>
<text top="525" left="546" width="192" height="17" font="5">In those with CAC=0, probability of </text>
<text top="544" left="546" width="193" height="17" font="5">remaining ASCVD event free&gt;90% </text>
<text top="574" left="546" width="225" height="17" font="5">11% of ASCVD events occurred in those </text>
<text top="593" left="546" width="193" height="17" font="5">with CAC score=0, 42% of ASCVD </text>
<text top="612" left="546" width="228" height="17" font="5">events occurred in those with CAC≥300.  </text>
<text top="642" left="546" width="84" height="17" font="5">ASCVD Event: </text>
<text top="673" left="546" width="202" height="17" font="5">Compared to a base model, a model </text>
<text top="691" left="546" width="185" height="17" font="5">excluding age and including CAC </text>
<text top="710" left="546" width="189" height="17" font="5">categories resulted in a significant </text>
<text top="728" left="546" width="225" height="17" font="5">change (C statistic=0.027, 95% CI 0.005-</text>
<text top="747" left="546" width="216" height="17" font="5">0.048), and a model excluding age and </text>
<text top="766" left="546" width="215" height="17" font="5">including continuous CAC resulted in a </text>
<text top="378" left="791" width="335" height="17" font="5">Summary: CAC score had a greater association with incident </text>
<text top="396" left="791" width="332" height="17" font="5">CHD and a modest association with stroke; use of traditional </text>
<text top="415" left="791" width="324" height="17" font="5">cardiovascular risk factors with CAC score and without age </text>
<text top="434" left="791" width="303" height="17" font="5">improved discrimination for incident CHD and modestly </text>
<text top="452" left="791" width="320" height="17" font="5">improved discrimination for stroke; including age and CAC </text>
<text top="471" left="791" width="275" height="17" font="5">score without cardiovascular risk factors improved </text>
<text top="489" left="791" width="334" height="17" font="5">discrimination for incident CHD but not for stroke; CAC score </text>
<text top="508" left="791" width="329" height="17" font="5">improved risk reclassification for incident ASCVD more than </text>
<text top="526" left="791" width="24" height="17" font="5">age </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="232" height="17" font="5">significant change (C statistic=0.025, 95% </text>
<text top="162" left="546" width="89" height="17" font="5">CI 0.004-0.047) </text>
<text top="192" left="546" width="67" height="17" font="5">CHD event: </text>
<text top="223" left="546" width="202" height="17" font="5">Compared to a base model, a model </text>
<text top="241" left="546" width="185" height="17" font="5">excluding age and including CAC </text>
<text top="260" left="546" width="213" height="17" font="5">categories resulted in a non-significant </text>
<text top="279" left="546" width="194" height="17" font="5">change (C statistic=0.030, 95% CI -</text>
<text top="297" left="546" width="210" height="17" font="5">0.0004-0.060), and a model excluding </text>
<text top="316" left="546" width="192" height="17" font="5">age and including continuous CAC </text>
<text top="334" left="546" width="202" height="17" font="5">resulted in a significant difference (C </text>
<text top="353" left="546" width="203" height="17" font="5">statistic=0.032, 95% CI 0.002-0.062) </text>
<text top="384" left="546" width="76" height="17" font="5">Stroke event: </text>
<text top="414" left="546" width="202" height="17" font="5">Compared to a base model, a model </text>
<text top="433" left="546" width="218" height="17" font="5">excluding age and including categorical </text>
<text top="451" left="546" width="226" height="17" font="5">CAC resulted in a non-significant change </text>
<text top="470" left="546" width="223" height="17" font="5">(C statistic=0.013, 95% CI -0.015-0.041) </text>
<text top="489" left="546" width="226" height="17" font="5">and a model excluding age and including </text>
<text top="507" left="546" width="187" height="17" font="5">continuous CAC resulted in a non-</text>
<text top="526" left="546" width="206" height="17" font="5">significant change (C Statistic=0.017, </text>
<text top="544" left="546" width="121" height="17" font="5">95% CI -0.011-0.045) </text>
<text top="575" left="546" width="230" height="17" font="5">CAC score had a greater association with </text>
<text top="593" left="546" width="222" height="17" font="5">incident CHD than age (C statistic 0.733 </text>
<text top="612" left="546" width="226" height="17" font="5">vs. 0.690, C statistic of difference=0.043, </text>
<text top="631" left="546" width="225" height="17" font="5">95% CI 0.009-0.075) and was somewhat </text>
<text top="649" left="546" width="211" height="17" font="5">greater for stroke (C statistic=0.695 vs </text>
<text top="668" left="546" width="211" height="17" font="5">0.670, C statistic for difference=0.025, </text>
<text top="686" left="546" width="138" height="17" font="5">95% CI -0.015 to 0.064). </text>
<text top="717" left="546" width="222" height="17" font="5">Replacing CAC score for risk factors but </text>
<text top="736" left="546" width="202" height="17" font="5">retaining age improved model fit and </text>
<text top="754" left="546" width="225" height="17" font="5">discrimination for CHD (C statistic=0.740 </text>
<text top="773" left="546" width="209" height="17" font="5">vs 0.703, C statistic difference=0.037, </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="189" height="17" font="5">95% CI 0.012-0.062), but reduced </text>
<text top="162" left="546" width="176" height="17" font="5">discrimination or incident stroke </text>
<text top="192" left="546" width="223" height="17" font="5">No significant interactions between CAC </text>
<text top="211" left="546" width="201" height="17" font="5">score and sex, race/ethnicity, or age </text>
<text top="241" left="546" width="175" height="17" font="5">Category free NRI in those who </text>
<text top="260" left="546" width="173" height="17" font="5">experienced ASCVD events for </text>
<text top="279" left="546" width="230" height="17" font="5">CAC=0.390 (95% CI 0.312-0.469) and for </text>
<text top="297" left="546" width="190" height="17" font="5">age=0.098 (95% CI -0.001-0.181). </text>
<text top="316" left="546" width="216" height="17" font="5">Category-free NRI in those who did not </text>
<text top="334" left="546" width="167" height="17" font="5">experience ASCVD events for </text>
<text top="353" left="546" width="223" height="17" font="5">CAC=0.105 (95% CI 0.08-0.137) and for </text>
<text top="372" left="546" width="203" height="17" font="5">age=0.199 (95% CI 0.171 – 0.225).   </text>
<text top="402" left="546" width="207" height="17" font="5">In European cohort, CAC had greater </text>
<text top="421" left="546" width="221" height="17" font="5">association with incident CHD than age, </text>
<text top="439" left="546" width="212" height="17" font="5">while age had greater association with </text>
<text top="458" left="546" width="203" height="17" font="5">stroke than CAC. Including CAC and </text>
<text top="476" left="546" width="184" height="17" font="5">excluding age provided improved </text>
<text top="495" left="546" width="208" height="17" font="5">discrimination for CHD but not stroke. </text>
<text top="514" left="546" width="199" height="17" font="5">Replacing risk factors with CAC in a </text>
<text top="532" left="546" width="177" height="17" font="5">model with age improved fit and </text>
<text top="551" left="546" width="195" height="17" font="5">discrimination for CHD but reduced </text>
<text top="569" left="546" width="140" height="17" font="5">discrimination for stroke.  </text>
<text top="589" left="75" width="107" height="17" font="5">Wilkins et al., 2012 </text>
<text top="607" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23117780">23117780</a></text>
<text top="607" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23117780"> </a></text>
<text top="589" left="205" width="25" height="17" font="5">Aim </text>
<text top="606" left="205" width="96" height="17" font="5">To calculate LTR </text>
<text top="623" left="205" width="119" height="17" font="5">estimates of tCVD by </text>
<text top="640" left="205" width="122" height="17" font="5">index age [45, 55, 65, </text>
<text top="658" left="205" width="115" height="17" font="5">75 years(y)] and risk </text>
<text top="675" left="205" width="106" height="17" font="5">factor strata and to </text>
<text top="692" left="205" width="112" height="17" font="5">estimate years lived </text>
<text top="709" left="205" width="107" height="17" font="5">free of CVD across </text>
<text top="726" left="205" width="91" height="17" font="5">risk factor strata </text>
<text top="744" left="205" width="3" height="17" font="5"> </text>
<text top="761" left="205" width="62" height="17" font="5">Study type </text>
<text top="589" left="342" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="607" left="342" width="144" height="17" font="5">Framingham Heart Study, </text>
<text top="626" left="342" width="167" height="17" font="5">Framingham Offspring Study,  </text>
<text top="644" left="342" width="162" height="17" font="5">Cardiovascular Health Study, </text>
<text top="663" left="342" width="128" height="17" font="5">Atherosclerosis Risk in </text>
<text top="682" left="342" width="184" height="17" font="5">Communities study, and Chicago </text>
<text top="700" left="342" width="155" height="17" font="5">Heart Association Detection </text>
<text top="719" left="342" width="144" height="17" font="5">Project in Industry Study.  </text>
<text top="737" left="342" width="3" height="17" font="5"> </text>
<text top="589" left="546" width="72" height="17" font="5">1° Endpoint: </text>
<text top="619" left="546" width="139" height="17" font="5">Lifetime risk of total CVD </text>
<text top="650" left="546" width="221" height="17" font="5">At index age of 45 years: overall lifetime </text>
<text top="669" left="546" width="227" height="17" font="5">risk through age 95=60.3% (95% CI 59.3-</text>
<text top="687" left="546" width="215" height="17" font="5">61.2) for men and 55.6% (95% CI 54.5-</text>
<text top="706" left="546" width="103" height="17" font="5">56.7 for women).   </text>
<text top="589" left="791" width="313" height="17" font="5">Summary: At index age 45, overall remaining lifetime risk </text>
<text top="607" left="791" width="328" height="17" font="5">estimates for total CVD to age 95 years were approximately </text>
<text top="626" left="791" width="344" height="17" font="5">60% in men and 55% in women. Risks for were greater in men </text>
<text top="644" left="791" width="318" height="17" font="5">than women at all but the oldest index ages. Lifetime risks </text>
<text top="663" left="791" width="347" height="17" font="5">were high regardless of index age.  Lower aggregate risk factor </text>
<text top="682" left="791" width="331" height="17" font="5">burden was associated with a lower lifetime risk through age </text>
<text top="700" left="791" width="341" height="17" font="5">95 years regardless of index age. Even those with optimal risk </text>
<text top="719" left="791" width="294" height="17" font="5">factor profiles had lifetime risks greater than 30%, but </text>
<text top="737" left="791" width="310" height="17" font="5">maintenance of low risk factor burden at middle age was </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="103" height="17" font="5">Pooled analysis of </text>
<text top="160" left="205" width="104" height="17" font="5">prospective cohort </text>
<text top="178" left="205" width="42" height="17" font="5">studies </text>
<text top="195" left="205" width="3" height="17" font="5"> </text>
<text top="212" left="205" width="105" height="17" font="5">N=905,115 person </text>
<text top="231" left="205" width="33" height="17" font="5">years </text>
<text top="143" left="341" width="178" height="18" font="5">•  Studies had to include cause-</text>
<text top="161" left="342" width="141" height="17" font="5">specific or cardiovascular </text>
<text top="179" left="342" width="171" height="17" font="5">mortality, and ascertainment of </text>
<text top="196" left="342" width="174" height="17" font="5">non-fatal cardiovascular events </text>
<text top="213" left="342" width="3" height="17" font="5"> </text>
<text top="232" left="342" width="97" height="17" font="5">Exclusion criteria </text>
<text top="262" left="344" width="96" height="17" font="5">pre-existing CVD </text>
<text top="143" left="546" width="221" height="17" font="5">At index age of 55 years: overall lifetime </text>
<text top="162" left="546" width="217" height="17" font="5">risk=60.2% (95% CI 59.1-61.2) for men </text>
<text top="180" left="546" width="230" height="17" font="5">and 56.3% (95% CI 55.2-57.4) for women </text>
<text top="211" left="546" width="208" height="17" font="5">At index age 65 years: overall lifetime </text>
<text top="230" left="546" width="217" height="17" font="5">risk=59.0% (95% CI 57.6-60.4) for men </text>
<text top="248" left="546" width="187" height="17" font="5">and 56.1% (54.7-57.5) for women </text>
<text top="279" left="546" width="208" height="17" font="5">At index age 75 years: overall lifetime </text>
<text top="297" left="546" width="217" height="17" font="5">risk=54.5% (95% CI 52.2-56.9) for men </text>
<text top="316" left="546" width="230" height="17" font="5">and 52.3% (95% CI 50.3-54.3) for women </text>
<text top="346" left="546" width="200" height="17" font="5">For all but index age 75, lifetime risk </text>
<text top="365" left="546" width="222" height="17" font="5">through age 95 was greater than 50% in </text>
<text top="384" left="546" width="225" height="17" font="5">those with 1 or more elevated risk factor, </text>
<text top="402" left="546" width="219" height="17" font="5">1 major risk factor, and 2 or more major </text>
<text top="421" left="546" width="215" height="17" font="5">risk factors in both men and women. In </text>
<text top="439" left="546" width="231" height="17" font="5">those with “not optimal” risk factors at age </text>
<text top="458" left="546" width="210" height="17" font="5">55 and 65, lifetime risk were &gt;40% for </text>
<text top="476" left="546" width="226" height="17" font="5">men and &gt;30% for women.  At index age </text>
<text top="495" left="546" width="216" height="17" font="5">55, men with optimal risk factor profiles </text>
<text top="514" left="546" width="211" height="17" font="5">had remaining lifetime risks &gt;40% and </text>
<text top="532" left="546" width="224" height="17" font="5">women had risks close to 30% to age 85 </text>
<text top="551" left="546" width="81" height="17" font="5">years of age.   </text>
<text top="581" left="546" width="223" height="17" font="5">Compared to those with 2 or more major </text>
<text top="600" left="546" width="225" height="17" font="5">risk factors, those with optimal risk factor </text>
<text top="618" left="546" width="215" height="17" font="5">levels had longer CVD-free and overall </text>
<text top="637" left="546" width="214" height="17" font="5">survival, though the difference in years </text>
<text top="656" left="546" width="182" height="17" font="5">lived free of CVD decreased with </text>
<text top="674" left="546" width="205" height="17" font="5">increasing age. At age 45, those with </text>
<text top="693" left="546" width="219" height="17" font="5">optimal risk factor profiles lived up to 14 </text>
<text top="711" left="546" width="221" height="17" font="5">years longer CVD free than those with 2 </text>
<text top="730" left="546" width="112" height="17" font="5">or more risk factors. </text>
<text top="143" left="791" width="317" height="17" font="5">associated with a delay in age at onset of total CVD by as </text>
<text top="162" left="791" width="206" height="17" font="5">much as 14 years for younger adults. </text>
<text top="749" left="75" width="105" height="17" font="5">Valenti et al., 2015 </text>
<text top="768" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26189116">26189116</a></text>
<text top="768" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26189116"> </a></text>
<text top="749" left="205" width="31" height="17" font="5">Aim:  </text>
<text top="749" left="342" width="92" height="17" font="5">Inclusion criteria </text>
<text top="749" left="546" width="72" height="17" font="5">1° Endpoint: </text>
<text top="749" left="791" width="319" height="17" font="5">Summary: The presence of CAC was a strong predictor of </text>
<text top="768" left="791" width="347" height="17" font="5">incident mortality, even when considering clinical risk scores by </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="123" height="17" font="5">To examine long-term </text>
<text top="160" left="205" width="108" height="17" font="5">prognosis of a zero </text>
<text top="178" left="205" width="86" height="17" font="5">coronary artery </text>
<text top="195" left="205" width="116" height="17" font="5">calcium (CAC) score </text>
<text top="212" left="205" width="120" height="17" font="5">among asymptomatic </text>
<text top="229" left="205" width="100" height="17" font="5">individuals and its </text>
<text top="247" left="205" width="113" height="17" font="5">associated warranty </text>
<text top="264" left="205" width="38" height="17" font="5">period </text>
<text top="281" left="205" width="3" height="17" font="5"> </text>
<text top="298" left="205" width="65" height="17" font="5">Study type: </text>
<text top="315" left="205" width="104" height="17" font="5">prospective cohort </text>
<text top="333" left="205" width="3" height="17" font="5"> </text>
<text top="350" left="205" width="50" height="17" font="5">N=9,715 </text>
<text top="143" left="341" width="161" height="18" font="5">•  No known coronary artery </text>
<text top="161" left="342" width="83" height="17" font="5">disease (CAD) </text>
<text top="179" left="341" width="186" height="18" font="5">•  referred by their physicians for </text>
<text top="197" left="342" width="92" height="17" font="5">CAD evaluation  </text>
<text top="214" left="344" width="177" height="17" font="5">underwent CAC testing electron </text>
<text top="233" left="344" width="160" height="17" font="5">beam computed tomography </text>
<text top="251" left="344" width="130" height="17" font="5">(EBCT) at a single site. </text>
<text top="143" left="546" width="103" height="17" font="5">All cause mortality </text>
<text top="174" left="546" width="202" height="17" font="5">CAC&gt;0 HR=2.67 (95% CI 2.29-3.11, </text>
<text top="192" left="546" width="63" height="17" font="5">p&lt;0.001).   </text>
<text top="223" left="546" width="107" height="17" font="5">Stratified analyses: </text>
<text top="254" left="546" width="43" height="17" font="5">CAC=0 </text>
<text top="284" left="546" width="184" height="17" font="5">Age HR=1.03 (95% CI 1.02-1.04, </text>
<text top="303" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="333" left="546" width="203" height="17" font="5">Female HR=1.01 (95% CI 0.78-1.32, </text>
<text top="352" left="546" width="46" height="17" font="5">p=0.92) </text>
<text top="382" left="546" width="204" height="17" font="5">Hypertension HR=1.48 (95% CI 1.21-</text>
<text top="401" left="546" width="83" height="17" font="5">2.06, p=0.001) </text>
<text top="432" left="546" width="232" height="17" font="5">Dyslipidemia HR=0.83 (95% CI 0.63-1.08, </text>
<text top="450" left="546" width="46" height="17" font="5">p=0.16) </text>
<text top="481" left="546" width="211" height="17" font="5">Diabetes HR=2.53 (95% CI 1.74-3.69, </text>
<text top="499" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="530" left="546" width="232" height="17" font="5">Family history HR=0.3 (95% CI 0.70-1.23) </text>
<text top="561" left="546" width="210" height="17" font="5">Smoking HR=1.95 (95% CI 1.50-2.53, </text>
<text top="579" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="610" left="546" width="3" height="17" font="5"> </text>
<text top="640" left="546" width="43" height="17" font="5">CAC&gt;0 </text>
<text top="671" left="546" width="184" height="17" font="5">Age HR=1.05 (95% CI 1.04-1.05, </text>
<text top="689" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="720" left="546" width="203" height="17" font="5">Female HR=0.93 (95% CI 0.80-1.09, </text>
<text top="739" left="546" width="46" height="17" font="5">p=0.37) </text>
<text top="143" left="791" width="335" height="17" font="5">Framingham or NCEP ATP III methods. CAC=0 confers a 15-</text>
<text top="162" left="791" width="324" height="17" font="5">year warranty period against mortality among individuals at </text>
<text top="180" left="791" width="342" height="17" font="5">low-to-intermediate risk, which is unaffected by age or gender. </text>
<text top="199" left="791" width="332" height="17" font="5">Furthermore, in individuals considered at high-risk by clinical </text>
<text top="218" left="791" width="345" height="17" font="5">risk scores the presence of CAC=0 confers better survival than </text>
<text top="236" left="791" width="316" height="17" font="5">in individuals at low-to-intermediate risk but with any CAC </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="204" height="17" font="5">Hypertension HR=1.62 (95% CI 1.39-</text>
<text top="162" left="546" width="83" height="17" font="5">1.89, p&lt;0.001) </text>
<text top="192" left="546" width="232" height="17" font="5">Dyslipidemia HR=0.65 (95% CI 0.56-0.75, </text>
<text top="211" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="241" left="546" width="211" height="17" font="5">Diabetes HR=2.15 (95% CI 1.79-2.57, </text>
<text top="260" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="291" left="546" width="208" height="17" font="5">Family history HR=0.71 (95% CI 0.61-</text>
<text top="309" left="546" width="80" height="17" font="5">083, p&lt;0.001) </text>
<text top="340" left="546" width="210" height="17" font="5">Smoking HR=1.77 (95% CI 1.52-2.05, </text>
<text top="359" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="389" left="546" width="214" height="17" font="5">Risk of all cause mortality in those with </text>
<text top="408" left="546" width="229" height="17" font="5">CAC&gt;0 and low cardiovascular risk: FRS: </text>
<text top="426" left="546" width="230" height="17" font="5">HR=3.3, 95% CI 2.49-4.32, NCEP ATP III </text>
<text top="445" left="546" width="218" height="17" font="5">HR=3.09, 95% CI 2.45-3.90.  Risk of all </text>
<text top="463" left="546" width="225" height="17" font="5">cause mortality in those with CAC=0 and </text>
<text top="482" left="546" width="212" height="17" font="5">high cardiovascular risk: FRS HR=2.8, </text>
<text top="501" left="546" width="181" height="17" font="5">95% CI 2.05-3.92, NCEP ATP III </text>
<text top="519" left="546" width="155" height="17" font="5">HR=2.94, 95% CI 2.15-4.01 </text>
<text top="550" left="546" width="107" height="17" font="7"><i>Adjusting for FRS</i>:  </text>
<text top="580" left="546" width="133" height="17" font="5">Compared with CAC=0: </text>
<text top="611" left="546" width="188" height="17" font="5">CAC 1-99 HR=2.08 (95% CI 2.08, </text>
<text top="629" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="660" left="546" width="206" height="17" font="5">CAC 100-399 HR=3.42 (95% CI 2.83-</text>
<text top="679" left="546" width="83" height="17" font="5">4.14, p&lt;0.001) </text>
<text top="709" left="546" width="206" height="17" font="5">CAC 400-999 HR=4.93 (95% CI 3.98-</text>
<text top="728" left="546" width="83" height="17" font="5">6.12, p&lt;0.001) </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="227" height="17" font="5">CAC ≥1000 HR=6.79 (95% CI 5.29-8.72, </text>
<text top="162" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="192" left="546" width="148" height="17" font="5">Adjusting for NCEP-ATPIII </text>
<text top="223" left="546" width="130" height="17" font="5">Compared with CAC=0 </text>
<text top="254" left="546" width="216" height="17" font="5">CAC 1-99 HR=2.03 (95% CI 1.70-2.42, </text>
<text top="272" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="303" left="546" width="206" height="17" font="5">CAC 100-399 HR=3.32 (95% CI 2.74-</text>
<text top="321" left="546" width="83" height="17" font="5">4.02, p&lt;0.001) </text>
<text top="352" left="546" width="206" height="17" font="5">CAC 400-999 HR=4.81 (95% CI 3.87-</text>
<text top="370" left="546" width="83" height="17" font="5">5.97, p&lt;0.001) </text>
<text top="401" left="546" width="227" height="17" font="5">CAC ≥1000 HR=6.99 (95% CI 5.46-8.95, </text>
<text top="420" left="546" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="450" left="546" width="3" height="17" font="5"> </text>
<text top="481" left="546" width="182" height="17" font="5">CAC=0 associated with &gt;15 year </text>
<text top="499" left="546" width="206" height="17" font="5">warranty period with observed rate of </text>
<text top="518" left="546" width="228" height="17" font="5">mortality &lt;1% during entirety of follow up. </text>
<text top="537" left="546" width="207" height="17" font="5">Mean event rate=0.3% events/year in </text>
<text top="555" left="546" width="204" height="17" font="5">initial 12 year, 0.4% events/year in 13</text>
<text top="556" left="751" width="7" height="11" font="8">th</text>
<text top="555" left="757" width="3" height="17" font="5"> </text>
<text top="574" left="546" width="162" height="17" font="5">year, 0.58% events/year in 14</text>
<text top="575" left="709" width="7" height="11" font="8">th</text>
<text top="574" left="716" width="53" height="17" font="5"> year. No </text>
<text top="592" left="546" width="193" height="17" font="5">apparent disparity among genders. </text>
<text top="611" left="546" width="201" height="17" font="5">Observed warranty period in CAC=0 </text>
<text top="629" left="546" width="208" height="17" font="5">slightly shorter for those 60 years and </text>
<text top="648" left="546" width="211" height="17" font="5">older. CAC=0 and high cardiovascular </text>
<text top="667" left="546" width="210" height="17" font="5">risk had warranty period of 5-6 years.  </text>
<text top="697" left="546" width="209" height="17" font="5">Compared with base model of FRS or </text>
<text top="716" left="546" width="194" height="17" font="5">NCEP ATP III alone, discrimination </text>
<text top="734" left="546" width="206" height="17" font="5">improved significantly with addition of </text>
<text top="753" left="546" width="210" height="17" font="5">CAC (AUC=0.71 vs. 0.64 for FRS and </text>
<text top="772" left="546" width="206" height="17" font="5">AUC=0.72 vs. 0.64 for NCEP ATP III, </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="165" height="17" font="5">p&lt;0.001).  CAC improved risk </text>
<text top="162" left="546" width="221" height="17" font="5">classification for those at risk versus not </text>
<text top="180" left="546" width="174" height="17" font="5">at risk for incident mortality (net </text>
<text top="199" left="546" width="207" height="17" font="5">reclassification improvement p&lt;0.001 </text>
<text top="218" left="546" width="185" height="17" font="5">overall and when stratified by risk </text>
<text top="236" left="546" width="55" height="17" font="5">category) </text>
<text top="256" left="75" width="106" height="17" font="5">Framingham Heart </text>
<text top="274" left="75" width="38" height="17" font="5">Study  </text>
<text top="305" left="75" width="112" height="17" font="5">Pencina et al., 2009 </text>
<text top="323" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19506114">19506114</a></text>
<text top="323" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19506114"> </a></text>
<text top="255" left="205" width="28" height="17" font="5">Aim: </text>
<text top="273" left="205" width="115" height="17" font="5">To develop a tool for </text>
<text top="290" left="205" width="105" height="17" font="5">estimating 30-year </text>
<text top="307" left="205" width="93" height="17" font="5">risk of hard CVD </text>
<text top="324" left="205" width="81" height="17" font="5">events among </text>
<text top="341" left="205" width="119" height="17" font="5">individuals free of the </text>
<text top="359" left="205" width="116" height="17" font="5">condition at baseline </text>
<text top="376" left="205" width="3" height="17" font="5"> </text>
<text top="393" left="205" width="62" height="17" font="5">Study type </text>
<text top="410" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="427" left="205" width="3" height="17" font="5"> </text>
<text top="445" left="205" width="50" height="17" font="5">N=4,506 </text>
<text top="256" left="342" width="92" height="17" font="5">Inclusion criteria </text>
<text top="274" left="341" width="190" height="18" font="5">•  Participants in the Framingham </text>
<text top="292" left="342" width="88" height="17" font="5">Offspring Study </text>
<text top="310" left="341" width="173" height="18" font="5">•  Between 20 and 59 years of </text>
<text top="328" left="342" width="24" height="17" font="5">age </text>
<text top="345" left="341" width="167" height="18" font="5">•  Free of CVD and cancer at </text>
<text top="363" left="342" width="49" height="17" font="5">baseline </text>
<text top="381" left="341" width="128" height="18" font="5">•  Not lost to follow up </text>
<text top="399" left="344" width="176" height="17" font="5">Had complete risk factor profile  </text>
<text top="256" left="546" width="72" height="17" font="5">1° Endpoint: </text>
<text top="286" left="546" width="183" height="17" font="5">Effect of risk factors measured at </text>
<text top="305" left="546" width="205" height="17" font="5">baseline on 30-year risk of hard CVD </text>
<text top="335" left="546" width="72" height="17" font="5">2° Endpoint: </text>
<text top="366" left="546" width="183" height="17" font="5">Effect of risk factors measured at </text>
<text top="384" left="546" width="193" height="17" font="5">baseline on 30-year risk of all CVD </text>
<text top="415" left="546" width="70" height="17" font="5">Main model: </text>
<text top="445" left="546" width="216" height="17" font="5">Male sex, HR=1.73 (95% CI 1.45-2.07) </text>
<text top="476" left="546" width="185" height="17" font="5">Age HR=2.09 (95% CI 1.88-2.31) </text>
<text top="507" left="546" width="225" height="17" font="5">Systolic BP HR=1.29 (95% CI 1.19-1.39) </text>
<text top="537" left="546" width="202" height="17" font="5">Antihypertensive treatment HR=1.48 </text>
<text top="556" left="546" width="107" height="17" font="5">(95% CI 1.10-2.00) </text>
<text top="586" left="546" width="211" height="17" font="5">Smoking HR=2.01 (95% CI 1.72-2.35) </text>
<text top="617" left="546" width="212" height="17" font="5">Diabetes HR=2.49 (95% CI 1.82-3.41) </text>
<text top="648" left="546" width="222" height="17" font="5">Total cholesterol HR=1.33 (95% CI 1.23-</text>
<text top="666" left="546" width="31" height="17" font="5">1.44) </text>
<text top="697" left="546" width="219" height="17" font="5">HDL cholesterol HR=0.78 (95% CI 0.72-</text>
<text top="715" left="546" width="31" height="17" font="5">0.84) </text>
<text top="256" left="791" width="59" height="17" font="5">Summary: </text>
<text top="286" left="791" width="332" height="17" font="5">Standard risk factors were strongly related to hard CVD over </text>
<text top="305" left="791" width="310" height="17" font="5">extended followup. 30-year functions offer additional risk </text>
<text top="323" left="791" width="201" height="17" font="5">burden information over 10-year risk </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="230" height="17" font="5">BMI (in place of total cholesterol and HDL </text>
<text top="162" left="546" width="208" height="17" font="5">cholesterol in simple model) HR=1.20 </text>
<text top="180" left="546" width="107" height="17" font="5">(95% CI 1.10-1.30) </text>
<text top="211" left="546" width="177" height="17" font="5">30-year risk model showed high </text>
<text top="230" left="546" width="178" height="17" font="5">discrimination (cross-validated c </text>
<text top="248" left="546" width="202" height="17" font="5">statistic=0.803, 95% CI 0.786-0.820, </text>
<text top="267" left="546" width="228" height="17" font="5">internally validated c statistic=0.802, 95% </text>
<text top="285" left="546" width="203" height="17" font="5">CI 0.772-0.832) and good calibration </text>
<text top="304" left="546" width="185" height="17" font="5">(cross-validated chi square=4.25, </text>
<text top="323" left="546" width="176" height="17" font="5">p=0.894; internally validated chi </text>
<text top="341" left="546" width="128" height="17" font="5">square=3.98, p=0.913) </text>
<text top="372" left="546" width="218" height="17" font="5">Mean estimated 30-yuear risk=7.9% for </text>
<text top="390" left="546" width="202" height="17" font="5">women and 18.0% for men. Ignoring </text>
<text top="409" left="546" width="204" height="17" font="5">competing risk of non-cardiovascular </text>
<text top="427" left="546" width="226" height="17" font="5">death, mean risks increased to 8.6% and </text>
<text top="446" left="546" width="45" height="17" font="5">20.4%.  </text>
<text top="465" left="75" width="38" height="17" font="5">MESA </text>
<text top="496" left="75" width="96" height="17" font="5">Patel et al., 2015 </text>
<text top="514" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26047825">26047825</a></text>
<text top="514" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26047825"> </a></text>
<text top="465" left="205" width="31" height="17" font="5">Aim:  </text>
<text top="482" left="205" width="123" height="17" font="5">To determine whether </text>
<text top="501" left="205" width="71" height="17" font="5">the extent of </text>
<text top="520" left="205" width="60" height="17" font="5">subclinical </text>
<text top="538" left="205" width="86" height="17" font="5">atherosclerosis </text>
<text top="557" left="205" width="126" height="17" font="5">burden (by either CAC </text>
<text top="575" left="205" width="120" height="17" font="5">or CIMT) could better </text>
<text top="594" left="205" width="126" height="17" font="5">stratify risk for ASCVD </text>
<text top="613" left="205" width="93" height="17" font="5">and CHD events </text>
<text top="631" left="205" width="123" height="17" font="5">beyond traditional risk </text>
<text top="650" left="205" width="81" height="17" font="5">factors among </text>
<text top="668" left="205" width="119" height="17" font="5">individuals with a self-</text>
<text top="687" left="205" width="83" height="17" font="5">reported FH of </text>
<text top="705" left="205" width="89" height="17" font="5">premature CHD </text>
<text top="736" left="205" width="65" height="17" font="5">Study type: </text>
<text top="755" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="465" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="496" left="341" width="136" height="18" font="5">•  45 to 84 years of age </text>
<text top="514" left="341" width="182" height="18" font="5">•  Caucasian, African American, </text>
<text top="532" left="342" width="172" height="17" font="5">Hispanic, or Chinese American </text>
<text top="550" left="341" width="159" height="18" font="5">•  Free of clinical ASCVD at </text>
<text top="568" left="342" width="49" height="17" font="5">baseline </text>
<text top="585" left="344" width="3" height="17" font="5"> </text>
<text top="616" left="344" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="646" left="344" width="160" height="17" font="5">Missing data from visit 1 or 2 </text>
<text top="665" left="344" width="165" height="17" font="5">(when family history and CAC </text>
<text top="683" left="344" width="85" height="17" font="5">were obtained) </text>
<text top="465" left="546" width="72" height="17" font="5">1° Endpoint: </text>
<text top="496" left="546" width="197" height="17" font="5">Hard CHD (MI, resuscitated cardiac </text>
<text top="514" left="546" width="220" height="17" font="5">arrest, or coronary heart disease death) </text>
<text top="545" left="546" width="215" height="17" font="5">Hard ASCVD: hard CHD plus stroke or </text>
<text top="564" left="546" width="71" height="17" font="5">stroke death </text>
<text top="594" left="546" width="197" height="17" font="5">Median follow up time of 10.2 years </text>
<text top="625" left="546" width="29" height="17" font="7"><i>CAC </i></text>
<text top="655" left="546" width="195" height="17" font="7"><i>Hard ASCVD events (no significant </i></text>
<text top="674" left="546" width="208" height="17" font="7"><i>interaction by family history, p=0.28):  </i></text>
<text top="705" left="546" width="201" height="17" font="5">In those with negative family history: </text>
<text top="723" left="546" width="201" height="17" font="5">Compared to CAC=0, HR for CAC 1-</text>
<text top="742" left="546" width="213" height="17" font="5">99=1.75 (95% CI 1.22-2.50), CAC 100-</text>
<text top="465" left="791" width="342" height="17" font="5">CAC testing is more effective than CIMT at stratifying absolute </text>
<text top="484" left="791" width="316" height="17" font="5">and relative risk for both ASCVD and CHD in those with a </text>
<text top="502" left="791" width="333" height="17" font="5">family history of premature CHD. The addition of CAC added </text>
<text top="521" left="791" width="326" height="17" font="5">significant prognostic information for discrimination for CHD </text>
<text top="540" left="791" width="317" height="17" font="5">events in persons with a family history of premature CHD, </text>
<text top="558" left="791" width="189" height="17" font="5">while the addition of CIMT did not. </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="50" height="17" font="5">N=6,125 </text>
<text top="143" left="546" width="195" height="17" font="5">399=2.78 (95% CI 1.91-4.06), CAC </text>
<text top="162" left="546" width="170" height="17" font="5">&gt;400=3.23 (95% CI 2.15-4.86) </text>
<text top="192" left="546" width="196" height="17" font="5">In those with positive family history: </text>
<text top="211" left="546" width="201" height="17" font="5">Compared to CAC=0, HR for CAC 1-</text>
<text top="230" left="546" width="213" height="17" font="5">99=1.64 (95% CI 0.94-2.87), CAC 100-</text>
<text top="248" left="546" width="195" height="17" font="5">399=2.45 (95% CI 1.31-4.58), CAC </text>
<text top="267" left="546" width="136" height="17" font="5">&gt;400=2.80 (1.44-5.43).   </text>
<text top="297" left="546" width="207" height="17" font="5">Compared to those without FH, those </text>
<text top="316" left="546" width="212" height="17" font="5">with FH HR=1.35 (95% CI 1.07-1.71).  </text>
<text top="334" left="546" width="198" height="17" font="5">After adjusting for CAC, association </text>
<text top="353" left="546" width="216" height="17" font="5">remained significant (HR=1.30, 95% CI </text>
<text top="372" left="546" width="199" height="17" font="5">1.03-1.64). There was no significant </text>
<text top="390" left="546" width="197" height="17" font="5">interaction between race and family </text>
<text top="409" left="546" width="203" height="17" font="5">history (HR white=1.08, 95% CI 0.74-</text>
<text top="427" left="546" width="221" height="17" font="5">1.56; HR black=2.09, 95% CI 1.37-3.19, </text>
<text top="446" left="546" width="230" height="17" font="5">HR Hispanic=1.34, 95% CI 0.85-2.13, HR </text>
<text top="465" left="546" width="186" height="17" font="5">Chinese=0.95, 95% CI 0.21-4.22) </text>
<text top="495" left="546" width="179" height="17" font="7"><i>Hard CHD events (no significant </i></text>
<text top="514" left="546" width="201" height="17" font="7"><i>interaction by family history, p=0.49) </i></text>
<text top="544" left="546" width="201" height="17" font="5">In those with negative family history: </text>
<text top="563" left="546" width="201" height="17" font="5">Compared to CAC=0, HR for CAC 1-</text>
<text top="581" left="546" width="213" height="17" font="5">99=2.35 (95% CI 1.46-3.78), CAC 100-</text>
<text top="600" left="546" width="195" height="17" font="5">399=3.54 (95% CI 2.14-5.85), CAC </text>
<text top="618" left="546" width="170" height="17" font="5">&gt;400=4.87 (95% CI 2.88-8.24) </text>
<text top="649" left="546" width="196" height="17" font="5">In those with positive family history: </text>
<text top="668" left="546" width="201" height="17" font="5">Compared to CAC=0, HR for CAC 1-</text>
<text top="686" left="546" width="213" height="17" font="5">99=1.93 (95% CI 0.91-4.10), CAC 100-</text>
<text top="705" left="546" width="192" height="17" font="5">399=3.52 (95%CI 1.58-7.84), CAC </text>
<text top="723" left="546" width="170" height="17" font="5">&gt;400=3.85 (95% CI 1.65-9.02) </text>
<text top="754" left="546" width="207" height="17" font="5">Compared to those without FH, those </text>
<text top="773" left="546" width="208" height="17" font="5">with FH HR=1.41 (95% CI 1.05-1.88). </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="197" height="17" font="5">After adjusting for CAC, association </text>
<text top="162" left="546" width="216" height="17" font="5">remained significant (HR=1.33, 95% CI </text>
<text top="180" left="546" width="60" height="17" font="5">1.00-1.78) </text>
<text top="211" left="546" width="33" height="17" font="7"><i>CIMT </i></text>
<text top="241" left="546" width="195" height="17" font="7"><i>Hard ASCVD events (no significant </i></text>
<text top="260" left="546" width="208" height="17" font="7"><i>interaction by family history, p=0.21):  </i></text>
<text top="291" left="546" width="201" height="17" font="5">In those with negative family history: </text>
<text top="309" left="546" width="126" height="17" font="5">Compared to CIMT≤50</text>
<text top="310" left="673" width="7" height="11" font="8">th</text>
<text top="309" left="679" width="85" height="17" font="5"> percentile, HR </text>
<text top="328" left="546" width="83" height="17" font="5">for CIMT 51-75</text>
<text top="329" left="629" width="7" height="11" font="8">th</text>
<text top="328" left="636" width="139" height="17" font="5"> percentile=0.93 (95% CI </text>
<text top="346" left="546" width="128" height="17" font="5">0.67-1.29), CIMT 75-90</text>
<text top="348" left="674" width="7" height="11" font="8">th</text>
<text top="346" left="681" width="60" height="17" font="5"> percentile </text>
<text top="365" left="546" width="217" height="17" font="5">HR=1.27 (95% CI 0.90-1.80), CIMT &gt;90</text>
<text top="366" left="764" width="7" height="11" font="8">th</text>
<text top="365" left="770" width="3" height="17" font="5"> </text>
<text top="384" left="546" width="217" height="17" font="5">percentile HR=1.11 (95% CI 0.75-1.63) </text>
<text top="414" left="546" width="196" height="17" font="5">In those with positive family history: </text>
<text top="433" left="546" width="126" height="17" font="5">Compared to CIMT≤50</text>
<text top="434" left="673" width="7" height="11" font="8">th</text>
<text top="433" left="679" width="85" height="17" font="5"> percentile, HR </text>
<text top="451" left="546" width="83" height="17" font="5">for CIMT 51-75</text>
<text top="452" left="629" width="7" height="11" font="8">th</text>
<text top="451" left="636" width="112" height="17" font="5"> percentile HR=1.18 </text>
<text top="470" left="546" width="176" height="17" font="5">(95% CI 0.71-1.95), CIMT 75-90</text>
<text top="471" left="722" width="7" height="11" font="8">th</text>
<text top="470" left="729" width="3" height="17" font="5"> </text>
<text top="489" left="546" width="220" height="17" font="5">percentile HR=1.30 (95% CI 0.74-2.28), </text>
<text top="507" left="546" width="54" height="17" font="5">CIMT &gt;90</text>
<text top="508" left="601" width="7" height="11" font="8">th</text>
<text top="507" left="607" width="160" height="17" font="5"> percentile HR=0.76 (95% CI </text>
<text top="526" left="546" width="60" height="17" font="5">0.39-1.50) </text>
<text top="556" left="546" width="179" height="17" font="7"><i>Hard CHD events (no significant </i></text>
<text top="575" left="546" width="201" height="17" font="7"><i>interaction by family history, p=0.51) </i></text>
<text top="605" left="546" width="201" height="17" font="5">In those with negative family history: </text>
<text top="624" left="546" width="126" height="17" font="5">Compared to CIMT≤50</text>
<text top="625" left="673" width="7" height="11" font="8">th</text>
<text top="624" left="679" width="85" height="17" font="5"> percentile, HR </text>
<text top="643" left="546" width="83" height="17" font="5">for CIMT 51-75</text>
<text top="644" left="629" width="7" height="11" font="8">th</text>
<text top="643" left="636" width="112" height="17" font="5"> percentile HR=0.70 </text>
<text top="661" left="546" width="176" height="17" font="5">(95% CI 0.46-1.08), CIMT 75-90</text>
<text top="662" left="722" width="7" height="11" font="8">th</text>
<text top="661" left="729" width="3" height="17" font="5"> </text>
<text top="680" left="546" width="220" height="17" font="5">percentile HR=1.20 (95% CI 0.79-1.84), </text>
<text top="698" left="546" width="54" height="17" font="5">CIMT &gt;90</text>
<text top="699" left="601" width="7" height="11" font="8">th</text>
<text top="698" left="607" width="160" height="17" font="5"> percentile HR=0.94 (95% CI </text>
<text top="717" left="546" width="60" height="17" font="5">0.58-1.52) </text>
<text top="747" left="546" width="196" height="17" font="5">In those with positive family history: </text>
<text top="766" left="546" width="126" height="17" font="5">Compared to CIMT≤50</text>
<text top="767" left="673" width="7" height="11" font="8">th</text>
<text top="766" left="679" width="85" height="17" font="5"> percentile, HR </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="83" height="17" font="5">for CIMT 51-75</text>
<text top="144" left="629" width="7" height="11" font="8">th</text>
<text top="143" left="636" width="112" height="17" font="5"> percentile HR=1.02 </text>
<text top="162" left="546" width="176" height="17" font="5">(95% CI 0.54-1.94), CIMT 75-90</text>
<text top="163" left="722" width="7" height="11" font="8">th</text>
<text top="162" left="729" width="3" height="17" font="5"> </text>
<text top="180" left="546" width="220" height="17" font="5">percentile HR=1.29 (95% CI 0.64-2.60), </text>
<text top="199" left="546" width="54" height="17" font="5">CIMT &gt;90</text>
<text top="200" left="601" width="7" height="11" font="8">th</text>
<text top="199" left="607" width="160" height="17" font="5"> percentile HR=0.87 (95% CI </text>
<text top="218" left="546" width="60" height="17" font="5">0.38-1.96) </text>
<text top="248" left="546" width="3" height="17" font="5"> </text>
<text top="265" left="546" width="215" height="17" font="5">The addition of CAC to the base model </text>
<text top="284" left="546" width="225" height="17" font="5">comprising the variables from the pooled </text>
<text top="303" left="546" width="174" height="17" font="5">cohort equation for ASCVD risk </text>
<text top="321" left="546" width="193" height="17" font="5">estimation led to an increase in the </text>
<text top="340" left="546" width="210" height="17" font="5">Harrell’s C-statistic for hard CHD from </text>
<text top="358" left="546" width="187" height="17" font="5">0.74 to 0.77 (p=0.0005), while the </text>
<text top="377" left="546" width="184" height="17" font="5">addition CIMT was not significant </text>
<text top="395" left="546" width="225" height="17" font="5">(p=0.97). Similar results for hard ASCVD </text>
<text top="414" left="546" width="225" height="17" font="5">were obtained when either CAC or CIMT </text>
<text top="432" left="546" width="231" height="17" font="5">were added to the base model [base AUC </text>
<text top="451" left="546" width="228" height="17" font="5">= 0.75; base plus CAC = 0.77 (p=0.0004) </text>
<text top="470" left="546" width="204" height="17" font="5">and base plus CIMT = 0.75 (p=0.70)] </text>
<text top="489" left="75" width="38" height="17" font="5">MESA </text>
<text top="506" left="75" width="107" height="17" font="5">Budoff, et al., 2018 </text>
<text top="525" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29688297">29688297</a></text>
<text top="525" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29688297"> </a></text>
<text top="489" left="205" width="31" height="17" font="5">Aim:  </text>
<text top="506" left="205" width="84" height="17" font="5">to evaluate the </text>
<text top="523" left="205" width="110" height="17" font="5">contribution of CAC </text>
<text top="541" left="205" width="114" height="17" font="5">using the population-</text>
<text top="558" left="205" width="113" height="17" font="5">based MESA cohort </text>
<text top="575" left="205" width="117" height="17" font="5">with over 10 years of </text>
<text top="592" left="205" width="116" height="17" font="5">follow-up for ASCVD </text>
<text top="609" left="205" width="114" height="17" font="5">events, and whether </text>
<text top="627" left="205" width="99" height="17" font="5">the association of </text>
<text top="644" left="205" width="94" height="17" font="5">CAC with events </text>
<text top="661" left="205" width="79" height="17" font="5">varied by sex, </text>
<text top="678" left="205" width="117" height="17" font="5">race/ethnicity, or age </text>
<text top="696" left="205" width="54" height="17" font="5">category. </text>
<text top="713" left="205" width="3" height="17" font="5"> </text>
<text top="730" left="205" width="69" height="17" font="5">Study Type: </text>
<text top="747" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="764" left="205" width="3" height="17" font="5"> </text>
<text top="489" left="344" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="506" left="341" width="182" height="18" font="5">•  Free of clinical cardiovascular </text>
<text top="524" left="342" width="46" height="17" font="5">disease </text>
<text top="542" left="341" width="140" height="18" font="5">•  Age 45-84 at baseline </text>
<text top="560" left="341" width="146" height="18" font="5">•  White, Black, Hispanic, </text>
<text top="578" left="342" width="49" height="17" font="5">Chinese </text>
<text top="595" left="344" width="3" height="17" font="5"> </text>
<text top="613" left="344" width="3" height="17" font="5"> </text>
<text top="489" left="546" width="72" height="17" font="5">1° Endpoint: </text>
<text top="506" left="546" width="206" height="17" font="5">Total events: Incident ASCVD events </text>
<text top="523" left="546" width="202" height="17" font="5">(definite or probably MI, resuscitated </text>
<text top="541" left="546" width="217" height="17" font="5">cardiac arrest, fatal CHD, fatal and non-</text>
<text top="558" left="546" width="150" height="17" font="5">fatal stroke (not TIA), other </text>
<text top="575" left="546" width="220" height="17" font="5">atherosclerotic death, other CVD death) </text>
<text top="592" left="546" width="3" height="17" font="5"> </text>
<text top="609" left="546" width="192" height="17" font="5">Hard ASCVD: MI, fatal or non-fatal </text>
<text top="627" left="546" width="210" height="17" font="5">strokes (not TIA), resuscitated cardiac </text>
<text top="644" left="546" width="95" height="17" font="5">arrest, fatal CHD </text>
<text top="661" left="546" width="3" height="17" font="5"> </text>
<text top="678" left="546" width="184" height="18" font="5">•  Median 11.1 years follow up </text>
<text top="697" left="546" width="3" height="17" font="5"> </text>
<text top="714" left="546" width="217" height="17" font="5">At 10 years of follow-up, all participants </text>
<text top="731" left="546" width="216" height="17" font="5">with CAC&gt; 100 were estimated to have </text>
<text top="748" left="546" width="210" height="17" font="5">&gt;7.5% risk regardless of demographic </text>
<text top="765" left="546" width="40" height="17" font="5">subset </text>
<text top="489" left="791" width="63" height="17" font="5">Summary:  </text>
<text top="520" left="791" width="309" height="18" font="5">• CAC is consistently associated with risk with the same </text>
<text top="539" left="791" width="345" height="17" font="5">magnitude of effect in all races, age groups, both sexes, and in </text>
<text top="558" left="791" width="217" height="17" font="5">people on and off lipid lowering therapy </text>
<text top="589" left="791" width="3" height="17" font="5"> </text>
<text top="619" left="791" width="66" height="17" font="5">Limitations: </text>
<text top="650" left="791" width="297" height="18" font="5">• Authors note a limitation in the use of electron beam </text>
<text top="670" left="791" width="300" height="17" font="5">tomography (EBT) and 4- and 16-detector CT systems </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="34" height="17" font="5">Size:  </text>
<text top="160" left="205" width="47" height="17" font="5">N=6814 </text>
<text top="143" left="546" width="3" height="17" font="5"> </text>
<text top="160" left="546" width="212" height="17" font="5">Ten-year ASCVD event rates increase </text>
<text top="178" left="546" width="217" height="17" font="5">with increasing CAC overall and across </text>
<text top="195" left="546" width="220" height="17" font="5">race/ethnicity, age, sex, and education.  </text>
<text top="212" left="546" width="231" height="17" font="5">10 year ASCVD event rates in the CAC=0 </text>
<text top="229" left="546" width="198" height="17" font="5">group range from 1.3-5.6% vs. 13.1-</text>
<text top="247" left="546" width="164" height="17" font="5">25.6% in the CAC&gt;300 group </text>
<text top="264" left="546" width="3" height="17" font="5"> </text>
<text top="281" left="546" width="83" height="17" font="5">Hard ASCVD:  </text>
<text top="298" left="545" width="205" height="18" font="5">•  adjusting for CAC in multivariable </text>
<text top="316" left="565" width="200" height="17" font="5">models attenuated associations, but </text>
<text top="333" left="565" width="198" height="17" font="5">associations between age, sex, and </text>
<text top="351" left="565" width="184" height="17" font="5">race and Hard ASCVD outcomes </text>
<text top="368" left="565" width="211" height="17" font="5">were still significant.  Doubling of CAC </text>
<text top="385" left="565" width="168" height="17" font="5">HR=1.14 (1.11-1.17, p&lt;0.001) </text>
<text top="402" left="545" width="190" height="18" font="5">•  association of CAC with risk of </text>
<text top="421" left="565" width="182" height="17" font="5">ASCVD did not vary by age, sex, </text>
<text top="438" left="565" width="168" height="17" font="5">race/ethnicity, or lipid lowering </text>
<text top="455" left="565" width="158" height="17" font="5">medication at baseline (p for </text>
<text top="472" left="565" width="162" height="17" font="5">interaction all non significant) </text>
<text top="490" left="546" width="3" height="17" font="5"> </text>
<text top="509" left="75" width="116" height="17" font="5">Multi-Ethnic Study of </text>
<text top="526" left="75" width="87" height="17" font="5">Atherosclerosis </text>
<text top="543" left="75" width="50" height="17" font="5">(MESA)  </text>
<text top="561" left="75" width="3" height="17" font="5"> </text>
<text top="578" left="75" width="99" height="17" font="5">Blaha et al., 2016 </text>
<text top="596" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26801055">26801055</a></text>
<text top="596" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26801055"> </a></text>
<text top="509" left="205" width="31" height="17" font="5">Aim:  </text>
<text top="526" left="205" width="85" height="17" font="5">to compare the </text>
<text top="543" left="205" width="89" height="17" font="5">relative value of </text>
<text top="561" left="205" width="115" height="17" font="5">various negative risk </text>
<text top="578" left="205" width="71" height="17" font="5">markers in a </text>
<text top="595" left="205" width="112" height="17" font="5">contemporary, multi-</text>
<text top="612" left="205" width="74" height="17" font="5">ethnic cohort </text>
<text top="629" left="205" width="3" height="17" font="5"> </text>
<text top="647" left="205" width="69" height="17" font="5">Study Type: </text>
<text top="664" left="205" width="108" height="17" font="5">Prospective Cohort </text>
<text top="681" left="205" width="3" height="17" font="5"> </text>
<text top="698" left="205" width="50" height="17" font="5">N=6,814 </text>
<text top="509" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="526" left="341" width="182" height="18" font="5">•  MESA participants were 45 to </text>
<text top="544" left="342" width="88" height="17" font="5">84 years of age </text>
<text top="562" left="344" width="126" height="17" font="5">Free of clinical CVD at </text>
<text top="580" left="344" width="65" height="17" font="5">recruitment </text>
<text top="510" left="546" width="7" height="17" font="5">1</text>
<text top="509" left="553" width="64" height="18" font="5"> endpoint  </text>
<text top="541" left="546" width="223" height="17" font="5">mean diagnostic likelihood ratios (DLRs) </text>
<text top="559" left="546" width="221" height="17" font="5">for the thirteen negative risk markers for </text>
<text top="578" left="546" width="228" height="17" font="5">the entire MESA population as well as for </text>
<text top="597" left="546" width="229" height="17" font="5">important subgroups (CAC=0, Low CIMT, </text>
<text top="615" left="546" width="146" height="17" font="5">Normal FMD, Normal ABI, </text>
<text top="634" left="546" width="166" height="17" font="5">hsCRP&lt;2mg/L, homocysteine </text>
<text top="653" left="546" width="21" height="17" font="5">&lt;10</text>
<text top="652" left="567" width="203" height="18" font="5">mol/L, NT-ProBNP &lt;100 pg/mL, no </text>
<text top="672" left="546" width="208" height="17" font="5">microalbuminuria, healthy lifestyle, no </text>
<text top="691" left="546" width="185" height="17" font="5">family history, no family history of </text>
<text top="709" left="546" width="228" height="17" font="5">premature CHD, no metabolic syndrome) </text>
<text top="740" left="546" width="3" height="17" font="5"> </text>
<text top="509" left="791" width="302" height="17" font="5">Among a wide range of negative risk markers including </text>
<text top="528" left="791" width="341" height="17" font="5">atherosclerosis imaging techniques, serum biomarkers clinical </text>
<text top="546" left="791" width="311" height="17" font="5">features, and other tests, CAC=0 resulted in the greatest </text>
<text top="565" left="791" width="325" height="17" font="5">reduction in post-test risk. The conclusions were consistent </text>
<text top="583" left="791" width="339" height="17" font="5">across gender and 10-year ASCVD risk categories, and using </text>
<text top="602" left="791" width="320" height="17" font="5">different baseline multivariable models. Carotid ultrasound </text>
<text top="620" left="791" width="322" height="17" font="5">imaging with a normal result showed the best performance </text>
<text top="639" left="791" width="333" height="17" font="5">after CAC=0, whereas the performance of the other negative </text>
<text top="658" left="791" width="335" height="17" font="5">risk markers was minimal or modest. CAC=0 also yielded the </text>
<text top="676" left="791" width="294" height="17" font="5">largest, most accurate reclassification of risk to below </text>
<text top="695" left="791" width="330" height="17" font="5">commonly accepted treatment thresholds. After CAC=0, low </text>
<text top="713" left="791" width="326" height="17" font="5">CIMT showed the best performance. Absence of any family </text>
<text top="732" left="791" width="277" height="17" font="5">history of CHD was most informative of the clinical </text>
<text top="750" left="791" width="85" height="17" font="5">characteristics. </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="191" height="17" font="5">NRI was calculated for each of the </text>
<text top="162" left="546" width="223" height="17" font="5">negative risk markers using different risk </text>
<text top="180" left="546" width="60" height="17" font="5">thresholds </text>
<text top="211" left="546" width="3" height="17" font="5"> </text>
<text top="241" left="546" width="177" height="17" font="5">Mean follow up time=10.3 years </text>
<text top="272" left="546" width="225" height="17" font="5">Among all negative risk markers, CAC=0 </text>
<text top="291" left="546" width="211" height="17" font="5">showed the best performance with the </text>
<text top="309" left="546" width="209" height="17" font="5">greatest pre-test to post-test risk shift. </text>
<text top="328" left="546" width="210" height="17" font="5">CAC=0 had stable risk factor adjusted </text>
<text top="346" left="546" width="228" height="17" font="5">DLRs across clinical characteristics (0.36 </text>
<text top="365" left="546" width="203" height="17" font="5">in men, 0.46 in women). CAC=0 was </text>
<text top="384" left="546" width="224" height="17" font="5">particularly informative in older ages and </text>
<text top="402" left="546" width="226" height="17" font="5">in those with higher pre-test predicted 10-</text>
<text top="421" left="546" width="106" height="17" font="5">year ASCVD risk.   </text>
<text top="451" left="546" width="222" height="17" font="5">DLR adjusted for traditional risk factors:  </text>
<text top="482" left="546" width="90" height="17" font="5">All CHD events: </text>
<text top="512" left="546" width="67" height="17" font="5">CAC: 0.41,  </text>
<text top="530" left="546" width="64" height="17" font="5">CIMT: 0.65 </text>
<text top="547" left="546" width="131" height="17" font="5">No carotid plaque: 0.84 </text>
<text top="564" left="546" width="61" height="17" font="5">FMD: 0.94 </text>
<text top="581" left="546" width="140" height="17" font="5">Ankle Brachial Index: .98 </text>
<text top="598" left="546" width="75" height="17" font="5">HsCRP: 0.90 </text>
<text top="616" left="546" width="112" height="17" font="5">Homocysteine: 0.96 </text>
<text top="633" left="546" width="99" height="17" font="5">NT-ProBNP: 0.86 </text>
<text top="650" left="546" width="144" height="17" font="5">No microalbuminura: 0.96 </text>
<text top="667" left="546" width="169" height="17" font="5">No family history of CHD: 0.76 </text>
<text top="685" left="546" width="215" height="17" font="5">No family history premature CHD: 0.97 </text>
<text top="702" left="546" width="163" height="17" font="5">No metabolic syndrome: 0.90 </text>
<text top="719" left="546" width="120" height="17" font="5">Healthy lifestyle: 0.90 </text>
<text top="736" left="546" width="3" height="17" font="5"> </text>
<text top="143" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="222" height="17" font="5">DLR adjusted for traditional risk factors:  </text>
<text top="174" left="546" width="100" height="17" font="5">Hard CHD events </text>
<text top="204" left="546" width="60" height="17" font="5">CAC: 0.51 </text>
<text top="221" left="546" width="64" height="17" font="5">CIMT: 0.78 </text>
<text top="239" left="546" width="131" height="17" font="5">No carotid plaque: 0.88 </text>
<text top="256" left="546" width="61" height="17" font="5">FMD: 0.86 </text>
<text top="273" left="546" width="146" height="17" font="5">Ankle Brachial Index: 0.97 </text>
<text top="290" left="546" width="75" height="17" font="5">HsCRP: 0.98 </text>
<text top="308" left="546" width="112" height="17" font="5">Homocysteine: 0.94 </text>
<text top="325" left="546" width="99" height="17" font="5">NT-ProBNP: 0.79 </text>
<text top="342" left="546" width="144" height="17" font="5">No microalbuminura: 0.97 </text>
<text top="359" left="546" width="169" height="17" font="5">No family history of CHD: 0.78 </text>
<text top="377" left="546" width="215" height="17" font="5">No family history premature CHD: 0.99 </text>
<text top="394" left="546" width="163" height="17" font="5">No metabolic syndrome: 0.91 </text>
<text top="411" left="546" width="120" height="17" font="5">Healthy lifestyle: 0.87 </text>
<text top="428" left="546" width="3" height="17" font="5"> </text>
<text top="459" left="546" width="86" height="17" font="5">All CVD events </text>
<text top="489" left="546" width="60" height="17" font="5">CAC: 0.54 </text>
<text top="507" left="546" width="64" height="17" font="5">CIMT: 0.75 </text>
<text top="524" left="546" width="131" height="17" font="5">No carotid plaque: 0.88 </text>
<text top="541" left="546" width="61" height="17" font="5">FMD: 0.91 </text>
<text top="558" left="546" width="146" height="17" font="5">Ankle Brachial Index: 1.00 </text>
<text top="575" left="546" width="75" height="17" font="5">HsCRP: 0.89 </text>
<text top="593" left="546" width="112" height="17" font="5">Homocysteine: 0.96 </text>
<text top="610" left="546" width="99" height="17" font="5">NT-ProBNP: 0.88 </text>
<text top="627" left="546" width="144" height="17" font="5">No microalbuminura: 0.97 </text>
<text top="644" left="546" width="169" height="17" font="5">No family history of CHD: 0.81 </text>
<text top="661" left="546" width="215" height="17" font="5">No family history premature CHD: 0.96 </text>
<text top="679" left="546" width="163" height="17" font="5">No metabolic syndrome: 0.91 </text>
<text top="696" left="546" width="120" height="17" font="5">Healthy lifestyle: 0.98 </text>
<text top="713" left="546" width="3" height="17" font="5"> </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="228" height="17" font="5">NRI analyses also showed CAC=0 as the </text>
<text top="162" left="546" width="206" height="17" font="5">largest, most accurate downward risk </text>
<text top="180" left="546" width="87" height="17" font="5">reclassification. </text>
<text top="200" left="75" width="85" height="17" font="5">Cardiovascular </text>
<text top="217" left="75" width="74" height="17" font="5">Lifetime Risk </text>
<text top="234" left="75" width="86" height="17" font="5">Pooling Project </text>
<text top="251" left="75" width="3" height="17" font="5"> </text>
<text top="268" left="75" width="97" height="17" font="5">Berry et al., 2012 </text>
<text top="287" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22276822">22276822</a></text>
<text top="287" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22276822"> </a></text>
<text top="200" left="205" width="25" height="17" font="5">Aim </text>
<text top="217" left="205" width="124" height="17" font="5">To report lifetime risks </text>
<text top="234" left="205" width="96" height="17" font="5">of cardiovascular </text>
<text top="251" left="205" width="96" height="17" font="5">disease have not </text>
<text top="268" left="205" width="120" height="17" font="5">been reported across </text>
<text top="286" left="205" width="111" height="17" font="5">the age spectrum in </text>
<text top="303" left="205" width="124" height="17" font="5">black adults and white </text>
<text top="320" left="205" width="36" height="17" font="5">adults </text>
<text top="337" left="205" width="3" height="17" font="5"> </text>
<text top="355" left="205" width="62" height="17" font="5">Study type </text>
<text top="372" left="205" width="92" height="17" font="5">Meta analysis of </text>
<text top="389" left="205" width="80" height="17" font="5">cohort studies </text>
<text top="406" left="205" width="3" height="17" font="5"> </text>
<text top="423" left="205" width="75" height="17" font="5">N=18 studies </text>
<text top="442" left="205" width="122" height="17" font="5">(257,384 participants) </text>
<text top="200" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="217" left="344" width="3" height="17" font="5"> </text>
<text top="234" left="341" width="125" height="18" font="5">•  Represented either </text>
<text top="252" left="342" width="179" height="17" font="5">community-based or  population-</text>
<text top="270" left="342" width="185" height="17" font="5">based samples or large volunteer </text>
<text top="287" left="342" width="44" height="17" font="5">cohorts </text>
<text top="304" left="341" width="183" height="18" font="5">•  Included at least one baseline </text>
<text top="322" left="342" width="128" height="17" font="5">examination with direct </text>
<text top="339" left="342" width="190" height="17" font="5">measurement of physiological and </text>
<text top="357" left="342" width="160" height="17" font="5">anthropometric (e.g., weight) </text>
<text top="374" left="342" width="53" height="17" font="5">variables </text>
<text top="391" left="341" width="177" height="18" font="5">•  Included 10 or more years of </text>
<text top="409" left="342" width="158" height="17" font="5">follow-up for fatal or nonfatal </text>
<text top="427" left="342" width="164" height="17" font="5">cardiovascular events or both </text>
<text top="444" left="344" width="3" height="17" font="5"> </text>
<text top="201" left="546" width="7" height="17" font="5">1</text>
<text top="200" left="553" width="64" height="18" font="5"> endpoint  </text>
<text top="231" left="546" width="211" height="17" font="7"><i>Lifetime risk of cardiovascular disease </i></text>
<text top="249" left="546" width="3" height="17" font="7"><i> </i></text>
<text top="266" left="546" width="228" height="17" font="5">Lifetime risk was higher among men than </text>
<text top="283" left="546" width="219" height="17" font="5">women (36.1% white men, 33.0% black </text>
<text top="300" left="546" width="218" height="17" font="5">men, 26.6% white women, 27.1% black </text>
<text top="318" left="546" width="47" height="17" font="5">women) </text>
<text top="335" left="546" width="3" height="17" font="5"> </text>
<text top="352" left="546" width="227" height="17" font="5">Lifetime risk of death from cardiovascular </text>
<text top="369" left="546" width="213" height="17" font="5">disease and coronary heart disease or </text>
<text top="386" left="546" width="230" height="17" font="5">nonfatal MI were approximately two times </text>
<text top="404" left="546" width="229" height="17" font="5">as high in men, lifetime risk of fatal stroke </text>
<text top="421" left="546" width="221" height="17" font="5">or nonfatal stroke did not vary by sex. In </text>
<text top="438" left="546" width="221" height="17" font="5">men at 55 years of age, white and black </text>
<text top="455" left="546" width="226" height="17" font="5">men with optimal risk factor profiles (total </text>
<text top="472" left="546" width="216" height="17" font="5">cholesterol &lt;180 mg per deciliter, &lt;120 </text>
<text top="490" left="546" width="224" height="17" font="5">mm HG systolic and 80 mm HG diastolic </text>
<text top="507" left="546" width="189" height="17" font="5">blood pressure, non smoking, and </text>
<text top="524" left="546" width="225" height="17" font="5">nondiabetic) had lower lifetime risks than </text>
<text top="541" left="546" width="224" height="17" font="5">those with two or more major risk factors </text>
<text top="559" left="546" width="200" height="17" font="5">(7.7% vs. 29.6% in all men, 4.0% vs </text>
<text top="576" left="546" width="217" height="17" font="5">26.6% for white men, 9.9% vs 27.9% in </text>
<text top="593" left="546" width="231" height="17" font="5">black men, 6.4% vs. 20.5% in all women). </text>
<text top="610" left="546" width="232" height="17" font="5">Adjusting for competing risks substantially </text>
<text top="627" left="546" width="216" height="17" font="5">decreased the lifetime risk (in men with </text>
<text top="645" left="546" width="224" height="17" font="5">2+ major risk factors, unadjusted Kaplan-</text>
<text top="662" left="546" width="232" height="17" font="5">Meier estimate=81.8% without adjustment </text>
<text top="679" left="546" width="191" height="17" font="5">for competing risk and 44.5% after </text>
<text top="696" left="546" width="172" height="17" font="5">adjustment for competing risk). </text>
<text top="714" left="546" width="3" height="17" font="5"> </text>
<text top="731" left="546" width="218" height="17" font="5">The 20-year adjusted risk of death from </text>
<text top="749" left="546" width="183" height="17" font="5">cardiovascular disease at age 55 </text>
<text top="768" left="546" width="214" height="17" font="5">decreased with increasing year of birth </text>
<text top="200" left="791" width="63" height="17" font="5">Summary:  </text>
<text top="217" left="791" width="7" height="17" font="5">  </text>
<text top="234" left="791" width="333" height="17" font="5">Risk factors were associated with significant increases in the </text>
<text top="251" left="791" width="347" height="17" font="5">long-term risk of cardiovascular disease, and optimal risk factor </text>
<text top="268" left="791" width="348" height="17" font="5">status was associated with a very low lifetime risk. The effect of </text>
<text top="286" left="791" width="343" height="17" font="5">risk factors was consistent across birth cohorts. Accounting for </text>
<text top="303" left="791" width="175" height="17" font="5">risk factors, the lifetime risks of  </text>
<text top="320" left="791" width="348" height="17" font="5">cardiovascular disease were similar between blacks and whites </text>
<text top="337" left="791" width="7" height="17" font="5">. </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="229" height="17" font="5">cohort (e.g., men in NHANES I compared </text>
<text top="162" left="546" width="204" height="17" font="5">to men in NHANES III had 17.7% vs. </text>
<text top="180" left="546" width="230" height="17" font="5">10.5% 20-year adjusted risk; women from </text>
<text top="199" left="546" width="204" height="17" font="5">NHANES I compared to women from </text>
<text top="218" left="546" width="230" height="17" font="5">NHANES III had 12.2% VS. 7.0% 20-year </text>
<text top="236" left="546" width="222" height="17" font="5">adjusted risk). The 20-year adjusted risk </text>
<text top="255" left="546" width="214" height="17" font="5">for each risk factor profile did not show </text>
<text top="273" left="546" width="168" height="17" font="5">evidence of change over time. </text>
<text top="293" left="75" width="114" height="17" font="5">Mahabadi AA, et al., </text>
<text top="311" left="75" width="49" height="17" font="5">(8) 2017 </text>
<text top="330" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27665163">27665163</a></text>
<text top="330" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27665163"> </a></text>
<text top="293" left="205" width="65" height="17" font="5">Study type: </text>
<text top="311" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="330" left="205" width="117" height="17" font="5">(Heinz-Nixdorf, 2000-</text>
<text top="348" left="205" width="35" height="17" font="5">2003) </text>
<text top="367" left="205" width="3" height="17" font="5"> </text>
<text top="386" left="205" width="61" height="17" font="5">Size: 3745 </text>
<text top="404" left="205" width="66" height="17" font="5">participants </text>
<text top="293" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="311" left="344" width="186" height="18" font="5">• Asymptomatic adults age 45-75 </text>
<text top="331" left="344" width="151" height="17" font="5">years from 3 German cities </text>
<text top="350" left="344" width="3" height="17" font="5"> </text>
<text top="368" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="387" left="344" width="179" height="17" font="5">Prevalent ASCVD, lipid lowering </text>
<text top="405" left="344" width="178" height="17" font="5">therapy, or missing risk factor or </text>
<text top="424" left="344" width="57" height="17" font="5">CAC data </text>
<text top="294" left="546" width="7" height="17" font="5">1</text>
<text top="293" left="553" width="204" height="18" font="5"> endpoint: Incident coronary events, </text>
<text top="311" left="546" width="171" height="17" font="5">stroke, or cardiovascular death </text>
<text top="328" left="546" width="215" height="17" font="5">comparing strategies of 2012 ESC and </text>
<text top="345" left="546" width="198" height="17" font="5">2013 ACC/AHA guidelines for statin </text>
<text top="362" left="546" width="53" height="17" font="5">eligibility; </text>
<text top="380" left="546" width="170" height="17" font="5">Median follow up of 10.4 years </text>
<text top="397" left="546" width="3" height="17" font="5"> </text>
<text top="414" left="546" width="48" height="17" font="5">Results: </text>
<text top="431" left="546" width="214" height="18" font="5">• Low CAC score (&lt;100) was common </text>
<text top="450" left="546" width="210" height="17" font="5">(60%) among those recommended for </text>
<text top="467" left="546" width="180" height="17" font="5">statin therapy by both guidelines </text>
<text top="484" left="546" width="120" height="18" font="5">• Events by guideline </text>
<text top="503" left="556" width="179" height="17" font="5">-  2012 ESC guideline statin not </text>
<text top="520" left="556" width="101" height="17" font="5">indicated, n=2457 </text>
<text top="537" left="556" width="163" height="17" font="5">CAC, median (IQR): 2 (0, 43) </text>
<text top="554" left="556" width="169" height="17" font="5">CVD events: 97 events (4.0%) </text>
<text top="571" left="556" width="194" height="17" font="5">Coronary events: 60 events (2.4%) </text>
<text top="589" left="556" width="214" height="17" font="5">-  2012 ESC guideline statin indicated, </text>
<text top="606" left="556" width="45" height="17" font="5">n=1288 </text>
<text top="623" left="556" width="176" height="17" font="5">CAC, median (IQR): 59 (5, 244) </text>
<text top="640" left="556" width="183" height="17" font="5">CVD events: 144 events (11.2%) </text>
<text top="657" left="556" width="194" height="17" font="5">Coronary events: 71 events (5.5%) </text>
<text top="675" left="556" width="182" height="17" font="5">-  2013 PCE statin not indicated, </text>
<text top="692" left="556" width="215" height="17" font="5">n=1254 (plus 396 with predicted risk=5-</text>
<text top="709" left="556" width="36" height="17" font="5">7.5%) </text>
<text top="726" left="556" width="163" height="17" font="5">CAC, median (IQR): 0 (0, 15) </text>
<text top="743" left="556" width="169" height="17" font="5">CVD events: 35 events (2.1%) </text>
<text top="761" left="556" width="194" height="17" font="5">Coronary events: 19 events (1.2%) </text>
<text top="293" left="790" width="325" height="18" font="5">•  “Quantification of CAC score in addition to the guidelines </text>
<text top="312" left="790" width="345" height="17" font="5">improves stratification between subjects at high versus low risk </text>
<text top="331" left="790" width="331" height="17" font="5">for coronary events, indicating that CAC scoring may help to </text>
<text top="349" left="790" width="318" height="17" font="5">match intensified risk factor modification to atherosclerotic </text>
<text top="368" left="790" width="336" height="17" font="5">plaque burden as well as actual risk while avoiding therapy in </text>
<text top="387" left="790" width="327" height="17" font="5">subjects with low coronary atherosclerosis that have low 10-</text>
<text top="405" left="790" width="93" height="17" font="5">year event rate.” </text>
<text top="436" left="790" width="240" height="18" font="5">•  Limitations: Limited racial/ethnic diversity </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="556" width="207" height="17" font="5">-  2013 PCE statin indicated, n=2095 </text>
<text top="160" left="556" width="176" height="17" font="5">CAC, median (IQR): 46 (3, 200) </text>
<text top="178" left="556" width="172" height="17" font="5">CVD events 206 events (9.8%) </text>
<text top="195" left="556" width="197" height="17" font="5">Coronary events 112 events (5.3%) </text>
<text top="212" left="546" width="57" height="18" font="5">• By CAC </text>
<text top="232" left="556" width="106" height="17" font="5">-  CAC=0, n=1272 </text>
<text top="250" left="556" width="129" height="17" font="5">CVD events: 30 (2.4%) </text>
<text top="269" left="556" width="154" height="17" font="5">Coronary events: 17 (1.3%) </text>
<text top="287" left="556" width="120" height="17" font="5">-  CAC 1-100, n=555 </text>
<text top="306" left="556" width="129" height="17" font="5">CVD events: 88 (5.7%) </text>
<text top="325" left="556" width="147" height="17" font="5">Coronary events: 8 (2.4%) </text>
<text top="343" left="556" width="126" height="17" font="5">-  CAC 100-399, n601 </text>
<text top="362" left="556" width="129" height="17" font="5">CVD events: 58 (9.7%) </text>
<text top="380" left="556" width="154" height="17" font="5">Coronary events: 36 (6.0%) </text>
<text top="399" left="556" width="107" height="17" font="5">-  CAC≥400, n=17 </text>
<text top="417" left="556" width="136" height="17" font="5">CVD events: 65 (20.5%) </text>
<text top="436" left="556" width="161" height="17" font="5">Coronary events: 40 (12.6%) </text>
<text top="455" left="546" width="3" height="17" font="5"> </text>
<text top="473" left="546" width="122" height="18" font="5">• By guideline + CAC </text>
<text top="493" left="546" width="155" height="17" font="5">-  2012 ESC statin indicated </text>
<text top="511" left="546" width="232" height="17" font="5">CAC=0: 5.7 per 1,000 p-y, 95% CI 2.7-8.7 </text>
<text top="530" left="546" width="226" height="17" font="5">CAC 1-99: 7.8 per 1,000 p-y, 95% CI 5.5-</text>
<text top="549" left="546" width="27" height="17" font="5">10.0 </text>
<text top="567" left="546" width="212" height="17" font="5">CAC≥100: 17.4 per 1,000 p-y, 95% CI </text>
<text top="586" left="546" width="55" height="17" font="5">14.1-20.7 </text>
<text top="604" left="546" width="176" height="17" font="5">-  2012 ESC statin not indicated </text>
<text top="623" left="546" width="232" height="17" font="5">CAC=0: 1.5 per 1,000 p-y, 95% CI 0.8-2.2 </text>
<text top="641" left="546" width="226" height="17" font="5">CAC 1-99: 4.3 per 1,000 p-y, 95% CI 3.1-</text>
<text top="660" left="546" width="21" height="17" font="5">5.5 </text>
<text top="679" left="546" width="226" height="17" font="5">CAC≥100: 8.7 per 1,000 p-y, 95% CI 6.0-</text>
<text top="697" left="546" width="27" height="17" font="5">11.5 </text>
<text top="716" left="546" width="155" height="17" font="5">-  2013 PCE statin indicated </text>
<text top="734" left="546" width="232" height="17" font="5">CAC=0: 5.4 per 1,000 p-y, 95% CI 3.2-7.5 </text>
<text top="753" left="546" width="222" height="17" font="5">CAC1-99: 7.5 per 1,000 p-y, 95% CI 5.8-</text>
<text top="772" left="546" width="27" height="17" font="5">10.9 </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="212" height="17" font="5">CAC≥100: 14.6 per 1,000 p-y, 95% CI </text>
<text top="162" left="546" width="55" height="17" font="5">12.2-17.1 </text>
<text top="180" left="546" width="176" height="17" font="5">-  2013 PCE statin not indicated </text>
<text top="199" left="546" width="232" height="17" font="5">CAC=0: 0.8 per 1,000 p-y, 95% CI 0.3-1.2 </text>
<text top="218" left="546" width="226" height="17" font="5">CAC 1-99: 2.8 per 1,000 p-y, 95% CI 1.5-</text>
<text top="236" left="546" width="21" height="17" font="5">4.0 </text>
<text top="255" left="546" width="226" height="17" font="5">CAC≥100: 6.5 per 1,000 p-y, 95% CI 2.2-</text>
<text top="273" left="546" width="31" height="17" font="5">11.8) </text>
<text top="292" left="546" width="3" height="17" font="5"> </text>
<text top="311" left="546" width="217" height="18" font="5">• Number needed to screen to detect 1 </text>
<text top="330" left="546" width="137" height="17" font="5">individual with CAC&gt;100 </text>
<text top="349" left="546" width="138" height="17" font="5">ESC statin indicated: 2.4 </text>
<text top="367" left="546" width="162" height="17" font="5">ESC statin not indicated: 6.3  </text>
<text top="386" left="546" width="168" height="17" font="5">ACC/AHA statin indicated: 2.6 </text>
<text top="404" left="546" width="195" height="17" font="5">ACC/AHA statin not indicated: 13.9 </text>
<text top="423" left="546" width="3" height="17" font="5"> </text>
<text top="441" left="75" width="100" height="17" font="5">McClelland RL, et </text>
<text top="459" left="75" width="69" height="17" font="5">al., (9) 2015 </text>
<text top="478" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26449133">26449133</a></text>
<text top="478" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26449133"> </a></text>
<text top="441" left="205" width="65" height="17" font="5">Study type: </text>
<text top="459" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="478" left="205" width="126" height="17" font="5">studies (MESA, Dallas </text>
<text top="497" left="205" width="115" height="17" font="5">Heart, Heinz-Nixdorf </text>
<text top="515" left="205" width="112" height="17" font="5">Recall Studies), risk </text>
<text top="534" left="205" width="114" height="17" font="5">score derivation and </text>
<text top="552" left="205" width="55" height="17" font="5">validation </text>
<text top="571" left="205" width="3" height="17" font="5"> </text>
<text top="589" left="205" width="61" height="17" font="5">Size: 6727 </text>
<text top="608" left="205" width="79" height="17" font="5">participants in </text>
<text top="627" left="205" width="98" height="17" font="5">derivation cohort; </text>
<text top="645" left="205" width="98" height="17" font="5">3692 and 1080 in </text>
<text top="664" left="205" width="99" height="17" font="5">validation cohorts </text>
<text top="441" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="459" left="344" width="150" height="17" font="5">• Adults age 45-84 years in </text>
<text top="478" left="344" width="179" height="17" font="5">derivation cohort; 45 to 75 years </text>
<text top="497" left="344" width="157" height="17" font="5">in HNR; 45-65 years in DHS </text>
<text top="515" left="344" width="3" height="17" font="5"> </text>
<text top="534" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="552" left="344" width="93" height="17" font="5">• Prevalent CVD </text>
<text top="571" left="344" width="80" height="17" font="5">• Missing data </text>
<text top="442" left="546" width="7" height="17" font="5">1</text>
<text top="441" left="553" width="223" height="18" font="5"> endpoint: Incident hard CHD, including </text>
<text top="461" left="546" width="231" height="17" font="5">MI, resuscitated cardiac arrest, fatal CHD, </text>
<text top="479" left="546" width="230" height="17" font="5">and revascularization in setting of angina; </text>
<text top="498" left="546" width="226" height="17" font="5">Median follow up 10.2 years in derivation </text>
<text top="516" left="546" width="38" height="17" font="5">cohort </text>
<text top="535" left="546" width="3" height="17" font="5"> </text>
<text top="554" left="546" width="48" height="17" font="5">Results: </text>
<text top="572" left="549" width="215" height="18" font="5">•  422 CHD events in derivation cohort </text>
<text top="593" left="549" width="228" height="18" font="5">•  Compared MESA score with traditional </text>
<text top="614" left="549" width="220" height="17" font="5">risk factors to MESA score + ln(CAC+1) </text>
<text top="634" left="549" width="177" height="18" font="5">•  In MESA, MESA score model </text>
<text top="654" left="549" width="207" height="17" font="5">performance vs. MESA score + CAC: </text>
<text top="674" left="546" width="142" height="17" font="5">C-statistics 0.75 and 0.80 </text>
<text top="693" left="546" width="212" height="17" font="5">Discrimination slopes 0.052 and 0.086 </text>
<text top="711" left="546" width="194" height="17" font="5">Calibration slopes 0.834 and 0.857 </text>
<text top="730" left="546" width="205" height="17" font="5">Hosmer-Lemeshow P &gt; 0.22 for both </text>
<text top="749" left="546" width="43" height="17" font="5">models </text>
<text top="441" left="791" width="328" height="18" font="5">•  Routine addition of CAC score to traditional risk scores in </text>
<text top="460" left="791" width="343" height="17" font="5">contemporary cohorts added significant utility to risk prediction </text>
<text top="491" left="791" width="313" height="18" font="5">•  Limitations: Implies universal CAC screening; targeted </text>
<text top="511" left="791" width="330" height="17" font="5">usage of preventive therapies for higher risk individuals may </text>
<text top="529" left="791" width="307" height="17" font="5">have resulted from intensive screening for CAC in these </text>
<text top="548" left="791" width="44" height="17" font="5">cohorts </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="228" height="18" font="5">•  In HNR and DHS, MESA score + CAC </text>
<text top="164" left="546" width="206" height="17" font="5">performed well with good to excellent </text>
<text top="184" left="546" width="214" height="17" font="5">discrimination and excellent calibration </text>
<text top="204" left="546" width="136" height="17" font="5">C-statistic 0.78 and 0.82 </text>
<text top="222" left="546" width="212" height="17" font="5">Discrimination slopes 0.095 and 0.078 </text>
<text top="241" left="546" width="187" height="17" font="5">Calibration slopes 0.899 and 1.19 </text>
<text top="259" left="546" width="3" height="17" font="5"> </text>
<text top="277" left="75" width="116" height="17" font="5">Kavousi M, et al., (7) </text>
<text top="296" left="75" width="31" height="17" font="5">2016 </text>
<text top="315" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27846641">27846641</a></text>
<text top="315" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27846641"> </a></text>
<text top="277" left="205" width="120" height="17" font="5">Study type: Individual </text>
<text top="296" left="205" width="119" height="17" font="5">participant data meta-</text>
<text top="315" left="205" width="48" height="17" font="5">analysis </text>
<text top="333" left="205" width="3" height="17" font="5"> </text>
<text top="352" left="205" width="124" height="17" font="5">Size: Meta-analysis of </text>
<text top="370" left="205" width="80" height="17" font="5">5 prospective, </text>
<text top="389" left="205" width="100" height="17" font="5">community-based </text>
<text top="407" left="205" width="119" height="17" font="5">cohorts (Dallas Heart </text>
<text top="426" left="205" width="111" height="17" font="5">Study, FHS, MESA, </text>
<text top="445" left="205" width="80" height="17" font="5">Heinz Nixdorf, </text>
<text top="463" left="205" width="99" height="17" font="5">Rotterdam), 6739 </text>
<text top="482" left="205" width="66" height="17" font="5">participants </text>
<text top="277" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="296" left="344" width="154" height="17" font="5">• Women with low predicted </text>
<text top="315" left="344" width="182" height="17" font="5">ASCVD risk using PCE variables </text>
<text top="333" left="344" width="186" height="17" font="5">(&lt; 7.5% predicted event rate over </text>
<text top="352" left="344" width="58" height="17" font="5">10 years)  </text>
<text top="370" left="344" width="3" height="17" font="5"> </text>
<text top="389" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="407" left="344" width="187" height="17" font="5">• In all cohorts, previous history of </text>
<text top="426" left="344" width="176" height="17" font="5">coronary artery disease, stroke, </text>
<text top="445" left="344" width="153" height="17" font="5">chronic kidney disease with </text>
<text top="463" left="344" width="185" height="17" font="5">glomerular filtration rate less than </text>
<text top="482" left="344" width="189" height="17" font="5">30 mL/min/1.73m2, treatment with </text>
<text top="500" left="344" width="176" height="17" font="5">statin, LDL-C ≥190 mg/dL , and </text>
<text top="519" left="344" width="133" height="17" font="5">age older than 79 years </text>
<text top="278" left="546" width="7" height="17" font="5">1</text>
<text top="277" left="553" width="211" height="18" font="5"> endpoint: Incident ASCVD, including </text>
<text top="297" left="546" width="218" height="17" font="5">nonfatal myocardial infarction, coronary </text>
<text top="316" left="546" width="217" height="17" font="5">heart disease (CHD) death, and stroke; </text>
<text top="334" left="546" width="195" height="17" font="5">Median follow-up of 7 to 11.6 years </text>
<text top="353" left="546" width="3" height="17" font="5"> </text>
<text top="371" left="546" width="48" height="17" font="5">Results: </text>
<text top="390" left="546" width="114" height="18" font="5">• Primary event rate </text>
<text top="410" left="556" width="120" height="17" font="5">-  CAC=0 (reference) </text>
<text top="429" left="556" width="215" height="17" font="5">62 events/4304 participants/44,043 p-y </text>
<text top="447" left="556" width="57" height="17" font="5">-  CAC&gt;0 </text>
<text top="466" left="556" width="222" height="17" font="5">103 events/2435 participants/23,785 p-y </text>
<text top="484" left="556" width="212" height="17" font="5">Incidence rate difference 2.92, 95% CI </text>
<text top="503" left="556" width="59" height="17" font="5">2.02- 3.83 </text>
<text top="521" left="556" width="203" height="17" font="5">Adjusted HR 2.04, 95% CI 1.44-2.90 </text>
<text top="540" left="556" width="77" height="17" font="5">-  CAC 1-100 </text>
<text top="559" left="556" width="212" height="17" font="5">59 events/1951 participants/19,238p-y </text>
<text top="577" left="556" width="212" height="17" font="5">Incidence rate difference 1.66, 95% CI </text>
<text top="596" left="556" width="55" height="17" font="5">0.80-2.52 </text>
<text top="614" left="556" width="203" height="17" font="5">Adjusted HR 1.53, 95% CI 1.02-2.29 </text>
<text top="633" left="556" width="70" height="17" font="5">-  CAC&gt;100 </text>
<text top="651" left="556" width="198" height="17" font="5">44 events/484 participants/4546 p-y </text>
<text top="670" left="556" width="212" height="17" font="5">Incidence rate difference 8.27, 95% CI </text>
<text top="689" left="556" width="66" height="17" font="5">5.39- 11.15 </text>
<text top="707" left="556" width="203" height="17" font="5">Adjusted HR 4.02, 95% CI 2.61-6.19 </text>
<text top="726" left="546" width="3" height="17" font="5"> </text>
<text top="744" left="546" width="204" height="18" font="5">• C-statistic with CAC added to base </text>
<text top="764" left="546" width="170" height="17" font="5">model: 0.77, 95% CI 0.74-0.81 </text>
<text top="277" left="791" width="324" height="18" font="5">•  In women from 5 cohort studies at low predicted 10-year </text>
<text top="297" left="791" width="335" height="17" font="5">ASCVD risk (&lt;7.5%), CAC was present in approximately one-</text>
<text top="315" left="791" width="326" height="17" font="5">third and was associated with increased risk of ASCVD and </text>
<text top="334" left="791" width="327" height="17" font="5">modest improvement in prognostic accuracy compared with </text>
<text top="353" left="791" width="123" height="17" font="5">traditional risk factors. </text>
<text top="383" left="791" width="3" height="17" font="5"> </text>
<text top="414" left="791" width="348" height="18" font="5">•  Limitations: Relatively few events; predominantly Caucasian; </text>
<text top="433" left="791" width="69" height="17" font="5">women only </text>
<text top="464" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="223" height="18" font="5">• Increase in C-statistic with CAC added </text>
<text top="163" left="546" width="214" height="17" font="5">to base model: 0.02, 95% CI 0.00-0.05 </text>
<text top="181" left="546" width="218" height="18" font="5">• Continuous NRI with CAC: 0.20 (95% </text>
<text top="201" left="546" width="78" height="17" font="5">CI 0.09, 0.31) </text>
<text top="220" left="546" width="211" height="18" font="5">• Results evaluating CHD as outcome </text>
<text top="239" left="546" width="182" height="17" font="5">similar but generally more robust </text>
<text top="258" left="546" width="3" height="17" font="5"> </text>
<text top="277" left="75" width="50" height="17" font="5">CARDIA </text>
<text top="296" left="75" width="77" height="17" font="5">Carr J, et al.,  </text>
<text top="314" left="75" width="31" height="17" font="5">2017 </text>
<text top="333" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28196265">28196265</a></text>
<text top="333" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28196265"> </a></text>
<text top="277" left="205" width="65" height="17" font="5">Study type: </text>
<text top="296" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="314" left="205" width="123" height="17" font="5">(CARDIA study, exam </text>
<text top="333" left="205" width="116" height="17" font="5">years 15, 20 and 25) </text>
<text top="351" left="205" width="3" height="17" font="5"> </text>
<text top="370" left="205" width="61" height="17" font="5">Size: 3036 </text>
<text top="389" left="205" width="66" height="17" font="5">participants </text>
<text top="277" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="296" left="344" width="151" height="18" font="5">• Black and white men and </text>
<text top="315" left="344" width="143" height="17" font="5">women attending Year 15 </text>
<text top="334" left="344" width="188" height="17" font="5">examination of the CARDIA Study </text>
<text top="353" left="344" width="118" height="17" font="5">and undergoing CAC </text>
<text top="371" left="344" width="79" height="17" font="5">measurement </text>
<text top="390" left="341" width="141" height="18" font="5">• Adults age 32-46 years </text>
<text top="409" left="344" width="3" height="17" font="5"> </text>
<text top="428" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="447" left="341" width="86" height="18" font="5">•  Missing data </text>
<text top="466" left="341" width="67" height="18" font="5">•  Pregnant </text>
<text top="486" left="344" width="86" height="17" font="5">Prevalent CHD </text>
<text top="278" left="546" width="7" height="17" font="5">1</text>
<text top="277" left="553" width="216" height="18" font="5"> endpoint: Incident clinical CHD, CVD, </text>
<text top="297" left="546" width="184" height="17" font="5">or all-cause mortality, considered </text>
<text top="315" left="546" width="64" height="17" font="5">separately; </text>
<text top="334" left="546" width="170" height="17" font="5">Median follow up of 12.5 years </text>
<text top="353" left="546" width="3" height="17" font="5"> </text>
<text top="371" left="546" width="48" height="17" font="5">Results: </text>
<text top="390" left="546" width="147" height="18" font="5">• Any CAC versus CAC=0 </text>
<text top="410" left="549" width="184" height="18" font="5">• All CHD (57 events/38,056 p-y) </text>
<text top="429" left="549" width="165" height="17" font="5">Any CAC: 30 events/3644 p-y </text>
<text top="448" left="549" width="165" height="17" font="5">CAC=0: 27 events/34,413 p-y </text>
<text top="466" left="549" width="185" height="17" font="5">Adjusted HR 5.0, 95% CI: 2.8-8.7 </text>
<text top="485" left="549" width="150" height="18" font="5">•  CHD excluding coronary </text>
<text top="505" left="549" width="211" height="17" font="5">revascularization without acute events </text>
<text top="523" left="549" width="127" height="17" font="5">(46 events/38,125 p-y) </text>
<text top="542" left="546" width="165" height="17" font="5">Any CAC: 23 events/3693 p-y </text>
<text top="560" left="546" width="165" height="17" font="5">CAC=0: 23 events/34,432 p-y </text>
<text top="579" left="546" width="185" height="17" font="5">Adjusted HR 4.1, 95% CI: 2.2-7.7 </text>
<text top="597" left="549" width="218" height="18" font="5">• Any CVD event (108 events/37,599 p-</text>
<text top="617" left="549" width="14" height="17" font="5">y) </text>
<text top="636" left="549" width="165" height="17" font="5">Any CAC: 38 events/3555 p-y </text>
<text top="654" left="549" width="122" height="17" font="5">CAC=0: 70/34,045p-y </text>
<text top="673" left="549" width="185" height="17" font="5">Adjusted HR 3.0, 95% CI, 1.9-4.7 </text>
<text top="691" left="549" width="223" height="18" font="5">•  All-cause mortality (107 events/38330 </text>
<text top="711" left="549" width="25" height="17" font="5">p-y) </text>
<text top="730" left="549" width="165" height="17" font="5">Any CAC: 25 events/3847 p-y </text>
<text top="748" left="549" width="165" height="17" font="5">CAC=0: 82 events/34,847 p-y </text>
<text top="767" left="549" width="182" height="17" font="5">Adjusted HR 1.6, 95% CI 1.0-2.6 </text>
<text top="277" left="790" width="341" height="18" font="5">•  CAC&gt;0 among adults age 32-46 years was associated with </text>
<text top="297" left="790" width="349" height="17" font="5">higher risk of fatal and nonfatal CHD; CAC&gt;100 was associated </text>
<text top="315" left="790" width="331" height="17" font="5">with nearly four-fold risk of all-cause mortality, most of which </text>
<text top="334" left="790" width="93" height="17" font="5">was due to CHD </text>
<text top="352" left="791" width="323" height="18" font="5">• There is a dose-response gradient for future CHD events </text>
<text top="372" left="791" width="334" height="17" font="5">evident for CAC scores even among younger adults aged 32-</text>
<text top="391" left="791" width="211" height="17" font="5">46 years over 12.5 years of follow up.  </text>
<text top="410" left="791" width="334" height="18" font="5">• Presence of risk factors for CVD in early adult life identified </text>
<text top="429" left="791" width="304" height="17" font="5">those above the median risk for developing CAC and, if </text>
<text top="448" left="791" width="328" height="17" font="5">applied, in a selective CAC screening strategy could reduce </text>
<text top="466" left="791" width="310" height="17" font="5">the number of people screened for CAC by 50% and the </text>
<text top="485" left="791" width="338" height="17" font="5">number imaged needed to find 1 person with CAC from 3.5 to </text>
<text top="504" left="791" width="24" height="17" font="5">2.2. </text>
<text top="522" left="790" width="342" height="18" font="5">•  Selective use of screening for CAC in adults before the age </text>
<text top="542" left="790" width="289" height="17" font="5">of 50, based on the presence of risk factors in young </text>
<text top="560" left="790" width="310" height="17" font="5">adulthood, might be considered to inform discussions on </text>
<text top="579" left="790" width="112" height="17" font="5">primary prevention.  </text>
<text top="597" left="791" width="3" height="17" font="5"> </text>
<text top="616" left="790" width="330" height="18" font="5">•  Limitations: Small number of events given younger age of </text>
<text top="636" left="791" width="38" height="17" font="5">cohort </text>
<text top="654" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="177" height="18" font="5">• CAC score ranges vs. CAC=0 </text>
<text top="163" left="549" width="57" height="18" font="5">• All CHD </text>
<text top="182" left="549" width="162" height="17" font="5">CAC 1-19: 7 events/1844 p-y </text>
<text top="201" left="549" width="188" height="17" font="5">Adjusted HR 2.6, 95% CI: 1.0, 5.7 </text>
<text top="220" left="549" width="179" height="17" font="5">CAC 20-99: 10 events/1177 p-y  </text>
<text top="238" left="549" width="189" height="17" font="5">Adjusted HR 5.8, 95% CI 2.6-12.1 </text>
<text top="257" left="549" width="166" height="17" font="5">CAC ≥100: 13 events/623-py  </text>
<text top="275" left="549" width="189" height="17" font="5">Adjusted HR 9.8, 95% CI 4.5-20.5 </text>
<text top="294" left="546" width="98" height="18" font="5">• Any CVD event </text>
<text top="314" left="549" width="172" height="17" font="5">CAC 1-19: 11 events/1814 p-y  </text>
<text top="332" left="549" width="182" height="17" font="5">Adjusted HR 1.8, 95% CI 0.9-3.4 </text>
<text top="351" left="549" width="179" height="17" font="5">CAC 20-99: 13 events/1150 p-y  </text>
<text top="369" left="549" width="182" height="17" font="5">Adjusted HR 3.6, 95% CI 1.8-6.5 </text>
<text top="388" left="549" width="169" height="17" font="5">CAC &gt;100: 14 events/591 p-y  </text>
<text top="406" left="549" width="189" height="17" font="5">Adjusted HR 5.7, 95% CI 2.8-10.9 </text>
<text top="425" left="549" width="114" height="18" font="5">• All-cause mortality </text>
<text top="445" left="546" width="165" height="17" font="5">CAC 1-19: 8 events/1897 p-y  </text>
<text top="463" left="546" width="182" height="17" font="5">Adjusted HR 1.1, 95% CI 0.5-2.1 </text>
<text top="482" left="546" width="172" height="17" font="5">CAC 20-99: 4 events/1243 p-y  </text>
<text top="500" left="546" width="182" height="17" font="5">Adjusted HR 0.9, 95% CI 0.3-2.7 </text>
<text top="519" left="546" width="162" height="17" font="5">CAC&gt;100: 13 events/706 p-y </text>
<text top="537" left="546" width="189" height="17" font="5">Adjusted HR 3.7, 95% CI 1.5-10.0 </text>
<text top="556" left="546" width="3" height="17" font="5"> </text>
<text top="575" left="546" width="227" height="18" font="5">• When participants were stratified into 3 </text>
<text top="594" left="546" width="199" height="17" font="5">tiers of Framingham CHD risk score </text>
<text top="613" left="546" width="221" height="17" font="5">(≤4%, 5%-11%, and ≥12%), CAC score </text>
<text top="631" left="546" width="220" height="17" font="5">further stratified CHD incidence density, </text>
<text top="650" left="546" width="186" height="17" font="5">with those with lower CAC scores </text>
<text top="669" left="546" width="210" height="17" font="5">experiencing substantially lower event </text>
<text top="687" left="546" width="227" height="17" font="5">rates than those with higher CAC scores, </text>
<text top="706" left="546" width="217" height="17" font="5">especially when CAC score ≥100 at 10-</text>
<text top="724" left="546" width="229" height="17" font="5">year CHD risk levels &gt;5% and when CAC </text>
<text top="743" left="546" width="205" height="17" font="5">score ≥20 at 10-year CHD risk levels </text>
<text top="761" left="546" width="36" height="17" font="5">≥12% </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="219" height="18" font="5">• Among participants predicted to be at </text>
<text top="163" left="546" width="193" height="17" font="5">lower risk for CAC&gt;0 in middle age </text>
<text top="181" left="546" width="204" height="17" font="5">(based on being below the median in </text>
<text top="200" left="546" width="225" height="17" font="5">predicted CAC risk from risk factor levels </text>
<text top="219" left="546" width="226" height="17" font="5">in early adulthood), CAC prevalence was </text>
<text top="237" left="546" width="216" height="17" font="5">13.2% for number needed to screen  to </text>
<text top="256" left="546" width="101" height="17" font="5">find CAC&gt;0 of 7.7 </text>
<text top="274" left="546" width="219" height="18" font="5">• Among participants predicted to be at </text>
<text top="294" left="546" width="198" height="17" font="5">higher risk for CAC&gt;0 in middle age </text>
<text top="312" left="546" width="231" height="17" font="5">(above the median in predicted CAC risk), </text>
<text top="331" left="546" width="219" height="17" font="5">CAC prevalence was 44.7% for number </text>
<text top="350" left="546" width="213" height="17" font="5">needed to screen to find CAC&gt;0 of 2.2 </text>
<text top="368" left="546" width="3" height="17" font="5"> </text>
<text top="387" left="75" width="100" height="17" font="5">Mortensen MB, et </text>
<text top="406" left="75" width="51" height="17" font="5">al., 2016 </text>
<text top="425" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27561760">27561760</a></text>
<text top="425" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27561760"> </a></text>
<text top="387" left="205" width="65" height="17" font="5">Study type: </text>
<text top="406" left="205" width="67" height="17" font="5">Prospective </text>
<text top="425" left="205" width="119" height="17" font="5">Observational Cohort </text>
<text top="443" left="205" width="92" height="17" font="5">study (BioImage </text>
<text top="462" left="205" width="105" height="17" font="5">Study, 2008-2009) </text>
<text top="480" left="205" width="3" height="17" font="5"> </text>
<text top="499" left="205" width="61" height="17" font="5">Size: 5805 </text>
<text top="518" left="205" width="66" height="17" font="5">participants </text>
<text top="387" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="406" left="344" width="173" height="18" font="5">• Men 55-80 years and women </text>
<text top="426" left="344" width="68" height="17" font="5">60-80 years </text>
<text top="445" left="344" width="3" height="17" font="5"> </text>
<text top="463" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="482" left="344" width="101" height="17" font="5">Prevalent ASCVD </text>
<text top="389" left="546" width="7" height="17" font="5">1</text>
<text top="388" left="553" width="222" height="18" font="5"> endpoints: Incident CHD, including MI, </text>
<text top="407" left="546" width="169" height="17" font="5">unstable angina, and coronary </text>
<text top="426" left="546" width="99" height="17" font="5">revascularization; </text>
<text top="445" left="546" width="215" height="17" font="5">Incident ASCVD, including CVD death, </text>
<text top="463" left="546" width="136" height="17" font="5">CHD or ischemic stroke; </text>
<text top="482" left="546" width="163" height="17" font="5">Median follow up of 2.7 years </text>
<text top="500" left="546" width="3" height="17" font="5"> </text>
<text top="519" left="546" width="48" height="17" font="5">Results: </text>
<text top="538" left="546" width="219" height="18" font="5">• Assessed strategy of using ACC/AHA </text>
<text top="557" left="546" width="221" height="17" font="5">statin eligibility recommendations based </text>
<text top="576" left="546" width="195" height="17" font="5">on PCE, and added reclassification </text>
<text top="594" left="546" width="230" height="17" font="5">strategy of down-classifying (to non-statin </text>
<text top="613" left="546" width="226" height="17" font="5">eligible) those with 10-year predicted risk </text>
<text top="632" left="546" width="174" height="17" font="5">≥7.5% but with CAC=0, and up-</text>
<text top="650" left="546" width="215" height="17" font="5">classifying (to statin eligible) those with </text>
<text top="669" left="546" width="219" height="17" font="5">10-year predicted risk 5% to &lt;7.5% and </text>
<text top="687" left="546" width="98" height="17" font="5">CAC score ≥100. </text>
<text top="706" left="556" width="213" height="18" font="5">•  91 CHD events; 138 ASCVD events </text>
<text top="725" left="556" width="218" height="18" font="5">•  Among these older participants, 86% </text>
<text top="745" left="569" width="207" height="17" font="5">were eligible for statins per ACC/AHA </text>
<text top="764" left="569" width="154" height="17" font="5">guideline recommendations </text>
<text top="388" left="791" width="346" height="18" font="5">• A simple theoretical reclassification strategy using CAC ≥100 </text>
<text top="407" left="791" width="341" height="17" font="5">to up-risk intermediate or CAC=0 to de-risk individuals with 10-</text>
<text top="426" left="791" width="285" height="17" font="5">year risk ≥7.5% and &lt;15% by PCE led to significant </text>
<text top="445" left="791" width="323" height="17" font="5">improvements in reclassification and correct assignment of </text>
<text top="463" left="791" width="44" height="17" font="5">therapy </text>
<text top="482" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="556" width="204" height="18" font="5">•  After reclassification by CAC, 64% </text>
<text top="163" left="569" width="129" height="17" font="5">were eligible for statins </text>
<text top="181" left="556" width="208" height="18" font="5">•  NRI of reclassification strategy was </text>
<text top="201" left="569" width="190" height="17" font="5">0.20 for CHD and 0.14 for ASCVD </text>
<text top="220" left="569" width="132" height="17" font="5">overall (both P&lt;0.0001) </text>
<text top="238" left="546" width="206" height="17" font="5">Among participants with predicted 10-</text>
<text top="257" left="546" width="159" height="17" font="5">year risk &lt;15%, CAC-guided </text>
<text top="275" left="546" width="226" height="17" font="5">reclassification strategy led to gain of 1% </text>
<text top="294" left="546" width="226" height="17" font="5">in sensitivity (P=0.56) and gain of 10% in </text>
<text top="312" left="546" width="180" height="17" font="5">specificity (P&lt;0.0001) for correct </text>
<text top="331" left="546" width="170" height="17" font="5">prediction of CHD (NRI = 0.11, </text>
<text top="350" left="546" width="65" height="17" font="5">P&lt;0.0001)) </text>
<text top="368" left="556" width="219" height="18" font="5">•  Among participants with predicted 10-</text>
<text top="388" left="569" width="159" height="17" font="5">year risk &lt;15%, CAC-guided </text>
<text top="406" left="569" width="204" height="17" font="5">reclassification strategy led to loss of </text>
<text top="425" left="569" width="206" height="17" font="5">2% in sensitivity (P=0.26) and gain of </text>
<text top="443" left="569" width="180" height="17" font="5">10% in specificity (P&lt;0.0001) for </text>
<text top="462" left="569" width="196" height="17" font="5">correct prediction of ASCVD (NRI = </text>
<text top="481" left="569" width="91" height="17" font="5">0.08, P&lt;0.0001) </text>
<text top="499" left="546" width="3" height="17" font="5"> </text>
<text top="519" left="75" width="73" height="17" font="5">Framingham </text>
<text top="537" left="75" width="104" height="17" font="5">Pursnani A, et al.,  </text>
<text top="556" left="75" width="31" height="17" font="5">2015 </text>
<text top="574" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26172893">26172893</a></text>
<text top="574" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26172893"> </a></text>
<text top="519" left="205" width="65" height="17" font="5">Study type: </text>
<text top="537" left="205" width="67" height="17" font="5">Prospective </text>
<text top="556" left="205" width="119" height="17" font="5">Observational Cohort </text>
<text top="574" left="205" width="33" height="17" font="5">study </text>
<text top="593" left="205" width="3" height="17" font="5"> </text>
<text top="611" left="205" width="77" height="17" font="5">Size: N=2435 </text>
<text top="630" left="205" width="66" height="17" font="5">participants </text>
<text top="519" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="537" left="344" width="184" height="18" font="5">• Framingham Offspring or Gen3 </text>
<text top="557" left="344" width="172" height="17" font="5">participants; men 35 and older, </text>
<text top="576" left="344" width="171" height="17" font="5">women 40 and older, weighted </text>
<text top="594" left="344" width="152" height="17" font="5">towards families with larger </text>
<text top="613" left="344" width="102" height="17" font="5">numbers in cohort </text>
<text top="631" left="344" width="3" height="17" font="5"> </text>
<text top="650" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="669" left="344" width="176" height="17" font="5">Participants with prevalent CVD </text>
<text top="687" left="344" width="151" height="17" font="5">or on lipid-lowering therapy </text>
<text top="520" left="546" width="7" height="17" font="5">1</text>
<text top="519" left="553" width="156" height="18" font="5"> endpoint: Incident ASCVD </text>
<text top="538" left="546" width="150" height="17" font="5">Median follow up 9.4 years </text>
<text top="557" left="546" width="3" height="17" font="5"> </text>
<text top="576" left="546" width="48" height="17" font="5">Results: </text>
<text top="594" left="546" width="219" height="18" font="5">• Among participants recommended for </text>
<text top="614" left="546" width="173" height="17" font="5">statin therapy by 2013 AC/AHA </text>
<text top="633" left="546" width="203" height="17" font="5">guidelines, 33% had CAC=0, with an </text>
<text top="651" left="546" width="211" height="17" font="5">associated ASCVD event rate of 1.6% </text>
<text top="670" left="546" width="81" height="17" font="5">over 9.4 years </text>
<text top="688" left="546" width="3" height="17" font="5"> </text>
<text top="519" left="791" width="306" height="18" font="5">• CAC = 0 identified individuals recommended for statin </text>
<text top="538" left="791" width="260" height="17" font="5">therapy who had very low ASCVD event rates.  </text>
<text top="557" left="791" width="3" height="17" font="5"> </text>
<text top="708" left="75" width="38" height="17" font="5">MESA </text>
<text top="726" left="75" width="99" height="17" font="5">Yeboah J., et al.,  </text>
<text top="745" left="75" width="31" height="17" font="5">2016 </text>
<text top="763" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26791059">26791059</a></text>
<text top="763" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26791059"> </a></text>
<text top="708" left="205" width="65" height="17" font="5">Study type: </text>
<text top="726" left="205" width="67" height="17" font="5">Prospective </text>
<text top="745" left="205" width="119" height="17" font="5">Observational Cohort </text>
<text top="763" left="205" width="79" height="17" font="5">study (MESA) </text>
<text top="708" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="726" left="344" width="174" height="18" font="5">• MESA participants age 45-84 </text>
<text top="746" left="344" width="33" height="17" font="5">years </text>
<text top="765" left="344" width="3" height="17" font="5"> </text>
<text top="709" left="546" width="7" height="17" font="5">1</text>
<text top="708" left="553" width="156" height="18" font="5"> endpoint: Incident ASCVD </text>
<text top="728" left="546" width="146" height="17" font="5">Median follow up 10 years </text>
<text top="746" left="546" width="3" height="17" font="5"> </text>
<text top="765" left="546" width="48" height="17" font="5">Results: </text>
<text top="708" left="791" width="332" height="18" font="5">• CAC improved discrimination and NRI beyond recalibrated </text>
<text top="728" left="791" width="309" height="17" font="5">PCE whereas other non-traditional risk markers did not.  </text>
<text top="746" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="3" height="17" font="5"> </text>
<text top="162" left="205" width="77" height="17" font="5">Size: N=5185 </text>
<text top="180" left="205" width="91" height="17" font="5">participants with </text>
<text top="199" left="205" width="124" height="17" font="5">recalibrated (to MESA </text>
<text top="218" left="205" width="109" height="17" font="5">sample) PCE score </text>
<text top="143" left="344" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="162" left="344" width="142" height="17" font="5">Missing data, participants </text>
<text top="180" left="344" width="148" height="17" font="5">receiving statin at baseline </text>
<text top="143" left="546" width="202" height="18" font="5">• CAC, ABI,  and family history were </text>
<text top="163" left="546" width="173" height="17" font="5">associated with ASCVD events </text>
<text top="182" left="546" width="185" height="17" font="5">independent of recalibrated PCE. </text>
<text top="200" left="546" width="3" height="17" font="5"> </text>
<text top="219" left="546" width="200" height="18" font="5">• Harrell’s C statistic with addition to </text>
<text top="238" left="546" width="100" height="17" font="5">recalibrated PCE: </text>
<text top="257" left="546" width="165" height="17" font="5">Recalibrated PCE alone: 0.74 </text>
<text top="275" left="546" width="155" height="17" font="5">+ CAC score: 0.76 (P=0.04) </text>
<text top="294" left="546" width="116" height="17" font="5">+ ABI: 0.75 (P=0.55) </text>
<text top="313" left="546" width="135" height="17" font="5">+ hsCRP: 0.74 (P=0.25) </text>
<text top="331" left="546" width="172" height="17" font="5">+ Family history: 0.74 (P=0.98) </text>
<text top="350" left="546" width="3" height="17" font="5"> </text>
<text top="368" left="546" width="219" height="18" font="5">• NRI for threshold of 7.5% 10-year risk </text>
<text top="388" left="546" width="185" height="17" font="5">with addition to recalibrated PCE: </text>
<text top="407" left="546" width="227" height="17" font="5">+ CAC score: 0.119, 95% CI 0.080-0.256 </text>
<text top="425" left="546" width="192" height="17" font="5">+ ABI: 0.017, 95% CI -0.031-0.058 </text>
<text top="444" left="546" width="211" height="17" font="5">+ hsCRP: 0.025, 95% CI -0.015-0.067 </text>
<text top="462" left="546" width="210" height="17" font="5">+ Family history: 0.051, 95% CI 0.000-</text>
<text top="481" left="546" width="34" height="17" font="5">0.109 </text>
<text top="499" left="546" width="3" height="17" font="5"> </text>
<text top="518" left="546" width="3" height="17" font="5"> </text>
<text top="537" left="75" width="89" height="17" font="5">Gupta A, et al.,  </text>
<text top="556" left="75" width="31" height="17" font="5">2017 </text>
<text top="575" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28797402">28797402</a></text>
<text top="575" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28797402"> </a></text>
<text top="537" left="205" width="65" height="17" font="5">Study type: </text>
<text top="556" left="205" width="103" height="17" font="5">Systematic review </text>
<text top="575" left="205" width="3" height="17" font="5"> </text>
<text top="593" left="205" width="83" height="17" font="5">Size: 8 studies </text>
<text top="612" left="205" width="67" height="17" font="5">identified (7 </text>
<text top="630" left="205" width="123" height="17" font="5">observational, 1 RCT) </text>
<text top="649" left="205" width="99" height="17" font="5">but only 6 studies </text>
<text top="667" left="205" width="115" height="17" font="5">(11,256 participants) </text>
<text top="686" left="205" width="114" height="17" font="5">included due to data </text>
<text top="705" left="205" width="64" height="17" font="5">availability. </text>
<text top="723" left="205" width="3" height="17" font="5"> </text>
<text top="742" left="205" width="96" height="17" font="5">Single arm (CAC </text>
<text top="760" left="205" width="96" height="17" font="5">measurement) of </text>
<text top="537" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="556" left="344" width="156" height="18" font="5">• Studies that evaluated the </text>
<text top="576" left="344" width="152" height="17" font="5">influence of CAC scores on </text>
<text top="594" left="344" width="187" height="17" font="5">subsequent lifestyle modifications </text>
<text top="613" left="344" width="176" height="17" font="5">or medication usage for primary </text>
<text top="632" left="344" width="107" height="17" font="5">prevention of CVD  </text>
<text top="650" left="344" width="3" height="17" font="5"> </text>
<text top="669" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="687" left="344" width="24" height="17" font="5">N/A </text>
<text top="539" left="546" width="7" height="17" font="5">1</text>
<text top="538" left="553" width="162" height="18" font="5"> endpoint: Use of preventive </text>
<text top="557" left="546" width="177" height="17" font="5">interventions (both initiation and </text>
<text top="576" left="546" width="206" height="17" font="5">continuation), including aspirin, blood </text>
<text top="594" left="546" width="206" height="17" font="5">pressure lowering, lipid lowering, and </text>
<text top="613" left="546" width="110" height="17" font="5">behavioral changes </text>
<text top="632" left="546" width="3" height="17" font="5"> </text>
<text top="650" left="546" width="48" height="17" font="5">Results: </text>
<text top="669" left="546" width="229" height="18" font="5">• Compared with individuals with CAC=0, </text>
<text top="689" left="546" width="160" height="17" font="5">individuals with CAC&gt;0 had:  </text>
<text top="707" left="556" width="214" height="18" font="5">•  Aspirin initiation OR 2.6, 95% CI 1.8-</text>
<text top="727" left="569" width="202" height="17" font="5">3.8 (30% vs. 15%, 4 studies with 1.6 </text>
<text top="745" left="569" width="130" height="17" font="5">to 6 years of follow up, I</text>
<text top="747" left="699" width="4" height="11" font="8">2</text>
<text top="745" left="703" width="39" height="17" font="5">=86%) </text>
<text top="538" left="791" width="346" height="18" font="5">• Identification of coronary atherosclerosis by coronary calcium </text>
<text top="557" left="791" width="308" height="17" font="5">scanning is significantly associated with the likelihood of </text>
<text top="576" left="791" width="308" height="17" font="5">initiation or continuation of pharmacological and lifestyle </text>
<text top="594" left="791" width="332" height="17" font="5">therapies for prevention of CVD in follow up of up to 6 years. </text>
<text top="613" left="791" width="3" height="17" font="5"> </text>
<text top="632" left="791" width="339" height="17" font="5">Limitations: Self-reported use of medications in at least half of </text>
<text top="650" left="791" width="321" height="17" font="5">studies; degree of exercise increase and dietary change ill-</text>
<text top="669" left="791" width="346" height="17" font="5">defined; predominantly Caucasian participants; variable means </text>
<text top="687" left="791" width="293" height="17" font="5">for informing participants of CAC presence and score </text>
<text top="706" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="82" height="17" font="5">EISNER study </text>
<text top="162" left="205" width="53" height="17" font="5">included. </text>
<text top="180" left="205" width="3" height="17" font="5"> </text>
<text top="199" left="205" width="120" height="17" font="5">Note 2 reports from 1 </text>
<text top="218" left="205" width="106" height="17" font="5">study with different </text>
<text top="236" left="205" width="57" height="17" font="5">outcomes </text>
<text top="255" left="205" width="3" height="17" font="5"> </text>
<text top="143" left="556" width="203" height="18" font="5">•  Lipid lowering medication initiation </text>
<text top="163" left="569" width="182" height="17" font="5">OR 2.9, 95% CI 1.9-4.4 (20% vs. </text>
<text top="181" left="569" width="201" height="17" font="5">10%, 3 studies with 1.6 to 6 years of </text>
<text top="200" left="569" width="59" height="17" font="5">follow up, I</text>
<text top="201" left="628" width="4" height="11" font="8">2</text>
<text top="200" left="632" width="43" height="17" font="5">=89%); </text>
<text top="219" left="556" width="212" height="18" font="5">•  Blood pressure lowering medication </text>
<text top="238" left="569" width="180" height="17" font="5">initiation OR 1.9, 95% CI 1.6-2.3 </text>
<text top="257" left="569" width="205" height="17" font="5">(19% vs. 11%, 2 studies with 1.6 to 4 </text>
<text top="275" left="569" width="106" height="17" font="5">years of follow up, I</text>
<text top="276" left="675" width="4" height="11" font="8">2</text>
<text top="275" left="679" width="43" height="17" font="5">=15%). </text>
<text top="294" left="556" width="214" height="18" font="5">•  Aspirin continuation OR 1.3, 95% CI </text>
<text top="314" left="569" width="202" height="17" font="5">0.8-2.2 (66% vs. 65%, 3 studies with </text>
<text top="332" left="569" width="150" height="17" font="5">3.2 to 6 years of follow up, I</text>
<text top="333" left="719" width="4" height="11" font="8">2</text>
<text top="332" left="724" width="43" height="17" font="5">=75%); </text>
<text top="351" left="556" width="155" height="18" font="5">•  Lipid lowering medication </text>
<text top="370" left="569" width="201" height="17" font="5">continuation OR 2.3, 95% CI 1.6-3.3 </text>
<text top="389" left="569" width="195" height="17" font="5">(75% vs. 69%, 4 studies with 3 to 6 </text>
<text top="407" left="569" width="106" height="17" font="5">years of follow up, I</text>
<text top="409" left="675" width="4" height="11" font="8">2</text>
<text top="407" left="679" width="46" height="17" font="5">=52%);  </text>
<text top="426" left="556" width="212" height="18" font="5">•  Blood pressure lowering medication </text>
<text top="446" left="569" width="193" height="17" font="5">continuation OR 1.4, 95% CI 0.9 to </text>
<text top="464" left="569" width="202" height="17" font="5">2.2 (73% vs. 64%, 2 studies with 3.2 </text>
<text top="483" left="569" width="130" height="17" font="5">to 4 years of follow up, I</text>
<text top="484" left="699" width="4" height="11" font="8">2</text>
<text top="483" left="703" width="43" height="17" font="5">=34%). </text>
<text top="501" left="556" width="216" height="18" font="5">•  Increase in exercise OR 1.8, 95% CI </text>
<text top="521" left="569" width="202" height="17" font="5">1.4-2.4 (51% vs. 32%; 3 studies with </text>
<text top="539" left="569" width="140" height="17" font="5">3 to 6 years of follow up, I</text>
<text top="541" left="709" width="4" height="11" font="8">2</text>
<text top="539" left="714" width="43" height="17" font="5">=43%); </text>
<text top="558" left="556" width="210" height="18" font="5">•  Dietary change OR 1.9, 95% CI 1.5-</text>
<text top="578" left="569" width="205" height="17" font="5">2.5 (45% vs. 27%, 2 studies with 3 to </text>
<text top="596" left="569" width="116" height="17" font="5">6 years of follow up, I</text>
<text top="597" left="685" width="4" height="11" font="8">2</text>
<text top="596" left="690" width="33" height="17" font="5">=0%) </text>
<text top="615" left="546" width="3" height="17" font="5"> </text>
<text top="633" left="546" width="3" height="17" font="5"> </text>
<text top="652" left="546" width="3" height="17" font="5"> </text>
<text top="671" left="75" width="117" height="17" font="5">Jackson Heart Study </text>
<text top="690" left="75" width="96" height="17" font="5">Shah R.V., et al., </text>
<text top="709" left="75" width="31" height="17" font="5">2017 </text>
<text top="727" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28315622">28315622</a></text>
<text top="727" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28315622"> </a></text>
<text top="671" left="205" width="65" height="17" font="5">Study type: </text>
<text top="690" left="205" width="67" height="17" font="5">Prospective </text>
<text top="709" left="205" width="119" height="17" font="5">Observational Cohort </text>
<text top="727" left="205" width="33" height="17" font="5">study </text>
<text top="746" left="205" width="3" height="17" font="5"> </text>
<text top="671" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="690" left="344" width="158" height="18" font="5">• African American men and </text>
<text top="710" left="344" width="135" height="17" font="5">women age 40-75 years </text>
<text top="728" left="344" width="3" height="17" font="5"> </text>
<text top="747" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="672" left="546" width="7" height="17" font="5">1</text>
<text top="671" left="553" width="156" height="18" font="5"> endpoint: Incident ASCVD </text>
<text top="691" left="546" width="146" height="17" font="5">Median follow up 10 years </text>
<text top="710" left="546" width="3" height="17" font="5"> </text>
<text top="728" left="546" width="48" height="17" font="5">Results: </text>
<text top="747" left="546" width="200" height="18" font="5">• 55 incident ASCVD events among </text>
<text top="767" left="546" width="122" height="17" font="5">those with CAC score </text>
<text top="671" left="791" width="311" height="18" font="5">• Among those who were recommended for statin by the </text>
<text top="691" left="791" width="328" height="17" font="5">ACC/AHA 2013 guideline, presence of CAC identified those </text>
<text top="710" left="791" width="344" height="17" font="5">with 10-year event rates &gt;7.5%, whereas absence of CAC was </text>
<text top="728" left="791" width="290" height="17" font="5">associated with event rates &lt;7.5%. Among those not </text>
<text top="747" left="791" width="318" height="17" font="5">recommended for statin, 10-year event rates were &lt;1.0%. </text>
<text top="766" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="12" size="12" family="Times" color="#0462c1"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="77" height="17" font="5">Size: N=2812 </text>
<text top="162" left="205" width="105" height="17" font="5">(N=1743 with CAC </text>
<text top="180" left="205" width="104" height="17" font="5">score) participants </text>
<text top="143" left="344" width="186" height="17" font="5">Prevalent CVD, on statin therapy, </text>
<text top="162" left="344" width="73" height="17" font="5">missing data </text>
<text top="143" left="546" width="3" height="17" font="5"> </text>
<text top="162" left="549" width="204" height="18" font="5">•  CAC &gt;0 prevalence increased in a </text>
<text top="181" left="549" width="211" height="17" font="5">dose dependent fashion from ~13% in </text>
<text top="200" left="549" width="201" height="17" font="5">those with 10-year predicted risk (by </text>
<text top="219" left="549" width="198" height="17" font="5">PCE) of 2.5% to ~75% in those with </text>
<text top="237" left="549" width="113" height="17" font="5">predicted risk ≥15% </text>
<text top="256" left="549" width="201" height="18" font="5">•  ASCVD event rate for participants </text>
<text top="275" left="549" width="207" height="17" font="5">recommended for statin by ACC/AHA </text>
<text top="294" left="549" width="87" height="17" font="5">2013 guideline: </text>
<text top="312" left="549" width="133" height="17" font="5">With CAC: 8.1/1000 p-y </text>
<text top="331" left="549" width="196" height="17" font="5">Without CAC: 3.1/1000 p-y; P=0.02 </text>
<text top="350" left="549" width="222" height="18" font="5">•  ASCVD event rate for participants not </text>
<text top="369" left="549" width="207" height="17" font="5">recommended for statin by ACC/AHA </text>
<text top="388" left="549" width="87" height="17" font="5">2013 guideline: </text>
<text top="406" left="546" width="133" height="17" font="5">With CAC: 0.9/1000 p-y </text>
<text top="425" left="546" width="196" height="17" font="5">Without CAC: 0.8/1000 p-y; P&gt;0.99 </text>
<text top="443" left="546" width="3" height="17" font="5"> </text>
<text top="463" left="75" width="55" height="17" font="5">JUPITER </text>
<text top="494" left="75" width="97" height="17" font="5">Ridker PM, et al., </text>
<text top="512" left="75" width="31" height="17" font="5">2008 </text>
<text top="543" left="75" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196">18997196</a></text>
<text top="543" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196"> </a></text>
<text top="463" left="205" width="108" height="17" font="5">Aim: To investigate </text>
<text top="481" left="205" width="103" height="17" font="5">whether treatment </text>
<text top="500" left="205" width="115" height="17" font="5">with rosuvastatin, 20 </text>
<text top="519" left="205" width="118" height="17" font="5">mg daily vs. placebo, </text>
<text top="537" left="205" width="89" height="17" font="5">would decrease </text>
<text top="556" left="205" width="113" height="17" font="5">MACE in apparently </text>
<text top="574" left="205" width="115" height="17" font="5">healthy persons with </text>
<text top="593" left="205" width="123" height="17" font="5">levels of LDL-C below </text>
<text top="611" left="205" width="97" height="17" font="5">current treatment </text>
<text top="630" left="205" width="106" height="17" font="5">thresholds but with </text>
<text top="649" left="205" width="77" height="17" font="5">elevated high-</text>
<text top="667" left="205" width="111" height="17" font="5">sensitivity (hs) CRP </text>
<text top="698" left="205" width="3" height="17" font="5"> </text>
<text top="728" left="205" width="65" height="17" font="5">Study type: </text>
<text top="747" left="205" width="113" height="17" font="5">Randomized double-</text>
<text top="463" left="344" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="494" left="344" width="188" height="18" font="5">•  Age: men &gt;50 and women &gt;60 </text>
<text top="512" left="361" width="10" height="17" font="5">y </text>
<text top="529" left="344" width="117" height="18" font="5">•  LDL-C&lt;130 mg/dl </text>
<text top="547" left="344" width="103" height="18" font="5">•  hsCRP &gt;2 mg/l </text>
<text top="565" left="344" width="141" height="18" font="5">•  triglyceride&lt;500 mg/dl </text>
<text top="584" left="344" width="3" height="17" font="5"> </text>
<text top="614" left="344" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="645" left="344" width="103" height="18" font="5">•  history of CVD  </text>
<text top="663" left="344" width="67" height="18" font="5">•  diabetes </text>
<text top="681" left="344" width="175" height="18" font="5">•  past or current lipid-lowering </text>
<text top="700" left="361" width="44" height="17" font="5">therapy </text>
<text top="717" left="344" width="143" height="18" font="5">•  PMP hormone therapy </text>
<text top="735" left="344" width="93" height="18" font="5">•  ALT&gt;2X ULN </text>
<text top="753" left="344" width="96" height="18" font="5">•  CPK&gt;3X ULN </text>
<text top="772" left="344" width="104" height="18" font="5">•  SCr ±2.0 mg/dl </text>
<text top="463" left="546" width="75" height="17" font="5">Intervention:  </text>
<text top="494" left="546" width="144" height="17" font="5"> Rosuvastatin 20 mg daily </text>
<text top="524" left="546" width="49" height="17" font="5">-n=8901 </text>
<text top="555" left="546" width="142" height="17" font="5">-median [IQR] 1 y LDL-C; </text>
<text top="585" left="546" width="92" height="17" font="5">55 [44-72] mg/dl </text>
<text top="616" left="546" width="155" height="17" font="5">- 50% reduction vs. placebo </text>
<text top="646" left="546" width="3" height="17" font="5"> </text>
<text top="677" left="546" width="172" height="17" font="5">Comparator: Matching placebo </text>
<text top="708" left="546" width="48" height="17" font="5">n=8901  </text>
<text top="738" left="546" width="142" height="17" font="5">-median [IQR] 1 y LDL-C; </text>
<text top="769" left="546" width="106" height="17" font="5">110 [94-125] mg/dl </text>
<text top="464" left="791" width="7" height="17" font="5">1</text>
<text top="463" left="798" width="67" height="18" font="5"> endpoint:  </text>
<text top="495" left="791" width="305" height="17" font="5">•Median follow-up 1.9 y; the study ended early because </text>
<text top="513" left="791" width="124" height="17" font="5">efficacy had been met </text>
<text top="544" left="791" width="287" height="17" font="5">•Primary endpoint: first nonfatal MI, non-fatal stroke, </text>
<text top="562" left="791" width="336" height="17" font="5">hospitalization for unstable angina, revascularization, or CVD </text>
<text top="581" left="791" width="38" height="17" font="5">death. </text>
<text top="612" left="791" width="48" height="17" font="5">Results: </text>
<text top="642" left="791" width="107" height="18" font="5">• n (rate/100pt.yrs) </text>
<text top="660" left="791" width="105" height="17" font="5">Rosuva 142 (0.77) </text>
<text top="691" left="791" width="107" height="17" font="5">Placebo 251 (1.36) </text>
<text top="722" left="791" width="223" height="17" font="5">HR: 0.56 ; 95% CI: 0.46–0.69; p&lt;0.0001 </text>
<text top="752" left="791" width="3" height="17" font="5"> </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="76" height="17" font="5">blind placebo </text>
<text top="162" left="205" width="120" height="17" font="5">controlled clinical trial </text>
<text top="192" left="205" width="3" height="17" font="5"> </text>
<text top="223" left="205" width="120" height="17" font="5">Size: 17,802 subjects </text>
<text top="143" left="344" width="116" height="18" font="5">•  uncontrolled HTN </text>
<text top="162" left="344" width="57" height="18" font="5">•  cancer </text>
<text top="180" left="344" width="121" height="18" font="5">•  inflammatory state </text>
<text top="198" left="344" width="103" height="18" font="5">•  hypothyroidism </text>
<text top="216" left="344" width="113" height="18" font="5">•  substance abuse </text>
<text top="234" left="344" width="3" height="17" font="5"> </text>
<text top="265" left="344" width="136" height="17" font="5">Baseline characteristics: </text>
<text top="296" left="344" width="111" height="18" font="5">•  mean [IQR] age; </text>
<text top="314" left="344" width="85" height="18" font="5">•  66 [60-71] y </text>
<text top="332" left="344" width="109" height="18" font="5">•  females 38-39% </text>
<text top="350" left="344" width="185" height="18" font="5">•  Metabolic syndrome (41-42%) </text>
<text top="369" left="344" width="131" height="17" font="5">mean LDL-C 108 mg/dl </text>
<text top="388" left="75" width="105" height="17" font="5">Ference BA, et al., </text>
<text top="406" left="75" width="31" height="17" font="5">2018 </text>
<text top="425" left="75" width="3" height="17" font="5"> </text>
<text top="444" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30165986">30165986</a></text>
<text top="444" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30165986"> </a></text>
<text top="388" left="205" width="63" height="17" font="5">Study Aim: </text>
<text top="406" left="205" width="70" height="17" font="5">describe the </text>
<text top="424" left="205" width="109" height="17" font="5">cumulative effect of </text>
<text top="441" left="205" width="72" height="17" font="5">lipid carrying </text>
<text top="458" left="205" width="104" height="17" font="5">lipoproteins on the </text>
<text top="475" left="205" width="119" height="17" font="5">risk of cardiovascular </text>
<text top="492" left="205" width="119" height="17" font="5">disease, estimate the </text>
<text top="510" left="205" width="95" height="17" font="5">magnitude of the </text>
<text top="527" left="205" width="90" height="17" font="5">potential clinical </text>
<text top="544" left="205" width="104" height="17" font="5">benefit that can be </text>
<text top="561" left="205" width="69" height="17" font="5">achieved by </text>
<text top="579" left="205" width="109" height="17" font="5">maintaining optimal </text>
<text top="596" left="205" width="106" height="17" font="5">lipid levels, identify </text>
<text top="613" left="205" width="100" height="17" font="5">the most effective </text>
<text top="630" left="205" width="54" height="17" font="5">timing for </text>
<text top="647" left="205" width="76" height="17" font="5">implementing </text>
<text top="665" left="205" width="124" height="17" font="5">strategies designed to </text>
<text top="682" left="205" width="119" height="17" font="5">achieve and maintain </text>
<text top="699" left="205" width="106" height="17" font="5">optimal lipid levels, </text>
<text top="716" left="205" width="115" height="17" font="5">and suggest specific </text>
<text top="734" left="205" width="97" height="17" font="5">strategies to help </text>
<text top="751" left="205" width="40" height="17" font="5">people </text>
<text top="768" left="205" width="3" height="17" font="5"> </text>
<text top="388" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="406" left="344" width="24" height="17" font="5">N/A </text>
<text top="425" left="344" width="3" height="17" font="5"> </text>
<text top="444" left="344" width="97" height="17" font="5">Exclusion criteria </text>
<text top="462" left="344" width="24" height="17" font="5">N/A </text>
<text top="389" left="546" width="7" height="17" font="5">1</text>
<text top="388" left="553" width="182" height="18" font="5"> endpoint: Not specified, and no </text>
<text top="408" left="546" width="181" height="17" font="5">quantitative summary conducted </text>
<text top="426" left="546" width="3" height="17" font="5"> </text>
<text top="445" left="546" width="3" height="17" font="5"> </text>
<text top="463" left="546" width="3" height="17" font="5"> </text>
<text top="388" left="791" width="119" height="17" font="5">Author’s Conclusions </text>
<text top="406" left="791" width="290" height="17" font="5">The causal effect of LDL and other apo B–containing </text>
<text top="424" left="791" width="346" height="17" font="5">lipoproteins on the risk of cardiovascular disease is determined </text>
<text top="441" left="791" width="347" height="17" font="5">by both the magnitude and the cumulative duration of exposure </text>
<text top="458" left="791" width="120" height="17" font="5">to these lipoproteins.  </text>
<text top="475" left="791" width="3" height="17" font="5"> </text>
<text top="492" left="791" width="342" height="17" font="5">The goal of maintaining optimal lipid levels throughout life is to </text>
<text top="510" left="791" width="321" height="17" font="5">keep the concentration of circulating LDL and other apo B–</text>
<text top="527" left="791" width="342" height="17" font="5">containing lipoproteins low to minimize the number of particles </text>
<text top="544" left="791" width="338" height="17" font="5">that become retained in the arterial wall and thereby minimize </text>
<text top="561" left="791" width="277" height="17" font="5">the rate of progression of atherosclerotic plaques.  </text>
<text top="579" left="791" width="3" height="17" font="5"> </text>
<text top="596" left="791" width="336" height="17" font="5">Because apo B–containing lipoproteins have both causal and </text>
<text top="614" left="791" width="341" height="17" font="5">cumulative effects on the risk of atherosclerotic cardiovascular </text>
<text top="633" left="791" width="337" height="17" font="5">disease, the most effective strategy to prevent cardiovascular </text>
<text top="652" left="791" width="283" height="17" font="5">events by slowing the rate of atherosclerotic plaque </text>
<text top="670" left="791" width="342" height="17" font="5">progression would be to achieve optimal lipid levels as early in </text>
<text top="689" left="791" width="294" height="17" font="5">life as possible and maintain those optimal lipid levels </text>
<text top="707" left="791" width="85" height="17" font="5">throughout life. </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="66" height="17" font="5">Study Type </text>
<text top="160" left="205" width="92" height="17" font="5">Narrative review </text>
<text top="178" left="205" width="3" height="17" font="5"> </text>
<text top="195" left="205" width="40" height="17" font="5">N=N/A </text>
<text top="226" left="75" width="116" height="17" font="5">Multi-Ethnic Study of </text>
<text top="245" left="75" width="87" height="17" font="5">Atherosclerosis </text>
<text top="263" left="75" width="46" height="17" font="5">(MESA) </text>
<text top="282" left="75" width="3" height="17" font="5"> </text>
<text top="301" left="75" width="112" height="17" font="5">Patel, J. et al., 2018 </text>
<text top="319" left="75" width="3" height="17" font="5"> </text>
<text top="338" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29555305">29555305</a></text>
<text top="338" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29555305"> </a></text>
<text top="226" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="245" left="205" width="123" height="17" font="5">To determine whether </text>
<text top="262" left="205" width="89" height="17" font="5">family history of </text>
<text top="279" left="205" width="83" height="17" font="5">coronary heart </text>
<text top="296" left="205" width="74" height="17" font="5">disease (FH) </text>
<text top="314" left="205" width="102" height="17" font="5">definitions differ in </text>
<text top="331" left="205" width="117" height="17" font="5">their association with </text>
<text top="348" left="205" width="83" height="17" font="5">atherosclerotic </text>
<text top="365" left="205" width="83" height="17" font="5">cardiovascular </text>
<text top="382" left="205" width="85" height="17" font="5">disease events </text>
<text top="400" left="205" width="3" height="17" font="5"> </text>
<text top="417" left="205" width="62" height="17" font="5">Study type </text>
<text top="434" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="451" left="205" width="3" height="17" font="5"> </text>
<text top="468" left="205" width="47" height="17" font="5">N=6200 </text>
<text top="226" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="245" left="344" width="60" height="17" font="5">Age 45-84 </text>
<text top="263" left="344" width="3" height="17" font="5"> </text>
<text top="282" left="344" width="175" height="17" font="5">Race: white, black, Hispanic, or </text>
<text top="301" left="344" width="104" height="17" font="5">Chinese American </text>
<text top="319" left="344" width="3" height="17" font="5"> </text>
<text top="338" left="344" width="142" height="17" font="5">Free of clinical ASCVD at </text>
<text top="356" left="344" width="49" height="17" font="5">baseline </text>
<text top="375" left="344" width="3" height="17" font="5"> </text>
<text top="393" left="344" width="171" height="17" font="5">Provided data on family history </text>
<text top="412" left="344" width="173" height="17" font="5">(attended visits at baseline and </text>
<text top="431" left="344" width="39" height="17" font="5">visit 2) </text>
<text top="449" left="344" width="3" height="17" font="5"> </text>
<text top="227" left="549" width="7" height="17" font="5">1</text>
<text top="226" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="246" left="549" width="199" height="18" font="5">•   hard CHD (myocardial infarction, </text>
<text top="266" left="549" width="195" height="17" font="5">resuscitated cardiac arrest, or CHD </text>
<text top="284" left="549" width="38" height="17" font="5">death) </text>
<text top="303" left="549" width="226" height="18" font="5">•  Angina (definite, probable, or absent).  </text>
<text top="322" left="549" width="182" height="18" font="5">•  Stroke (fatal or nonfatal due to </text>
<text top="342" left="549" width="125" height="17" font="5">hemorrhage or infarct) </text>
<text top="361" left="549" width="197" height="18" font="5">•  Peripheral artery disease (PAD):  </text>
<text top="380" left="549" width="184" height="18" font="5">•  Congestive heart failure (CHF) </text>
<text top="400" left="546" width="3" height="17" font="5"> </text>
<text top="418" left="546" width="30" height="17" font="7"><i>CHD </i></text>
<text top="437" left="546" width="208" height="17" font="5">Any FH: HR=1.37 (95% CI 1.06-1.77) </text>
<text top="456" left="546" width="212" height="17" font="5">Premature FH: HR=1.33 (95% CI 0.96-</text>
<text top="474" left="546" width="31" height="17" font="5">1.83) </text>
<text top="493" left="546" width="231" height="17" font="5">Moderate familial risk (vs. weak) HR=1.40 </text>
<text top="511" left="546" width="107" height="17" font="5">(95% CI 1.00-1.96) </text>
<text top="530" left="546" width="215" height="17" font="5">Strong familial risk (vs. weak) HR=1.37 </text>
<text top="548" left="546" width="103" height="17" font="5">(95% CI 1.00-1.87 </text>
<text top="567" left="546" width="3" height="17" font="5"> </text>
<text top="586" left="546" width="232" height="17" font="5">Addition of FH status to base model led to </text>
<text top="604" left="546" width="230" height="17" font="5">increase in C statistic from 0.736 to 0.737 </text>
<text top="623" left="546" width="212" height="17" font="5">for premature FH (p=0.09). Addition of </text>
<text top="641" left="546" width="208" height="17" font="5">Familial Risk Assessment to the base </text>
<text top="660" left="546" width="223" height="17" font="5">model improved C statistic from 0.736 to </text>
<text top="678" left="546" width="84" height="17" font="5">0.739 (p=0.05) </text>
<text top="697" left="546" width="3" height="17" font="5"> </text>
<text top="716" left="546" width="42" height="17" font="7"><i>Angina </i></text>
<text top="734" left="546" width="208" height="17" font="5">Any FH: HR=1.60 (95% CI 1.24-2.06) </text>
<text top="753" left="546" width="209" height="17" font="5">Premature FH: HR=1.58 (95% CI1.17-</text>
<text top="771" left="546" width="31" height="17" font="5">2.14) </text>
<text top="226" left="791" width="56" height="17" font="5">Summary </text>
<text top="243" left="791" width="332" height="17" font="5">All the approaches to defining FH considered in this analysis </text>
<text top="261" left="791" width="334" height="17" font="5">seemed to perform similarly in improving CHD risk prediction </text>
<text top="278" left="791" width="3" height="17" font="5"> </text>
<text top="295" left="791" width="318" height="17" font="5">The association of FH and events was limited to CHD and </text>
<text top="314" left="791" width="340" height="17" font="5">angina, and other noncoronary cardiovascular outcomes were </text>
<text top="332" left="791" width="213" height="17" font="5">not statistically significantly associated </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="182" height="17" font="5">Moderate familial risk (vs. weak): </text>
<text top="162" left="546" width="160" height="17" font="5">HR=1.33 (95% CI 0.94-1.87) </text>
<text top="180" left="546" width="219" height="17" font="5">Strong familial risk (vs. weak): HR=1.80 </text>
<text top="199" left="546" width="64" height="17" font="5">(1.35-2.40) </text>
<text top="218" left="546" width="3" height="17" font="5"> </text>
<text top="236" left="546" width="187" height="17" font="7"><i>Stroke</i>: No significant differences  </text>
<text top="255" left="546" width="3" height="17" font="5"> </text>
<text top="273" left="546" width="173" height="17" font="7"><i>PAD</i>: No significant differences </text>
<text top="292" left="546" width="3" height="17" font="5"> </text>
<text top="310" left="546" width="173" height="17" font="7"><i>CHF</i>: No significant differences </text>
<text top="329" left="546" width="3" height="17" font="7"><i> </i></text>
<text top="348" left="546" width="108" height="17" font="7"><i>Composite ASCVD </i></text>
<text top="366" left="546" width="208" height="17" font="5">Any FH: HR=1.28 (95% CI 1.10-1.49) </text>
<text top="385" left="546" width="212" height="17" font="5">Premature FH: HR=1.29 (95% CI 1.07-</text>
<text top="403" left="546" width="31" height="17" font="5">1.55) </text>
<text top="422" left="546" width="182" height="17" font="5">Moderate familial risk (vs. weak): </text>
<text top="440" left="546" width="160" height="17" font="5">HR=1.20 (95% CI 0.98-1.47) </text>
<text top="459" left="546" width="219" height="17" font="5">Strong familial risk (vs. weak): HR=1.35 </text>
<text top="478" left="546" width="107" height="17" font="5">(95% CI 1.13-1.61) </text>
<text top="496" left="546" width="232" height="17" font="5">Addition of FH status to base model led to </text>
<text top="515" left="546" width="230" height="17" font="5">increase in C statistic from 0.740 to 0.743 </text>
<text top="533" left="546" width="217" height="17" font="5">(p&lt;0.001) for any FH and from 0.740 to </text>
<text top="552" left="546" width="188" height="17" font="5">0.742 for premature FH (p&lt;0.05).  </text>
<text top="571" left="546" width="214" height="17" font="5">Addition of Familial Risk Score to base </text>
<text top="589" left="546" width="223" height="17" font="5">model improved C statistic from 0.740 to </text>
<text top="608" left="546" width="219" height="17" font="5">0.744 (p=0.001) and provided improved </text>
<text top="626" left="546" width="201" height="17" font="5">discrimination over premature FH (C </text>
<text top="645" left="546" width="215" height="17" font="5">statistic increased from 0.742 to 0.744, </text>
<text top="663" left="546" width="46" height="17" font="5">p=0.05) </text>
<text top="682" left="546" width="3" height="17" font="5"> </text>
<text top="701" left="546" width="220" height="17" font="5">NRI Analysis for incident cardiovascular </text>
<text top="719" left="546" width="231" height="17" font="5">events with addition of FH to Framingham </text>
<text top="738" left="546" width="56" height="17" font="5">risk score </text>
<text top="756" left="546" width="3" height="17" font="5"> </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="91" height="17" font="5">Total population </text>
<text top="162" left="546" width="30" height="17" font="7"><i>CHD </i></text>
<text top="180" left="546" width="224" height="17" font="5">FRS+ any FH NRI=0.162 (95% CI 0.061-</text>
<text top="199" left="546" width="38" height="17" font="5">0.264) </text>
<text top="218" left="546" width="225" height="17" font="5">FRS+premature FH NRI=0.069 (95% CI -</text>
<text top="236" left="546" width="73" height="17" font="5">0.106-0.179) </text>
<text top="255" left="546" width="218" height="17" font="5">FRS+FH risk strata NRI=0.164 (95% CI </text>
<text top="273" left="546" width="73" height="17" font="5">0.067-0.260) </text>
<text top="292" left="546" width="3" height="17" font="5"> </text>
<text top="310" left="546" width="108" height="17" font="5">Composite ASCVD </text>
<text top="329" left="546" width="30" height="17" font="7"><i>CHD </i></text>
<text top="348" left="546" width="220" height="17" font="5">FRS+any FH NRI=0.166 (95% CI 0.094-</text>
<text top="366" left="546" width="38" height="17" font="5">0.243) </text>
<text top="385" left="546" width="218" height="17" font="5">FRS+premature FH NR=0.076 (95% CI </text>
<text top="403" left="546" width="73" height="17" font="5">0.014-0.135) </text>
<text top="422" left="546" width="218" height="17" font="5">FRS+FH risk strata NRI=0.165 (95% CI </text>
<text top="440" left="546" width="73" height="17" font="5">0.090-0.237) </text>
<text top="459" left="546" width="3" height="17" font="5"> </text>
<text top="478" left="546" width="213" height="17" font="5">Population at intermediate risk by FRS </text>
<text top="496" left="546" width="3" height="17" font="7"><i> </i></text>
<text top="515" left="546" width="30" height="17" font="7"><i>CHD </i></text>
<text top="533" left="546" width="189" height="17" font="5">FRS+any FH NRI=0.160 (95% CI -</text>
<text top="552" left="546" width="76" height="17" font="5">0.200p0.323) </text>
<text top="571" left="546" width="225" height="17" font="5">FRS+premature FH NRI=0.064 (95% CI -</text>
<text top="589" left="546" width="66" height="17" font="5">1.90-0.206) </text>
<text top="608" left="546" width="223" height="17" font="5">FRS+FH risk strata NRI+0.159 (95% CI -</text>
<text top="626" left="546" width="73" height="17" font="5">0.201-0.318) </text>
<text top="645" left="546" width="3" height="17" font="5"> </text>
<text top="663" left="546" width="108" height="17" font="7"><i>Composite ASCVD </i></text>
<text top="682" left="546" width="220" height="17" font="5">FRS+any FH NRI=0.143 (95% CI 0.041-</text>
<text top="701" left="546" width="38" height="17" font="5">0.244) </text>
<text top="719" left="546" width="225" height="17" font="5">FRS+premature FH NRI=0.036 (95% CI -</text>
<text top="738" left="546" width="73" height="17" font="5">0.108-0.111) </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="231" height="17" font="5">FRS+FH risk strata NRI=-0.209 (-0.155 to </text>
<text top="162" left="546" width="38" height="17" font="5">0.205) </text>
<text top="193" left="75" width="116" height="17" font="5">ORALE (Outcome of </text>
<text top="212" left="75" width="115" height="17" font="5">Rheumatoid Arthritis </text>
<text top="230" left="75" width="70" height="17" font="5">Longitudinal </text>
<text top="249" left="75" width="68" height="17" font="5">Evaluation)  </text>
<text top="267" left="75" width="3" height="17" font="5"> </text>
<text top="286" left="75" width="99" height="17" font="5">del Rincon, ID. Et </text>
<text top="305" left="75" width="51" height="17" font="5">al., 2001 </text>
<text top="323" left="75" width="3" height="17" font="5"> </text>
<text top="342" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11762933">11762933</a></text>
<text top="342" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11762933"> </a></text>
<text top="360" left="75" width="3" height="17" font="5"> </text>
<text top="193" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="212" left="205" width="90" height="17" font="5">To compare the </text>
<text top="229" left="205" width="69" height="17" font="5">incidence of </text>
<text top="246" left="205" width="111" height="17" font="5">cardiovascular (CV) </text>
<text top="263" left="205" width="125" height="17" font="5">events in persons with </text>
<text top="281" left="205" width="109" height="17" font="5">rheumatoid arthritis </text>
<text top="298" left="205" width="91" height="17" font="5">(RA) with that in </text>
<text top="315" left="205" width="89" height="17" font="5">people from the </text>
<text top="332" left="205" width="108" height="17" font="5">general population, </text>
<text top="349" left="205" width="70" height="17" font="5">adjusting for </text>
<text top="367" left="205" width="100" height="17" font="5">traditional CV risk </text>
<text top="384" left="205" width="40" height="17" font="5">factors </text>
<text top="401" left="205" width="3" height="17" font="5"> </text>
<text top="420" left="205" width="62" height="17" font="5">Study type </text>
<text top="438" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="457" left="205" width="36" height="17" font="5">study  </text>
<text top="475" left="205" width="3" height="17" font="5"> </text>
<text top="494" left="205" width="40" height="17" font="5">N=236 </text>
<text top="193" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="212" left="344" width="153" height="17" font="5">- presented for a scheduled </text>
<text top="229" left="344" width="106" height="17" font="5">appointment with a </text>
<text top="246" left="344" width="132" height="17" font="5">rheumatologist at 1 of 3 </text>
<text top="263" left="344" width="157" height="17" font="5">participating clinical centers  </text>
<text top="281" left="344" width="3" height="17" font="5"> </text>
<text top="298" left="344" width="162" height="17" font="5">-met the American College of </text>
<text top="315" left="344" width="156" height="17" font="5">Rheumatology 1987 revised </text>
<text top="332" left="344" width="186" height="17" font="5">criteria for the classification of RA </text>
<text top="349" left="344" width="3" height="17" font="5"> </text>
<text top="367" left="344" width="186" height="17" font="5">-Non-RA cohort were those in the </text>
<text top="384" left="344" width="184" height="17" font="5">San Antonio Heart Study (SAHS) </text>
<text top="401" left="344" width="38" height="17" font="5">cohort </text>
<text top="418" left="344" width="3" height="17" font="5"> </text>
<text top="194" left="549" width="7" height="17" font="5">1</text>
<text top="193" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="213" left="546" width="3" height="17" font="5"> </text>
<text top="230" left="546" width="200" height="17" font="5">CV event (any hospitalization due to </text>
<text top="249" left="546" width="202" height="17" font="5">myocardial infarction, stroke or other </text>
<text top="267" left="546" width="193" height="17" font="5">arterial occlusive events, or arterial </text>
<text top="286" left="546" width="222" height="17" font="5">revascularization procedures; death due </text>
<text top="305" left="546" width="178" height="17" font="5">to CV causes (immediate or first </text>
<text top="323" left="546" width="152" height="17" font="5">underlying cause of death)) </text>
<text top="342" left="546" width="3" height="17" font="5"> </text>
<text top="360" left="546" width="228" height="17" font="5">Incidence in ORALE cohort=3.43 per 100 </text>
<text top="379" left="546" width="206" height="17" font="5">patient years vs. 0.59 per 100 person </text>
<text top="397" left="546" width="121" height="17" font="5">years in SAHS cohort </text>
<text top="416" left="546" width="3" height="17" font="5"> </text>
<text top="434" left="546" width="221" height="17" font="7"><i>Incidence Rate Ratio ORALE RA cohort </i></text>
<text top="453" left="546" width="139" height="17" font="7"><i>vs. SAHS non-RA cohort </i></text>
<text top="472" left="546" width="212" height="17" font="5">Women 25-54 IRR=4.61 (95% CI 0.11-</text>
<text top="490" left="546" width="38" height="17" font="5">27.39) </text>
<text top="509" left="546" width="212" height="17" font="5">Women 55-65 IRR=1.68 (95% CI 0.04-</text>
<text top="527" left="546" width="31" height="17" font="5">9.83) </text>
<text top="546" left="546" width="232" height="17" font="5">Men 25-54 IRR=9.57 (95% CI 0.24-55.86) </text>
<text top="565" left="546" width="217" height="17" font="5">Men 55-65 IRR=4.70 (95% 1.24-12.58) </text>
<text top="583" left="546" width="207" height="17" font="5">Weighted Mantel-Haenszel IRR=3.96 </text>
<text top="602" left="546" width="107" height="17" font="5">(95% CI 1.86-8.43) </text>
<text top="620" left="546" width="3" height="17" font="5"> </text>
<text top="639" left="546" width="148" height="17" font="5">Multivariate analysis IRRs: </text>
<text top="658" left="546" width="226" height="17" font="5">ORALE vs. SAHS cohort IRR=3.17 (95% </text>
<text top="676" left="546" width="75" height="17" font="5">CI 1.33-6.36) </text>
<text top="695" left="546" width="192" height="17" font="5">Age IRR=2.15 (95% CI: 1.83-2.55) </text>
<text top="713" left="546" width="226" height="17" font="5">Sex (men vs. women) IRR=1.99 (95% CI </text>
<text top="732" left="546" width="60" height="17" font="5">1.50-2.66) </text>
<text top="750" left="546" width="229" height="17" font="5">Diabetes mellitus IRR=2.28 (95% CI 1.65-</text>
<text top="769" left="546" width="31" height="17" font="5">3.12) </text>
<text top="193" left="791" width="56" height="17" font="5">Summary </text>
<text top="212" left="791" width="278" height="17" font="5">increased incidence of CV events in RA patients is </text>
<text top="230" left="791" width="225" height="17" font="5">independent of traditional CV risk factors </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="218" height="17" font="5">Systolic blood pressure IRR=1.18 (95% </text>
<text top="162" left="546" width="75" height="17" font="5">CI 1.03-1.33) </text>
<text top="180" left="546" width="205" height="17" font="5">Body mass index IRR=-1.13 (95% CI </text>
<text top="199" left="546" width="60" height="17" font="5">0.99-1.28) </text>
<text top="218" left="546" width="206" height="17" font="5">Cigarette smoking IRR=1.37 (95% CI </text>
<text top="236" left="546" width="60" height="17" font="5">1.01-1.83) </text>
<text top="255" left="546" width="226" height="17" font="5">Hypercholesterolemia IRR=1.35 (95% CI </text>
<text top="273" left="546" width="60" height="17" font="5">1.01-1.82) </text>
<text top="305" left="75" width="88" height="17" font="5">Manzi, S. et al., </text>
<text top="323" left="75" width="31" height="17" font="5">1997 </text>
<text top="342" left="75" width="3" height="17" font="5"> </text>
<text top="360" left="75" width="48" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9048514">9048514</a></text>
<text top="360" left="122" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9048514"> </a></text>
<text top="305" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="323" left="205" width="92" height="17" font="5">Determined age-</text>
<text top="340" left="205" width="100" height="17" font="5">specific incidence </text>
<text top="358" left="205" width="44" height="17" font="5">rates of </text>
<text top="375" left="205" width="126" height="17" font="5">cardiovascular events, </text>
<text top="392" left="205" width="115" height="17" font="5">including myocardial </text>
<text top="409" left="205" width="117" height="17" font="5">infarction and angina </text>
<text top="426" left="205" width="106" height="17" font="5">pectoris, in women </text>
<text top="444" left="205" width="109" height="17" font="5">with systemic lupus </text>
<text top="461" left="205" width="87" height="17" font="5">erythematosus  </text>
<text top="478" left="205" width="3" height="17" font="5"> </text>
<text top="495" left="205" width="66" height="17" font="5">Study Type </text>
<text top="512" left="205" width="116" height="17" font="5">Retrospective cohort </text>
<text top="530" left="205" width="33" height="17" font="5">study </text>
<text top="547" left="205" width="3" height="17" font="5"> </text>
<text top="564" left="205" width="108" height="17" font="5">N=498 women with </text>
<text top="581" left="205" width="84" height="17" font="5">systemic lupus </text>
<text top="598" left="205" width="84" height="17" font="5">erythematosus </text>
<text top="616" left="205" width="3" height="17" font="5"> </text>
<text top="633" left="205" width="106" height="17" font="5">N=2,208 women in </text>
<text top="652" left="205" width="126" height="17" font="5">Framingham Offspring </text>
<text top="670" left="205" width="35" height="17" font="5">Study </text>
<text top="305" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="323" left="344" width="185" height="17" font="5">-consecutive female patients with </text>
<text top="340" left="344" width="163" height="17" font="5">a diagnosis of systemic lupus </text>
<text top="358" left="344" width="148" height="17" font="5">erythematosus seen at the </text>
<text top="375" left="344" width="175" height="17" font="5">University of Pittsburgh Medical </text>
<text top="392" left="344" width="185" height="17" font="5">Center between January 1, 1980, </text>
<text top="409" left="344" width="135" height="17" font="5">and December 31, 1993 </text>
<text top="426" left="344" width="3" height="17" font="5"> </text>
<text top="444" left="344" width="178" height="17" font="5">-met the 1982 revised American </text>
<text top="461" left="344" width="182" height="17" font="5">College of Rheumatology criteria </text>
<text top="478" left="344" width="147" height="17" font="5">for classification as having </text>
<text top="495" left="344" width="142" height="17" font="5">definite or probable lupus </text>
<text top="512" left="344" width="182" height="17" font="5">-Comparison group were women </text>
<text top="530" left="344" width="182" height="17" font="5">of similar age in the Framingham </text>
<text top="547" left="344" width="92" height="17" font="5">Offspring Study  </text>
<text top="564" left="344" width="3" height="17" font="5"> </text>
<text top="581" left="344" width="97" height="17" font="5">Exclusion criteria </text>
<text top="598" left="344" width="175" height="17" font="5">-patients residing outside a 100-</text>
<text top="616" left="344" width="184" height="17" font="5">mile radius of the medical center  </text>
<text top="633" left="344" width="3" height="17" font="5"> </text>
<text top="650" left="344" width="3" height="17" font="5"> </text>
<text top="306" left="549" width="7" height="17" font="5">1</text>
<text top="305" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="324" left="546" width="223" height="17" font="5">Incidence rates of cardiovascular events </text>
<text top="343" left="546" width="3" height="17" font="5"> </text>
<text top="362" left="546" width="117" height="17" font="7"><i>Myocardial Infarction </i></text>
<text top="380" left="546" width="225" height="17" font="5">RR age 35-44=52.43 (95% CI 21.6-98.5) </text>
<text top="399" left="546" width="205" height="17" font="5">RR age 45-54=2.47 (95% CI 0.8-6.0) </text>
<text top="417" left="546" width="205" height="17" font="5">RR age 55-64=4.21 (95% CI 1.7-7.9) </text>
<text top="436" left="546" width="3" height="17" font="5"> </text>
<text top="454" left="546" width="42" height="17" font="7"><i>Angina </i></text>
<text top="473" left="546" width="205" height="17" font="5">RR age 25-34=1.96 (95% CI 0.0-9.0) </text>
<text top="492" left="546" width="212" height="17" font="5">RR age 35-44=2.35 (95% CI 0.4-11.1) </text>
<text top="510" left="546" width="205" height="17" font="5">RR age 45-54=1.03 (95% CI 0.2-4.6) </text>
<text top="529" left="546" width="205" height="17" font="5">RR age 55-64=2.33 (95% CI 0.9-5.5) </text>
<text top="547" left="546" width="3" height="17" font="5"> </text>
<text top="566" left="546" width="200" height="17" font="7"><i>Death rates in women with systemic </i></text>
<text top="584" left="546" width="117" height="17" font="7"><i>lupus erythematosus </i></text>
<text top="603" left="546" width="223" height="17" font="5">Rate age 15-24 =12.6 (95% CI 1.5-45.6) </text>
<text top="622" left="546" width="220" height="17" font="5">Rate age 25-34=14.6 (95% CI 7.6-25.5) </text>
<text top="640" left="546" width="213" height="17" font="5">Rate age 35-44=9.9 (95% CI 5.3-16.9) </text>
<text top="659" left="546" width="220" height="17" font="5">Rate age 45-54=11.2 (95% CI 4.5-23.1) </text>
<text top="677" left="546" width="227" height="17" font="5">Rate age 55-64=39.1 (95% CI 21.3-65.6) </text>
<text top="696" left="546" width="181" height="17" font="5">Rate age 23.8 (95% CI 8.7-51.8) </text>
<text top="715" left="546" width="3" height="17" font="5"> </text>
<text top="733" left="546" width="3" height="17" font="5"> </text>
<text top="305" left="791" width="56" height="17" font="5">Summary </text>
<text top="323" left="791" width="324" height="17" font="5">-Rates of cardiovascular events were higher in women with </text>
<text top="342" left="791" width="33" height="17" font="5">lupus </text>
<text top="360" left="791" width="320" height="17" font="5">-High rates of cardiovascular disease were found in young </text>
<text top="379" left="791" width="101" height="17" font="5">women with lupus </text>
<text top="764" left="75" width="105" height="17" font="5">Wu, P. et al., 2017 </text>
<text top="764" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="764" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="766" left="549" width="7" height="17" font="5">1</text>
<text top="765" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="764" left="794" width="56" height="17" font="5">Summary </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="3" height="17" font="5"> </text>
<text top="162" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28228456">28228456</a></text>
<text top="162" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28228456"> </a></text>
<text top="143" left="205" width="93" height="17" font="5">to systematically </text>
<text top="160" left="205" width="120" height="17" font="5">evaluate and quantify </text>
<text top="178" left="205" width="111" height="17" font="5">the evidence on the </text>
<text top="195" left="205" width="116" height="17" font="5">relationship between </text>
<text top="212" left="205" width="121" height="17" font="5">preeclampsia and the </text>
<text top="229" left="205" width="71" height="17" font="5">future risk of </text>
<text top="247" left="205" width="83" height="17" font="5">cardiovascular </text>
<text top="264" left="205" width="55" height="17" font="5">diseases. </text>
<text top="281" left="205" width="3" height="17" font="5"> </text>
<text top="298" left="205" width="66" height="17" font="5">Study Type </text>
<text top="315" left="205" width="102" height="17" font="5">Systematic review </text>
<text top="333" left="205" width="106" height="17" font="5">and meta analysis  </text>
<text top="350" left="205" width="3" height="17" font="5"> </text>
<text top="367" left="205" width="107" height="17" font="5">N=22 studies (&gt;6.4 </text>
<text top="386" left="205" width="85" height="17" font="5">million women) </text>
<text top="143" left="344" width="166" height="17" font="5">-studies investigating the long-</text>
<text top="160" left="344" width="181" height="17" font="5">term cardiovascular outcomes of </text>
<text top="178" left="344" width="134" height="17" font="5">women with and without </text>
<text top="195" left="344" width="80" height="17" font="5">preeclampsia  </text>
<text top="212" left="344" width="120" height="17" font="5">-published in English  </text>
<text top="229" left="344" width="165" height="17" font="5">-published between 2005 and </text>
<text top="247" left="344" width="73" height="17" font="5">August 2015 </text>
<text top="264" left="344" width="185" height="17" font="5">- no restriction on the definition of </text>
<text top="281" left="344" width="77" height="17" font="5">preeclampsia </text>
<text top="298" left="344" width="162" height="17" font="5">-had at least 2 groups (1 with </text>
<text top="315" left="344" width="153" height="17" font="5">preeclampsia and 1 without </text>
<text top="333" left="344" width="81" height="17" font="5">preeclampsia) </text>
<text top="350" left="344" width="181" height="17" font="5">- reported sufficient data to allow </text>
<text top="367" left="344" width="178" height="17" font="5">for accurate risk estimates to be </text>
<text top="384" left="344" width="66" height="17" font="5">calculated.  </text>
<text top="401" left="344" width="3" height="17" font="5"> </text>
<text top="419" left="344" width="97" height="17" font="5">Exclusion criteria </text>
<text top="436" left="344" width="163" height="17" font="5">-Studies assessing outcomes </text>
<text top="453" left="344" width="166" height="17" font="5">during antepartum or before 6 </text>
<text top="470" left="344" width="107" height="17" font="5">weeks postpartum  </text>
<text top="488" left="344" width="3" height="17" font="5"> </text>
<text top="143" left="546" width="204" height="17" font="5">heart failure; coronary heart disease; </text>
<text top="160" left="546" width="230" height="17" font="5">death because of coronary heart disease; </text>
<text top="178" left="546" width="232" height="17" font="5">composite cardiovascular disease defined </text>
<text top="195" left="546" width="156" height="17" font="5">as a combination of cardiac, </text>
<text top="212" left="546" width="225" height="17" font="5">cerebrovascular, and peripheral vascular </text>
<text top="229" left="546" width="206" height="17" font="5">disease; death because of composite </text>
<text top="247" left="546" width="196" height="17" font="5">cardiovascular disease; stroke; and </text>
<text top="264" left="546" width="75" height="17" font="5">stroke death. </text>
<text top="281" left="546" width="3" height="17" font="5"> </text>
<text top="299" left="546" width="75" height="17" font="7"><i>Heart Failure </i></text>
<text top="318" left="546" width="204" height="17" font="5">Pooled RR for adjusted studies=4.19 </text>
<text top="337" left="546" width="107" height="17" font="5">(95% CI 2.09-8.38) </text>
<text top="355" left="546" width="83" height="17" font="5">Heterogeneity I</text>
<text top="356" left="630" width="4" height="11" font="8">2</text>
<text top="355" left="634" width="35" height="17" font="5">=71% </text>
<text top="374" left="546" width="3" height="17" font="5"> </text>
<text top="392" left="546" width="218" height="17" font="5">Pooled RR for unadjusted studies=3.08 </text>
<text top="411" left="546" width="153" height="17" font="5">(95% CI 1.67-5.69) I2=76% </text>
<text top="430" left="546" width="3" height="17" font="5"> </text>
<text top="448" left="546" width="178" height="17" font="5">Overall pooled RR adjusted and </text>
<text top="467" left="546" width="202" height="17" font="5">unadjusted=3.62 (95% CI 2.25-5.85) </text>
<text top="485" left="546" width="3" height="17" font="5">I</text>
<text top="486" left="550" width="4" height="11" font="8">2</text>
<text top="485" left="554" width="35" height="17" font="5">=83% </text>
<text top="504" left="546" width="201" height="17" font="5">RR for adjusted studies with &lt;1 year </text>
<text top="523" left="546" width="222" height="17" font="5">follow up=4.10 (95% CI 2.90-5.80), 1-10 </text>
<text top="541" left="546" width="230" height="17" font="5">years=8.42 (95% CI 4.39-16.17), and &gt;10 </text>
<text top="560" left="546" width="224" height="17" font="5">years follow up=1.60 (95% CI 0.73-3.50) </text>
<text top="578" left="546" width="3" height="17" font="5"> </text>
<text top="597" left="546" width="209" height="17" font="5">Sensitivity analysis controlling for Age </text>
<text top="615" left="546" width="222" height="17" font="5">RR=3.89 (95% CI 1.83-8.26), controlling </text>
<text top="634" left="546" width="213" height="17" font="5">for BMI/Weight RR=1.84 (95% CI 1.23-</text>
<text top="652" left="546" width="214" height="17" font="5">2.74), controlling for diabetes RR=2.16 </text>
<text top="671" left="546" width="188" height="17" font="5">(95% CI 1.03-4.52), controlling for </text>
<text top="690" left="546" width="212" height="17" font="5">smoking RR=1.56 (95% CI 1.11-2.20), </text>
<text top="708" left="546" width="227" height="17" font="5">and controlling for hypertension RR=3.84 </text>
<text top="727" left="546" width="114" height="17" font="5">(95% CI 0.81-18.16) </text>
<text top="745" left="546" width="3" height="17" font="5"> </text>
<text top="764" left="546" width="131" height="17" font="7"><i>Coronary heart disease </i></text>
<text top="143" left="791" width="339" height="17" font="5">There was an association of preeclampsia with future incident </text>
<text top="162" left="791" width="323" height="17" font="5">coronary heart disease, composite cardiovascular disease, </text>
<text top="180" left="791" width="323" height="17" font="5">heart failure, stroke, and deaths because of coronary heart </text>
<text top="199" left="791" width="328" height="17" font="5">disease. The adjusted risk ranged between 1.8-and 2.5-fold </text>
<text top="218" left="791" width="328" height="17" font="5">compared with those without a history of preeclampsia in all </text>
<text top="236" left="791" width="309" height="17" font="5">cardiac outcomes, except in heart failure, where a 4-fold </text>
<text top="255" left="791" width="145" height="17" font="5">increase in risk was found </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="204" height="17" font="5">Pooled RR for adjusted studies=2.50 </text>
<text top="162" left="546" width="107" height="17" font="5">(95% CI 1.43-4.37) </text>
<text top="180" left="546" width="3" height="17" font="5">I</text>
<text top="182" left="550" width="4" height="11" font="8">2</text>
<text top="180" left="554" width="35" height="17" font="5">=89% </text>
<text top="199" left="546" width="3" height="17" font="5"> </text>
<text top="218" left="546" width="218" height="17" font="5">Pooled RR for unadjusted studies=2.04 </text>
<text top="236" left="546" width="107" height="17" font="5">(95% CI 1.61-2.59) </text>
<text top="255" left="546" width="3" height="17" font="5">I</text>
<text top="256" left="550" width="4" height="11" font="8">2</text>
<text top="255" left="554" width="35" height="17" font="5">=70% </text>
<text top="273" left="546" width="3" height="17" font="5"> </text>
<text top="292" left="546" width="178" height="17" font="5">Overall pooled RR adjusted and </text>
<text top="310" left="546" width="206" height="17" font="5">unadjusted=2.11 (95% CI 1.60-2.77). </text>
<text top="329" left="546" width="3" height="17" font="5">I</text>
<text top="330" left="550" width="4" height="11" font="8">2</text>
<text top="329" left="554" width="35" height="17" font="5">=87% </text>
<text top="348" left="546" width="3" height="17" font="5"> </text>
<text top="366" left="546" width="201" height="17" font="5">RR for adjusted studies with &lt;1 year </text>
<text top="385" left="546" width="222" height="17" font="5">follow up=3.10 (95% CI 1.56-6.15), 1-10 </text>
<text top="403" left="546" width="230" height="17" font="5">years=3.78 (95% CI 0.43-77.30), and &gt;10 </text>
<text top="422" left="546" width="224" height="17" font="5">years follow up=1.46 (95% CI 0.95-2.25) </text>
<text top="440" left="546" width="3" height="17" font="5"> </text>
<text top="459" left="546" width="222" height="17" font="5">RR adjusting for age=2.63 (95% CI 1.74-</text>
<text top="478" left="546" width="31" height="17" font="5">3.98) </text>
<text top="496" left="546" width="3" height="17" font="5"> </text>
<text top="515" left="546" width="79" height="17" font="7"><i>CVD Mortality </i></text>
<text top="533" left="546" width="163" height="17" font="5">RR=2.21 (95% CI 1.83-2.66)  </text>
<text top="552" left="546" width="3" height="17" font="5">I</text>
<text top="553" left="550" width="4" height="11" font="8">2</text>
<text top="552" left="554" width="35" height="17" font="5">=54% </text>
<text top="571" left="546" width="3" height="17" font="5"> </text>
<text top="589" left="546" width="208" height="17" font="5">Sensitivity analysis controlling for age </text>
<text top="608" left="546" width="160" height="17" font="5">RR=2.21 (95% CI 1.83-2.66) </text>
<text top="626" left="546" width="3" height="17" font="5"> </text>
<text top="645" left="546" width="39" height="17" font="7"><i>Stroke </i></text>
<text top="663" left="546" width="204" height="17" font="5">Pooled RR for adjusted studies=1.81 </text>
<text top="682" left="546" width="107" height="17" font="5">(95% CI 1.29-2.55) </text>
<text top="701" left="546" width="3" height="17" font="5">I</text>
<text top="702" left="550" width="4" height="11" font="8">2</text>
<text top="701" left="554" width="35" height="17" font="5">=74% </text>
<text top="719" left="546" width="3" height="17" font="5"> </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="218" height="17" font="5">Pooled RR for unadjusted studies=1.60 </text>
<text top="162" left="546" width="232" height="17" font="5">(95% CI 1.47=1.74) (note: estimate based </text>
<text top="180" left="546" width="78" height="17" font="5">on one study) </text>
<text top="199" left="546" width="3" height="17" font="5">I</text>
<text top="200" left="550" width="4" height="11" font="8">2</text>
<text top="199" left="554" width="31" height="17" font="5">=N/A </text>
<text top="218" left="546" width="3" height="17" font="5"> </text>
<text top="236" left="546" width="178" height="17" font="5">Overall pooled RR adjusted and </text>
<text top="255" left="546" width="202" height="17" font="5">unadjusted=1.71 (95% CI 1.38-2.11) </text>
<text top="273" left="546" width="3" height="17" font="5">I</text>
<text top="274" left="550" width="4" height="11" font="8">2</text>
<text top="273" left="554" width="35" height="17" font="5">=69% </text>
<text top="292" left="546" width="3" height="17" font="5"> </text>
<text top="310" left="546" width="201" height="17" font="5">RR for adjusted studies with &lt;1 year </text>
<text top="329" left="546" width="222" height="17" font="5">follow up=2.22 (95% CI 1.73-2.85), 1-10 </text>
<text top="348" left="546" width="193" height="17" font="5">years follow up=3.56 (95% CI 0.52-</text>
<text top="366" left="546" width="211" height="17" font="5">24.28), and &gt;10 years=1.18 (95% CCI </text>
<text top="385" left="546" width="60" height="17" font="5">0.95-1.46) </text>
<text top="403" left="546" width="3" height="17" font="5"> </text>
<text top="422" left="546" width="208" height="17" font="5">Sensitivity analysis controlling for age </text>
<text top="440" left="546" width="222" height="17" font="5">RR=2.04 (95% CI 1.60-2.60), controlling </text>
<text top="459" left="546" width="213" height="17" font="5">for BMI/Weight RR=1.94 (95% CI 1.42-</text>
<text top="478" left="546" width="214" height="17" font="5">2.65), controlling for diabetes RR=2.46 </text>
<text top="496" left="546" width="212" height="17" font="5">(95% CI 1.11-5.43), and controlling for </text>
<text top="515" left="546" width="209" height="17" font="5">smoking RR=1.64 (95% CI 1.12-2.40) </text>
<text top="546" left="75" width="84" height="17" font="5">Nurses’ Health </text>
<text top="565" left="75" width="90" height="17" font="5">Study II (NHSII) </text>
<text top="583" left="75" width="3" height="17" font="5"> </text>
<text top="602" left="75" width="91" height="17" font="5">Tanz, LJ., et al., </text>
<text top="620" left="75" width="31" height="17" font="5">2017 </text>
<text top="639" left="75" width="3" height="17" font="5"> </text>
<text top="658" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28153993">28153993</a></text>
<text top="658" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28153993"> </a></text>
<text top="546" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="565" left="205" width="3" height="17" font="5"> </text>
<text top="582" left="205" width="88" height="17" font="5">To evaluate the </text>
<text top="599" left="205" width="115" height="17" font="5">association between </text>
<text top="616" left="205" width="115" height="17" font="5">preterm delivery and </text>
<text top="633" left="205" width="96" height="17" font="5">CVD (myocardial </text>
<text top="651" left="205" width="109" height="17" font="5">infarction or stroke) </text>
<text top="668" left="205" width="94" height="17" font="5">and whether this </text>
<text top="685" left="205" width="77" height="17" font="5">association is </text>
<text top="702" left="205" width="94" height="17" font="5">accounted for by </text>
<text top="719" left="205" width="65" height="17" font="5">postpartum </text>
<text top="737" left="205" width="87" height="17" font="5">development of </text>
<text top="754" left="205" width="108" height="17" font="5">traditional CVD risk </text>
<text top="771" left="205" width="87" height="17" font="5">factors (chronic </text>
<text top="546" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="565" left="344" width="161" height="17" font="5">-participant in Nurses’ Health </text>
<text top="583" left="344" width="35" height="17" font="5">Study </text>
<text top="602" left="344" width="3" height="17" font="5"> </text>
<text top="620" left="344" width="97" height="17" font="5">Exclusion criteria </text>
<text top="639" left="344" width="179" height="17" font="5">-Self-reported pre-baseline CVD </text>
<text top="658" left="344" width="174" height="17" font="5">-did not complete 2001 or 2009 </text>
<text top="676" left="344" width="157" height="17" font="5">questionnaires documenting </text>
<text top="695" left="344" width="111" height="17" font="5">reproductive history </text>
<text top="713" left="344" width="111" height="17" font="5">-nulliparous in 2009 </text>
<text top="732" left="344" width="152" height="17" font="5">-&lt;age18 or &gt;45 at first birth </text>
<text top="547" left="549" width="7" height="17" font="5">1</text>
<text top="546" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="566" left="546" width="3" height="17" font="5"> </text>
<text top="583" left="546" width="185" height="17" font="5">Composite cardiovascular events </text>
<text top="602" left="546" width="189" height="17" font="5">(myocardial infarction and stroke ) </text>
<text top="620" left="546" width="3" height="17" font="5"> </text>
<text top="640" left="549" width="7" height="17" font="5">2</text>
<text top="639" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="659" left="546" width="150" height="17" font="5">Coronary revascularization </text>
<text top="677" left="546" width="3" height="17" font="5"> </text>
<text top="697" left="546" width="7" height="17" font="5">1</text>
<text top="696" left="553" width="64" height="18" font="5"> endpoint: </text>
<text top="716" left="546" width="66" height="17" font="7"><i>All subjects </i></text>
<text top="734" left="546" width="159" height="17" font="5">HR preterm (&lt;37 weeks ) for </text>
<text top="753" left="546" width="201" height="17" font="5">cardiovascular events=1.42 (95% CI </text>
<text top="772" left="546" width="60" height="17" font="5">1.16-1.72) </text>
<text top="546" left="791" width="56" height="17" font="5">Summary </text>
<text top="565" left="791" width="3" height="17" font="5"> </text>
<text top="582" left="791" width="331" height="17" font="5">Women who deliver a preterm infant are at a 40% increased </text>
<text top="600" left="791" width="326" height="17" font="5">risk of future CVD events while those who deliver before 32 </text>
<text top="619" left="791" width="289" height="17" font="5">weeks experience a doubling of CVD risk, even after </text>
<text top="638" left="791" width="338" height="17" font="5">accounting for pre-pregnancy sociodemographic, lifestyle and </text>
<text top="656" left="791" width="341" height="17" font="5">CVD risk factors. This increased risk is only partially explained </text>
<text top="675" left="791" width="340" height="17" font="5">by the subsequent development of traditional CVD risk factors </text>
<text top="693" left="791" width="329" height="17" font="5">such as chronic hypertension, hypercholesterolemia, weight </text>
<text top="712" left="791" width="249" height="17" font="5">gain and T2DM in the years after the delivery </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="13" size="7" family="Times" color="#000000"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="77" height="17" font="5">hypertension, </text>
<text top="160" left="205" width="124" height="17" font="5">hypercholesterolemia, </text>
<text top="178" left="205" width="87" height="17" font="5">type 2 diabetes </text>
<text top="195" left="205" width="117" height="17" font="5">mellitus (T2DM), and </text>
<text top="212" left="205" width="33" height="17" font="5">BMI). </text>
<text top="229" left="205" width="3" height="17" font="5"> </text>
<text top="247" left="205" width="62" height="17" font="5">Study type </text>
<text top="264" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="281" left="205" width="33" height="17" font="5">study </text>
<text top="298" left="205" width="3" height="17" font="5"> </text>
<text top="315" left="205" width="57" height="17" font="5">N=70,182 </text>
<text top="143" left="344" width="184" height="17" font="5">-missing information on gestation </text>
<text top="162" left="344" width="153" height="17" font="5">length or year of pregnancy </text>
<text top="143" left="546" width="3" height="17" font="5"> </text>
<text top="162" left="546" width="190" height="17" font="5">HR moderate preterm (≥32 to &lt;37 </text>
<text top="180" left="546" width="181" height="17" font="5">weeks)=1.22 (95% CI 0.96-1.54) </text>
<text top="199" left="546" width="3" height="17" font="5"> </text>
<text top="218" left="546" width="227" height="17" font="5">HR very preterm (&lt;32 weeks)=2.01 (95% </text>
<text top="236" left="546" width="75" height="17" font="5">CI 1.47-2.75) </text>
<text top="255" left="546" width="3" height="17" font="5"> </text>
<text top="273" left="546" width="106" height="17" font="5">P&lt;0.0001 for trend </text>
<text top="292" left="546" width="3" height="17" font="5"> </text>
<text top="310" left="546" width="221" height="17" font="7"><i>Those without hypertensive disorders of </i></text>
<text top="329" left="546" width="158" height="17" font="7"><i>pregnancy in first pregnancy </i></text>
<text top="348" left="546" width="3" height="17" font="5"> </text>
<text top="366" left="546" width="159" height="17" font="5">HR preterm (&lt;37 weeks ) for </text>
<text top="385" left="546" width="201" height="17" font="5">cardiovascular events=1.35 (95% CI </text>
<text top="403" left="546" width="60" height="17" font="5">1.06-1.72) </text>
<text top="422" left="546" width="3" height="17" font="5"> </text>
<text top="440" left="546" width="190" height="17" font="5">HR moderate preterm (≥32 to &lt;37 </text>
<text top="459" left="546" width="181" height="17" font="5">weeks)=1.12 (95% CI 0.83-1.52) </text>
<text top="478" left="546" width="3" height="17" font="5"> </text>
<text top="496" left="546" width="227" height="17" font="5">HR very preterm (&lt;32 weeks)=2.01 (95% </text>
<text top="515" left="546" width="75" height="17" font="5">CI 1.38-2.93) </text>
<text top="533" left="546" width="3" height="17" font="5"> </text>
<text top="552" left="546" width="223" height="17" font="7"><i>Among women with no births at age 40+ </i></text>
<text top="571" left="546" width="205" height="17" font="7"><i>HRs compared to referent group with </i></text>
<text top="589" left="546" width="123" height="17" font="7"><i>First pregnancy term/2</i></text>
<text top="590" left="669" width="9" height="11" font="13"><i>nd</i></text>
<text top="589" left="678" width="77" height="17" font="7"><i>+pregnancies </i></text>
<text top="608" left="546" width="28" height="17" font="7"><i>term </i></text>
<text top="626" left="546" width="3" height="17" font="5"> </text>
<text top="645" left="546" width="7" height="17" font="5">1</text>
<text top="646" left="553" width="6" height="11" font="8">st</text>
<text top="645" left="559" width="99" height="17" font="5"> pregnancy term/2</text>
<text top="646" left="658" width="9" height="11" font="8">nd</text>
<text top="645" left="667" width="108" height="17" font="5">+ preterm HR=1.34 </text>
<text top="663" left="546" width="107" height="17" font="5">(95% CI 1.01-1.76) </text>
<text top="682" left="546" width="3" height="17" font="5"> </text>
<text top="701" left="546" width="7" height="17" font="5">1</text>
<text top="702" left="553" width="6" height="11" font="8">st</text>
<text top="701" left="559" width="116" height="17" font="5"> pregnancy term/no 2</text>
<text top="702" left="675" width="9" height="11" font="8">nd</text>
<text top="701" left="684" width="77" height="17" font="5">+prengnacies </text>
<text top="719" left="546" width="160" height="17" font="5">HR=1.21 (95% CI 0.99-1.46) </text>
<text top="738" left="546" width="3" height="17" font="5"> </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="133" height="17" font="5">1st pregnancy preterm/2</text>
<text top="144" left="680" width="9" height="11" font="8">nd</text>
<text top="143" left="689" width="84" height="17" font="5"> + pregnancies </text>
<text top="162" left="546" width="188" height="17" font="5">term HR=1.38 (95% CI 1.00-1.90) </text>
<text top="180" left="546" width="3" height="17" font="5"> </text>
<text top="199" left="546" width="7" height="17" font="5">1</text>
<text top="200" left="553" width="6" height="11" font="8">st</text>
<text top="199" left="559" width="99" height="17" font="5"> pregnancy term/2</text>
<text top="200" left="658" width="9" height="11" font="8">nd</text>
<text top="199" left="667" width="77" height="17" font="5">+pregnancies </text>
<text top="218" left="546" width="206" height="17" font="5">preterm HR=1.65 (95% CI 1.20-2.28) </text>
<text top="236" left="546" width="3" height="17" font="5"> </text>
<text top="255" left="546" width="7" height="17" font="5">1</text>
<text top="256" left="553" width="6" height="11" font="8">st</text>
<text top="255" left="559" width="131" height="17" font="5"> pregnancy preterm/ no </text>
<text top="273" left="546" width="7" height="17" font="5">2</text>
<text top="274" left="553" width="9" height="11" font="8">nd</text>
<text top="273" left="562" width="206" height="17" font="5">+pregnancies HR=1.45 (95% CI 0.97-</text>
<text top="292" left="546" width="31" height="17" font="5">2.17) </text>
<text top="310" left="546" width="3" height="17" font="5"> </text>
<text top="329" left="546" width="210" height="17" font="5">When examining a model adjusted for </text>
<text top="348" left="546" width="163" height="17" font="5">age at first birth, age in 1989, </text>
<text top="366" left="546" width="232" height="17" font="5">race/ethnicity, and parental education, the </text>
<text top="385" left="546" width="218" height="17" font="5">proportion of the association accounted </text>
<text top="403" left="546" width="188" height="17" font="5">for by the intermediates of chronic </text>
<text top="422" left="546" width="224" height="17" font="5">hypertension hypercholesterolemia, type </text>
<text top="440" left="546" width="221" height="17" font="5">2 diabetes mellitus, and BMI was 13.3% </text>
<text top="459" left="546" width="222" height="17" font="5">(95% CI 7.9-21.4) for &lt;37 weeks, 17.1% </text>
<text top="478" left="546" width="223" height="17" font="5">(95% CI 5.5-42.5) for ≥32 to &lt;37 weeks, </text>
<text top="496" left="546" width="205" height="17" font="5">and 12.0% (95% CI 8.6-16.5) for &lt;32 </text>
<text top="515" left="546" width="42" height="17" font="5">weeks. </text>
<text top="533" left="546" width="3" height="17" font="5"> </text>
<text top="552" left="546" width="210" height="17" font="5">When examining a model adjusted for </text>
<text top="571" left="546" width="163" height="17" font="5">age at first birth, age in 1989, </text>
<text top="589" left="546" width="209" height="17" font="5">race/ethnicity, parental education, pre-</text>
<text top="608" left="546" width="225" height="17" font="5">pregnancy BMI, pre-pregnancy smoking, </text>
<text top="626" left="546" width="227" height="17" font="5">pre-pregnancy Alternative Healthy Eating </text>
<text top="645" left="546" width="195" height="17" font="5">Index score, pre-pregnancy alcohol </text>
<text top="663" left="546" width="209" height="17" font="5">intake, physical activity at age 18, pre-</text>
<text top="682" left="546" width="212" height="17" font="5">pregnancy oral contraceptive use, and </text>
<text top="701" left="546" width="219" height="17" font="5">family history of MI or stroke before age </text>
<text top="719" left="546" width="199" height="17" font="5">60, the proportion of the association </text>
<text top="738" left="546" width="206" height="17" font="5">accounted for by the intermediates of </text>
<text top="756" left="546" width="117" height="17" font="5">chronic hypertension </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="210" height="17" font="5">hypercholesterolemia, type 2 diabetes </text>
<text top="162" left="546" width="209" height="17" font="5">mellitus, and BMI was 12.8% (95% CI </text>
<text top="180" left="546" width="222" height="17" font="5">7.1-21.9) for &lt;37 weeks, 14.5% (95% CI </text>
<text top="199" left="546" width="195" height="17" font="5">4.0-41.1 for ≥32 to &lt;37 weeks, and </text>
<text top="218" left="546" width="223" height="17" font="5">13.1% (95% CI 9.0-18.7) for &lt;32 weeks. </text>
<text top="236" left="546" width="3" height="17" font="5"> </text>
<text top="255" left="546" width="210" height="17" font="5">When examining a model adjusted for </text>
<text top="273" left="546" width="163" height="17" font="5">age at first birth, age in 1989, </text>
<text top="292" left="546" width="209" height="17" font="5">race/ethnicity, parental education, pre-</text>
<text top="310" left="546" width="225" height="17" font="5">pregnancy BMI, pre-pregnancy smoking, </text>
<text top="329" left="546" width="227" height="17" font="5">pre-pregnancy Alternative Healthy Eating </text>
<text top="348" left="546" width="195" height="17" font="5">Index score, pre-pregnancy alcohol </text>
<text top="366" left="546" width="209" height="17" font="5">intake, physical activity at age 18, pre-</text>
<text top="385" left="546" width="212" height="17" font="5">pregnancy oral contraceptive use, and </text>
<text top="403" left="546" width="219" height="17" font="5">family history of MI or stroke before age </text>
<text top="422" left="546" width="199" height="17" font="5">60, the proportion of the association </text>
<text top="440" left="546" width="206" height="17" font="5">accounted for by the intermediates of </text>
<text top="459" left="546" width="117" height="17" font="5">chronic hypertension </text>
<text top="478" left="546" width="210" height="17" font="5">hypercholesterolemia, type 2 diabetes </text>
<text top="496" left="546" width="204" height="17" font="5">mellitus, BMI, and breastfeeding was </text>
<text top="515" left="546" width="222" height="17" font="5">15.9% (95% CI 8.7-27.3) for &lt;37 weeks, </text>
<text top="533" left="546" width="220" height="17" font="5">20.7% (95% CI 5.5-53.8) for ≥32 to &lt;37 </text>
<text top="552" left="546" width="222" height="17" font="5">weeks, and 14.0% (95% CI 9.5-20.1) for </text>
<text top="571" left="546" width="66" height="17" font="5">&lt;32 weeks. </text>
<text top="602" left="75" width="116" height="17" font="5">Multi-Ethnic Study of </text>
<text top="620" left="75" width="87" height="17" font="5">Atherosclerosis </text>
<text top="639" left="75" width="46" height="17" font="5">(MESA) </text>
<text top="658" left="75" width="3" height="17" font="5"> </text>
<text top="676" left="75" width="101" height="17" font="5">Wellons, M. et al., </text>
<text top="695" left="75" width="31" height="17" font="5">2012 </text>
<text top="713" left="75" width="3" height="17" font="5"> </text>
<text top="732" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22692332">22692332</a></text>
<text top="732" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22692332"> </a></text>
<text top="602" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="620" left="205" width="115" height="17" font="5">to determine if a self-</text>
<text top="639" left="205" width="79" height="17" font="5">reported early </text>
<text top="658" left="205" width="68" height="17" font="5">menopause </text>
<text top="676" left="205" width="102" height="17" font="5">(menopause at an </text>
<text top="695" left="205" width="104" height="17" font="5">age &lt;46) identifies </text>
<text top="713" left="205" width="113" height="17" font="5">women as at risk for </text>
<text top="732" left="205" width="118" height="17" font="5">future coronary heart </text>
<text top="750" left="205" width="97" height="17" font="5">disease or stroke </text>
<text top="769" left="205" width="3" height="17" font="5"> </text>
<text top="602" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="620" left="344" width="44" height="17" font="5">-female </text>
<text top="638" left="344" width="174" height="17" font="5">-identified themselves as white, </text>
<text top="655" left="344" width="160" height="17" font="5">black, Hispanic, or Chinese, -</text>
<text top="672" left="344" width="168" height="17" font="5">reported that they were free of </text>
<text top="689" left="344" width="92" height="17" font="5">CVD at baseline </text>
<text top="707" left="344" width="186" height="17" font="5">-45 to 84 years of age at baseline </text>
<text top="724" left="344" width="3" height="17" font="5"> </text>
<text top="742" left="344" width="97" height="17" font="5">Exclusion criteria </text>
<text top="603" left="549" width="7" height="17" font="5">1</text>
<text top="602" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="622" left="546" width="210" height="17" font="5">Incident CHD (definite or probable MI, </text>
<text top="640" left="546" width="224" height="17" font="5">resuscitated cardiac arrest, definite CHD </text>
<text top="659" left="546" width="45" height="17" font="5">death),  </text>
<text top="677" left="546" width="194" height="17" font="5">Incident stroke (fatal and non-fatal) </text>
<text top="696" left="546" width="3" height="17" font="5"> </text>
<text top="715" left="546" width="71" height="17" font="7"><i>CHD Events </i></text>
<text top="733" left="546" width="192" height="17" font="5">Annualized rate in group with early </text>
<text top="752" left="546" width="147" height="17" font="5">menopause=7.33/1000/yr  </text>
<text top="770" left="546" width="3" height="17" font="5"> </text>
<text top="602" left="791" width="56" height="17" font="5">Summary </text>
<text top="620" left="791" width="241" height="17" font="5">early menopause is a moderate predictor of </text>
<text top="639" left="791" width="331" height="17" font="5">CHD and stroke, even after adjusting for traditional CVD risk </text>
<text top="658" left="791" width="167" height="17" font="5">factors in a diverse population </text>
<text top="676" left="791" width="77" height="17" font="5">of US women </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="62" height="17" font="5">Study type </text>
<text top="162" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="180" left="205" width="33" height="17" font="5">study </text>
<text top="199" left="205" width="3" height="17" font="5"> </text>
<text top="218" left="205" width="47" height="17" font="5">N=2509 </text>
<text top="143" left="344" width="123" height="17" font="5">-hysterectomy without </text>
<text top="162" left="344" width="81" height="17" font="5">oophorectomy </text>
<text top="180" left="344" width="73" height="17" font="5">Missing data </text>
<text top="199" left="344" width="155" height="17" font="5">-inconsistent data regarding </text>
<text top="218" left="344" width="107" height="17" font="5">menopausal status </text>
<text top="236" left="344" width="3" height="17" font="5"> </text>
<text top="143" left="546" width="209" height="17" font="5">Annualized rate in group without early </text>
<text top="162" left="546" width="143" height="17" font="5">menopause=3.22/1000/yr </text>
<text top="180" left="546" width="3" height="17" font="5"> </text>
<text top="199" left="546" width="212" height="17" font="5">HR fully adjusted model=1.85 (95% CI </text>
<text top="218" left="546" width="111" height="17" font="5">1.01-3.37), p=0.045 </text>
<text top="236" left="546" width="3" height="17" font="5"> </text>
<text top="255" left="546" width="160" height="17" font="5">C-statistics for traditional risk </text>
<text top="273" left="546" width="218" height="17" font="5">factors=0.68, when early menopause is </text>
<text top="292" left="546" width="179" height="17" font="5">added, C-statistic=0.70 (p=0.55) </text>
<text top="310" left="546" width="3" height="17" font="7"><i> </i></text>
<text top="329" left="546" width="80" height="17" font="7"><i>Stroke Events </i></text>
<text top="348" left="546" width="192" height="17" font="5">Annualized rate in group with early </text>
<text top="366" left="546" width="119" height="17" font="5">menopause=1000/yr  </text>
<text top="385" left="546" width="3" height="17" font="5"> </text>
<text top="403" left="546" width="209" height="17" font="5">Annualized rate in group without early </text>
<text top="422" left="546" width="119" height="17" font="5">menopause=/1000/yr </text>
<text top="440" left="546" width="212" height="17" font="5">HR fully adjusted model=2.03 (95% CI </text>
<text top="459" left="546" width="111" height="17" font="5">1.00-4.10), p=0.049 </text>
<text top="478" left="546" width="3" height="17" font="5"> </text>
<text top="496" left="546" width="231" height="17" font="5">Adjustment for type of menopause did not </text>
<text top="515" left="546" width="162" height="17" font="5">alter results (data not shown) </text>
<text top="533" left="546" width="226" height="17" font="5">No evidence of interaction between early </text>
<text top="552" left="546" width="228" height="17" font="5">menopause and use of hormone therapy, </text>
<text top="571" left="546" width="231" height="17" font="5">type of menopause, or ever drinking (data </text>
<text top="589" left="546" width="64" height="17" font="5">not shown) </text>
<text top="620" left="75" width="116" height="17" font="5">Multi-Ethnic Study of </text>
<text top="639" left="75" width="87" height="17" font="5">Atherosclerosis </text>
<text top="658" left="75" width="46" height="17" font="5">(MESA) </text>
<text top="676" left="75" width="3" height="17" font="5"> </text>
<text top="695" left="75" width="102" height="17" font="5">Uddin, SMI. Et al., </text>
<text top="713" left="75" width="31" height="17" font="5">2018 </text>
<text top="732" left="75" width="3" height="17" font="5"> </text>
<text top="750" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29891569">29891569</a></text>
<text top="750" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29891569"> </a></text>
<text top="620" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="639" left="205" width="117" height="17" font="5">to examine the value </text>
<text top="658" left="205" width="86" height="17" font="5">of self-reported </text>
<text top="676" left="205" width="108" height="17" font="5">erectile dysfunction </text>
<text top="695" left="205" width="120" height="17" font="5">for predicting incident </text>
<text top="713" left="205" width="83" height="17" font="5">coronary heart </text>
<text top="732" left="205" width="112" height="17" font="5">disease and CVD in </text>
<text top="750" left="205" width="105" height="17" font="5">those free of these </text>
<text top="620" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="639" left="344" width="38" height="17" font="5">-Male  </text>
<text top="656" left="344" width="112" height="17" font="5">-MESA participants  </text>
<text top="673" left="344" width="174" height="17" font="5">- attended visit 5 and answered </text>
<text top="691" left="344" width="171" height="17" font="5">the single Massachusetts Male </text>
<text top="708" left="344" width="147" height="17" font="5">Aging Study question 3 on </text>
<text top="725" left="344" width="168" height="17" font="5">erectile dysfunction symptoms </text>
<text top="742" left="344" width="3" height="17" font="5"> </text>
<text top="761" left="344" width="97" height="17" font="5">Exclusion criteria </text>
<text top="622" left="549" width="7" height="17" font="5">1</text>
<text top="620" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="640" left="546" width="98" height="17" font="5">CHD hard events </text>
<text top="659" left="546" width="97" height="17" font="5">CVD hard events </text>
<text top="677" left="546" width="3" height="17" font="5"> </text>
<text top="696" left="546" width="98" height="17" font="7"><i>CHD hard events </i></text>
<text top="715" left="546" width="231" height="17" font="5">Proportion of participants with and without </text>
<text top="733" left="546" width="222" height="17" font="5">ED who experienced an event=3.4% vs. </text>
<text top="752" left="546" width="87" height="17" font="5">1.4%, p&lt;0.001) </text>
<text top="770" left="546" width="3" height="17" font="5"> </text>
<text top="620" left="791" width="56" height="17" font="5">Summary </text>
<text top="639" left="791" width="302" height="17" font="5">ED was found to be a significant predictor of hard CVD </text>
<text top="658" left="791" width="302" height="17" font="5">events after adjustment for traditional CVD risk factors, </text>
<text top="676" left="791" width="168" height="17" font="5">depression, and β-blocker use </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="83" height="17" font="5">CVD events at </text>
<text top="162" left="205" width="49" height="17" font="5">baseline </text>
<text top="180" left="205" width="3" height="17" font="5"> </text>
<text top="199" left="205" width="62" height="17" font="5">Study type </text>
<text top="218" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="236" left="205" width="3" height="17" font="5"> </text>
<text top="255" left="205" width="47" height="17" font="5">N=1914 </text>
<text top="143" left="344" width="144" height="17" font="5">-CVD event prior to visit 5 </text>
<text top="143" left="546" width="200" height="17" font="5">Unadjusted HR=2.5, 95% CI 1.3-4.8 </text>
<text top="162" left="546" width="214" height="17" font="5">Fully adjusted HR=1.8, 95% CI 0.8-4.0 </text>
<text top="180" left="546" width="3" height="17" font="5"> </text>
<text top="199" left="546" width="97" height="17" font="7"><i>CVD hard events </i></text>
<text top="218" left="546" width="231" height="17" font="5">Proportion of participants with and without </text>
<text top="236" left="546" width="225" height="17" font="5">ED who experienced an event =6.3% vs. </text>
<text top="255" left="546" width="83" height="17" font="5">2.6%, p&lt;0.001 </text>
<text top="273" left="546" width="3" height="17" font="5"> </text>
<text top="292" left="546" width="200" height="17" font="5">Unadjusted HR=2.6, 95% CI 1.6-4.1 </text>
<text top="310" left="546" width="214" height="17" font="5">Fully adjusted HR=1.9, 95% CI 1.1-3.4 </text>
<text top="329" left="546" width="3" height="17" font="5"> </text>
<text top="348" left="546" width="229" height="17" font="5">Time shifted cross-sectional analysis, OR </text>
<text top="366" left="546" width="223" height="17" font="5">between prior CVD event and ED at visit </text>
<text top="385" left="546" width="221" height="17" font="5">5=2.1, 95% CI 1.4-3.2 (OR=1.7, 95% CI </text>
<text top="403" left="546" width="228" height="17" font="5">1.1-2.6 when adjusted for medication use </text>
<text top="422" left="546" width="92" height="17" font="5">and depression) </text>
<text top="440" left="546" width="3" height="17" font="5"> </text>
<text top="472" left="75" width="111" height="17" font="5">Partners HIV cohort </text>
<text top="490" left="75" width="3" height="17" font="5"> </text>
<text top="509" left="75" width="96" height="17" font="5">Triant, VA. Et al., </text>
<text top="528" left="75" width="31" height="17" font="5">2018 </text>
<text top="546" left="75" width="3" height="17" font="5"> </text>
<text top="565" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29444987">29444987</a></text>
<text top="565" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29444987"> </a></text>
<text top="472" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="490" left="205" width="76" height="17" font="5">to assess the </text>
<text top="509" left="205" width="96" height="17" font="5">performance of 3 </text>
<text top="528" left="205" width="117" height="17" font="5">established CVD risk </text>
<text top="546" left="205" width="122" height="17" font="5">prediction functions in </text>
<text top="565" left="205" width="113" height="17" font="5">a longitudinal cohort </text>
<text top="583" left="205" width="111" height="17" font="5">of HIV infected men </text>
<text top="602" left="205" width="3" height="17" font="5"> </text>
<text top="620" left="205" width="62" height="17" font="5">Study type </text>
<text top="639" left="205" width="105" height="17" font="5">Prospective cohort </text>
<text top="658" left="205" width="3" height="17" font="5"> </text>
<text top="676" left="205" width="47" height="17" font="5">N=1272 </text>
<text top="472" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="490" left="344" width="40" height="17" font="5">-males </text>
<text top="509" left="344" width="73" height="17" font="5">-HIV positive </text>
<text top="527" left="344" width="185" height="17" font="5">-≥1 clinical encounter in calendar </text>
<text top="545" left="344" width="109" height="17" font="5">years 2006 to 2008 </text>
<text top="562" left="344" width="178" height="17" font="5">-a blood pressure measurement </text>
<text top="579" left="344" width="140" height="17" font="5">available in 2006 to 2008 </text>
<text top="596" left="344" width="178" height="17" font="5">-lipid laboratory values available </text>
<text top="614" left="344" width="172" height="17" font="5">in calendar years 2004 to 2008 </text>
<text top="631" left="344" width="155" height="17" font="5">-smoking status available at </text>
<text top="648" left="344" width="122" height="17" font="5">baseline (2006–2008) </text>
<text top="665" left="344" width="156" height="17" font="5">-first HIV code that occurred </text>
<text top="682" left="344" width="184" height="17" font="5">before the start of observation for </text>
<text top="700" left="344" width="85" height="17" font="5">each individual </text>
<text top="717" left="344" width="3" height="17" font="5"> </text>
<text top="736" left="344" width="97" height="17" font="5">Exclusion criteria </text>
<text top="754" left="344" width="3" height="17" font="5"> </text>
<text top="473" left="549" width="7" height="17" font="5">1</text>
<text top="472" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="492" left="546" width="185" height="17" font="5">Hard CHD (MI or coronary death) </text>
<text top="510" left="546" width="3" height="17" font="5"> </text>
<text top="529" left="546" width="215" height="17" font="5">ASCVD (MI, stroke, or coronary death) </text>
<text top="547" left="546" width="222" height="17" font="5">Global CVD (MI, stroke, coronary death, </text>
<text top="566" left="546" width="219" height="17" font="5">coronary insufficiency, angina, transient </text>
<text top="584" left="546" width="184" height="17" font="5">ischemic attack, peripheral artery </text>
<text top="603" left="546" width="132" height="17" font="5">disease, or heart failure </text>
<text top="622" left="546" width="3" height="17" font="5"> </text>
<text top="641" left="549" width="7" height="17" font="5">1</text>
<text top="640" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="660" left="546" width="3" height="17" font="5"> </text>
<text top="679" left="546" width="204" height="17" font="5">The 5-year hard CHD event rate was </text>
<text top="697" left="546" width="219" height="17" font="5">3.8% (48/1272), and the 5-year ASCVD </text>
<text top="716" left="546" width="174" height="17" font="5">event rate was 6.1% (78/1272). </text>
<text top="734" left="546" width="3" height="17" font="5"> </text>
<text top="753" left="546" width="217" height="17" font="7"><i>Framingham Health Study CHD model</i>: </text>
<text top="772" left="546" width="208" height="17" font="5">C-statistic original=0.68 (95% CI 0.61-</text>
<text top="472" left="791" width="70" height="17" font="5">Conclusions </text>
<text top="490" left="791" width="346" height="17" font="5">The three models evaluated systematically underestimate CVD </text>
<text top="509" left="791" width="347" height="17" font="5">risk in HIV. Discrimination and calibration were both suboptimal </text>
<text top="528" left="791" width="341" height="17" font="5">when applying the functions to a cohort of largely antiretroviral </text>
<text top="546" left="791" width="236" height="17" font="5">therapy–treated men engaged in HIV care. </text>
<text top="565" left="791" width="3" height="17" font="5"> </text>
<text top="583" left="791" width="320" height="17" font="5">Established CVD risk functions do not provide an accurate </text>
<text top="602" left="791" width="335" height="17" font="5">estimation of risk in the setting of HIV disease and may fail to </text>
<text top="620" left="791" width="334" height="17" font="5">identify patients at elevated CVD risk who would benefit from </text>
<text top="639" left="791" width="143" height="17" font="5">aggressive risk reduction. </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="344" width="189" height="17" font="5">-history of a CVD event before the </text>
<text top="160" left="344" width="108" height="17" font="5">start of observation </text>
<text top="178" left="344" width="176" height="17" font="5">-&lt;30 or &gt;74 years of age for the </text>
<text top="195" left="344" width="184" height="17" font="5">FHS CHD and ASCVD functions, </text>
<text top="212" left="344" width="176" height="17" font="5">and &lt;40 or &gt;79 years of age for </text>
<text top="229" left="344" width="171" height="17" font="5">the ACC/AHA ASCVD function </text>
<text top="247" left="344" width="3" height="17" font="5"> </text>
<text top="143" left="546" width="223" height="17" font="5">0.75), C-statistic HIV=0.73 (95% CI 0.67-</text>
<text top="162" left="546" width="38" height="17" font="5">0.81).  </text>
<text top="180" left="546" width="3" height="17" font="5"> </text>
<text top="198" left="546" width="230" height="17" font="5">For the FHS CHD function, the calibration </text>
<text top="215" left="546" width="154" height="17" font="5">χ2 statistic=13.6 (P=0.019). </text>
<text top="232" left="546" width="3" height="17" font="5"> </text>
<text top="251" left="546" width="3" height="17" font="5"> </text>
<text top="269" left="546" width="202" height="17" font="7"><i>ACC/AHA ASCVD model</i>: C-statistic </text>
<text top="288" left="546" width="198" height="17" font="5">original=0.65 (95% CI 0.59-0.71), C-</text>
<text top="306" left="546" width="207" height="17" font="5">statistic HIV=0.66 (95% CI 0.60-0.73) </text>
<text top="325" left="546" width="3" height="17" font="5"> </text>
<text top="344" left="546" width="230" height="17" font="5">For the ACC/AHA function, the calibration </text>
<text top="362" left="546" width="157" height="17" font="5">χ2 statistic=23.9 (P=0.001).  </text>
<text top="381" left="546" width="3" height="17" font="7"><i> </i></text>
<text top="399" left="546" width="231" height="17" font="7"><i>FHS ASCVD</i>: c-statistic original=0.6 (95% </text>
<text top="418" left="546" width="217" height="17" font="5">CI 0.61-0.73), c-statistic HIV 0.67 (95% </text>
<text top="436" left="546" width="75" height="17" font="5">CI 0.61-0.73) </text>
<text top="455" left="546" width="3" height="17" font="5"> </text>
<text top="472" left="546" width="187" height="17" font="5">For the FHS ASCVD function, the </text>
<text top="489" left="546" width="182" height="17" font="5">calibration χ2= 24.6 (P=0.0004).  </text>
<text top="507" left="546" width="3" height="17" font="5"> </text>
<text top="524" left="546" width="230" height="17" font="5">Observed risk exceeded predicted risk for </text>
<text top="541" left="546" width="228" height="17" font="5">all categories in all three functions except </text>
<text top="558" left="546" width="227" height="17" font="5">for &gt;7.5% predicted risk for the FHS hard </text>
<text top="575" left="546" width="224" height="17" font="5">CHD function (data presented in graphs) </text>
<text top="593" left="546" width="3" height="17" font="5"> </text>
<text top="610" left="546" width="183" height="17" font="5">FHS and ACC/AHA models were </text>
<text top="627" left="546" width="207" height="17" font="5">recalibrated to attempt to improve the </text>
<text top="644" left="546" width="217" height="17" font="5">model fit by using baseline survival and </text>
<text top="661" left="546" width="202" height="17" font="5">mean risk factor values from the HIV </text>
<text top="679" left="546" width="215" height="17" font="5">cohort instead of the FHS or ACC/AHA </text>
<text top="696" left="546" width="189" height="17" font="5">cohorts values. After recalibration, </text>
<text top="713" left="546" width="199" height="17" font="5">goodness of fit remained poor for all </text>
<text top="730" left="546" width="230" height="17" font="5">functions, and model performance did not </text>
<text top="748" left="546" width="206" height="17" font="5">improve (data not shown).  To further </text>
<text top="765" left="546" width="181" height="17" font="5">confirm that each function poorly </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="223" height="17" font="5">discriminated and underestimated risk in </text>
<text top="160" left="546" width="217" height="17" font="5">the HIV cohort, we conducted analyses </text>
<text top="178" left="546" width="187" height="17" font="5">stratified by race and showed that </text>
<text top="195" left="546" width="212" height="17" font="5">discrimination remained moderate and </text>
<text top="212" left="546" width="142" height="17" font="5">calibration remained poor </text>
<text top="229" left="546" width="3" height="17" font="5"> </text>
<text top="247" left="546" width="215" height="17" font="5">-generated a new model (HIV function) </text>
<text top="265" left="546" width="195" height="17" font="5">among men and women combined, </text>
<text top="284" left="546" width="230" height="17" font="5">including significant interaction terms with </text>
<text top="302" left="546" width="127" height="17" font="5">sex for each risk factor </text>
<text top="334" left="75" width="113" height="17" font="5">Volgman, AS. Et al., </text>
<text top="352" left="75" width="31" height="17" font="5">2018 </text>
<text top="371" left="75" width="3" height="17" font="5"> </text>
<text top="389" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29794080">29794080</a></text>
<text top="389" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29794080"> </a></text>
<text top="334" left="205" width="59" height="17" font="5">Study Aim </text>
<text top="352" left="205" width="81" height="17" font="5">To summarize </text>
<text top="369" left="205" width="68" height="17" font="5">literature on </text>
<text top="387" left="205" width="104" height="17" font="5">demographics and </text>
<text top="404" left="205" width="78" height="17" font="5">biological and </text>
<text top="421" left="205" width="75" height="17" font="5">nonbiological </text>
<text top="438" left="205" width="72" height="17" font="5">mechanisms </text>
<text top="455" left="205" width="122" height="17" font="5">contributing to excess </text>
<text top="473" left="205" width="86" height="17" font="5">ASCVD, health </text>
<text top="490" left="205" width="84" height="17" font="5">behaviors, and </text>
<text top="507" left="205" width="121" height="17" font="5">interventions in South </text>
<text top="524" left="205" width="40" height="17" font="5">Asians </text>
<text top="541" left="205" width="3" height="17" font="5"> </text>
<text top="559" left="205" width="62" height="17" font="5">Study type </text>
<text top="576" left="205" width="107" height="17" font="5">Narrative summary </text>
<text top="593" left="205" width="3" height="17" font="5"> </text>
<text top="610" left="205" width="39" height="17" font="5">N=N/a </text>
<text top="334" left="344" width="92" height="17" font="5">Inclusion criteria </text>
<text top="352" left="344" width="148" height="17" font="5">-English-language studies  </text>
<text top="369" left="344" width="135" height="17" font="5">- Inductive methods and </text>
<text top="388" left="344" width="175" height="17" font="5">descriptive studies that focused </text>
<text top="407" left="344" width="178" height="17" font="5">on ASCVD outcomes incidence, </text>
<text top="425" left="344" width="180" height="17" font="5">prevalence, treatment response, </text>
<text top="444" left="344" width="56" height="17" font="5">and risks  </text>
<text top="335" left="549" width="7" height="17" font="5">1</text>
<text top="334" left="556" width="67" height="18" font="5"> endpoint:  </text>
<text top="353" left="546" width="232" height="17" font="5">None specified, no quantitative outcomes  </text>
<text top="372" left="546" width="3" height="17" font="5"> </text>
<text top="391" left="546" width="3" height="17" font="5"> </text>
<text top="334" left="791" width="116" height="17" font="5">Authors’ conclusions </text>
<text top="352" left="791" width="341" height="17" font="5">-A majority of the risk in South Asians can be explained by the </text>
<text top="369" left="791" width="330" height="17" font="5">increased prevalence of known risk factors, especially those </text>
<text top="387" left="791" width="335" height="17" font="5">related to insulin resistance, and no unique risk factors in this </text>
<text top="404" left="791" width="159" height="17" font="5">population have been found  </text>
<text top="421" left="791" width="3" height="17" font="5"> </text>
<text top="438" left="791" width="325" height="17" font="5">-Although several population-specific risk assessment tools </text>
<text top="455" left="791" width="335" height="17" font="5">exist, none of the currently available models are derived from </text>
<text top="473" left="791" width="255" height="17" font="5">or prospectively validated in US South Asians. </text>
<text top="490" left="791" width="3" height="17" font="5"> </text>
<text top="507" left="791" width="311" height="17" font="5">Risk calculators underestimate CVD risk in South Asians </text>
<text top="526" left="791" width="332" height="17" font="5">because they have not been derived from or validated in this </text>
<text top="544" left="791" width="96" height="17" font="5">higher-risk group </text>
<text top="642" left="66" width="3" height="17" font="5"> </text>
<text top="672" left="66" width="426" height="21" font="4"><b>Data Supplement 4. RCTs of Nutrition and Diet (Section 3.1.) </b></text>
<text top="694" left="104" width="38" height="17" font="3"><b>Study </b></text>
<text top="711" left="92" width="61" height="17" font="3"><b>Acronym; </b></text>
<text top="728" left="99" width="48" height="17" font="3"><b>Author; </b></text>
<text top="745" left="77" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="694" left="198" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="711" left="203" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="728" left="197" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="694" left="346" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="694" left="524" width="126" height="17" font="3"><b>Study Intervention (# </b></text>
<text top="711" left="557" width="62" height="17" font="3"><b>patients) / </b></text>
<text top="728" left="525" width="125" height="17" font="3"><b>Study Comparator (# </b></text>
<text top="745" left="560" width="55" height="17" font="3"><b>patients) </b></text>
<text top="694" left="741" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="711" left="681" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="728" left="751" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="695" left="940" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="694" left="1005" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="712" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="729" left="982" width="96" height="17" font="3"><b>Adverse Events </b></text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="68" height="17" font="5">PREDIMED </text>
<text top="108" left="75" width="3" height="17" font="5"> </text>
<text top="125" left="75" width="79" height="17" font="5">Estruch, 2018 </text>
<text top="142" left="75" width="96" height="17" font="5">(re-analysis) (13) </text>
<text top="160" left="75" width="3" height="17" font="5"> </text>
<text top="177" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29897866">29897866</a></text>
<text top="177" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29897866"> </a></text>
<text top="91" left="184" width="31" height="17" font="5">Aim:  </text>
<text top="108" left="184" width="3" height="17" font="5"> </text>
<text top="125" left="184" width="72" height="17" font="5">Randomized </text>
<text top="142" left="184" width="80" height="17" font="5">controlled trial </text>
<text top="160" left="184" width="3" height="17" font="5"> </text>
<text top="177" left="184" width="50" height="17" font="5">N=7,447 </text>
<text top="91" left="308" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="108" left="308" width="170" height="17" font="5">Men 55 to 80 years of age and </text>
<text top="125" left="308" width="162" height="17" font="5">women 60 to 80 years of age </text>
<text top="142" left="308" width="185" height="17" font="5">with type 2 diabetes mellitus or at </text>
<text top="160" left="308" width="180" height="17" font="5">least three risk factors (smoking, </text>
<text top="177" left="308" width="153" height="17" font="5">hypertension, elevated LDL </text>
<text top="194" left="308" width="182" height="17" font="5">cholesterol, low HDL cholesterol, </text>
<text top="211" left="308" width="173" height="17" font="5">overweight or obesity, or family </text>
<text top="229" left="308" width="164" height="17" font="5">history of premature coronary </text>
<text top="246" left="308" width="77" height="17" font="5">heart disease </text>
<text top="91" left="508" width="68" height="17" font="5">Intervention </text>
<text top="108" left="508" width="153" height="17" font="5">Mediterranean diet training, </text>
<text top="125" left="508" width="137" height="17" font="5">supplemented with extra-</text>
<text top="142" left="508" width="158" height="17" font="5">virgin olive oil (~1 liter/week) </text>
<text top="160" left="508" width="118" height="17" font="5">or 30 g of mixed nuts </text>
<text top="177" left="508" width="3" height="17" font="5"> </text>
<text top="194" left="508" width="106" height="17" font="5">Mediterranean diet </text>
<text top="211" left="508" width="131" height="17" font="5">recommendations were </text>
<text top="229" left="508" width="155" height="17" font="5">olive oil (&gt;=4 tbsp/day), tree </text>
<text top="246" left="508" width="126" height="17" font="5">nuts and peanuts (&gt;=3 </text>
<text top="263" left="508" width="136" height="17" font="5">servings/wk), fresh fruits </text>
<text top="280" left="508" width="109" height="17" font="5">(&gt;=3 servings/day), </text>
<text top="297" left="508" width="92" height="17" font="5">vegetables (&gt;=2 </text>
<text top="315" left="508" width="149" height="17" font="5">servings/day), fish/seafood </text>
<text top="332" left="508" width="154" height="17" font="5">(&gt;=3 servings/wk), legumes </text>
<text top="349" left="508" width="141" height="17" font="5">(&gt;=3 servings/wk), sofrito </text>
<text top="366" left="508" width="136" height="17" font="5">(&gt;=2 servings/wk), white </text>
<text top="383" left="508" width="151" height="17" font="5">meat (instead of red meat), </text>
<text top="401" left="508" width="144" height="17" font="5">wine with meals (optional, </text>
<text top="418" left="508" width="92" height="17" font="5">&gt;=7 glasses/wk) </text>
<text top="435" left="508" width="147" height="17" font="5">Discouraged: Soda drinks, </text>
<text top="452" left="508" width="147" height="17" font="5">commercial bakery goods, </text>
<text top="469" left="508" width="119" height="17" font="5">sweets, and pastries, </text>
<text top="487" left="508" width="137" height="17" font="5">spread fats, and red and </text>
<text top="504" left="508" width="97" height="17" font="5">processed meats </text>
<text top="521" left="508" width="3" height="17" font="5"> </text>
<text top="538" left="508" width="68" height="17" font="5">Comparator </text>
<text top="556" left="508" width="3" height="17" font="5"> </text>
<text top="573" left="508" width="111" height="17" font="5">Low-fat diet training </text>
<text top="590" left="508" width="3" height="17" font="5"> </text>
<text top="607" left="508" width="135" height="17" font="5">Low-fat dietary products </text>
<text top="624" left="508" width="109" height="17" font="5">(&gt;=3 servings/day), </text>
<text top="642" left="508" width="142" height="17" font="5">bread/potatoes/pasta/rice </text>
<text top="659" left="508" width="139" height="17" font="5">(&gt;=3 servings/day), fresh </text>
<text top="676" left="508" width="139" height="17" font="5">fruits (&gt;=3 servings/day), </text>
<text top="693" left="508" width="92" height="17" font="5">vegetables (&gt;=2 </text>
<text top="710" left="508" width="106" height="17" font="5">servings/day), lean </text>
<text top="728" left="508" width="98" height="17" font="5">fish/seafood (&gt;=3 </text>
<text top="745" left="508" width="72" height="17" font="5">servings/wk) </text>
<text top="92" left="680" width="7" height="17" font="5">1</text>
<text top="91" left="687" width="64" height="18" font="5"> endpoint: </text>
<text top="109" left="680" width="224" height="17" font="5">CV death, nonfatal MI, or nonfatal stroke </text>
<text top="126" left="680" width="3" height="17" font="5"> </text>
<text top="144" left="680" width="210" height="17" font="5">A: Mediterranean diet with extra virgin </text>
<text top="161" left="680" width="139" height="17" font="5">olive oil: 3.8% (96/2,543) </text>
<text top="178" left="680" width="208" height="17" font="5">B: Mediterranean diet with nuts: 3.4% </text>
<text top="195" left="680" width="60" height="17" font="5">(83/2,454) </text>
<text top="212" left="680" width="184" height="17" font="5">C: Low-fat diet: 4.4% (109/2,450) </text>
<text top="230" left="680" width="3" height="17" font="5"> </text>
<text top="247" left="680" width="76" height="17" font="5">Adjusted HR  </text>
<text top="264" left="680" width="194" height="17" font="5">A vs. C: 0.69 (95% CI 0.53 to 0.91) </text>
<text top="281" left="680" width="194" height="17" font="5">B vs. C: 0.72 (95% CI 0.54 to 0.95) </text>
<text top="299" left="680" width="220" height="17" font="5">A or B vs. C: 0.70 (95% CI 0.55 to 0.89) </text>
<text top="316" left="680" width="3" height="17" font="5"> </text>
<text top="333" left="680" width="219" height="17" font="5">[Annual cardiovascular event risk (%) in </text>
<text top="350" left="680" width="211" height="17" font="5">placebo arm: 1.12 (CV death, nonfatal </text>
<text top="367" left="680" width="127" height="17" font="5">MI, or nonfatal stroke)] </text>
<text top="385" left="680" width="3" height="17" font="5"> </text>
<text top="402" left="680" width="57" height="17" font="5">CV Death </text>
<text top="419" left="680" width="210" height="17" font="5">A: Mediterranean diet with extra virgin </text>
<text top="436" left="680" width="139" height="17" font="5">olive oil: 1.0% (26/2,543) </text>
<text top="453" left="680" width="208" height="17" font="5">B: Mediterranean diet with nuts: 1.3% </text>
<text top="471" left="680" width="60" height="17" font="5">(31/2,454) </text>
<text top="488" left="680" width="177" height="17" font="5">C: Low-fat diet: 1.2% (30/2,450) </text>
<text top="505" left="680" width="3" height="17" font="5"> </text>
<text top="522" left="680" width="73" height="17" font="5">Adjusted HR </text>
<text top="539" left="680" width="194" height="17" font="5">A vs. C: 0.62 (95% CI 0.36 to 1.06) </text>
<text top="557" left="680" width="194" height="17" font="5">B vs. C: 1.02 (95% CI 0.63 to 1.67) </text>
<text top="574" left="680" width="220" height="17" font="5">A or B vs. C: 0.80 (95% CI 0.51 to 1.24) </text>
<text top="591" left="680" width="3" height="17" font="5"> </text>
<text top="608" left="680" width="39" height="17" font="5">Stroke </text>
<text top="626" left="680" width="210" height="17" font="5">A: Mediterranean diet with extra virgin </text>
<text top="643" left="680" width="139" height="17" font="5">olive oil: 1.9% (49/2,543) </text>
<text top="660" left="680" width="208" height="17" font="5">B: Mediterranean diet with nuts: 1.3% </text>
<text top="677" left="680" width="60" height="17" font="5">(32/2,454) </text>
<text top="694" left="680" width="177" height="17" font="5">C: Low-fat diet: 2.4% (58/2,450) </text>
<text top="712" left="680" width="3" height="17" font="5"> </text>
<text top="729" left="680" width="73" height="17" font="5">Adjusted HR </text>
<text top="746" left="680" width="194" height="17" font="5">A vs. C: 0.65 (95% CI 0.44 to 0.95) </text>
<text top="763" left="680" width="194" height="17" font="5">B vs. C: 0.54 (95% CI 0.35 to 0.82) </text>
<text top="92" left="920" width="7" height="17" font="5">2</text>
<text top="91" left="926" width="66" height="18" font="5"> endpoints </text>
<text top="109" left="920" width="3" height="17" font="5"> </text>
<text top="126" left="920" width="63" height="17" font="5">Adherence </text>
<text top="144" left="920" width="211" height="17" font="5">Score for adherence to Mediterranean </text>
<text top="161" left="920" width="218" height="17" font="5">diet ~10.5 to 11 from year 1 to year 6 in </text>
<text top="178" left="920" width="212" height="17" font="5">Mediterranean diet groups and ~8.8 to </text>
<text top="195" left="920" width="131" height="17" font="5">9.3 in low-fat diet group </text>
<text top="212" left="920" width="3" height="17" font="5"> </text>
<text top="230" left="920" width="107" height="17" font="5">All-Cause Mortality </text>
<text top="247" left="920" width="210" height="17" font="5">A: Mediterranean diet with extra virgin </text>
<text top="264" left="920" width="146" height="17" font="5">olive oil: 4.6% (118/2,543) </text>
<text top="281" left="920" width="208" height="17" font="5">B: Mediterranean diet with nuts: 4.7% </text>
<text top="299" left="920" width="66" height="17" font="5">(116/2,454) </text>
<text top="316" left="920" width="184" height="17" font="5">C: Low-fat diet: 4.7% (114/2,450) </text>
<text top="333" left="920" width="3" height="17" font="5"> </text>
<text top="350" left="920" width="73" height="17" font="5">Adjusted HR </text>
<text top="367" left="920" width="194" height="17" font="5">A vs. C: 0.90 (95% CI 0.69 to 1.18) </text>
<text top="385" left="920" width="194" height="17" font="5">B vs. C: 1.12 (95% CI 0.86 to 1.47) </text>
<text top="402" left="920" width="189" height="17" font="5">A or B vs. C: 0.98 (95% CI 0.77 to </text>
<text top="419" left="920" width="31" height="17" font="5">1.24) </text>
<text top="436" left="920" width="3" height="17" font="5"> </text>
<text top="453" left="920" width="114" height="17" font="5">Fatal or non-fatal MI </text>
<text top="471" left="920" width="210" height="17" font="5">A: Mediterranean diet with extra virgin </text>
<text top="488" left="920" width="139" height="17" font="5">olive oil: 1.5% (37/2,543) </text>
<text top="505" left="920" width="208" height="17" font="5">B: Mediterranean diet with nuts: 1.3% </text>
<text top="522" left="920" width="60" height="17" font="5">(31/2,454) </text>
<text top="539" left="920" width="177" height="17" font="5">C: Low-fat diet: 1.6% (38/2,450) </text>
<text top="557" left="920" width="3" height="17" font="5"> </text>
<text top="574" left="920" width="73" height="17" font="5">Adjusted HR </text>
<text top="591" left="920" width="194" height="17" font="5">A vs. C: 0.82 (95% CI 0.52 to 1.30) </text>
<text top="608" left="920" width="194" height="17" font="5">B vs. C: 0.76 (95% CI 0.47 to 1.25) </text>
<text top="626" left="920" width="189" height="17" font="5">A or B vs. C: 0.80 (95% CI 0.51 to </text>
<text top="643" left="920" width="31" height="17" font="5">1.24) </text>
<text top="660" left="920" width="3" height="17" font="5"> </text>
<text top="677" left="920" width="63" height="17" font="5">Comments </text>
<text top="694" left="920" width="192" height="17" font="5">Re-analysis due to deviations from </text>
<text top="712" left="920" width="190" height="17" font="5">randomization protocol in ~20% of </text>
<text top="729" left="920" width="204" height="17" font="5">sample. Model stratified according to </text>
<text top="746" left="920" width="196" height="17" font="5">sex, recruiting site, and educational </text>
<text top="763" left="920" width="200" height="17" font="5">level, and adjusted for age, smoking </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="508" width="156" height="17" font="5">Discouraged: Vegetable oils </text>
<text top="108" left="508" width="108" height="17" font="5">(including olive oil), </text>
<text top="125" left="508" width="106" height="17" font="5">commercial bakery </text>
<text top="142" left="508" width="128" height="17" font="5">goods/sweets/pastries, </text>
<text top="160" left="508" width="99" height="17" font="5">nuts/fried snacks, </text>
<text top="177" left="508" width="159" height="17" font="5">red/processed meats, visible </text>
<text top="194" left="508" width="157" height="17" font="5">fat in meats and soups, fatty </text>
<text top="211" left="508" width="145" height="17" font="5">fish/seafood canned in oil, </text>
<text top="229" left="508" width="105" height="17" font="5">spread fats, sofrito </text>
<text top="91" left="680" width="220" height="17" font="5">A or B vs. C: 0.58 (95% CI 0.42 to 0.82) </text>
<text top="91" left="920" width="208" height="17" font="5">status, HTN, dyslipidemia, DM, family </text>
<text top="108" left="920" width="211" height="17" font="5">history of premature CHD&lt; BMI, waist-</text>
<text top="125" left="920" width="198" height="17" font="5">to-height ratio, physical activity, and </text>
<text top="142" left="920" width="169" height="17" font="5">propensity score (based on 30 </text>
<text top="160" left="920" width="176" height="17" font="5">variables) for intervention group </text>
<text top="177" left="920" width="182" height="17" font="5">assignment. Adherence adjusted </text>
<text top="194" left="920" width="199" height="17" font="5">estimated for Mediterranean diet vs. </text>
<text top="211" left="920" width="203" height="17" font="5">control diet on primary outcome 0.42 </text>
<text top="229" left="920" width="173" height="17" font="5">(95% CI 0.24 to 0.63); absolute </text>
<text top="246" left="920" width="176" height="17" font="5">differences 0.67, 1.38, and 2.00 </text>
<text top="263" left="920" width="197" height="17" font="5">percentage points at 12, 24, and 36 </text>
<text top="280" left="920" width="119" height="17" font="5">months, respectively. </text>
<text top="298" left="75" width="47" height="17" font="5">Trials of </text>
<text top="315" left="75" width="76" height="17" font="5">Hypertension </text>
<text top="333" left="75" width="89" height="17" font="5">Prevention long-</text>
<text top="350" left="75" width="81" height="17" font="5">term follow-up </text>
<text top="367" left="75" width="3" height="17" font="5"> </text>
<text top="384" left="75" width="66" height="17" font="5">Cook, 2007 </text>
<text top="401" left="75" width="3" height="17" font="5"> </text>
<text top="419" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17449506">17449506</a></text>
<text top="419" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17449506"> </a></text>
<text top="298" left="184" width="104" height="17" font="5">Aim: to investigate </text>
<text top="315" left="184" width="108" height="17" font="5">long term effects of </text>
<text top="333" left="184" width="83" height="17" font="5">dietary sodium </text>
<text top="350" left="184" width="71" height="17" font="5">reduction on </text>
<text top="367" left="184" width="83" height="17" font="5">cardiovascular </text>
<text top="384" left="184" width="103" height="17" font="5">disease outcomes </text>
<text top="401" left="184" width="3" height="17" font="5"> </text>
<text top="419" left="184" width="110" height="17" font="5">Study type: 2 RCTs </text>
<text top="436" left="184" width="81" height="17" font="5">with long-term </text>
<text top="453" left="184" width="81" height="17" font="5">follow-up after </text>
<text top="470" left="184" width="96" height="17" font="5">study completion </text>
<text top="487" left="184" width="3" height="17" font="5"> </text>
<text top="505" left="184" width="106" height="17" font="5">N=2,415 long-term </text>
<text top="522" left="184" width="53" height="17" font="5">follow-up </text>
<text top="298" left="308" width="171" height="17" font="5">Inclusion criteria: TOHP I: Men </text>
<text top="315" left="308" width="162" height="17" font="5">and women 30 to 54 years of </text>
<text top="333" left="308" width="168" height="17" font="5">age, mean DBP 80-89 mm Hg </text>
<text top="350" left="308" width="3" height="17" font="5"> </text>
<text top="367" left="308" width="176" height="17" font="5">TOHP II: Men and women 30 to </text>
<text top="384" left="308" width="165" height="17" font="5">54 years of age, 110-165% of </text>
<text top="401" left="308" width="183" height="17" font="5">desirable weight, and DBP 83-89 </text>
<text top="419" left="308" width="126" height="17" font="5">and SBP &lt;140 mm Hg </text>
<text top="298" left="508" width="143" height="17" font="5">Intervention: Low salt diet </text>
<text top="315" left="508" width="133" height="17" font="5">counseling, goal urinary </text>
<text top="333" left="508" width="147" height="17" font="5">sodium excretion 80 mmol </text>
<text top="350" left="508" width="111" height="17" font="5">(1800 mg)/24 hours </text>
<text top="367" left="508" width="3" height="17" font="5"> </text>
<text top="384" left="508" width="134" height="17" font="5">Comparator: Usual care </text>
<text top="299" left="680" width="7" height="17" font="5">1</text>
<text top="298" left="687" width="204" height="18" font="5"> endpoint: CV death, nonfatal MI, or </text>
<text top="318" left="680" width="96" height="17" font="5">revascularization </text>
<text top="349" left="680" width="165" height="17" font="5">CV death: Low salt diet: 0.7% </text>
<text top="367" left="680" width="223" height="17" font="5">(10/1,518). Usual care: 0.9% (15/1,608). </text>
<text top="386" left="680" width="224" height="17" font="5">Adjusted HR: 0.62 (95% CI 0.28 to 1.40) </text>
<text top="416" left="680" width="141" height="17" font="5">Nonfatal MI: Not reported </text>
<text top="299" left="920" width="7" height="17" font="5">2</text>
<text top="298" left="926" width="67" height="18" font="5"> endpoint:  </text>
<text top="317" left="920" width="214" height="17" font="5">All-cause mortality: Low salt diet: 2.3% </text>
<text top="334" left="920" width="60" height="17" font="5">(35/1,518) </text>
<text top="351" left="920" width="157" height="17" font="5">Usual care: 2.6% (42/1,608) </text>
<text top="368" left="920" width="192" height="17" font="5">Adjusted HR: 0.80 (95% CI 0.51 to </text>
<text top="385" left="920" width="31" height="17" font="5">1.26) </text>
<text top="540" left="75" width="67" height="17" font="5">Sacks et al, </text>
<text top="557" left="75" width="31" height="17" font="5">2001 </text>
<text top="574" left="75" width="3" height="17" font="5"> </text>
<text top="591" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11136953">11136953</a></text>
<text top="591" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/11136953"> </a></text>
<text top="540" left="184" width="104" height="17" font="5">Aim: to investigate </text>
<text top="557" left="184" width="106" height="17" font="5">the extent to which </text>
<text top="574" left="184" width="109" height="17" font="5">the reduction of the </text>
<text top="591" left="184" width="108" height="17" font="5">sodium level, in the </text>
<text top="609" left="184" width="105" height="17" font="5">context of a typical </text>
<text top="626" left="184" width="100" height="17" font="5">United States diet </text>
<text top="643" left="184" width="106" height="17" font="5">and in combination </text>
<text top="660" left="184" width="110" height="17" font="5">with the DASH diet, </text>
<text top="678" left="184" width="72" height="17" font="5">lowers blood </text>
<text top="695" left="184" width="51" height="17" font="5">pressure </text>
<text top="712" left="184" width="3" height="17" font="5"> </text>
<text top="729" left="184" width="97" height="17" font="5">Study type:  RCT </text>
<text top="746" left="184" width="3" height="17" font="5"> </text>
<text top="764" left="184" width="43" height="17" font="5">N=412  </text>
<text top="540" left="308" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="557" left="306" width="105" height="18" font="5">•  Age 22 or older </text>
<text top="575" left="306" width="157" height="18" font="5">•  Average systolic BP on 3 </text>
<text top="594" left="307" width="174" height="17" font="5">screening visits of 120-159 mm </text>
<text top="611" left="307" width="19" height="17" font="5">Hg </text>
<text top="628" left="306" width="169" height="18" font="5">•  Average diastolic BP 80-95 </text>
<text top="646" left="307" width="46" height="17" font="5">mm Hg  </text>
<text top="663" left="308" width="3" height="17" font="5"> </text>
<text top="681" left="308" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="698" left="306" width="97" height="18" font="5">•  Heart disease </text>
<text top="716" left="306" width="123" height="18" font="5">•  Renal insufficiency </text>
<text top="734" left="306" width="112" height="18" font="5">•  Poorly controlled </text>
<text top="753" left="307" width="147" height="17" font="5">hyperlipidemia or diabetes </text>
<text top="770" left="306" width="159" height="18" font="5">•  Diabetes requiring insulin </text>
<text top="540" left="508" width="75" height="17" font="5">Intervention:  </text>
<text top="557" left="508" width="43" height="17" font="5">2 diets: </text>
<text top="574" left="508" width="3" height="17" font="5"> </text>
<text top="591" left="508" width="140" height="17" font="5">Control (typical American </text>
<text top="609" left="508" width="76" height="17" font="5">diet) (N=204) </text>
<text top="626" left="508" width="3" height="17" font="5"> </text>
<text top="643" left="508" width="109" height="17" font="5">DASH diet (N=208) </text>
<text top="660" left="508" width="3" height="17" font="5"> </text>
<text top="678" left="508" width="159" height="17" font="5">Participants provided with all </text>
<text top="695" left="508" width="158" height="17" font="5">food, energy intake adjusted </text>
<text top="712" left="508" width="148" height="17" font="5">to ensure weight remained </text>
<text top="729" left="508" width="50" height="17" font="5">constant </text>
<text top="746" left="508" width="3" height="17" font="5"> </text>
<text top="541" left="680" width="7" height="17" font="5">1</text>
<text top="540" left="687" width="206" height="18" font="5"> endpoint: systolic blood pressure at </text>
<text top="560" left="680" width="146" height="17" font="5">end of each 30 day period </text>
<text top="590" left="680" width="134" height="17" font="5">Systolic blood pressure: </text>
<text top="621" left="680" width="193" height="17" font="5">Significant interaction between diet </text>
<text top="640" left="680" width="215" height="17" font="5">group and sodium level (p&lt;0.001), with </text>
<text top="658" left="680" width="219" height="17" font="5">nearly twice the effect of dietary sodium </text>
<text top="677" left="680" width="220" height="17" font="5">on blood pressure in control than DASH </text>
<text top="695" left="680" width="185" height="17" font="5">diet. Control diet+high sodium vs. </text>
<text top="714" left="680" width="113" height="17" font="5">DASH+low sodium= </text>
<text top="732" left="680" width="220" height="17" font="5">-11.5 mm Hg in those with hypertension </text>
<text top="751" left="680" width="172" height="17" font="5">vs -7.1 mm Hg in those without </text>
<text top="770" left="680" width="225" height="17" font="5">hypertension (p=0.004), and -6.8 mm Hg </text>
<text top="541" left="920" width="7" height="17" font="5">2</text>
<text top="540" left="926" width="67" height="18" font="5"> endpoint:  </text>
<text top="558" left="920" width="135" height="17" font="5">Diastolic blood pressure </text>
<text top="575" left="920" width="3" height="17" font="5"> </text>
<text top="593" left="920" width="199" height="17" font="5">Diastolic blood pressure  decreased </text>
<text top="610" left="920" width="215" height="17" font="5">between High and Intermediate dietary </text>
<text top="627" left="920" width="191" height="17" font="5">sodium periods in both the Control </text>
<text top="644" left="920" width="202" height="17" font="5">group (-1.1; 95% CI -1.9 to -0.2) and </text>
<text top="661" left="920" width="217" height="17" font="5">the DASH diet group (-2.5; 95% CI -4.1 </text>
<text top="679" left="920" width="211" height="17" font="5">to  -0.8, and between the Intermediate </text>
<text top="696" left="920" width="217" height="17" font="5">and Low dietary sodium periods in both </text>
<text top="713" left="920" width="213" height="17" font="5">the Control group (-2.4; 95% CI -3.3 to </text>
<text top="730" left="920" width="201" height="17" font="5">-1.5) and the DASH diet group (-1.0; </text>
<text top="748" left="920" width="114" height="17" font="5">95% CI -1.9 to 0.1).  </text>
<text top="765" left="920" width="3" height="17" font="5"> </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="306" width="176" height="18" font="5">•  Special dietary requirements </text>
<text top="109" left="306" width="129" height="18" font="5">•  Intake &gt;14 alcoholic </text>
<text top="127" left="307" width="68" height="17" font="5">drinks/week </text>
<text top="144" left="306" width="183" height="18" font="5">•  Use of antihypertensive drugs </text>
<text top="163" left="307" width="168" height="17" font="5">or other mediations that would </text>
<text top="180" left="307" width="177" height="17" font="5">affect blood pressure or nutrient </text>
<text top="197" left="307" width="66" height="17" font="5">metabolism </text>
<text top="91" left="508" width="105" height="17" font="5">Within diet groups, </text>
<text top="108" left="508" width="144" height="17" font="5">participants ate at each of </text>
<text top="125" left="508" width="144" height="17" font="5">three sodium levels for 30 </text>
<text top="142" left="508" width="156" height="17" font="5">consecutive days in random </text>
<text top="160" left="508" width="36" height="17" font="5">order: </text>
<text top="177" left="508" width="3" height="17" font="5"> </text>
<text top="194" left="508" width="135" height="17" font="5">High sodium (target 150 </text>
<text top="211" left="508" width="144" height="17" font="5">mmol per day with energy </text>
<text top="229" left="508" width="110" height="17" font="5">intake of 2100 kcal) </text>
<text top="246" left="508" width="3" height="17" font="5"> </text>
<text top="263" left="508" width="148" height="17" font="5">Intermediate (target of 100 </text>
<text top="280" left="508" width="82" height="17" font="5">mmol per day) </text>
<text top="297" left="508" width="3" height="17" font="5"> </text>
<text top="315" left="508" width="157" height="17" font="5">Low (target of 50 mmol/day) </text>
<text top="332" left="508" width="3" height="17" font="5"> </text>
<text top="349" left="508" width="3" height="17" font="5"> </text>
<text top="366" left="508" width="107" height="17" font="5">Comparator: Usual </text>
<text top="91" left="680" width="190" height="17" font="5">in men vs. -10.5 mm Hg in women </text>
<text top="109" left="680" width="49" height="17" font="5">(p=0.02) </text>
<text top="140" left="680" width="127" height="17" font="7"><i>Effect of Sodium Level </i></text>
<text top="171" left="680" width="191" height="17" font="5">SBP<i> </i>decreased between High and </text>
<text top="189" left="680" width="212" height="17" font="5">Intermediate dietary sodium periods in </text>
<text top="208" left="680" width="226" height="17" font="5">both the Control group (-2.1; 95% CI -3.4 </text>
<text top="226" left="680" width="215" height="17" font="5">to -0.8) and the DASH diet group (-1.3; </text>
<text top="245" left="680" width="204" height="17" font="5">95% CI -2.6 to 0.0), and between the </text>
<text top="263" left="680" width="205" height="17" font="5">Intermediate and Low dietary sodium </text>
<text top="282" left="680" width="215" height="17" font="5">periods in both the Control group (-4.6; </text>
<text top="301" left="680" width="216" height="17" font="5">95% CI -5.9 to -3.2) and the DASH diet </text>
<text top="319" left="680" width="185" height="17" font="5">group (-1.7; 95% CI -3.0 to -0.4).  </text>
<text top="350" left="680" width="212" height="17" font="5">Effects of sodium greater in those with </text>
<text top="368" left="680" width="196" height="17" font="5">hypertension (interaction p=0.01 on </text>
<text top="387" left="680" width="211" height="17" font="5">control diet, p-0.003 on DASH diet), in </text>
<text top="405" left="680" width="226" height="17" font="5">Blacks on control diet than those of other </text>
<text top="424" left="680" width="178" height="17" font="5">races on control diet (interaction </text>
<text top="443" left="680" width="218" height="17" font="5">p=0.007), and in women on DASH than </text>
<text top="461" left="680" width="192" height="17" font="5">men on DASH (interaction p=0.04) </text>
<text top="492" left="680" width="172" height="17" font="7"><i>Effect of Control vs. DASH diet </i></text>
<text top="522" left="680" width="221" height="17" font="5">High Sodium Level: -5.9 (95% CI -8.0 to </text>
<text top="541" left="680" width="29" height="17" font="5">-3.7) </text>
<text top="571" left="680" width="225" height="17" font="5">Intermediate Sodium Level: -5.0 (95% CI </text>
<text top="590" left="680" width="70" height="17" font="5">-7.6 to -2.5)  </text>
<text top="621" left="680" width="218" height="17" font="5">Low Sodium level: -2.2 (95% CI -4.4 to -</text>
<text top="639" left="680" width="25" height="17" font="5">0.1) </text>
<text top="91" left="920" width="123" height="17" font="5">Control vs. DASH diet </text>
<text top="108" left="920" width="3" height="17" font="5"> </text>
<text top="125" left="920" width="207" height="17" font="5">High Sodium Level: -2.9 (95% CI -4.3 </text>
<text top="142" left="920" width="42" height="17" font="5">to -1.5) </text>
<text top="160" left="920" width="3" height="17" font="5"> </text>
<text top="177" left="920" width="210" height="17" font="5">Intermediate Sodium Level: -2.5 (95% </text>
<text top="194" left="920" width="83" height="17" font="5">CI -4.1 to -0.8) </text>
<text top="211" left="920" width="3" height="17" font="5"> </text>
<text top="229" left="920" width="218" height="17" font="5">Low Sodium Level: -1.0 (95% CI -2.5 to </text>
<text top="246" left="920" width="25" height="17" font="5">0.4) </text>
<text top="263" left="920" width="3" height="17" font="5"> </text>
<text top="280" left="920" width="88" height="17" font="5">Adverse events </text>
<text top="297" left="920" width="219" height="17" font="5">Headache: 47% during the high sodium </text>
<text top="315" left="920" width="204" height="17" font="5">phase of the control diet, 39% during </text>
<text top="332" left="920" width="204" height="17" font="5">low-sodium phase of the control diet, </text>
<text top="349" left="920" width="202" height="17" font="5">36% during the low-sodium phase of </text>
<text top="366" left="920" width="58" height="17" font="5">the DASH </text>
<text top="383" left="920" width="213" height="17" font="5">diet (P&lt;0.05 for both comparisons with </text>
<text top="401" left="920" width="209" height="17" font="5">the high-sodium phase of control diet) </text>
<text top="418" left="920" width="3" height="17" font="5"> </text>
<text top="435" left="920" width="197" height="17" font="5">Number not completing intervention </text>
<text top="452" left="920" width="204" height="17" font="5">period similar during all three sodium </text>
<text top="469" left="920" width="35" height="17" font="5">levels </text>
<text top="671" left="66" width="3" height="17" font="5"> </text>
<text top="710" left="59" width="835" height="21" font="4"><b>Data Supplement 5. Nonrandomized Trials, Observational Studies, and/or Registries of Nutrition and Diet (Section 3.1.) </b></text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="98" height="17" font="5">Intake of trans fat </text>
<text top="160" left="75" width="76" height="17" font="5">and all-cause </text>
<text top="178" left="75" width="83" height="17" font="5">mortality in the </text>
<text top="195" left="75" width="70" height="17" font="5">Reasons for </text>
<text top="212" left="75" width="100" height="17" font="5">Geographical and </text>
<text top="229" left="75" width="103" height="17" font="5">Racial Differences </text>
<text top="247" left="75" width="52" height="17" font="5">in Stroke </text>
<text top="264" left="75" width="72" height="17" font="5">(REGARDS) </text>
<text top="281" left="75" width="38" height="17" font="5">cohort </text>
<text top="298" left="75" width="3" height="17" font="5"> </text>
<text top="315" left="75" width="94" height="17" font="5">Kiage, 2013 (14) </text>
<text top="333" left="75" width="3" height="17" font="5"> </text>
<text top="350" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23553155">23553155</a></text>
<text top="350" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23553155"> </a></text>
<text top="143" left="193" width="105" height="17" font="5">Study type: Cohort </text>
<text top="160" left="193" width="33" height="17" font="5">study </text>
<text top="178" left="193" width="3" height="17" font="5"> </text>
<text top="195" left="193" width="57" height="17" font="5">N=18,513 </text>
<text top="143" left="326" width="163" height="17" font="5">Inclusion criteria: REGARDS  </text>
<text top="144" left="535" width="7" height="17" font="5">1</text>
<text top="143" left="542" width="207" height="18" font="5"> endpoint: Age, sex, smoking status, </text>
<text top="162" left="535" width="232" height="17" font="5">race, region, alcohol use, education, waist </text>
<text top="179" left="535" width="235" height="17" font="5">circumference, physical activity, DM, CHD, </text>
<text top="196" left="535" width="226" height="17" font="5">HTN, stroke, heart failure, chronic kidney </text>
<text top="213" left="535" width="216" height="17" font="5">disease, statin use, total energy intake, </text>
<text top="230" left="535" width="222" height="17" font="5">energy adjusted intake of saturated fatty </text>
<text top="248" left="535" width="197" height="17" font="5">acids, monounsaturated fatty acids, </text>
<text top="265" left="535" width="228" height="17" font="5">polyunsaturated fatty acids, proteins, and </text>
<text top="282" left="535" width="81" height="17" font="5">carbohydrates </text>
<text top="299" left="535" width="3" height="17" font="5"> </text>
<text top="317" left="535" width="141" height="17" font="5">Age: p for interaction=0.6 </text>
<text top="334" left="535" width="147" height="17" font="5">Sex: p for interaction=0.36 </text>
<text top="143" left="786" width="3" height="17" font="5"> </text>
<text top="368" left="75" width="95" height="17" font="5">Southern Dietary </text>
<text top="385" left="75" width="55" height="17" font="5">Pattern is </text>
<text top="402" left="75" width="91" height="17" font="5">Associated With </text>
<text top="419" left="75" width="91" height="17" font="5">Hazard of Acute </text>
<text top="437" left="75" width="87" height="17" font="5">Coronary Heart </text>
<text top="454" left="75" width="81" height="17" font="5">Disease in the </text>
<text top="471" left="75" width="70" height="17" font="5">Reasons for </text>
<text top="488" left="75" width="91" height="17" font="5">Geographic and </text>
<text top="505" left="75" width="103" height="17" font="5">Racial Differences </text>
<text top="523" left="75" width="52" height="17" font="5">in Stroke </text>
<text top="540" left="75" width="72" height="17" font="5">(REGARDS) </text>
<text top="557" left="75" width="35" height="17" font="5">Study </text>
<text top="574" left="75" width="3" height="17" font="5"> </text>
<text top="591" left="75" width="81" height="17" font="5">Shikany, 2015 </text>
<text top="609" left="75" width="3" height="17" font="5"> </text>
<text top="626" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26260732">26260732</a></text>
<text top="626" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26260732"> </a></text>
<text top="368" left="193" width="105" height="17" font="5">Study type: Cohort </text>
<text top="385" left="193" width="33" height="17" font="5">study </text>
<text top="402" left="193" width="3" height="17" font="5"> </text>
<text top="419" left="193" width="57" height="17" font="5">N=17,418 </text>
<text top="368" left="326" width="181" height="17" font="5">Inclusion criteria: REGARDS (no </text>
<text top="386" left="326" width="97" height="17" font="5">CHD at baseline) </text>
<text top="369" left="535" width="7" height="17" font="5">1</text>
<text top="368" left="542" width="209" height="18" font="5"> endpoint: Age, sex, race, education, </text>
<text top="386" left="535" width="215" height="17" font="5">household income, region, total energy </text>
<text top="403" left="535" width="213" height="17" font="5">intake, smoking, physical activity, BMI, </text>
<text top="420" left="535" width="222" height="17" font="5">waist circumference, HTN, dyslipidemia, </text>
<text top="438" left="535" width="22" height="17" font="5">DM </text>
<text top="368" left="786" width="3" height="17" font="5"> </text>
<text top="644" left="75" width="80" height="17" font="5">Association of </text>
<text top="661" left="75" width="89" height="17" font="5">Specific Dietary </text>
<text top="678" left="75" width="86" height="17" font="5">Fats With Total </text>
<text top="696" left="75" width="64" height="17" font="5">and Cause-</text>
<text top="713" left="75" width="96" height="17" font="5">Specific Mortality </text>
<text top="730" left="75" width="3" height="17" font="5"> </text>
<text top="747" left="75" width="70" height="17" font="5">Wang, 2016 </text>
<text top="764" left="75" width="3" height="17" font="5"> </text>
<text top="644" left="193" width="105" height="17" font="5">Study type: Cohort </text>
<text top="661" left="193" width="33" height="17" font="5">study </text>
<text top="678" left="193" width="3" height="17" font="5"> </text>
<text top="696" left="193" width="64" height="17" font="5">N=126,233 </text>
<text top="644" left="326" width="185" height="17" font="5">Inclusion criteria: NHS and HPFS </text>
<text top="663" left="326" width="192" height="17" font="5">(no CV disease or DM at baseline) </text>
<text top="645" left="535" width="7" height="17" font="5">1</text>
<text top="644" left="542" width="203" height="18" font="5"> endpoint: Age, race, marital status, </text>
<text top="662" left="535" width="210" height="17" font="5">BMI, physical activity, smoking status, </text>
<text top="679" left="535" width="214" height="17" font="5">alcohol consumption, multivitamin use, </text>
<text top="697" left="535" width="236" height="17" font="5">vitamin E use, aspirin use, family history of </text>
<text top="714" left="535" width="224" height="17" font="5">MI, family history of DM, family history of </text>
<text top="731" left="535" width="236" height="17" font="5">cancer, HTN, hypercholesterolemia, intake </text>
<text top="748" left="535" width="212" height="17" font="5">of total energy and dietary cholesterol, </text>
<text top="766" left="535" width="224" height="17" font="5">percentage of energy intake from dietary </text>
<text top="644" left="786" width="331" height="17" font="5">Comments: Replacing 5% of energy from saturated fats with </text>
<text top="661" left="786" width="330" height="17" font="5">equivalent energy from PUFA or MUFA was associated with </text>
<text top="678" left="786" width="351" height="17" font="5">esimated reductions in total mortality of 27% (adjusted HR 0.73, </text>
<text top="696" left="786" width="341" height="17" font="5">95% CI 0.70 to 0.77) and 13% (adjusted HR 0.87, 95 5CI 0.82 </text>
<text top="713" left="786" width="117" height="17" font="5">to 0.93), respectively </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27379574">27379574</a></text>
<text top="143" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27379574"> </a></text>
<text top="143" left="535" width="229" height="17" font="5">protein, menopausal status/hormone use, </text>
<text top="160" left="535" width="215" height="17" font="5">percentage of energy intake from other </text>
<text top="178" left="535" width="59" height="17" font="5">fatty acids </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="236" height="17" font="5">All-cause mortality: Adjusted HR, quintile 5 </text>
<text top="229" left="535" width="92" height="17" font="5">versus quintile 1 </text>
<text top="247" left="535" width="163" height="17" font="5">A: 0.95 (95% CI 0.94 to 0.96) </text>
<text top="264" left="535" width="163" height="17" font="5">B: 1.08 (95% CI 1.04 to 1.11) </text>
<text top="281" left="535" width="163" height="17" font="5">C: 0.85 (95% CI 0.83 to 0.87) </text>
<text top="298" left="535" width="163" height="17" font="5">D: 0.73 (95% CI 0.69 to 0.77) </text>
<text top="315" left="535" width="163" height="17" font="5">E: 0.90 (95% CI 0.87 to 0.94) </text>
<text top="333" left="535" width="162" height="17" font="5">F: 1.16 (95% CI 1.09 to 1.24) </text>
<text top="350" left="535" width="164" height="17" font="5">G: 0.90 (95% CI 0.88 to 0.93) </text>
<text top="367" left="535" width="163" height="17" font="5">H: 0.88 (95% CI 0.86 to 0.91) </text>
<text top="384" left="535" width="158" height="17" font="5">I: 0.58 (95% CI 0.47 to 0.73) </text>
<text top="401" left="535" width="161" height="17" font="5">J: 0.97 (95% CI 0.94 to 0.99) </text>
<text top="419" left="535" width="163" height="17" font="5">K: 0.98 (95% CI 0.94 to 1.02) </text>
<text top="436" left="535" width="161" height="17" font="5">L: 0.93 (95% CI 0.89 to 0.98) </text>
<text top="453" left="535" width="161" height="17" font="5">M: 1.00 (95% CI 0.99 to 1.00 </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="75" width="104" height="17" font="5">Prospective Urban </text>
<text top="523" left="75" width="33" height="17" font="5">Rural </text>
<text top="540" left="75" width="77" height="17" font="5">Epidemiology </text>
<text top="557" left="75" width="79" height="17" font="5">(PURE) study </text>
<text top="574" left="75" width="3" height="17" font="5"> </text>
<text top="591" left="75" width="83" height="17" font="5">Dehghan et al, </text>
<text top="609" left="75" width="31" height="17" font="5">2017 </text>
<text top="626" left="75" width="3" height="17" font="5"> </text>
<text top="643" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28864332">28864332</a></text>
<text top="643" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28864332"> </a></text>
<text top="505" left="193" width="62" height="17" font="5">Study type </text>
<text top="523" left="193" width="75" height="17" font="5">Cohort Study </text>
<text top="540" left="193" width="3" height="17" font="5"> </text>
<text top="557" left="193" width="64" height="17" font="5">N=135,335 </text>
<text top="505" left="326" width="59" height="17" font="5">Inclusion:  </text>
<text top="523" left="324" width="183" height="18" font="5">•  Households in one of 18 low-, </text>
<text top="541" left="325" width="195" height="17" font="5">middle-, and high-income countries </text>
<text top="558" left="325" width="166" height="17" font="5">with at least one member was </text>
<text top="575" left="325" width="182" height="17" font="5">between 35 and 70 years of age, </text>
<text top="593" left="325" width="105" height="17" font="5">and the household </text>
<text top="610" left="324" width="186" height="18" font="5">•  Householders intended to stay </text>
<text top="628" left="325" width="195" height="17" font="5">in the current address for another 4 </text>
<text top="645" left="325" width="33" height="17" font="5">years </text>
<text top="662" left="324" width="178" height="18" font="5">•  plausible energy intake (500–</text>
<text top="681" left="325" width="105" height="17" font="5">5000 kcal per day) </text>
<text top="698" left="324" width="183" height="18" font="5">•  no missing values on age and </text>
<text top="716" left="325" width="26" height="17" font="5">sex. </text>
<text top="733" left="325" width="3" height="17" font="5"> </text>
<text top="764" left="326" width="60" height="17" font="5">Exclusion: </text>
<text top="507" left="535" width="7" height="17" font="5">1</text>
<text top="505" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="524" left="535" width="217" height="17" font="5">total mortality and major cardiovascular </text>
<text top="541" left="535" width="227" height="17" font="5">events (fatal cardiovascular disease, non-</text>
<text top="558" left="535" width="210" height="17" font="5">fatal myocardial infarction, stroke, and </text>
<text top="575" left="535" width="225" height="17" font="5">heart failure). Secondary outcomes were </text>
<text top="593" left="535" width="182" height="17" font="5">all myocardial infarctions, stroke, </text>
<text top="610" left="535" width="230" height="17" font="5">cardiovascular disease mortality, and non-</text>
<text top="627" left="535" width="185" height="17" font="5">cardiovascular disease mortality.  </text>
<text top="644" left="535" width="3" height="17" font="5"> </text>
<text top="661" left="535" width="164" height="17" font="5">Median follow-up of 7.4 years </text>
<text top="679" left="589" width="3" height="17" font="5"> </text>
<text top="696" left="535" width="228" height="17" font="7"><i>Total carbohydrate intake for quintile 5 vs </i></text>
<text top="713" left="535" width="56" height="17" font="7"><i>quintile 1: </i></text>
<text top="730" left="535" width="216" height="17" font="5">Total mortality; HR=1.28 (95% CI: 1.12-</text>
<text top="748" left="535" width="143" height="17" font="5">1.46; p for trend=0.0001)  </text>
<text top="505" left="786" width="350" height="17" font="5">Summary: High carbohydrate intake was associated with higher </text>
<text top="523" left="786" width="352" height="17" font="5">risk of total mortality, whereas total fat and individual types of fat </text>
<text top="540" left="786" width="333" height="17" font="5">were related to lower total mortality. Total fat and types of fat </text>
<text top="557" left="786" width="333" height="17" font="5">were not associated with cardiovascular disease, myocardial </text>
<text top="574" left="786" width="303" height="17" font="5">infarction, or cardiovascular disease mortality, whereas </text>
<text top="591" left="786" width="287" height="17" font="5">saturated fat had an inverse association with stroke. </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="326" width="3" height="17" font="5"> </text>
<text top="161" left="324" width="180" height="18" font="5">•  follow-up information was not </text>
<text top="179" left="325" width="55" height="17" font="5">available  </text>
<text top="196" left="324" width="153" height="18" font="5">•  history of cardiovascular </text>
<text top="214" left="325" width="46" height="17" font="5">disease </text>
<text top="143" left="535" width="218" height="17" font="5">Major cardiovascular disease; HR=1.01 </text>
<text top="160" left="535" width="201" height="17" font="5">(95% CI 0.88-1.15, p for trend=0.62) </text>
<text top="178" left="535" width="219" height="17" font="5">Myocardial infarction; HR=0.90 (95% CI </text>
<text top="195" left="535" width="150" height="17" font="5">0.73-1.10, p for trend 0.40) </text>
<text top="212" left="535" width="229" height="17" font="5">Stroke: HR=1.11 (95% CI 0.92-1.35, p for </text>
<text top="229" left="535" width="67" height="17" font="5">trend=0.10) </text>
<text top="247" left="535" width="237" height="17" font="5">Cardiovascular disease mortality: HR=1.13 </text>
<text top="264" left="535" width="201" height="17" font="5">(95% CI 0.89-1.44, p for trend=0.50) </text>
<text top="281" left="535" width="208" height="17" font="5">Non-cardiovascular disease mortality: </text>
<text top="298" left="535" width="230" height="17" font="5">Total carbohydrate intake HR=1.36  (95% </text>
<text top="315" left="535" width="186" height="17" font="5">CI 1.16-1.60, p for trend &lt;0.0001) </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="350" left="535" width="223" height="17" font="7"><i>Total fat intake for quintile 5 vs quintile 1 </i></text>
<text top="367" left="535" width="212" height="17" font="5">Total mortality: HR=0.77 (95% CI 0.67-</text>
<text top="384" left="535" width="139" height="17" font="5">0.87; p for trend&lt;0.0001) </text>
<text top="401" left="535" width="226" height="17" font="5">Major cardiovascular disease: HR= (95% </text>
<text top="419" left="535" width="86" height="17" font="5">CI ; p for trend) </text>
<text top="436" left="535" width="220" height="17" font="5">Myocardial infarction: HR=1.12 (95% CI </text>
<text top="453" left="535" width="146" height="17" font="5">0.92-1.37; p for trend0.40) </text>
<text top="470" left="535" width="229" height="17" font="5">Stroke: HR=0.82 (95% CI 0.68-1.00, p for </text>
<text top="487" left="535" width="70" height="17" font="5">trend=0.05). </text>
<text top="505" left="535" width="213" height="17" font="5">Cardiovascular disease mortality: HR= </text>
<text top="522" left="535" width="225" height="17" font="5">0.92 (95% CI 0.72-1.16; p for trend 0.50) </text>
<text top="539" left="535" width="208" height="17" font="5">Non-cardiovascular disease mortality: </text>
<text top="556" left="535" width="187" height="17" font="5">HR=0.70 (95% CI 0.60-0.82, p for </text>
<text top="573" left="535" width="80" height="17" font="5">trend&lt;0.0001) </text>
<text top="591" left="535" width="3" height="17" font="5"> </text>
<text top="608" left="535" width="236" height="17" font="7"><i>Total protein intake for quintile 5 vs quintile </i></text>
<text top="625" left="535" width="10" height="17" font="7"><i>1 </i></text>
<text top="642" left="535" width="212" height="17" font="5">Total mortality: HR=0.88 (95% CI 0.77-</text>
<text top="660" left="535" width="139" height="17" font="5">1.00, p for trend=0.0030) </text>
<text top="677" left="535" width="222" height="17" font="5">Major cardiovascular disease: HR= 0.96 </text>
<text top="694" left="535" width="198" height="17" font="5">(95% CI 0.84-1.10; p for trend 0.86) </text>
<text top="711" left="535" width="219" height="17" font="5">Myocardial infarction: HR=1.02 (95% CI </text>
<text top="728" left="535" width="150" height="17" font="5">0.83-1.24; p for trend 0.67) </text>
<text top="746" left="535" width="233" height="17" font="5">Stroke: HR= 0.90 (95% CI 0.74-1.09; p for </text>
<text top="763" left="535" width="63" height="17" font="5">trend 0.47) </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="213" height="17" font="5">Cardiovascular disease mortality: HR= </text>
<text top="160" left="535" width="225" height="17" font="5">0.90 (95% CI 0.71-1.15; p for trend 0.26) </text>
<text top="178" left="535" width="205" height="17" font="5">Non-cardiovascular disease mortality </text>
<text top="195" left="535" width="187" height="17" font="5">HR=0.85 (95% CI 0.73-0.99, p for </text>
<text top="212" left="535" width="91" height="17" font="5">trend=0.0022).   </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="230" height="17" font="7"><i>% energy from saturated fats quintile 5 vs </i></text>
<text top="264" left="535" width="53" height="17" font="7"><i>quintile 1 </i></text>
<text top="281" left="535" width="212" height="17" font="5">Total mortality: HR=0.86 (95% CI 0.76-</text>
<text top="298" left="535" width="139" height="17" font="5">0.99; p for trend=0.0088) </text>
<text top="315" left="535" width="222" height="17" font="5">Major cardiovascular disease: HR= 0.95 </text>
<text top="333" left="535" width="201" height="17" font="5">(95% CI 0.83-1.10; p for trend=0.49) </text>
<text top="350" left="535" width="223" height="17" font="5">Myocardial infarction: HR= 1.17 (95% CI </text>
<text top="367" left="535" width="150" height="17" font="5">0.94-1.45; p for trend 0.40) </text>
<text top="384" left="535" width="233" height="17" font="5">Stroke: HR= 0.79 (95% CI 0.64-0.98; p for </text>
<text top="401" left="535" width="84" height="17" font="5">trend 0.0498)   </text>
<text top="419" left="535" width="240" height="17" font="5">Cardiovascular disease mortality: HR=0.83  </text>
<text top="436" left="535" width="212" height="17" font="5">(95% CI 0.65-1.07; p for trend=0.20) :  </text>
<text top="453" left="535" width="233" height="17" font="5">Non-cardiovascular disease mortality HR= </text>
<text top="470" left="535" width="162" height="17" font="5">0.86 (95% CI 0.79-1.01; p for </text>
<text top="487" left="535" width="87" height="17" font="5">trend=0.0108):  </text>
<text top="505" left="535" width="3" height="17" font="5"> </text>
<text top="522" left="535" width="206" height="17" font="7"><i>% energy from monounsaturated fats </i></text>
<text top="539" left="535" width="121" height="17" font="7"><i>quintile 5 vs quintile 1 </i></text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="216" height="17" font="5">Total mortality: HR= 0.81 (95% CI 0.71-</text>
<text top="591" left="535" width="139" height="17" font="5">0.92; p for trend&lt;0.0001) </text>
<text top="608" left="535" width="222" height="17" font="5">Major cardiovascular disease: HR= 0.95 </text>
<text top="625" left="535" width="201" height="17" font="5">(95% CI 0.84-1.09; p for trend=0.54) </text>
<text top="642" left="535" width="223" height="17" font="5">Myocardial infarction: HR= 1.12 (95% CI </text>
<text top="660" left="535" width="154" height="17" font="5">0.92-1.38; p for trend=0.40) </text>
<text top="677" left="535" width="233" height="17" font="5">Stroke: HR= 0.85 (95% CI 0.70-1.03; p for </text>
<text top="694" left="535" width="73" height="17" font="5">trend=0.10)   </text>
<text top="711" left="535" width="237" height="17" font="5">Cardiovascular disease mortality: HR=0.85 </text>
<text top="728" left="535" width="208" height="17" font="5">(95% CI 0.66-1.09; p for trend=0.10):  </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="205" height="17" font="5">Non-cardiovascular disease mortality </text>
<text top="160" left="535" width="187" height="17" font="5">HR=0.79 (95% CI 0.68-0.93; p for </text>
<text top="178" left="535" width="87" height="17" font="5">trend=0.0003):  </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="197" height="17" font="7"><i>% energy from polyunsaturated fats </i></text>
<text top="229" left="535" width="121" height="17" font="7"><i>quintile 5 vs quintile 1 </i></text>
<text top="247" left="535" width="212" height="17" font="5">Total mortality: HR=0.80 (95% CI 0.71-</text>
<text top="264" left="535" width="139" height="17" font="5">0.89; p for trend&lt;0.0001) </text>
<text top="281" left="535" width="218" height="17" font="5">Major cardiovascular disease: HR=1.01 </text>
<text top="298" left="535" width="201" height="17" font="5">(95% CI 0.90-1.14; p for trend=0.94) </text>
<text top="315" left="535" width="219" height="17" font="5">Myocardial infarction: HR=1.12 (95% CI </text>
<text top="333" left="535" width="154" height="17" font="5">0.93-1.34; p for trend=0.40) </text>
<text top="350" left="535" width="229" height="17" font="5">Stroke: HR=0.92 (95% CI 0.78-1.09; p for </text>
<text top="367" left="535" width="73" height="17" font="5">trend=0.30)   </text>
<text top="384" left="535" width="237" height="17" font="5">Cardiovascular disease mortality: HR=0.94 </text>
<text top="401" left="535" width="212" height="17" font="5">(95% CI 0.76-1.15; p for trend=0.20) :  </text>
<text top="419" left="535" width="205" height="17" font="5">Non-cardiovascular disease mortality </text>
<text top="436" left="535" width="187" height="17" font="5">HR=0.75 (95% CI 0.65-0.86; p for </text>
<text top="453" left="535" width="87" height="17" font="5">trend=0.0002):  </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="488" left="75" width="87" height="17" font="5">Atherosclerosis </text>
<text top="505" left="75" width="40" height="17" font="5">Risk in </text>
<text top="523" left="75" width="75" height="17" font="5">Communities </text>
<text top="540" left="75" width="41" height="17" font="5">(ARIC) </text>
<text top="557" left="75" width="3" height="17" font="5"> </text>
<text top="574" left="75" width="95" height="17" font="5">Seidelmann et al </text>
<text top="591" left="75" width="31" height="17" font="5">2018 </text>
<text top="609" left="75" width="3" height="17" font="5"> </text>
<text top="626" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30122560">30122560</a></text>
<text top="626" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30122560"> </a></text>
<text top="488" left="193" width="62" height="17" font="5">Study type </text>
<text top="505" left="193" width="105" height="17" font="5">Prospective cohort </text>
<text top="523" left="193" width="97" height="17" font="5">study (ARIC) and </text>
<text top="540" left="193" width="79" height="17" font="5">meta-analysis </text>
<text top="557" left="193" width="3" height="17" font="5"> </text>
<text top="574" left="193" width="90" height="17" font="5">N=15,428 ARIC </text>
<text top="591" left="193" width="3" height="17" font="5"> </text>
<text top="609" left="193" width="121" height="17" font="5">N=8 studies (432,179 </text>
<text top="626" left="193" width="102" height="17" font="5">participants) meta-</text>
<text top="643" left="193" width="48" height="17" font="5">analysis </text>
<text top="488" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="507" left="324" width="76" height="18" font="5">•  age 45-64 </text>
<text top="525" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="556" left="324" width="188" height="18" font="5">•  incomplete dietary information  </text>
<text top="574" left="324" width="175" height="18" font="5">•  extreme caloric intake (&lt;600 </text>
<text top="592" left="325" width="192" height="17" font="5">kcal or &gt;4200 kcal per day for men </text>
<text top="609" left="325" width="179" height="17" font="5">and &lt;500 kcal or &gt;3600 kcal per </text>
<text top="627" left="325" width="92" height="17" font="5">day for women). </text>
<text top="644" left="326" width="3" height="17" font="5"> </text>
<text top="674" left="326" width="175" height="17" font="5">Inclusion criteria meta-analysis: </text>
<text top="705" left="324" width="155" height="18" font="5">•  published full-text report, </text>
<text top="723" left="325" width="195" height="17" font="5">observational study, or randomized </text>
<text top="740" left="325" width="83" height="17" font="5">controlled trial  </text>
<text top="758" left="324" width="161" height="18" font="5">•  minimum 1 year follow-up </text>
<text top="489" left="533" width="7" height="17" font="5">1</text>
<text top="488" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="508" left="532" width="218" height="18" font="5">•  Median length of follow up=25 years </text>
<text top="526" left="533" width="3" height="17" font="5"> </text>
<text top="545" left="533" width="104" height="17" font="7"><i>All-cause mortality </i></text>
<text top="564" left="532" width="208" height="18" font="5">•  relationship between carbohydrate </text>
<text top="582" left="533" width="208" height="17" font="5">consumption and risk of mortality was </text>
<text top="599" left="533" width="231" height="17" font="5">significantly nonlinear (p&lt;0·001), resulting </text>
<text top="616" left="533" width="232" height="17" font="5">in a U-shaped association, with the lowest </text>
<text top="633" left="533" width="164" height="17" font="5">observed risk associated with </text>
<text top="651" left="533" width="214" height="17" font="5">carbohydrate consumption of 50–55%  </text>
<text top="668" left="532" width="189" height="18" font="5">•  In the ARIC cohort and in meta </text>
<text top="686" left="533" width="235" height="17" font="5">analysis, increased consumption of animal-</text>
<text top="703" left="533" width="176" height="17" font="5">based protein and fat instead of </text>
<text top="720" left="533" width="198" height="17" font="5">carbohydrate was associated with a </text>
<text top="738" left="533" width="224" height="17" font="5">significant increase in all-cause mortality </text>
<text top="755" left="533" width="63" height="17" font="5">(p&lt;0·0001; </text>
<text top="488" left="786" width="301" height="17" font="5">Summary: mid-life dietary patterns marked by both low </text>
<text top="505" left="786" width="327" height="17" font="5">carbohydrate (&lt;40% of energy from carbohydrate) and high </text>
<text top="523" left="786" width="349" height="17" font="5">carbohydrate (&gt;70% of energy from carbohydrate) consumption </text>
<text top="540" left="786" width="312" height="17" font="5">were associated with increased mortality risk and shorter </text>
<text top="557" left="786" width="338" height="17" font="5">residual lifespan, with minimum risk observed with 50–55% of </text>
<text top="574" left="786" width="340" height="17" font="5">energy from carbohydrate.  Low carbohydrate dietary patterns </text>
<text top="591" left="786" width="313" height="17" font="5">that replaced energy from carbohydrate with energy from </text>
<text top="609" left="786" width="342" height="17" font="5">animal-derived protein or fat were associated with greater risk. </text>
<text top="626" left="786" width="345" height="17" font="5">This association was reversed when energy from carbohydrate </text>
<text top="643" left="786" width="252" height="17" font="5">was replaced with plant-derived protein or fat. </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="324" width="189" height="18" font="5">•  reported relative risks (ie, HRs, </text>
<text top="161" left="325" width="189" height="17" font="5">risk ratios, or odds ratios with CIs) </text>
<text top="179" left="324" width="193" height="18" font="5">•  adjusted for at least three of the </text>
<text top="197" left="325" width="194" height="17" font="5">following factors: age, sex, obesity, </text>
<text top="214" left="325" width="142" height="17" font="5">smoking status, diabetes, </text>
<text top="231" left="325" width="77" height="17" font="5">hypertension, </text>
<text top="248" left="325" width="177" height="17" font="5">hypercholesterolemia, history of </text>
<text top="266" left="325" width="191" height="17" font="5">cardiovascular disease, and family </text>
<text top="283" left="325" width="185" height="17" font="5">history of cardiovascular disease  </text>
<text top="300" left="325" width="3" height="17" font="5"> </text>
<text top="331" left="326" width="179" height="17" font="5">Exclusion criteria meta-analysis: </text>
<text top="361" left="326" width="3" height="17" font="5"> </text>
<text top="143" left="532" width="228" height="18" font="5">•  Increased consumption of plant based </text>
<text top="161" left="533" width="214" height="17" font="5">protein and fat instead of carbohydrate </text>
<text top="179" left="533" width="235" height="17" font="5">was associated with a significant decrease </text>
<text top="196" left="533" width="186" height="17" font="5">in all-cause mortality (p&lt;0·0001).  </text>
<text top="213" left="532" width="225" height="18" font="5">•  Animal and plant based findings were </text>
<text top="231" left="533" width="208" height="17" font="5">consistent for cardiovascular and non-</text>
<text top="248" left="533" width="133" height="17" font="5">cardiovascular mortality </text>
<text top="266" left="533" width="3" height="17" font="7"><i> </i></text>
<text top="284" left="533" width="126" height="17" font="7"><i>Meta-analysis results</i>:  </text>
<text top="303" left="532" width="230" height="18" font="5">•  significantly increased risk of all-cause </text>
<text top="321" left="533" width="204" height="17" font="5">mortality among participants with low </text>
<text top="338" left="533" width="170" height="17" font="5">carbohydrate versus moderate </text>
<text top="356" left="533" width="214" height="17" font="5">carbohydrate consumption (pooled HR </text>
<text top="373" left="533" width="208" height="17" font="5">1·20, 95% CI 1·09–1·32; p&lt;0·0001).   </text>
<text top="390" left="532" width="219" height="18" font="5">•  High carbohydrate consumption was </text>
<text top="408" left="533" width="239" height="17" font="5">associated with a significantly higher risk of </text>
<text top="425" left="533" width="186" height="17" font="5">all-cause mortality compared with </text>
<text top="443" left="533" width="204" height="17" font="5">moderate carbohydrate consumption </text>
<text top="460" left="533" width="158" height="17" font="5">(1·23, 1·11–1·36; p&lt;0·0001) </text>
<text top="478" left="75" width="59" height="17" font="5">Kim, 2018 </text>
<text top="495" left="75" width="3" height="17" font="5"> </text>
<text top="512" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29659968">29659968</a></text>
<text top="512" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29659968"> </a></text>
<text top="478" left="193" width="73" height="17" font="5">Cohort study </text>
<text top="495" left="193" width="3" height="17" font="5"> </text>
<text top="512" left="193" width="60" height="17" font="5">N= 11,879 </text>
<text top="478" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="496" left="326" width="87" height="18" font="5">•  NHANES III  </text>
<text top="515" left="326" width="3" height="17" font="5"> </text>
<text top="545" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="576" left="326" width="178" height="18" font="5">•  No stroke, MI, CHD, or DM at </text>
<text top="594" left="353" width="49" height="17" font="5">baseline </text>
<text top="611" left="326" width="3" height="17" font="5"> </text>
<text top="642" left="325" width="3" height="17" font="5"> </text>
<text top="479" left="533" width="7" height="17" font="5">1</text>
<text top="478" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="498" left="533" width="193" height="17" font="5">Age, sex, race, total energy intake, </text>
<text top="516" left="533" width="217" height="17" font="5">education, federal poverty level, marital </text>
<text top="535" left="533" width="221" height="17" font="5">status, smoking status, physical activity, </text>
<text top="553" left="533" width="217" height="17" font="5">alcohol consumption, margarine intake, </text>
<text top="572" left="533" width="204" height="17" font="5">BMI, HTN, serum cholesterol, kidney </text>
<text top="591" left="533" width="187" height="17" font="5">function, menopause (for women) </text>
<text top="609" left="533" width="3" height="17" font="5"> </text>
<text top="640" left="535" width="3" height="17" font="5"> </text>
<text top="670" left="533" width="27" height="17" font="5">Men </text>
<text top="689" left="533" width="166" height="17" font="5">A: 1.04 (95% CI 0.99  to 1.07) </text>
<text top="708" left="533" width="231" height="17" font="5">B: 1.01 (95% CI 0.92 to 1.10) in subgroup </text>
<text top="726" left="533" width="219" height="17" font="5">less than  median, 0.95 (95% CI 0.89 to </text>
<text top="745" left="533" width="209" height="17" font="5">1.01) in subgroup at median or higher </text>
<text top="763" left="533" width="163" height="17" font="5">C: 1.01 (95% CI 0.98 to 1.06) </text>
<text top="478" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="3" height="17" font="5"> </text>
<text top="162" left="533" width="46" height="17" font="5">Women </text>
<text top="180" left="533" width="163" height="17" font="5">A: 0.98 (95% CI 0.95 to 1.00) </text>
<text top="199" left="533" width="230" height="17" font="5">B: 1.09 (95% CI 0.98 to 1.19) in subgroup </text>
<text top="218" left="533" width="216" height="17" font="5">less than median, 0.94 (95% CI 0.88 to </text>
<text top="236" left="533" width="209" height="17" font="5">0.99) in subgroup at median or higher </text>
<text top="255" left="533" width="163" height="17" font="5">C: 1.01 (95% CI 0.98 to 1.05) </text>
<text top="273" left="533" width="3" height="17" font="5"> </text>
<text top="293" left="533" width="7" height="17" font="5">2</text>
<text top="292" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="312" left="533" width="122" height="17" font="5">Cardiovascular Death </text>
<text top="330" left="533" width="188" height="17" font="5">Adjusted HR, per 10-unit increase </text>
<text top="349" left="533" width="170" height="17" font="5">A: 1.05 (95% CI 0.99 to 1.12),  </text>
<text top="367" left="533" width="163" height="17" font="5">B: 1.02 (95% CI 0.97 to 1.08) </text>
<text top="386" left="533" width="163" height="17" font="5">C: 1.02 (95% CI 0.96 to 1.08) </text>
<text top="405" left="533" width="3" height="17" font="5"> </text>
<text top="423" left="533" width="27" height="17" font="5">Men </text>
<text top="442" left="533" width="163" height="17" font="5">A: 1.08 (95% CI 0.99 to 1.17) </text>
<text top="460" left="533" width="163" height="17" font="5">B: 1.03 (95% CI 0.96 to 1.10) </text>
<text top="479" left="533" width="163" height="17" font="5">C: 1.04 (95% CI 0.96 to 1.13) </text>
<text top="498" left="533" width="3" height="17" font="5"> </text>
<text top="516" left="533" width="46" height="17" font="5">Women </text>
<text top="535" left="533" width="163" height="17" font="5">A: 1.03 (95% CI 0.96 to 1.10) </text>
<text top="553" left="533" width="163" height="17" font="5">B: 1.00 (95% CI 0.93 to 1.07) </text>
<text top="572" left="533" width="159" height="17" font="5">C: 1.03 (95% CI 0.95 to 1.10 </text>
<text top="590" left="533" width="3" height="17" font="5"> </text>
<text top="609" left="533" width="107" height="17" font="5">All-Cause Mortality </text>
<text top="627" left="533" width="188" height="17" font="5">Adjusted HR, per 10-unit increase </text>
<text top="646" left="533" width="163" height="17" font="5">A: 1.01 (95% CI 0.98 to 1.03) </text>
<text top="665" left="533" width="231" height="17" font="5">B: 1.04 (95% CI 0.97 to 1.12) in subgroup </text>
<text top="683" left="533" width="216" height="17" font="5">less than median, 0.95 (95% CI 0.91 to </text>
<text top="702" left="533" width="208" height="17" font="5">0.98) in subgroup at or above median </text>
<text top="720" left="533" width="163" height="17" font="5">C: 1.00 (95% CI 0.98 to 1.04) </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="73" height="17" font="5">Reedy, 2014 </text>
<text top="160" left="75" width="3" height="17" font="5"> </text>
<text top="178" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24572039">24572039</a></text>
<text top="178" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24572039"> </a></text>
<text top="143" left="193" width="109" height="17" font="5">Study Type: Cohort </text>
<text top="160" left="193" width="64" height="17" font="5">N=492,823 </text>
<text top="143" left="325" width="186" height="17" font="5">Inclusion Criteria: NIH-AARP Diet </text>
<text top="162" left="325" width="196" height="17" font="5">and Health Study (no heart disease </text>
<text top="180" left="325" width="67" height="17" font="5">at baseline) </text>
<text top="144" left="533" width="7" height="17" font="5">1</text>
<text top="143" left="540" width="231" height="18" font="5"> endpoint: Age, race/ethnicity, education, </text>
<text top="163" left="533" width="225" height="17" font="5">marital status, physical activity, smoking, </text>
<text top="182" left="533" width="237" height="17" font="5">energy intake, BMI, DM, alcohol (HEI-2010 </text>
<text top="200" left="533" width="215" height="17" font="5">and DASH). Analyses stratified by sex. </text>
<text top="219" left="533" width="3" height="17" font="5"> </text>
<text top="238" left="533" width="7" height="17" font="5">2</text>
<text top="237" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="257" left="533" width="221" height="17" font="5">Adjusted HR, quintile 5 versus quintile 1 </text>
<text top="276" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="294" left="533" width="27" height="17" font="5">Men </text>
<text top="313" left="533" width="163" height="17" font="5">A: 0.78 (95% CI 0.76 to 0.80) </text>
<text top="332" left="533" width="163" height="17" font="5">B: 0.76 (95% CI 0.74 to 0.78) </text>
<text top="350" left="533" width="163" height="17" font="5">C: 0.77 (95% CI 0.75 to 0.79) </text>
<text top="369" left="533" width="163" height="17" font="5">D: 0.83 (95% CI 0.80 to 0.85) </text>
<text top="387" left="533" width="3" height="17" font="5"> </text>
<text top="406" left="533" width="46" height="17" font="5">Women </text>
<text top="424" left="533" width="163" height="17" font="5">A: 0.77 (95% CI 0.74 to 0.80) </text>
<text top="443" left="533" width="163" height="17" font="5">B: 0.76 (95% CI 0.74 to 0.79) </text>
<text top="461" left="533" width="163" height="17" font="5">C: 0.76 (95% CI 0.73 to 0.79) </text>
<text top="480" left="533" width="163" height="17" font="5">D: 0.78 (95% CI 0.75 to 0.81) </text>
<text top="499" left="533" width="3" height="17" font="5"> </text>
<text top="517" left="533" width="70" height="17" font="5">CV mortality </text>
<text top="536" left="533" width="27" height="17" font="5">Men </text>
<text top="554" left="533" width="162" height="17" font="5">A: 0.85 (95% Ci 0.80 to 0.89) </text>
<text top="573" left="533" width="163" height="17" font="5">B: 0.74 (95% CI 0.70 to 0.78) </text>
<text top="592" left="533" width="163" height="17" font="5">C: 0.80 (95% CI 0.76 to 0.84) </text>
<text top="610" left="533" width="163" height="17" font="5">D: 0.86 (95% CI 0.81 to 0.91) </text>
<text top="629" left="533" width="3" height="17" font="5"> </text>
<text top="647" left="533" width="46" height="17" font="5">Women </text>
<text top="666" left="533" width="163" height="17" font="5">A: 0.79 (95% CI 0.73 to 0.85) </text>
<text top="685" left="533" width="163" height="17" font="5">B: 0.72 (95% CI 0.67 to 0.78) </text>
<text top="703" left="533" width="163" height="17" font="5">C: 0.78 (95% CI 0.72 to 0.84) </text>
<text top="722" left="533" width="163" height="17" font="5">D: 0.78 (95% CI 0.72 to 0.83) </text>
<text top="143" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="68" height="17" font="5">Satija, 2017 </text>
<text top="160" left="75" width="3" height="17" font="5"> </text>
<text top="178" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28728684">28728684</a></text>
<text top="178" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28728684"> </a></text>
<text top="143" left="193" width="109" height="17" font="5">Study Type: Cohort </text>
<text top="160" left="193" width="64" height="17" font="5">N=209,298 </text>
<text top="143" left="325" width="171" height="17" font="5">Inclusion Criteria: NHS, NHS2, </text>
<text top="162" left="325" width="158" height="17" font="5">HPFS (no CHD at baseline)  </text>
<text top="144" left="533" width="7" height="17" font="5">1</text>
<text top="143" left="540" width="229" height="18" font="5"> endpoint: Age, smoking status, physical </text>
<text top="163" left="533" width="218" height="17" font="5">activity, alcohol intake, multiviamin use, </text>
<text top="182" left="533" width="188" height="17" font="5">aspirin use, family history of CHD, </text>
<text top="200" left="533" width="228" height="17" font="5">margarine intake, energy intake, baseline </text>
<text top="219" left="533" width="225" height="17" font="5">hypertension, hypercholesterolemia, and </text>
<text top="237" left="533" width="232" height="17" font="5">diabetes, BMI, post-menopausal hormone </text>
<text top="256" left="533" width="169" height="17" font="5">use (NHS and NHS2) and oral </text>
<text top="275" left="533" width="144" height="17" font="5">contraceptive use (NHS2) </text>
<text top="293" left="533" width="3" height="17" font="5"> </text>
<text top="312" left="533" width="32" height="17" font="5">Age:  </text>
<text top="330" left="533" width="194" height="17" font="5">Adjusted HR, decile 10 vs. decile 1 </text>
<text top="349" left="533" width="58" height="17" font="5">&lt;55 years </text>
<text top="367" left="533" width="36" height="17" font="5">A: NR </text>
<text top="386" left="533" width="163" height="17" font="5">B: 0.59 (95% CI 0.43 to 0.82) </text>
<text top="405" left="533" width="163" height="17" font="5">C: 1.82 (95% CI 1.33 to 2.47) </text>
<text top="423" left="533" width="3" height="17" font="5"> </text>
<text top="442" left="533" width="65" height="17" font="5">&gt;=55 years </text>
<text top="460" left="533" width="36" height="17" font="5">A: NR </text>
<text top="479" left="533" width="163" height="17" font="5">B: 0.76 (95% CI 0.69 to 0.85) </text>
<text top="498" left="533" width="163" height="17" font="5">C: 1.27 (95% CI 1.14 to 1.42) </text>
<text top="516" left="533" width="3" height="17" font="5"> </text>
<text top="535" left="533" width="29" height="17" font="5">BMI: </text>
<text top="553" left="533" width="194" height="17" font="5">Adjusted HR, decile 10 vs. decile 1 </text>
<text top="572" left="533" width="24" height="17" font="5">&lt;30 </text>
<text top="590" left="533" width="36" height="17" font="5">A: NR </text>
<text top="609" left="533" width="163" height="17" font="5">B: 0.72 (95% CI 0.64 to 0.80) </text>
<text top="627" left="533" width="163" height="17" font="5">C: 1.27 (95% CI 1.13 to 1.43) </text>
<text top="646" left="533" width="3" height="17" font="5"> </text>
<text top="665" left="533" width="31" height="17" font="5">&gt;=30 </text>
<text top="683" left="533" width="36" height="17" font="5">A: NR </text>
<text top="702" left="533" width="163" height="17" font="5">B: 0.84 (95% CI 0.66 to 1.05) </text>
<text top="720" left="533" width="163" height="17" font="5">C: 1.38 (95% CI 1.11 to 1.72) </text>
<text top="739" left="533" width="3" height="17" font="5"> </text>
<text top="758" left="533" width="91" height="17" font="5">Smoking status: </text>
<text top="143" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="194" height="17" font="5">Adjusted HR, decile 10 vs. decile 1 </text>
<text top="162" left="533" width="73" height="17" font="5">Ever smoker </text>
<text top="180" left="533" width="36" height="17" font="5">A: NR </text>
<text top="199" left="533" width="163" height="17" font="5">B: 0.66 (95% CI 0.58 to 0.75) </text>
<text top="218" left="533" width="163" height="17" font="5">C: 1.42 (95% CI 1.25 to 1.62) </text>
<text top="236" left="533" width="3" height="17" font="5"> </text>
<text top="255" left="533" width="80" height="17" font="5">Never smoker </text>
<text top="273" left="533" width="36" height="17" font="5">A: NR </text>
<text top="292" left="533" width="163" height="17" font="5">B: 0.78 (95% CI 0.66 to 0.92) </text>
<text top="310" left="533" width="163" height="17" font="5">C: 1.30 (95% CI 1.10 to 1.52) </text>
<text top="329" left="533" width="3" height="17" font="5"> </text>
<text top="349" left="533" width="7" height="17" font="5">2</text>
<text top="348" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="367" left="533" width="3" height="17" font="5"> </text>
<text top="386" left="533" width="117" height="17" font="5">Fatal or non-fatal MI: </text>
<text top="405" left="533" width="221" height="17" font="5">Adjusted HR, decile 10 vs. decile 1, and </text>
<text top="423" left="533" width="157" height="17" font="5">per 10 unit increase in index </text>
<text top="442" left="533" width="225" height="17" font="5">A: 0.92 (95% CI 0.83 to 1.01), 0.93 (95% </text>
<text top="460" left="533" width="88" height="17" font="5">CI 0.90 to 0.97) </text>
<text top="479" left="533" width="225" height="17" font="5">B: 0.75 (95% CI 0.68 to 0.83), 0.88 (95% </text>
<text top="498" left="533" width="88" height="17" font="5">CI 0.85 to 0.91) </text>
<text top="516" left="533" width="226" height="17" font="5">C: 1.32 (95% CI 1.20 to 1.46), 1.10 (95% </text>
<text top="535" left="533" width="88" height="17" font="5">CI 1.06 to 1.14) </text>
<text top="553" left="533" width="3" height="17" font="5"> </text>
<text top="584" left="75" width="105" height="17" font="5">Sotos-Prieto, 2017 </text>
<text top="602" left="75" width="3" height="17" font="5"> </text>
<text top="619" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28700845">28700845</a></text>
<text top="619" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28700845"> </a></text>
<text top="584" left="193" width="109" height="17" font="5">Study Type: Cohort </text>
<text top="602" left="193" width="57" height="17" font="5">N=73,739 </text>
<text top="584" left="325" width="98" height="17" font="5">Inclusion Criteria: </text>
<text top="603" left="325" width="153" height="17" font="5">NHS and HPFS (no CVD at </text>
<text top="622" left="325" width="53" height="17" font="5">baseline) </text>
<text top="586" left="533" width="7" height="17" font="5">1</text>
<text top="584" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="604" left="533" width="225" height="17" font="5">Age, initial diet quality score, race, family </text>
<text top="623" left="533" width="225" height="17" font="5">history (MI, DM or cancer), use of aspirin </text>
<text top="642" left="533" width="210" height="17" font="5">or multivitamins, BMI, smoking status, </text>
<text top="660" left="533" width="232" height="17" font="5">pack-years of smoking, menopausla stsus </text>
<text top="679" left="533" width="228" height="17" font="5">and use of hormone replacement therapy </text>
<text top="697" left="533" width="215" height="17" font="5">in women, HTN, hypercholesterolemia, </text>
<text top="716" left="533" width="224" height="17" font="5">DM, weight change, cholesterol lowering </text>
<text top="734" left="533" width="235" height="17" font="5">medications, antihypertensive medications </text>
<text top="753" left="533" width="3" height="17" font="5"> </text>
<text top="584" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="144" left="533" width="7" height="17" font="5">2</text>
<text top="143" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="163" left="533" width="3" height="17" font="5"> </text>
<text top="182" left="533" width="58" height="17" font="5">CV death: </text>
<text top="200" left="533" width="234" height="17" font="5">Adjusted HR, per 20 percentile increase in </text>
<text top="219" left="533" width="33" height="17" font="5">score </text>
<text top="237" left="533" width="163" height="17" font="5">A: 0.85 (95% CI 0.76 to 0.96) </text>
<text top="256" left="533" width="163" height="17" font="5">B: 0.93 (95% CI 0.88 to 0.99) </text>
<text top="275" left="533" width="163" height="17" font="5">C: 0.96 (95% CI 0.88 to 1.05) </text>
<text top="293" left="533" width="3" height="17" font="5"> </text>
<text top="312" left="533" width="107" height="17" font="5">All-cause mortality: </text>
<text top="330" left="533" width="221" height="17" font="5">Adjusted HR, quintile 5 versus quintile 3 </text>
<text top="349" left="533" width="215" height="17" font="5">and per 20 percentile increase in score </text>
<text top="367" left="533" width="225" height="17" font="5">A: 0.91 (95% CI 0.85 to 0.97), 0.83 (95% </text>
<text top="386" left="533" width="88" height="17" font="5">CI 0.78 to 0.88) </text>
<text top="405" left="533" width="225" height="17" font="5">B: 0.84 (95% CI 0.78 to 0.91), 0.92 (95% </text>
<text top="423" left="533" width="88" height="17" font="5">CI 0.89 to 0.95) </text>
<text top="442" left="533" width="226" height="17" font="5">C: 0.89 (95% CI 0.84 to 0.95), 0.90 (95% </text>
<text top="460" left="533" width="88" height="17" font="5">CI 0.86 to 0.94) </text>
<text top="492" left="75" width="79" height="17" font="5">Whalen, 2017 </text>
<text top="509" left="75" width="3" height="17" font="5"> </text>
<text top="526" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28179490">28179490</a></text>
<text top="526" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28179490"> </a></text>
<text top="492" left="193" width="109" height="17" font="5">Study Type: Cohort </text>
<text top="509" left="193" width="57" height="17" font="5">N=21,423 </text>
<text top="492" left="325" width="98" height="17" font="5">Inclusion Criteria: </text>
<text top="510" left="325" width="64" height="17" font="5">REGARDS </text>
<text top="493" left="533" width="7" height="17" font="5">1</text>
<text top="492" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="512" left="533" width="221" height="17" font="5">Age, sex, race, total energy intake, BMI, </text>
<text top="530" left="533" width="221" height="17" font="5">physical activity, smoking status, annual </text>
<text top="549" left="533" width="237" height="17" font="5">income, hormone replacement therapy use </text>
<text top="567" left="533" width="51" height="17" font="5">(women) </text>
<text top="586" left="533" width="3" height="17" font="5"> </text>
<text top="604" left="533" width="29" height="17" font="5">Age: </text>
<text top="623" left="533" width="70" height="17" font="5">&lt;=65 or &gt;65 </text>
<text top="642" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="660" left="533" width="131" height="17" font="5">A: p for interaction 0.99 </text>
<text top="679" left="533" width="131" height="17" font="5">B: p for interaction 0.15 </text>
<text top="697" left="533" width="3" height="17" font="5"> </text>
<text top="716" left="533" width="28" height="17" font="5">Sex: </text>
<text top="734" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="753" left="533" width="131" height="17" font="5">A: p for interaction 0.81 </text>
<text top="772" left="533" width="131" height="17" font="5">B: p for interaction 0.06 </text>
<text top="492" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="3" height="17" font="5"> </text>
<text top="162" left="533" width="29" height="17" font="5">BMI: </text>
<text top="180" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="199" left="533" width="232" height="17" font="5">Underweight/normal vs. overweight/obese </text>
<text top="218" left="533" width="131" height="17" font="5">A: p for interaction 0.27 </text>
<text top="236" left="533" width="131" height="17" font="5">B: p for interaction 0.73 </text>
<text top="255" left="533" width="3" height="17" font="5"> </text>
<text top="273" left="533" width="91" height="17" font="5">Smoking status: </text>
<text top="292" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="310" left="533" width="226" height="17" font="5">Current smoker, former smoker, or never </text>
<text top="329" left="533" width="46" height="17" font="5">smoked </text>
<text top="348" left="533" width="131" height="17" font="5">A: p for interaction 0.04 </text>
<text top="366" left="533" width="131" height="17" font="5">B: p for interaction 0.86 </text>
<text top="385" left="533" width="3" height="17" font="5"> </text>
<text top="404" left="533" width="7" height="17" font="5">2</text>
<text top="403" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="423" left="533" width="3" height="17" font="5"> </text>
<text top="442" left="533" width="58" height="17" font="5">CV death: </text>
<text top="460" left="533" width="221" height="17" font="5">Adjusted HR, quintile 5 versus quintile 1 </text>
<text top="479" left="533" width="163" height="17" font="5">A: 0.78 (95% CI 0.61 to 1.00) </text>
<text top="498" left="533" width="163" height="17" font="5">B: 0.68 (95% CI 0.53 to 0.88) </text>
<text top="516" left="533" width="3" height="17" font="5"> </text>
<text top="535" left="533" width="107" height="17" font="5">All-cause mortality: </text>
<text top="553" left="533" width="221" height="17" font="5">Adjusted HR, quintile 5 versus quintile 1 </text>
<text top="572" left="533" width="163" height="17" font="5">A: 0.77 (95% CI 0.67 to 0.89) </text>
<text top="590" left="533" width="163" height="17" font="5">B: 0.64 (95% CI 0.55 to 0.74) </text>
<text top="622" left="75" width="60" height="17" font="5">Bao, 2013 </text>
<text top="639" left="75" width="3" height="17" font="5"> </text>
<text top="656" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24256379">24256379</a></text>
<text top="656" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24256379"> </a></text>
<text top="622" left="193" width="109" height="17" font="5">Study Type: Cohort </text>
<text top="639" left="193" width="64" height="17" font="5">N=118,962 </text>
<text top="622" left="325" width="98" height="17" font="5">Inclusion Criteria: </text>
<text top="640" left="325" width="188" height="17" font="5">NHS and HPFS (no heart disease </text>
<text top="659" left="325" width="118" height="17" font="5">or stroke at baseline) </text>
<text top="623" left="533" width="7" height="17" font="5">1</text>
<text top="622" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="642" left="533" width="230" height="17" font="5">Age, race, BMI, physical activity, smoking </text>
<text top="660" left="533" width="199" height="17" font="5">status, physical exam for screening, </text>
<text top="679" left="533" width="233" height="17" font="5">multivitamin use, aspirin use family history </text>
<text top="697" left="533" width="229" height="17" font="5">(DM, MI, or cancer), history (DM, HTN, or </text>
<text top="716" left="533" width="195" height="17" font="5">hypercholesterolemia), intake (total </text>
<text top="734" left="533" width="226" height="17" font="5">energy, alcohol, red or processed meats, </text>
<text top="753" left="533" width="234" height="17" font="5">fruits, vegetables), menopausal status and </text>
<text top="772" left="533" width="127" height="17" font="5">hormone use (women) </text>
<text top="622" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="3" height="17" font="5"> </text>
<text top="162" left="533" width="29" height="17" font="5">Age: </text>
<text top="180" left="533" width="217" height="17" font="5">Adjusted HR, any nut consumption &gt;=2 </text>
<text top="199" left="533" width="220" height="17" font="5">times per week versus never consumed </text>
<text top="218" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="236" left="533" width="183" height="17" font="5">&gt;=60: 0.86 (95% CI 0.83 to 0.90) </text>
<text top="255" left="533" width="176" height="17" font="5">&lt;60: 0.80 (95% CI 0.67 to 0.96) </text>
<text top="273" left="533" width="116" height="17" font="5">p for interaction 0.86 </text>
<text top="292" left="533" width="3" height="17" font="5"> </text>
<text top="310" left="533" width="28" height="17" font="5">Sex: </text>
<text top="329" left="533" width="217" height="17" font="5">Adjusted HR, any nut consumption &gt;=5 </text>
<text top="348" left="533" width="220" height="17" font="5">times per week versus never consumed </text>
<text top="366" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="385" left="533" width="197" height="17" font="5">Women: 0.84 (95% CI 0.77 to 0.92) </text>
<text top="403" left="533" width="179" height="17" font="5">Men: 0.82 (95% CI 0.76 to 0.88) </text>
<text top="422" left="533" width="3" height="17" font="5"> </text>
<text top="440" left="533" width="70" height="17" font="5">CV mortality </text>
<text top="459" left="533" width="197" height="17" font="5">Women: 0.82 (95% CI 0.66 to 1.01) </text>
<text top="478" left="533" width="179" height="17" font="5">Men: 0.73 (95% CI 0.64 to 0.83) </text>
<text top="496" left="533" width="3" height="17" font="5"> </text>
<text top="515" left="533" width="29" height="17" font="5">BMI: </text>
<text top="533" left="533" width="217" height="17" font="5">Adjusted HR, any nut consumption &gt;=2 </text>
<text top="552" left="533" width="220" height="17" font="5">times per week versus never consumed </text>
<text top="571" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="589" left="533" width="176" height="17" font="5">&lt;25: 0.91 (95% CI 0.86 to 0.96) </text>
<text top="608" left="533" width="206" height="17" font="5">25 to &lt;30: 0.76 (95% CI 0.68 to 0.84) </text>
<text top="626" left="533" width="183" height="17" font="5">&gt;=30: 0.78 (95% CI 0.63 to 0.96) </text>
<text top="645" left="533" width="116" height="17" font="5">p for interaction 0.04 </text>
<text top="663" left="533" width="3" height="17" font="5"> </text>
<text top="682" left="533" width="91" height="17" font="5">Smoking status: </text>
<text top="701" left="533" width="217" height="17" font="5">Adjusted HR, any nut consumption &gt;=2 </text>
<text top="719" left="533" width="220" height="17" font="5">times per week versus never consumed </text>
<text top="738" left="533" width="104" height="17" font="5">All-cause mortality </text>
<text top="756" left="533" width="180" height="17" font="5">Ever: 0.83 (95% CI 0.79 to 0.88) </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="183" height="17" font="5">Never: 0.89 (955 CI 0.84 to 0.95) </text>
<text top="162" left="533" width="116" height="17" font="5">p for interaction 0.61 </text>
<text top="180" left="533" width="3" height="17" font="5"> </text>
<text top="200" left="533" width="7" height="17" font="5">2</text>
<text top="199" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="219" left="533" width="3" height="17" font="5"> </text>
<text top="237" left="533" width="58" height="17" font="5">CV death: </text>
<text top="256" left="533" width="221" height="17" font="5">Adjusted HR, consumption  five or more </text>
<text top="275" left="533" width="160" height="17" font="5">times per week versus never </text>
<text top="293" left="533" width="163" height="17" font="5">A: 0.75 (95% CI 0.62 to 0.84) </text>
<text top="312" left="533" width="36" height="17" font="5">B: NR </text>
<text top="330" left="533" width="37" height="17" font="5">C: NR </text>
<text top="349" left="533" width="3" height="17" font="5"> </text>
<text top="367" left="533" width="107" height="17" font="5">All-cause mortality: </text>
<text top="386" left="533" width="238" height="17" font="5">Adjusted HR, consumption 2 or more times </text>
<text top="405" left="533" width="234" height="17" font="5">per week versus never consumed and five </text>
<text top="423" left="533" width="206" height="17" font="5">or more times per week versus never </text>
<text top="442" left="533" width="225" height="17" font="5">A: 0.86 (95% CI 0.82 to 0.89), 0.83 (95% </text>
<text top="460" left="533" width="73" height="17" font="5">0.78 to 0.88) </text>
<text top="479" left="533" width="187" height="17" font="5">B: 0.88 (95% CI 0.84 to 0.93), NR </text>
<text top="498" left="533" width="188" height="17" font="5">C: 0.83 (95% CI 0.79 to 0.88), NR </text>
<text top="516" left="533" width="3" height="17" font="5"> </text>
<text top="535" left="533" width="51" height="17" font="5">Fatal MI: </text>
<text top="553" left="533" width="238" height="17" font="5">Adjusted HR, consumption 2 or more times </text>
<text top="572" left="533" width="234" height="17" font="5">per week versus never consumed and five </text>
<text top="590" left="533" width="206" height="17" font="5">or more times per week versus never </text>
<text top="609" left="533" width="225" height="17" font="5">A: 0.74 (95% CI 0.68 to 0.81), 0.71 (95% </text>
<text top="627" left="533" width="88" height="17" font="5">CI 0.63 to 0.81) </text>
<text top="646" left="533" width="187" height="17" font="5">B: 0.76 (95% CI 0.68 to 0.84), NR </text>
<text top="665" left="533" width="188" height="17" font="5">C: 0.76 (95% CI 0.67 to 0.85), NR </text>
<text top="683" left="533" width="3" height="17" font="5"> </text>
<text top="702" left="533" width="71" height="17" font="5">Fatal stroke: </text>
<text top="720" left="533" width="238" height="17" font="5">Adjusted HR, consumption 2 or more times </text>
<text top="739" left="533" width="234" height="17" font="5">per week versus never consumed and five </text>
<text top="758" left="533" width="206" height="17" font="5">or more times per week versus never </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="225" height="17" font="5">A: 0.92 (95% CI 0.79 to 1.08), 0.89 (95% </text>
<text top="162" left="533" width="88" height="17" font="5">CI 0.67 to 1.19) </text>
<text top="180" left="533" width="187" height="17" font="5">B: 0.97 (95% CI 0.67 to 1.40), NR </text>
<text top="199" left="533" width="188" height="17" font="5">C: 0.96 (95% CI 0.78 to 1.19), NR </text>
<text top="218" left="533" width="3" height="17" font="5"> </text>
<text top="249" left="75" width="89" height="17" font="5">Bernstein, 2010 </text>
<text top="266" left="75" width="70" height="17" font="5">(Circulation) </text>
<text top="283" left="75" width="3" height="17" font="5"> </text>
<text top="300" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20713902">20713902</a></text>
<text top="300" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20713902"> </a></text>
<text top="249" left="193" width="65" height="17" font="5">Study type: </text>
<text top="266" left="193" width="40" height="17" font="5">Cohort </text>
<text top="283" left="193" width="57" height="17" font="5">N=84,136 </text>
<text top="249" left="325" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="267" left="325" width="184" height="17" font="5">NHS (no CVD or DM at baseline) </text>
<text top="250" left="533" width="7" height="17" font="5">1</text>
<text top="249" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="269" left="533" width="235" height="17" font="5">Age, time period, total energy, cereal fiber, </text>
<text top="287" left="533" width="229" height="17" font="5">alcohol, trans fat, BMI, cigarette smoking, </text>
<text top="306" left="533" width="211" height="17" font="5">menopausal status, parental history of </text>
<text top="324" left="533" width="218" height="17" font="5">early myocardial infarction, multivitamin </text>
<text top="343" left="533" width="237" height="17" font="5">use, vitamin E supplement use, aspirin use </text>
<text top="362" left="533" width="227" height="17" font="5">at least once per week, physical exercise </text>
<text top="380" left="533" width="3" height="17" font="5"> </text>
<text top="400" left="533" width="7" height="17" font="5">2</text>
<text top="399" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="419" left="533" width="3" height="17" font="5"> </text>
<text top="437" left="533" width="117" height="17" font="5">Fatal or non-fatal MI: </text>
<text top="456" left="533" width="233" height="17" font="5">Adjusted RR, 5th vs. 1st quintile and per 1 </text>
<text top="474" left="533" width="138" height="17" font="5">serving per day increase </text>
<text top="493" left="533" width="225" height="17" font="5">A: 1.22 (95% CI 1.06 to 1.40), 1.13 (95% </text>
<text top="512" left="533" width="88" height="17" font="5">CI 1.07 to 1.20) </text>
<text top="530" left="533" width="225" height="17" font="5">B: 1.29 (95% CI 1.12 to 1.49), 1.16 (95% </text>
<text top="549" left="533" width="88" height="17" font="5">CI 1.09 to 1.23) </text>
<text top="567" left="533" width="226" height="17" font="5">C: 1.13 (95% CI 0.99 to 1.30), 1.19 (95% </text>
<text top="586" left="533" width="88" height="17" font="5">CI 1.07 to 1.32) </text>
<text top="604" left="533" width="226" height="17" font="5">D: 0.92 (95% CI 0.80 to 1.06), 0.90 (95% </text>
<text top="623" left="533" width="88" height="17" font="5">CI 0.75 to 1.08) </text>
<text top="642" left="533" width="225" height="17" font="5">E: 0.81 (95% CI 0.72 to 0.90), 0.81 (95% </text>
<text top="660" left="533" width="88" height="17" font="5">CI 0.66 to 1.00) </text>
<text top="679" left="533" width="187" height="17" font="5">F: 1.26 (95% CI 1.11 to 1.43), NR </text>
<text top="697" left="533" width="189" height="17" font="5">G: 1.28 (95% CI 1.12 to 1.46), NR </text>
<text top="716" left="533" width="226" height="17" font="5">H: 1.09 (95% CI 0.97 to 1.22), 1.03 (95% </text>
<text top="734" left="533" width="88" height="17" font="5">CI 1.00 to 1.06) </text>
<text top="753" left="533" width="236" height="17" font="5">I: 0.90 (95% CI 0.80 to 1.01), 1.01 (95% CI </text>
<text top="772" left="533" width="73" height="17" font="5">0.96 to 1.04) </text>
<text top="249" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="223" height="17" font="5">J: 0.96 (95% CI 0.85 to 1.09), 1.04 (95% </text>
<text top="162" left="533" width="88" height="17" font="5">CI 0.93 to 1.16) </text>
<text top="180" left="533" width="225" height="17" font="5">K: 0.68 (95% CI 0.60 to 0.76), 0.78 (95% </text>
<text top="199" left="533" width="88" height="17" font="5">CI 0.66 to 0.93) </text>
<text top="218" left="533" width="224" height="17" font="5">L: 0.89 (95% CI 0.80 to 0.99), 0.76 (95% </text>
<text top="236" left="533" width="88" height="17" font="5">CI 0.50 to 1.14) </text>
<text top="255" left="533" width="228" height="17" font="5">M: 1.02 (95% CI 0.90 to 1.14), 0.97 (95% </text>
<text top="273" left="533" width="88" height="17" font="5">CI 0.79 to 1.19) </text>
<text top="292" left="533" width="226" height="17" font="5">N: 0.91 (95% CI 0.82 to 1.02), 0.94 (95% </text>
<text top="310" left="533" width="88" height="17" font="5">CI 0.72 to 1.23) </text>
<text top="329" left="533" width="227" height="17" font="5">O: 1.03 (95% CI 0.91 to 1.15), 1.41 (95% </text>
<text top="348" left="533" width="88" height="17" font="5">CI 1.12 to 1.76) </text>
<text top="366" left="533" width="225" height="17" font="5">P: 1.11 (95% CI 0.99 to 1.23), 1.35 (95% </text>
<text top="385" left="533" width="88" height="17" font="5">CI 0.94 to 1.93) </text>
<text top="403" left="533" width="227" height="17" font="5">Q: 1.09 (95% CI 0.98 to 1.22), 1.23 (95% </text>
<text top="422" left="533" width="88" height="17" font="5">CI 1.01 to 1.49) </text>
<text top="440" left="533" width="226" height="17" font="5">R: 1.10 (95% CI 0.96 to 1.27), 1.08 (95% </text>
<text top="459" left="533" width="88" height="17" font="5">CI 0.92 to 1.27) </text>
<text top="478" left="533" width="225" height="17" font="5">S: 1.09 (95% CI 0.98 to 1.23), 1.42 (95% </text>
<text top="496" left="533" width="88" height="17" font="5">CI 1.10 to 1.84) </text>
<text top="515" left="533" width="225" height="17" font="5">T: 1.05 (95% CI 0.93 to 1.17), 1.20 (95% </text>
<text top="533" left="533" width="88" height="17" font="5">CI 1.03 to 1.40) </text>
<text top="552" left="533" width="226" height="17" font="5">U: 0.97 (95% CI 0.82 to 1.15), 1.05 (95% </text>
<text top="571" left="533" width="84" height="17" font="5">CI 0.72 to 1.54 </text>
<text top="589" left="533" width="187" height="17" font="5">V: NR, 0.96 (95% CI 0.37 to 2.52) </text>
<text top="608" left="533" width="229" height="17" font="5">W: 0.91 (95% CI 0.75 to 1.11), 0.88 (95% </text>
<text top="626" left="533" width="88" height="17" font="5">CI 0.52 to 1.49) </text>
<text top="658" left="75" width="66" height="17" font="5">Song, 2016 </text>
<text top="675" left="75" width="3" height="17" font="5"> </text>
<text top="692" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27479196">27479196</a></text>
<text top="692" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27479196"> </a></text>
<text top="658" left="193" width="105" height="17" font="5">Study type: Cohort </text>
<text top="675" left="193" width="64" height="17" font="5">N=131,342 </text>
<text top="658" left="325" width="185" height="17" font="5">Inclusion criteria: NHS and HPFS </text>
<text top="676" left="325" width="154" height="17" font="5">(no CVD or DM at baseline) </text>
<text top="659" left="533" width="7" height="17" font="5">1</text>
<text top="658" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="677" left="533" width="201" height="17" font="5">Age, sex, calendar time, total caloric </text>
<text top="696" left="533" width="187" height="17" font="5">intake, percentage of energy from </text>
<text top="715" left="533" width="180" height="17" font="5">saturated fat, polunsaturated fat, </text>
<text top="733" left="533" width="196" height="17" font="5">monounsaturated fat, and trans-fat, </text>
<text top="752" left="533" width="214" height="17" font="5">multivitamin use, smoking status, pack-</text>
<text top="770" left="533" width="221" height="17" font="5">years of smoking, BMI, physical activity, </text>
<text top="658" left="786" width="333" height="17" font="5">Risk of mortality with replacing 3% of energy from processed </text>
<text top="675" left="786" width="352" height="17" font="5">red meat with plant protein: 0.66 (95% CI 0.59 to 0.75); for other </text>
<text top="692" left="786" width="295" height="17" font="5">animal protein sources HR's ranged from 0.81 to 0.94 </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="193" height="17" font="5">alcohol consumption, hypertension </text>
<text top="162" left="533" width="211" height="17" font="5">diagnosis, intake of whole grains, total </text>
<text top="180" left="533" width="219" height="17" font="5">fiber, fruits, and vegetables, and protein </text>
<text top="199" left="533" width="40" height="17" font="5">source </text>
<text top="218" left="533" width="3" height="17" font="5"> </text>
<text top="237" left="533" width="7" height="17" font="5">2</text>
<text top="236" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="256" left="533" width="3" height="17" font="5"> </text>
<text top="275" left="533" width="58" height="17" font="5">CV death: </text>
<text top="293" left="533" width="216" height="17" font="5">Adjusted HR, category 5 (&gt;18% of total </text>
<text top="312" left="533" width="221" height="17" font="5">energy) vs. category 1 (&lt;=10%) and per </text>
<text top="330" left="533" width="231" height="17" font="5">10% increment (animal protein) or per 3% </text>
<text top="349" left="533" width="137" height="17" font="5">increment (plant protein) </text>
<text top="367" left="533" width="225" height="17" font="5">A: 1.09 (95% CI 0.99 to 1.20), 1.08 (95% </text>
<text top="386" left="533" width="88" height="17" font="5">CI 1.01 to 1.16) </text>
<text top="405" left="533" width="225" height="17" font="5">B: 0.85 (95% CI 0.74 to 0.97), 0.88 (95% </text>
<text top="423" left="533" width="88" height="17" font="5">CI 0.80 to 0.97) </text>
<text top="442" left="533" width="3" height="17" font="5"> </text>
<text top="460" left="533" width="107" height="17" font="5">All-cause mortality: </text>
<text top="479" left="533" width="216" height="17" font="5">Adjusted HR, category 5 (&gt;18% of total </text>
<text top="498" left="533" width="221" height="17" font="5">energy) vs. category 1 (&lt;=10%) and per </text>
<text top="516" left="533" width="231" height="17" font="5">10% increment (animal protein) or per 3% </text>
<text top="535" left="533" width="137" height="17" font="5">increment (plant protein) </text>
<text top="553" left="533" width="225" height="17" font="5">A: 1.09 (95% CI 0.99 to 1.20), 1.08 (95% </text>
<text top="572" left="533" width="88" height="17" font="5">CI 1.01 to 1.16) </text>
<text top="590" left="533" width="225" height="17" font="5">B: 0.85 (95% CI 0.74 to 0.97), 0.88 (95% </text>
<text top="609" left="533" width="88" height="17" font="5">CI 0.80 to 0.97) </text>
<text top="640" left="75" width="80" height="17" font="5">Tharrey, 2018 </text>
<text top="657" left="75" width="3" height="17" font="5"> </text>
<text top="675" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29618018">29618018</a></text>
<text top="675" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29618018"> </a></text>
<text top="640" left="193" width="105" height="17" font="5">Study type: Cohort </text>
<text top="657" left="193" width="57" height="17" font="5">N=81,337 </text>
<text top="640" left="325" width="189" height="17" font="5">Inclusion criteria: Adventist Health </text>
<text top="659" left="325" width="163" height="17" font="5">Study 2 (no CVD at baseline) </text>
<text top="641" left="533" width="7" height="17" font="5">1</text>
<text top="640" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="660" left="533" width="207" height="17" font="5">Variables adjusted for in the analysis: </text>
<text top="679" left="533" width="195" height="17" font="5">Age, sex, race, energy intake, BMI, </text>
<text top="697" left="533" width="223" height="17" font="5">physical activity, smoking status, alcohol </text>
<text top="716" left="533" width="223" height="17" font="5">consumption, income, education, marital </text>
<text top="734" left="533" width="239" height="17" font="5">status, type of diet on vegetarian spectrum, </text>
<text top="753" left="533" width="234" height="17" font="5">polyunsaturated fatty acids, saturated fatty </text>
<text top="772" left="533" width="229" height="17" font="5">acids, sodium, fiber, vitamins A, C, E, B6, </text>
<text top="640" left="786" width="318" height="17" font="5">Each 18-g increase in animal protein associated with 12% </text>
<text top="657" left="786" width="318" height="17" font="5">increase in risk of CV mortality and each 18-g increase in  </text>
<text top="675" left="786" width="323" height="17" font="5">protein associated with 5% decrease in risk of CV mortality </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="236" height="17" font="5">B9, and B12, fat from meat product and fat </text>
<text top="162" left="533" width="55" height="17" font="5">from nuts </text>
<text top="180" left="533" width="3" height="17" font="5"> </text>
<text top="199" left="533" width="58" height="17" font="5">CV death: </text>
<text top="218" left="533" width="224" height="17" font="5">Adjusted  HR, quintile 5 versus quintile 1 </text>
<text top="236" left="533" width="166" height="17" font="5">A: 0.93 (98.75% CI 0.76 1.13) </text>
<text top="255" left="533" width="180" height="17" font="5">B: 1.12 (98.75% CI 0.90 to 1.41) </text>
<text top="273" left="533" width="181" height="17" font="5">C: 1.46 (98.75% CI 0.98 to 2.18) </text>
<text top="292" left="533" width="181" height="17" font="5">D: 1.04 (98.75% CI 0.84 to 1.28) </text>
<text top="310" left="533" width="180" height="17" font="5">E: 0.56 (98.75% CI 0.38 to 0.81) </text>
<text top="342" left="75" width="94" height="17" font="5">Micha et al 2017 </text>
<text top="359" left="75" width="3" height="17" font="5"> </text>
<text top="376" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28267855">28267855</a></text>
<text top="376" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28267855"> </a></text>
<text top="342" left="193" width="65" height="17" font="5">Study type: </text>
<text top="359" left="193" width="97" height="17" font="5">Risk model using </text>
<text top="376" left="193" width="98" height="17" font="5">data from various </text>
<text top="393" left="193" width="46" height="17" font="5">sources </text>
<text top="342" left="325" width="98" height="17" font="5">Inclusion Criteria: </text>
<text top="360" left="325" width="176" height="17" font="5">Identified 17 dietary factors with </text>
<text top="379" left="325" width="170" height="17" font="5">associations with CHD, stroke, </text>
<text top="398" left="325" width="177" height="17" font="5">type 2 diabetes, BMI, or systolic </text>
<text top="416" left="325" width="189" height="17" font="5">blood pressure using Bradford-Hill </text>
<text top="435" left="325" width="130" height="17" font="5">criteria and considering </text>
<text top="453" left="325" width="182" height="17" font="5">consistency with other criteria for </text>
<text top="472" left="325" width="173" height="17" font="5">assessing potential causality of </text>
<text top="490" left="325" width="176" height="17" font="5">diet-disease relationships; 10 of </text>
<text top="509" left="325" width="184" height="17" font="5">the 17 were included (7 excluded </text>
<text top="528" left="325" width="150" height="17" font="5">based on major overlap for </text>
<text top="546" left="325" width="133" height="17" font="5">estimating joing effects) </text>
<text top="565" left="325" width="3" height="17" font="5"> </text>
<text top="583" left="325" width="166" height="17" font="5">All observational studies used </text>
<text top="602" left="325" width="185" height="17" font="5">multivariable adjustment for other </text>
<text top="620" left="325" width="63" height="17" font="5">risk factors </text>
<text top="343" left="533" width="7" height="17" font="5">1</text>
<text top="342" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="362" left="533" width="238" height="17" font="5">Absolute number and percentage of overall </text>
<text top="380" left="533" width="217" height="17" font="5">cardiometabolic deaths associated with </text>
<text top="399" left="533" width="217" height="17" font="5">suboptimal intake of each dietary factor </text>
<text top="417" left="533" width="3" height="17" font="5"> </text>
<text top="436" left="533" width="223" height="17" font="7"><i>Associations with all US cardiometabolic </i></text>
<text top="454" left="533" width="219" height="17" font="7"><i>deaths in 2012 vs. optimal consumption </i></text>
<text top="473" left="533" width="35" height="17" font="7"><i>levels </i></text>
<text top="492" left="533" width="3" height="17" font="5"> </text>
<text top="510" left="533" width="208" height="17" font="5">The 10 dietary factors in combination: </text>
<text top="529" left="533" width="92" height="17" font="5">45.4% of deaths </text>
<text top="547" left="533" width="3" height="17" font="5"> </text>
<text top="566" left="533" width="217" height="17" font="5">High sodium: 9.5% of deaths (10.2% of </text>
<text top="584" left="533" width="206" height="17" font="5">CHD deaths; 10.7% of stroke deaths, </text>
<text top="603" left="533" width="193" height="17" font="5">21.4% hypertensive heart disease) </text>
<text top="622" left="533" width="3" height="17" font="5"> </text>
<text top="640" left="533" width="234" height="17" font="5">Low nuts/seeds: 8.5% of deaths (14.7% of </text>
<text top="659" left="533" width="75" height="17" font="5">CHD deaths) </text>
<text top="677" left="533" width="3" height="17" font="5"> </text>
<text top="696" left="533" width="215" height="17" font="5">High processed meats: 8.2% of deaths </text>
<text top="715" left="533" width="205" height="17" font="5">(12.3% of CHD deaths, 17.5% type 2 </text>
<text top="733" left="533" width="94" height="17" font="5">diabetes deaths) </text>
<text top="752" left="533" width="3" height="17" font="5"> </text>
<text top="342" left="786" width="56" height="17" font="5">Summary </text>
<text top="359" left="784" width="343" height="17" font="5">Estimated 45.4% of all cardiometabolic deaths associated with </text>
<text top="378" left="784" width="317" height="17" font="5">suboptimal intakes of 10 dietary factors in 2012 in the US. </text>
<text top="396" left="784" width="340" height="17" font="5">Larger proportion of deaths due to diet in men than in women, </text>
<text top="415" left="784" width="345" height="17" font="5">younger vs older ages, among blacks and Hispanics vs whites, </text>
<text top="433" left="784" width="343" height="17" font="5">and among individuals with low and medium education vs high </text>
<text top="452" left="784" width="57" height="17" font="5">education </text>
<text top="470" left="784" width="3" height="17" font="5"> </text>
<text top="501" left="786" width="3" height="17" font="5"> </text>
<text top="532" left="961" width="3" height="17" font="5"> </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="237" height="17" font="5">Low seafood omega-3 fats: 7.8% of deaths </text>
<text top="162" left="533" width="131" height="17" font="5">(14.7% of CHD deaths) </text>
<text top="180" left="533" width="3" height="17" font="5"> </text>
<text top="199" left="533" width="234" height="17" font="5">Low vegetables: 7.6% of deaths (21.9% of </text>
<text top="218" left="533" width="77" height="17" font="5">stoke deaths) </text>
<text top="236" left="533" width="3" height="17" font="5"> </text>
<text top="255" left="533" width="234" height="17" font="5">Low fruits: 7.5% of deaths (22.4% of stoke </text>
<text top="273" left="533" width="44" height="17" font="5">deaths) </text>
<text top="292" left="533" width="3" height="17" font="5"> </text>
<text top="310" left="533" width="235" height="17" font="5">High sugar sweetened beverages: 7.4% of </text>
<text top="329" left="533" width="222" height="17" font="5">deaths (10.8% of CHD deaths, 14.8% of </text>
<text top="348" left="533" width="131" height="17" font="5">type 2 diabetes deaths) </text>
<text top="366" left="533" width="3" height="17" font="5"> </text>
<text top="385" left="533" width="229" height="17" font="5">Low polyunsaturated fats: 2.3% of deaths </text>
<text top="403" left="533" width="3" height="17" font="5"> </text>
<text top="422" left="533" width="209" height="17" font="5">High unprocessed red meats: 0.4% of </text>
<text top="440" left="533" width="40" height="17" font="5">deaths </text>
<text top="459" left="533" width="3" height="17" font="5"> </text>
<text top="478" left="533" width="191" height="17" font="5">Low whole grains (17.1% of type 2 </text>
<text top="496" left="533" width="94" height="17" font="5">diabetes deaths) </text>
<text top="515" left="533" width="3" height="17" font="5"> </text>
<text top="533" left="533" width="44" height="17" font="7"><i>Gender </i></text>
<text top="552" left="533" width="208" height="17" font="5">Mortality associated with each dietary </text>
<text top="571" left="533" width="235" height="17" font="5">factor modestly higher in men than women </text>
<text top="589" left="533" width="226" height="17" font="5">because of higher proportion of men with </text>
<text top="608" left="533" width="168" height="17" font="5">unhealthy consumption levels. </text>
<text top="626" left="533" width="204" height="17" font="5">Men, suboptimal diet associated with </text>
<text top="645" left="533" width="211" height="17" font="5">48.6% of deaths. Top 5 dietary factors </text>
<text top="663" left="533" width="221" height="17" font="5">associated with cardiometabolic deaths: </text>
<text top="682" left="533" width="195" height="17" font="5">excess processed meats (10.8% of </text>
<text top="701" left="533" width="237" height="17" font="5">deaths), excess sodium (10.0% of deaths), </text>
<text top="719" left="533" width="207" height="17" font="5">sugar sweetened beverages (9.3% of </text>
<text top="738" left="533" width="221" height="17" font="5">deaths), insufficient nuts/seeds (8.8% of </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="219" height="17" font="5">deaths), seafood omega-3 fats (8.8% of </text>
<text top="162" left="533" width="44" height="17" font="5">deaths) </text>
<text top="180" left="533" width="3" height="17" font="5"> </text>
<text top="199" left="533" width="223" height="17" font="5">Women: suboptimal diet associated with </text>
<text top="218" left="533" width="211" height="17" font="5">41.8% of deaths. Top 5 dietary factors </text>
<text top="236" left="533" width="221" height="17" font="5">associated with cardiometabolic deaths: </text>
<text top="255" left="533" width="189" height="17" font="5">excess sodium (8.8%), insufficient </text>
<text top="273" left="533" width="223" height="17" font="5">nuts/seeds (8.1% of deaths), vegetables </text>
<text top="292" left="533" width="224" height="17" font="5">(7.4% of deaths), fruits (7.1% of deaths), </text>
<text top="310" left="533" width="172" height="17" font="5">omega-3 fats (6.7% of deaths.  </text>
<text top="329" left="533" width="3" height="17" font="5"> </text>
<text top="348" left="533" width="25" height="17" font="7"><i>Age </i></text>
<text top="366" left="533" width="223" height="17" font="5">25-64 year olds: Overall, suboptimal diet </text>
<text top="385" left="533" width="229" height="17" font="5">associated with 64.2% of cardiometabolic </text>
<text top="403" left="533" width="195" height="17" font="5">deaths. Dietary factors with highest </text>
<text top="422" left="533" width="230" height="17" font="5">associations with cardiometabolic deaths: </text>
<text top="440" left="533" width="203" height="17" font="5">excess sugar sweetened beverages, </text>
<text top="459" left="533" width="139" height="17" font="5">excess processed meats </text>
<text top="478" left="533" width="3" height="17" font="5"> </text>
<text top="496" left="533" width="219" height="17" font="5">65+: overall, suboptimal diet associated </text>
<text top="515" left="533" width="239" height="17" font="5">with 35.7% of cardiometabolic deaths.  Top </text>
<text top="533" left="533" width="222" height="17" font="5">Dietary factors with highest associations </text>
<text top="552" left="533" width="200" height="17" font="5">with cardiometabolic deaths: excess </text>
<text top="571" left="533" width="236" height="17" font="5">sodium, insufficient nuts/seeds, insufficient </text>
<text top="589" left="533" width="63" height="17" font="5">vegetables </text>
<text top="608" left="533" width="3" height="17" font="5"> </text>
<text top="626" left="533" width="32" height="17" font="7"><i>Race </i></text>
<text top="645" left="533" width="232" height="17" font="5">Estimated proportion of deaths due to diet </text>
<text top="663" left="533" width="226" height="17" font="5">higher among Blacks and Hispanics than </text>
<text top="682" left="533" width="209" height="17" font="5">other races, except with omega-3 fats </text>
<text top="701" left="533" width="225" height="17" font="5">which were higher in whites. Rankings of </text>
<text top="719" left="533" width="200" height="17" font="5">dietary factors were similar by race.  </text>
<text top="738" left="533" width="197" height="17" font="5">Associations of suboptimal diet with </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="228" height="17" font="5">cardiometabolic mortality: Blacks=53.1%, </text>
<text top="162" left="533" width="189" height="17" font="5">Hispanics=50.0%, Whites=42.8%. </text>
<text top="180" left="533" width="3" height="17" font="5"> </text>
<text top="199" left="533" width="96" height="17" font="7"><i>Educational level </i></text>
<text top="218" left="533" width="228" height="17" font="5">Proportion of deaths due to diet generally </text>
<text top="236" left="533" width="236" height="17" font="5">higher in low or medium education vs. high </text>
<text top="255" left="533" width="212" height="17" font="5">education population (e.g.,low vs. high </text>
<text top="273" left="533" width="234" height="17" font="5">education effect of nuts/seseds=10.7% vs. </text>
<text top="292" left="533" width="228" height="17" font="5">6.2%, sugar sweetened beverages=8.4% </text>
<text top="310" left="533" width="184" height="17" font="5">vs. 4.5%, fruits=8.5% vs. 6.4% ).  </text>
<text top="329" left="533" width="227" height="17" font="5">Suboptimal diet associated with 46.8% of </text>
<text top="348" left="533" width="232" height="17" font="5">deaths for low education, 45.7% of deaths </text>
<text top="366" left="533" width="219" height="17" font="5">for medium education, 39.1% for higher </text>
<text top="385" left="533" width="57" height="17" font="5">education </text>
<text top="403" left="533" width="3" height="17" font="5"> </text>
<text top="422" left="533" width="132" height="17" font="5">Trends from 2002-2012 </text>
<text top="440" left="533" width="200" height="17" font="5">Total number of population-adjusted </text>
<text top="459" left="533" width="207" height="17" font="5">cardiometabolic deaths decreased by </text>
<text top="478" left="533" width="192" height="17" font="5">26.5%. Improvements in intakes of </text>
<text top="496" left="533" width="221" height="17" font="5">polyunsaturated fats, nuts/seeds, SSBs, </text>
<text top="515" left="533" width="236" height="17" font="5">whole grains, and fruits led to decreases in </text>
<text top="533" left="533" width="219" height="17" font="5">numbers of diet-related cardiometabolic </text>
<text top="552" left="533" width="238" height="17" font="5">deaths. Estimated diet-associated mortality </text>
<text top="571" left="533" width="235" height="17" font="5">declined for polyunsaturated fats (-20.8%), </text>
<text top="589" left="533" width="229" height="17" font="5">nuts/seeds (-18.0%), SSBs (-14.5%), and </text>
<text top="608" left="533" width="181" height="17" font="5">increased for sodium (5.8%) and </text>
<text top="626" left="533" width="224" height="17" font="5">unprocessed red meats (14.4%). Trends </text>
<text top="645" left="533" width="221" height="17" font="5">were similar by sex and age. Insufficient </text>
<text top="663" left="533" width="232" height="17" font="5">nuts/seeds declined in whites only (10.0% </text>
<text top="682" left="533" width="227" height="17" font="5">to 7.9%), deaths due to insufficient whole </text>
<text top="701" left="533" width="238" height="17" font="5">grains declined in Hispanics only (12.9% to </text>
<text top="719" left="533" width="207" height="17" font="5">7.6^%). Trends by education: percent </text>
<text top="738" left="533" width="227" height="17" font="5">associated with low nuts/seeds decline in </text>
<text top="756" left="533" width="206" height="17" font="5">high education group (8.7% to 6.2%), </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="213" height="17" font="5">SSBs declined more in those with high </text>
<text top="162" left="533" width="209" height="17" font="5">education (5.9% to 4.5% compared to </text>
<text top="180" left="533" width="207" height="17" font="5">9.2% to 8.4% in low education group) </text>
<text top="212" left="75" width="89" height="17" font="5">Epidemiological </text>
<text top="229" left="75" width="76" height="17" font="5">Study of Risk </text>
<text top="246" left="75" width="97" height="17" font="5">Factors for LADA </text>
<text top="263" left="75" width="65" height="17" font="5">and Type 2 </text>
<text top="281" left="75" width="52" height="17" font="5">Diabetes </text>
<text top="298" left="75" width="89" height="17" font="5">(ESTRID) study </text>
<text top="315" left="75" width="94" height="17" font="5">nested in ANDIS </text>
<text top="332" left="75" width="65" height="17" font="5">and ANDiU </text>
<text top="349" left="75" width="42" height="17" font="5">studies </text>
<text top="367" left="75" width="3" height="17" font="5"> </text>
<text top="384" left="75" width="95" height="17" font="5">Lofvenborg et al, </text>
<text top="401" left="75" width="31" height="17" font="5">2016 </text>
<text top="418" left="75" width="3" height="17" font="5"> </text>
<text top="435" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27926472">27926472</a></text>
<text top="435" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27926472"> </a></text>
<text top="212" left="193" width="25" height="17" font="5">Aim </text>
<text top="229" left="193" width="3" height="17" font="5"> </text>
<text top="246" left="193" width="76" height="17" font="5">to investigate </text>
<text top="263" left="193" width="117" height="17" font="5">sweetened beverage </text>
<text top="281" left="193" width="96" height="17" font="5">intake and risk of </text>
<text top="298" left="193" width="104" height="17" font="5">latent autoimmune </text>
<text top="315" left="193" width="99" height="17" font="5">diabetes in adults </text>
<text top="332" left="193" width="104" height="17" font="5">(LADA) and type 2 </text>
<text top="349" left="193" width="50" height="17" font="5">diabetes </text>
<text top="367" left="193" width="3" height="17" font="5"> </text>
<text top="384" left="193" width="99" height="17" font="5">Population-based </text>
<text top="401" left="193" width="103" height="17" font="5">case-control study </text>
<text top="418" left="193" width="3" height="17" font="5"> </text>
<text top="435" left="193" width="89" height="17" font="5">N=2864 (n=357 </text>
<text top="453" left="193" width="120" height="17" font="5">LADA, n=1136 type 2 </text>
<text top="470" left="193" width="98" height="17" font="5">diabetes, n=1371 </text>
<text top="487" left="193" width="51" height="17" font="5">controls) </text>
<text top="212" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="230" left="325" width="161" height="17" font="5">All newly diagnosed cases of </text>
<text top="249" left="325" width="171" height="17" font="5">LADA and a random sample of </text>
<text top="267" left="325" width="193" height="17" font="5">incident type 2 diabetes cases (4:1 </text>
<text top="286" left="325" width="138" height="17" font="5">ratio diabetes to LADA).  </text>
<text top="317" left="326" width="3" height="17" font="5"> </text>
<text top="347" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="378" left="326" width="145" height="17" font="5">Incomplete information on </text>
<text top="396" left="326" width="158" height="17" font="5">exposure or main covariates </text>
<text top="427" left="326" width="187" height="17" font="5">Reported total daily energy intake </text>
<text top="445" left="326" width="191" height="17" font="5">that deviated more than 3 SD from </text>
<text top="464" left="326" width="191" height="17" font="5">log-transformed sex-specific mean </text>
<text top="483" left="326" width="77" height="17" font="5">energy intake </text>
<text top="213" left="533" width="7" height="17" font="5">1</text>
<text top="212" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="232" left="533" width="35" height="17" font="7"><i>LADA </i></text>
<text top="250" left="533" width="194" height="17" font="5">2+ sweetened beverages/day vs. 0 </text>
<text top="269" left="533" width="217" height="17" font="5">servings OR=1.99 (95% CI 1.11-3.56).  </text>
<text top="287" left="533" width="3" height="17" font="5"> </text>
<text top="306" left="533" width="219" height="17" font="5">&gt;5 servings/day OR=4.47 (95% CI 1.21-</text>
<text top="324" left="533" width="45" height="17" font="5">16.47).  </text>
<text top="343" left="533" width="3" height="17" font="5"> </text>
<text top="362" left="533" width="231" height="17" font="5">each daily serving OR=1.15 (95% CI 1.02-</text>
<text top="380" left="533" width="38" height="17" font="5">1.29).  </text>
<text top="399" left="533" width="3" height="17" font="5"> </text>
<text top="417" left="533" width="199" height="17" font="5">each daily serving sugar sweetened </text>
<text top="436" left="533" width="221" height="17" font="5">beverages OR=1.18 (95% CI 1.00-1.39) </text>
<text top="454" left="533" width="3" height="17" font="5"> </text>
<text top="473" left="533" width="219" height="17" font="5">each daily serving artificially sweetened </text>
<text top="492" left="533" width="217" height="17" font="5">beverage intake OR=1.12 (95% ci 0.95-</text>
<text top="510" left="533" width="31" height="17" font="5">1.32) </text>
<text top="529" left="533" width="3" height="17" font="5"> </text>
<text top="547" left="533" width="231" height="17" font="5">Increased risk observed after stratification </text>
<text top="566" left="533" width="212" height="17" font="5">by sex, age, family history of diabetes, </text>
<text top="584" left="533" width="146" height="17" font="5">BMI, median GADA levels </text>
<text top="603" left="533" width="222" height="17" font="5">association between servings per day of </text>
<text top="622" left="533" width="226" height="17" font="5">water consumption and LADA (OR=0.98, </text>
<text top="640" left="533" width="103" height="17" font="5">95% CI 0.94-1.02) </text>
<text top="659" left="533" width="3" height="17" font="5"> </text>
<text top="677" left="533" width="91" height="17" font="7"><i>Type 2 diabetes </i></text>
<text top="696" left="533" width="194" height="17" font="5">2+ sweetened beverages/day vs. 0 </text>
<text top="715" left="533" width="217" height="17" font="5">servings OR=2.39 (95% CI 1.39-4.09).  </text>
<text top="733" left="533" width="3" height="17" font="5"> </text>
<text top="752" left="533" width="226" height="17" font="5">&gt;5 servings/day OR=10.53 (95% CI 2.75-</text>
<text top="770" left="533" width="45" height="17" font="5">40.33).  </text>
<text top="212" left="786" width="56" height="17" font="5">Summary </text>
<text top="229" left="786" width="344" height="17" font="5">Increased intake of sweetened beverages was associated with </text>
<text top="246" left="786" width="313" height="17" font="5">increased risk of LADA and type 2 diabetes. Effects were </text>
<text top="263" left="786" width="309" height="17" font="5">observed for sugar sweetened and artificially sweetened </text>
<text top="281" left="786" width="61" height="17" font="5">beverages </text>
<text top="298" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="3" height="17" font="5"> </text>
<text top="162" left="533" width="231" height="17" font="5">each daily serving OR=1.20 (95% CI 1.07-</text>
<text top="180" left="533" width="38" height="17" font="5">1.34).  </text>
<text top="199" left="533" width="3" height="17" font="5"> </text>
<text top="218" left="533" width="199" height="17" font="5">each daily serving sugar sweetened </text>
<text top="236" left="533" width="221" height="17" font="5">beverages OR=1.21 (95% CI 1.05-1.41) </text>
<text top="255" left="533" width="3" height="17" font="5"> </text>
<text top="273" left="533" width="219" height="17" font="5">each daily serving artificially sweetened </text>
<text top="292" left="533" width="217" height="17" font="5">beverage intake OR=1.18 (95% ci 1.01-</text>
<text top="310" left="533" width="31" height="17" font="5">1.38) </text>
<text top="329" left="533" width="3" height="17" font="5"> </text>
<text top="348" left="533" width="231" height="17" font="5">Increased risk observed after stratification </text>
<text top="366" left="533" width="237" height="17" font="5">by sex, age, family history of diabetes, BMI </text>
<text top="385" left="533" width="3" height="17" font="5"> </text>
<text top="415" left="535" width="223" height="17" font="5">Association between servings per day of </text>
<text top="434" left="535" width="217" height="17" font="5">water consumption and type 2 diabetes </text>
<text top="452" left="535" width="164" height="17" font="5">(OR=0.99, 95% CI 0.96-1.03) </text>
<text top="483" left="535" width="3" height="17" font="5"> </text>
<text top="514" left="75" width="78" height="17" font="5">NHANES and </text>
<text top="532" left="75" width="68" height="17" font="5">NHANES III </text>
<text top="549" left="75" width="89" height="17" font="5">Linked Mortality </text>
<text top="566" left="75" width="38" height="17" font="5">cohort </text>
<text top="583" left="75" width="3" height="17" font="5"> </text>
<text top="600" left="75" width="93" height="17" font="5">Yang et al, 2014 </text>
<text top="618" left="75" width="3" height="17" font="5"> </text>
<text top="635" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24493081">24493081</a></text>
<text top="635" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24493081"> </a></text>
<text top="514" left="193" width="66" height="17" font="5">Study Aims </text>
<text top="532" left="193" width="94" height="17" font="5">To examine time </text>
<text top="549" left="193" width="89" height="17" font="5">trends of added </text>
<text top="566" left="193" width="107" height="17" font="5">sugar consumption </text>
<text top="583" left="193" width="95" height="17" font="5">as percentage of </text>
<text top="600" left="193" width="108" height="17" font="5">daily calories in the </text>
<text top="618" left="193" width="101" height="17" font="5">United States and </text>
<text top="635" left="193" width="83" height="17" font="5">investigate the </text>
<text top="652" left="193" width="101" height="17" font="5">association of this </text>
<text top="669" left="193" width="98" height="17" font="5">consumption with </text>
<text top="687" left="193" width="83" height="17" font="5">CVD mortality  </text>
<text top="704" left="193" width="3" height="17" font="5"> </text>
<text top="721" left="193" width="105" height="17" font="5">Prospective cohort </text>
<text top="738" left="193" width="33" height="17" font="5">study </text>
<text top="755" left="193" width="3" height="17" font="5"> </text>
<text top="514" left="325" width="95" height="17" font="5">Inclusion Criteria </text>
<text top="533" left="325" width="111" height="17" font="5">Nonpregnant adults </text>
<text top="552" left="325" width="3" height="17" font="5"> </text>
<text top="570" left="325" width="99" height="17" font="5">Exclusion Criteria </text>
<text top="589" left="325" width="172" height="17" font="5">Incomplete data on first-day 24 </text>
<text top="607" left="325" width="101" height="17" font="5">hour dietary recall </text>
<text top="626" left="325" width="159" height="17" font="5">History of MI, stroke, or CHF </text>
<text top="644" left="325" width="133" height="17" font="5">Diabetes or on diabetes </text>
<text top="663" left="325" width="69" height="17" font="5">medications </text>
<text top="682" left="325" width="43" height="17" font="5">Cancer </text>
<text top="700" left="325" width="56" height="17" font="5">BMI&lt;18.5 </text>
<text top="719" left="325" width="161" height="17" font="5">Missing values on covariates </text>
<text top="516" left="533" width="7" height="17" font="5">1</text>
<text top="514" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="534" left="533" width="230" height="17" font="5">Trends of consumption of added sugar as </text>
<text top="553" left="533" width="180" height="17" font="5">percentage of total daily calories </text>
<text top="571" left="533" width="3" height="17" font="5"> </text>
<text top="590" left="533" width="223" height="17" font="5">Association between sugar consumption </text>
<text top="609" left="533" width="103" height="17" font="5">and CVD mortality </text>
<text top="627" left="533" width="3" height="17" font="5"> </text>
<text top="646" left="533" width="235" height="17" font="7"><i>Trends</i>: Mean percentage off calories from </text>
<text top="664" left="533" width="227" height="17" font="5">added sugar increased from 15.7% (95% </text>
<text top="683" left="533" width="227" height="17" font="5">CI 15.0-16.4%, p) in 1988-1994 to 16.8% </text>
<text top="701" left="533" width="222" height="17" font="5">(16.0-17.7%, p&lt;0.02) in 1999-2004, and </text>
<text top="720" left="533" width="197" height="17" font="5">decreased to 14.9% (14.2%-15.5%, </text>
<text top="739" left="533" width="128" height="17" font="5">p&lt;0.001) in 2005-2010 </text>
<text top="757" left="533" width="3" height="17" font="5"> </text>
<text top="514" left="786" width="56" height="17" font="5">Summary </text>
<text top="532" left="786" width="318" height="17" font="5">usual percentage of calories from added sugar among US </text>
<text top="549" left="786" width="302" height="17" font="5">adults increased from the late 1980s to 1999-2004 and </text>
<text top="566" left="786" width="349" height="17" font="5">decreased during 2005-2010. Most adults consumed more than </text>
<text top="583" left="786" width="348" height="17" font="5">10% of their total calories from added sugar, and approximately </text>
<text top="600" left="786" width="337" height="17" font="5">10% of adults consumed 25% or more of calories from added </text>
<text top="618" left="786" width="318" height="17" font="5">sugar in 2005-2010. Compared with those who consumed </text>
<text top="635" left="786" width="335" height="17" font="5">approximately 8.0% of calories from added sugar (quintile 1), </text>
<text top="652" left="786" width="344" height="17" font="5">those who consumed approximately 17% to 21% (quintile 4) of </text>
<text top="669" left="786" width="311" height="17" font="5">calories from added sugar had a 38% higher risk of CVD </text>
<text top="687" left="786" width="318" height="17" font="5">mortality, and those who consumed approximately 25% of </text>
<text top="704" left="786" width="317" height="17" font="5">calories from added sugar had double the risk (HR=2.03). </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="193" width="68" height="17" font="5">NHANES III </text>
<text top="160" left="193" width="57" height="17" font="5">N=11,733 </text>
<text top="178" left="193" width="3" height="17" font="5"> </text>
<text top="195" left="193" width="120" height="17" font="5"> NHANES 1999-2004 </text>
<text top="212" left="193" width="50" height="17" font="5">N=8,786 </text>
<text top="229" left="193" width="3" height="17" font="5"> </text>
<text top="247" left="193" width="117" height="17" font="5">NHANES 2005-2010 </text>
<text top="264" left="193" width="57" height="17" font="5">N=10,628 </text>
<text top="143" left="533" width="211" height="17" font="7"><i>Association between quintiles of usual </i></text>
<text top="162" left="533" width="210" height="17" font="7"><i>percentage of calories from sugar and </i></text>
<text top="180" left="533" width="79" height="17" font="7"><i>CVD mortality </i></text>
<text top="199" left="533" width="3" height="17" font="5"> </text>
<text top="218" left="533" width="217" height="17" font="5">Quintile 1 vs. 2: HR=1.07 (95% CI 1.02-</text>
<text top="236" left="533" width="31" height="17" font="5">1.12) </text>
<text top="255" left="533" width="217" height="17" font="5">Quintile 1 vs. 3: HR=1.18 (95% CI 1.06-</text>
<text top="273" left="533" width="31" height="17" font="5">1.31) </text>
<text top="292" left="533" width="213" height="17" font="5">Quintile 1 vs 4: HR=1.38 (95% CI 1.11-</text>
<text top="310" left="533" width="31" height="17" font="5">1.70) </text>
<text top="329" left="533" width="201" height="17" font="5">Quintile1 vs. 5: HR=2.03 (1.26-3.27) </text>
<text top="348" left="533" width="99" height="17" font="5">P for trend=0.004 </text>
<text top="366" left="533" width="3" height="17" font="5"> </text>
<text top="385" left="533" width="222" height="17" font="5">Risk of mortality compared to those who </text>
<text top="403" left="533" width="234" height="17" font="5">consume 0 to&lt;10% of calories from added </text>
<text top="422" left="533" width="38" height="17" font="5">sugar: </text>
<text top="440" left="533" width="212" height="17" font="5">10 to &lt;25% calories form added sugar </text>
<text top="459" left="533" width="160" height="17" font="5">HR=1.30 (95% CI 1.09-1.55) </text>
<text top="478" left="533" width="196" height="17" font="5">≥25% of calories from added sugar </text>
<text top="496" left="533" width="160" height="17" font="5">HR=2.75 (95% CI 1.40-5.42) </text>
<text top="515" left="533" width="99" height="17" font="5">P for trend=0.004 </text>
<text top="533" left="533" width="3" height="17" font="5"> </text>
<text top="552" left="533" width="231" height="17" font="5">Risk of mortality was increased in Quintile </text>
<text top="571" left="533" width="215" height="17" font="5">5 vs. Quintile 1 in all subgroups of age, </text>
<text top="589" left="533" width="236" height="17" font="5">sex, race/ethnicity (except in Non-Hispanic </text>
<text top="608" left="533" width="219" height="17" font="5">Blacks, where risk was non significantly </text>
<text top="626" left="533" width="232" height="17" font="5">reduced), education, healthy eating index, </text>
<text top="645" left="533" width="206" height="17" font="5">physical activity, and BMI, though not </text>
<text top="663" left="533" width="108" height="17" font="5">always significantly </text>
<text top="682" left="533" width="3" height="17" font="5"> </text>
<text top="701" left="533" width="209" height="17" font="5">Significant association between sugar </text>
<text top="719" left="533" width="237" height="17" font="5">sweetened beverage consumption and risk </text>
<text top="738" left="533" width="225" height="17" font="5">of CVD mortality (HR=1.29, 95% CI 1.04-</text>
<text top="756" left="533" width="221" height="17" font="5">1.60) in those with 7+ servings/week vs. </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="226" height="17" font="5">those who consumed 1 serving per week </text>
<text top="162" left="533" width="40" height="17" font="5">or less </text>
<text top="193" left="75" width="73" height="17" font="5">EPIC (Greek </text>
<text top="210" left="75" width="68" height="17" font="5">component) </text>
<text top="227" left="75" width="104" height="17" font="5">Trichopoulou et al, </text>
<text top="245" left="75" width="31" height="17" font="5">2007 </text>
<text top="262" left="75" width="3" height="17" font="5"> </text>
<text top="279" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17136037">17136037</a></text>
<text top="279" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17136037"> </a></text>
<text top="193" left="193" width="73" height="17" font="5">Aim of Study </text>
<text top="210" left="193" width="88" height="17" font="5">To evaluate the </text>
<text top="227" left="193" width="120" height="17" font="5">effects on mortality of </text>
<text top="245" left="193" width="68" height="17" font="5">habitual low </text>
<text top="262" left="193" width="106" height="17" font="5">carbohydrate–high-</text>
<text top="279" left="193" width="115" height="17" font="5">protein diets that are </text>
<text top="296" left="193" width="116" height="17" font="5">thought to contribute </text>
<text top="314" left="193" width="93" height="17" font="5">to weight control </text>
<text top="331" left="193" width="3" height="17" font="5"> </text>
<text top="348" left="193" width="105" height="17" font="5">Prospective cohort </text>
<text top="365" left="193" width="33" height="17" font="5">study </text>
<text top="382" left="193" width="3" height="17" font="5"> </text>
<text top="400" left="193" width="54" height="17" font="5">N=22944 </text>
<text top="193" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="212" left="325" width="84" height="17" font="5">Greek resident </text>
<text top="230" left="325" width="60" height="17" font="5">Age 20-86 </text>
<text top="249" left="325" width="3" height="17" font="5"> </text>
<text top="267" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="286" left="325" width="144" height="17" font="5">Missing data from dietary, </text>
<text top="305" left="325" width="144" height="17" font="5">anthropometric or lifestyle </text>
<text top="323" left="325" width="53" height="17" font="5">variables </text>
<text top="342" left="325" width="92" height="17" font="5">Lost to follow up </text>
<text top="360" left="325" width="191" height="17" font="5">History of coronary artery disease, </text>
<text top="379" left="325" width="177" height="17" font="5">diabetes mellitus, and/or cancer </text>
<text top="194" left="533" width="7" height="17" font="5">1</text>
<text top="193" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="213" left="533" width="209" height="17" font="5">All cause and cause-specific mortality </text>
<text top="232" left="533" width="3" height="17" font="5"> </text>
<text top="250" left="533" width="154" height="17" font="5">Mean follow up of 4.9 years </text>
<text top="269" left="533" width="3" height="17" font="5"> </text>
<text top="287" left="533" width="225" height="17" font="5">Increasing LC/HP score was significantly </text>
<text top="306" left="533" width="197" height="17" font="5">associated with mortality (p=0.001). </text>
<text top="324" left="533" width="193" height="17" font="5">Increase in LC/HP score by 2 units </text>
<text top="343" left="533" width="224" height="17" font="5">Mortality Ratio=1.08 (95% CI 1.03-1.13). </text>
<text top="362" left="533" width="203" height="17" font="5">Increase of LC/HP score of five units </text>
<text top="380" left="533" width="204" height="17" font="5">(corresponding to increase of protein </text>
<text top="399" left="533" width="195" height="17" font="5">intake by 15 g/day and decrease of </text>
<text top="417" left="533" width="215" height="17" font="5">carbohydrates by 50 g/day) associated </text>
<text top="436" left="533" width="238" height="17" font="5">with 22% increase in overall mortality (95% </text>
<text top="454" left="533" width="62" height="17" font="5">CI 9-36%). </text>
<text top="473" left="533" width="3" height="17" font="5"> </text>
<text top="492" left="533" width="187" height="17" font="5">Reference group LC/HP score≤6: </text>
<text top="510" left="533" width="227" height="17" font="5">LC/HP score 7-9, MR=1.20 (95% CI 0.89-</text>
<text top="529" left="533" width="31" height="17" font="5">1.62) </text>
<text top="547" left="533" width="213" height="17" font="5">LC/HP score 10-12, MR=1.42 (95% CI </text>
<text top="566" left="533" width="60" height="17" font="5">1.06-1.89) </text>
<text top="584" left="533" width="213" height="17" font="5">LC-HP score 13-15, MR=1.56 (95% CI </text>
<text top="603" left="533" width="60" height="17" font="5">1.13-2.13) </text>
<text top="622" left="533" width="228" height="17" font="5">LC/HP score≥16, MR=1.71 (95% CI 1.22-</text>
<text top="640" left="533" width="31" height="17" font="5">2.41) </text>
<text top="659" left="533" width="3" height="17" font="5"> </text>
<text top="677" left="533" width="237" height="17" font="5">CVD deaths: Mortality Ratio=1.09 (95% CI: </text>
<text top="696" left="533" width="60" height="17" font="5">1.01-1.17) </text>
<text top="715" left="533" width="3" height="17" font="5"> </text>
<text top="733" left="533" width="232" height="17" font="5">Cancer deaths: Mortality Ratio=1.07 (95% </text>
<text top="752" left="533" width="75" height="17" font="5">CI 0.99-1.15) </text>
<text top="770" left="533" width="3" height="17" font="5"> </text>
<text top="193" left="786" width="56" height="17" font="5">Summary </text>
<text top="210" left="786" width="285" height="17" font="5">Individuals with habitual (not short term) diets low in </text>
<text top="227" left="786" width="334" height="17" font="5">carbohydrates and high in protein tend to have higher overall </text>
<text top="245" left="786" width="326" height="17" font="5">mortality, compared to individuals with habitual diets high in </text>
<text top="262" left="786" width="181" height="17" font="5">carbohydrates and low in protein </text>
<text top="279" left="786" width="3" height="17" font="5"> </text>
<text top="296" left="786" width="62" height="17" font="5">Limitations </text>
<text top="314" left="786" width="186" height="17" font="5">Potential for residual confounding </text>
<text top="331" left="786" width="193" height="17" font="5">Potential for limited generalizability </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="178" height="17" font="5">Other causes of death: Mortality </text>
<text top="162" left="533" width="171" height="17" font="5">Ratio=1.11 (95% CI 1.00-1.23) </text>
<text top="180" left="533" width="3" height="17" font="5"> </text>
<text top="199" left="533" width="219" height="17" font="5">In separate Greek EPIC population with </text>
<text top="218" left="533" width="195" height="17" font="5">CAD at baseline, model for a 2-unit </text>
<text top="236" left="533" width="232" height="17" font="5">increase in LC/HP score (energy-adjusted </text>
<text top="255" left="533" width="235" height="17" font="5">components) Mortality Ratio=1.05 (95% CI </text>
<text top="273" left="533" width="238" height="17" font="5">0.96-1.14).  Analogous model in population </text>
<text top="292" left="533" width="192" height="17" font="5">with diabetes at baseline, mortality </text>
<text top="310" left="533" width="166" height="17" font="5">ratio=1.06 (95% CI 0.95-1.17) </text>
<text top="342" left="75" width="90" height="17" font="5">Noto et al, 2013 </text>
<text top="359" left="75" width="3" height="17" font="5"> </text>
<text top="376" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23372809">23372809</a></text>
<text top="376" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23372809"> </a></text>
<text top="342" left="193" width="66" height="17" font="5">Study Aims </text>
<text top="359" left="193" width="3" height="17" font="5"> </text>
<text top="376" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="393" left="193" width="116" height="17" font="5">and Meta analysis of </text>
<text top="411" left="193" width="119" height="17" font="5">observational studies </text>
<text top="428" left="193" width="3" height="17" font="5"> </text>
<text top="445" left="193" width="75" height="17" font="5">N=17 studies </text>
<text top="462" left="193" width="56" height="17" font="5">(272,216) </text>
<text top="342" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="360" left="325" width="3" height="17" font="5"> </text>
<text top="379" left="325" width="189" height="17" font="5">Studies assessing risk of mortality </text>
<text top="398" left="325" width="187" height="17" font="5">or CVD incidence associated with </text>
<text top="416" left="325" width="137" height="17" font="5">low carbohydrate intake  </text>
<text top="435" left="325" width="3" height="17" font="5"> </text>
<text top="453" left="325" width="135" height="17" font="5">Published full text report </text>
<text top="472" left="325" width="3" height="17" font="5"> </text>
<text top="490" left="325" width="192" height="17" font="5">RCTs or observational studies of 1 </text>
<text top="509" left="325" width="142" height="17" font="5">year+ follow up (no RCTs </text>
<text top="528" left="325" width="57" height="17" font="5">identified) </text>
<text top="546" left="325" width="3" height="17" font="5"> </text>
<text top="565" left="325" width="126" height="17" font="5">Reported relative risks </text>
<text top="583" left="325" width="3" height="17" font="5"> </text>
<text top="602" left="325" width="163" height="17" font="5">Adjusted for at least 3 of age, </text>
<text top="620" left="325" width="180" height="17" font="5">gender, obesity, smoking status, </text>
<text top="639" left="325" width="130" height="17" font="5">diabetes, hypertension, </text>
<text top="658" left="325" width="191" height="17" font="5">hypercholesterolemia, prior history </text>
<text top="676" left="325" width="165" height="17" font="5">of CVD, family history of CVD </text>
<text top="343" left="533" width="7" height="17" font="5">1</text>
<text top="342" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="362" left="533" width="228" height="17" font="5">Pooled estimates of adjusted RRs for low </text>
<text top="380" left="533" width="238" height="17" font="5">carbohydrate intake and effect on all cause </text>
<text top="399" left="533" width="159" height="17" font="5">mortality and CVD incidence </text>
<text top="417" left="533" width="3" height="17" font="5"> </text>
<text top="436" left="533" width="103" height="17" font="7"><i>All cause mortality </i></text>
<text top="454" left="533" width="230" height="17" font="5">Pooled RR of low carbohydrate diet for all </text>
<text top="473" left="533" width="230" height="17" font="5">cause mortality from 4 studies=1.31 (95% </text>
<text top="492" left="533" width="210" height="17" font="5">CI 1.07-1.59) p=0.007, with significant </text>
<text top="510" left="533" width="81" height="17" font="5">heterogeneity I</text>
<text top="511" left="615" width="4" height="11" font="8">2</text>
<text top="510" left="619" width="151" height="17" font="5">=53% (p=0.09). Among the </text>
<text top="529" left="533" width="219" height="17" font="5">sources of heterogeneity explored, RRs </text>
<text top="547" left="533" width="228" height="17" font="5">were significantly elevated in both the US </text>
<text top="566" left="533" width="230" height="17" font="5">(RR=1.12, 95% CI 1.01-1.24) and Europe </text>
<text top="584" left="533" width="234" height="17" font="5">(RR=1.42, 95% CI 1.18-1.72), studies with </text>
<text top="603" left="533" width="199" height="17" font="5">follow up 0of less than 10 years had </text>
<text top="622" left="533" width="217" height="17" font="5">significant RRs (RR=1.40, 95% CI 1.12-</text>
<text top="640" left="533" width="231" height="17" font="5">1.74) while those with longer follow up did </text>
<text top="659" left="533" width="224" height="17" font="5">not have significant RRs (RR=1.27, 95% </text>
<text top="677" left="533" width="173" height="17" font="5">CI 0.88-1.84).  RR for men was </text>
<text top="696" left="533" width="220" height="17" font="5">significantly elevated (RR=1.19, 95% CI </text>
<text top="715" left="533" width="221" height="17" font="5">1.08-1.31) while that for women was not </text>
<text top="733" left="533" width="163" height="17" font="5">(RR=1.34, 95% CI 0.96-1.87) </text>
<text top="752" left="533" width="3" height="17" font="5"> </text>
<text top="342" left="786" width="56" height="17" font="5">Summary </text>
<text top="359" left="786" width="322" height="17" font="5">low-carbohydrate diets were associated with a significantly </text>
<text top="376" left="786" width="324" height="17" font="5">higher risk of all-cause mortality, but not CVD mortality and </text>
<text top="393" left="786" width="55" height="17" font="5">incidence </text>
<text top="411" left="786" width="3" height="17" font="5"> </text>
<text top="428" left="786" width="7" height="17" font="5">  </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="79" height="17" font="7"><i>CVD mortality </i></text>
<text top="174" left="535" width="220" height="17" font="5">RR low carbohydrate diet=1.10 (95% CI </text>
<text top="192" left="535" width="111" height="17" font="5">0.98-1.24), p=0.12, I</text>
<text top="193" left="646" width="4" height="11" font="8">2</text>
<text top="192" left="650" width="106" height="17" font="5">=0% (p=0.41).  RR </text>
<text top="211" left="535" width="207" height="17" font="5">low carbohydrate diet in women=0.98 </text>
<text top="230" left="535" width="159" height="17" font="5">(95% CI 0.78-1.24), p=0.87, I</text>
<text top="231" left="694" width="4" height="11" font="8">2</text>
<text top="230" left="698" width="35" height="17" font="5">=53% </text>
<text top="248" left="535" width="49" height="17" font="5">(p=0.09) </text>
<text top="279" left="535" width="3" height="17" font="5"> </text>
<text top="309" left="535" width="225" height="17" font="5">RR using LC/HP score=1.53 (0.88-2.67), </text>
<text top="328" left="535" width="48" height="17" font="5">p=0.13, I</text>
<text top="329" left="583" width="4" height="11" font="8">2</text>
<text top="328" left="587" width="85" height="17" font="5">=61% (p=0.05) </text>
<text top="359" left="75" width="51" height="17" font="5">Martinez-</text>
<text top="376" left="75" width="89" height="17" font="5">Gonzalez et al., </text>
<text top="394" left="75" width="31" height="17" font="5">2014 </text>
<text top="411" left="75" width="3" height="17" font="5"> </text>
<text top="428" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24871477">24871477</a></text>
<text top="428" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24871477"> </a></text>
<text top="359" left="193" width="59" height="17" font="5">Study Aim </text>
<text top="376" left="193" width="76" height="17" font="5">to identify the </text>
<text top="394" left="193" width="115" height="17" font="5">association between </text>
<text top="411" left="193" width="105" height="17" font="5">an a priori–defined </text>
<text top="428" left="193" width="98" height="17" font="5">provegetarian FP </text>
<text top="445" left="193" width="76" height="17" font="5">and all-cause </text>
<text top="462" left="193" width="50" height="17" font="5">mortality </text>
<text top="480" left="193" width="3" height="17" font="5"> </text>
<text top="497" left="193" width="62" height="17" font="5">Study type </text>
<text top="514" left="193" width="115" height="17" font="5">RCT being analyzed </text>
<text top="531" left="193" width="120" height="17" font="5">as prospective cohort </text>
<text top="548" left="193" width="33" height="17" font="5">study </text>
<text top="566" left="193" width="3" height="17" font="5"> </text>
<text top="583" left="193" width="47" height="17" font="5">N=7216 </text>
<text top="359" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="378" left="325" width="3" height="17" font="5"> </text>
<text top="408" left="326" width="167" height="17" font="5">-men aged 55–80 y or women </text>
<text top="425" left="326" width="78" height="17" font="5">aged 60–80 y </text>
<text top="443" left="326" width="154" height="17" font="5">- no previously documented </text>
<text top="460" left="326" width="132" height="17" font="5">cardiovascular disease  </text>
<text top="477" left="326" width="191" height="17" font="5">- at high cardiovascular risk (either </text>
<text top="494" left="326" width="157" height="17" font="5">type 2 diabetes or ≥ 3 major </text>
<text top="512" left="326" width="159" height="17" font="5">cardiovascular risk factors at </text>
<text top="529" left="326" width="146" height="17" font="5">baseline, including current </text>
<text top="546" left="326" width="180" height="17" font="5">smoking, hypertension (≥140/90 </text>
<text top="563" left="326" width="138" height="17" font="5">mm Hg or treatment with </text>
<text top="580" left="326" width="193" height="17" font="5">antihypertensive agents), high LDL </text>
<text top="598" left="326" width="185" height="17" font="5">cholesterol &gt;160 mg/dL, low HDL </text>
<text top="615" left="326" width="136" height="17" font="5">cholesterol (&lt;40 mg/dL), </text>
<text top="632" left="326" width="194" height="17" font="5">overweight/obesity [BMI ≥ 25], or a </text>
<text top="649" left="326" width="178" height="17" font="5">family history of premature CAD </text>
<text top="667" left="325" width="3" height="17" font="5"> </text>
<text top="685" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="716" left="326" width="172" height="17" font="5">- previous medical diagnosis of </text>
<text top="733" left="326" width="186" height="17" font="5">CAD, stroke, or peripheral arterial </text>
<text top="750" left="326" width="46" height="17" font="5">disease </text>
<text top="360" left="533" width="7" height="17" font="5">1</text>
<text top="359" left="540" width="64" height="18" font="5"> endpoint: </text>
<text top="379" left="533" width="107" height="17" font="5">All cause mortality  </text>
<text top="398" left="533" width="3" height="17" font="5"> </text>
<text top="416" left="533" width="202" height="17" font="5">Mortality rate by quintiles of baseline </text>
<text top="435" left="533" width="148" height="17" font="5">provegetarian food pattern </text>
<text top="453" left="533" width="3" height="17" font="5"> </text>
<text top="472" left="533" width="202" height="17" font="5">Quintile 1 : 12.78/1000 person years </text>
<text top="490" left="533" width="198" height="17" font="5">Quintile 2: 11.68/1000 person years </text>
<text top="509" left="533" width="163" height="17" font="5">(HR=0.98, 95% CI 0.72-1.32) </text>
<text top="528" left="533" width="198" height="17" font="5">Quintile 3: 10.02/1000 person years </text>
<text top="546" left="533" width="163" height="17" font="5">(HR=0.81, 95% CI 0.57-1.14) </text>
<text top="565" left="533" width="191" height="17" font="5">Quintile 4: 8.31/1000 person years </text>
<text top="583" left="533" width="163" height="17" font="5">(HR=0.70, 95% CI 0.49-0.99) </text>
<text top="602" left="533" width="191" height="17" font="5">Quintile 5: 8.20/1000 person years </text>
<text top="620" left="533" width="167" height="17" font="5">(HR=0.66, 95% CI 0.46-0..96) </text>
<text top="639" left="533" width="99" height="17" font="5">P for trend=0.006 </text>
<text top="658" left="533" width="3" height="17" font="5"> </text>
<text top="676" left="533" width="213" height="17" font="7"><i>HR of death by baseline provegetarian </i></text>
<text top="695" left="533" width="193" height="17" font="7"><i>food pattern (compared to very low </i></text>
<text top="713" left="533" width="184" height="17" font="7"><i>provegetarian food pattern (&lt;30)) </i></text>
<text top="732" left="533" width="3" height="17" font="5"> </text>
<text top="751" left="533" width="229" height="17" font="5">Low (30-34): HR=0.71 (95% CI0.50-1.02) </text>
<text top="359" left="786" width="56" height="17" font="5">Summary </text>
<text top="376" left="786" width="350" height="17" font="5">the preference for plant derived foods in the customary diet was </text>
<text top="394" left="786" width="317" height="17" font="5">associated with reduced all-cause mortality during a 4.8-y </text>
<text top="411" left="786" width="328" height="17" font="5">follow-up compared with preferential selection of foods from </text>
<text top="428" left="786" width="86" height="17" font="5">animal sources </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="326" width="194" height="17" font="5">-any severe chronic illness, drug or </text>
<text top="160" left="326" width="95" height="17" font="5">alcohol addiction </text>
<text top="178" left="326" width="188" height="17" font="5">-history of allergy or intolerance to </text>
<text top="195" left="326" width="86" height="17" font="5">olive oil or nuts </text>
<text top="212" left="326" width="151" height="17" font="5">- low predicted likelihood of </text>
<text top="229" left="326" width="186" height="17" font="5">changing dietary habits according </text>
<text top="247" left="326" width="173" height="17" font="5">to the stages-of- change model </text>
<text top="264" left="325" width="52" height="17" font="5">-illiteracy </text>
<text top="143" left="533" width="230" height="17" font="5">Moderate (35-39): HR=0.68 (95% CI 0.48-</text>
<text top="162" left="533" width="31" height="17" font="5">0.96) </text>
<text top="180" left="533" width="219" height="17" font="5">High/very high (≥40): HR=0.59 (95% CI </text>
<text top="199" left="533" width="60" height="17" font="5">0.40-0.88) </text>
<text top="218" left="533" width="99" height="17" font="5">P for trend=0.027 </text>
<text top="236" left="533" width="3" height="17" font="5"> </text>
<text top="255" left="533" width="169" height="17" font="7"><i>HR of death by yearly updated </i></text>
<text top="273" left="533" width="224" height="17" font="7"><i>provegetarian food pattern (compared to </i></text>
<text top="292" left="533" width="53" height="17" font="7"><i>very low) </i></text>
<text top="310" left="533" width="3" height="17" font="5"> </text>
<text top="329" left="533" width="232" height="17" font="5">Low (30-34): HR=0.76 (95% CI 0.53-1.10) </text>
<text top="348" left="533" width="230" height="17" font="5">Moderate (35-39): HR=0.79 (95% CI 0.55-</text>
<text top="366" left="533" width="31" height="17" font="5">1.13) </text>
<text top="385" left="533" width="219" height="17" font="5">High/very high (≥40): HR=0.59 (95% CI </text>
<text top="403" left="533" width="60" height="17" font="5">0.39-0.89) </text>
<text top="422" left="533" width="99" height="17" font="5">P for trend=0.028 </text>
<text top="440" left="533" width="3" height="17" font="5"> </text>
<text top="459" left="533" width="231" height="17" font="7"><i>HR of death by adherence to the absolute </i></text>
<text top="478" left="533" width="236" height="17" font="7"><i>serving based index (compared to low, &lt;4)</i> </text>
<text top="496" left="533" width="3" height="17" font="5"> </text>
<text top="515" left="533" width="237" height="17" font="5">Moderate (4): HR=0.85 (95% CI 0.65-1.11) </text>
<text top="533" left="533" width="217" height="17" font="5">High (&gt;4): HR=0.70 (95% CI 0.51-0.95) </text>
<text top="552" left="533" width="99" height="17" font="5">P for trend=0.003 </text>
<text top="571" left="533" width="3" height="17" font="5"> </text>
<text top="589" left="533" width="3" height="17" font="5"> </text>
<text top="620" left="66" width="3" height="17" font="5"> </text>
<text top="651" left="66" width="514" height="21" font="4"><b>Data Supplement 6. RCTs of Exercise and Physical Activity (Section 3.2.) </b></text>
<text top="672" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="690" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="707" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="672" left="211" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="690" left="216" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="707" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="672" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="672" left="536" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="690" left="554" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="707" left="536" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="724" left="557" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="672" left="727" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="690" left="667" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="707" left="737" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="674" left="935" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="673" left="1000" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="691" left="970" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="708" left="977" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="742" left="75" width="98" height="17" font="5">Orrow et al, 2012 </text>
<text top="759" left="75" width="25" height="17" font="5">(15) </text>
<text top="742" left="193" width="62" height="17" font="5">Study type </text>
<text top="742" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="761" left="324" width="52" height="18" font="5">•  RCTs </text>
<text top="742" left="535" width="94" height="17" font="5">Intervention: any </text>
<text top="759" left="535" width="81" height="17" font="5">intervention of </text>
<text top="743" left="662" width="7" height="17" font="5">1</text>
<text top="742" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="760" left="662" width="3" height="17" font="5"> </text>
<text top="742" left="910" width="92" height="17" font="5">Adverse events: </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="3" height="17" font="5"> </text>
<text top="108" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23243114">23243114</a></text>
<text top="108" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23243114"> </a></text>
<text top="91" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="108" left="193" width="103" height="17" font="5">and meta analysis </text>
<text top="125" left="193" width="3" height="17" font="5"> </text>
<text top="142" left="193" width="101" height="17" font="5">N=15 randomized </text>
<text top="160" left="193" width="86" height="17" font="5">controlled trials </text>
<text top="177" left="193" width="109" height="17" font="5">(8.745 participants) </text>
<text top="91" left="324" width="176" height="18" font="5">•  adults aged 16 years or over </text>
<text top="109" left="324" width="193" height="18" font="5">•  determined as sedentary during </text>
<text top="127" left="325" width="188" height="17" font="5">participant recruitment or baseline </text>
<text top="144" left="325" width="146" height="17" font="5">measurement at trial entry </text>
<text top="162" left="324" width="189" height="18" font="5">•  recruited through primary care  </text>
<text top="180" left="324" width="167" height="18" font="5">•  study of any intervention of </text>
<text top="198" left="325" width="150" height="17" font="5">physical activity promotion, </text>
<text top="215" left="325" width="176" height="17" font="5">provided that the primary stated </text>
<text top="233" left="325" width="171" height="17" font="5">goal was to increase activity or </text>
<text top="250" left="325" width="153" height="17" font="5">fitness levels in participants </text>
<text top="267" left="324" width="184" height="18" font="5">•  outcome of physical activity or </text>
<text top="285" left="325" width="39" height="17" font="5">fitness </text>
<text top="303" left="324" width="197" height="18" font="5">•  minimum follow up of 12 months </text>
<text top="321" left="325" width="109" height="17" font="5">after randomization </text>
<text top="338" left="324" width="158" height="18" font="5">•  reported intention to treat </text>
<text top="356" left="325" width="94" height="17" font="5">analysis results.  </text>
<text top="373" left="325" width="3" height="17" font="5"> </text>
<text top="392" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="411" left="324" width="195" height="18" font="5">•  multifactorial interventions, such </text>
<text top="429" left="325" width="184" height="17" font="5">as promoting dietary modification </text>
<text top="446" left="325" width="162" height="17" font="5">in addition to physical activity </text>
<text top="91" left="535" width="89" height="17" font="5">physical activity </text>
<text top="108" left="535" width="112" height="17" font="5">promotion, provided </text>
<text top="125" left="535" width="89" height="17" font="5">that the primary </text>
<text top="142" left="535" width="102" height="17" font="5">stated goal was to </text>
<text top="160" left="535" width="105" height="17" font="5">increase activity or </text>
<text top="177" left="535" width="87" height="17" font="5">fitness levels in </text>
<text top="194" left="535" width="66" height="17" font="5">participants </text>
<text top="211" left="535" width="3" height="17" font="5"> </text>
<text top="229" left="535" width="61" height="17" font="5">control: no </text>
<text top="246" left="535" width="90" height="17" font="5">restrictions (in 7 </text>
<text top="263" left="535" width="103" height="17" font="5">studies control=no </text>
<text top="280" left="535" width="93" height="17" font="5">intervention, in 8 </text>
<text top="297" left="535" width="109" height="17" font="5">studies there was a </text>
<text top="315" left="535" width="66" height="17" font="5">comparator </text>
<text top="332" left="535" width="71" height="17" font="5">intervention) </text>
<text top="91" left="662" width="235" height="17" font="5">Effect of physical activity promotion on self </text>
<text top="108" left="662" width="219" height="17" font="5">reported physical activity: (dichotomous </text>
<text top="125" left="662" width="192" height="17" font="5">data) OR=1.42 (95% CI 1.17-1.73) </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="235" height="17" font="5">Effect of physical activity promotion on self </text>
<text top="177" left="662" width="212" height="17" font="5">reported physical activity at 12 months </text>
<text top="194" left="662" width="208" height="17" font="5">(continuous data) SMD=0.25 (95% CI </text>
<text top="211" left="662" width="60" height="17" font="5">0.11-0.38) </text>
<text top="229" left="662" width="3" height="17" font="5"> </text>
<text top="246" left="662" width="213" height="17" font="5">Effect of physical activity promotion on </text>
<text top="263" left="662" width="208" height="17" font="5">cardiorespiratory fitness at 12 months </text>
<text top="280" left="662" width="177" height="17" font="5">(SMD=0.51 (95% CI -0.18-1.20) </text>
<text top="297" left="662" width="3" height="17" font="5"> </text>
<text top="315" left="662" width="196" height="17" font="5">Effect of physical activity promotion </text>
<text top="332" left="662" width="221" height="17" font="5">(exercise referral; dichotomous data) on </text>
<text top="349" left="662" width="232" height="17" font="5">self reported physical activity at12 months </text>
<text top="366" left="662" width="117" height="17" font="5">OR=1.38 (0.98-1.95) </text>
<text top="383" left="662" width="3" height="17" font="5"> </text>
<text top="401" left="662" width="196" height="17" font="5">Effect of physical activity promotion </text>
<text top="418" left="662" width="233" height="17" font="5">(exercise referral; continuous data) on self </text>
<text top="435" left="662" width="209" height="17" font="5">reported physical activity at12 months </text>
<text top="452" left="662" width="121" height="17" font="5">OR=0.20 (-0.21-0.61) </text>
<text top="469" left="662" width="3" height="17" font="5"> </text>
<text top="487" left="662" width="227" height="17" font="5">In studies that compared physical activity </text>
<text top="504" left="662" width="192" height="17" font="5">promotion to no intervention (n=6), </text>
<text top="521" left="662" width="198" height="17" font="5">significant intervention effect on self </text>
<text top="538" left="662" width="212" height="17" font="5">reported physical activity at 12 months </text>
<text top="556" left="662" width="218" height="17" font="5">(OR=1.74, 95% CI 1.39 to 2.18); SMD= </text>
<text top="573" left="662" width="219" height="17" font="5">0.36 (95% CI 0.28 to 0.43) compared to </text>
<text top="590" left="662" width="197" height="17" font="5">non-significant effect in studies with </text>
<text top="607" left="662" width="227" height="17" font="5">comparator interventions (OR=1.18, 95% </text>
<text top="624" left="662" width="79" height="17" font="5">CI 0.95-1.48). </text>
<text top="91" left="910" width="188" height="17" font="5">Only one study found a significant </text>
<text top="108" left="910" width="208" height="17" font="5">intervention effect on adverse events, </text>
<text top="125" left="910" width="221" height="17" font="5">reporting a relative 11% increase in falls </text>
<text top="142" left="910" width="202" height="17" font="5">and a 6% increase in injuries among </text>
<text top="160" left="910" width="183" height="17" font="5">intervention participants between </text>
<text top="177" left="910" width="193" height="17" font="5">baseline and 12 months’ follow-up, </text>
<text top="194" left="910" width="190" height="17" font="5">compared with control participants </text>
<text top="642" left="75" width="78" height="17" font="5">Sanchez et al </text>
<text top="660" left="75" width="39" height="17" font="5">(2015) </text>
<text top="677" left="75" width="3" height="17" font="5"> </text>
<text top="694" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25263343">25263343</a></text>
<text top="694" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25263343"> </a></text>
<text top="642" left="193" width="62" height="17" font="5">Study type </text>
<text top="660" left="193" width="107" height="17" font="5">Narrative summary </text>
<text top="677" left="193" width="85" height="17" font="5">of a systematic </text>
<text top="694" left="193" width="114" height="17" font="5">review of systematic </text>
<text top="711" left="193" width="100" height="17" font="5">reviews and meta-</text>
<text top="728" left="193" width="52" height="17" font="5">analyses </text>
<text top="746" left="193" width="3" height="17" font="5"> </text>
<text top="763" left="193" width="76" height="17" font="5">N=10 studies </text>
<text top="642" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="661" left="324" width="178" height="18" font="5">•  literature reviews, systematic </text>
<text top="679" left="325" width="132" height="17" font="5">reviews, meta-analyses </text>
<text top="696" left="324" width="190" height="18" font="5">•  adults aged 18 years and older </text>
<text top="715" left="324" width="181" height="18" font="5">•  any intervention performed or </text>
<text top="733" left="325" width="180" height="17" font="5">initiated in a primary care setting </text>
<text top="750" left="325" width="186" height="17" font="5">with the goal of increasing the PA </text>
<text top="642" left="535" width="91" height="17" font="5">Intervention any </text>
<text top="660" left="535" width="67" height="17" font="5">intervention </text>
<text top="677" left="535" width="74" height="17" font="5">performed or </text>
<text top="694" left="535" width="113" height="17" font="5">initiated in a primary </text>
<text top="711" left="535" width="92" height="17" font="5">care setting with </text>
<text top="728" left="535" width="100" height="17" font="5">goal of increasing </text>
<text top="746" left="535" width="83" height="17" font="5">the PA level of </text>
<text top="763" left="535" width="83" height="17" font="5">participation of </text>
<text top="643" left="662" width="7" height="17" font="5">1</text>
<text top="642" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="661" left="662" width="3" height="17" font="5"> </text>
<text top="678" left="662" width="229" height="17" font="5">High-quality causal evidence of a positive </text>
<text top="695" left="662" width="213" height="17" font="5">effect of interventions on achieving the </text>
<text top="712" left="662" width="231" height="17" font="5">predetermined PA level was shown in five </text>
<text top="730" left="662" width="195" height="17" font="5">systematic reviews. Four of the five </text>
<text top="747" left="662" width="196" height="17" font="5">obtained a small to moderate mean </text>
<text top="764" left="662" width="218" height="17" font="5">standardized effect (0.17−0.28), but the </text>
<text top="642" left="910" width="62" height="17" font="5">Limitations </text>
<text top="660" left="910" width="194" height="17" font="5">Narrative summary, no quantitative </text>
<text top="677" left="910" width="152" height="17" font="5">summary measure of effect </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="325" width="184" height="17" font="5">level or participation of sedentary </text>
<text top="108" left="325" width="160" height="17" font="5">or insufficiently active adults; </text>
<text top="125" left="324" width="139" height="18" font="5">•  comparison group: no </text>
<text top="143" left="325" width="171" height="17" font="5">intervention control, usual care </text>
<text top="161" left="325" width="185" height="17" font="5">control, or alternative intervention </text>
<text top="178" left="325" width="40" height="17" font="5">control </text>
<text top="195" left="324" width="180" height="18" font="5">•  interventions initiated in a PC </text>
<text top="213" left="325" width="181" height="17" font="5">context with PC professionals as </text>
<text top="230" left="325" width="144" height="17" font="5">main intervention agents.  </text>
<text top="248" left="324" width="193" height="18" font="5">•  reported outcome of increase in </text>
<text top="266" left="325" width="182" height="17" font="5">PA level or proportion of patients </text>
<text top="283" left="325" width="186" height="17" font="5">meeting predefined PA level, with </text>
<text top="300" left="325" width="161" height="17" font="5">at least one post-intervention </text>
<text top="318" left="325" width="131" height="17" font="5">follow-up measurement </text>
<text top="335" left="325" width="3" height="17" font="5"> </text>
<text top="353" left="325" width="97" height="17" font="5">Exclusion criteria </text>
<text top="372" left="324" width="179" height="18" font="5">•  Clinical practice guidelines or </text>
<text top="390" left="325" width="169" height="17" font="5">recommendations involving no </text>
<text top="407" left="325" width="168" height="17" font="5">literature search and review of </text>
<text top="425" left="325" width="157" height="17" font="5">studies analyzing evidence;  </text>
<text top="442" left="324" width="159" height="18" font="5">•  Reviews in which primary </text>
<text top="460" left="325" width="177" height="17" font="5">studies carried out in PC did not </text>
<text top="477" left="325" width="161" height="17" font="5">constitute at least 50% of the </text>
<text top="495" left="325" width="95" height="17" font="5">included articles; </text>
<text top="512" left="324" width="184" height="18" font="5">•   Studies conducted in settings </text>
<text top="530" left="325" width="165" height="17" font="5">that were not generalizable to </text>
<text top="547" left="325" width="177" height="17" font="5">primary care, including inpatient </text>
<text top="564" left="325" width="185" height="17" font="5">care, emergency departments, or </text>
<text top="582" left="325" width="125" height="17" font="5">occupational settings;  </text>
<text top="599" left="324" width="196" height="18" font="5">•  Reviews of secondary or tertiary </text>
<text top="617" left="325" width="181" height="17" font="5">prevention, or population studies </text>
<text top="634" left="325" width="146" height="17" font="5">focused only on pathology </text>
<text top="652" left="324" width="163" height="18" font="5">•  Exercise referral schemes </text>
<text top="91" left="535" width="72" height="17" font="5">sedentary or </text>
<text top="108" left="535" width="106" height="17" font="5">insufficiently active </text>
<text top="125" left="535" width="36" height="17" font="5">adults </text>
<text top="142" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="63" height="17" font="5">Control: no </text>
<text top="177" left="535" width="103" height="17" font="5">intervention, usual </text>
<text top="194" left="535" width="58" height="17" font="5">control, or </text>
<text top="211" left="535" width="60" height="17" font="5">alternative </text>
<text top="229" left="535" width="67" height="17" font="5">intervention </text>
<text top="91" left="662" width="232" height="17" font="5">reviews on which these were based found </text>
<text top="108" left="662" width="158" height="17" font="5">evidence of a high degree of </text>
<text top="125" left="662" width="85" height="17" font="5">heterogeneity (I</text>
<text top="126" left="747" width="4" height="11" font="8">2</text>
<text top="125" left="752" width="129" height="17" font="5"> range: 67% to 83.5%)l </text>
<text top="142" left="662" width="3" height="17" font="5"> </text>
<text top="160" left="662" width="188" height="17" font="5">Of the three systematic reviews of </text>
<text top="177" left="662" width="216" height="17" font="5">average quality and with a moderate or </text>
<text top="194" left="662" width="236" height="17" font="5">low degree of evidence, only one  reported </text>
<text top="211" left="662" width="233" height="17" font="5">acceptable evidence that the interventions </text>
<text top="229" left="662" width="195" height="17" font="5">that addressed PA behaviors in PC </text>
<text top="246" left="662" width="206" height="17" font="5">patients could achieve improvements </text>
<text top="263" left="662" width="3" height="17" font="5"> </text>
<text top="280" left="662" width="198" height="17" font="5">No clear evidence of an association </text>
<text top="297" left="662" width="196" height="17" font="5">between patient characteristics and </text>
<text top="315" left="662" width="166" height="17" font="5">effectiveness of interventions  </text>
<text top="671" left="66" width="3" height="17" font="5"> </text>
<text top="710" left="59" width="924" height="21" font="4"><b>Data Supplement 7. Nonrandomized Trials, Observational Studies, and/or Registries of Exercise and Physical Activity (Section 3.2.) </b></text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="78" height="17" font="5">Ekelund et al, </text>
<text top="160" left="75" width="56" height="17" font="5">2016 (16) </text>
<text top="178" left="75" width="3" height="17" font="5"> </text>
<text top="195" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27475271">27475271</a></text>
<text top="195" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27475271"> </a></text>
<text top="143" left="193" width="62" height="17" font="5">Study type </text>
<text top="160" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="178" left="193" width="103" height="17" font="5">and meta analysis </text>
<text top="195" left="193" width="3" height="17" font="5"> </text>
<text top="212" left="193" width="33" height="17" font="5">N=16 </text>
<text top="143" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="161" left="324" width="185" height="18" font="5">•  English-language, prospective </text>
<text top="179" left="325" width="84" height="17" font="5">cohort studies  </text>
<text top="196" left="324" width="178" height="18" font="5">•  had individual level exposure </text>
<text top="214" left="325" width="156" height="17" font="5">and outcome data, provided </text>
<text top="231" left="324" width="187" height="18" font="5">•  data on both daily sitting or TV-</text>
<text top="250" left="325" width="187" height="17" font="5">viewing time and physical activity  </text>
<text top="267" left="324" width="190" height="18" font="5">•  reported effect estimates for all-</text>
<text top="285" left="325" width="172" height="17" font="5">cause mortality, cardiovascular </text>
<text top="302" left="325" width="191" height="17" font="5">disease mortality, or breast, colon, </text>
<text top="319" left="325" width="170" height="17" font="5">and colorectal cancer mortality </text>
<text top="144" left="535" width="7" height="17" font="5">1</text>
<text top="143" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="175" left="535" width="103" height="17" font="7"><i>All cause mortality </i></text>
<text top="192" left="535" width="3" height="17" font="5"> </text>
<text top="209" left="535" width="64" height="17" font="5">Sitting time </text>
<text top="227" left="535" width="185" height="17" font="5">All cause mortality increased with </text>
<text top="244" left="535" width="231" height="17" font="5">increasing siting time in all but the highest </text>
<text top="261" left="535" width="217" height="17" font="5">quartile of physical activity.  The RR for </text>
<text top="278" left="535" width="222" height="17" font="5">sitting &gt;8 h/day compared to &lt;4 h/day in </text>
<text top="296" left="535" width="231" height="17" font="5">the four quartiles of physical activity were: </text>
<text top="313" left="535" width="7" height="17" font="5">1</text>
<text top="314" left="542" width="6" height="11" font="8">st</text>
<text top="313" left="548" width="213" height="17" font="5"> Quartile: RR=1.27 (95% CI 1.22-1.32) </text>
<text top="330" left="535" width="7" height="17" font="5">2</text>
<text top="331" left="542" width="9" height="11" font="8">nd</text>
<text top="330" left="551" width="216" height="17" font="5"> Quartile: RR=1.12 (95% CI: 1.07-1.17) </text>
<text top="347" left="535" width="224" height="17" font="5">3r Quartile: RR=1.10 (95% CI 1.04-1.16) </text>
<text top="364" left="535" width="7" height="17" font="5">4</text>
<text top="366" left="542" width="7" height="11" font="8">th</text>
<text top="364" left="548" width="213" height="17" font="5"> Quartile: RR=1.04 (95% CI 0.98-1.10) </text>
<text top="382" left="535" width="3" height="17" font="5"> </text>
<text top="399" left="535" width="208" height="17" font="5">When comparing each of the physical </text>
<text top="416" left="535" width="215" height="17" font="5">activity by sitting time subgroups to the </text>
<text top="433" left="535" width="227" height="17" font="5">reference group with the highest physical </text>
<text top="450" left="535" width="200" height="17" font="5">activity (≥35.5 MET-h/w) and lowest </text>
<text top="468" left="535" width="208" height="17" font="5">sedentary time (&lt;4 h/day), most other </text>
<text top="485" left="535" width="219" height="17" font="5">groups had a greater all cause mortality </text>
<text top="502" left="535" width="233" height="17" font="5">risk:  RRs increased with increasing sitting </text>
<text top="519" left="535" width="234" height="17" font="5">time regardless of PA, and decreased with </text>
<text top="537" left="535" width="219" height="17" font="5">increasing PA regardless of sitting time. </text>
<text top="554" left="535" width="3" height="17" font="5"> </text>
<text top="571" left="535" width="7" height="17" font="5">1</text>
<text top="572" left="542" width="6" height="11" font="8">st</text>
<text top="571" left="548" width="71" height="17" font="5"> quartile PA: </text>
<text top="588" left="535" width="222" height="17" font="5">lowest PA/lowest sitting time (≤2.5 MET-</text>
<text top="605" left="535" width="232" height="17" font="5">h/w and &lt;4 h/day) RR=1.27 (95% CI 1.22, </text>
<text top="623" left="535" width="31" height="17" font="5">1.30) </text>
<text top="640" left="535" width="3" height="17" font="5"> </text>
<text top="657" left="535" width="226" height="17" font="5">lowest PA/highest sitting time (≤2.5 MET-</text>
<text top="674" left="535" width="237" height="17" font="5">h/w and &gt;8 h/day sitting) RR=1.59 (95% CI </text>
<text top="691" left="535" width="60" height="17" font="5">1.52-1.66) </text>
<text top="709" left="535" width="3" height="17" font="5"> </text>
<text top="726" left="535" width="7" height="17" font="5">2</text>
<text top="727" left="542" width="9" height="11" font="8">nd</text>
<text top="726" left="551" width="145" height="17" font="5"> quartile PA (16 MET-h/w) </text>
<text top="743" left="535" width="205" height="17" font="5">Risk significantly higher than referent </text>
<text top="760" left="535" width="220" height="17" font="5">category for all categories of sitting time </text>
<text top="143" left="786" width="63" height="17" font="5">Summary:  </text>
<text top="160" left="786" width="345" height="17" font="5">High levels of moderate intensity physical activity (ie, about 60–</text>
<text top="178" left="786" width="209" height="17" font="5">75 min per day) seem to eliminate the </text>
<text top="195" left="786" width="307" height="17" font="5">increased risk of death associated with high sitting time. </text>
<text top="212" left="786" width="310" height="17" font="5">However, this high activity level attenuates, but does not </text>
<text top="229" left="786" width="331" height="17" font="5">eliminate the increased risk associated with high TV-viewing </text>
<text top="247" left="786" width="30" height="17" font="5">time. </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="218" height="17" font="5">(e.g., RR 1.27, 95% CI 1.21-1.33 for &gt;8 </text>
<text top="160" left="535" width="74" height="17" font="5">hours sitting) </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="7" height="17" font="5">3</text>
<text top="196" left="542" width="7" height="11" font="8">rd</text>
<text top="195" left="549" width="145" height="17" font="5"> quartile PA (30 MET-h/w) </text>
<text top="212" left="535" width="205" height="17" font="5">Risk significantly higher than referent </text>
<text top="229" left="535" width="233" height="17" font="5">category for those sitting 4+ hours per day </text>
<text top="247" left="535" width="218" height="17" font="5">(e.g., RR 1.13, 95% CI 1.07-1.19 for &gt;8 </text>
<text top="264" left="535" width="70" height="17" font="5">hours sitting </text>
<text top="281" left="535" width="3" height="17" font="5"> </text>
<text top="298" left="535" width="7" height="17" font="5">4</text>
<text top="299" left="542" width="7" height="11" font="8">th</text>
<text top="298" left="548" width="162" height="17" font="5"> quartile PA (&gt;35.5 MET-h/w) </text>
<text top="315" left="535" width="227" height="17" font="5">highest PA/highest sitting time (&gt;35 MET-</text>
<text top="333" left="535" width="232" height="17" font="5">h/w and &gt;8 h/day) RR=1.04 (95% CI 0.99, </text>
<text top="350" left="535" width="31" height="17" font="5">1.10) </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="210" height="17" font="5">Similar patterns were observed for TV </text>
<text top="401" left="535" width="225" height="17" font="5">viewing time, though the effect estimates </text>
<text top="419" left="535" width="98" height="17" font="5">were less precise </text>
<text top="436" left="535" width="185" height="17" font="5">All cause mortality increased with </text>
<text top="453" left="535" width="197" height="17" font="5">increasing TV time in all quartiles of </text>
<text top="470" left="535" width="230" height="17" font="5">physical activity.  The RR for watching TV </text>
<text top="487" left="535" width="233" height="17" font="5">≥5 h/day compared to &lt;1 h/day in the four </text>
<text top="505" left="535" width="186" height="17" font="5">quartiles of physical activity were: </text>
<text top="522" left="535" width="7" height="17" font="5">1</text>
<text top="523" left="542" width="6" height="11" font="8">st</text>
<text top="522" left="548" width="213" height="17" font="5"> Quartile: RR=1.44 (95% CI 1.34-1.56) </text>
<text top="539" left="535" width="7" height="17" font="5">2</text>
<text top="540" left="542" width="9" height="11" font="8">nd</text>
<text top="539" left="551" width="216" height="17" font="5"> Quartile: RR=1.29 (95% CI: 1.19-1.39) </text>
<text top="556" left="535" width="224" height="17" font="5">3r Quartile: RR=1.41 (95% CI 1.28-1.56) </text>
<text top="573" left="535" width="7" height="17" font="5">4</text>
<text top="575" left="542" width="7" height="11" font="8">th</text>
<text top="573" left="548" width="213" height="17" font="5"> Quartile: RR=1.15 (95% CI 1.05-1.27) </text>
<text top="591" left="535" width="3" height="17" font="5"> </text>
<text top="608" left="535" width="227" height="17" font="5">Physical activity by TV time subgroups to </text>
<text top="625" left="535" width="199" height="17" font="5">the reference group with the highest </text>
<text top="642" left="535" width="209" height="17" font="5">physical activity (≥35.5 MET-h/w) and </text>
<text top="660" left="535" width="185" height="17" font="5">lowest sedentary time (&lt;1 h/day): </text>
<text top="677" left="535" width="3" height="17" font="5"> </text>
<text top="694" left="535" width="7" height="17" font="5">1</text>
<text top="695" left="542" width="6" height="11" font="8">st</text>
<text top="694" left="548" width="152" height="17" font="5"> quartile PA (≤2.5 MT-h/w): </text>
<text top="711" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="728" left="535" width="204" height="17" font="5">category for all categories of TV time </text>
<text top="746" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="228" height="17" font="5">lowest PA/lowest TV time (≤2.5 MET-h/w </text>
<text top="160" left="535" width="210" height="17" font="5">and &lt;1 h/day) RR=1.32 (95% CI 1.20, </text>
<text top="178" left="535" width="31" height="17" font="5">1.46) </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="232" height="17" font="5">lowest PA/highest TV time (≤2.5 MET-h/w </text>
<text top="229" left="535" width="215" height="17" font="5">and ≥5 h/day sitting) RR=1.93 (95% CI </text>
<text top="247" left="535" width="60" height="17" font="5">1.76-2.01) </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="7" height="17" font="5">2</text>
<text top="282" left="542" width="9" height="11" font="8">nd</text>
<text top="281" left="551" width="145" height="17" font="5"> quartile PA (16 MET-h/w) </text>
<text top="298" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="315" left="535" width="235" height="17" font="5">category for all categories of TV time (e.g., </text>
<text top="333" left="535" width="222" height="17" font="5">RR 1.48, 95% CI 1.35-1.61 for ≥5 hours </text>
<text top="350" left="535" width="50" height="17" font="5">TV time) </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="7" height="17" font="5">3</text>
<text top="385" left="542" width="7" height="11" font="8">rd</text>
<text top="384" left="549" width="145" height="17" font="5"> quartile PA (30 MET-h/w) </text>
<text top="401" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="419" left="535" width="225" height="17" font="5">category for those watching TV 3+ hours </text>
<text top="436" left="535" width="227" height="17" font="5">per day (e.g., RR 1.35, 95% CI 1.23-1.49 </text>
<text top="453" left="535" width="120" height="17" font="5">for ≥5 hours TV time) </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="487" left="535" width="7" height="17" font="5">4</text>
<text top="489" left="542" width="7" height="11" font="8">th</text>
<text top="487" left="548" width="163" height="17" font="5"> quartile PA (≥35.5 MET-h/w) </text>
<text top="505" left="535" width="222" height="17" font="5">highest PA/highest TV time (≥35.5 MET-</text>
<text top="522" left="535" width="233" height="17" font="5">h/w and ≥5 hours TV time) RR=1.16 (95% </text>
<text top="539" left="535" width="78" height="17" font="5">CI 1.05, 1.28) </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="79" height="17" font="7"><i>CVD mortality </i></text>
<text top="591" left="535" width="3" height="17" font="5"> </text>
<text top="608" left="535" width="64" height="17" font="5">Sitting time </text>
<text top="625" left="535" width="231" height="17" font="5">Compared to the reference group with the </text>
<text top="642" left="535" width="228" height="17" font="5">highest physical activity (≥35.5 MET-h/w) </text>
<text top="660" left="535" width="209" height="17" font="5">and lowest sedentary time (&lt;4 h/day), </text>
<text top="677" left="535" width="208" height="17" font="5">most other groups had a greater CVD </text>
<text top="694" left="535" width="217" height="17" font="5">mortality risk:  RRs generally increased </text>
<text top="711" left="535" width="235" height="17" font="5">with increasing sitting time, and decreased </text>
<text top="728" left="535" width="215" height="17" font="5">with increasing PA regardless of sitting </text>
<text top="746" left="535" width="30" height="17" font="5">time. </text>
<text top="763" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="7" height="17" font="5">1</text>
<text top="144" left="542" width="6" height="11" font="8">st</text>
<text top="143" left="548" width="71" height="17" font="5"> quartile PA: </text>
<text top="160" left="535" width="215" height="17" font="5">RRs significantly higher than reference </text>
<text top="178" left="535" width="220" height="17" font="5">category for all categories of sitting time </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="222" height="17" font="5">lowest PA/lowest sitting time (≤2.5 MET-</text>
<text top="229" left="535" width="232" height="17" font="5">h/w and &lt;4 h/day) RR=1.34 (95% CI 1.24, </text>
<text top="247" left="535" width="31" height="17" font="5">1.43) </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="226" height="17" font="5">lowest PA/highest sitting time (≤2.5 MET-</text>
<text top="298" left="535" width="237" height="17" font="5">h/w and &gt;8 h/day sitting) RR=1.74 (95% CI </text>
<text top="315" left="535" width="60" height="17" font="5">1.60-1.90) </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="350" left="535" width="7" height="17" font="5">2</text>
<text top="351" left="542" width="9" height="11" font="8">nd</text>
<text top="350" left="551" width="145" height="17" font="5"> quartile PA (16 MET-h/w) </text>
<text top="367" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="384" left="535" width="220" height="17" font="5">category for all categories of sitting time </text>
<text top="401" left="535" width="218" height="17" font="5">(e.g., RR 1.37, 95% CI 1.25-1.50 for &gt;8 </text>
<text top="419" left="535" width="74" height="17" font="5">hours sitting) </text>
<text top="436" left="535" width="3" height="17" font="5"> </text>
<text top="453" left="535" width="7" height="17" font="5">3</text>
<text top="454" left="542" width="7" height="11" font="8">rd</text>
<text top="453" left="549" width="145" height="17" font="5"> quartile PA (30 MET-h/w) </text>
<text top="470" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="487" left="535" width="221" height="17" font="5">category for those sitting 4-&lt;6 hours per </text>
<text top="505" left="535" width="237" height="17" font="5">day and those sitting &gt;8 hours per day (RR </text>
<text top="522" left="535" width="234" height="17" font="5">1.14, 95% CI 1.06-1.22 and RR 1.16, 95% </text>
<text top="539" left="535" width="147" height="17" font="5">CI 1.04-1.28, respectively) </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="7" height="17" font="5">4</text>
<text top="575" left="542" width="7" height="11" font="8">th</text>
<text top="573" left="548" width="163" height="17" font="5"> quartile PA (≥35.5 MET-h/w) </text>
<text top="591" left="535" width="227" height="17" font="5">highest PA/highest sitting time (&gt;35 MET-</text>
<text top="608" left="535" width="232" height="17" font="5">h/w and &gt;8 h/day) RR=1.07 (95% CI 0.96, </text>
<text top="625" left="535" width="31" height="17" font="5">1.20) </text>
<text top="642" left="535" width="3" height="17" font="5"> </text>
<text top="660" left="535" width="210" height="17" font="5">Similar patterns were observed for TV </text>
<text top="677" left="535" width="71" height="17" font="5">viewing time </text>
<text top="694" left="535" width="3" height="17" font="5"> </text>
<text top="711" left="535" width="7" height="17" font="5">1</text>
<text top="712" left="542" width="6" height="11" font="8">st</text>
<text top="711" left="548" width="152" height="17" font="5"> quartile PA (≤2.5 MT-h/w): </text>
<text top="728" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="746" left="535" width="204" height="17" font="5">category for all categories of TV time </text>
<text top="763" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="228" height="17" font="5">lowest PA/lowest TV time (≤2.5 MET-h/w </text>
<text top="160" left="535" width="210" height="17" font="5">and &lt;1 h/day) RR=1.45 (95% CI 1.21, </text>
<text top="178" left="535" width="31" height="17" font="5">1.73) </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="232" height="17" font="5">lowest PA/highest TV time (≤2.5 MET-h/w </text>
<text top="229" left="535" width="215" height="17" font="5">and ≥5 h/day sitting) RR=2.26 (95% CI </text>
<text top="247" left="535" width="60" height="17" font="5">1.93-2.66) </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="7" height="17" font="5">2</text>
<text top="282" left="542" width="9" height="11" font="8">nd</text>
<text top="281" left="551" width="145" height="17" font="5"> quartile PA (16 MET-h/w) </text>
<text top="298" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="315" left="535" width="235" height="17" font="5">category for all categories of TV time (e.g., </text>
<text top="333" left="535" width="222" height="17" font="5">RR 1.71, 95% CI 1.46-2.01 for ≥5 hours </text>
<text top="350" left="535" width="50" height="17" font="5">TV time) </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="7" height="17" font="5">3</text>
<text top="385" left="542" width="7" height="11" font="8">rd</text>
<text top="384" left="549" width="145" height="17" font="5"> quartile PA (30 MET-h/w) </text>
<text top="401" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="419" left="535" width="224" height="17" font="5">category for those watching TV 3+ hours </text>
<text top="436" left="535" width="227" height="17" font="5">per day (e.g., RR 1.48, 95% CI 1.24-1.78 </text>
<text top="453" left="535" width="120" height="17" font="5">for ≥5 hours TV time) </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="487" left="535" width="7" height="17" font="5">4</text>
<text top="489" left="542" width="7" height="11" font="8">th</text>
<text top="487" left="548" width="163" height="17" font="5"> quartile PA (≥35.5 MET-h/w) </text>
<text top="505" left="535" width="222" height="17" font="5">highest PA/highest TV time (≥35.5 MET-</text>
<text top="522" left="535" width="233" height="17" font="5">h/w and ≥5 hours TV time) RR=1.19 (95% </text>
<text top="539" left="535" width="78" height="17" font="5">CI 0.99, 1.24) </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="3" height="17" font="5"> </text>
<text top="591" left="535" width="93" height="17" font="7"><i>Cancer mortality </i></text>
<text top="608" left="535" width="3" height="17" font="5"> </text>
<text top="625" left="535" width="64" height="17" font="5">Sitting time </text>
<text top="642" left="535" width="3" height="17" font="5"> </text>
<text top="660" left="535" width="7" height="17" font="5">1</text>
<text top="661" left="542" width="6" height="11" font="8">st</text>
<text top="660" left="548" width="160" height="17" font="5"> quartile PA (≤2.5 MET-h/w): </text>
<text top="677" left="535" width="215" height="17" font="5">RRs significantly higher than reference </text>
<text top="694" left="535" width="220" height="17" font="5">category for all categories of sitting time </text>
<text top="711" left="535" width="3" height="17" font="5"> </text>
<text top="728" left="535" width="222" height="17" font="5">lowest PA/lowest sitting time (≤2.5 MET-</text>
<text top="746" left="535" width="232" height="17" font="5">h/w and &lt;4 h/day) RR=1.12 (95% CI 1.06, </text>
<text top="763" left="535" width="31" height="17" font="5">1.19) </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="226" height="17" font="5">lowest PA/highest sitting time (≤2.5 MET-</text>
<text top="178" left="535" width="237" height="17" font="5">h/w and &gt;8 h/day sitting) RR=1.22 (95% CI </text>
<text top="195" left="535" width="60" height="17" font="5">1.13-1.31) </text>
<text top="212" left="535" width="3" height="17" font="5"> </text>
<text top="229" left="535" width="7" height="17" font="5">2</text>
<text top="230" left="542" width="9" height="11" font="8">nd</text>
<text top="229" left="551" width="145" height="17" font="5"> quartile PA (16 MET-h/w) </text>
<text top="247" left="535" width="226" height="17" font="5">RRs not significantly higher than referent </text>
<text top="264" left="535" width="218" height="17" font="5">category for any category of sitting time </text>
<text top="281" left="535" width="218" height="17" font="5">(e.g., RR 1.07, 95% CI 0.98-1.16 for &gt;8 </text>
<text top="298" left="535" width="74" height="17" font="5">hours sitting) </text>
<text top="315" left="535" width="3" height="17" font="5"> </text>
<text top="333" left="535" width="7" height="17" font="5">3</text>
<text top="334" left="542" width="7" height="11" font="8">rd</text>
<text top="333" left="549" width="145" height="17" font="5"> quartile PA (30 MET-h/w) </text>
<text top="350" left="535" width="226" height="17" font="5">RRs not significantly higher than referent </text>
<text top="367" left="535" width="218" height="17" font="5">category for any category of sitting time </text>
<text top="384" left="535" width="218" height="17" font="5">(e.g., RR 0.99, 95% CI 0.90-1.08 for &gt;8 </text>
<text top="401" left="535" width="74" height="17" font="5">hours sitting) </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="436" left="535" width="7" height="17" font="5">4</text>
<text top="437" left="542" width="7" height="11" font="8">th</text>
<text top="436" left="548" width="163" height="17" font="5"> quartile PA (≥35.5 MET-h/w) </text>
<text top="453" left="535" width="228" height="17" font="5">highest PA/highest sitting time (≥35 MET-</text>
<text top="470" left="535" width="232" height="17" font="5">h/w and &gt;8 h/day) RR=0.97 (95% CI 0.88, </text>
<text top="487" left="535" width="31" height="17" font="5">1.06) </text>
<text top="505" left="535" width="3" height="17" font="5"> </text>
<text top="522" left="535" width="210" height="17" font="5">Similar patterns were observed for TV </text>
<text top="539" left="535" width="71" height="17" font="5">viewing time </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="7" height="17" font="5">1</text>
<text top="575" left="542" width="6" height="11" font="8">st</text>
<text top="573" left="548" width="152" height="17" font="5"> quartile PA (≤2.5 MT-h/w): </text>
<text top="591" left="535" width="222" height="17" font="5">RRs higher than referent category for all </text>
<text top="608" left="535" width="120" height="17" font="5">categories of TV time </text>
<text top="625" left="535" width="3" height="17" font="5"> </text>
<text top="642" left="535" width="228" height="17" font="5">lowest PA/lowest TV time (≤2.5 MET-h/w </text>
<text top="660" left="535" width="207" height="17" font="5">and &lt;1 h/day) RR=1.12 (95% CI 0.96-</text>
<text top="677" left="535" width="31" height="17" font="5">1.30) </text>
<text top="694" left="535" width="3" height="17" font="5"> </text>
<text top="711" left="535" width="232" height="17" font="5">lowest PA/highest TV time (≤2.5 MET-h/w </text>
<text top="728" left="535" width="215" height="17" font="5">and ≥5 h/day sitting) RR=1.26 (95% CI </text>
<text top="746" left="535" width="60" height="17" font="5">1.10-1.45) </text>
<text top="763" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="7" height="17" font="5">2</text>
<text top="144" left="542" width="9" height="11" font="8">nd</text>
<text top="143" left="551" width="145" height="17" font="5"> quartile PA (16 MET-h/w) </text>
<text top="160" left="535" width="205" height="17" font="5">RRs significantly higher than referent </text>
<text top="178" left="535" width="221" height="17" font="5">category for highest category of TV time </text>
<text top="195" left="535" width="226" height="17" font="5">(RR 1.20, 95% CI 1.05-1.37 for ≥5 hours </text>
<text top="212" left="535" width="50" height="17" font="5">TV time) </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="7" height="17" font="5">3</text>
<text top="248" left="542" width="7" height="11" font="8">rd</text>
<text top="247" left="549" width="145" height="17" font="5"> quartile PA (30 MET-h/w) </text>
<text top="264" left="535" width="226" height="17" font="5">RRs not significantly higher than referent </text>
<text top="281" left="535" width="219" height="17" font="5">category for any TV time category (e.g., </text>
<text top="298" left="535" width="222" height="17" font="5">RR 1.15, 95% CI 0.99-1.33 for ≥5 hours </text>
<text top="315" left="535" width="50" height="17" font="5">TV time) </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="350" left="535" width="7" height="17" font="5">4</text>
<text top="351" left="542" width="7" height="11" font="8">th</text>
<text top="350" left="548" width="163" height="17" font="5"> quartile PA (≥35.5 MET-h/w) </text>
<text top="367" left="535" width="222" height="17" font="5">highest PA/highest TV time (≥35.5 MET-</text>
<text top="384" left="535" width="233" height="17" font="5">h/w and ≥5 hours TV time) RR=1.05 (95% </text>
<text top="401" left="535" width="78" height="17" font="5">CI 0.91, 1.22) </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="437" left="75" width="101" height="17" font="5">Hamer et al, 2008 </text>
<text top="454" left="75" width="3" height="17" font="5"> </text>
<text top="471" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18048441">18048441</a></text>
<text top="471" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18048441"> </a></text>
<text top="437" left="193" width="62" height="17" font="5">Study type </text>
<text top="454" left="193" width="82" height="17" font="5">Meta analysis  </text>
<text top="471" left="193" width="3" height="17" font="5"> </text>
<text top="488" left="193" width="75" height="17" font="5">N=18 studies </text>
<text top="505" left="193" width="52" height="17" font="5">(459,833 </text>
<text top="523" left="193" width="70" height="17" font="5">participants) </text>
<text top="437" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="455" left="324" width="172" height="18" font="5">•  English language full-length </text>
<text top="473" left="325" width="167" height="17" font="5">publication in a peer-reviewed </text>
<text top="491" left="325" width="47" height="17" font="5">journal;  </text>
<text top="508" left="324" width="177" height="18" font="5">•  Prospective cohort studies in </text>
<text top="526" left="325" width="151" height="17" font="5">healthy men and women at </text>
<text top="543" left="325" width="49" height="17" font="5">baseline </text>
<text top="561" left="324" width="172" height="18" font="5">•  measures of CVD (fatal and </text>
<text top="579" left="325" width="192" height="17" font="5">nonfatal) and/or all-cause mortality </text>
<text top="596" left="325" width="66" height="17" font="5">at follow-up </text>
<text top="613" left="324" width="179" height="18" font="5">•  measures of habitual walking </text>
<text top="631" left="325" width="190" height="17" font="5">volume (time/distance) or intensity </text>
<text top="649" left="325" width="63" height="17" font="5">at baseline </text>
<text top="438" left="535" width="7" height="17" font="5">1</text>
<text top="437" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="468" left="535" width="193" height="17" font="5">Incident CVD (death from coronary </text>
<text top="486" left="535" width="206" height="17" font="5">causes, myocardial infarction, angina </text>
<text top="503" left="535" width="224" height="17" font="5">pectoris, stroke, congestive heart failure, </text>
<text top="520" left="535" width="171" height="17" font="5">and coronary revascularization </text>
<text top="537" left="535" width="69" height="17" font="5">procedures) </text>
<text top="555" left="535" width="3" height="17" font="5"> </text>
<text top="572" left="535" width="44" height="17" font="5">Results </text>
<text top="589" left="535" width="147" height="17" font="5">Mean 11.3 years follow up </text>
<text top="606" left="535" width="3" height="17" font="5"> </text>
<text top="623" left="535" width="29" height="17" font="7"><i>CVD </i></text>
<text top="641" left="535" width="233" height="17" font="5">Highest walking category (on average, 5.2 </text>
<text top="658" left="535" width="229" height="17" font="5">hours per week or more than 17.2 km per </text>
<text top="675" left="535" width="218" height="17" font="5">week, but varied by study) compared to </text>
<text top="692" left="535" width="200" height="17" font="5">lowest HR=0.69 (95% CI 0.61–0.77, </text>
<text top="709" left="535" width="215" height="17" font="5">p,0.001) with significant between study </text>
<text top="727" left="535" width="224" height="17" font="5">heterogeneity (p&lt;0.001) and evidence of </text>
<text top="744" left="535" width="88" height="17" font="5">publication bias </text>
<text top="761" left="535" width="3" height="17" font="5"> </text>
<text top="437" left="786" width="59" height="17" font="5">Summary: </text>
<text top="454" left="786" width="346" height="17" font="5">There is an inverse relationship between walking and CVD and </text>
<text top="471" left="786" width="333" height="17" font="5">all cause mortality, including at moderate walking levels. The </text>
<text top="488" left="786" width="332" height="17" font="5">effect was stronger for walking pace than for walking volume </text>
<text top="505" left="786" width="326" height="17" font="5">(time and distance). There was no evidence of difference in </text>
<text top="523" left="786" width="105" height="17" font="5">effects by gender.  </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="210" height="17" font="5">Analysis comparing moderate walking </text>
<text top="160" left="535" width="221" height="17" font="5">levels with the lowest category (average </text>
<text top="178" left="535" width="209" height="17" font="5">walking time/distance in the moderate </text>
<text top="195" left="535" width="220" height="17" font="5">walking categories was approximately 3 </text>
<text top="212" left="535" width="233" height="17" font="5">hours per week or 9.8 km per week, which </text>
<text top="229" left="535" width="225" height="17" font="5">equated to a casual or moderate walking </text>
<text top="247" left="535" width="211" height="17" font="5">pace of approximately 3 km per hour): </text>
<text top="264" left="535" width="220" height="17" font="5">pooled HR =0.84 (0.79 to 0.90, p,0.001, </text>
<text top="281" left="535" width="221" height="17" font="5">and 0.80 (0.71 to 0.91, p,0.001; x2 (9) = </text>
<text top="298" left="535" width="210" height="17" font="5">29.78, p,0.001) for all-cause mortality. </text>
<text top="315" left="535" width="3" height="17" font="5"> </text>
<text top="333" left="535" width="219" height="17" font="5">No significant differences in effect sizes </text>
<text top="350" left="535" width="144" height="17" font="5">between men and women </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="103" height="17" font="7"><i>All cause mortality </i></text>
<text top="401" left="535" width="233" height="17" font="5">Highest walking category (on average, 5.2 </text>
<text top="419" left="535" width="229" height="17" font="5">hours per week or more than 17.2 km per </text>
<text top="436" left="535" width="218" height="17" font="5">week, but varied by study) compared to </text>
<text top="453" left="535" width="203" height="17" font="5">lowest HR=0.68 (95% CI: 0.59–0.78, </text>
<text top="470" left="535" width="215" height="17" font="5">p,0.001) with significant between study </text>
<text top="487" left="535" width="224" height="17" font="5">heterogeneity (p&lt;0.001) but no evidence </text>
<text top="505" left="535" width="102" height="17" font="5">of publication bias </text>
<text top="522" left="535" width="3" height="17" font="5"> </text>
<text top="539" left="535" width="210" height="17" font="5">Analysis comparing moderate walking </text>
<text top="556" left="535" width="221" height="17" font="5">levels with the lowest category (average </text>
<text top="573" left="535" width="209" height="17" font="5">walking time/distance in the moderate </text>
<text top="591" left="535" width="220" height="17" font="5">walking categories was approximately 3 </text>
<text top="608" left="535" width="233" height="17" font="5">hours per week or 9.8 km per week, which </text>
<text top="625" left="535" width="225" height="17" font="5">equated to a casual or moderate walking </text>
<text top="642" left="535" width="211" height="17" font="5">pace of approximately 3 km per hour): </text>
<text top="660" left="535" width="222" height="17" font="5">pooled HR = 0.80 (95% CI: 0.71 to 0.91, </text>
<text top="677" left="535" width="49" height="17" font="5">p,0.001) </text>
<text top="694" left="535" width="3" height="17" font="5"> </text>
<text top="711" left="535" width="219" height="17" font="5">No significant differences in effect sizes </text>
<text top="728" left="535" width="144" height="17" font="5">between men and women </text>
<text top="746" left="535" width="3" height="17" font="5"> </text>
<text top="763" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="99" height="17" font="7"><i>Volume and pace </i></text>
<text top="160" left="535" width="212" height="17" font="5">In a combined analysis of CVD and all-</text>
<text top="178" left="535" width="208" height="17" font="5">cause mortality the effects were more </text>
<text top="195" left="535" width="233" height="17" font="5">stronger for brisk walking pace ,HR = 0.52 </text>
<text top="212" left="535" width="226" height="17" font="5">(95% CI 0.48 to 0.57, p,0.001) compared </text>
<text top="229" left="535" width="213" height="17" font="5">with higher walking volume, HR = 0.74 </text>
<text top="247" left="535" width="179" height="17" font="5">(95% CI 0.69 to 0.80, p,0.001),.  </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="220" height="17" font="5">Effects were observed at lower levels of </text>
<text top="298" left="535" width="234" height="17" font="5">activity; moderate pace walking (HR=0.71, </text>
<text top="315" left="535" width="221" height="17" font="5">95% CI 0.62 to 0.81, p,0.001) and lower </text>
<text top="333" left="535" width="224" height="17" font="5">levels of walking volume (HR=0.90, 95% </text>
<text top="350" left="535" width="140" height="17" font="5">CI 0.85 to 0.95, p,0.001). </text>
<text top="368" left="75" width="86" height="17" font="5">Kyu et al, 2016 </text>
<text top="385" left="75" width="3" height="17" font="5"> </text>
<text top="402" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27510511">27510511</a></text>
<text top="402" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27510511"> </a></text>
<text top="368" left="193" width="62" height="17" font="5">Study type </text>
<text top="385" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="402" left="193" width="103" height="17" font="5">and meta analysis </text>
<text top="419" left="193" width="3" height="17" font="5"> </text>
<text top="437" left="193" width="82" height="17" font="5">N=174 studies </text>
<text top="454" left="193" width="103" height="17" font="5">(149,184,285 total </text>
<text top="471" left="193" width="109" height="17" font="5">person years; n=43 </text>
<text top="488" left="193" width="100" height="17" font="5">for ischemic heart </text>
<text top="505" left="193" width="101" height="17" font="5">disease and n=26 </text>
<text top="523" left="193" width="111" height="17" font="5">studies for ischemic </text>
<text top="540" left="193" width="41" height="17" font="5">stroke) </text>
<text top="368" left="326" width="52" height="17" font="5">Inclusion </text>
<text top="385" left="324" width="147" height="18" font="5">•  Published from 1980 to </text>
<text top="403" left="325" width="104" height="17" font="5">February 27, 2016 </text>
<text top="420" left="325" width="3" height="17" font="5"> </text>
<text top="438" left="324" width="183" height="18" font="5">•  English language publications </text>
<text top="456" left="325" width="127" height="17" font="5">and studies in humans </text>
<text top="473" left="324" width="168" height="18" font="5">•  Prospective cohort studies  </text>
<text top="491" left="324" width="178" height="18" font="5">•  assessed physical activity as </text>
<text top="510" left="325" width="193" height="17" font="5">the exposure variable (total activity </text>
<text top="527" left="325" width="167" height="17" font="5">or domain specific activity that </text>
<text top="544" left="325" width="197" height="17" font="5">allowed conversion to total activity)  </text>
<text top="561" left="324" width="196" height="18" font="5">•  assessed at least one of the five </text>
<text top="579" left="325" width="183" height="17" font="5">chosen diseases as an outcome  </text>
<text top="597" left="324" width="193" height="18" font="5">•  provided risk estimates (relative </text>
<text top="615" left="325" width="174" height="17" font="5">risk, hazard ratio, or odds ratio) </text>
<text top="632" left="325" width="152" height="17" font="5">with confidence intervals or </text>
<text top="649" left="325" width="184" height="17" font="5">standard errors (or sufficient data </text>
<text top="667" left="325" width="100" height="17" font="5">to calculate them) </text>
<text top="684" left="326" width="3" height="17" font="5"> </text>
<text top="701" left="326" width="56" height="17" font="5">Exclusion </text>
<text top="718" left="326" width="3" height="17" font="5"> </text>
<text top="369" left="535" width="7" height="17" font="5">1</text>
<text top="368" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="400" left="535" width="232" height="17" font="5">Continuous physical activity: Higher levels </text>
<text top="417" left="535" width="222" height="17" font="5">of total physical activity were associated </text>
<text top="434" left="535" width="170" height="17" font="5">with lower risk of all outcomes. </text>
<text top="451" left="535" width="213" height="17" font="5">Major gains occurred at lower levels of </text>
<text top="468" left="535" width="204" height="17" font="5">activity, and the decrease in risk was </text>
<text top="486" left="535" width="222" height="17" font="5">minimal at levels higher than 3000-4000 </text>
<text top="503" left="535" width="108" height="17" font="5">MET minutes/week </text>
<text top="520" left="535" width="3" height="17" font="5"> </text>
<text top="537" left="535" width="226" height="17" font="5">Categorical physical activity (reference is </text>
<text top="555" left="535" width="232" height="17" font="5">physical activity<i> &lt;600 MET minutes/week) </i></text>
<text top="572" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="589" left="535" width="89" height="17" font="7"><i>Breast Cancer</i>:  </text>
<text top="606" left="535" width="222" height="17" font="5">600-3999 MET minutes/week RR=0.967 </text>
<text top="623" left="535" width="215" height="17" font="5">(95% Uncertainty Interval 0.937-0.998) </text>
<text top="641" left="535" width="3" height="17" font="5"> </text>
<text top="658" left="535" width="229" height="17" font="5">4000-7999 MET minutes/week RR=0.941 </text>
<text top="675" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.904 to 0.981) </text>
<text top="692" left="535" width="3" height="17" font="5"> </text>
<text top="709" left="535" width="206" height="17" font="5">≥8000 MET minutes/week RR=0.863 </text>
<text top="727" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.829 to 0.900) </text>
<text top="744" left="535" width="3" height="17" font="5"> </text>
<text top="761" left="535" width="232" height="17" font="5">No significant evidence of publication bias </text>
<text top="368" left="786" width="291" height="17" font="5">Summary: higher levels of total physical activity were </text>
<text top="385" left="786" width="337" height="17" font="5">significantly associated with lower risk for all outcomes: major </text>
<text top="402" left="786" width="305" height="17" font="5">gains occurred at lower levels of activity and there were </text>
<text top="419" left="786" width="312" height="17" font="5">diminishing returns at levels higher than 3000-4000 MET </text>
<text top="437" left="786" width="79" height="17" font="5">minutes/week </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="85" height="17" font="7"><i>Colon Cancer</i>:  </text>
<text top="178" left="535" width="222" height="17" font="5">600-3999 MET minutes/week RR=0.903 </text>
<text top="195" left="535" width="215" height="17" font="5">(95% Uncertainty Interval 0.851-0.952) </text>
<text top="212" left="535" width="3" height="17" font="5"> </text>
<text top="229" left="535" width="229" height="17" font="5">4000-7999 MET minutes/week RR=0.833 </text>
<text top="247" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.771 to 0.896) </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="206" height="17" font="5">≥8000 MET minutes/week RR=0.789 </text>
<text top="298" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.735 to 0.850) </text>
<text top="315" left="535" width="3" height="17" font="5"> </text>
<text top="333" left="535" width="232" height="17" font="5">No significant evidence of publication bias </text>
<text top="350" left="535" width="3" height="17" font="5"> </text>
<text top="367" left="535" width="59" height="17" font="7"><i>Diabetes</i>:  </text>
<text top="384" left="535" width="222" height="17" font="5">600-3999 MET minutes/week RR=0.857 </text>
<text top="401" left="535" width="215" height="17" font="5">(95% Uncertainty Interval 0.816-0.902) </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="436" left="535" width="229" height="17" font="5">4000-7999 MET minutes/week RR=0.748 </text>
<text top="453" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.701 to 0.799) </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="487" left="535" width="206" height="17" font="5">≥8000 MET minutes/week RR=0.722 </text>
<text top="505" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.678 to 0.768) </text>
<text top="522" left="535" width="3" height="17" font="5"> </text>
<text top="539" left="535" width="199" height="17" font="5">Egger’s test for publication bias was </text>
<text top="556" left="535" width="233" height="17" font="5">significant  (P&lt;0.05).  Results were similar </text>
<text top="573" left="535" width="215" height="17" font="5">in sensitivity analysis using trim-and-fill </text>
<text top="591" left="535" width="188" height="17" font="5">method to include missing studies </text>
<text top="608" left="535" width="3" height="17" font="5"> </text>
<text top="625" left="535" width="140" height="17" font="7"><i>Ischemic Heart Disease</i>:  </text>
<text top="642" left="535" width="222" height="17" font="5">600-3999 MET minutes/week RR=0.837 </text>
<text top="660" left="535" width="215" height="17" font="5">(95% Uncertainty Interval 0.791-0.886) </text>
<text top="677" left="535" width="3" height="17" font="5"> </text>
<text top="694" left="535" width="229" height="17" font="5">4000-7999 MET minutes/week RR=0.769 </text>
<text top="711" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.698 to 0.838) </text>
<text top="728" left="535" width="3" height="17" font="5"> </text>
<text top="746" left="535" width="206" height="17" font="5">≥8000 MET minutes/week RR=0.754 </text>
<text top="763" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.704 to 0.809) </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="199" height="17" font="5">Egger’s test for publication bias was </text>
<text top="178" left="535" width="229" height="17" font="5">significant  (P&lt;0.05). Results were similar </text>
<text top="195" left="535" width="215" height="17" font="5">in sensitivity analysis using trim-and-fill </text>
<text top="212" left="535" width="188" height="17" font="5">method to include missing studies </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="98" height="17" font="7"><i>Ischemic Stroke</i>:  </text>
<text top="264" left="535" width="223" height="17" font="5">600-3999 MET minutes/week RR=0.843 </text>
<text top="281" left="535" width="215" height="17" font="5">(95% Uncertainty Interval 0.779-0.918) </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="229" height="17" font="5">4000-7999 MET minutes/week RR=0.810 </text>
<text top="333" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.690 to 0.937) </text>
<text top="350" left="535" width="3" height="17" font="5"> </text>
<text top="367" left="535" width="206" height="17" font="5">≥8000 MET minutes/week RR=0.736 </text>
<text top="384" left="535" width="228" height="17" font="5">(95% Uncertainty Interval 0.659 to 0.811) </text>
<text top="401" left="535" width="3" height="17" font="5"> </text>
<text top="419" left="535" width="199" height="17" font="5">Egger’s test for publication bias was </text>
<text top="436" left="535" width="229" height="17" font="5">significant  (P&lt;0.05). Results were similar </text>
<text top="453" left="535" width="215" height="17" font="5">in sensitivity analysis using trim-and-fill </text>
<text top="470" left="535" width="188" height="17" font="5">method to include missing studies </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="3" height="17" font="5"> </text>
<text top="523" left="75" width="83" height="17" font="5">Patterson et al </text>
<text top="540" left="75" width="39" height="17" font="5">(2018) </text>
<text top="557" left="75" width="3" height="17" font="5"> </text>
<text top="574" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29589226">29589226</a></text>
<text top="574" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29589226"> </a></text>
<text top="523" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="540" left="193" width="116" height="17" font="5">and meta analysis of </text>
<text top="557" left="193" width="66" height="17" font="5">prospective </text>
<text top="574" left="193" width="119" height="17" font="5">observational studies </text>
<text top="591" left="193" width="3" height="17" font="5"> </text>
<text top="609" left="193" width="76" height="17" font="5">N=34 studies </text>
<text top="523" left="325" width="92" height="17" font="5">Inclusion criteria </text>
<text top="541" left="324" width="158" height="18" font="5">•  assessed the association </text>
<text top="559" left="325" width="105" height="17" font="5">between total daily </text>
<text top="577" left="325" width="174" height="17" font="5">sitting/sedentary, TV viewing or </text>
<text top="594" left="325" width="196" height="17" font="5">leisure sitting time, and at least one </text>
<text top="611" left="325" width="169" height="17" font="5">of the outcomes of interest (all-</text>
<text top="628" left="325" width="177" height="17" font="5">cause, CVD or cancer mortality, </text>
<text top="645" left="325" width="185" height="17" font="5">incident (fatal and non-fatal) CVD </text>
<text top="663" left="325" width="107" height="17" font="5">and incident T2D).  </text>
<text top="680" left="324" width="191" height="18" font="5">•  primary research studies with a </text>
<text top="698" left="325" width="106" height="17" font="5">prospective design </text>
<text top="716" left="324" width="185" height="18" font="5">•  at least an abstract in English  </text>
<text top="734" left="324" width="163" height="18" font="5">•  investigated non-diseased </text>
<text top="752" left="325" width="184" height="17" font="5">adults (≥ 18 years) in the general </text>
<text top="769" left="325" width="60" height="17" font="5">population </text>
<text top="524" left="535" width="7" height="17" font="5">1</text>
<text top="523" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="555" left="535" width="104" height="17" font="5">All-cause mortality </text>
<text top="572" left="535" width="79" height="17" font="5">CVD mortality </text>
<text top="589" left="535" width="93" height="17" font="5">Cancer mortality </text>
<text top="606" left="535" width="91" height="17" font="5">Type 2 diabetes </text>
<text top="623" left="535" width="3" height="17" font="5"> </text>
<text top="641" left="535" width="44" height="17" font="5">Results </text>
<text top="658" left="535" width="3" height="17" font="5"> </text>
<text top="675" left="535" width="104" height="17" font="7"><i>All-cause mortality </i></text>
<text top="692" left="535" width="232" height="17" font="5">Non-linear association between sedentary </text>
<text top="709" left="535" width="176" height="17" font="5">behavior and all cause mortality </text>
<text top="727" left="535" width="3" height="17" font="5"> </text>
<text top="744" left="535" width="210" height="17" font="5">Adjusted for physical activity RR=1.01 </text>
<text top="761" left="535" width="211" height="17" font="5">(95% CI 1.00-1.01) for each additional </text>
<text top="523" left="786" width="63" height="17" font="5">Summary:  </text>
<text top="540" left="786" width="327" height="17" font="5">increased risk for all-cause mortality and CVD mortality and </text>
<text top="557" left="786" width="334" height="17" font="5">incidence of T2D with higher levels of total sedentary time as </text>
<text top="574" left="786" width="311" height="17" font="5">well as TV viewing time, independent of physical activity. </text>
<text top="591" left="786" width="338" height="17" font="5">Associations with TV viewing were stronger than associations </text>
<text top="609" left="786" width="335" height="17" font="5">with sedentary time, with the strongest association being that </text>
<text top="626" left="786" width="171" height="17" font="5">between TV viewing and T2D.  </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="199" height="17" font="5">hour of exposure below 8 h/day and </text>
<text top="160" left="535" width="236" height="17" font="5">RR=1.04 (95% CI 1.03-1.05) for each hour </text>
<text top="178" left="535" width="81" height="17" font="5">above 8 h/day </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="194" height="17" font="5">Non-linear association between TV </text>
<text top="229" left="535" width="204" height="17" font="5">viewing time and all cause mortality.  </text>
<text top="247" left="535" width="3" height="17" font="5"> </text>
<text top="264" left="535" width="210" height="17" font="5">Adjusted for physical activity RR=1.03 </text>
<text top="281" left="535" width="236" height="17" font="5">(95% CI 1.01-1.04) per hour per day below </text>
<text top="298" left="535" width="234" height="17" font="5">3.5 h/day and 1.06 (95% CI 1.05-1.08) per </text>
<text top="315" left="535" width="142" height="17" font="5">hour/day above 3.5 h/day </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="350" left="535" width="231" height="17" font="5">Population attributable fraction associated </text>
<text top="367" left="535" width="161" height="17" font="5">with TV viewing=8% (6-10%) </text>
<text top="384" left="535" width="3" height="17" font="5"> </text>
<text top="401" left="535" width="79" height="17" font="7"><i>CVD mortality </i></text>
<text top="419" left="535" width="232" height="17" font="5">Non-linear association between sedentary </text>
<text top="436" left="535" width="154" height="17" font="5">behavior and CVD mortality </text>
<text top="453" left="535" width="3" height="17" font="5"> </text>
<text top="470" left="535" width="210" height="17" font="5">Adjusted for physical activity RR=1.01 </text>
<text top="487" left="535" width="211" height="17" font="5">(95% CI 0.99-1.02) for each additional </text>
<text top="505" left="535" width="199" height="17" font="5">hour of exposure below 6 h/day and </text>
<text top="522" left="535" width="236" height="17" font="5">RR=1.04 (95% CI 1.03-1.04) for each hour </text>
<text top="539" left="535" width="77" height="17" font="5">above 6h/day </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="573" left="535" width="194" height="17" font="5">Non-linear association between TV </text>
<text top="591" left="535" width="181" height="17" font="5">viewing time and CVD mortality.  </text>
<text top="608" left="535" width="3" height="17" font="5"> </text>
<text top="625" left="535" width="210" height="17" font="5">Adjusted for physical activity RR=1.02 </text>
<text top="642" left="535" width="204" height="17" font="5">(95% CI  0.99-1.04) per hour per day </text>
<text top="660" left="535" width="238" height="17" font="5">below 4 h/day and 1.08 (95% CI 1.05-1.12) </text>
<text top="677" left="535" width="153" height="17" font="5">per hour/day above 4 h/day </text>
<text top="694" left="535" width="3" height="17" font="5"> </text>
<text top="711" left="535" width="232" height="17" font="5">Population attributable fraction associated </text>
<text top="728" left="535" width="154" height="17" font="5">with TV viewing=5% (1-8%) </text>
<text top="746" left="535" width="3" height="17" font="5"> </text>
<text top="763" left="535" width="93" height="17" font="7"><i>Cancer mortality </i></text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="233" height="17" font="5">Non-significant linear association between </text>
<text top="160" left="535" width="226" height="17" font="5">sedentary behavior and cancer mortality  </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="210" height="17" font="5">Adjusted for physical activity RR=1.01 </text>
<text top="212" left="535" width="107" height="17" font="5">(95% CI 1.00-1.02) </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="216" height="17" font="5">Linear association between TV viewing </text>
<text top="264" left="535" width="208" height="17" font="5">time and cancer mortality adjusted for </text>
<text top="281" left="535" width="220" height="17" font="5">physical activity (RR=1.02, 95% CI 1.01-</text>
<text top="298" left="535" width="31" height="17" font="5">1.03) </text>
<text top="315" left="535" width="3" height="17" font="5"> </text>
<text top="333" left="535" width="231" height="17" font="5">Population attributable fraction associated </text>
<text top="350" left="535" width="154" height="17" font="5">with TV viewing=5% (2-7%) </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="91" height="17" font="7"><i>Type 2 diabetes </i></text>
<text top="401" left="535" width="210" height="17" font="5">Linear association between sedentary </text>
<text top="419" left="535" width="165" height="17" font="5">behavior and type 2 diabetes  </text>
<text top="436" left="535" width="3" height="17" font="5"> </text>
<text top="453" left="535" width="210" height="17" font="5">Adjusted for physical activity RR=1.01 </text>
<text top="470" left="535" width="107" height="17" font="5">(95% CI 1.00-1.01) </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="233" height="17" font="5">Equivocally linear association between TV </text>
<text top="522" left="535" width="195" height="17" font="5">viewing time and type 2 diabetes in </text>
<text top="539" left="535" width="189" height="17" font="5">physical activity adjusted estimate </text>
<text top="556" left="535" width="163" height="17" font="5">(RR=1.09; 95% CI 1.07-1.12) </text>
<text top="573" left="535" width="3" height="17" font="5"> </text>
<text top="591" left="535" width="231" height="17" font="5">Population attributable fraction associated </text>
<text top="608" left="535" width="175" height="17" font="5">with TV viewing=29% (26-32%) </text>
<text top="626" left="75" width="85" height="17" font="5">Sattelmair et al </text>
<text top="643" left="75" width="39" height="17" font="5">(2011) </text>
<text top="660" left="75" width="3" height="17" font="5"> </text>
<text top="678" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21810663">21810663</a></text>
<text top="678" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21810663"> </a></text>
<text top="626" left="193" width="62" height="17" font="5">Study type </text>
<text top="643" left="193" width="79" height="17" font="5">Meta analysis </text>
<text top="660" left="193" width="3" height="17" font="5"> </text>
<text top="678" left="193" width="76" height="17" font="5">N=33 studies </text>
<text top="626" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="643" left="324" width="163" height="18" font="5">•  prospective cohort studies </text>
<text top="662" left="324" width="130" height="18" font="5">•  published in English </text>
<text top="680" left="324" width="184" height="18" font="5">•  published between January 1, </text>
<text top="698" left="325" width="142" height="17" font="5">1995, and July 31, 2009,  </text>
<text top="715" left="324" width="98" height="18" font="5">•  human adults  </text>
<text top="733" left="324" width="187" height="18" font="5">•  measured effect sizes (relative </text>
<text top="752" left="325" width="159" height="17" font="5">risks [RRs]) of CHD (primary </text>
<text top="769" left="325" width="171" height="17" font="5">prevention) by level of physical </text>
<text top="627" left="535" width="7" height="17" font="5">1</text>
<text top="626" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="658" left="535" width="131" height="17" font="5">Coronary heart disease </text>
<text top="675" left="535" width="3" height="17" font="5"> </text>
<text top="692" left="535" width="44" height="17" font="5">Results </text>
<text top="709" left="535" width="187" height="17" font="5">Pooled RRs for highest vs. lowest </text>
<text top="727" left="535" width="220" height="17" font="5">(referent) categories.  Overall estimated </text>
<text top="744" left="535" width="160" height="17" font="5">RR=0.75 (95% CI 0.71-0.79) </text>
<text top="761" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="626" left="786" width="59" height="17" font="5">Summary: </text>
<text top="643" left="786" width="352" height="17" font="5">Individuals who met the basic US PA guideline had a 14% lower </text>
<text top="660" left="786" width="328" height="17" font="5">risk of CHD compared with those with no LTPA, while those </text>
<text top="678" left="786" width="341" height="17" font="5">meeting the advanced guideline had a 20% lower risk of CHD. </text>
<text top="695" left="786" width="345" height="17" font="5">Modest increments of risk reduction at higher levels of physical </text>
<text top="712" left="786" width="351" height="17" font="5">activity. Protective effects were observed at PA levels below the </text>
<text top="729" left="786" width="88" height="17" font="5">basic guideline. </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="325" width="196" height="17" font="5">activity (providing either confidence </text>
<text top="160" left="325" width="129" height="17" font="5">intervals [CIs] or SEs).  </text>
<text top="178" left="324" width="173" height="18" font="5">•  All types of physical activity, </text>
<text top="196" left="325" width="149" height="17" font="5">including LTPA, time spent </text>
<text top="213" left="325" width="126" height="17" font="5">walking, walking pace, </text>
<text top="230" left="325" width="165" height="17" font="5">occupational physical activity, </text>
<text top="247" left="325" width="144" height="17" font="5">transport physical activity, </text>
<text top="265" left="325" width="176" height="17" font="5">nonleisure physical activity, and </text>
<text top="282" left="325" width="149" height="17" font="5">total physical activity, were </text>
<text top="299" left="325" width="56" height="17" font="5">included.  </text>
<text top="316" left="324" width="145" height="18" font="5">•  If multiple articles were </text>
<text top="335" left="325" width="179" height="17" font="5">published from the same cohort, </text>
<text top="352" left="325" width="194" height="17" font="5">article with the most detailed report </text>
<text top="369" left="325" width="177" height="17" font="5">for each type of physical activity </text>
<text top="386" left="325" width="75" height="17" font="5">was included </text>
<text top="143" left="535" width="178" height="17" font="5">No evidence for publication bias </text>
<text top="160" left="535" width="3" height="17" font="5"> </text>
<text top="178" left="535" width="90" height="17" font="7"><i>Leisure time PA </i></text>
<text top="195" left="535" width="160" height="17" font="5">RR=0.74 (95% CI 0.69-0.78) </text>
<text top="212" left="535" width="208" height="17" font="5">RR for men<i> =</i>0.78 (95% CI 0.73-0.82) </text>
<text top="229" left="535" width="221" height="17" font="5">RR for women=0.67 (95% CI 0.61-0.74) </text>
<text top="247" left="535" width="3" height="17" font="5"> </text>
<text top="264" left="535" width="221" height="17" font="5">Those who met the basic guideline (150 </text>
<text top="281" left="535" width="205" height="17" font="5">minutes of moderate intensity PA per </text>
<text top="298" left="535" width="225" height="17" font="5">week) had a 14% lower risk of CHD than </text>
<text top="315" left="535" width="234" height="17" font="5">those who engaged in no LTPA (RR, 0.86; </text>
<text top="333" left="535" width="234" height="17" font="5">95% CI, 0.77 to 0.96).  Those who met the </text>
<text top="350" left="535" width="197" height="17" font="5">advanced guideline (300 minutes of </text>
<text top="367" left="535" width="215" height="17" font="5">moderate intensity PA per week) had a </text>
<text top="384" left="535" width="231" height="17" font="5">20% lower risk (RR, 0.80; 95% CI, 0.74 to </text>
<text top="401" left="535" width="224" height="17" font="5">0.88).  Risk for those who had PA at half </text>
<text top="419" left="535" width="237" height="17" font="5">the basic guideline (275 kcal/wk) RR=0.86, </text>
<text top="436" left="535" width="99" height="17" font="5">95% CI 0.76-0.97 </text>
<text top="453" left="535" width="3" height="17" font="5"> </text>
<text top="470" left="535" width="182" height="17" font="5">Men who met the basic guideline </text>
<text top="487" left="535" width="159" height="17" font="5">RR=0.91, 95% CI 0.79-1.04) </text>
<text top="505" left="535" width="207" height="17" font="5">Men who met the advanced guideline </text>
<text top="522" left="535" width="159" height="17" font="5">RR=0.82, 95% CI 0.74-0.91) </text>
<text top="539" left="535" width="3" height="17" font="5"> </text>
<text top="556" left="535" width="201" height="17" font="5">Women who met the basic guideline </text>
<text top="573" left="535" width="159" height="17" font="5">RR=0.80, 95% CI 0.69-0.92) </text>
<text top="591" left="535" width="225" height="17" font="5">Women who met the advanced guideline </text>
<text top="608" left="535" width="159" height="17" font="5">RR=0.72, 95% CI 0.63-0.83) </text>
<text top="625" left="535" width="3" height="17" font="5"> </text>
<text top="642" left="535" width="201" height="17" font="5">No interaction by geographic region, </text>
<text top="660" left="535" width="199" height="17" font="5">adjustment strategy for confounding </text>
<text top="677" left="535" width="151" height="17" font="5">variables, or CHD outcome </text>
<text top="694" left="535" width="3" height="17" font="5"> </text>
<text top="711" left="535" width="74" height="17" font="7"><i>Walking time </i></text>
<text top="728" left="535" width="160" height="17" font="5">RR=0.71 (95% CI 0.59-0.84) </text>
<text top="746" left="535" width="208" height="17" font="5">RR for men<i> =0.63</i> (95% CI 0.34-1.17) </text>
<text top="763" left="535" width="221" height="17" font="5">RR for women=0.65 (95% CI 0.55-0.76) </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="77" height="17" font="7"><i>Walking pace </i></text>
<text top="178" left="535" width="160" height="17" font="5">RR=0.53 (95% CI0.43-0.66 ) </text>
<text top="195" left="535" width="208" height="17" font="5">RR for men<i> =0.53</i> (95% CI 0.42-0.67) </text>
<text top="212" left="535" width="158" height="17" font="5">RR for women=not available </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="95" height="17" font="7"><i>Occupational PA </i></text>
<text top="264" left="535" width="160" height="17" font="5">RR=0.84 (95% CI 0.79-0.90) </text>
<text top="281" left="535" width="208" height="17" font="5">RR for men<i> =0.87</i> (95% CI 0.81-0.99) </text>
<text top="298" left="535" width="164" height="17" font="5">RR for women= Not available </text>
<text top="315" left="535" width="3" height="17" font="5"> </text>
<text top="333" left="535" width="76" height="17" font="7"><i>Transport PA </i></text>
<text top="350" left="535" width="160" height="17" font="5">RR=0.87 (95% CI 0.74-1.02) </text>
<text top="367" left="535" width="208" height="17" font="5">RR for men<i> =0.93</i> (95% CI 0.85-1.02) </text>
<text top="384" left="535" width="221" height="17" font="5">RR for women= 0.74(95% CI 0.57-0.97) </text>
<text top="401" left="535" width="3" height="17" font="5"> </text>
<text top="419" left="535" width="51" height="17" font="7"><i>Total PA </i></text>
<text top="436" left="535" width="156" height="17" font="5">RR=0.74 (95% CI0.62-0.90) </text>
<text top="453" left="535" width="208" height="17" font="5">RR for men<i> =0.79</i> (95% CI 0.59-1.07) </text>
<text top="470" left="535" width="221" height="17" font="5">RR for women=0.66 (95% CI 0.44-0.99) </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="75" width="99" height="17" font="5">Wahid et al, 2016 </text>
<text top="523" left="75" width="3" height="17" font="5"> </text>
<text top="540" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27628572">27628572</a></text>
<text top="540" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27628572"> </a></text>
<text top="505" left="193" width="62" height="17" font="5">Study type </text>
<text top="523" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="540" left="193" width="103" height="17" font="5">and Meta analysis </text>
<text top="557" left="193" width="3" height="17" font="5"> </text>
<text top="574" left="193" width="75" height="17" font="5">N=36 studies </text>
<text top="591" left="193" width="62" height="17" font="5">(3,439,874 </text>
<text top="609" left="193" width="70" height="17" font="5">participants) </text>
<text top="505" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="523" left="324" width="165" height="18" font="5">•  Prospective cohort studies </text>
<text top="541" left="324" width="161" height="18" font="5">•  Measured PA in at least 2 </text>
<text top="559" left="325" width="196" height="17" font="5">domains (leisure, household, active </text>
<text top="576" left="325" width="155" height="17" font="5">travel, occupational activity) </text>
<text top="594" left="324" width="180" height="18" font="5">•  Reported RR for incidence or </text>
<text top="612" left="325" width="167" height="17" font="5">mortality from incident CVD or </text>
<text top="629" left="325" width="37" height="17" font="5">T2DM </text>
<text top="646" left="324" width="181" height="18" font="5">•  RR adjusted for a measure of </text>
<text top="664" left="325" width="69" height="17" font="5">body weight </text>
<text top="682" left="324" width="118" height="18" font="5">•  English language  </text>
<text top="700" left="324" width="191" height="18" font="5">•  Published January 1981-March </text>
<text top="718" left="325" width="31" height="17" font="5">2014 </text>
<text top="735" left="326" width="3" height="17" font="5"> </text>
<text top="753" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="507" left="535" width="7" height="17" font="5">1</text>
<text top="505" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="537" left="535" width="85" height="17" font="5">CVD Incidence </text>
<text top="555" left="535" width="79" height="17" font="5">CVD mortality </text>
<text top="572" left="535" width="94" height="17" font="5">Stroke incidence </text>
<text top="589" left="535" width="85" height="17" font="5">CHD incidence </text>
<text top="606" left="535" width="80" height="17" font="5">CHD mortality </text>
<text top="623" left="535" width="126" height="17" font="5">Heart failure incidence </text>
<text top="641" left="535" width="73" height="17" font="5">MI incidence </text>
<text top="658" left="535" width="92" height="17" font="5">T2DM incidence </text>
<text top="675" left="535" width="3" height="17" font="5"> </text>
<text top="692" left="535" width="44" height="17" font="5">Results </text>
<text top="709" left="535" width="226" height="17" font="5">Effect of an increase in PA of 11.25 MET </text>
<text top="727" left="535" width="191" height="17" font="5">h/week (equivalent to moving from </text>
<text top="744" left="535" width="161" height="17" font="5">inactivity to achieving current </text>
<text top="761" left="535" width="206" height="17" font="5">recommendations), adjusted for body </text>
<text top="505" left="786" width="316" height="17" font="5">Summary: Increasing levels of PA were associated with a </text>
<text top="523" left="786" width="352" height="17" font="5">decrease in the risk of all cardiovascular outcomes and diabetes </text>
<text top="540" left="786" width="333" height="17" font="5">mellitus incidence. The RRs were only marginally attenuated </text>
<text top="557" left="786" width="337" height="17" font="5">when adjusting for a measure of body weight, suggesting that </text>
<text top="574" left="786" width="343" height="17" font="5">the majority of the health benefit from increasing PA is through </text>
<text top="591" left="786" width="248" height="17" font="5">mechanisms other than weight maintenance. </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="324" width="190" height="18" font="5">•  PA measure was one of fitness </text>
<text top="161" left="325" width="182" height="17" font="5">as opposed to a measure of time </text>
<text top="179" left="325" width="91" height="17" font="5">or volume of PA </text>
<text top="196" left="326" width="3" height="17" font="5"> </text>
<text top="143" left="535" width="173" height="17" font="5">weight, assuming a 0.25 power </text>
<text top="160" left="535" width="82" height="17" font="5">transformation </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="85" height="17" font="7"><i>CVD Incidence </i></text>
<text top="212" left="535" width="163" height="17" font="5">RR=0.83 (95% CI 0.77-0.89)  </text>
<text top="229" left="535" width="3" height="17" font="5"> </text>
<text top="247" left="535" width="79" height="17" font="7"><i>CVD mortality </i></text>
<text top="264" left="535" width="230" height="17" font="5">RR=0.77 (95% CI 0.71-0.84) (evidence of </text>
<text top="281" left="535" width="140" height="17" font="5">significant heterogeneity) </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="94" height="17" font="7"><i>Stroke incidence </i></text>
<text top="333" left="535" width="163" height="17" font="5">RR=0.82 (95% CI 0.77-0.87)  </text>
<text top="350" left="535" width="3" height="17" font="5"> </text>
<text top="367" left="535" width="85" height="17" font="7"><i>CHD incidence </i></text>
<text top="384" left="535" width="163" height="17" font="5">RR=0.80 (95% CI 0.75-0.86)  </text>
<text top="401" left="535" width="3" height="17" font="5"> </text>
<text top="419" left="535" width="80" height="17" font="7"><i>CHD mortality </i></text>
<text top="436" left="535" width="163" height="17" font="5">RR=0.80 (95% CI 0.58-1.09)  </text>
<text top="453" left="535" width="211" height="17" font="5">(evidence of significant heterogeneity) </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="487" left="535" width="126" height="17" font="7"><i>Heart failure incidence </i></text>
<text top="505" left="535" width="163" height="17" font="5">RR=0.81 (95% CI 0.76-0.86)  </text>
<text top="522" left="535" width="3" height="17" font="5"> </text>
<text top="539" left="535" width="73" height="17" font="7"><i>MI incidence </i></text>
<text top="556" left="535" width="163" height="17" font="5">RR=0.75 (95% CI 0.62-0.89)  </text>
<text top="573" left="535" width="3" height="17" font="5"> </text>
<text top="591" left="535" width="92" height="17" font="7"><i>T2DM incidence </i></text>
<text top="608" left="535" width="163" height="17" font="5">RR=0.74 (95% CI 0.72-0.77)  </text>
<text top="625" left="535" width="3" height="17" font="5"> </text>
<text top="642" left="535" width="235" height="17" font="5">Effect estimates for levels of PA compared </text>
<text top="660" left="535" width="223" height="17" font="5">to baseline of inactive behavior (low=0.1-</text>
<text top="677" left="535" width="215" height="17" font="5">11.5 METs h/week; medium=11.5-29.5 </text>
<text top="694" left="535" width="228" height="17" font="5">METs h/week; high=29.5+ METs h/week) </text>
<text top="711" left="535" width="3" height="17" font="5"> </text>
<text top="728" left="535" width="85" height="17" font="7"><i>CVD Incidence </i></text>
<text top="746" left="535" width="209" height="17" font="5">Low PA RR=0.89 (95% CI 0.82-0.98)  </text>
<text top="763" left="535" width="227" height="17" font="5">Medium PA RR=0.79 (95% CI 0.69-0.89) </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="208" height="17" font="5">High PA RR=0.75 (95% CI 0.64-0.87) </text>
<text top="160" left="535" width="3" height="17" font="5"> </text>
<text top="178" left="535" width="79" height="17" font="7"><i>CVD mortality </i></text>
<text top="195" left="535" width="209" height="17" font="5">Low PA RR=0.72 (95% CI 0.67-0.77)  </text>
<text top="212" left="535" width="227" height="17" font="5">Medium PA RR=0.72 (95% CI 0.66-0.78) </text>
<text top="229" left="535" width="208" height="17" font="5">High PA RR=0.73 (95% CI 0.67-0.79) </text>
<text top="247" left="535" width="3" height="17" font="5"> </text>
<text top="264" left="535" width="94" height="17" font="7"><i>Stroke incidence </i></text>
<text top="281" left="535" width="209" height="17" font="5">Low PA RR=0.85 (95% CI 0.80-0.91)  </text>
<text top="298" left="535" width="227" height="17" font="5">Medium PA RR=0.81 (95% CI 0.74-0.88) </text>
<text top="315" left="535" width="208" height="17" font="5">High PA RR=0.76 (95% CI 0.68-0.85) </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="350" left="535" width="85" height="17" font="7"><i>CHD incidence </i></text>
<text top="367" left="535" width="209" height="17" font="5">Low PA RR=0.87 (95% CI 0.80-0.95)  </text>
<text top="384" left="535" width="227" height="17" font="5">Medium PA RR=0.78 (95% CI 0.74-0.82) </text>
<text top="401" left="535" width="208" height="17" font="5">High PA RR=0.70 (95% CI 0.66-0.75) </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="436" left="535" width="80" height="17" font="7"><i>CHD mortality </i></text>
<text top="453" left="535" width="149" height="17" font="5">Low PA RR= Not available </text>
<text top="470" left="535" width="227" height="17" font="5">Medium PA RR=0.76 (95% CI 0.63-0.93) </text>
<text top="487" left="535" width="151" height="17" font="5">High PA RR= Not available </text>
<text top="505" left="535" width="3" height="17" font="5"> </text>
<text top="522" left="535" width="126" height="17" font="7"><i>Heart failure incidence </i></text>
<text top="539" left="535" width="145" height="17" font="5">Low PA RR=Not available </text>
<text top="556" left="535" width="227" height="17" font="5">Medium PA RR=0.79 (95% CI 0.72-0.85) </text>
<text top="573" left="535" width="208" height="17" font="5">High PA RR=0.74 (95% CI 0.68-0.79) </text>
<text top="591" left="535" width="3" height="17" font="5"> </text>
<text top="608" left="535" width="73" height="17" font="7"><i>MI incidence </i></text>
<text top="625" left="535" width="149" height="17" font="5">Low PA RR= Not available </text>
<text top="642" left="535" width="227" height="17" font="5">Medium PA RR=0.76 (95% CI 0.66-0.87) </text>
<text top="660" left="535" width="151" height="17" font="5">High PA RR= Not available </text>
<text top="677" left="535" width="3" height="17" font="5"> </text>
<text top="694" left="535" width="92" height="17" font="7"><i>T2DM incidence </i></text>
<text top="711" left="535" width="209" height="17" font="5">Low PA RR=0.77 (95% CI 0.74-0.80)  </text>
<text top="728" left="535" width="227" height="17" font="5">Medium PA RR=0.70 (95% CI 0.54-0.90) </text>
<text top="746" left="535" width="151" height="17" font="5">High PA RR= Not available </text>
<text top="763" left="535" width="3" height="17" font="5"> </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="75" width="99" height="17" font="5">Zheng et al, 2009 </text>
<text top="160" left="75" width="3" height="17" font="5"> </text>
<text top="178" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19306107">19306107</a></text>
<text top="178" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19306107"> </a></text>
<text top="143" left="193" width="62" height="17" font="5">Study type </text>
<text top="160" left="193" width="79" height="17" font="5">Meta analysis </text>
<text top="178" left="193" width="3" height="17" font="5"> </text>
<text top="195" left="193" width="75" height="17" font="5">N=12 studies </text>
<text top="212" left="193" width="52" height="17" font="5">(295,177 </text>
<text top="229" left="193" width="70" height="17" font="5">participants) </text>
<text top="143" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="161" left="324" width="168" height="18" font="5">•  limited to English-language </text>
<text top="179" left="325" width="161" height="17" font="5">papers only. The search was </text>
<text top="196" left="325" width="176" height="17" font="5">restricted to 1954 to September </text>
<text top="213" left="324" width="165" height="18" font="5">•  primary prevention studies </text>
<text top="231" left="324" width="132" height="18" font="5">•  walking as exposure </text>
<text top="250" left="324" width="114" height="18" font="5">•  CHD as outcome </text>
<text top="268" left="324" width="191" height="18" font="5">•  Reported estimates and SEs or </text>
<text top="286" left="325" width="178" height="17" font="5">Cis of RRs of effect of waling on </text>
<text top="303" left="325" width="188" height="17" font="5">CHD or provided sufficient data to </text>
<text top="321" left="325" width="196" height="17" font="5">allow calculation of those estimates </text>
<text top="338" left="324" width="181" height="18" font="5">•  Adjusted minimally for age as </text>
<text top="356" left="325" width="65" height="17" font="5">confounder </text>
<text top="373" left="324" width="175" height="18" font="5">•  Only most recent publication </text>
<text top="391" left="325" width="176" height="17" font="5">chosen for papers based on the </text>
<text top="409" left="325" width="127" height="17" font="5">same study population </text>
<text top="426" left="326" width="3" height="17" font="5"> </text>
<text top="443" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="460" left="324" width="178" height="18" font="5">•  Walking combined with other </text>
<text top="478" left="325" width="66" height="17" font="5">types of PA </text>
<text top="496" left="324" width="170" height="18" font="5">•  CVD as outcome instead of </text>
<text top="514" left="325" width="30" height="17" font="5">CHD </text>
<text top="144" left="535" width="7" height="17" font="5">1</text>
<text top="143" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="175" left="535" width="30" height="17" font="5">CHD </text>
<text top="192" left="535" width="3" height="17" font="5"> </text>
<text top="209" left="535" width="44" height="17" font="5">Results </text>
<text top="227" left="535" width="174" height="17" font="5">No evidence of publication bias </text>
<text top="244" left="535" width="200" height="17" font="7"><i>Walking intensity (MET-hours/week) </i></text>
<text top="261" left="535" width="224" height="17" font="5">Risk of CHD decreased by 11% (95% CI </text>
<text top="278" left="535" width="236" height="17" font="5">4-18%) for increase of 8 MET-h/week, with </text>
<text top="296" left="535" width="201" height="17" font="5">no evidence of heterogeneity across </text>
<text top="313" left="535" width="42" height="17" font="5">studies </text>
<text top="330" left="535" width="3" height="17" font="5"> </text>
<text top="347" left="535" width="117" height="17" font="7"><i>Walking Pace (km/h) </i></text>
<text top="364" left="535" width="227" height="17" font="5">Increment of 2 km/h associated with 21% </text>
<text top="382" left="535" width="232" height="17" font="5">reduced risk of CHD (95% CI 15-27%), no </text>
<text top="399" left="535" width="144" height="17" font="5">evidence of heterogeneity </text>
<text top="416" left="535" width="3" height="17" font="5"> </text>
<text top="433" left="535" width="148" height="17" font="7"><i>Walking time (hours/week) </i></text>
<text top="450" left="535" width="233" height="17" font="5">Increment of 3.5 h/week of normal walking </text>
<text top="468" left="535" width="212" height="17" font="5">associated with 32% reduction in CHD </text>
<text top="485" left="535" width="210" height="17" font="5">(95% CI 11-48%), with no evidence of </text>
<text top="502" left="535" width="81" height="17" font="5">heterogeneity  </text>
<text top="519" left="535" width="3" height="17" font="5"> </text>
<text top="537" left="535" width="232" height="17" font="5">No evidence of heterogeneity in results by </text>
<text top="554" left="535" width="196" height="17" font="5">gender (p-0.67), mean age of study </text>
<text top="571" left="535" width="225" height="17" font="5">population (p-0.52), or follow-up duration </text>
<text top="588" left="535" width="49" height="17" font="5">(p=0.77) </text>
<text top="143" left="786" width="56" height="17" font="5">Summary </text>
<text top="160" left="786" width="321" height="17" font="5">Walking was associated with a dose-responsive protective </text>
<text top="178" left="786" width="84" height="17" font="5">effect on CHD. </text>
<text top="606" left="75" width="103" height="17" font="5">Biswas et al, 2015 </text>
<text top="623" left="75" width="3" height="17" font="5"> </text>
<text top="641" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25599350">25599350</a></text>
<text top="641" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25599350"> </a></text>
<text top="606" left="193" width="68" height="17" font="5">Study aims: </text>
<text top="623" left="193" width="85" height="17" font="5">To quantify the </text>
<text top="641" left="193" width="115" height="17" font="5">association between </text>
<text top="658" left="193" width="108" height="17" font="5">sedentary time and </text>
<text top="675" left="193" width="107" height="17" font="5">hospitalizations, all-</text>
<text top="692" left="193" width="89" height="17" font="5">cause mortality, </text>
<text top="709" left="193" width="83" height="17" font="5">cardiovascular </text>
<text top="727" left="193" width="102" height="17" font="5">disease, diabetes, </text>
<text top="744" left="193" width="113" height="17" font="5">and cancer in adults </text>
<text top="606" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="623" left="326" width="193" height="17" font="5">English language primary research </text>
<text top="641" left="326" width="42" height="17" font="5">articles </text>
<text top="658" left="326" width="3" height="17" font="5"> </text>
<text top="675" left="326" width="175" height="17" font="5">Published through August 2014 </text>
<text top="692" left="326" width="3" height="17" font="5"> </text>
<text top="709" left="326" width="178" height="17" font="5">Assessed sedentary behavior in </text>
<text top="727" left="326" width="172" height="17" font="5">adults, independent of physical </text>
<text top="744" left="326" width="193" height="17" font="5">activity, and correlated to at least 1 </text>
<text top="761" left="326" width="88" height="17" font="5">health outcome </text>
<text top="607" left="535" width="7" height="17" font="5">1</text>
<text top="606" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="638" left="535" width="224" height="17" font="5">All cause mortality, CVD incidence, CVD </text>
<text top="657" left="535" width="193" height="17" font="5">mortality, cancer incidence, cancer </text>
<text top="675" left="535" width="199" height="17" font="5">mortality, type 2 diabetes incidence  </text>
<text top="706" left="535" width="229" height="17" font="5">All cause mortality. Statistical evidence of </text>
<text top="724" left="535" width="189" height="17" font="5">publication bias (Egger regression </text>
<text top="743" left="535" width="207" height="17" font="5">intercept=2.63, p-0.015). High vs. low </text>
<text top="761" left="535" width="199" height="17" font="5">sedentary time adjusted for physical </text>
<text top="606" left="786" width="56" height="17" font="5">Summary </text>
<text top="623" left="786" width="352" height="17" font="5">Sedentary time (assessed as either daily overall sedentary time, </text>
<text top="641" left="786" width="319" height="17" font="5">sitting time, television or screen time, or leisure time spent </text>
<text top="658" left="786" width="341" height="17" font="5">sitting) was independently associated with a greater risk for all </text>
<text top="675" left="786" width="341" height="17" font="5">cause mortality, cardiovascular disease incidence or mortality, </text>
<text top="692" left="786" width="327" height="17" font="5">cancer incidence or mortality), and type 2 diabetes in adults </text>
<text top="709" left="786" width="295" height="17" font="5">after adjusting for physical activity. The increased risk </text>
<text top="727" left="786" width="344" height="17" font="5">associated with high sedentary time was stronger in those with </text>
<text top="744" left="786" width="165" height="17" font="5">low than high physical activity </text>
<text top="761" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="193" width="85" height="17" font="5">independent of </text>
<text top="160" left="193" width="89" height="17" font="5">physical activity </text>
<text top="178" left="193" width="3" height="17" font="5"> </text>
<text top="195" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="212" left="193" width="103" height="17" font="5">and meta analysis </text>
<text top="229" left="193" width="3" height="17" font="5"> </text>
<text top="247" left="193" width="76" height="17" font="5">N=47 articles </text>
<text top="143" left="326" width="3" height="17" font="5"> </text>
<text top="160" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="178" left="326" width="119" height="17" font="5">Nonadult populations </text>
<text top="195" left="326" width="3" height="17" font="5"> </text>
<text top="212" left="326" width="181" height="17" font="5">Didn’t adjust for physical activity  </text>
<text top="229" left="326" width="3" height="17" font="5"> </text>
<text top="247" left="326" width="192" height="17" font="5">Only assessed sedentary behavior </text>
<text top="264" left="326" width="189" height="17" font="5">as reference category to effects of </text>
<text top="281" left="326" width="89" height="17" font="5">physical activity </text>
<text top="298" left="326" width="3" height="17" font="5"> </text>
<text top="315" left="326" width="182" height="17" font="5">Measured sedentary behavior as </text>
<text top="333" left="326" width="187" height="17" font="5">lowest category of daily or weekly </text>
<text top="350" left="326" width="89" height="17" font="5">physical activity </text>
<text top="367" left="326" width="3" height="17" font="5"> </text>
<text top="143" left="535" width="207" height="17" font="5">activity HR=1.24 (95% CI 1.09-1.41).  </text>
<text top="162" left="535" width="3" height="17" font="5">I</text>
<text top="163" left="538" width="4" height="11" font="8">2</text>
<text top="162" left="543" width="103" height="17" font="5">=94.95, p&lt;0.001.   </text>
<text top="192" left="535" width="216" height="17" font="5">Participants with high levels of physical </text>
<text top="211" left="535" width="217" height="17" font="5">activity: association between sedentary </text>
<text top="230" left="535" width="237" height="17" font="5">time and all cause mortality HR=1.16 (95% </text>
<text top="248" left="535" width="72" height="17" font="5">ci 0.84-1.59) </text>
<text top="279" left="535" width="211" height="17" font="5">Participants with low levels of physical </text>
<text top="297" left="535" width="217" height="17" font="5">activity: association between sedentary </text>
<text top="316" left="535" width="237" height="17" font="5">time and all cause mortality HR=1.46 (95% </text>
<text top="334" left="535" width="75" height="17" font="5">CI 1.22-1.75) </text>
<text top="365" left="535" width="219" height="17" font="5">CVD incidence.  High vs. low sedentary </text>
<text top="384" left="535" width="235" height="17" font="5">time adjusted for physical activity HR=1.14 </text>
<text top="402" left="535" width="114" height="17" font="5">(95% CI 1.00-1.30). I</text>
<text top="403" left="649" width="4" height="11" font="8">2</text>
<text top="402" left="653" width="93" height="17" font="5">=82.12, p=0.004 </text>
<text top="433" left="535" width="3" height="17" font="5"> </text>
<text top="463" left="535" width="236" height="17" font="5">CVD mortality. High vs. low sedentary time </text>
<text top="482" left="535" width="209" height="17" font="5">adjusted for physical activity HR=1.18 </text>
<text top="501" left="535" width="114" height="17" font="5">(95% CI 1.11-1.24). I</text>
<text top="502" left="649" width="4" height="11" font="8">2</text>
<text top="501" left="653" width="93" height="17" font="5">=19.22, p=0.170 </text>
<text top="531" left="535" width="3" height="17" font="5"> </text>
<text top="531" left="652" width="3" height="17" font="5"> </text>
<text top="562" left="535" width="221" height="17" font="5">Cancer incidence Statistical evidence of </text>
<text top="580" left="535" width="189" height="17" font="5">publication bias (Egger regression </text>
<text top="599" left="535" width="217" height="17" font="5">intercept=0.957, p=0.156). High vs. low </text>
<text top="617" left="535" width="199" height="17" font="5">sedentary time adjusted for physical </text>
<text top="636" left="535" width="204" height="17" font="5">activity HR=1.13 (95% CI 1.05-1.21). </text>
<text top="654" left="535" width="3" height="17" font="5">I</text>
<text top="656" left="538" width="4" height="11" font="8">2</text>
<text top="654" left="543" width="79" height="17" font="5">=0.00, p=0.39 </text>
<text top="685" left="535" width="3" height="17" font="5"> </text>
<text top="716" left="535" width="223" height="17" font="5">Cancer mortality: High vs. low sedentary </text>
<text top="734" left="535" width="235" height="17" font="5">time adjusted for physical activity HR=1.16 </text>
<text top="753" left="535" width="114" height="17" font="5">(95% CI 1.10-1.22). I</text>
<text top="754" left="649" width="4" height="11" font="8">2</text>
<text top="753" left="653" width="79" height="17" font="5">=0.23, p=0.54 </text>
<text top="143" left="786" width="62" height="17" font="5">Limitations </text>
<text top="160" left="786" width="343" height="17" font="5">Evidence for publication bias on all cause mortality and cancer </text>
<text top="178" left="786" width="55" height="17" font="5">incidence </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="174" left="535" width="223" height="17" font="5">Type 2 diabetes incidence.  High vs. low </text>
<text top="192" left="535" width="199" height="17" font="5">sedentary time adjusted for physical </text>
<text top="211" left="535" width="201" height="17" font="5">activity HR=1.91 (95% CI 1.64-2.22) </text>
<text top="241" left="535" width="3" height="17" font="5"> </text>
<text top="272" left="535" width="3" height="17" font="5"> </text>
<text top="303" left="75" width="93" height="17" font="5">Women’s Health </text>
<text top="321" left="75" width="48" height="17" font="5">Initiative </text>
<text top="338" left="75" width="79" height="17" font="5">Observational </text>
<text top="355" left="75" width="92" height="17" font="5">Study (WHI-OS) </text>
<text top="372" left="75" width="3" height="17" font="5"> </text>
<text top="389" left="75" width="91" height="17" font="5">Chomistek et al, </text>
<text top="407" left="75" width="31" height="17" font="5">2013 </text>
<text top="424" left="75" width="3" height="17" font="5"> </text>
<text top="441" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23583242">23583242</a></text>
<text top="441" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23583242"> </a></text>
<text top="303" left="193" width="64" height="17" font="5">Study aims </text>
<text top="321" left="193" width="84" height="17" font="5">to examine the </text>
<text top="338" left="193" width="95" height="17" font="5">independent and </text>
<text top="355" left="193" width="111" height="17" font="5">joint associations of </text>
<text top="372" left="193" width="86" height="17" font="5">sitting time and </text>
<text top="389" left="193" width="114" height="17" font="5">physical activity with </text>
<text top="407" left="193" width="82" height="17" font="5">risk of incident </text>
<text top="424" left="193" width="83" height="17" font="5">cardiovascular </text>
<text top="441" left="193" width="87" height="17" font="5">disease (CVD). </text>
<text top="458" left="193" width="3" height="17" font="5"> </text>
<text top="476" left="193" width="105" height="17" font="5">Prospective cohort </text>
<text top="493" left="193" width="33" height="17" font="5">study </text>
<text top="510" left="193" width="3" height="17" font="5"> </text>
<text top="527" left="193" width="57" height="17" font="5">N=71,018 </text>
<text top="303" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="321" left="326" width="149" height="17" font="5">Age 50-79 at student entry </text>
<text top="338" left="326" width="3" height="17" font="5"> </text>
<text top="355" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="372" left="326" width="191" height="17" font="5">Presence of any medical condition </text>
<text top="389" left="326" width="187" height="17" font="5">associated with predicted survival </text>
<text top="407" left="326" width="110" height="17" font="5">of less than 3 years </text>
<text top="424" left="326" width="3" height="17" font="5"> </text>
<text top="441" left="326" width="63" height="17" font="5">Alcoholism </text>
<text top="458" left="326" width="3" height="17" font="5"> </text>
<text top="476" left="326" width="78" height="17" font="5">Mental illness </text>
<text top="493" left="326" width="3" height="17" font="5"> </text>
<text top="510" left="326" width="56" height="17" font="5">Dementia </text>
<text top="527" left="326" width="3" height="17" font="5"> </text>
<text top="544" left="326" width="153" height="17" font="5">History of CVD or cancer at </text>
<text top="562" left="326" width="49" height="17" font="5">baseline </text>
<text top="579" left="326" width="3" height="17" font="5"> </text>
<text top="596" left="326" width="183" height="17" font="5">Reported inability to walk at least </text>
<text top="613" left="326" width="56" height="17" font="5">one block </text>
<text top="631" left="326" width="3" height="17" font="5"> </text>
<text top="648" left="326" width="191" height="17" font="5">Missing sedentary time or physical </text>
<text top="665" left="326" width="68" height="17" font="5">activity data </text>
<text top="305" left="535" width="7" height="17" font="5">1</text>
<text top="303" left="542" width="64" height="18" font="5"> endpoint  </text>
<text top="335" left="535" width="221" height="17" font="5">Incident CHD (including nonfatal MI and </text>
<text top="354" left="535" width="122" height="17" font="5">fatal CHD) and stroke </text>
<text top="384" left="535" width="30" height="17" font="7"><i>CHD </i></text>
<text top="415" left="535" width="189" height="17" font="5">Sitting time ≥10 hours/day (vs. ≤5 </text>
<text top="434" left="535" width="134" height="17" font="5">hours/day) multivariable </text>
<text top="452" left="535" width="184" height="17" font="5">adjusted+adjustment for BMI and </text>
<text top="471" left="535" width="204" height="17" font="5">comorbidities HR=1.13 (95% CI 1.01-</text>
<text top="489" left="535" width="125" height="17" font="5">1.26), p for trend=0.04 </text>
<text top="520" left="535" width="238" height="17" font="5">Physical activity ≤1.7 MET hours/week (vs. </text>
<text top="539" left="535" width="196" height="17" font="5">&gt;20 MET hours/week) multivariable </text>
<text top="557" left="535" width="184" height="17" font="5">adjusted+adjustment for BMI and </text>
<text top="576" left="535" width="204" height="17" font="5">comorbidities HR=1.43 (95% CI 1.25-</text>
<text top="594" left="535" width="132" height="17" font="5">1.63), p for trend&lt;0.001 </text>
<text top="625" left="535" width="39" height="17" font="5">Stroke </text>
<text top="655" left="535" width="189" height="17" font="5">Sitting time ≥10 hours/day (vs. ≤5 </text>
<text top="674" left="535" width="134" height="17" font="5">hours/day) multivariable </text>
<text top="692" left="535" width="184" height="17" font="5">adjusted+adjustment for BMI and </text>
<text top="711" left="535" width="204" height="17" font="5">comorbidities HR=1.18 (95% CI 1.04-</text>
<text top="730" left="535" width="132" height="17" font="5">1.34), p for trend=0.008 </text>
<text top="303" left="786" width="56" height="17" font="5">Summary </text>
<text top="321" left="786" width="346" height="17" font="5">Sitting time was positively associated with risk of incident CHD, </text>
<text top="338" left="786" width="323" height="17" font="5">stroke, and total CVD, independent of leisure-time physical </text>
<text top="355" left="786" width="334" height="17" font="5">activity.  Low levels of leisure-time physical activity were also </text>
<text top="372" left="786" width="333" height="17" font="5">associated with increased CVD risk, after adjusting for sitting </text>
<text top="389" left="786" width="27" height="17" font="5">time </text>
<text top="407" left="786" width="3" height="17" font="5"> </text>
<text top="424" left="786" width="62" height="17" font="5">Limitations </text>
<text top="441" left="786" width="341" height="17" font="5">Generalizability unclear given restriction of study population to </text>
<text top="458" left="786" width="137" height="17" font="5">postmenopausal women </text>
<text top="476" left="786" width="252" height="17" font="5">Self reported sitting time and physical activity  </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="238" height="17" font="5">Physical activity ≤1.7 MET hours/week (vs. </text>
<text top="162" left="535" width="197" height="17" font="5">&gt;20 MET hours/week) multivariable </text>
<text top="180" left="535" width="184" height="17" font="5">adjusted+adjustment for BMI and </text>
<text top="199" left="535" width="204" height="17" font="5">comorbidities HR=1.30 (95% CI 1.13-</text>
<text top="218" left="535" width="132" height="17" font="5">1.50), p for trend&lt;0.001 </text>
<text top="248" left="535" width="141" height="17" font="7"><i>Total CVD (CHD+Stroke) </i></text>
<text top="279" left="535" width="189" height="17" font="5">Sitting time ≥10 hours/day (vs. ≤5 </text>
<text top="297" left="535" width="134" height="17" font="5">hours/day) multivariable </text>
<text top="316" left="535" width="184" height="17" font="5">adjusted+adjustment for BMI and </text>
<text top="334" left="535" width="204" height="17" font="5">comorbidities HR=1.15 (95% CI 1.05-</text>
<text top="353" left="535" width="205" height="17" font="5">1.25), p for trend=0.002.  Continuous </text>
<text top="372" left="535" width="231" height="17" font="5">sitting time: each hour/day HR=1.02 (95% </text>
<text top="390" left="535" width="235" height="17" font="5">CI 1.01-1.03). No evidence of non-linearity </text>
<text top="409" left="535" width="226" height="17" font="5">of effect (p=0.87).  In those who reported </text>
<text top="427" left="535" width="211" height="17" font="5">an increase in sitting time over a three </text>
<text top="446" left="535" width="210" height="17" font="5">year period vs. those who reported no </text>
<text top="465" left="535" width="224" height="17" font="5">change, HR=1.18 (95% CI 1.07-1.31). In </text>
<text top="483" left="535" width="216" height="17" font="5">those who decreased sitting time by 2+ </text>
<text top="502" left="535" width="227" height="17" font="5">hours/day, HR=1.01 (95% CI 0.91-1.13).  </text>
<text top="520" left="535" width="212" height="17" font="5">Continuous increase in sitting time, for </text>
<text top="539" left="535" width="193" height="17" font="5">every 1 hour/day increase in sitting </text>
<text top="557" left="535" width="221" height="17" font="5">HR=1.014 (95% CI 1.001-1.027, p=0.03 </text>
<text top="588" left="535" width="238" height="17" font="5">Physical activity ≤1.7 MET hours/week (vs. </text>
<text top="607" left="535" width="196" height="17" font="5">&gt;20 MET hours/week) multivariable </text>
<text top="625" left="535" width="184" height="17" font="5">adjusted+adjustment for BMI and </text>
<text top="644" left="535" width="204" height="17" font="5">comorbidities HR=1.35 (95% CI 1.23-</text>
<text top="662" left="535" width="208" height="17" font="5">1.493), p for trend&lt;0.001. Continuous </text>
<text top="681" left="535" width="212" height="17" font="5">physical activity: each MET hour/week </text>
<text top="700" left="535" width="203" height="17" font="5">HR=0.990 (95% CI 0.987-0.992). No </text>
<text top="718" left="535" width="233" height="17" font="5">evidence of non-linearity of effect (p=0.60) </text>
<text top="749" left="535" width="70" height="17" font="7"><i>Interactions: </i></text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="235" height="17" font="5">Sitting time x Physical activity: Highest risk </text>
<text top="162" left="535" width="210" height="17" font="5">in physically inactive women who also </text>
<text top="180" left="535" width="181" height="17" font="5">reported ≥10 hours/day of sitting </text>
<text top="199" left="535" width="204" height="17" font="5">(HR=1.63, 95% CI 1.39-1.90), but no </text>
<text top="218" left="535" width="230" height="17" font="5">significant interaction between sitting time </text>
<text top="236" left="535" width="162" height="17" font="5">and physical activity (p=0.94) </text>
<text top="267" left="535" width="219" height="17" font="5">No significant interactions of sitting time </text>
<text top="285" left="535" width="207" height="17" font="5">with CVD risk by employment status.  </text>
<text top="316" left="535" width="219" height="17" font="5">Significant interaction between BMI and </text>
<text top="334" left="535" width="202" height="17" font="5">sitting time (significant association in </text>
<text top="353" left="535" width="206" height="17" font="5">women with BMI ≥25 but not BMI&lt;25 </text>
<text top="372" left="535" width="135" height="17" font="5">(HR=1.26 vs HR=1.02).  </text>
<text top="402" left="535" width="232" height="17" font="5">Significant interaction between sitting time </text>
<text top="421" left="535" width="231" height="17" font="5">and age (significant association in women </text>
<text top="439" left="535" width="217" height="17" font="5">70+ but not &lt;70 HR=1.22, 95% CI 1.09-</text>
<text top="458" left="535" width="218" height="17" font="5">1.3, p for trend&lt; 0.001 vs. 1.08, 95% CI </text>
<text top="476" left="535" width="149" height="17" font="5">0.94-1.25, p for trend=0.23 </text>
<text top="508" left="66" width="3" height="17" font="5"> </text>
<text top="538" left="66" width="516" height="21" font="4"><b>Data Supplement 8. RCTs of Obesity and Being Overweight (Section 4.1.) </b></text>
<text top="560" left="104" width="38" height="17" font="3"><b>Study </b></text>
<text top="577" left="93" width="61" height="17" font="3"><b>Acronym; </b></text>
<text top="594" left="99" width="48" height="17" font="3"><b>Author; </b></text>
<text top="611" left="77" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="560" left="199" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="577" left="204" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="594" left="198" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="560" left="348" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="560" left="525" width="126" height="17" font="3"><b>Study Intervention (# </b></text>
<text top="577" left="557" width="62" height="17" font="3"><b>patients) / </b></text>
<text top="594" left="525" width="125" height="17" font="3"><b>Study Comparator (# </b></text>
<text top="611" left="560" width="55" height="17" font="3"><b>patients) </b></text>
<text top="560" left="740" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="577" left="679" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="594" left="749" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="561" left="940" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="560" left="1005" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="578" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="595" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="629" left="75" width="82" height="17" font="5">LeBlanc, 2018 </text>
<text top="647" left="75" width="25" height="17" font="5">(17) </text>
<text top="664" left="75" width="3" height="17" font="5"> </text>
<text top="681" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30326501">30326501</a></text>
<text top="681" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30326501"> </a></text>
<text top="629" left="185" width="76" height="17" font="5">Aim of Study: </text>
<text top="647" left="185" width="110" height="17" font="5">To support the U.S. </text>
<text top="664" left="185" width="112" height="17" font="5">Preventive Services </text>
<text top="681" left="185" width="30" height="17" font="5">Task </text>
<text top="698" left="185" width="108" height="17" font="5">Force (USPSTF) in </text>
<text top="715" left="185" width="109" height="17" font="5">updating their 2012 </text>
<text top="733" left="185" width="112" height="17" font="5">recommendation on </text>
<text top="750" left="185" width="98" height="17" font="5">screening for and </text>
<text top="767" left="185" width="99" height="17" font="5">treatment of adult </text>
<text top="629" left="310" width="102" height="17" font="5">Inclusion Criteria:  </text>
<text top="647" left="310" width="3" height="17" font="5"> </text>
<text top="664" left="310" width="70" height="17" font="5">Key studies: </text>
<text top="681" left="310" width="169" height="18" font="5">•  Overweight persons (BMI </text>
<text top="699" left="337" width="132" height="17" font="5">&gt;25) who were 40 to 65 </text>
<text top="716" left="337" width="152" height="17" font="5">years old and had impaired </text>
<text top="734" left="337" width="100" height="17" font="5">glucose tolerance </text>
<text top="751" left="310" width="179" height="18" font="5">•  &gt;25 years, BMI &gt;24 (&gt;22 in </text>
<text top="769" left="337" width="121" height="17" font="5">Asians), and a fasting </text>
<text top="629" left="510" width="138" height="17" font="5">Behavioral interventions  </text>
<text top="647" left="510" width="103" height="17" font="5">Most interventions </text>
<text top="664" left="510" width="129" height="17" font="5">recommended diet and </text>
<text top="681" left="510" width="146" height="17" font="5">exercise with a goal of 5% </text>
<text top="698" left="510" width="150" height="17" font="5">weight loss, using a variety </text>
<text top="715" left="510" width="133" height="17" font="5">of forms, frequency and </text>
<text top="733" left="510" width="147" height="17" font="5">duration of counseling and </text>
<text top="750" left="510" width="144" height="17" font="5">support given individually, </text>
<text top="767" left="510" width="152" height="17" font="5">in groups, mixed group and </text>
<text top="631" left="678" width="7" height="17" font="5">1</text>
<text top="629" left="685" width="64" height="18" font="5"> endpoint: </text>
<text top="648" left="678" width="3" height="17" font="5"> </text>
<text top="665" left="678" width="172" height="17" font="5">Weight Loss and Maintenance: </text>
<text top="682" left="678" width="3" height="17" font="5"> </text>
<text top="699" left="678" width="226" height="17" font="5">Behavioral Interventions (12-18 months)  </text>
<text top="717" left="678" width="212" height="17" font="5">Mean difference (N = 67 RCTs): −2.39 </text>
<text top="734" left="678" width="206" height="17" font="5">kg, 95% CI −2.86 to −1.93, I2=90.0% </text>
<text top="751" left="678" width="3" height="17" font="5"> </text>
<text top="629" left="919" width="90" height="17" font="5">Adverse Events </text>
<text top="647" left="919" width="3" height="17" font="5"> </text>
<text top="664" left="919" width="139" height="17" font="5">Behavioral Interventions  </text>
<text top="681" left="919" width="168" height="17" font="5">Serious adverse events: None </text>
<text top="698" left="919" width="182" height="17" font="5">Overall adverse events: few  ; no </text>
<text top="715" left="919" width="155" height="17" font="5">differences between groups </text>
<text top="733" left="919" width="159" height="17" font="5">Withdrawals due to AEs: NR </text>
<text top="750" left="919" width="213" height="17" font="5">Specific AEs:  musculoskeletal events: </text>
<text top="767" left="919" width="188" height="17" font="5">Differences not consistently found </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="185" width="46" height="17" font="5">obesity. </text>
<text top="108" left="185" width="3" height="17" font="5"> </text>
<text top="125" left="185" width="62" height="17" font="5">Study type </text>
<text top="142" left="185" width="103" height="17" font="5">Systematic review </text>
<text top="160" left="185" width="3" height="17" font="5"> </text>
<text top="177" left="185" width="59" height="17" font="5">124 RCTs </text>
<text top="194" left="185" width="65" height="17" font="5">89 RCTs of </text>
<text top="211" left="185" width="88" height="17" font="5">behavior-based </text>
<text top="229" left="185" width="85" height="17" font="5">weight loss: 80 </text>
<text top="246" left="185" width="100" height="17" font="5">RCTs of behavior-</text>
<text top="263" left="185" width="101" height="17" font="5">based weight loss </text>
<text top="280" left="185" width="86" height="17" font="5">and 9 RCTs of  </text>
<text top="297" left="185" width="64" height="17" font="5">weight loss </text>
<text top="315" left="185" width="77" height="17" font="5">maintenance. </text>
<text top="332" left="185" width="3" height="17" font="5"> </text>
<text top="349" left="185" width="65" height="17" font="5">35 RCTs of </text>
<text top="366" left="185" width="87" height="17" font="5">medications for </text>
<text top="383" left="185" width="85" height="17" font="5">weight loss: 32 </text>
<text top="401" left="185" width="56" height="17" font="5">studies of </text>
<text top="418" left="185" width="81" height="17" font="5">medication for </text>
<text top="435" left="185" width="92" height="17" font="5">weight loss and  </text>
<text top="452" left="185" width="88" height="17" font="5">3 of weight loss </text>
<text top="469" left="185" width="81" height="17" font="5">maintenance.  </text>
<text top="487" left="185" width="3" height="17" font="5"> </text>
<text top="504" left="185" width="67" height="17" font="5">Key studies </text>
<text top="521" left="185" width="53" height="17" font="5">included: </text>
<text top="538" left="185" width="47" height="17" font="5">4 RCTS </text>
<text top="556" left="185" width="50" height="17" font="5">N=8,902 </text>
<text top="573" left="185" width="3" height="17" font="5"> </text>
<text top="590" left="185" width="46" height="17" font="5">1. DPS, </text>
<text top="607" left="185" width="102" height="17" font="5">Tuomilehto, 2001  </text>
<text top="624" left="185" width="98" height="17" font="5">2. DPP Research </text>
<text top="642" left="185" width="72" height="17" font="5">Group, 2002 </text>
<text top="659" left="185" width="105" height="17" font="5">3. Pi-Sunyer, 2015 </text>
<text top="676" left="185" width="88" height="17" font="5">4. Gadde, 2011 </text>
<text top="693" left="185" width="3" height="17" font="5"> </text>
<text top="710" left="185" width="3" height="17" font="5"> </text>
<text top="91" left="337" width="157" height="17" font="5">plasma glucose of 95 to 125 </text>
<text top="108" left="337" width="123" height="17" font="5">mg/dL and 140 to 199 </text>
<text top="125" left="337" width="150" height="17" font="5">mg/dL two hours after a 75-</text>
<text top="142" left="337" width="107" height="17" font="5">g oral glucose load </text>
<text top="160" left="310" width="172" height="18" font="5">•  Adults without Type 1 or 2 </text>
<text top="178" left="337" width="126" height="17" font="5">Diabetes Mellitus with  </text>
<text top="195" left="337" width="137" height="17" font="5">stable BMI ≥ 30, or ≥ 27 </text>
<text top="212" left="337" width="111" height="17" font="5">with dyslipidemia or </text>
<text top="229" left="337" width="74" height="17" font="5">hypertension </text>
<text top="247" left="310" width="180" height="18" font="5">•  Overweight or obese adults </text>
<text top="265" left="337" width="149" height="17" font="5">(aged 18–70 years), with a </text>
<text top="282" left="337" width="148" height="17" font="5">body-mass index of 27–45 </text>
<text top="299" left="337" width="129" height="17" font="5">kg/m2 and two or more </text>
<text top="317" left="337" width="157" height="17" font="5">comorbidities (hypertension, </text>
<text top="334" left="337" width="145" height="17" font="5">dyslipidaemia, diabetes or </text>
<text top="351" left="337" width="145" height="17" font="5">prediabetes, or abdominal </text>
<text top="368" left="337" width="46" height="17" font="5">obesity) </text>
<text top="91" left="510" width="154" height="17" font="5">individual, via technology or </text>
<text top="108" left="510" width="145" height="17" font="5">via written materials. Most </text>
<text top="125" left="510" width="141" height="17" font="5">also provided some other </text>
<text top="142" left="510" width="129" height="17" font="5">form of motivation (e.g. </text>
<text top="160" left="510" width="137" height="17" font="5">pedometer, videos). The </text>
<text top="177" left="510" width="154" height="17" font="5">median number of sessions </text>
<text top="194" left="510" width="145" height="17" font="5">for individual interventions </text>
<text top="211" left="510" width="126" height="17" font="5">was 12 in the 1st year, </text>
<text top="229" left="510" width="149" height="17" font="5">compared with 23 in group-</text>
<text top="246" left="510" width="146" height="17" font="5">based intervention studies </text>
<text top="263" left="510" width="152" height="17" font="5">(such as weight watchers).  </text>
<text top="280" left="510" width="3" height="17" font="5"> </text>
<text top="297" left="510" width="139" height="17" font="5">Medication interventions  </text>
<text top="315" left="510" width="149" height="17" font="5">Liraglutide: 1.8 mg and 3.0 </text>
<text top="332" left="510" width="49" height="17" font="5">mg daily </text>
<text top="349" left="510" width="3" height="17" font="5"> </text>
<text top="366" left="510" width="133" height="17" font="5">Lorcaserin: 10 mg twice </text>
<text top="383" left="510" width="29" height="17" font="5">daily </text>
<text top="401" left="510" width="3" height="17" font="5"> </text>
<text top="418" left="510" width="124" height="17" font="5">Naltrexone/bupropion: </text>
<text top="435" left="510" width="155" height="17" font="5">16/180 mg three times daily </text>
<text top="452" left="510" width="3" height="17" font="5"> </text>
<text top="469" left="510" width="148" height="17" font="5">Orlistat 120 mg and 60 mg </text>
<text top="487" left="510" width="29" height="17" font="5">daily </text>
<text top="504" left="510" width="3" height="17" font="5"> </text>
<text top="521" left="510" width="138" height="17" font="5">Phentermine/topiramate: </text>
<text top="538" left="510" width="137" height="17" font="5">15/92 mg and 7.5/46 mg </text>
<text top="556" left="510" width="29" height="17" font="5">daily </text>
<text top="91" left="678" width="208" height="17" font="5">Mean absolute change: Interventions: </text>
<text top="108" left="678" width="216" height="17" font="5">−0.5 kg to −9.3 kg; Controls: +1.4 kg to </text>
<text top="125" left="678" width="46" height="17" font="5">−5.6Kg  </text>
<text top="142" left="678" width="194" height="17" font="5">Probability of losing 5% of baseline </text>
<text top="160" left="678" width="221" height="17" font="5">weight: (N = 38 RCTs) RR 1.94 (95% CI </text>
<text top="177" left="678" width="185" height="17" font="5">1.70 to 2.22, I2=67.2%; NNT = 8) </text>
<text top="194" left="678" width="211" height="17" font="5">Weight loss maintenance (8 RCTs, 12-</text>
<text top="211" left="678" width="65" height="17" font="5">18 months) </text>
<text top="229" left="678" width="194" height="17" font="5">Mean difference: −1.59 kg (95% CI </text>
<text top="246" left="678" width="146" height="17" font="5">−2.38 to −0.79, I2=26.8%) </text>
<text top="263" left="678" width="3" height="17" font="5"> </text>
<text top="280" left="678" width="140" height="17" font="5">Medication Interventions  </text>
<text top="297" left="678" width="217" height="17" font="5">Liraglutide versus placebo (2 RCTs, 12-</text>
<text top="315" left="678" width="65" height="17" font="5">18 months) </text>
<text top="332" left="678" width="224" height="17" font="5">Mean absolute change in weight: −7.8 to </text>
<text top="349" left="678" width="229" height="17" font="5">−8.4 kg versus −2.0 to −2.8 kg; p&lt;0.001)  </text>
<text top="366" left="678" width="194" height="17" font="5">Probability of losing 5% of baseline </text>
<text top="383" left="678" width="203" height="17" font="5">weight: 63 to 79% versus 27 to 29%  </text>
<text top="401" left="678" width="3" height="17" font="5"> </text>
<text top="418" left="678" width="204" height="17" font="5">Weight loss maintenance (1 RCT, 13 </text>
<text top="435" left="678" width="48" height="17" font="5">months) </text>
<text top="452" left="678" width="220" height="17" font="5">Mean difference: -6.0 kg versus -0.1 kg; </text>
<text top="469" left="678" width="56" height="17" font="5">(p&lt;.0001) </text>
<text top="487" left="678" width="3" height="17" font="5"> </text>
<text top="504" left="678" width="217" height="17" font="5">Lorcaserin versus placebo (2 RCTs, 12 </text>
<text top="521" left="678" width="48" height="17" font="5">months) </text>
<text top="538" left="678" width="225" height="17" font="5">Mean absolute change in weight: LSM of </text>
<text top="556" left="678" width="201" height="17" font="5">-5.8 kg versus -2.2 to 2.9 kg; p&lt;.001 </text>
<text top="573" left="678" width="194" height="17" font="5">Probability of losing 5% of baseline </text>
<text top="590" left="678" width="184" height="17" font="5">weight: 47% vs. 20-25%; p&lt;.001  </text>
<text top="607" left="678" width="3" height="17" font="5"> </text>
<text top="624" left="678" width="223" height="17" font="5">Naltrexone/Bupropion versus placebo (3 </text>
<text top="642" left="678" width="103" height="17" font="5">RCTs, 13 months) </text>
<text top="659" left="678" width="213" height="17" font="5">Mean difference:  LSM −6.1 to −6.2 kg </text>
<text top="676" left="678" width="170" height="17" font="5">versus −1.3 to −1.4 kg; p&lt;.001 </text>
<text top="693" left="678" width="194" height="17" font="5">Probability of losing 5% of baseline </text>
<text top="710" left="678" width="203" height="17" font="5">weight: 48 to 66% versus 16 to 42%; </text>
<text top="728" left="678" width="35" height="17" font="5">p&lt;.01 </text>
<text top="745" left="678" width="3" height="17" font="5"> </text>
<text top="91" left="919" width="3" height="17" font="5"> </text>
<text top="108" left="919" width="140" height="17" font="5">Medication Interventions  </text>
<text top="125" left="919" width="199" height="17" font="5">Liraglutide (12 to 36 months) versus </text>
<text top="142" left="919" width="100" height="17" font="5">placebo (3 RCTs) </text>
<text top="160" left="919" width="218" height="17" font="5">Serious AEs: 6 to 15% versus 3 to 13% </text>
<text top="177" left="919" width="201" height="17" font="5">Overall AEs: 80 to 96% versus 63 to </text>
<text top="194" left="919" width="28" height="17" font="5">89% </text>
<text top="211" left="919" width="183" height="17" font="5">Withdrawal due to AEs: 8 to 33% </text>
<text top="229" left="919" width="85" height="17" font="5">versus 0 to 6% </text>
<text top="246" left="919" width="193" height="17" font="5">Specific AEs: gastrointestinal 77 to </text>
<text top="263" left="919" width="203" height="17" font="5">79% versus 31 to 46%;  pancreatitis: </text>
<text top="280" left="919" width="153" height="17" font="5">0.7%  versus 0.3% (1 RCT) </text>
<text top="297" left="919" width="3" height="17" font="5"> </text>
<text top="315" left="919" width="193" height="17" font="5">Lorcaserin (1 to 12 months) versus </text>
<text top="332" left="919" width="100" height="17" font="5">placebo (4 RCTs) </text>
<text top="349" left="919" width="204" height="17" font="5">Serious AEs: 0 to 3% versus 0 to 2% </text>
<text top="366" left="919" width="217" height="17" font="5">Overall AEs: 12% at 1 month, 83% at 1 </text>
<text top="383" left="919" width="205" height="17" font="5">year versus 4% at 1 month, 75% at 1 </text>
<text top="401" left="919" width="27" height="17" font="5">year </text>
<text top="418" left="919" width="216" height="17" font="5">Withdrawal due to AEs: 7% versus 5 to </text>
<text top="435" left="919" width="68" height="17" font="5">7% (1 RCT) </text>
<text top="452" left="919" width="185" height="17" font="5">Specific AEs: dizziness: 8 to 10% </text>
<text top="469" left="919" width="61" height="17" font="5">versus 4% </text>
<text top="487" left="919" width="3" height="17" font="5"> </text>
<text top="504" left="919" width="198" height="17" font="5">Naltrexone and Bupropion (12 to 13 </text>
<text top="521" left="919" width="187" height="17" font="5">months) versus placebo (3 RCTs) </text>
<text top="538" left="919" width="215" height="17" font="5">Serious AEs: 0.3 to 2% versus 0 to 1% </text>
<text top="556" left="919" width="201" height="17" font="5">Overall AEs: 83 to 86% versus 69 to </text>
<text top="573" left="919" width="28" height="17" font="5">75% </text>
<text top="590" left="919" width="190" height="17" font="5">Withdrawal due to AEs: 20 to 25% </text>
<text top="607" left="919" width="98" height="17" font="5">versus 10 to 14% </text>
<text top="624" left="919" width="3" height="17" font="5"> </text>
<text top="642" left="919" width="178" height="17" font="5">Orlistat (6 to 18 ,months) versus </text>
<text top="659" left="919" width="193" height="17" font="5">placebo (17 RCTs, 2 observational </text>
<text top="676" left="919" width="46" height="17" font="5">studies) </text>
<text top="693" left="919" width="218" height="17" font="5">Serious AEs: 0 to 15% versus 2 to 26% </text>
<text top="710" left="919" width="60" height="17" font="5">(13 RCTs) </text>
<text top="728" left="919" width="201" height="17" font="5">Overall AEs: 80 to 96% versus 67 to </text>
<text top="745" left="919" width="218" height="17" font="5">94% (8 RCTs, p&lt;.05 in 3, NR in others) </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="678" width="217" height="17" font="5">Orlistat 120 /60 mg TID versus placebo </text>
<text top="108" left="678" width="128" height="17" font="5">(11 RCTs, 12 months): </text>
<text top="125" left="678" width="212" height="17" font="5">Mean difference at 12 months: -1.0 to -</text>
<text top="142" left="678" width="40" height="17" font="5">4.4 kg  </text>
<text top="160" left="678" width="211" height="17" font="5">Mean difference at 18-48 months: 120 </text>
<text top="177" left="678" width="216" height="17" font="5">mg −3.1 to −3.37 kg and 60 mg −2.3 to </text>
<text top="194" left="678" width="96" height="17" font="5">−2.81 kg ;  p&lt;.01 </text>
<text top="211" left="678" width="194" height="17" font="5">Probability of losing 5% of baseline </text>
<text top="229" left="678" width="129" height="17" font="5">weight: (N = 10 RCTs): </text>
<text top="246" left="678" width="182" height="17" font="5">35 to 73% vs. 21 to 49%; p&lt;0.05 </text>
<text top="263" left="678" width="3" height="17" font="5"> </text>
<text top="280" left="678" width="141" height="17" font="5">Weight loss maintenance </text>
<text top="297" left="678" width="221" height="17" font="5">Mean difference at 12-18 months (N = 2 </text>
<text top="315" left="678" width="39" height="17" font="5">RCTs) </text>
<text top="332" left="678" width="213" height="17" font="5">120 mg TID +2.6 to 2.8 kg vs. Placebo </text>
<text top="349" left="678" width="82" height="17" font="5">+4.4 to 4.7 kg  </text>
<text top="366" left="678" width="175" height="17" font="5">60 mg TID: +3.8 kg vs +4.4 kg   </text>
<text top="383" left="678" width="216" height="17" font="5">Mean difference at 36 months (1 RCT): </text>
<text top="401" left="678" width="220" height="17" font="5">120 mg TID +5.1 kg versus Placebo 7.1 </text>
<text top="418" left="678" width="68" height="17" font="5">kg; p=0.028 </text>
<text top="435" left="678" width="3" height="17" font="5"> </text>
<text top="452" left="678" width="225" height="17" font="5">Phentermine and Topiramate (15/92 mg, </text>
<text top="469" left="678" width="218" height="17" font="5">7.5/46 mg) versus placebo (2 RCTs, 12 </text>
<text top="487" left="678" width="48" height="17" font="5">months) </text>
<text top="504" left="678" width="221" height="17" font="5">Mean difference (kg): LSM: −8.1 kg with </text>
<text top="521" left="678" width="196" height="17" font="5">15/92 mg, −10.2 kg with 7.5/46 mg, </text>
<text top="538" left="678" width="218" height="17" font="5">versus−1.4 kg with placebo; p&lt;.0001 (1 </text>
<text top="556" left="678" width="40" height="17" font="5">RCT);  </text>
<text top="573" left="678" width="213" height="17" font="5">Mean difference (% loss): LSM: 10.9% </text>
<text top="590" left="678" width="224" height="17" font="5">(doses combined) versus 1.5%; p&lt;.0001 </text>
<text top="607" left="678" width="47" height="17" font="5">(1 RCT) </text>
<text top="624" left="678" width="194" height="17" font="5">Probability of losing 5% of baseline </text>
<text top="642" left="678" width="212" height="17" font="5">weight: 67 to 70% with 15/92 mg, 62% </text>
<text top="659" left="678" width="195" height="17" font="5">with 7.5/46 mg, and 17 to 21% with </text>
<text top="676" left="678" width="98" height="17" font="5">placebo; p&lt;.0001 </text>
<text top="693" left="678" width="3" height="17" font="5"> </text>
<text top="710" left="678" width="21" height="17" font="5">CV </text>
<text top="728" left="678" width="219" height="17" font="5">Behavioral Interventions versus control: </text>
<text top="745" left="678" width="160" height="17" font="5">All-Cause Mortality (4 RCTs) </text>
<text top="91" left="919" width="183" height="17" font="5">Withdrawal due to AEs: 2 to 16% </text>
<text top="108" left="919" width="145" height="17" font="5">versus 0 to 7% (14 RCTs) </text>
<text top="125" left="919" width="196" height="17" font="5">Specific AEs: gastrointestinal: 63 to </text>
<text top="142" left="919" width="186" height="17" font="5">91% versus 39 to 65% (16 RCTs, </text>
<text top="160" left="919" width="174" height="17" font="5">p&lt;0.05 in 3, NR in others); beta </text>
<text top="177" left="919" width="171" height="17" font="5">carotene or vitamins A, D, or E </text>
<text top="194" left="919" width="192" height="17" font="5">deficiency: 0 to 12% vs. 0 to 8% (6 </text>
<text top="211" left="919" width="182" height="17" font="5">RCTs, p&lt;0.01 in 1, NR in others) </text>
<text top="229" left="919" width="3" height="17" font="5"> </text>
<text top="246" left="919" width="201" height="17" font="5">Phentermine and Topiramate (15/92 </text>
<text top="263" left="919" width="215" height="17" font="5">mg, 7.5/46 mg)(6 to 12 months) versus </text>
<text top="280" left="919" width="100" height="17" font="5">placebo (3 RCTs) </text>
<text top="297" left="919" width="218" height="17" font="5">Serious AEs: 2 to 5%, 1 to 3% versus 0 </text>
<text top="315" left="919" width="35" height="17" font="5">to 4% </text>
<text top="332" left="919" width="202" height="17" font="5">Overall AEs: 85% - 15/92 mg versus </text>
<text top="349" left="919" width="75" height="17" font="5">73% placebo </text>
<text top="366" left="919" width="197" height="17" font="5">Withdrawal due to AEs: 16 to 21% - </text>
<text top="383" left="919" width="183" height="17" font="5">15/92 mg, 12 to 15% - 7.5/46 mg </text>
<text top="401" left="919" width="85" height="17" font="5">versus 7 to 9% </text>
<text top="418" left="919" width="205" height="17" font="5">Specific AEs: anxiety: 4% -15/92 mg, </text>
<text top="435" left="919" width="217" height="17" font="5">7.5/46 mg – “not increased” versus 1 to </text>
<text top="452" left="919" width="171" height="17" font="5">2% placebo (p≤.01); Irritability: </text>
<text top="469" left="919" width="209" height="17" font="5">combined doses 2 to 5% versus &lt;1 to </text>
<text top="487" left="919" width="181" height="17" font="5">2% placebo (p&lt;=.05); Insomnia:  </text>
<text top="504" left="919" width="208" height="17" font="5">combined doses 6 to 12% versus 5 to </text>
<text top="521" left="919" width="208" height="17" font="5">6% (p&lt;=.05); disturbance in attention: </text>
<text top="538" left="919" width="178" height="17" font="5">combined doses 3 to 7% versus </text>
<text top="556" left="919" width="78" height="17" font="5">&lt;1%(p&lt;.001). </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="678" width="223" height="17" font="5">DPP: (4.5 years): 0.1 versus 0.2 per 100 </text>
<text top="108" left="678" width="75" height="17" font="5">person-years </text>
<text top="125" left="678" width="212" height="17" font="5">TOHP II: 5 versus 2 events at  2 years </text>
<text top="142" left="678" width="214" height="17" font="5">Finnish DPS:  6 versus 10 deaths; HR, </text>
<text top="160" left="678" width="215" height="17" font="5">0.57 (95% CI, 0.21 to 1.58) at 10 years </text>
<text top="177" left="678" width="216" height="17" font="5">TONE: (hypertensive adults aged 60 to </text>
<text top="194" left="678" width="169" height="17" font="5">80): HR, 0.82 (95% CI, 0.55 to </text>
<text top="211" left="678" width="96" height="17" font="5">1.22) at 16 years </text>
<text top="229" left="678" width="3" height="17" font="5"> </text>
<text top="246" left="678" width="189" height="17" font="5">Cardiovascular Disease (stroke or </text>
<text top="263" left="678" width="120" height="17" font="5">myocardial infarction) </text>
<text top="280" left="678" width="199" height="17" font="5">DPP: nonfatal CV events: 2.2% (9.7 </text>
<text top="297" left="678" width="220" height="17" font="5">events/1000 patient-years) versus 1.7% </text>
<text top="315" left="678" width="198" height="17" font="5">(7.3 events/1000 patient-years) (not </text>
<text top="332" left="678" width="62" height="17" font="5">significant) </text>
<text top="349" left="678" width="202" height="17" font="5">CV-related deaths 2 versus 4 events </text>
<text top="366" left="678" width="210" height="17" font="5">Finnish DPS: 57 new CV events (22.9 </text>
<text top="383" left="678" width="191" height="17" font="5">per 1,000 person-years) versus 54 </text>
<text top="401" left="678" width="209" height="17" font="5">events (22.0 per 1,000 person-years); </text>
<text top="418" left="678" width="179" height="17" font="5">HR, 1.04 (95% CI, 0.72 to 1.51). </text>
<text top="435" left="678" width="3" height="17" font="5"> </text>
<text top="452" left="678" width="140" height="17" font="5">Medication Interventions  </text>
<text top="469" left="678" width="133" height="17" font="5">Cardiovascular Disease </text>
<text top="487" left="678" width="217" height="17" font="5">Liraglutide. 3 (0.12%) versus 3 (0.24%) </text>
<text top="504" left="678" width="75" height="17" font="5">at 13 months </text>
<text top="521" left="678" width="226" height="17" font="5">Subgroup with prediabetes at baseline: 2 </text>
<text top="538" left="678" width="197" height="17" font="5">additional CV events versus 0 at 36 </text>
<text top="556" left="678" width="74" height="17" font="5">months total  </text>
<text top="573" left="678" width="3" height="17" font="5"> </text>
<text top="590" left="678" width="193" height="17" font="5">Phentermine and topiramate: 0.4% </text>
<text top="607" left="678" width="217" height="17" font="5">versus 0.6% versus 0.7% at 13 months </text>
<text top="625" left="75" width="55" height="17" font="5">Ma, 2017 </text>
<text top="642" left="75" width="3" height="17" font="5"> </text>
<text top="660" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29138133">29138133</a></text>
<text top="660" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29138133"> </a></text>
<text top="625" left="185" width="76" height="17" font="5">Aim of Study: </text>
<text top="642" left="185" width="106" height="17" font="5">To assess whether </text>
<text top="660" left="185" width="64" height="17" font="5">weight loss </text>
<text top="677" left="185" width="91" height="17" font="5">interventions for </text>
<text top="694" left="185" width="104" height="17" font="5">adults with obesity </text>
<text top="711" left="185" width="89" height="17" font="5">affect all cause, </text>
<text top="728" left="185" width="110" height="17" font="5">cardiovascular, and </text>
<text top="746" left="185" width="94" height="17" font="5">cancer mortality, </text>
<text top="763" left="185" width="83" height="17" font="5">cardiovascular </text>
<text top="625" left="310" width="102" height="17" font="5">Inclusion Criteria:  </text>
<text top="642" left="310" width="3" height="17" font="5"> </text>
<text top="660" left="310" width="70" height="17" font="5">Key studies: </text>
<text top="677" left="310" width="154" height="18" font="5">•  Moderately overweight </text>
<text top="695" left="337" width="154" height="17" font="5">individuals with high-normal </text>
<text top="712" left="337" width="153" height="17" font="5">diastolic BP (diastolic BP of </text>
<text top="730" left="337" width="148" height="17" font="5">83 to 89 mm Hg, a systolic </text>
<text top="747" left="337" width="150" height="17" font="5">BP lower than 140 mm Hg, </text>
<text top="764" left="337" width="154" height="17" font="5">and a body mass index (the </text>
<text top="625" left="510" width="60" height="17" font="5">Most were </text>
<text top="642" left="510" width="151" height="17" font="5">recommendations for a low </text>
<text top="660" left="510" width="133" height="17" font="5">fat weight reduction diet </text>
<text top="677" left="510" width="153" height="17" font="5">(usually ≤30% of energy as </text>
<text top="694" left="510" width="84" height="17" font="5">fat).  Most also </text>
<text top="711" left="510" width="149" height="17" font="5">recommended reduction in </text>
<text top="728" left="510" width="85" height="17" font="5">saturated fats.  </text>
<text top="746" left="510" width="3" height="17" font="5"> </text>
<text top="626" left="678" width="7" height="17" font="5">1</text>
<text top="625" left="685" width="64" height="18" font="5"> endpoint: </text>
<text top="643" left="678" width="3" height="17" font="5"> </text>
<text top="661" left="678" width="172" height="17" font="5">Weight Loss and Maintenance: </text>
<text top="678" left="678" width="223" height="17" font="5">Weight change after one year (44 trials): </text>
<text top="695" left="678" width="219" height="17" font="5">Mean difference -3.42 kg (95% CI -4.09 </text>
<text top="712" left="678" width="49" height="17" font="5">to -2.75) </text>
<text top="730" left="678" width="227" height="17" font="5">Weight change after two years (20 trials): </text>
<text top="747" left="678" width="219" height="17" font="5">Mean difference -2.51 kg (95% CI -3.42 </text>
<text top="764" left="678" width="49" height="17" font="5">to -1.60) </text>
<text top="625" left="919" width="3" height="17" font="5"> </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="185" width="93" height="17" font="5">disease, cancer, </text>
<text top="108" left="185" width="96" height="17" font="5">and body weight. </text>
<text top="125" left="185" width="3" height="17" font="5"> </text>
<text top="142" left="185" width="62" height="17" font="5">Study type </text>
<text top="160" left="185" width="103" height="17" font="5">Systematic review </text>
<text top="177" left="185" width="3" height="17" font="5"> </text>
<text top="194" left="185" width="55" height="17" font="5">54 RCTs  </text>
<text top="211" left="185" width="65" height="17" font="5">(N=30,206) </text>
<text top="229" left="185" width="113" height="17" font="5">All but 1 studied low </text>
<text top="246" left="185" width="103" height="17" font="5">fat diets for weight </text>
<text top="263" left="185" width="85" height="17" font="5">reduction (e.g., </text>
<text top="280" left="185" width="94" height="17" font="5">&lt;30% of calories </text>
<text top="297" left="185" width="104" height="17" font="5">from fat, with most </text>
<text top="315" left="185" width="111" height="17" font="5">also recommending </text>
<text top="332" left="185" width="105" height="17" font="5">reducing saturated </text>
<text top="349" left="185" width="61" height="17" font="5">fat intake). </text>
<text top="366" left="185" width="3" height="17" font="5"> </text>
<text top="383" left="185" width="94" height="17" font="5">Examples of diet </text>
<text top="401" left="185" width="85" height="17" font="5">programs used </text>
<text top="418" left="185" width="100" height="17" font="5">include the DASH </text>
<text top="435" left="185" width="99" height="17" font="5">diet, US Diabetes </text>
<text top="452" left="185" width="113" height="17" font="5">Prevention Program </text>
<text top="469" left="185" width="94" height="17" font="5">diet, and content </text>
<text top="487" left="185" width="74" height="17" font="5">based on the </text>
<text top="504" left="185" width="104" height="17" font="5">Dietary Guidelines </text>
<text top="521" left="185" width="86" height="17" font="5">for Americans.  </text>
<text top="538" left="185" width="3" height="17" font="5"> </text>
<text top="556" left="185" width="112" height="17" font="5">Most recommended </text>
<text top="573" left="185" width="109" height="17" font="5">increased exercise, </text>
<text top="590" left="185" width="85" height="17" font="5">but few offered </text>
<text top="607" left="185" width="103" height="17" font="5">specific programs. </text>
<text top="624" left="185" width="100" height="17" font="5">2 RCTs (N = 316) </text>
<text top="642" left="185" width="49" height="17" font="5">included </text>
<text top="659" left="185" width="91" height="17" font="5">participants with </text>
<text top="676" left="185" width="57" height="17" font="5">prior CVD </text>
<text top="693" left="185" width="3" height="17" font="5"> </text>
<text top="710" left="185" width="67" height="17" font="5">Key studies </text>
<text top="728" left="185" width="53" height="17" font="5">included: </text>
<text top="745" left="185" width="47" height="17" font="5">4 RCTS </text>
<text top="762" left="185" width="58" height="17" font="5">(N=8,430) </text>
<text top="91" left="337" width="150" height="17" font="5">weight in kilograms divided </text>
<text top="108" left="337" width="149" height="17" font="5">by the square of the height </text>
<text top="125" left="337" width="58" height="17" font="5">in meters) </text>
<text top="143" left="310" width="184" height="18" font="5">•  Overweight and obese  men </text>
<text top="161" left="337" width="153" height="17" font="5">and women age 60 or older </text>
<text top="178" left="337" width="129" height="17" font="5">with knee osteoarthritis </text>
<text top="195" left="310" width="187" height="18" font="5">•  Men and women age 60 - 80 </text>
<text top="213" left="337" width="124" height="17" font="5">years with an average </text>
<text top="230" left="337" width="159" height="17" font="5">systolic blood pressure &lt;145 </text>
<text top="248" left="337" width="145" height="17" font="5">mmHg and diastolic blood </text>
<text top="265" left="337" width="158" height="17" font="5">pressure &lt;85 mmgHg taking </text>
<text top="282" left="337" width="138" height="17" font="5">a single antihypertensive </text>
<text top="299" left="337" width="94" height="17" font="5">agent or a single </text>
<text top="317" left="337" width="145" height="17" font="5">combination regiment of a </text>
<text top="334" left="337" width="148" height="17" font="5">diuretic and a non-diuretic. </text>
<text top="351" left="337" width="148" height="17" font="5">This study is a follow-up of </text>
<text top="368" left="337" width="123" height="17" font="5">the patients who were </text>
<text top="386" left="337" width="128" height="17" font="5">overweight or obese at </text>
<text top="403" left="337" width="81" height="17" font="5">randomization </text>
<text top="420" left="310" width="168" height="18" font="5">•  45 to 75 years old, type 2 </text>
<text top="438" left="337" width="152" height="17" font="5">diabetes, BMI &gt;25.0 (&gt;27.0 </text>
<text top="455" left="337" width="155" height="17" font="5">if on insulin); HbA1c &lt; 11%; </text>
<text top="473" left="337" width="159" height="17" font="5">systolic blood pressure &lt;160 </text>
<text top="490" left="337" width="128" height="17" font="5">mm Hg; diastolic blood </text>
<text top="507" left="337" width="129" height="17" font="5">pressure &lt;100 mm Hg; </text>
<text top="524" left="337" width="145" height="17" font="5">triglycerides &lt; 600 mg/dL; </text>
<text top="541" left="337" width="132" height="17" font="5">the ability to complete a </text>
<text top="559" left="337" width="154" height="17" font="5">valid maximal exercise test; </text>
<text top="576" left="337" width="107" height="17" font="5">and an established </text>
<text top="593" left="337" width="146" height="17" font="5">relationship with a primary </text>
<text top="610" left="337" width="75" height="17" font="5">care provider </text>
<text top="91" left="510" width="144" height="17" font="5">4 trials were based on the </text>
<text top="108" left="510" width="128" height="17" font="5">DASH diet, and 8 were </text>
<text top="125" left="510" width="152" height="17" font="5">based on the diet in the US </text>
<text top="142" left="510" width="114" height="17" font="5">Diabetes Prevention </text>
<text top="160" left="510" width="57" height="17" font="5">Program.  </text>
<text top="177" left="510" width="3" height="17" font="5"> </text>
<text top="194" left="510" width="138" height="17" font="5">Most also recommended </text>
<text top="211" left="510" width="144" height="17" font="5">an exercise program, with </text>
<text top="229" left="510" width="148" height="17" font="5">20 providing a program for </text>
<text top="246" left="510" width="121" height="17" font="5">participants to attend. </text>
<text top="91" left="678" width="3" height="17" font="5"> </text>
<text top="108" left="678" width="24" height="17" font="5">CV: </text>
<text top="125" left="678" width="181" height="17" font="5">All cause mortality (34 trials, 685 </text>
<text top="142" left="678" width="218" height="17" font="5">events): Risk ratio 0.82 (95% CI 0.71 to </text>
<text top="160" left="678" width="171" height="17" font="5">0.95); 6 fewer deaths per 1000 </text>
<text top="177" left="678" width="159" height="17" font="5">participants (95% CI 2 to 10) </text>
<text top="194" left="678" width="212" height="17" font="5">Cardiovascular mortality (8 RCTs, 134 </text>
<text top="211" left="678" width="218" height="17" font="5">events): Risk ratio 0.93 (95% CI 0.67 to </text>
<text top="229" left="678" width="31" height="17" font="5">1.31) </text>
<text top="246" left="678" width="210" height="17" font="5">New cardiovascular events (24 RCTs, </text>
<text top="263" left="678" width="207" height="17" font="5">1,043 events: Risk ratio 0.93 (95% CI </text>
<text top="280" left="678" width="73" height="17" font="5">0.83 to 1.04) </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="185" width="112" height="17" font="5">Largest studies with </text>
<text top="108" left="185" width="99" height="17" font="5">good methods for </text>
<text top="125" left="185" width="79" height="17" font="5">identifying CV </text>
<text top="142" left="185" width="43" height="17" font="5">events: </text>
<text top="160" left="185" width="96" height="17" font="5">1. TOHP II, 2007 </text>
<text top="177" left="185" width="92" height="17" font="5">2. ADAPT, 2010 </text>
<text top="194" left="185" width="85" height="17" font="5">3. TONE, 2011 </text>
<text top="211" left="185" width="93" height="17" font="5">4. Look-AHEAD, </text>
<text top="229" left="185" width="31" height="17" font="5">2013 </text>
<text top="268" left="59" width="926" height="21" font="4"><b>Data Supplement 9. Nonrandomized Trials, Observational Studies, and/or Registries of Obesity and Being Overweight (Section 4.1.) </b></text>
<text top="298" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="315" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="332" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="298" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="315" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="298" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="298" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="315" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="298" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="315" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="350" left="75" width="39" height="17" font="5">Health </text>
<text top="368" left="75" width="77" height="17" font="5">Professionals </text>
<text top="385" left="75" width="103" height="17" font="5">Follow-up Study &amp; </text>
<text top="402" left="75" width="84" height="17" font="5">Nurses’ Health </text>
<text top="419" left="75" width="35" height="17" font="5">Study </text>
<text top="436" left="75" width="3" height="17" font="5"> </text>
<text top="454" left="75" width="87" height="17" font="5">Flint et al, 2010 </text>
<text top="471" left="75" width="3" height="17" font="5"> </text>
<text top="488" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21116472">21116472</a></text>
<text top="488" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21116472"> </a></text>
<text top="350" left="193" width="62" height="17" font="5">Study type </text>
<text top="368" left="193" width="107" height="17" font="5">Meta-analysis from </text>
<text top="385" left="193" width="104" height="17" font="5">prospective cohort </text>
<text top="402" left="193" width="33" height="17" font="5">study </text>
<text top="419" left="193" width="57" height="17" font="5">N=69,393 </text>
<text top="350" left="326" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="381" left="324" width="189" height="18" font="5">•  Health Professionals Follow up </text>
<text top="399" left="325" width="150" height="17" font="5">Study includes male health </text>
<text top="416" left="325" width="155" height="17" font="5">professionals aged 40-75 at </text>
<text top="434" left="325" width="182" height="17" font="5">enrollment in 1986 with follow up </text>
<text top="451" left="325" width="103" height="17" font="5">data through 2004 </text>
<text top="468" left="324" width="182" height="18" font="5">•  Nurses Health Study includes </text>
<text top="486" left="325" width="193" height="17" font="5">female nurses aged 30-55 at study </text>
<text top="503" left="325" width="187" height="17" font="5">entry, with follow up through 2004 </text>
<text top="521" left="326" width="3" height="17" font="5"> </text>
<text top="551" left="326" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="582" left="326" width="172" height="17" font="5">Health Professionals Follow up </text>
<text top="600" left="326" width="35" height="17" font="5">Study </text>
<text top="631" left="324" width="152" height="18" font="5">•  known acute myocardial </text>
<text top="649" left="325" width="53" height="17" font="5">infarction </text>
<text top="666" left="324" width="188" height="18" font="5">•  self-reported angina in 1986 or </text>
<text top="685" left="325" width="38" height="17" font="5">before </text>
<text top="702" left="324" width="113" height="18" font="5">•  cancer diagnosis </text>
<text top="720" left="324" width="178" height="18" font="5">•  missing data on BMI or waist </text>
<text top="738" left="325" width="81" height="17" font="5">circumference </text>
<text top="756" left="326" width="119" height="17" font="5">Nurses’ Health Study </text>
<text top="351" left="535" width="7" height="17" font="5">1</text>
<text top="350" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="369" left="533" width="228" height="17" font="5">Incident CHD (acute non fatal myocardial </text>
<text top="387" left="533" width="195" height="17" font="5">infarction or fatal CHD outcome) by </text>
<text top="406" left="533" width="206" height="17" font="5">gender, BMI and waist circumference </text>
<text top="424" left="533" width="51" height="17" font="5">category </text>
<text top="443" left="533" width="3" height="17" font="5"> </text>
<text top="462" left="533" width="27" height="17" font="5">Men </text>
<text top="480" left="533" width="25" height="17" font="7"><i>BMI </i></text>
<text top="499" left="533" width="214" height="17" font="5">Compared to those with BMI 18.5-22.9 </text>
<text top="517" left="533" width="231" height="17" font="5">RR=1.22 (95% CI 1.04-1.43) for BMI 23.0-</text>
<text top="536" left="533" width="27" height="17" font="5">24.9 </text>
<text top="555" left="533" width="231" height="17" font="5">RR=1.53 (95% CI 1.31-1.78) for BMI 25.0-</text>
<text top="573" left="533" width="27" height="17" font="5">26.9 </text>
<text top="592" left="533" width="231" height="17" font="5">RR=1.71 (95% CI 1.44-2.02) for BMI 27.0-</text>
<text top="610" left="533" width="27" height="17" font="5">29.9 </text>
<text top="629" left="533" width="227" height="17" font="5">RR=1.81 (95% CI 1.48-2.22) for BMI 30+ </text>
<text top="647" left="533" width="3" height="17" font="7"><i> </i></text>
<text top="666" left="533" width="115" height="17" font="7"><i>Waist circumference </i></text>
<text top="685" left="533" width="233" height="17" font="5">Compared with waist circumference &lt;84.0 </text>
<text top="703" left="533" width="229" height="17" font="5">RR=1.39 (95% CI 1.11-1.74) for WC 84.0-</text>
<text top="722" left="533" width="27" height="17" font="5">93.9 </text>
<text top="740" left="533" width="229" height="17" font="5">RR=1.55 (95% CI 1.23-1.95) for WC 94.0-</text>
<text top="759" left="533" width="34" height="17" font="5">102.0 </text>
<text top="350" left="784" width="345" height="17" font="5">Summary: BMI and WC predict future risk of CH, with both WC </text>
<text top="369" left="784" width="324" height="17" font="5">and BMI adding significantly to models containing the other </text>
<text top="387" left="784" width="343" height="17" font="5">measure in predicting CHD-risk. WC better predicted CHD risk </text>
<text top="406" left="784" width="308" height="17" font="5">than BMI, and became increasingly more predictive with </text>
<text top="425" left="784" width="339" height="17" font="5">increasing age. Lower WC cutoffs may be useful in identifying </text>
<text top="443" left="784" width="124" height="17" font="5">an ideal WC threshold </text>
<text top="462" left="784" width="7" height="17" font="5">. </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="324" width="183" height="18" font="5">•  known CHD in 1988 or before </text>
<text top="162" left="324" width="113" height="18" font="5">•  cancer diagnosis </text>
<text top="180" left="324" width="178" height="18" font="5">•  missing data on BMI or waist </text>
<text top="198" left="325" width="84" height="17" font="5">circumference, </text>
<text top="215" left="324" width="191" height="18" font="5">•  death or withdrawal from follow-</text>
<text top="233" left="325" width="90" height="17" font="5">up prior to 1986 </text>
<text top="143" left="533" width="201" height="17" font="5">RR=2.25 (95% CI 1.77-2.84) for WC </text>
<text top="162" left="533" width="41" height="17" font="5">&gt;102.0 </text>
<text top="180" left="533" width="3" height="17" font="5"> </text>
<text top="199" left="533" width="220" height="17" font="5">40.4% of cases occurred in women with </text>
<text top="218" left="533" width="107" height="17" font="5">WC below 80.0 cm </text>
<text top="236" left="533" width="3" height="17" font="5"> </text>
<text top="267" left="535" width="237" height="17" font="5">In model of WC deciles, CHD risk began to </text>
<text top="284" left="535" width="212" height="17" font="5">increase with the second decile of WC </text>
<text top="301" left="535" width="235" height="17" font="5">(approximately 84 cm) in men and with the </text>
<text top="318" left="535" width="210" height="17" font="5">third decile of WC (71 cm). Addition of </text>
<text top="335" left="535" width="219" height="17" font="5">aspirin intake or physical activity did not </text>
<text top="353" left="535" width="228" height="17" font="5">result in substantial change in estimates.  </text>
<text top="370" left="535" width="228" height="17" font="5">Results were similar in analysis restricted </text>
<text top="387" left="535" width="105" height="17" font="5">to never smokers.  </text>
<text top="404" left="535" width="3" height="17" font="5"> </text>
<text top="422" left="533" width="209" height="17" font="5">In models with both BMI category and </text>
<text top="440" left="533" width="235" height="17" font="5">waist circumference, there were significant </text>
<text top="459" left="533" width="184" height="17" font="5">main effects of both BMI and WC </text>
<text top="477" left="533" width="199" height="17" font="5">(likelihood ratio test p&lt;0.0001) , and </text>
<text top="496" left="533" width="232" height="17" font="5">addition of either resulted in attenuation of </text>
<text top="515" left="533" width="230" height="17" font="5">RR for the other. There was no significant </text>
<text top="533" left="533" width="230" height="17" font="5">interaction between WC and BMI on CHD </text>
<text top="552" left="533" width="26" height="17" font="5">risk. </text>
<text top="582" left="535" width="3" height="17" font="5"> </text>
<text top="599" left="533" width="46" height="17" font="5">Women </text>
<text top="618" left="533" width="214" height="17" font="5">Compared to those with BMI 18.5-22.9 </text>
<text top="637" left="533" width="231" height="17" font="5">RR=1.10 (95% CI 0.93-1.30) for BMI 23.0-</text>
<text top="655" left="533" width="27" height="17" font="5">24.9 </text>
<text top="674" left="533" width="231" height="17" font="5">RR=1.34 (95% CI 1.11-1.61) for BMI 25.0-</text>
<text top="692" left="533" width="27" height="17" font="5">26.9 </text>
<text top="711" left="533" width="231" height="17" font="5">RR=1.53 (95% CI 1.27-1.84) for BMI 27.0-</text>
<text top="730" left="533" width="27" height="17" font="5">29.9 </text>
<text top="748" left="533" width="227" height="17" font="5">RR=2.16 (95% CI 1.81-2.58) for BMI 30+ </text>
<text top="767" left="533" width="3" height="17" font="5"> </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="233" height="17" font="5">Compared with waist circumference &lt;71.0 </text>
<text top="162" left="533" width="20" height="17" font="5">cm </text>
<text top="180" left="533" width="229" height="17" font="5">RR=1.57 (95% CI 1.26-1.95) for WC 71.0-</text>
<text top="199" left="533" width="47" height="17" font="5">79.9 cm </text>
<text top="218" left="533" width="229" height="17" font="5">RR=1.90 (95% CI 1.51-2.38) for WC 80.0-</text>
<text top="236" left="533" width="47" height="17" font="5">87.9 cm </text>
<text top="255" left="533" width="236" height="17" font="5">RR=2.75 (95% CI 2.20-3.45) for WC &gt;88.0 </text>
<text top="273" left="533" width="20" height="17" font="5">cm </text>
<text top="292" left="533" width="3" height="17" font="5"> </text>
<text top="310" left="533" width="220" height="17" font="5">41.9% of cases occurred in women with </text>
<text top="329" left="533" width="107" height="17" font="5">WC below 80.0 cm </text>
<text top="348" left="533" width="3" height="17" font="5"> </text>
<text top="378" left="535" width="237" height="17" font="5">In model of WC deciles, CHD risk began to </text>
<text top="395" left="535" width="217" height="17" font="5">increase with the third decile of WC (71 </text>
<text top="413" left="535" width="227" height="17" font="5">cm). Addition of aspirin intake or physical </text>
<text top="430" left="535" width="234" height="17" font="5">activity did not result in substantial change </text>
<text top="447" left="535" width="202" height="17" font="5">in estimates.  Results were similar in </text>
<text top="464" left="535" width="203" height="17" font="5">analysis restricted to never smokers. </text>
<text top="481" left="533" width="3" height="17" font="5"> </text>
<text top="500" left="533" width="209" height="17" font="5">In models with both BMI category and </text>
<text top="519" left="533" width="235" height="17" font="5">waist circumference, there were significant </text>
<text top="537" left="533" width="184" height="17" font="5">main effects of both BMI and WC </text>
<text top="556" left="533" width="196" height="17" font="5">(likelihood ratio test p&lt;0.0001), and </text>
<text top="574" left="533" width="232" height="17" font="5">addition of either resulted in attenuation of </text>
<text top="593" left="533" width="230" height="17" font="5">RR for the other. There was no significant </text>
<text top="611" left="533" width="230" height="17" font="5">interaction between WC and BMI on CHD </text>
<text top="630" left="533" width="26" height="17" font="5">risk. </text>
<text top="649" left="533" width="3" height="17" font="5"> </text>
<text top="679" left="535" width="205" height="17" font="5">A model including deciles of WC was </text>
<text top="696" left="535" width="234" height="17" font="5">compared to a model containing deciles of </text>
<text top="714" left="535" width="231" height="17" font="5">BMI; the model with WC fit the data better </text>
<text top="731" left="535" width="185" height="17" font="5">than the model using BMI deciles </text>
<text top="748" left="535" width="234" height="17" font="5">according to Akaike’s Information Criterion </text>
<text top="765" left="535" width="32" height="17" font="5">(AIC) </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="533" width="3" height="17" font="5"> </text>
<text top="165" left="75" width="84" height="17" font="5">Million Women </text>
<text top="182" left="75" width="38" height="17" font="5">Study  </text>
<text top="199" left="75" width="3" height="17" font="5"> </text>
<text top="216" left="75" width="100" height="17" font="5">Canoy et al, 2013 </text>
<text top="234" left="75" width="3" height="17" font="5"> </text>
<text top="251" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23723327">23723327</a></text>
<text top="251" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23723327"> </a></text>
<text top="165" left="193" width="66" height="17" font="5">Study Aims </text>
<text top="182" left="193" width="88" height="17" font="5">To examine the </text>
<text top="199" left="193" width="66" height="17" font="5">prospective </text>
<text top="216" left="193" width="110" height="17" font="5">associations of BMI </text>
<text top="234" left="193" width="55" height="17" font="5">and waist </text>
<text top="251" left="193" width="106" height="17" font="5">circumference with </text>
<text top="268" left="193" width="30" height="17" font="5">CHD </text>
<text top="285" left="193" width="3" height="17" font="5"> </text>
<text top="303" left="193" width="105" height="17" font="5">Prospective cohort </text>
<text top="320" left="193" width="33" height="17" font="5">study </text>
<text top="337" left="193" width="3" height="17" font="5"> </text>
<text top="354" left="193" width="64" height="17" font="5">N=496,225 </text>
<text top="165" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="195" left="326" width="44" height="17" font="5">Female </text>
<text top="226" left="326" width="138" height="17" font="5">Had information on waist </text>
<text top="245" left="326" width="129" height="17" font="5">circumference and BMi </text>
<text top="275" left="326" width="185" height="17" font="5">No known heart disease, strsoke, </text>
<text top="294" left="326" width="184" height="17" font="5">or cancer (except non-melanoma </text>
<text top="312" left="326" width="70" height="17" font="5">skin cancer) </text>
<text top="166" left="535" width="7" height="17" font="5">1</text>
<text top="165" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="183" left="535" width="226" height="17" font="5">First hospital admission with diagnosis of </text>
<text top="200" left="535" width="210" height="17" font="5">CHD or death with CHD as underlying </text>
<text top="218" left="535" width="36" height="17" font="5">cause </text>
<text top="235" left="535" width="3" height="17" font="5"> </text>
<text top="252" left="535" width="183" height="17" font="5">Average of 5.1 years of follow up </text>
<text top="269" left="535" width="3" height="17" font="5"> </text>
<text top="287" left="535" width="208" height="17" font="5">Cumulative incidence of CHD over 20 </text>
<text top="304" left="535" width="217" height="17" font="5">years from age 55 was 9.7 (95% CI 9.5-</text>
<text top="321" left="535" width="113" height="17" font="5">9.9) per 100 women </text>
<text top="338" left="535" width="3" height="17" font="5"> </text>
<text top="355" left="535" width="118" height="17" font="7"><i>Waist Circumference </i></text>
<text top="373" left="535" width="120" height="17" font="5">Cumulative incidence </text>
<text top="390" left="535" width="3" height="17" font="5"> </text>
<text top="407" left="535" width="225" height="17" font="5">&lt;70 cm: 8.1 per 100 women (95% CI 7.1-</text>
<text top="424" left="535" width="25" height="17" font="5">9.1) </text>
<text top="441" left="535" width="228" height="17" font="5">79-79.9 cm:  8.1 per 100 women (95% CI </text>
<text top="459" left="535" width="53" height="17" font="5">9.1-10.0) </text>
<text top="476" left="535" width="215" height="17" font="5">≥80 cm:  10.8 per 100 women (95% CI </text>
<text top="493" left="535" width="53" height="17" font="5">9.8-11.9) </text>
<text top="510" left="535" width="3" height="17" font="5"> </text>
<text top="527" left="535" width="229" height="17" font="5">Incidence increased with increasing waist </text>
<text top="545" left="535" width="235" height="17" font="5">circumference in every BMI category (p for </text>
<text top="562" left="535" width="201" height="17" font="5">trend &lt;0.001 for each BMI category) </text>
<text top="579" left="535" width="3" height="17" font="5"> </text>
<text top="596" left="535" width="221" height="17" font="5">Apolipoprotein B/A1 ratio increased with </text>
<text top="613" left="535" width="215" height="17" font="5">increasing BMI in Waist Circumference </text>
<text top="631" left="535" width="221" height="17" font="5">&lt;70 and 70-79.9 cm groups  (p for trend </text>
<text top="648" left="535" width="167" height="17" font="5">&lt;0.001 in each), but not Waist </text>
<text top="665" left="535" width="201" height="17" font="5">Circumference ≥80 (p for trend=0.1) </text>
<text top="682" left="535" width="3" height="17" font="5"> </text>
<text top="700" left="535" width="25" height="17" font="7"><i>BMI </i></text>
<text top="717" left="535" width="120" height="17" font="5">Cumulative incidence </text>
<text top="734" left="535" width="230" height="17" font="5">&lt;25: 8.8 per 100 women (95% CI 8.0-9.6) </text>
<text top="751" left="535" width="233" height="17" font="5">25-29.9: 10.3 per 100 women (95% CI 9.8-</text>
<text top="768" left="535" width="31" height="17" font="5">10.8) </text>
<text top="165" left="786" width="56" height="17" font="5">Summary </text>
<text top="182" left="786" width="337" height="17" font="5">Waist circumference and BMI were both positively associated </text>
<text top="199" left="786" width="351" height="17" font="5">with risk of a first onset of CHD. The risk for CHD was higher for </text>
<text top="216" left="786" width="352" height="17" font="5">women who reported larger waist circumference than those who </text>
<text top="234" left="786" width="295" height="17" font="5">have smaller waist circumferences, regardless of BMI </text>
<text top="251" left="786" width="3" height="17" font="5"> </text>
<text top="268" left="786" width="65" height="17" font="5">Lilmitations </text>
<text top="285" left="786" width="239" height="17" font="5">Self reported BMI and waist circumference  </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="220" height="17" font="5">≥30: 11.9 per 100 women (95% CI 10.5-</text>
<text top="160" left="535" width="31" height="17" font="5">13.3) </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="236" height="17" font="5">Incidence increased with increasing BMI in </text>
<text top="212" left="535" width="230" height="17" font="5">each Waist Circumference category (p for </text>
<text top="229" left="535" width="233" height="17" font="5">trend &lt;0.001 for each waist circumference </text>
<text top="247" left="535" width="55" height="17" font="5">category) </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="221" height="17" font="5">Apolipoprotein B/A1 ratio increased with </text>
<text top="298" left="535" width="234" height="17" font="5">increasing waist circumference in BMI &lt;25 </text>
<text top="315" left="535" width="210" height="17" font="5">(p for trend &lt;0.001) and 25-29.9 (p for </text>
<text top="333" left="535" width="194" height="17" font="5">trend=0.03), but not BMI ≥30 (p for </text>
<text top="350" left="535" width="70" height="17" font="5">trend=0.6).   </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="385" left="75" width="97" height="17" font="5">Faith Activity and </text>
<text top="402" left="75" width="98" height="17" font="5">Nutrition program </text>
<text top="419" left="75" width="36" height="17" font="5">(FAN) </text>
<text top="437" left="75" width="3" height="17" font="5"> </text>
<text top="454" left="75" width="105" height="17" font="5">Warren et al, 2012 </text>
<text top="471" left="75" width="3" height="17" font="5"> </text>
<text top="488" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22632742">22632742</a></text>
<text top="488" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22632742"> </a></text>
<text top="385" left="193" width="66" height="17" font="5">Study Aims </text>
<text top="402" left="193" width="89" height="17" font="5">investigates the </text>
<text top="419" left="193" width="71" height="17" font="5">independent </text>
<text top="437" left="193" width="110" height="17" font="5">association of waist </text>
<text top="454" left="193" width="106" height="17" font="5">circumference with </text>
<text top="471" left="193" width="98" height="17" font="5">hypertension and </text>
<text top="488" left="193" width="104" height="17" font="5">diabetes in African </text>
<text top="505" left="193" width="98" height="17" font="5">American women </text>
<text top="523" left="193" width="3" height="17" font="5"> </text>
<text top="540" left="193" width="89" height="17" font="5">Cross Sectional </text>
<text top="557" left="193" width="33" height="17" font="5">study </text>
<text top="574" left="193" width="3" height="17" font="5"> </text>
<text top="591" left="193" width="40" height="17" font="5">N=843 </text>
<text top="385" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="416" left="326" width="140" height="17" font="5">African American women </text>
<text top="446" left="326" width="195" height="17" font="5">Members of participating churches  </text>
<text top="465" left="326" width="166" height="17" font="5">in 4 districts in South Carolina </text>
<text top="495" left="326" width="95" height="17" font="5">18+ years of age </text>
<text top="526" left="326" width="190" height="17" font="5">Free of serious medical conditions </text>
<text top="544" left="326" width="167" height="17" font="5">or disabilities that would make </text>
<text top="563" left="326" width="131" height="17" font="5">physical activity difficult </text>
<text top="594" left="326" width="150" height="17" font="5">Attend worship services 1+ </text>
<text top="612" left="326" width="70" height="17" font="5">times/month </text>
<text top="643" left="326" width="195" height="17" font="5">Planned to reside in area for next 2 </text>
<text top="661" left="326" width="33" height="17" font="5">years </text>
<text top="692" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="723" left="326" width="175" height="17" font="5">Missing data on study variables </text>
<text top="386" left="535" width="7" height="17" font="5">1</text>
<text top="385" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="403" left="535" width="129" height="17" font="5">Diabetes, hypertension </text>
<text top="420" left="535" width="3" height="17" font="5"> </text>
<text top="438" left="535" width="76" height="17" font="7"><i>Hypertension </i></text>
<text top="455" left="535" width="3" height="17" font="5"> </text>
<text top="472" left="535" width="231" height="17" font="5">Compared to normal waist circumference, </text>
<text top="489" left="535" width="116" height="17" font="5">fully adjusted model: </text>
<text top="507" left="535" width="3" height="17" font="5"> </text>
<text top="524" left="535" width="213" height="17" font="5"> increased WC OR=2.79 (95% CI 1.44-</text>
<text top="541" left="535" width="31" height="17" font="5">5.41) </text>
<text top="558" left="535" width="3" height="17" font="5"> </text>
<text top="575" left="535" width="207" height="17" font="5">Substantially increased WC OR=5.53 </text>
<text top="593" left="535" width="215" height="17" font="5">(95% CI 2.66-11.48), p for trend&lt;0.001 </text>
<text top="610" left="535" width="3" height="17" font="5"> </text>
<text top="627" left="535" width="52" height="17" font="7"><i>Diabetes </i></text>
<text top="644" left="535" width="3" height="17" font="5"> </text>
<text top="661" left="535" width="231" height="17" font="5">Compared to normal waist circumference, </text>
<text top="679" left="535" width="116" height="17" font="5">fully adjusted model: </text>
<text top="696" left="535" width="3" height="17" font="5"> </text>
<text top="713" left="535" width="213" height="17" font="5"> increased WC OR=3.25 (95% CI 1.19-</text>
<text top="730" left="535" width="31" height="17" font="5">8.88) </text>
<text top="748" left="535" width="3" height="17" font="5"> </text>
<text top="385" left="786" width="56" height="17" font="5">Summary </text>
<text top="402" left="786" width="315" height="17" font="5">After controlling for all variables, waist circumference was </text>
<text top="419" left="786" width="320" height="17" font="5">independently associated with a significant  3-5-fold risk in </text>
<text top="437" left="786" width="294" height="17" font="5">hypertension and diabetes in African American wome </text>
<text top="454" left="786" width="3" height="17" font="5"> </text>
<text top="471" left="786" width="62" height="17" font="5">Limitations </text>
<text top="488" left="786" width="124" height="17" font="5">Self reported diabetes </text>
<text top="505" left="786" width="128" height="17" font="5">Cross-sectional design </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="207" height="17" font="5">Substantially increased WC OR=5.38 </text>
<text top="160" left="535" width="215" height="17" font="5">(95% CI 1.94-14.71), p for trend&lt;0.001 </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="213" left="75" width="98" height="17" font="5">Czernichow et al, </text>
<text top="230" left="75" width="31" height="17" font="5">2011 </text>
<text top="247" left="75" width="3" height="17" font="5"> </text>
<text top="264" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21521449">21521449</a></text>
<text top="264" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21521449"> </a></text>
<text top="213" left="193" width="64" height="17" font="5">Study aims </text>
<text top="230" left="193" width="115" height="17" font="5">To examine whether </text>
<text top="247" left="193" width="74" height="17" font="5">the impact of </text>
<text top="264" left="193" width="98" height="17" font="5">adiposity on CVD </text>
<text top="282" left="193" width="76" height="17" font="5">and all cause </text>
<text top="299" left="193" width="62" height="17" font="5">mortality is </text>
<text top="316" left="193" width="118" height="17" font="5">independent of blood </text>
<text top="333" left="193" width="119" height="17" font="5">cholesterol, diabetes, </text>
<text top="350" left="193" width="112" height="17" font="5">and blood pressure, </text>
<text top="368" left="193" width="100" height="17" font="5">and to assess the </text>
<text top="385" left="193" width="70" height="17" font="5">difference in </text>
<text top="402" left="193" width="78" height="17" font="5">discriminative </text>
<text top="419" left="193" width="102" height="17" font="5">capability of these </text>
<text top="437" left="193" width="103" height="17" font="5">adiposity markers  </text>
<text top="454" left="193" width="3" height="17" font="5"> </text>
<text top="471" left="193" width="79" height="17" font="5">Meta analysis </text>
<text top="488" left="193" width="3" height="17" font="5"> </text>
<text top="505" left="193" width="112" height="17" font="5">N=9 cross-sectional </text>
<text top="523" left="193" width="119" height="17" font="5">studies with follow up </text>
<text top="540" left="193" width="68" height="17" font="5">for mortality </text>
<text top="557" left="193" width="59" height="17" font="5">(n=82.864 </text>
<text top="574" left="193" width="70" height="17" font="5">participants) </text>
<text top="213" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="243" left="326" width="166" height="17" font="5">Participants sampled from the </text>
<text top="262" left="326" width="175" height="17" font="5">general populations in Scotland </text>
<text top="281" left="326" width="73" height="17" font="5">and England </text>
<text top="214" left="535" width="7" height="17" font="5">1</text>
<text top="213" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="231" left="535" width="207" height="17" font="5">All cause mortality and CVD mortality </text>
<text top="248" left="535" width="3" height="17" font="5"> </text>
<text top="266" left="535" width="237" height="17" font="5">Mean of 98.7 months mortality surveillance </text>
<text top="283" left="535" width="3" height="17" font="5"> </text>
<text top="300" left="535" width="103" height="17" font="7"><i>All cause mortality </i></text>
<text top="317" left="535" width="215" height="17" font="5">BMI: one SD higher BMI, fully adjusted </text>
<text top="334" left="535" width="214" height="17" font="5">model HR=0.95 (95% CI: 0.91-0.99), p-</text>
<text top="352" left="535" width="223" height="17" font="5">0.73.  AUC=0.847 (95% CI 0.840-0.855) </text>
<text top="369" left="535" width="3" height="17" font="5"> </text>
<text top="386" left="535" width="227" height="17" font="5">Waist Circumference: one SD higher WC </text>
<text top="403" left="535" width="225" height="17" font="5">HR=1.05 (95% CI 1.00-1.09), p&lt;0.0001.  </text>
<text top="420" left="535" width="188" height="17" font="5">AUC=0.847 (95% CI 0.839-0.855) </text>
<text top="438" left="535" width="3" height="17" font="5"> </text>
<text top="455" left="535" width="220" height="17" font="5">Waist to Hip Ratio: one SD higher WHR </text>
<text top="472" left="535" width="225" height="17" font="5">HR=1.12 (95% CI 1.06-1.18), p&lt;0.0001.  </text>
<text top="489" left="535" width="188" height="17" font="5">AUC=0.848 (95% CI 0.840-0.856) </text>
<text top="507" left="535" width="3" height="17" font="5"> </text>
<text top="524" left="535" width="185" height="17" font="5">Relative integrated discrimination </text>
<text top="541" left="535" width="161" height="17" font="5">improvement (RIDI) statistics </text>
<text top="558" left="535" width="228" height="17" font="5">WC vs. BMI=0.150 (95% CI 0.140-0.160) </text>
<text top="575" left="535" width="233" height="17" font="5">WHR vs BMI=0.335 (95% CI 0.321-0.348) </text>
<text top="593" left="535" width="231" height="17" font="5">WHR vs WC=0.184 (95% CI 0.175-0.193) </text>
<text top="610" left="535" width="3" height="17" font="5"> </text>
<text top="627" left="535" width="79" height="17" font="7"><i>CVD mortality </i></text>
<text top="644" left="535" width="236" height="17" font="5">BMI: one SD higher BMI HR=1.05 (95% CI </text>
<text top="661" left="535" width="226" height="17" font="5">0.98-1.14), p=0.01.  AUC=0.868 (95% CI </text>
<text top="679" left="535" width="73" height="17" font="5">0.856-0.880) </text>
<text top="696" left="535" width="3" height="17" font="5"> </text>
<text top="713" left="535" width="227" height="17" font="5">Waist Circumference: one SD higher WC </text>
<text top="730" left="535" width="225" height="17" font="5">HR=1.15 (95% CI 1.05-1.25), p&lt;0.0001.  </text>
<text top="748" left="535" width="182" height="17" font="5">AUC=0.868 (95% CI 0.86-0.880) </text>
<text top="765" left="535" width="3" height="17" font="5"> </text>
<text top="213" left="786" width="56" height="17" font="5">Summary </text>
<text top="230" left="786" width="339" height="17" font="5">BMi, WC, and WHR were associated with an increased risk of </text>
<text top="247" left="786" width="318" height="17" font="5">cardiovascular disease mortality. In a fully-adjusted model </text>
<text top="264" left="786" width="350" height="17" font="5">including adjustment for potentially  mediating variables such as </text>
<text top="282" left="786" width="352" height="17" font="5">systolic blood pressure and diabetes status, the effects were not </text>
<text top="299" left="786" width="351" height="17" font="5">statistically significant at conventional levels for BMI, suggesting </text>
<text top="316" left="786" width="350" height="17" font="5">that some, if not all, of the impact of BMI on CVD risk occurs via </text>
<text top="333" left="786" width="320" height="17" font="5">these variables. In all models, WHR was the most strongly </text>
<text top="350" left="786" width="341" height="17" font="5">associated with CVD mortality compared to either WC or even </text>
<text top="368" left="786" width="325" height="17" font="5">BMI. Comparison of the discrimination capacity of the three </text>
<text top="385" left="786" width="344" height="17" font="5">adiposity indices indicated no differences using the AUC and a </text>
<text top="402" left="786" width="250" height="17" font="5">marginal benefit when using the RIDI statistic </text>
<text top="419" left="786" width="3" height="17" font="5"> </text>
<text top="437" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="14" size="16" family="Times" color="#000000"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="220" height="17" font="5">Waist to Hip Ratio: one SD higher WHR </text>
<text top="160" left="535" width="234" height="17" font="5">HR=1.15 (95% CI 1.04-1.27).  AUC=0.858 </text>
<text top="178" left="535" width="121" height="17" font="5">(95% CI 0.856-0.880) </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="185" height="17" font="5">Relative integrated discrimination </text>
<text top="229" left="535" width="161" height="17" font="5">improvement (RIDI) statistics </text>
<text top="247" left="535" width="228" height="17" font="5">WC vs. BMI=0.543 (95% CI 0.524-0.563) </text>
<text top="264" left="535" width="233" height="17" font="5">WHR vs BMI=0.265 (95% CI 0.236-0.295) </text>
<text top="281" left="535" width="218" height="17" font="5">WHR vs WC=-0.276 (95% CI -0.302 to -</text>
<text top="298" left="535" width="38" height="17" font="5">0.250) </text>
<text top="315" left="535" width="3" height="17" font="5"> </text>
<text top="333" left="535" width="3" height="17" font="5"> </text>
<text top="351" left="66" width="4" height="21" font="14"> </text>
<text top="385" left="66" width="482" height="21" font="4"><b>Data Supplement 10. RCTs of Type 2 Diabetes Mellitus (Section 4.2.) </b></text>
<text top="406" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="423" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="441" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="406" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="423" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="441" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="406" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="406" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="423" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="441" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="458" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="406" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="423" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="441" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="407" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="406" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="425" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="442" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="476" left="75" width="91" height="17" font="5">Azadbakht et al, </text>
<text top="493" left="75" width="60" height="17" font="5">2011 (18)  </text>
<text top="510" left="75" width="3" height="17" font="5"> </text>
<text top="527" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20843978">20843978</a></text>
<text top="527" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20843978"> </a></text>
<text top="476" left="186" width="130" height="17" font="5">Aim: assessed how the </text>
<text top="493" left="186" width="116" height="17" font="5">DASH eating pattern </text>
<text top="510" left="186" width="129" height="17" font="5">affects cardiometabolic </text>
<text top="527" left="186" width="124" height="17" font="5">risks in type 2 diabetic </text>
<text top="545" left="186" width="46" height="17" font="5">patients </text>
<text top="562" left="186" width="3" height="17" font="5"> </text>
<text top="579" left="186" width="69" height="17" font="5">Study Type: </text>
<text top="596" left="186" width="123" height="17" font="5">Crossover clinical trial </text>
<text top="613" left="186" width="3" height="17" font="5"> </text>
<text top="631" left="186" width="33" height="17" font="5">N=31 </text>
<text top="476" left="345" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="494" left="344" width="116" height="18" font="5">•  age 50–75 years  </text>
<text top="513" left="344" width="169" height="18" font="5">•  fasting plasma glucose 126 </text>
<text top="531" left="345" width="179" height="17" font="5">mg/dl or was taking oral glucose </text>
<text top="548" left="345" width="142" height="17" font="5">lowering agents or insulin </text>
<text top="565" left="345" width="3" height="17" font="5"> </text>
<text top="596" left="346" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="613" left="344" width="150" height="18" font="5">•  any secondary cause of </text>
<text top="631" left="345" width="83" height="17" font="5">hyperglycemia </text>
<text top="649" left="344" width="150" height="18" font="5">•  use of estrogen therapy </text>
<text top="667" left="344" width="159" height="18" font="5">•  untreated hypothyroidism </text>
<text top="685" left="344" width="66" height="18" font="5">•  smoking </text>
<text top="703" left="344" width="148" height="18" font="5">•  kidney or liver diseases </text>
<text top="476" left="547" width="96" height="17" font="5">Intervention Diet: </text>
<text top="493" left="547" width="64" height="17" font="5">DASH diet  </text>
<text top="510" left="547" width="3" height="17" font="5"> </text>
<text top="527" left="547" width="3" height="17" font="5"> </text>
<text top="545" left="547" width="73" height="17" font="5">Control diet:  </text>
<text top="562" left="547" width="79" height="17" font="5">macronutrient </text>
<text top="579" left="547" width="100" height="17" font="5">composition of 50-</text>
<text top="596" left="547" width="113" height="17" font="5">60% carbohydrates, </text>
<text top="613" left="547" width="90" height="17" font="5">15-20% protein, </text>
<text top="631" left="547" width="106" height="17" font="5">&lt;30% total fat, and </text>
<text top="648" left="547" width="117" height="17" font="5">&lt;5% of caloric intake </text>
<text top="665" left="547" width="118" height="17" font="5">from simple sugars.   </text>
<text top="682" left="547" width="7" height="17" font="5">  </text>
<text top="477" left="677" width="7" height="17" font="5">1</text>
<text top="476" left="684" width="212" height="18" font="5"> endpoint: fasting blood glucose, AlC, </text>
<text top="494" left="677" width="207" height="17" font="5">weight, waist circumference, and lipid </text>
<text top="511" left="677" width="43" height="17" font="5">profiles </text>
<text top="529" left="677" width="182" height="17" font="5">Results: No significant difference </text>
<text top="546" left="677" width="153" height="17" font="5">between groups in calories, </text>
<text top="563" left="677" width="174" height="17" font="5">carbohydrates, protein, or fats.  </text>
<text top="580" left="677" width="3" height="17" font="5"> </text>
<text top="597" left="677" width="143" height="17" font="5">Control vs. DASH results: </text>
<text top="615" left="677" width="3" height="17" font="5"> </text>
<text top="632" left="677" width="160" height="17" font="5">SBP: -3.1 vs. -13.6, (p=0.02) </text>
<text top="649" left="677" width="143" height="17" font="5">DBP: -.7 vs. -9.5 (p=0.04) </text>
<text top="666" left="677" width="203" height="17" font="5">Triglycerides -10.9 to -14.4, (p=0.79) </text>
<text top="683" left="677" width="161" height="17" font="5">HDL-C: 1.3 vs. 4.3 (p=0.001) </text>
<text top="701" left="677" width="167" height="17" font="5">LDL-C: -2.7 vs. -17.2 (p=0.02) </text>
<text top="718" left="677" width="218" height="17" font="5">Total cholesterol: -8.3 vs. 22.1 (p=0.11) </text>
<text top="735" left="677" width="7" height="17" font="5">. </text>
<text top="752" left="677" width="3" height="17" font="5"> </text>
<text top="476" left="918" width="220" height="17" font="5">Limitations: Patients unblinded, lab staff </text>
<text top="493" left="918" width="194" height="17" font="5">measuring outcomes were blinded. </text>
<text top="510" left="918" width="216" height="17" font="5">31/44 enrolled completed the study (11 </text>
<text top="527" left="918" width="180" height="17" font="5">did not follow the study protocol) </text>
<text top="545" left="918" width="3" height="17" font="5"> </text>
<text top="562" left="918" width="210" height="17" font="5">patients were given recommendations </text>
<text top="579" left="918" width="203" height="17" font="5">to follow a particular diet (rather than </text>
<text top="596" left="918" width="146" height="17" font="5">receiving prepared foods). </text>
<text top="613" left="918" width="3" height="17" font="5"> </text>
<text top="631" left="918" width="118" height="17" font="5">Short-term (8 weeks) </text>
<text top="648" left="918" width="3" height="17" font="5"> </text>
<text top="665" left="918" width="166" height="17" font="5">No control for physical activity </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="15" size="12" family="Times" color="#221f1f"/>
	<fontspec id="16" size="12" family="Times" color="#221f1f"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="75" width="93" height="17" font="15">HART-D (Health </text>
<text top="178" left="75" width="61" height="17" font="15">Benefits of </text>
<text top="195" left="75" width="69" height="17" font="15">Aerobic and </text>
<text top="212" left="75" width="64" height="17" font="15">Resistance </text>
<text top="229" left="75" width="52" height="17" font="15">Training) </text>
<text top="247" left="75" width="74" height="17" font="15">in individuals </text>
<text top="264" left="75" width="62" height="17" font="15">with type 2 </text>
<text top="281" left="75" width="50" height="17" font="15">diabetes </text>
<text top="298" left="75" width="3" height="17" font="5"> </text>
<text top="315" left="75" width="70" height="17" font="5">Church et al </text>
<text top="333" left="75" width="39" height="17" font="5">(2010) </text>
<text top="350" left="75" width="3" height="17" font="5"> </text>
<text top="367" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21098771">21098771</a></text>
<text top="367" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21098771"> </a></text>
<text top="160" left="186" width="25" height="17" font="5">Aim </text>
<text top="178" left="186" width="135" height="17" font="5">To examine the benefits </text>
<text top="195" left="186" width="138" height="17" font="5">of aerobic training alone, </text>
<text top="212" left="186" width="140" height="17" font="5">resistance training alone, </text>
<text top="229" left="186" width="145" height="17" font="5">and a combination of both </text>
<text top="247" left="186" width="108" height="17" font="5">on hemoglobin A1c </text>
<text top="264" left="186" width="122" height="17" font="5">(HbA1c) in individuals </text>
<text top="281" left="186" width="112" height="17" font="5">with type 2 diabetes </text>
<text top="298" left="186" width="3" height="17" font="5"> </text>
<text top="315" left="186" width="66" height="17" font="5">Study Type </text>
<text top="333" left="186" width="29" height="17" font="5">RCT </text>
<text top="350" left="186" width="3" height="17" font="5"> </text>
<text top="367" left="186" width="40" height="17" font="5">N=262 </text>
<text top="160" left="346" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="191" left="344" width="159" height="18" font="5">•  sedentary (defined as not </text>
<text top="209" left="345" width="181" height="17" font="5">exercising more than 20 minutes </text>
<text top="226" left="345" width="145" height="17" font="5">on 3 or more days a week </text>
<text top="244" left="344" width="127" height="18" font="5">•  30- to 75-years old  </text>
<text top="262" left="344" width="172" height="18" font="5">•  Type 2 diabetes and HbA1c </text>
<text top="280" left="345" width="139" height="17" font="5">levels of 6.5% to 11.0%.  </text>
<text top="297" left="344" width="21" height="18" font="5">•   </text>
<text top="316" left="346" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="346" left="344" width="152" height="18" font="5">•  body mass index ≥48.0  </text>
<text top="365" left="344" width="102" height="18" font="5">•  blood pressure </text>
<text top="383" left="345" width="92" height="17" font="5">≥160/100mmHg </text>
<text top="400" left="344" width="158" height="18" font="5">•  fasting triglycerides ≥500 </text>
<text top="418" left="345" width="41" height="17" font="5">mg/dL, </text>
<text top="435" left="344" width="151" height="18" font="5">•  use of an insulin pump,  </text>
<text top="454" left="344" width="165" height="18" font="5">•  urine protein &gt;100 mg/dL,  </text>
<text top="472" left="344" width="184" height="18" font="5">•  serum creatinine &gt;1.5 mg/dL,  </text>
<text top="490" left="344" width="167" height="18" font="5">•  history of stroke, advanced </text>
<text top="508" left="345" width="185" height="17" font="5">neuropathy or retinopathy, or any </text>
<text top="525" left="345" width="165" height="17" font="5">serious medical condition that </text>
<text top="543" left="345" width="152" height="17" font="5">prevented participants from </text>
<text top="560" left="345" width="147" height="17" font="5">adhering to the protocol or </text>
<text top="577" left="345" width="94" height="17" font="5">exercising safely </text>
<text top="594" left="345" width="3" height="17" font="5"> </text>
<text top="613" left="345" width="40" height="17" font="5">N=262 </text>
<text top="160" left="547" width="71" height="17" font="5">Intervention: </text>
<text top="178" left="547" width="108" height="17" font="5">Resistance training </text>
<text top="195" left="547" width="82" height="17" font="5">3 days a week </text>
<text top="212" left="547" width="39" height="17" font="5">(n=73) </text>
<text top="229" left="547" width="3" height="17" font="5"> </text>
<text top="247" left="547" width="94" height="17" font="5">Aerobic exercise </text>
<text top="264" left="547" width="79" height="17" font="5">(expended 12 </text>
<text top="281" left="547" width="99" height="17" font="5">kcal/kg per week) </text>
<text top="298" left="547" width="39" height="17" font="5">(n=72) </text>
<text top="315" left="547" width="3" height="17" font="5"> </text>
<text top="333" left="547" width="103" height="17" font="5">Combined aerobic </text>
<text top="350" left="547" width="83" height="17" font="5">and resistance </text>
<text top="367" left="547" width="91" height="17" font="15">training in which </text>
<text top="384" left="547" width="101" height="17" font="15">they expended 10 </text>
<text top="401" left="547" width="95" height="17" font="15">kcal/kg per week </text>
<text top="419" left="547" width="88" height="17" font="15">and engaged in </text>
<text top="436" left="547" width="103" height="17" font="15">resistance training </text>
<text top="453" left="547" width="113" height="17" font="15">twice a week (n=76) </text>
<text top="470" left="547" width="3" height="17" font="5"> </text>
<text top="487" left="547" width="72" height="17" font="5">Comparator: </text>
<text top="505" left="547" width="7" height="17" font="5">  </text>
<text top="522" left="547" width="75" height="17" font="15">Non exercise </text>
<text top="539" left="547" width="87" height="17" font="15">(offered weekly </text>
<text top="556" left="547" width="81" height="17" font="15">stretching and </text>
<text top="573" left="547" width="101" height="17" font="15">relaxation classes </text>
<text top="591" left="547" width="99" height="17" font="15">and was asked to </text>
<text top="608" left="547" width="92" height="17" font="15">maintain current </text>
<text top="625" left="547" width="110" height="17" font="15">activity during the 9-</text>
<text top="642" left="547" width="112" height="17" font="15">month study period) </text>
<text top="660" left="547" width="43" height="17" font="15">(n=41)  </text>
<text top="677" left="547" width="3" height="17" font="5"> </text>
<text top="162" left="677" width="7" height="17" font="5">1</text>
<text top="161" left="684" width="64" height="18" font="5"> endpoint: </text>
<text top="179" left="677" width="191" height="17" font="15">change in HbA1c levels (assessed </text>
<text top="196" left="677" width="54" height="17" font="15">monthly). </text>
<text top="196" left="731" width="3" height="17" font="5"> </text>
<text top="213" left="677" width="3" height="17" font="5"> </text>
<text top="230" left="677" width="172" height="17" font="5">Results: Compared to changes </text>
<text top="230" left="849" width="53" height="17" font="15">in HbA1c </text>
<text top="248" left="677" width="209" height="17" font="15">in the control group, change in HbA1c </text>
<text top="265" left="677" width="168" height="17" font="15">was significantly greater in the </text>
<text top="282" left="677" width="201" height="17" font="15">combination training group (−0.34%; </text>
<text top="299" left="677" width="222" height="17" font="16"><i>P</i>=.03), while the differences in changes </text>
<text top="317" left="677" width="202" height="17" font="15">were not significant in the resistance </text>
<text top="334" left="677" width="170" height="17" font="15">training (resistance training vs. </text>
<text top="351" left="677" width="212" height="17" font="15">control=−0.16%; <i>P</i>=.32) or the aerobic </text>
<text top="368" left="677" width="177" height="17" font="15">exercise group(−0.24%;  <i>P</i>=.14) </text>
<text top="385" left="677" width="167" height="17" font="15">compared to the control group </text>
<text top="385" left="845" width="3" height="17" font="5"> </text>
<text top="162" left="918" width="7" height="17" font="5">2</text>
<text top="161" left="925" width="66" height="18" font="5"> endpoints </text>
<text top="179" left="918" width="200" height="17" font="15">measures of anthropometry, fitness, </text>
<text top="196" left="918" width="188" height="17" font="15">strength, and changes in diabetes </text>
<text top="213" left="918" width="215" height="17" font="15">medications (assessed at baseline and </text>
<text top="230" left="918" width="83" height="17" font="15">follow-up only) </text>
<text top="248" left="918" width="3" height="17" font="5"> </text>
<text top="265" left="918" width="206" height="17" font="5">Results (comparisons made between </text>
<text top="282" left="918" width="174" height="17" font="5">control group and each of three </text>
<text top="299" left="918" width="210" height="17" font="5">intervention groups for each outcome; </text>
<text top="317" left="918" width="204" height="17" font="5">only significant differences reported): </text>
<text top="334" left="918" width="3" height="17" font="5"> </text>
<text top="351" left="918" width="165" height="17" font="5">Peak Vo2: combination group </text>
<text top="368" left="918" width="187" height="17" font="5">significantly greater increase than </text>
<text top="385" left="918" width="199" height="17" font="5">control and resistance only (p&lt;0.05) </text>
<text top="403" left="918" width="3" height="17" font="5"> </text>
<text top="420" left="918" width="191" height="17" font="5">Peak lean Vo2: combination group </text>
<text top="437" left="918" width="187" height="17" font="5">significantly greater increase than </text>
<text top="454" left="918" width="199" height="17" font="5">control and resistance only (p&lt;0.05) </text>
<text top="471" left="918" width="3" height="17" font="5"> </text>
<text top="489" left="918" width="206" height="17" font="5">Time on treadmill: combination group </text>
<text top="506" left="918" width="212" height="17" font="5">and aerobic group significantly greater </text>
<text top="523" left="918" width="201" height="17" font="5">increase than control and resistance </text>
<text top="540" left="918" width="154" height="17" font="5">only. Resistance only group </text>
<text top="557" left="918" width="187" height="17" font="5">significantly greater increase than </text>
<text top="575" left="918" width="125" height="17" font="5">control group (p&lt;0.05) </text>
<text top="592" left="918" width="3" height="17" font="5"> </text>
<text top="609" left="918" width="167" height="17" font="5">Speed/grade estimated MET:  </text>
<text top="626" left="918" width="207" height="17" font="5">combination group and aerobic group </text>
<text top="643" left="918" width="187" height="17" font="5">significantly greater increase than </text>
<text top="661" left="918" width="217" height="17" font="5">control and resistance only. Resistance </text>
<text top="678" left="918" width="220" height="17" font="5">only group significantly greater increase </text>
<text top="695" left="918" width="152" height="17" font="5">than control group (p&lt;0.05) </text>
<text top="712" left="918" width="3" height="17" font="5"> </text>
<text top="730" left="918" width="215" height="17" font="5">Muscular work: combination group and </text>
<text top="747" left="918" width="187" height="17" font="5">resistance only group significantly </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="202" height="17" font="5">greater change than all other groups </text>
<text top="178" left="918" width="49" height="17" font="5">(p&lt;0.05) </text>
<text top="195" left="918" width="3" height="17" font="5"> </text>
<text top="212" left="918" width="189" height="17" font="5">Muscular torque: combination and </text>
<text top="229" left="918" width="193" height="17" font="5">resistance only groups significantly </text>
<text top="247" left="918" width="198" height="17" font="5">greater increase than aerobic group </text>
<text top="264" left="918" width="49" height="17" font="5">(p&lt;0.05) </text>
<text top="281" left="918" width="3" height="17" font="5"> </text>
<text top="298" left="918" width="172" height="17" font="5">Body mass: combination group </text>
<text top="315" left="918" width="191" height="17" font="5">significantly greater decrease than </text>
<text top="333" left="918" width="214" height="17" font="5">control and resistance groups (p&lt;0.05) </text>
<text top="350" left="918" width="3" height="17" font="5"> </text>
<text top="367" left="918" width="219" height="17" font="5">Fat mass: resistance group significantly </text>
<text top="384" left="918" width="202" height="17" font="5">greater decrease than control group. </text>
<text top="401" left="918" width="217" height="17" font="5">Combination group significantly greater </text>
<text top="419" left="918" width="189" height="17" font="5">decrease than control and aerobic </text>
<text top="436" left="918" width="84" height="17" font="5">group (p&lt;0.05) </text>
<text top="453" left="918" width="3" height="17" font="5"> </text>
<text top="470" left="918" width="204" height="17" font="5">Lean mass: aerobic and combination </text>
<text top="487" left="918" width="219" height="17" font="5">group had significantly smaller increase </text>
<text top="505" left="918" width="171" height="17" font="5">than resistance group (p&lt;0.05) </text>
<text top="522" left="918" width="3" height="17" font="5"> </text>
<text top="539" left="918" width="183" height="17" font="5">Waist circumference: all exercise </text>
<text top="556" left="918" width="174" height="17" font="5">groups had significantly greater </text>
<text top="573" left="918" width="212" height="17" font="5">decreases than control group (p&lt;0.05) </text>
<text top="591" left="918" width="3" height="17" font="5"> </text>
<text top="608" left="918" width="96" height="17" font="5">Adverse Events:  </text>
<text top="625" left="918" width="218" height="17" font="15">(control, 3 events; resistance training, 8 </text>
<text top="642" left="918" width="167" height="17" font="15">events; aerobic, 6 events; and </text>
<text top="660" left="918" width="216" height="17" font="15">combination taring, 4 events), including </text>
<text top="677" left="918" width="215" height="17" font="15">diverticulitis, emergency hysterectomy, </text>
<text top="694" left="918" width="209" height="17" font="15">lung cancer, 5 cardiovascular disease </text>
<text top="711" left="918" width="208" height="17" font="15">events (all reported to be unrelated to </text>
<text top="728" left="918" width="196" height="17" font="15">intervention), blood clot. No serious </text>
<text top="746" left="918" width="219" height="17" font="15">adverse event occurred during exercise </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="193" height="17" font="15">training and only 1 was considered </text>
<text top="178" left="918" width="133" height="17" font="15">associated with exercise</text>
<text top="178" left="1052" width="3" height="17" font="5"> </text>
<text top="196" left="75" width="54" height="17" font="5">SPREAD-</text>
<text top="213" left="75" width="91" height="17" font="5">DIMCAD (Study </text>
<text top="230" left="75" width="96" height="17" font="5">on the Prognosis </text>
<text top="247" left="75" width="72" height="17" font="5">and Effect of </text>
<text top="264" left="75" width="67" height="17" font="5">Antidiabetic </text>
<text top="282" left="75" width="94" height="17" font="5">Drugs on Type 2 </text>
<text top="299" left="75" width="97" height="17" font="5">Diabetes Mellitus </text>
<text top="316" left="75" width="79" height="17" font="5">with Coronary </text>
<text top="333" left="75" width="88" height="17" font="5">Artery Disease) </text>
<text top="350" left="75" width="3" height="17" font="5"> </text>
<text top="368" left="75" width="98" height="17" font="5">Hong et al (2013) </text>
<text top="385" left="75" width="3" height="17" font="5"> </text>
<text top="402" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23230096">23230096</a></text>
<text top="402" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23230096"> </a></text>
<text top="196" left="186" width="25" height="17" font="5">Aim </text>
<text top="213" left="186" width="139" height="17" font="5">to compare the effects of </text>
<text top="230" left="186" width="135" height="17" font="5">the two major classes of </text>
<text top="247" left="186" width="129" height="17" font="5">blood glucose-lowering </text>
<text top="264" left="186" width="113" height="17" font="5">agents, sulfonylurea </text>
<text top="282" left="186" width="141" height="17" font="5">(glipizide) and metformin, </text>
<text top="299" left="186" width="120" height="17" font="5">on the cardiovascular </text>
<text top="316" left="186" width="126" height="17" font="5">events and mortality in </text>
<text top="333" left="186" width="109" height="17" font="5">304 Chinese type 2 </text>
<text top="350" left="186" width="142" height="17" font="5">diabetic patients who had </text>
<text top="368" left="186" width="115" height="17" font="5">a history of coronary </text>
<text top="385" left="186" width="122" height="17" font="5">artery disease (CAD). </text>
<text top="402" left="186" width="3" height="17" font="5"> </text>
<text top="419" left="186" width="66" height="17" font="5">Study Type </text>
<text top="437" left="186" width="29" height="17" font="5">RCT </text>
<text top="454" left="186" width="3" height="17" font="5"> </text>
<text top="471" left="186" width="40" height="17" font="5">N=304 </text>
<text top="196" left="346" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="226" left="344" width="182" height="18" font="5">•  diagnosed with CAD by either </text>
<text top="244" left="345" width="136" height="17" font="5">having a history of acute </text>
<text top="262" left="345" width="179" height="17" font="5">myocardial infarction, diagnosed </text>
<text top="279" left="345" width="141" height="17" font="5">by a representative set of </text>
<text top="296" left="345" width="154" height="17" font="5">electrocardiograms, cardiac </text>
<text top="313" left="345" width="151" height="17" font="5">enzyme values, and typical </text>
<text top="330" left="345" width="182" height="17" font="5">symptoms or by angiographically </text>
<text top="348" left="345" width="164" height="17" font="5">identified stenosis of &gt;50% of </text>
<text top="365" left="345" width="168" height="17" font="5">lumen diameter in at least one </text>
<text top="382" left="345" width="180" height="17" font="5">major epicardial coronary artery  </text>
<text top="399" left="344" width="189" height="18" font="5">•  diagnosed with type 2 diabetes </text>
<text top="418" left="345" width="154" height="17" font="5">(fasting plasma glucose ≥ 7 </text>
<text top="435" left="345" width="173" height="17" font="5">mmol/L and/or 2-h oral glucose </text>
<text top="452" left="345" width="180" height="17" font="5">tolerance test ≥11.1 mmol/L and </text>
<text top="469" left="345" width="128" height="17" font="5">fasting plasma glucose </text>
<text top="486" left="345" width="76" height="17" font="5">&lt;15mmol/L);  </text>
<text top="504" left="344" width="188" height="18" font="5">•  no more than 80 years of age.  </text>
<text top="522" left="346" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="553" left="344" width="152" height="18" font="5">•  severe liver dysfunction, </text>
<text top="571" left="345" width="132" height="17" font="5">including serum alanine </text>
<text top="588" left="345" width="175" height="17" font="5">aminotransferase concentration </text>
<text top="605" left="345" width="178" height="17" font="5">&gt;2.5 times above the upper limit </text>
<text top="622" left="345" width="168" height="17" font="5">of normal range and abnormal </text>
<text top="640" left="345" width="176" height="17" font="5">renal function (serum creatinine </text>
<text top="657" left="345" width="82" height="17" font="5">&gt;132 μmol/L);  </text>
<text top="674" left="344" width="189" height="18" font="5">•  severe dysfunction of the heart </text>
<text top="692" left="345" width="160" height="17" font="5">(New York Heart Association </text>
<text top="709" left="345" width="100" height="17" font="5">class &gt;phase III);  </text>
<text top="727" left="344" width="168" height="18" font="5">•  psychiatric disease, severe </text>
<text top="745" left="345" width="154" height="17" font="5">infection, severe anemia, or </text>
<text top="762" left="345" width="75" height="17" font="5">neutropenia;  </text>
<text top="196" left="547" width="71" height="17" font="5">Intervention: </text>
<text top="213" left="547" width="101" height="17" font="5">metformin (≤1.5 g </text>
<text top="230" left="547" width="98" height="17" font="5">daily, mean 1.4 ± </text>
<text top="247" left="547" width="108" height="17" font="5">0.2 g) plus glipizide </text>
<text top="264" left="547" width="108" height="17" font="5">placebo for 3 years </text>
<text top="282" left="547" width="46" height="17" font="5">(n=156) </text>
<text top="299" left="547" width="3" height="17" font="5"> </text>
<text top="316" left="547" width="72" height="17" font="5">Comparator: </text>
<text top="333" left="547" width="7" height="17" font="5">  </text>
<text top="350" left="547" width="94" height="17" font="5">glipizide(≤30 mg </text>
<text top="368" left="547" width="93" height="17" font="5">daily, mean 28.3 </text>
<text top="385" left="547" width="76" height="17" font="5">±3.9mg) plus </text>
<text top="402" left="547" width="104" height="17" font="5">metformin placebo </text>
<text top="419" left="547" width="42" height="17" font="5">(n=148 </text>
<text top="197" left="677" width="7" height="17" font="5">1</text>
<text top="196" left="684" width="64" height="18" font="5"> endpoint: </text>
<text top="214" left="677" width="3" height="17" font="5"> </text>
<text top="231" left="677" width="197" height="17" font="5">Composite recurrent cardiovascular </text>
<text top="248" left="677" width="205" height="17" font="5">events, including nonfatal myocardial </text>
<text top="266" left="677" width="196" height="17" font="5">infarction, nonfatal stroke or arterial </text>
<text top="283" left="677" width="190" height="17" font="5">revascularization by percutaneous </text>
<text top="300" left="677" width="186" height="17" font="5">transluminal coronary angioplasty </text>
<text top="317" left="677" width="203" height="17" font="5">(PTCA) or by coronary artery bypass </text>
<text top="334" left="677" width="226" height="17" font="5">graft, death from a cardiovascular cause, </text>
<text top="352" left="677" width="146" height="17" font="5">and death from any cause </text>
<text top="369" left="677" width="3" height="17" font="5"> </text>
<text top="386" left="677" width="48" height="17" font="5">Results: </text>
<text top="403" left="677" width="213" height="17" font="5">Median follow-up period was 5.0 years </text>
<text top="420" left="677" width="3" height="17" font="5"> </text>
<text top="438" left="677" width="226" height="17" font="5">The HR for the composite cardiovascular </text>
<text top="455" left="677" width="171" height="17" font="5">events for metformin treatment </text>
<text top="472" left="677" width="216" height="17" font="5">compared to glipizide was 0.54 (95%CI </text>
<text top="489" left="677" width="214" height="17" font="5">0.30–0.90; P = 0.026) after adjustment </text>
<text top="507" left="677" width="215" height="17" font="5">for the duration of diabetes, duration of </text>
<text top="524" left="677" width="213" height="17" font="5">CAD, age, sex, and smoking history at </text>
<text top="541" left="677" width="49" height="17" font="5">baseline </text>
<text top="558" left="677" width="3" height="17" font="5"> </text>
<text top="575" left="677" width="218" height="17" font="5">No significant difference in the mortality </text>
<text top="593" left="677" width="220" height="17" font="5">rate between the two groups (P = 0.55.) </text>
<text top="610" left="677" width="7" height="17" font="5">  </text>
<text top="627" left="677" width="226" height="17" font="5">No significant between-group differences </text>
<text top="644" left="677" width="201" height="17" font="5">in glycated hemoglobin level, fasting </text>
<text top="661" left="677" width="206" height="17" font="5">plasma glucose, postload 2-h plasma </text>
<text top="679" left="677" width="189" height="17" font="5">glucose, systolic or diastolic blood </text>
<text top="696" left="677" width="175" height="17" font="5">pressure, total cholesterol, HDL </text>
<text top="713" left="677" width="198" height="17" font="5">cholesterol, LDL cholesterol, fasting </text>
<text top="730" left="677" width="216" height="17" font="5">serum triglyceride, or serum creatinine, </text>
<text top="748" left="677" width="213" height="17" font="5">glucose lowering medications, or other </text>
<text top="765" left="677" width="221" height="17" font="5">medications except statins for which the </text>
<text top="197" left="918" width="7" height="17" font="5">2</text>
<text top="196" left="925" width="66" height="18" font="5"> endpoints </text>
<text top="214" left="918" width="184" height="17" font="5">new or worsening angina, new or </text>
<text top="231" left="918" width="195" height="17" font="5">worsening heart failure, new critical </text>
<text top="248" left="918" width="216" height="17" font="5">cardiac arrhythmia, and new peripheral </text>
<text top="266" left="918" width="89" height="17" font="5">vascular events </text>
<text top="283" left="918" width="3" height="17" font="5"> </text>
<text top="300" left="918" width="48" height="17" font="5">Results: </text>
<text top="317" left="918" width="3" height="17" font="5"> </text>
<text top="334" left="918" width="203" height="17" font="5">new or worsening heart failure: 6.8% </text>
<text top="352" left="918" width="199" height="17" font="5">glipizide group and 5.8%  metformin </text>
<text top="369" left="918" width="208" height="17" font="5">group (adjusted HR 0.82, P = 0.677);  </text>
<text top="386" left="918" width="3" height="17" font="5"> </text>
<text top="403" left="918" width="210" height="17" font="5">new critical cardiac arrhythmia: 18.2% </text>
<text top="420" left="918" width="203" height="17" font="5">glipizide group and 19.2% metformin </text>
<text top="438" left="918" width="208" height="17" font="5">group (adjusted HR 1.01; P = 0.958);  </text>
<text top="455" left="918" width="219" height="17" font="5">new or worsening angina: 48% glipizide </text>
<text top="472" left="918" width="190" height="17" font="5">group and 49.4% metformin group </text>
<text top="489" left="918" width="194" height="17" font="5">(adjusted HR 1.07; P = 0.696); and </text>
<text top="507" left="918" width="107" height="17" font="5">peripheral vascular </text>
<text top="524" left="918" width="216" height="17" font="5">events:  4.1% glipizide group and 0.6% </text>
<text top="541" left="918" width="96" height="17" font="5">metformin group  </text>
<text top="558" left="918" width="170" height="17" font="5">(adjusted HR 0.13; P = 0.059). </text>
<text top="575" left="918" width="3" height="17" font="5"> </text>
<text top="593" left="918" width="163" height="17" font="5">No significant between-group </text>
<text top="610" left="918" width="208" height="17" font="5">differences in number of patients who </text>
<text top="627" left="918" width="197" height="17" font="5">reported one or more hypoglycemic </text>
<text top="644" left="918" width="194" height="17" font="5">attacks (P = 0.651 overall, p=0.080 </text>
<text top="661" left="918" width="164" height="17" font="5">when excluding insulin users) </text>
<text top="679" left="918" width="3" height="17" font="5"> </text>
<text top="696" left="918" width="3" height="17" font="5"> </text>
<text top="713" left="918" width="69" height="17" font="5">Limitations:  </text>
<text top="730" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="161" left="344" width="164" height="18" font="5">•  other severe organic heart </text>
<text top="179" left="345" width="152" height="17" font="5">diseases, including, but not </text>
<text top="196" left="345" width="147" height="17" font="5">limited to, congenital heart </text>
<text top="213" left="345" width="187" height="17" font="5">disease, rheumatic heart disease, </text>
<text top="230" left="345" width="149" height="17" font="5">and hypertrophic or dilated </text>
<text top="247" left="345" width="97" height="17" font="5">cardiomyopathy;  </text>
<text top="265" left="344" width="140" height="18" font="5">•  pregnant or lactating;  </text>
<text top="283" left="344" width="147" height="18" font="5">•  allergic to study drugs;  </text>
<text top="301" left="344" width="187" height="18" font="5">•  using insulin therapy for type 2 </text>
<text top="319" left="345" width="144" height="17" font="5">diabetes and could not be </text>
<text top="337" left="345" width="184" height="17" font="5">changed to oral glucose-lowering </text>
<text top="354" left="345" width="41" height="17" font="5">drugs;  </text>
<text top="371" left="344" width="180" height="18" font="5">•  recent drug or alcohol abuse. </text>
<text top="160" left="677" width="217" height="17" font="5">metformin group had significantly lower </text>
<text top="178" left="677" width="149" height="17" font="5">use at follow up (p=0.013). </text>
<text top="195" left="677" width="3" height="17" font="5"> </text>
<text top="212" left="677" width="217" height="17" font="5">Metformin group had significantly lower </text>
<text top="229" left="677" width="156" height="17" font="5">BMI, body weight, and waist </text>
<text top="247" left="677" width="221" height="17" font="5">circumference at follow up than glipizide </text>
<text top="264" left="677" width="84" height="17" font="5">group (p&lt;0.01) </text>
<text top="281" left="677" width="3" height="17" font="5"> </text>
<text top="298" left="677" width="3" height="17" font="5"> </text>
<text top="160" left="918" width="191" height="17" font="5">secondary end points and adverse </text>
<text top="178" left="918" width="217" height="17" font="5">events were recorded only during the 3-</text>
<text top="195" left="918" width="220" height="17" font="5">year period of study drug administration </text>
<text top="212" left="918" width="3" height="17" font="5"> </text>
<text top="390" left="75" width="87" height="17" font="5">Huo et al, 2015 </text>
<text top="407" left="75" width="3" height="17" font="5"> </text>
<text top="424" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25369829">25369829</a></text>
<text top="424" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25369829"> </a></text>
<text top="390" left="186" width="58" height="17" font="5">Study aim </text>
<text top="407" left="186" width="70" height="17" font="5">to conduct a </text>
<text top="424" left="186" width="111" height="17" font="5">comprehensive and </text>
<text top="442" left="186" width="134" height="17" font="5">updated overview of the </text>
<text top="459" left="186" width="63" height="17" font="5">effects of a </text>
<text top="476" left="186" width="135" height="17" font="5">Mediterranean-style diet </text>
<text top="493" left="186" width="107" height="17" font="5">(MSD) on glycemic </text>
<text top="511" left="186" width="132" height="17" font="5">control, weight loss and </text>
<text top="528" left="186" width="145" height="17" font="5">cardiovascular risk factors </text>
<text top="545" left="186" width="111" height="17" font="5">in patients with T2D </text>
<text top="562" left="186" width="3" height="17" font="5"> </text>
<text top="579" left="186" width="62" height="17" font="5">Study type </text>
<text top="597" left="186" width="79" height="17" font="5">Meta-analysis </text>
<text top="614" left="186" width="3" height="17" font="5"> </text>
<text top="631" left="186" width="103" height="17" font="5">N=9 studies (1178 </text>
<text top="648" left="186" width="51" height="17" font="5">patients) </text>
<text top="390" left="346" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="421" left="344" width="55" height="18" font="5">•  RCTs  </text>
<text top="439" left="344" width="182" height="18" font="5">•   adult patients with diagnosed </text>
<text top="457" left="345" width="30" height="17" font="5">T2D, </text>
<text top="474" left="344" width="176" height="18" font="5">•  evaluated the effect of MSD  </text>
<text top="493" left="344" width="182" height="18" font="5">•  intervention period ≥4 weeks  </text>
<text top="511" left="344" width="176" height="18" font="5">•  reported at least hemoglobin </text>
<text top="529" left="345" width="155" height="17" font="5">A1c (HbA1c) outcome data. </text>
<text top="546" left="346" width="3" height="17" font="5"> </text>
<text top="577" left="346" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="608" left="344" width="169" height="18" font="5">•  no randomization or control </text>
<text top="626" left="345" width="58" height="17" font="5">diet group </text>
<text top="643" left="344" width="176" height="18" font="5">•  cohort, case-control or cross-</text>
<text top="661" left="345" width="92" height="17" font="5">sectional design </text>
<text top="678" left="344" width="177" height="18" font="5">•  included subjects with type 1 </text>
<text top="697" left="345" width="180" height="17" font="5">diabetes, gestational diabetes or </text>
<text top="714" left="345" width="138" height="17" font="5">at high risk for diabetes,  </text>
<text top="731" left="344" width="171" height="18" font="5">•  did not report relevant data  </text>
<text top="749" left="344" width="185" height="18" font="5">•  performed a post hoc analysis </text>
<text top="768" left="345" width="106" height="17" font="5">of previous studies </text>
<text top="390" left="547" width="71" height="17" font="5">Intervention: </text>
<text top="407" left="547" width="111" height="17" font="5">Mediterranean style </text>
<text top="424" left="547" width="27" height="17" font="5">diet  </text>
<text top="442" left="547" width="3" height="17" font="5"> </text>
<text top="459" left="547" width="72" height="17" font="5">Comparator: </text>
<text top="476" left="547" width="7" height="17" font="5">  </text>
<text top="493" left="547" width="72" height="17" font="15">Control diets </text>
<text top="511" left="547" width="115" height="17" font="15">included low-fat diet, </text>
<text top="528" left="547" width="113" height="17" font="15">usual dietary habits, </text>
<text top="545" left="547" width="114" height="17" font="15">nonrestricted calorie </text>
<text top="562" left="547" width="98" height="17" font="15">low-carbohydrate </text>
<text top="579" left="547" width="78" height="17" font="15">diet, the 2003 </text>
<text top="597" left="547" width="107" height="17" font="15">American Diabetes </text>
<text top="614" left="547" width="103" height="17" font="15">Association (ADA) </text>
<text top="631" left="547" width="74" height="17" font="15">diet and high-</text>
<text top="648" left="547" width="98" height="17" font="15">carbohydrate diet </text>
<text top="665" left="547" width="3" height="17" font="5"> </text>
<text top="683" left="547" width="99" height="17" font="5">N=9 studies total, </text>
<text top="700" left="547" width="104" height="17" font="5">number of studies, </text>
<text top="717" left="547" width="104" height="17" font="5">arms, and patients </text>
<text top="734" left="547" width="107" height="17" font="5">varied by outcome  </text>
<text top="391" left="677" width="7" height="17" font="5">1</text>
<text top="390" left="684" width="64" height="18" font="5"> endpoint: </text>
<text top="409" left="675" width="223" height="18" font="5">•  glycemic control including changes in </text>
<text top="427" left="676" width="212" height="17" font="5">HbA1c, fasting plasma glucose (FPG), </text>
<text top="444" left="676" width="211" height="17" font="5">fasting insulin and homeostasis model </text>
<text top="461" left="676" width="181" height="17" font="5">assessment of insulin resistance </text>
<text top="478" left="675" width="211" height="18" font="5">•  weight control including changes in </text>
<text top="497" left="676" width="226" height="17" font="5">body weight, body mass index (BMI) and </text>
<text top="514" left="676" width="112" height="17" font="5">waist circumference </text>
<text top="531" left="675" width="215" height="18" font="5">•  cardiovascular risk factors including </text>
<text top="549" left="676" width="222" height="17" font="5">changes in total cholesterol, triglyceride, </text>
<text top="566" left="676" width="217" height="17" font="5">high-density lipoprotein cholesterol and </text>
<text top="584" left="676" width="191" height="17" font="5">low-density lipoprotein cholesterol, </text>
<text top="601" left="676" width="204" height="17" font="5">systolic and diastolic blood pressure. </text>
<text top="618" left="677" width="3" height="17" font="5"> </text>
<text top="649" left="677" width="48" height="17" font="5">Results: </text>
<text top="679" left="677" width="98" height="17" font="7"><i>Glycemic control</i>: </text>
<text top="679" left="775" width="90" height="17" font="15">MSD group had </text>
<text top="696" left="677" width="216" height="17" font="15">significantly greater reduction in HbA1c </text>
<text top="714" left="677" width="208" height="17" font="15">than control (mean difference, − 0.30; </text>
<text top="731" left="677" width="203" height="17" font="15">95% CI, − 0.46 to − 0.14) (significant </text>
<text top="748" left="677" width="169" height="17" font="15">between-study heterogeneity). </text>
<text top="765" left="677" width="3" height="17" font="15"> </text>
<text top="391" left="918" width="7" height="17" font="5">2</text>
<text top="390" left="925" width="66" height="18" font="5"> endpoints </text>
<text top="408" left="918" width="3" height="17" font="5"> </text>
<text top="426" left="918" width="69" height="17" font="5">Limitations:  </text>
<text top="443" left="918" width="210" height="17" font="15">No evidence of substantial publication </text>
<text top="460" left="918" width="210" height="17" font="15">bias from Begg’s test (P&gt;0.05) for any </text>
<text top="477" left="918" width="217" height="17" font="15">outcome examined, but some evidence </text>
<text top="494" left="918" width="210" height="17" font="15">of potential publication bias for HbA1c </text>
<text top="512" left="918" width="204" height="17" font="15">(P = 0.001) and total cholesterol (P = </text>
<text top="529" left="918" width="115" height="17" font="15">0.025) (Egger’s test) </text>
<text top="546" left="918" width="3" height="17" font="5"> </text>
<text top="563" left="918" width="194" height="17" font="5">Heterogeneity detected for multiple </text>
<text top="580" left="918" width="171" height="17" font="5">outcomes (HbA1c, FPG levels, </text>
<text top="598" left="918" width="124" height="17" font="5">triglycerides, and HDL </text>
<text top="615" left="918" width="3" height="17" font="5"> </text>
<text top="632" left="918" width="141" height="17" font="5">No consistent control diet </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="161" left="344" width="149" height="18" font="5">•  commentaries, reviews, </text>
<text top="179" left="345" width="168" height="17" font="5">letters, editorials, duplications, </text>
<text top="196" left="345" width="128" height="17" font="5">nonhuman studies and </text>
<text top="213" left="345" width="161" height="17" font="5">extensions of original studies </text>
<text top="230" left="530" width="3" height="17" font="5"> </text>
<text top="160" left="677" width="217" height="17" font="15">MSD group had significantly decreased </text>
<text top="178" left="677" width="214" height="17" font="15">FPG levels compared to control (−0.72 </text>
<text top="195" left="677" width="218" height="17" font="15">mmol/l; CI, − 1.24 to − 0.21) (significant </text>
<text top="212" left="677" width="172" height="17" font="15">between study heterogeneity).  </text>
<text top="229" left="677" width="3" height="17" font="15"> </text>
<text top="247" left="677" width="199" height="17" font="15">MSD group had significantly greater </text>
<text top="264" left="677" width="212" height="17" font="15">decrease than control in fasting insulin </text>
<text top="281" left="677" width="225" height="17" font="15">levels (−0.55 μU/ml; CI, − 0.81 to − 0.29) </text>
<text top="298" left="677" width="165" height="17" font="15">(no significant heterogeneity). </text>
<text top="315" left="677" width="3" height="17" font="5"> </text>
<text top="333" left="677" width="172" height="17" font="15">No significant effect of MSD on </text>
<text top="350" left="677" width="192" height="17" font="15">homeostasis model assessment of </text>
<text top="367" left="677" width="207" height="17" font="15">insulin resistance  (mean difference,− </text>
<text top="384" left="677" width="220" height="17" font="15">0.55; CI, − 1.53 to 0.42) (non-significant </text>
<text top="401" left="677" width="224" height="17" font="15">moderate between study heterogeneity). </text>
<text top="419" left="677" width="3" height="17" font="5"> </text>
<text top="436" left="677" width="89" height="17" font="7"><i>Weight control</i>:  </text>
<text top="453" left="677" width="3" height="17" font="5"> </text>
<text top="470" left="677" width="217" height="17" font="15">Significantly greater decrease in BMI in </text>
<text top="487" left="677" width="179" height="17" font="15">MSD that control patients (mean </text>
<text top="505" left="677" width="225" height="17" font="15">difference (− 0.29 kg/m2; 95% CI, − 0.46 </text>
<text top="522" left="677" width="59" height="17" font="15">to − 0.12). </text>
<text top="539" left="677" width="3" height="17" font="15"> </text>
<text top="556" left="677" width="219" height="17" font="15">Significantly greater weight loss in MSD </text>
<text top="573" left="677" width="224" height="17" font="15">than control group (0.29 kg; CI, − 0.55 to </text>
<text top="591" left="677" width="46" height="17" font="15">− 0.04)  </text>
<text top="608" left="677" width="3" height="17" font="15"> </text>
<text top="625" left="677" width="215" height="17" font="15">No significant difference in reduction in </text>
<text top="642" left="677" width="204" height="17" font="15">waist circumference (−0.41 cm; CI, − </text>
<text top="660" left="677" width="69" height="17" font="15">0.89 to 0.08)</text>
<text top="660" left="746" width="3" height="17" font="5"> </text>
<text top="677" left="677" width="3" height="17" font="5"> </text>
<text top="694" left="677" width="152" height="17" font="7"><i>Cardiovascular risk factors</i>: </text>
<text top="711" left="677" width="209" height="17" font="15">Significantly greater decrease in MSD </text>
<text top="728" left="677" width="205" height="17" font="15">than control group in total cholesterol </text>
<text top="746" left="677" width="224" height="17" font="15">(mean difference,− 0.14 mmol/l; 95% CI, </text>
<text top="763" left="677" width="219" height="17" font="15">− 0.19 to − 0.09) and triglyceride (−0.29 </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="180" height="17" font="15">mmol/l; CI, − 0.47 to − 0.10) and </text>
<text top="178" left="677" width="219" height="17" font="15">increased HDL (0.06 mmol/l; CI, 0.02 to </text>
<text top="195" left="677" width="219" height="17" font="15">0.10). No significant difference between </text>
<text top="212" left="677" width="218" height="17" font="15">groups in change in LDL (−0.11 mmol/l; </text>
<text top="229" left="677" width="109" height="17" font="15">CI, − 0.24 to 0.01).  </text>
<text top="247" left="677" width="3" height="17" font="15"> </text>
<text top="264" left="677" width="225" height="17" font="15">Significantly greater decrease in MSD vs </text>
<text top="281" left="677" width="182" height="17" font="15">control in systolic blood pressure </text>
<text top="298" left="677" width="211" height="17" font="15">(−1.45mmHg; CI,− 1.97 to − 0.94) and </text>
<text top="315" left="677" width="214" height="17" font="15">diastolic blood pressure (−1.41 mmHg; </text>
<text top="333" left="677" width="113" height="17" font="15">CI, − 1.84 to − 0.97).</text>
<text top="333" left="790" width="3" height="17" font="5"> </text>
<text top="350" left="677" width="3" height="17" font="5"> </text>
<text top="368" left="75" width="83" height="17" font="5">Snowling et al, </text>
<text top="385" left="75" width="31" height="17" font="5">2006 </text>
<text top="402" left="75" width="3" height="17" font="5"> </text>
<text top="419" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17065697">17065697</a></text>
<text top="419" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17065697"> </a></text>
<text top="368" left="186" width="111" height="17" font="5">to meta-analyze the </text>
<text top="385" left="186" width="141" height="17" font="5">effects of different modes </text>
<text top="402" left="186" width="124" height="17" font="5">of exercise training on </text>
<text top="419" left="186" width="117" height="17" font="5">measures of glucose </text>
<text top="437" left="186" width="118" height="17" font="5">control and other risk </text>
<text top="454" left="186" width="136" height="17" font="5">factors for complications </text>
<text top="471" left="186" width="64" height="17" font="5">of diabetes </text>
<text top="488" left="186" width="3" height="17" font="5"> </text>
<text top="505" left="186" width="62" height="17" font="5">Study type </text>
<text top="523" left="186" width="79" height="17" font="5">Meta analysis </text>
<text top="540" left="186" width="3" height="17" font="5"> </text>
<text top="557" left="186" width="114" height="17" font="5">N=27 studies (1,003 </text>
<text top="574" left="186" width="51" height="17" font="5">patients) </text>
<text top="591" left="186" width="3" height="17" font="5"> </text>
<text top="368" left="346" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="398" left="344" width="130" height="18" font="5">•  published in English </text>
<text top="417" left="344" width="120" height="18" font="5">•  through May 2006 </text>
<text top="435" left="344" width="107" height="18" font="5">•  controlled trials  </text>
<text top="453" left="344" width="173" height="18" font="5">•  supervised exercise training </text>
<text top="471" left="345" width="55" height="17" font="5">programs </text>
<text top="489" left="344" width="146" height="18" font="5">•  type 2 diabetic patients </text>
<text top="507" left="344" width="149" height="18" font="5">•  at least one measure of </text>
<text top="525" left="345" width="86" height="17" font="5">glucose control </text>
<text top="542" left="345" width="3" height="17" font="5"> </text>
<text top="573" left="346" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="603" left="344" width="131" height="18" font="5">•  lack of control group </text>
<text top="622" left="344" width="149" height="18" font="5">•  control group of healthy </text>
<text top="640" left="345" width="56" height="17" font="5">subjected </text>
<text top="657" left="344" width="178" height="18" font="5">•  exercise program interrupted </text>
<text top="675" left="344" width="176" height="18" font="5">•  program participation did not </text>
<text top="694" left="345" width="165" height="17" font="5">significantly increase physical </text>
<text top="711" left="345" width="41" height="17" font="5">activity </text>
<text top="728" left="344" width="171" height="18" font="5">•  insufficient data to calculate </text>
<text top="746" left="345" width="176" height="17" font="5">magnitude of mean effect or SE </text>
<text top="368" left="547" width="71" height="17" font="5">Intervention: </text>
<text top="385" left="547" width="111" height="17" font="5">Aerobic, resistance, </text>
<text top="402" left="547" width="84" height="17" font="5">or combination </text>
<text top="419" left="547" width="53" height="17" font="5">exercise  </text>
<text top="437" left="547" width="3" height="17" font="5"> </text>
<text top="454" left="547" width="72" height="17" font="5">Comparator: </text>
<text top="471" left="547" width="7" height="17" font="5">  </text>
<text top="488" left="547" width="3" height="17" font="5"> </text>
<text top="369" left="677" width="7" height="17" font="5">1</text>
<text top="368" left="684" width="64" height="18" font="5"> endpoint: </text>
<text top="386" left="677" width="40" height="17" font="5">HbA1c </text>
<text top="403" left="677" width="90" height="17" font="5">Fasting glucose </text>
<text top="420" left="677" width="118" height="17" font="5">Postprandial glucose </text>
<text top="438" left="677" width="96" height="17" font="5">Insulin sensitivity </text>
<text top="455" left="677" width="82" height="17" font="5">Fasting insulin </text>
<text top="472" left="677" width="64" height="17" font="5">Body mass </text>
<text top="489" left="677" width="54" height="17" font="5">Fat mass </text>
<text top="507" left="677" width="89" height="17" font="5">LDL cholesterol </text>
<text top="524" left="677" width="91" height="17" font="5">HDL cholesterol </text>
<text top="541" left="677" width="94" height="17" font="5">Total cholesterol </text>
<text top="558" left="677" width="69" height="17" font="5">triglycerides </text>
<text top="575" left="677" width="132" height="17" font="5">Systolic Blood pressure </text>
<text top="593" left="677" width="135" height="17" font="5">Diastolic blood pressure </text>
<text top="610" left="677" width="3" height="17" font="5"> </text>
<text top="627" left="677" width="202" height="17" font="5">Results (only showing those that are </text>
<text top="646" left="677" width="200" height="17" font="5">small to large; all other comparisons </text>
<text top="664" left="677" width="202" height="17" font="5">were unclear or trivial. All results are </text>
<text top="683" left="677" width="189" height="17" font="5">beneficial unless otherwise noted) </text>
<text top="713" left="677" width="7" height="17" font="5">: </text>
<text top="731" left="677" width="218" height="17" font="5">HbA1c: -0.37 aerobic, --2.9 resistance, -</text>
<text top="748" left="677" width="84" height="17" font="5">0.43 combined </text>
<text top="765" left="677" width="3" height="17" font="5"> </text>
<text top="369" left="918" width="7" height="17" font="5">2</text>
<text top="368" left="925" width="66" height="18" font="5"> endpoints </text>
<text top="386" left="918" width="3" height="17" font="5"> </text>
<text top="403" left="918" width="69" height="17" font="5">Limitations:  </text>
<text top="420" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="345" width="150" height="17" font="5">for at least one measure of </text>
<text top="178" left="345" width="86" height="17" font="5">glucose control </text>
<text top="195" left="346" width="3" height="17" font="5"> </text>
<text top="160" left="677" width="203" height="17" font="5">Fasting glucose: -0.20 aerobic, -0.53 </text>
<text top="178" left="677" width="57" height="17" font="5">combined </text>
<text top="195" left="677" width="3" height="17" font="5"> </text>
<text top="212" left="677" width="204" height="17" font="5">Postprandial glucose: -0.44 aerobic, -</text>
<text top="229" left="677" width="84" height="17" font="5">0.28 combined </text>
<text top="247" left="677" width="3" height="17" font="5"> </text>
<text top="264" left="677" width="201" height="17" font="5">Insulin sensitivity: 0.74 aerobic, 0.34 </text>
<text top="281" left="677" width="147" height="17" font="5">resistance, 2.20 combined </text>
<text top="298" left="677" width="3" height="17" font="5"> </text>
<text top="315" left="677" width="196" height="17" font="5">Fasting insulin: -0.47 aerobic, -0.78 </text>
<text top="333" left="677" width="60" height="17" font="5">resistance </text>
<text top="350" left="677" width="3" height="17" font="5"> </text>
<text top="367" left="677" width="156" height="17" font="5">Body mass: -0.32 combined </text>
<text top="384" left="677" width="3" height="17" font="5"> </text>
<text top="401" left="677" width="219" height="17" font="5">Body fat: -0.35 aerobic, -0.46 combined </text>
<text top="419" left="677" width="3" height="17" font="5"> </text>
<text top="436" left="677" width="123" height="17" font="5">LDL cholesterol: none </text>
<text top="453" left="677" width="179" height="17" font="5">HDL cholesterol: 0.49 combined </text>
<text top="470" left="677" width="128" height="17" font="5">Total cholesterol: none </text>
<text top="487" left="677" width="152" height="17" font="5">Triglycerides: -0.23 aerobic </text>
<text top="505" left="677" width="218" height="17" font="5">Systolic Blood pressure: -0.22 aerobic, -</text>
<text top="522" left="677" width="84" height="17" font="5">0.35 combined </text>
<text top="539" left="677" width="221" height="17" font="5">Diastolic blood pressure: -0.21 aerobic, -</text>
<text top="556" left="677" width="84" height="17" font="5">0.63 combined </text>
<text top="573" left="677" width="3" height="17" font="5"> </text>
<text top="591" left="677" width="221" height="17" font="5">Total exercise time had trivial or unclear </text>
<text top="608" left="677" width="219" height="17" font="5">effects on the outcomes except for HDL </text>
<text top="625" left="677" width="212" height="17" font="5">cholesterol (0.23, representing a small </text>
<text top="642" left="677" width="35" height="17" font="5">harm) </text>
<text top="660" left="677" width="3" height="17" font="5"> </text>
<text top="677" left="677" width="213" height="17" font="5">Exercise intensity had trivial or unclear </text>
<text top="694" left="677" width="191" height="17" font="5">effects on the outcomes except for </text>
<text top="711" left="677" width="217" height="17" font="5">HbA1c (-0.29), HDL cholesterol (-0.23), </text>
<text top="728" left="677" width="174" height="17" font="5">and body fat (0.23, small harm) </text>
<text top="746" left="677" width="3" height="17" font="5"> </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="203" height="17" font="5">Dietary co-interventions had trivial or </text>
<text top="178" left="677" width="217" height="17" font="5">unclear effects on the outcomes except </text>
<text top="195" left="677" width="160" height="17" font="5">fasting glucose (-0.27), waist </text>
<text top="212" left="677" width="209" height="17" font="5">circumference (0.25), total cholesterol </text>
<text top="229" left="677" width="219" height="17" font="5">(0.23, small harm), and LDL cholesterol </text>
<text top="247" left="677" width="103" height="17" font="5">(0.21, small harm) </text>
<text top="264" left="75" width="92" height="17" font="5">Maruthur, NM et </text>
<text top="282" left="75" width="51" height="17" font="5">al., 2016 </text>
<text top="299" left="75" width="3" height="17" font="5"> </text>
<text top="316" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27088241">27088241</a></text>
<text top="316" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27088241"> </a></text>
<text top="333" left="75" width="3" height="17" font="5"> </text>
<text top="350" left="75" width="3" height="17" font="5"> </text>
<text top="264" left="186" width="25" height="17" font="5">Aim </text>
<text top="282" left="186" width="88" height="17" font="5">To evaluate the </text>
<text top="299" left="186" width="145" height="17" font="5">comparative effectiveness </text>
<text top="316" left="186" width="74" height="17" font="5">and safety of </text>
<text top="333" left="186" width="75" height="17" font="5">monotherapy </text>
<text top="350" left="186" width="108" height="17" font="5">(thiazolidinediones, </text>
<text top="368" left="186" width="61" height="17" font="5">metformin, </text>
<text top="385" left="186" width="131" height="17" font="5">sulfonylureas,dipeptidyl </text>
<text top="402" left="186" width="114" height="17" font="5">peptidase-4 [DPP-4] </text>
<text top="419" left="186" width="102" height="17" font="5">inhibitors, sodium–</text>
<text top="437" left="186" width="132" height="17" font="5">glucose cotransporter 2 </text>
<text top="454" left="186" width="133" height="17" font="5">[SGLT-2] inhibitors, and </text>
<text top="471" left="186" width="130" height="17" font="5">glucagon-like peptide-1 </text>
<text top="488" left="186" width="94" height="17" font="5">[GLP-1] receptor </text>
<text top="505" left="186" width="126" height="17" font="5">agonists) and selected </text>
<text top="523" left="186" width="96" height="17" font="5">metformin-based </text>
<text top="540" left="186" width="125" height="17" font="5">combinations in adults </text>
<text top="557" left="186" width="112" height="17" font="5">with type 2 diabetes </text>
<text top="574" left="186" width="3" height="17" font="5"> </text>
<text top="591" left="186" width="62" height="17" font="5">Study type </text>
<text top="609" left="186" width="138" height="17" font="5">Meta analysis-(update of </text>
<text top="626" left="186" width="124" height="17" font="5">prior review). Updated </text>
<text top="643" left="186" width="103" height="17" font="5">findings where the </text>
<text top="660" left="186" width="114" height="17" font="5">strength of evidence </text>
<text top="678" left="186" width="115" height="17" font="5">changed from low or </text>
<text top="695" left="186" width="145" height="17" font="5">insufficient to moderate or </text>
<text top="712" left="186" width="27" height="17" font="5">high </text>
<text top="729" left="186" width="3" height="17" font="5"> </text>
<text top="265" left="346" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="295" left="344" width="180" height="18" font="5">•  date restrictions of April 2009 </text>
<text top="313" left="345" width="114" height="17" font="5">through March 2015 </text>
<text top="331" left="344" width="68" height="18" font="5">•  .English  </text>
<text top="349" left="344" width="128" height="18" font="5">•  Nonpregnant adults </text>
<text top="367" left="344" width="108" height="18" font="5">•  Type 2 diabetes </text>
<text top="385" left="344" width="187" height="18" font="5">•  Evaluated 3+ months of use of </text>
<text top="403" left="345" width="165" height="17" font="5">a diabetes medication or drug </text>
<text top="421" left="345" width="131" height="17" font="5">combination of interest  </text>
<text top="438" left="344" width="185" height="18" font="5">•  RCTs or observational studies </text>
<text top="456" left="345" width="165" height="17" font="5">that adequately accounted for </text>
<text top="473" left="345" width="70" height="17" font="5">confounding </text>
<text top="491" left="344" width="172" height="18" font="5">•  Included all cause mortality, </text>
<text top="509" left="345" width="143" height="17" font="5">macrovascular outcomes, </text>
<text top="526" left="345" width="139" height="17" font="5">microvascular outcomes, </text>
<text top="543" left="345" width="182" height="17" font="5">intermediate outcomes, or safety </text>
<text top="561" left="345" width="3" height="17" font="5"> </text>
<text top="591" left="346" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="622" left="344" width="160" height="18" font="5">•  Did not specify adjunctive </text>
<text top="640" left="345" width="69" height="17" font="5">medications </text>
<text top="657" left="344" width="129" height="18" font="5">•  Studies of acarbose </text>
<text top="675" left="346" width="3" height="17" font="5"> </text>
<text top="264" left="547" width="71" height="17" font="5">Intervention: </text>
<text top="282" left="547" width="76" height="17" font="5">head-to head </text>
<text top="299" left="547" width="75" height="17" font="5">monotherapy </text>
<text top="316" left="547" width="87" height="17" font="5">comparisons of </text>
<text top="333" left="547" width="61" height="17" font="5">metformin, </text>
<text top="350" left="547" width="104" height="17" font="5">thiazolidinediones, </text>
<text top="368" left="547" width="109" height="17" font="5">sulfonylureas, DPP-</text>
<text top="385" left="547" width="113" height="17" font="5">4 inhibitors, SGLT-2 </text>
<text top="402" left="547" width="109" height="17" font="5">inhibitors, and GLP-</text>
<text top="419" left="547" width="111" height="17" font="5">1 receptor agonists; </text>
<text top="437" left="547" width="87" height="17" font="5">comparisons of </text>
<text top="454" left="547" width="117" height="17" font="5">metformin alone with </text>
<text top="471" left="547" width="96" height="17" font="5">metformin-based </text>
<text top="488" left="547" width="73" height="17" font="5">combination; </text>
<text top="505" left="547" width="87" height="17" font="5">comparisons of </text>
<text top="523" left="547" width="96" height="17" font="5">metformin-based </text>
<text top="540" left="547" width="113" height="17" font="5">combinations where </text>
<text top="557" left="547" width="106" height="17" font="5">second medication </text>
<text top="574" left="547" width="63" height="17" font="5">was one of </text>
<text top="591" left="547" width="85" height="17" font="5">monotherapies </text>
<text top="609" left="547" width="115" height="17" font="5">studied or a basal or </text>
<text top="626" left="547" width="92" height="17" font="5">premixed insulin </text>
<text top="643" left="547" width="72" height="17" font="5">Comparator: </text>
<text top="660" left="547" width="7" height="17" font="5">  </text>
<text top="678" left="547" width="3" height="17" font="5"> </text>
<text top="266" left="677" width="7" height="17" font="5">1</text>
<text top="265" left="684" width="64" height="18" font="5"> endpoint: </text>
<text top="283" left="677" width="103" height="17" font="5">All cause mortality </text>
<text top="300" left="677" width="79" height="17" font="5">CVD mortality </text>
<text top="317" left="677" width="83" height="17" font="5">CVD morbidity </text>
<text top="334" left="677" width="40" height="17" font="5">HbA1c </text>
<text top="352" left="677" width="3" height="17" font="5"> </text>
<text top="369" left="677" width="48" height="17" font="5">Results: </text>
<text top="386" left="677" width="190" height="17" font="7"><i>All cause mortality</i>: low strength of </text>
<text top="403" left="677" width="223" height="17" font="5">evidence metformin was associated with </text>
<text top="420" left="677" width="218" height="17" font="5">lower risk compared with sulfonylureas. </text>
<text top="438" left="677" width="203" height="17" font="5">(Range of RRs from RCT=0.5 to 1.0; </text>
<text top="455" left="677" width="199" height="17" font="5">range in risk difference from RCTs=-</text>
<text top="472" left="677" width="183" height="17" font="5">5.0% to -0.1%; adjusted HR from </text>
<text top="489" left="677" width="202" height="17" font="5">observational studies=0.5 to 0.8). All </text>
<text top="507" left="677" width="211" height="17" font="5">other evidence for all of the other drug </text>
<text top="524" left="677" width="196" height="17" font="5">comparisons was of low strength or </text>
<text top="541" left="677" width="179" height="17" font="5">insufficient (data not presented). </text>
<text top="558" left="677" width="3" height="17" font="5"> </text>
<text top="575" left="677" width="200" height="17" font="7"><i>CVD mortality</i>: moderate strength of </text>
<text top="593" left="677" width="210" height="17" font="5">evidence that metformin monotherapy </text>
<text top="610" left="677" width="224" height="17" font="5">was associated with lower long-term (≥2 </text>
<text top="627" left="677" width="170" height="17" font="5">years) cardiovascular mortality </text>
<text top="644" left="677" width="153" height="17" font="5">compared with sulfonylurea </text>
<text top="661" left="677" width="176" height="17" font="5">monotherapy (range in RR from </text>
<text top="679" left="677" width="209" height="17" font="5">RCTs=0.6 to 0.7, 2 studies with 3,199 </text>
<text top="696" left="677" width="226" height="17" font="5">participants; range in risk difference from </text>
<text top="713" left="677" width="205" height="17" font="5">RCTs=-2.9% to -0.1%, 2 studies with </text>
<text top="730" left="677" width="207" height="17" font="5">3,199 participants); adjusted HR from </text>
<text top="748" left="677" width="191" height="17" font="5">observational studies (0.6 to 0.9, 3 </text>
<text top="765" left="677" width="210" height="17" font="5">studies with 115,105 participants).  All </text>
<text top="266" left="918" width="7" height="17" font="5">2</text>
<text top="265" left="925" width="66" height="18" font="5"> endpoints </text>
<text top="283" left="918" width="3" height="17" font="5"> </text>
<text top="300" left="918" width="69" height="17" font="5">Limitations:  </text>
<text top="317" left="918" width="208" height="17" font="5">About 45% of the RCTs did not report </text>
<text top="334" left="918" width="193" height="17" font="5">race/ethnicity. When reported, only </text>
<text top="352" left="918" width="211" height="17" font="5">10% to 30% of the enrolled population </text>
<text top="369" left="918" width="195" height="17" font="5">was of nonwhite race. Most studies </text>
<text top="386" left="918" width="213" height="17" font="5">excluded older persons and those with </text>
<text top="403" left="918" width="220" height="17" font="5">clinically significant comorbid conditions </text>
<text top="420" left="918" width="131" height="17" font="5">Adverse Events/Safety: </text>
<text top="438" left="918" width="87" height="17" font="7"><i>Hypoglycemia</i>:  </text>
<text top="455" left="918" width="195" height="17" font="5">Sulfonylureas were associated with </text>
<text top="472" left="918" width="216" height="17" font="5">increased risk for severe hypoglycemia </text>
<text top="489" left="918" width="179" height="17" font="5">as monotherapy (compared with </text>
<text top="507" left="918" width="208" height="17" font="5">metformin or thiazolidinedione) and in </text>
<text top="524" left="918" width="215" height="17" font="5">combination with metformin (compared </text>
<text top="541" left="918" width="220" height="17" font="5">with metformin plus a DPP-4 inhibitor or </text>
<text top="558" left="918" width="198" height="17" font="5">metformin plus an SGLT-2 inhibitor) </text>
<text top="575" left="918" width="3" height="17" font="5"> </text>
<text top="593" left="918" width="218" height="17" font="5">Sulfonylureas alone and in combination </text>
<text top="610" left="918" width="201" height="17" font="5">with metformin increased the risk for </text>
<text top="627" left="918" width="208" height="17" font="5">mild, moderate, or total hypoglycemia </text>
<text top="644" left="918" width="215" height="17" font="5">compared with all other monotherapies </text>
<text top="661" left="918" width="213" height="17" font="5">and metformin-based combinations for </text>
<text top="679" left="918" width="206" height="17" font="5">which there was evidence. Metformin </text>
<text top="696" left="918" width="175" height="17" font="5">plus a basal or premixed insulin </text>
<text top="713" left="918" width="196" height="17" font="5">increased the risk for hypoglycemia </text>
<text top="730" left="918" width="209" height="17" font="5">over metformin plus a GLP-1 receptor </text>
<text top="748" left="918" width="197" height="17" font="5">agonist, and metformin plus a basal </text>
<text top="765" left="918" width="177" height="17" font="5">insulin conferred a lower risk for </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="186" width="145" height="17" font="5">N=204 studies (116 newly </text>
<text top="178" left="186" width="113" height="17" font="5">identified in updated </text>
<text top="195" left="186" width="43" height="17" font="5">review) </text>
<text top="160" left="677" width="211" height="17" font="5">other evidence for all of the other drug </text>
<text top="178" left="677" width="196" height="17" font="5">comparisons was of low strength or </text>
<text top="195" left="677" width="179" height="17" font="5">insufficient (data not presented). </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="3" height="17" font="5"> </text>
<text top="247" left="677" width="222" height="17" font="7"><i>CVD morbidity</i>: low strength of evidence </text>
<text top="264" left="677" width="226" height="17" font="5">metformin was associated with lower risk </text>
<text top="281" left="677" width="217" height="17" font="5">compared with sulfonylureas (Range of </text>
<text top="298" left="677" width="216" height="17" font="5">RRs from RCT=0.7 to 1.6; range in risk </text>
<text top="315" left="677" width="215" height="17" font="5">difference from RCTs=-0.4% to 10.1%; </text>
<text top="333" left="677" width="175" height="17" font="5">adjusted HR from observational </text>
<text top="350" left="677" width="227" height="17" font="5">studies=0.3 to 0.9). All other evidence for </text>
<text top="367" left="677" width="221" height="17" font="5">all of the other drug comparisons was of </text>
<text top="384" left="677" width="197" height="17" font="5">low strength or insufficient (data not </text>
<text top="401" left="677" width="66" height="17" font="5">presented). </text>
<text top="419" left="677" width="3" height="17" font="5"> </text>
<text top="436" left="677" width="223" height="17" font="7"><i>HbA1c</i>: Most diabetes medications used </text>
<text top="453" left="677" width="157" height="17" font="5">as monotherapy (metformin, </text>
<text top="470" left="677" width="209" height="17" font="5">thiazolidinediones, and sulfonylureas) </text>
<text top="487" left="677" width="202" height="17" font="5">reduced hemoglobin A1c to a similar </text>
<text top="505" left="677" width="224" height="17" font="5">degree in the short term, except for DPP-</text>
<text top="522" left="677" width="206" height="17" font="5">4 inhibitors, which were less effective </text>
<text top="539" left="677" width="222" height="17" font="5">than metformin or sulfonylureas.  2-drug </text>
<text top="556" left="677" width="207" height="17" font="5">combination therapies with metformin </text>
<text top="573" left="677" width="196" height="17" font="5">were more effective than metformin </text>
<text top="591" left="677" width="206" height="17" font="5">monotherapy in reducing hemoglobin </text>
<text top="608" left="677" width="219" height="17" font="5">A1c.  the combination of metformin plus </text>
<text top="625" left="677" width="189" height="17" font="5">a GLP-1 receptor agonist reduced </text>
<text top="642" left="677" width="208" height="17" font="5">hemoglobin A1c more than metformin </text>
<text top="660" left="677" width="187" height="17" font="5">plus DPP-4 inhibitors.  Most other </text>
<text top="677" left="677" width="212" height="17" font="5">combination therapy comparisons with </text>
<text top="694" left="677" width="210" height="17" font="5">moderate strength of evidence had no </text>
<text top="711" left="677" width="198" height="17" font="5">clinically meaningful between-group </text>
<text top="728" left="677" width="223" height="17" font="5">differences (≥0.3%) in hemoglobin A1c.  </text>
<text top="746" left="677" width="155" height="17" font="5">Most of the evidence for the </text>
<text top="763" left="677" width="186" height="17" font="5">comparisons with GLP-1 receptor </text>
<text top="160" left="918" width="182" height="17" font="5">hypoglycemia compared with the </text>
<text top="178" left="918" width="167" height="17" font="5">combination of metformin plus </text>
<text top="195" left="918" width="92" height="17" font="5">premixed insulin </text>
<text top="212" left="918" width="3" height="17" font="5"> </text>
<text top="229" left="918" width="92" height="17" font="5">GI Side Effects:  </text>
<text top="247" left="918" width="169" height="17" font="5">Metformin and GLP-1 receptor </text>
<text top="264" left="918" width="171" height="17" font="5">agonists, as monotherapy or in </text>
<text top="281" left="918" width="191" height="17" font="5">combination, were associated with </text>
<text top="298" left="918" width="218" height="17" font="5">more GI side effects than were all other </text>
<text top="315" left="918" width="206" height="17" font="5">medications with sufficient studies for </text>
<text top="333" left="918" width="70" height="17" font="5">comparison  </text>
<text top="350" left="918" width="3" height="17" font="5"> </text>
<text top="367" left="918" width="182" height="17" font="5">Metformin plus a GLP-1 receptor </text>
<text top="384" left="918" width="199" height="17" font="5">agonist yielded more GI side effects </text>
<text top="401" left="918" width="204" height="17" font="5">than metformin plus DPP-4 inhibitors </text>
<text top="419" left="918" width="212" height="17" font="5">and metformin plus thiazolidinediones. </text>
<text top="436" left="918" width="180" height="17" font="5">Nausea and vomiting were more </text>
<text top="453" left="918" width="212" height="17" font="5">common with GLP-1 receptor agonists </text>
<text top="470" left="918" width="219" height="17" font="5">than with metformin. Metformin resulted </text>
<text top="487" left="918" width="214" height="17" font="5">in more diarrhea than metformin plus a </text>
<text top="505" left="918" width="193" height="17" font="5">thiazolidinedione AEs with SGLT-2 </text>
<text top="522" left="918" width="60" height="17" font="5">Inhibitors:  </text>
<text top="539" left="918" width="3" height="17" font="5"> </text>
<text top="556" left="918" width="198" height="17" font="5">Metformin resulted in more diarrhea </text>
<text top="573" left="918" width="224" height="17" font="5">thanmetformin plus a thiazolidinedione.   </text>
<text top="591" left="918" width="3" height="17" font="5"> </text>
<text top="608" left="918" width="207" height="17" font="5">Risk for fracture for SGLT-2 inhibitors </text>
<text top="625" left="918" width="214" height="17" font="5">as monotherapy or in combination with </text>
<text top="642" left="918" width="195" height="17" font="5">metformin was of low or insufficient </text>
<text top="660" left="918" width="211" height="17" font="5">strength.  comparative safety of SGLT-</text>
<text top="677" left="918" width="170" height="17" font="5">2 inhibitor–based comparisons </text>
<text top="694" left="918" width="195" height="17" font="5">regarding renal impairment, urinary </text>
<text top="711" left="918" width="200" height="17" font="5">tract infection, and volume depletion </text>
<text top="728" left="918" width="211" height="17" font="5">was also insufficient or of low strength </text>
<text top="746" left="918" width="3" height="17" font="5"> </text>
<text top="763" left="918" width="146" height="17" font="5">Congestive Heart Failure:  </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="171" height="17" font="5">agonists and comparisons with </text>
<text top="178" left="677" width="171" height="17" font="5">metformin plus injectables was </text>
<text top="195" left="677" width="163" height="17" font="5">insufficient or of low strength. </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="77" height="17" font="7"><i>Body weight:  </i></text>
<text top="247" left="677" width="220" height="17" font="5">Metformin decreased body weight more </text>
<text top="264" left="677" width="173" height="17" font="5">than DPP-4 inhibitors, whereas </text>
<text top="281" left="677" width="224" height="17" font="5">sulfonylureas caused slightly less weight </text>
<text top="298" left="677" width="219" height="17" font="5">gain than thiazolidinediones. The SGLT-</text>
<text top="315" left="677" width="221" height="17" font="5">2 inhibitors decreased weight more than </text>
<text top="333" left="677" width="180" height="17" font="5">metformin and more than DPP-4 </text>
<text top="350" left="677" width="170" height="17" font="5">inhibitors. The combinations of </text>
<text top="367" left="677" width="225" height="17" font="5">metformin plus a GLP-1 receptor agonist </text>
<text top="384" left="677" width="218" height="17" font="5">and metformin plus an SGLT-2 inhibitor </text>
<text top="401" left="677" width="219" height="17" font="5">were both favored over the combination </text>
<text top="419" left="677" width="221" height="17" font="5">of metformin plus a DPP-4 inhibitor, and </text>
<text top="436" left="677" width="225" height="17" font="5">metformin plus a GLP-1 receptor agonist </text>
<text top="453" left="677" width="191" height="17" font="5">was favored over metformin plus a </text>
<text top="470" left="677" width="190" height="17" font="5">premixed insulin. Metformin plus a </text>
<text top="487" left="677" width="218" height="17" font="5">sulfonylurea had more favorable weight </text>
<text top="505" left="677" width="215" height="17" font="5">effects than metformin plus a premixed </text>
<text top="522" left="677" width="223" height="17" font="5">or basal insulin.  Prior guideline’s finding </text>
<text top="539" left="677" width="198" height="17" font="5">not updated that metformin reduced </text>
<text top="556" left="677" width="221" height="17" font="5">weight ~ 2.5 kg versus thiazolidinedione </text>
<text top="573" left="677" width="224" height="17" font="5">and sulfonylurea monotherapy, with high </text>
<text top="591" left="677" width="114" height="17" font="5">strength of evidence </text>
<text top="608" left="677" width="3" height="17" font="5"> </text>
<text top="625" left="677" width="156" height="17" font="7"><i>Systolic BP and Heart Rate: </i></text>
<text top="642" left="677" width="199" height="17" font="5">Evaluated for SGLT-2 inhibitors and </text>
<text top="660" left="677" width="225" height="17" font="5">GLP-1 receptor agonists only.  moderate </text>
<text top="677" left="677" width="205" height="17" font="5">strength of evidence that the SGLT-2 </text>
<text top="694" left="677" width="177" height="17" font="5">inhibitors reduced systolic blood </text>
<text top="711" left="677" width="203" height="17" font="5">pressure by 3 to 5 mm Hg compared </text>
<text top="728" left="677" width="226" height="17" font="5">with other monotherapy when there were </text>
<text top="746" left="677" width="217" height="17" font="5">sufficient studies for pooling. metformin </text>
<text top="763" left="677" width="218" height="17" font="5">plus an SGLT-2 inhibitor and metformin </text>
<text top="160" left="918" width="221" height="17" font="5">low strength of evidence that the risk for </text>
<text top="178" left="918" width="215" height="17" font="5">congestive heart failure was 1.2- to 1.6-</text>
<text top="195" left="918" width="219" height="17" font="5">fold greater with thiazolidinediones than </text>
<text top="212" left="918" width="203" height="17" font="5">with sulfonylureas (pooled odds ratio </text>
<text top="229" left="918" width="214" height="17" font="5">[OR], 1.6 [CI, 0.96 to 2.8]; range in risk </text>
<text top="247" left="918" width="208" height="17" font="5">difference, 0% to 2%) or metformin (2 </text>
<text top="264" left="918" width="206" height="17" font="5">short RCTs with no events and one 4-</text>
<text top="281" left="918" width="210" height="17" font="5">year RCT with a risk difference of 3%; </text>
<text top="298" left="918" width="210" height="17" font="5">range in hazards ratios, 1.2 to 1.5 in 2 </text>
<text top="315" left="918" width="212" height="17" font="5">observational studies with 6 to 8 years </text>
<text top="333" left="918" width="175" height="17" font="5">of follow-up). Low or insufficient </text>
<text top="350" left="918" width="152" height="17" font="5">strength of evidence on the </text>
<text top="367" left="918" width="213" height="17" font="5">comparative safety of DPP-4 inhibitors </text>
<text top="384" left="918" width="189" height="17" font="5">regarding congestive heart failure. </text>
<text top="401" left="918" width="3" height="17" font="5"> </text>
<text top="419" left="918" width="217" height="17" font="5">Other: - The evidence on the outcomes </text>
<text top="436" left="918" width="158" height="17" font="5">of liver injury, lactic acidosis, </text>
<text top="453" left="918" width="196" height="17" font="5">pancreatitis, cancer, severe allergic </text>
<text top="470" left="918" width="193" height="17" font="5">reactions, and macular edema and </text>
<text top="487" left="918" width="219" height="17" font="5">decreased vision was of low strength or </text>
<text top="505" left="918" width="65" height="17" font="5">insufficient. </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="215" height="17" font="5">plus a GLP-1 receptor agonist reduced </text>
<text top="178" left="677" width="222" height="17" font="5">systolic blood pressure by 3 to 5 mm Hg </text>
<text top="195" left="677" width="179" height="17" font="5">more than metformin alone, with </text>
<text top="212" left="677" width="210" height="17" font="5">moderate to high strength of evidence </text>
<text top="229" left="677" width="3" height="17" font="5"> </text>
<text top="247" left="677" width="193" height="17" font="5">heart rate, only 2 comparisons had </text>
<text top="264" left="677" width="217" height="17" font="5">sufficient data to grade the evidence as </text>
<text top="281" left="677" width="218" height="17" font="5">more than insufficient or low. Metformin </text>
<text top="298" left="677" width="197" height="17" font="5">plus an SGLT-2 inhibitor decreased </text>
<text top="315" left="677" width="209" height="17" font="5">heart rate more than metformin plus a </text>
<text top="333" left="677" width="200" height="17" font="5">sulfonylurea (pooled between-group </text>
<text top="350" left="677" width="207" height="17" font="5">difference in heart rate, 1.5 beats/min </text>
<text top="367" left="677" width="197" height="17" font="5">[95% CI, 0.6 to 2.3 beats/min]). The </text>
<text top="384" left="677" width="200" height="17" font="5">GLP-1 receptor agonists showed no </text>
<text top="401" left="677" width="218" height="17" font="5">between-group differences in heart rate </text>
<text top="419" left="677" width="217" height="17" font="5">compared with metformin monotherapy </text>
<text top="436" left="677" width="3" height="17" font="5"> </text>
<text top="454" left="75" width="58" height="17" font="5">Metformin </text>
<text top="472" left="75" width="95" height="17" font="5">(seminal UKPDS </text>
<text top="491" left="75" width="62" height="17" font="5">study, also </text>
<text top="510" left="75" width="83" height="17" font="5">included in the </text>
<text top="528" left="75" width="83" height="17" font="5">metformin SR) </text>
<text top="559" left="75" width="48" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9742977">9742977</a></text>
<text top="559" left="122" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9742977"> </a></text>
<text top="589" left="75" width="3" height="17" font="5"> </text>
<text top="454" left="186" width="98" height="17" font="5">Study Type: RCT </text>
<text top="471" left="186" width="50" height="17" font="5">N=4,209 </text>
<text top="488" left="186" width="70" height="17" font="5">Country: UK </text>
<text top="454" left="346" width="184" height="17" font="5">Inclusion Criteria: Age 25-65 with </text>
<text top="472" left="346" width="159" height="17" font="5">fasting plasma glucose &gt;108 </text>
<text top="491" left="346" width="163" height="17" font="5">mg/dL on two occasions after </text>
<text top="510" left="346" width="183" height="17" font="5">being diagnosed as diabetic, and </text>
<text top="528" left="346" width="154" height="17" font="5">&gt;120% of ideal body weight </text>
<text top="454" left="547" width="92" height="17" font="5">Interventions: A. </text>
<text top="471" left="547" width="111" height="17" font="5">Metformin (n=279);  </text>
<text top="488" left="547" width="90" height="17" font="5">A. Sulfylnurea + </text>
<text top="505" left="547" width="81" height="17" font="5">insulin (2,118) </text>
<text top="455" left="677" width="7" height="17" font="5">1</text>
<text top="454" left="684" width="180" height="18" font="5"> endpoint: Any diabetes-related </text>
<text top="472" left="677" width="198" height="17" font="5">endpoint (sudden death, death from </text>
<text top="489" left="677" width="220" height="17" font="5">hyperglycemia or hypoglycemia, fatal or </text>
<text top="507" left="677" width="224" height="17" font="5">nonfatal MI, angina, heart failure, fatal or </text>
<text top="524" left="677" width="226" height="17" font="5">nonfatal stroke, renal failure, amputation, </text>
<text top="541" left="677" width="156" height="17" font="5">vitreous hemorrhage, retinal </text>
<text top="558" left="677" width="219" height="17" font="5">photocoagulation, blindness in one eye, </text>
<text top="575" left="677" width="217" height="17" font="5">or cataract extraction), diabetes-related </text>
<text top="593" left="677" width="222" height="17" font="5">death, death from all causes, MI, stroke, </text>
<text top="610" left="677" width="171" height="17" font="5">peripheral vascular disease, or </text>
<text top="627" left="677" width="125" height="17" font="5">microvascular disease </text>
<text top="454" left="918" width="3" height="17" font="5"> </text>
<text top="645" left="75" width="70" height="17" font="5">Griffin, 2017 </text>
<text top="676" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28770324">28770324</a></text>
<text top="676" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28770324"> </a></text>
<text top="645" left="186" width="146" height="17" font="5">Aim: Efficacy of metformin </text>
<text top="662" left="186" width="141" height="17" font="5">to prevent cardiovascular </text>
<text top="679" left="186" width="105" height="17" font="5">events in diabetics </text>
<text top="697" left="186" width="3" height="17" font="5"> </text>
<text top="714" left="186" width="121" height="17" font="5">Study Type: 13 RCTs </text>
<text top="731" left="186" width="116" height="17" font="5">N=2,079 allocated to </text>
<text top="748" left="186" width="135" height="17" font="5">metformin and &#34;a similar </text>
<text top="645" left="346" width="3" height="17" font="5"> </text>
<text top="645" left="547" width="3" height="17" font="5"> </text>
<text top="645" left="677" width="212" height="17" font="5">Results: Metformin vs. placebo/control </text>
<text top="662" left="677" width="204" height="17" font="5">All-cause mortality (6 trials): RR 0.96 </text>
<text top="679" left="677" width="120" height="17" font="5">(95% CI 0.84 to 1.09) </text>
<text top="697" left="677" width="218" height="17" font="5">CV mortality (5 trials): RR 0.97 (95% CI </text>
<text top="714" left="677" width="73" height="17" font="5">0.80 to 1.16) </text>
<text top="731" left="677" width="206" height="17" font="5">MI (7 trials): RR 0.89 (95% CI 0.75 to </text>
<text top="748" left="677" width="31" height="17" font="5">1.06) </text>
<text top="645" left="918" width="165" height="17" font="5">Adverse Events: Not reported </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="186" width="130" height="17" font="5">number&#34; of comparison </text>
<text top="178" left="186" width="49" height="17" font="5">subjects </text>
<text top="160" left="677" width="228" height="17" font="5">Stroke (4 trials): RR 1.04 (95% CI 0.73 to </text>
<text top="178" left="677" width="31" height="17" font="5">1.48) </text>
<text top="196" left="75" width="54" height="17" font="5">CANVAS </text>
<text top="213" left="75" width="54" height="17" font="5">Program  </text>
<text top="230" left="75" width="90" height="17" font="5">Neal et al, 2017 </text>
<text top="247" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28605608">28605608</a></text>
<text top="247" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28605608"> </a></text>
<text top="196" left="186" width="25" height="17" font="5">Aim </text>
<text top="213" left="186" width="146" height="17" font="5">To detect plausible effects </text>
<text top="230" left="186" width="102" height="17" font="5">of canagliflozin on </text>
<text top="247" left="186" width="128" height="17" font="5">cardiovascular, kidney, </text>
<text top="264" left="186" width="117" height="17" font="5">and safety outcomes </text>
<text top="282" left="186" width="3" height="17" font="5"> </text>
<text top="299" left="186" width="62" height="17" font="5">Study type </text>
<text top="316" left="186" width="138" height="17" font="5">Pooled analysis of RCTs </text>
<text top="333" left="186" width="3" height="17" font="5"> </text>
<text top="350" left="186" width="57" height="17" font="5">N=10.142 </text>
<text top="196" left="346" width="92" height="17" font="5">Inclusion criteria </text>
<text top="226" left="346" width="91" height="17" font="5">Type 2 diabetes </text>
<text top="257" left="346" width="158" height="17" font="5">30 years of age or older with </text>
<text top="275" left="346" width="126" height="17" font="5">history of symptomatic </text>
<text top="294" left="346" width="166" height="17" font="5">atherosclerotic cardiovascular </text>
<text top="313" left="346" width="163" height="17" font="5">disease OR 50 years or older </text>
<text top="331" left="346" width="166" height="17" font="5">with 2 or more of: diabetes for </text>
<text top="350" left="346" width="138" height="17" font="5">10+ years, systolic blood </text>
<text top="368" left="346" width="183" height="17" font="5">pressure higher than 140 mm Hg </text>
<text top="387" left="346" width="177" height="17" font="5">while receiving antihypertensive </text>
<text top="405" left="346" width="138" height="17" font="5">agents, current smoking, </text>
<text top="424" left="346" width="111" height="17" font="5">microalbuminuria or </text>
<text top="443" left="346" width="147" height="17" font="5">macroalbuminuria, or HDL </text>
<text top="461" left="346" width="180" height="17" font="5">cholesterol less than 1 mmol per </text>
<text top="480" left="346" width="23" height="17" font="5">liter </text>
<text top="510" left="346" width="3" height="17" font="5"> </text>
<text top="541" left="346" width="166" height="17" font="5">Estimated glomerular filtration </text>
<text top="559" left="346" width="175" height="17" font="5">rate at entry of more than 30 ml </text>
<text top="578" left="346" width="174" height="17" font="5">per minute per 1.73 m2 of body </text>
<text top="597" left="346" width="72" height="17" font="5">surface area </text>
<text top="627" left="346" width="97" height="17" font="5">Exclusion criteria </text>
<text top="658" left="346" width="3" height="17" font="5"> </text>
<text top="196" left="547" width="68" height="17" font="5">Intervention </text>
<text top="213" left="547" width="106" height="17" font="5">Canagliflozen (300 </text>
<text top="230" left="547" width="83" height="17" font="5">mg or 100 mg) </text>
<text top="247" left="547" width="3" height="17" font="5"> </text>
<text top="264" left="547" width="68" height="17" font="5">Comparator </text>
<text top="282" left="547" width="46" height="17" font="5">placebo </text>
<text top="299" left="547" width="3" height="17" font="5"> </text>
<text top="197" left="677" width="7" height="17" font="5">1</text>
<text top="196" left="684" width="64" height="18" font="5"> endpoint: </text>
<text top="214" left="677" width="221" height="17" font="5">Composite of death from cardiovascular </text>
<text top="231" left="677" width="212" height="17" font="5">causes, nonfatal MI, or nonfatal stroke </text>
<text top="248" left="677" width="3" height="17" font="5"> </text>
<text top="266" left="677" width="199" height="17" font="5">Mean follow up time of 188.2 weeks </text>
<text top="283" left="677" width="200" height="17" font="5">29.2% assigned to canagliflozin and </text>
<text top="300" left="677" width="223" height="17" font="5">29.9% assigned to placebo discontinued </text>
<text top="317" left="677" width="68" height="17" font="5">prematurely </text>
<text top="334" left="677" width="3" height="17" font="5"> </text>
<text top="352" left="677" width="210" height="17" font="5">Differences between canagliflozin and </text>
<text top="369" left="677" width="227" height="17" font="5">placebo group for intermediate outcomes </text>
<text top="386" left="677" width="196" height="17" font="5">all p&lt;0.001): glycated hemoglobin (-</text>
<text top="403" left="677" width="206" height="17" font="5">0.58%, , 95% CI -0.61 to -0.56); body </text>
<text top="420" left="677" width="222" height="17" font="5">weight (-1.60 kg; 95% CI -1.70 to -1.51); </text>
<text top="438" left="677" width="211" height="17" font="5">systolic blood pressure (-3.93 mm Hg, </text>
<text top="455" left="677" width="209" height="17" font="5">95% CI -4.30 to -3.56); diastolic blood </text>
<text top="472" left="677" width="222" height="17" font="5">pressure (-1.39 mm Hg, 95% CI -1.61 to </text>
<text top="489" left="677" width="211" height="17" font="5">-1.17). Use of other antihyperglycemic </text>
<text top="507" left="677" width="226" height="17" font="5">agents 9.3% lower (95% CI -11.0 to -7.6) </text>
<text top="524" left="677" width="219" height="17" font="5">canagliflozin vs. placebo. HDL higher in </text>
<text top="541" left="677" width="206" height="17" font="5">canagliflozin vs placebo (2.06 mg per </text>
<text top="558" left="677" width="195" height="17" font="5">deciliter, 95% CI 1.77 to 2.33), LDL </text>
<text top="575" left="677" width="203" height="17" font="5">higher (4.68 mg per deciliter, 95% CI </text>
<text top="593" left="677" width="76" height="17" font="5">3.64 to 5.73). </text>
<text top="610" left="677" width="3" height="17" font="5"> </text>
<text top="627" left="677" width="208" height="17" font="5">Significantly lower composite death in </text>
<text top="644" left="677" width="227" height="17" font="5">canagliflozin than placebo group (36.9 vs </text>
<text top="661" left="677" width="212" height="17" font="5">31.5 per 1000 patient years, HR=0.86, </text>
<text top="679" left="677" width="205" height="17" font="5">95% CI 0.75 to 0.97, p&lt;0.001 for non </text>
<text top="696" left="677" width="187" height="17" font="5">inferiority, p=0.02 for superiority).  </text>
<text top="713" left="677" width="3" height="17" font="5"> </text>
<text top="197" left="918" width="7" height="17" font="5">2</text>
<text top="196" left="925" width="64" height="18" font="5"> endpoint: </text>
<text top="214" left="918" width="189" height="17" font="5">Death from any cause, death from </text>
<text top="231" left="918" width="210" height="17" font="5">cardiovascular causes, progression of </text>
<text top="248" left="918" width="206" height="17" font="5">albuminuria, composite of death from </text>
<text top="266" left="918" width="149" height="17" font="5">cardiovascular causes and </text>
<text top="283" left="918" width="171" height="17" font="5">hospitalization for heart failure  </text>
<text top="300" left="918" width="3" height="17" font="5"> </text>
<text top="317" left="918" width="193" height="17" font="5">Exploratory outcomes: nonfatal MI, </text>
<text top="334" left="918" width="218" height="17" font="5">nonfatal stroke, hospitalization for heart </text>
<text top="352" left="918" width="216" height="17" font="5">failure, regression of albuminuria, renal </text>
<text top="369" left="918" width="217" height="17" font="5">composite comprising 40% reduction in </text>
<text top="386" left="918" width="219" height="17" font="5">eGFR sustained for 2+ measures, need </text>
<text top="403" left="918" width="202" height="17" font="5">for renal replacement therapy, death </text>
<text top="420" left="918" width="219" height="17" font="5">from renal causes, total hospitalizations </text>
<text top="438" left="918" width="3" height="17" font="5"> </text>
<text top="455" left="918" width="217" height="17" font="5">No significant superiority for death from </text>
<text top="472" left="918" width="188" height="17" font="5">any cause (p=0.24) so hypothesis </text>
<text top="489" left="918" width="168" height="17" font="5">testing discontinued; therefore </text>
<text top="507" left="918" width="204" height="17" font="5">differences in deathy from any cause </text>
<text top="524" left="918" width="211" height="17" font="5">and death from cardiovascular causes </text>
<text top="541" left="918" width="163" height="17" font="5">are not considered significant </text>
<text top="558" left="918" width="199" height="17" font="5">(HR=0.87, 95% CI 0.74 to 1.01; and </text>
<text top="575" left="918" width="175" height="17" font="5">HR=0.87, 95% CI 0.72 to 1.06). </text>
<text top="593" left="918" width="3" height="17" font="5"> </text>
<text top="610" left="918" width="193" height="17" font="5">Death from cardiovascular causes: </text>
<text top="627" left="918" width="160" height="17" font="5">HR=0.87 (95% CI 0.72-1.06) </text>
<text top="644" left="918" width="3" height="17" font="5"> </text>
<text top="661" left="918" width="218" height="17" font="5">Nonfatal stroke: HR=0.90 (95% CI 0.71-</text>
<text top="679" left="918" width="31" height="17" font="5">1.13) </text>
<text top="696" left="918" width="3" height="17" font="5"> </text>
<text top="713" left="918" width="198" height="17" font="5">Nonfatal MI: HR=0.85 (95% CI 0.69-</text>
<text top="730" left="918" width="31" height="17" font="5">1.05) </text>
<text top="748" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="173" height="17" font="5">Hospitalization for heart failure: </text>
<text top="178" left="918" width="163" height="17" font="5">HR=0.57 (95% CI 0.52-0..87) </text>
<text top="195" left="918" width="3" height="17" font="5"> </text>
<text top="212" left="918" width="211" height="17" font="5">Death from any cause: HR=0.87 (95% </text>
<text top="229" left="918" width="75" height="17" font="5">CI 0.74-1.01) </text>
<text top="247" left="918" width="3" height="17" font="5"> </text>
<text top="264" left="918" width="200" height="17" font="5">Albuminuria: HR=0.73 (95% CI 0.67-</text>
<text top="281" left="918" width="31" height="17" font="5">0.79) </text>
<text top="298" left="918" width="3" height="17" font="5"> </text>
<text top="315" left="918" width="210" height="17" font="5">Composite of 40% reduction in eGFR, </text>
<text top="333" left="918" width="189" height="17" font="5">requirement for renal-replacement </text>
<text top="350" left="918" width="201" height="17" font="5">therapy, or death from renal causes: </text>
<text top="367" left="918" width="160" height="17" font="5">HR=0.60 (95% CI 0.47-0.77) </text>
<text top="384" left="918" width="3" height="17" font="5"> </text>
<text top="401" left="918" width="92" height="17" font="5">Adverse events: </text>
<text top="419" left="918" width="160" height="17" font="5">Serious AEs less common in </text>
<text top="436" left="918" width="218" height="17" font="5">canagliflozin than placebo group (104.3 </text>
<text top="453" left="918" width="182" height="17" font="5">vs. 120.0 per 1000 patient years, </text>
<text top="470" left="918" width="159" height="17" font="5">HR=0.93, 95% CI 0.87-1.00) </text>
<text top="487" left="918" width="3" height="17" font="5"> </text>
<text top="505" left="918" width="191" height="17" font="5">Higher risk in canaglilozin group of </text>
<text top="522" left="918" width="213" height="17" font="5">amputation of toes, feet or legs (6.3 vs </text>
<text top="539" left="918" width="205" height="17" font="5">3.4 per 1000 patient years, HR=1.97, </text>
<text top="556" left="918" width="103" height="17" font="5">95% CI 1.41-2.75) </text>
<text top="573" left="918" width="3" height="17" font="5"> </text>
<text top="591" left="918" width="204" height="17" font="5">No difference in risk of hypoglycemia </text>
<text top="608" left="918" width="197" height="17" font="5">(50.0 vs 46.4 per 1000 patient year, </text>
<text top="625" left="918" width="207" height="17" font="5">p=0.20), hyperkalemia (6.9 vs 4.4 per </text>
<text top="642" left="918" width="184" height="17" font="5">1000 patient year, p=0.10), acute </text>
<text top="660" left="918" width="185" height="17" font="5">kidney injury (3.0 vs 4.1 per 1000 </text>
<text top="677" left="918" width="211" height="17" font="5">patient year, p=0.33), pancreatitis (0.5 </text>
<text top="694" left="918" width="214" height="17" font="5">vs 0.4 per 1000 patient years, p=0.63), </text>
<text top="711" left="918" width="171" height="17" font="5">malignancies (p&gt;0.17), venous </text>
<text top="728" left="918" width="218" height="17" font="5">thromboembolism (1.7 per 1000 patient </text>
<text top="746" left="918" width="164" height="17" font="5">years in both groups, p=0.63) </text>
<text top="763" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="192" height="17" font="5">Differences in infections of male or </text>
<text top="178" left="918" width="192" height="17" font="5">female genitalia (p&lt;0.001), volume </text>
<text top="195" left="918" width="212" height="17" font="5">depletion (p0.009), diruresis (p&lt;0.001) </text>
<text top="212" left="918" width="3" height="17" font="5"> </text>
<text top="229" left="918" width="219" height="17" font="5">Higher rate of all fractures (15.4 vs 11.9 </text>
<text top="247" left="918" width="213" height="17" font="5">per 1000 patient years, HR=1.26, 95% </text>
<text top="264" left="918" width="208" height="17" font="5">CI 1.04 to 1.52) and similar trend with </text>
<text top="281" left="918" width="216" height="17" font="5">low trauma fracture events (11.6 vs 9.2 </text>
<text top="298" left="918" width="209" height="17" font="5">per 1000 patient years, HR=1.23 95% </text>
<text top="315" left="918" width="88" height="17" font="5">CI 0.99 to 1.52) </text>
<text top="333" left="918" width="3" height="17" font="5"> </text>
<text top="350" left="918" width="210" height="17" font="5">Small number of diabetic ketoacidosis </text>
<text top="367" left="918" width="190" height="17" font="5">(0.6 vs 0.3 per 1000 patient years, </text>
<text top="384" left="918" width="172" height="17" font="5">HR=2.33, 95% CI 0.75 to 7.17) </text>
<text top="402" left="75" width="98" height="17" font="5">Marso et al, 2016 </text>
<text top="433" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27295427">27295427</a></text>
<text top="433" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27295427"> </a></text>
<text top="402" left="186" width="25" height="17" font="5">Aim </text>
<text top="419" left="186" width="135" height="17" font="5">To assess the long-term </text>
<text top="437" left="186" width="126" height="17" font="5">effects of liraglutide on </text>
<text top="454" left="186" width="139" height="17" font="5">cardiovascular outcomes </text>
<text top="471" left="186" width="104" height="17" font="5">and other clinically </text>
<text top="488" left="186" width="98" height="17" font="5">important events, </text>
<text top="505" left="186" width="3" height="17" font="5"> </text>
<text top="523" left="186" width="66" height="17" font="5">Study Type </text>
<text top="540" left="186" width="29" height="17" font="5">RCT </text>
<text top="557" left="186" width="3" height="17" font="5"> </text>
<text top="574" left="186" width="47" height="17" font="5">N=9340 </text>
<text top="402" left="346" width="95" height="17" font="5">Inclusion Criteria </text>
<text top="433" left="346" width="186" height="17" font="5">Patients with type 2 diabetes who </text>
<text top="451" left="346" width="185" height="17" font="5">had glycated hemoglobin of 7.0% </text>
<text top="470" left="346" width="46" height="17" font="5">or more </text>
<text top="501" left="346" width="169" height="17" font="5">Had not received drugs for the </text>
<text top="519" left="346" width="180" height="17" font="5">condition previously or had been </text>
<text top="538" left="346" width="108" height="17" font="5">treated with 1+ oral </text>
<text top="556" left="346" width="150" height="17" font="5">antihyperglyemic agents or </text>
<text top="575" left="346" width="179" height="17" font="5">insulin or a combination of these </text>
<text top="593" left="346" width="40" height="17" font="5">agents </text>
<text top="624" left="346" width="3" height="17" font="5"> </text>
<text top="654" left="346" width="142" height="17" font="5">Age 50+ with at least one </text>
<text top="673" left="346" width="141" height="17" font="5">cardiovascular coesisting </text>
<text top="692" left="346" width="181" height="17" font="5">condition (CHD, cerebrovascular </text>
<text top="710" left="346" width="156" height="17" font="5">disease, peripheral vascular </text>
<text top="729" left="346" width="177" height="17" font="5">disease, chronic kidney disease </text>
<text top="747" left="346" width="179" height="17" font="5">stage 3 or greater, chronic heart </text>
<text top="766" left="346" width="181" height="17" font="5">failure class II or III) OR age 60+ </text>
<text top="402" left="572" width="68" height="17" font="5">Intervention </text>
<text top="419" left="553" width="105" height="17" font="5">Liraglitude (1.8 mg </text>
<text top="437" left="570" width="71" height="17" font="5">or maximum </text>
<text top="454" left="561" width="89" height="17" font="5">tolerated dose). </text>
<text top="471" left="582" width="47" height="17" font="5">N=4668 </text>
<text top="488" left="604" width="3" height="17" font="5"> </text>
<text top="505" left="571" width="68" height="17" font="5">Comparator </text>
<text top="523" left="556" width="98" height="17" font="5">Placebo. N=4672 </text>
<text top="540" left="604" width="3" height="17" font="5"> </text>
<text top="557" left="547" width="85" height="17" font="5">Randomization </text>
<text top="574" left="547" width="67" height="17" font="5">stratified on </text>
<text top="591" left="547" width="57" height="17" font="5">estimated </text>
<text top="609" left="547" width="108" height="17" font="5">glomerular filtration </text>
<text top="626" left="547" width="95" height="17" font="5">rate at screening </text>
<text top="643" left="547" width="106" height="17" font="5">(&lt;30 or ≥30 ml per </text>
<text top="660" left="547" width="109" height="17" font="5">minute per 1.73 m2 </text>
<text top="678" left="547" width="87" height="17" font="5">of body surface </text>
<text top="695" left="547" width="32" height="17" font="5">area) </text>
<text top="712" left="547" width="3" height="17" font="5"> </text>
<text top="729" left="547" width="85" height="17" font="5">Addition of any </text>
<text top="746" left="547" width="98" height="17" font="5">antihyperflycemic </text>
<text top="764" left="547" width="107" height="17" font="5">agents except FLP-</text>
<text top="403" left="677" width="7" height="17" font="5">1</text>
<text top="402" left="684" width="64" height="18" font="5"> endpoint: </text>
<text top="420" left="677" width="222" height="17" font="5">Composite outcome: First occurrence of </text>
<text top="438" left="677" width="191" height="17" font="5">death from cardiovascular causes, </text>
<text top="455" left="677" width="166" height="17" font="5">nonfatal MI, or nonfatal stroke </text>
<text top="472" left="677" width="3" height="17" font="5"> </text>
<text top="489" left="677" width="3" height="17" font="5"> </text>
<text top="507" left="677" width="219" height="17" font="5">Median exposure 3.5 years, median 3.8 </text>
<text top="524" left="677" width="85" height="17" font="5">years follow up </text>
<text top="541" left="677" width="3" height="17" font="5"> </text>
<text top="558" left="677" width="219" height="17" font="5">Changes in liraglutide vs placebo group </text>
<text top="575" left="677" width="205" height="17" font="5">at 36 months: glycated hemoglobin =-</text>
<text top="593" left="677" width="221" height="17" font="5">0.40 percentage points, 95% CI -0.45 to </text>
<text top="610" left="677" width="218" height="17" font="5">-0.34; greater weight loss=-2.3 kg (95% </text>
<text top="627" left="677" width="188" height="17" font="5">CI 2.5 to 2.0), lower systolic blood </text>
<text top="644" left="677" width="200" height="17" font="5">pressure (1.2 mm Hg, 95% CI 1.9 to </text>
<text top="661" left="677" width="223" height="17" font="5">0.5), higher diastolic blood pressure (0.6 </text>
<text top="679" left="677" width="221" height="17" font="5">mm Hg, 95% CI 0.2 to 1.0), higher heart </text>
<text top="696" left="677" width="225" height="17" font="5">rate (3.0 beats per minute, 95% CI 2.5 to </text>
<text top="713" left="677" width="25" height="17" font="5">3.4) </text>
<text top="730" left="677" width="3" height="17" font="5"> </text>
<text top="748" left="677" width="207" height="17" font="5">Primary composite outcome occurred </text>
<text top="765" left="677" width="225" height="17" font="5">less frequently in liraglutide than placebo </text>
<text top="403" left="918" width="7" height="17" font="5">2</text>
<text top="402" left="925" width="64" height="18" font="5"> endpoint: </text>
<text top="420" left="918" width="201" height="17" font="5">Expanded composite cardiovascular </text>
<text top="438" left="918" width="199" height="17" font="5">outcome (death from cardiovascular </text>
<text top="455" left="918" width="201" height="17" font="5">causes, nonfatal MI, nonfatal stroke, </text>
<text top="472" left="918" width="150" height="17" font="5">coronary revascularization, </text>
<text top="489" left="918" width="189" height="17" font="5">hospitalization for unstable angina </text>
<text top="507" left="918" width="199" height="17" font="5">pectoris or heart failure), death from </text>
<text top="524" left="918" width="214" height="17" font="5">any cause, composite renal and retinal </text>
<text top="541" left="918" width="206" height="17" font="5">microvascular outcome (nephropathy </text>
<text top="558" left="918" width="162" height="17" font="5">and retinopathy), neoplasms, </text>
<text top="575" left="918" width="66" height="17" font="5">pancreatitis </text>
<text top="593" left="918" width="3" height="17" font="5"> </text>
<text top="610" left="918" width="215" height="17" font="7"><i>Expanded composite outcome</i>: 20.3 vs </text>
<text top="627" left="918" width="200" height="17" font="5">22.7%, HR=0.88, 95% CI 0.81-0.96, </text>
<text top="644" left="918" width="48" height="17" font="5">p=0.005 </text>
<text top="661" left="918" width="3" height="17" font="5"> </text>
<text top="679" left="918" width="193" height="17" font="7"><i>Death from cardiovascular causes</i>: </text>
<text top="696" left="918" width="212" height="17" font="5">lower in liraglutide group (4.7 vs 6.0%, </text>
<text top="713" left="918" width="211" height="17" font="5">HR=0.78, 95% CI 0.66-0.93, p=0.007) </text>
<text top="730" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="346" width="175" height="17" font="5">with at least one cardiovascular </text>
<text top="179" left="346" width="172" height="17" font="5">risk factor (microalbuminuria or </text>
<text top="198" left="346" width="182" height="17" font="5">proteinuria, hypertension and left </text>
<text top="216" left="346" width="152" height="17" font="5">ventricular hypertrophy, left </text>
<text top="235" left="346" width="166" height="17" font="5">ventricular systolic or diastolic </text>
<text top="253" left="346" width="163" height="17" font="5">dysfunction, or ankle-brachial </text>
<text top="272" left="346" width="124" height="17" font="5">index of less than 0.9) </text>
<text top="303" left="346" width="97" height="17" font="5">Exclusion criteria </text>
<text top="333" left="346" width="91" height="17" font="5">Type 1 diabetes </text>
<text top="364" left="346" width="176" height="17" font="5">Use of GLP-1 receptor agonists </text>
<text top="394" left="346" width="180" height="17" font="5">Dipeptidyl peptidase 4 inhibitors, </text>
<text top="413" left="346" width="187" height="17" font="5">pramlintide, or rapid acting insulin </text>
<text top="443" left="346" width="164" height="17" font="5">Familial or personal history of </text>
<text top="462" left="346" width="186" height="17" font="5">multiple endocrine neoplasia type </text>
<text top="481" left="346" width="162" height="17" font="5">2 or medullary thyroid cancer </text>
<text top="511" left="346" width="180" height="17" font="5">Occurrence of acute coronary or </text>
<text top="530" left="346" width="176" height="17" font="5">cerebrovascular event within 14 </text>
<text top="548" left="346" width="148" height="17" font="5">days before screening and </text>
<text top="567" left="346" width="81" height="17" font="5">randomization </text>
<text top="597" left="346" width="3" height="17" font="5"> </text>
<text top="160" left="547" width="112" height="17" font="5">1-receptor agonists, </text>
<text top="178" left="547" width="110" height="17" font="5">DPP-4 inhibitors, or </text>
<text top="195" left="547" width="89" height="17" font="5">pramlintide was </text>
<text top="212" left="547" width="55" height="17" font="5">permitted </text>
<text top="229" left="547" width="3" height="17" font="5"> </text>
<text top="160" left="677" width="218" height="17" font="5">group (13.0% vs 14.9%, HR=0.87, 95% </text>
<text top="178" left="677" width="160" height="17" font="5">CI 0.78n to 0.97, p&lt;0.001 for </text>
<text top="195" left="677" width="211" height="17" font="5">noninferiority, p=0.01 for superiority).   </text>
<text top="160" left="918" width="173" height="17" font="7"><i>Death from any cause</i>: lower in </text>
<text top="178" left="918" width="205" height="17" font="5">liraglutide than placebo (8.2 vs 9.6%, </text>
<text top="195" left="918" width="204" height="17" font="5">HR=0.85, 95% CI 0.74-0.97, p=0.02) </text>
<text top="212" left="918" width="3" height="17" font="5"> </text>
<text top="229" left="918" width="196" height="17" font="7"><i>Nonfatal MI</i>: 6.0 vs 6.8%, HR=0.88, </text>
<text top="247" left="918" width="144" height="17" font="5">95% CI 0.75-1.03, p=0.11 </text>
<text top="264" left="918" width="3" height="17" font="5"> </text>
<text top="281" left="918" width="209" height="17" font="7"><i>Fatal MI</i>: 0.4 vs. 0.6%, HR=0.60, 95% </text>
<text top="298" left="918" width="113" height="17" font="5">CI 0.33-1.10, p-0.10 </text>
<text top="315" left="918" width="3" height="17" font="5"> </text>
<text top="333" left="918" width="213" height="17" font="7"><i>Silent MI</i>: 1.3 vs. 1.6%, HR=0.86, 95% </text>
<text top="350" left="918" width="116" height="17" font="5">CI 0.61-1.20, p=0.37 </text>
<text top="367" left="918" width="3" height="17" font="5"> </text>
<text top="384" left="918" width="200" height="17" font="7"><i>TIA</i>: 1.0 vs. 1.3%, HR=0.79, 95% CI </text>
<text top="401" left="918" width="100" height="17" font="5">0.54-1.16, p=0.23 </text>
<text top="419" left="918" width="3" height="17" font="5"> </text>
<text top="436" left="918" width="193" height="17" font="7"><i>Coronary revascularization</i>: 8.7 vs. </text>
<text top="453" left="918" width="204" height="17" font="5">9.4%, HR=0.91, 95% CI 0.80-1.04, p-</text>
<text top="470" left="918" width="27" height="17" font="5">0.18 </text>
<text top="487" left="918" width="3" height="17" font="5"> </text>
<text top="505" left="918" width="220" height="17" font="7"><i>Nonfatal stroke</i>: 3.4 vs. 3.8%, HR=0.89, </text>
<text top="522" left="918" width="148" height="17" font="5">95% CI 0.72-1.11, p=0.30) </text>
<text top="539" left="918" width="3" height="17" font="5"> </text>
<text top="556" left="918" width="198" height="17" font="7"><i>Fatal stroke</i>: 0.3 vs. 0.5%, HR=0.64 </text>
<text top="573" left="918" width="144" height="17" font="5">95% CI 0.34-1.19, p=0.16 </text>
<text top="591" left="918" width="3" height="17" font="5"> </text>
<text top="608" left="918" width="215" height="17" font="7"><i>Hospitalization for unstable angina</i>: 2.6 </text>
<text top="625" left="918" width="209" height="17" font="5">vs. 2.7%, HR=0.98 95% CI 0.76-12.6, </text>
<text top="642" left="918" width="41" height="17" font="5">p=0.87 </text>
<text top="660" left="918" width="3" height="17" font="5"> </text>
<text top="677" left="918" width="209" height="17" font="7"><i>Hospitalization for heart failure</i>: 4.7 vs </text>
<text top="694" left="918" width="193" height="17" font="5">5.3%, HR=0.87, 95% CI 0.73-1.05, </text>
<text top="711" left="918" width="41" height="17" font="5">p=0.14 </text>
<text top="728" left="918" width="3" height="17" font="5"> </text>
<text top="746" left="918" width="191" height="17" font="7"><i>Microvascular event</i>: 7.6 vs. 8.9%, </text>
<text top="763" left="918" width="200" height="17" font="5">HR=0.84, 95% CI 0.73-0.97, p=0.02 </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="3" height="17" font="5"> </text>
<text top="178" left="918" width="90" height="17" font="5">Adverse Events </text>
<text top="195" left="918" width="180" height="17" font="5">Any AE: no significant difference </text>
<text top="212" left="918" width="191" height="17" font="5">between groups (62.3% vs 60.8%, </text>
<text top="229" left="918" width="46" height="17" font="5">p=0.12) </text>
<text top="247" left="918" width="3" height="17" font="5"> </text>
<text top="264" left="918" width="215" height="17" font="5">Non significantly higher rates of benign </text>
<text top="281" left="918" width="209" height="17" font="5">(3.6 vs. 3.1%, p=0.18)) and malignant </text>
<text top="298" left="918" width="211" height="17" font="5">neoplasms (6.3% vs. 6.0%, p=0.46) in </text>
<text top="315" left="918" width="188" height="17" font="5">liraglutide vs placebo group (more </text>
<text top="333" left="918" width="209" height="17" font="5">patients in liaglutide than placebo had </text>
<text top="350" left="918" width="209" height="17" font="5">pancreatic cancer, fewer had prostate </text>
<text top="367" left="918" width="121" height="17" font="5">cancer and leukemia) </text>
<text top="384" left="918" width="3" height="17" font="5"> </text>
<text top="401" left="918" width="191" height="17" font="5">Acute pancreatitis in 18 patients in </text>
<text top="419" left="918" width="148" height="17" font="5">liraglutide vs 23 in placebo </text>
<text top="436" left="918" width="3" height="17" font="5"> </text>
<text top="453" left="918" width="193" height="17" font="5">Mean levels of serum amylase and </text>
<text top="470" left="918" width="216" height="17" font="5">lipase higher in liraglutide than placebo </text>
<text top="487" left="918" width="35" height="17" font="5">group </text>
<text top="505" left="918" width="3" height="17" font="5"> </text>
<text top="522" left="918" width="215" height="17" font="5">Acute gallstone disease more common </text>
<text top="539" left="918" width="178" height="17" font="5">in liraglutide than placebo group </text>
<text top="556" left="918" width="3" height="17" font="5"> </text>
<text top="573" left="918" width="173" height="17" font="5">Fewer in liraglutide treated with </text>
<text top="591" left="918" width="221" height="17" font="5">hypoglycemic medications than placebo </text>
<text top="608" left="918" width="3" height="17" font="5"> </text>
<text top="625" left="918" width="210" height="17" font="5">Severe hypoglycemia less common in </text>
<text top="642" left="918" width="217" height="17" font="5">liraglutide than placebo (RR=0.69, 95% </text>
<text top="660" left="918" width="88" height="17" font="5">CI 0.51 to 0.93) </text>
<text top="677" left="918" width="3" height="17" font="5"> </text>
<text top="694" left="918" width="215" height="17" font="5">Confirmed hypoglycemia less common </text>
<text top="711" left="918" width="201" height="17" font="5">in liraglutide (RR=0.80, 95% CI 0.74-</text>
<text top="728" left="918" width="31" height="17" font="5">0.88) </text>
<text top="746" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="145" height="17" font="5">AEs leading to permanent </text>
<text top="178" left="918" width="202" height="17" font="5">discontinuation of trial regimen more </text>
<text top="195" left="918" width="197" height="17" font="5">common in liraglutide than placebo, </text>
<text top="212" left="918" width="188" height="17" font="5">apparently driven by GI disorders  </text>
<text top="229" left="918" width="138" height="17" font="5">(9.5% vs 7.3%, p&lt;0.001) </text>
<text top="247" left="75" width="74" height="17" font="5">Dapagliflozin </text>
<text top="264" left="75" width="52" height="17" font="5">Effect on </text>
<text top="282" left="75" width="85" height="17" font="5">Cardiovascular </text>
<text top="299" left="75" width="44" height="17" font="5">Events–</text>
<text top="316" left="75" width="89" height="17" font="5">Thrombolysis in </text>
<text top="333" left="75" width="63" height="17" font="5">Myocardial </text>
<text top="350" left="75" width="74" height="17" font="5">Infarction 58  </text>
<text top="368" left="75" width="94" height="17" font="5">(DECLARE-TIMI </text>
<text top="385" left="75" width="44" height="17" font="5">58 trial) </text>
<text top="414" left="75" width="70" height="17" font="5">Wiviott et al, </text>
<text top="433" left="75" width="31" height="17" font="5">2018 </text>
<text top="463" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30415602">30415602</a></text>
<text top="463" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30415602"> </a></text>
<text top="247" left="186" width="59" height="17" font="5">Study Aim </text>
<text top="264" left="186" width="141" height="17" font="5">To evaluate the effects of </text>
<text top="282" left="186" width="89" height="17" font="5">dapagliflozin on </text>
<text top="299" left="186" width="137" height="17" font="5">cardiovascular and renal </text>
<text top="316" left="186" width="115" height="17" font="5">outcomes in a broad </text>
<text top="333" left="186" width="146" height="17" font="5">population of patients who </text>
<text top="350" left="186" width="122" height="17" font="5">had or were at risk for </text>
<text top="368" left="186" width="83" height="17" font="5">atherosclerotic </text>
<text top="385" left="186" width="129" height="17" font="5">cardiovascular disease </text>
<text top="402" left="186" width="3" height="17" font="5"> </text>
<text top="419" left="186" width="66" height="17" font="5">Study Type </text>
<text top="437" left="186" width="29" height="17" font="5">RCT </text>
<text top="454" left="186" width="3" height="17" font="5"> </text>
<text top="471" left="186" width="57" height="17" font="5">N=17.160 </text>
<text top="247" left="346" width="92" height="17" font="5">Inclusion criteria </text>
<text top="278" left="346" width="141" height="17" font="5">-40 years of age or older  </text>
<text top="295" left="346" width="154" height="17" font="5">-type 2 diabetes, a glycated </text>
<text top="312" left="346" width="184" height="17" font="5">hemoglobin level of at least 6.5% </text>
<text top="329" left="346" width="149" height="17" font="5">but less than 12.0%, and a </text>
<text top="347" left="346" width="175" height="17" font="5">creatinine clearance of 60 ml or </text>
<text top="364" left="346" width="93" height="17" font="5">more per minute </text>
<text top="381" left="346" width="158" height="17" font="5">- had multiple risk factors for </text>
<text top="398" left="346" width="166" height="17" font="5">atherosclerotic cardiovascular </text>
<text top="416" left="346" width="149" height="17" font="5">disease or had established </text>
<text top="433" left="346" width="166" height="17" font="5">atherosclerotic cardiovascular </text>
<text top="450" left="346" width="159" height="17" font="5">disease (defined as clinically </text>
<text top="467" left="346" width="175" height="17" font="5">evident ischemic heart disease, </text>
<text top="484" left="346" width="142" height="17" font="5">ischemic cerebrovascular </text>
<text top="502" left="346" width="156" height="17" font="5">disease, or peripheral artery </text>
<text top="519" left="346" width="50" height="17" font="5">disease) </text>
<text top="536" left="346" width="7" height="17" font="5">. </text>
<text top="247" left="547" width="68" height="17" font="5">Intervention </text>
<text top="264" left="547" width="109" height="17" font="5">10 mg dapagliflozin </text>
<text top="282" left="547" width="82" height="17" font="5">daily (n=8582) </text>
<text top="299" left="547" width="3" height="17" font="5"> </text>
<text top="316" left="547" width="70" height="17" font="5">Comparison </text>
<text top="333" left="555" width="101" height="17" font="5">Placebo (n=8578) </text>
<text top="248" left="677" width="7" height="17" font="5">1</text>
<text top="247" left="684" width="70" height="18" font="5"> endpoints: </text>
<text top="266" left="677" width="206" height="17" font="5">Safety: Major adverse cardiovascular </text>
<text top="283" left="677" width="211" height="17" font="5">events (MACE) (cardiovascular death, </text>
<text top="300" left="677" width="185" height="17" font="5">myocardial infarction, or ischemic </text>
<text top="317" left="677" width="48" height="17" font="5">stroke).  </text>
<text top="334" left="677" width="3" height="17" font="5"> </text>
<text top="352" left="677" width="196" height="17" font="5">Efficacy: MACE and a composite of </text>
<text top="369" left="677" width="212" height="17" font="5">cardiovascular death or hospitalization </text>
<text top="386" left="677" width="90" height="17" font="5">for heart failure. </text>
<text top="403" left="677" width="3" height="17" font="5"> </text>
<text top="420" left="677" width="3" height="17" font="5"> </text>
<text top="439" left="677" width="7" height="17" font="5">1</text>
<text top="438" left="684" width="66" height="18" font="5"> endpoints </text>
<text top="456" left="677" width="215" height="17" font="7"><i>Cardiovascular death or hospitalization </i></text>
<text top="473" left="677" width="86" height="17" font="7"><i>for heart failure </i></text>
<text top="490" left="677" width="3" height="17" font="5"> </text>
<text top="508" left="677" width="200" height="17" font="5">4.9% dapagliflozin vs. 5.8% placebo </text>
<text top="525" left="677" width="3" height="17" font="5"> </text>
<text top="542" left="677" width="165" height="17" font="5">Rate=12.2/1000 patient years </text>
<text top="559" left="677" width="223" height="17" font="5">dapagliflozin vs. 14.7/1000 patient years </text>
<text top="577" left="677" width="46" height="17" font="5">placebo </text>
<text top="594" left="677" width="3" height="17" font="5"> </text>
<text top="611" left="677" width="211" height="17" font="5">HR=0.83 (95% CI 0.73-0.95), p=0.005 </text>
<text top="628" left="677" width="78" height="17" font="5">for superiority </text>
<text top="645" left="677" width="3" height="17" font="5"> </text>
<text top="663" left="677" width="209" height="17" font="5">HR ASCVD group=0.83 (95% CI 0.71-</text>
<text top="680" left="677" width="223" height="17" font="5">0.98) vs. HR=0.84 (95% CI 0.67-1.04) in </text>
<text top="697" left="677" width="175" height="17" font="5">multiple risk factors group, p for </text>
<text top="714" left="677" width="91" height="17" font="5">interaction=0.99 </text>
<text top="732" left="677" width="3" height="17" font="5"> </text>
<text top="749" left="677" width="178" height="17" font="5">HR in those with history of heart </text>
<text top="766" left="677" width="213" height="17" font="5">failure=0.79 (95% CI 0.63-0.99), HR in </text>
<text top="248" left="918" width="7" height="17" font="5">2</text>
<text top="247" left="925" width="70" height="18" font="5"> endpoints: </text>
<text top="266" left="918" width="3" height="17" font="5"> </text>
<text top="283" left="918" width="206" height="17" font="5">Renal composite outcome (sustained </text>
<text top="300" left="918" width="211" height="17" font="5">decrease of 40% or more in estimated </text>
<text top="317" left="918" width="210" height="17" font="5">glomerular filtration rate (eGFR)), new </text>
<text top="334" left="918" width="215" height="17" font="5">end-stage renal disease, or death from </text>
<text top="352" left="918" width="173" height="17" font="5">renal or cardiovascular causes. </text>
<text top="369" left="918" width="198" height="17" font="5">Additional renal composite outcome </text>
<text top="386" left="918" width="196" height="17" font="5">included all these criteria except for </text>
<text top="403" left="918" width="120" height="17" font="5">cardiovascular .death </text>
<text top="420" left="918" width="3" height="17" font="5"> </text>
<text top="438" left="918" width="103" height="17" font="5">All cause mortality </text>
<text top="455" left="918" width="3" height="17" font="5"> </text>
<text top="473" left="918" width="7" height="17" font="5">2</text>
<text top="472" left="925" width="70" height="18" font="5"> endpoints: </text>
<text top="490" left="918" width="3" height="17" font="5"> </text>
<text top="508" left="918" width="95" height="17" font="7"><i>Renal composite </i></text>
<text top="525" left="918" width="165" height="17" font="5">Rate=10.8/1000 patient years </text>
<text top="542" left="918" width="189" height="17" font="5">dapagliflozin vs. 14.1/1000 patient </text>
<text top="559" left="918" width="80" height="17" font="5">years placebo </text>
<text top="577" left="918" width="3" height="17" font="5"> </text>
<text top="594" left="918" width="160" height="17" font="5">HR=0.76 (95% CI 0.67-0.87) </text>
<text top="611" left="918" width="3" height="17" font="5"> </text>
<text top="628" left="918" width="103" height="17" font="7"><i>All cause mortality </i></text>
<text top="645" left="918" width="200" height="17" font="5">6.2% dapagliflozin vs. 6.6% placebo </text>
<text top="663" left="918" width="3" height="17" font="5"> </text>
<text top="680" left="918" width="166" height="17" font="5">Rate=15.1/1000 person years </text>
<text top="697" left="918" width="190" height="17" font="5">dapagliflozin vs. 16.4/1000 person </text>
<text top="714" left="918" width="80" height="17" font="5">years placebo </text>
<text top="732" left="918" width="3" height="17" font="5"> </text>
<text top="749" left="918" width="160" height="17" font="5">HR=0.93 (95% CI 0.82-1.04) </text>
<text top="766" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="160" height="17" font="5">those with no history of heart </text>
<text top="178" left="677" width="207" height="17" font="5">failure=0.84 (95% CI 0.72-0.99), p for </text>
<text top="195" left="677" width="91" height="17" font="5">interaction=0.60 </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="74" height="17" font="5">HR by eGFR </text>
<text top="247" left="677" width="164" height="17" font="5">≥90=0.96 (95% CI 0.77-1.19) </text>
<text top="264" left="677" width="194" height="17" font="5">60 to &lt;90=0.79 (95% CI 0.66-0.95) </text>
<text top="281" left="677" width="163" height="17" font="5">&lt;60=0.78 (95% CI 0.55-1.09) </text>
<text top="298" left="677" width="121" height="17" font="5">P for interaction=0.37 </text>
<text top="315" left="677" width="3" height="17" font="5"> </text>
<text top="333" left="677" width="39" height="17" font="7"><i>MACE </i></text>
<text top="350" left="677" width="200" height="17" font="5">8.8% dapagliflozin vs. 5.8% placebo </text>
<text top="367" left="677" width="3" height="17" font="5"> </text>
<text top="384" left="677" width="165" height="17" font="5">Rate=22.6/1000 patient years </text>
<text top="401" left="677" width="223" height="17" font="5">dapagliflozin vs. 24.2/1000 patient years </text>
<text top="419" left="677" width="46" height="17" font="5">placebo </text>
<text top="436" left="677" width="3" height="17" font="5"> </text>
<text top="453" left="677" width="159" height="17" font="5">Met prespecified criterion for </text>
<text top="470" left="677" width="225" height="17" font="5">noninferiority (upper boundary of 95% CI </text>
<text top="487" left="677" width="84" height="17" font="5">&lt;1.3, p&lt;0.001) </text>
<text top="505" left="677" width="3" height="17" font="5"> </text>
<text top="522" left="677" width="222" height="17" font="5">HR=0.93 (95% CI 0.84-1.03), p=0.17 for </text>
<text top="539" left="677" width="60" height="17" font="5">superiority </text>
<text top="556" left="677" width="3" height="17" font="5"> </text>
<text top="573" left="677" width="209" height="17" font="5">HR ASCVD group=0.90 (95% CI 0.79-</text>
<text top="591" left="677" width="223" height="17" font="5">1.02) vs. HR=1.01 (95% CI 0.86-1.20) in </text>
<text top="608" left="677" width="175" height="17" font="5">multiple risk factors group, p for </text>
<text top="625" left="677" width="91" height="17" font="5">interaction=0.25 </text>
<text top="642" left="677" width="3" height="17" font="5"> </text>
<text top="660" left="677" width="178" height="17" font="5">HR in those with history of heart </text>
<text top="677" left="677" width="213" height="17" font="5">failure=1.01 (95% CI 0.81-1.27), HR in </text>
<text top="694" left="677" width="160" height="17" font="5">those with no history of heart </text>
<text top="711" left="677" width="207" height="17" font="5">failure=0.92 (95% CI 0.82-1.02), p for </text>
<text top="728" left="677" width="91" height="17" font="5">interaction=0.46 </text>
<text top="746" left="677" width="3" height="17" font="5"> </text>
<text top="763" left="677" width="74" height="17" font="5">HR by eGFR </text>
<text top="160" left="918" width="120" height="17" font="7"><i>Cardiovascular death </i></text>
<text top="178" left="918" width="200" height="17" font="5">2.9% dapagliflozin vs. 2.9% placebo </text>
<text top="195" left="918" width="158" height="17" font="5">Rate=7.0/1000 patient years </text>
<text top="212" left="918" width="216" height="17" font="5">dapagliflozin vs. 7.1/1000 patient years </text>
<text top="229" left="918" width="210" height="17" font="5">placebo, HR=0.98 (95% CI 0.82-1.17) </text>
<text top="247" left="918" width="3" height="17" font="5"> </text>
<text top="264" left="918" width="138" height="17" font="7"><i>noncardiovascular death </i></text>
<text top="281" left="918" width="204" height="17" font="5">2.5% dapagliflozin  vs. 2.8% placebo </text>
<text top="298" left="918" width="162" height="17" font="5">Rate=6.0/1000 patient years  </text>
<text top="315" left="918" width="216" height="17" font="5">dapagliflozin vs. 6.8/1000 patient years </text>
<text top="333" left="918" width="210" height="17" font="5">placebo, HR=0.88 (95% CI 0.73-1.06) </text>
<text top="350" left="918" width="3" height="17" font="5"> </text>
<text top="367" left="918" width="90" height="17" font="5">Adverse Events </text>
<text top="384" left="918" width="220" height="17" font="7"><i>Serious adverse event, dapagliflozin vs. </i></text>
<text top="401" left="918" width="69" height="17" font="7"><i>placebo (%) </i></text>
<text top="419" left="918" width="199" height="17" font="5">34.1% vs. 36.2%, HR=0.91 (95% CI </text>
<text top="436" left="918" width="111" height="17" font="5">0.87-0.96), p&lt;0.001 </text>
<text top="453" left="918" width="3" height="17" font="5"> </text>
<text top="470" left="918" width="199" height="17" font="7"><i>AE leading to discontinuation of trial </i></text>
<text top="487" left="918" width="48" height="17" font="7"><i>regimen </i></text>
<text top="505" left="918" width="214" height="17" font="5">0.7% vs. 1.0%, HR=0.68 (95% CI 0.49-</text>
<text top="522" left="918" width="76" height="17" font="5">0.95), p=0.01 </text>
<text top="539" left="918" width="3" height="17" font="5"> </text>
<text top="556" left="918" width="146" height="17" font="7"><i>Major hypoglycemic event </i></text>
<text top="573" left="918" width="214" height="17" font="5">0.7% vs. 1.0%, HR=0.68 (95% CI 0.49-</text>
<text top="591" left="918" width="76" height="17" font="5">0.95), p=0.02 </text>
<text top="608" left="918" width="3" height="17" font="5"> </text>
<text top="625" left="918" width="119" height="17" font="7"><i>Diabetic ketoacidosis </i></text>
<text top="642" left="918" width="214" height="17" font="5">0.3% vs. 0.1%, HR=2.18 (95% CI 1.10-</text>
<text top="660" left="918" width="76" height="17" font="5">4.30), p=0.02 </text>
<text top="677" left="918" width="3" height="17" font="5"> </text>
<text top="694" left="918" width="66" height="17" font="7"><i>Amputation </i></text>
<text top="711" left="918" width="214" height="17" font="5">1.4% vs. 1.3%, HR=1.09 (95% CI 0.84-</text>
<text top="728" left="918" width="76" height="17" font="5">1.40), p=0.53 </text>
<text top="746" left="918" width="3" height="17" font="5"> </text>
<text top="763" left="918" width="49" height="17" font="7"><i>Fracture </i></text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="164" height="17" font="5">≥90=0.94 (95% CI 0.80-1.10) </text>
<text top="178" left="677" width="194" height="17" font="5">60 to &lt;90=0.95 (95% CI 0.82-1.09) </text>
<text top="195" left="677" width="163" height="17" font="5">&lt;60=0.92 (95% CI 0.69-1.23) </text>
<text top="212" left="677" width="121" height="17" font="5">P for interaction=0.99 </text>
<text top="229" left="677" width="3" height="17" font="5"> </text>
<text top="247" left="677" width="168" height="17" font="7"><i>hospitalization for heart failure </i></text>
<text top="264" left="677" width="204" height="17" font="5">2.5% dapagliflozin  vs. 3.3% placebo </text>
<text top="281" left="677" width="224" height="17" font="5">Rate=6.2/1000 patient year dapagliflozin </text>
<text top="298" left="677" width="194" height="17" font="5">vs. 8.5/1000 patient years placebo, </text>
<text top="315" left="677" width="160" height="17" font="5">HR=0.73 (95% CI 0.61-0.88) </text>
<text top="333" left="677" width="3" height="17" font="5"> </text>
<text top="350" left="677" width="116" height="17" font="7"><i>myocardial infarction </i></text>
<text top="367" left="677" width="200" height="17" font="5">4.6% dapagliflozin vs. 5.1% placebo </text>
<text top="384" left="677" width="226" height="17" font="5">Rate=6.2/100 patient years  dapagliflozin </text>
<text top="401" left="677" width="197" height="17" font="5">vs. 8.5//1000 patient years placebo, </text>
<text top="419" left="677" width="160" height="17" font="5">HR=0.89 (95% CI 0.77-1.01) </text>
<text top="436" left="677" width="3" height="17" font="5"> </text>
<text top="453" left="677" width="88" height="17" font="7"><i>ischemic stroke </i></text>
<text top="470" left="677" width="200" height="17" font="5">2.7% dapagliflozin vs. 2.7% placebo </text>
<text top="487" left="677" width="158" height="17" font="5">Rate=6.9/1000 patient years </text>
<text top="505" left="677" width="210" height="17" font="5">dapagliflozin vs. 6.8/1000 patient year </text>
<text top="522" left="677" width="210" height="17" font="5">placebo, HR=1.01 (95% CI 0.84-1.21) </text>
<text top="539" left="677" width="3" height="17" font="5"> </text>
<text top="556" left="677" width="117" height="17" font="7"><i>cardiovascular death </i></text>
<text top="573" left="677" width="200" height="17" font="5">2.9% dapagliflozin vs. 2.9% placebo </text>
<text top="591" left="677" width="158" height="17" font="5">Rate=7.0/1000 patient years </text>
<text top="608" left="677" width="216" height="17" font="5">dapagliflozin vs. 7.1/1000 patient years </text>
<text top="625" left="677" width="210" height="17" font="5">placebo, HR=0.98 (95% CI 0.82-1.17) </text>
<text top="642" left="677" width="3" height="17" font="5"> </text>
<text top="660" left="677" width="3" height="17" font="5"> </text>
<text top="677" left="677" width="3" height="17" font="5"> </text>
<text top="160" left="918" width="214" height="17" font="5">5.3% vs. 5.1%, HR=1.04 (95% CI 0.91-</text>
<text top="178" left="918" width="76" height="17" font="5">1.18), p=0.59 </text>
<text top="195" left="918" width="3" height="17" font="5"> </text>
<text top="212" left="918" width="172" height="17" font="7"><i>Symptoms of volume depletion </i></text>
<text top="229" left="918" width="214" height="17" font="5">2.5% vs. 2.4%, HR=1.00 (95% CI 0.83-</text>
<text top="247" left="918" width="76" height="17" font="5">1.21), p=0.99 </text>
<text top="264" left="918" width="3" height="17" font="5"> </text>
<text top="281" left="918" width="107" height="17" font="7"><i>Acute kidney injury </i></text>
<text top="298" left="918" width="214" height="17" font="5">1.5% vs. 2.0%, HR=0.69 (95% CI 0.55-</text>
<text top="315" left="918" width="83" height="17" font="5">0.87), p=0.002 </text>
<text top="333" left="918" width="3" height="17" font="5"> </text>
<text top="350" left="918" width="92" height="17" font="7"><i>Genital infection </i></text>
<text top="367" left="918" width="214" height="17" font="5">0.9% vs. 0.1%, HR=8.36 (95% CI 4.19-</text>
<text top="384" left="918" width="90" height="17" font="5">16.68), p&lt;0.001 </text>
<text top="401" left="918" width="3" height="17" font="5"> </text>
<text top="419" left="918" width="123" height="17" font="7"><i>Urinary tract infection  </i></text>
<text top="436" left="918" width="214" height="17" font="5">1.5% vs. 1.6%, HR=0.93 (95% CI 0.73-</text>
<text top="453" left="918" width="76" height="17" font="5">1.18), p=0.54 </text>
<text top="470" left="918" width="3" height="17" font="5"> </text>
<text top="487" left="918" width="43" height="17" font="7"><i>Cancer </i></text>
<text top="505" left="918" width="214" height="17" font="5">5.6% vs. 5.7%, HR=0.99 (95% CI 0.87-</text>
<text top="522" left="918" width="76" height="17" font="5">1.12), p=0.83 </text>
<text top="539" left="918" width="3" height="17" font="5"> </text>
<text top="556" left="918" width="86" height="17" font="7"><i>Bladder cancer </i></text>
<text top="573" left="918" width="214" height="17" font="5">0.3% vs. 0.5%, HR=0.57 (95% CI 0.35-</text>
<text top="591" left="918" width="76" height="17" font="5">0.93), p=0.02 </text>
<text top="608" left="918" width="3" height="17" font="5"> </text>
<text top="625" left="918" width="79" height="17" font="7"><i>Breast cancer </i></text>
<text top="642" left="918" width="214" height="17" font="5">0.4% vs. 0.4%, HR=1.02 (95% CI 0.64-</text>
<text top="660" left="918" width="76" height="17" font="5">1.63), p=0.92 </text>
<text top="677" left="918" width="3" height="17" font="5"> </text>
<text top="694" left="918" width="90" height="17" font="7"><i>Hypersensitivity </i></text>
<text top="711" left="918" width="214" height="17" font="5">0.4% vs. 0.4%, HR=0.87 (95% CI 0.54-</text>
<text top="728" left="918" width="76" height="17" font="5">1.40), p=0.57 </text>
<text top="746" left="918" width="3" height="17" font="5"> </text>
<text top="763" left="918" width="79" height="17" font="7"><i>Hepatic event </i></text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="214" height="17" font="5">1.0% vs. 1.0%, HR=0.92 (95% CI 0.68-</text>
<text top="178" left="918" width="76" height="17" font="5">1.25), p=0.60 </text>
<text top="196" left="75" width="94" height="17" font="5">Hernandez et al, </text>
<text top="214" left="75" width="31" height="17" font="5">2018 </text>
<text top="245" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30291013">30291013</a></text>
<text top="245" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30291013"> </a></text>
<text top="196" left="186" width="59" height="17" font="5">Study Aim </text>
<text top="213" left="186" width="133" height="17" font="5">To determine the safety </text>
<text top="230" left="186" width="141" height="17" font="5">and efficacy of albiglutide </text>
<text top="247" left="186" width="74" height="17" font="5">in preventing </text>
<text top="264" left="186" width="120" height="17" font="5">cardiovascular death, </text>
<text top="282" left="186" width="134" height="17" font="5">myocardial infarction, or </text>
<text top="299" left="186" width="37" height="17" font="5">stroke </text>
<text top="316" left="186" width="3" height="17" font="5"> </text>
<text top="333" left="186" width="66" height="17" font="5">Study Type </text>
<text top="350" left="186" width="29" height="17" font="5">RCT </text>
<text top="368" left="186" width="3" height="17" font="5"> </text>
<text top="385" left="186" width="47" height="17" font="5">N=9463 </text>
<text top="196" left="346" width="92" height="17" font="5">Inclusion criteria </text>
<text top="226" left="346" width="131" height="17" font="5">-aged 40 years or older </text>
<text top="243" left="346" width="163" height="17" font="5">-diagnosis of type 2 diabetes  </text>
<text top="261" left="346" width="149" height="17" font="5">-established disease of the </text>
<text top="278" left="346" width="175" height="17" font="5">coronary (myocardial infarction, </text>
<text top="295" left="346" width="156" height="17" font="5">at least 50% stenosis in one </text>
<text top="312" left="346" width="150" height="17" font="5">coronary artery or more, or </text>
<text top="329" left="346" width="101" height="17" font="5">previous coronary </text>
<text top="347" left="346" width="103" height="17" font="5">revascularization), </text>
<text top="364" left="346" width="187" height="17" font="5">cerebrovascular (ischemic stroke, </text>
<text top="381" left="346" width="146" height="17" font="5">at least 50% carotid artery </text>
<text top="398" left="346" width="167" height="17" font="5">stenosis, or a previous carotid </text>
<text top="416" left="346" width="130" height="17" font="5">vascular procedure), or </text>
<text top="433" left="346" width="158" height="17" font="5">peripheral arterial circulation </text>
<text top="450" left="346" width="178" height="17" font="5">(intermittent claudication and an </text>
<text top="467" left="346" width="182" height="17" font="5">ankle to brachial index &lt;0·9, non-</text>
<text top="484" left="346" width="146" height="17" font="5">traumatic amputation, or a </text>
<text top="502" left="346" width="157" height="17" font="5">previous peripheral vascular </text>
<text top="519" left="346" width="66" height="17" font="5">procedure)  </text>
<text top="536" left="346" width="120" height="17" font="5">-glycated hemoglobin </text>
<text top="553" left="346" width="182" height="17" font="5">concentration of more than 7·0% </text>
<text top="570" left="346" width="110" height="17" font="5">(53 mmol per mole) </text>
<text top="588" left="346" width="3" height="17" font="5"> </text>
<text top="605" left="346" width="97" height="17" font="5">Exclusion criteria </text>
<text top="635" left="346" width="169" height="17" font="5">-estimated glomerular filtration </text>
<text top="653" left="346" width="187" height="17" font="5">rate less than 30 mL/min per 1·73 </text>
<text top="670" left="346" width="18" height="17" font="5">m² </text>
<text top="687" left="346" width="122" height="17" font="5">-severe gastroparesis </text>
<text top="704" left="346" width="138" height="17" font="5">- previous pancreatitis or </text>
<text top="721" left="346" width="143" height="17" font="5">substantial risk factors for </text>
<text top="739" left="346" width="66" height="17" font="5">pancreatitis </text>
<text top="756" left="346" width="171" height="17" font="5">- a personal or family history of </text>
<text top="773" left="346" width="151" height="17" font="5">medullary carcinoma of the </text>
<text top="196" left="547" width="68" height="17" font="5">Intervention </text>
<text top="213" left="547" width="115" height="17" font="5">Albiglutide 30-50 mg </text>
<text top="230" left="547" width="53" height="17" font="5">(n=4731) </text>
<text top="247" left="547" width="3" height="17" font="5"> </text>
<text top="264" left="547" width="70" height="17" font="5">Comparison </text>
<text top="282" left="555" width="101" height="17" font="5">Placebo (n=4732) </text>
<text top="197" left="677" width="7" height="17" font="5">1</text>
<text top="196" left="684" width="60" height="18" font="5"> endpoint </text>
<text top="214" left="677" width="176" height="17" font="5">composite outcome (death from </text>
<text top="231" left="677" width="191" height="17" font="5">cardiovascular causes, myocardial </text>
<text top="248" left="677" width="122" height="17" font="5">infarction, and stroke) </text>
<text top="266" left="677" width="3" height="17" font="5"> </text>
<text top="283" left="677" width="173" height="17" font="5">7% albiglutide vs. 9% placebo j </text>
<text top="300" left="677" width="3" height="17" font="5"> </text>
<text top="317" left="677" width="218" height="17" font="5">Rate=4.57/100 person years albiglutide </text>
<text top="334" left="677" width="204" height="17" font="5">vs. 5.87/100 person years albiglutide </text>
<text top="352" left="677" width="3" height="17" font="5"> </text>
<text top="369" left="677" width="216" height="17" font="5">HR=0.78 (95% CI 0.68-0.90), p for non-</text>
<text top="386" left="677" width="129" height="17" font="5">inferiority&lt;0.0001, p for </text>
<text top="403" left="677" width="105" height="17" font="5">superiority=0.0006 </text>
<text top="197" left="918" width="7" height="17" font="5">2</text>
<text top="196" left="925" width="66" height="18" font="5"> endpoints </text>
<text top="214" left="918" width="3" height="17" font="5"> </text>
<text top="231" left="918" width="142" height="17" font="5">Cardiovascular outcomes </text>
<text top="248" left="918" width="218" height="17" font="5">four-component composite (the primary </text>
<text top="266" left="918" width="207" height="17" font="5">composite, with the addition of urgent </text>
<text top="283" left="918" width="215" height="17" font="5">revascularization for unstable angina),  </text>
<text top="300" left="918" width="3" height="17" font="5"> </text>
<text top="317" left="918" width="180" height="17" font="5">the individual components of the </text>
<text top="334" left="918" width="95" height="17" font="5">primary endpoint </text>
<text top="352" left="918" width="3" height="17" font="5"> </text>
<text top="369" left="918" width="210" height="17" font="5">the composite of cardiovascular death </text>
<text top="386" left="918" width="214" height="17" font="5">or hospital admission because of heart </text>
<text top="403" left="918" width="40" height="17" font="5">failure. </text>
<text top="420" left="918" width="3" height="17" font="5"> </text>
<text top="438" left="918" width="113" height="17" font="5">Metabolic outcomes </text>
<text top="455" left="918" width="184" height="17" font="5">time to initiation of chronic insulin </text>
<text top="472" left="918" width="44" height="17" font="5">therapy </text>
<text top="489" left="918" width="3" height="17" font="5"> </text>
<text top="507" left="918" width="179" height="17" font="5">time to the first occurrence of an </text>
<text top="524" left="918" width="168" height="17" font="5">important microvascular event </text>
<text top="541" left="918" width="3" height="17" font="5"> </text>
<text top="558" left="918" width="203" height="17" font="5">changes in glycated hemoglobin and </text>
<text top="575" left="918" width="66" height="17" font="5">bodyweight </text>
<text top="593" left="918" width="3" height="17" font="5"> </text>
<text top="610" left="918" width="212" height="17" font="5">proportion of participants who attained </text>
<text top="627" left="918" width="174" height="17" font="5">glycemic control without severe </text>
<text top="644" left="918" width="194" height="17" font="5">hypoglycemia and who gained less </text>
<text top="661" left="918" width="216" height="17" font="5">than 5% of their bodyweight by the end </text>
<text top="679" left="918" width="70" height="17" font="5">of the study. </text>
<text top="696" left="918" width="3" height="17" font="5"> </text>
<text top="713" left="918" width="98" height="17" font="5">Safety outcomes  </text>
<text top="730" left="918" width="197" height="17" font="5">change in blood pressure and heart </text>
<text top="748" left="918" width="25" height="17" font="5">rate </text>
<text top="765" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="346" width="158" height="17" font="5">thyroid or multiple endocrine </text>
<text top="178" left="346" width="93" height="17" font="5">neoplasia type 2 </text>
<text top="195" left="346" width="128" height="17" font="5">-a history of pancreatic </text>
<text top="212" left="346" width="124" height="17" font="5">neuroendocrine tumor </text>
<text top="229" left="346" width="184" height="17" font="5">- current use of a GLP-1 receptor </text>
<text top="247" left="346" width="43" height="17" font="5">agonist </text>
<text top="264" left="346" width="3" height="17" font="5"> </text>
<text top="294" left="346" width="3" height="17" font="5"> </text>
<text top="160" left="918" width="93" height="17" font="5">change in eGFR </text>
<text top="178" left="918" width="3" height="17" font="5"> </text>
<text top="195" left="918" width="189" height="17" font="5">adverse events of special interest, </text>
<text top="212" left="918" width="209" height="17" font="5">including development of prespecified </text>
<text top="229" left="918" width="220" height="17" font="5">malignancies (medullary thyroid cancer, </text>
<text top="247" left="918" width="207" height="17" font="5">pancreatic cancer, and hematological </text>
<text top="264" left="918" width="193" height="17" font="5">malignancies), pancreatitis, severe </text>
<text top="281" left="918" width="210" height="17" font="5">hypoglycemia, injection site reactions, </text>
<text top="298" left="918" width="185" height="17" font="5">immunological reactions, diabetic </text>
<text top="315" left="918" width="208" height="17" font="5">retinopathy, worsening renal function, </text>
<text top="333" left="918" width="146" height="17" font="5">and death from any cause </text>
<text top="350" left="918" width="3" height="17" font="5"> </text>
<text top="367" left="918" width="44" height="17" font="5">Results </text>
<text top="384" left="918" width="3" height="17" font="7"><i> </i></text>
<text top="401" left="918" width="169" height="17" font="7"><i>Expanded composite outcome </i></text>
<text top="419" left="918" width="174" height="17" font="5">8% albiglutide vs. 10% placebo </text>
<text top="436" left="918" width="3" height="17" font="5"> </text>
<text top="453" left="918" width="218" height="17" font="5">Rate=5.06/100 person years albiglutide </text>
<text top="470" left="918" width="192" height="17" font="5">vs. 6.45/100 person years placebo </text>
<text top="487" left="918" width="3" height="17" font="5"> </text>
<text top="505" left="918" width="218" height="17" font="5">HR=0.78 (95% CI 0.69-0.90), p=0.0005 </text>
<text top="522" left="918" width="3" height="17" font="5"> </text>
<text top="539" left="918" width="189" height="17" font="7"><i>Death from cardiovascular causes </i></text>
<text top="556" left="918" width="167" height="17" font="5">3% albiglutide vs. 3% placebo </text>
<text top="573" left="918" width="3" height="17" font="5"> </text>
<text top="591" left="918" width="218" height="17" font="5">Rate=1.61/100 person years albiglutide </text>
<text top="608" left="918" width="192" height="17" font="5">vs. 1.72/100 person years placebo </text>
<text top="625" left="918" width="3" height="17" font="5"> </text>
<text top="642" left="918" width="211" height="17" font="5">HR=0.93 (95% CI 0.73-1.19), p=0.578 </text>
<text top="660" left="918" width="3" height="17" font="5"> </text>
<text top="677" left="918" width="213" height="17" font="7"><i>Fatal or non-fatal myocardial infarction </i></text>
<text top="694" left="918" width="167" height="17" font="5">4% albiglutide vs. 5% placebo </text>
<text top="711" left="918" width="3" height="17" font="5"> </text>
<text top="728" left="918" width="218" height="17" font="5">Rate=2.43/100 person years albiglutide </text>
<text top="746" left="918" width="192" height="17" font="5">vs. 3.26/100 person years placebo </text>
<text top="763" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="211" height="17" font="5">HR=0.75 (95% CI 0.61-0.90), p=0.578 </text>
<text top="178" left="918" width="3" height="17" font="5"> </text>
<text top="195" left="918" width="133" height="17" font="7"><i>Fatal or non-fatal stroke </i></text>
<text top="212" left="918" width="167" height="17" font="5">2% albiglutide vs. 2% placebo </text>
<text top="229" left="918" width="3" height="17" font="5"> </text>
<text top="247" left="918" width="218" height="17" font="5">Rate=1.25/100 person years albiglutide </text>
<text top="264" left="918" width="192" height="17" font="5">vs. 1.45/100 person years placebo </text>
<text top="281" left="918" width="3" height="17" font="5"> </text>
<text top="298" left="918" width="211" height="17" font="5">HR=0.86 (95% CI 0.66-1.14), p=0.300 </text>
<text top="315" left="918" width="3" height="17" font="5"> </text>
<text top="333" left="918" width="221" height="17" font="7"><i>Composite of death from cardiovascular </i></text>
<text top="350" left="918" width="210" height="17" font="7"><i>causes or hospital admission for heart </i></text>
<text top="367" left="918" width="37" height="17" font="7"><i>failure </i></text>
<text top="384" left="918" width="167" height="17" font="5">4% albiglutide vs. 5% placebo </text>
<text top="401" left="918" width="3" height="17" font="5"> </text>
<text top="419" left="918" width="218" height="17" font="5">Rate=2.49/100 person years albiglutide </text>
<text top="436" left="918" width="192" height="17" font="5">vs. 2.92/100 person years placebo </text>
<text top="453" left="918" width="3" height="17" font="5"> </text>
<text top="470" left="918" width="211" height="17" font="5">HR=0.85 (95% CI 0.70-1.04), p=0.113 </text>
<text top="487" left="918" width="3" height="17" font="5"> </text>
<text top="505" left="918" width="103" height="17" font="7"><i>All cause mortality </i></text>
<text top="522" left="918" width="167" height="17" font="5">4% albiglutide vs. 4% placebo </text>
<text top="539" left="918" width="3" height="17" font="5"> </text>
<text top="556" left="918" width="218" height="17" font="5">Rate=2.44/100 person years albiglutide </text>
<text top="573" left="918" width="192" height="17" font="5">vs. 2.56/100 person years placebo </text>
<text top="591" left="918" width="3" height="17" font="5"> </text>
<text top="608" left="918" width="211" height="17" font="5">HR=0.95 (95% CI 0.79-1.16), p=0.644 </text>
<text top="625" left="918" width="3" height="17" font="5"> </text>
<text top="642" left="918" width="213" height="17" font="5">Adverse events albiglutide vs. placebo </text>
<text top="660" left="918" width="3" height="17" font="5"> </text>
<text top="677" left="918" width="121" height="17" font="7"><i>Severe hypoglycemia </i></text>
<text top="694" left="918" width="193" height="17" font="5">1% vs. 1%, RR=0.56 (95% CI 0.36-</text>
<text top="711" left="918" width="31" height="17" font="5">0.87) </text>
<text top="728" left="918" width="3" height="17" font="5"> </text>
<text top="746" left="918" width="68" height="17" font="7"><i>Pancreatitis </i></text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="204" height="17" font="5">&lt;1% vs. &lt;1%, RR=1.43 (95% CI0.54-</text>
<text top="178" left="918" width="31" height="17" font="5">3.75) </text>
<text top="195" left="918" width="3" height="17" font="5"> </text>
<text top="212" left="918" width="125" height="17" font="7"><i>Injection site reactions </i></text>
<text top="229" left="918" width="193" height="17" font="5">2% vs. 1%, RR=2.96 (95% CI 1.95-</text>
<text top="247" left="918" width="31" height="17" font="5">4.51) </text>
<text top="264" left="918" width="3" height="17" font="5"> </text>
<text top="281" left="918" width="88" height="17" font="7"><i>Thyroid cancer  </i></text>
<text top="298" left="918" width="62" height="17" font="5">0% vs. 0% </text>
<text top="315" left="918" width="3" height="17" font="5"> </text>
<text top="333" left="918" width="138" height="17" font="7"><i>Hematological neoplasia </i></text>
<text top="350" left="918" width="207" height="17" font="5">&lt;1% vs. &lt;1%, RR=1.80 (95% CI 0.60-</text>
<text top="367" left="918" width="31" height="17" font="5">5.36) </text>
<text top="384" left="918" width="3" height="17" font="5"> </text>
<text top="401" left="918" width="102" height="17" font="7"><i>Pancreatic cancer </i></text>
<text top="419" left="918" width="207" height="17" font="5">&lt;1% vs. &lt;1%, RR=1.20 (95% CI 0.37-</text>
<text top="436" left="918" width="31" height="17" font="5">3.93) </text>
<text top="453" left="918" width="3" height="17" font="5"> </text>
<text top="470" left="918" width="221" height="17" font="7"><i>Hypersensitivity syndrome or symptoms </i></text>
<text top="487" left="918" width="193" height="17" font="5">1% vs. 1%, RR=0.94 (95% CI 0.63-</text>
<text top="505" left="918" width="31" height="17" font="5">1.40) </text>
<text top="522" left="918" width="3" height="17" font="5"> </text>
<text top="539" left="918" width="129" height="17" font="7"><i>Hepatobiliary disorders </i></text>
<text top="556" left="918" width="193" height="17" font="5">1% vs. 1%, RR=0.94 (95% CI 0.63-</text>
<text top="573" left="918" width="31" height="17" font="5">1.40) </text>
<text top="591" left="918" width="3" height="17" font="5"> </text>
<text top="608" left="918" width="210" height="17" font="7"><i>Alanine aminotransferase of at least 3 </i></text>
<text top="625" left="918" width="81" height="17" font="7"><i>times the ULN </i></text>
<text top="642" left="918" width="200" height="17" font="5">&lt;1% vs. 1%, RR=0.57 (95% CI 0.31-</text>
<text top="660" left="918" width="31" height="17" font="5">1.03) </text>
<text top="677" left="918" width="3" height="17" font="5"> </text>
<text top="694" left="918" width="210" height="17" font="7"><i>Alanine aminotransferase of at least 5 </i></text>
<text top="711" left="918" width="81" height="17" font="7"><i>times the ULN </i></text>
<text top="728" left="918" width="207" height="17" font="5">&lt;1% vs. &lt;1%, RR=0.35 (95% CI 0.14-</text>
<text top="746" left="918" width="31" height="17" font="5">0.89) </text>
<text top="763" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="184" height="17" font="7"><i>Bilirubin of at least twice the ULN </i></text>
<text top="178" left="918" width="207" height="17" font="5">&lt;1% vs. &lt;1%, RR=1.71 (95% CI 0.68-</text>
<text top="195" left="918" width="31" height="17" font="5">4.35) </text>
<text top="212" left="918" width="3" height="17" font="5"> </text>
<text top="229" left="918" width="171" height="17" font="7"><i>Serious gastrointestinal events </i></text>
<text top="247" left="918" width="193" height="17" font="5">2% vs. 2%, RR=1.06 (95% CI 0.79-</text>
<text top="264" left="918" width="31" height="17" font="5">1.41) </text>
<text top="281" left="918" width="3" height="17" font="5"> </text>
<text top="298" left="918" width="70" height="17" font="7"><i>Appendicitis </i></text>
<text top="315" left="918" width="207" height="17" font="5">&lt;1% vs. &lt;1%, RR=0.37 (95% CI 0.10-</text>
<text top="333" left="918" width="31" height="17" font="5">1.41) </text>
<text top="350" left="918" width="3" height="17" font="5"> </text>
<text top="367" left="918" width="135" height="17" font="7"><i>Atrial fibrillation or flutter </i></text>
<text top="384" left="918" width="193" height="17" font="5">2% vs. 3%, RR=0.82 (95% CI 0.64-</text>
<text top="401" left="918" width="31" height="17" font="5">1.06) </text>
<text top="419" left="918" width="3" height="17" font="5"> </text>
<text top="436" left="918" width="69" height="17" font="7"><i>Pneumonia  </i></text>
<text top="453" left="918" width="193" height="17" font="5">3% vs. 3%, RR=0.95 (95% CI 0.75-</text>
<text top="470" left="918" width="31" height="17" font="5">1.20) </text>
<text top="487" left="918" width="3" height="17" font="5"> </text>
<text top="505" left="918" width="100" height="17" font="7"><i>Renal impairment </i></text>
<text top="522" left="918" width="193" height="17" font="5">6% vs. 7%, RR=0.87 (95% CI 0.75-</text>
<text top="539" left="918" width="31" height="17" font="5">1.02) </text>
<text top="556" left="918" width="3" height="17" font="5"> </text>
<text top="573" left="918" width="112" height="17" font="7"><i>Diabetic retinopathy </i></text>
<text top="591" left="918" width="193" height="17" font="5">2% vs. 2%, RR=0.88 (95% CI 0.65-</text>
<text top="608" left="918" width="31" height="17" font="5">1.18) </text>
<text top="625" left="918" width="3" height="17" font="5"> </text>
<text top="642" left="918" width="3" height="17" font="5"> </text>
<text top="660" left="75" width="81" height="17" font="5">Zelniker et al., </text>
<text top="679" left="75" width="31" height="17" font="5">2018 </text>
<text top="710" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30424892">30424892</a></text>
<text top="710" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30424892"> </a></text>
<text top="660" left="186" width="59" height="17" font="5">Study Aim </text>
<text top="678" left="186" width="135" height="17" font="5">to combine data from all </text>
<text top="695" left="186" width="131" height="17" font="5">the large-scale placebo-</text>
<text top="712" left="186" width="139" height="17" font="5">controlled cardiovascular </text>
<text top="729" left="186" width="139" height="17" font="5">outcome trials of SGLT2i </text>
<text top="746" left="186" width="115" height="17" font="5">to gain more reliable </text>
<text top="764" left="186" width="135" height="17" font="5">estimates of the efficacy </text>
<text top="660" left="346" width="92" height="17" font="5">Inclusion criteria </text>
<text top="691" left="346" width="183" height="17" font="5">-randomized, placebo-controlled, </text>
<text top="708" left="346" width="176" height="17" font="5">cardiovascular outcome trials of </text>
<text top="725" left="346" width="181" height="17" font="5">SGLT2i published up to Sept 24, </text>
<text top="743" left="346" width="31" height="17" font="5">2018 </text>
<text top="760" left="346" width="3" height="17" font="5"> </text>
<text top="660" left="547" width="68" height="17" font="5">Intervention </text>
<text top="678" left="547" width="49" height="17" font="5">SGLT2i  </text>
<text top="695" left="547" width="3" height="17" font="5"> </text>
<text top="712" left="547" width="70" height="17" font="5">Comparison </text>
<text top="729" left="581" width="48" height="17" font="5">Placebo </text>
<text top="661" left="677" width="7" height="17" font="5">1</text>
<text top="660" left="684" width="60" height="18" font="5"> endpoint </text>
<text top="679" left="677" width="103" height="17" font="5">Efficacy endpoints </text>
<text top="696" left="677" width="3" height="17" font="5"> </text>
<text top="713" left="677" width="204" height="17" font="5">Major adverse cardiovascular events </text>
<text top="730" left="677" width="217" height="17" font="5">(the composite of myocardial infarction, </text>
<text top="748" left="677" width="199" height="17" font="5">stroke, or cardiovascular death), the </text>
<text top="765" left="677" width="204" height="17" font="5">composite of cardiovascular death or </text>
<text top="660" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="186" width="118" height="17" font="5">and safety of specific </text>
<text top="178" left="186" width="133" height="17" font="5">outcomes overall and in </text>
<text top="195" left="186" width="111" height="17" font="5">relevant subgroups. </text>
<text top="212" left="186" width="3" height="17" font="5"> </text>
<text top="229" left="186" width="62" height="17" font="5">Study type </text>
<text top="247" left="186" width="126" height="17" font="5">Systematic review and </text>
<text top="264" left="186" width="79" height="17" font="5">meta analysis </text>
<text top="281" left="186" width="3" height="17" font="5"> </text>
<text top="298" left="186" width="101" height="17" font="5">N=3 trials (34,322 </text>
<text top="315" left="186" width="51" height="17" font="5">patients) </text>
<text top="160" left="346" width="3" height="17" font="5"> </text>
<text top="160" left="677" width="198" height="17" font="5">hospitalization for heart failure, their </text>
<text top="178" left="677" width="162" height="17" font="5">individual components, and a </text>
<text top="195" left="677" width="178" height="17" font="5">standardized composite of renal </text>
<text top="212" left="677" width="208" height="17" font="5">outcomes including worsening eGFR, </text>
<text top="229" left="677" width="224" height="17" font="5">end-stage renal disease, or renal death.  </text>
<text top="247" left="677" width="3" height="17" font="5"> </text>
<text top="264" left="677" width="98" height="17" font="5">Safety endpoints  </text>
<text top="281" left="677" width="211" height="17" font="5">non-traumatic lower limb amputations, </text>
<text top="298" left="677" width="199" height="17" font="5">fractures, and diabetic ketoacidosis. </text>
<text top="315" left="677" width="3" height="17" font="5"> </text>
<text top="333" left="677" width="44" height="17" font="5">Results </text>
<text top="350" left="677" width="3" height="17" font="5"> </text>
<text top="367" left="677" width="204" height="17" font="7"><i>Major adverse cardiovascular events </i></text>
<text top="384" left="677" width="60" height="17" font="7"><i>composite </i></text>
<text top="401" left="677" width="3" height="17" font="5"> </text>
<text top="419" left="677" width="156" height="17" font="5">Patients with atherosclerotic </text>
<text top="436" left="677" width="216" height="17" font="5">cardiovascular disease: HR=0.86 (95% </text>
<text top="453" left="677" width="134" height="17" font="5">CI 0.80-0.93), p=0.0002 </text>
<text top="470" left="677" width="3" height="17" font="5"> </text>
<text top="487" left="677" width="185" height="17" font="5">Patients with multiple risk factors: </text>
<text top="505" left="677" width="204" height="17" font="5">HR=1.00 (95% CI 0.87-1.16), p=0.98 </text>
<text top="522" left="677" width="3" height="17" font="5"> </text>
<text top="539" left="677" width="209" height="17" font="5">Patients with eGFR &lt;60 mL/min per m</text>
<text top="540" left="886" width="4" height="11" font="8">2</text>
<text top="539" left="890" width="3" height="17" font="5"> </text>
<text top="556" left="677" width="218" height="17" font="5">HR=0.82 (95% CI 0.70-0.95), p=0.0077 </text>
<text top="573" left="677" width="3" height="17" font="5"> </text>
<text top="591" left="677" width="208" height="17" font="5">Patients with eGFR 60 to &lt;90 mL/min </text>
<text top="608" left="677" width="31" height="17" font="5">per m</text>
<text top="609" left="709" width="4" height="11" font="8">2</text>
<text top="608" left="713" width="3" height="17" font="5"> </text>
<text top="625" left="677" width="218" height="17" font="5">HR=0.91 (95% CI 0.82-1.00), p=0.0520 </text>
<text top="642" left="677" width="3" height="17" font="5"> </text>
<text top="660" left="677" width="210" height="17" font="5">Patients with eGFR ≥90 mL/min per m</text>
<text top="661" left="887" width="7" height="11" font="8">2 </text>
<text top="677" left="677" width="204" height="17" font="5">HR=0.94 (95% CI 0.82-1.07), p=0.35 </text>
<text top="694" left="677" width="3" height="17" font="5"> </text>
<text top="711" left="677" width="3" height="17" font="5"> </text>
<text top="728" left="677" width="193" height="17" font="7"><i>Hospitalization for heart failure and </i></text>
<text top="746" left="677" width="117" height="17" font="7"><i>cardiovascular death </i></text>
<text top="763" left="677" width="3" height="17" font="5"> </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="156" height="17" font="5">Patients with atherosclerotic </text>
<text top="178" left="677" width="216" height="17" font="5">cardiovascular disease: HR=0.76 (95% </text>
<text top="195" left="677" width="130" height="17" font="5">CI0.69-0.84), p&lt;0.0001 </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="185" height="17" font="5">Patients with multiple risk factors: </text>
<text top="247" left="677" width="218" height="17" font="5">HR=0.84 (95% CI 0.69-1.01), p=0.0634 </text>
<text top="264" left="677" width="3" height="17" font="5"> </text>
<text top="281" left="677" width="198" height="17" font="5">Patients with history of heart failure: </text>
<text top="298" left="677" width="218" height="17" font="5">HR=0.71 (95% CI 0.61-0.84), p&lt;0.0001 </text>
<text top="315" left="677" width="3" height="17" font="5"> </text>
<text top="333" left="677" width="215" height="17" font="5">Patients with no history of heart failure: </text>
<text top="350" left="677" width="218" height="17" font="5">HR=0.79 (95% CI 0.71-0.88), p&lt;0.0001 </text>
<text top="367" left="677" width="3" height="17" font="5"> </text>
<text top="384" left="677" width="209" height="17" font="5">Patients with eGFR &lt;60 mL/min per m</text>
<text top="385" left="886" width="4" height="11" font="8">2</text>
<text top="384" left="890" width="3" height="17" font="5"> </text>
<text top="401" left="677" width="218" height="17" font="5">HR=0.60 (95% CI 0.47-0.77), p&lt;0.0001 </text>
<text top="419" left="677" width="3" height="17" font="5"> </text>
<text top="436" left="677" width="208" height="17" font="5">Patients with eGFR 60 to &lt;90 mL/min </text>
<text top="453" left="677" width="31" height="17" font="5">per m</text>
<text top="454" left="709" width="4" height="11" font="8">2</text>
<text top="453" left="713" width="3" height="17" font="5"> </text>
<text top="470" left="677" width="218" height="17" font="5">HR=0.69 (95% CI 0.57-0.83), p&lt;0.0001 </text>
<text top="487" left="677" width="3" height="17" font="5"> </text>
<text top="505" left="677" width="210" height="17" font="5">Patients with eGFR ≥90 mL/min per m</text>
<text top="506" left="887" width="7" height="11" font="8">2 </text>
<text top="522" left="677" width="204" height="17" font="5">HR=0.88 (95% CI 0.68-1.13), p=0.31 </text>
<text top="539" left="677" width="3" height="17" font="5"> </text>
<text top="556" left="677" width="227" height="17" font="7"><i>Composite of renal worsening, end stage </i></text>
<text top="573" left="677" width="159" height="17" font="7"><i>renal disease, or renal death </i></text>
<text top="591" left="677" width="3" height="17" font="5"> </text>
<text top="608" left="677" width="156" height="17" font="5">Patients with atherosclerotic </text>
<text top="625" left="677" width="129" height="17" font="5">cardiovascular disease </text>
<text top="642" left="677" width="218" height="17" font="5">HR=0.56 (95% CI 0.47-0.67), p&lt;0.0001 </text>
<text top="660" left="677" width="3" height="17" font="5"> </text>
<text top="677" left="677" width="182" height="17" font="5">Patients with multiple risk factors </text>
<text top="694" left="677" width="218" height="17" font="5">HR=0.54 (95% CI 0.42-0.71), p&lt;0.0001 </text>
<text top="711" left="677" width="3" height="17" font="5"> </text>
<text top="728" left="677" width="209" height="17" font="5">Patients with eGFR &lt;60 mL/min per m</text>
<text top="730" left="886" width="4" height="11" font="8">2</text>
<text top="728" left="890" width="3" height="17" font="5"> </text>
<text top="746" left="677" width="218" height="17" font="5">HR=0.67 (95% CI 0.51-0.89), p=0.0054 </text>
<text top="763" left="677" width="3" height="17" font="5"> </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="208" height="17" font="5">Patients with eGFR 60 to &lt;90 mL/min </text>
<text top="178" left="677" width="31" height="17" font="5">per m</text>
<text top="179" left="709" width="4" height="11" font="8">2</text>
<text top="178" left="713" width="3" height="17" font="5"> </text>
<text top="195" left="677" width="218" height="17" font="5">HR=0.56 (95% CI 0.46-0.70), p&lt;0.0001 </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="210" height="17" font="5">Patients with eGFR ≥90 mL/min per m</text>
<text top="230" left="887" width="7" height="11" font="8">2 </text>
<text top="247" left="677" width="218" height="17" font="5">HR=0.44 (95% CI 0.32-0.59), p&lt;0.0001 </text>
<text top="264" left="677" width="3" height="17" font="5"> </text>
<text top="282" left="75" width="69" height="17" font="5">EMPA-REG </text>
<text top="311" left="75" width="78" height="17" font="5">Zinman et al., </text>
<text top="330" left="75" width="31" height="17" font="5">2015 </text>
<text top="360" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26378978">26378978</a></text>
<text top="360" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26378978"> </a></text>
<text top="282" left="186" width="59" height="17" font="5">Study Aim </text>
<text top="299" left="186" width="141" height="17" font="5">To examine the effects of </text>
<text top="316" left="186" width="95" height="17" font="5">empagliflozin, as </text>
<text top="333" left="186" width="133" height="17" font="5">compared with placebo, </text>
<text top="350" left="186" width="100" height="17" font="5">on cardiovascular </text>
<text top="368" left="186" width="140" height="17" font="5">morbidity and mortality in </text>
<text top="385" left="186" width="108" height="17" font="5">patients with type 2 </text>
<text top="402" left="186" width="130" height="17" font="5">diabetes at high risk for </text>
<text top="419" left="186" width="122" height="17" font="5">cardiovascular events </text>
<text top="437" left="186" width="108" height="17" font="5">who were receiving </text>
<text top="454" left="186" width="79" height="17" font="5">standard care </text>
<text top="471" left="186" width="3" height="17" font="5"> </text>
<text top="488" left="186" width="66" height="17" font="5">Study Type </text>
<text top="505" left="186" width="29" height="17" font="5">RCT </text>
<text top="523" left="186" width="47" height="17" font="5">N=7020 </text>
<text top="282" left="346" width="92" height="17" font="5">Inclusion criteria </text>
<text top="312" left="346" width="153" height="17" font="5">type 2 diabetes were adults </text>
<text top="329" left="346" width="171" height="17" font="5">(≥18 years of age) with a body-</text>
<text top="347" left="346" width="177" height="17" font="5">mass index of 45 or less and an </text>
<text top="364" left="346" width="57" height="17" font="5">estimated </text>
<text top="381" left="346" width="177" height="17" font="5">glomerular filtration rate (eGFR) </text>
<text top="398" left="346" width="90" height="17" font="5">of at least 30 ml </text>
<text top="416" left="346" width="175" height="17" font="5">per minute per 1.73 m2 of body-</text>
<text top="433" left="346" width="132" height="17" font="5">surface area, according </text>
<text top="450" left="346" width="155" height="17" font="5">to the Modification of Diet in </text>
<text top="467" left="346" width="36" height="17" font="5">Renal </text>
<text top="484" left="346" width="175" height="17" font="5">Disease criteria. All the patients </text>
<text top="502" left="346" width="90" height="17" font="5">had established </text>
<text top="519" left="346" width="149" height="17" font="5">cardiovascular disease (as </text>
<text top="536" left="346" width="114" height="17" font="5">defined in Section C </text>
<text top="553" left="346" width="178" height="17" font="5">in the Supplementary Appendix) </text>
<text top="570" left="346" width="98" height="17" font="5">and had received </text>
<text top="588" left="346" width="185" height="17" font="5">no glucose-lowering agents for at </text>
<text top="605" left="346" width="85" height="17" font="5">least 12 weeks </text>
<text top="622" left="346" width="177" height="17" font="5">before randomization and had a </text>
<text top="639" left="346" width="116" height="17" font="5">glycated hemoglobin </text>
<text top="656" left="346" width="158" height="17" font="5">level of at least 7.0% and no </text>
<text top="674" left="346" width="59" height="17" font="5">more than </text>
<text top="691" left="346" width="156" height="17" font="5">9.0% or had received stable </text>
<text top="708" left="346" width="96" height="17" font="5">glucose-lowering </text>
<text top="725" left="346" width="160" height="17" font="5">therapy for at least 12 weeks </text>
<text top="743" left="346" width="119" height="17" font="5">before randomization </text>
<text top="282" left="547" width="68" height="17" font="5">Intervention </text>
<text top="299" left="547" width="97" height="17" font="5">Empagliflozin (10 </text>
<text top="316" left="547" width="76" height="17" font="5">mg or 25 mg) </text>
<text top="333" left="547" width="3" height="17" font="5"> </text>
<text top="350" left="547" width="70" height="17" font="5">Comparison </text>
<text top="368" left="581" width="48" height="17" font="5">Placebo </text>
<text top="283" left="677" width="7" height="17" font="5">1</text>
<text top="282" left="684" width="60" height="18" font="5"> endpoint </text>
<text top="300" left="677" width="211" height="17" font="5">Composite (death from cardiovascular </text>
<text top="317" left="677" width="212" height="17" font="5">causes, nonfatal myocardial infarction, </text>
<text top="334" left="677" width="88" height="17" font="5">nonfatal stroke) </text>
<text top="352" left="677" width="3" height="17" font="5"> </text>
<text top="369" left="677" width="44" height="17" font="5">Results </text>
<text top="386" left="677" width="3" height="17" font="5"> </text>
<text top="403" left="677" width="217" height="17" font="5">12.1% placebo vs. 10.5% empagliflozin </text>
<text top="420" left="677" width="224" height="17" font="5">Rate=43.9/1000 patient year placebo vs. </text>
<text top="438" left="677" width="211" height="17" font="5">37.4/1000 patient years empagliflozin  </text>
<text top="455" left="677" width="3" height="17" font="5"> </text>
<text top="472" left="677" width="222" height="17" font="5">HR=0.86 (95% CI 0.74-0.99), p=0.04 for </text>
<text top="489" left="677" width="203" height="17" font="5">superiority, p&lt;0.001 for noninferiority </text>
<text top="507" left="677" width="3" height="17" font="5"> </text>
<text top="524" left="677" width="197" height="17" font="5">p≥0.20 for interaction terms on sex, </text>
<text top="541" left="677" width="185" height="17" font="5">blood pressure control, estimated </text>
<text top="558" left="677" width="214" height="17" font="5">glomerular filtration rate, urine albumin-</text>
<text top="575" left="677" width="210" height="17" font="5">to-creatinine ratio, cardiovascular risk, </text>
<text top="593" left="677" width="154" height="17" font="5">insulin, statins or ezetimibe, </text>
<text top="610" left="677" width="216" height="17" font="5">antihypertensive therapy, ACE inhibitor </text>
<text top="627" left="677" width="187" height="17" font="5">or ARB, beta blocker, and diuretic </text>
<text top="644" left="677" width="199" height="17" font="5">P&lt;0.20 for interaction terms on age, </text>
<text top="661" left="677" width="200" height="17" font="5">race, glycated hemoglobin, and BMI </text>
<text top="283" left="918" width="7" height="17" font="5">2</text>
<text top="282" left="925" width="66" height="18" font="5"> endpoints </text>
<text top="300" left="918" width="214" height="17" font="5">composite of the primary outcome plus </text>
<text top="317" left="918" width="190" height="17" font="5">hospitalization for unstable angina </text>
<text top="334" left="918" width="3" height="17" font="5"> </text>
<text top="352" left="918" width="191" height="17" font="7"><i>Composite (plus hospitalization for </i></text>
<text top="369" left="918" width="94" height="17" font="7"><i>unstable angina) </i></text>
<text top="386" left="918" width="217" height="17" font="5">14.3% placebo vs. 12.8% empagliflozin </text>
<text top="403" left="918" width="211" height="17" font="5">Rate=52.5/1000 patient years placebo </text>
<text top="420" left="918" width="151" height="17" font="5">vs. 46.4/1000 patient years </text>
<text top="438" left="918" width="75" height="17" font="5">empagliflozin </text>
<text top="455" left="918" width="211" height="17" font="5">HR=0.89 (95% CI 0.78-1.01), p&lt;0.001 </text>
<text top="472" left="918" width="179" height="17" font="5">noninferiority, p=0.08 superiority </text>
<text top="489" left="918" width="3" height="17" font="5"> </text>
<text top="507" left="918" width="189" height="17" font="7"><i>Death from cardiovascular causes </i></text>
<text top="524" left="918" width="204" height="17" font="5">5.9% placebo vs. 3.7% empagliflozin </text>
<text top="541" left="918" width="205" height="17" font="5">Rate=20.2/1000 patient year placebo </text>
<text top="558" left="918" width="151" height="17" font="5">vs. 12.4/1000 patient years </text>
<text top="575" left="918" width="79" height="17" font="5">empagliflozin  </text>
<text top="593" left="918" width="211" height="17" font="5">HR=0.62 (95% CI 0.49-0.77), p&lt;0.001 </text>
<text top="610" left="918" width="3" height="17" font="5"> </text>
<text top="627" left="918" width="199" height="17" font="5">p≥0.20 for interaction terms on age, </text>
<text top="644" left="918" width="210" height="17" font="5">sex, race, glycated hemoglobin, blood </text>
<text top="661" left="918" width="187" height="17" font="5">pressure control, urine albumin-to-</text>
<text top="679" left="918" width="196" height="17" font="5">creatinine ratio, cardiovascular risk, </text>
<text top="696" left="918" width="154" height="17" font="5">insulin, statins or ezetimibe, </text>
<text top="713" left="918" width="216" height="17" font="5">antihypertensive therapy, ACE inhibitor </text>
<text top="730" left="918" width="183" height="17" font="5">or ARB, Beta-blocker, or diuretic  </text>
<text top="748" left="918" width="220" height="17" font="5">p&lt;0.20 for interaction terms on BMI and </text>
<text top="765" left="918" width="189" height="17" font="5">estimated glomerular filtration rate </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="346" width="174" height="17" font="5">and had a glycated hemoglobin </text>
<text top="178" left="346" width="56" height="17" font="5">level of at </text>
<text top="195" left="346" width="160" height="17" font="5">least 7.0% and no more than </text>
<text top="212" left="346" width="42" height="17" font="5">10.0%. </text>
<text top="229" left="346" width="3" height="17" font="5"> </text>
<text top="160" left="918" width="3" height="17" font="5"> </text>
<text top="178" left="918" width="127" height="17" font="7"><i>Death from any cause  </i></text>
<text top="195" left="918" width="204" height="17" font="5">8.3% placebo vs. 5.7% empagliflozin </text>
<text top="212" left="918" width="205" height="17" font="5">Rate=28.6/1000 patient year placebo </text>
<text top="229" left="918" width="224" height="17" font="5">vs. 19.4/1000 patient year empagliflozin  </text>
<text top="247" left="918" width="213" height="17" font="5">HR=0.68 (95% CI 0.57-0.82), P&lt;0.001 </text>
<text top="264" left="918" width="3" height="17" font="5"> </text>
<text top="281" left="918" width="170" height="17" font="7"><i>Hospitalization for heart failure </i></text>
<text top="298" left="918" width="207" height="17" font="5">4.1% placebo vs. 2.7% empagliflozin  </text>
<text top="315" left="918" width="208" height="17" font="5">Rate=14.5/1000 placebo vs. 9.4/1000 </text>
<text top="333" left="918" width="152" height="17" font="5">patient years empagliflozin  </text>
<text top="350" left="918" width="211" height="17" font="5">HR=0.65 (95% CI 0.50-0.85), p=0.002 </text>
<text top="367" left="918" width="3" height="17" font="5"> </text>
<text top="384" left="918" width="208" height="17" font="5">Fatal or nonfatal myocardial infarction </text>
<text top="401" left="918" width="204" height="17" font="5">excluding silent myocardial infarction </text>
<text top="419" left="918" width="204" height="17" font="5">HR=0.87 (95% CI 0.70-1.09), p=0.23 </text>
<text top="436" left="918" width="3" height="17" font="5"> </text>
<text top="453" left="918" width="221" height="17" font="5">Nonfatal myocardial infarction excluding </text>
<text top="470" left="918" width="148" height="17" font="5">silent myocardial infarction </text>
<text top="487" left="918" width="204" height="17" font="5">HR=0.87 (95% CI 0.70-1.09), p=0.22 </text>
<text top="505" left="918" width="3" height="17" font="5"> </text>
<text top="522" left="918" width="150" height="17" font="5">Silent myocardial infarction </text>
<text top="539" left="918" width="204" height="17" font="5">HR=1.28 (95% CI 0.70-2.33), p=0.42 </text>
<text top="556" left="918" width="3" height="17" font="5"> </text>
<text top="573" left="918" width="192" height="17" font="5">Hospitalization for unstable angina </text>
<text top="591" left="918" width="204" height="17" font="5">HR=0.99 (95% CI 0.74-1.34), p=0.97 </text>
<text top="608" left="918" width="3" height="17" font="5"> </text>
<text top="625" left="918" width="209" height="17" font="5">Coronary revascularization procedure </text>
<text top="642" left="918" width="204" height="17" font="5">HR=0.86 (95% CI 0.72-1.04), p=0.11 </text>
<text top="660" left="918" width="3" height="17" font="5"> </text>
<text top="677" left="918" width="129" height="17" font="5">Fatal or nonfatal stroke </text>
<text top="694" left="918" width="204" height="17" font="5">HR=1.18 (95% CI 0.89-1.56), p=0.26 </text>
<text top="711" left="918" width="3" height="17" font="5"> </text>
<text top="728" left="918" width="86" height="17" font="5">Nonfatal stroke </text>
<text top="746" left="918" width="204" height="17" font="5">HR=1.24 (95% CI 0.92-1.67), p=0.16 </text>
<text top="763" left="918" width="3" height="17" font="5"> </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="142" height="17" font="5">Transient ischemic attack </text>
<text top="178" left="918" width="204" height="17" font="5">HR=0.85 (95% CI 0.51-1.42), p=0.54 </text>
<text top="195" left="918" width="3" height="17" font="5"> </text>
<text top="212" left="918" width="170" height="17" font="5">Hospitalization for heart failure </text>
<text top="229" left="918" width="211" height="17" font="5">HR=0.65 (95% CI 0.50-0.85), p=0.002 </text>
<text top="247" left="918" width="3" height="17" font="5"> </text>
<text top="264" left="918" width="218" height="17" font="5">Hospitalization for heart failure or death </text>
<text top="281" left="918" width="208" height="17" font="5">from cardiovascular causes excluding </text>
<text top="298" left="918" width="64" height="17" font="5">fatal stroke </text>
<text top="315" left="918" width="211" height="17" font="5">HR=0.66 (95% CI 0.55-0.79), p&lt;0.001 </text>
<text top="333" left="918" width="3" height="17" font="5"> </text>
<text top="350" left="918" width="159" height="17" font="5">Adverse Events (placebo vs. </text>
<text top="367" left="918" width="207" height="17" font="5">empagliflozin 10 mg vs. empagliflozin </text>
<text top="384" left="918" width="42" height="17" font="5">25 mg) </text>
<text top="401" left="918" width="3" height="17" font="5"> </text>
<text top="419" left="918" width="192" height="17" font="5">Any adverse event: 91.7%, 90.1%, </text>
<text top="436" left="918" width="38" height="17" font="5">90.4% </text>
<text top="453" left="918" width="210" height="17" font="5">Severe adverse event: 25.4%, 22.9%, </text>
<text top="470" left="918" width="38" height="17" font="5">24.1% </text>
<text top="487" left="918" width="202" height="17" font="5">Serious adverse event (any): 42.3%, </text>
<text top="505" left="918" width="80" height="17" font="5">37.4%, 39.0% </text>
<text top="522" left="918" width="206" height="17" font="5">Serious adverse event (death): 5.1%, </text>
<text top="539" left="918" width="66" height="17" font="5">4.1%, 3.4% </text>
<text top="556" left="918" width="138" height="17" font="5">Adverse event leading to </text>
<text top="573" left="918" width="212" height="17" font="5">discontinuation of a study drug: 19.4% </text>
<text top="591" left="918" width="115" height="17" font="5">vs. 17.7% vs. 17.0% </text>
<text top="608" left="918" width="219" height="17" font="5">Confirmed hypoglycemic adverse event </text>
<text top="625" left="918" width="188" height="17" font="5">(any): 27.9% vs. 28.0% vs. 27.6% </text>
<text top="642" left="918" width="219" height="17" font="5">Confirmed hypoglycemic adverse event </text>
<text top="660" left="918" width="206" height="17" font="5">(requiring assistance): 1.5% vs. 1.4% </text>
<text top="677" left="918" width="51" height="17" font="5">vs. 1.3% </text>
<text top="694" left="918" width="187" height="17" font="5">Event consistent with urinary tract </text>
<text top="711" left="918" width="199" height="17" font="5">infection (male): 9.4% vs. 10.9% vs. </text>
<text top="728" left="918" width="38" height="17" font="5">10.1% </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="918" width="187" height="17" font="5">Event consistent with urinary tract </text>
<text top="178" left="918" width="216" height="17" font="5">infection (female): 40.6% vs. 35.5% vs. </text>
<text top="195" left="918" width="38" height="17" font="5">37.3% </text>
<text top="212" left="918" width="189" height="17" font="5">Complicated urinary tract infection </text>
<text top="229" left="918" width="137" height="17" font="5">(1.8% vs. 1.4% vs. 2.0% </text>
<text top="247" left="918" width="208" height="17" font="5">Event consistent with genital infection </text>
<text top="264" left="918" width="221" height="17" font="5">(male patients): 1.5% vs. 5.4% vs. 4.6% </text>
<text top="281" left="918" width="208" height="17" font="5">Event consistent with genital infection </text>
<text top="298" left="918" width="199" height="17" font="5">(female patients): 2.6% vs. 9.2% vs. </text>
<text top="315" left="918" width="38" height="17" font="5">10.8% </text>
<text top="333" left="918" width="219" height="17" font="5">Event consistent with volume depletion: </text>
<text top="350" left="918" width="133" height="17" font="5">4.9% vs. 4.9% vs. 5.3% </text>
<text top="367" left="918" width="207" height="17" font="5">Acute renal failure: 6.6% vs. 5.2% vs. </text>
<text top="384" left="918" width="31" height="17" font="5">5.3% </text>
<text top="401" left="918" width="211" height="17" font="5">Acute kidney injury: 1.6% vs. 1.1% vs. </text>
<text top="419" left="918" width="31" height="17" font="5">0.8% </text>
<text top="436" left="918" width="211" height="17" font="5">Diabetic ketoacidosis: &lt;0.1% vs. 0.1% </text>
<text top="453" left="918" width="58" height="17" font="5">vs. &lt;0.1% </text>
<text top="470" left="918" width="214" height="17" font="5">Thromboembolic event: 0.9% vs. 0.4% </text>
<text top="487" left="918" width="51" height="17" font="5">vs. 0.9% </text>
<text top="505" left="918" width="213" height="17" font="5">Bone fracture: 3.9% vs. 3.9% vs. 3.7% </text>
<text top="523" left="66" width="3" height="17" font="5"> </text>
<text top="553" left="66" width="478" height="21" font="4"><b>Data Supplement 11. RCTs of High Blood Cholesterol (Section 4.3.)  </b></text>
<text top="592" left="82" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="609" left="108" width="48" height="17" font="3"><b>Author; </b></text>
<text top="627" left="86" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="592" left="229" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="609" left="234" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="627" left="228" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="609" left="376" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="584" left="542" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="601" left="560" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="618" left="542" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="635" left="563" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="592" left="736" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="609" left="720" width="137" height="17" font="3"><b>(Absolute Event Rates, </b></text>
<text top="627" left="698" width="181" height="17" font="3"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="593" left="917" width="61" height="17" font="3"><b>Relevant 2</b></text>
<text top="592" left="978" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="610" left="949" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="627" left="956" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="653" left="75" width="94" height="17" font="5">Baigent C, et al., </text>
<text top="670" left="75" width="56" height="17" font="5">2010 (19) </text>
<text top="688" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804">21067804</a></text>
<text top="688" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804"> </a></text>
<text top="653" left="202" width="132" height="17" font="5">Aim: To evaluate safety </text>
<text top="670" left="202" width="114" height="17" font="5">and efficacy of more </text>
<text top="688" left="202" width="115" height="17" font="5">intensive lowering of </text>
<text top="705" left="202" width="89" height="17" font="5">LDL cholesterol </text>
<text top="722" left="202" width="3" height="17" font="5"> </text>
<text top="739" left="202" width="120" height="17" font="5">Study type: Individual </text>
<text top="757" left="202" width="101" height="17" font="5">patient-level meta-</text>
<text top="774" left="202" width="78" height="17" font="5">analysis of 26 </text>
<text top="653" left="353" width="154" height="17" font="5">Inclusion criteria: All eligible </text>
<text top="670" left="353" width="155" height="17" font="5">statin trials published by the </text>
<text top="688" left="353" width="102" height="17" font="5">end of 2009, main </text>
<text top="705" left="353" width="152" height="17" font="5">intervention to lower LDL-C </text>
<text top="722" left="353" width="156" height="17" font="5">using statin therapy, at least </text>
<text top="739" left="353" width="148" height="17" font="5">1000 participants recruited </text>
<text top="757" left="353" width="102" height="17" font="5">with at least 2 y of </text>
<text top="774" left="353" width="111" height="17" font="5">scheduled duration. </text>
<text top="653" left="524" width="143" height="17" font="5">Intervention/Comparator:  </text>
<text top="670" left="524" width="3" height="17" font="5"> </text>
<text top="688" left="524" width="115" height="17" font="5">1. Statin (n= 64744)/ </text>
<text top="705" left="524" width="130" height="17" font="5">placebo (n= 64782) [21 </text>
<text top="722" left="524" width="33" height="17" font="5">trials] </text>
<text top="739" left="524" width="3" height="17" font="5"> </text>
<text top="757" left="524" width="138" height="17" font="5">2. More (high) [n=19829] </text>
<text top="774" left="524" width="104" height="17" font="5">/less intense statin </text>
<text top="653" left="683" width="68" height="17" font="5">Endpoints:   </text>
<text top="670" left="683" width="3" height="17" font="5"> </text>
<text top="688" left="683" width="133" height="17" font="5">Statin (S) / Placebo (P): </text>
<text top="705" left="683" width="3" height="17" font="5"> </text>
<text top="722" left="683" width="195" height="17" font="5">Average LDL-C difference between </text>
<text top="739" left="683" width="190" height="17" font="5">statin and placebo = 1.07 mmol/L* </text>
<text top="757" left="683" width="3" height="17" font="5"> </text>
<text top="653" left="906" width="172" height="18" font="5">• No heterogeneity of effect for </text>
<text top="672" left="906" width="164" height="17" font="5">major vascular events among </text>
<text top="689" left="906" width="158" height="17" font="5">those with previous vascular </text>
<text top="706" left="906" width="185" height="17" font="5">disease versus those without any </text>
<text top="723" left="906" width="177" height="17" font="5">previous vascular disease (p for </text>
<text top="741" left="906" width="117" height="17" font="5">heterogeneity = 0.3)  </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="202" width="111" height="17" font="5">randomized trials of </text>
<text top="108" left="202" width="77" height="17" font="5">statin therapy </text>
<text top="125" left="202" width="3" height="17" font="5"> </text>
<text top="142" left="202" width="75" height="17" font="5">Size: 170000 </text>
<text top="160" left="202" width="111" height="17" font="5">participants from 26 </text>
<text top="177" left="202" width="111" height="17" font="5">randomized trials of </text>
<text top="194" left="202" width="77" height="17" font="5">statin therapy </text>
<text top="91" left="353" width="3" height="17" font="5"> </text>
<text top="108" left="353" width="133" height="17" font="5">Exclusion criteria: Trials </text>
<text top="125" left="353" width="125" height="17" font="5">where other risk factor </text>
<text top="142" left="353" width="152" height="17" font="5">modification (except LDL-C </text>
<text top="160" left="353" width="146" height="17" font="5">reduction via statins) were </text>
<text top="177" left="353" width="60" height="17" font="5">excluded.  </text>
<text top="194" left="353" width="3" height="17" font="5"> </text>
<text top="211" left="353" width="3" height="17" font="5"> </text>
<text top="229" left="353" width="154" height="17" font="5">-5 trials of more versus less </text>
<text top="246" left="353" width="120" height="17" font="5">intense statin therapy </text>
<text top="263" left="353" width="156" height="17" font="5">included 100% patients with </text>
<text top="280" left="353" width="33" height="17" font="5">CHD. </text>
<text top="297" left="353" width="149" height="17" font="5">-Proportion of patients with </text>
<text top="315" left="353" width="138" height="17" font="5">CHD in the remaining 21 </text>
<text top="332" left="353" width="122" height="17" font="5">trials varied from &lt;1% </text>
<text top="349" left="353" width="117" height="17" font="5">(AFCAPS/TexCAPS, </text>
<text top="366" left="353" width="124" height="17" font="5">ASCOT LLA, CARDS, </text>
<text top="383" left="353" width="150" height="17" font="5">MEGA, JUPITER) to 100% </text>
<text top="401" left="353" width="155" height="17" font="5">(SSSS, CARE, Post-CABG, </text>
<text top="418" left="353" width="123" height="17" font="5">LIPID, GISSI-P, LIPS, </text>
<text top="435" left="353" width="70" height="17" font="5">ALLIANCE). </text>
<text top="452" left="353" width="158" height="17" font="5">-Overall, 52% of the patients </text>
<text top="469" left="353" width="82" height="17" font="5">had prior CHD </text>
<text top="487" left="353" width="137" height="17" font="5">-15% had other vascular </text>
<text top="504" left="353" width="103" height="17" font="5">disease (history of </text>
<text top="521" left="353" width="109" height="17" font="5">intracerebral bleed, </text>
<text top="538" left="353" width="141" height="17" font="5">transient ischemic attack, </text>
<text top="556" left="353" width="144" height="17" font="5">ischemic stroke, unknown </text>
<text top="573" left="353" width="133" height="17" font="5">stroke, peripheral artery </text>
<text top="590" left="353" width="136" height="17" font="5">disease, or heart failure) </text>
<text top="607" left="353" width="151" height="17" font="5">-41% with no prior vascular </text>
<text top="624" left="353" width="145" height="17" font="5">disease (no known history </text>
<text top="642" left="353" width="138" height="17" font="5">of CHD or other vascular </text>
<text top="659" left="353" width="60" height="17" font="5">disease).   </text>
<text top="676" left="353" width="3" height="17" font="5"> </text>
<text top="91" left="524" width="118" height="17" font="5">therapy (n=19783) [5 </text>
<text top="108" left="524" width="33" height="17" font="5">trials] </text>
<text top="125" left="524" width="7" height="17" font="5">  </text>
<text top="142" left="524" width="131" height="17" font="5">Definition of Outcomes: </text>
<text top="160" left="524" width="3" height="17" font="5"> </text>
<text top="177" left="524" width="136" height="17" font="5">1. Major vascular events </text>
<text top="194" left="524" width="128" height="17" font="5">(first occurrence of any </text>
<text top="211" left="524" width="122" height="17" font="5">major coronary event, </text>
<text top="229" left="524" width="51" height="17" font="5">coronary </text>
<text top="246" left="524" width="113" height="17" font="5">revascularization, or </text>
<text top="263" left="524" width="41" height="17" font="5">stroke) </text>
<text top="280" left="524" width="133" height="17" font="5">2. Major coronary event </text>
<text top="297" left="524" width="129" height="17" font="5">(coronary death or non-</text>
<text top="315" left="524" width="48" height="17" font="5">fatal MI) </text>
<text top="332" left="524" width="68" height="17" font="5">3. Coronary </text>
<text top="349" left="524" width="96" height="17" font="5">revascularization </text>
<text top="366" left="524" width="126" height="17" font="5">(angioplasty or bypass </text>
<text top="383" left="524" width="49" height="17" font="5">grafting) </text>
<text top="401" left="524" width="138" height="17" font="5">4. Stroke (any, ischemic, </text>
<text top="418" left="524" width="132" height="17" font="5">hemorrhagic, unknown) </text>
<text top="435" left="524" width="109" height="17" font="5">5. First cancer after </text>
<text top="452" left="524" width="81" height="17" font="5">randomization </text>
<text top="469" left="524" width="111" height="17" font="5">6. Mortality (overall, </text>
<text top="487" left="524" width="130" height="17" font="5">vascular, non-vascular, </text>
<text top="504" left="524" width="135" height="17" font="5">unknown) [described for </text>
<text top="521" left="524" width="122" height="17" font="5">all 26 trials combined] </text>
<text top="538" left="524" width="144" height="17" font="5">- Median follow-up = 4.8 y </text>
<text top="556" left="524" width="122" height="17" font="5">in statin/placebo trials </text>
<text top="573" left="524" width="143" height="17" font="5">-Median follow-up 5.1 y in </text>
<text top="590" left="524" width="129" height="17" font="5">more versus less statin </text>
<text top="607" left="524" width="36" height="17" font="5">trials.  </text>
<text top="91" left="683" width="190" height="17" font="5">1. Major vascular events: S= 2.8% </text>
<text top="108" left="683" width="181" height="17" font="5">per annum, P = 3.6% per annum </text>
<text top="125" left="683" width="170" height="17" font="5">(RR: 0.78; 95% CI: 0.76-0.81). </text>
<text top="142" left="683" width="207" height="17" font="5">2. Major coronary event: S= 1.3% per </text>
<text top="160" left="683" width="189" height="17" font="5">annum, P = 1.7% per annum (RR: </text>
<text top="177" left="683" width="141" height="17" font="5">0.73; 95% CI: 0.70-0.77). </text>
<text top="194" left="683" width="189" height="17" font="5">3. Coronary revascularization: S = </text>
<text top="211" left="683" width="172" height="17" font="5">1.2% per annum, P = 1.6% per </text>
<text top="229" left="683" width="207" height="17" font="5">annum (RR: 0.75; 95% CI: 0.72-0.79) </text>
<text top="246" left="683" width="198" height="17" font="5">4. Stroke: S = 0.7% per annum, P = </text>
<text top="263" left="683" width="197" height="17" font="5">per annum (RR: 0.85; 95% CI: 0.80-</text>
<text top="280" left="683" width="35" height="17" font="5">0.91). </text>
<text top="297" left="683" width="3" height="17" font="5"> </text>
<text top="315" left="683" width="189" height="17" font="5">More statin (MS) / less statin (LS): </text>
<text top="332" left="683" width="195" height="17" font="5">Average LDL-C difference between </text>
<text top="349" left="683" width="146" height="17" font="5">MS and LS = 0.51 mmol/L </text>
<text top="366" left="683" width="3" height="17" font="5"> </text>
<text top="383" left="683" width="204" height="17" font="5">1. Major vascular events; MS = 4.5% </text>
<text top="401" left="683" width="188" height="17" font="5">per annum, LS = 5.3% per annum </text>
<text top="418" left="683" width="170" height="17" font="5">(RR: 0.85; 95% CI: 0.82-0.89). </text>
<text top="435" left="683" width="206" height="17" font="5">2. Major coronary events: MS = 1.9% </text>
<text top="452" left="683" width="188" height="17" font="5">per annum, LS = 2.2% per annum </text>
<text top="469" left="683" width="170" height="17" font="5">(RR: 0.87; 95% CI: 0.81-0.93). </text>
<text top="487" left="683" width="188" height="17" font="5">3. Coronary revascularization; MS </text>
<text top="504" left="683" width="209" height="17" font="5">2.6% per annum, LS 3.2% per annum </text>
<text top="521" left="683" width="166" height="17" font="5">(RR: 0.81; 95% CI: 0.76-0.85) </text>
<text top="538" left="683" width="193" height="17" font="5">4. Stroke; MS 0.6% per annum, LS </text>
<text top="556" left="683" width="200" height="17" font="5">0.7% per annum (RR: 0.86; 95% CI: </text>
<text top="573" left="683" width="63" height="17" font="5">0.77-0.96). </text>
<text top="590" left="683" width="3" height="17" font="5"> </text>
<text top="607" left="683" width="204" height="17" font="5">For all 26 trials combined (Described </text>
<text top="624" left="683" width="178" height="17" font="5">per mmol/L reduction in LDL-C): </text>
<text top="642" left="683" width="3" height="17" font="5"> </text>
<text top="659" left="683" width="171" height="17" font="5">-Mortality: Statin/MS (2.1% per </text>
<text top="676" left="683" width="171" height="17" font="5">annum) versus P/LS (2.3% per </text>
<text top="693" left="683" width="180" height="17" font="5">annum)- RR: 0.90; 95% CI: 0.87-</text>
<text top="710" left="683" width="31" height="17" font="5">0.93. </text>
<text top="728" left="683" width="201" height="17" font="5">-Vascular mortality: Statin/MS (1.2% </text>
<text top="745" left="683" width="193" height="17" font="5">per annum) versus P/LS (1.3% per </text>
<text top="91" left="906" width="177" height="17" font="5">-History of prior CHD: Statin/MS </text>
<text top="108" left="906" width="171" height="17" font="5">(4.5% per annum) versus P/LS </text>
<text top="125" left="906" width="192" height="17" font="5">(5.6% per annum) - RR: 0.79; 95% </text>
<text top="142" left="906" width="78" height="17" font="5">CI: 0.76-0.82. </text>
<text top="160" left="906" width="167" height="17" font="5">- History of non-CHD vascular </text>
<text top="177" left="906" width="162" height="17" font="5">disease: Statin/MS (3.1% per </text>
<text top="194" left="906" width="171" height="17" font="5">annum) versus P/LS (3.7% per </text>
<text top="211" left="906" width="180" height="17" font="5">annum)- RR: 0.81; 95% CI: 0.71-</text>
<text top="229" left="906" width="31" height="17" font="5">0.92. </text>
<text top="246" left="906" width="154" height="17" font="5">-No history of prior vascular </text>
<text top="263" left="906" width="162" height="17" font="5">disease: Statin/MS (1.4% per </text>
<text top="280" left="906" width="171" height="17" font="5">annum) versus P/LS (1.8% per </text>
<text top="297" left="906" width="180" height="17" font="5">annum)- RR: 0.75; 95% CI: 0.69-</text>
<text top="315" left="906" width="31" height="17" font="5">0.82. </text>
<text top="332" left="906" width="185" height="18" font="5">• No significant reduction in CHD </text>
<text top="350" left="906" width="189" height="17" font="5">death when comparing MS versus </text>
<text top="367" left="906" width="188" height="17" font="5">LS (RR: 0.93; 95% CI: 0.81-1.07). </text>
<text top="385" left="906" width="196" height="17" font="5">Significant reduction in non-fatal MI </text>
<text top="402" left="906" width="173" height="17" font="5">(RR: 0.85; 95% CI: 0.76- 0.94), </text>
<text top="419" left="906" width="175" height="17" font="5">coronary revascularization (RR: </text>
<text top="436" left="906" width="192" height="17" font="5">0.81; 95% CI: 0.76-0.85), ischemic </text>
<text top="453" left="906" width="172" height="17" font="5">stroke (RR: 0.84; 95% CI: 0.74-</text>
<text top="471" left="906" width="186" height="17" font="5">0.99) when comparing MS versus </text>
<text top="488" left="906" width="22" height="17" font="5">LS. </text>
<text top="505" left="906" width="185" height="18" font="5">• Although major vascular events </text>
<text top="523" left="906" width="172" height="17" font="5">reduced non-significantly when </text>
<text top="541" left="906" width="193" height="17" font="5">comparing patients with CHD aged </text>
<text top="558" left="906" width="195" height="17" font="5">&gt;75 y receiving MS versus LS (RR: </text>
<text top="575" left="906" width="141" height="17" font="5">0.78, 99% CI: 0.52-1.18); </text>
<text top="592" left="906" width="149" height="17" font="5">heterogeneity; p=0.8 when </text>
<text top="609" left="906" width="180" height="17" font="5">comparing MS versus LS across </text>
<text top="627" left="906" width="186" height="17" font="5">groups of CHD patients aged &lt;65 </text>
<text top="644" left="906" width="163" height="17" font="5">y, &gt;65 y to &lt;75 y, and &gt;75 y.  </text>
<text top="661" left="906" width="183" height="18" font="5">• For major vascular events, RR: </text>
<text top="679" left="906" width="192" height="17" font="5">0.71 (99% CI: 0.63-0.80) for males </text>
<text top="697" left="906" width="183" height="17" font="5">and RR 0.75 (99% CI: 0.58-0.97) </text>
<text top="714" left="906" width="179" height="17" font="5">for females when comparing MS </text>
<text top="731" left="906" width="185" height="17" font="5">versus LS among males/ females </text>
<text top="748" left="906" width="149" height="17" font="5">(p for heterogeneity = 0.6). </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="180" height="17" font="5">annum)- RR: 0.86; 95% CI: 0.82-</text>
<text top="108" left="683" width="31" height="17" font="5">0.90. </text>
<text top="125" left="683" width="156" height="17" font="5">-Any non-vascular mortality: </text>
<text top="142" left="683" width="198" height="17" font="5">Statin/MS (0.8% per annum) versus </text>
<text top="160" left="683" width="191" height="17" font="5">P/LS (0.8% per annum)- RR: 0.97; </text>
<text top="177" left="683" width="106" height="17" font="5">95% CI: 0.92-1.03. </text>
<text top="194" left="683" width="162" height="17" font="5">-Unknown cause of mortality: </text>
<text top="211" left="683" width="198" height="17" font="5">Statin/MS (0.1% per annum) versus </text>
<text top="229" left="683" width="191" height="17" font="5">P/LS (0.1% per annum)- RR: 0.87; </text>
<text top="246" left="683" width="106" height="17" font="5">95% CI: 0.73-1.03. </text>
<text top="263" left="683" width="3" height="17" font="5"> </text>
<text top="280" left="683" width="204" height="17" font="5">-Although mortality data not provided </text>
<text top="297" left="683" width="168" height="17" font="5">for separately for statin versus </text>
<text top="315" left="683" width="203" height="17" font="5">placebo and more versus less statin, </text>
<text top="332" left="683" width="143" height="17" font="5">the authors state that “the </text>
<text top="349" left="683" width="199" height="17" font="5">proportional reduction in risk per 1.0 </text>
<text top="366" left="683" width="206" height="17" font="5">mmol/L LDL cholesterol reduction did </text>
<text top="383" left="683" width="191" height="17" font="5">not differ between the two types of </text>
<text top="401" left="683" width="204" height="17" font="5">trial comparisons (all heterogeneity p </text>
<text top="418" left="683" width="78" height="17" font="5">values &gt;0.1).  </text>
<text top="435" left="683" width="7" height="17" font="5">  </text>
<text top="452" left="683" width="161" height="17" font="5">Safety endpoint (if relevant):  </text>
<text top="469" left="683" width="3" height="17" font="5"> </text>
<text top="487" left="683" width="192" height="17" font="5">-Cancer: S = 1.4% per annum, P = </text>
<text top="504" left="683" width="200" height="17" font="5">1.4% per annum (RR: 1.00, 95% CI: </text>
<text top="521" left="683" width="66" height="17" font="5">0.95-1.04).  </text>
<text top="538" left="683" width="3" height="17" font="5"> </text>
<text top="556" left="683" width="209" height="17" font="5">-Cancer: MS = 1.6% per annum, LS = </text>
<text top="573" left="683" width="200" height="17" font="5">1.6% per annum (RR: 1.00, 95% CI: </text>
<text top="590" left="683" width="63" height="17" font="5">0.93-1.07). </text>
<text top="607" left="683" width="3" height="17" font="5"> </text>
<text top="624" left="683" width="203" height="17" font="5">- Rhabdomyolysis: Observed excess </text>
<text top="642" left="683" width="117" height="17" font="5">of rhabdomyolysis =  </text>
<text top="659" left="683" width="202" height="17" font="5">  1 (SE 1) per 10,000 in 21 trials of S </text>
<text top="676" left="683" width="145" height="17" font="5">versus P (14 vs. 9 cases)  </text>
<text top="693" left="683" width="206" height="17" font="5">  4 (SE 2) per 10,000 in 5 trials of MS </text>
<text top="710" left="683" width="169" height="17" font="5">versus LS (14 vs. 6 cases) [All </text>
<text top="728" left="683" width="196" height="17" font="5">excess cases occurred in SEARCH </text>
<text top="745" left="683" width="200" height="17" font="5">and A to Z study (simvastatin 80 mg </text>
<text top="762" left="683" width="57" height="17" font="5">po daily)]. </text>
<text top="92" left="906" width="3" height="17" font="5"> </text>
<text top="91" left="910" width="187" height="18" font="5">•RR: 0.85 (99% CI: 0.73-0.99) for </text>
<text top="109" left="906" width="169" height="17" font="5">major vascular events in those </text>
<text top="126" left="906" width="188" height="17" font="5">aged &gt;75 y comparing S versus P </text>
<text top="144" left="906" width="174" height="17" font="5">(p for heterogeneity = 0.4 when </text>
<text top="161" left="906" width="165" height="17" font="5">comparing S versus P among </text>
<text top="178" left="906" width="186" height="17" font="5">those aged &lt;65 y, &gt;65 y to &lt;75 y, </text>
<text top="195" left="906" width="65" height="17" font="5">and &gt;75 y). </text>
<text top="212" left="906" width="7" height="17" font="5">  </text>
<text top="231" left="906" width="3" height="17" font="5"> </text>
<text top="230" left="910" width="183" height="18" font="5">•Among comparison of 5 trials of </text>
<text top="248" left="906" width="164" height="17" font="5">MS versus LS, large absolute </text>
<text top="265" left="906" width="186" height="17" font="5">reduction in LDL cholesterol were </text>
<text top="283" left="906" width="191" height="17" font="5">associated with larger proportional </text>
<text top="300" left="906" width="151" height="17" font="5">risk reduction (p for trend = </text>
<text top="317" left="906" width="185" height="17" font="5">0.0004). After adjustment for LDL </text>
<text top="334" left="906" width="187" height="17" font="5">cholesterol differences, there was </text>
<text top="351" left="906" width="196" height="17" font="5">little residual variation (p for trend = </text>
<text top="369" left="906" width="38" height="17" font="5">0.05).  </text>
<text top="386" left="906" width="3" height="17" font="5"> </text>
<text top="403" left="906" width="66" height="17" font="5">Limitations: </text>
<text top="420" left="906" width="193" height="17" font="5">1. Individual patient-level data on 3 </text>
<text top="437" left="906" width="150" height="17" font="5">trials (CORONA, SPARCL, </text>
<text top="455" left="906" width="156" height="17" font="5">GREACE) not available and </text>
<text top="472" left="906" width="129" height="17" font="5">therefore, not included. </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="3" height="17" font="5"> </text>
<text top="108" left="683" width="124" height="17" font="5">-Hemorrhagic Stroke:  </text>
<text top="125" left="683" width="191" height="17" font="5">S= 0.1% per annum, P = 0.1% per </text>
<text top="142" left="683" width="207" height="17" font="5">annum, RR: 1.15 (99% CI: 0.87-1.51) </text>
<text top="160" left="683" width="190" height="17" font="5">MS = 0.1% per annum, LS = 0.1% </text>
<text top="177" left="683" width="196" height="17" font="5">per annum, RR: 1.21, 99% CI: 0.76-</text>
<text top="194" left="683" width="38" height="17" font="5">1.91).  </text>
<text top="212" left="66" width="3" height="17" font="5"> </text>
<text top="232" left="66" width="4" height="14" font="5"> </text>
<text top="229" left="282" width="3" height="17" font="5"> </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="98" width="35" height="17" font="5">Study </text>
<text top="108" left="87" width="55" height="17" font="5">Acronym; </text>
<text top="125" left="94" width="43" height="17" font="5">Author; </text>
<text top="142" left="100" width="29" height="17" font="5">Year </text>
<text top="160" left="86" width="57" height="17" font="5">Published </text>
<text top="91" left="202" width="76" height="17" font="5">Aim of Study; </text>
<text top="108" left="205" width="69" height="17" font="5">Study Type; </text>
<text top="125" left="198" width="83" height="17" font="5">Study Size (N) </text>
<text top="91" left="354" width="102" height="17" font="5">Patient population </text>
<text top="91" left="506" width="102" height="17" font="5">Study Intervention </text>
<text top="108" left="521" width="72" height="17" font="5">(# patients) / </text>
<text top="125" left="506" width="103" height="17" font="5">Study Comparator </text>
<text top="142" left="525" width="65" height="17" font="5">(# patients) </text>
<text top="91" left="681" width="96" height="17" font="5">Endpoint Results </text>
<text top="108" left="630" width="199" height="17" font="5">(Absolute Event Rates, P value; OR </text>
<text top="125" left="680" width="98" height="17" font="5">or RR; &amp; 95% CI) </text>
<text top="91" left="883" width="165" height="17" font="5">Relevant 2° Endpoint (if any); </text>
<text top="108" left="915" width="100" height="17" font="5">Study Limitations; </text>
<text top="125" left="921" width="90" height="17" font="5">Adverse Events </text>
<text top="178" left="75" width="58" height="17" font="5">Silverman </text>
<text top="195" left="75" width="60" height="17" font="5">MG, et al., </text>
<text top="212" left="75" width="34" height="17" font="5">2016  </text>
<text top="229" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27673306">27673306</a></text>
<text top="229" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27673306"> </a></text>
<text top="178" left="169" width="28" height="17" font="5">Aim: </text>
<text top="178" left="220" width="18" height="17" font="5">To </text>
<text top="178" left="261" width="50" height="17" font="5">evaluate </text>
<text top="195" left="169" width="142" height="17" font="5">association between LDL </text>
<text top="212" left="169" width="142" height="17" font="5">cholesterol  lowering  and </text>
<text top="229" left="169" width="142" height="17" font="5">relative  cardiovascular </text>
<text top="247" left="169" width="142" height="17" font="5">risk  reduction  employing </text>
<text top="264" left="169" width="142" height="17" font="5">statin  and  non-statin </text>
<text top="281" left="169" width="54" height="17" font="5">therapies </text>
<text top="298" left="169" width="3" height="17" font="5"> </text>
<text top="315" left="169" width="35" height="17" font="5">Study </text>
<text top="315" left="225" width="30" height="17" font="5">type: </text>
<text top="315" left="276" width="31" height="17" font="5">Meta-</text>
<text top="333" left="169" width="99" height="17" font="5">analysis of RCT’s </text>
<text top="350" left="169" width="3" height="17" font="5"> </text>
<text top="367" left="169" width="95" height="17" font="5">Size: N=312,175 </text>
<text top="178" left="324" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="195" left="324" width="163" height="17" font="5">49  RCT’s  of  9  different </text>
<text top="212" left="324" width="68" height="17" font="5">approaches </text>
<text top="212" left="413" width="14" height="17" font="5">to </text>
<text top="212" left="448" width="39" height="17" font="5">LDL-C </text>
<text top="229" left="324" width="163" height="17" font="5">reduction  with  reported </text>
<text top="247" left="324" width="46" height="17" font="5">ASCVD </text>
<text top="247" left="388" width="57" height="17" font="5">outcomes </text>
<text top="247" left="462" width="24" height="17" font="5">that </text>
<text top="264" left="324" width="49" height="17" font="5">included </text>
<text top="264" left="424" width="63" height="17" font="5">myocardial </text>
<text top="281" left="324" width="53" height="17" font="5">infarction </text>
<text top="298" left="324" width="3" height="17" font="5"> </text>
<text top="315" left="324" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="333" left="324" width="163" height="17" font="5">RCT’s  of  &lt;6  mo  duration  or </text>
<text top="350" left="324" width="163" height="17" font="5">with  fewer  than  50  clinical </text>
<text top="367" left="324" width="40" height="17" font="5">events </text>
<text top="178" left="499" width="109" height="17" font="5">Intervention/compar</text>
<text top="195" left="499" width="28" height="17" font="5">ator: </text>
<text top="212" left="499" width="96" height="17" font="5">Drug vs. placebo </text>
<text top="178" left="628" width="67" height="17" font="5">1⁰endpoint: </text>
<text top="195" left="628" width="203" height="17" font="5">Relative risk of major vascular events </text>
<text top="212" left="628" width="203" height="17" font="5">(a  composite  of  cardiovascular </text>
<text top="230" left="628" width="203" height="17" font="5">death,  acute  MI  or  other  acute </text>
<text top="247" left="628" width="51" height="17" font="5">coronary </text>
<text top="247" left="699" width="61" height="17" font="5">syndrome, </text>
<text top="247" left="780" width="51" height="17" font="5">coronary </text>
<text top="264" left="628" width="99" height="17" font="5">revascularization, </text>
<text top="264" left="751" width="14" height="17" font="5">or </text>
<text top="264" left="790" width="41" height="17" font="5">stroke) </text>
<text top="281" left="628" width="203" height="17" font="5">associated  with  the  absolute </text>
<text top="298" left="628" width="203" height="17" font="5">reduction in LDL-C level; 5-y rate of </text>
<text top="316" left="628" width="203" height="17" font="5">major  coronary  events  (coronary </text>
<text top="333" left="628" width="203" height="17" font="5">death  or  MI)  associated  with </text>
<text top="350" left="628" width="124" height="17" font="5">achieved LDL-C level. </text>
<text top="367" left="628" width="203" height="17" font="5">1.  Relative  risk  for  major  vascular </text>
<text top="385" left="628" width="203" height="17" font="5">events  per  38.7  mg/dL  reduction  in </text>
<text top="402" left="628" width="203" height="17" font="5">LDL-C was 0.77 (95% CI: 0.71-0.84), </text>
<text top="419" left="628" width="203" height="17" font="5">p&lt;0.001) and was 0.75 for non-statin </text>
<text top="436" left="628" width="203" height="17" font="5">interventions  that  work  primarily  by </text>
<text top="453" left="628" width="75" height="17" font="5">up-regulation </text>
<text top="453" left="723" width="14" height="17" font="5">of </text>
<text top="453" left="756" width="75" height="17" font="5">LDL-receptor </text>
<text top="471" left="628" width="203" height="17" font="5">expression,  including  diet,  bile  acid </text>
<text top="488" left="628" width="203" height="17" font="5">sequestrants,  ileal  bypass  and </text>
<text top="505" left="628" width="56" height="17" font="5">ezetimibe </text>
<text top="505" left="741" width="90" height="17" font="5">(between-group </text>
<text top="522" left="628" width="203" height="17" font="5">significance,  p=0.72).  Combined </text>
<text top="539" left="628" width="203" height="17" font="5">therapies  were  associated  with  a </text>
<text top="557" left="628" width="203" height="17" font="5">relative  risk  reduction  of  0.77  (95% </text>
<text top="574" left="628" width="134" height="17" font="5">CI: 0.75-0.79, p&lt;0.001). </text>
<text top="591" left="628" width="203" height="17" font="5">2.  Achieved  absolute  LDL-C  level </text>
<text top="608" left="628" width="203" height="17" font="5">was  associated  with  the  absolute </text>
<text top="625" left="628" width="203" height="17" font="5">rate  of  major  coronary  events </text>
<text top="643" left="628" width="45" height="17" font="5">(11,301 </text>
<text top="643" left="690" width="51" height="17" font="5">coronary </text>
<text top="643" left="759" width="40" height="17" font="5">deaths </text>
<text top="643" left="816" width="14" height="17" font="5">or </text>
<text top="660" left="628" width="203" height="17" font="5">myocardial  infarctions  for  primary </text>
<text top="677" left="628" width="203" height="17" font="5">prevention  trials  (1.5%  lower  event </text>
<text top="694" left="628" width="203" height="17" font="5">rate  [95%  CI:  0.5-2.6%]  per  each </text>
<text top="712" left="628" width="203" height="17" font="5">38.7  mg/dL  lower  LDL-C  level; </text>
<text top="729" left="628" width="203" height="17" font="5">p=0.008)  and  secondary  prevention </text>
<text top="746" left="628" width="203" height="17" font="5">trials (4.6% lower event rate [95% CI: </text>
<text top="178" left="844" width="69" height="17" font="5">Limitations:  </text>
<text top="195" left="844" width="244" height="17" font="5">PCSK9  inhibitor  outcome  trial  results  were </text>
<text top="212" left="844" width="243" height="17" font="5">not available to be included in the results of </text>
<text top="229" left="844" width="55" height="17" font="5">this study </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="628" width="203" height="17" font="5">2.9-6.4%] for each 38.7 mg/dL lower </text>
<text top="108" left="628" width="98" height="17" font="5">LDL-C; p&lt;0.001). </text>
<text top="125" left="628" width="203" height="17" font="5">3.  Interventions  (in  aggregate)  that </text>
<text top="142" left="628" width="203" height="17" font="5">lower  LDL-C  via  other  mechanisms </text>
<text top="160" left="628" width="203" height="17" font="5">did  not  demonstrate  ASCVD  risk </text>
<text top="177" left="628" width="61" height="17" font="5">reduction.  </text>
<text top="195" left="75" width="70" height="17" font="5">Shepherd J, </text>
<text top="212" left="75" width="68" height="17" font="5">et al., 1995  </text>
<text top="229" left="75" width="3" height="17" font="6"> </text>
<text top="247" left="75" width="51" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7566020">7566020 </a></text>
<text top="264" left="75" width="3" height="17" font="5"> </text>
<text top="281" left="75" width="3" height="17" font="5"> </text>
<text top="195" left="169" width="142" height="17" font="5">Aim: To assess the effect </text>
<text top="212" left="169" width="142" height="17" font="5">of pravastatin therapy on </text>
<text top="229" left="169" width="142" height="17" font="5">the incidence of non-fatal </text>
<text top="247" left="169" width="142" height="17" font="5">MI  and  coronary  heart </text>
<text top="264" left="169" width="46" height="17" font="5">disease </text>
<text top="264" left="239" width="34" height="17" font="5">death </text>
<text top="264" left="298" width="13" height="17" font="5">in </text>
<text top="281" left="169" width="119" height="17" font="5">hypercholesterolemic </text>
<text top="298" left="169" width="75" height="17" font="5">Scottish men </text>
<text top="315" left="169" width="3" height="17" font="5"> </text>
<text top="333" left="169" width="142" height="17" font="5">Study  Design:  Double </text>
<text top="350" left="169" width="142" height="17" font="5">blind  placebo  controlled </text>
<text top="367" left="169" width="29" height="17" font="5">RCT </text>
<text top="384" left="169" width="3" height="17" font="5"> </text>
<text top="401" left="169" width="81" height="17" font="5">Size: N= 6595 </text>
<text top="195" left="324" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="212" left="324" width="163" height="17" font="5">Men  45-64  y  of  age  with  no </text>
<text top="229" left="324" width="163" height="17" font="5">history  of  MI  with  LDL-C  ≥ </text>
<text top="247" left="324" width="163" height="17" font="5">155 mg/dL during and at least </text>
<text top="264" left="324" width="163" height="17" font="5">one  value  174-232  mg/dL </text>
<text top="281" left="324" width="38" height="17" font="5">during </text>
<text top="281" left="384" width="103" height="17" font="5">pre-randomization </text>
<text top="298" left="324" width="163" height="17" font="5">visits. Patients with a history </text>
<text top="315" left="324" width="163" height="17" font="5">of  stable  angina  could  be </text>
<text top="333" left="324" width="163" height="17" font="5">enrolled  if  no  hospitalization </text>
<text top="350" left="324" width="129" height="17" font="5">in the preceding 12 mo </text>
<text top="367" left="324" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="384" left="324" width="163" height="17" font="5">1.  No  history  or  ECG </text>
<text top="401" left="324" width="84" height="17" font="5">evidence of MI </text>
<text top="419" left="324" width="163" height="17" font="5">2. No atrial fibrillation, flutter, </text>
<text top="436" left="324" width="49" height="17" font="5">frequent </text>
<text top="436" left="427" width="59" height="17" font="5">premature </text>
<text top="453" left="324" width="163" height="17" font="5">ventricular beats, high grade </text>
<text top="470" left="324" width="116" height="17" font="5">atrioventricular block </text>
<text top="487" left="324" width="163" height="17" font="5">3.  Blood  pressure  &gt;180/110 </text>
<text top="505" left="324" width="43" height="17" font="5">mm Hg </text>
<text top="522" left="324" width="130" height="17" font="5">4. History of rheumatic, </text>
<text top="539" left="324" width="163" height="17" font="5">congenital  or  pulmonary </text>
<text top="556" left="324" width="77" height="17" font="5">heart disease </text>
<text top="573" left="324" width="163" height="17" font="5">5.  Cardiomegaly,  congestive </text>
<text top="591" left="324" width="163" height="17" font="5">heart  failure  or  significant </text>
<text top="608" left="324" width="123" height="17" font="5">valvular heart disease </text>
<text top="625" left="324" width="114" height="17" font="5">6. Psychiatric illness </text>
<text top="642" left="324" width="163" height="17" font="5">7.  Current  lipid  lowering </text>
<text top="660" left="324" width="44" height="17" font="5">therapy </text>
<text top="677" left="324" width="14" height="17" font="5">8. </text>
<text top="677" left="355" width="132" height="17" font="5">Excluding  laboratory </text>
<text top="694" left="324" width="163" height="17" font="5">values, including triglycerides </text>
<text top="711" left="324" width="69" height="17" font="5">&gt;534 mg/dL </text>
<text top="195" left="499" width="109" height="17" font="5">Intervention/compar</text>
<text top="212" left="499" width="28" height="17" font="5">ator: </text>
<text top="229" left="499" width="115" height="17" font="5">Pravastatin  40  mg </text>
<text top="247" left="499" width="115" height="17" font="5">daily  vs.  placebo </text>
<text top="264" left="499" width="112" height="17" font="5">over a  mean follow-</text>
<text top="281" left="499" width="98" height="17" font="5">up period of 4.9 y </text>
<text top="195" left="628" width="74" height="17" font="5">1⁰ endpoint:  </text>
<text top="212" left="628" width="203" height="17" font="5">1. Combined occurrence of nonfatal </text>
<text top="230" left="628" width="203" height="17" font="5">MI  or  death  from  coronary  heart </text>
<text top="247" left="628" width="136" height="17" font="5">disease as a first event.  </text>
<text top="264" left="628" width="203" height="17" font="5">2.  Occurrence  of  death  from </text>
<text top="281" left="628" width="203" height="17" font="5">coronary heart disease and nonfatal </text>
<text top="298" left="628" width="21" height="17" font="5">MI. </text>
<text top="316" left="628" width="3" height="17" font="5"> </text>
<text top="333" left="628" width="48" height="17" font="5">Results: </text>
<text top="350" left="628" width="203" height="17" font="5">1. In the pravastatin group there was </text>
<text top="367" left="628" width="203" height="17" font="5">a  31%  relative  risk  reduction  (95% </text>
<text top="385" left="628" width="203" height="17" font="5">CI:  17-43%,  p&lt;0.001)  in  the </text>
<text top="402" left="628" width="200" height="17" font="5">combined  endpoint  of  definite  non-</text>
<text top="419" left="628" width="203" height="17" font="5">fatal MI and coronary heart disease </text>
<text top="436" left="628" width="201" height="17" font="5">death (absolute risk reduction 2.4%) </text>
<text top="195" left="844" width="70" height="17" font="5">2⁰ endpoint: </text>
<text top="212" left="844" width="147" height="17" font="5">Death from cardiovascular </text>
<text top="230" left="844" width="243" height="17" font="5">causes,  death  from  any  cause,  and  the </text>
<text top="247" left="844" width="218" height="17" font="5">frequency of coronary revascularization </text>
<text top="264" left="844" width="68" height="17" font="5">procedures. </text>
<text top="281" left="844" width="243" height="17" font="5">Results: In the pravastatin group there was </text>
<text top="298" left="844" width="243" height="17" font="5">a 32% relative risk reduction in risk of death </text>
<text top="316" left="844" width="240" height="17" font="5">from all cardiovascular causes (95%  CI: 3-</text>
<text top="333" left="844" width="244" height="17" font="5">53%,  p=0.0333)  and  a  37%  reduction  in </text>
<text top="350" left="844" width="240" height="17" font="5">revascularization  procedures  (95%  CI:  11-</text>
<text top="367" left="844" width="84" height="17" font="5">56%; p=0.009) </text>
<text top="385" left="844" width="243" height="17" font="5">Adverse  events  were  similar  in  pravastatin </text>
<text top="402" left="844" width="115" height="17" font="5">and placebo groups. </text>
<text top="419" left="844" width="3" height="17" font="5"> </text>
<text top="436" left="844" width="119" height="17" font="5">Limitations: Men only </text>
<text top="729" left="66" width="3" height="17" font="5"> </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="99" left="87" width="90" height="17" font="5">Study Acronym; </text>
<text top="117" left="110" width="43" height="17" font="5">Author; </text>
<text top="134" left="88" width="87" height="17" font="5">Year Published </text>
<text top="99" left="233" width="76" height="17" font="5">Aim of Study; </text>
<text top="117" left="236" width="69" height="17" font="5">Study Type; </text>
<text top="134" left="230" width="83" height="17" font="5">Study Size (N) </text>
<text top="117" left="381" width="103" height="17" font="5">Patient Population </text>
<text top="91" left="546" width="103" height="17" font="5">Study Intervention </text>
<text top="108" left="561" width="72" height="17" font="5">(# patients) / </text>
<text top="125" left="546" width="103" height="17" font="5">Study Comparator </text>
<text top="142" left="565" width="65" height="17" font="5">(# patients) </text>
<text top="99" left="740" width="96" height="17" font="5">Endpoint Results </text>
<text top="117" left="724" width="129" height="17" font="5">(Absolute Event Rates, </text>
<text top="134" left="701" width="174" height="17" font="5">P values; OR or RR; &amp; 95% CI) </text>
<text top="100" left="922" width="59" height="17" font="5">Relevant 2</text>
<text top="99" left="981" width="106" height="18" font="5"> Endpoint (if any); </text>
<text top="117" left="954" width="100" height="17" font="5">Study Limitations; </text>
<text top="134" left="960" width="90" height="17" font="5">Adverse Events </text>
<text top="160" left="75" width="29" height="17" font="5">HPS </text>
<text top="178" left="75" width="89" height="17" font="5">Collins R, et al., </text>
<text top="195" left="75" width="34" height="17" font="5">2003  </text>
<text top="212" left="75" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12814710">12814710</a></text>
<text top="212" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12814710"> </a></text>
<text top="160" left="202" width="31" height="17" font="5">Aim:  </text>
<text top="178" left="202" width="125" height="18" font="5">• To evaluate whether </text>
<text top="196" left="202" width="112" height="17" font="5">(moderate intensity) </text>
<text top="213" left="202" width="124" height="17" font="5">statin therapy reduces </text>
<text top="230" left="202" width="106" height="17" font="5">CVD morbidity and </text>
<text top="248" left="202" width="137" height="17" font="5">mortality in subjects with </text>
<text top="265" left="202" width="113" height="17" font="5">diabetes and with or </text>
<text top="282" left="202" width="130" height="17" font="5">without CVD compared </text>
<text top="299" left="202" width="64" height="17" font="5">to placebo. </text>
<text top="317" left="202" width="72" height="18" font="5">• This report </text>
<text top="335" left="202" width="128" height="17" font="5">summarizes findings in </text>
<text top="352" left="202" width="98" height="17" font="5">the pre- specified </text>
<text top="369" left="202" width="135" height="17" font="5">subgroup of participants </text>
<text top="386" left="202" width="118" height="17" font="5">without ASCVD only. </text>
<text top="404" left="202" width="3" height="17" font="5"> </text>
<text top="421" left="202" width="137" height="17" font="5">Study type: Randomized </text>
<text top="438" left="202" width="121" height="17" font="5">double-blind placebo- </text>
<text top="455" left="202" width="120" height="17" font="5">controlled clinical trial </text>
<text top="473" left="202" width="3" height="17" font="5"> </text>
<text top="490" left="202" width="113" height="17" font="5">Size: 5,963 subjects </text>
<text top="507" left="202" width="113" height="17" font="5">with diabetes 615 of </text>
<text top="524" left="202" width="135" height="17" font="5">whom had T1DM; 3,051 </text>
<text top="541" left="202" width="118" height="17" font="5">subjects had ASCVD </text>
<text top="559" left="202" width="119" height="17" font="5">and 2,912 individuals </text>
<text top="576" left="202" width="47" height="17" font="5">did not.  </text>
<text top="160" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="178" left="353" width="80" height="18" font="5">• Age 40-80 y </text>
<text top="196" left="353" width="98" height="18" font="5">• T1DM or T2DM </text>
<text top="215" left="353" width="139" height="18" font="5">• Non-fasting cholesterol </text>
<text top="233" left="353" width="133" height="17" font="5">&gt;3.5 mmol/l (135 mg/dl) </text>
<text top="250" left="353" width="139" height="18" font="5">• treated hypertension (if </text>
<text top="268" left="353" width="154" height="17" font="5">also male and aged at least </text>
<text top="286" left="353" width="31" height="17" font="5">65 y) </text>
<text top="303" left="353" width="3" height="17" font="5"> </text>
<text top="320" left="353" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="337" left="353" width="119" height="18" font="5">• No CVD for the pre-</text>
<text top="356" left="353" width="157" height="17" font="5">specified primary prevention </text>
<text top="373" left="353" width="55" height="17" font="5">subgroup </text>
<text top="390" left="353" width="118" height="18" font="5">• Subject’s physician </text>
<text top="408" left="353" width="132" height="17" font="5">assessment that statins </text>
<text top="426" left="353" width="106" height="17" font="5">clearly indicated or </text>
<text top="443" left="353" width="87" height="17" font="5">contraindicated </text>
<text top="460" left="353" width="82" height="18" font="5">• liver disease </text>
<text top="478" left="353" width="127" height="18" font="5">• severe renal disease </text>
<text top="497" left="353" width="132" height="18" font="5">• cyclosporine, fibrates, </text>
<text top="515" left="353" width="36" height="17" font="5">niacin </text>
<text top="532" left="353" width="137" height="18" font="5">• Baseline LDL-C; mean </text>
<text top="551" left="353" width="126" height="17" font="5">(SD) 3·2 (0·82) mmol/l </text>
<text top="568" left="353" width="90" height="17" font="5">[125 (32) mg/dl] </text>
<text top="585" left="353" width="3" height="17" font="5"> </text>
<text top="160" left="524" width="75" height="17" font="5">Intervention:  </text>
<text top="178" left="524" width="104" height="17" font="5">Simva 40 mg daily </text>
<text top="195" left="524" width="53" height="17" font="5">(n=1455) </text>
<text top="212" left="524" width="125" height="17" font="5"> -average statin usage </text>
<text top="229" left="524" width="31" height="17" font="5">83%, </text>
<text top="247" left="524" width="115" height="17" font="5"> -average LDL-C 2.2 </text>
<text top="264" left="524" width="98" height="17" font="5">mmol/l (86 mg/dl) </text>
<text top="281" left="524" width="75" height="17" font="5">Comparator:  </text>
<text top="298" left="524" width="101" height="17" font="5">Placebo (n=1457) </text>
<text top="315" left="524" width="125" height="17" font="5"> -average statin usage </text>
<text top="333" left="524" width="28" height="17" font="5">11% </text>
<text top="350" left="524" width="115" height="17" font="5"> -average LDL-C 3.1 </text>
<text top="367" left="524" width="109" height="17" font="5">mmol/L (121 mg/dl) </text>
<text top="384" left="524" width="3" height="17" font="5"> </text>
<text top="402" left="524" width="106" height="18" font="5">• LDL-C difference </text>
<text top="420" left="524" width="109" height="17" font="5">between simva and </text>
<text top="437" left="524" width="122" height="17" font="5">placebo 0.9 mmol (35 </text>
<text top="454" left="524" width="38" height="17" font="5">mg/dl) </text>
<text top="471" left="524" width="122" height="18" font="5">• Mean duration 4.8 y </text>
<text top="490" left="524" width="3" height="17" font="5"> </text>
<text top="162" left="683" width="7" height="17" font="5">1</text>
<text top="161" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="179" left="683" width="169" height="18" font="5">• Non-fatal MI, death from any </text>
<text top="197" left="683" width="97" height="17" font="5">coronary disease </text>
<text top="214" left="683" width="3" height="17" font="5"> </text>
<text top="232" left="683" width="48" height="17" font="5">Results: </text>
<text top="249" left="683" width="95" height="18" font="5">• n (rate ratio %) </text>
<text top="267" left="683" width="105" height="17" font="5">Simva; 135 (9.3%) </text>
<text top="284" left="683" width="122" height="17" font="5">Placebo; 196 (13.5%) </text>
<text top="302" left="683" width="150" height="17" font="5">RRR 33% (95% CI: 17–46; </text>
<text top="319" left="683" width="60" height="17" font="5">p=0·0003) </text>
<text top="336" left="683" width="202" height="18" font="5">• Men: RRR [SE] 33% [10], p=0·002 </text>
<text top="355" left="683" width="177" height="18" font="5">• Women RRR 30% [19], p=0·1 </text>
<text top="373" left="683" width="181" height="18" font="5">• 40-64 y of age: RRR 33% [12], </text>
<text top="391" left="683" width="49" height="17" font="5">p=0·006 </text>
<text top="408" left="683" width="181" height="18" font="5">• 65-80 y of age: RRR 31% [14], </text>
<text top="427" left="683" width="41" height="17" font="5">p=0.03 </text>
<text top="161" left="906" width="185" height="18" font="5">• Adverse events: (full group with </text>
<text top="179" left="906" width="54" height="17" font="5">diabetes) </text>
<text top="196" left="906" width="141" height="18" font="5">• Liver enzymes &gt;4X UL  </text>
<text top="214" left="906" width="170" height="17" font="5">Simvastatin: n (%) 14 [0·47%]  </text>
<text top="232" left="906" width="118" height="17" font="5">Placebo: 11 [0·37%]) </text>
<text top="249" left="906" width="82" height="18" font="5">• CK &gt;10X UL </text>
<text top="267" left="906" width="97" height="17" font="5">Simva: 4 [0·13%] </text>
<text top="284" left="906" width="107" height="17" font="5">Placebo: 2 [0·07%] </text>
<text top="302" left="906" width="3" height="17" font="5"> </text>
<text top="610" left="75" width="46" height="17" font="5">CARDS </text>
<text top="628" left="75" width="108" height="17" font="5">Colhoun HM, et al., </text>
<text top="645" left="75" width="31" height="17" font="5">2004 </text>
<text top="662" left="75" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15325833">15325833</a></text>
<text top="662" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15325833"> </a></text>
<text top="610" left="202" width="89" height="17" font="5">Aim: To test the </text>
<text top="628" left="202" width="89" height="17" font="5">effectiveness of </text>
<text top="645" left="202" width="122" height="17" font="5">atorvastatin 10 mg for </text>
<text top="662" left="202" width="119" height="17" font="5">primary prevention of </text>
<text top="679" left="202" width="116" height="17" font="5">major CVD events in </text>
<text top="697" left="202" width="108" height="17" font="5">patients with T2DM </text>
<text top="714" left="202" width="108" height="17" font="5">without high LDL-C </text>
<text top="731" left="202" width="3" height="17" font="5"> </text>
<text top="610" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="628" left="353" width="153" height="18" font="5">• Men and women aged 40-</text>
<text top="646" left="353" width="17" height="17" font="5">75 </text>
<text top="663" left="353" width="47" height="18" font="5">• T2DM </text>
<text top="682" left="353" width="92" height="18" font="5">• At least one of </text>
<text top="700" left="353" width="145" height="17" font="5">hypertension, retinopathy, </text>
<text top="717" left="353" width="121" height="17" font="5">microalbuminuria and </text>
<text top="734" left="353" width="49" height="17" font="5">smoking </text>
<text top="752" left="353" width="3" height="17" font="5"> </text>
<text top="769" left="353" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="610" left="524" width="127" height="17" font="5">Intervention: Atorva 10 </text>
<text top="628" left="524" width="53" height="17" font="5">mg daily  </text>
<text top="645" left="524" width="53" height="17" font="5">(n=1428) </text>
<text top="662" left="524" width="7" height="17" font="5">  </text>
<text top="679" left="524" width="75" height="17" font="5">Comparator:  </text>
<text top="697" left="524" width="111" height="18" font="5">• Placebo (n=1410) </text>
<text top="715" left="524" width="73" height="18" font="5">• 1 y LDL -C </text>
<text top="733" left="524" width="120" height="18" font="5">• Mean (SD) mmol/l/  </text>
<text top="752" left="524" width="33" height="17" font="5">mg/dl </text>
<text top="612" left="683" width="7" height="17" font="5">1</text>
<text top="611" left="690" width="188" height="18" font="5"> endpoint: (first acute CHD event </text>
<text top="629" left="683" width="175" height="17" font="5">[MI including silent MI, unstable </text>
<text top="646" left="683" width="181" height="17" font="5">angina, CHD death, resuscitated </text>
<text top="663" left="683" width="136" height="17" font="5">cardiac arrest], coronary </text>
<text top="680" left="683" width="154" height="17" font="5">revascularization, or stroke) </text>
<text top="698" left="683" width="3" height="17" font="5"> </text>
<text top="715" left="683" width="51" height="17" font="5">Results:  </text>
<text top="732" left="683" width="202" height="18" font="5">• The trial was terminated 2 y earlier </text>
<text top="750" left="683" width="197" height="17" font="5">than expected (median duration 3.9 </text>
<text top="768" left="683" width="187" height="17" font="5">y) because efficacy had been met </text>
<text top="612" left="906" width="7" height="17" font="5">2</text>
<text top="611" left="913" width="65" height="18" font="5"> Endpoint: </text>
<text top="629" left="906" width="172" height="18" font="5">• Acute coronary events, n (%) </text>
<text top="647" left="906" width="95" height="17" font="5">  Atorva: 51 (3.6) </text>
<text top="664" left="906" width="104" height="17" font="5">  Placebo: 77 (5.5) </text>
<text top="682" left="906" width="185" height="18" font="5">• Acute coronary events, rate per </text>
<text top="700" left="906" width="55" height="17" font="5">100 per y </text>
<text top="717" left="906" width="80" height="17" font="5">   Atorva: 0.94 </text>
<text top="734" left="906" width="89" height="17" font="5">   Placebo: 1.47 </text>
<text top="752" left="906" width="179" height="17" font="5">   HR: 0.64; 95% CI: 0.45 - 0.91; </text>
<text top="769" left="906" width="39" height="17" font="5"> p=NR </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="202" width="137" height="17" font="5">Study type: Randomized </text>
<text top="108" left="202" width="121" height="17" font="5">double-blind placebo- </text>
<text top="125" left="202" width="120" height="17" font="5">controlled clinical trial </text>
<text top="142" left="202" width="3" height="17" font="5"> </text>
<text top="160" left="202" width="65" height="17" font="5">Size: 2,838 </text>
<text top="91" left="353" width="64" height="18" font="5">• Any CVD </text>
<text top="109" left="353" width="114" height="18" font="5">• LDL-C &gt;160 mg/dl </text>
<text top="128" left="353" width="138" height="18" font="5">• triglyceride &gt;160 mg/dl </text>
<text top="146" left="353" width="141" height="18" font="5">• plasma creatinine &gt;150 </text>
<text top="164" left="353" width="33" height="17" font="5">mol/L </text>
<text top="182" left="353" width="86" height="18" font="5">• HbA1c &gt;12% </text>
<text top="200" left="353" width="111" height="18" font="5">• &lt;80% compliance </text>
<text top="218" left="353" width="140" height="18" font="5">• with placebo during the </text>
<text top="237" left="353" width="86" height="17" font="5">baseline phase </text>
<text top="254" left="353" width="137" height="18" font="5">• Baseline LDL-C: mean </text>
<text top="272" left="353" width="105" height="17" font="5">(SD) mmol/l/mg/dl  </text>
<text top="289" left="353" width="155" height="17" font="5">Atorva: 3.04 (0.72)/118 (28) </text>
<text top="307" left="353" width="138" height="17" font="5">Placebo: 3.02 (0.70)/118 </text>
<text top="324" left="353" width="25" height="17" font="5">(27) </text>
<text top="91" left="524" width="122" height="17" font="5">Atorva:1.86 (0.69)/ 70 </text>
<text top="108" left="524" width="29" height="17" font="5">(39)  </text>
<text top="125" left="524" width="141" height="17" font="5">Placebo: 3.10 (0.80)/ 121 </text>
<text top="142" left="524" width="25" height="17" font="5">(31) </text>
<text top="160" left="524" width="103" height="18" font="5">• Mean change % </text>
<text top="178" left="524" width="70" height="17" font="5">Atorva: 38.8 </text>
<text top="195" left="524" width="79" height="17" font="5">Placebo; 2.65 </text>
<text top="212" left="524" width="116" height="17" font="5">Absolute change %,  </text>
<text top="230" left="524" width="84" height="17" font="5">Atorva: -1.1/46 </text>
<text top="247" left="524" width="89" height="17" font="5">Placebo: 0.08/3 </text>
<text top="264" left="524" width="101" height="18" font="5">• Between-group  </text>
<text top="283" left="524" width="91" height="17" font="5">Difference, 40% </text>
<text top="300" left="524" width="3" height="17" font="5"> </text>
<text top="91" left="683" width="84" height="18" font="5">• Events n (%) </text>
<text top="109" left="683" width="102" height="17" font="5">    Atorva: 83 (5.8) </text>
<text top="126" left="683" width="118" height="17" font="5">    Placebo: 127 (9.0) </text>
<text top="144" left="683" width="109" height="18" font="5">• Rate per 100 pt-y </text>
<text top="162" left="683" width="84" height="17" font="5">    Atorva: 1.54 </text>
<text top="179" left="683" width="92" height="17" font="5">    Placebo: 2.46 </text>
<text top="196" left="683" width="182" height="17" font="5">    HR: 0.63; 95% CI: 0.48 - 0.83; </text>
<text top="214" left="683" width="58" height="17" font="5">   p=0.001 </text>
<text top="231" left="683" width="138" height="18" font="5">• Death from any cause  </text>
<text top="249" left="683" width="140" height="17" font="5">   HR: 0.73; 95% CI: 0.52 </text>
<text top="266" left="683" width="90" height="17" font="5">  -1.01; p=0.059 </text>
<text top="284" left="683" width="192" height="18" font="5">• NNT is 37 major vascular events </text>
<text top="302" left="683" width="109" height="17" font="5">   per 1000 over 4 y </text>
<text top="91" left="906" width="168" height="18" font="5">• Any acute CVD event, n (%) </text>
<text top="109" left="906" width="105" height="17" font="5">   Atorva: 134 (9.4) </text>
<text top="126" left="906" width="121" height="17" font="5">   Placebo: 189 (13.4) </text>
<text top="144" left="906" width="181" height="17" font="5">   HR: 0.68; 95% CI: 0.55 – 0.85; </text>
<text top="161" left="906" width="52" height="17" font="5"> p=0.001 </text>
<text top="178" left="906" width="86" height="18" font="5">• Stroke, n (%) </text>
<text top="196" left="906" width="98" height="17" font="5">   Atorva: 21 (1.7) </text>
<text top="214" left="906" width="107" height="17" font="5">   Placebo: 39 (2.8) </text>
<text top="231" left="906" width="185" height="17" font="5">   HR: 0.52; 95% CI: 0.31 – 0.89;  </text>
<text top="248" left="906" width="39" height="17" font="5"> p=NR </text>
<text top="265" left="906" width="196" height="18" font="5">• Coronary revascularization, n (%) </text>
<text top="284" left="906" width="92" height="17" font="5"> Atorva: 24 (1.7) </text>
<text top="301" left="906" width="101" height="17" font="5"> Placebo: 34 (2.4) </text>
<text top="318" left="906" width="174" height="17" font="5"> HR: 0.69; 95% CI: 0.41 – 1.16; </text>
<text top="335" left="906" width="35" height="17" font="5">p=NR </text>
<text top="353" left="906" width="3" height="17" font="5"> </text>
<text top="370" left="906" width="166" height="17" font="5">Adverse events: No excess of </text>
<text top="387" left="906" width="179" height="17" font="5">adverse events was noted in the </text>
<text top="404" left="906" width="102" height="17" font="5">atorvastatin group </text>
<text top="421" left="906" width="3" height="17" font="5"> </text>
<text top="439" left="906" width="161" height="17" font="5">Limitations: 15% drop-in lipid </text>
<text top="456" left="906" width="142" height="17" font="5">lowering meds in placebo </text>
<text top="474" left="75" width="72" height="17" font="5">ASCOT-LLA </text>
<text top="491" left="75" width="92" height="17" font="5">Sever PS, et al., </text>
<text top="508" left="75" width="34" height="17" font="5">2005  </text>
<text top="525" left="75" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15855581">15855581</a></text>
<text top="525" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15855581"> </a></text>
<text top="474" left="202" width="31" height="17" font="5">Aim:  </text>
<text top="491" left="202" width="100" height="18" font="5">• To establish the </text>
<text top="509" left="202" width="109" height="17" font="5">benefits of lowering </text>
<text top="526" left="202" width="122" height="17" font="5">cholesterol in patients </text>
<text top="544" left="202" width="107" height="17" font="5">with well-controlled </text>
<text top="561" left="202" width="98" height="17" font="5">hypertension and </text>
<text top="578" left="202" width="132" height="17" font="5">average/below-average </text>
<text top="595" left="202" width="63" height="17" font="5">cholesterol </text>
<text top="613" left="202" width="107" height="17" font="5">concentrations, but </text>
<text top="630" left="202" width="108" height="17" font="5">without established </text>
<text top="647" left="202" width="100" height="17" font="5">coronary disease. </text>
<text top="664" left="202" width="135" height="18" font="5">• This report focuses on </text>
<text top="683" left="202" width="130" height="17" font="5">the group with diabetes </text>
<text top="700" left="202" width="137" height="17" font="5">which was analyzed and </text>
<text top="717" left="202" width="109" height="17" font="5">reported separately </text>
<text top="734" left="202" width="3" height="17" font="5"> </text>
<text top="474" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="491" left="353" width="149" height="18" font="5">• Men and women 40-80 y </text>
<text top="509" left="353" width="86" height="18" font="5">• Hypertension </text>
<text top="528" left="353" width="131" height="18" font="5">• Total chol &lt;6.5mmol/l </text>
<text top="546" left="353" width="66" height="17" font="5">(253 mg/dl) </text>
<text top="563" left="353" width="158" height="18" font="5">• 3 of; T2DM, male sex, age </text>
<text top="582" left="353" width="149" height="17" font="5">&gt;55 y, microalbuminuria or </text>
<text top="599" left="353" width="117" height="17" font="5">proteinuria, smoking, </text>
<text top="616" left="353" width="148" height="17" font="5">total/HDL-C &gt;6, premature </text>
<text top="633" left="353" width="149" height="17" font="5">FH of CHD, LVH, specified </text>
<text top="651" left="353" width="142" height="17" font="5">ECG abnormalities, PAD, </text>
<text top="668" left="353" width="74" height="17" font="5">stroke or TIA </text>
<text top="685" left="353" width="3" height="17" font="5"> </text>
<text top="702" left="353" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="720" left="353" width="113" height="18" font="5">• MI current angina, </text>
<text top="738" left="353" width="137" height="17" font="5">cerebrovascular event in </text>
<text top="755" left="353" width="57" height="17" font="5">past 3 mo </text>
<text top="772" left="353" width="135" height="18" font="5">• uncontrolled arrythmia </text>
<text top="474" left="524" width="75" height="17" font="5">Intervention:  </text>
<text top="491" left="524" width="115" height="18" font="5">• Atorva 10 mg daily </text>
<text top="509" left="524" width="53" height="17" font="5">(n=1258) </text>
<text top="526" left="524" width="134" height="17" font="5"> - Baseline LDL-C mean </text>
<text top="544" left="524" width="109" height="17" font="5">(SD) mmol.l/ mg/dl; </text>
<text top="561" left="524" width="102" height="17" font="5">3.3 (0.7)/ 128 (27) </text>
<text top="578" left="524" width="70" height="17" font="5"> -1 y LDL-C; </text>
<text top="595" left="524" width="98" height="17" font="5">2.1 (0.66)/82 (26) </text>
<text top="613" left="524" width="3" height="17" font="5"> </text>
<text top="630" left="524" width="68" height="17" font="5">Comparator </text>
<text top="647" left="524" width="111" height="18" font="5">• Placebo (n=1274) </text>
<text top="665" left="524" width="124" height="17" font="5"> - Baseline LDL-C; 3.3 </text>
<text top="683" left="524" width="78" height="17" font="5">(0.8)/128 (31) </text>
<text top="700" left="524" width="70" height="17" font="5"> -1 y LDL-C; </text>
<text top="717" left="524" width="98" height="17" font="5">3.3 (0.8)/128 (31) </text>
<text top="734" left="524" width="3" height="17" font="5"> </text>
<text top="752" left="524" width="128" height="18" font="5">• Differences in LDL-C </text>
<text top="770" left="524" width="105" height="17" font="5">between treatment </text>
<text top="475" left="683" width="7" height="17" font="5">1</text>
<text top="474" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="492" left="683" width="210" height="18" font="5">• The trial was terminated earlier than </text>
<text top="510" left="683" width="183" height="17" font="5">expected (median duration 3.3 y) </text>
<text top="528" left="683" width="178" height="17" font="5">because efficacy for the primary </text>
<text top="545" left="683" width="197" height="17" font="5">endpoint for the full group had been </text>
<text top="562" left="683" width="199" height="17" font="5">met. However, this meant there was </text>
<text top="579" left="683" width="187" height="17" font="5">insufficient power in the subgroup </text>
<text top="597" left="683" width="158" height="17" font="5">with diabetes for the primary </text>
<text top="614" left="683" width="193" height="17" font="5">outcome, which was non-fatal MI + </text>
<text top="631" left="683" width="57" height="17" font="5">fatal CHD </text>
<text top="648" left="683" width="194" height="18" font="5">• Diabetes group results: n(%) [per </text>
<text top="667" left="683" width="61" height="17" font="5">1000 pt. y] </text>
<text top="684" left="683" width="112" height="17" font="5">Atorva: 38(3.0) [9.6] </text>
<text top="701" left="683" width="139" height="17" font="5">Placebo: 46(3.6%) [11.4] </text>
<text top="718" left="683" width="201" height="17" font="5">HR: 0.84 (95% CI: 0.55-1.29); p=NR </text>
<text top="736" left="683" width="181" height="18" font="5">• Accordingly, the subgroup with </text>
<text top="754" left="683" width="202" height="17" font="5">diabetes was analyzed based on the </text>
<text top="474" left="906" width="178" height="18" font="5">• 2° endpoint for the main study </text>
<text top="492" left="906" width="147" height="17" font="5">which became the primary </text>
<text top="509" left="906" width="180" height="17" font="5">endpoint for the diabetes cohort: </text>
<text top="528" left="917" width="13" height="16" font="5">o </text>
<text top="526" left="937" width="132" height="17" font="5">Total CVD events; CVD </text>
<text top="544" left="937" width="121" height="17" font="5">mortality, nonfatal MI, </text>
<text top="561" left="937" width="137" height="17" font="5">unstable angina, chronic </text>
<text top="578" left="937" width="165" height="17" font="5">stable angina, life-threatening </text>
<text top="595" left="937" width="154" height="17" font="5">arrhythmias, non-fatal heart </text>
<text top="613" left="937" width="164" height="17" font="5">failure, non-fatal stroke, PAD, </text>
<text top="630" left="937" width="104" height="17" font="5">retinal thrombosis, </text>
<text top="647" left="937" width="149" height="17" font="5">revascularization, TIA, and </text>
<text top="664" left="937" width="108" height="17" font="5">reversible ischemic </text>
<text top="681" left="937" width="115" height="17" font="5">neurological deficits. </text>
<text top="699" left="906" width="140" height="18" font="5">• Diabetes group results: </text>
<text top="719" left="917" width="13" height="16" font="5">o </text>
<text top="717" left="937" width="154" height="17" font="5">Total CVD events n(%) [per </text>
<text top="734" left="937" width="61" height="17" font="5">1000 pt. y] </text>
<text top="753" left="917" width="13" height="16" font="5">o </text>
<text top="752" left="937" width="137" height="17" font="5">Atorva: 116(9.2%) [30.2] </text>
<text top="770" left="917" width="13" height="16" font="5">o </text>
<text top="769" left="937" width="152" height="17" font="5">Placebo: 151(11.9%) [39.1] </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="202" width="137" height="17" font="5">Study type: Randomized </text>
<text top="108" left="202" width="117" height="17" font="5">double-blind placebo </text>
<text top="125" left="202" width="120" height="17" font="5">controlled clinical trial </text>
<text top="142" left="202" width="3" height="17" font="5"> </text>
<text top="160" left="202" width="134" height="17" font="5">Size: 10,305 subjects of </text>
<text top="177" left="202" width="128" height="17" font="5">whom 2532 had T2DM </text>
<text top="91" left="353" width="138" height="18" font="5">• fasting trig &gt;4.5 mmol/l </text>
<text top="109" left="353" width="66" height="17" font="5">(400 mg/dl) </text>
<text top="126" left="353" width="114" height="18" font="5">• clinically important </text>
<text top="145" left="353" width="135" height="17" font="5">laboratory abnormalities </text>
<text top="162" left="353" width="143" height="18" font="5">• no current statin/ fibrate </text>
<text top="180" left="353" width="3" height="17" font="5"> </text>
<text top="198" left="353" width="140" height="17" font="5">Baseline characteristics:  </text>
<text top="215" left="353" width="156" height="18" font="5">• Mean age 64 &gt;60 y (66%) </text>
<text top="233" left="353" width="112" height="18" font="5">• 16% had previous </text>
<text top="252" left="353" width="151" height="17" font="5">cerebrovascular disease or </text>
<text top="269" left="353" width="29" height="17" font="5">PAD </text>
<text top="286" left="353" width="141" height="18" font="5">• Mean no. of risk factors </text>
<text top="304" left="353" width="123" height="17" font="5">including diabetes = 4 </text>
<text top="91" left="524" width="130" height="17" font="5">groups not provided for </text>
<text top="108" left="524" width="105" height="17" font="5">diabetes subgroup </text>
<text top="125" left="524" width="3" height="17" font="5"> </text>
<text top="91" left="683" width="170" height="17" font="5">study trial secondary outcome, </text>
<text top="108" left="683" width="139" height="17" font="5">namely total CVD events </text>
<text top="92" left="917" width="13" height="16" font="5">o </text>
<text top="91" left="937" width="161" height="17" font="5">HR: 0.77; 95% CI: 0.61-0.98; </text>
<text top="108" left="937" width="48" height="17" font="5">p=0.036 </text>
<text top="127" left="917" width="13" height="16" font="5">o </text>
<text top="125" left="937" width="165" height="17" font="5">Excluding those with baseline </text>
<text top="142" left="937" width="152" height="17" font="5">CVD (12%); HR: 0.75; 95% </text>
<text top="160" left="937" width="130" height="17" font="5">CI: 0.57-0.99; p=0.038. </text>
<text top="178" left="917" width="13" height="16" font="5">o </text>
<text top="177" left="937" width="162" height="17" font="5">No difference in liver enzyme </text>
<text top="194" left="937" width="133" height="17" font="5">or other adverse events </text>
<text top="211" left="937" width="158" height="17" font="5">between atorva and placebo </text>
<text top="229" left="937" width="41" height="17" font="5">groups </text>
<text top="246" left="906" width="3" height="17" font="5"> </text>
<text top="263" left="906" width="182" height="17" font="5">Limitation: There was insufficient </text>
<text top="280" left="906" width="186" height="17" font="5">power to test the efficacy of statin </text>
<text top="297" left="906" width="190" height="17" font="5">therapy on the primary outcome in </text>
<text top="315" left="906" width="105" height="17" font="5">the diabetes group </text>
<text top="332" left="906" width="3" height="17" font="5"> </text>
<text top="350" left="75" width="45" height="17" font="5">ASPEN </text>
<text top="367" left="75" width="97" height="17" font="5">Knopp RH, et al., </text>
<text top="384" left="75" width="34" height="17" font="5">2006  </text>
<text top="401" left="75" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16801565">16801565</a></text>
<text top="401" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16801565"> </a></text>
<text top="350" left="202" width="31" height="17" font="5">Aim:  </text>
<text top="367" left="202" width="125" height="18" font="5">• To evaluate whether </text>
<text top="385" left="202" width="112" height="17" font="5">(moderate intensity) </text>
<text top="403" left="202" width="77" height="17" font="5">statin therapy </text>
<text top="420" left="202" width="109" height="17" font="5">(atorvastatin 10 mg </text>
<text top="437" left="202" width="109" height="17" font="5">daily) reduces CVD </text>
<text top="454" left="202" width="127" height="17" font="5">morbidity and mortality </text>
<text top="471" left="202" width="109" height="17" font="5">in subjects with DM </text>
<text top="489" left="202" width="118" height="17" font="5">compared to placebo </text>
<text top="506" left="202" width="95" height="18" font="5">• This study was </text>
<text top="524" left="202" width="132" height="17" font="5">originally designed as a </text>
<text top="541" left="202" width="81" height="17" font="5">4-y secondary </text>
<text top="559" left="202" width="133" height="17" font="5">prevention trial but after </text>
<text top="576" left="202" width="131" height="17" font="5">2 y it became a primary </text>
<text top="593" left="202" width="114" height="17" font="5">prevention trial. This </text>
<text top="610" left="202" width="119" height="17" font="5">report focuses on the </text>
<text top="627" left="202" width="126" height="17" font="5">group without baseline </text>
<text top="645" left="202" width="46" height="17" font="5">ASCVD </text>
<text top="662" left="202" width="3" height="17" font="5"> </text>
<text top="679" left="202" width="137" height="17" font="5">Study type: Randomized </text>
<text top="696" left="202" width="117" height="17" font="5">double-blind placebo </text>
<text top="714" left="202" width="120" height="17" font="5">controlled clinical trial </text>
<text top="731" left="202" width="3" height="17" font="5"> </text>
<text top="350" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="367" left="353" width="149" height="18" font="5">• Men and women 40-75 y </text>
<text top="385" left="353" width="47" height="18" font="5">• T2DM </text>
<text top="404" left="353" width="99" height="18" font="5">• LDL cholesterol </text>
<text top="422" left="353" width="61" height="17" font="5">&lt;160mg/dl </text>
<text top="439" left="353" width="142" height="18" font="5">• Triglyceride &lt;600 mg/dl </text>
<text top="458" left="353" width="3" height="17" font="5"> </text>
<text top="475" left="353" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="492" left="353" width="47" height="18" font="5">• T1DM </text>
<text top="511" left="353" width="40" height="18" font="5">• CVD </text>
<text top="529" left="353" width="82" height="18" font="5">• HbA1c&gt;10% </text>
<text top="547" left="353" width="119" height="18" font="5">• hepatic dysfunction </text>
<text top="565" left="353" width="127" height="18" font="5">• severe renal disease </text>
<text top="583" left="353" width="85" height="18" font="5">• BP &gt;160/100 </text>
<text top="602" left="353" width="60" height="18" font="5">• BMI &gt;35 </text>
<text top="620" left="353" width="90" height="18" font="5">• alcohol abuse </text>
<text top="638" left="353" width="127" height="18" font="5">• &lt;80% placebo run-in </text>
<text top="656" left="363" width="66" height="17" font="5">compliance </text>
<text top="674" left="353" width="133" height="18" font="5">• Excluded medications </text>
<text top="692" left="353" width="3" height="17" font="5"> </text>
<text top="709" left="353" width="85" height="17" font="5">Baseline data:  </text>
<text top="726" left="353" width="53" height="18" font="5">• Atorva: </text>
<text top="746" left="363" width="13" height="16" font="5">o </text>
<text top="745" left="377" width="95" height="17" font="5">mean age 60.5 y </text>
<text top="763" left="363" width="13" height="16" font="5">o </text>
<text top="762" left="377" width="108" height="17" font="5">&gt;65 y n=332 (35%) </text>
<text top="350" left="524" width="75" height="17" font="5">Intervention:  </text>
<text top="367" left="524" width="115" height="18" font="5">• Atorva 10 mg daily </text>
<text top="385" left="535" width="111" height="17" font="5">(Primary prevention </text>
<text top="402" left="535" width="42" height="17" font="5">n=959) </text>
<text top="421" left="546" width="13" height="16" font="5">o </text>
<text top="420" left="559" width="89" height="17" font="5">Baseline LDL-C </text>
<text top="437" left="559" width="86" height="17" font="5">mg/dl; 114 (26) </text>
<text top="456" left="546" width="13" height="16" font="5">o </text>
<text top="454" left="559" width="108" height="17" font="5">End of treatment % </text>
<text top="471" left="559" width="72" height="17" font="5">change from </text>
<text top="489" left="559" width="88" height="17" font="5">baseline LDL-C </text>
<text top="506" left="524" width="53" height="18" font="5">• -30.5% </text>
<text top="524" left="524" width="3" height="17" font="5"> </text>
<text top="541" left="524" width="75" height="17" font="5">Comparator:  </text>
<text top="559" left="524" width="124" height="18" font="5">•  Placebo (Primary </text>
<text top="577" left="551" width="103" height="17" font="5">prevention n=946) </text>
<text top="595" left="546" width="13" height="16" font="5">o </text>
<text top="594" left="559" width="89" height="17" font="5">Baseline LDL-C </text>
<text top="611" left="559" width="49" height="17" font="5">114 (26) </text>
<text top="630" left="546" width="13" height="16" font="5">o </text>
<text top="628" left="559" width="108" height="17" font="5">End of treatment % </text>
<text top="645" left="559" width="72" height="17" font="5">change from </text>
<text top="663" left="559" width="88" height="17" font="5">baseline LDL-C </text>
<text top="680" left="524" width="63" height="18" font="5">•  -0.5% </text>
<text top="351" left="683" width="7" height="17" font="5">1</text>
<text top="350" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="368" left="680" width="206" height="18" font="5">•  time to first CVD death, nonfatal or </text>
<text top="386" left="693" width="140" height="17" font="5">silent MI, nonfatal stroke, </text>
<text top="404" left="693" width="168" height="17" font="5">revascularization, resuscitated </text>
<text top="421" left="693" width="172" height="17" font="5">cardiac arrest, unstable angina </text>
<text top="438" left="680" width="203" height="18" font="5">•  Duration; median duration was 4 y </text>
<text top="456" left="693" width="187" height="17" font="5">overall; mean duration for primary </text>
<text top="473" left="693" width="151" height="17" font="5">prevention group was 2.4 y </text>
<text top="491" left="693" width="165" height="17" font="5">(reflecting change in protocol) </text>
<text top="508" left="683" width="3" height="17" font="5"> </text>
<text top="526" left="683" width="7" height="17" font="5">1</text>
<text top="525" left="690" width="157" height="18" font="5"> endpoint results: n (rate%) </text>
<text top="543" left="683" width="113" height="17" font="5">Atorva: 100 (10.4%) </text>
<text top="561" left="683" width="122" height="17" font="5">Placebo: 102 (10.8%) </text>
<text top="578" left="683" width="169" height="17" font="5">HR: (0.97; 95% CI: 0.74–1.28) </text>
<text top="595" left="683" width="3" height="17" font="5"> </text>
<text top="350" left="906" width="163" height="17" font="5">Reasons proposed for lack of </text>
<text top="367" left="906" width="102" height="17" font="5">significant benefit: </text>
<text top="384" left="906" width="178" height="18" font="5">• 26.9% drop-in lipid lowering in </text>
<text top="402" left="917" width="81" height="17" font="5">placebo group </text>
<text top="420" left="906" width="178" height="18" font="5">• relatively short duration of trial </text>
<text top="438" left="906" width="165" height="18" font="5">• lower number of risk factors </text>
<text top="456" left="906" width="184" height="18" font="5">• younger cohort than other trials </text>
<text top="474" left="906" width="136" height="18" font="5">• requirement that study </text>
<text top="493" left="917" width="180" height="17" font="5">medication be discontinued after </text>
<text top="510" left="917" width="102" height="17" font="5">end point reached </text>
<text top="527" left="906" width="174" height="18" font="5">• inclusion of hospitalization for </text>
<text top="545" left="917" width="160" height="17" font="5">angina in endpoint may have </text>
<text top="562" left="917" width="106" height="17" font="5">diluted statin effect </text>
<text top="580" left="906" width="3" height="17" font="5"> </text>
<text top="597" left="906" width="92" height="17" font="5">Adverse events: </text>
<text top="614" left="906" width="103" height="18" font="5">•  abnormal LFTs </text>
<text top="632" left="906" width="87" height="18" font="5">•  Atorva 1.4% </text>
<text top="651" left="906" width="96" height="18" font="5">•  Placebo 1.2% </text>
<text top="669" left="906" width="63" height="18" font="5">•  myalgia </text>
<text top="687" left="906" width="77" height="18" font="5">•  Atorva 3% </text>
<text top="705" left="906" width="96" height="18" font="5">•  Placebo 1.6% </text>
<text top="724" left="906" width="59" height="18" font="5">•  rhabdo </text>
<text top="742" left="906" width="66" height="18" font="5">•  Atorva 1 </text>
<text top="760" left="906" width="75" height="18" font="5">•  Placebo 1 </text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="202" width="113" height="17" font="5">Size: 2,410 subjects </text>
<text top="108" left="202" width="113" height="17" font="5">with T2DM. 505 had </text>
<text top="125" left="202" width="128" height="17" font="5">CVD and 1,905 did not </text>
<text top="92" left="363" width="13" height="16" font="5">o </text>
<text top="91" left="377" width="118" height="17" font="5">diabetes duration 8 y </text>
<text top="109" left="363" width="13" height="16" font="5">o </text>
<text top="108" left="377" width="105" height="17" font="5">hypertension; 55% </text>
<text top="125" left="353" width="62" height="18" font="5">• Placebo: </text>
<text top="144" left="363" width="109" height="18" font="5">•  mean age 60.4 y </text>
<text top="162" left="363" width="122" height="18" font="5">•  &gt;65 y n=305 (32%) </text>
<text top="180" left="363" width="104" height="18" font="5">•  DM duration 8 y </text>
<text top="198" left="363" width="119" height="18" font="5">•  hypertension; 53% </text>
<text top="217" left="75" width="106" height="17" font="5">de Vries FM, et al., </text>
<text top="234" left="75" width="34" height="17" font="5">2012  </text>
<text top="252" left="75" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23186103">23186103</a></text>
<text top="252" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23186103"> </a></text>
<text top="217" left="202" width="108" height="17" font="5">Aim: To assess the </text>
<text top="234" left="202" width="131" height="17" font="5">efficacy of statins in the </text>
<text top="252" left="202" width="119" height="17" font="5">primary prevention of </text>
<text top="269" left="202" width="126" height="17" font="5">major ASCVD event in </text>
<text top="286" left="202" width="122" height="17" font="5">patients with diabetes </text>
<text top="303" left="202" width="3" height="17" font="5"> </text>
<text top="321" left="202" width="138" height="17" font="5">Study type: Fixed effects </text>
<text top="338" left="202" width="133" height="17" font="5">meta- analysis of 4 high </text>
<text top="355" left="202" width="109" height="17" font="5">quality clinical trials </text>
<text top="372" left="202" width="116" height="17" font="5">comparing moderate </text>
<text top="389" left="202" width="104" height="17" font="5">statin to therapy to </text>
<text top="407" left="202" width="131" height="17" font="5">placebo in patients with </text>
<text top="424" left="202" width="133" height="17" font="5">diabetes for the primary </text>
<text top="441" left="202" width="109" height="17" font="5">prevention of major </text>
<text top="458" left="202" width="46" height="17" font="5">ASCVD </text>
<text top="475" left="202" width="3" height="17" font="5"> </text>
<text top="493" left="202" width="124" height="17" font="5">Size: 10,187 subjects, </text>
<text top="510" left="202" width="111" height="17" font="5">5100 on statins and </text>
<text top="527" left="202" width="94" height="17" font="5">5087 on placebo </text>
<text top="217" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="234" left="353" width="104" height="18" font="5">•  double-blinded, </text>
<text top="253" left="370" width="100" height="17" font="5">randomized study </text>
<text top="270" left="353" width="157" height="18" font="5">•  separate data on primary </text>
<text top="288" left="370" width="109" height="17" font="5">prevention subjects </text>
<text top="305" left="353" width="108" height="18" font="5">•  minimum of 500 </text>
<text top="324" left="370" width="66" height="17" font="5">participants </text>
<text top="341" left="353" width="145" height="18" font="5">•  mean follow-up of &gt;2 y </text>
<text top="359" left="353" width="130" height="18" font="5">•  high quality – Jadad </text>
<text top="377" left="370" width="51" height="17" font="5">score &gt;4 </text>
<text top="394" left="353" width="3" height="17" font="5"> </text>
<text top="412" left="353" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="429" left="353" width="144" height="17" font="5">•11 reports were retrieved </text>
<text top="446" left="353" width="158" height="17" font="5">for detailed evaluation and 7 </text>
<text top="463" left="353" width="117" height="17" font="5">were excluded; 2 not </text>
<text top="481" left="353" width="141" height="17" font="5">double-blinded, 2 too few </text>
<text top="498" left="353" width="147" height="17" font="5">subjects, 1 used surrogate </text>
<text top="515" left="353" width="111" height="17" font="5">endpoints, 1 had no </text>
<text top="532" left="353" width="150" height="17" font="5">separate results and 1 was </text>
<text top="549" left="353" width="128" height="17" font="5">in a specific population </text>
<text top="567" left="353" width="149" height="17" font="5">•Trials included were HPS, </text>
<text top="584" left="353" width="145" height="17" font="5">CARDS, ASPEN, ASCOT-</text>
<text top="601" left="353" width="25" height="17" font="5">LLA </text>
<text top="618" left="353" width="126" height="17" font="5">•Baseline data in the 4 </text>
<text top="635" left="353" width="33" height="17" font="5">trials: </text>
<text top="653" left="353" width="157" height="18" font="5">• Men; 77%, 62%, 68%, NR </text>
<text top="671" left="353" width="155" height="18" font="5">• Mean age; 60, 62, 64, NR </text>
<text top="689" left="353" width="143" height="18" font="5">• HTN%; 52, 84, 100, NR </text>
<text top="707" left="353" width="155" height="18" font="5">• Smokers; 20.4, 12, 23 NR </text>
<text top="726" left="353" width="147" height="18" font="5">• Mean LDL-C mmol/l 3.3, </text>
<text top="744" left="363" width="69" height="17" font="5">2.9, 3.0, NR </text>
<text top="217" left="524" width="75" height="17" font="5">Intervention:  </text>
<text top="234" left="524" width="126" height="17" font="5"> Statin; n=5100 (simva </text>
<text top="252" left="524" width="122" height="17" font="5">40mg daily in 1 study, </text>
<text top="269" left="524" width="138" height="17" font="5">atorva 10mg in 3 studies </text>
<text top="286" left="524" width="3" height="17" font="5"> </text>
<text top="303" left="524" width="75" height="17" font="5">Comparator:  </text>
<text top="321" left="524" width="96" height="17" font="5">Placebo; n=5087 </text>
<text top="338" left="524" width="130" height="17" font="5">Mean(range) follow-up; </text>
<text top="355" left="524" width="80" height="17" font="5">3.8 (2.4-4.8) y </text>
<text top="218" left="683" width="7" height="17" font="5">1</text>
<text top="217" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="236" left="683" width="145" height="17" font="5">•Major cardiovascular and </text>
<text top="253" left="683" width="138" height="17" font="5">cerebrovascular events;  </text>
<text top="270" left="683" width="85" height="17" font="5">•Results: n (%) </text>
<text top="287" left="683" width="98" height="17" font="5">Statin 434 (8.5%) </text>
<text top="304" left="683" width="118" height="17" font="5">Placebo 576 (11.3%) </text>
<text top="322" left="683" width="185" height="17" font="5">RR: 0.75; 95% CI: 0.67–0.85; 3/4 </text>
<text top="339" left="683" width="131" height="17" font="5">studies were significant </text>
<text top="356" left="683" width="180" height="17" font="5">•NNT/3.8 y; 35; (95% CI: 25–58) </text>
<text top="373" left="683" width="3" height="17" font="5"> </text>
<text top="217" left="906" width="80" height="17" font="5">2° endpoints:  </text>
<text top="234" left="906" width="190" height="18" font="5">•  -Fatal/non-fatal stroke events </text>
<text top="253" left="933" width="83" height="17" font="5">(n) (3 studies)  </text>
<text top="270" left="906" width="79" height="18" font="5">•  Statin 75 </text>
<text top="288" left="906" width="99" height="18" font="5">•  Placebo 109 </text>
<text top="306" left="906" width="145" height="18" font="5">•  RR 0.69 (0.51–0.92)  </text>
<text top="325" left="906" width="149" height="18" font="5">•  NNT 0.69 (0.51–0.92) </text>
<text top="343" left="906" width="184" height="18" font="5">•  Fatal/non-fatal MI events (n) </text>
<text top="361" left="933" width="64" height="17" font="5">(3 studies)  </text>
<text top="378" left="906" width="79" height="18" font="5">•  Statin 99 </text>
<text top="397" left="906" width="99" height="18" font="5">•  Placebo 141 </text>
<text top="415" left="906" width="142" height="18" font="5">•  RR 0.70 (0.54–0.90) </text>
<text top="433" left="906" width="125" height="18" font="5">•  NNT 86 (50–290) </text>
<text top="451" left="906" width="189" height="18" font="5">•  All-cause mortality events (n) </text>
<text top="469" left="933" width="64" height="17" font="5">(2 studies)  </text>
<text top="487" left="906" width="86" height="18" font="5">•  Statin 105 </text>
<text top="505" left="906" width="99" height="18" font="5">•  Placebo 123 </text>
<text top="523" left="906" width="142" height="18" font="5">•  RR 0.84 (0.65–1.09) </text>
<text top="541" left="906" width="80" height="18" font="5">•  NNT 130 </text>
<text top="560" left="906" width="3" height="17" font="5"> </text>
<text top="577" left="906" width="66" height="17" font="5">Limitations: </text>
<text top="594" left="906" width="179" height="18" font="5">• differences between studies in </text>
<text top="612" left="917" width="171" height="17" font="5">endpoints although these were </text>
<text top="629" left="917" width="34" height="17" font="5">minor </text>
<text top="647" left="906" width="196" height="18" font="5">• included some subjects with CVD </text>
<text top="665" left="917" width="128" height="17" font="5">(~12% in ASCOT-LLA) </text>
<text top="682" left="906" width="173" height="18" font="5">• diagnostic criteria of diabetes </text>
<text top="700" left="917" width="44" height="17" font="5">differed </text>
<text top="718" left="906" width="159" height="18" font="5">• differences in baseline risk </text>
<text top="736" left="906" width="190" height="18" font="5">• in HPS and ASCOT-LLA subject </text>
<text top="754" left="917" width="170" height="17" font="5">with diabetes were a subgroup </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="906" width="176" height="18" font="5">• Drop-in statin used in placebo </text>
<text top="109" left="917" width="44" height="17" font="5">groups. </text>
<text top="133" left="75" width="55" height="17" font="5">JUPITER </text>
<text top="151" left="75" width="97" height="17" font="5">Ridker PM, et al., </text>
<text top="168" left="75" width="31" height="17" font="5">2008 </text>
<text top="185" left="75" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196">18997196</a></text>
<text top="185" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196"> </a></text>
<text top="133" left="202" width="108" height="17" font="5">Aim: To investigate </text>
<text top="151" left="202" width="128" height="17" font="5">whether treatment with </text>
<text top="168" left="202" width="111" height="17" font="5">rosuvastatin, 20 mg </text>
<text top="185" left="202" width="133" height="17" font="5">daily vs. placebo, would </text>
<text top="202" left="202" width="106" height="17" font="5">decrease MACE in </text>
<text top="220" left="202" width="104" height="17" font="5">apparently healthy </text>
<text top="237" left="202" width="121" height="17" font="5">persons with levels of </text>
<text top="254" left="202" width="116" height="17" font="5">LDL-C below current </text>
<text top="271" left="202" width="136" height="17" font="5">treatment thresholds but </text>
<text top="288" left="202" width="102" height="17" font="5">with elevated high-</text>
<text top="306" left="202" width="111" height="17" font="5">sensitivity (hs) CRP </text>
<text top="323" left="202" width="3" height="17" font="5"> </text>
<text top="340" left="202" width="137" height="17" font="5">Study type: Randomized </text>
<text top="357" left="202" width="117" height="17" font="5">double-blind placebo </text>
<text top="374" left="202" width="120" height="17" font="5">controlled clinical trial </text>
<text top="392" left="202" width="3" height="17" font="5"> </text>
<text top="409" left="202" width="120" height="17" font="5">Size: 17,802 subjects </text>
<text top="133" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="151" left="353" width="121" height="18" font="5">•  Age: men &gt;50 and </text>
<text top="169" left="370" width="77" height="17" font="5">women &gt;60 y </text>
<text top="186" left="353" width="117" height="18" font="5">•  LDL-C&lt;130 mg/dl </text>
<text top="204" left="353" width="103" height="18" font="5">•  hsCRP &gt;2 mg/l </text>
<text top="223" left="353" width="141" height="18" font="5">•  triglyceride&lt;500 mg/dl </text>
<text top="241" left="353" width="3" height="17" font="5"> </text>
<text top="258" left="353" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="275" left="353" width="103" height="18" font="5">•  history of CVD  </text>
<text top="294" left="353" width="67" height="18" font="5">•  diabetes </text>
<text top="312" left="353" width="126" height="18" font="5">•  past or current lipid-</text>
<text top="330" left="370" width="94" height="17" font="5">lowering therapy </text>
<text top="347" left="353" width="143" height="18" font="5">•  PMP hormone therapy </text>
<text top="365" left="353" width="93" height="18" font="5">•  ALT&gt;2X ULN </text>
<text top="384" left="353" width="96" height="18" font="5">•  CPK&gt;3X ULN </text>
<text top="402" left="353" width="104" height="18" font="5">•  SCr ±2.0 mg/dl </text>
<text top="420" left="353" width="116" height="18" font="5">•  uncontrolled HTN </text>
<text top="438" left="353" width="57" height="18" font="5">•  cancer </text>
<text top="457" left="353" width="121" height="18" font="5">•  inflammatory state </text>
<text top="475" left="353" width="103" height="18" font="5">•  hypothyroidism </text>
<text top="493" left="353" width="113" height="18" font="5">•  substance abuse </text>
<text top="511" left="353" width="3" height="17" font="5"> </text>
<text top="528" left="353" width="136" height="17" font="5">Baseline characteristics: </text>
<text top="546" left="353" width="111" height="18" font="5">•  mean [IQR] age; </text>
<text top="564" left="353" width="85" height="18" font="5">•  66 [60-71] y </text>
<text top="582" left="353" width="109" height="18" font="5">•  females 38-39% </text>
<text top="601" left="353" width="152" height="18" font="5">•  Metabolic syndrome (41-</text>
<text top="619" left="370" width="32" height="17" font="5">42%) </text>
<text top="636" left="353" width="148" height="18" font="5">•  mean LDL-C 108 mg/dl </text>
<text top="133" left="524" width="75" height="17" font="5">Intervention:  </text>
<text top="151" left="524" width="144" height="17" font="5"> Rosuvastatin 20 mg daily </text>
<text top="168" left="524" width="49" height="17" font="5">-n=8901 </text>
<text top="185" left="524" width="142" height="17" font="5">-median [IQR] 1 y LDL-C; </text>
<text top="202" left="524" width="92" height="17" font="5">55 [44-72] mg/dl </text>
<text top="220" left="524" width="108" height="17" font="5">- 50% reduction vs. </text>
<text top="237" left="524" width="46" height="17" font="5">placebo </text>
<text top="254" left="524" width="3" height="17" font="5"> </text>
<text top="271" left="524" width="125" height="17" font="5">Comparator: Matching </text>
<text top="288" left="524" width="46" height="17" font="5">placebo </text>
<text top="306" left="524" width="48" height="17" font="5">n=8901  </text>
<text top="323" left="524" width="142" height="17" font="5">-median [IQR] 1 y LDL-C; </text>
<text top="340" left="524" width="106" height="17" font="5">110 [94-125] mg/dl </text>
<text top="135" left="683" width="7" height="17" font="5">1</text>
<text top="134" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="152" left="683" width="188" height="17" font="5">•Median follow-up 1.9 y; the study </text>
<text top="169" left="683" width="187" height="17" font="5">ended early because efficacy had </text>
<text top="186" left="683" width="55" height="17" font="5">been met </text>
<text top="203" left="683" width="195" height="17" font="5">•Primary endpoint: first nonfatal MI, </text>
<text top="221" left="683" width="191" height="17" font="5">non-fatal stroke, hospitalization for </text>
<text top="238" left="683" width="207" height="17" font="5">unstable angina, revascularization, or </text>
<text top="255" left="683" width="67" height="17" font="5">CVD death. </text>
<text top="272" left="683" width="48" height="17" font="5">Results: </text>
<text top="290" left="683" width="107" height="18" font="5">• n (rate/100pt.yrs) </text>
<text top="308" left="683" width="105" height="17" font="5">Rosuva 142 (0.77) </text>
<text top="325" left="683" width="107" height="17" font="5">Placebo 251 (1.36) </text>
<text top="342" left="683" width="167" height="17" font="5">HR: 0.56 ; 95% CI: 0.46–0.69; </text>
<text top="359" left="683" width="55" height="17" font="5">p&lt;0.0001 </text>
<text top="377" left="683" width="3" height="17" font="5"> </text>
<text top="133" left="906" width="163" height="17" font="5">2° Endpoint n (rate/100pt.yr): </text>
<text top="151" left="906" width="34" height="18" font="5">•  MI </text>
<text top="170" left="923" width="13" height="16" font="5">o </text>
<text top="169" left="944" width="98" height="17" font="5">Rosuva 31 (0.17) </text>
<text top="188" left="923" width="13" height="16" font="5">o </text>
<text top="186" left="944" width="101" height="17" font="5">Placebo 68 (0.37) </text>
<text top="205" left="923" width="13" height="16" font="5">o </text>
<text top="203" left="944" width="113" height="17" font="5">HR: 0.46;0.30–0.70; </text>
<text top="220" left="944" width="55" height="17" font="5">p=0.0002 </text>
<text top="238" left="906" width="56" height="18" font="5">•  Stroke </text>
<text top="257" left="923" width="13" height="16" font="5">o </text>
<text top="256" left="944" width="98" height="17" font="5">Rosuva 33 (0.18) </text>
<text top="275" left="923" width="13" height="16" font="5">o </text>
<text top="273" left="944" width="101" height="17" font="5">Placebo 64 (0.34) </text>
<text top="292" left="923" width="13" height="16" font="5">o </text>
<text top="290" left="944" width="133" height="17" font="5">HR: 0.52; 95% CI: 0.34–</text>
<text top="308" left="944" width="79" height="17" font="5">0.79; p=0.002 </text>
<text top="325" left="906" width="117" height="18" font="5">•  Revascularization </text>
<text top="345" left="923" width="13" height="16" font="5">o </text>
<text top="343" left="944" width="98" height="17" font="5">Rosuva 71 (0.38) </text>
<text top="362" left="923" width="13" height="16" font="5">o </text>
<text top="360" left="944" width="107" height="17" font="5">Placebo 131 (0.71) </text>
<text top="379" left="923" width="13" height="16" font="5">o </text>
<text top="377" left="944" width="133" height="17" font="5">HR: 0.54; 95% CI: 0.41–</text>
<text top="395" left="944" width="86" height="17" font="5">0.72; p&lt;0.0001 </text>
<text top="412" left="906" width="53" height="18" font="5">•  Death </text>
<text top="432" left="923" width="13" height="16" font="5">o </text>
<text top="430" left="944" width="105" height="17" font="5">Rosuva 198 (1.00) </text>
<text top="449" left="923" width="13" height="16" font="5">o </text>
<text top="447" left="944" width="107" height="17" font="5">Placebo 247 (1.25) </text>
<text top="466" left="923" width="13" height="16" font="5">o </text>
<text top="465" left="944" width="130" height="17" font="5">HR: 0.80; 95% CI: 0.67-</text>
<text top="482" left="944" width="72" height="17" font="5">0.97; p&lt;0.02 </text>
<text top="499" left="906" width="3" height="17" font="5"> </text>
<text top="516" left="906" width="121" height="17" font="5">Adverse events n(%): </text>
<text top="534" left="906" width="119" height="18" font="5">•  Muscle symptoms </text>
<text top="552" left="906" width="128" height="18" font="5">•  Rosuva 1421 (16.0) </text>
<text top="570" left="906" width="172" height="18" font="5">•  Placebo 1375 (15.4) p=0.34 </text>
<text top="588" left="906" width="93" height="18" font="5">•  ALT &gt;3XULN </text>
<text top="606" left="906" width="128" height="18" font="5">•  Rosuva 23 (0.3) 17  </text>
<text top="625" left="906" width="152" height="18" font="5">•  Placebo 17 (0.2) p=0.34 </text>
<text top="643" left="906" width="95" height="18" font="5">•  New diabetes </text>
<text top="661" left="906" width="118" height="18" font="5">•  Rosuva 270 (3.0)  </text>
<text top="679" left="906" width="159" height="18" font="5">•  Placebo 216 (2.4) p&lt;0.01 </text>
<text top="698" left="906" width="3" height="17" font="5"> </text>
<text top="715" left="906" width="66" height="17" font="5">Limitations: </text>
<text top="732" left="906" width="156" height="18" font="5">•  Non-diabetic participants </text>
<text top="750" left="906" width="184" height="18" font="5">•  age restricted to men &gt;50 and </text>
<text top="768" left="923" width="77" height="17" font="5">women &gt;60 y </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="118" height="17" font="5">AFCAPS-TEXCAPS  </text>
<text top="108" left="75" width="96" height="17" font="5">Downs JR, et al., </text>
<text top="125" left="75" width="31" height="17" font="5">1998 </text>
<text top="142" left="75" width="48" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9613910">9613910</a></text>
<text top="142" left="122" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9613910"> </a></text>
<text top="160" left="75" width="3" height="17" font="5"> </text>
<text top="91" left="202" width="134" height="17" font="5">Does lowering of LDL-C </text>
<text top="108" left="202" width="135" height="17" font="5">with statins benefit men, </text>
<text top="125" left="202" width="111" height="17" font="5">women, elderly with </text>
<text top="142" left="202" width="103" height="17" font="5">normal TC levels.  </text>
<text top="160" left="202" width="3" height="17" font="5"> </text>
<text top="177" left="202" width="128" height="17" font="5">Study Type: RCT 6805 </text>
<text top="194" left="202" width="68" height="17" font="5">Participants </text>
<text top="211" left="202" width="137" height="17" font="5">Size: 5608 men and 997 </text>
<text top="229" left="202" width="46" height="17" font="5">women. </text>
<text top="246" left="202" width="7" height="17" font="5">  </text>
<text top="263" left="202" width="87" height="17" font="5">Duration: 5.2 y  </text>
<text top="280" left="202" width="110" height="17" font="5">Included Hispanics, </text>
<text top="297" left="202" width="138" height="17" font="5">African Ameri- cans, and </text>
<text top="315" left="202" width="131" height="17" font="5">older persons (baseline </text>
<text top="332" left="202" width="137" height="17" font="5">mean age, 58.2 y; upper </text>
<text top="349" left="202" width="117" height="17" font="5">limit, 73 y; 21% older </text>
<text top="366" left="202" width="62" height="17" font="5">than 65 y). </text>
<text top="383" left="202" width="3" height="17" font="5"> </text>
<text top="91" left="353" width="102" height="17" font="5">Inclusion Criteria:  </text>
<text top="108" left="353" width="109" height="17" font="5">Men aged 45-73 y;  </text>
<text top="125" left="353" width="141" height="17" font="5">Postmenopausal Women </text>
<text top="142" left="353" width="141" height="17" font="5">aged 55-73 y; Men: 85%; </text>
<text top="160" left="353" width="81" height="17" font="5">Women 15%.  </text>
<text top="177" left="353" width="3" height="17" font="5"> </text>
<text top="194" left="353" width="102" height="17" font="5">Exclusion Criteria: </text>
<text top="211" left="353" width="149" height="17" font="5">Uncontrolled hypertension, </text>
<text top="229" left="353" width="146" height="17" font="5">secondary hyperlipidemia, </text>
<text top="246" left="353" width="138" height="17" font="5">type 1 or type 2 diabetes </text>
<text top="263" left="353" width="125" height="17" font="5">mellitus managed with </text>
<text top="280" left="353" width="154" height="17" font="5">insulin, a glycol-hemoglobin </text>
<text top="297" left="353" width="155" height="17" font="5">level ≥ 10%, or body weight </text>
<text top="315" left="353" width="130" height="17" font="5">≥ 50% greater than the </text>
<text top="332" left="353" width="137" height="17" font="5">desirable limit for height. </text>
<text top="349" left="353" width="3" height="17" font="5"> </text>
<text top="366" left="353" width="100" height="17" font="5">Lipid entry criteria </text>
<text top="383" left="353" width="146" height="17" font="5">TC 180-264; (4.65 - 6.82)  </text>
<text top="401" left="353" width="161" height="17" font="5">LDL-C, 130-190 (3.36- 4.91)  </text>
<text top="418" left="353" width="133" height="17" font="5">HDL-C: men: &lt;45 mg/dl </text>
<text top="435" left="353" width="39" height="17" font="5">(1.16)  </text>
<text top="452" left="353" width="148" height="17" font="5">HDL-C:  women &lt;47 mg/dl </text>
<text top="469" left="353" width="39" height="17" font="5">(1.22)  </text>
<text top="487" left="353" width="134" height="17" font="5">TG&lt;400 mg/dl; (4.52) at </text>
<text top="504" left="353" width="128" height="17" font="5">both 4 and 2 wk before </text>
<text top="521" left="353" width="144" height="17" font="5">randomization, with &lt;15% </text>
<text top="538" left="353" width="152" height="17" font="5">change in LDL-C values. In </text>
<text top="556" left="353" width="148" height="17" font="5">addition, those with LDL-C </text>
<text top="573" left="353" width="132" height="17" font="5">between 125-129 mg/dl </text>
<text top="590" left="353" width="117" height="17" font="5">(3.23 and 3.34) were </text>
<text top="607" left="353" width="154" height="17" font="5">included if the ratio of TC to </text>
<text top="624" left="353" width="76" height="17" font="5">HDL-C &gt; 6.0. </text>
<text top="91" left="524" width="131" height="17" font="5">G1: Lovastatin 20 or 40 </text>
<text top="108" left="524" width="81" height="17" font="5">mg/d N=3304  </text>
<text top="125" left="524" width="121" height="17" font="5">G2: Placebo N=3301  </text>
<text top="142" left="524" width="3" height="17" font="5"> </text>
<text top="160" left="524" width="131" height="17" font="5">Definition of Outcomes: </text>
<text top="177" left="524" width="126" height="17" font="5">Primary outcome (PO) </text>
<text top="194" left="524" width="95" height="17" font="5">First acute major </text>
<text top="211" left="524" width="145" height="17" font="5">coronary event defined as </text>
<text top="229" left="524" width="88" height="17" font="5">fatal or nonfatal </text>
<text top="246" left="524" width="119" height="17" font="5">myocardial infarction, </text>
<text top="263" left="524" width="108" height="17" font="5">unstable angina, or </text>
<text top="280" left="524" width="128" height="17" font="5">sudden cardiac death.  </text>
<text top="297" left="524" width="110" height="17" font="5">AFCAPS found that </text>
<text top="315" left="524" width="113" height="17" font="5">approximately equal </text>
<text top="332" left="524" width="121" height="17" font="5">numbers present with </text>
<text top="349" left="524" width="125" height="17" font="5">unstable angina or MI. </text>
<text top="366" left="524" width="3" height="17" font="5"> </text>
<text top="91" left="683" width="103" height="17" font="5">Primary Outcome  </text>
<text top="108" left="683" width="109" height="17" font="5">G1 116/3301; 3.5% </text>
<text top="125" left="683" width="113" height="17" font="5">G2: 183/3304; 5.5% </text>
<text top="142" left="683" width="146" height="17" font="5">0.63; (0.50-0.70) p&lt;0.001  </text>
<text top="160" left="683" width="138" height="17" font="5">Rates per 1000 patient y </text>
<text top="177" left="683" width="129" height="17" font="5">G1 6.8% vs. G2 10.9% </text>
<text top="194" left="683" width="3" height="17" font="5"> </text>
<text top="211" left="683" width="169" height="17" font="5">The differences between the 2 </text>
<text top="229" left="683" width="198" height="17" font="5">treatment groups appeared as early </text>
<text top="246" left="683" width="211" height="17" font="5">as 1 y (40 w/events in G2 vs.23 in G1  </text>
<text top="263" left="683" width="208" height="17" font="5">For the primary end point, these rates </text>
<text top="280" left="683" width="202" height="17" font="5">correspond to cumulative incidences </text>
<text top="297" left="683" width="194" height="17" font="5">of 4.0% and 6.8% for the lovastatin </text>
<text top="315" left="683" width="187" height="17" font="5">and placebo groups, respectively, </text>
<text top="332" left="683" width="188" height="17" font="5">during the study period (p 0.001).  </text>
<text top="349" left="683" width="89" height="17" font="5">LDL-C changes </text>
<text top="366" left="683" width="203" height="17" font="5">G1: LDL-C 151 (3.89) (lower by 25% </text>
<text top="383" left="683" width="121" height="17" font="5">reduced to 115 (2.96) </text>
<text top="401" left="683" width="3" height="17" font="5"> </text>
<text top="91" left="906" width="173" height="17" font="5">Primary endpoint risk reduction </text>
<text top="108" left="906" width="158" height="17" font="5">with lovastatin was apparent </text>
<text top="125" left="906" width="187" height="17" font="5">across all baseline LDL-C tertiles  </text>
<text top="142" left="906" width="150" height="17" font="5">with no threshold to benefit </text>
<text top="160" left="906" width="182" height="17" font="5">observed across baseline LDL-C </text>
<text top="177" left="906" width="194" height="17" font="5">levels LDL-C ≤142 (3.67); 143-156 </text>
<text top="194" left="906" width="139" height="17" font="5">(3.67-4.05) ≥157 (&gt;4.05) </text>
<text top="211" left="906" width="179" height="17" font="5">There were no clinically relevant </text>
<text top="229" left="906" width="178" height="17" font="5">differences in safety parameters </text>
<text top="246" left="906" width="153" height="17" font="5">between treatment groups.  </text>
<text top="263" left="906" width="3" height="17" font="5"> </text>
<text top="280" left="906" width="166" height="17" font="5">Study Limitations: Inclusion of </text>
<text top="297" left="906" width="168" height="17" font="5">unstable angina in the primary </text>
<text top="315" left="906" width="167" height="17" font="5">endpoint; but in this trial equal </text>
<text top="332" left="906" width="185" height="17" font="5">numbers presented with unstable </text>
<text top="349" left="906" width="127" height="17" font="5">angina or non-fatal MI. </text>
<text top="366" left="906" width="133" height="17" font="5">New Onset of Diabetes  </text>
<text top="383" left="906" width="40" height="17" font="5">G1: 74 </text>
<text top="401" left="906" width="40" height="17" font="5">G2: 72 </text>
<text top="418" left="906" width="3" height="17" font="5"> </text>
<text top="643" left="75" width="46" height="17" font="5">SHARP </text>
<text top="660" left="75" width="94" height="17" font="5">Baigent C, et al., </text>
<text top="678" left="75" width="31" height="17" font="5">2011 </text>
<text top="695" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21663949">21663949</a></text>
<text top="695" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21663949"> </a></text>
<text top="643" left="202" width="124" height="17" font="5">Aim: To assess safety </text>
<text top="660" left="202" width="133" height="17" font="5">and efficacy of reducing </text>
<text top="678" left="202" width="111" height="17" font="5">LDL in persons with </text>
<text top="695" left="202" width="29" height="17" font="5">CKD </text>
<text top="712" left="202" width="132" height="17" font="5">Placebo vs. simvastatin </text>
<text top="729" left="202" width="118" height="17" font="5">20mg + ezetimibe 10 </text>
<text top="746" left="202" width="49" height="17" font="5">mg daily </text>
<text top="764" left="202" width="3" height="17" font="5"> </text>
<text top="643" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="660" left="353" width="152" height="18" font="5">• Age ≥40, Cr 1.7 men, 1.5 </text>
<text top="679" left="353" width="131" height="17" font="5">women, With or without </text>
<text top="696" left="353" width="44" height="17" font="5">dialysis </text>
<text top="713" left="353" width="146" height="18" font="5">• Total randomized: 9,438 </text>
<text top="732" left="353" width="3" height="17" font="5"> </text>
<text top="749" left="353" width="103" height="17" font="5">Exclusion criteria:  </text>
<text top="643" left="524" width="119" height="17" font="5">Intervention: Placebo </text>
<text top="660" left="524" width="142" height="17" font="5">(N=4,620) vs. simvastatin </text>
<text top="678" left="524" width="138" height="17" font="5">20mg + ezetimibe 10 mg </text>
<text top="695" left="524" width="87" height="17" font="5">daily (N=4,650) </text>
<text top="712" left="524" width="7" height="17" font="5">  </text>
<text top="729" left="524" width="75" height="17" font="5">Comparator:  </text>
<text top="747" left="524" width="109" height="18" font="5">• Placebo, N=4620 </text>
<text top="765" left="524" width="138" height="18" font="5">• Duration: median 4.9 y </text>
<text top="644" left="683" width="7" height="17" font="5">1</text>
<text top="643" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="662" left="683" width="196" height="18" font="5">• major atherosclerotic events (non-</text>
<text top="680" left="683" width="172" height="17" font="5">fatal MI or coronary death, non-</text>
<text top="697" left="683" width="153" height="17" font="5">hemorrhagic stroke, arterial </text>
<text top="714" left="683" width="100" height="17" font="5">revascularization) </text>
<text top="732" left="683" width="132" height="18" font="5">• Placebo: 619 (13.4%) </text>
<text top="750" left="683" width="152" height="18" font="5">• Intervention: 526 (11.3%) </text>
<text top="768" left="683" width="190" height="18" font="5">• RR 0.83 (0.74 to 0.94), p 0.0021 </text>
<text top="643" left="906" width="148" height="18" font="5">• lack of power for dialysis </text>
<text top="661" left="906" width="55" height="17" font="5">subgroup </text>
<text top="679" left="906" width="173" height="18" font="5">• Crossover: 33% discontinued </text>
<text top="697" left="906" width="158" height="17" font="5">intervention, 14% in placebo </text>
<text top="714" left="906" width="143" height="17" font="5">started non-statin therapy </text>
<text top="732" left="906" width="158" height="18" font="5">• Few persons on peritoneal </text>
<text top="750" left="906" width="44" height="17" font="5">dialysis </text>
<text top="767" left="906" width="3" height="17" font="5"> </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="202" width="94" height="17" font="5">Study type: RCT </text>
<text top="108" left="202" width="3" height="17" font="5"> </text>
<text top="125" left="202" width="133" height="17" font="5">Size: 9,270 randomized </text>
<text top="142" left="202" width="106" height="17" font="5">Study duration: 4 y </text>
<text top="160" left="202" width="82" height="17" font="5">(median 4.9 y) </text>
<text top="91" left="353" width="137" height="18" font="5">• 6 wk run-in period with </text>
<text top="109" left="353" width="102" height="17" font="5">placebo to identify </text>
<text top="126" left="353" width="77" height="17" font="5">noncompliers </text>
<text top="144" left="353" width="69" height="18" font="5">• Prior CVD </text>
<text top="162" left="353" width="148" height="18" font="5">• Note re egfr: among non-</text>
<text top="180" left="353" width="143" height="17" font="5">dialysis, mean eGFR was </text>
<text top="198" left="353" width="151" height="17" font="5">26.6 (SD 13). 36% stage 3, </text>
<text top="215" left="353" width="151" height="17" font="5">43% stage 4, 20% stage 5  </text>
<text top="232" left="353" width="155" height="17" font="5">20% ACR &lt;30, 38% 30-300 </text>
<text top="249" left="353" width="83" height="17" font="5">and 42% &gt;300 </text>
<text top="267" left="353" width="99" height="18" font="5">• 33% on dialysis </text>
<text top="285" left="353" width="88" height="18" font="5">• 23% diabetes </text>
<text top="303" left="353" width="3" height="17" font="5"> </text>
<text top="91" left="683" width="208" height="18" font="5">• LDL chol. reduction for intervention: </text>
<text top="109" left="683" width="183" height="17" font="5">Overall, -1.08 y 1, -0.84 at 44 mo </text>
<text top="126" left="683" width="204" height="18" font="5">• 1.1 mmol/ L for non-dialysis (39%), </text>
<text top="145" left="683" width="96" height="17" font="5">- 0.75 for dialysis </text>
<text top="162" left="683" width="186" height="18" font="5">• Effects consistent across eGFR </text>
<text top="180" left="683" width="54" height="17" font="5">category  </text>
<text top="198" left="683" width="150" height="18" font="5">• No statistically significant </text>
<text top="216" left="683" width="143" height="17" font="5">differences by CKD stage </text>
<text top="233" left="683" width="3" height="17" font="5"> </text>
<text top="250" left="683" width="104" height="17" font="5">Dialysis subgroup: </text>
<text top="268" left="683" width="204" height="17" font="5">3023 on dialysis (2527 hemodialysis, </text>
<text top="285" left="683" width="129" height="17" font="5">496 peritoneal dialysis) </text>
<text top="302" left="683" width="3" height="17" font="5"> </text>
<text top="319" left="683" width="142" height="18" font="5">• Intervention: 230 (15%) </text>
<text top="338" left="683" width="132" height="18" font="5">• Placebo: 246 (16.5%) </text>
<text top="356" left="683" width="136" height="18" font="5">• RR 0.90 (0.75 to 1.08) </text>
<text top="374" left="683" width="3" height="17" font="5"> </text>
<text top="392" left="683" width="161" height="17" font="5">Safety endpoint (if relevant):  </text>
<text top="409" left="683" width="103" height="17" font="5">• No differences in </text>
<text top="426" left="683" width="160" height="17" font="5">Cancer, cancer mortality, CK </text>
<text top="443" left="683" width="141" height="17" font="5">concentration, myopathy, </text>
<text top="460" left="683" width="195" height="17" font="5">rhabdomyolysis, persistently raised </text>
<text top="478" left="683" width="202" height="17" font="5">transaminases, hepatitis, gallstones, </text>
<text top="495" left="683" width="66" height="17" font="5">pancreatitis </text>
<text top="512" left="683" width="189" height="18" font="5">• Note: 34% transitioned to ESRD </text>
<text top="530" left="683" width="81" height="17" font="5">during the trial </text>
<text top="91" left="906" width="196" height="17" font="5">Important Note: initially randomized </text>
<text top="108" left="906" width="165" height="17" font="5">3 ways (placebo, statin alone, </text>
<text top="125" left="906" width="185" height="17" font="5">ezetimibe plus simva) – the statin </text>
<text top="142" left="906" width="175" height="17" font="5">only was then re-randomized to </text>
<text top="160" left="906" width="181" height="17" font="5">intervention vs. placebo after 1 y </text>
<text top="177" left="906" width="3" height="17" font="5"> </text>
<text top="548" left="75" width="65" height="17" font="5">Cholesterol </text>
<text top="566" left="75" width="108" height="17" font="5">Treatment Trialists’ </text>
<text top="583" left="75" width="36" height="17" font="5">(CTT) </text>
<text top="600" left="75" width="81" height="17" font="5">Collaboration* </text>
<text top="617" left="75" width="102" height="17" font="5">Herrington WG, et </text>
<text top="634" left="75" width="54" height="17" font="5">al., 2016  </text>
<text top="652" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27477773">27477773</a></text>
<text top="652" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27477773"> </a></text>
<text top="548" left="202" width="130" height="17" font="5">Aim: Compare Effect of </text>
<text top="566" left="202" width="138" height="17" font="5">statin by renal function -  </text>
<text top="583" left="202" width="127" height="17" font="5">Please check the ref is </text>
<text top="600" left="202" width="72" height="17" font="5">the following </text>
<text top="617" left="202" width="3" height="17" font="5"> </text>
<text top="634" left="202" width="96" height="17" font="5">Study type: Meta-</text>
<text top="652" left="202" width="48" height="17" font="5">analysis </text>
<text top="669" left="202" width="3" height="17" font="5"> </text>
<text top="686" left="202" width="80" height="17" font="5">Size: 28 trials, </text>
<text top="703" left="202" width="64" height="17" font="5">N=183,419 </text>
<text top="548" left="353" width="145" height="17" font="5">Inclusion criteria: Included </text>
<text top="566" left="353" width="158" height="17" font="5">all trials in renal populations, </text>
<text top="583" left="353" width="128" height="17" font="5">primary and secondary </text>
<text top="600" left="353" width="61" height="17" font="5">prevention </text>
<text top="617" left="353" width="3" height="17" font="5"> </text>
<text top="634" left="353" width="154" height="17" font="5">Exclusion criteria: trials with </text>
<text top="652" left="353" width="137" height="17" font="5">no information on kidney </text>
<text top="669" left="353" width="57" height="17" font="5">measures </text>
<text top="548" left="524" width="125" height="17" font="5">Intervention: Statin vs. </text>
<text top="566" left="524" width="46" height="17" font="5">placebo </text>
<text top="583" left="524" width="46" height="17" font="5">23 trials </text>
<text top="600" left="524" width="3" height="17" font="5"> </text>
<text top="617" left="524" width="130" height="17" font="5">5 trials compared statin </text>
<text top="634" left="524" width="30" height="17" font="5">dose </text>
<text top="652" left="524" width="7" height="17" font="5">  </text>
<text top="669" left="524" width="120" height="17" font="5">Comparator: Placebo </text>
<text top="550" left="683" width="7" height="17" font="5">1</text>
<text top="548" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="567" left="683" width="209" height="18" font="5">• Major vascular events (non-fatal MI, </text>
<text top="585" left="683" width="180" height="17" font="5">coronary death, stroke, coronary </text>
<text top="602" left="683" width="100" height="17" font="5">revascularization) </text>
<text top="620" left="683" width="199" height="17" font="5">Note: able to readjudicate AURORA </text>
<text top="637" left="683" width="96" height="17" font="5">coronary deaths) </text>
<text top="654" left="683" width="207" height="18" font="5">• Estimates as rate ratios per mmol/L </text>
<text top="672" left="683" width="89" height="17" font="5">of LDL lowering </text>
<text top="690" left="683" width="181" height="18" font="5">• Overall, RR 0.79 (0.77 to 0.81) </text>
<text top="708" left="683" width="184" height="18" font="5">• Smaller relative effects as GFR </text>
<text top="726" left="683" width="199" height="17" font="5">declined (p=0.008 for trend), benefit </text>
<text top="744" left="683" width="111" height="17" font="5">not seen on dialysis </text>
<text top="761" left="683" width="3" height="17" font="5"> </text>
<text top="548" left="906" width="173" height="18" font="5">• Particular strength: considers </text>
<text top="567" left="906" width="190" height="17" font="5">differences in achieved LDL levels </text>
<text top="584" left="906" width="183" height="17" font="5">across trials, uniform definition of </text>
<text top="601" left="906" width="192" height="17" font="5">outcome in dialysis trials (coronary </text>
<text top="618" left="906" width="38" height="17" font="5">death) </text>
<text top="636" left="906" width="3" height="17" font="5"> </text>
<text top="653" left="906" width="60" height="17" font="5">Limitation: </text>
<text top="670" left="906" width="163" height="18" font="5">• Concern over agreement of </text>
<text top="689" left="906" width="139" height="17" font="5">causes of vascular death </text>
<text top="706" left="906" width="193" height="17" font="5">adjudication in patients with kidney </text>
<text top="723" left="906" width="46" height="17" font="5">disease </text>
<text top="740" left="906" width="3" height="17" font="5"> </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="183" height="17" font="5">N, % events per year, and RR by </text>
<text top="108" left="683" width="36" height="17" font="5">eGFR </text>
<text top="125" left="683" width="147" height="18" font="5">• eGFR 45-60 (N=34,417) </text>
<text top="144" left="683" width="85" height="17" font="5"> 4.6% vs. 3.6% </text>
<text top="161" left="683" width="104" height="17" font="5">0.76 (0.70 to 0.81) </text>
<text top="178" left="683" width="147" height="18" font="5">• eGFR 30-45 (N=10,634) </text>
<text top="196" left="683" width="71" height="17" font="5">5.2 vs. 4.5% </text>
<text top="214" left="683" width="107" height="17" font="5"> 0.85 (0.75 to 0.96) </text>
<text top="231" left="683" width="113" height="18" font="5">• eGFR &lt;30 (5,368) </text>
<text top="249" left="683" width="60" height="17" font="5">3.5 vs. 3.0 </text>
<text top="266" left="683" width="104" height="17" font="5">0.85 (0.71 to 1.02) </text>
<text top="284" left="683" width="111" height="18" font="5">• Dialysis (N=7053) </text>
<text top="302" left="683" width="60" height="17" font="5">5.0 vs. 4.7 </text>
<text top="319" left="683" width="104" height="17" font="5">0.94 (0.79 to 1.11) </text>
<text top="337" left="75" width="106" height="17" font="5">Justification for the </text>
<text top="354" left="75" width="91" height="17" font="5">Use of statins in </text>
<text top="372" left="75" width="83" height="17" font="5">Prevention: an </text>
<text top="389" left="75" width="95" height="17" font="5">Intervention Trial </text>
<text top="406" left="75" width="61" height="17" font="5">Evaluating </text>
<text top="423" left="75" width="71" height="17" font="5">Rosuvastain </text>
<text top="440" left="75" width="63" height="17" font="5">(JUPITER) </text>
<text top="458" left="75" width="3" height="17" font="5"> </text>
<text top="475" left="75" width="100" height="17" font="5">Ridker et al, 2016 </text>
<text top="492" left="75" width="3" height="17" font="5"> </text>
<text top="509" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26916794">26916794</a></text>
<text top="509" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26916794"> </a></text>
<text top="337" left="202" width="136" height="17" font="5">Aim: assess relationship </text>
<text top="354" left="202" width="128" height="17" font="5">of per cent reduction in </text>
<text top="372" left="202" width="100" height="17" font="5">LDLC with clinical </text>
<text top="389" left="202" width="80" height="17" font="5">outcomes in a </text>
<text top="406" left="202" width="79" height="17" font="5">contemporary </text>
<text top="423" left="202" width="104" height="17" font="5">randomized trial of </text>
<text top="440" left="202" width="107" height="17" font="5">rosuvastatin 20 mg </text>
<text top="458" left="202" width="116" height="17" font="5">when compared with </text>
<text top="475" left="202" width="124" height="17" font="5">placebo in the primary </text>
<text top="492" left="202" width="74" height="17" font="5">prevention of </text>
<text top="509" left="202" width="122" height="17" font="5">cardiovascular events </text>
<text top="526" left="202" width="3" height="17" font="5"> </text>
<text top="544" left="202" width="94" height="17" font="5">Study type: RCT </text>
<text top="561" left="202" width="116" height="17" font="5">(secondary analysis) </text>
<text top="578" left="202" width="3" height="17" font="5"> </text>
<text top="595" left="202" width="72" height="17" font="5">Size: 17.082 </text>
<text top="337" left="353" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="355" left="353" width="76" height="18" font="5">•asyptomatic </text>
<text top="373" left="353" width="112" height="18" font="5">•Women ≥60 years </text>
<text top="391" left="353" width="93" height="18" font="5">•Men ≥50 years </text>
<text top="410" left="353" width="111" height="18" font="5">•LDLC &lt;130 mg/dL </text>
<text top="428" left="353" width="105" height="18" font="5">•hsCRP≥2.0 mg/L </text>
<text top="446" left="353" width="145" height="18" font="5">•triglycerides &lt;500 mg/dL </text>
<text top="465" left="353" width="3" height="17" font="5"> </text>
<text top="482" left="353" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="499" left="353" width="146" height="18" font="5">•history of CVD, diabetes, </text>
<text top="517" left="353" width="126" height="17" font="5">or use of lipid lowering </text>
<text top="535" left="353" width="44" height="17" font="5">therapy </text>
<text top="552" left="353" width="3" height="17" font="5"> </text>
<text top="337" left="524" width="141" height="17" font="5">Intervention: rosuvastatin </text>
<text top="354" left="524" width="66" height="17" font="5">20 mg daily </text>
<text top="372" left="524" width="3" height="17" font="5"> </text>
<text top="389" left="524" width="118" height="17" font="5">Comparator: placebo </text>
<text top="338" left="683" width="7" height="17" font="5">1</text>
<text top="337" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="356" left="683" width="149" height="17" font="5">Composite endpoint of first </text>
<text top="373" left="683" width="192" height="17" font="5">occurrence of non-fatal myocardial </text>
<text top="390" left="683" width="148" height="17" font="5">infarction, non-fatal stroke, </text>
<text top="407" left="683" width="193" height="17" font="5">hospitalization for unstable angina, </text>
<text top="424" left="683" width="154" height="17" font="5">arterial revascularization, or </text>
<text top="442" left="683" width="117" height="17" font="5">cardiovascular death </text>
<text top="459" left="683" width="3" height="17" font="5"> </text>
<text top="476" left="683" width="51" height="17" font="5">Results:  </text>
<text top="493" left="683" width="200" height="17" font="7"><i>By LDLC reduction: </i>significant trend </text>
<text top="510" left="683" width="152" height="17" font="5">by group in incidence (p for </text>
<text top="528" left="683" width="188" height="17" font="5">trend&lt;0.000001), and relationship </text>
<text top="545" left="683" width="196" height="17" font="5">between percent reduction in group </text>
<text top="562" left="683" width="167" height="17" font="5">on active rosuvastatin p=0.01. </text>
<text top="579" left="683" width="3" height="17" font="7"><i> </i></text>
<text top="597" left="683" width="205" height="17" font="5">Placebo: 11.2 per 1000 person years </text>
<text top="614" left="683" width="100" height="17" font="5">(95% CI 9.7-12.9) </text>
<text top="631" left="683" width="3" height="17" font="5"> </text>
<text top="648" left="683" width="175" height="17" font="5">No LDL reduction: 9.2 per 1000 </text>
<text top="665" left="683" width="200" height="17" font="5">person years (95% CI 5.6-15.3) (HR </text>
<text top="683" left="683" width="207" height="17" font="5">vs placebo=0.91, 95% CI 0.54-1.53),  </text>
<text top="700" left="683" width="3" height="17" font="5"> </text>
<text top="717" left="683" width="191" height="17" font="5">LDL reduction &lt;50%: 6.7 per 1000 </text>
<text top="734" left="683" width="209" height="17" font="5">person years (95% CI 5.1-8.9) (HR vs </text>
<text top="752" left="683" width="184" height="17" font="5">placebo=0.61, 95% CI 0.44-0.83) </text>
<text top="769" left="683" width="3" height="17" font="5"> </text>
<text top="337" left="906" width="3" height="17" font="5"> </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="192" height="17" font="5">LDL reduction ≥50%: 4.8 per 1000 </text>
<text top="108" left="683" width="209" height="17" font="5">person years (95% CI 3.5-6.6) (HR vs </text>
<text top="125" left="683" width="191" height="17" font="5">placebo=0.42, 95% CI 0.30-0.60)   </text>
<text top="142" left="683" width="3" height="17" font="5"> </text>
<text top="160" left="683" width="195" height="17" font="7"><i>By non-HDLC reduction: significant </i></text>
<text top="177" left="683" width="183" height="17" font="7"><i>trend by group in incidence (p for </i></text>
<text top="194" left="683" width="194" height="17" font="7"><i>trend &lt;0.000001)</i> , and relationship </text>
<text top="211" left="683" width="196" height="17" font="5">between percent reduction in group </text>
<text top="229" left="683" width="171" height="17" font="5">on active rosuvastatin p=0.046<i> </i></text>
<text top="246" left="683" width="3" height="17" font="5"> </text>
<text top="263" left="683" width="205" height="17" font="5">Placebo: 11.1 per 1000 person years </text>
<text top="280" left="683" width="104" height="17" font="5">(95% CI 9.6-12.8)  </text>
<text top="297" left="683" width="3" height="17" font="5"> </text>
<text top="315" left="683" width="189" height="17" font="5">No Non-HDLC reduction: 10.0 per </text>
<text top="332" left="683" width="202" height="17" font="5">1000 peson years (95% CI 6.1-16.3) </text>
<text top="349" left="683" width="197" height="17" font="5">(HR vs. placebo=0.99, 95% CI 0.60-</text>
<text top="366" left="683" width="31" height="17" font="5">1.66) </text>
<text top="383" left="683" width="3" height="17" font="5"> </text>
<text top="401" left="683" width="198" height="17" font="5">Non-HDLC reduction &lt;50%: 6.0 per </text>
<text top="418" left="683" width="199" height="17" font="5">1000 person years (95% CI 4.7-7.6) </text>
<text top="435" left="683" width="190" height="17" font="5">(HR vs placebo 0.54, 95% CI 0.41-</text>
<text top="452" left="683" width="31" height="17" font="5">0.71) </text>
<text top="469" left="683" width="3" height="17" font="5"> </text>
<text top="487" left="683" width="199" height="17" font="5">Non-HDLC reduction ≥50%: 5.2 per </text>
<text top="504" left="683" width="199" height="17" font="5">1000 person years (95% CI 3.6-7.7) </text>
<text top="521" left="683" width="190" height="17" font="5">(HR vs placebo 0.46, 95% CI 0.31-</text>
<text top="538" left="683" width="31" height="17" font="5">0.70) </text>
<text top="556" left="683" width="3" height="17" font="5"> </text>
<text top="573" left="683" width="167" height="17" font="5">By apolipoprotein B reduction: </text>
<text top="590" left="683" width="209" height="17" font="5">significant trend by group in incidence </text>
<text top="607" left="683" width="171" height="17" font="5">(p for trend, p&lt;0.000001) , and </text>
<text top="624" left="683" width="160" height="17" font="5">relationship between percent </text>
<text top="642" left="683" width="154" height="17" font="5">reduction in group on active </text>
<text top="659" left="683" width="118" height="17" font="5">rosuvastatin p=0.024 </text>
<text top="676" left="683" width="3" height="17" font="5"> </text>
<text top="693" left="683" width="205" height="17" font="5">Placebo: 11.0 per 1000 person years </text>
<text top="710" left="683" width="100" height="17" font="5">(95% CI 9.6-12.8) </text>
<text top="728" left="683" width="3" height="17" font="5"> </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="188" height="17" font="5">No apoB reduction: 11.9 per 1000 </text>
<text top="108" left="683" width="200" height="17" font="5">person years (95% CI 7.0-20.1) (HR </text>
<text top="125" left="683" width="193" height="17" font="5">vs placebo 1.14, 95% CI0.66-1.97) </text>
<text top="142" left="683" width="3" height="17" font="5"> </text>
<text top="160" left="683" width="197" height="17" font="5">&lt;50% apoB reduction: 5.7 per 1000 </text>
<text top="177" left="683" width="209" height="17" font="5">person years (95% CI 4.6-7.2) (HR vs </text>
<text top="194" left="683" width="181" height="17" font="5">placebo=0.51, 95% CI0.39-0.67) </text>
<text top="211" left="683" width="3" height="17" font="5"> </text>
<text top="229" left="683" width="198" height="17" font="5">≥50% apoB reduction: 4.7 per 1000 </text>
<text top="246" left="683" width="209" height="17" font="5">person years (95% CI 2.8-7.9) (HR vs </text>
<text top="263" left="683" width="184" height="17" font="5">placebo=0.43, 95% CI 0.25-0.75) </text>
<text top="281" left="75" width="102" height="17" font="5">Taylor et al., 2013 </text>
<text top="298" left="75" width="3" height="17" font="5"> </text>
<text top="315" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23440795">23440795</a></text>
<text top="315" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23440795"> </a></text>
<text top="281" left="202" width="59" height="17" font="5">Study Aim </text>
<text top="298" left="202" width="123" height="17" font="5">To assess the effects, </text>
<text top="315" left="202" width="89" height="17" font="5">both harms and </text>
<text top="333" left="202" width="115" height="17" font="5">benefits, of statins in </text>
<text top="350" left="202" width="136" height="17" font="5">people with no history of </text>
<text top="367" left="202" width="29" height="17" font="5">CVD </text>
<text top="384" left="202" width="3" height="17" font="5"> </text>
<text top="401" left="202" width="66" height="17" font="5">Study Type </text>
<text top="419" left="202" width="3" height="17" font="5"> </text>
<text top="436" left="202" width="63" height="17" font="5">N=18 trials </text>
<text top="453" left="202" width="3" height="17" font="5"> </text>
<text top="281" left="353" width="92" height="17" font="5">Inclusion criteria </text>
<text top="298" left="353" width="158" height="17" font="5">-randomized controlled trials </text>
<text top="315" left="353" width="153" height="17" font="5">of statins versus placebo or </text>
<text top="333" left="353" width="104" height="17" font="5">usual care control  </text>
<text top="350" left="353" width="116" height="17" font="5">- minimum treatment </text>
<text top="367" left="353" width="137" height="17" font="5">duration of one year and </text>
<text top="384" left="353" width="129" height="17" font="5">follow-up of six months </text>
<text top="401" left="353" width="120" height="17" font="5">-adults (18 and older) </text>
<text top="419" left="353" width="149" height="17" font="5">- 10% or less had a history </text>
<text top="436" left="353" width="43" height="17" font="5">of CVD </text>
<text top="453" left="353" width="3" height="17" font="5"> </text>
<text top="470" left="353" width="97" height="17" font="5">Exclusion criteria </text>
<text top="487" left="353" width="154" height="17" font="5">-Trials in which statins were </text>
<text top="505" left="353" width="126" height="17" font="5">used to treat or control </text>
<text top="522" left="353" width="133" height="17" font="5">chronic conditions (e.g., </text>
<text top="539" left="353" width="116" height="17" font="5">Alzheimer’s disease, </text>
<text top="556" left="353" width="143" height="17" font="5">rheumatoid arthritis, renal </text>
<text top="573" left="353" width="96" height="17" font="5">disease, macular </text>
<text top="591" left="353" width="112" height="17" font="5">degeneration, aortic </text>
<text top="608" left="353" width="53" height="17" font="5">stenosis) </text>
<text top="281" left="524" width="110" height="17" font="5">Intervention: statins </text>
<text top="298" left="524" width="121" height="17" font="5">(HMG CoA reductase </text>
<text top="315" left="524" width="57" height="17" font="5">inhibitors) </text>
<text top="333" left="524" width="3" height="17" font="5"> </text>
<text top="350" left="524" width="133" height="17" font="5">Comparator: placebo or </text>
<text top="367" left="524" width="60" height="17" font="5">usual care </text>
<text top="282" left="683" width="7" height="17" font="5">1</text>
<text top="281" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="299" left="683" width="3" height="17" font="5"> </text>
<text top="317" left="683" width="103" height="17" font="5">All cause mortality </text>
<text top="334" left="683" width="3" height="17" font="5"> </text>
<text top="351" left="683" width="189" height="17" font="5">fatal and non-fatal CHD, CVD and </text>
<text top="368" left="683" width="80" height="17" font="5">stroke events; </text>
<text top="385" left="683" width="3" height="17" font="5"> </text>
<text top="403" left="683" width="187" height="17" font="5">combined endpoint (fatal and non-</text>
<text top="420" left="683" width="195" height="17" font="5">fatal CHD, CHD and stroke events) </text>
<text top="437" left="683" width="3" height="17" font="5"> </text>
<text top="454" left="683" width="205" height="17" font="5">change in blood total and low density </text>
<text top="471" left="683" width="200" height="17" font="5">lipoprotein cholesterol concentration </text>
<text top="489" left="683" width="3" height="17" font="5"> </text>
<text top="506" left="683" width="96" height="17" font="5">revascularization </text>
<text top="523" left="683" width="3" height="17" font="5"> </text>
<text top="540" left="683" width="87" height="17" font="5">adverse events </text>
<text top="557" left="683" width="3" height="17" font="5"> </text>
<text top="575" left="683" width="72" height="17" font="5">quality of life </text>
<text top="592" left="683" width="3" height="17" font="5"> </text>
<text top="609" left="683" width="32" height="17" font="5">costs </text>
<text top="626" left="683" width="3" height="17" font="5"> </text>
<text top="643" left="683" width="44" height="17" font="5">Results </text>
<text top="661" left="683" width="103" height="17" font="7"><i>All cause mortality </i></text>
<text top="678" left="683" width="191" height="17" font="5">4.4% in statin vs. 5.1% in placebo. </text>
<text top="695" left="683" width="205" height="17" font="5">NNT for 5 years=96 (95% CI 64-244) </text>
<text top="712" left="683" width="183" height="17" font="5">OR=0.86 (95% CI 0.79-0.94). No </text>
<text top="730" left="683" width="135" height="17" font="5">heterogeneity observed. </text>
<text top="747" left="683" width="3" height="17" font="5"> </text>
<text top="764" left="683" width="176" height="17" font="7"><i>Fatal and non-fatal CHD events </i></text>
<text top="281" left="906" width="90" height="17" font="5">Adverse Events </text>
<text top="298" left="906" width="3" height="17" font="5"> </text>
<text top="315" left="906" width="194" height="17" font="5">19% of all participants experienced </text>
<text top="333" left="906" width="183" height="17" font="5">an adverse event (range 0-97%). </text>
<text top="350" left="906" width="160" height="17" font="5">RR=1.00 (95% CI 0.97-1.03) </text>
<text top="367" left="906" width="3" height="17" font="5"> </text>
<text top="384" left="906" width="177" height="17" font="7"><i>Cancer</i>: 5.8% of all participants. </text>
<text top="401" left="906" width="180" height="17" font="5">RR=1.01 (95% CI 0.93-1.10), no </text>
<text top="419" left="906" width="136" height="17" font="5">significant heterogeneity </text>
<text top="436" left="906" width="3" height="17" font="5"> </text>
<text top="453" left="906" width="184" height="17" font="7"><i>Myalgia</i>: 3551/37939 participants </text>
<text top="470" left="906" width="163" height="17" font="5">RR=1.03 (95% CI 0.97-1.09), </text>
<text top="487" left="906" width="119" height="17" font="5">some heterogeneity (I</text>
<text top="489" left="1025" width="4" height="11" font="8">2</text>
<text top="487" left="1030" width="39" height="17" font="5">=41%) </text>
<text top="505" left="906" width="3" height="17" font="5"> </text>
<text top="522" left="906" width="145" height="17" font="7"><i>Rhabdomyolysis</i>: 3/19410 </text>
<text top="539" left="906" width="122" height="17" font="5">participants on statins </text>
<text top="556" left="906" width="160" height="17" font="5">RR=1.00 (95% CI 0.23-4.38) </text>
<text top="573" left="906" width="3" height="17" font="5"> </text>
<text top="591" left="906" width="91" height="17" font="7"><i>Type 2 diabetes </i></text>
<text top="608" left="906" width="121" height="17" font="5">2.8% statins vs. 2.4% </text>
<text top="625" left="906" width="190" height="17" font="5">control/placebo. RR=1.18 (95% CI </text>
<text top="642" left="906" width="60" height="17" font="5">1.01-1.39) </text>
<text top="660" left="906" width="3" height="17" font="5"> </text>
<text top="677" left="906" width="111" height="17" font="7"><i>Hemorrhagic stroke </i></text>
<text top="694" left="906" width="167" height="17" font="5">0.2% of participants. RR=0.97 </text>
<text top="711" left="906" width="107" height="17" font="5">(95% CI 0.54-1.75) </text>
<text top="728" left="906" width="3" height="17" font="5"> </text>
<text top="746" left="906" width="191" height="17" font="7"><i>Liver enzyme elevations</i>: RR=1.16 </text>
<text top="763" left="906" width="107" height="17" font="5">(95% CI 0.87-1.54) </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="3" height="17" font="5"> </text>
<text top="108" left="683" width="196" height="17" font="5">3.4% statin group vs. 4.6% placebo </text>
<text top="125" left="683" width="197" height="17" font="5">group. NNT for 5 years=56 (95% CI </text>
<text top="142" left="683" width="39" height="17" font="5">46-75) </text>
<text top="160" left="683" width="160" height="17" font="5">RR=0.73 (95% CI 0.67-0.80) </text>
<text top="177" left="683" width="3" height="17" font="5"> </text>
<text top="194" left="683" width="100" height="17" font="7"><i>Fatal CHD events </i></text>
<text top="211" left="683" width="165" height="17" font="5">1.1% statin vs. 1.3% placebo. </text>
<text top="229" left="683" width="182" height="17" font="5">RR=0.82 (95% CI 0.70-0.96). No </text>
<text top="246" left="683" width="193" height="17" font="5">significant heterogeneity observed. </text>
<text top="263" left="683" width="3" height="17" font="5"> </text>
<text top="280" left="683" width="83" height="17" font="7"><i>Non-fatal CHD </i></text>
<text top="297" left="683" width="203" height="17" font="5">1.9% statin vs. 2.8%. RR=0.67 (95% </text>
<text top="315" left="683" width="156" height="17" font="5">CI 0.59-0.76). No significant </text>
<text top="332" left="683" width="135" height="17" font="5">heterogeneity observed. </text>
<text top="349" left="683" width="3" height="17" font="5"> </text>
<text top="366" left="683" width="175" height="17" font="7"><i>Fatal and non-fatal CVD events </i></text>
<text top="383" left="683" width="171" height="17" font="5">9.3% statin vs. 12.2% placebo. </text>
<text top="401" left="683" width="182" height="17" font="5">RR=0.75 (95% CI 0.70-0.81). No </text>
<text top="418" left="683" width="206" height="17" font="5">evidence of significant heterogeneity. </text>
<text top="435" left="683" width="3" height="17" font="5"> </text>
<text top="452" left="683" width="100" height="17" font="7"><i>Fatal CVD events </i></text>
<text top="469" left="683" width="178" height="17" font="5">17.4% statin vs. 20.8% placebo, </text>
<text top="487" left="683" width="182" height="17" font="5">RR=0.83 (95% CI 0.72-0.96). No </text>
<text top="504" left="683" width="139" height="17" font="5">significant heterogeneity. </text>
<text top="521" left="683" width="3" height="17" font="5"> </text>
<text top="538" left="683" width="122" height="17" font="7"><i>Non-fatal CVD events </i></text>
<text top="556" left="683" width="196" height="17" font="5">3% statin vs. 4% placebo. RR=0.77 </text>
<text top="573" left="683" width="188" height="17" font="5">(95% CI 0.62-0.96). No significant </text>
<text top="590" left="683" width="81" height="17" font="5">heterogeneity. </text>
<text top="607" left="683" width="3" height="17" font="5"> </text>
<text top="624" left="683" width="183" height="17" font="7"><i>Fatal and non-fatal stroke events </i></text>
<text top="642" left="683" width="189" height="17" font="5">17% statin group vs. 22% placebo </text>
<text top="659" left="683" width="198" height="17" font="5">group. RR=0.78 (95% CI 0.68-0.89) </text>
<text top="676" left="683" width="3" height="17" font="5"> </text>
<text top="693" left="683" width="107" height="17" font="7"><i>Fatal stroke events </i></text>
<text top="710" left="683" width="194" height="17" font="5">No observed difference. Significant </text>
<text top="728" left="683" width="85" height="17" font="5">heterogeneity (i</text>
<text top="729" left="768" width="4" height="11" font="8">2</text>
<text top="728" left="772" width="39" height="17" font="5">=68%) </text>
<text top="745" left="683" width="3" height="17" font="5"> </text>
<text top="762" left="683" width="130" height="17" font="7"><i>Non-fatal stroke events </i></text>
<text top="91" left="906" width="189" height="17" font="7"><i>Renal dysfunction</i>: RR=1.11 (95% </text>
<text top="108" left="906" width="75" height="17" font="5">CI 0.99-1.26) </text>
<text top="125" left="906" width="177" height="17" font="5">Arthritis: RR=1.20 (95% CI 0.82-</text>
<text top="142" left="906" width="32" height="17" font="5">1.75) </text>
<text top="160" left="906" width="3" height="17" font="5"> </text>
<text top="177" left="906" width="195" height="17" font="7"><i>Treatment compliance</i>: 77% statins </text>
<text top="194" left="906" width="181" height="17" font="5">vs. 70% placebo. RR=1.08 (95% </text>
<text top="211" left="906" width="75" height="17" font="5">CI 0.98-1.18) </text>
<text top="229" left="906" width="3" height="17" font="5"> </text>
<text top="246" left="906" width="75" height="17" font="7"><i>Quality of life </i></text>
<text top="263" left="906" width="90" height="17" font="5">No reliable data </text>
<text top="280" left="906" width="3" height="17" font="5"> </text>
</page>
<page number="206" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="207" height="17" font="5">1.3% statin vs. 2% placebo. RR=0.69 </text>
<text top="108" left="683" width="107" height="17" font="5">(95% CI 0.58-0.83) </text>
<text top="125" left="683" width="3" height="17" font="5"> </text>
<text top="142" left="683" width="189" height="17" font="7"><i>Combined endpoint (fatal and non-</i></text>
<text top="160" left="683" width="195" height="17" font="7"><i>fatal CHD, CHD and stroke events) </i></text>
<text top="177" left="683" width="171" height="17" font="5">2.4% statins vs. 3.8% placebo. </text>
<text top="194" left="683" width="160" height="17" font="5">RR=0.65 (95% CI 0.58-0.73) </text>
<text top="211" left="683" width="3" height="17" font="5"> </text>
<text top="229" left="683" width="185" height="17" font="5">Cholesterol (total and low density </text>
<text top="246" left="683" width="127" height="17" font="5">lipoprotein cholesterol) </text>
<text top="263" left="683" width="182" height="17" font="5">Total cholesterol: net difference= </text>
<text top="280" left="683" width="204" height="17" font="5">-1.05 mmol/L (95% CI -1.35 to -0.76) </text>
<text top="297" left="683" width="8" height="17" font="5">(I</text>
<text top="298" left="691" width="4" height="11" font="8">2</text>
<text top="297" left="695" width="46" height="17" font="5">=100%) </text>
<text top="315" left="683" width="198" height="17" font="5">LDL: net difference= -1.00 (95% CI -</text>
<text top="332" left="683" width="160" height="17" font="5">1.16 to -0.85). Heterogeneity </text>
<text top="349" left="683" width="8" height="17" font="5">(I</text>
<text top="350" left="691" width="4" height="11" font="8">2</text>
<text top="349" left="695" width="39" height="17" font="5">=99%) </text>
<text top="366" left="683" width="3" height="17" font="5"> </text>
<text top="383" left="683" width="100" height="17" font="7"><i>Revascularization </i></text>
<text top="401" left="683" width="165" height="17" font="5">1.4% statin vs. 2.2% placebo. </text>
<text top="418" left="683" width="160" height="17" font="5">RR=0.62 (95% CI 0.54-0.72) </text>
<text top="436" left="75" width="93" height="17" font="5">Heart Outcomes </text>
<text top="453" left="75" width="62" height="17" font="5">Prevention </text>
<text top="470" left="75" width="111" height="17" font="5">Evaluation (HOPE)–</text>
<text top="487" left="75" width="33" height="17" font="5">3 trial </text>
<text top="505" left="75" width="3" height="17" font="5"> </text>
<text top="522" left="75" width="99" height="17" font="5">Yusuf et al., 2016 </text>
<text top="539" left="75" width="3" height="17" font="5"> </text>
<text top="556" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27040132">27040132</a></text>
<text top="556" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27040132"> </a></text>
<text top="436" left="202" width="66" height="17" font="5">Study Aims </text>
<text top="453" left="202" width="135" height="17" font="5">evaluating the long-term </text>
<text top="470" left="202" width="137" height="17" font="5">effects of rosuvastatin at </text>
<text top="487" left="202" width="136" height="17" font="5">a dose of 10 mg per day </text>
<text top="505" left="202" width="76" height="17" font="5">(without dose </text>
<text top="522" left="202" width="103" height="17" font="5">adjustment or lipid </text>
<text top="539" left="202" width="133" height="17" font="5">targets) among persons </text>
<text top="556" left="202" width="93" height="17" font="5">of various ethnic </text>
<text top="573" left="202" width="109" height="17" font="5">backgrounds on six </text>
<text top="591" left="202" width="126" height="17" font="5">continents who did not </text>
<text top="608" left="202" width="113" height="17" font="5">have cardiovascular </text>
<text top="625" left="202" width="113" height="17" font="5">disease and were at </text>
<text top="642" left="202" width="94" height="17" font="5">intermediate risk </text>
<text top="660" left="202" width="3" height="17" font="5"> </text>
<text top="677" left="202" width="66" height="17" font="5">Study Type </text>
<text top="694" left="202" width="29" height="17" font="5">RCT </text>
<text top="711" left="202" width="3" height="17" font="5"> </text>
<text top="728" left="202" width="57" height="17" font="5">N=12,705 </text>
<text top="436" left="353" width="92" height="17" font="5">Inclusion criteria </text>
<text top="453" left="353" width="133" height="17" font="5">55 years of age or older </text>
<text top="470" left="353" width="35" height="17" font="5">(men) </text>
<text top="487" left="353" width="3" height="17" font="5"> </text>
<text top="505" left="353" width="133" height="17" font="5">65 years of age or older </text>
<text top="522" left="353" width="140" height="17" font="5">(women) (60+ for women </text>
<text top="539" left="353" width="110" height="17" font="5">with 2+ risk factors) </text>
<text top="556" left="353" width="3" height="17" font="5"> </text>
<text top="573" left="353" width="154" height="17" font="5">At least one of the following </text>
<text top="591" left="353" width="149" height="17" font="5">cardiovascular risk factors: </text>
<text top="608" left="353" width="147" height="17" font="5">elevated waist-to-hip ratio, </text>
<text top="625" left="353" width="155" height="17" font="5">history of a low level of high-</text>
<text top="642" left="353" width="102" height="17" font="5">density lipoprotein </text>
<text top="660" left="353" width="122" height="17" font="5">cholesterol, current or </text>
<text top="677" left="353" width="111" height="17" font="5">recent tobacco use, </text>
<text top="694" left="353" width="149" height="17" font="5">dysglycemia, family history </text>
<text top="711" left="353" width="124" height="17" font="5">of premature coronary </text>
<text top="728" left="353" width="130" height="17" font="5">disease, and mild renal </text>
<text top="746" left="353" width="66" height="17" font="5">dysfunction </text>
<text top="763" left="353" width="3" height="17" font="5"> </text>
<text top="436" left="524" width="68" height="17" font="5">Intervention </text>
<text top="453" left="524" width="126" height="17" font="5">Rsuvastatin 10 mg per </text>
<text top="470" left="524" width="96" height="17" font="5">day without dose </text>
<text top="487" left="524" width="144" height="17" font="5">adjustment or lipid targets </text>
<text top="505" left="524" width="3" height="17" font="5"> </text>
<text top="522" left="524" width="70" height="17" font="5">Comparison </text>
<text top="539" left="524" width="46" height="17" font="5">placebo </text>
<text top="437" left="683" width="7" height="17" font="5">1</text>
<text top="436" left="690" width="67" height="18" font="5"> endpoint:  </text>
<text top="454" left="683" width="135" height="17" font="5">composite of death from </text>
<text top="471" left="683" width="175" height="17" font="5">cardiovascular causes, nonfatal </text>
<text top="489" left="683" width="181" height="17" font="5">myocardial infarction, or nonfatal </text>
<text top="506" left="683" width="37" height="17" font="5">stroke </text>
<text top="523" left="683" width="3" height="17" font="5"> </text>
<text top="540" left="683" width="135" height="17" font="5">composite of death from </text>
<text top="557" left="683" width="175" height="17" font="5">cardiovascular causes, nonfatal </text>
<text top="575" left="683" width="181" height="17" font="5">myocardial infarction, or nonfatal </text>
<text top="592" left="683" width="179" height="17" font="5">stroke plus  resuscitated cardiac </text>
<text top="609" left="683" width="134" height="17" font="5">arrest, heart failure, and </text>
<text top="626" left="683" width="96" height="17" font="5">revascularization </text>
<text top="643" left="683" width="3" height="17" font="5"> </text>
<text top="661" left="683" width="44" height="17" font="5">Results </text>
<text top="678" left="683" width="135" height="17" font="7"><i>composite of death from </i></text>
<text top="695" left="683" width="175" height="17" font="7"><i>cardiovascular causes, nonfatal </i></text>
<text top="712" left="683" width="181" height="17" font="7"><i>myocardial infarction, or nonfatal </i></text>
<text top="730" left="683" width="37" height="17" font="7"><i>stroke </i></text>
<text top="747" left="683" width="3" height="17" font="5"> </text>
<text top="437" left="906" width="7" height="17" font="5">2</text>
<text top="436" left="913" width="67" height="18" font="5"> endpoint:  </text>
<text top="454" left="906" width="135" height="17" font="5">composite of death from </text>
<text top="471" left="906" width="175" height="17" font="5">cardiovascular causes, nonfatal </text>
<text top="489" left="906" width="181" height="17" font="5">myocardial infarction, or nonfatal </text>
<text top="506" left="906" width="179" height="17" font="5">stroke plus  resuscitated cardiac </text>
<text top="523" left="906" width="110" height="17" font="5">arrest, heart failure, </text>
<text top="540" left="906" width="165" height="17" font="5">revascularization, angina with </text>
<text top="557" left="906" width="118" height="17" font="5">evidence of ischemia </text>
<text top="575" left="906" width="3" height="17" font="5"> </text>
<text top="592" left="906" width="102" height="17" font="5">all cause mortality </text>
<text top="609" left="906" width="3" height="17" font="5"> </text>
<text top="626" left="906" width="113" height="17" font="5">new onset diabetes  </text>
<text top="643" left="906" width="3" height="17" font="5"> </text>
<text top="661" left="906" width="187" height="17" font="5">death from cardiovascular causes </text>
<text top="678" left="906" width="116" height="17" font="5">myocardial infarction </text>
<text top="695" left="906" width="3" height="17" font="5"> </text>
<text top="712" left="906" width="37" height="17" font="5">stroke </text>
<text top="730" left="906" width="3" height="17" font="5"> </text>
<text top="747" left="906" width="148" height="17" font="5">resuscitated cardiac arrest </text>
<text top="764" left="906" width="3" height="17" font="5"> </text>
</page>
<page number="207" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="353" width="97" height="17" font="5">Exclusion criteria </text>
<text top="108" left="353" width="135" height="17" font="5">Cardiovascular disease  </text>
<text top="125" left="353" width="3" height="17" font="5"> </text>
<text top="142" left="353" width="104" height="17" font="5">an indication for or </text>
<text top="160" left="353" width="145" height="17" font="5">contraindication to statins, </text>
<text top="177" left="353" width="116" height="17" font="5">angiotensin-receptor </text>
<text top="194" left="353" width="120" height="17" font="5">blockers, angiotensin-</text>
<text top="211" left="353" width="110" height="17" font="5">converting–enzyme </text>
<text top="229" left="353" width="116" height="17" font="5">inhibitors, or thiazide </text>
<text top="246" left="353" width="49" height="17" font="5">diuretics </text>
<text top="91" left="683" width="202" height="17" font="5">3.7% rosuvastatin vs. 4.8% placebo. </text>
<text top="108" left="683" width="163" height="17" font="5">HR=0.76 (95% CI 0.64-0.91), </text>
<text top="125" left="683" width="48" height="17" font="5">p=0.002 </text>
<text top="142" left="683" width="3" height="17" font="5"> </text>
<text top="160" left="683" width="135" height="17" font="7"><i>composite of death from </i></text>
<text top="177" left="683" width="175" height="17" font="7"><i>cardiovascular causes, nonfatal </i></text>
<text top="194" left="683" width="181" height="17" font="7"><i>myocardial infarction, or nonfatal </i></text>
<text top="211" left="683" width="179" height="17" font="7"><i>stroke plus  resuscitated cardiac </i></text>
<text top="229" left="683" width="134" height="17" font="7"><i>arrest, heart failure, and </i></text>
<text top="246" left="683" width="96" height="17" font="7"><i>revascularization </i></text>
<text top="263" left="683" width="202" height="17" font="5">4.4% rosuvastatin vs. 5.7% placebo. </text>
<text top="280" left="683" width="163" height="17" font="5">HR=0.75 (95% CI 0.64-0.88), </text>
<text top="297" left="683" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="315" left="683" width="3" height="17" font="5"> </text>
<text top="332" left="683" width="180" height="17" font="5">Total number of events (first and </text>
<text top="349" left="683" width="188" height="17" font="5">recurrent). HR=0.75 (95% CI 0.64-</text>
<text top="366" left="683" width="83" height="17" font="5">0.89), p=0.001 </text>
<text top="91" left="906" width="96" height="17" font="5">revascularization </text>
<text top="108" left="906" width="3" height="17" font="5"> </text>
<text top="125" left="906" width="68" height="17" font="5">heart failure </text>
<text top="142" left="906" width="3" height="17" font="5"> </text>
<text top="160" left="906" width="184" height="17" font="5">angina with evidence of ischemia </text>
<text top="177" left="906" width="3" height="17" font="5"> </text>
<text top="194" left="906" width="44" height="17" font="5">Results </text>
<text top="211" left="906" width="135" height="17" font="7"><i>composite of death from </i></text>
<text top="229" left="906" width="175" height="17" font="7"><i>cardiovascular causes, nonfatal </i></text>
<text top="246" left="906" width="181" height="17" font="7"><i>myocardial infarction, or nonfatal </i></text>
<text top="263" left="906" width="175" height="17" font="7"><i>stroke plus resuscitated cardiac </i></text>
<text top="280" left="906" width="110" height="17" font="7"><i>arrest, heart failure, </i></text>
<text top="297" left="906" width="165" height="17" font="7"><i>revascularization, angina with </i></text>
<text top="315" left="906" width="118" height="17" font="7"><i>evidence of ischemia </i></text>
<text top="332" left="906" width="151" height="17" font="5">4.8% rosuvastatin vs. 6.2% </text>
<text top="349" left="906" width="178" height="17" font="5">placebo. HR=0.77 (95% CI 0.66-</text>
<text top="366" left="906" width="83" height="17" font="5">0.89), p&lt;0.001 </text>
<text top="383" left="906" width="3" height="17" font="5"> </text>
<text top="401" left="906" width="102" height="17" font="7"><i>all cause mortality </i></text>
<text top="418" left="906" width="151" height="17" font="5">5.3% rosuvastatin vs. 5.6% </text>
<text top="435" left="906" width="181" height="17" font="5">placebo. HR=0.93 995% CI 0.80-</text>
<text top="452" left="906" width="76" height="17" font="5">1.08), p=0.32 </text>
<text top="469" left="906" width="3" height="17" font="5"> </text>
<text top="487" left="906" width="113" height="17" font="7"><i>new onset diabetes  </i></text>
<text top="504" left="906" width="151" height="17" font="5">3.9% rosuvastatin vs. 3.8% </text>
<text top="521" left="906" width="178" height="17" font="5">placebo. HR=1.02 (95% CI 0.85-</text>
<text top="538" left="906" width="76" height="17" font="5">1.23), p=0.82 </text>
<text top="556" left="906" width="3" height="17" font="5"> </text>
<text top="573" left="906" width="187" height="17" font="7"><i>death from cardiovascular causes </i></text>
<text top="590" left="906" width="152" height="17" font="5">2.4% rosuvastatin vs. 2.7% </text>
<text top="607" left="906" width="178" height="17" font="5">placebo. HR=0.89 (95% CI 0.72-</text>
<text top="624" left="906" width="32" height="17" font="5">1.11) </text>
<text top="642" left="906" width="3" height="17" font="5"> </text>
<text top="659" left="906" width="116" height="17" font="7"><i>myocardial infarction </i></text>
<text top="676" left="906" width="151" height="17" font="5">0.7% rosuvastatin vs. 1.1% </text>
<text top="693" left="906" width="178" height="17" font="5">placebo. HR=0.65 (95% CI 0.44-</text>
<text top="710" left="906" width="32" height="17" font="5">0.94) </text>
<text top="728" left="906" width="3" height="17" font="5"> </text>
<text top="745" left="906" width="37" height="17" font="7"><i>stroke </i></text>
</page>
<page number="208" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="906" width="151" height="17" font="5">1.1% rosuvastatin vs. 1.6% </text>
<text top="108" left="906" width="178" height="17" font="5">placebo. HR=0.70 (95% CI 0.52-</text>
<text top="125" left="906" width="32" height="17" font="5">0.95) </text>
<text top="142" left="906" width="3" height="17" font="5"> </text>
<text top="160" left="906" width="148" height="17" font="7"><i>resuscitated cardiac arrest </i></text>
<text top="177" left="906" width="152" height="17" font="5">0.1% rosuvastatin vs. 0.1% </text>
<text top="194" left="906" width="178" height="17" font="5">placebo. HR=0.99 (95% CI 0.25-</text>
<text top="211" left="906" width="32" height="17" font="5">3.97) </text>
<text top="229" left="906" width="3" height="17" font="7"><i> </i></text>
<text top="246" left="906" width="96" height="17" font="7"><i>revascularization </i></text>
<text top="263" left="906" width="151" height="17" font="7"><i>0.9% </i>rosuvastatin vs. 1.3% </text>
<text top="280" left="906" width="168" height="17" font="5">placebo. HR=0.68 (95% CI 48-</text>
<text top="297" left="906" width="32" height="17" font="5">0.95) </text>
<text top="315" left="906" width="3" height="17" font="7"><i> </i></text>
<text top="332" left="906" width="68" height="17" font="7"><i>heart failure </i></text>
<text top="349" left="906" width="151" height="17" font="7"><i>0.3% </i>rosuvastatin vs. 0.5% </text>
<text top="366" left="906" width="178" height="17" font="5">placebo. HR=0.72 (95% CI 0.41-</text>
<text top="383" left="906" width="32" height="17" font="5">1.26) </text>
<text top="401" left="906" width="3" height="17" font="7"><i> </i></text>
<text top="418" left="906" width="184" height="17" font="7"><i>angina with evidence of ischemia </i></text>
<text top="435" left="906" width="151" height="17" font="5">0.9% rosuvastatin vs. 1.0% </text>
<text top="452" left="906" width="181" height="17" font="5">placebo. HR=0.87 (95% CI 0..61-</text>
<text top="469" left="906" width="32" height="17" font="5">1.24) </text>
<text top="487" left="906" width="3" height="17" font="5"> </text>
<text top="504" left="906" width="131" height="17" font="7"><i>Coronary heart disease </i></text>
<text top="521" left="906" width="151" height="17" font="5">1.7% rosuvastatin vs. 2.2% </text>
<text top="538" left="906" width="178" height="17" font="5">placebo. HR=0.74 (95% CI 0.58-</text>
<text top="556" left="906" width="76" height="17" font="5">0.96). p=0.02 </text>
<text top="573" left="906" width="3" height="17" font="5"> </text>
<text top="590" left="906" width="190" height="17" font="7"><i>Hospitalizations for cardiovascular </i></text>
<text top="607" left="906" width="43" height="17" font="7"><i>causes </i></text>
<text top="624" left="906" width="151" height="17" font="5">4.4% rosuvastatin vs. 5.8% </text>
<text top="642" left="906" width="178" height="17" font="5">placebo. HR=0.75 (95% CI 0.64-</text>
<text top="659" left="906" width="83" height="17" font="5">0.88), p&lt;0.001 </text>
<text top="676" left="906" width="3" height="17" font="5"> </text>
<text top="693" left="906" width="107" height="17" font="7"><i>Hospitalizations for </i></text>
<text top="710" left="906" width="146" height="17" font="7"><i>noncardiovascular causes </i></text>
<text top="728" left="906" width="165" height="17" font="5">13.9% rosuvastatin vs. 13.9% </text>
<text top="745" left="906" width="178" height="17" font="5">placebo. HR=1.00 (95% CI 0.91-</text>
<text top="762" left="906" width="76" height="17" font="5">1.10), p=0.99 </text>
</page>
<page number="209" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="94" height="17" font="5">Chou et al, 2016 </text>
<text top="108" left="75" width="3" height="17" font="5"> </text>
<text top="125" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27905702">27905702</a></text>
<text top="125" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27905702"> </a></text>
<text top="91" left="202" width="64" height="17" font="3"><b>Study Aim </b></text>
<text top="108" left="202" width="126" height="17" font="5">To assess the benefits </text>
<text top="125" left="202" width="133" height="17" font="5">of treatment with statins </text>
<text top="142" left="202" width="137" height="17" font="5">that target LDL-C versus </text>
<text top="160" left="202" width="87" height="17" font="5">other treatment </text>
<text top="177" left="202" width="130" height="17" font="5">strategies in adults age </text>
<text top="194" left="202" width="138" height="17" font="5">40 years or older without </text>
<text top="211" left="202" width="125" height="17" font="5">prior CVD events (one </text>
<text top="229" left="202" width="133" height="17" font="5">review in a larger report </text>
<text top="246" left="202" width="129" height="17" font="5">with 5 study questions) </text>
<text top="263" left="202" width="3" height="17" font="3"><b> </b></text>
<text top="280" left="202" width="70" height="17" font="3"><b>Study Type </b></text>
<text top="297" left="202" width="110" height="17" font="5">Systematic Review, </text>
<text top="315" left="202" width="130" height="17" font="5">including meta analysis </text>
<text top="332" left="202" width="113" height="17" font="5">of some parameters </text>
<text top="349" left="202" width="3" height="17" font="5"> </text>
<text top="366" left="202" width="120" height="17" font="5">N=19 studies (71,344 </text>
<text top="383" left="202" width="51" height="17" font="5">patients) </text>
<text top="91" left="353" width="102" height="17" font="3"><b>Inclusion criteria </b></text>
<text top="108" left="353" width="3" height="17" font="5"> </text>
<text top="125" left="353" width="35" height="17" font="5">RCTs </text>
<text top="142" left="353" width="3" height="17" font="5"> </text>
<text top="160" left="353" width="145" height="17" font="5">Asymptomatic adults (age </text>
<text top="177" left="353" width="133" height="17" font="5">≥40 years) without prior </text>
<text top="194" left="353" width="100" height="17" font="5">CVD events (e.g., </text>
<text top="211" left="353" width="120" height="17" font="5">myocardial infarction, </text>
<text top="229" left="353" width="143" height="17" font="5">angina, revascularization, </text>
<text top="246" left="353" width="148" height="17" font="5">CVA, or transient ischemic </text>
<text top="263" left="353" width="143" height="17" font="5">attack), including persons </text>
<text top="280" left="353" width="158" height="17" font="5">who are at increased risk for </text>
<text top="297" left="353" width="141" height="17" font="5">CVD events based on 10-</text>
<text top="315" left="353" width="84" height="17" font="5">year or lifetime </text>
<text top="332" left="353" width="158" height="17" font="5">individualized CVD risk level </text>
<text top="349" left="353" width="156" height="17" font="5">or presence of specific CVD </text>
<text top="366" left="353" width="63" height="17" font="5">risk factors </text>
<text top="383" left="353" width="3" height="17" font="5"> </text>
<text top="401" left="353" width="143" height="17" font="5">Treatment with statins vs. </text>
<text top="418" left="353" width="149" height="17" font="5">No treatment or usual care </text>
<text top="435" left="353" width="75" height="17" font="5">without statin </text>
<text top="452" left="353" width="3" height="17" font="5"> </text>
<text top="469" left="353" width="126" height="17" font="5">Examined CHD and/or </text>
<text top="487" left="353" width="138" height="17" font="5">CVA-related morbidity or </text>
<text top="504" left="353" width="156" height="17" font="5">mortality; all-cause mortality </text>
<text top="521" left="353" width="3" height="17" font="5"> </text>
<text top="538" left="353" width="132" height="17" font="5">Primary care or primary </text>
<text top="556" left="353" width="107" height="17" font="5">care–generalizable </text>
<text top="573" left="353" width="3" height="17" font="5"> </text>
<text top="91" left="524" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="108" left="524" width="41" height="17" font="5">Statins </text>
<text top="125" left="524" width="3" height="17" font="3"><b> </b></text>
<text top="142" left="524" width="75" height="17" font="3"><b>Comparison </b></text>
<text top="160" left="524" width="122" height="17" font="5">No treatment or usual </text>
<text top="177" left="524" width="103" height="17" font="5">care without statin </text>
<text top="194" left="524" width="3" height="17" font="5"> </text>
<text top="92" left="683" width="7" height="17" font="3"><b>1</b></text>
<text top="91" left="690" width="65" height="18" font="5"><b> endpoint </b></text>
<text top="109" left="683" width="206" height="17" font="5">CHD and/or CVA-related morbidity or </text>
<text top="126" left="683" width="156" height="17" font="5">mortality; all-cause mortality </text>
<text top="144" left="683" width="3" height="17" font="5"> </text>
<text top="161" left="683" width="50" height="17" font="7"><i>Findings </i></text>
<text top="178" left="683" width="208" height="17" font="5">No study directly compared treatment </text>
<text top="195" left="683" width="187" height="17" font="5">with statins titrated to attain target </text>
<text top="212" left="683" width="204" height="17" font="5">cholesterol levels vs. other treatment </text>
<text top="230" left="683" width="64" height="17" font="5">strategies.  </text>
<text top="247" left="683" width="189" height="17" font="5">There were no clear differences in </text>
<text top="264" left="683" width="197" height="17" font="5">risk of all-cause or CV mortality, MI, </text>
<text top="281" left="683" width="193" height="17" font="5">or stroke between 3 trials of statins </text>
<text top="299" left="683" width="208" height="17" font="5">vs. placebo or no statin that permitted </text>
<text top="316" left="683" width="197" height="17" font="5">limited dose titration and 16 trials of </text>
<text top="333" left="683" width="171" height="17" font="5">fixed-dose statin therapy.  This </text>
<text top="350" left="683" width="208" height="17" font="5">finding was rated as being consistent, </text>
<text top="367" left="683" width="167" height="17" font="5">having high applicability to US </text>
<text top="385" left="683" width="206" height="17" font="5">primary care settings, but was limited </text>
<text top="402" left="683" width="204" height="17" font="5">by lack of direct evidence (all studies </text>
<text top="419" left="683" width="199" height="17" font="5">were evaluated as providing indirect </text>
<text top="436" left="683" width="166" height="17" font="5">evidence), and limited indirect </text>
<text top="453" left="683" width="191" height="17" font="5">evidence from 3 trials, and were of </text>
<text top="471" left="683" width="107" height="17" font="5">poor overall quality </text>
<text top="488" left="683" width="3" height="17" font="5"> </text>
<text top="505" left="683" width="201" height="17" font="5">Meta analyses of statins vs. placebo </text>
<text top="522" left="683" width="200" height="17" font="5">(presented for separate questions in </text>
<text top="539" left="683" width="80" height="17" font="5">same review): </text>
<text top="557" left="683" width="3" height="17" font="5"> </text>
<text top="574" left="683" width="107" height="17" font="5">All-Cause Mortality </text>
<text top="591" left="683" width="166" height="17" font="5">RR=0.86 (95% CI 0.80-0.93). I</text>
<text top="592" left="850" width="4" height="11" font="8">2</text>
<text top="591" left="854" width="32" height="17" font="5"> =0% </text>
<text top="608" left="683" width="3" height="17" font="5"> </text>
<text top="626" left="683" width="135" height="17" font="5">Cardiovascular Mortality </text>
<text top="643" left="683" width="170" height="17" font="5">RR=0.69 (95% CI 0.54-0.88).  I</text>
<text top="644" left="853" width="4" height="11" font="8">2</text>
<text top="643" left="857" width="3" height="17" font="5"> </text>
<text top="660" left="683" width="35" height="17" font="5">=54% </text>
<text top="677" left="683" width="3" height="17" font="5"> </text>
<text top="694" left="683" width="139" height="17" font="5">Fatal and nonfatal stroke </text>
<text top="712" left="683" width="166" height="17" font="5">RR=0.71 (95% CI 0.62-0.82). I</text>
<text top="713" left="850" width="4" height="11" font="8">2</text>
<text top="712" left="854" width="32" height="17" font="5"> =0% </text>
<text top="729" left="683" width="3" height="17" font="5"> </text>
<text top="746" left="683" width="165" height="17" font="5">Fatal and nonfatal myocardial </text>
<text top="763" left="683" width="53" height="17" font="5">infarction </text>
<text top="91" left="906" width="59" height="17" font="3"><b>Summary </b></text>
<text top="108" left="906" width="152" height="17" font="5">No study directly compared </text>
<text top="125" left="906" width="174" height="17" font="5">treatment with statins titrated to </text>
<text top="142" left="906" width="166" height="17" font="5">attain target cholesterol levels </text>
<text top="160" left="906" width="167" height="17" font="5">versus other (e.g., fixed-dose) </text>
<text top="177" left="906" width="181" height="17" font="5">treatment strategies. There were </text>
<text top="194" left="906" width="176" height="17" font="5">no clear differences in risk of all-</text>
<text top="211" left="906" width="187" height="17" font="5">cause or cardiovascular mortality, </text>
<text top="229" left="906" width="196" height="17" font="5">MI, or stroke between three trials of </text>
<text top="246" left="906" width="189" height="17" font="5">statins versus placebo or no statin </text>
<text top="263" left="906" width="191" height="17" font="5">that permitted limited dose titration </text>
<text top="280" left="906" width="177" height="17" font="5">and 15 trials of fixed-dose statin </text>
<text top="297" left="906" width="44" height="17" font="5">therapy </text>
</page>
<page number="210" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="683" width="160" height="17" font="5">RR=0.64 (95% CI 0.57-0.71) </text>
<text top="108" left="683" width="3" height="17" font="5">I</text>
<text top="109" left="687" width="4" height="11" font="8">2</text>
<text top="108" left="691" width="32" height="17" font="5"> =0% </text>
<text top="125" left="683" width="3" height="17" font="5"> </text>
<text top="142" left="683" width="104" height="17" font="5">Revascularization  </text>
<text top="160" left="683" width="160" height="17" font="5">RR=0.63 (95% CI 0.56-0.72) </text>
<text top="177" left="683" width="3" height="17" font="5">I</text>
<text top="178" left="687" width="4" height="11" font="8">2</text>
<text top="177" left="691" width="32" height="17" font="5"> =0% </text>
<text top="194" left="683" width="3" height="17" font="5"> </text>
<text top="211" left="683" width="207" height="17" font="5">Composite Cardiovascular Outcomes </text>
<text top="229" left="683" width="160" height="17" font="5">RR=0.70 (95% CI 0.63-0.78) </text>
<text top="246" left="683" width="3" height="17" font="5">I</text>
<text top="247" left="687" width="4" height="11" font="8">2</text>
<text top="246" left="691" width="39" height="17" font="5"> =36% </text>
<text top="264" left="75" width="27" height="17" font="5">CTT </text>
<text top="281" left="75" width="65" height="17" font="5">Cholesterol </text>
<text top="298" left="75" width="59" height="17" font="5">Treatment </text>
<text top="315" left="75" width="48" height="17" font="5">Trialists’ </text>
<text top="333" left="75" width="80" height="17" font="5">Collaborators, </text>
<text top="350" left="75" width="31" height="17" font="5">2012 </text>
<text top="367" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22607822">22607822</a></text>
<text top="367" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22607822"> </a></text>
<text top="264" left="202" width="74" height="17" font="3"><b>Study Type: </b></text>
<text top="281" left="202" width="118" height="17" font="5">Metaanalysis of RCT </text>
<text top="298" left="202" width="3" height="17" font="5"> </text>
<text top="315" left="202" width="81" height="17" font="3"><b>Size</b>: 22 RCT. </text>
<text top="333" left="202" width="64" height="17" font="5">N=134,537 </text>
<text top="264" left="353" width="140" height="17" font="3"><b>Inclusion criteria</b>: A trial </text>
<text top="281" left="353" width="86" height="17" font="5">was eligible if it </text>
<text top="298" left="353" width="140" height="17" font="5">1. it included at least one </text>
<text top="315" left="353" width="136" height="17" font="5">intervention whose main </text>
<text top="333" left="353" width="131" height="17" font="5">effect was to lower LDL </text>
<text top="350" left="353" width="140" height="17" font="5">cholesterol concentration </text>
<text top="367" left="353" width="155" height="17" font="5">2. it was unconfounded with </text>
<text top="384" left="353" width="147" height="17" font="5">respect to this intervention </text>
<text top="401" left="353" width="152" height="17" font="5">(i.e., no other differences in </text>
<text top="419" left="353" width="126" height="17" font="5">risk factor modification </text>
<text top="436" left="353" width="126" height="17" font="5">between the treatment </text>
<text top="453" left="353" width="126" height="17" font="5">groups were intended) </text>
<text top="470" left="353" width="149" height="17" font="5">3. it recruited at least 1000 </text>
<text top="487" left="353" width="151" height="17" font="5">participants with scheduled </text>
<text top="505" left="353" width="131" height="17" font="5">treatment duration of at </text>
<text top="522" left="353" width="49" height="17" font="5">least 2y. </text>
<text top="264" left="524" width="111" height="17" font="3"><b>Intervention: </b>statin </text>
<text top="281" left="524" width="44" height="17" font="5">therapy<b> </b></text>
<text top="298" left="524" width="118" height="17" font="3"><b>Comparator: </b>control<b> </b></text>
<text top="264" left="683" width="49" height="17" font="3"><b>Overall: </b></text>
<text top="281" left="683" width="205" height="17" font="5">• Reduction of LDL cholesterol with a </text>
<text top="298" left="683" width="171" height="17" font="5">statin reduced the risk of major </text>
<text top="315" left="683" width="196" height="17" font="5">vascular events (RR: 0·79, 95% CI: </text>
<text top="333" left="683" width="207" height="17" font="5">0·77–0·81, per 1·0 mmol/L reduction) </text>
<text top="350" left="683" width="206" height="17" font="5">• Among adults ≥70, effects on major </text>
<text top="367" left="683" width="174" height="17" font="5">vascular events per 1.0 mmol/L </text>
<text top="384" left="683" width="93" height="17" font="5">reduction in LDL </text>
<text top="401" left="683" width="207" height="17" font="5">cholesterol (RR: 0.83; 95% CI: 0.78 − </text>
<text top="419" left="683" width="90" height="17" font="5">0.87; p&lt;0.0001) </text>
<text top="264" left="906" width="24" height="17" font="5">N/A </text>
<text top="540" left="66" width="3" height="17" font="5"> </text>
<text top="589" left="66" width="888" height="21" font="4"><b>Data Supplement 12. Nonrandomized Trials, Observational Studies, and/or Registries of High Blood Cholesterol (Section 4.3.)  </b></text>
<text top="613" left="86" width="98" height="17" font="3"><b>Study Acronym: </b></text>
<text top="630" left="111" width="48" height="17" font="3"><b>Author; </b></text>
<text top="647" left="89" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="613" left="224" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="630" left="251" width="66" height="17" font="3"><b>Study Size </b></text>
<text top="613" left="421" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="613" left="616" width="195" height="17" font="3"><b>Primary Endpoint and Results (P </b></text>
<text top="630" left="629" width="169" height="17" font="3"><b>values; OR or RR; &amp; 95% CI) </b></text>
<text top="613" left="863" width="205" height="17" font="3"><b>Summary/Conclusion Comment(s) </b></text>
<text top="665" left="75" width="97" height="17" font="5">Perak, AM, et al., </text>
<text top="682" left="75" width="56" height="17" font="5">2016 (20) </text>
<text top="700" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27358432">27358432</a></text>
<text top="700" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27358432"> </a></text>
<text top="665" left="209" width="148" height="17" font="5">Study Type: Pooled cohort </text>
<text top="682" left="209" width="137" height="17" font="5">analysis from 6 large US </text>
<text top="700" left="209" width="132" height="17" font="5">epidemiological cohorts </text>
<text top="717" left="209" width="3" height="17" font="5"> </text>
<text top="734" left="209" width="118" height="17" font="5">Size: 68565 baseline </text>
<text top="751" left="209" width="111" height="17" font="5">person-examination </text>
<text top="665" left="371" width="190" height="17" font="5">Inclusion criteria: Men and women </text>
<text top="682" left="371" width="194" height="17" font="5">stratified by LDL-C at ages 20-79 y </text>
<text top="700" left="371" width="197" height="17" font="5">with at least 1 baseline examination </text>
<text top="717" left="371" width="188" height="17" font="5">with direct measurement of serum </text>
<text top="734" left="371" width="132" height="17" font="5">lipids, physiological and </text>
<text top="751" left="371" width="187" height="17" font="5">anthropometric variables. Primary </text>
<text top="768" left="371" width="189" height="17" font="5">analysis defined FH phenotype as </text>
<text top="665" left="595" width="202" height="17" font="5">1⁰endpoint: long term CHD and total </text>
<text top="683" left="595" width="207" height="17" font="5">ASCVD risks in UD adults with an FH </text>
<text top="700" left="595" width="64" height="17" font="5">phenotype. </text>
<text top="717" left="595" width="7" height="17" font="5">  </text>
<text top="734" left="595" width="48" height="17" font="5">Results: </text>
<text top="752" left="595" width="234" height="17" font="5">After co-variate adjustment, FH phenotype </text>
<text top="769" left="595" width="221" height="17" font="5">was associated with HR: up to 5.0 (95% </text>
<text top="665" left="844" width="59" height="17" font="5">Summary: </text>
<text top="682" left="844" width="237" height="17" font="5">FH phenotype is associated with increased </text>
<text top="700" left="844" width="239" height="17" font="5">risk for ASCVD and accelerates risk in both </text>
<text top="717" left="844" width="98" height="17" font="5">men and women. </text>
<text top="734" left="844" width="3" height="17" font="5"> </text>
<text top="751" left="844" width="210" height="17" font="5">Limitations:  1. Phenotypic rather than </text>
<text top="768" left="844" width="148" height="17" font="5">genotypic diagnosis of FH. </text>
</page>
<page number="211" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="371" width="182" height="17" font="5">LDL-C ≥ 190 mg/dL and referent </text>
<text top="108" left="371" width="69" height="17" font="5">&lt;130 mg/dL </text>
<text top="125" left="371" width="3" height="17" font="5"> </text>
<text top="142" left="371" width="124" height="17" font="5">Exclusion criteria: N/A </text>
<text top="91" left="595" width="220" height="17" font="5">CI: 1.1-21.7). CHD risk was accelerated </text>
<text top="108" left="595" width="229" height="17" font="5">by 10-20 y in men and 20-30 y in women. </text>
<text top="125" left="595" width="212" height="17" font="5">Total ASCVD risk was associated with </text>
<text top="142" left="595" width="180" height="17" font="5">HR: up to 4.1 (95% CI: 1.2-13.4) </text>
<text top="91" left="844" width="200" height="17" font="5">2. Single measurement of LDL-C for </text>
<text top="108" left="844" width="51" height="17" font="5">inclusion </text>
<text top="125" left="844" width="242" height="17" font="5">3. Secondary hypercholesterolemia was not </text>
<text top="142" left="844" width="56" height="17" font="5">excluded. </text>
<text top="160" left="844" width="172" height="17" font="5">4. Limited family data available </text>
<text top="178" left="75" width="103" height="17" font="5">Besseling J, et al., </text>
<text top="195" left="75" width="31" height="17" font="5">2016 </text>
<text top="212" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27417002">27417002</a></text>
<text top="212" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27417002"> </a></text>
<text top="229" left="75" width="3" height="17" font="5"> </text>
<text top="178" left="209" width="66" height="17" font="5">Study Type </text>
<text top="195" left="209" width="149" height="17" font="5">Retrospective cohort study </text>
<text top="212" left="209" width="102" height="17" font="5">of the database of </text>
<text top="229" left="209" width="136" height="17" font="5">the national FH cascade </text>
<text top="247" left="209" width="139" height="17" font="5">screening program in the </text>
<text top="264" left="209" width="145" height="17" font="5">Netherlands and a patient-</text>
<text top="281" left="209" width="114" height="17" font="5">centric data network </text>
<text top="298" left="209" width="124" height="17" font="5">of multiple health care </text>
<text top="315" left="209" width="60" height="17" font="5">databases </text>
<text top="333" left="209" width="108" height="17" font="5">Size: 1559 patients </text>
<text top="178" left="371" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="195" left="371" width="196" height="17" font="5">Patients’ age ≥18 y with genetically </text>
<text top="212" left="371" width="185" height="17" font="5">determined deleterious mutations </text>
<text top="229" left="371" width="210" height="17" font="5">associated with FH and free of clinical </text>
<text top="247" left="371" width="154" height="17" font="5">CAD at entry into the study. </text>
<text top="264" left="371" width="3" height="17" font="5"> </text>
<text top="281" left="371" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="298" left="371" width="210" height="17" font="5">Patients with homozygous, compound </text>
<text top="315" left="371" width="209" height="17" font="5">heterozygous or double heterozygous </text>
<text top="333" left="371" width="191" height="17" font="5">FH or carriers of a non-deleterious </text>
<text top="350" left="371" width="54" height="17" font="5">mutation. </text>
<text top="178" left="595" width="209" height="17" font="5">1⁰endpoint: Relative risk reduction for </text>
<text top="195" left="595" width="193" height="17" font="5">CAD (myocardial infarction, angina </text>
<text top="212" left="595" width="227" height="17" font="5">pectoris, or other forms of atherosclerotic </text>
<text top="230" left="595" width="208" height="17" font="5">or ischemic heart disease or coronary </text>
<text top="247" left="595" width="227" height="17" font="5">artery bypass graft or PCI), and all-cause </text>
<text top="264" left="595" width="215" height="17" font="5">mortality by statins in heterozygous FH </text>
<text top="281" left="595" width="50" height="17" font="5">patients. </text>
<text top="298" left="595" width="3" height="17" font="5"> </text>
<text top="316" left="595" width="3" height="17" font="5"> </text>
<text top="333" left="595" width="48" height="17" font="5">Results: </text>
<text top="350" left="595" width="217" height="17" font="5">Patients treated with statins (n = 1,041) </text>
<text top="367" left="595" width="199" height="17" font="5">(most often simvastatin 40 mg daily] </text>
<text top="385" left="595" width="193" height="17" font="5">[23.1%] or atorvastatin 40 mg daily </text>
<text top="402" left="595" width="200" height="17" font="5">[22.8%]) had 89 CAD events and 17 </text>
<text top="419" left="595" width="219" height="17" font="5">deaths during 11,674 person-y of follow-</text>
<text top="436" left="595" width="230" height="17" font="5">up versus those never treated with statins </text>
<text top="453" left="595" width="227" height="17" font="5">(n = 518), who had 22 CAD events and 9 </text>
<text top="471" left="595" width="224" height="17" font="5">deaths during 4,892 person-y (combined </text>
<text top="488" left="595" width="201" height="17" font="5">rates 8.8 vs. 5.3 per 1,000 person-y, </text>
<text top="505" left="595" width="206" height="17" font="5">respectively; p&lt;0.001). After applying </text>
<text top="522" left="595" width="232" height="17" font="5">IPTW and adjusting for other medications, </text>
<text top="539" left="595" width="229" height="17" font="5">the hazard ratio of statin use for CAD and </text>
<text top="557" left="595" width="187" height="17" font="5">all-cause mortality was 0.56 (95% </text>
<text top="574" left="595" width="185" height="17" font="5">confidence interval: 0.33 to 0.96). </text>
<text top="178" left="844" width="59" height="17" font="5">Summary: </text>
<text top="195" left="844" width="186" height="17" font="5">In patients with heterozygous FH, </text>
<text top="212" left="844" width="226" height="17" font="5">moderate- to high-intensity statin therapy </text>
<text top="229" left="844" width="213" height="17" font="5">lowered the risk for CAD and all-cause </text>
<text top="247" left="844" width="98" height="17" font="5">mortality by 44%. </text>
<text top="264" left="844" width="3" height="17" font="5"> </text>
<text top="281" left="844" width="66" height="17" font="5">Limitations: </text>
<text top="298" left="844" width="228" height="17" font="5">1. Because of the observational nature of </text>
<text top="315" left="844" width="232" height="17" font="5">the study, indication bias could have been </text>
<text top="333" left="844" width="48" height="17" font="5">present. </text>
<text top="350" left="844" width="238" height="17" font="5">2. Time lag between the first observation in </text>
<text top="367" left="844" width="200" height="17" font="5">the database and the first visit in the </text>
<text top="384" left="844" width="210" height="17" font="5">screening program may have affected </text>
<text top="401" left="844" width="40" height="17" font="5">results </text>
<text top="419" left="844" width="202" height="17" font="5">3. Cause of death was not specified. </text>
<text top="593" left="76" width="122" height="17" font="5">Rana JS, et al., 2016  </text>
<text top="610" left="76" width="58" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26666660">26666660 </a></text>
<text top="627" left="76" width="3" height="17" font="5"> </text>
<text top="593" left="209" width="132" height="17" font="5">Study type: Prospective </text>
<text top="610" left="209" width="135" height="17" font="5">population-based cohort </text>
<text top="627" left="209" width="103" height="17" font="5">case-control study </text>
<text top="644" left="209" width="3" height="17" font="5"> </text>
<text top="661" left="209" width="128" height="17" font="5">Design: Comparison of </text>
<text top="679" left="209" width="112" height="17" font="5">risk of incident CHD </text>
<text top="696" left="209" width="129" height="17" font="5">events over 10 y (2002-</text>
<text top="713" left="209" width="144" height="17" font="5">2011) among members of </text>
<text top="730" left="209" width="148" height="17" font="5">Kaiser Permanente with or </text>
<text top="748" left="209" width="137" height="17" font="5">without diabetes or CHD </text>
<text top="765" left="209" width="3" height="17" font="5"> </text>
<text top="593" left="371" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="610" left="371" width="129" height="18" font="5">• continuously enrolled </text>
<text top="628" left="371" width="55" height="18" font="5">• 30-90 y </text>
<text top="647" left="371" width="3" height="17" font="5"> </text>
<text top="664" left="371" width="124" height="17" font="5">Exclusion criteria: N/A </text>
<text top="594" left="594" width="7" height="17" font="5">1</text>
<text top="593" left="601" width="204" height="18" font="5"> endpoint: Age-adjusted rate of new </text>
<text top="611" left="594" width="236" height="17" font="5">fatal or non-fatal CHD or revascularization; </text>
<text top="628" left="594" width="120" height="17" font="5">n/1,000 pt.-y (95%CI) </text>
<text top="645" left="594" width="3" height="17" font="5"> </text>
<text top="663" left="594" width="51" height="17" font="5">Results:  </text>
<text top="680" left="594" width="98" height="18" font="5">• With CHD only; </text>
<text top="698" left="594" width="146" height="17" font="5">Overall; 22.5 (22.0–22.98) </text>
<text top="716" left="594" width="164" height="18" font="5">• With DM only (n=118,952);  </text>
<text top="734" left="594" width="200" height="17" font="5">Overall; 12.2 (95% CI: 12.02–12.49) </text>
<text top="751" left="594" width="234" height="17" font="5">HR: 3.7 (95% CI: 3.6–3.8) vs. no DM/CHD </text>
<text top="768" left="594" width="179" height="17" font="5">men; 15.2 (95% CI: 14.8–15.53) </text>
<text top="593" left="844" width="63" height="17" font="5">Summary:  </text>
<text top="610" left="844" width="240" height="18" font="5">• Overall incident CHD rates were 15.2% in </text>
<text top="628" left="844" width="238" height="17" font="5">men and 8.8% in women. By age subgroup </text>
<text top="645" left="844" width="243" height="17" font="5">rates rose from 5% or less for those 30-39 y </text>
<text top="663" left="844" width="196" height="17" font="5">old and rose incrementally with age </text>
<text top="680" left="844" width="189" height="17" font="5">reaching 15-25% for age 60-69 y.  </text>
<text top="697" left="844" width="228" height="17" font="5">-There was a modest increase of incident </text>
<text top="714" left="844" width="240" height="17" font="5">CHD in those with duration of diabetes &lt;5 y </text>
<text top="732" left="844" width="236" height="17" font="5">(compared to those without DM) and event </text>
<text top="749" left="844" width="242" height="17" font="5">rates increased with duration until it was not </text>
</page>
<page number="212" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="209" width="139" height="17" font="5">Size: 1,586,061 adults of </text>
<text top="108" left="209" width="108" height="17" font="5">whom 138,507 had </text>
<text top="125" left="209" width="108" height="17" font="5">diabetes (ICD code </text>
<text top="142" left="209" width="60" height="17" font="5">diagnosis) </text>
<text top="91" left="594" width="177" height="17" font="5">women 8.8 (95% CI: 8.58–9.14) </text>
<text top="108" left="594" width="116" height="18" font="5">• By age subgroups; </text>
<text top="126" left="594" width="119" height="17" font="5">- 40-49 y (n=19,746); </text>
<text top="144" left="594" width="55" height="17" font="5"> men 9.0, </text>
<text top="161" left="594" width="67" height="17" font="5"> women 6.6 </text>
<text top="178" left="594" width="210" height="18" font="5">• Rates for other subgroups are taken </text>
<text top="196" left="594" width="227" height="17" font="5">from a figure and are therefore not exact, </text>
<text top="214" left="594" width="222" height="17" font="5">but because their importance are shown </text>
<text top="231" left="594" width="179" height="18" font="5">• 30-39y; men~5%; women&lt;5% </text>
<text top="249" left="594" width="196" height="18" font="5">• 50-59 y; men~18%; women~10% </text>
<text top="268" left="594" width="196" height="18" font="5">• 60-69 y; men~25%; women~15% </text>
<text top="286" left="594" width="197" height="18" font="5">• By DM duration: risk increased by </text>
<text top="304" left="594" width="222" height="17" font="5">duration with no tabulated data provided </text>
<text top="322" left="594" width="234" height="17" font="5">but data from a figure were taken because </text>
<text top="339" left="594" width="233" height="17" font="5">of their importance and are shown as HRs </text>
<text top="356" left="594" width="234" height="17" font="5">by duration compared to the group without </text>
<text top="373" left="594" width="103" height="17" font="5">diabetes and CVD </text>
<text top="391" left="594" width="65" height="18" font="5">• &lt;5 y ~1.4 </text>
<text top="409" left="594" width="65" height="18" font="5">• 5-9 y~1.8 </text>
<text top="427" left="594" width="224" height="18" font="5">• &gt;10 y~2.5 (not different from the group </text>
<text top="445" left="594" width="148" height="17" font="5">with prior CHD but no DM) </text>
<text top="91" left="844" width="233" height="17" font="5">different from those with prior CVD and no </text>
<text top="108" left="844" width="207" height="17" font="5">diabetes in those with duration &gt;10 y. </text>
<text top="125" left="844" width="241" height="18" font="5">• Overall the risk for a CHD event in a large </text>
<text top="144" left="844" width="226" height="17" font="5">cohort with diabetes but no CVD is about </text>
<text top="161" left="844" width="221" height="17" font="5">half that in subjects without diabetes but </text>
<text top="178" left="844" width="55" height="17" font="5">with CHD </text>
<text top="195" left="844" width="3" height="17" font="5"> </text>
<text top="212" left="844" width="66" height="17" font="5">Limitations: </text>
<text top="230" left="844" width="227" height="18" font="5">• All diagnoses were based on electronic </text>
<text top="248" left="844" width="237" height="17" font="5">records only, including CHD ascertainment </text>
<text top="265" left="844" width="226" height="18" font="5">• All subjects were insured and therefore </text>
<text top="284" left="844" width="226" height="17" font="5">results may not be generalizable to other </text>
<text top="301" left="844" width="151" height="17" font="5">segments of the population </text>
<text top="318" left="844" width="3" height="17" font="5"> </text>
<text top="463" left="76" width="101" height="17" font="5">Mulnier HE, et al., </text>
<text top="481" left="76" width="31" height="17" font="5">2008 </text>
<text top="498" left="76" width="55" height="17" font="12"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18581091">18581091</a></text>
<text top="498" left="131" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18581091"> </a></text>
<text top="463" left="209" width="132" height="17" font="5">Study type: Prospective </text>
<text top="481" left="209" width="74" height="17" font="5">case- control </text>
<text top="498" left="209" width="147" height="17" font="5">observational cohort study </text>
<text top="515" left="209" width="3" height="17" font="5"> </text>
<text top="532" left="209" width="49" height="17" font="5">Design:  </text>
<text top="550" left="209" width="97" height="18" font="5">•  Comparison of </text>
<text top="568" left="223" width="111" height="17" font="5">adjudicated MI over </text>
<text top="585" left="223" width="135" height="17" font="5">time in patients with and </text>
<text top="602" left="223" width="134" height="17" font="5">without DM and no prior </text>
<text top="620" left="223" width="108" height="17" font="5">MI in the very large </text>
<text top="637" left="223" width="95" height="17" font="5">General Practice </text>
<text top="654" left="223" width="112" height="17" font="5">Research Database </text>
<text top="671" left="223" width="134" height="17" font="5">representing ~5% of the </text>
<text top="688" left="223" width="81" height="17" font="5">UK population </text>
<text top="706" left="209" width="95" height="18" font="5">•  This permitted </text>
<text top="724" left="223" width="132" height="17" font="5">estimates of incident MI </text>
<text top="741" left="223" width="107" height="17" font="5">by age, specifically </text>
<text top="758" left="223" width="67" height="17" font="5">those &gt;75 y </text>
<text top="463" left="371" width="99" height="17" font="5">Inclusion criteria:  </text>
<text top="481" left="371" width="177" height="17" font="5">• Men and women aged 35-89 y </text>
<text top="498" left="371" width="84" height="17" font="5">• Free of CHD  </text>
<text top="515" left="371" width="3" height="17" font="5"> </text>
<text top="532" left="371" width="136" height="17" font="5">Baseline characteristics: </text>
<text top="550" left="371" width="206" height="18" font="5">• Average baseline age in DM group; </text>
<text top="568" left="381" width="138" height="17" font="5">men 65 y, women 68.5 y </text>
<text top="585" left="371" width="200" height="18" font="5">• n&gt;75 y of age; men 4,952, women </text>
<text top="603" left="381" width="34" height="17" font="5">6,746 </text>
<text top="621" left="371" width="199" height="18" font="5">• MI diagnosed by diagnostic codes </text>
<text top="639" left="371" width="3" height="17" font="5"> </text>
<text top="656" left="371" width="124" height="17" font="5">Exclusion criteria: N/A </text>
<text top="465" left="594" width="7" height="17" font="5">1</text>
<text top="464" left="601" width="147" height="18" font="5"> endpoint: 7 y Incident MI </text>
<text top="482" left="594" width="3" height="17" font="5"> </text>
<text top="499" left="594" width="51" height="17" font="5">Results:  </text>
<text top="516" left="594" width="228" height="17" font="5">Incident MI: rate/1000 pt. y (95% CI) over </text>
<text top="534" left="594" width="120" height="17" font="5">mean follow-up of 7 y </text>
<text top="551" left="594" width="199" height="18" font="5">•  DM 18.03 (95% CI: 17.41–18.69) </text>
<text top="569" left="594" width="197" height="18" font="5">•  No DM 7.00 (95% CI: 6.82–7.18) </text>
<text top="587" left="594" width="235" height="18" font="5">•  RR (adjusted) 2.47 (95% CI: 2.36–2.59) </text>
<text top="606" left="594" width="205" height="18" font="5">•  MI events (n) and rates/1,000 pt. y </text>
<text top="624" left="609" width="212" height="17" font="5">(95% CI) by attained age in group with </text>
<text top="641" left="609" width="26" height="17" font="5">DM; </text>
<text top="658" left="594" width="42" height="18" font="5">•  Men </text>
<text top="678" left="609" width="13" height="16" font="5">o </text>
<text top="676" left="622" width="185" height="17" font="5">35-54 y: 119, 8.64 (95% CI: 7.22–</text>
<text top="694" left="622" width="38" height="17" font="5">10.34) </text>
<text top="712" left="609" width="13" height="16" font="5">o </text>
<text top="711" left="622" width="198" height="17" font="5">55-64 y: 328, 14.03 (95% CI: 12.59–</text>
<text top="728" left="622" width="38" height="17" font="5">15.64) </text>
<text top="747" left="609" width="13" height="16" font="5">o </text>
<text top="745" left="622" width="198" height="17" font="5">65-74 y: 655, 19.40 (95% CI: 18.27–</text>
<text top="763" left="622" width="32" height="17" font="5">20.6) </text>
<text top="464" left="844" width="217" height="18" font="5">• The primary objective of this study, to </text>
<text top="482" left="854" width="220" height="17" font="5">compare incident MI rates in DM versus </text>
<text top="499" left="854" width="230" height="17" font="5">no DM, demonstrated overall more than a </text>
<text top="516" left="854" width="98" height="17" font="5">2-fold excess risk </text>
<text top="534" left="844" width="213" height="18" font="5">• The study also demonstrated that MI </text>
<text top="552" left="854" width="223" height="17" font="5">rates in the DM cohort increase with age </text>
<text top="569" left="854" width="229" height="17" font="5">and are greater in those &gt;75 y than those </text>
<text top="586" left="854" width="169" height="17" font="5">&lt;75 y in both men and women </text>
<text top="603" left="844" width="240" height="18" font="5">• The excess risk for MI in subjects with vs. </text>
<text top="622" left="854" width="212" height="17" font="5">without DM persisted in those &gt;75 y of </text>
<text top="639" left="854" width="73" height="17" font="5">age (~2-fold) </text>
<text top="656" left="844" width="211" height="18" font="5">• The limitation is that incident MI was </text>
<text top="674" left="854" width="172" height="17" font="5">diagnosed by diagnostic codes </text>
<text top="691" left="844" width="3" height="17" font="5"> </text>
</page>
<page number="213" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="17" size="12" family="Times" color="#0000ff"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="209" width="3" height="17" font="5"> </text>
<text top="108" left="209" width="145" height="17" font="5">Size: 40,727 subjects with </text>
<text top="125" left="209" width="137" height="17" font="5">and 194,913 without DM </text>
<text top="92" left="609" width="13" height="16" font="5">o </text>
<text top="91" left="622" width="183" height="17" font="5">75-84 y: 517, 25.61 (24.1–27.22) </text>
<text top="109" left="609" width="13" height="16" font="5">o </text>
<text top="108" left="622" width="182" height="17" font="5">&gt;85 y:  120, 27.91 (24.88–31.32) </text>
<text top="125" left="594" width="60" height="18" font="5">•  Women </text>
<text top="145" left="609" width="13" height="16" font="5">o </text>
<text top="143" left="621" width="162" height="17" font="5">35-54 y: 40, 4.32 (3.17–5.88) </text>
<text top="162" left="609" width="13" height="16" font="5">o </text>
<text top="161" left="621" width="183" height="17" font="5">55-64 y: 177, 10.30 (8.89–11.94) </text>
<text top="179" left="609" width="13" height="16" font="5">o </text>
<text top="178" left="621" width="190" height="17" font="5">65-74 y: 405, 15.88 (14.41–17.51) </text>
<text top="197" left="609" width="13" height="16" font="5">o </text>
<text top="195" left="621" width="190" height="17" font="5">75-84 y: 517, 23.24 (21.32–25.34) </text>
<text top="214" left="609" width="13" height="16" font="5">o </text>
<text top="212" left="621" width="182" height="17" font="5">&gt;85 y:  170, 25.32 (21.78–29.42) </text>
<text top="231" left="75" width="103" height="17" font="5">FHS, MESA, CHS </text>
<text top="248" left="75" width="84" height="17" font="5">Yano Y, et al.,  </text>
<text top="265" left="75" width="31" height="17" font="5">2017 </text>
<text top="283" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28746709">28746709</a></text>
<text top="283" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28746709"> </a></text>
<text top="231" left="216" width="132" height="18" font="5">•  Prospective cohort </text>
<text top="249" left="243" width="106" height="17" font="5">study using pooled </text>
<text top="266" left="243" width="115" height="17" font="5">individual participant </text>
<text top="284" left="243" width="86" height="17" font="5">data from 3 US </text>
<text top="301" left="243" width="121" height="17" font="5">cohorts (FHS, MESA, </text>
<text top="318" left="243" width="114" height="17" font="5">CHS), examined the </text>
<text top="335" left="243" width="104" height="17" font="5">predictive ability of </text>
<text top="353" left="243" width="106" height="17" font="5">CAC score vs. age </text>
<text top="370" left="243" width="119" height="17" font="5">for ASCVD, including </text>
<text top="387" left="243" width="94" height="17" font="5">CHD and stroke. </text>
<text top="404" left="216" width="127" height="18" font="5">•  4778 participants, </text>
<text top="422" left="243" width="120" height="17" font="5">2582 women, aged ≥ </text>
<text top="440" left="243" width="27" height="17" font="5">60 y </text>
<text top="231" left="378" width="95" height="17" font="5">Inclusion Criteria </text>
<text top="248" left="378" width="149" height="18" font="5">•  Adults older than 60 y </text>
<text top="267" left="378" width="154" height="18" font="5">•  Without known CVD at </text>
<text top="285" left="405" width="49" height="17" font="5">baseline </text>
<text top="302" left="378" width="133" height="18" font="5">•  Participant in FHS, </text>
<text top="320" left="405" width="85" height="17" font="5">MESA, or CHS </text>
<text top="337" left="378" width="3" height="17" font="5"> </text>
<text top="355" left="378" width="103" height="17" font="5">Exclusion Criteria: </text>
<text top="372" left="378" width="144" height="18" font="5">•  Younger than 60 y of </text>
<text top="390" left="405" width="24" height="17" font="5">age </text>
<text top="407" left="378" width="156" height="18" font="5">•  Known CHD, stroke, or </text>
<text top="425" left="405" width="131" height="17" font="5">heart failure at baseline </text>
<text top="231" left="553" width="268" height="17" font="5">Incident ASCVD during follow-up, including CHD </text>
<text top="248" left="553" width="61" height="17" font="5">and stroke </text>
<text top="265" left="553" width="255" height="18" font="5">•  598 ASCVD events during median 10.7 y </text>
<text top="284" left="580" width="53" height="17" font="5">follow-up </text>
<text top="301" left="553" width="253" height="18" font="5">•  Event rates increased across CAC strata </text>
<text top="319" left="553" width="268" height="18" font="5">•  11% of ASCVD events (8% of CHD, 16% of </text>
<text top="337" left="580" width="206" height="17" font="5">stroke) occurred with CAC=0; 42% of </text>
<text top="355" left="580" width="247" height="17" font="5">ASCVD events (45% of CHD, 38% of stroke) </text>
<text top="372" left="580" width="141" height="17" font="5">occurred with CAC ≥ 300 </text>
<text top="389" left="553" width="264" height="18" font="5">•  CAC score vs. age had greater association </text>
<text top="407" left="580" width="219" height="17" font="5">with incident CHD (C statistic, 0.733 vs. </text>
<text top="424" left="580" width="234" height="17" font="5">0.690; C statistics difference, +0.043; 95% </text>
<text top="442" left="580" width="223" height="17" font="5">CI: 0.009-0.075) and modestly improved </text>
<text top="459" left="580" width="111" height="17" font="5">prediction of stroke. </text>
<text top="476" left="553" width="277" height="18" font="5">•  Cox analysis including CAC score and all risk </text>
<text top="494" left="580" width="245" height="17" font="5">factors including age and an interaction term </text>
<text top="512" left="580" width="245" height="17" font="5">suggested no significant interaction between </text>
<text top="529" left="580" width="245" height="17" font="5">CAC score and sex. Sex-specific C statistics </text>
<text top="546" left="580" width="180" height="17" font="5">analyses showed similar results. </text>
<text top="231" left="844" width="224" height="17" font="5">In older adults without known CVD, CAC </text>
<text top="248" left="844" width="241" height="17" font="5">score instead of chronological age provided </text>
<text top="265" left="844" width="226" height="17" font="5">better discrimination for incident ASCVD, </text>
<text top="283" left="844" width="256" height="17" font="5">especially CHD, over an 11-y follow-up period. </text>
<text top="300" left="844" width="232" height="17" font="5">When deciding to initiate statin therapy for </text>
<text top="317" left="844" width="235" height="17" font="5">primary prevention, obtaining a CAC score </text>
<text top="334" left="844" width="226" height="17" font="5">may assist in shared decision-making for </text>
<text top="351" left="844" width="126" height="17" font="5">patients ≥ 60 y of age. </text>
<text top="564" left="75" width="55" height="17" font="5">BioImage </text>
<text top="581" left="75" width="120" height="17" font="5">Mortensen MB, et al., </text>
<text top="598" left="75" width="31" height="17" font="5">2016 </text>
<text top="616" left="75" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27561760">27561760</a></text>
<text top="616" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27561760"> </a></text>
<text top="564" left="216" width="31" height="17" font="5">Aim:  </text>
<text top="581" left="216" width="89" height="17" font="5">Disease-guided </text>
<text top="598" left="216" width="84" height="17" font="5">reclassification </text>
<text top="616" left="216" width="3" height="17" font="5"> </text>
<text top="633" left="216" width="69" height="17" font="5">Study Type: </text>
<text top="650" left="216" width="143" height="17" font="5">prospective observational </text>
<text top="667" left="216" width="41" height="17" font="5">cohort  </text>
<text top="685" left="216" width="3" height="17" font="5"> </text>
<text top="702" left="216" width="101" height="17" font="5">Size: 5,805 adults </text>
<text top="719" left="216" width="145" height="17" font="5">men and women 55–80 y; </text>
<text top="736" left="216" width="77" height="17" font="5">mean 68.9±6 </text>
<text top="753" left="216" width="139" height="17" font="5">Follow-up: median follow-</text>
<text top="771" left="216" width="64" height="17" font="5">up of 2.7 y. </text>
<text top="564" left="378" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="581" left="378" width="140" height="17" font="5">without known ASCVD at </text>
<text top="598" left="378" width="122" height="17" font="5">baseline examination  </text>
<text top="616" left="378" width="3" height="17" font="5"> </text>
<text top="633" left="378" width="154" height="17" font="5">Those with an estimated 10 </text>
<text top="650" left="378" width="147" height="17" font="5">y ASCVD risk ≥7.5% were </text>
<text top="667" left="378" width="148" height="17" font="5">down-classified from statin </text>
<text top="685" left="378" width="116" height="17" font="5">eligible to ineligible if </text>
<text top="702" left="378" width="141" height="17" font="5">imaging revealed CAC=0 </text>
<text top="719" left="378" width="3" height="17" font="5"> </text>
<text top="736" left="378" width="156" height="17" font="5">Intermediate-risk individuals </text>
<text top="753" left="378" width="130" height="17" font="5">were up-classified from </text>
<text top="564" left="573" width="72" height="17" font="5">1° Endpoint: </text>
<text top="581" left="552" width="263" height="18" font="5">•  With CAC-guided reclassification, specificity </text>
<text top="599" left="573" width="240" height="17" font="5">for coronary heart disease events improved </text>
<text top="617" left="552" width="273" height="18" font="5">•  22% (p&lt;0.0001) without any significant loss in </text>
<text top="635" left="573" width="257" height="17" font="5">sensitivity, yielding a binary net reclassification </text>
<text top="652" left="573" width="107" height="17" font="5">index (NRI) of 0.20 </text>
<text top="669" left="552" width="90" height="18" font="5">•  (p&lt;0.0001).  </text>
<text top="688" left="552" width="254" height="18" font="5">•  CAC scores of 0 were common (32%) and </text>
<text top="706" left="553" width="198" height="17" font="5">were associated with low event rate </text>
<text top="564" left="844" width="3" height="17" font="5"> </text>
<text top="581" left="844" width="3" height="17" font="5"> </text>
<text top="598" left="844" width="3" height="17" font="5"> </text>
<text top="616" left="844" width="3" height="17" font="5"> </text>
</page>
<page number="214" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="378" width="152" height="17" font="5">optional to statin eligibility if </text>
<text top="108" left="378" width="87" height="17" font="5">CAC was ≥100 </text>
<text top="126" left="75" width="95" height="17" font="5">General Practice </text>
<text top="143" left="75" width="112" height="17" font="5">Research Database </text>
<text top="160" left="75" width="47" height="17" font="5">(GPRD) </text>
<text top="178" left="75" width="115" height="17" font="5">Soedamah-Muthu et </text>
<text top="195" left="75" width="47" height="17" font="5">al, 2006 </text>
<text top="212" left="75" width="3" height="17" font="5"> </text>
<text top="229" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16567818">16567818</a></text>
<text top="229" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16567818"> </a></text>
<text top="126" left="216" width="31" height="17" font="5">Aim:  </text>
<text top="143" left="216" width="138" height="17" font="5">To estimate the absolute </text>
<text top="160" left="216" width="103" height="17" font="5">and relative risk of </text>
<text top="178" left="216" width="128" height="17" font="5">cardiovascular disease </text>
<text top="195" left="216" width="149" height="17" font="5">(CVD) in patients with type </text>
<text top="212" left="216" width="121" height="17" font="5">1 diabetes in the U.K. </text>
<text top="229" left="216" width="3" height="17" font="5"> </text>
<text top="247" left="216" width="69" height="17" font="5">Study Type: </text>
<text top="264" left="216" width="109" height="17" font="5">Prospective cohort  </text>
<text top="281" left="216" width="3" height="17" font="5"> </text>
<text top="298" left="216" width="34" height="17" font="5">Size:  </text>
<text top="315" left="216" width="57" height="17" font="5">N=45,595 </text>
<text top="126" left="378" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="143" left="378" width="152" height="18" font="5">• ≥6 months of data before </text>
<text top="161" left="388" width="88" height="17" font="5">January 1 1992 </text>
<text top="179" left="378" width="119" height="18" font="5">• Diagnosis of Type I </text>
<text top="197" left="388" width="117" height="17" font="5">diabetes (n=7479) or </text>
<text top="214" left="388" width="133" height="17" font="5">nondiabetic comparison </text>
<text top="231" left="388" width="136" height="17" font="5">group (n=38,116) (5 age </text>
<text top="248" left="388" width="137" height="17" font="5">and sex matched control </text>
<text top="266" left="388" width="126" height="17" font="5">per diabetic patient) or </text>
<text top="283" left="388" width="29" height="17" font="5">CVD </text>
<text top="300" left="378" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="318" left="378" width="14" height="18" font="5">•  </text>
<text top="126" left="573" width="72" height="17" font="5">1° Endpoint: </text>
<text top="143" left="553" width="277" height="17" font="5">Cumulative incidence of a first major incident CVD </text>
<text top="160" left="553" width="266" height="17" font="5">event in Type 1 diabetic patients vs. comparison </text>
<text top="178" left="553" width="275" height="17" font="5">patients=3% vs. 0.76%.  HR=4.5 (95% CI 3.8-5.4)<i> </i></text>
<text top="195" left="553" width="3" height="17" font="7"><i> </i></text>
<text top="212" left="553" width="133" height="17" font="7"><i>Acute Coronary Events</i>  </text>
<text top="229" left="552" width="190" height="18" font="5">•  Men; HR=3.0 (95% CI 2.2-4.1) </text>
<text top="248" left="552" width="216" height="18" font="5">•  Women; HR=7.6 (95% CI 4.9-12.0) </text>
<text top="266" left="573" width="3" height="17" font="5"> </text>
<text top="283" left="553" width="156" height="17" font="7"><i>Coronary revascularizations </i></text>
<text top="300" left="552" width="190" height="18" font="5">•  Men; HR=5.0 (95% CI 3.2-7.8) </text>
<text top="319" left="552" width="222" height="18" font="5">•  Women; HR=16.8 (95% CI 7.3-37.5) </text>
<text top="337" left="573" width="3" height="17" font="5"> </text>
<text top="354" left="553" width="149" height="17" font="7"><i>Stroke (fatal and non-fatal) </i></text>
<text top="371" left="552" width="190" height="18" font="5">•  Men, HR=3.7 (95% CI 2.6-5.3) </text>
<text top="389" left="552" width="209" height="18" font="5">•  Women; HR=4.8 (95% CI 3.0-7.9) </text>
<text top="407" left="573" width="3" height="17" font="5"> </text>
<text top="425" left="553" width="64" height="17" font="7"><i>Major CHD </i></text>
<text top="442" left="552" width="190" height="18" font="5">•  Men; HR=3.6 (95% CI 2.8-4.6) </text>
<text top="460" left="552" width="216" height="18" font="5">•  Women; HR=9.6 (95% CI 6.4-14.5) </text>
<text top="478" left="573" width="3" height="17" font="5"> </text>
<text top="496" left="553" width="60" height="17" font="7"><i>Fatal CVD </i></text>
<text top="513" left="552" width="190" height="18" font="5">•  Men; HR=5.8 (95% CI 3.9-8.6) </text>
<text top="531" left="552" width="222" height="18" font="5">•  Women; HR=11.6 (95% CI 6.7-20.1) </text>
<text top="549" left="552" width="276" height="18" font="5">•  Type I diabetic patients reach a 10-year risk of </text>
<text top="568" left="573" width="248" height="17" font="5">fatal CVD≥5% around 50 years of age vs. 60 </text>
<text top="585" left="573" width="252" height="17" font="5">years of age in nondiabetic comparison group </text>
<text top="602" left="573" width="141" height="17" font="5">(data presented in graph) </text>
<text top="619" left="553" width="3" height="17" font="5"> </text>
<text top="636" left="553" width="64" height="17" font="7"><i>Major CVD </i></text>
<text top="654" left="553" width="274" height="17" font="5">HR men vs. women=1.3 (95% CI 1.0-1.7, p=0.07) </text>
<text top="671" left="553" width="226" height="17" font="5">in type I patients vs. 2.6 (95% CI 2.0-3.4, </text>
<text top="688" left="553" width="255" height="17" font="5">p&lt;0.0001) in nondiabetic comparison patients. </text>
<text top="705" left="553" width="244" height="17" font="5">Significant interaction between diabetes and </text>
<text top="723" left="553" width="214" height="17" font="5">gender (likelihood ratio test, p=0.0007) </text>
<text top="740" left="553" width="3" height="17" font="5"> </text>
<text top="757" left="553" width="27" height="17" font="5">Men </text>
<text top="126" left="844" width="63" height="17" font="5">Summary:  </text>
<text top="143" left="844" width="217" height="18" font="5">• Increased risks of CVD morbidity and </text>
<text top="161" left="854" width="245" height="17" font="5">mortality were observed in patients with type </text>
<text top="179" left="854" width="219" height="17" font="5">1 diabetes compared with those without </text>
<text top="196" left="854" width="230" height="17" font="5">diabetes. Increased risks were reached in </text>
<text top="213" left="854" width="216" height="17" font="5">patients with type 1 diabetes at a much </text>
<text top="230" left="854" width="221" height="17" font="5">younger age compared with nondiabetic </text>
<text top="247" left="854" width="46" height="17" font="5">patients </text>
<text top="265" left="844" width="3" height="17" font="5"> </text>
<text top="282" left="844" width="66" height="17" font="5">Limitations: </text>
<text top="299" left="844" width="170" height="18" font="5">• Potential for loss to follow up </text>
</page>
<page number="215" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="552" width="202" height="18" font="5">•  Overall HR=3.6 (95% CI 2.9-4.5) </text>
<text top="109" left="552" width="49" height="18" font="5">•  Age: </text>
<text top="127" left="573" width="178" height="17" font="5">≤35 HR=11.3 (95% CI 2.9-43.8) </text>
<text top="144" left="573" width="174" height="17" font="5">35-45 HR=4.4 (95% CI 2.5-7.6) </text>
<text top="162" left="573" width="174" height="17" font="5">45-55 HR=3.0 (95% CI 1.9-4.8) </text>
<text top="179" left="573" width="174" height="17" font="5">55-65 HR=4.1 (95% CI 2.8-6.0) </text>
<text top="196" left="573" width="174" height="17" font="5">65-75 HR=2.3 (95% CI 1.3-4.1) </text>
<text top="213" left="573" width="163" height="17" font="5">&gt;75 HR=3.5 (95% CI 1.6-7.3) </text>
<text top="230" left="573" width="3" height="17" font="5"> </text>
<text top="248" left="553" width="46" height="17" font="5">Women </text>
<text top="265" left="552" width="212" height="18" font="5">•  Overall; HR=7.7 (95% CI 5.5-10.7) </text>
<text top="283" left="552" width="46" height="18" font="5">•  Age </text>
<text top="301" left="573" width="171" height="17" font="5">≤35 HR=9.8 (95% CI 1.8-53.6) </text>
<text top="319" left="573" width="188" height="17" font="5">35-45 HR=15.4 (95% CI 5.0-47.3) </text>
<text top="336" left="573" width="188" height="17" font="5">45-55 HR=10.1 (95% CI 5.0-20.4) </text>
<text top="353" left="573" width="181" height="17" font="5">55-65 HR=5.7 (95% CI 3.2-10.4) </text>
<text top="370" left="573" width="181" height="17" font="5">65-75 HR=8.3 (95% CI 4.0-17.2) </text>
<text top="387" left="573" width="170" height="17" font="5">&gt;75 HR=4.0 (95% CI 1.4-11.2) </text>
<text top="405" left="553" width="3" height="17" font="7"><i> </i></text>
<text top="422" left="553" width="129" height="17" font="7"><i>Major Coronary Events </i></text>
<text top="439" left="553" width="208" height="17" font="5">Men: HR=1.3 (95% CI 0.9-1.7, p=0.2) </text>
<text top="456" left="553" width="247" height="17" font="5">Women; HR=3.0 (95% CI 2.1-4.2, p&lt;0.0001) </text>
<text top="474" left="553" width="244" height="17" font="5">Significant interaction between diabetes and </text>
<text top="491" left="553" width="276" height="17" font="5">gender where gender difference was only found in </text>
<text top="508" left="553" width="271" height="17" font="5">those without diabetes (likelihood ratio p=0.0001) </text>
<text top="525" left="573" width="3" height="17" font="5"> </text>
<text top="543" left="75" width="97" height="17" font="5">Willeit et al, 2014 </text>
<text top="561" left="75" width="3" height="17" font="5"> </text>
<text top="578" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25169167">25169167</a></text>
<text top="578" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25169167"> </a></text>
<text top="543" left="216" width="31" height="17" font="5">Aim:  </text>
<text top="561" left="216" width="148" height="17" font="5">To determine wether Lp(a) </text>
<text top="578" left="216" width="105" height="17" font="5">improves CVD risk </text>
<text top="595" left="216" width="57" height="17" font="5">prediction </text>
<text top="612" left="216" width="3" height="17" font="5"> </text>
<text top="629" left="216" width="69" height="17" font="5">Study Type: </text>
<text top="647" left="216" width="105" height="17" font="5">Prospective cohort </text>
<text top="664" left="216" width="3" height="17" font="5"> </text>
<text top="681" left="216" width="34" height="17" font="5">Size:  </text>
<text top="698" left="216" width="40" height="17" font="5">N=826 </text>
<text top="543" left="378" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="561" left="378" width="160" height="18" font="5">• Residents of Bruneck, Italy </text>
<text top="579" left="378" width="3" height="17" font="5"> </text>
<text top="596" left="378" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="613" left="378" width="3" height="17" font="5"> </text>
<text top="543" left="573" width="72" height="17" font="5">1° Endpoint: </text>
<text top="561" left="552" width="260" height="18" font="5">•  Composite CVD endpoint of vascular death </text>
<text top="579" left="573" width="215" height="17" font="5">(ischemic stroke, myocardial infarction, </text>
<text top="596" left="573" width="215" height="17" font="5">sudden cardiac death, aortic aneurysm </text>
<text top="613" left="573" width="244" height="17" font="5">rupture), acute CAD (nonfatal MI, new onset </text>
<text top="630" left="573" width="234" height="17" font="5">unstable angina, crescendo angina or new </text>
<text top="647" left="573" width="202" height="17" font="5">onset severe angina, acute coronary </text>
<text top="665" left="573" width="256" height="17" font="5">interventions) and ischemic stroke ascertained </text>
<text top="682" left="573" width="62" height="17" font="5">1995-2010 </text>
<text top="699" left="553" width="254" height="17" font="5">Mean Lp(a) No CVD No vs Yes CVD=23.3 vs. </text>
<text top="716" left="553" width="79" height="17" font="5">39.1, p&lt;0.001 </text>
<text top="734" left="553" width="219" height="17" font="5">High Lp(a) (&gt;45 mg/dL) No CVD vs Yes </text>
<text top="751" left="553" width="177" height="17" font="5">CVD=16.8% vs 34.5%, p&lt;0.001 </text>
<text top="768" left="553" width="3" height="17" font="5"> </text>
<text top="543" left="844" width="63" height="17" font="5">Summary:  </text>
<text top="561" left="844" width="252" height="18" font="5">• adding Lp(a) to the Framingham Risk Score </text>
<text top="579" left="844" width="195" height="17" font="5">and Reynolds Risk Score improves </text>
<text top="596" left="844" width="252" height="17" font="5">discrimination and reclassification of CVD risk </text>
<text top="613" left="844" width="242" height="17" font="5">in 15-year follow-up in a general population, </text>
<text top="630" left="844" width="220" height="17" font="5">particularly in those of intermediate risk. </text>
<text top="648" left="844" width="3" height="17" font="5"> </text>
<text top="665" left="844" width="3" height="17" font="5"> </text>
</page>
<page number="216" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="553" width="259" height="17" font="5">Overall incidence=15.0 per 1,000 person years </text>
<text top="108" left="553" width="107" height="17" font="5">(95% CI 12.8-17.7) </text>
<text top="125" left="553" width="3" height="17" font="5"> </text>
<text top="142" left="553" width="269" height="17" font="5">Highest quintile of Lp(a) vs reminder adjusted for </text>
<text top="160" left="553" width="230" height="17" font="5">age and sex HR=2.34 (95% CI 1.67-3.29, </text>
<text top="177" left="553" width="272" height="17" font="5">p&lt;0.001). HR per 1 SD higher level of Lp(a)=1.38 </text>
<text top="194" left="553" width="244" height="17" font="5">(95% CI 1.23-1.56; p&lt;0.001). HRs remained </text>
<text top="211" left="553" width="225" height="17" font="5">significant after adjustment for remaining </text>
<text top="229" left="553" width="268" height="17" font="5">Framingham Risk Score variables, Reynolds risk </text>
<text top="246" left="553" width="252" height="17" font="5">Score Variables, and for apo(a) isoform major </text>
<text top="263" left="553" width="32" height="17" font="5">allele </text>
<text top="280" left="553" width="3" height="17" font="5"> </text>
<text top="297" left="553" width="264" height="17" font="7"><i>Discrimination</i>: Addition of Lp(a) to Framingham </text>
<text top="315" left="553" width="242" height="17" font="5">model improved C-index by 0.0165 (95% CI </text>
<text top="332" left="553" width="270" height="17" font="5">0.0019-0.0308, p=0.027).  Replacement of “total” </text>
<text top="349" left="553" width="264" height="17" font="5">Lp(a) with allele-specific Lp(a) levels associated </text>
<text top="366" left="553" width="256" height="17" font="5">with low- versus high-molecular-weight apo9a) </text>
<text top="383" left="553" width="232" height="17" font="5">isoforms did not further increase C-index.  </text>
<text top="401" left="553" width="3" height="17" font="5"> </text>
<text top="418" left="553" width="272" height="17" font="5">C index for Reynolds Risk Score was 0.762 (95% </text>
<text top="435" left="553" width="252" height="17" font="5">CI 0.725-0.798); addition of Lp(a) improved C-</text>
<text top="452" left="553" width="277" height="17" font="5">index by 0.0155 (95% CI 0.0014-0.0297, p=0.031) </text>
<text top="469" left="553" width="3" height="17" font="5"> </text>
<text top="487" left="553" width="247" height="17" font="5">Net Reclassification Improvement in those at </text>
<text top="504" left="553" width="236" height="17" font="5">intermediate risk (15-&lt;30%) was 22.5% for </text>
<text top="521" left="553" width="243" height="17" font="5">noncases (95% CI 10.6-34.4) and 17.1% for </text>
<text top="538" left="553" width="245" height="17" font="5">cases (95% CI -1.4-35.6), and 39.6% overall </text>
<text top="556" left="553" width="243" height="17" font="5">(95% CI 17.6-61.6)).  Analogous statistics in </text>
<text top="573" left="553" width="240" height="17" font="5">participations without diabetes are 18.9% in </text>
<text top="590" left="553" width="255" height="17" font="5">noncases (95% CI 6.1-31.7), 13.9% in cases (-</text>
<text top="607" left="553" width="255" height="17" font="5">5.7-33.5), and 32.8% overall (9.3-56.2).  Allele </text>
<text top="624" left="553" width="245" height="17" font="5">specific Lp(a) levels did not add to predictive </text>
<text top="642" left="553" width="269" height="17" font="5">ability of Framingham Risk Score, Reynolds Risk </text>
<text top="659" left="553" width="89" height="17" font="5">Score, or Lp(a)  </text>
<text top="676" left="573" width="3" height="17" font="5"> </text>
<text top="694" left="75" width="38" height="17" font="5">MESA </text>
<text top="711" left="75" width="93" height="17" font="5">Malik et al, 2017 </text>
<text top="728" left="75" width="3" height="17" font="5"> </text>
<text top="746" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29117273">29117273</a></text>
<text top="746" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29117273"> </a></text>
<text top="694" left="216" width="31" height="17" font="5">Aim:  </text>
<text top="711" left="216" width="143" height="17" font="5">To compare improvement </text>
<text top="728" left="216" width="68" height="17" font="5">in long-term </text>
<text top="746" left="216" width="146" height="17" font="5">prognostication of incident </text>
<text top="763" left="216" width="132" height="17" font="5">CHD and ASCVD using </text>
<text top="694" left="378" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="711" left="378" width="77" height="18" font="5">• Ages 45-84 </text>
<text top="730" left="378" width="98" height="18" font="5">• No known CVD </text>
<text top="748" left="378" width="149" height="18" font="5">• White, African American, </text>
<text top="766" left="388" width="103" height="17" font="5">Hispanic, Chinese </text>
<text top="694" left="573" width="72" height="17" font="5">1° Endpoint: </text>
<text top="711" left="553" width="253" height="17" font="5">Incident CHD events (MI, resuscitated cardiac </text>
<text top="728" left="553" width="107" height="17" font="5">arrest, CHD death) </text>
<text top="746" left="553" width="3" height="17" font="5"> </text>
<text top="763" left="573" width="72" height="17" font="5">2° Endpoint: </text>
<text top="694" left="844" width="63" height="17" font="5">Summary:  </text>
<text top="711" left="844" width="206" height="18" font="5">• addition of CAC score to global risk </text>
<text top="730" left="844" width="248" height="17" font="5">assessment was associated with significantly </text>
<text top="747" left="844" width="253" height="17" font="5">improved risk classification in those with MetS </text>
</page>
<page number="217" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="216" width="143" height="17" font="5">CAC scores among those </text>
<text top="108" left="216" width="128" height="17" font="5">with diabetes, MetS, or </text>
<text top="125" left="216" width="94" height="17" font="5">neither condition </text>
<text top="142" left="216" width="69" height="17" font="5">Study Type: </text>
<text top="160" left="216" width="109" height="17" font="5">Prospective cohort  </text>
<text top="177" left="216" width="3" height="17" font="5"> </text>
<text top="194" left="216" width="78" height="17" font="5">Size: N=6814 </text>
<text top="211" left="216" width="3" height="17" font="5"> </text>
<text top="91" left="378" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="108" left="378" width="14" height="18" font="5">•  </text>
<text top="91" left="553" width="273" height="17" font="5">ASCVD (CHD events and fatal or nonfatal stroke) </text>
<text top="108" left="553" width="3" height="17" font="5"> </text>
<text top="125" left="553" width="3" height="17" font="5"> </text>
<text top="143" left="552" width="208" height="18" font="5">•  Mean follow up time of 11.1 years </text>
<text top="161" left="552" width="270" height="18" font="5">•  In each group, stepwise increase in CHD and </text>
<text top="179" left="573" width="230" height="17" font="5">ASCVD events with increasing severity of </text>
<text top="196" left="573" width="63" height="17" font="5">CAC score </text>
<text top="213" left="553" width="30" height="17" font="5">CHD </text>
<text top="230" left="553" width="90" height="17" font="7"><i>Diabetes Group </i></text>
<text top="248" left="553" width="273" height="17" font="5">HR CAC 1-99 vs CAC 0=2.13 (95% CI 1.13-4.73) </text>
<text top="265" left="553" width="261" height="17" font="5">HR CAC 100-399 vs CAC 0=3.52 (95% CI 1.66-</text>
<text top="282" left="553" width="31" height="17" font="5">7.46) </text>
<text top="299" left="553" width="245" height="17" font="5">HR CAC ≥400 vs CAC 0=5.60 (95% CI 2.79-</text>
<text top="317" left="553" width="38" height="17" font="5">11.23) </text>
<text top="334" left="553" width="3" height="17" font="5"> </text>
<text top="351" left="553" width="162" height="17" font="7"><i>MetS without diabetes Group </i></text>
<text top="368" left="553" width="273" height="17" font="5">HR CAC 1-99 vs CAC 0=2.63 (95% CI 1.46-4.73) </text>
<text top="386" left="553" width="261" height="17" font="5">HR CAC 100-399 vs CAC 0=5.43 (95% CI 3.03-</text>
<text top="403" left="553" width="31" height="17" font="5">9.74) </text>
<text top="420" left="553" width="277" height="17" font="5">HR CAC ≥400 vs CAC 0=6.42 (95% CI 3.38-12.2) </text>
<text top="437" left="553" width="3" height="17" font="5"> </text>
<text top="454" left="553" width="207" height="17" font="7"><i>Group with neither diabetes nor MetS </i></text>
<text top="472" left="553" width="273" height="17" font="5">HR CAC 1-99 vs CAC 0=2.33 (95% CI 1.44-3.78) </text>
<text top="489" left="553" width="261" height="17" font="5">HR CAC 100-399 vs CAC 0=5.07 (95% CI 3.11-</text>
<text top="506" left="553" width="31" height="17" font="5">8.27) </text>
<text top="523" left="553" width="245" height="17" font="5">HR CAC ≥400 vs CAC 0=7.87 (95% CI 4.74-</text>
<text top="540" left="553" width="38" height="17" font="5">13.08) </text>
<text top="558" left="553" width="3" height="17" font="5"> </text>
<text top="575" left="553" width="46" height="17" font="5">ASCVD </text>
<text top="592" left="553" width="90" height="17" font="7"><i>Diabetes Group </i></text>
<text top="609" left="553" width="273" height="17" font="5">HR CAC 1-99 vs CAC 0=1.64 (95% CI 0.98-2.77) </text>
<text top="626" left="553" width="261" height="17" font="5">HR CAC 100-399 vs CAC 0=2.51 (95% CI 1.44-</text>
<text top="644" left="553" width="31" height="17" font="5">4.35) </text>
<text top="661" left="553" width="277" height="17" font="5">HR CAC ≥400 vs CAC 0=3.48 (95% CI 2.06-5.86) </text>
<text top="678" left="553" width="3" height="17" font="5"> </text>
<text top="695" left="553" width="162" height="17" font="7"><i>MetS without diabetes Group </i></text>
<text top="713" left="553" width="273" height="17" font="5">HR CAC 1-99 vs CAC 0=1.87 (95% CI 1.21-2.90) </text>
<text top="730" left="553" width="261" height="17" font="5">HR CAC 100-399 vs CAC 0=2.81 (95% CI 1.78-</text>
<text top="747" left="553" width="31" height="17" font="5">4.45) </text>
<text top="764" left="553" width="277" height="17" font="5">HR CAC ≥400 vs CAC 0=3.16 (95% CI 1.91-5.22) </text>
<text top="91" left="844" width="240" height="17" font="5">and diabetes, even if diabetes duration was </text>
<text top="108" left="844" width="119" height="17" font="5">longer than a decade </text>
<text top="125" left="844" width="3" height="17" font="5"> </text>
<text top="142" left="844" width="66" height="17" font="5">Limitations: </text>
<text top="160" left="844" width="247" height="18" font="5">• CAC measurements are from baseline, not </text>
<text top="178" left="844" width="70" height="17" font="5">time-varying </text>
</page>
<page number="218" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="18" size="12" family="Times" color="#0460c1"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="553" width="3" height="17" font="5"> </text>
<text top="108" left="553" width="207" height="17" font="7"><i>Group with neither diabetes nor MetS </i></text>
<text top="125" left="553" width="273" height="17" font="5">HR CAC 1-99 vs CAC 0=1.89 (95% CI 1.32-2.72) </text>
<text top="142" left="553" width="261" height="17" font="5">HR CAC 100-399 vs CAC 0=3.23 (95% CI 3.19-</text>
<text top="160" left="553" width="31" height="17" font="5">4.77) </text>
<text top="177" left="553" width="277" height="17" font="5">HR CAC ≥400 vs CAC 0=3.88 (95% CI 2.57-5.85) </text>
<text top="194" left="553" width="3" height="17" font="5"> </text>
<text top="211" left="553" width="84" height="17" font="5">Discrimination: </text>
<text top="229" left="553" width="253" height="17" font="5">Diabetes group: NRI=0.23 (95% CI 0.10-0.37, </text>
<text top="246" left="553" width="52" height="17" font="5">p&lt;0.001) </text>
<text top="263" left="553" width="3" height="17" font="5"> </text>
<text top="280" left="553" width="234" height="17" font="5">MetS group: NRI=0.22 (95% CI 0.09-0.35) </text>
<text top="297" left="553" width="3" height="17" font="5"> </text>
<text top="315" left="553" width="272" height="17" font="5">Neither diabetes nor MetS group: NRI=0.25 (95% </text>
<text top="332" left="553" width="75" height="17" font="5">CI 0.15-0.35) </text>
<text top="350" left="75" width="124" height="17" font="5">Sniderman et al, 2011 </text>
<text top="367" left="75" width="3" height="17" font="5"> </text>
<text top="384" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21487090">21487090</a></text>
<text top="384" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21487090"> </a></text>
<text top="350" left="216" width="31" height="17" font="5">Aim:  </text>
<text top="367" left="216" width="132" height="17" font="5">to determine the overall </text>
<text top="384" left="216" width="133" height="17" font="5">balance of the evidence </text>
<text top="401" left="216" width="81" height="17" font="5">comparing the </text>
<text top="419" left="216" width="124" height="17" font="5">standardized RRRs of </text>
<text top="436" left="216" width="125" height="17" font="5">apoB, non-HDL-C and </text>
<text top="453" left="216" width="42" height="17" font="5">LDL-C  </text>
<text top="470" left="216" width="69" height="17" font="5">Study Type: </text>
<text top="487" left="216" width="82" height="17" font="5">Meta analysis  </text>
<text top="505" left="216" width="3" height="17" font="5"> </text>
<text top="522" left="216" width="105" height="17" font="5">Size: N=12 reports </text>
<text top="539" left="216" width="105" height="17" font="5">(233,455 subjects) </text>
<text top="556" left="216" width="3" height="17" font="5"> </text>
<text top="350" left="378" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="367" left="378" width="149" height="18" font="5">• Studies reporting risks of </text>
<text top="385" left="388" width="122" height="17" font="5">non-HDL-C and apoB </text>
<text top="402" left="378" width="3" height="17" font="5"> </text>
<text top="420" left="378" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="437" left="378" width="3" height="17" font="5"> </text>
<text top="350" left="573" width="72" height="17" font="5">1° Endpoint: </text>
<text top="367" left="552" width="273" height="18" font="5">•  apoB: RRR=1.43 (95% CI 1.35-1.51) p&lt;0.001 </text>
<text top="385" left="552" width="255" height="18" font="5">•  non-HDL-C RRR=1.34 (95% CI 1.24-1.44) </text>
<text top="404" left="573" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="421" left="552" width="276" height="18" font="5">•  LDL-C RRR=1.25 (95% CI 1.18-1.33) p&lt;0.001 </text>
<text top="439" left="552" width="275" height="18" font="5">•  Overall, apoB RRR was 5.7% higher than non-</text>
<text top="457" left="573" width="251" height="17" font="5">HDL-C RRR (95% CI 2.4-9.1%, p&lt;0.001). On </text>
<text top="474" left="573" width="256" height="17" font="5">average RRR of non-HDL-C was 5.0% greater </text>
<text top="492" left="573" width="217" height="17" font="5">than LDL-C RRR (95% CI 0.9% to 9.1!, </text>
<text top="509" left="573" width="228" height="17" font="5">p=0.017).  On average RRR of apoB was </text>
<text top="526" left="573" width="238" height="17" font="5">12.0% greater than RRR of LDL-C (95% CI </text>
<text top="543" left="573" width="156" height="17" font="5">8.5% to 15.4%, p&lt;0.0001).   </text>
<text top="561" left="552" width="240" height="18" font="5">•  Meta regression indicated no significant </text>
<text top="579" left="573" width="244" height="17" font="5">impact of year of publication (p=0.49), mean </text>
<text top="596" left="573" width="231" height="17" font="5">age (p=0.60), range of apoB (p=0.48), but </text>
<text top="613" left="573" width="230" height="17" font="5">there was a significant difference of mean </text>
<text top="630" left="573" width="253" height="17" font="5">HDL-C concentrations (HDL-C concentrations </text>
<text top="647" left="573" width="256" height="17" font="5">negatively associated with size of difference in </text>
<text top="665" left="573" width="257" height="17" font="5">RRR between apoB and non-HDL-C, p=0.064, </text>
<text top="682" left="573" width="9" height="17" font="5">R</text>
<text top="683" left="581" width="4" height="11" font="8">2</text>
<text top="682" left="586" width="46" height="17" font="5">=0.565) </text>
<text top="699" left="552" width="252" height="18" font="5">•  No significant evidence of publication bias </text>
<text top="350" left="844" width="63" height="17" font="5">Summary:  </text>
<text top="367" left="844" width="224" height="18" font="5">• apoB was the most accurate marker of </text>
<text top="385" left="844" width="243" height="17" font="5">cardiovascular risk, followed by non-HDL-C, </text>
<text top="403" left="844" width="164" height="17" font="5">which was followed by LDL-C </text>
<text top="420" left="844" width="256" height="18" font="5">• Authors calculate that over a 10-year period, </text>
<text top="438" left="844" width="247" height="17" font="5">using non-HDL-C as a marker would prevent </text>
<text top="455" left="844" width="243" height="17" font="5">300,000 more events in the US than LDL-C, </text>
<text top="473" left="844" width="248" height="17" font="5">and using apoB would prevent 500,000 more </text>
<text top="490" left="844" width="190" height="17" font="5">events than a non-HDL-C strategy </text>
<text top="507" left="844" width="3" height="17" font="5"> </text>
<text top="718" left="75" width="124" height="17" font="5">Wong ND, et al., 2012 </text>
<text top="735" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22377485">22377485</a></text>
<text top="735" left="129" width="7" height="17" font="18"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22377485">  </a></text>
<text top="753" left="75" width="3" height="17" font="5"> </text>
<text top="718" left="216" width="105" height="17" font="3"><b>Study type</b>: Cross </text>
<text top="735" left="216" width="138" height="17" font="5">sectional cohort analysis </text>
<text top="753" left="216" width="3" height="17" font="5"> </text>
<text top="770" left="216" width="132" height="17" font="3"><b>Design</b>: Assessment of </text>
<text top="718" left="378" width="142" height="17" font="3"><b>Inclusion criteria</b>: adults </text>
<text top="735" left="378" width="92" height="17" font="5">30-74 y with DM </text>
<text top="753" left="378" width="3" height="17" font="5"> </text>
<text top="770" left="378" width="134" height="17" font="3"><b>Exclusion criteria:</b> N/A </text>
<text top="718" left="573" width="254" height="17" font="3"><b>1° endpoint</b>: 10 y total CVD events estimated </text>
<text top="735" left="573" width="167" height="17" font="5">by the Framingham algorithm. </text>
<text top="753" left="573" width="3" height="17" font="5"> </text>
<text top="770" left="573" width="52" height="17" font="3"><b>Results: </b></text>
<text top="718" left="844" width="64" height="17" font="3"><b>Summary: </b></text>
<text top="735" left="844" width="214" height="17" font="5">• 75% of subjects without CVD were at </text>
<text top="753" left="844" width="138" height="17" font="5">intermediate or high risk. </text>
<text top="770" left="844" width="236" height="17" font="5">• A minority of adults with T2DM and about </text>
</page>
<page number="219" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="216" width="133" height="17" font="5">distribution of 10 y CVD </text>
<text top="108" left="216" width="148" height="17" font="5">risk in a representative US </text>
<text top="125" left="216" width="131" height="17" font="5">sample of subjects with </text>
<text top="142" left="216" width="144" height="17" font="5">diabetes (NHANES 2003- </text>
<text top="160" left="216" width="140" height="17" font="5">6) using the Framingham </text>
<text top="177" left="216" width="137" height="17" font="5">score which divides 10 y </text>
<text top="194" left="216" width="144" height="17" font="5">CVD risk into low (&lt;10%), </text>
<text top="211" left="216" width="149" height="17" font="5">intermediate (10-20%) and </text>
<text top="229" left="216" width="93" height="17" font="5">high risk (&gt;20%) </text>
<text top="246" left="216" width="64" height="17" font="5">categories. </text>
<text top="263" left="216" width="3" height="17" font="5"> </text>
<text top="280" left="216" width="83" height="17" font="3"><b>Size</b>: n=1,114, </text>
<text top="297" left="216" width="138" height="17" font="5">representing 18.2 million </text>
<text top="91" left="573" width="250" height="17" font="5">• Among those without pre-existing CVD 27% </text>
<text top="108" left="573" width="236" height="17" font="5">had &lt;10%, 23% had 10-20% and 50% had </text>
<text top="125" left="573" width="35" height="17" font="5">&gt;20% </text>
<text top="142" left="573" width="53" height="17" font="5">10 y risk. </text>
<text top="160" left="573" width="97" height="17" font="5">• Age subgroups: </text>
<text top="177" left="573" width="211" height="17" font="5">o 40-49 y, low risk 47%; high risk 15% </text>
<text top="194" left="573" width="211" height="17" font="5">o 50-59 y, low risk 17%; high risk 33% </text>
<text top="211" left="573" width="204" height="17" font="5">o 60-69 y, low risk 6%, high risk 42% </text>
<text top="229" left="573" width="237" height="17" font="5">• 49.3% of subjects with T1DM, 10.3% with </text>
<text top="246" left="573" width="37" height="17" font="5">type 2 </text>
<text top="263" left="573" width="243" height="17" font="5">and 17.5% with previously undiagnosed DM </text>
<text top="280" left="573" width="30" height="17" font="5">were </text>
<text top="297" left="573" width="62" height="17" font="5">at low risk. </text>
<text top="315" left="573" width="188" height="17" font="5">• Low risk subgroups (% low risk): </text>
<text top="332" left="573" width="183" height="17" font="5">Sex; Female/Male: 26.8%/18.6% </text>
<text top="349" left="573" width="235" height="17" font="5">Race/Ethnicity; Black/Hispanic/Caucasian: </text>
<text top="366" left="573" width="115" height="17" font="5">30.6%/32.4%/16.8% </text>
<text top="383" left="573" width="222" height="17" font="5">• 59% of low risk subjects had metabolic </text>
<text top="401" left="573" width="159" height="17" font="5">syndrome and 7% had CKD. </text>
<text top="91" left="844" width="226" height="17" font="5">half of those with T1DM are at &lt;10% 10y </text>
<text top="108" left="844" width="215" height="17" font="5">CVD risk using the Framingham score, </text>
<text top="125" left="844" width="218" height="17" font="5">especially those &lt;50 y, females&gt;males, </text>
<text top="142" left="844" width="131" height="17" font="5">minorities&gt;Caucasians. </text>
<text top="160" left="844" width="250" height="17" font="5">• Half the cohort were at high risk (&gt;20% 10 y </text>
<text top="177" left="844" width="59" height="17" font="5">CVD risk). </text>
<text top="194" left="844" width="192" height="17" font="5">• Low risk subjects frequently have </text>
<text top="211" left="844" width="236" height="17" font="5">comorbidities that increase their long-term. </text>
<text top="229" left="844" width="3" height="17" font="3"><b> </b></text>
<text top="246" left="844" width="73" height="17" font="3"><b>Limitations: </b></text>
<text top="263" left="844" width="253" height="17" font="5">• Though representative of the US population, </text>
<text top="280" left="844" width="188" height="17" font="5">the study group is relatively small. </text>
<text top="297" left="844" width="246" height="17" font="5">• The Framingham score may underestimate </text>
<text top="315" left="844" width="240" height="17" font="5">risk and its validity in subjects with diabetes </text>
<text top="332" left="844" width="121" height="17" font="5">has been questioned. </text>
<text top="419" left="75" width="124" height="17" font="5">Khera AV, et al., 2016 </text>
<text top="436" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27050191">27050191</a></text>
<text top="436" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27050191"> </a></text>
<text top="419" left="216" width="115" height="17" font="3"><b>Study Type</b>: Pooled </text>
<text top="436" left="216" width="139" height="17" font="5">cohort analysis of 7 CAD </text>
<text top="453" left="216" width="138" height="17" font="5">case control cohorts and </text>
<text top="470" left="216" width="114" height="17" font="5">5 prospective cohort </text>
<text top="487" left="216" width="44" height="17" font="5">Studies </text>
<text top="505" left="216" width="3" height="17" font="5"> </text>
<text top="522" left="216" width="121" height="17" font="3"><b>Size</b>: 20,485 subjects<b> </b></text>
<text top="419" left="378" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="436" left="378" width="162" height="17" font="5">1386 subjects were identified </text>
<text top="453" left="378" width="137" height="17" font="5">with LDLC ≥ 190 mg/dL. </text>
<text top="470" left="378" width="109" height="17" font="5">Whole exome gene </text>
<text top="487" left="378" width="139" height="17" font="5">sequencing was done on </text>
<text top="505" left="378" width="133" height="17" font="5">those with LDL-C ≥ 190 </text>
<text top="522" left="378" width="139" height="17" font="5">mg/dL comparing risk for </text>
<text top="539" left="378" width="162" height="17" font="5">CAD in those with vs. without </text>
<text top="556" left="378" width="127" height="17" font="5">FH-causing mutations. </text>
<text top="573" left="378" width="133" height="17" font="3"><b>Exclusion criteria</b>: N/A </text>
<text top="419" left="573" width="188" height="17" font="3"><b>1</b>⁰<b>endpoint:</b> Prevalence of an FH </text>
<text top="436" left="573" width="191" height="17" font="5">mutation among those with severe </text>
<text top="453" left="573" width="222" height="17" font="5">hypercholesterolemia and determination </text>
<text top="471" left="573" width="219" height="17" font="5">of whether CAD risk varies according to </text>
<text top="488" left="573" width="205" height="17" font="5">mutation status beyond the observed </text>
<text top="505" left="573" width="71" height="17" font="5">LDL-C level. </text>
<text top="522" left="573" width="3" height="17" font="5"> </text>
<text top="539" left="573" width="52" height="17" font="3"><b>Results: </b></text>
<text top="557" left="573" width="226" height="17" font="5">1. Those with LDL-C ≥190 mg/dL and no </text>
<text top="574" left="573" width="217" height="17" font="5">FH mutation had a 6-fold higher risk for </text>
<text top="591" left="573" width="211" height="17" font="5">CAD (odds ratio: 6.0; 95% CI: 5.2-6.9) </text>
<text top="608" left="573" width="231" height="17" font="5">than those with LDL-C &lt;130 mg/dl and no </text>
<text top="625" left="573" width="215" height="17" font="5">mutation. Those with both LDL-C ≥190 </text>
<text top="643" left="573" width="220" height="17" font="5">mg/dl and an FH mutation had a 22-fold </text>
<text top="660" left="573" width="222" height="17" font="5">increased risk (odds ratio: 22.3; 95% CI: </text>
<text top="677" left="573" width="63" height="17" font="5">10.7-53.2). </text>
<text top="694" left="573" width="212" height="17" font="5">2. Cumulative exposure to high LDL-C </text>
<text top="712" left="573" width="203" height="17" font="5">was assessed using a cohort from of </text>
<text top="729" left="573" width="162" height="17" font="5">5,727 Atherosclerosis Risk in </text>
<text top="746" left="573" width="214" height="17" font="5">Communities Study cohort participants </text>
<text top="763" left="573" width="199" height="17" font="5">and 2,714 Framingham Heart Study </text>
<text top="419" left="844" width="64" height="17" font="3"><b>Summary: </b></text>
<text top="436" left="844" width="248" height="17" font="5">CAD risk is higher in those with LDL-C ≥ 190 </text>
<text top="453" left="844" width="244" height="17" font="5">mg/dL than in those with LDL-C &lt;130 mg/dL </text>
<text top="470" left="844" width="247" height="17" font="5">and the risk is more than tripled in those with </text>
<text top="487" left="844" width="233" height="17" font="5">LDL-C ≥190 mg/dL and a concomitant FH </text>
<text top="505" left="844" width="97" height="17" font="5">causing mutation </text>
<text top="522" left="844" width="224" height="17" font="5">3. These findings may be mediated via a </text>
<text top="539" left="844" width="210" height="17" font="5">higher cumulative exposure to LDL-C. </text>
<text top="556" left="844" width="3" height="17" font="5"> </text>
<text top="573" left="844" width="107" height="17" font="3"><b>Study limitations: </b></text>
<text top="591" left="844" width="252" height="17" font="5">1. Study participants could not be stratified by </text>
<text top="608" left="844" width="207" height="17" font="5">family history or physical examination </text>
<text top="625" left="844" width="224" height="17" font="5">2. Assumption of 30% LDL-C lowering in </text>
<text top="642" left="844" width="33" height="17" font="5">those </text>
<text top="660" left="844" width="208" height="17" font="5">treated with statin therapy may not be </text>
<text top="677" left="844" width="51" height="17" font="5">accurate </text>
<text top="694" left="844" width="240" height="17" font="5">3. Those with LDL mutations may have had </text>
<text top="711" left="844" width="95" height="17" font="5">survivorship bias<b> </b></text>
</page>
<page number="220" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="573" width="220" height="17" font="5">participants and in those with serial lipid </text>
<text top="108" left="573" width="201" height="17" font="5">measurements over many y. Among </text>
<text top="125" left="573" width="228" height="17" font="5">these subjects 25 participants with an FH </text>
<text top="142" left="573" width="196" height="17" font="5">mutation and LDL cholesterol ≥130 </text>
<text top="160" left="573" width="207" height="17" font="5">mg/dL were identified Compared with </text>
<text top="177" left="573" width="223" height="17" font="5">matched non-carriers with similar LDL-C </text>
<text top="194" left="573" width="214" height="17" font="5">levels participants with an FH mutation </text>
<text top="211" left="573" width="201" height="17" font="5">had a 17 mg/dl (95% CI: 5-29 mg/dl; </text>
<text top="229" left="573" width="227" height="17" font="5">p=0.007) higher average LDL cholesterol </text>
<text top="246" left="573" width="226" height="17" font="5">exposure in the y preceding the last visit.<b> </b></text>
<text top="264" left="75" width="102" height="17" font="5">Nanchen D, et al., </text>
<text top="281" left="75" width="31" height="17" font="5">2016 </text>
<text top="298" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27462068">27462068</a></text>
<text top="298" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27462068"> </a></text>
<text top="264" left="216" width="133" height="17" font="3"><b>Study type</b>: Multicenter </text>
<text top="281" left="216" width="137" height="17" font="5">prospective cohort study </text>
<text top="298" left="216" width="3" height="17" font="5"> </text>
<text top="315" left="216" width="109" height="17" font="3"><b>Size</b>: 4534 patients </text>
<text top="264" left="378" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="281" left="378" width="159" height="17" font="5">1. Patients ≥ age 18 y with a </text>
<text top="298" left="378" width="132" height="17" font="5">primary diagnosis of ST </text>
<text top="315" left="378" width="117" height="17" font="5">elevation MI, non-ST </text>
<text top="333" left="378" width="134" height="17" font="5">elevation MI or unstable </text>
<text top="350" left="378" width="137" height="17" font="5">angina, hospitalized with </text>
<text top="367" left="378" width="155" height="17" font="5">acute coronary syndrome in </text>
<text top="384" left="378" width="148" height="17" font="5">Switzerland between 2009 </text>
<text top="401" left="378" width="135" height="17" font="5">and 2013 and who were </text>
<text top="419" left="378" width="135" height="17" font="5">individually screened for </text>
<text top="436" left="378" width="114" height="17" font="5">clinical FH using the </text>
<text top="453" left="378" width="148" height="17" font="5">definitions of the American </text>
<text top="470" left="378" width="141" height="17" font="5">Heart Association, Simon </text>
<text top="487" left="378" width="94" height="17" font="5">Broome, and the </text>
<text top="505" left="378" width="142" height="17" font="5">Dutch Lipid Clinic criteria. </text>
<text top="522" left="378" width="140" height="17" font="5">2. Patients with complete </text>
<text top="539" left="378" width="151" height="17" font="5">baseline and follow-up lipid </text>
<text top="556" left="378" width="144" height="17" font="5">measurements and family </text>
<text top="573" left="378" width="107" height="17" font="5">history information. </text>
<text top="591" left="378" width="3" height="17" font="5"> </text>
<text top="608" left="378" width="148" height="17" font="3"><b>Exclusion criteria:</b> Those </text>
<text top="625" left="378" width="145" height="17" font="5">with missing lipid or family </text>
<text top="642" left="378" width="107" height="17" font="5">history information. </text>
<text top="264" left="573" width="208" height="17" font="3"><b>1</b>⁰<b> endpoint</b>: 1-y risk of first recurrent </text>
<text top="281" left="573" width="216" height="17" font="5">coronary death or myocardial infarction </text>
<text top="298" left="573" width="223" height="17" font="5">after multivariable adjustment, assessed </text>
<text top="316" left="573" width="234" height="17" font="5">by telephone monitoring and by a followup </text>
<text top="333" left="573" width="194" height="17" font="5">clinic visit 1 y after the acute event. </text>
<text top="350" left="573" width="213" height="17" font="5">Results: The risk of recurrent coronary </text>
<text top="367" left="573" width="212" height="17" font="5">events was greater in patients with FH </text>
<text top="385" left="573" width="212" height="17" font="5">than in those without, with an adjusted </text>
<text top="402" left="573" width="204" height="17" font="5">hazard ratio of 2.46 (95% confidence </text>
<text top="419" left="573" width="199" height="17" font="5">interval: 1.07–5.65; p=0.034) for the </text>
<text top="436" left="573" width="211" height="17" font="5">American Heart Association definition, </text>
<text top="453" left="573" width="203" height="17" font="5">2.73 (95% confidence interval: 1.46– </text>
<text top="471" left="573" width="206" height="17" font="5">5.11; p=0.002) for the Simon Broome </text>
<text top="488" left="573" width="203" height="17" font="5">definition, and 3.53 (95% confidence </text>
<text top="505" left="573" width="199" height="17" font="5">interval: 1.26–9.94; p=0.017) for the </text>
<text top="522" left="573" width="217" height="17" font="5">Dutch Lipid Clinic definition. Depending </text>
<text top="539" left="573" width="204" height="17" font="5">on which clinical definition of FH was </text>
<text top="557" left="573" width="198" height="17" font="5">used, between 94.5% and 99.1% of </text>
<text top="574" left="573" width="202" height="17" font="5">patients with FH were discharged on </text>
<text top="591" left="573" width="213" height="17" font="5">statins and between 74.0% and 82.3% </text>
<text top="608" left="573" width="132" height="17" font="5">on high-intensity statins </text>
<text top="264" left="844" width="232" height="17" font="3"><b>Summary</b>: Recurrent coronary events are </text>
<text top="281" left="844" width="228" height="17" font="5">more likely in those with FH than in those </text>
<text top="298" left="844" width="182" height="17" font="5">without despite high-dose statins </text>
<text top="315" left="844" width="3" height="17" font="5"> </text>
<text top="333" left="844" width="73" height="17" font="3"><b>Limitations: </b></text>
<text top="350" left="844" width="244" height="17" font="5">1. Possible selection bias of MI patients with </text>
<text top="367" left="844" width="249" height="17" font="5">vs. without FH presenting with recurrent ACS </text>
<text top="384" left="844" width="241" height="17" font="5">2. No genetic testing was performed, so the </text>
<text top="401" left="844" width="243" height="17" font="5">presence of polygenic hypercholesterolemia </text>
<text top="419" left="844" width="127" height="17" font="5">could not be excluded. </text>
<text top="436" left="844" width="249" height="17" font="5">3. No data were collected on family history or </text>
<text top="453" left="844" width="217" height="17" font="5">physical findings related to possible FH </text>
<text top="470" left="844" width="252" height="17" font="5">4. Lower LDL-C values on blood collected 12- </text>
<text top="487" left="844" width="203" height="17" font="5">24 H after ACS may have resulted in </text>
<text top="505" left="844" width="205" height="17" font="5">underestimation of prevalence of FH. </text>
<text top="660" left="75" width="114" height="17" font="5">Versmissen J, et al., </text>
<text top="678" left="75" width="31" height="17" font="5">2008 </text>
<text top="695" left="75" width="3" height="17" font="5"> </text>
<text top="712" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19001495">19001495</a></text>
<text top="712" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19001495"> </a></text>
<text top="660" left="216" width="74" height="17" font="3"><b>Study Type: </b></text>
<text top="678" left="216" width="116" height="17" font="5">Retrospective cohort </text>
<text top="695" left="216" width="146" height="17" font="5">study of 27 outpatient lipid </text>
<text top="712" left="216" width="70" height="17" font="5">clinics in the </text>
<text top="729" left="216" width="73" height="17" font="5">Netherlands. </text>
<text top="746" left="216" width="113" height="17" font="3"><b>Size:</b> 2146 patients  </text>
<text top="660" left="378" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="678" left="378" width="136" height="17" font="5">Patients with phenotypic </text>
<text top="695" left="378" width="162" height="17" font="5">familial hypercholesterolemia </text>
<text top="712" left="378" width="149" height="17" font="5">identified in a Dutch cohort </text>
<text top="729" left="378" width="114" height="17" font="5">from 1/1/90 to 2002. </text>
<text top="746" left="378" width="139" height="17" font="5">Enrollees had to have no </text>
<text top="661" left="573" width="219" height="17" font="3"><b>1</b>⁰<b>endpoint:</b> Relative risk of myocardial </text>
<text top="678" left="573" width="224" height="17" font="5">infarction in statin treated patients and in </text>
<text top="695" left="573" width="226" height="17" font="5">those who were delayed in starting statin </text>
<text top="712" left="573" width="235" height="17" font="5">treatment compared with a Cox regression </text>
<text top="730" left="573" width="203" height="17" font="5">model in which statin use was a time </text>
<text top="747" left="573" width="111" height="17" font="5">dependent variable. </text>
<text top="764" left="573" width="3" height="17" font="5"> </text>
<text top="660" left="844" width="236" height="17" font="3"><b>Summary:</b> Statin therapy reduces incident </text>
<text top="678" left="844" width="226" height="17" font="5">myocardial infarction risk in subjects with </text>
<text top="695" left="844" width="162" height="17" font="5">familial hypercholesterolemia </text>
<text top="712" left="844" width="3" height="17" font="5"> </text>
<text top="729" left="844" width="73" height="17" font="3"><b>Limitations: </b></text>
<text top="746" left="844" width="226" height="17" font="5">1. Possible selection bias favoring earlier </text>
<text top="764" left="844" width="235" height="17" font="5">treatment of patients with perceived higher </text>
</page>
<page number="221" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="378" width="154" height="17" font="5">documented coronary heart </text>
<text top="108" left="378" width="129" height="17" font="5">disease prior to 1/1/90. </text>
<text top="125" left="378" width="3" height="17" font="5"> </text>
<text top="142" left="378" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="160" left="378" width="128" height="17" font="5">Those with established </text>
<text top="177" left="378" width="83" height="17" font="5">coronary heart </text>
<text top="194" left="378" width="129" height="17" font="5">disease prior to 1/1/90. </text>
<text top="91" left="573" width="220" height="17" font="3"><b>Results</b>: In January 1990, 413 (21%) of </text>
<text top="108" left="573" width="226" height="17" font="5">the patients had been started on a statin, </text>
<text top="125" left="573" width="228" height="17" font="5">and during follow-up 1294 patients (66%) </text>
<text top="142" left="573" width="215" height="17" font="5">started after a mean delay of 4.3 y (SD </text>
<text top="160" left="573" width="218" height="17" font="5">3.3 y). During a mean follow-up of 8.5 y </text>
<text top="177" left="573" width="193" height="17" font="5">(SD 3.1 y) there was a reduction in </text>
<text top="194" left="573" width="206" height="17" font="5">myocardial infarction risk reduction of </text>
<text top="211" left="573" width="217" height="17" font="5">76% (hazard ratio: 0.24; CI: 0.18-0.30), </text>
<text top="229" left="573" width="208" height="17" font="5">p&lt;0.001) in those initially started on a </text>
<text top="246" left="573" width="204" height="17" font="5">statin as compared to those in whom </text>
<text top="263" left="573" width="217" height="17" font="5">statin administration had been delayed. </text>
<text top="280" left="573" width="206" height="17" font="5">After additional reduction for baseline </text>
<text top="297" left="573" width="210" height="17" font="5">characteristics, there was an 82% risk </text>
<text top="315" left="573" width="220" height="17" font="5">reduction (HR: 0.18; 95% CI: 0.13-0.25; </text>
<text top="332" left="573" width="56" height="17" font="5">p&lt;0.001). </text>
<text top="91" left="844" width="26" height="17" font="5">risk. </text>
<text top="108" left="844" width="144" height="17" font="5">2. Lack of placebo control </text>
<text top="125" left="844" width="256" height="17" font="5">3. Intention to treat analysis was not employed </text>
<text top="350" left="75" width="39" height="17" font="3"><b>MESA </b></text>
<text top="367" left="75" width="84" height="17" font="5">Nasir K, et al.,  </text>
<text top="384" left="75" width="31" height="17" font="5">2015 </text>
<text top="401" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26449135">26449135</a></text>
<text top="401" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26449135"> </a></text>
<text top="350" left="216" width="138" height="17" font="3"><b>Study type:</b> Prospective </text>
<text top="367" left="216" width="119" height="17" font="5">Observational Cohort </text>
<text top="384" left="216" width="79" height="17" font="5">study (MESA) </text>
<text top="401" left="216" width="3" height="17" font="5"> </text>
<text top="419" left="216" width="63" height="17" font="3"><b>Size:</b> 4758<b> </b></text>
<text top="350" left="378" width="109" height="17" font="3"><b>Inclusion criteria:</b>  </text>
<text top="367" left="378" width="141" height="18" font="5">• Adults age 45-75 y with </text>
<text top="385" left="378" width="161" height="17" font="5">complete data for risk factors </text>
<text top="403" left="378" width="72" height="17" font="5">used in PCE </text>
<text top="420" left="378" width="3" height="17" font="5"> </text>
<text top="437" left="378" width="114" height="17" font="3"><b>Exclusion criteria:</b>  </text>
<text top="454" left="378" width="152" height="18" font="5">• Lipid-lowering medication </text>
<text top="473" left="378" width="23" height="17" font="5">use </text>
<text top="490" left="378" width="115" height="18" font="5">• Prevalent ASCVD  </text>
<text top="508" left="378" width="94" height="18" font="5">• LDL &lt;70 mg/dl<b> </b></text>
<text top="351" left="553" width="7" height="17" font="3"><b>1</b></text>
<text top="350" left="560" width="233" height="18" font="5"><b> endpoint:</b> Incident ASCVD (CHD death, </text>
<text top="368" left="553" width="270" height="17" font="5">resuscitated cardiac arrest, myocardial infarction, </text>
<text top="385" left="553" width="68" height="17" font="5">and stroke); </text>
<text top="403" left="553" width="146" height="17" font="5">Median follow up of 10.3 y<b> </b></text>
<text top="420" left="553" width="3" height="17" font="5"> </text>
<text top="437" left="553" width="52" height="17" font="3"><b>Results: </b></text>
<text top="454" left="552" width="248" height="18" font="5">•  247 ASCVD events; 155 hard CHD events </text>
<text top="473" left="552" width="264" height="18" font="5">•  Event rates based on recommendation status </text>
<text top="491" left="552" width="229" height="17" font="5">for statins per 2013 ACC/AHA guidelines: </text>
<text top="508" left="565" width="262" height="17" font="5">-  Recommended for statins based on PCE (10-</text>
<text top="525" left="565" width="255" height="17" font="5">y predicted risk ≥7.5% or LDL-C 190 mg/dL or </text>
<text top="542" left="565" width="232" height="17" font="5">diabetes): 9.1/1000 person-y, 95% CI: 7.9-</text>
<text top="560" left="565" width="35" height="17" font="5">10.5); </text>
<text top="577" left="565" width="265" height="17" font="5">-  Considered for statins (10-y predicted risk 5% </text>
<text top="594" left="565" width="259" height="17" font="5">- &lt;7.5%): 4.00/1000 person-y, 95% CI: 2.6-6.0; </text>
<text top="611" left="553" width="262" height="17" font="5">Not statin candidates (10-y predicted risk &lt;5%): </text>
<text top="628" left="553" width="209" height="17" font="5">1.62/1000 person-y, 95% CI: 1.2-2.3. <b> </b></text>
<text top="350" left="844" width="181" height="18" font="5">• PCE rank-ordered ASCVD risk </text>
<text top="368" left="844" width="249" height="17" font="5">appropriately, but there was evidence for mis-</text>
<text top="385" left="844" width="233" height="17" font="5">calibration with overprediction of observed </text>
<text top="403" left="844" width="138" height="17" font="5">event rates in this cohort </text>
<text top="420" left="844" width="3" height="17" font="5"> </text>
<text top="437" left="844" width="211" height="18" font="5">• Limitations: No formal discrimination </text>
<text top="455" left="844" width="256" height="17" font="5">/calibration assessment, as the purpose of this </text>
<text top="473" left="844" width="241" height="17" font="5">study was not as much to evaluate the PCE </text>
<text top="490" left="844" width="257" height="17" font="5">as it was to evaluate the additive value of CAC </text>
<text top="507" left="844" width="63" height="17" font="5">to the PCE </text>
<text top="524" left="844" width="3" height="17" font="5"> </text>
<text top="541" left="844" width="175" height="17" font="5">OVERALL QUALITY: Moderate </text>
<text top="646" left="75" width="38" height="17" font="5">MESA </text>
<text top="664" left="75" width="107" height="17" font="5">Budoff, et al., 2018 </text>
<text top="681" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29688297">29688297</a></text>
<text top="681" left="129" width="3" height="17" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29688297"><b> </b></a></text>
<text top="646" left="216" width="31" height="17" font="5">Aim:  </text>
<text top="664" left="216" width="84" height="17" font="5">to evaluate the </text>
<text top="681" left="216" width="143" height="17" font="5">contribution of CAC using </text>
<text top="698" left="216" width="118" height="17" font="5">the population-based </text>
<text top="715" left="216" width="145" height="17" font="5">MESA cohort with over 10 </text>
<text top="732" left="216" width="117" height="17" font="5">years of follow-up for </text>
<text top="750" left="216" width="113" height="17" font="5">ASCVD events, and </text>
<text top="767" left="216" width="146" height="17" font="5">whether the association of </text>
<text top="646" left="378" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="664" left="376" width="100" height="18" font="5">•  Free of clinical </text>
<text top="682" left="377" width="129" height="17" font="5">cardiovascular disease </text>
<text top="699" left="376" width="140" height="18" font="5">•  Age 45-84 at baseline </text>
<text top="717" left="376" width="146" height="18" font="5">•  White, Black, Hispanic, </text>
<text top="736" left="377" width="49" height="17" font="5">Chinese </text>
<text top="753" left="378" width="3" height="17" font="5"> </text>
<text top="770" left="378" width="3" height="17" font="3"><b> </b></text>
<text top="646" left="553" width="72" height="17" font="5">1° Endpoint: </text>
<text top="664" left="553" width="267" height="17" font="5">Total events: Incident ASCVD events (definite or </text>
<text top="681" left="553" width="249" height="17" font="5">probably MI, resuscitated cardiac arrest, fatal </text>
<text top="698" left="553" width="258" height="17" font="5">CHD, fatal and non-fatal stroke (not TIA), other </text>
<text top="715" left="553" width="220" height="17" font="5">atherosclerotic death, other CVD death) </text>
<text top="732" left="553" width="3" height="17" font="5"> </text>
<text top="750" left="553" width="260" height="17" font="5">Hard ASCVD: MI, fatal or non-fatal strokes (not </text>
<text top="767" left="553" width="238" height="17" font="5">TIA), resuscitated cardiac arrest, fatal CHD </text>
<text top="646" left="844" width="63" height="17" font="5">Summary:  </text>
<text top="664" left="844" width="255" height="18" font="5">• CAC is consistently associated with risk with </text>
<text top="682" left="844" width="251" height="17" font="5">the same magnitude of effect in all races, age </text>
<text top="699" left="844" width="246" height="17" font="5">groups, both sexes, and in people on and off </text>
<text top="716" left="844" width="119" height="17" font="5">lipid lowering therapy </text>
<text top="734" left="844" width="3" height="17" font="5"> </text>
<text top="751" left="844" width="66" height="17" font="5">Limitations: </text>
</page>
<page number="222" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="216" width="147" height="17" font="5">CAC with events varied by </text>
<text top="108" left="216" width="143" height="17" font="5">sex, race/ethnicity, or age </text>
<text top="125" left="216" width="54" height="17" font="5">category. </text>
<text top="142" left="216" width="3" height="17" font="5"> </text>
<text top="160" left="216" width="69" height="17" font="5">Study Type: </text>
<text top="177" left="216" width="105" height="17" font="5">Prospective cohort </text>
<text top="194" left="216" width="3" height="17" font="5"> </text>
<text top="211" left="216" width="34" height="17" font="5">Size:  </text>
<text top="229" left="216" width="47" height="17" font="5">N=6814<b> </b></text>
<text top="91" left="553" width="3" height="17" font="5"> </text>
<text top="108" left="553" width="184" height="18" font="5">•  Median 11.1 years follow up </text>
<text top="126" left="553" width="3" height="17" font="5"> </text>
<text top="143" left="553" width="243" height="17" font="5">At 10 years of follow-up, all participants with </text>
<text top="161" left="553" width="252" height="17" font="5">CAC&gt; 100 were estimated to have &gt;7.5% risk </text>
<text top="178" left="553" width="189" height="17" font="5">regardless of demographic subset </text>
<text top="195" left="553" width="3" height="17" font="5"> </text>
<text top="212" left="553" width="238" height="17" font="5">Ten-year ASCVD event rates increase with </text>
<text top="229" left="553" width="271" height="17" font="5">increasing CAC overall and across race/ethnicity, </text>
<text top="247" left="553" width="265" height="17" font="5">age, sex, and education.  10 year ASCVD event </text>
<text top="264" left="553" width="277" height="17" font="5">rates in the CAC=0 group range from 1.3-5.6% vs. </text>
<text top="281" left="553" width="192" height="17" font="5">13.1-25.6% in the CAC&gt;300 group </text>
<text top="298" left="553" width="3" height="17" font="5"> </text>
<text top="316" left="553" width="83" height="17" font="5">Hard ASCVD:  </text>
<text top="333" left="552" width="248" height="18" font="5">•  adjusting for CAC in multivariable models </text>
<text top="351" left="573" width="228" height="17" font="5">attenuated associations, but associations </text>
<text top="368" left="573" width="254" height="17" font="5">between age, sex, and race and Hard ASCVD </text>
<text top="386" left="573" width="238" height="17" font="5">outcomes were still significant.  Doubling of </text>
<text top="403" left="573" width="197" height="17" font="5">CAC HR=1.14 (1.11-1.17, p&lt;0.001) </text>
<text top="420" left="552" width="276" height="18" font="5">•  association of CAC with risk of ASCVD did not </text>
<text top="438" left="573" width="215" height="17" font="5">vary by age, sex, race/ethnicity, or lipid </text>
<text top="455" left="573" width="207" height="17" font="5">lowering medication at baseline (p for </text>
<text top="473" left="573" width="162" height="17" font="5">interaction all non significant) </text>
<text top="490" left="553" width="3" height="17" font="3"><b> </b></text>
<text top="91" left="844" width="216" height="18" font="5">• Authors note a limitation in the use of </text>
<text top="109" left="844" width="248" height="17" font="5">electron beam tomography (EBT) and 4- and </text>
<text top="126" left="844" width="134" height="17" font="5">16-detector CT systems </text>
<text top="508" left="66" width="3" height="17" font="5"> </text>
<text top="556" left="66" width="574" height="21" font="4"><b>Data Supplement 13. RCTs of High Blood Pressure or Hypertension (Section 4.4.) </b></text>
<text top="590" left="87" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="607" left="113" width="48" height="17" font="3"><b>Author; </b></text>
<text top="624" left="90" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="590" left="240" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="607" left="245" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="624" left="239" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="607" left="426" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="581" left="637" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="598" left="654" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="616" left="637" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="633" left="658" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="581" left="816" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="598" left="799" width="137" height="17" font="3"><b>(Absolute Event Rates, </b></text>
<text top="616" left="788" width="160" height="17" font="3"><b>P values; OR or RR; &amp; 95% </b></text>
<text top="633" left="858" width="20" height="17" font="3"><b>CI) </b></text>
<text top="582" left="970" width="61" height="17" font="3"><b>Relevant 2</b></text>
<text top="581" left="1032" width="81" height="18" font="5"><b> Endpoint (if </b></text>
<text top="599" left="1025" width="33" height="17" font="3"><b>any); </b></text>
<text top="616" left="986" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="634" left="994" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="651" left="83" width="76" height="17" font="5">The Action to </text>
<text top="668" left="83" width="43" height="17" font="5">Control </text>
<text top="685" left="83" width="85" height="17" font="5">Cardiovascular </text>
<text top="702" left="83" width="92" height="17" font="5">Risk in Diabetes </text>
<text top="719" left="83" width="72" height="17" font="5">Study Group </text>
<text top="736" left="83" width="75" height="17" font="5">(2008) (21).   </text>
<text top="753" left="83" width="3" height="17" font="5"> </text>
<text top="771" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18539917">18539917</a></text>
<text top="771" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18539917"> </a></text>
<text top="652" left="220" width="115" height="17" font="5">To examine whether </text>
<text top="669" left="220" width="110" height="17" font="5">intensive therapy to </text>
<text top="686" left="220" width="76" height="17" font="5">target normal </text>
<text top="703" left="220" width="49" height="17" font="5">glycated </text>
<text top="720" left="220" width="102" height="17" font="5">hemoglobin levels </text>
<text top="738" left="220" width="76" height="17" font="5">would reduce </text>
<text top="755" left="220" width="83" height="17" font="5">cardiovascular </text>
<text top="772" left="220" width="99" height="17" font="5">events in patients </text>
<text top="651" left="373" width="92" height="17" font="5">Inclusion criteria </text>
<text top="668" left="373" width="99" height="17" font="5">• Type 2 diabetes </text>
<text top="685" left="373" width="215" height="17" font="5">• Glycated hemoglobin level of 7.5% or </text>
<text top="702" left="373" width="32" height="17" font="5">more </text>
<text top="719" left="373" width="206" height="17" font="5">• Either between ages 40-79 and had </text>
<text top="736" left="373" width="200" height="17" font="5">cardiovascular disease OR between </text>
<text top="753" left="373" width="199" height="17" font="5">ages 55 and 79 and had anatomical </text>
<text top="770" left="373" width="214" height="17" font="5">evidence of significant atherosclerosis, </text>
<text top="651" left="619" width="71" height="17" font="5">Intervention: </text>
<text top="668" left="619" width="138" height="17" font="5">comprehensive intensive </text>
<text top="685" left="619" width="145" height="17" font="5">therapy targeting glycated </text>
<text top="702" left="619" width="134" height="17" font="5">hemoglobin level of less </text>
<text top="719" left="619" width="112" height="17" font="5">than 6.0% (n=5128) </text>
<text top="736" left="619" width="3" height="17" font="5"> </text>
<text top="653" left="786" width="14" height="17" font="5">  1</text>
<text top="652" left="800" width="60" height="18" font="5"> endpoint </text>
<text top="670" left="794" width="105" height="17" font="5">First occurrence of </text>
<text top="687" left="794" width="110" height="17" font="5">nonfatal myocardial </text>
<text top="704" left="794" width="115" height="17" font="5">infarction or nonfatal </text>
<text top="721" left="794" width="113" height="17" font="5">stroke or death from </text>
<text top="739" left="794" width="125" height="17" font="5">cardiovascular causes </text>
<text top="756" left="794" width="96" height="17" font="5">(MI, heart failure, </text>
<text top="773" left="794" width="113" height="17" font="5">arrhythmia, invasive </text>
<text top="653" left="971" width="7" height="17" font="5">2</text>
<text top="652" left="977" width="60" height="18" font="5"> endpoint </text>
<text top="670" left="971" width="103" height="17" font="5">All cause mortality </text>
<text top="687" left="971" width="3" height="17" font="5"> </text>
<text top="704" left="971" width="106" height="17" font="5">All cause mortality: </text>
<text top="721" left="971" width="102" height="17" font="5">higher in intensive </text>
<text top="739" left="971" width="130" height="17" font="5">therapy group (5.0% vs </text>
<text top="756" left="971" width="118" height="17" font="5">4.0%, HR=1.22, 95% </text>
<text top="773" left="971" width="117" height="17" font="5">CI 1.01-1.46, p-0.04) </text>
</page>
<page number="223" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="112" height="17" font="5">with type 2 diabetes </text>
<text top="108" left="220" width="84" height="17" font="5">who had either </text>
<text top="125" left="220" width="65" height="17" font="5">established </text>
<text top="142" left="220" width="83" height="17" font="5">cardiovascular </text>
<text top="160" left="220" width="60" height="17" font="5">disease or </text>
<text top="177" left="220" width="56" height="17" font="5">additional </text>
<text top="194" left="220" width="105" height="17" font="5">cardiovascular risk </text>
<text top="211" left="220" width="40" height="17" font="5">factors </text>
<text top="229" left="220" width="3" height="17" font="5"> </text>
<text top="246" left="220" width="94" height="17" font="5">Study type: RCT </text>
<text top="263" left="220" width="3" height="17" font="5"> </text>
<text top="280" left="212" width="57" height="17" font="5">N=10,251 </text>
<text top="90" left="373" width="222" height="17" font="5">albuminuria, left ventricular hypertrophy, </text>
<text top="107" left="373" width="169" height="17" font="5">or at least two of the following: </text>
<text top="124" left="373" width="193" height="17" font="5">dyslipidemia, hypertension, current </text>
<text top="142" left="373" width="104" height="17" font="5">smoker, or obesity </text>
<text top="158" left="373" width="3" height="17" font="5"> </text>
<text top="176" left="373" width="97" height="17" font="5">Exclusion criteria </text>
<text top="193" left="373" width="155" height="17" font="5">• Frequent or recent serious </text>
<text top="210" left="373" width="118" height="17" font="5">hypoglycemic events </text>
<text top="227" left="373" width="191" height="17" font="5">• Unwillingness to do home gluose </text>
<text top="244" left="373" width="146" height="17" font="5">monitoring or inject insulin </text>
<text top="261" left="373" width="54" height="17" font="5">• BMI&gt;45 </text>
<text top="278" left="373" width="199" height="17" font="5">• Serum creatinine level&gt;1.5 mg per </text>
<text top="295" left="373" width="46" height="17" font="5">deciliter </text>
<text top="312" left="365" width="123" height="17" font="5">• Other serious illness </text>
<text top="91" left="611" width="124" height="17" font="5">Comparison: standard </text>
<text top="108" left="611" width="145" height="17" font="5">therapy targeting glycated </text>
<text top="125" left="611" width="144" height="17" font="5">hemoglobin 7.0  (n=5123) </text>
<text top="91" left="794" width="83" height="17" font="5">cardiovascular </text>
<text top="108" left="794" width="76" height="17" font="5">interventions, </text>
<text top="125" left="794" width="125" height="17" font="5">cardiovascular causes </text>
<text top="142" left="794" width="131" height="17" font="5">after noncardiovascular </text>
<text top="160" left="794" width="88" height="17" font="5">surgery, stroke, </text>
<text top="177" left="794" width="101" height="17" font="5">unexpected death </text>
<text top="194" left="794" width="117" height="17" font="5">presumed to be from </text>
<text top="211" left="794" width="134" height="17" font="5">ischemic cardiovascular </text>
<text top="229" left="794" width="134" height="17" font="5">disease occurring within </text>
<text top="246" left="794" width="126" height="17" font="5">24 hours after onset of </text>
<text top="263" left="794" width="125" height="17" font="5">symptoms, death from </text>
<text top="280" left="794" width="131" height="17" font="5">other vascular disease) </text>
<text top="297" left="794" width="3" height="17" font="5"> </text>
<text top="315" left="794" width="94" height="17" font="5">Rates of primary </text>
<text top="332" left="794" width="110" height="17" font="5">composite endpoint </text>
<text top="349" left="794" width="136" height="17" font="5">began to separate in the </text>
<text top="366" left="794" width="102" height="17" font="5">two groups after 3 </text>
<text top="383" left="794" width="134" height="17" font="5">years, but the trend was </text>
<text top="401" left="794" width="78" height="17" font="5">not significant </text>
<text top="418" left="794" width="129" height="17" font="5">(rate=6.9% in intensive </text>
<text top="435" left="794" width="135" height="17" font="5">therapy group and 7.2% </text>
<text top="452" left="794" width="109" height="17" font="5">in standard therapy </text>
<text top="469" left="794" width="137" height="17" font="5">group, HR=0.90, 95% CI </text>
<text top="487" left="794" width="111" height="17" font="5">0.78-1.04, p=0.16).  </text>
<text top="504" left="794" width="61" height="17" font="5">There was </text>
<text top="521" left="794" width="103" height="17" font="5">heterogeneity with </text>
<text top="538" left="794" width="117" height="17" font="5">patients who had not </text>
<text top="556" left="794" width="117" height="17" font="5">had a cardiovascular </text>
<text top="573" left="794" width="125" height="17" font="5">event before the study </text>
<text top="590" left="794" width="96" height="17" font="5">and those whose </text>
<text top="607" left="794" width="98" height="17" font="5">baseline glycated </text>
<text top="624" left="794" width="121" height="17" font="5">hemoglobin level was </text>
<text top="642" left="794" width="110" height="17" font="5">8.0% or less having </text>
<text top="659" left="794" width="105" height="17" font="5">fewer events (p for </text>
<text top="676" left="794" width="125" height="17" font="5">interaction=0.04 and p </text>
<text top="693" left="794" width="112" height="17" font="5">for interaction=0.03, </text>
<text top="710" left="794" width="73" height="17" font="5">respectively) </text>
<text top="728" left="794" width="3" height="17" font="5"> </text>
<text top="745" left="794" width="115" height="17" font="5">Nonfatal MI: lower in </text>
<text top="762" left="794" width="131" height="17" font="5">intensive therapy group </text>
<text top="91" left="971" width="3" height="17" font="5"> </text>
<text top="108" left="962" width="144" height="17" font="5">Adverse events: Intensive </text>
<text top="125" left="962" width="103" height="17" font="5">therapy group had </text>
<text top="142" left="962" width="140" height="17" font="5">significant higher rates of </text>
<text top="160" left="962" width="145" height="17" font="5">hypoglycemia (annualized </text>
<text top="177" left="962" width="129" height="17" font="5">rate of events requiring </text>
<text top="194" left="962" width="142" height="17" font="5">medical assistance=3.1% </text>
<text top="211" left="962" width="115" height="17" font="5">vs. 1.0% in standard </text>
<text top="229" left="962" width="152" height="17" font="5">therapy group), weight gain </text>
<text top="246" left="962" width="154" height="17" font="5">(3.5 kg at 3 years vs. 0.4 kg </text>
<text top="263" left="962" width="151" height="17" font="5">in standard therapy group), </text>
<text top="280" left="962" width="101" height="17" font="5">and fluid retention </text>
</page>
<page number="224" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="135" height="17" font="5">(3.6% vs 4.6%, HR=0.6, </text>
<text top="108" left="794" width="102" height="17" font="5">95% CI 0.62-0.92, </text>
<text top="125" left="794" width="52" height="17" font="5">p=0.004) </text>
<text top="142" left="794" width="3" height="17" font="5"> </text>
<text top="160" left="794" width="89" height="17" font="5">Death rate from </text>
<text top="177" left="794" width="128" height="17" font="5">cardiovascular causes: </text>
<text top="194" left="794" width="102" height="17" font="5">higher in intensive </text>
<text top="211" left="794" width="130" height="17" font="5">therapy group (2.6% vs </text>
<text top="229" left="794" width="134" height="17" font="5">1.8%, HR=1.35, 95% CI </text>
<text top="246" left="794" width="108" height="17" font="5">1.04-1.76, p=0.02). </text>
<text top="263" left="794" width="3" height="17" font="5"> </text>
<text top="280" left="786" width="111" height="17" font="5">Non-fatal stroke: no </text>
<text top="297" left="786" width="150" height="17" font="5">significant difference, 1.3% </text>
<text top="315" left="786" width="144" height="17" font="5">in intensive therapy group </text>
<text top="332" left="786" width="159" height="17" font="5">vs. 1.2% in standard therapy </text>
<text top="349" left="786" width="137" height="17" font="5">group, HR=1.06, 95% CI </text>
<text top="366" left="786" width="101" height="17" font="5">0.75-1.50, p-0.74) </text>
<text top="384" left="83" width="88" height="17" font="5">Appel LJ, et al., </text>
<text top="401" left="83" width="56" height="17" font="5">1997 (22) </text>
<text top="418" left="83" width="48" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9099655?dopt=Citation">9099655</a></text>
<text top="418" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9099655?dopt=Citation"> </a></text>
<text top="384" left="220" width="83" height="17" font="5">Aim: Study the </text>
<text top="401" left="220" width="87" height="17" font="5">effect of dietary </text>
<text top="419" left="220" width="85" height="17" font="5">patterns on BP </text>
<text top="436" left="212" width="3" height="17" font="5"> </text>
<text top="454" left="220" width="65" height="17" font="5">Study type: </text>
<text top="471" left="220" width="102" height="18" font="5">• Multicenter RCT </text>
<text top="489" left="220" width="127" height="18" font="5">• 3 arm parallel design </text>
<text top="508" left="220" width="64" height="18" font="5">• 3 wk pre- </text>
<text top="526" left="220" width="102" height="17" font="5">randomization run-</text>
<text top="543" left="220" width="50" height="17" font="5">in phase </text>
<text top="561" left="220" width="116" height="18" font="5">• Feeding study with </text>
<text top="579" left="220" width="109" height="17" font="5">8 wk of intervention </text>
<text top="596" left="212" width="3" height="17" font="5"> </text>
<text top="614" left="220" width="94" height="17" font="5">Size: 459 adults, </text>
<text top="631" left="220" width="88" height="17" font="5">mean age 44 y. </text>
<text top="648" left="220" width="109" height="17" font="5">(326 normotensive) </text>
<text top="384" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="401" left="373" width="83" height="18" font="5">• Adults ≥22 y </text>
<text top="420" left="373" width="199" height="18" font="5">• SBP&lt;160 mm Hg and DBP 80–95 </text>
<text top="438" left="373" width="43" height="17" font="5">mm Hg </text>
<text top="455" left="373" width="185" height="18" font="5">• No antihypertensive medication </text>
<text top="474" left="365" width="3" height="17" font="5"> </text>
<text top="491" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="508" left="373" width="138" height="18" font="5">• CVD event within 6 mo </text>
<text top="527" left="373" width="142" height="18" font="5">• Poorly controlled DM or </text>
<text top="545" left="373" width="83" height="17" font="5">hyperlipidemia </text>
<text top="562" left="373" width="61" height="18" font="5">• BMI ≥35 </text>
<text top="581" left="373" width="136" height="18" font="5">• Pregnancy or lactation </text>
<text top="599" left="373" width="153" height="18" font="5">• Chronic illness that would </text>
<text top="617" left="373" width="144" height="17" font="5">interfere with participation </text>
<text top="635" left="373" width="165" height="18" font="5">• Unwillingness to stop taking </text>
<text top="653" left="373" width="171" height="17" font="5">vitamins, mineral supplements, </text>
<text top="670" left="373" width="84" height="17" font="5">Ca++ Antacids </text>
<text top="687" left="373" width="152" height="18" font="5">• Consuming ≥14 alcoholic </text>
<text top="706" left="373" width="167" height="17" font="5">drinks with Renal insufficiency </text>
<text top="722" left="373" width="3" height="17" font="5"> </text>
<text top="384" left="619" width="71" height="17" font="5">Intervention: </text>
<text top="401" left="619" width="128" height="18" font="5">• Diet high in fruits and </text>
<text top="419" left="619" width="63" height="17" font="5">vegetables </text>
<text top="437" left="619" width="141" height="18" font="5">• “Combination” diet high </text>
<text top="455" left="619" width="135" height="17" font="5">in fruits, vegetables, low-</text>
<text top="472" left="619" width="124" height="17" font="5">fat dairy products, and </text>
<text top="489" left="619" width="95" height="17" font="5">reduced total fat, </text>
<text top="507" left="619" width="96" height="17" font="5">saturated fat and </text>
<text top="524" left="619" width="66" height="17" font="5">cholesterol. </text>
<text top="541" left="611" width="3" height="17" font="5"> </text>
<text top="558" left="619" width="107" height="17" font="5">Comparator: Usual </text>
<text top="575" left="619" width="51" height="17" font="5">U.S. diet </text>
<text top="384" left="794" width="128" height="17" font="5">1  endpoint: Compared </text>
<text top="401" left="794" width="128" height="17" font="5">to the control diet, both </text>
<text top="419" left="794" width="96" height="17" font="5">intervention diets </text>
<text top="436" left="794" width="113" height="17" font="5">reduced BP, with an </text>
<text top="453" left="794" width="126" height="17" font="5">overall mean (95% CI) </text>
<text top="470" left="794" width="71" height="17" font="5">reduction of: </text>
<text top="487" left="794" width="122" height="18" font="5">•Fruits and Veg. Diet: </text>
<text top="506" left="801" width="143" height="17" font="5">SBP: -2.8 (95% CI: -4.7– -</text>
<text top="523" left="801" width="25" height="17" font="5">0.9) </text>
<text top="540" left="801" width="143" height="17" font="5">DBP: -1.1 (95% CI: -2.4– -</text>
<text top="557" left="801" width="25" height="17" font="5">0.3) </text>
<text top="574" left="794" width="111" height="18" font="5">• Combination Diet: </text>
<text top="593" left="801" width="143" height="17" font="5">SBP: -5.5 (95% CI: -7.4– -</text>
<text top="610" left="801" width="25" height="17" font="5">3.7) </text>
<text top="627" left="801" width="143" height="17" font="5">DBP: -3.0 (95% CI: -4.3– -</text>
<text top="644" left="801" width="25" height="17" font="5">1.6) </text>
<text top="662" left="786" width="3" height="17" font="5"> </text>
<text top="680" left="794" width="128" height="17" font="5">The BP changes in the </text>
<text top="697" left="794" width="108" height="17" font="5">subgroup with HTN </text>
<text top="714" left="794" width="33" height="17" font="5">were: </text>
<text top="731" left="794" width="69" height="18" font="5">• Fruits and </text>
<text top="750" left="801" width="57" height="17" font="5">Veg. Diet: </text>
<text top="767" left="801" width="64" height="17" font="5">SBP: -7.2 (-</text>
<text top="384" left="958" width="145" height="17" font="5">● This trial was the first of </text>
<text top="401" left="971" width="114" height="17" font="5">several to document </text>
<text top="419" left="971" width="87" height="17" font="5">the value of the </text>
<text top="436" left="971" width="124" height="17" font="5">combination diet (later </text>
<text top="453" left="971" width="110" height="17" font="5">renamed the DASH </text>
<text top="470" left="971" width="31" height="17" font="5">diet). </text>
<text top="487" left="958" width="117" height="17" font="5">● The BP reductions </text>
<text top="505" left="971" width="80" height="17" font="5">noted with the </text>
<text top="522" left="971" width="115" height="17" font="5">DASH (combination) </text>
<text top="539" left="971" width="115" height="17" font="5">diet were substantial </text>
<text top="556" left="971" width="115" height="17" font="5">and well maintained. </text>
<text top="573" left="958" width="125" height="17" font="5">● Generalizability was </text>
<text top="591" left="971" width="97" height="17" font="5">limited due to the </text>
<text top="608" left="971" width="72" height="17" font="5">nature of the </text>
<text top="625" left="971" width="115" height="17" font="5">intervention (feeding </text>
<text top="642" left="971" width="133" height="17" font="5">study) and the relatively </text>
<text top="660" left="971" width="82" height="17" font="5">short period of </text>
<text top="677" left="971" width="130" height="17" font="5">intervention experience </text>
<text top="694" left="971" width="37" height="17" font="5">(8 wk) </text>
</page>
<page number="225" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="801" width="60" height="17" font="5">11.4, -3.0) </text>
<text top="108" left="801" width="65" height="17" font="5">DBP: -2.8 (-</text>
<text top="125" left="801" width="52" height="17" font="5">5.4, -0.3) </text>
<text top="143" left="791" width="147" height="18" font="5">• Combination Diet: SBP: -</text>
<text top="161" left="801" width="131" height="17" font="5">11.4 (-15.9, -6.9) DBP: -</text>
<text top="178" left="801" width="81" height="17" font="5">5.5 (-8.2, -2.7) </text>
<text top="195" left="791" width="3" height="17" font="5"> </text>
<text top="212" left="786" width="156" height="17" font="5">The corresponding changes </text>
<text top="229" left="786" width="102" height="17" font="5">in the subgroup of </text>
<text top="247" left="786" width="117" height="17" font="5">normotensives were: </text>
<text top="264" left="791" width="129" height="18" font="5">• Fruits and Veg. Diet:  </text>
<text top="282" left="801" width="113" height="17" font="5">SBP: -0.8 (-2.7, 1.1) </text>
<text top="299" left="801" width="114" height="17" font="5">DBP: -0.3 (-1.9, 1.3) </text>
<text top="317" left="791" width="111" height="18" font="5">• Combination Diet: </text>
<text top="335" left="801" width="117" height="17" font="5">SBP: -3.5 (-5.3, -1.6) </text>
<text top="352" left="801" width="118" height="17" font="5">DBP: -2.1 (-3.6, -0.5) </text>
<text top="369" left="786" width="161" height="17" font="5">1 Safety endpoint: Infrequent </text>
<text top="386" left="786" width="24" height="17" font="5">and </text>
<text top="404" left="786" width="117" height="17" font="5">similar occurrence of </text>
<text top="421" left="786" width="158" height="17" font="5">gastrointestinal symptoms in </text>
<text top="438" left="786" width="30" height="17" font="5">each </text>
<text top="455" left="786" width="35" height="17" font="5">group </text>
<text top="473" left="83" width="95" height="17" font="5">Sacks FM, et al., </text>
<text top="490" left="83" width="56" height="17" font="5">2001 (77) </text>
<text top="508" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11136953?dopt=Citation">11136953</a></text>
<text top="508" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11136953?dopt=Citation"> </a></text>
<text top="473" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="490" left="220" width="110" height="17" font="5">of different levels of </text>
<text top="508" left="220" width="116" height="17" font="5">sodium intake on BP </text>
<text top="525" left="220" width="111" height="17" font="5">during consumption </text>
<text top="542" left="220" width="108" height="17" font="5">of a DASH or usual </text>
<text top="559" left="220" width="51" height="17" font="5">U.S. diet </text>
<text top="577" left="212" width="3" height="17" font="5"> </text>
<text top="595" left="220" width="65" height="17" font="5">Study type: </text>
<text top="612" left="220" width="102" height="18" font="5">• Multicenter RCT </text>
<text top="630" left="220" width="102" height="17" font="5">with 2 parallel diet </text>
<text top="647" left="220" width="110" height="17" font="5">arms (DASH diet or </text>
<text top="665" left="220" width="33" height="17" font="5">usual </text>
<text top="681" left="220" width="55" height="17" font="5">U.S. diet) </text>
<text top="699" left="220" width="106" height="18" font="5">• Within each arm, </text>
<text top="717" left="220" width="101" height="17" font="5">randomized cross-</text>
<text top="734" left="220" width="86" height="17" font="5">over trial with 3 </text>
<text top="752" left="220" width="83" height="17" font="5">periods testing </text>
<text top="769" left="220" width="96" height="17" font="5">different levels of </text>
<text top="473" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="490" left="373" width="83" height="18" font="5">• Adults ≥22 y </text>
<text top="509" left="373" width="188" height="18" font="5">• Average SBP between 120–159 </text>
<text top="527" left="373" width="193" height="17" font="5">mm Hg and average DBP between </text>
<text top="544" left="373" width="81" height="17" font="5">80–95 mm Hg </text>
<text top="561" left="373" width="154" height="18" font="5">• No use of antihypertensive </text>
<text top="580" left="373" width="63" height="17" font="5">medication </text>
<text top="598" left="365" width="3" height="17" font="5"> </text>
<text top="615" left="373" width="213" height="17" font="5">Exclusion criteria: Heart disease, renal </text>
<text top="631" left="373" width="167" height="17" font="5">insufficiency, poorly controlled </text>
<text top="649" left="373" width="197" height="17" font="5">hyperlipidemia or DM, DM requiring </text>
<text top="666" left="373" width="202" height="17" font="5">insulin, special dietary requirements, </text>
<text top="683" left="373" width="137" height="17" font="5">&gt;14 alcoholic drinks /wk. </text>
<text top="473" left="619" width="130" height="17" font="5">Intervention: 3 levels of </text>
<text top="490" left="619" width="115" height="17" font="5">dietary sodium while </text>
<text top="508" left="619" width="125" height="17" font="5">consuming a DASH or </text>
<text top="525" left="619" width="146" height="17" font="5">usual U.S. diet. The target </text>
<text top="542" left="619" width="142" height="17" font="5">sodium intake levels for a </text>
<text top="559" left="619" width="119" height="17" font="5">daily energy intake of </text>
<text top="577" left="619" width="93" height="17" font="5">2,100 kcal were: </text>
<text top="594" left="619" width="128" height="17" font="5">High: 150 mmol (3,450 </text>
<text top="611" left="619" width="35" height="17" font="5">mg)/d </text>
<text top="628" left="619" width="133" height="17" font="5">Intermediate: 100 mmol </text>
<text top="645" left="619" width="73" height="17" font="5">(2,300 mg)/d </text>
<text top="663" left="619" width="118" height="17" font="5">Low: 50 mmol (1,150 </text>
<text top="680" left="619" width="35" height="17" font="5">mg)/d </text>
<text top="697" left="611" width="3" height="17" font="5"> </text>
<text top="714" left="619" width="146" height="17" font="5">The mean achieved levels </text>
<text top="732" left="619" width="145" height="17" font="5">of sodium during the high, </text>
<text top="749" left="619" width="117" height="17" font="5">intermediate and low </text>
<text top="766" left="619" width="144" height="17" font="5">sodium periods were 144, </text>
<text top="474" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="492" left="794" width="141" height="18" font="5">• At each level of sodium </text>
<text top="510" left="794" width="120" height="17" font="5">intake, SBP and DBP </text>
<text top="527" left="794" width="100" height="17" font="5">were lower during </text>
<text top="544" left="794" width="145" height="17" font="5">consumption of the DASH </text>
<text top="562" left="794" width="115" height="17" font="5">diet compared to the </text>
<text top="579" left="794" width="107" height="17" font="5">usual U.S. diet, the </text>
<text top="596" left="794" width="139" height="17" font="5">difference being greatest </text>
<text top="613" left="794" width="131" height="17" font="5">with high sodium intake </text>
<text top="630" left="794" width="109" height="17" font="5">and lowest with low </text>
<text top="648" left="794" width="128" height="17" font="5">sodium intake, with the </text>
<text top="665" left="794" width="119" height="17" font="5">mean SBP difference </text>
<text top="682" left="794" width="132" height="17" font="5">between the DASH and </text>
<text top="699" left="794" width="120" height="17" font="5">usual US diets during </text>
<text top="717" left="794" width="125" height="17" font="5">high, intermediate and </text>
<text top="734" left="794" width="139" height="17" font="5">low sodium intake being -</text>
<text top="751" left="794" width="139" height="17" font="5">5.9 (95% CI: -8.0– -3.7), -</text>
<text top="768" left="794" width="135" height="17" font="5">5.0 (95% CI: -7.6– -2.5), </text>
<text top="473" left="971" width="100" height="17" font="5">This trial provided </text>
<text top="490" left="971" width="56" height="17" font="5">additional </text>
<text top="508" left="971" width="118" height="17" font="5">documentation of the </text>
<text top="525" left="971" width="99" height="17" font="5">effectiveness of a </text>
<text top="542" left="971" width="123" height="17" font="5">DASH diet in lowering </text>
<text top="559" left="971" width="116" height="17" font="5">BP in normotensives </text>
<text top="577" left="971" width="111" height="17" font="5">(and hypertensives) </text>
<text top="594" left="971" width="132" height="17" font="5">and the complementary </text>
<text top="611" left="971" width="127" height="17" font="5">benefit of consuming a </text>
<text top="628" left="971" width="98" height="17" font="5">reduced intake of </text>
<text top="645" left="971" width="46" height="17" font="5">sodium. </text>
</page>
<page number="226" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="100" height="17" font="5">sodium intake (no </text>
<text top="108" left="220" width="53" height="17" font="5">washout) </text>
<text top="126" left="212" width="3" height="17" font="5"> </text>
<text top="143" left="220" width="111" height="17" font="5">Size: 412, with 59% </text>
<text top="160" left="220" width="66" height="17" font="5">(243) being </text>
<text top="177" left="220" width="73" height="17" font="5">normotensive </text>
<text top="91" left="619" width="142" height="17" font="5">107 and 67 mmol/d in the </text>
<text top="108" left="619" width="119" height="17" font="5">DASH diet group and </text>
<text top="125" left="619" width="140" height="17" font="5">141, 106, and 64 mmol/d </text>
<text top="142" left="619" width="117" height="17" font="5">in the usual U.S. diet </text>
<text top="160" left="619" width="38" height="17" font="5">group. </text>
<text top="178" left="611" width="3" height="17" font="5"> </text>
<text top="194" left="619" width="97" height="17" font="5">Comparator: See </text>
<text top="211" left="619" width="100" height="17" font="5">description above </text>
<text top="91" left="794" width="135" height="17" font="5">and -2.2 (95% CI: -4.4– -</text>
<text top="108" left="794" width="134" height="17" font="5">0.1). The corresponding </text>
<text top="125" left="794" width="140" height="17" font="5">differences for DBP were </text>
<text top="142" left="794" width="139" height="17" font="5">-2.9 (95% CI: -4.3– -1.5), </text>
<text top="160" left="794" width="143" height="17" font="5">-2.5 (95% CI: -4.1– - 0.8), </text>
<text top="177" left="794" width="128" height="17" font="5">and -1.0 (95% CI: -2.5, </text>
<text top="194" left="794" width="28" height="17" font="5">0.4). </text>
<text top="211" left="794" width="133" height="18" font="5">• In both the DASH and </text>
<text top="229" left="794" width="117" height="17" font="5">usual U.S. diet arms, </text>
<text top="247" left="794" width="111" height="17" font="5">SBP and DBP were </text>
<text top="264" left="794" width="137" height="17" font="5">significantly lower during </text>
<text top="281" left="794" width="129" height="17" font="5">intermediate compared </text>
<text top="298" left="794" width="123" height="17" font="5">to high sodium intake, </text>
<text top="316" left="794" width="83" height="17" font="5">and during low </text>
<text top="333" left="794" width="72" height="17" font="5">compared to </text>
<text top="350" left="794" width="114" height="17" font="5">intermediate sodium </text>
<text top="367" left="794" width="85" height="17" font="5">intake, with the </text>
<text top="384" left="794" width="137" height="17" font="5">decrement being greater </text>
<text top="402" left="794" width="116" height="17" font="5">for the latter change. </text>
<text top="419" left="794" width="94" height="17" font="5">In comparison to </text>
<text top="436" left="794" width="130" height="17" font="5">consumption of a usual </text>
<text top="453" left="794" width="140" height="17" font="5">U.S. diet at the high level </text>
<text top="470" left="794" width="117" height="17" font="5">of sodium intake, the </text>
<text top="488" left="794" width="112" height="17" font="5">normotensive group </text>
<text top="505" left="794" width="144" height="17" font="5">consuming the DASH diet </text>
<text top="522" left="794" width="141" height="17" font="5">at the low level of sodium </text>
<text top="539" left="794" width="132" height="17" font="5">intake had a mean SBP </text>
<text top="557" left="794" width="135" height="17" font="5">difference of 7.1 mm Hg </text>
<text top="574" left="794" width="60" height="17" font="5">(p&lt;0.001). </text>
<text top="591" left="786" width="3" height="17" font="5"> </text>
<text top="608" left="794" width="106" height="17" font="5">1  Safety endpoint: </text>
<text top="625" left="794" width="122" height="17" font="5">Participants tended to </text>
<text top="643" left="794" width="120" height="17" font="5">report less symptoms </text>
<text top="660" left="794" width="143" height="17" font="5">during periods of reduced </text>
<text top="677" left="794" width="118" height="17" font="5">sodium intake, with a </text>
<text top="694" left="794" width="121" height="17" font="5">statistically significant </text>
<text top="712" left="794" width="122" height="17" font="5">reduction in reports of </text>
<text top="729" left="794" width="57" height="17" font="5">headache </text>
<text top="746" left="794" width="133" height="17" font="5">(p&lt;0.05) consistent with </text>
<text top="763" left="794" width="125" height="17" font="5">prior experience in the </text>
</page>
<page number="227" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="19" size="12" family="Times" color="#4616f6"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="64" height="17" font="5">TONE trial. </text>
<text top="176" left="83" width="68" height="17" font="5">Neter JE, et </text>
<text top="194" left="83" width="83" height="17" font="5">al., 2003 (103) </text>
<text top="211" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12975389?dopt=Citation">12975389</a></text>
<text top="211" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12975389?dopt=Citation"> </a></text>
<text top="176" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="194" left="220" width="115" height="17" font="5">of weight loss on BP </text>
<text top="211" left="212" width="3" height="17" font="5"> </text>
<text top="229" left="220" width="65" height="17" font="5">Study type: </text>
<text top="246" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="263" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="280" left="212" width="3" height="17" font="5"> </text>
<text top="297" left="220" width="104" height="17" font="5">Size: 25 RCTs (34 </text>
<text top="315" left="220" width="102" height="17" font="5">comparisons) with </text>
<text top="332" left="220" width="109" height="17" font="5">4,874 pts; 17 of the </text>
<text top="349" left="220" width="103" height="17" font="5">comparisons were </text>
<text top="366" left="220" width="73" height="17" font="5">conducted in </text>
<text top="384" left="220" width="97" height="17" font="5">normotensive pts </text>
<text top="176" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="193" left="373" width="99" height="18" font="5">• RCT in humans </text>
<text top="212" left="373" width="170" height="18" font="5">• English language publication </text>
<text top="230" left="373" width="117" height="17" font="5">between 1966– 2002 </text>
<text top="248" left="373" width="110" height="18" font="5">• Nonpharmacologic </text>
<text top="266" left="373" width="67" height="17" font="5">intervention </text>
<text top="283" left="365" width="3" height="17" font="5"> </text>
<text top="300" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="317" left="373" width="96" height="18" font="5">• Duration &lt;8 wk </text>
<text top="336" left="373" width="83" height="18" font="5">• Missing data </text>
<text top="354" left="373" width="150" height="18" font="5">• Objective not weight loss </text>
<text top="372" left="373" width="154" height="17" font="5">Concomitant intervention(s) </text>
<text top="176" left="619" width="113" height="17" font="5">Intervention: Weight </text>
<text top="194" left="619" width="126" height="17" font="5">loss (calorie reduction, </text>
<text top="211" left="619" width="107" height="17" font="5">physical activity, or </text>
<text top="228" left="619" width="115" height="17" font="5">combination of both) </text>
<text top="246" left="611" width="3" height="17" font="5"> </text>
<text top="263" left="619" width="130" height="17" font="5">Comparator: No weight </text>
<text top="280" left="619" width="92" height="17" font="5">loss prescription </text>
<text top="177" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="195" left="794" width="131" height="18" font="5">• For the overall group, </text>
<text top="213" left="794" width="113" height="17" font="5">mean baseline body </text>
<text top="230" left="794" width="132" height="17" font="5">weight was 88.3 kg and </text>
<text top="247" left="794" width="121" height="17" font="5">mean change in body </text>
<text top="265" left="794" width="110" height="17" font="5">weight following the </text>
<text top="282" left="794" width="135" height="17" font="5">application of the weight </text>
<text top="299" left="794" width="121" height="17" font="5">loss intervention was -</text>
<text top="316" left="794" width="118" height="17" font="5">5.1 (95% CI: -6.03– - </text>
<text top="333" left="794" width="78" height="17" font="5">4.25) kg. This </text>
<text top="351" left="794" width="106" height="17" font="5">represents a mean </text>
<text top="368" left="794" width="106" height="17" font="5">percent change of -</text>
<text top="385" left="794" width="35" height="17" font="5">5.8%. </text>
<text top="402" left="794" width="109" height="18" font="5">• There was strong </text>
<text top="421" left="794" width="100" height="17" font="5">evidence for a BP </text>
<text top="438" left="794" width="135" height="17" font="5">lowering effect of weight </text>
<text top="455" left="794" width="142" height="17" font="5">loss on BP, overall and in </text>
<text top="472" left="794" width="135" height="17" font="5">normotensive subgroup. </text>
<text top="490" left="794" width="111" height="17" font="5">In the normotensive </text>
<text top="507" left="794" width="111" height="17" font="5">group, the mean for </text>
<text top="524" left="794" width="137" height="17" font="5">change in SBP was 4.08 </text>
<text top="541" left="794" width="132" height="17" font="5">(95% CI: - 6.01– -2.16). </text>
<text top="559" left="794" width="93" height="18" font="5">• Overall, a 1 kg </text>
<text top="577" left="794" width="136" height="17" font="5">reduction in body weight </text>
<text top="594" left="794" width="123" height="17" font="5">was associated with a </text>
<text top="611" left="794" width="137" height="17" font="5">mean change in SBP of -</text>
<text top="628" left="794" width="116" height="17" font="5">1.05 (95% CI: -1.43– </text>
<text top="645" left="794" width="82" height="17" font="5">-0.66) mm Hg. </text>
<text top="663" left="786" width="3" height="17" font="5"> </text>
<text top="681" left="794" width="130" height="17" font="5">1  Safety endpoint: N/A </text>
<text top="177" left="971" width="142" height="18" font="5">• Substantial  evidence </text>
<text top="194" left="971" width="142" height="17" font="5">for  a  reduction  in  BP, </text>
<text top="211" left="971" width="40" height="17" font="5">overall </text>
<text top="211" left="1043" width="24" height="17" font="5">and </text>
<text top="211" left="1100" width="13" height="17" font="5">in </text>
<text top="229" left="971" width="87" height="17" font="5">normotensives. </text>
<text top="246" left="971" width="118" height="17" font="5">With the exception of </text>
<text top="263" left="971" width="106" height="17" font="5">the mean (95% CI) </text>
<text top="280" left="971" width="108" height="17" font="5">changes in BP, this </text>
<text top="297" left="971" width="124" height="17" font="5">paper provides limited </text>
<text top="314" left="971" width="66" height="17" font="5">data for the </text>
<text top="332" left="971" width="112" height="17" font="5">normotensive group </text>
<text top="700" left="83" width="86" height="17" font="5">TOHP, Phase I </text>
<text top="717" left="83" width="56" height="17" font="5">1992 (79) </text>
<text top="734" left="83" width="48" height="17" font="19"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation">1586398</a></text>
<text top="734" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation"> </a></text>
<text top="700" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="717" left="220" width="115" height="17" font="5">of weight loss on BP </text>
<text top="734" left="220" width="98" height="17" font="5">and prevention of </text>
<text top="751" left="220" width="29" height="17" font="5">HTN </text>
<text top="769" left="212" width="3" height="17" font="5"> </text>
<text top="700" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="717" left="373" width="80" height="18" font="5">• Community- </text>
<text top="735" left="373" width="131" height="17" font="5">dwelling adults 30–54 y </text>
<text top="753" left="373" width="142" height="18" font="5">• Not on antihypertensive </text>
<text top="771" left="373" width="63" height="17" font="5">medication </text>
<text top="700" left="619" width="123" height="17" font="5">Intervention: Behavior </text>
<text top="717" left="619" width="111" height="17" font="5">change intervention </text>
<text top="734" left="619" width="111" height="17" font="5">(combination of diet </text>
<text top="751" left="619" width="115" height="17" font="5">change and physical </text>
<text top="769" left="619" width="45" height="17" font="5">activity) </text>
<text top="700" left="794" width="127" height="17" font="5">1  endpoint: Change in </text>
<text top="719" left="794" width="29" height="17" font="5">DBP </text>
<text top="736" left="786" width="3" height="17" font="5"> </text>
<text top="754" left="794" width="155" height="17" font="5">2  endpoint: Change in SBP </text>
<text top="771" left="786" width="3" height="17" font="5"> </text>
<text top="700" left="971" width="112" height="18" font="5">•<b> </b>Significantly lower </text>
<text top="718" left="971" width="99" height="17" font="5">DBP (2.3 mm Hg; </text>
<text top="735" left="971" width="122" height="17" font="5">p&lt;0.01) and SBP (2.9 </text>
<text top="752" left="971" width="125" height="17" font="5">mm Hg; p&lt;0.01) in the </text>
<text top="770" left="971" width="99" height="17" font="5">weight loss group </text>
</page>
<page number="228" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="65" height="17" font="5">Study type: </text>
<text top="108" left="220" width="76" height="17" font="5">Randomized, </text>
<text top="125" left="220" width="57" height="17" font="5">controlled </text>
<text top="142" left="220" width="73" height="17" font="5">factorial trial. </text>
<text top="160" left="212" width="3" height="17" font="5"> </text>
<text top="177" left="220" width="110" height="17" font="5">Size: Overall, 2,182 </text>
<text top="194" left="220" width="109" height="17" font="5">adults, with the 308 </text>
<text top="91" left="373" width="117" height="18" font="5">• DBP 80-89 mm Hg </text>
<text top="109" left="373" width="55" height="18" font="5">• Healthy </text>
<text top="128" left="365" width="3" height="17" font="5"> </text>
<text top="146" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="162" left="373" width="48" height="17" font="5">Disease </text>
<text top="91" left="611" width="3" height="17" font="5"> </text>
<text top="109" left="619" width="107" height="17" font="5">Comparator: Usual </text>
<text top="126" left="619" width="27" height="17" font="5">care </text>
<text top="91" left="794" width="121" height="17" font="5">Safety endpoint: CVD </text>
<text top="110" left="794" width="126" height="17" font="5">events, symptoms and </text>
<text top="128" left="794" width="127" height="17" font="5">general and well being </text>
<text top="91" left="971" width="105" height="17" font="5">compared to usual </text>
<text top="108" left="971" width="27" height="17" font="5">care </text>
<text top="125" left="971" width="106" height="18" font="5">•<b> </b>Few CVD events </text>
<text top="144" left="971" width="30" height="18" font="5">•<b> </b>No </text>
<text top="162" left="971" width="70" height="17" font="5">difference in </text>
<text top="179" left="971" width="59" height="17" font="5">symptoms </text>
<text top="196" left="971" width="71" height="18" font="5">•<b> </b>Significant </text>
<text top="214" left="971" width="132" height="17" font="5">improvement in general </text>
<text top="231" left="971" width="82" height="17" font="5">well-being at 6 </text>
<text top="248" left="971" width="111" height="17" font="5">and 18 mo (p&lt;0.05) </text>
<text top="266" left="83" width="77" height="17" font="5">NUTRICODE </text>
<text top="283" left="83" width="97" height="17" font="5">Mozaffarian D, et </text>
<text top="301" left="83" width="76" height="17" font="5">al., 2014 (74) </text>
<text top="318" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25119608?dopt=Citation">25119608</a></text>
<text top="318" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25119608?dopt=Citation"> </a></text>
<text top="266" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="283" left="220" width="111" height="17" font="5">of sodium reduction </text>
<text top="301" left="220" width="90" height="17" font="5">on BP and CVD </text>
<text top="318" left="220" width="50" height="17" font="5">mortality </text>
<text top="336" left="212" width="3" height="17" font="5"> </text>
<text top="353" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="370" left="220" width="109" height="17" font="5">regression analysis </text>
<text top="387" left="212" width="3" height="17" font="5"> </text>
<text top="404" left="220" width="118" height="17" font="5">Size: 103 RCTs (107 </text>
<text top="422" left="220" width="102" height="17" font="5">comparisons) with </text>
<text top="439" left="220" width="109" height="17" font="5">6,970 pts; 38 of the </text>
<text top="456" left="220" width="97" height="17" font="5">107 comparisons </text>
<text top="473" left="220" width="103" height="17" font="5">were conducted in </text>
<text top="491" left="220" width="97" height="17" font="5">normotensive pts </text>
<text top="266" left="373" width="198" height="17" font="5">Inclusion criteria: RCT in 2 previous </text>
<text top="283" left="373" width="140" height="17" font="5">Cochrane meta-analyses </text>
<text top="301" left="365" width="3" height="17" font="5"> </text>
<text top="319" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="336" left="373" width="96" height="18" font="5">• Duration &lt;1 wk </text>
<text top="354" left="373" width="204" height="18" font="5">• Mean 24-h collections or estimates </text>
<text top="373" left="373" width="203" height="17" font="5">of urinary sodium reduced &lt;20 mmol </text>
<text top="390" left="373" width="206" height="17" font="5">in the intervention group compared to </text>
<text top="407" left="373" width="40" height="17" font="5">control </text>
<text top="424" left="373" width="142" height="17" font="5">Concomitant interventions </text>
<text top="266" left="619" width="116" height="17" font="5">Intervention: Sodium </text>
<text top="283" left="619" width="54" height="17" font="5">reduction </text>
<text top="301" left="611" width="3" height="17" font="5"> </text>
<text top="318" left="619" width="91" height="17" font="5">Comparator: No </text>
<text top="336" left="619" width="97" height="17" font="5">sodium reduction </text>
<text top="267" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="285" left="794" width="130" height="18" font="5">• Strong evidence for a </text>
<text top="303" left="794" width="100" height="17" font="5">linear relationship </text>
<text top="320" left="794" width="117" height="17" font="5">between reduction in </text>
<text top="337" left="794" width="136" height="17" font="5">sodium intake and lower </text>
<text top="354" left="794" width="139" height="17" font="5">levels of SBP throughout </text>
<text top="372" left="794" width="131" height="17" font="5">the entire distribution of </text>
<text top="389" left="794" width="115" height="17" font="5">sodium studied, with </text>
<text top="406" left="794" width="139" height="17" font="5">larger reductions in older </text>
<text top="423" left="794" width="89" height="17" font="5">persons, blacks </text>
<text top="440" left="794" width="142" height="17" font="5">(compared to whites) and </text>
<text top="458" left="794" width="141" height="17" font="5">hypertensives (compared </text>
<text top="475" left="794" width="137" height="17" font="5">to normotensives). For a </text>
<text top="492" left="794" width="113" height="17" font="5">white, normotensive </text>
<text top="509" left="794" width="128" height="17" font="5">population at age 50 y, </text>
<text top="527" left="794" width="122" height="17" font="5">each reduction of 100 </text>
<text top="544" left="794" width="146" height="17" font="5">mmol/d (2.3 g/d) in dietary </text>
<text top="561" left="794" width="144" height="17" font="5">sodium lowered SBP by a </text>
<text top="578" left="794" width="116" height="17" font="5">mean: 3.74 (95% CI: </text>
<text top="595" left="794" width="66" height="17" font="5">5.18–2.29). </text>
<text top="613" left="794" width="117" height="18" font="5">• Modeling based on </text>
<text top="631" left="794" width="106" height="17" font="5">global estimates of </text>
<text top="648" left="794" width="130" height="17" font="5">sodium intake, effect of </text>
<text top="665" left="794" width="137" height="17" font="5">sodium reduction on BP, </text>
<text top="683" left="794" width="145" height="17" font="5">and effect of BP reduction </text>
<text top="700" left="794" width="96" height="17" font="5">on CVD mortality </text>
<text top="717" left="794" width="120" height="17" font="5">attributed 1.65 million </text>
<text top="734" left="794" width="141" height="17" font="5">CVD deaths annually due </text>
<text top="751" left="794" width="143" height="17" font="5">sodium intake &gt;2 g/d. this </text>
<text top="769" left="794" width="122" height="17" font="5">would represent 9.5% </text>
<text top="266" left="970" width="133" height="17" font="5">● RCT meta-regression </text>
<text top="283" left="970" width="122" height="17" font="5">analysis that provides </text>
<text top="301" left="970" width="139" height="17" font="5">evidence for BP lowering </text>
<text top="318" left="970" width="128" height="17" font="5">following a reduction in </text>
<text top="335" left="970" width="123" height="17" font="5">dietary sodium intake, </text>
<text top="352" left="970" width="76" height="17" font="5">overall and in </text>
<text top="369" left="970" width="128" height="17" font="5">normotensive persons, </text>
<text top="387" left="970" width="135" height="17" font="5">with a more pronounced </text>
<text top="404" left="970" width="136" height="17" font="5">effect in those who were </text>
<text top="421" left="970" width="124" height="17" font="5">older, black and had a </text>
<text top="438" left="970" width="124" height="17" font="5">higher starting level of </text>
<text top="456" left="970" width="23" height="17" font="5">BP. </text>
<text top="473" left="970" width="115" height="17" font="5">● These findings are </text>
<text top="490" left="970" width="115" height="17" font="5">consistent with other </text>
<text top="507" left="970" width="45" height="17" font="5">reports. </text>
<text top="524" left="971" width="142" height="17" font="5">The  modeling  analysis </text>
<text top="541" left="971" width="60" height="17" font="5">suggested </text>
<text top="541" left="1069" width="43" height="17" font="5">sodium </text>
<text top="558" left="971" width="142" height="17" font="5">reduction  would  yield </text>
<text top="575" left="971" width="55" height="17" font="5">important </text>
<text top="575" left="1053" width="60" height="17" font="5">population </text>
<text top="592" left="971" width="142" height="17" font="5">health benefits but did not </text>
<text top="609" left="971" width="142" height="17" font="5">specify  the  magnitude  of </text>
<text top="626" left="971" width="142" height="17" font="5">the  potential  benefit  for </text>
<text top="643" left="971" width="142" height="17" font="5">pts within the normal BP </text>
<text top="660" left="971" width="38" height="17" font="5">range. </text>
</page>
<page number="229" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="120" height="17" font="5">(95% CI: 6.4–12.8) of </text>
<text top="108" left="794" width="98" height="17" font="5">all CVD mortality. </text>
<text top="125" left="794" width="108" height="17" font="5">Estimates were not </text>
<text top="142" left="794" width="128" height="17" font="5">provided separately for </text>
<text top="160" left="794" width="97" height="17" font="5">hypertensive and </text>
<text top="177" left="794" width="128" height="17" font="5">normotensive persons. </text>
<text top="194" left="786" width="3" height="17" font="5"> </text>
<text top="212" left="794" width="130" height="17" font="5">1  Safety endpoint: N/A </text>
<text top="230" left="83" width="73" height="17" font="5">He FJ, et al., </text>
<text top="247" left="83" width="56" height="17" font="5">2013 (75) </text>
<text top="265" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22437256?dopt=Citation">22437256</a></text>
<text top="265" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22437256?dopt=Citation"> </a></text>
<text top="230" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="247" left="220" width="111" height="17" font="5">of sodium reduction </text>
<text top="265" left="220" width="37" height="17" font="5">on BP </text>
<text top="283" left="212" width="3" height="17" font="5"> </text>
<text top="300" left="220" width="65" height="17" font="5">Study type: </text>
<text top="317" left="220" width="106" height="17" font="5">Systematic review, </text>
<text top="334" left="220" width="103" height="17" font="5">meta-analysis and </text>
<text top="351" left="220" width="92" height="17" font="5">meta-regression </text>
<text top="369" left="220" width="48" height="17" font="5">analysis </text>
<text top="386" left="212" width="3" height="17" font="5"> </text>
<text top="403" left="220" width="106" height="17" font="5">Size: Overall study </text>
<text top="420" left="220" width="117" height="17" font="5">included 34 trials (37 </text>
<text top="438" left="220" width="77" height="17" font="5">comparisons) </text>
<text top="455" left="220" width="107" height="17" font="5">conducted in 3,230 </text>
<text top="472" left="220" width="109" height="17" font="5">pts. 12 of the RCTs </text>
<text top="489" left="220" width="98" height="17" font="5">(14 comparisons) </text>
<text top="506" left="220" width="103" height="17" font="5">were conducted in </text>
<text top="524" left="220" width="111" height="17" font="5">2,240 normotensive </text>
<text top="541" left="220" width="27" height="17" font="5">pts.  </text>
<text top="230" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="247" left="373" width="45" height="18" font="5">•<b> </b>RCTs </text>
<text top="266" left="373" width="126" height="18" font="5">•<b> </b>Healthy adults ≥18 y </text>
<text top="284" left="373" width="122" height="18" font="5">•<b> </b>Trial duration ≥4 wk </text>
<text top="303" left="373" width="175" height="18" font="5">•<b> </b>Sodium intake only difference </text>
<text top="321" left="373" width="169" height="17" font="5">between treatment and control </text>
<text top="338" left="373" width="35" height="17" font="5">group </text>
<text top="356" left="373" width="209" height="18" font="5">•<b> </b>24-h urine sodium ≥40 mmol less in </text>
<text top="374" left="373" width="167" height="17" font="5">treatment compared to control </text>
<text top="391" left="365" width="3" height="17" font="5"> </text>
<text top="408" left="373" width="180" height="17" font="5">Exclusion criteria: Lack of above </text>
<text top="230" left="619" width="116" height="17" font="5">Intervention: Sodium </text>
<text top="247" left="619" width="54" height="17" font="5">reduction </text>
<text top="265" left="611" width="3" height="17" font="5"> </text>
<text top="283" left="619" width="91" height="17" font="5">Comparator: No </text>
<text top="300" left="619" width="97" height="17" font="5">sodium reduction </text>
<text top="230" left="794" width="138" height="17" font="5">1  endpoint: In an overall </text>
<text top="247" left="794" width="112" height="17" font="5">pooled analysis, the </text>
<text top="265" left="794" width="146" height="17" font="5">change for SBP was -4.18 </text>
<text top="282" left="794" width="128" height="17" font="5">(95% CI: - 5.18– -3.18) </text>
<text top="299" left="794" width="124" height="17" font="5">mm Hg. In the trials of </text>
<text top="316" left="794" width="125" height="17" font="5">persons with HTN, the </text>
<text top="333" left="794" width="135" height="17" font="5">mean change was -5.39 </text>
<text top="351" left="794" width="125" height="17" font="5">(95% CI: -6.62– -4.15) </text>
<text top="368" left="794" width="110" height="17" font="5">mm Hg. In the trials </text>
<text top="385" left="794" width="73" height="17" font="5">conducted in </text>
<text top="402" left="794" width="107" height="17" font="5">normotensives, the </text>
<text top="420" left="794" width="141" height="17" font="5">change in SBP was -2.42 </text>
<text top="437" left="794" width="125" height="17" font="5">(95% CI: -3.56– -1.29) </text>
<text top="454" left="794" width="24" height="17" font="5">mm </text>
<text top="471" left="794" width="22" height="17" font="5">Hg. </text>
<text top="488" left="794" width="3" height="17" font="5"> </text>
<text top="505" left="794" width="3" height="17" font="5"> </text>
<text top="522" left="794" width="114" height="17" font="5">• In meta-regression </text>
<text top="539" left="794" width="136" height="17" font="5">analysis, change in 24-h </text>
<text top="556" left="794" width="109" height="17" font="5">urinary sodium was </text>
<text top="573" left="794" width="154" height="17" font="5">significantly associated with </text>
<text top="590" left="794" width="143" height="17" font="5">reduction in SBP (4.3 mm </text>
<text top="607" left="794" width="104" height="17" font="5">Hg for a 100 mmol </text>
<text top="624" left="794" width="136" height="17" font="5">reduction in 24-h urinary </text>
<text top="641" left="794" width="51" height="17" font="5">sodium). </text>
<text top="658" left="794" width="3" height="17" font="5"> </text>
<text top="675" left="794" width="92" height="17" font="5">Safety endpoint: </text>
<text top="692" left="794" width="125" height="17" font="5">In the small number of </text>
<text top="709" left="794" width="115" height="17" font="5">relevant trials (which </text>
<text top="726" left="794" width="149" height="17" font="5">included both hypertensive </text>
<text top="743" left="794" width="24" height="17" font="5">and </text>
<text top="760" left="794" width="125" height="17" font="5">normotensive pts) that </text>
<text top="230" left="970" width="46" height="17" font="5">● Study </text>
<text top="247" left="970" width="106" height="17" font="5">inclusion/exclusion </text>
<text top="265" left="970" width="136" height="17" font="5">criteria designed to yield </text>
<text top="282" left="970" width="112" height="17" font="5">a group of trials that </text>
<text top="299" left="970" width="119" height="17" font="5">would provide results </text>
<text top="316" left="970" width="128" height="17" font="5">that have relevance for </text>
<text top="333" left="970" width="110" height="17" font="5">clinical practice and </text>
<text top="351" left="970" width="112" height="17" font="5">public health. In this </text>
<text top="368" left="970" width="137" height="17" font="5">context, reduced sodium </text>
<text top="385" left="970" width="106" height="17" font="5">intake resulted in a </text>
<text top="402" left="970" width="82" height="17" font="5">significant and </text>
<text top="420" left="970" width="113" height="17" font="5">potentially important </text>
<text top="437" left="970" width="98" height="17" font="5">reduction in SBP. </text>
<text top="454" left="971" width="25" height="17" font="5">The </text>
<text top="454" left="1020" width="92" height="17" font="5">meta-regression </text>
<text top="471" left="971" width="142" height="17" font="5">results  were  consistent </text>
<text top="488" left="971" width="142" height="17" font="5">with  a  dose-  response </text>
<text top="505" left="971" width="66" height="17" font="5">relationship </text>
<text top="505" left="1100" width="13" height="17" font="5">in </text>
<text top="522" left="971" width="97" height="17" font="5">normotensive pts </text>
</page>
<page number="230" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="90" left="794" width="87" height="17" font="5">provided safety </text>
<text top="107" left="794" width="135" height="17" font="5">endpoint measurements </text>
<text top="124" left="794" width="146" height="17" font="5">(4–14 trials), there was no </text>
<text top="142" left="794" width="131" height="17" font="5">change in total, LDL- or </text>
<text top="158" left="794" width="113" height="17" font="5">HDL- cholesterol, or </text>
<text top="176" left="794" width="136" height="17" font="5">triglyceride levels. There </text>
<text top="193" left="794" width="120" height="17" font="5">were small significant </text>
<text top="210" left="794" width="143" height="17" font="5">increases in plasma renin </text>
<text top="227" left="794" width="140" height="17" font="5">activity, aldosterone, and </text>
<text top="244" left="794" width="134" height="17" font="5">noradrenaline levels but </text>
<text top="261" left="794" width="64" height="17" font="5">these were </text>
<text top="278" left="794" width="137" height="17" font="5">consistent with expected </text>
<text top="295" left="794" width="64" height="17" font="5">physiologic </text>
<text top="313" left="794" width="117" height="17" font="5">responses to sodium </text>
<text top="331" left="794" width="57" height="17" font="5">reduction. </text>
<text top="349" left="83" width="38" height="17" font="5">TONE </text>
<text top="367" left="83" width="85" height="17" font="5">Whelton PK, et </text>
<text top="384" left="83" width="83" height="17" font="5">al., 1998 (107) </text>
<text top="401" left="83" width="48" height="17" font="19"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=Citation">9515998</a></text>
<text top="401" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=Citation"> </a></text>
<text top="349" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="367" left="220" width="115" height="17" font="5">of weight loss on BP </text>
<text top="384" left="220" width="73" height="17" font="5">and need for </text>
<text top="401" left="220" width="93" height="17" font="5">antihypertensive </text>
<text top="418" left="220" width="73" height="17" font="5">drug therapy </text>
<text top="436" left="212" width="3" height="17" font="5"> </text>
<text top="453" left="220" width="65" height="17" font="5">Study type: </text>
<text top="470" left="220" width="118" height="17" font="5">RCT, factorial design </text>
<text top="488" left="212" width="3" height="17" font="5"> </text>
<text top="505" left="220" width="100" height="17" font="5">Size: 585 (obese) </text>
<text top="522" left="220" width="66" height="17" font="5">participants </text>
<text top="349" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="367" left="373" width="208" height="18" font="5">• Community-dwelling adults 60–80 y </text>
<text top="384" left="373" width="165" height="18" font="5">• SBP &lt;145 mm Hg and DBP </text>
<text top="403" left="373" width="188" height="17" font="5">&lt;85 mm Hg on 1 antihypertensive </text>
<text top="420" left="373" width="63" height="17" font="5">medication </text>
<text top="438" left="365" width="3" height="17" font="5"> </text>
<text top="456" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="473" left="373" width="196" height="18" font="5">• Heart attack or stroke within 6 mo </text>
<text top="491" left="373" width="163" height="18" font="5">• Current angina, HF, insulin- </text>
<text top="509" left="373" width="84" height="17" font="5">dependent DM </text>
<text top="526" left="373" width="173" height="17" font="5">Inability to comply with protocol </text>
<text top="349" left="619" width="123" height="17" font="5">Intervention: Behavior </text>
<text top="367" left="619" width="111" height="17" font="5">change intervention </text>
<text top="384" left="619" width="111" height="17" font="5">(combination of diet </text>
<text top="401" left="619" width="115" height="17" font="5">change and physical </text>
<text top="418" left="619" width="45" height="17" font="5">activity) </text>
<text top="436" left="611" width="3" height="17" font="5"> </text>
<text top="453" left="619" width="107" height="17" font="5">Comparator: Usual </text>
<text top="471" left="619" width="123" height="17" font="5">care, with similar level </text>
<text top="488" left="619" width="128" height="17" font="5">of contact compared to </text>
<text top="505" left="619" width="102" height="17" font="5">active intervention </text>
<text top="522" left="619" width="35" height="17" font="5">group </text>
<text top="349" left="794" width="135" height="17" font="5">1  endpoint: Recurrence </text>
<text top="367" left="794" width="93" height="17" font="5">of HTN following </text>
<text top="384" left="794" width="75" height="17" font="5">withdrawal of </text>
<text top="401" left="794" width="93" height="17" font="5">antihypertensive </text>
<text top="418" left="794" width="110" height="17" font="5">medication (or CVD </text>
<text top="435" left="794" width="38" height="17" font="5">event) </text>
<text top="453" left="786" width="3" height="17" font="5"> </text>
<text top="471" left="794" width="87" height="17" font="5">2  endpoint: BP </text>
<text top="488" left="794" width="74" height="17" font="5">(while still on </text>
<text top="505" left="794" width="93" height="17" font="5">antihypertensive </text>
<text top="522" left="794" width="104" height="17" font="5">medication prior to </text>
<text top="539" left="794" width="61" height="17" font="5">tapering of </text>
<text top="557" left="794" width="67" height="17" font="5">medication) </text>
<text top="575" left="786" width="3" height="17" font="5"> </text>
<text top="593" left="794" width="121" height="17" font="5">Safety endpoint: CVD </text>
<text top="611" left="794" width="102" height="17" font="5">events, symptoms </text>
<text top="629" left="794" width="127" height="17" font="5">(including headaches), </text>
<text top="647" left="794" width="109" height="17" font="5">dietary composition </text>
<text top="349" left="971" width="138" height="18" font="5">•<b> </b>Significant reduction in </text>
<text top="368" left="971" width="131" height="17" font="5">SBP prior to withdrawal </text>
<text top="385" left="971" width="107" height="17" font="5">of antihypertensive </text>
<text top="402" left="971" width="133" height="17" font="5">medication (mean±SE=-</text>
<text top="419" left="971" width="93" height="17" font="5">4.0±1.3 mm Hg) </text>
<text top="437" left="971" width="77" height="18" font="5">•<b> </b>1° outcome </text>
<text top="455" left="971" width="92" height="17" font="5">significantly less </text>
<text top="472" left="971" width="127" height="17" font="5">common in weight loss </text>
<text top="489" left="971" width="139" height="17" font="5">group compared to usual </text>
<text top="506" left="971" width="118" height="17" font="5">care – Rel. HR: 0.70; </text>
<text top="524" left="971" width="109" height="17" font="5">95% CI, 0.57–0.87; </text>
<text top="541" left="971" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="558" left="971" width="142" height="17" font="5">No  overt  evidence  for </text>
<text top="575" left="971" width="47" height="17" font="5">adverse </text>
<text top="575" left="1039" width="40" height="17" font="5">effects </text>
<text top="575" left="1099" width="14" height="17" font="5">of </text>
<text top="592" left="971" width="67" height="17" font="5">intervention </text>
<text top="666" left="83" width="85" height="17" font="5">Whelton PK, et </text>
<text top="683" left="83" width="76" height="17" font="5">al., 1997 (67) </text>
<text top="700" left="83" width="48" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9168293?dopt=Citation">9168293</a></text>
<text top="700" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9168293?dopt=Citation"> </a></text>
<text top="666" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="683" left="220" width="73" height="17" font="5">of potassium </text>
<text top="700" left="220" width="111" height="17" font="5">supplementation on </text>
<text top="717" left="220" width="20" height="17" font="5">BP </text>
<text top="735" left="212" width="3" height="17" font="5"> </text>
<text top="752" left="220" width="65" height="17" font="5">Study type: </text>
<text top="770" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="665" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="682" left="373" width="82" height="18" font="5">• Human RCT </text>
<text top="701" left="373" width="84" height="18" font="5">• Without HTN </text>
<text top="720" left="373" width="183" height="18" font="5">• Potassium supplementation vs. </text>
<text top="738" left="373" width="40" height="17" font="5">control </text>
<text top="755" left="373" width="164" height="18" font="5">• No concurrent interventions </text>
<text top="773" left="365" width="3" height="17" font="5"> </text>
<text top="666" left="619" width="132" height="17" font="5">Intervention: Potassium </text>
<text top="683" left="619" width="141" height="17" font="5">supplementation in 1,049 </text>
<text top="700" left="619" width="130" height="17" font="5">pts (potassium chloride </text>
<text top="717" left="619" width="141" height="17" font="5">tabs in 10 RCTs with 618 </text>
<text top="734" left="619" width="119" height="17" font="5">pts and diet in 2 RCT </text>
<text top="752" left="619" width="73" height="17" font="5">with 431 pts) </text>
<text top="770" left="611" width="3" height="17" font="5"> </text>
<text top="666" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="684" left="794" width="138" height="18" font="5">• Significant reduction in </text>
<text top="703" left="794" width="23" height="17" font="5">BP. </text>
<text top="721" left="794" width="145" height="18" font="5">• Overall  (hypertensives </text>
<text top="739" left="794" width="24" height="17" font="5">and </text>
<text top="739" left="848" width="91" height="17" font="5">normotensives), </text>
<text top="756" left="794" width="145" height="17" font="5">mean: 3.11 mm Hg; 95% </text>
<text top="773" left="794" width="134" height="17" font="5">CI: -4.32– -1.91 mm Hg. </text>
<text top="666" left="971" width="100" height="18" font="5">• This is the most </text>
<text top="684" left="971" width="87" height="17" font="5">comprehensive </text>
<text top="701" left="971" width="105" height="17" font="5">presentation of the </text>
<text top="718" left="971" width="130" height="17" font="5">effects of potassium on </text>
<text top="735" left="971" width="75" height="17" font="5">BP, including </text>
<text top="752" left="971" width="76" height="17" font="5">experience in </text>
<text top="769" left="971" width="87" height="17" font="5">normotensives. </text>
</page>
<page number="231" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="20" size="12" family="Times" color="#090904"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="108" left="212" width="3" height="17" font="5"> </text>
<text top="125" left="220" width="34" height="17" font="5">Size:  </text>
<text top="142" left="215" width="103" height="17" font="5">● Overall, 33 RCT </text>
<text top="160" left="227" width="56" height="17" font="5">(n=2,609) </text>
<text top="178" left="215" width="114" height="17" font="5">● 2 RCTs (n=1,049) </text>
<text top="195" left="220" width="96" height="17" font="5">in normotensives </text>
<text top="90" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="107" left="373" width="95" height="17" font="5">Missing key data </text>
<text top="91" left="619" width="91" height="17" font="5">Comparator: No </text>
<text top="108" left="619" width="59" height="17" font="5">potassium </text>
<text top="125" left="619" width="89" height="17" font="5">supplementation </text>
<text top="142" left="619" width="133" height="17" font="5">(placebo in 10 RCT and </text>
<text top="160" left="619" width="112" height="17" font="5">usual diet in 2 RCT) </text>
<text top="91" left="794" width="91" height="18" font="5">• In the 12 trials </text>
<text top="109" left="794" width="72" height="17" font="5">conducted in </text>
<text top="126" left="794" width="129" height="17" font="5">normotensives, mean: -</text>
<text top="143" left="794" width="145" height="17" font="5">1.8 mm Hg; 95% CI: -2.9– </text>
<text top="161" left="794" width="25" height="17" font="5">-0.6 </text>
<text top="178" left="794" width="137" height="17" font="5">mm Hg for SBP and -1.0 </text>
<text top="195" left="794" width="142" height="17" font="5">mm Hg; 95% CI: -2.1–0.0 </text>
<text top="212" left="794" width="46" height="17" font="5">for DBP </text>
<text top="230" left="794" width="91" height="18" font="5">• In the 20 trials </text>
<text top="248" left="794" width="72" height="17" font="5">conducted in </text>
<text top="265" left="794" width="145" height="17" font="5">hypertensives, mean: -4.4 </text>
<text top="282" left="794" width="129" height="17" font="5">mm Hg; 95% CI: -6.6– -</text>
<text top="299" left="794" width="139" height="17" font="5">2.2 for SBP and -2.5 mm </text>
<text top="317" left="794" width="143" height="17" font="5">Hg; 95% CI: -4.9– -0.1 for </text>
<text top="334" left="794" width="29" height="17" font="5">DBP </text>
<text top="352" left="786" width="3" height="17" font="5"> </text>
<text top="370" left="794" width="116" height="17" font="5">Safety endpoint: N/A </text>
<text top="91" left="971" width="124" height="18" font="5">• Significant reduction </text>
<text top="109" left="971" width="117" height="17" font="5">in SBP overall and in </text>
<text top="126" left="971" width="130" height="17" font="5">the subgroups with and </text>
<text top="144" left="971" width="74" height="17" font="5">without HTN. </text>
<text top="161" left="971" width="101" height="18" font="5">• In a subsequent </text>
<text top="179" left="971" width="110" height="17" font="5">meta-analysis of 23 </text>
<text top="196" left="971" width="135" height="17" font="5">trials, Geleijnse JM, Kok </text>
<text top="214" left="971" width="130" height="17" font="5">FJ, and Grobbee DE (J </text>
<text top="231" left="971" width="92" height="17" font="5">Hum Hypertens. </text>
<text top="248" left="971" width="101" height="17" font="5">2003;17:471-480) </text>
<text top="265" left="971" width="132" height="17" font="5">reported a similar effect </text>
<text top="283" left="971" width="131" height="17" font="5">of potassium on SBP in </text>
<text top="300" left="971" width="130" height="17" font="5">both hypertensives and </text>
<text top="317" left="971" width="100" height="17" font="5">nonhypertensives </text>
<text top="334" left="971" width="58" height="17" font="5">(mean of - </text>
<text top="351" left="971" width="115" height="17" font="5">3.2 and -1.4 mm Hg, </text>
<text top="369" left="971" width="76" height="17" font="5">respectively). </text>
<text top="386" left="971" width="134" height="18" font="5">• The 1 RCT conducted </text>
<text top="404" left="971" width="117" height="17" font="5">in African-Americans </text>
<text top="421" left="971" width="136" height="17" font="5">(n=87) identified a mean </text>
<text top="438" left="971" width="127" height="17" font="5">treatment effect size of </text>
<text top="455" left="971" width="4" height="17" font="5">-</text>
<text top="455" left="975" width="135" height="17" font="20">6.9 mm Hg; 95% CI: -9.3</text>
<text top="455" left="1110" width="10" height="17" font="5">– </text>
<text top="473" left="971" width="67" height="17" font="20">-4.4 for SBP</text>
<text top="473" left="1037" width="3" height="17" font="5"> </text>
<text top="490" left="971" width="129" height="17" font="20">(p&lt;0.001) and -2.5 mm </text>
<text top="507" left="971" width="91" height="17" font="20">Hg; 95% CI: -4.3</text>
<text top="507" left="1061" width="10" height="17" font="5">– </text>
<text top="507" left="1072" width="25" height="17" font="20">-0.8 </text>
<text top="525" left="971" width="103" height="17" font="20">for DBP (p=0.004).</text>
<text top="525" left="1073" width="3" height="17" font="5"> </text>
<text top="542" left="971" width="116" height="18" font="5">• In the entire cohort </text>
<text top="560" left="971" width="126" height="17" font="5">(trials conducted in pts </text>
<text top="577" left="971" width="78" height="17" font="5">with HTN and </text>
<text top="595" left="971" width="106" height="17" font="5">normotension), net </text>
<text top="612" left="971" width="115" height="17" font="5">changes in SBP and </text>
<text top="629" left="971" width="101" height="17" font="5">DBP were directly </text>
<text top="646" left="971" width="137" height="17" font="5">related to level of urinary </text>
<text top="663" left="971" width="142" height="17" font="5">sodium  excretion  during </text>
<text top="680" left="971" width="47" height="17" font="5">the trial. </text>
<text top="698" left="83" width="75" height="17" font="5">Aburto NJ, et </text>
<text top="715" left="83" width="76" height="17" font="5">al., 2013 (68) </text>
<text top="733" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23558164?dopt=Citation">23558164</a></text>
<text top="733" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23558164?dopt=Citation"> </a></text>
<text top="698" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="715" left="220" width="73" height="17" font="5">of potassium </text>
<text top="733" left="220" width="111" height="17" font="5">supplementation on </text>
<text top="750" left="220" width="20" height="17" font="5">BP </text>
<text top="768" left="212" width="3" height="17" font="5"> </text>
<text top="698" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="715" left="373" width="99" height="18" font="5">• RCT in humans </text>
<text top="733" left="373" width="97" height="18" font="5">• Duration ≥4 wk </text>
<text top="752" left="373" width="153" height="18" font="5">• 24-h collections of urinary </text>
<text top="770" left="373" width="60" height="17" font="5">potassium </text>
<text top="698" left="619" width="132" height="17" font="5">Intervention: Potassium </text>
<text top="715" left="619" width="124" height="17" font="5">supplementation in 20 </text>
<text top="733" left="619" width="132" height="17" font="5">trials, supplements plus </text>
<text top="750" left="619" width="130" height="17" font="5">diet/education in 1 trial, </text>
<text top="767" left="619" width="137" height="17" font="5">and diet/education alone </text>
<text top="699" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="717" left="794" width="109" height="18" font="5">• Overall change in </text>
<text top="735" left="794" width="121" height="17" font="5">SBP=- 5.93; 95% CI: -</text>
<text top="752" left="794" width="105" height="17" font="5">10.15– -1.70. After </text>
<text top="769" left="794" width="144" height="17" font="5">removing outlier trials, the </text>
<text top="698" left="971" width="124" height="18" font="5">• 1 trial (TOHP Phase </text>
<text top="716" left="971" width="115" height="17" font="5">I) incorrectly entered </text>
<text top="734" left="971" width="113" height="17" font="5">twice so only 2 trials </text>
<text top="751" left="971" width="88" height="17" font="5">really available. </text>
<text top="768" left="971" width="128" height="17" font="5">However, this does not </text>
</page>
<page number="232" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="65" height="17" font="5">Study type: </text>
<text top="108" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="125" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="143" left="212" width="3" height="17" font="5"> </text>
<text top="160" left="220" width="83" height="17" font="5">Size: 21 RCTs </text>
<text top="178" left="220" width="110" height="17" font="5">(n=1,892); 16 in pts </text>
<text top="195" left="220" width="100" height="17" font="5">with HTN (n=818) </text>
<text top="212" left="220" width="102" height="17" font="5">and 3 RCTs in pts </text>
<text top="229" left="220" width="117" height="17" font="5">without HTN (n=757) </text>
<text top="91" left="373" width="172" height="18" font="5">• No concomitant interventions </text>
<text top="110" left="365" width="3" height="17" font="5"> </text>
<text top="126" left="373" width="219" height="17" font="5">Exclusion criteria: Pts who were acutely </text>
<text top="143" left="373" width="198" height="17" font="5">ill, HIV positive, hospitalized, or had </text>
<text top="160" left="373" width="218" height="17" font="5">impaired urinary excretion of potassium </text>
<text top="91" left="619" width="56" height="17" font="5">in 2 trials. </text>
<text top="109" left="611" width="3" height="17" font="5"> </text>
<text top="126" left="619" width="91" height="17" font="5">Comparator: No </text>
<text top="143" left="619" width="59" height="17" font="5">potassium </text>
<text top="160" left="619" width="93" height="17" font="5">supplementation </text>
<text top="178" left="619" width="125" height="17" font="5">(placebo or usual diet) </text>
<text top="91" left="794" width="124" height="17" font="5">change was -3.49 mm </text>
<text top="108" left="794" width="139" height="17" font="5">Hg; 95% CI: -5.15– -1.82 </text>
<text top="125" left="794" width="46" height="17" font="5">mm Hg. </text>
<text top="143" left="794" width="131" height="18" font="5">• In 16 trials conducted </text>
<text top="161" left="794" width="139" height="17" font="5">in hypertensives, change </text>
<text top="178" left="794" width="121" height="17" font="5">in SBP was -5.32 mm </text>
<text top="195" left="794" width="112" height="17" font="5">Hg; 95% CI: -7.20– -</text>
<text top="212" left="794" width="31" height="17" font="5">3.43. </text>
<text top="230" left="794" width="147" height="17" font="5">In the 3 trials conducted in </text>
<text top="248" left="794" width="122" height="17" font="5">persons without HTN, </text>
<text top="266" left="794" width="137" height="17" font="5">change in SBP was 0.09 </text>
<text top="285" left="794" width="128" height="17" font="5">mm Hg; 95% CI: -0.77–</text>
<text top="303" left="794" width="31" height="17" font="5">0.95. </text>
<text top="91" left="971" width="126" height="17" font="5">change overall finding. </text>
<text top="108" left="971" width="142" height="17" font="5">The  negative  results  for </text>
<text top="125" left="971" width="142" height="17" font="5">normotensives  in  this </text>
<text top="142" left="971" width="79" height="17" font="5">meta-analysis </text>
<text top="142" left="1084" width="28" height="17" font="5">(and </text>
<text top="159" left="971" width="57" height="17" font="5">difference </text>
<text top="159" left="1047" width="25" height="17" font="5">with </text>
<text top="159" left="1092" width="21" height="17" font="5">the </text>
<text top="176" left="971" width="142" height="17" font="5">findings by Whelton et al) </text>
<text top="193" left="971" width="142" height="17" font="5">probably  reflects  the </text>
<text top="210" left="971" width="69" height="17" font="5">requirement </text>
<text top="210" left="1062" width="18" height="17" font="5">for </text>
<text top="210" left="1102" width="10" height="17" font="5">a </text>
<text top="227" left="971" width="142" height="17" font="5">duration of ≥4 wk and the </text>
<text top="244" left="971" width="142" height="17" font="5">fact that few trials of this </text>
<text top="261" left="971" width="142" height="17" font="5">duration  have  been </text>
<text top="278" left="971" width="60" height="17" font="5">conducted </text>
<text top="278" left="1100" width="13" height="17" font="5">in </text>
<text top="295" left="971" width="87" height="17" font="5">normotensives. </text>
<text top="321" left="83" width="105" height="17" font="5">Cornelissen VA, et </text>
<text top="339" left="83" width="76" height="17" font="5">al., 2013 (97) </text>
<text top="356" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23525435?dopt=Citation">23525435</a></text>
<text top="356" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23525435?dopt=Citation"> </a></text>
<text top="321" left="219" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="339" left="219" width="108" height="17" font="5">of different types of </text>
<text top="356" left="219" width="106" height="17" font="5">physical activity on </text>
<text top="373" left="219" width="20" height="17" font="5">BP </text>
<text top="390" left="219" width="61" height="18" font="5">• Dynamic </text>
<text top="409" left="219" width="44" height="17" font="5">aerobic </text>
<text top="426" left="219" width="62" height="17" font="5">endurance </text>
<text top="443" left="219" width="118" height="18" font="5">• Resistance training </text>
<text top="461" left="219" width="59" height="17" font="5">- Dynamic </text>
<text top="478" left="219" width="103" height="17" font="5">- Static (Isometric) </text>
<text top="496" left="212" width="3" height="17" font="5"> </text>
<text top="513" left="219" width="65" height="17" font="5">Study type: </text>
<text top="530" left="219" width="102" height="17" font="5">Systematic review </text>
<text top="547" left="219" width="103" height="17" font="5">and meta-analysis </text>
<text top="565" left="212" width="3" height="17" font="5"> </text>
<text top="583" left="219" width="94" height="17" font="5">Size: Overall, 93 </text>
<text top="600" left="219" width="112" height="17" font="5">studies (&gt;5,000 pts) </text>
<text top="617" left="219" width="78" height="18" font="5">• 59 Dynamic </text>
<text top="635" left="219" width="108" height="17" font="5">Aerobic Endurance </text>
<text top="652" left="219" width="42" height="17" font="5">studies </text>
<text top="669" left="219" width="78" height="18" font="5">• 13 Dynamic </text>
<text top="688" left="219" width="64" height="17" font="5">Resistance </text>
<text top="705" left="219" width="48" height="17" font="5">Training </text>
<text top="722" left="219" width="42" height="17" font="5">studies </text>
<text top="740" left="219" width="80" height="18" font="5">• 5 Combined </text>
<text top="758" left="219" width="120" height="17" font="5">Dynamic Aerobic and </text>
<text top="321" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="338" left="373" width="114" height="18" font="5">• Parallel arm RCTs </text>
<text top="357" left="373" width="79" height="18" font="5">• Adults≥18 y </text>
<text top="375" left="373" width="169" height="18" font="5">• Peer reviewed journals up to </text>
<text top="394" left="373" width="83" height="17" font="5">February 2012 </text>
<text top="411" left="373" width="122" height="18" font="5">• Trial duration ≥4 wk </text>
<text top="430" left="365" width="3" height="17" font="5"> </text>
<text top="447" left="373" width="217" height="17" font="5">Exclusion criteria: Inadequate reporting </text>
<text top="463" left="373" width="62" height="17" font="5">of the data </text>
<text top="321" left="619" width="120" height="17" font="5">Intervention: Physical </text>
<text top="339" left="619" width="41" height="17" font="5">activity </text>
<text top="357" left="611" width="3" height="17" font="5"> </text>
<text top="374" left="619" width="91" height="17" font="5">Comparator: No </text>
<text top="391" left="619" width="128" height="17" font="5">prescription of physical </text>
<text top="408" left="619" width="41" height="17" font="5">activity </text>
<text top="321" left="794" width="143" height="17" font="5">1  endpoint: Overall (trials </text>
<text top="339" left="794" width="116" height="17" font="5">in hypertensives and </text>
<text top="356" left="794" width="125" height="17" font="5">normotensive), pooled </text>
<text top="373" left="794" width="126" height="17" font="5">experience identified a </text>
<text top="390" left="794" width="145" height="17" font="5">significant reduction in BP </text>
<text top="407" left="794" width="137" height="17" font="5">with all forms of physical </text>
<text top="425" left="794" width="140" height="17" font="5">activity (aerobic and both </text>
<text top="442" left="794" width="107" height="17" font="5">forms of resistance </text>
<text top="459" left="794" width="111" height="17" font="5">training), with mean </text>
<text top="476" left="794" width="139" height="17" font="5">reductions in SBP of -3.5 </text>
<text top="494" left="794" width="138" height="17" font="5">mm Hg following aerobic </text>
<text top="511" left="794" width="116" height="17" font="5">endurance training, - </text>
<text top="528" left="794" width="115" height="17" font="5">1.8 mm Hg following </text>
<text top="545" left="794" width="108" height="17" font="5">dynamic resistance </text>
<text top="562" left="794" width="146" height="17" font="5">training, and -10.9 mm Hg </text>
<text top="580" left="794" width="144" height="17" font="5">following static (isometric) </text>
<text top="597" left="794" width="103" height="17" font="5">resistance training </text>
<text top="614" left="794" width="91" height="17" font="5">(p&lt;0.001 for the </text>
<text top="631" left="794" width="128" height="17" font="5">difference between the </text>
<text top="649" left="794" width="142" height="17" font="5">effect size following static </text>
<text top="666" left="794" width="115" height="17" font="5">[isometric] and other </text>
<text top="683" left="794" width="144" height="17" font="5">forms of physical activity). </text>
<text top="700" left="794" width="119" height="17" font="5">In subgroup analysis, </text>
<text top="717" left="794" width="93" height="17" font="5">dynamic aerobic </text>
<text top="735" left="794" width="135" height="17" font="5">endurance and dynamic </text>
<text top="752" left="794" width="103" height="17" font="5">resistance training </text>
<text top="769" left="794" width="122" height="17" font="5">resulted in mean SBP </text>
<text top="321" left="970" width="101" height="18" font="5">• Most recent in a </text>
<text top="340" left="970" width="126" height="17" font="5">series of progressively </text>
<text top="357" left="970" width="116" height="17" font="5">updated publications </text>
<text top="374" left="970" width="116" height="17" font="5">from Dr. Cornelissen </text>
<text top="391" left="970" width="111" height="17" font="5">and her colleagues. </text>
<text top="409" left="970" width="137" height="18" font="5">• The findings suggest a </text>
<text top="427" left="970" width="118" height="17" font="5">beneficial effect of all </text>
<text top="444" left="970" width="137" height="17" font="5">forms of physical activity </text>
<text top="461" left="970" width="76" height="17" font="5">on BP, with a </text>
<text top="478" left="970" width="131" height="17" font="5">disproportionately large </text>
<text top="496" left="970" width="106" height="17" font="5">effect of resistance </text>
<text top="513" left="970" width="84" height="17" font="5">training on BP. </text>
<text top="530" left="971" width="142" height="17" font="5">Many  of  the  available </text>
<text top="547" left="971" width="142" height="17" font="5">RCTs have been small, of </text>
<text top="564" left="971" width="142" height="17" font="5">short  duration,  and  of </text>
<text top="581" left="971" width="96" height="17" font="5">uncertain quality. </text>
</page>
<page number="233" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="219" width="108" height="17" font="5">Resistance training </text>
<text top="108" left="219" width="55" height="18" font="5">• 4 Static </text>
<text top="126" left="219" width="61" height="17" font="5">(Isometric) </text>
<text top="143" left="219" width="64" height="17" font="5">Resistance </text>
<text top="161" left="220" width="67" height="17" font="5">12 Different </text>
<text top="178" left="220" width="117" height="17" font="5">interventions within 1 </text>
<text top="195" left="220" width="23" height="17" font="5">trial </text>
<text top="91" left="794" width="120" height="17" font="5">changes of -2.1 (95% </text>
<text top="108" left="794" width="135" height="17" font="5">CI: -3.3– -0.83) and -4.3 </text>
<text top="125" left="794" width="122" height="17" font="5">(95% CI: -7.7– -0.90), </text>
<text top="142" left="794" width="125" height="17" font="5">respectively, in the pts </text>
<text top="160" left="794" width="146" height="17" font="5">with pre-HTN and smaller, </text>
<text top="177" left="794" width="139" height="17" font="5">nonsignificant reductions </text>
<text top="194" left="794" width="146" height="17" font="5">in the remaining pts with a </text>
<text top="211" left="794" width="64" height="17" font="5">normal BP. </text>
<text top="229" left="786" width="3" height="17" font="5"> </text>
<text top="247" left="794" width="116" height="17" font="5">Safety endpoint: N/A </text>
<text top="265" left="83" width="85" height="17" font="5">Whelton SP, et </text>
<text top="283" left="83" width="76" height="17" font="5">al., 2002 (96) </text>
<text top="300" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11926784?dopt=Citation">11926784</a></text>
<text top="300" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11926784?dopt=Citation"> </a></text>
<text top="265" left="219" width="116" height="17" font="5">Aim: Study the effect </text>
<text top="283" left="219" width="116" height="17" font="5">of  aerobic  exercise </text>
<text top="300" left="219" width="37" height="17" font="5">on BP </text>
<text top="318" left="212" width="3" height="17" font="5"> </text>
<text top="335" left="219" width="65" height="17" font="5">Study type: </text>
<text top="352" left="219" width="102" height="17" font="5">Systematic review </text>
<text top="369" left="219" width="103" height="17" font="5">and meta-analysis </text>
<text top="387" left="212" width="3" height="17" font="5"> </text>
<text top="405" left="220" width="111" height="17" font="5">Size: 38 reports (54 </text>
<text top="422" left="220" width="102" height="17" font="5">comparisons) with </text>
<text top="439" left="220" width="109" height="17" font="5">2,419 pts; 27 of the </text>
<text top="456" left="220" width="103" height="17" font="5">comparisons were </text>
<text top="473" left="220" width="73" height="17" font="5">conducted in </text>
<text top="491" left="220" width="97" height="17" font="5">normotensive pts </text>
<text top="265" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="282" left="373" width="54" height="18" font="5">• English </text>
<text top="283" left="446" width="54" height="17" font="5">language </text>
<text top="283" left="519" width="63" height="17" font="5">publication </text>
<text top="301" left="373" width="115" height="17" font="5">between 1966–2001 </text>
<text top="318" left="373" width="123" height="18" font="5">• RCT in adults ≥18 y </text>
<text top="336" left="373" width="97" height="18" font="5">• Duration ≥2 wk </text>
<text top="355" left="373" width="164" height="18" font="5">• No concurrent interventions </text>
<text top="373" left="365" width="3" height="17" font="5"> </text>
<text top="390" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="407" left="373" width="92" height="17" font="5">Missing BP data </text>
<text top="265" left="619" width="116" height="17" font="5">Intervention: Aerobic </text>
<text top="283" left="619" width="49" height="17" font="5">exercise </text>
<text top="300" left="611" width="3" height="17" font="5"> </text>
<text top="318" left="619" width="91" height="17" font="5">Comparator: No </text>
<text top="335" left="619" width="110" height="17" font="5">exercise prescribed </text>
<text top="266" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="284" left="794" width="141" height="18" font="5">• For the overall group, a </text>
<text top="302" left="794" width="102" height="17" font="5">pooled analysis of </text>
<text top="319" left="794" width="123" height="17" font="5">experience in 53 trials </text>
<text top="336" left="794" width="117" height="17" font="5">identified a mean net </text>
<text top="354" left="794" width="133" height="17" font="5">change in SBP of - 3.84 </text>
<text top="371" left="794" width="142" height="17" font="5">(95% CI: -4.97– -2.72). In </text>
<text top="388" left="794" width="126" height="17" font="5">subgroup analysis, the </text>
<text top="405" left="794" width="106" height="17" font="5">effect was noted in </text>
<text top="422" left="794" width="141" height="17" font="5">different ethnic groups, in </text>
<text top="440" left="794" width="110" height="17" font="5">trials that employed </text>
<text top="457" left="794" width="97" height="17" font="5">different designs, </text>
<text top="474" left="794" width="124" height="17" font="5">durations, and sample </text>
<text top="491" left="794" width="143" height="17" font="5">sizes, in trials with obese, </text>
<text top="508" left="794" width="118" height="17" font="5">overweight or normal </text>
<text top="526" left="794" width="128" height="17" font="5">weight pts, and in trials </text>
<text top="543" left="794" width="128" height="17" font="5">that employed different </text>
<text top="560" left="794" width="123" height="17" font="5">types, intensity levels, </text>
<text top="577" left="794" width="129" height="17" font="5">and duration of aerobic </text>
<text top="595" left="794" width="53" height="17" font="5">exercise. </text>
<text top="612" left="794" width="120" height="17" font="5">In the subgroup of 15 </text>
<text top="629" left="794" width="145" height="17" font="5">trials in hypertensives, the </text>
<text top="646" left="794" width="139" height="17" font="5">mean net change in SBP </text>
<text top="663" left="794" width="112" height="17" font="5">was -4.94 (95% CI: -</text>
<text top="681" left="794" width="72" height="17" font="5">7.17– -2.70). </text>
<text top="698" left="794" width="147" height="18" font="5">• In  the  subgroup  of  27 </text>
<text top="716" left="794" width="29" height="17" font="5">trials </text>
<text top="716" left="846" width="60" height="17" font="5">conducted </text>
<text top="716" left="928" width="13" height="17" font="5">in </text>
<text top="733" left="794" width="147" height="17" font="5">normotensives,  the  mean </text>
<text top="751" left="794" width="144" height="17" font="5">net  change  in  SBP  was  -</text>
<text top="768" left="794" width="144" height="17" font="5">4.04  (95%  CI:  -5.32–  -</text>
<text top="265" left="970" width="118" height="17" font="5">● This meta-analysis </text>
<text top="283" left="970" width="100" height="17" font="5">provides the most </text>
<text top="300" left="970" width="134" height="17" font="5">comprehensive analysis </text>
<text top="317" left="970" width="125" height="17" font="5">of the effect of aerobic </text>
<text top="334" left="970" width="110" height="17" font="5">exercise on BP and </text>
<text top="351" left="970" width="140" height="17" font="5">provides strong evidence </text>
<text top="369" left="970" width="115" height="17" font="5">in support of aerobic </text>
<text top="386" left="970" width="83" height="17" font="5">exercise as an </text>
<text top="403" left="970" width="133" height="17" font="5">intervention to lower BP </text>
<text top="420" left="970" width="100" height="17" font="5">in normotensives. </text>
<text top="438" left="971" width="142" height="17" font="5">Recognizing this, many of </text>
<text top="454" left="971" width="142" height="17" font="5">the trials were small and </text>
<text top="472" left="971" width="95" height="17" font="5">of short duration. </text>
</page>
<page number="234" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="35" height="17" font="5">2.75). </text>
<text top="109" left="786" width="3" height="17" font="5"> </text>
<text top="127" left="794" width="130" height="17" font="5">1  Safety endpoint: N/A </text>
<text top="176" left="83" width="87" height="17" font="5">Roerecke M, et </text>
<text top="194" left="83" width="51" height="17" font="5">al., 2017 </text>
<text top="211" left="83" width="77" height="17" font="5">Lancet Public </text>
<text top="228" left="83" width="42" height="17" font="5">Health. </text>
<text top="245" left="83" width="73" height="17" font="5">2017;2:e108-</text>
<text top="263" left="83" width="27" height="17" font="5">120. </text>
<text top="280" left="83" width="3" height="17" font="5"> </text>
<text top="297" left="83" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29253389">29253389</a></text>
<text top="297" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29253389"> </a></text>
<text top="176" left="220" width="117" height="17" font="5">Aim: Study the effect </text>
<text top="194" left="220" width="104" height="17" font="5">of reduced alcohol </text>
<text top="211" left="220" width="77" height="17" font="5">intake on BP. </text>
<text top="229" left="212" width="3" height="17" font="5"> </text>
<text top="246" left="220" width="65" height="17" font="5">Study type: </text>
<text top="263" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="281" left="220" width="107" height="17" font="5">and meta-analysis. </text>
<text top="298" left="212" width="3" height="17" font="5"> </text>
<text top="315" left="220" width="102" height="17" font="5">Size: 36 RCT with </text>
<text top="332" left="220" width="101" height="17" font="5">2865 participants. </text>
<text top="350" left="212" width="3" height="17" font="5"> </text>
<text top="367" left="220" width="45" height="17" font="5">Design: </text>
<text top="385" left="220" width="96" height="18" font="5">• 15 parallel-arm </text>
<text top="403" left="220" width="29" height="17" font="5">trials </text>
<text top="420" left="220" width="113" height="18" font="5">• 21 crossover trials </text>
<text top="439" left="212" width="3" height="17" font="5"> </text>
<text top="456" left="220" width="45" height="17" font="5">Setting: </text>
<text top="474" left="220" width="114" height="18" font="5">• 13 in hypertension </text>
<text top="492" left="220" width="118" height="18" font="5">• 13 in normotension </text>
<text top="510" left="220" width="100" height="18" font="5">• 12 HTN and NT </text>
<text top="529" left="220" width="68" height="17" font="5">Only 3 trials </text>
<text top="546" left="220" width="103" height="17" font="5">presented data for </text>
<text top="563" left="220" width="46" height="17" font="5">women. </text>
<text top="176" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="194" left="373" width="129" height="18" font="5">• RCT in adult humans </text>
<text top="212" left="373" width="190" height="18" font="5">• Publication on or before July 13, </text>
<text top="230" left="373" width="34" height="17" font="5">2016. </text>
<text top="247" left="373" width="102" height="18" font="5">• Full text articles. </text>
<text top="265" left="373" width="192" height="17" font="5">Change in alcohol intake for ≥1 wk </text>
<text top="176" left="619" width="130" height="17" font="5">Intervention: Reduction </text>
<text top="194" left="619" width="132" height="17" font="5">in alcohol consumption. </text>
<text top="211" left="619" width="114" height="17" font="5">Strategy varied from </text>
<text top="228" left="619" width="106" height="17" font="5">controlled inpatient </text>
<text top="245" left="619" width="93" height="17" font="5">administration to </text>
<text top="263" left="619" width="128" height="17" font="5">randomization to “light” </text>
<text top="280" left="619" width="113" height="17" font="5">alcohol to pragmatic </text>
<text top="297" left="619" width="126" height="17" font="5">primary care trials with </text>
<text top="314" left="619" width="119" height="17" font="5">counselling to reduce </text>
<text top="332" left="619" width="82" height="17" font="5">alcohol intake. </text>
<text top="349" left="611" width="3" height="17" font="5"> </text>
<text top="367" left="619" width="110" height="17" font="5">Duration: Follow-up </text>
<text top="384" left="619" width="90" height="17" font="5">from 1 wk to 2 y </text>
<text top="401" left="619" width="84" height="17" font="5">(median 4 wk). </text>
<text top="177" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="195" left="794" width="98" height="18" font="5">• Overall, alcohol </text>
<text top="213" left="794" width="141" height="17" font="5">reduction was associated </text>
<text top="230" left="794" width="93" height="17" font="5">with a significant </text>
<text top="248" left="794" width="143" height="17" font="5">reduction in mean SBP of </text>
<text top="265" left="794" width="125" height="17" font="5">-3.31 (95% CI: -4.10– -</text>
<text top="282" left="794" width="129" height="17" font="5">2.52) and DBP of -2.04 </text>
<text top="299" left="794" width="128" height="17" font="5">(95% CI: -2.58– -1.49). </text>
<text top="317" left="794" width="123" height="18" font="5">• In the subgroup of 7 </text>
<text top="335" left="794" width="120" height="17" font="5">RCTs in persons with </text>
<text top="352" left="794" width="137" height="17" font="5">HTN, the mean changes </text>
<text top="369" left="794" width="123" height="17" font="5">in SBP and DBP were </text>
<text top="386" left="794" width="118" height="17" font="5">SBP: -3.13 (95% CI: -</text>
<text top="404" left="794" width="73" height="17" font="5">3.93– - 2.32) </text>
<text top="420" left="794" width="153" height="17" font="5">DBP: -2.00 (95% CI: -2.65– </text>
<text top="438" left="794" width="8" height="17" font="5">- </text>
<text top="455" left="794" width="35" height="17" font="5">1.35). </text>
<text top="472" left="794" width="116" height="18" font="5">• In meta-regression </text>
<text top="490" left="794" width="118" height="17" font="5">analysis, there was a </text>
<text top="508" left="794" width="104" height="17" font="5">strong relationship </text>
<text top="525" left="794" width="141" height="17" font="5">between the extent of BP </text>
<text top="542" left="794" width="135" height="17" font="5">reduction and change in </text>
<text top="559" left="794" width="132" height="17" font="5">BP, with no reduction in </text>
<text top="577" left="794" width="144" height="17" font="5">BP for those consuming 2 </text>
<text top="594" left="794" width="139" height="17" font="5">or less drinks at baseline </text>
<text top="611" left="794" width="139" height="17" font="5">but increasing reductions </text>
<text top="628" left="794" width="109" height="17" font="5">in BP for those with </text>
<text top="645" left="794" width="113" height="17" font="5">progressively higher </text>
<text top="663" left="794" width="112" height="17" font="5">intakes of alcohol at </text>
<text top="680" left="794" width="140" height="17" font="5">baseline. For instance, in </text>
<text top="697" left="794" width="96" height="17" font="5">those consuming </text>
<text top="714" left="794" width="102" height="17" font="5">≥6 drinks/day and </text>
<text top="732" left="794" width="120" height="17" font="5">reducing their alcohol </text>
<text top="749" left="794" width="132" height="17" font="5">intake by approximately </text>
<text top="766" left="794" width="108" height="17" font="5">50%, the estimated </text>
<text top="176" left="971" width="24" height="17" font="5">N/A </text>
</page>
<page number="235" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="119" height="17" font="5">reduction in SBP and </text>
<text top="108" left="794" width="62" height="17" font="5">DBP were: </text>
<text top="125" left="794" width="153" height="17" font="5">SBP: -5.5 (95% CI: -6.70– - </text>
<text top="142" left="794" width="31" height="17" font="5">4.30) </text>
<text top="159" left="794" width="153" height="17" font="5">DBP: -3.97 (95% CI: -4.70– </text>
<text top="176" left="794" width="8" height="17" font="5">- </text>
<text top="195" left="794" width="137" height="17" font="5">3.25). Similar patterns of </text>
<text top="213" left="794" width="117" height="17" font="5">the effect of baseline </text>
<text top="231" left="794" width="151" height="17" font="5">alcohol intake on treatment </text>
<text top="249" left="794" width="126" height="17" font="5">effect were noted for a </text>
<text top="268" left="794" width="118" height="17" font="5">variety of subgroups. </text>
<text top="286" left="794" width="3" height="17" font="5"> </text>
<text top="304" left="794" width="130" height="17" font="5">1  Safety endpoint: N/A </text>
<text top="322" left="83" width="85" height="17" font="5">Law MR, et al., </text>
<text top="340" left="83" width="56" height="17" font="5">2009 (18) </text>
<text top="357" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation">19454737</a></text>
<text top="357" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19454737?dopt=Citation"> </a></text>
<text top="322" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="340" left="220" width="98" height="17" font="5">analysis of use of </text>
<text top="357" left="220" width="107" height="17" font="5">BP- lowering drugs </text>
<text top="374" left="220" width="87" height="17" font="5">in prevention of </text>
<text top="391" left="220" width="81" height="17" font="5">CVD from 147 </text>
<text top="409" left="220" width="97" height="17" font="5">randomized trials </text>
<text top="426" left="212" width="3" height="17" font="5"> </text>
<text top="443" left="220" width="71" height="17" font="5">Size: Of 147 </text>
<text top="461" left="220" width="111" height="17" font="5">randomized trials of </text>
<text top="478" left="220" width="88" height="17" font="5">464,000 pts, 37 </text>
<text top="495" left="220" width="111" height="17" font="5">trials of BBs in CAD </text>
<text top="512" left="220" width="113" height="17" font="5">included 38,892 pts, </text>
<text top="529" left="220" width="116" height="17" font="5">and 37 trials of other </text>
<text top="547" left="220" width="93" height="17" font="5">antihypertensive </text>
<text top="564" left="220" width="76" height="17" font="5">drugs in CAD </text>
<text top="581" left="220" width="110" height="17" font="5">included 85,395 pts </text>
<text top="322" left="373" width="174" height="17" font="5">Inclusion criteria: The database </text>
<text top="340" left="373" width="194" height="17" font="5">search used Medline (1966 to Dec. </text>
<text top="357" left="373" width="202" height="17" font="5">2007) to identify randomized trials of </text>
<text top="374" left="373" width="181" height="17" font="5">BP-lowering drugs in which CAD </text>
<text top="391" left="373" width="207" height="17" font="5">events or strokes were recorded. The </text>
<text top="409" left="373" width="193" height="17" font="5">search also included the Cochrane </text>
<text top="426" left="373" width="189" height="17" font="5">Collaboration and Web of Science </text>
<text top="443" left="373" width="195" height="17" font="5">databases and the citations in trials </text>
<text top="460" left="373" width="181" height="17" font="5">and previous meta-analyses and </text>
<text top="477" left="373" width="85" height="17" font="5">review articles. </text>
<text top="495" left="365" width="3" height="17" font="5"> </text>
<text top="512" left="373" width="216" height="17" font="5">Exclusion criteria: Trials were excluded </text>
<text top="529" left="373" width="224" height="17" font="5">if there were &lt;5 CAD events and strokes </text>
<text top="546" left="373" width="194" height="17" font="5">or if treatment duration was &lt;6 mo. </text>
<text top="322" left="619" width="24" height="17" font="5">N/A </text>
<text top="323" left="794" width="140" height="17" font="5">1  endpoint: CAD events; </text>
<text top="341" left="794" width="37" height="17" font="5">stroke </text>
<text top="359" left="786" width="3" height="17" font="5"> </text>
<text top="377" left="794" width="141" height="17" font="5">Results: In 37 trials of pts </text>
<text top="394" left="794" width="141" height="17" font="5">with a history of CAD, BB </text>
<text top="411" left="794" width="145" height="17" font="5">reduced CAD events 29% </text>
<text top="428" left="794" width="135" height="17" font="5">(95% CI: 22%– 34%). In </text>
<text top="445" left="794" width="120" height="17" font="5">27 trials in which BBs </text>
<text top="463" left="794" width="142" height="17" font="5">were used after acute MI, </text>
<text top="480" left="794" width="136" height="17" font="5">BB reduced CAD events </text>
<text top="497" left="794" width="110" height="17" font="5">31% (95% CI: 24%–</text>
<text top="514" left="794" width="132" height="17" font="5">38%), and in 11 trials in </text>
<text top="532" left="794" width="143" height="17" font="5">which BB were used after </text>
<text top="549" left="794" width="108" height="17" font="5">long-term CAD, BB </text>
<text top="566" left="794" width="124" height="17" font="5">insignificantly reduced </text>
<text top="583" left="794" width="124" height="17" font="5">CAD events 13%. In 7 </text>
<text top="600" left="794" width="137" height="17" font="5">trials, BB reduced stroke </text>
<text top="618" left="794" width="139" height="17" font="5">17% (95% CI: 1%–30%). </text>
<text top="635" left="794" width="98" height="17" font="5">CAD events were </text>
<text top="652" left="794" width="152" height="17" font="5">reduced 14% (95% CI: 2%–</text>
<text top="669" left="794" width="105" height="17" font="5">25%) in 11 trials of </text>
<text top="687" left="794" width="126" height="17" font="5">thiazide diuretics, 17% </text>
<text top="704" left="794" width="145" height="17" font="5">(95% CI: 11%–22%) in 21 </text>
<text top="721" left="794" width="85" height="17" font="5">trials of ACEIs, </text>
<text top="738" left="794" width="128" height="17" font="5">insignificantly 14% in 4 </text>
<text top="755" left="794" width="109" height="17" font="5">trials of angiotensin </text>
<text top="773" left="794" width="125" height="17" font="5">receptor blockers, and </text>
<text top="322" left="971" width="142" height="17" font="5">With the exception of the </text>
<text top="339" left="971" width="142" height="17" font="5">extra  protective  effect  of </text>
<text top="356" left="971" width="142" height="17" font="5">BB  given  shortly  after  a </text>
<text top="373" left="971" width="142" height="17" font="5">MI  and  the  minor </text>
<text top="390" left="971" width="142" height="17" font="5">additional effect of CCBs </text>
<text top="407" left="971" width="142" height="17" font="5">in  preventing  stroke,  all </text>
<text top="424" left="971" width="139" height="17" font="5">the  classes  of  BP-</text>
<text top="441" left="971" width="142" height="17" font="5">lowering  drugs  have  a </text>
<text top="458" left="971" width="142" height="17" font="5">similar  effect  in  reducing </text>
<text top="475" left="971" width="142" height="17" font="5">CAD  events  and  stroke </text>
<text top="492" left="971" width="142" height="17" font="5">for  a  given  reduction  in </text>
<text top="509" left="971" width="23" height="17" font="5">BP. </text>
</page>
<page number="236" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="136" height="17" font="5">15% (95% CI: 8%–22%) </text>
<text top="108" left="794" width="145" height="17" font="5">in 22 trials of CCB. Stroke </text>
<text top="125" left="794" width="133" height="17" font="5">was reduced 38% (95% </text>
<text top="142" left="794" width="142" height="17" font="5">CI: 28%–47%) in 10 trials </text>
<text top="160" left="794" width="60" height="17" font="5">of thiazide </text>
<text top="176" left="794" width="132" height="17" font="5">diuretics, 22% (95% CI: </text>
<text top="194" left="794" width="130" height="17" font="5">8%–34%) in 13 trials of </text>
<text top="212" left="794" width="139" height="17" font="5">ACEI, and 34% (95% CI: </text>
<text top="230" left="794" width="130" height="17" font="5">25%–42%) in 9 trials of </text>
<text top="248" left="794" width="33" height="17" font="5">CCB. </text>
<text top="267" left="83" width="95" height="17" font="5">Ettehad D, et al., </text>
<text top="284" left="83" width="56" height="17" font="5">2016 (17) </text>
<text top="301" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178?dopt=Citation">26724178</a></text>
<text top="301" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26724178?dopt=Citation"> </a></text>
<text top="267" left="220" width="116" height="17" font="5">Aim: This systematic </text>
<text top="284" left="220" width="94" height="17" font="5">review and meta-</text>
<text top="301" left="220" width="91" height="17" font="5">analysis aims to </text>
<text top="318" left="220" width="121" height="17" font="5">combine data from all </text>
<text top="335" left="220" width="119" height="17" font="5">published large-scale </text>
<text top="353" left="220" width="113" height="17" font="5">BP-lowering trials to </text>
<text top="370" left="220" width="120" height="17" font="5">quantify the effects of </text>
<text top="387" left="220" width="111" height="17" font="5">BP reduction on CV </text>
<text top="404" left="220" width="115" height="17" font="5">outcomes and death </text>
<text top="422" left="220" width="83" height="17" font="5">across various </text>
<text top="439" left="220" width="107" height="17" font="5">baseline BP levels, </text>
<text top="456" left="220" width="113" height="17" font="5">major comorbidities, </text>
<text top="473" left="220" width="72" height="17" font="5">and different </text>
<text top="490" left="220" width="88" height="17" font="5">pharmacological </text>
<text top="508" left="220" width="77" height="17" font="5">interventions. </text>
<text top="526" left="212" width="3" height="17" font="5"> </text>
<text top="543" left="220" width="65" height="17" font="5">Study type: </text>
<text top="560" left="220" width="83" height="17" font="5">Meta- analysis </text>
<text top="577" left="220" width="49" height="17" font="5">of RCTs </text>
<text top="595" left="212" width="3" height="17" font="5"> </text>
<text top="612" left="220" width="97" height="17" font="5">Size: 123 studies </text>
<text top="629" left="220" width="93" height="17" font="5">with 613,815 pts </text>
<text top="266" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="284" left="373" width="184" height="18" font="5">• RCTs of BP-lowering treatment </text>
<text top="302" left="373" width="185" height="17" font="5">that included a minimum of 1,000 </text>
<text top="319" left="373" width="37" height="17" font="5">pt-y of </text>
<text top="337" left="373" width="205" height="17" font="5">follow-up in each study arm. No trials </text>
<text top="354" left="373" width="214" height="17" font="5">were excluded because of presence of </text>
<text top="371" left="373" width="195" height="17" font="5">baseline comorbidities, and trials of </text>
<text top="388" left="373" width="206" height="17" font="5">antihypertensive drugs for indications </text>
<text top="405" left="373" width="162" height="17" font="5">other than HTN were eligible. </text>
<text top="423" left="373" width="212" height="18" font="5">• Eligible studies fell into 3 categories: </text>
<text top="441" left="373" width="202" height="17" font="5">1st, random allocation of pts to a BP-</text>
<text top="458" left="373" width="214" height="17" font="5">lowering drug or placebo; 2nd, random </text>
<text top="475" left="373" width="171" height="17" font="5">allocation of pts to different BP-</text>
<text top="493" left="373" width="186" height="17" font="5">lowering drugs; and third, random </text>
<text top="510" left="373" width="171" height="17" font="5">allocation of pts to different BP-</text>
<text top="527" left="373" width="94" height="17" font="5">lowering targets. </text>
<text top="545" left="365" width="3" height="17" font="5"> </text>
<text top="562" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="579" left="373" width="174" height="17" font="5">&lt;1,000 pt y of follow-up in each </text>
<text top="597" left="373" width="94" height="17" font="5">treatment group. </text>
<text top="613" left="373" width="3" height="17" font="5"> </text>
<text top="267" left="619" width="141" height="17" font="5">Intervention: BP-lowering </text>
<text top="284" left="619" width="33" height="17" font="5">meds </text>
<text top="301" left="619" width="3" height="17" font="5"> </text>
<text top="318" left="619" width="123" height="17" font="5">Comparator: Placebo, </text>
<text top="335" left="619" width="115" height="17" font="5">active comparator or </text>
<text top="353" left="619" width="133" height="17" font="5">less intensive treatment </text>
<text top="268" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="285" left="794" width="43" height="18" font="5">• CVD. </text>
<text top="304" left="794" width="74" height="18" font="5">• Major CVD </text>
<text top="322" left="794" width="76" height="17" font="5">events, CHD, </text>
<text top="339" left="794" width="94" height="17" font="5">stroke, HF, renal </text>
<text top="356" left="794" width="81" height="17" font="5">failure, and all-</text>
<text top="373" left="794" width="89" height="17" font="5">cause mortality. </text>
<text top="390" left="794" width="125" height="18" font="5">• Standardized RR for </text>
<text top="408" left="794" width="117" height="17" font="5">10 mm Hg difference </text>
<text top="425" left="794" width="41" height="17" font="5">in SBP </text>
<text top="442" left="794" width="143" height="18" font="5">• CVD RR: 0.80 (95% CI: </text>
<text top="461" left="804" width="62" height="17" font="5">0.77–0.83) </text>
<text top="479" left="786" width="3" height="17" font="5"> </text>
<text top="496" left="794" width="94" height="17" font="5">Other endpoints: </text>
<text top="513" left="794" width="133" height="17" font="5">CHD RR: 0.83 (95% CI: </text>
<text top="530" left="794" width="62" height="17" font="5">0.78–0.88) </text>
<text top="547" left="794" width="142" height="17" font="5">Stroke RR: 0.73 (95% CI: </text>
<text top="564" left="794" width="62" height="17" font="5">0.68–0.77) </text>
<text top="582" left="794" width="123" height="17" font="5">HF RR: 0.72 (95% CI: </text>
<text top="599" left="794" width="62" height="17" font="5">0.67–0.78) </text>
<text top="616" left="794" width="155" height="17" font="5">Total deaths RR: 0.87 (95% </text>
<text top="634" left="794" width="81" height="17" font="5">CI: 0.84–0.91) </text>
<text top="652" left="786" width="3" height="17" font="5"> </text>
<text top="669" left="794" width="77" height="17" font="5">Other results: </text>
<text top="686" left="794" width="123" height="18" font="5">• Benefit for CVD and </text>
<text top="704" left="794" width="109" height="17" font="5">other endpoints not </text>
<text top="722" left="794" width="113" height="17" font="5">different by baseline </text>
<text top="739" left="794" width="138" height="17" font="5">SBP, including &lt;130 mm </text>
<text top="756" left="794" width="94" height="17" font="5">Hg fig 4 in paper </text>
<text top="773" left="794" width="141" height="17" font="5">CVD: 0.63; 95% CI: 0.50–</text>
<text top="267" left="971" width="80" height="18" font="5">• BP-lowering </text>
<text top="285" left="971" width="114" height="17" font="5">significantly reduces </text>
<text top="302" left="971" width="111" height="17" font="5">vascular risk across </text>
<text top="319" left="971" width="112" height="17" font="5">various baseline BP </text>
<text top="337" left="971" width="138" height="17" font="5">levels and comorbidities. </text>
<text top="354" left="971" width="107" height="17" font="5">Our results provide </text>
<text top="371" left="971" width="100" height="17" font="5">strong support for </text>
<text top="388" left="971" width="138" height="17" font="5">lowering BP to SBP&lt;130 </text>
<text top="405" left="971" width="120" height="17" font="5">mm Hg and providing </text>
<text top="423" left="971" width="139" height="17" font="5">BP-lowering treatment to </text>
<text top="440" left="971" width="136" height="17" font="5">individuals with a history </text>
<text top="457" left="971" width="120" height="17" font="5">of CVD, CHD, stroke, </text>
<text top="474" left="971" width="106" height="17" font="5">DM, HF, and CKD. </text>
<text top="492" left="971" width="129" height="18" font="5">• In stratified analyses, </text>
<text top="510" left="971" width="99" height="17" font="5">we saw no strong </text>
<text top="527" left="971" width="76" height="17" font="5">evidence that </text>
<text top="544" left="971" width="138" height="17" font="5">proportional effects were </text>
<text top="561" left="971" width="128" height="17" font="5">diminished in trials that </text>
<text top="579" left="971" width="115" height="17" font="5">included people with </text>
<text top="596" left="971" width="110" height="17" font="5">lower baseline SBP </text>
<text top="613" left="971" width="110" height="17" font="5">(&lt;130 mm Hg), and </text>
<text top="630" left="971" width="124" height="17" font="5">major CV events were </text>
<text top="648" left="971" width="127" height="17" font="5">clearly reduced in high-</text>
<text top="665" left="971" width="110" height="17" font="5">risk pts with various </text>
<text top="682" left="971" width="128" height="17" font="5">baseline comorbidities. </text>
<text top="699" left="971" width="110" height="17" font="5">Both of these major </text>
<text top="716" left="971" width="134" height="17" font="5">findings—the efficacy of </text>
<text top="734" left="971" width="129" height="17" font="5">BP-lowering below 130 </text>
<text top="751" left="971" width="126" height="17" font="5">mm Hg and the similar </text>
<text top="768" left="971" width="121" height="17" font="5">proportional effects in </text>
</page>
<page number="237" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="90" left="794" width="72" height="17" font="5">0.80; p=0.22 </text>
<text top="108" left="794" width="142" height="17" font="5">CHD: 0.55; 95% CI: 0.42–</text>
<text top="125" left="794" width="72" height="17" font="5">0.72; p=0.93 </text>
<text top="142" left="794" width="151" height="17" font="5">Stroke: 0.65; 95% CI: 0.27–</text>
<text top="159" left="794" width="72" height="17" font="5">1.57; p=0.38 </text>
<text top="177" left="794" width="132" height="17" font="5">HF: 0.83; 95% CI: 0.41–</text>
<text top="194" left="794" width="72" height="17" font="5">1.70; p=0.27 </text>
<text top="211" left="794" width="152" height="17" font="5">Total deaths: 0.53; 95% CI: </text>
<text top="229" left="794" width="103" height="17" font="5">0.37–0.76; p=0.79 </text>
<text top="246" left="794" width="94" height="18" font="5">• More precision </text>
<text top="264" left="794" width="111" height="17" font="5">around estimates of </text>
<text top="281" left="794" width="115" height="17" font="5">benefits in SBP 130–</text>
<text top="298" left="794" width="130" height="17" font="5">139 at baseline, fig 4 in </text>
<text top="315" left="794" width="35" height="17" font="5">paper </text>
<text top="332" left="794" width="106" height="18" font="5">• Results similar in </text>
<text top="350" left="794" width="108" height="17" font="5">trials of people with </text>
<text top="368" left="794" width="109" height="17" font="5">and without CVD at </text>
<text top="385" left="794" width="93" height="17" font="5">baseline figure 5 </text>
<text top="403" left="794" width="146" height="17" font="5">CVD+ 0.77 (95% CI: 0.71–</text>
<text top="421" left="794" width="31" height="17" font="5">0.81) </text>
<text top="438" left="794" width="143" height="17" font="5">CVD- 0.74 (95% CI: 0.67–</text>
<text top="455" left="794" width="31" height="17" font="5">0.83) </text>
<text top="472" left="794" width="71" height="17" font="5">Total deaths </text>
<text top="490" left="794" width="146" height="17" font="5">CVD+ 0.90 (95% CI: 0.83–</text>
<text top="507" left="794" width="31" height="17" font="5">0.98) </text>
<text top="524" left="794" width="143" height="17" font="5">CVD- 0.84 (95% CI: 0.75–</text>
<text top="541" left="794" width="31" height="17" font="5">0.93) </text>
<text top="558" left="794" width="151" height="17" font="5">Other outcomes similarly in </text>
<text top="576" left="794" width="44" height="17" font="5">figure 5 </text>
<text top="593" left="794" width="141" height="18" font="5">• In appendix, in general, </text>
<text top="611" left="794" width="93" height="17" font="5">benefits for CVD </text>
<text top="629" left="794" width="145" height="17" font="5">prevention seen in groups </text>
<text top="646" left="794" width="141" height="17" font="5">with and without baseline </text>
<text top="663" left="794" width="131" height="17" font="5">CHD, Stroke, DM, CKD </text>
<text top="680" left="794" width="133" height="17" font="5">and HF when examined </text>
<text top="698" left="794" width="101" height="17" font="5">separately, but no </text>
<text top="715" left="794" width="143" height="17" font="5">absolute risks provided to </text>
<text top="732" left="794" width="139" height="17" font="5">enable estimation of how </text>
<text top="749" left="794" width="143" height="17" font="5">far down the absolute risk </text>
<text top="766" left="794" width="143" height="17" font="5">curve these findings have </text>
<text top="91" left="971" width="124" height="17" font="5">high risk populations—</text>
<text top="108" left="971" width="129" height="17" font="5">are consistent with and </text>
<text top="125" left="971" width="141" height="17" font="5">extend the findings of the </text>
<text top="142" left="971" width="75" height="17" font="5">SPRINT trial. </text>
<text top="160" left="962" width="3" height="17" font="5"> </text>
<text top="178" left="970" width="66" height="17" font="5">Limitations: </text>
<text top="195" left="971" width="130" height="18" font="5">• Lack  of  individual  pt </text>
<text top="213" left="971" width="130" height="17" font="5">data, which would have </text>
<text top="230" left="971" width="130" height="17" font="5">allowed a more reliable </text>
<text top="247" left="971" width="69" height="17" font="5">assessment </text>
<text top="247" left="1087" width="14" height="17" font="5">of </text>
<text top="265" left="971" width="130" height="17" font="5">treatment  effects  in </text>
<text top="282" left="971" width="106" height="17" font="5">different pt groups. </text>
<text top="299" left="971" width="142" height="17" font="5">Interpretation:  Lowering </text>
<text top="316" left="971" width="142" height="17" font="5">of BP into what has been </text>
<text top="333" left="971" width="53" height="17" font="5">regarded </text>
<text top="333" left="1092" width="20" height="17" font="5">the </text>
<text top="350" left="971" width="77" height="17" font="5">normotensive </text>
<text top="350" left="1078" width="35" height="17" font="5">range </text>
<text top="367" left="971" width="142" height="17" font="5">should  therefore  be </text>
<text top="384" left="971" width="142" height="17" font="5">routinely  considered  for </text>
<text top="401" left="971" width="142" height="17" font="5">the  prevention  of  CVD </text>
<text top="418" left="971" width="142" height="17" font="5">among  those  deemed  to </text>
<text top="435" left="971" width="142" height="17" font="5">be  of  sufficient  absolute </text>
<text top="452" left="971" width="26" height="17" font="5">risk. </text>
</page>
<page number="238" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="113" height="17" font="5">been demonstrated. </text>
<text top="108" left="794" width="112" height="18" font="5">• Some evidence of </text>
<text top="126" left="794" width="118" height="17" font="5">BB inferiority to other </text>
<text top="144" left="794" width="119" height="17" font="5">med classes in figure </text>
<text top="161" left="794" width="14" height="17" font="5">6. </text>
<text top="178" left="794" width="128" height="17" font="5">Did not report absolute </text>
<text top="197" left="794" width="148" height="17" font="5">risks so do not know lower </text>
<text top="215" left="794" width="120" height="17" font="5">level of risk in treated </text>
<text top="233" left="794" width="70" height="17" font="5">populations. </text>
<text top="252" left="83" width="76" height="17" font="5">Sundstrom J, </text>
<text top="269" left="83" width="87" height="17" font="5">BPLTTC, et al., </text>
<text top="286" left="83" width="31" height="17" font="5">2014 </text>
<text top="303" left="83" width="32" height="17" font="5">(112) </text>
<text top="320" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25131978?dopt=Citation">25131978</a></text>
<text top="320" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25131978?dopt=Citation"> </a></text>
<text top="252" left="220" width="100" height="17" font="5">Aim: We aimed to </text>
<text top="269" left="220" width="109" height="17" font="5">investigate whether </text>
<text top="286" left="220" width="105" height="17" font="5">the benefits of BP- </text>
<text top="303" left="220" width="104" height="17" font="5">lowering drugs are </text>
<text top="321" left="220" width="82" height="17" font="5">proportional to </text>
<text top="338" left="220" width="109" height="17" font="5">baseline CV risk, to </text>
<text top="355" left="220" width="99" height="17" font="5">establish whether </text>
<text top="372" left="220" width="122" height="17" font="5">absolute risk could be </text>
<text top="389" left="220" width="81" height="17" font="5">used to inform </text>
<text top="407" left="220" width="110" height="17" font="5">treatment decisions </text>
<text top="424" left="220" width="87" height="17" font="5">for BP-lowering </text>
<text top="441" left="220" width="76" height="17" font="5">therapy, as is </text>
<text top="458" left="220" width="100" height="17" font="5">recommended for </text>
<text top="475" left="220" width="123" height="17" font="5">lipid-lowering therapy. </text>
<text top="493" left="212" width="3" height="17" font="5"> </text>
<text top="511" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="528" left="220" width="96" height="17" font="5">analysis of RCTs </text>
<text top="545" left="212" width="3" height="17" font="5"> </text>
<text top="562" left="220" width="101" height="17" font="5">Size: 11 trials and </text>
<text top="579" left="220" width="85" height="17" font="5">26 randomized </text>
<text top="597" left="220" width="107" height="17" font="5">groups with 67,475 </text>
<text top="614" left="220" width="20" height="17" font="5">pts </text>
<text top="631" left="220" width="92" height="17" font="5">(51,917 pts data </text>
<text top="648" left="220" width="90" height="17" font="5">available for the </text>
<text top="665" left="220" width="118" height="17" font="5">calculation of the risk </text>
<text top="683" left="220" width="61" height="17" font="5">equations) </text>
<text top="700" left="220" width="3" height="17" font="5"> </text>
<text top="717" left="220" width="3" height="17" font="5"> </text>
<text top="252" left="373" width="209" height="17" font="5">Inclusion criteria: BPLTTC: trials were </text>
<text top="269" left="373" width="165" height="17" font="5">eligible if they met the original </text>
<text top="286" left="373" width="177" height="17" font="5">inclusion criteria specified in the </text>
<text top="303" left="373" width="180" height="17" font="5">protocol, 11 and were part of the </text>
<text top="321" left="373" width="174" height="17" font="5">subset of studies that randomly </text>
<text top="338" left="373" width="200" height="17" font="5">allocated pts to either a BP-lowering </text>
<text top="355" left="373" width="162" height="17" font="5">drug or placebo, or to a more </text>
<text top="372" left="373" width="163" height="17" font="5">intensive or less intensive BP </text>
<text top="389" left="373" width="163" height="17" font="5">regimen. Trials had to have a </text>
<text top="407" left="373" width="186" height="17" font="5">minimum of 1,000 pt-y of planned </text>
<text top="424" left="373" width="202" height="17" font="5">follow-up in each randomized group, </text>
<text top="441" left="373" width="200" height="17" font="5">and should not have presented their </text>
<text top="458" left="373" width="201" height="17" font="5">main results before the protocol was </text>
<text top="475" left="373" width="125" height="17" font="5">finalized in July, 1995. </text>
<text top="493" left="365" width="3" height="17" font="5"> </text>
<text top="510" left="373" width="159" height="17" font="5">Exclusion criteria: Not stated </text>
<text top="252" left="619" width="91" height="17" font="5">Intervention: BP-</text>
<text top="269" left="619" width="83" height="17" font="5">lowering meds </text>
<text top="287" left="611" width="3" height="17" font="5"> </text>
<text top="304" left="619" width="119" height="17" font="5">Comparator: Placebo </text>
<text top="321" left="619" width="91" height="17" font="5">or less intensive </text>
<text top="338" left="619" width="55" height="17" font="5">treatment </text>
<text top="252" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="270" left="794" width="95" height="18" font="5">• Total major CV </text>
<text top="288" left="794" width="115" height="17" font="5">events, consisting of </text>
<text top="305" left="794" width="125" height="17" font="5">stroke (nonfatal stroke </text>
<text top="323" left="794" width="76" height="17" font="5">or death from </text>
<text top="340" left="794" width="91" height="17" font="5">cerebrovascular </text>
<text top="357" left="794" width="134" height="17" font="5">disease), CHD (nonfatal </text>
<text top="374" left="794" width="124" height="17" font="5">MI or death from CHD </text>
<text top="391" left="794" width="137" height="17" font="5">including sudden death), </text>
<text top="409" left="794" width="135" height="17" font="5">HF (resulting in death or </text>
<text top="426" left="794" width="140" height="17" font="5">admission to hospital), or </text>
<text top="443" left="794" width="77" height="17" font="5">CV morbidity. </text>
<text top="460" left="794" width="126" height="18" font="5">• The mean estimated </text>
<text top="478" left="794" width="139" height="17" font="5">baseline levels of 5-y CV </text>
<text top="496" left="794" width="137" height="17" font="5">risk for each of the 4 risk </text>
<text top="513" left="794" width="130" height="17" font="5">groups were 6.0% (SD: </text>
<text top="530" left="794" width="143" height="17" font="5">2–0), 12.1% (1–5), 17.7% </text>
<text top="547" left="794" width="133" height="17" font="5">(1–7), and 26.8% (5–4). </text>
<text top="565" left="794" width="122" height="18" font="5">• In each consecutive </text>
<text top="583" left="794" width="119" height="17" font="5">higher risk group, BP-</text>
<text top="600" left="794" width="104" height="17" font="5">lowering treatment </text>
<text top="617" left="794" width="125" height="17" font="5">reduced the risk of CV </text>
<text top="634" left="794" width="136" height="17" font="5">events relatively by 18% </text>
<text top="652" left="794" width="117" height="17" font="5">(95% CI: 7–27), 15% </text>
<text top="669" left="794" width="117" height="17" font="5">(95% CI: 4–25), 13% </text>
<text top="686" left="794" width="141" height="17" font="5">(95% CI: 2–22), and 15% </text>
<text top="703" left="794" width="93" height="17" font="5">(95% CI: 5– 24), </text>
<text top="721" left="794" width="132" height="17" font="5">respectively (p=0·30 for </text>
<text top="738" left="794" width="139" height="17" font="5">trend) in each group with </text>
<text top="755" left="794" width="143" height="17" font="5">BP-lowering treatment for </text>
<text top="772" left="794" width="117" height="17" font="5">5 y would prevent 14 </text>
<text top="251" left="971" width="59" height="17" font="5">Summary: </text>
<text top="269" left="971" width="133" height="18" font="5">• Lowering BP provides </text>
<text top="287" left="971" width="139" height="17" font="5">similar relative protection </text>
<text top="304" left="971" width="127" height="17" font="5">at all levels of baseline </text>
<text top="321" left="971" width="67" height="17" font="5">CV risk, but </text>
<text top="339" left="971" width="118" height="17" font="5">progressively greater </text>
<text top="356" left="971" width="132" height="17" font="5">absolute risk reductions </text>
<text top="373" left="971" width="88" height="17" font="5">as baseline risk </text>
<text top="390" left="971" width="137" height="17" font="5">increases. These results </text>
<text top="407" left="971" width="102" height="17" font="5">support the use of </text>
<text top="425" left="971" width="132" height="17" font="5">predicted baseline CVD </text>
<text top="442" left="971" width="130" height="17" font="5">risk equations to inform </text>
<text top="459" left="971" width="125" height="17" font="5">BP-lowering treatment </text>
<text top="476" left="971" width="58" height="17" font="5">decisions. </text>
<text top="493" left="971" width="142" height="17" font="5">Lowest  risk  group  had </text>
<text top="510" left="971" width="142" height="17" font="5">&gt;83%  with  a  risk  that </text>
<text top="527" left="971" width="73" height="17" font="5">exceeds 4%. </text>
</page>
<page number="239" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="139" height="17" font="5">(95% CI: 8–21), 20 (95% </text>
<text top="108" left="794" width="139" height="17" font="5">CI: 8–31), 24 (95% CI: 8–</text>
<text top="125" left="794" width="97" height="17" font="5">40), and 38 (95% </text>
<text top="143" left="794" width="124" height="17" font="5">CI: 16–61) CV events, </text>
<text top="161" left="794" width="131" height="17" font="5">respectively (p=0.04 for </text>
<text top="180" left="794" width="39" height="17" font="5">trend). </text>
<text top="198" left="83" width="89" height="17" font="5">Sundstrom J, et </text>
<text top="215" left="83" width="76" height="17" font="5">al., 2015 (19) </text>
<text top="232" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531552?dopt=Citation">25531552</a></text>
<text top="232" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25531552?dopt=Citation"> </a></text>
<text top="198" left="220" width="108" height="17" font="5">Aim: To investigate </text>
<text top="215" left="220" width="47" height="17" font="5">whether </text>
<text top="232" left="220" width="103" height="17" font="5">pharmacologic BP </text>
<text top="249" left="220" width="104" height="17" font="5">reduction prevents </text>
<text top="267" left="220" width="21" height="17" font="5">CV </text>
<text top="284" left="220" width="117" height="17" font="5">events and deaths in </text>
<text top="301" left="220" width="122" height="17" font="5">pts with grade 1 HTN. </text>
<text top="318" left="220" width="3" height="17" font="5"> </text>
<text top="336" left="220" width="65" height="17" font="5">Study type: </text>
<text top="353" left="220" width="83" height="17" font="5">Meta- analysis </text>
<text top="370" left="220" width="49" height="17" font="5">of RCTs </text>
<text top="388" left="212" width="3" height="17" font="5"> </text>
<text top="405" left="220" width="108" height="17" font="5">Size: 10 RTCs with </text>
<text top="422" left="220" width="61" height="17" font="5">15,266 pts </text>
<text top="198" left="373" width="207" height="17" font="5">Inclusion criteria: RCTs of at least 1 y </text>
<text top="215" left="373" width="194" height="17" font="5">duration; pts ≥18 y, at least 80% of </text>
<text top="232" left="373" width="175" height="17" font="5">whom had grade 1 HTN and no </text>
<text top="249" left="373" width="79" height="17" font="5">previous CVD </text>
<text top="267" left="373" width="184" height="17" font="5">(MI, angina pectoris, CABG, PCI, </text>
<text top="284" left="373" width="154" height="17" font="5">stroke, TIA, carotid surgery, </text>
<text top="301" left="373" width="211" height="17" font="5">peripheral arterial surgery, intermittent </text>
<text top="318" left="373" width="185" height="17" font="5">claudication, or renal failure); and </text>
<text top="336" left="373" width="196" height="17" font="5">compared an antihypertensive drug </text>
<text top="353" left="373" width="167" height="17" font="5">provided as monotherapy or a </text>
<text top="370" left="373" width="209" height="17" font="5">stepped-care algorithm vs. placebo or </text>
<text top="387" left="373" width="137" height="17" font="5">another control regimen. </text>
<text top="404" left="373" width="3" height="17" font="5"> </text>
<text top="421" left="373" width="223" height="17" font="5">Exclusion criteria: Excluded trials did not </text>
<text top="438" left="373" width="183" height="17" font="5">contribute an event for any of the </text>
<text top="455" left="373" width="118" height="17" font="5">outcomes of interest. </text>
<text top="198" left="619" width="24" height="17" font="5">N/A </text>
<text top="198" left="794" width="133" height="17" font="5">1  endpoint: Total major </text>
<text top="215" left="794" width="126" height="17" font="5">CV events, comprising </text>
<text top="232" left="794" width="139" height="17" font="5">stroke (nonfatal stroke or </text>
<text top="249" left="794" width="62" height="17" font="5">death from </text>
<text top="266" left="794" width="144" height="17" font="5">cerebrovascular disease), </text>
<text top="283" left="794" width="91" height="17" font="5">coronary events </text>
<text top="300" left="794" width="117" height="17" font="5">(nonfatal MI or death </text>
<text top="317" left="794" width="113" height="17" font="5">from CHD, including </text>
<text top="334" left="794" width="105" height="17" font="5">sudden death), HF </text>
<text top="351" left="794" width="98" height="17" font="5">(causing death or </text>
<text top="369" left="794" width="63" height="17" font="5">resulting in </text>
<text top="386" left="794" width="124" height="17" font="5">hospitalization), or CV </text>
<text top="403" left="794" width="122" height="17" font="5">death; OR: 0.86 (95% </text>
<text top="420" left="794" width="81" height="17" font="5">CI: 0.74–1.01) </text>
<text top="438" left="794" width="3" height="17" font="5"> </text>
<text top="456" left="794" width="94" height="17" font="5">Other endpoints: </text>
<text top="474" left="794" width="102" height="17" font="5">Each of the above </text>
<text top="492" left="794" width="140" height="17" font="5">outcomes independently; </text>
<text top="510" left="794" width="94" height="17" font="5">and total deaths. </text>
<text top="528" left="794" width="3" height="17" font="5"> </text>
<text top="546" left="794" width="139" height="17" font="5">CHD 0.91 (95% CI: 0.74–</text>
<text top="563" left="794" width="31" height="17" font="5">1.12) </text>
<text top="580" left="794" width="148" height="17" font="5">Stroke 0.72 (95% CI: 0.55–</text>
<text top="597" left="794" width="31" height="17" font="5">0.99) </text>
<text top="615" left="794" width="129" height="17" font="5">HF 0.80 (95% CI: 0.57–</text>
<text top="632" left="794" width="31" height="17" font="5">1.12) </text>
<text top="649" left="794" width="148" height="17" font="5">CVD deaths 0.75 (95% CI: </text>
<text top="667" left="794" width="62" height="17" font="5">0.57–0.98) </text>
<text top="684" left="794" width="149" height="17" font="5">Total deaths 0.78 (95% CI: </text>
<text top="703" left="794" width="62" height="17" font="5">0.67–0.92) </text>
<text top="721" left="794" width="3" height="17" font="5"> </text>
<text top="746" left="794" width="134" height="17" font="5">Only the first event for a </text>
<text top="764" left="794" width="107" height="17" font="5">pt was used for the </text>
<text top="196" left="968" width="137" height="18" font="5">• BP-lowering therapy is </text>
<text top="214" left="978" width="126" height="17" font="5">likely to prevent stroke </text>
<text top="231" left="978" width="116" height="17" font="5">and death in pts with </text>
<text top="248" left="978" width="128" height="17" font="5">uncomplicated grade 1 </text>
<text top="265" left="978" width="32" height="17" font="5">HTN. </text>
<text top="283" left="971" width="142" height="17" font="5">5  y  risks  in  BPLTTC </text>
<text top="299" left="971" width="142" height="17" font="5">control  groups  CVD </text>
<text top="317" left="971" width="142" height="17" font="5">events 7.4%, CVD deaths </text>
<text top="333" left="971" width="31" height="17" font="5">3.1% </text>
</page>
<page number="240" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="91" height="17" font="5">analysis of each </text>
<text top="108" left="794" width="124" height="17" font="5">outcome, but a pt who </text>
<text top="125" left="794" width="119" height="17" font="5">had &gt;1 outcome type </text>
<text top="142" left="794" width="135" height="17" font="5">could contribute to more </text>
<text top="160" left="794" width="38" height="17" font="5">than 1 </text>
<text top="177" left="794" width="108" height="17" font="5">analysis. They also </text>
<text top="196" left="794" width="94" height="17" font="5">tabulated overall </text>
<text top="214" left="794" width="91" height="17" font="5">withdrawals and </text>
<text top="232" left="794" width="152" height="17" font="5">withdrawals due to adverse </text>
<text top="250" left="794" width="43" height="17" font="5">events. </text>
<text top="269" left="83" width="70" height="17" font="5">Xie X, et al., </text>
<text top="286" left="83" width="56" height="17" font="5">2015 (21) </text>
<text top="303" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation">26559744</a></text>
<text top="303" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26559744?dopt=Citation"> </a></text>
<text top="269" left="220" width="108" height="17" font="5">Aim: To assess the </text>
<text top="286" left="220" width="119" height="17" font="5">efficacy and safety of </text>
<text top="303" left="220" width="72" height="17" font="5">intensive BP-</text>
<text top="320" left="220" width="109" height="17" font="5">lowering strategies. </text>
<text top="338" left="212" width="3" height="17" font="5"> </text>
<text top="355" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="373" left="220" width="96" height="17" font="5">analysis of RCTs </text>
<text top="390" left="212" width="3" height="17" font="5"> </text>
<text top="407" left="220" width="108" height="17" font="5">Size: 19 RCTs with </text>
<text top="424" left="220" width="61" height="17" font="5">44,989 pts </text>
<text top="269" left="373" width="209" height="17" font="5">Inclusion criteria: RCTs with at least 6 </text>
<text top="286" left="373" width="204" height="17" font="5">mo follow-up that randomly assigned </text>
<text top="303" left="373" width="213" height="17" font="5">pts to more intensive vs. less intensive </text>
<text top="320" left="373" width="205" height="17" font="5">BP- lowering treatment, with different </text>
<text top="338" left="373" width="193" height="17" font="5">BP targets or different BP changes </text>
<text top="355" left="373" width="81" height="17" font="5">from baseline. </text>
<text top="372" left="373" width="195" height="17" font="5">Reference lists from identified trials </text>
<text top="389" left="373" width="188" height="17" font="5">and review articles were manually </text>
<text top="406" left="373" width="208" height="17" font="5">scanned to identify any other relevant </text>
<text top="424" left="373" width="46" height="17" font="5">studies. </text>
<text top="441" left="373" width="3" height="17" font="5"> </text>
<text top="458" left="373" width="124" height="17" font="5">Exclusion criteria: N/A </text>
<text top="269" left="619" width="91" height="17" font="5">Intervention: BP-</text>
<text top="286" left="619" width="83" height="17" font="5">lowering meds </text>
<text top="304" left="611" width="3" height="17" font="5"> </text>
<text top="321" left="619" width="72" height="17" font="5">Comparator: </text>
<text top="338" left="619" width="146" height="18" font="5">• Less intensive treatment </text>
<text top="356" left="619" width="128" height="18" font="5">• BP difference 6.8/3.5 </text>
<text top="375" left="619" width="136" height="18" font="5">• The  mean  follow-up </text>
<text top="393" left="619" width="136" height="17" font="5">BP  levels  in  the  less </text>
<text top="411" left="619" width="122" height="17" font="5">intensive BP-lowering </text>
<text top="428" left="619" width="113" height="17" font="5">regimen group were </text>
<text top="445" left="619" width="87" height="17" font="5">140/81 mm Hg, </text>
<text top="462" left="619" width="124" height="17" font="5">compared with 133/76 </text>
<text top="479" left="619" width="108" height="17" font="5">mm Hg in the more </text>
<text top="497" left="619" width="107" height="17" font="5">intensive treatment </text>
<text top="514" left="619" width="38" height="17" font="5">group. </text>
<text top="269" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="287" left="794" width="129" height="18" font="5">• CVD, other major CV </text>
<text top="305" left="794" width="134" height="17" font="5">events, defined as a MI, </text>
<text top="323" left="794" width="136" height="17" font="5">stroke, HF, or CV death, </text>
<text top="340" left="794" width="144" height="17" font="5">separately and combined; </text>
<text top="357" left="794" width="110" height="17" font="5">nonvascular and all-</text>
<text top="374" left="794" width="130" height="17" font="5">cause mortality; ESKD, </text>
<text top="391" left="794" width="114" height="17" font="5">and adverse events. </text>
<text top="409" left="794" width="83" height="17" font="5">Progression of </text>
<text top="426" left="794" width="131" height="17" font="5">albuminuria (defined as </text>
<text top="443" left="794" width="111" height="17" font="5">new onset of micro- </text>
<text top="460" left="794" width="105" height="17" font="5">albuminuria/macro-</text>
<text top="477" left="794" width="135" height="17" font="5">albuminuria or a change </text>
<text top="495" left="794" width="129" height="17" font="5">from micro-albuminuria </text>
<text top="512" left="794" width="123" height="17" font="5">to macro-albuminuria) </text>
<text top="529" left="794" width="88" height="17" font="5">and retinopathy </text>
<text top="546" left="794" width="68" height="17" font="5">(retinopathy </text>
<text top="563" left="794" width="137" height="17" font="5">progression of 2 or more </text>
<text top="580" left="794" width="145" height="17" font="5">steps) were also recorded </text>
<text top="597" left="794" width="145" height="17" font="5">for trials that were done in </text>
<text top="614" left="794" width="68" height="17" font="5">pts with DM </text>
<text top="631" left="794" width="140" height="17" font="5">• CVD RR: 0.86 (95% CI: </text>
<text top="648" left="794" width="66" height="17" font="5">0.78– 0.96) </text>
<text top="665" left="794" width="3" height="17" font="5"> </text>
<text top="682" left="794" width="94" height="17" font="5">Other endpoints: </text>
<text top="699" left="794" width="120" height="17" font="5">MI RR: 0.87 (95% CI: </text>
<text top="716" left="794" width="114" height="17" font="5">0.76–1.00; p=0.042) </text>
<text top="733" left="794" width="142" height="17" font="5">Stroke RR: 0.78 (95% CI: </text>
<text top="750" left="794" width="62" height="17" font="5">0.68–0.90) </text>
<text top="767" left="794" width="123" height="17" font="5">HF RR: 0.85 (95% CI: </text>
<text top="269" left="971" width="136" height="17" font="5">Summary: Intensive BP- </text>
<text top="286" left="971" width="118" height="17" font="5">lowering, including to </text>
<text top="303" left="971" width="127" height="17" font="5">&lt;130 mm Hg, provided </text>
<text top="320" left="971" width="92" height="17" font="5">greater vascular </text>
<text top="338" left="971" width="136" height="17" font="5">protection than standard </text>
<text top="355" left="971" width="121" height="17" font="5">regimens. In high-risk </text>
<text top="372" left="971" width="132" height="17" font="5">pts, there are additional </text>
<text top="389" left="971" width="106" height="17" font="5">benefits from more </text>
<text top="406" left="971" width="128" height="17" font="5">intensive BP- lowering, </text>
<text top="424" left="971" width="128" height="17" font="5">including for those with </text>
<text top="441" left="971" width="116" height="17" font="5">SPB &lt;140 mm Hg at </text>
<text top="458" left="971" width="98" height="17" font="5">baseline. The net </text>
<text top="475" left="971" width="110" height="17" font="5">absolute benefits of </text>
<text top="492" left="971" width="138" height="17" font="5">intensive BP- lowering in </text>
<text top="510" left="971" width="132" height="17" font="5">high-risk individuals are </text>
<text top="527" left="971" width="34" height="17" font="5">large. </text>
<text top="545" left="962" width="3" height="17" font="5"> </text>
<text top="562" left="971" width="66" height="17" font="5">Limitations: </text>
<text top="579" left="968" width="121" height="18" font="5">• Lack of individual pt </text>
<text top="598" left="978" width="101" height="17" font="5">data, which would </text>
<text top="615" left="978" width="117" height="17" font="5">have allowed a more </text>
<text top="632" left="978" width="126" height="17" font="5">reliable assessment of </text>
<text top="649" left="978" width="108" height="17" font="5">treatment effects in </text>
<text top="666" left="978" width="106" height="17" font="5">different pt groups. </text>
<text top="684" left="968" width="90" height="18" font="5">• Interpretation: </text>
<text top="702" left="978" width="97" height="17" font="5">Supports treating </text>
<text top="719" left="978" width="104" height="17" font="5">pt with and without </text>
<text top="736" left="978" width="97" height="17" font="5">CVD at threshold </text>
<text top="754" left="978" width="50" height="17" font="5">of 130 to </text>
<text top="771" left="971" width="142" height="17" font="5">&lt;130.  Supports  treating </text>
</page>
<page number="241" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="62" height="17" font="5">0.66–1.11) </text>
<text top="108" left="794" width="115" height="17" font="5">CVD death RR: 0.91 </text>
<text top="125" left="794" width="114" height="17" font="5">(95% CI: 0.74–1.11) </text>
<text top="142" left="794" width="123" height="17" font="5">Total deaths RR: 0.91 </text>
<text top="159" left="794" width="114" height="17" font="5">(95% CI: 0.81–1.03) </text>
<text top="176" left="794" width="3" height="17" font="5"> </text>
<text top="193" left="794" width="77" height="17" font="5">Other results: </text>
<text top="210" left="794" width="113" height="17" font="5">•Benefit for CVD not </text>
<text top="227" left="794" width="142" height="17" font="5">different by baseline SBP </text>
<text top="244" left="794" width="133" height="17" font="5">120–139: 0.89 (95% CI: </text>
<text top="261" left="794" width="62" height="17" font="5">0.76–1.05) </text>
<text top="278" left="794" width="133" height="17" font="5">140–160: 0.83 (95% CI: </text>
<text top="295" left="794" width="62" height="17" font="5">0.68–1.00) </text>
<text top="312" left="794" width="144" height="17" font="5">&gt;160: 0.89 (95% CI: 0.73–</text>
<text top="329" left="794" width="151" height="17" font="5">1.09) p-heterogeneity: 0.60 </text>
<text top="346" left="794" width="137" height="18" font="5">• Benefit  for  CVD  not </text>
<text top="364" left="794" width="48" height="17" font="5">different </text>
<text top="364" left="861" width="18" height="17" font="5">for </text>
<text top="364" left="900" width="31" height="17" font="5">more </text>
<text top="382" left="794" width="52" height="17" font="5">intensive </text>
<text top="382" left="864" width="24" height="17" font="5">and </text>
<text top="382" left="906" width="25" height="17" font="5">less </text>
<text top="399" left="794" width="137" height="17" font="5">intensive  targets  in </text>
<text top="416" left="794" width="87" height="17" font="5">intensive group </text>
<text top="433" left="794" width="150" height="17" font="5">&lt;140 or &lt;150 mm Hg: 0.76 </text>
<text top="450" left="794" width="32" height="17" font="5">(95% </text>
<text top="467" left="794" width="81" height="17" font="5">CI: 0.60–0.97) </text>
<text top="485" left="794" width="143" height="17" font="5">&lt;120– &lt;130 mm Hg: 0.91 </text>
<text top="502" left="794" width="51" height="17" font="5">(95% CI: </text>
<text top="519" left="794" width="66" height="17" font="5">0.84–1.00)  </text>
<text top="536" left="794" width="80" height="17" font="5">p-hetero: 0.06 </text>
<text top="554" left="794" width="108" height="18" font="5">• Absolute benefits </text>
<text top="572" left="794" width="98" height="17" font="5">were proportional </text>
<text top="589" left="794" width="89" height="17" font="5">to absolute risk. </text>
<text top="606" left="794" width="125" height="18" font="5">• For trials in which all </text>
<text top="625" left="794" width="142" height="17" font="5">pts had vascular disease, </text>
<text top="642" left="794" width="130" height="17" font="5">renal disease, or DM at </text>
<text top="659" left="794" width="121" height="17" font="5">baseline, the average </text>
<text top="676" left="794" width="113" height="17" font="5">control group rate of </text>
<text top="694" left="794" width="123" height="17" font="5">major vascular events </text>
<text top="711" left="794" width="88" height="17" font="5">was 2·9% per y </text>
<text top="728" left="794" width="136" height="17" font="5">compared with 0·9% per </text>
<text top="745" left="794" width="131" height="17" font="5">y in other trials, and the </text>
<text top="762" left="794" width="137" height="17" font="5">numbers needed to treat </text>
<text top="91" left="971" width="142" height="17" font="5">at threshold of about 130 </text>
<text top="108" left="971" width="142" height="17" font="5">even  down  to  a  CVD </text>
<text top="125" left="971" width="138" height="17" font="5">event rate of 0.9% per y. </text>
</page>
<page number="242" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="119" height="17" font="5">were 94 (95% CI: 44–</text>
<text top="108" left="794" width="123" height="17" font="5">782) in these trials vs. </text>
<text top="125" left="794" width="134" height="17" font="5">186 (95% CI: 107– 708) </text>
<text top="142" left="794" width="93" height="17" font="5">in all other trials. </text>
<text top="160" left="794" width="114" height="18" font="5">• Increase in severe </text>
<text top="178" left="794" width="124" height="17" font="5">hypotension: 0.3% vs. </text>
<text top="195" left="794" width="128" height="17" font="5">0.1% per person y OR: </text>
<text top="212" left="794" width="141" height="17" font="5">2.68 (95% CI: 1.21–5.89) </text>
<text top="231" left="83" width="49" height="17" font="5">SPRINT </text>
<text top="248" left="83" width="73" height="17" font="5">Wright JT Jr, </text>
<text top="265" left="83" width="64" height="17" font="5">et al., 2015 </text>
<text top="282" left="83" width="32" height="17" font="5">(114) </text>
<text top="300" left="83" width="3" height="17" font="5"> </text>
<text top="317" left="83" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26551272">26551272</a></text>
<text top="317" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26551272"> </a></text>
<text top="231" left="220" width="90" height="17" font="5">Aim: To test the </text>
<text top="248" left="220" width="99" height="17" font="5">effectiveness of a </text>
<text top="265" left="220" width="106" height="17" font="5">goal SBP&lt;120 mm </text>
<text top="282" left="220" width="75" height="17" font="5">Hg vs. a goal </text>
<text top="300" left="220" width="99" height="17" font="5">SBP&lt;140 mm Hg </text>
<text top="317" left="220" width="113" height="17" font="5">for the prevention of </text>
<text top="334" left="220" width="87" height="17" font="5">CVD in pts with </text>
<text top="351" left="220" width="113" height="17" font="5">SBP≥130 mm Hg at </text>
<text top="368" left="220" width="53" height="17" font="5">baseline. </text>
<text top="386" left="220" width="3" height="17" font="5"> </text>
<text top="403" left="220" width="94" height="17" font="5">Study type: RCT </text>
<text top="420" left="212" width="3" height="17" font="5"> </text>
<text top="437" left="220" width="81" height="17" font="5">Size: 9361 pts </text>
<text top="455" left="220" width="106" height="17" font="5">followed median of </text>
<text top="472" left="220" width="40" height="17" font="5">3.26 y. </text>
<text top="489" left="220" width="3" height="17" font="5"> </text>
<text top="231" left="365" width="152" height="17" font="5">Inclusion criteria: SBP≥130 </text>
<text top="248" left="365" width="175" height="17" font="5">mm Hg, with upper limit varying </text>
<text top="265" left="365" width="144" height="17" font="5">as number of pre-trial BP- </text>
<text top="282" left="365" width="143" height="17" font="5">lowering meds increased. </text>
<text top="300" left="365" width="59" height="17" font="5">age ≥50 y </text>
<text top="317" left="365" width="212" height="17" font="5">Presence of at least 1 of the following: </text>
<text top="334" left="365" width="155" height="17" font="5">• Clinical or subclinical CVD </text>
<text top="351" left="365" width="89" height="17" font="5">• CKD stage ≥3 </text>
<text top="368" left="365" width="55" height="17" font="5">• Age≥75 </text>
<text top="386" left="365" width="225" height="17" font="5">• Framingham General CVD risk≥15% in </text>
<text top="403" left="365" width="27" height="17" font="5">10 y </text>
<text top="420" left="365" width="3" height="17" font="5"> </text>
<text top="437" left="373" width="219" height="17" font="5">Exclusion criteria: DM, history of stroke, </text>
<text top="454" left="373" width="106" height="17" font="5">ESRD (eGFR &lt;20) </text>
<text top="231" left="619" width="124" height="17" font="5">Intervention: Intensive </text>
<text top="248" left="619" width="142" height="17" font="5">BP- lowering treatment to </text>
<text top="265" left="619" width="129" height="17" font="5">goal SBP &lt;120 mm Hg </text>
<text top="283" left="611" width="3" height="17" font="5"> </text>
<text top="300" left="619" width="73" height="17" font="5">Comparison: </text>
<text top="318" left="619" width="133" height="18" font="5">• Standard BP-lowering </text>
<text top="336" left="619" width="96" height="17" font="5">treatment to goal </text>
<text top="353" left="619" width="99" height="17" font="5">SBP&lt;140 mm Hg </text>
<text top="370" left="619" width="145" height="18" font="5">• Net treatment difference </text>
<text top="389" left="619" width="97" height="17" font="5">~3 drugs (2.8) on </text>
<text top="406" left="619" width="111" height="17" font="5">average vs. 2 drugs </text>
<text top="423" left="619" width="94" height="17" font="5">(1.8) on average </text>
<text top="440" left="619" width="121" height="17" font="5">During the trial, mean </text>
<text top="458" left="619" width="107" height="17" font="5">SBP was 121.5 vs. </text>
<text top="475" left="619" width="38" height="17" font="5">134.6. </text>
<text top="231" left="794" width="124" height="17" font="5">1° endpoint: CVD (MI, </text>
<text top="248" left="794" width="125" height="17" font="5">ACS, stroke, HF, CVD </text>
<text top="265" left="794" width="141" height="17" font="5">death) HR: 0.75 (95% CI: </text>
<text top="282" left="794" width="62" height="17" font="5">0.64, 0.89) </text>
<text top="299" left="794" width="3" height="17" font="5"> </text>
<text top="316" left="794" width="94" height="17" font="5">Other endpoints: </text>
<text top="333" left="794" width="131" height="17" font="5">• Total deaths HR: 0.73 </text>
<text top="350" left="794" width="114" height="17" font="5">(95% CI: 0.60–0.90) </text>
<text top="367" left="794" width="124" height="17" font="5">• 1° or death HR: 0.78 </text>
<text top="384" left="794" width="51" height="17" font="5">(95% CI: </text>
<text top="401" left="794" width="62" height="17" font="5">0.67–0.90) </text>
<text top="418" left="794" width="111" height="17" font="5">• Components of 1° </text>
<text top="435" left="794" width="98" height="17" font="5">composite mostly </text>
<text top="452" left="794" width="121" height="17" font="5">consistent in direction </text>
<text top="469" left="794" width="115" height="17" font="5">other than ACS – no </text>
<text top="486" left="794" width="61" height="17" font="5">difference. </text>
<text top="503" left="794" width="3" height="17" font="5"> </text>
<text top="520" left="794" width="90" height="17" font="5">CKD outcomes: </text>
<text top="537" left="794" width="143" height="17" font="5">• 1° in CKD pts: reduction </text>
<text top="554" left="794" width="144" height="17" font="5">in GFR of ≥50% or ESRD </text>
<text top="571" left="794" width="134" height="17" font="5">HR: 0.89 (95% CI: 0.42, </text>
<text top="588" left="794" width="31" height="17" font="5">1.87) </text>
<text top="605" left="794" width="121" height="17" font="5">• Incident albuminuria </text>
<text top="622" left="794" width="115" height="17" font="5">HR: 0.72 (95% 0.48, </text>
<text top="639" left="794" width="31" height="17" font="5">1.07) </text>
<text top="656" left="794" width="116" height="17" font="5">• In pts without CKD: </text>
<text top="673" left="794" width="132" height="17" font="5">reduction in GFR ≥30% </text>
<text top="690" left="794" width="62" height="17" font="5">and to &lt;60 </text>
<text top="707" left="794" width="141" height="17" font="5">• HR: 3.49 (95% CI: 2.44–</text>
<text top="724" left="794" width="31" height="17" font="5">5.10) </text>
<text top="741" left="794" width="121" height="17" font="5">• Incident albuminuria </text>
<text top="758" left="794" width="52" height="17" font="5">HR: 0.81 </text>
<text top="230" left="971" width="59" height="17" font="5">Summary: </text>
<text top="248" left="971" width="121" height="18" font="5">• More intensive SBP </text>
<text top="266" left="971" width="113" height="17" font="5">lowering to a goal of </text>
<text top="283" left="971" width="99" height="17" font="5">&lt;120 mm Hg with </text>
<text top="301" left="971" width="100" height="17" font="5">achieved mean of </text>
<text top="318" left="971" width="128" height="17" font="5">approximately 121 mm </text>
<text top="335" left="971" width="134" height="17" font="5">Hg resulted in less CVD </text>
<text top="352" left="971" width="132" height="17" font="5">and lower total mortality </text>
<text top="369" left="971" width="77" height="17" font="5">over 3.26 y in </text>
<text top="387" left="971" width="129" height="17" font="5">comparison with a goal </text>
<text top="404" left="971" width="28" height="17" font="5">SBP </text>
<text top="421" left="971" width="98" height="17" font="5">&lt;140 mm Hg and </text>
<text top="438" left="971" width="94" height="17" font="5">achieved SBP of </text>
<text top="456" left="971" width="78" height="17" font="5">~135 mm Hg. </text>
<text top="473" left="971" width="108" height="18" font="5">• There were small </text>
<text top="491" left="971" width="102" height="17" font="5">increases in some </text>
<text top="508" left="971" width="91" height="17" font="5">expected SAEs. </text>
<text top="525" left="971" width="130" height="17" font="5">Perhaps unexpected, a </text>
<text top="543" left="971" width="104" height="17" font="5">sizable increase in </text>
<text top="560" left="971" width="117" height="17" font="5">reduced eGFR in the </text>
<text top="577" left="971" width="113" height="17" font="5">non-CKD group and </text>
<text top="594" left="971" width="116" height="17" font="5">AKI/ARF overall was </text>
<text top="611" left="971" width="139" height="17" font="5">observed in the intensive </text>
<text top="629" left="971" width="86" height="17" font="5">group. While of </text>
<text top="646" left="971" width="124" height="17" font="5">uncertain etiology and </text>
<text top="663" left="971" width="115" height="17" font="5">significance, there is </text>
<text top="680" left="971" width="138" height="17" font="5">speculation this could be </text>
<text top="698" left="971" width="130" height="17" font="5">an acute hemodynamic </text>
<text top="715" left="971" width="127" height="17" font="5">effect, especially given </text>
<text top="732" left="971" width="122" height="17" font="5">the findings regarding </text>
<text top="749" left="971" width="70" height="17" font="5">albuminuria. </text>
<text top="767" left="962" width="3" height="17" font="5"> </text>
</page>
<page number="243" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="114" height="17" font="5">(95% CI: 0.63–1.04) </text>
<text top="108" left="794" width="3" height="17" font="5"> </text>
<text top="125" left="794" width="92" height="17" font="5">Adverse events: </text>
<text top="142" left="794" width="118" height="17" font="5">• SAEs: 1.04; p=0.25 </text>
<text top="159" left="794" width="118" height="17" font="5">• Significant absolute </text>
<text top="176" left="794" width="99" height="17" font="5">increases seen in </text>
<text top="193" left="794" width="104" height="17" font="5">intensive group for </text>
<text top="210" left="794" width="102" height="17" font="5">hypotension (1%), </text>
<text top="227" left="794" width="92" height="17" font="5">syncope (0.6%), </text>
<text top="244" left="794" width="126" height="17" font="5">electrolyte abnormality </text>
<text top="261" left="794" width="43" height="17" font="5">(0.8%), </text>
<text top="278" left="794" width="138" height="17" font="5">acute kidney injury/acute </text>
<text top="295" left="794" width="135" height="17" font="5">renal failure (1.6%) over </text>
<text top="312" left="794" width="94" height="17" font="5">the study period. </text>
<text top="329" left="794" width="116" height="17" font="5">• 1.7% fewer pts had </text>
<text top="348" left="794" width="143" height="17" font="5">orthostatic hypotension in </text>
<text top="366" left="794" width="135" height="17" font="5">intensive group; p=0.01. </text>
<text top="91" left="971" width="142" height="17" font="5">Limitations: Few pts were </text>
<text top="108" left="971" width="142" height="17" font="5">untreated  at  baseline </text>
<text top="125" left="971" width="32" height="17" font="5">~9%, </text>
<text top="125" left="1025" width="16" height="17" font="5">so </text>
<text top="125" left="1064" width="49" height="17" font="5">SPRINT </text>
<text top="142" left="971" width="142" height="17" font="5">provides  little  if  any </text>
<text top="159" left="971" width="39" height="17" font="5">insight </text>
<text top="159" left="1032" width="14" height="17" font="5">at </text>
<text top="159" left="1068" width="45" height="17" font="5">present </text>
<text top="176" left="971" width="142" height="17" font="5">regarding  BP-lowering </text>
<text top="193" left="971" width="142" height="17" font="5">medication  initiation  for </text>
<text top="210" left="971" width="142" height="17" font="5">untreated  people  with </text>
<text top="227" left="971" width="83" height="17" font="5">SBP 130–139. </text>
<text top="384" left="83" width="93" height="17" font="5">Czernichow S et </text>
<text top="401" left="83" width="51" height="17" font="5">al., 2011 </text>
<text top="418" left="83" width="32" height="17" font="5">(121) </text>
<text top="436" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20881867">20881867</a></text>
<text top="436" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20881867"> </a></text>
<text top="384" left="220" width="118" height="17" font="5">Aim: The objective of </text>
<text top="401" left="220" width="123" height="17" font="5">this systematic review </text>
<text top="419" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="436" left="220" width="111" height="17" font="5">was to compare the </text>
<text top="453" left="220" width="116" height="17" font="5">relative reductions in </text>
<text top="470" left="220" width="100" height="17" font="5">risk achieved with </text>
<text top="487" left="220" width="92" height="17" font="5">different starting </text>
<text top="505" left="220" width="96" height="17" font="5">levels of BP (and </text>
<text top="522" left="220" width="117" height="17" font="5">treatment regimens). </text>
<text top="540" left="212" width="3" height="17" font="5"> </text>
<text top="557" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="574" left="220" width="96" height="17" font="5">analysis of RCTs </text>
<text top="592" left="212" width="3" height="17" font="5"> </text>
<text top="610" left="220" width="102" height="17" font="5">Size: 32 trials with </text>
<text top="627" left="220" width="68" height="17" font="5">201,566 pts </text>
<text top="644" left="220" width="45" height="17" font="5">(20,079 </text>
<text top="661" left="220" width="111" height="17" font="5">1° outcome events) </text>
<text top="384" left="373" width="168" height="17" font="5">Inclusion criteria: RCTs of BP- </text>
<text top="401" left="373" width="180" height="17" font="5">lowering (drug vs. control or less </text>
<text top="419" left="373" width="174" height="17" font="5">intensive treatment) or different </text>
<text top="436" left="373" width="214" height="17" font="5">classes of drug therapy that included a </text>
<text top="453" left="373" width="208" height="17" font="5">minimum of 1,000 pt- y of follow-up in </text>
<text top="470" left="373" width="91" height="17" font="5">each study arm. </text>
<text top="487" left="365" width="3" height="17" font="5"> </text>
<text top="504" left="373" width="214" height="17" font="5">Exclusion criteria: &lt;1,000 pt-y of follow-</text>
<text top="521" left="373" width="154" height="17" font="5">up in each treatment group. </text>
<text top="384" left="619" width="91" height="17" font="5">Intervention: BP-</text>
<text top="401" left="619" width="83" height="17" font="5">lowering meds </text>
<text top="419" left="611" width="3" height="17" font="5"> </text>
<text top="437" left="619" width="123" height="17" font="5">Comparator: Placebo, </text>
<text top="454" left="619" width="115" height="17" font="5">active comparator or </text>
<text top="471" left="619" width="133" height="17" font="5">less intensive treatment </text>
<text top="385" left="794" width="68" height="17" font="5">1  endpoint: </text>
<text top="403" left="794" width="143" height="18" font="5">• Major  CVD  events </text>
<text top="421" left="794" width="125" height="17" font="5">(stroke, CHD, and HF. </text>
<text top="438" left="794" width="149" height="17" font="5">No evidence of differences </text>
<text top="457" left="794" width="136" height="17" font="5">in the ratio of risk across </text>
<text top="475" left="794" width="141" height="17" font="5">varying levels of baseline </text>
<text top="493" left="794" width="146" height="17" font="5">BP (with all classes of BP- </text>
<text top="511" left="794" width="126" height="17" font="5">lowering medications). </text>
<text top="384" left="971" width="59" height="17" font="5">Summary: </text>
<text top="401" left="971" width="120" height="18" font="5">• Effectiveness of BP-</text>
<text top="420" left="971" width="119" height="17" font="5">lowering regiments in </text>
<text top="437" left="971" width="119" height="17" font="5">reducing RR of major </text>
<text top="454" left="971" width="119" height="17" font="5">CVD events does not </text>
<text top="471" left="971" width="124" height="17" font="5">seem to be influenced </text>
<text top="489" left="971" width="126" height="17" font="5">by starting level of BP. </text>
<text top="507" left="962" width="3" height="17" font="5"> </text>
<text top="524" left="971" width="66" height="17" font="5">Limitations: </text>
<text top="541" left="971" width="115" height="18" font="5">• The majority of the </text>
<text top="559" left="971" width="109" height="17" font="5">participants studied </text>
<text top="577" left="971" width="110" height="17" font="5">were at high risk for </text>
<text top="594" left="971" width="33" height="17" font="5">CVD. </text>
<text top="611" left="971" width="142" height="17" font="5">Information  pertaining  to </text>
<text top="628" left="971" width="142" height="17" font="5">the effect of treatment on </text>
<text top="645" left="971" width="142" height="17" font="5">absolute  risk  was  not </text>
<text top="662" left="971" width="58" height="17" font="5">presented </text>
<text top="662" left="1053" width="13" height="17" font="5">in </text>
<text top="662" left="1090" width="22" height="17" font="5">this </text>
<text top="679" left="971" width="67" height="17" font="5">manuscript. </text>
<text top="694" left="83" width="44" height="17" font="5">REIN-2 </text>
<text top="710" left="83" width="108" height="17" font="5">Ruggeneti P, et al., </text>
<text top="726" left="83" width="63" height="17" font="5">2005 (171) </text>
<text top="743" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15766995?dopt=Citation">15766995</a></text>
<text top="743" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15766995?dopt=Citation"> </a></text>
<text top="695" left="220" width="104" height="17" font="5">Aim: To determine </text>
<text top="710" left="220" width="119" height="17" font="5">whether intensive BP </text>
<text top="726" left="220" width="106" height="17" font="5">control will achieve </text>
<text top="741" left="220" width="121" height="17" font="5">further renoprotection </text>
<text top="756" left="220" width="118" height="17" font="5">(delayed progression </text>
<text top="772" left="220" width="113" height="17" font="5">to ESRD) compared </text>
<text top="695" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="712" left="373" width="151" height="18" font="5">• Adults, age 18–70 y, with </text>
<text top="730" left="373" width="198" height="17" font="5">nondiabetic nephropathy, persistent </text>
<text top="748" left="373" width="201" height="17" font="5">proteinuria (urinary protein excretion </text>
<text top="765" left="373" width="178" height="17" font="5">&gt;1 g/24 h for ≥3 mo) and not on </text>
<text top="695" left="619" width="71" height="17" font="5">Intervention: </text>
<text top="712" left="619" width="113" height="18" font="5">• Intensive: BP goal </text>
<text top="730" left="619" width="91" height="17" font="5">&lt;130/80 mm Hg </text>
<text top="748" left="619" width="117" height="18" font="5">• Conventional: DBP </text>
<text top="766" left="619" width="97" height="17" font="5">goal &lt;90 mm Hg, </text>
<text top="697" left="794" width="67" height="17" font="5">1° endpoint </text>
<text top="715" left="794" width="121" height="18" font="5">• Time to ESRD; over </text>
<text top="734" left="794" width="92" height="17" font="5">36 mo follow-up, </text>
<text top="751" left="794" width="81" height="17" font="5">median 19 mo </text>
<text top="768" left="794" width="121" height="17" font="5">1° outcome: ESRD in </text>
<text top="695" left="971" width="123" height="17" font="5">Limitations: The study </text>
<text top="714" left="971" width="126" height="17" font="5">was stopped at the 1st </text>
<text top="729" left="971" width="106" height="17" font="5">interim analysis for </text>
<text top="744" left="971" width="126" height="17" font="5">futility. Median time 19 </text>
<text top="759" left="971" width="21" height="17" font="5">mo </text>
</page>
<page number="244" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="89" left="220" width="85" height="17" font="5">to standard BP </text>
<text top="104" left="220" width="98" height="17" font="5">control in pts with </text>
<text top="120" left="220" width="43" height="17" font="5">chronic </text>
<text top="135" left="220" width="81" height="17" font="5">nephropathies </text>
<text top="152" left="212" width="3" height="17" font="5"> </text>
<text top="169" left="220" width="65" height="17" font="5">Study type: </text>
<text top="187" left="220" width="106" height="17" font="5">Multicenter RCT of </text>
<text top="204" left="220" width="92" height="17" font="5">pts all placed on </text>
<text top="221" left="220" width="97" height="17" font="5">ACEI (ramipril) at </text>
<text top="238" left="220" width="87" height="17" font="5">maximum dose </text>
<text top="256" left="220" width="111" height="17" font="5">tolerated to achieve </text>
<text top="273" left="220" width="80" height="17" font="5">DBP &lt;90 then </text>
<text top="290" left="220" width="66" height="17" font="5">assigned to </text>
<text top="307" left="220" width="87" height="17" font="5">conventional or </text>
<text top="324" left="220" width="78" height="17" font="5">intensified BP </text>
<text top="342" left="220" width="115" height="17" font="5">control. Add-on drug </text>
<text top="359" left="220" width="112" height="17" font="5">was dihydropyridine </text>
<text top="376" left="220" width="118" height="17" font="5">felodipine 5–10 mg/d </text>
<text top="394" left="212" width="3" height="17" font="5"> </text>
<text top="411" left="220" width="102" height="17" font="5">Size: 335 (median </text>
<text top="428" left="220" width="68" height="17" font="5">time 19 mo) </text>
<text top="91" left="373" width="129" height="17" font="5">ACEIs in previous 6 wk </text>
<text top="108" left="373" width="180" height="18" font="5">• Pts with proteinuria 1–3 g/24 h </text>
<text top="126" left="373" width="86" height="17" font="5">included if CrCl </text>
<text top="147" left="373" width="116" height="17" font="5">&lt;70 mL/min/1.73 m2 </text>
<text top="164" left="373" width="201" height="18" font="5">• For overall population, mean SBP, </text>
<text top="183" left="373" width="43" height="17" font="5">mm Hg </text>
<text top="183" left="416" width="25" height="17" font="15">(SD)</text>
<text top="183" left="441" width="133" height="17" font="5">: Intensive: 137.0 (16.7) </text>
<text top="200" left="373" width="148" height="17" font="5">Conventional: 136.4 (17.0) </text>
<text top="217" left="373" width="202" height="18" font="5">• For overall population, mean DBP, </text>
<text top="235" left="373" width="43" height="17" font="5">mm Hg </text>
<text top="235" left="416" width="25" height="17" font="15">(SD)</text>
<text top="235" left="441" width="119" height="17" font="5">: Intensive: 84.3 (9.0) </text>
<text top="252" left="373" width="141" height="17" font="5">Conventional: 83.9 (10.4) </text>
<text top="270" left="365" width="3" height="17" font="5"> </text>
<text top="287" left="373" width="170" height="17" font="5">Exclusion criteria: Urinary tract </text>
<text top="305" left="373" width="204" height="17" font="5">infection, CHF class III–IV, treatment </text>
<text top="322" left="373" width="162" height="17" font="5">with corticosteroids, NSAIDs, </text>
<text top="339" left="373" width="218" height="17" font="5">immunosuppression, acute MI or stroke </text>
<text top="356" left="373" width="41" height="17" font="5">in prior </text>
<text top="374" left="373" width="177" height="17" font="5">6 mo, severe uncontrolled HTN, </text>
<text top="391" left="373" width="73" height="17" font="5">suspicion for </text>
<text top="408" left="373" width="123" height="17" font="5">renovascular disease, </text>
<text top="425" left="373" width="118" height="17" font="5">obstructive uropathy, </text>
<text top="442" left="373" width="135" height="17" font="5">DM-1, collagen vascular </text>
<text top="460" left="373" width="143" height="17" font="5">disease, cancer, elevated </text>
<text top="477" left="373" width="135" height="17" font="5">aspartate transaminase, </text>
<text top="494" left="373" width="137" height="17" font="5">chronic cough, history of </text>
<text top="511" left="373" width="136" height="17" font="5">allergy or poor tolerance </text>
<text top="528" left="373" width="126" height="17" font="5">to study meds, alcohol </text>
<text top="546" left="373" width="105" height="17" font="5">abuse, pregnancy, </text>
<text top="563" left="373" width="140" height="17" font="5">breastfeeding, ineffective </text>
<text top="580" left="373" width="81" height="17" font="5">contraception. </text>
<text top="91" left="619" width="108" height="17" font="5">irrespective of SBP </text>
<text top="108" left="619" width="81" height="18" font="5">• For baseline </text>
<text top="126" left="619" width="126" height="17" font="5">proteinuria subgroups, </text>
<text top="144" left="619" width="113" height="17" font="5">result BP values NR </text>
<text top="161" left="619" width="92" height="18" font="5">• For the overall </text>
<text top="179" left="619" width="139" height="17" font="5">population, achieved BP, </text>
<text top="196" left="619" width="43" height="17" font="5">mm Hg </text>
<text top="196" left="662" width="25" height="17" font="15">(SD)</text>
<text top="196" left="688" width="3" height="17" font="5"> </text>
<text top="213" left="619" width="117" height="17" font="5">Intensive: 129.6/79.5 </text>
<text top="231" left="619" width="56" height="17" font="5">(10.9/5.3) </text>
<text top="248" left="619" width="140" height="17" font="5">Conventional: 133.7/82.3 </text>
<text top="265" left="619" width="56" height="17" font="5">(12.6/7.1) </text>
<text top="282" left="619" width="103" height="17" font="5">p=0.0019/&lt;0.0001 </text>
<text top="300" left="619" width="92" height="18" font="5">• For the overall </text>
<text top="318" left="619" width="64" height="17" font="5">population, </text>
<text top="335" left="619" width="123" height="17" font="5">change in BP, mm Hg </text>
<text top="352" left="619" width="105" height="17" font="5">Intensive: -7.4/-4.8 </text>
<text top="369" left="619" width="128" height="17" font="5">Conventional: -2.7/-1.6 </text>
<text top="387" left="619" width="35" height="17" font="5">p=NR </text>
<text top="404" left="619" width="92" height="18" font="5">• For the overall </text>
<text top="422" left="619" width="64" height="17" font="5">population, </text>
<text top="439" left="619" width="126" height="17" font="5">BP difference between </text>
<text top="456" left="619" width="129" height="17" font="5">groups, mm Hg 4.1/2.8 </text>
<text top="474" left="619" width="35" height="17" font="5">p=NR </text>
<text top="491" left="619" width="3" height="17" font="5"> </text>
<text top="508" left="619" width="109" height="17" font="5">Comparator: By BP </text>
<text top="525" left="619" width="33" height="17" font="5">goals </text>
<text top="91" left="794" width="94" height="17" font="5">pts with baseline </text>
<text top="108" left="794" width="123" height="17" font="5">proteinuria 1–3 g/24 h </text>
<text top="125" left="794" width="136" height="17" font="5">HR (95% CI): 1.06 (95% </text>
<text top="142" left="794" width="123" height="17" font="5">CI: 0.51–2.20) p=0.89 </text>
<text top="159" left="794" width="155" height="18" font="5">• ESRD in pts with baseline </text>
<text top="179" left="805" width="62" height="17" font="5">proteinuria </text>
<text top="196" left="794" width="55" height="17" font="5">&gt;3 g/24 h </text>
<text top="214" left="794" width="136" height="17" font="5">HR (95% CI): 1.09 (95% </text>
<text top="231" left="794" width="123" height="17" font="5">CI: 0.55–2.19) p=0.81 </text>
<text top="248" left="794" width="128" height="18" font="5">• 23% of intensive and </text>
<text top="266" left="794" width="114" height="17" font="5">20% of conventional </text>
<text top="283" left="794" width="81" height="17" font="5">control groups </text>
<text top="301" left="794" width="120" height="17" font="5">progressed to ESRD. </text>
<text top="318" left="794" width="92" height="18" font="5">• Median rate of </text>
<text top="336" left="794" width="75" height="17" font="5">GFR decline, </text>
<text top="357" left="794" width="112" height="17" font="5">mL/min/1.73 m2/mo </text>
<text top="375" left="794" width="91" height="17" font="5">(IQR) in pts with </text>
<text top="392" left="794" width="111" height="17" font="5">baseline proteinuria </text>
<text top="409" left="794" width="104" height="17" font="5">&lt;3 g/24: Intensive: </text>
<text top="426" left="794" width="109" height="17" font="5">0.18 (95% CI: 0.03–</text>
<text top="443" left="794" width="110" height="17" font="5">0.49) Conventional: </text>
<text top="460" left="794" width="59" height="17" font="5">0.21 (95% </text>
<text top="477" left="794" width="54" height="17" font="5">CI: -0.03–</text>
<text top="494" left="794" width="31" height="17" font="5">0.40) </text>
<text top="512" left="794" width="41" height="17" font="5">p=0.89 </text>
<text top="529" left="794" width="111" height="17" font="5">Median rate of GFR </text>
<text top="547" left="794" width="151" height="17" font="5">decline, mL/min/1.73 m/mo </text>
<text top="566" left="794" width="140" height="17" font="5">(IQR) in pts with baseline </text>
<text top="584" left="794" width="111" height="17" font="5">proteinuria ≥3 g/24: </text>
<text top="602" left="794" width="134" height="17" font="5">Intensive: 0.51; 95% CI: </text>
<text top="620" left="794" width="137" height="17" font="5">0.16–1.05 Conventional: </text>
<text top="639" left="794" width="129" height="17" font="5">0.39; 95% CI: 0.030.98 </text>
<text top="657" left="794" width="41" height="17" font="5">p=0.39 </text>
<text top="91" left="962" width="3" height="17" font="5"> </text>
<text top="108" left="971" width="118" height="17" font="5">Summary: In pts with </text>
<text top="126" left="971" width="108" height="17" font="5">non-DM proteinuric </text>
<text top="143" left="971" width="81" height="17" font="5">nephropathies </text>
<text top="160" left="971" width="120" height="17" font="5">receiving background </text>
<text top="177" left="971" width="97" height="17" font="5">ACEI therapy, no </text>
<text top="194" left="971" width="102" height="17" font="5">additional benefits </text>
<text top="212" left="971" width="87" height="17" font="5">from further BP </text>
<text top="229" left="971" width="70" height="17" font="5">reduction by </text>
<text top="246" left="971" width="106" height="17" font="5">felodipine could be </text>
<text top="263" left="971" width="42" height="17" font="5">shown. </text>
<text top="280" left="971" width="142" height="17" font="5">Dihydropyridine CCBs do </text>
<text top="297" left="971" width="20" height="17" font="5">not </text>
<text top="297" left="1010" width="28" height="17" font="5">offer </text>
<text top="297" left="1057" width="56" height="17" font="5">additional </text>
<text top="314" left="971" width="142" height="17" font="5">renoprotection  to  ACEIs </text>
<text top="331" left="971" width="53" height="17" font="5">or ARBs. </text>
<text top="673" left="83" width="36" height="17" font="5">AASK </text>
<text top="689" left="83" width="93" height="17" font="5">Wright JT, et al., </text>
<text top="704" left="83" width="63" height="17" font="5">2002 (172) </text>
<text top="721" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12435255?dopt=Citation">12435255</a></text>
<text top="721" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12435255?dopt=Citation"> </a></text>
<text top="674" left="220" width="117" height="17" font="5">Aim: To compare the </text>
<text top="689" left="220" width="112" height="17" font="5">effects of 2 levels of </text>
<text top="704" left="220" width="54" height="17" font="5">BP and 3 </text>
<text top="719" left="220" width="121" height="17" font="5">antihypertensive drug </text>
<text top="735" left="220" width="91" height="17" font="5">classes on GFR </text>
<text top="750" left="220" width="84" height="17" font="5">decline in HTN </text>
<text top="765" left="220" width="3" height="17" font="5"> </text>
<text top="673" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="689" left="373" width="222" height="17" font="5">• Adult African- Americans,18–70 y, with </text>
<text top="704" left="373" width="196" height="17" font="5">HTN (DBP ≥95) and GFR of 20–65 </text>
<text top="720" left="373" width="135" height="17" font="5">mL/min/1.73 m2, no DM </text>
<text top="735" left="373" width="171" height="17" font="5">• At entry: mean MAP, mm Hg: </text>
<text top="750" left="373" width="79" height="17" font="5">Low: 115 (27) </text>
<text top="766" left="373" width="88" height="17" font="5">Usual: 113 (15) </text>
<text top="673" left="619" width="71" height="17" font="5">Intervention: </text>
<text top="691" left="619" width="122" height="18" font="5">• Low: MAP goal ≤92 </text>
<text top="709" left="619" width="43" height="17" font="5">mm Hg </text>
<text top="726" left="619" width="126" height="17" font="5">Usual: MAP goal 102– </text>
<text top="743" left="619" width="67" height="17" font="5">107 mm Hg </text>
<text top="761" left="619" width="132" height="18" font="5">• Initial treatment with a </text>
<text top="675" left="794" width="70" height="17" font="5">1° endpoint: </text>
<text top="692" left="794" width="138" height="18" font="5">• 1° outcome: difference </text>
<text top="710" left="794" width="123" height="17" font="5">in mean slopes, acute </text>
<text top="728" left="794" width="137" height="17" font="5">GFR slope, mL/min/1.73 </text>
<text top="749" left="794" width="83" height="17" font="5">m2/3 mo (SE): </text>
<text top="766" left="794" width="73" height="18" font="5">• 1.82 (0.54) </text>
<text top="676" left="971" width="66" height="17" font="5">Limitations: </text>
<text top="694" left="971" width="105" height="18" font="5">• Based on DSMD </text>
<text top="712" left="971" width="98" height="17" font="5">recommendation, </text>
<text top="730" left="971" width="124" height="17" font="5">amlodipine arm halted </text>
<text top="747" left="971" width="107" height="17" font="5">early and those pts </text>
<text top="764" left="971" width="125" height="17" font="5">switched to open label </text>
</page>
<page number="245" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="89" left="220" width="65" height="17" font="5">Study type: </text>
<text top="104" left="220" width="104" height="17" font="5">• Randomized 3×2 </text>
<text top="120" left="220" width="70" height="17" font="5">factorial trial </text>
<text top="135" left="220" width="120" height="17" font="5">• Measured GFR with </text>
<text top="150" left="220" width="67" height="17" font="5">iothalamate </text>
<text top="166" left="220" width="3" height="17" font="5"> </text>
<text top="182" left="220" width="65" height="17" font="5">Size: 1,094 </text>
<text top="89" left="373" width="149" height="17" font="5">• Mean SBP, mm Hg (SD): </text>
<text top="104" left="373" width="75" height="17" font="5">Low:152 (25) </text>
<text top="120" left="373" width="88" height="17" font="5">Usual: 149 (23) </text>
<text top="135" left="373" width="121" height="17" font="5">• Mean DBP, mm Hg: </text>
<text top="151" left="373" width="72" height="17" font="5">Low: 96 (15) </text>
<text top="166" left="373" width="81" height="17" font="5">Usual: 95 (14) </text>
<text top="181" left="373" width="3" height="17" font="5"> </text>
<text top="197" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="212" left="373" width="132" height="17" font="5">DBP&lt;95, history of DM, </text>
<text top="227" left="373" width="141" height="17" font="5">Urinary protein/creatinine </text>
<text top="243" left="373" width="140" height="17" font="5">ratio &gt;2.5, accelerated or </text>
<text top="258" left="373" width="133" height="17" font="5">malignant HTN, non-BP </text>
<text top="274" left="373" width="124" height="17" font="5">related cause of CKD, </text>
<text top="289" left="373" width="144" height="17" font="5">serious systemic disease, </text>
<text top="304" left="373" width="117" height="17" font="5">clinical CHF, specific </text>
<text top="321" left="373" width="220" height="17" font="5">indication or contraindication for a study </text>
<text top="338" left="373" width="101" height="17" font="5">drug or procedure </text>
<text top="91" left="619" width="128" height="17" font="5">B Blocker (metoprolol), </text>
<text top="108" left="619" width="132" height="17" font="5">and ACEI (ramipril) or a </text>
<text top="125" left="619" width="87" height="17" font="5">dihydropyridine </text>
<text top="142" left="619" width="127" height="17" font="5">(amlodipine) with open </text>
<text top="160" left="619" width="121" height="17" font="5">label agents added to </text>
<text top="177" left="619" width="98" height="17" font="5">achieve BP goals </text>
<text top="191" left="619" width="96" height="18" font="5">• Study duration: </text>
<text top="208" left="619" width="44" height="17" font="5">3–6.4 y </text>
<text top="224" left="619" width="137" height="18" font="5">• BP similar across drug </text>
<text top="240" left="619" width="134" height="17" font="5">groups except 2 mm Hg </text>
<text top="255" left="619" width="108" height="17" font="5">lower in amlodipine </text>
<text top="270" left="619" width="35" height="17" font="5">group </text>
<text top="287" left="619" width="117" height="18" font="5">• Mean from 3 mo to </text>
<text top="305" left="619" width="57" height="17" font="5">study end </text>
<text top="323" left="619" width="87" height="18" font="5">• MAP, mm Hg </text>
<text top="324" left="705" width="25" height="17" font="15">(SD)</text>
<text top="324" left="731" width="3" height="17" font="5"> </text>
<text top="341" left="619" width="75" height="17" font="5">Low: 95.8 (8) </text>
<text top="358" left="619" width="81" height="17" font="5">Usual: 104 (7) </text>
<text top="375" left="619" width="113" height="18" font="5">• SBP/DBP, mm Hg </text>
<text top="376" left="732" width="25" height="17" font="15">(SD)</text>
<text top="376" left="757" width="3" height="17" font="5"> </text>
<text top="393" left="619" width="144" height="17" font="5">Low: 128/78 (12/8) Usual: </text>
<text top="411" left="619" width="77" height="17" font="5">141/85 (12/7) </text>
<text top="426" left="619" width="149" height="17" font="5">MAP change, mm Hg Low: </text>
<text top="441" left="619" width="21" height="17" font="5">-20 </text>
<text top="458" left="619" width="53" height="17" font="5">Usual: -9 </text>
<text top="476" left="619" width="138" height="18" font="5">• SBP/DBP change, mm </text>
<text top="494" left="619" width="19" height="17" font="5">Hg </text>
<text top="511" left="619" width="65" height="17" font="5">Low: -24/-8 </text>
<text top="528" left="619" width="81" height="17" font="5">Usual: -18/-10 </text>
<text top="546" left="619" width="118" height="18" font="5">• Achieved mean BP </text>
<text top="564" left="619" width="107" height="17" font="5">difference between </text>
<text top="581" left="619" width="121" height="17" font="5">groups, mm Hg MAP: </text>
<text top="598" left="619" width="17" height="17" font="5">11 </text>
<text top="615" left="619" width="49" height="17" font="5">SBP: 16 </text>
<text top="633" left="619" width="42" height="17" font="5">DBP: 8 </text>
<text top="651" left="611" width="3" height="17" font="5"> </text>
<text top="668" left="619" width="96" height="17" font="5">Comparator: N/A </text>
<text top="91" left="794" width="55" height="17" font="5">in low BP </text>
<text top="108" left="794" width="35" height="17" font="5">group </text>
<text top="125" left="794" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="142" left="794" width="138" height="18" font="5">• 1° outcome: difference </text>
<text top="160" left="794" width="132" height="17" font="5">in mean slopes, chronic </text>
<text top="177" left="794" width="137" height="17" font="5">GFR slope, mL/min/1.73 </text>
<text top="198" left="794" width="124" height="17" font="5">m2/y (SE): 0.21 (0.22) </text>
<text top="215" left="794" width="62" height="17" font="5">p=0.33 NS </text>
<text top="233" left="794" width="117" height="18" font="5">• Difference in mean </text>
<text top="251" left="794" width="134" height="17" font="5">slopes, total GFR slope, </text>
<text top="272" left="794" width="142" height="17" font="5">mL/min/1.73 m2/y (SE):    </text>
<text top="289" left="794" width="112" height="17" font="5">-0.25 (0.22) p=0.24  </text>
<text top="307" left="794" width="95" height="18" font="5">• Main 2º clinical </text>
<text top="325" left="794" width="113" height="17" font="5">composite outcome: </text>
<text top="342" left="794" width="122" height="17" font="5">GFR event, ESRD, or </text>
<text top="359" left="794" width="38" height="17" font="5">death, </text>
<text top="376" left="794" width="146" height="17" font="5">% risk reduction (95% CI): </text>
<text top="393" left="794" width="149" height="17" font="5">2 (95% CI: -22–21) p=0.85 </text>
<text top="411" left="794" width="128" height="18" font="5">• GFR event or ESRD, </text>
<text top="429" left="794" width="121" height="17" font="5">% Risk Reduction: -2; </text>
<text top="446" left="794" width="134" height="17" font="5">95% CI: -31–20; p=0.87 </text>
<text top="463" left="794" width="100" height="18" font="5">• ESRD or death, </text>
<text top="482" left="794" width="115" height="17" font="5">% risk reduction: 12; </text>
<text top="499" left="794" width="92" height="17" font="5">95% CI: -13–32; </text>
<text top="516" left="794" width="41" height="17" font="5">p=0.31 </text>
<text top="533" left="794" width="85" height="18" font="5">• ESRD alone, </text>
<text top="553" left="794" width="155" height="17" font="5">% risk reduction: 6; 95% CI: </text>
<text top="570" left="794" width="87" height="17" font="5">-29–31; p=0.72 </text>
<text top="588" left="794" width="151" height="18" font="5">• 2º outcome: urine protein </text>
<text top="606" left="805" width="53" height="17" font="5">excretion </text>
<text top="624" left="786" width="3" height="17" font="5"> </text>
<text top="641" left="794" width="92" height="17" font="5">Safety endpoint: </text>
<text top="658" left="794" width="114" height="17" font="5">● Acute and chronic </text>
<text top="676" left="794" width="124" height="17" font="5">rate of change in GFR </text>
<text top="693" left="794" width="44" height="17" font="5">(slope): </text>
<text top="710" left="794" width="81" height="17" font="5">NS for chronic </text>
<text top="727" left="794" width="96" height="17" font="5">and total slope in </text>
<text top="745" left="794" width="55" height="17" font="5">subgroup </text>
<text top="762" left="794" width="68" height="17" font="5">analyses by </text>
<text top="91" left="971" width="111" height="17" font="5">Rx, continued study </text>
<text top="108" left="971" width="130" height="17" font="5">schedule and same BP </text>
<text top="125" left="971" width="33" height="17" font="5">goals </text>
<text top="143" left="962" width="3" height="17" font="5"> </text>
<text top="160" left="971" width="59" height="17" font="5">Summary: </text>
<text top="178" left="971" width="100" height="18" font="5">• No difference in </text>
<text top="196" left="971" width="97" height="17" font="5">GFR decline with </text>
<text top="213" left="971" width="120" height="17" font="5">lower BP goal and no </text>
<text top="230" left="971" width="70" height="17" font="5">difference in </text>
<text top="247" left="971" width="100" height="17" font="5">composite clinical </text>
<text top="265" left="971" width="57" height="17" font="5">endpoints </text>
<text top="282" left="971" width="127" height="18" font="5">• Average rate of GFR </text>
<text top="300" left="971" width="118" height="17" font="5">decline 2 mL/min/y is </text>
<text top="317" left="971" width="118" height="17" font="5">similar or slower than </text>
<text top="335" left="971" width="91" height="17" font="5">previous reports </text>
<text top="352" left="971" width="113" height="18" font="5">• There was a trend </text>
<text top="370" left="971" width="120" height="17" font="5">favoring the lower BP </text>
<text top="387" left="971" width="113" height="17" font="5">goal in subjects with </text>
<text top="404" left="971" width="87" height="17" font="5">higher baseline </text>
<text top="422" left="971" width="106" height="17" font="5">proteinuria and the </text>
<text top="439" left="971" width="133" height="17" font="5">opposite trend for those </text>
<text top="456" left="971" width="104" height="17" font="5">without proteinuria </text>
<text top="473" left="971" width="142" height="17" font="5">Ramipril treatment group </text>
<text top="490" left="971" width="142" height="17" font="5">had  slower  progression </text>
<text top="507" left="971" width="58" height="17" font="5">compared </text>
<text top="507" left="1087" width="25" height="17" font="5">with </text>
<text top="524" left="971" width="61" height="17" font="5">metoprolol </text>
<text top="524" left="1089" width="24" height="17" font="5">and </text>
<text top="541" left="971" width="63" height="17" font="5">amlodipine </text>
<text top="541" left="1052" width="60" height="17" font="5">combined, </text>
<text top="558" left="971" width="142" height="17" font="5">less  evident  between </text>
<text top="575" left="971" width="128" height="17" font="5">ramipril and metoprolol </text>
</page>
<page number="246" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="49" height="17" font="5">baseline </text>
<text top="108" left="794" width="96" height="17" font="5">proteinuria strata </text>
<text top="125" left="794" width="143" height="17" font="5">● Acute slope: p=0.08 for </text>
<text top="142" left="794" width="60" height="17" font="5">interaction </text>
<text top="159" left="794" width="139" height="17" font="5">● Total slope: p=0.04 for </text>
<text top="176" left="794" width="60" height="17" font="5">interaction </text>
<text top="194" left="794" width="154" height="17" font="5">● Chronic slope: p=0.16 for </text>
<text top="211" left="794" width="60" height="17" font="5">interaction </text>
<text top="228" left="794" width="115" height="17" font="5">● Clinical composite </text>
<text top="246" left="794" width="102" height="17" font="5">outcome: includes </text>
<text top="263" left="794" width="141" height="17" font="5">reduction in GFR by 50% </text>
<text top="280" left="794" width="113" height="17" font="5">or by 25 mL/min/m², </text>
<text top="297" left="794" width="112" height="17" font="5">ESRD, death, NS in </text>
<text top="314" left="794" width="123" height="17" font="5">subgroup analyses by </text>
<text top="332" left="794" width="111" height="17" font="5">baseline proteinuria </text>
<text top="349" left="794" width="104" height="17" font="5">strata; p=0.007 for </text>
<text top="366" left="794" width="60" height="17" font="5">interaction </text>
<text top="383" left="794" width="131" height="17" font="5">● For above outcomes, </text>
<text top="401" left="794" width="135" height="17" font="5">trends favored the lower </text>
<text top="418" left="794" width="127" height="17" font="5">BP goal over the usual </text>
<text top="435" left="794" width="131" height="17" font="5">goal in participants with </text>
<text top="452" left="794" width="87" height="17" font="5">higher baseline </text>
<text top="469" left="794" width="135" height="17" font="5">proteinuria and opposite </text>
<text top="487" left="794" width="142" height="17" font="5">trends in participants with </text>
<text top="504" left="794" width="118" height="17" font="5">little or no proteinuria </text>
<text top="521" left="794" width="134" height="17" font="5">Within each drug group, </text>
<text top="538" left="794" width="138" height="17" font="5">risk reductions for any 2º </text>
<text top="556" left="794" width="125" height="17" font="5">clinical outcome of the </text>
<text top="573" left="794" width="120" height="17" font="5">low vs. usual BP goal </text>
<text top="590" left="794" width="117" height="17" font="5">were not significantly </text>
<text top="607" left="794" width="117" height="17" font="5">different between pts </text>
<text top="624" left="794" width="105" height="17" font="5">with baseline urine </text>
<text top="642" left="794" width="139" height="17" font="5">protein to creatinine ratio </text>
<text top="659" left="794" width="59" height="17" font="5">≤0.22 and </text>
<text top="677" left="794" width="77" height="17" font="5">&gt;0.22 (p=NS) </text>
<text top="695" left="83" width="65" height="17" font="5">LV J, et al., </text>
<text top="712" left="83" width="63" height="17" font="5">2013 (127) </text>
<text top="730" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459">23798459</a></text>
<text top="730" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23798459"> </a></text>
<text top="695" left="219" width="100" height="17" font="5">Study type: MA of </text>
<text top="712" left="219" width="106" height="17" font="5">RTC that randomly </text>
<text top="730" left="219" width="113" height="17" font="5">assigned individuals </text>
<text top="747" left="219" width="116" height="17" font="5">to different target BP </text>
<text top="764" left="219" width="35" height="17" font="5">levels </text>
<text top="694" left="373" width="24" height="17" font="5">N/A </text>
<text top="695" left="619" width="24" height="17" font="5">N/A </text>
<text top="695" left="794" width="104" height="17" font="5">7.5/4.5 mm Hg BP </text>
<text top="712" left="794" width="133" height="17" font="5">difference. Intensive BP </text>
<text top="730" left="794" width="126" height="17" font="5">lowering achieved. RR </text>
<text top="747" left="794" width="18" height="17" font="5">for </text>
<text top="764" left="794" width="139" height="18" font="5">• Major CV events: 11%; </text>
<text top="695" left="971" width="142" height="17" font="5">More  intensive  strategy </text>
<text top="712" left="971" width="142" height="17" font="5">for  BP  control  reduced </text>
<text top="729" left="971" width="119" height="17" font="5">cardio-renal endpoint </text>
</page>
<page number="247" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="92" left="212" width="3" height="17" font="5"> </text>
<text top="109" left="220" width="112" height="17" font="5">Size: 37,348 pts, 15 </text>
<text top="126" left="220" width="29" height="17" font="5">trials </text>
<text top="92" left="794" width="103" height="17" font="5">95% CI: 1%–21%) </text>
<text top="109" left="794" width="133" height="18" font="5">• MI: 13%; 95% CI: 0%–</text>
<text top="127" left="804" width="28" height="17" font="5">25% </text>
<text top="144" left="794" width="131" height="18" font="5">• Stroke: 24%; 95% CI: </text>
<text top="164" left="804" width="53" height="17" font="5">8%–37% </text>
<text top="181" left="794" width="130" height="18" font="5">• ESRD: 11%; 95% CI: </text>
<text top="201" left="805" width="53" height="17" font="5">3%–18% </text>
<text top="218" left="794" width="141" height="18" font="5">• Albuminuria: 10%; 95% </text>
<text top="237" left="805" width="71" height="17" font="5">CI: 4%–16% </text>
<text top="256" left="794" width="147" height="17" font="5">Retinopathy 19%; 95% CI: </text>
<text top="274" left="794" width="101" height="17" font="5">0%–34% p=0.051 </text>
<text top="292" left="83" width="91" height="17" font="5">Arguedas JA, et </text>
<text top="309" left="83" width="83" height="17" font="5">al., 2013 (244) </text>
<text top="327" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24170669?dopt=Citation">24170669</a></text>
<text top="327" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24170669?dopt=Citation"> </a></text>
<text top="292" left="220" width="114" height="17" font="5">Aim: To determine if </text>
<text top="309" left="220" width="102" height="17" font="5">“lower” BP targets </text>
<text top="326" left="220" width="62" height="17" font="5">(any target </text>
<text top="344" left="220" width="95" height="17" font="5">&lt;130/85 mm Hg) </text>
<text top="361" left="220" width="83" height="17" font="5">are associated </text>
<text top="378" left="220" width="92" height="17" font="5">with reduction in </text>
<text top="395" left="220" width="74" height="17" font="5">mortality and </text>
<text top="413" left="220" width="53" height="17" font="5">morbidity </text>
<text top="430" left="220" width="72" height="17" font="5">compared to </text>
<text top="447" left="220" width="79" height="17" font="5">“standard” BP </text>
<text top="464" left="220" width="83" height="17" font="5">targets (&lt;140– </text>
<text top="481" left="220" width="92" height="17" font="5">160/90–100 mm </text>
<text top="499" left="220" width="23" height="17" font="5">Hg) </text>
<text top="516" left="220" width="84" height="17" font="5">in pts with DM. </text>
<text top="534" left="212" width="3" height="17" font="5"> </text>
<text top="551" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="568" left="220" width="100" height="17" font="5">analysis of RCTs. </text>
<text top="586" left="212" width="3" height="17" font="5"> </text>
<text top="604" left="220" width="76" height="17" font="5">Size: 5 RCTs </text>
<text top="621" left="220" width="104" height="17" font="5">recruiting a total of </text>
<text top="638" left="220" width="54" height="17" font="5">7,314 ps. </text>
<text top="656" left="212" width="3" height="17" font="5"> </text>
<text top="673" left="220" width="111" height="17" font="5">Mean follow-up: 4.5 </text>
<text top="690" left="220" width="10" height="17" font="5">y </text>
<text top="292" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="309" left="373" width="173" height="17" font="5">RCTs in which individuals were </text>
<text top="326" left="373" width="216" height="17" font="5">randomized to a “lower” compared with </text>
<text top="344" left="373" width="128" height="17" font="5">a “standard” BP target. </text>
<text top="362" left="365" width="3" height="17" font="5"> </text>
<text top="379" left="373" width="209" height="17" font="5">Exclusion criteria: Studies that did not </text>
<text top="396" left="373" width="200" height="17" font="5">meet the inclusion criteria. Excluded </text>
<text top="413" left="373" width="194" height="17" font="5">studies were UKPDS 1998, HTN in </text>
<text top="431" left="373" width="182" height="17" font="5">Diabetes Study IV 1996, SANDS </text>
<text top="448" left="373" width="191" height="17" font="5">2008, Lewis 1999 and the Steno-2 </text>
<text top="465" left="373" width="36" height="17" font="5">study. </text>
<text top="482" left="373" width="3" height="17" font="5"> </text>
<text top="499" left="373" width="3" height="17" font="5"> </text>
<text top="293" left="619" width="132" height="18" font="5">• Pts with HTN and DM </text>
<text top="310" left="619" width="84" height="17" font="5">were randomly </text>
<text top="328" left="619" width="87" height="17" font="5">assigned to the </text>
<text top="345" left="619" width="117" height="17" font="5">intensive or standard </text>
<text top="362" left="619" width="98" height="17" font="5">BP control group. </text>
<text top="292" left="792" width="105" height="17" font="5">1  outcomes: Total </text>
<text top="309" left="792" width="123" height="17" font="5">mortality, total serious </text>
<text top="327" left="792" width="111" height="17" font="5">adverse events, MI, </text>
<text top="344" left="792" width="96" height="17" font="5">stroke, CHF, and </text>
<text top="361" left="792" width="41" height="17" font="5">ESRD. </text>
<text top="378" left="792" width="3" height="17" font="5"> </text>
<text top="396" left="794" width="110" height="17" font="5">Results: Only 1 trial </text>
<text top="413" left="794" width="123" height="17" font="5">(ACCORD) compared </text>
<text top="430" left="794" width="144" height="17" font="5">outcomes associated with </text>
<text top="447" left="794" width="134" height="17" font="5">'lower' (&lt;120 mm Hg) or </text>
<text top="464" left="794" width="138" height="17" font="5">'standard' (&lt;140 mm Hg) </text>
<text top="482" left="794" width="136" height="17" font="5">SBP targets in 4734 pts. </text>
<text top="499" left="794" width="110" height="17" font="5">Despite achieving a </text>
<text top="516" left="794" width="119" height="17" font="5">significantly lower BP </text>
<text top="533" left="794" width="128" height="17" font="5">(119.3/64.4 mm Hg vs. </text>
<text top="550" left="794" width="108" height="17" font="5">133.5/70.5 mm Hg, </text>
<text top="568" left="794" width="119" height="17" font="5">p&lt;0.0001), and using </text>
<text top="585" left="794" width="124" height="17" font="5">more antihypertensive </text>
<text top="602" left="794" width="119" height="17" font="5">medications, the only </text>
<text top="619" left="794" width="132" height="17" font="5">significant benefit in the </text>
<text top="636" left="794" width="138" height="17" font="5">group assigned to 'lower' </text>
<text top="654" left="794" width="130" height="17" font="5">SBP was a reduction in </text>
<text top="671" left="794" width="130" height="17" font="5">the incidence of stroke: </text>
<text top="688" left="794" width="137" height="17" font="5">RR: 0.58; (95% CI: 0.39–</text>
<text top="705" left="794" width="31" height="17" font="5">0.88; </text>
<text top="723" left="794" width="128" height="17" font="5">p=0.009), absolute risk </text>
<text top="740" left="794" width="147" height="17" font="5">reduction 1.1%. The effect </text>
<text top="757" left="794" width="100" height="17" font="5">of SBP targets on </text>
<text top="292" left="971" width="142" height="17" font="5">Conclusions:  Evidence </text>
<text top="309" left="971" width="142" height="17" font="5">from  RCTs  does  not </text>
<text top="326" left="971" width="142" height="17" font="5">support BP targets lower </text>
<text top="343" left="971" width="142" height="17" font="5">than  standard  targets  in </text>
<text top="360" left="971" width="124" height="17" font="5">pts with HTN and DM. </text>
</page>
<page number="248" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="138" height="17" font="5">mortality was compatible </text>
<text top="108" left="794" width="141" height="17" font="5">with both a reduction and </text>
<text top="125" left="794" width="140" height="17" font="5">increase in risk: RR: 1.05 </text>
<text top="142" left="794" width="138" height="17" font="5">(95% CI: 0.84, 1.30), low </text>
<text top="160" left="794" width="146" height="17" font="5">quality evidence. Trying to </text>
<text top="177" left="794" width="132" height="17" font="5">achieve the 'lower' SBP </text>
<text top="194" left="794" width="148" height="17" font="5">target was associated with </text>
<text top="211" left="794" width="131" height="17" font="5">a significant increase in </text>
<text top="229" left="794" width="111" height="17" font="5">the number of other </text>
<text top="246" left="794" width="133" height="17" font="5">serious adverse events: </text>
<text top="263" left="794" width="137" height="17" font="5">RR: 2.58, (95% CI: 1.70–</text>
<text top="280" left="794" width="146" height="17" font="5">3.91; p&lt;0.00001, absolute </text>
<text top="297" left="794" width="147" height="17" font="5">risk increase 2.0%. 4 trials </text>
<text top="315" left="794" width="112" height="17" font="5">(ABCD-H, ABCD-N, </text>
<text top="332" left="794" width="60" height="17" font="5">ABCD-2V, </text>
<text top="349" left="794" width="131" height="17" font="5">and a subgroup of HTN </text>
<text top="366" left="794" width="109" height="17" font="5">Optimal Treatment) </text>
<text top="383" left="794" width="121" height="17" font="5">specifically compared </text>
<text top="401" left="794" width="97" height="17" font="5">clinical outcomes </text>
<text top="418" left="794" width="144" height="17" font="5">associated with 'lower' vs. </text>
<text top="435" left="794" width="143" height="17" font="5">'standard' targets for DBP </text>
<text top="452" left="794" width="135" height="17" font="5">in pts with DM. The total </text>
<text top="469" left="794" width="141" height="17" font="5">number of pts included in </text>
<text top="487" left="794" width="132" height="17" font="5">the DBP target analysis </text>
<text top="504" left="794" width="133" height="17" font="5">was 2580. Pts assigned </text>
<text top="521" left="794" width="114" height="17" font="5">to 'lower' DBP had a </text>
<text top="538" left="794" width="100" height="17" font="5">significantly lower </text>
<text top="556" left="794" width="141" height="17" font="5">achieved BP: 128/76 mm </text>
<text top="573" left="794" width="126" height="17" font="5">Hg vs. 135/83 mm Hg; </text>
<text top="590" left="794" width="129" height="17" font="5">p&lt;0.0001. There was a </text>
<text top="607" left="794" width="145" height="17" font="5">trend towards reduction in </text>
<text top="624" left="794" width="145" height="17" font="5">total mortality in the group </text>
<text top="642" left="794" width="124" height="17" font="5">assigned to the 'lower' </text>
<text top="659" left="794" width="119" height="17" font="5">DBP target: RR: 0.73 </text>
<text top="676" left="794" width="117" height="17" font="5">(95% CI: 0.53–1.01), </text>
<text top="693" left="794" width="132" height="17" font="5">mainly due to a trend to </text>
<text top="710" left="794" width="131" height="17" font="5">lower non-CV mortality. </text>
<text top="728" left="794" width="135" height="17" font="5">There was no difference </text>
<text top="745" left="794" width="141" height="17" font="5">in stroke: RR: 0.67, (95% </text>
<text top="762" left="794" width="143" height="17" font="5">CI: 0.42–1.05), in MI: RR: </text>
</page>
<page number="249" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="113" height="17" font="5">0.95 (95% CI: 0.64– </text>
<text top="108" left="794" width="143" height="17" font="5">1.40) or in CHF: RR: 1.06 </text>
<text top="125" left="794" width="85" height="17" font="5">(95% CI: 0.58– </text>
<text top="143" left="794" width="96" height="17" font="5">1.92), low-quality </text>
<text top="160" left="794" width="146" height="17" font="5">evidence. End-stage renal </text>
<text top="177" left="794" width="130" height="17" font="5">failure and total serious </text>
<text top="194" left="794" width="137" height="17" font="5">adverse events were not </text>
<text top="211" left="794" width="120" height="17" font="5">reported in any of the </text>
<text top="229" left="794" width="101" height="17" font="5">trials. A sensitivity </text>
<text top="246" left="794" width="91" height="17" font="5">analysis of trials </text>
<text top="263" left="794" width="130" height="17" font="5">comparing DBP targets </text>
<text top="280" left="794" width="148" height="17" font="5">&lt;80 mm Hg (as suggested </text>
<text top="298" left="794" width="135" height="17" font="5">in clinical guidelines) vs. </text>
<text top="315" left="794" width="113" height="17" font="5">&lt;90 mm Hg showed </text>
<text top="332" left="794" width="143" height="17" font="5">similar results. There was </text>
<text top="349" left="794" width="125" height="17" font="5">a high risk of selection </text>
<text top="366" left="794" width="128" height="17" font="5">bias for every outcome </text>
<text top="384" left="794" width="130" height="17" font="5">analyzed in favor of the </text>
<text top="401" left="794" width="37" height="17" font="5">'lower' </text>
<text top="419" left="794" width="147" height="17" font="5">target in the trials included </text>
<text top="437" left="794" width="128" height="17" font="5">for the analysis of DBP </text>
<text top="455" left="794" width="44" height="17" font="5">targets. </text>
<text top="474" left="83" width="82" height="17" font="5">Margolis KL et </text>
<text top="491" left="83" width="83" height="17" font="5">al., 2014 (235) </text>
<text top="508" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24595629?dopt=Citation">24595629</a></text>
<text top="508" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24595629?dopt=Citation"> </a></text>
<text top="474" left="220" width="97" height="17" font="5">Aim: To compare </text>
<text top="491" left="220" width="53" height="17" font="5">effects of </text>
<text top="508" left="220" width="89" height="17" font="5">combinations of </text>
<text top="525" left="220" width="75" height="17" font="5">standard and </text>
<text top="542" left="220" width="121" height="17" font="5">intensive treatment of </text>
<text top="560" left="220" width="108" height="17" font="5">glycemia and BP in </text>
<text top="577" left="220" width="104" height="17" font="5">the ACCORD trial. </text>
<text top="595" left="212" width="3" height="17" font="5"> </text>
<text top="612" left="220" width="94" height="17" font="5">Study type: RCT </text>
<text top="630" left="212" width="3" height="17" font="5"> </text>
<text top="647" left="220" width="108" height="17" font="5">Size: 4,733 pts, 4.7 </text>
<text top="664" left="220" width="62" height="17" font="5">y follow-up </text>
<text top="474" left="373" width="185" height="17" font="5">Inclusion criteria: Type 2 DM with </text>
<text top="491" left="373" width="215" height="17" font="5">HgbA1c  7.5%;  40 y with CVD or  55 y </text>
<text top="508" left="373" width="154" height="17" font="5">with anatomical evidence of </text>
<text top="525" left="373" width="205" height="17" font="5">atherosclerosis, albuminuria, LVH, or </text>
<text top="542" left="373" width="190" height="17" font="5">at least 2 additional risk factors for </text>
<text top="560" left="373" width="33" height="17" font="5">CVD. </text>
<text top="578" left="365" width="3" height="17" font="5"> </text>
<text top="594" left="373" width="187" height="17" font="5">Exclusion criteria: BMI  45, serum </text>
<text top="611" left="373" width="186" height="17" font="5">creatinine &gt;1.5, and other serious </text>
<text top="628" left="373" width="41" height="17" font="5">illness. </text>
<text top="474" left="619" width="105" height="17" font="5">Pts were randomly </text>
<text top="491" left="619" width="118" height="17" font="5">assigned to intensive </text>
<text top="508" left="619" width="124" height="17" font="5">therapy SBP&lt;120 mm </text>
<text top="525" left="619" width="129" height="17" font="5">Hg or standard therapy </text>
<text top="542" left="619" width="102" height="17" font="5">SBP&lt;140 mm Hg. </text>
<text top="474" left="794" width="123" height="17" font="5">1  outcomes: Nonfatal </text>
<text top="491" left="794" width="143" height="17" font="5">MI, nonfatal stroke, or CV </text>
<text top="508" left="794" width="38" height="17" font="5">death. </text>
<text top="526" left="786" width="3" height="17" font="5"> </text>
<text top="543" left="794" width="128" height="17" font="5">Results: In the BP trial, </text>
<text top="560" left="794" width="123" height="17" font="5">risk of the 1° outcome </text>
<text top="578" left="794" width="132" height="17" font="5">was lower in the groups </text>
<text top="595" left="794" width="120" height="17" font="5">intensively treated for </text>
<text top="612" left="794" width="136" height="17" font="5">glycemia HR: 0.67 (95% </text>
<text top="629" left="794" width="50" height="17" font="5">CI: 0.50, </text>
<text top="646" left="794" width="139" height="17" font="5">0.91), BP HR: 0.74 (95% </text>
<text top="664" left="794" width="99" height="17" font="5">CI: 0.55, 1.00), or </text>
<text top="681" left="794" width="130" height="17" font="5">both HR: 0.71 (95% CI: </text>
<text top="698" left="794" width="62" height="17" font="5">0.52, 0.96) </text>
<text top="716" left="794" width="140" height="17" font="5">compared with combined </text>
<text top="734" left="794" width="147" height="17" font="5">standard BP and glycemia </text>
<text top="752" left="794" width="95" height="17" font="5">treatment. For 2º </text>
<text top="771" left="794" width="102" height="17" font="5">outcomes, MI was </text>
<text top="474" left="971" width="130" height="17" font="5">Limitations: 2  analysis; </text>
<text top="491" left="971" width="132" height="17" font="5">results analyzed across </text>
<text top="508" left="971" width="106" height="17" font="5">individual cells of a </text>
<text top="525" left="971" width="111" height="17" font="5">factorial design with </text>
<text top="542" left="971" width="125" height="17" font="5">shorter follow- up than </text>
<text top="560" left="971" width="102" height="17" font="5">originally intended </text>
<text top="577" left="971" width="138" height="17" font="5">reducing power to detect </text>
<text top="594" left="971" width="127" height="17" font="5">meaningful differences </text>
<text top="611" left="971" width="133" height="17" font="5">and interactions; results </text>
<text top="628" left="971" width="94" height="17" font="5">may not apply to </text>
<text top="646" left="971" width="102" height="17" font="5">younger, healthier </text>
<text top="663" left="971" width="55" height="17" font="5">diabetics. </text>
<text top="681" left="962" width="3" height="17" font="5"> </text>
<text top="698" left="971" width="109" height="17" font="5">Conclusions: Either </text>
<text top="715" left="971" width="138" height="17" font="5">intensive BP or glycemia </text>
<text top="732" left="971" width="122" height="17" font="5">control reduced major </text>
<text top="750" left="971" width="113" height="17" font="5">CVD compared with </text>
<text top="767" left="971" width="108" height="17" font="5">combined standard </text>
</page>
<page number="250" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="131" height="17" font="5">significantly reduced by </text>
<text top="110" left="794" width="104" height="17" font="5">intensive glycemia </text>
<text top="128" left="794" width="133" height="17" font="5">treatment and stroke by </text>
<text top="146" left="794" width="130" height="17" font="5">intensive BP treatment; </text>
<text top="164" left="794" width="119" height="17" font="5">most other HRs were </text>
<text top="182" left="794" width="152" height="17" font="5">neutral or favored intensive </text>
<text top="201" left="794" width="100" height="17" font="5">treatment groups. </text>
<text top="91" left="971" width="100" height="17" font="5">treatment, but the </text>
<text top="108" left="971" width="112" height="17" font="5">combination was no </text>
<text top="125" left="971" width="138" height="17" font="5">better than the individual </text>
<text top="142" left="971" width="129" height="17" font="5">intensive interventions. </text>
<text top="219" left="83" width="88" height="17" font="5">Lewington S, et </text>
<text top="236" left="83" width="51" height="17" font="5">al., 2002 </text>
<text top="253" left="83" width="25" height="17" font="5">(16) </text>
<text top="271" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12493255?dopt=Citation">12493255</a></text>
<text top="271" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12493255?dopt=Citation"> </a></text>
<text top="219" left="220" width="116" height="17" font="5">Aim: To describe the </text>
<text top="236" left="220" width="69" height="17" font="5">age-specific </text>
<text top="254" left="220" width="104" height="17" font="5">relevance of BP to </text>
<text top="271" left="220" width="81" height="17" font="5">cause-specific </text>
<text top="288" left="220" width="50" height="17" font="5">mortality </text>
<text top="306" left="212" width="3" height="17" font="5"> </text>
<text top="323" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="340" left="220" width="99" height="17" font="5">analysis of cohort </text>
<text top="358" left="220" width="42" height="17" font="5">studies </text>
<text top="376" left="212" width="3" height="17" font="5"> </text>
<text top="393" left="220" width="114" height="17" font="5">Size: 61 prospective </text>
<text top="410" left="220" width="95" height="17" font="5">studies with 12.7 </text>
<text top="427" left="220" width="103" height="17" font="5">million person-y of </text>
<text top="444" left="220" width="111" height="17" font="5">observation, 56,000 </text>
<text top="462" left="220" width="102" height="17" font="5">vascular deaths in </text>
<text top="479" left="220" width="54" height="17" font="5">40– 89 y. </text>
<text top="219" left="373" width="197" height="17" font="5">Inclusion criteria: Collaboration was </text>
<text top="236" left="373" width="191" height="17" font="5">sought from the investigators of all </text>
<text top="254" left="373" width="198" height="17" font="5">prospective observational studies in </text>
<text top="271" left="373" width="202" height="17" font="5">which data on BP, blood cholesterol, </text>
<text top="288" left="373" width="189" height="17" font="5">date of birth (or age), and sex had </text>
<text top="305" left="373" width="212" height="17" font="5">been recorded at a baseline screening </text>
<text top="322" left="373" width="201" height="17" font="5">visit, and in which cause and date of </text>
<text top="340" left="373" width="183" height="17" font="5">death (or age at death) had been </text>
<text top="357" left="373" width="208" height="17" font="5">routinely sought for all screens during </text>
<text top="374" left="373" width="211" height="17" font="5">more than 5,000 person-y of follow-up </text>
<text top="391" left="373" width="95" height="17" font="5">(see appendix A; </text>
<text top="409" left="373" width="178" height="17" font="17"><a href="http://image.thelancet.com/extras/01art8300webappendixA.pdf">http://image.thelancet.com/extra </a></text>
<text top="426" left="373" width="166" height="17" font="17"><a href="http://image.thelancet.com/extras/01art8300webappendixA.pdf">s/01art8300webappendixA.pdf</a></text>
<text top="426" left="539" width="11" height="17" font="5"><a href="http://image.thelancet.com/extras/01art8300webappendixA.pdf">). </a></text>
<text top="443" left="373" width="177" height="17" font="5">Relevant studies were identified </text>
<text top="460" left="373" width="213" height="17" font="5">through computer searches of Medline </text>
<text top="477" left="373" width="194" height="17" font="5">and Embase, by hand- searches of </text>
<text top="495" left="373" width="199" height="17" font="5">meeting abstracts, and by extensive </text>
<text top="512" left="373" width="168" height="17" font="5">discussions with investigators. </text>
<text top="530" left="365" width="3" height="17" font="5"> </text>
<text top="547" left="373" width="190" height="17" font="5">Exclusion criteria: To minimize the </text>
<text top="564" left="373" width="203" height="17" font="5">effects of reverse causality (whereby </text>
<text top="581" left="373" width="208" height="17" font="5">established disease could change the </text>
<text top="598" left="373" width="195" height="17" font="5">usual BP), studies were excluded if </text>
<text top="616" left="373" width="213" height="17" font="5">they had selected pts on the basis of a </text>
<text top="633" left="373" width="181" height="17" font="5">positive history of stroke or heart </text>
<text top="650" left="373" width="162" height="17" font="5">disease, and individuals from </text>
<text top="667" left="373" width="192" height="17" font="5">contributing studies were excluded </text>
<text top="685" left="373" width="93" height="17" font="5">from the present </text>
<text top="701" left="373" width="191" height="17" font="5">analyses if they had such a history </text>
<text top="718" left="373" width="118" height="17" font="5">recorded at baseline. </text>
<text top="219" left="619" width="95" height="17" font="5">Intervention: N/A </text>
<text top="237" left="611" width="3" height="17" font="5"> </text>
<text top="254" left="619" width="96" height="17" font="5">Comparator: N/A </text>
<text top="272" left="611" width="3" height="17" font="5"> </text>
<text top="289" left="619" width="98" height="17" font="5">The exposures of </text>
<text top="306" left="619" width="123" height="17" font="5">interest were the level </text>
<text top="323" left="619" width="118" height="17" font="5">of SBP and DBP and </text>
<text top="341" left="619" width="63" height="17" font="5">age-group. </text>
<text top="219" left="794" width="70" height="17" font="5">1° endpoint: </text>
<text top="236" left="794" width="128" height="18" font="5">• Not completely clear, </text>
<text top="255" left="794" width="117" height="17" font="5">but for our purposes, </text>
<text top="272" left="794" width="119" height="17" font="5">stroke and IHD death </text>
<text top="289" left="794" width="117" height="17" font="5">would be co-1°. Also </text>
<text top="306" left="794" width="134" height="17" font="5">looked at other vascular </text>
<text top="323" left="794" width="44" height="17" font="5">deaths. </text>
<text top="341" left="794" width="92" height="18" font="5">• HRs for stroke </text>
<text top="359" left="794" width="137" height="17" font="5">mortality for a 20 mm Hg </text>
<text top="376" left="794" width="137" height="17" font="5">lower SBP by age-group </text>
<text top="393" left="794" width="120" height="17" font="5">40–49: 0.36 (95% CI: </text>
<text top="411" left="794" width="131" height="17" font="5">0.32–0.40) 50–59: 0.38 </text>
<text top="428" left="794" width="134" height="17" font="5">(95% CI: 0.35–0.40) 60–</text>
<text top="445" left="794" width="130" height="17" font="5">69: 0.43 (95% CI: 0.41–</text>
<text top="462" left="794" width="132" height="17" font="5">0.45) 70–79: 0.50 (95% </text>
<text top="479" left="794" width="122" height="17" font="5">CI: 0.48–0.52) 80–89: </text>
<text top="497" left="794" width="108" height="17" font="5">0.67 (95% CI: 0.63–</text>
<text top="514" left="794" width="31" height="17" font="5">0.71) </text>
<text top="531" left="794" width="130" height="18" font="5">• HRs for IHD mortality </text>
<text top="550" left="794" width="121" height="17" font="5">for a 20 mm Hg lower </text>
<text top="567" left="794" width="124" height="17" font="5">SBP by age-group 40–</text>
<text top="584" left="794" width="129" height="17" font="5">49: 0.49 (95% CI: 0.45–</text>
<text top="601" left="794" width="132" height="17" font="5">0.53) 50–59: 0.50 (95% </text>
<text top="618" left="794" width="121" height="17" font="5">CI: 0.49–0.52) 60–69: </text>
<text top="636" left="794" width="108" height="17" font="5">0.54 (95% CI: 0.53–</text>
<text top="653" left="794" width="132" height="17" font="5">0.55) 70–79: 0.60 (95% </text>
<text top="670" left="794" width="121" height="17" font="5">CI: 0.58–0.61) 80–89: </text>
<text top="687" left="794" width="108" height="17" font="5">0.67 (95% CI: 0.64–</text>
<text top="704" left="794" width="31" height="17" font="5">0.70) </text>
<text top="722" left="794" width="136" height="18" font="5">• HRs for other vascular </text>
<text top="740" left="794" width="138" height="17" font="5">mortality for a 20 mm Hg </text>
<text top="757" left="794" width="140" height="17" font="5">lower SBP by age- group </text>
<text top="219" left="971" width="142" height="17" font="5">Summary:  Throughout </text>
<text top="236" left="971" width="142" height="17" font="5">middle and old age, usual </text>
<text top="253" left="971" width="142" height="17" font="5">BP is strongly and directly </text>
<text top="270" left="971" width="142" height="17" font="5">related  to  vascular  (and </text>
<text top="287" left="971" width="142" height="17" font="5">overall) mortality, without </text>
<text top="304" left="971" width="142" height="17" font="5">any  evidence  of  a </text>
<text top="321" left="971" width="142" height="17" font="5">threshold down to at least </text>
<text top="338" left="971" width="87" height="17" font="5">115/75 mm Hg. </text>
</page>
<page number="251" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="90" left="794" width="150" height="17" font="5">40–49: 0.43 (95% CI: 0.38–</text>
<text top="108" left="794" width="31" height="17" font="5">0.48) </text>
<text top="125" left="794" width="150" height="17" font="5">50–59: 0.50 (95% CI: 0.47–</text>
<text top="142" left="794" width="31" height="17" font="5">0.54) </text>
<text top="159" left="794" width="150" height="17" font="5">60–69: 0.53 (95% CI: 0.51–</text>
<text top="176" left="794" width="31" height="17" font="5">0.56) </text>
<text top="193" left="794" width="150" height="17" font="5">70–79: 0.64 (95% CI: 0.61–</text>
<text top="211" left="794" width="31" height="17" font="5">0.67) </text>
<text top="228" left="794" width="150" height="17" font="5">80–89: 0.70 (95% CI: 0.65–</text>
<text top="245" left="794" width="31" height="17" font="5">0.75) </text>
<text top="263" left="794" width="109" height="18" font="5">• Similar results for </text>
<text top="281" left="794" width="114" height="17" font="5">DBP also in figure 1. </text>
<text top="299" left="794" width="149" height="17" font="5">Similar results for men and </text>
<text top="317" left="794" width="121" height="17" font="5">women separately for </text>
<text top="335" left="794" width="140" height="17" font="5">stroke, figure 3, and IHD, </text>
<text top="353" left="794" width="48" height="17" font="5">figure 5. </text>
<text top="372" left="83" width="89" height="17" font="5">Kassai B, et al., </text>
<text top="389" left="83" width="63" height="17" font="5">2005 (120) </text>
<text top="406" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17315403?dopt=Citation">17315403</a></text>
<text top="406" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17315403?dopt=Citation"> </a></text>
<text top="372" left="220" width="121" height="17" font="5">Aim: Consideration of </text>
<text top="389" left="220" width="95" height="17" font="5">absolute risk has </text>
<text top="406" left="220" width="113" height="17" font="5">been recommended </text>
<text top="423" left="220" width="115" height="17" font="5">for making decisions </text>
<text top="441" left="220" width="124" height="17" font="5">concerning preventive </text>
<text top="458" left="220" width="100" height="17" font="5">treatment in HTN. </text>
<text top="475" left="220" width="108" height="17" font="5">Aim to estimate the </text>
<text top="492" left="220" width="54" height="17" font="5">benefit of </text>
<text top="510" left="220" width="93" height="17" font="5">antihypertensive </text>
<text top="527" left="220" width="105" height="17" font="5">therapy over a life- </text>
<text top="544" left="220" width="30" height="17" font="5">time. </text>
<text top="562" left="212" width="3" height="17" font="5"> </text>
<text top="579" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="596" left="220" width="119" height="17" font="5">analysis on individual </text>
<text top="613" left="220" width="93" height="17" font="5">data in HTN and </text>
<text top="631" left="220" width="94" height="17" font="5">specific cause of </text>
<text top="648" left="220" width="109" height="17" font="5">death from national </text>
<text top="665" left="220" width="102" height="17" font="5">statistics. Disease-</text>
<text top="682" left="220" width="109" height="17" font="5">free survival curves </text>
<text top="700" left="220" width="118" height="17" font="5">until all pts have died </text>
<text top="717" left="220" width="109" height="17" font="5">were built using the </text>
<text top="734" left="220" width="106" height="17" font="5">“life-table” method. </text>
<text top="751" left="220" width="113" height="17" font="5">The treatment effect </text>
<text top="768" left="220" width="85" height="17" font="5">estimated from </text>
<text top="372" left="373" width="209" height="17" font="5">Inclusion criteria: To estimate the rate </text>
<text top="389" left="373" width="162" height="17" font="5">of cv and non-CV deaths in a </text>
<text top="406" left="373" width="170" height="17" font="5">hypothetical U.S. population of </text>
<text top="423" left="373" width="201" height="17" font="5">untreated hypertensive pts, we used </text>
<text top="441" left="373" width="202" height="17" font="5">the following procedure: age-specific </text>
<text top="458" left="373" width="170" height="17" font="5">death rates in the U.S. general </text>
<text top="475" left="373" width="215" height="17" font="5">population were obtained from national </text>
<text top="492" left="373" width="210" height="17" font="5">vital statistics (1994), and in untreated </text>
<text top="510" left="373" width="190" height="17" font="5">hypertensive population they were </text>
<text top="527" left="373" width="215" height="17" font="5">obtained from the control groups of the </text>
<text top="544" left="373" width="199" height="17" font="5">INDANA database. This latter group </text>
<text top="561" left="373" width="205" height="17" font="5">represents a unique cohort of 14 942 </text>
<text top="579" left="373" width="159" height="17" font="5">untreated or placebo-treated </text>
<text top="596" left="373" width="186" height="17" font="5">hypertensive pts, 26–96 y with an </text>
<text top="613" left="373" width="134" height="17" font="5">average follow-up of 5 y </text>
<text top="631" left="365" width="3" height="17" font="5"> </text>
<text top="647" left="373" width="124" height="17" font="5">Exclusion criteria: N/A </text>
<text top="372" left="619" width="122" height="17" font="5">Intervention: The gain </text>
<text top="389" left="619" width="97" height="17" font="5">in life expectancy </text>
<text top="406" left="619" width="116" height="17" font="5">without stroke, CHD, </text>
<text top="423" left="619" width="109" height="17" font="5">and CV events was </text>
<text top="441" left="619" width="133" height="17" font="5">estimated from the area </text>
<text top="458" left="619" width="126" height="17" font="5">between the 2 survival </text>
<text top="475" left="619" width="119" height="17" font="5">curves of treated and </text>
<text top="492" left="619" width="109" height="17" font="5">control groups. The </text>
<text top="510" left="619" width="102" height="17" font="5">relative gain in life </text>
<text top="527" left="619" width="91" height="17" font="5">expectancy was </text>
<text top="544" left="619" width="122" height="17" font="5">defined as the ratio of </text>
<text top="561" left="619" width="124" height="17" font="5">gain in life expectancy </text>
<text top="579" left="619" width="102" height="17" font="5">to life expectancy. </text>
<text top="372" left="794" width="130" height="17" font="5">1  endpoint: Stroke and </text>
<text top="389" left="794" width="67" height="17" font="5">CHD co- 1° </text>
<text top="406" left="786" width="3" height="17" font="5"> </text>
<text top="423" left="794" width="48" height="17" font="5">Results: </text>
<text top="440" left="794" width="30" height="17" font="5">CHD </text>
<text top="458" left="794" width="25" height="17" font="15">Age </text>
<text top="458" left="848" width="23" height="17" font="15">ABb</text>
<text top="475" left="794" width="3" height="17" font="15"> </text>
<text top="475" left="848" width="40" height="17" font="15">RGLEe</text>
<text top="475" left="889" width="3" height="17" font="5"> </text>
<text top="492" left="794" width="145" height="17" font="15">Y  RRa (%) NNTc GLEd </text>
<text top="509" left="794" width="19" height="17" font="15">(%)</text>
<text top="509" left="813" width="3" height="17" font="5"> </text>
<text top="526" left="794" width="102" height="17" font="15">40   0.86  0.3  333 </text>
<text top="526" left="921" width="17" height="17" font="15">20 </text>
<text top="544" left="794" width="17" height="17" font="15">4.1</text>
<text top="544" left="811" width="3" height="17" font="5"> </text>
<text top="561" left="794" width="102" height="17" font="15">50   0.88  1.0  100 </text>
<text top="561" left="921" width="17" height="17" font="15">17 </text>
<text top="578" left="794" width="17" height="17" font="15">4.3</text>
<text top="578" left="811" width="3" height="17" font="5"> </text>
<text top="595" left="794" width="99" height="17" font="15">60   0.90  1.9   53 </text>
<text top="595" left="921" width="17" height="17" font="15">13 </text>
<text top="612" left="794" width="17" height="17" font="15">3.4</text>
<text top="612" left="811" width="3" height="17" font="5"> </text>
<text top="630" left="794" width="99" height="17" font="15">70   0.91  3.9   26 </text>
<text top="630" left="921" width="17" height="17" font="15">10 </text>
<text top="647" left="794" width="17" height="17" font="15">5.4</text>
<text top="647" left="811" width="3" height="17" font="5"> </text>
<text top="665" left="786" width="3" height="17" font="5"> </text>
<text top="682" left="794" width="35" height="17" font="15">Stroke</text>
<text top="682" left="830" width="3" height="17" font="5"> </text>
<text top="699" left="794" width="25" height="17" font="15">Age </text>
<text top="699" left="848" width="23" height="17" font="15">ABb</text>
<text top="716" left="794" width="3" height="17" font="15"> </text>
<text top="716" left="848" width="40" height="17" font="15">RGLEe</text>
<text top="716" left="889" width="3" height="17" font="5"> </text>
<text top="734" left="794" width="145" height="17" font="15">Y  RRa (%) NNTc GLEd </text>
<text top="751" left="794" width="19" height="17" font="15">(%)</text>
<text top="751" left="813" width="3" height="17" font="5"> </text>
<text top="768" left="794" width="102" height="17" font="15">40   0.80  0.4  250 </text>
<text top="768" left="917" width="17" height="17" font="15">32 </text>
<text top="372" left="971" width="110" height="17" font="5">Summary: Absolute </text>
<text top="389" left="971" width="130" height="17" font="5">gains in life expectancy </text>
<text top="406" left="971" width="143" height="17" font="5">are likely to be greater for </text>
<text top="423" left="971" width="107" height="17" font="5">younger, lower risk </text>
<text top="441" left="971" width="139" height="17" font="5">people with HTN than for </text>
<text top="458" left="971" width="134" height="17" font="5">older, higher risk people </text>
<text top="475" left="971" width="133" height="17" font="5">with HTN. However, the </text>
<text top="492" left="971" width="137" height="17" font="5">NNT to prevent an event </text>
<text top="510" left="971" width="111" height="17" font="5">will likely be greater </text>
<text top="527" left="971" width="122" height="17" font="5">especially in the short </text>
<text top="544" left="971" width="125" height="17" font="5">term in younger, lower </text>
<text top="561" left="971" width="66" height="17" font="5">risk people. </text>
<text top="578" left="971" width="142" height="17" font="5">This  modeling  analysis </text>
<text top="595" left="971" width="142" height="17" font="5">provides  support  for </text>
<text top="612" left="971" width="142" height="17" font="5">treating  younger,  lower </text>
<text top="629" left="971" width="142" height="17" font="5">risk individuals with HTN, </text>
<text top="646" left="971" width="142" height="17" font="5">but  relies  on  the </text>
<text top="663" left="971" width="142" height="17" font="5">assumption  that  the </text>
<text top="680" left="971" width="43" height="17" font="5">relative </text>
<text top="680" left="1033" width="46" height="17" font="5">benefits </text>
<text top="680" left="1099" width="14" height="17" font="5">of </text>
<text top="697" left="971" width="142" height="17" font="5">treatments  observed  in </text>
<text top="714" left="971" width="142" height="17" font="5">short-term trials of higher </text>
<text top="731" left="971" width="142" height="17" font="5">risk  individuals  applies </text>
<text top="748" left="971" width="142" height="17" font="5">over  a  longer  term  to </text>
<text top="765" left="971" width="120" height="17" font="5">lower risk individuals. </text>
</page>
<page number="252" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="118" height="17" font="5">INDANA was applied </text>
<text top="108" left="220" width="120" height="17" font="5">to this curve to obtain </text>
<text top="125" left="220" width="92" height="17" font="5">the disease-free </text>
<text top="142" left="220" width="113" height="17" font="5">survival curve of the </text>
<text top="160" left="220" width="88" height="17" font="5">life-long treated </text>
<text top="177" left="220" width="112" height="17" font="5">population. Gains in </text>
<text top="194" left="220" width="78" height="17" font="5">event-free life </text>
<text top="211" left="220" width="95" height="17" font="5">expectancy were </text>
<text top="229" left="220" width="85" height="17" font="5">estimated from </text>
<text top="246" left="220" width="100" height="17" font="5">survival curves. A </text>
<text top="263" left="220" width="104" height="17" font="5">sensitivity analysis </text>
<text top="280" left="220" width="98" height="17" font="5">was performed to </text>
<text top="297" left="220" width="115" height="17" font="5">assess the impact of </text>
<text top="315" left="220" width="83" height="17" font="5">possible death </text>
<text top="332" left="220" width="102" height="17" font="5">misclassifications. </text>
<text top="349" left="220" width="3" height="17" font="5"> </text>
<text top="374" left="220" width="128" height="17" font="5">Size: 6 RCTs, ~30,000 </text>
<text top="391" left="220" width="21" height="17" font="5">Pts </text>
<text top="91" left="794" width="17" height="17" font="15">5.9</text>
<text top="91" left="811" width="3" height="17" font="5"> </text>
<text top="108" left="794" width="102" height="17" font="15">50   0.84  1.0  100 </text>
<text top="108" left="917" width="17" height="17" font="15">26 </text>
<text top="125" left="794" width="17" height="17" font="15">5.7</text>
<text top="125" left="811" width="3" height="17" font="5"> </text>
<text top="142" left="794" width="99" height="17" font="15">60   0.86  2.3   44 </text>
<text top="142" left="917" width="17" height="17" font="15">21 </text>
<text top="159" left="794" width="17" height="17" font="15">7.1</text>
<text top="159" left="811" width="3" height="17" font="5"> </text>
<text top="177" left="794" width="99" height="17" font="15">70   0.87  5.7   18 </text>
<text top="177" left="917" width="17" height="17" font="15">17 </text>
<text top="194" left="794" width="17" height="17" font="15">9.1</text>
<text top="194" left="811" width="3" height="17" font="5"> </text>
<text top="212" left="786" width="3" height="17" font="5"> </text>
<text top="229" left="794" width="10" height="17" font="15">a </text>
<text top="229" left="805" width="21" height="17" font="5">RR </text>
<text top="229" left="826" width="37" height="17" font="15">at 10 y</text>
<text top="229" left="863" width="3" height="17" font="5"> </text>
<text top="247" left="794" width="61" height="17" font="15">b Absolute </text>
<text top="264" left="794" width="90" height="17" font="15">benefit at 10 y c </text>
<text top="281" left="794" width="29" height="17" font="5">NNT </text>
<text top="281" left="823" width="57" height="17" font="15">to avoid 1 </text>
<text top="298" left="794" width="33" height="17" font="15">event.</text>
<text top="298" left="828" width="3" height="17" font="5"> </text>
<text top="315" left="794" width="150" height="17" font="15">d Gain in life expectancy in </text>
<text top="332" left="794" width="106" height="17" font="15">mo without events. </text>
<text top="350" left="794" width="10" height="17" font="5">e </text>
<text top="350" left="805" width="106" height="17" font="15">Relative gain in life </text>
<text top="369" left="794" width="148" height="17" font="15">expectancy without events.</text>
<text top="369" left="942" width="3" height="17" font="5"> </text>
<text top="409" left="83" width="94" height="17" font="5">Thomopolous C, </text>
<text top="427" left="83" width="90" height="17" font="5">et al., 2016 (54) </text>
<text top="444" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994">26848994</a></text>
<text top="444" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26848994"> </a></text>
<text top="409" left="220" width="100" height="17" font="5">Study type: Meta- </text>
<text top="427" left="220" width="110" height="17" font="5">analysis of RTCs of </text>
<text top="444" left="220" width="76" height="17" font="5">more vs. less </text>
<text top="461" left="220" width="103" height="17" font="5">intense BP control </text>
<text top="410" left="373" width="184" height="18" font="5">• 16 trials (52,235 pts) compared </text>
<text top="428" left="373" width="174" height="17" font="5">more vs. less intense treatment </text>
<text top="445" left="373" width="69" height="17" font="5">34 (138,127 </text>
<text top="461" left="373" width="125" height="17" font="5">pts) active vs. placebo </text>
<text top="409" left="619" width="3" height="17" font="5"> </text>
<text top="409" left="794" width="94" height="17" font="5">More intense BP </text>
<text top="426" left="794" width="152" height="18" font="5">• Stroke RR: 0.71; 95% CI: </text>
<text top="446" left="804" width="62" height="17" font="5">0.60–0.84) </text>
<text top="463" left="794" width="143" height="18" font="5">• CHD RR: 0.80; 95% CI: </text>
<text top="483" left="804" width="62" height="17" font="5">0.68–0.95) </text>
<text top="500" left="794" width="129" height="18" font="5">• Major CV events RR: </text>
<text top="519" left="805" width="136" height="17" font="5">0.75; 95% CI: 0.68–0.85 </text>
<text top="537" left="794" width="136" height="18" font="5">• CV mortality RR: 0.79; </text>
<text top="555" left="805" width="105" height="17" font="5">95% CI: 0.63–0.97 </text>
<text top="573" left="786" width="3" height="17" font="5"> </text>
<text top="590" left="794" width="113" height="17" font="5">Stratification of SBP </text>
<text top="607" left="794" width="115" height="17" font="5">cutoffs (150,140 and </text>
<text top="625" left="794" width="117" height="17" font="5">130 mm Hg) showed </text>
<text top="642" left="794" width="91" height="17" font="5">that a SBP/DBP </text>
<text top="659" left="794" width="122" height="17" font="5">difference of 10/5 mm </text>
<text top="676" left="794" width="122" height="17" font="5">Hg across each cutoff </text>
<text top="694" left="794" width="70" height="17" font="5">reduced risk </text>
<text top="711" left="794" width="86" height="17" font="5">of all outcomes </text>
<text top="409" left="971" width="142" height="17" font="5">Intensive  BP  reduction </text>
<text top="426" left="971" width="142" height="17" font="5">improves  CV  outcomes </text>
<text top="443" left="971" width="142" height="17" font="5">compared to less intense </text>
<text top="460" left="971" width="142" height="17" font="5">Achieved  BP  &lt;130/80 </text>
<text top="477" left="971" width="142" height="17" font="5">may  be  associated  with </text>
<text top="494" left="971" width="64" height="17" font="5">CV benefit. </text>
</page>
<page number="253" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="83" width="90" height="17" font="5">Verdecchia P et </text>
<text top="108" left="83" width="51" height="17" font="5">al., 2016 </text>
<text top="125" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27456518">27456518</a></text>
<text top="125" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27456518"> </a></text>
<text top="91" left="220" width="65" height="17" font="5">Study type: </text>
<text top="108" left="220" width="100" height="17" font="5">Cumulative meta- </text>
<text top="125" left="220" width="110" height="17" font="5">analysis of RCTs to </text>
<text top="142" left="220" width="118" height="17" font="5">study benefit of more </text>
<text top="160" left="220" width="116" height="17" font="5">vs. less intensive BP </text>
<text top="177" left="220" width="49" height="17" font="5">lowering </text>
<text top="195" left="212" width="3" height="17" font="5"> </text>
<text top="212" left="220" width="77" height="17" font="5">Size: 18 trials </text>
<text top="229" left="220" width="63" height="17" font="5">(n=53,405) </text>
<text top="90" left="373" width="24" height="17" font="5">N/A </text>
<text top="91" left="619" width="24" height="17" font="5">N/A </text>
<text top="91" left="794" width="129" height="18" font="5">• Stroke, MI, HF, CVD </text>
<text top="109" left="794" width="129" height="17" font="5">mortality, and all-cause </text>
<text top="126" left="794" width="50" height="17" font="5">mortality </text>
<text top="144" left="794" width="135" height="18" font="5">• Difference in achieved </text>
<text top="162" left="794" width="125" height="17" font="5">SBP/DBP=7.6/4.5 mm </text>
<text top="179" left="794" width="19" height="17" font="5">Hg </text>
<text top="196" left="794" width="131" height="18" font="5">• For stroke and MI the </text>
<text top="214" left="794" width="106" height="17" font="5">cumulative Z score </text>
<text top="231" left="794" width="112" height="17" font="5">crossed the efficacy </text>
<text top="248" left="794" width="129" height="17" font="5">boundary after addition </text>
<text top="266" left="794" width="122" height="17" font="5">of the SPRINT results </text>
<text top="283" left="794" width="135" height="18" font="5">• For CVD mortality and </text>
<text top="301" left="794" width="117" height="17" font="5">HF, the cumulative Z </text>
<text top="319" left="794" width="100" height="17" font="5">curve crossed the </text>
<text top="336" left="794" width="72" height="17" font="5">conventional </text>
<text top="353" left="794" width="122" height="17" font="5">significance boundary </text>
<text top="370" left="794" width="125" height="17" font="5">(but not the sequential </text>
<text top="387" left="794" width="120" height="17" font="5">monitoring boundary) </text>
<text top="405" left="794" width="138" height="18" font="5">• For all-cause mortality, </text>
<text top="423" left="794" width="127" height="17" font="5">the cumulative Z curve </text>
<text top="440" left="794" width="145" height="17" font="5">did not reside in the futility </text>
<text top="457" left="794" width="135" height="17" font="5">are but did not cross the </text>
<text top="474" left="794" width="140" height="17" font="5">conventional significance </text>
<text top="492" left="794" width="55" height="17" font="5">boundary </text>
<text top="91" left="971" width="142" height="17" font="5">The  results  strongly </text>
<text top="108" left="971" width="142" height="17" font="5">supported  the  benefit  of </text>
<text top="125" left="971" width="142" height="17" font="5">intensive BP reduction for </text>
<text top="142" left="971" width="142" height="17" font="5">prevention  of  stroke  and </text>
<text top="159" left="971" width="142" height="17" font="5">MI and suggested benefit </text>
<text top="176" left="971" width="142" height="17" font="5">for  prevention  of  CVD </text>
<text top="193" left="971" width="94" height="17" font="5">mortality and HF </text>
<text top="511" left="83" width="88" height="17" font="5">Bangalore S, et </text>
<text top="528" left="83" width="51" height="17" font="5">al., 2017 </text>
<text top="545" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28109971">28109971</a></text>
<text top="545" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28109971"> </a></text>
<text top="511" left="220" width="113" height="17" font="5">Study type: Network </text>
<text top="528" left="220" width="96" height="17" font="5">meta- analysis in </text>
<text top="545" left="220" width="100" height="17" font="5">which the authors </text>
<text top="562" left="220" width="72" height="17" font="5">attempted to </text>
<text top="579" left="220" width="118" height="17" font="5">compare the benefits </text>
<text top="597" left="220" width="111" height="17" font="5">and adverse effects </text>
<text top="614" left="220" width="78" height="17" font="5">resulting from </text>
<text top="631" left="220" width="119" height="17" font="5">intensive reduction in </text>
<text top="648" left="220" width="28" height="17" font="5">SBP </text>
<text top="666" left="212" width="3" height="17" font="5"> </text>
<text top="683" left="220" width="77" height="17" font="5">Size: 17 trials </text>
<text top="701" left="220" width="63" height="17" font="5">(n=55,163) </text>
<text top="510" left="373" width="24" height="17" font="5">N/A </text>
<text top="511" left="619" width="24" height="17" font="5">N/A </text>
<text top="511" left="794" width="81" height="18" font="5">• There was a </text>
<text top="529" left="794" width="125" height="17" font="5">significant reduction in </text>
<text top="546" left="794" width="138" height="17" font="5">stroke (RR: 0.54) and MI </text>
<text top="563" left="794" width="59" height="17" font="5">(RR: 0.68) </text>
<text top="581" left="794" width="115" height="18" font="5">• The point estimate </text>
<text top="599" left="794" width="97" height="17" font="5">favored all-cause </text>
<text top="616" left="794" width="132" height="17" font="5">mortality, CVD mortality </text>
<text top="633" left="794" width="124" height="17" font="5">and HF but the results </text>
<text top="650" left="794" width="86" height="17" font="5">did not achieve </text>
<text top="668" left="794" width="68" height="17" font="5">significance </text>
<text top="685" left="794" width="134" height="18" font="5">• SBP targets &lt;120 and </text>
<text top="703" left="794" width="132" height="17" font="5">&lt;130 mm Hg ranked #1 </text>
<text top="721" left="794" width="108" height="17" font="5">and #2 as the most </text>
<text top="738" left="794" width="62" height="17" font="5">efficacious </text>
<text top="755" left="794" width="142" height="18" font="5">• Serious adverse effects </text>
<text top="773" left="794" width="136" height="17" font="5">were more common at a </text>
<text top="510" left="971" width="142" height="17" font="5">Overall,  the  beneficial </text>
<text top="528" left="971" width="142" height="17" font="5">effects of treatment were </text>
<text top="544" left="971" width="142" height="17" font="5">consistent  with  other </text>
<text top="562" left="971" width="142" height="17" font="5">reports. The cluster plots </text>
<text top="579" left="971" width="142" height="17" font="5">of  treatment  benefit  vs. </text>
<text top="595" left="971" width="142" height="17" font="5">risk  are  difficult  to </text>
<text top="613" left="971" width="142" height="17" font="5">interpret due to limitations </text>
<text top="629" left="971" width="142" height="17" font="5">of the available data base </text>
<text top="647" left="971" width="142" height="17" font="5">and the authors’ decision </text>
<text top="663" left="971" width="14" height="17" font="5">to </text>
<text top="663" left="1001" width="111" height="17" font="5">weight  treatment </text>
<text top="681" left="971" width="142" height="17" font="5">benefits  and  potential </text>
<text top="698" left="971" width="132" height="17" font="5">adverse effects equally. </text>
</page>
<page number="254" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="90" left="794" width="146" height="17" font="5">lower SBP (120 vs. 150 or </text>
<text top="108" left="794" width="71" height="17" font="5">140 mm Hg) </text>
<text top="125" left="794" width="100" height="18" font="5">• Cluster plots for </text>
<text top="143" left="794" width="126" height="17" font="5">combined efficacy and </text>
<text top="160" left="794" width="107" height="17" font="5">safety suggested a </text>
<text top="178" left="794" width="28" height="17" font="5">SBP </text>
<text top="196" left="794" width="154" height="17" font="5">&lt;130 mm Hg as the optimal </text>
<text top="214" left="794" width="134" height="17" font="5">target for SBP reduction </text>
<text top="232" left="794" width="93" height="17" font="5">during treatment </text>
<text top="250" left="83" width="94" height="17" font="5">Bundy JD, et al., </text>
<text top="268" left="83" width="31" height="17" font="5">2017 </text>
<text top="285" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28564682">28564682</a></text>
<text top="285" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28564682"> </a></text>
<text top="250" left="220" width="65" height="17" font="5">Study type: </text>
<text top="268" left="220" width="83" height="17" font="5">Network meta- </text>
<text top="285" left="220" width="48" height="17" font="5">analysis </text>
<text top="303" left="212" width="3" height="17" font="5"> </text>
<text top="320" left="220" width="79" height="17" font="5">Size: 144,220 </text>
<text top="337" left="220" width="115" height="17" font="5">patients in 42 RCTs. </text>
<text top="250" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="267" left="373" width="156" height="18" font="5">• Random allocation into an </text>
<text top="286" left="373" width="158" height="17" font="5">antihypertensive medication, </text>
<text top="303" left="373" width="145" height="17" font="5">control or treatment target </text>
<text top="320" left="373" width="173" height="18" font="5">• Allocation to antihypertensive </text>
<text top="338" left="373" width="174" height="17" font="5">Antihypertensive treatment was </text>
<text top="355" left="373" width="172" height="17" font="5">independent of other treatment </text>
<text top="373" left="373" width="54" height="17" font="5">regimens </text>
<text top="390" left="373" width="187" height="18" font="5">• ≥100 patients in each treatment </text>
<text top="408" left="373" width="35" height="17" font="5">group </text>
<text top="425" left="373" width="128" height="18" font="5">• Trial duration ≥ 6 mo </text>
<text top="444" left="373" width="170" height="18" font="5">• One or more events for each </text>
<text top="462" left="373" width="139" height="17" font="5">treatment group reported </text>
<text top="479" left="373" width="214" height="18" font="5">• Minimum 5 mm Hg difference in SBP </text>
<text top="498" left="373" width="206" height="17" font="5">level between the 2 treatment groups </text>
<text top="514" left="373" width="216" height="17" font="5">Outcomes included major CVD, stroke, </text>
<text top="531" left="373" width="182" height="17" font="5">CHD, CVD mortality or all- cause </text>
<text top="548" left="373" width="50" height="17" font="5">mortality </text>
<text top="250" left="619" width="24" height="17" font="5">N/A </text>
<text top="250" left="794" width="110" height="18" font="5">• There were linear </text>
<text top="268" left="794" width="121" height="17" font="5">associations between </text>
<text top="286" left="794" width="138" height="17" font="5">mean achieved SBP and </text>
<text top="303" left="794" width="119" height="17" font="5">risk of cardiovascular </text>
<text top="320" left="794" width="123" height="17" font="5">disease and mortality, </text>
<text top="337" left="794" width="144" height="17" font="5">with the lowest risk at 120 </text>
<text top="355" left="794" width="84" height="17" font="5">to 124 mm Hg. </text>
<text top="372" left="794" width="138" height="17" font="5">Randomized groups with </text>
<text top="389" left="794" width="138" height="17" font="5">a mean achieved SBP of </text>
<text top="406" left="794" width="139" height="17" font="5">120 to 124 mm Hg had a </text>
<text top="423" left="794" width="115" height="17" font="5">hazard ratio (HR) for </text>
<text top="441" left="794" width="117" height="17" font="5">major cardiovascular </text>
<text top="458" left="794" width="138" height="17" font="5">disease of 0.71 (95% CI: </text>
<text top="475" left="794" width="146" height="17" font="5">0.60–0.83) compared with </text>
<text top="492" left="794" width="144" height="17" font="5">randomized groups with a </text>
<text top="510" left="794" width="128" height="17" font="5">mean achieved SBP of </text>
<text top="527" left="794" width="146" height="17" font="5">130 to 134 mm Hg, an HR </text>
<text top="544" left="794" width="123" height="17" font="5">of 0.58 (95% CI: 0.48–</text>
<text top="561" left="794" width="115" height="17" font="5">0.72) compared with </text>
<text top="579" left="794" width="103" height="17" font="5">those with a mean </text>
<text top="596" left="794" width="132" height="17" font="5">achieved SBP of 140 to </text>
<text top="613" left="794" width="122" height="17" font="5">144 mm Hg, an HR of </text>
<text top="630" left="794" width="141" height="17" font="5">0.46 (95% CI: 0.34–0.63) </text>
<text top="647" left="794" width="142" height="17" font="5">compared with those with </text>
<text top="665" left="794" width="138" height="17" font="5">a mean achieved SBP of </text>
<text top="682" left="794" width="132" height="17" font="5">150 to 154 mm Hg, and </text>
<text top="699" left="794" width="131" height="17" font="5">an HR of 0.36 (95% CI: </text>
<text top="716" left="794" width="62" height="17" font="5">0.26–0.51) </text>
<text top="734" left="794" width="152" height="17" font="5">compared with those with a </text>
<text top="752" left="794" width="152" height="17" font="5">mean achieved SBP of 160 </text>
<text top="770" left="794" width="92" height="17" font="5">mm Hg or more. </text>
<text top="250" left="971" width="142" height="17" font="5">This  study  suggests  that </text>
<text top="267" left="971" width="142" height="17" font="5">reducing  SBP  to  levels </text>
<text top="284" left="971" width="35" height="17" font="5">below </text>
<text top="284" left="1062" width="51" height="17" font="5">currently </text>
<text top="301" left="971" width="82" height="17" font="5">recommended </text>
<text top="301" left="1072" width="41" height="17" font="5">targets </text>
<text top="318" left="971" width="142" height="17" font="5">significantly  reduces  the </text>
<text top="335" left="971" width="142" height="17" font="5">risk  of  cardiovascular </text>
<text top="352" left="971" width="142" height="17" font="5">disease  and  all-  cause </text>
<text top="369" left="971" width="142" height="17" font="5">mortality  and  strongly </text>
<text top="386" left="971" width="142" height="17" font="5">support  more  intensive </text>
<text top="403" left="971" width="142" height="17" font="5">control  of  SBP  among </text>
<text top="420" left="971" width="138" height="17" font="5">adults with hypertension. </text>
</page>
<page number="255" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="83" width="89" height="17" font="5">Lonn EM, et al., </text>
<text top="108" left="83" width="34" height="17" font="5">2016  </text>
<text top="125" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27041480">27041480</a></text>
<text top="125" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27041480"> </a></text>
<text top="91" left="220" width="87" height="17" font="5">Aim: To assess </text>
<text top="108" left="220" width="119" height="17" font="5">efficacy of fixed-dose </text>
<text top="125" left="220" width="93" height="17" font="5">antihypertensive </text>
<text top="142" left="220" width="119" height="17" font="5">therapy in adults with </text>
<text top="160" left="220" width="100" height="17" font="5">intermediate CVD </text>
<text top="177" left="220" width="26" height="17" font="5">risk. </text>
<text top="195" left="212" width="3" height="17" font="5"> </text>
<text top="212" left="220" width="111" height="17" font="5">Study type: Double- </text>
<text top="229" left="220" width="83" height="17" font="5">blind, placebo- </text>
<text top="247" left="220" width="89" height="17" font="5">controlled RCT, </text>
<text top="264" left="220" width="86" height="17" font="5">factorial design </text>
<text top="282" left="212" width="3" height="17" font="5"> </text>
<text top="299" left="220" width="92" height="17" font="5">Size: 12,705 pts </text>
<text top="91" left="373" width="182" height="17" font="5">Inclusion criteria: Men ≥55 y and </text>
<text top="108" left="373" width="203" height="17" font="5">women ≥60 y at intermediate risk for </text>
<text top="125" left="373" width="138" height="17" font="5">CVD. No BP restrictions. </text>
<text top="143" left="365" width="3" height="17" font="5"> </text>
<text top="160" left="373" width="100" height="17" font="5">Exclusion criteria: </text>
<text top="177" left="373" width="80" height="18" font="5">• Known CVD </text>
<text top="196" left="373" width="196" height="18" font="5">• Indications or contraindications to </text>
<text top="214" left="373" width="66" height="17" font="5">study meds </text>
<text top="231" left="373" width="124" height="18" font="5">• Mod/advanced CKD </text>
<text top="249" left="373" width="144" height="17" font="5">Symptomatic hypotension </text>
<text top="91" left="619" width="142" height="17" font="5">Intervention: FDC of ARB </text>
<text top="108" left="619" width="127" height="17" font="5">(candesartan 16 mg/d) </text>
<text top="125" left="619" width="67" height="17" font="5">and diuretic </text>
<text top="142" left="619" width="141" height="17" font="5">(hydrochlorothiazide 12.5 </text>
<text top="160" left="619" width="96" height="17" font="5">mg/d) or placebo </text>
<text top="178" left="611" width="3" height="17" font="5"> </text>
<text top="195" left="619" width="128" height="17" font="5">Follow-up: Median=5.6 </text>
<text top="212" left="619" width="10" height="17" font="5">y </text>
<text top="91" left="794" width="111" height="17" font="5">1  endpoint: 1 co-1° </text>
<text top="108" left="794" width="89" height="17" font="5">CVD composite </text>
<text top="125" left="794" width="57" height="17" font="5">outcomes </text>
<text top="142" left="794" width="93" height="18" font="5">• CVD mortality, </text>
<text top="160" left="794" width="68" height="17" font="5">nonfatal MI, </text>
<text top="178" left="794" width="84" height="17" font="5">nonfatal stroke </text>
<text top="195" left="794" width="145" height="17" font="5">Above plus cardiac arrest, </text>
<text top="214" left="794" width="119" height="17" font="5">HF, revascularization </text>
<text top="90" left="971" width="59" height="17" font="5">Summary: </text>
<text top="108" left="971" width="67" height="18" font="5">• SBP/DBP </text>
<text top="126" left="971" width="68" height="17" font="5">reduction of </text>
<text top="144" left="971" width="84" height="17" font="5">6.0/3.0 mm Hg </text>
<text top="161" left="962" width="3" height="17" font="5"> </text>
<text top="178" left="971" width="100" height="18" font="5">• No difference in </text>
<text top="196" left="971" width="89" height="17" font="5">treatment effect </text>
<text top="213" left="971" width="63" height="18" font="5">• 1st co-1° </text>
<text top="231" left="974" width="94" height="17" font="5">0.93 (0.79–1.10) </text>
<text top="249" left="971" width="67" height="18" font="5">• 2nd co-1° </text>
<text top="267" left="974" width="94" height="17" font="5">0.95 (0.81–1.11) </text>
<text top="285" left="962" width="3" height="17" font="5"> </text>
<text top="303" left="971" width="99" height="18" font="5">• Suggestion of a </text>
<text top="321" left="971" width="135" height="17" font="5">subgroup effect in tertile </text>
<text top="338" left="971" width="88" height="17" font="5">with the highest </text>
<text top="355" left="971" width="49" height="17" font="5">baseline </text>
<text top="355" left="1044" width="20" height="17" font="5">BP </text>
<text top="355" left="1089" width="24" height="17" font="5">and </text>
<text top="372" left="971" width="112" height="17" font="5">increased CVD risk. </text>
<text top="390" left="83" width="98" height="17" font="5">Neaton JD, et al., </text>
<text top="407" left="83" width="56" height="17" font="5">1993 (23) </text>
<text top="424" left="83" width="48" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8336373">8336373</a></text>
<text top="424" left="131" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8336373"> </a></text>
<text top="390" left="219" width="107" height="17" font="5">Aim: To compare 6 </text>
<text top="407" left="219" width="93" height="17" font="5">antihypertensive </text>
<text top="424" left="219" width="110" height="17" font="5">drugs (representing </text>
<text top="442" left="219" width="76" height="17" font="5">different drug </text>
<text top="459" left="219" width="49" height="17" font="5">classes) </text>
<text top="477" left="212" width="3" height="17" font="5"> </text>
<text top="494" left="219" width="111" height="17" font="5">Study type: Double- </text>
<text top="511" left="219" width="83" height="17" font="5">blind, placebo- </text>
<text top="528" left="219" width="85" height="17" font="5">controlled RCT </text>
<text top="546" left="212" width="3" height="17" font="5"> </text>
<text top="563" left="220" width="100" height="17" font="5">Size: 902 pts with </text>
<text top="580" left="220" width="73" height="17" font="5">stage 1 HTN </text>
<text top="390" left="373" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="407" left="373" width="152" height="18" font="5">• Men and women 45–69 y </text>
<text top="426" left="373" width="33" height="18" font="5">• Not </text>
<text top="427" left="430" width="36" height="17" font="5">taking </text>
<text top="427" left="490" width="93" height="17" font="5">antihypertensive </text>
<text top="444" left="373" width="206" height="17" font="5">medications, with DBP 90–99 mm Hg </text>
<text top="461" left="373" width="210" height="17" font="5">Taking 1 antihypertensive medication, </text>
<text top="477" left="373" width="215" height="17" font="5">with DBP &lt;95 mm Hg and between 85–</text>
<text top="494" left="373" width="183" height="17" font="5">99 mm Hg after withdrawal of BP </text>
<text top="511" left="373" width="69" height="17" font="5">medications </text>
<text top="390" left="619" width="71" height="17" font="5">Intervention: </text>
<text top="407" left="619" width="59" height="17" font="5">Treatment </text>
<text top="424" left="619" width="57" height="17" font="5">(number): </text>
<text top="442" left="619" width="61" height="17" font="5">Once daily </text>
<text top="459" left="619" width="33" height="17" font="5">(AM): </text>
<text top="476" left="619" width="90" height="18" font="5">• Placebo (234) </text>
<text top="494" left="619" width="141" height="18" font="5">• Chlorthalidone 15 mg/d </text>
<text top="514" left="630" width="32" height="17" font="5">(136) </text>
<text top="531" left="619" width="126" height="18" font="5">• Acebutolol 400 mg/d </text>
<text top="550" left="630" width="32" height="17" font="5">(132) </text>
<text top="568" left="619" width="144" height="18" font="5">• Doxazosin 2 mg/d (134) </text>
<text top="586" left="619" width="147" height="18" font="5">• Amlodipine 5 mg/d (131) </text>
<text top="605" left="619" width="134" height="18" font="5">• Enalapril 5 mg/d (135) </text>
<text top="624" left="611" width="3" height="17" font="5"> </text>
<text top="641" left="619" width="128" height="17" font="5">Follow-up: Median=4.4 </text>
<text top="658" left="619" width="10" height="17" font="5">y </text>
<text top="391" left="794" width="147" height="17" font="5">1  endpoint: BP, QoL, side </text>
<text top="409" left="794" width="145" height="17" font="5">effects, chemistries, ECG, </text>
<text top="427" left="794" width="80" height="17" font="5">clinical events </text>
<text top="390" left="971" width="59" height="17" font="5">Summary: </text>
<text top="407" left="971" width="135" height="18" font="5">• Drugs (plus diet) more </text>
<text top="425" left="971" width="121" height="17" font="5">effective compared to </text>
<text top="443" left="971" width="122" height="17" font="5">placebo (plus diet) for </text>
<text top="460" left="971" width="77" height="17" font="5">control of BP. </text>
<text top="477" left="971" width="46" height="17" font="5">Minimal </text>
<text top="477" left="1049" width="64" height="17" font="5">differences </text>
<text top="494" left="971" width="131" height="17" font="5">between drug regimens </text>
<text top="676" left="83" width="85" height="17" font="5">Whelton PK, et </text>
<text top="693" left="83" width="51" height="17" font="5">al., 1997 </text>
<text top="711" left="83" width="48" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9168293?dopt=Citation">9168293</a></text>
<text top="711" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9168293?dopt=Citation"> </a></text>
<text top="676" left="220" width="119" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="693" left="220" width="73" height="17" font="5">of potassium </text>
<text top="711" left="220" width="111" height="17" font="5">supplementation on </text>
<text top="728" left="220" width="20" height="17" font="5">BP </text>
<text top="746" left="212" width="3" height="17" font="3"><b> </b></text>
<text top="763" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="676" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="693" left="373" width="82" height="18" font="5">• Human RCT </text>
<text top="711" left="373" width="84" height="18" font="5">• Without HTN </text>
<text top="730" left="373" width="183" height="18" font="5">• Potassium supplementation vs. </text>
<text top="748" left="373" width="40" height="17" font="5">control </text>
<text top="766" left="373" width="164" height="18" font="5">• No concurrent interventions </text>
<text top="676" left="619" width="139" height="17" font="3"><b>Intervention: </b>Potassium </text>
<text top="693" left="619" width="141" height="17" font="5">supplementation in 1,049 </text>
<text top="711" left="619" width="130" height="17" font="5">pts (potassium chloride </text>
<text top="728" left="619" width="141" height="17" font="5">tabs in 10 RCTs with 618 </text>
<text top="745" left="619" width="119" height="17" font="5">pts and diet in 2 RCT </text>
<text top="762" left="619" width="73" height="17" font="5">with 431 pts) </text>
<text top="677" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="694" left="794" width="138" height="18" font="5">• Significant reduction in </text>
<text top="714" left="794" width="23" height="17" font="5">BP. </text>
<text top="731" left="794" width="145" height="18" font="5">• Overall  (hypertensives </text>
<text top="750" left="794" width="24" height="17" font="5">and </text>
<text top="750" left="848" width="91" height="17" font="5">normotensives), </text>
<text top="767" left="794" width="145" height="17" font="5">mean: 3.11 mm Hg; 95% </text>
<text top="676" left="971" width="100" height="18" font="5">• This is the most </text>
<text top="694" left="971" width="87" height="17" font="5">comprehensive </text>
<text top="711" left="971" width="105" height="17" font="5">presentation of the </text>
<text top="728" left="971" width="130" height="17" font="5">effects of potassium on </text>
<text top="745" left="971" width="75" height="17" font="5">BP, including </text>
<text top="762" left="971" width="76" height="17" font="5">experience in </text>
</page>
<page number="256" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="108" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="125" left="212" width="3" height="17" font="3"><b> </b></text>
<text top="142" left="219" width="32" height="17" font="3"><b>Size: </b></text>
<text top="160" left="220" width="101" height="18" font="5">• Overall, 33 RCT </text>
<text top="178" left="220" width="56" height="17" font="5">(n=2,609) </text>
<text top="195" left="220" width="111" height="18" font="5">• 2 RCTs (n=1,049) </text>
<text top="214" left="219" width="96" height="17" font="5">in normotensives </text>
<text top="231" left="219" width="3" height="17" font="5"> </text>
<text top="91" left="365" width="3" height="17" font="3"><b> </b></text>
<text top="108" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="125" left="373" width="95" height="17" font="5">Missing key data </text>
<text top="92" left="611" width="3" height="17" font="3"><b> </b></text>
<text top="109" left="619" width="77" height="17" font="3"><b>Comparator: </b></text>
<text top="126" left="619" width="78" height="17" font="5">No potassium </text>
<text top="143" left="619" width="89" height="17" font="5">supplementation </text>
<text top="160" left="619" width="3" height="17" font="5"> </text>
<text top="178" left="619" width="81" height="17" font="5">(placebo in 10 </text>
<text top="195" left="619" width="85" height="17" font="5">RCT and usual </text>
<text top="212" left="619" width="79" height="17" font="5">diet in 2 RCT) </text>
<text top="91" left="794" width="134" height="17" font="5">CI: -4.32– -1.91 mm Hg. </text>
<text top="108" left="794" width="91" height="18" font="5">• In the 12 trials </text>
<text top="126" left="794" width="72" height="17" font="5">conducted in </text>
<text top="143" left="794" width="129" height="17" font="5">normotensives, mean: -</text>
<text top="161" left="794" width="145" height="17" font="5">1.8 mm Hg; 95% CI: -2.9– </text>
<text top="178" left="794" width="25" height="17" font="5">-0.6 </text>
<text top="196" left="794" width="137" height="17" font="5">mm Hg for SBP and -1.0 </text>
<text top="214" left="794" width="142" height="17" font="5">mm Hg; 95% CI: -2.1–0.0 </text>
<text top="232" left="794" width="46" height="17" font="5">for DBP </text>
<text top="250" left="794" width="91" height="18" font="5">• In the 20 trials </text>
<text top="268" left="794" width="72" height="17" font="5">conducted in </text>
<text top="285" left="794" width="145" height="17" font="5">hypertensives, mean: -4.4 </text>
<text top="303" left="794" width="129" height="17" font="5">mm Hg; 95% CI: -6.6– -</text>
<text top="320" left="794" width="139" height="17" font="5">2.2 for SBP and -2.5 mm </text>
<text top="337" left="794" width="143" height="17" font="5">Hg; 95% CI: -4.9– -0.1 for </text>
<text top="354" left="794" width="29" height="17" font="5">DBP </text>
<text top="372" left="786" width="3" height="17" font="5"> </text>
<text top="390" left="794" width="124" height="17" font="3"><b>Safety endpoint: </b>N/A </text>
<text top="91" left="971" width="87" height="17" font="5">normotensives. </text>
<text top="108" left="971" width="124" height="18" font="5">• Significant reduction </text>
<text top="126" left="971" width="117" height="17" font="5">in SBP overall and in </text>
<text top="144" left="971" width="130" height="17" font="5">the subgroups with and </text>
<text top="161" left="971" width="74" height="17" font="5">without HTN. </text>
<text top="178" left="971" width="101" height="18" font="5">• In a subsequent </text>
<text top="196" left="971" width="110" height="17" font="5">meta-analysis of 23 </text>
<text top="213" left="971" width="135" height="17" font="5">trials, Geleijnse JM, Kok </text>
<text top="231" left="971" width="130" height="17" font="5">FJ, and Grobbee DE (J </text>
<text top="248" left="971" width="92" height="17" font="5">Hum Hypertens. </text>
<text top="265" left="971" width="101" height="17" font="5">2003;17:471-480) </text>
<text top="282" left="971" width="132" height="17" font="5">reported a similar effect </text>
<text top="300" left="971" width="131" height="17" font="5">of potassium on SBP in </text>
<text top="317" left="971" width="130" height="17" font="5">both hypertensives and </text>
<text top="334" left="971" width="100" height="17" font="5">nonhypertensives </text>
<text top="351" left="971" width="58" height="17" font="5">(mean of - </text>
<text top="368" left="971" width="115" height="17" font="5">3.2 and -1.4 mm Hg, </text>
<text top="385" left="971" width="76" height="17" font="5">respectively). </text>
<text top="403" left="971" width="134" height="18" font="5">• The 1 RCT conducted </text>
<text top="421" left="971" width="117" height="17" font="5">in African-Americans </text>
<text top="438" left="971" width="136" height="17" font="5">(n=87) identified a mean </text>
<text top="455" left="971" width="127" height="17" font="5">treatment effect size of </text>
<text top="472" left="971" width="4" height="17" font="5">-</text>
<text top="472" left="975" width="135" height="17" font="20">6.9 mm Hg; 95% CI: -9.3</text>
<text top="472" left="1110" width="10" height="17" font="5">– </text>
<text top="490" left="971" width="67" height="17" font="20">-4.4 for SBP</text>
<text top="490" left="1037" width="3" height="17" font="5"> </text>
<text top="507" left="971" width="129" height="17" font="20">(p&lt;0.001) and -2.5 mm </text>
<text top="524" left="971" width="91" height="17" font="20">Hg; 95% CI: -4.3</text>
<text top="524" left="1061" width="10" height="17" font="5">– </text>
<text top="524" left="1072" width="25" height="17" font="20">-0.8 </text>
<text top="541" left="971" width="103" height="17" font="20">for DBP (p=0.004).</text>
<text top="541" left="1073" width="3" height="17" font="5"> </text>
<text top="559" left="971" width="116" height="18" font="5">• In the entire cohort </text>
<text top="577" left="971" width="126" height="17" font="5">(trials conducted in pts </text>
<text top="594" left="971" width="78" height="17" font="5">with HTN and </text>
<text top="611" left="971" width="106" height="17" font="5">normotension), net </text>
<text top="629" left="971" width="115" height="17" font="5">changes in SBP and </text>
<text top="646" left="971" width="101" height="17" font="5">DBP were directly </text>
<text top="663" left="971" width="137" height="17" font="5">related to level of urinary </text>
<text top="680" left="971" width="134" height="17" font="5">sodium excretion during </text>
<text top="698" left="971" width="47" height="17" font="5">the trial. </text>
</page>
<page number="257" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="89" left="83" width="91" height="17" font="3"><b>TOHP, Phase II </b></text>
<text top="104" left="83" width="76" height="17" font="5">Hypertension </text>
<text top="119" left="83" width="62" height="17" font="5">Prevention </text>
<text top="134" left="83" width="75" height="17" font="5">Collaborative </text>
<text top="150" left="83" width="97" height="17" font="5">Research Group, </text>
<text top="167" left="83" width="34" height="17" font="5">1997  </text>
<text top="185" left="83" width="48" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation">9080920</a></text>
<text top="185" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation"> </a></text>
<text top="89" left="220" width="120" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="104" left="220" width="115" height="17" font="5">of weight loss on BP </text>
<text top="119" left="220" width="98" height="17" font="5">and prevention of </text>
<text top="136" left="220" width="32" height="17" font="5">HTN. </text>
<text top="153" left="220" width="3" height="17" font="3"><b> </b></text>
<text top="170" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="187" left="220" width="76" height="17" font="5">Randomized, </text>
<text top="205" left="220" width="57" height="17" font="5">controlled </text>
<text top="222" left="220" width="73" height="17" font="5">factorial trial. </text>
<text top="240" left="212" width="3" height="17" font="5"> </text>
<text top="257" left="220" width="103" height="17" font="3"><b>Size: </b>2,382 pts, of </text>
<text top="274" left="220" width="100" height="17" font="5">whom 1,192 were </text>
<text top="292" left="220" width="92" height="17" font="5">randomized to a </text>
<text top="309" left="220" width="64" height="17" font="5">weight loss </text>
<text top="326" left="220" width="91" height="17" font="5">intervention and </text>
<text top="343" left="220" width="64" height="17" font="5">1,190 were </text>
<text top="360" left="220" width="109" height="17" font="5">randomized to a no </text>
<text top="378" left="220" width="64" height="17" font="5">weight loss </text>
<text top="395" left="220" width="70" height="17" font="5">intervention.<b> </b></text>
<text top="90" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="107" left="373" width="212" height="17" font="5">Healthy community-dwelling adults 30–</text>
<text top="124" left="373" width="26" height="17" font="5">54 y </text>
<text top="141" left="373" width="3" height="17" font="3"><b> </b></text>
<text top="159" left="373" width="192" height="18" font="5">• BMI between 110% and 165% of </text>
<text top="177" left="373" width="122" height="17" font="5">desirable body weight </text>
<text top="194" left="373" width="138" height="18" font="5">• Not taking BP-lowering </text>
<text top="212" left="373" width="63" height="17" font="5">medication </text>
<text top="229" left="373" width="170" height="18" font="5">• Mean SBP &lt;140 mm Hg and </text>
<text top="248" left="373" width="106" height="17" font="5">DBP 83-89 mm Hg </text>
<text top="266" left="365" width="3" height="17" font="5"> </text>
<text top="283" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="300" left="373" width="143" height="18" font="5">• Taking antihypertensive </text>
<text top="319" left="373" width="63" height="17" font="5">medication </text>
<text top="336" left="373" width="173" height="18" font="5">• Heart disease, renal disease, </text>
<text top="354" left="373" width="191" height="17" font="5">poorly controlled hyperlipidemia or </text>
<text top="371" left="373" width="182" height="17" font="5">DM, DM requiring insulin, special </text>
<text top="388" left="373" width="115" height="17" font="5">dietary requirements </text>
<text top="405" left="373" width="79" height="17" font="5">&gt;14 drinks/wk<b> </b></text>
<text top="89" left="619" width="130" height="17" font="3"><b>Intervention: </b>Behavior </text>
<text top="104" left="619" width="111" height="17" font="5">change intervention </text>
<text top="119" left="619" width="111" height="17" font="5">(combination of diet </text>
<text top="134" left="619" width="116" height="17" font="5">change and physical </text>
<text top="151" left="619" width="145" height="17" font="5">activity) aimed at studying </text>
<text top="168" left="619" width="128" height="17" font="5">the effects of a modest </text>
<text top="185" left="619" width="136" height="17" font="5">reduction in body weight </text>
<text top="202" left="619" width="106" height="17" font="5">during up to 48 mo </text>
<text top="220" left="619" width="113" height="17" font="5">(minimum 36 mo) of </text>
<text top="237" left="619" width="56" height="17" font="5">follow-up. </text>
<text top="255" left="611" width="3" height="17" font="5"> </text>
<text top="272" left="619" width="139" height="17" font="3"><b>Comparator: </b>Usual care </text>
<text top="289" left="619" width="35" height="17" font="5">group<b> </b></text>
<text top="91" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="109" left="794" width="87" height="17" font="5">Change in SBP </text>
<text top="126" left="794" width="138" height="17" font="5">Compared to usual care, </text>
<text top="143" left="794" width="119" height="17" font="5">the weight loss group </text>
<text top="160" left="794" width="139" height="17" font="5">experienced a significant </text>
<text top="178" left="794" width="143" height="17" font="5">mean reduction of -4.5 kg </text>
<text top="195" left="794" width="130" height="17" font="5">in body weight and -3.7 </text>
<text top="212" left="794" width="147" height="17" font="5">(SD: 0.5; p&lt;0.001) mm Hg </text>
<text top="229" left="794" width="138" height="17" font="5">in SBP at 6 mo (-6.0 mm </text>
<text top="247" left="794" width="117" height="17" font="5">Hg in the weight loss </text>
<text top="264" left="794" width="139" height="17" font="5">group and -2.2 mm Hg in </text>
<text top="281" left="794" width="123" height="17" font="5">the usual care group). </text>
<text top="298" left="794" width="143" height="18" font="5">• A progressive reduction </text>
<text top="316" left="794" width="116" height="17" font="5">in the effect sizes for </text>
<text top="334" left="794" width="138" height="17" font="5">body weight and BP was </text>
<text top="351" left="794" width="117" height="17" font="5">noted over time, with </text>
<text top="368" left="794" width="131" height="17" font="5">mean for SBP at 18, 36 </text>
<text top="385" left="794" width="127" height="17" font="5">mo and termination of -</text>
<text top="402" left="794" width="132" height="17" font="5">1.8 (SD: 0.5; p&lt;0.001), -</text>
<text top="420" left="794" width="121" height="17" font="5">1.3 (SD: 0.5; p=0.01), </text>
<text top="437" left="794" width="104" height="17" font="5">and - 1.1 (SD: 0.5; </text>
<text top="454" left="794" width="49" height="17" font="5">p=0.04). </text>
<text top="472" left="786" width="3" height="17" font="5"> </text>
<text top="489" left="794" width="105" height="17" font="5">Prevention of HTN </text>
<text top="507" left="794" width="122" height="18" font="5">• At 6 mo of follow-up </text>
<text top="525" left="794" width="115" height="17" font="5">the incidence of new </text>
<text top="542" left="794" width="115" height="17" font="5">onset HTN was 42% </text>
<text top="559" left="794" width="132" height="17" font="5">lower in the participants </text>
<text top="576" left="794" width="120" height="17" font="5">randomized to weight </text>
<text top="594" left="794" width="117" height="17" font="5">loss compared to the </text>
<text top="611" left="794" width="95" height="17" font="5">usual care group </text>
<text top="628" left="794" width="53" height="17" font="5">(p=0.02). </text>
<text top="645" left="794" width="81" height="18" font="5">• During more </text>
<text top="664" left="794" width="135" height="17" font="5">prolonged follow-up, the </text>
<text top="681" left="794" width="119" height="17" font="5">effect size decreased </text>
<text top="698" left="794" width="133" height="17" font="5">but remained borderline </text>
<text top="715" left="794" width="137" height="17" font="5">significant after 48 mo of </text>
<text top="732" left="794" width="85" height="17" font="5">follow-up (13% </text>
<text top="750" left="794" width="106" height="17" font="5">reduction; p=0.06). </text>
<text top="767" left="794" width="135" height="17" font="5">Overall, the incidence of </text>
<text top="91" left="960" width="130" height="18" font="5">• Largest trial of weight </text>
<text top="109" left="971" width="113" height="17" font="5">loss in prevention of </text>
<text top="126" left="971" width="128" height="17" font="5">HTN and also provides </text>
<text top="143" left="971" width="125" height="17" font="5">the longest duration of </text>
<text top="160" left="971" width="53" height="17" font="5">follow-up </text>
<text top="177" left="960" width="135" height="18" font="5">• The assumptions for a </text>
<text top="195" left="971" width="116" height="17" font="5">main effects factorial </text>
<text top="212" left="971" width="132" height="17" font="5">analysis (independence </text>
<text top="230" left="971" width="111" height="17" font="5">of the interventions) </text>
<text top="247" left="971" width="133" height="17" font="5">were not demonstrated. </text>
<text top="264" left="971" width="121" height="17" font="5">Given this finding, the </text>
<text top="281" left="971" width="134" height="17" font="5">most reliable analysis of </text>
<text top="299" left="971" width="71" height="17" font="5">this trial was </text>
<text top="316" left="971" width="101" height="17" font="5">comparison of the </text>
<text top="333" left="971" width="106" height="17" font="5">experience in each </text>
<text top="350" left="971" width="102" height="17" font="5">active intervention </text>
<text top="367" left="971" width="113" height="17" font="5">group with the usual </text>
<text top="385" left="971" width="132" height="17" font="5">care group. This results </text>
<text top="402" left="971" width="90" height="17" font="5">in a reduction in </text>
<text top="419" left="971" width="94" height="17" font="5">statistical power. </text>
<text top="436" left="960" width="117" height="18" font="5">• Consistent with the </text>
<text top="454" left="971" width="139" height="17" font="5">pattern in the proceeding </text>
<text top="472" left="971" width="132" height="17" font="5">TOHP I trial weight loss </text>
<text top="489" left="971" width="112" height="17" font="5">reduced BP and the </text>
<text top="506" left="971" width="138" height="17" font="5">incidence of HTN but the </text>
<text top="523" left="971" width="121" height="17" font="5">effect sizes for weight </text>
<text top="541" left="971" width="126" height="17" font="5">loss and BP as well as </text>
<text top="558" left="971" width="82" height="17" font="5">the difficulty of </text>
<text top="575" left="971" width="87" height="17" font="5">maintaining the </text>
<text top="592" left="971" width="115" height="17" font="5">intervention in highly </text>
<text top="609" left="971" width="81" height="17" font="5">motivated and </text>
<text top="627" left="971" width="126" height="17" font="5">extensively counselled </text>
<text top="644" left="971" width="137" height="17" font="5">participants underscores </text>
<text top="661" left="971" width="136" height="17" font="5">the difficulty of achieving </text>
<text top="678" left="971" width="119" height="17" font="5">and maintaining ideal </text>
<text top="696" left="971" width="102" height="17" font="5">body weight in the </text>
<text top="713" left="960" width="131" height="18" font="5">• general population by </text>
<text top="731" left="971" width="98" height="17" font="5">means of lifestyle </text>
<text top="748" left="971" width="47" height="17" font="5">change. </text>
</page>
<page number="258" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="118" height="17" font="5">HTN was reduced by </text>
<text top="108" left="794" width="81" height="17" font="5">21% (p=0.02). </text>
<text top="126" left="786" width="3" height="17" font="5"> </text>
<text top="144" left="794" width="124" height="17" font="3"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="176" left="83" width="59" height="17" font="3"><b>PREMIER </b></text>
<text top="194" left="83" width="88" height="17" font="5">Appel LJ, et al., </text>
<text top="211" left="83" width="56" height="17" font="5">2003 (83) </text>
<text top="226" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12709466">12709466</a></text>
<text top="226" left="137" width="3" height="17" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12709466"><b> </b></a></text>
<text top="175" left="220" width="119" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="190" left="220" width="84" height="17" font="5">of 2 behavioral </text>
<text top="205" left="220" width="127" height="17" font="5">interventions, aimed at </text>
<text top="220" left="220" width="125" height="17" font="5">dietary change, on BP </text>
<text top="235" left="220" width="3" height="17" font="3"><b> </b></text>
<text top="260" left="220" width="70" height="17" font="3"><b>Study type: </b></text>
<text top="278" left="220" width="102" height="18" font="5">• Multicenter RCT </text>
<text top="296" left="220" width="112" height="17" font="5">with 3 parallel arms: </text>
<text top="312" left="220" width="77" height="18" font="5">• Established </text>
<text top="331" left="220" width="77" height="18" font="5">• Established </text>
<text top="349" left="220" width="87" height="17" font="5">plus DASH diet </text>
<text top="365" left="220" width="66" height="17" font="5">Advice only </text>
<text top="380" left="220" width="3" height="17" font="3"><b> </b></text>
<text top="405" left="220" width="32" height="17" font="3"><b>Size: </b></text>
<text top="422" left="220" width="117" height="17" font="5">810 adults, with 62% </text>
<text top="437" left="220" width="128" height="17" font="5">(506) normotensive. At </text>
<text top="452" left="220" width="114" height="17" font="5">baseline, mean age, </text>
<text top="467" left="220" width="106" height="17" font="5">BMI and SBP/DBP </text>
<text top="483" left="220" width="118" height="17" font="5">were 50 y, 33 kg/m2, </text>
<text top="498" left="220" width="111" height="17" font="5">and 135/85 mm Hg, </text>
<text top="513" left="220" width="68" height="17" font="5">respectively </text>
<text top="528" left="220" width="3" height="17" font="3"><b> </b></text>
<text top="543" left="220" width="117" height="17" font="3"><b>Duration: </b>6 mo, with </text>
<text top="558" left="220" width="131" height="17" font="5">observations at 3 and 6 </text>
<text top="573" left="220" width="24" height="17" font="5">mo.<b> </b></text>
<text top="176" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="193" left="373" width="79" height="18" font="5">• Adults ≥25y </text>
<text top="212" left="373" width="188" height="18" font="5">• Average SBP between 120–159 </text>
<text top="230" left="373" width="193" height="17" font="5">mm Hg and average DBP between </text>
<text top="247" left="373" width="81" height="17" font="5">80–95 mm Hg </text>
<text top="265" left="373" width="154" height="18" font="5">• No use of antihypertensive </text>
<text top="283" left="373" width="63" height="17" font="5">medication </text>
<text top="303" left="373" width="190" height="18" font="5">• BMI between 18.5 and 45 kg/m2 </text>
<text top="322" left="365" width="3" height="17" font="5"> </text>
<text top="339" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="356" left="373" width="185" height="18" font="5">• Regular use of drugs that affect </text>
<text top="375" left="373" width="20" height="17" font="5">BP </text>
<text top="392" left="373" width="169" height="18" font="5">• Target organ damage or DM </text>
<text top="410" left="373" width="147" height="18" font="5">• Use of weight-loss meds </text>
<text top="428" left="373" width="91" height="18" font="5">• Hx CVD event </text>
<text top="447" left="373" width="176" height="18" font="5">• HF, angina, cancer, within 2 y </text>
<text top="465" left="373" width="175" height="18" font="5">• Consumption of &gt;21 alcoholic </text>
<text top="483" left="373" width="58" height="17" font="5">drinks /wk </text>
<text top="500" left="373" width="177" height="17" font="5">Pregnancy, planned pregnancy, </text>
<text top="517" left="373" width="49" height="17" font="5">lactation<b> </b></text>
<text top="176" left="619" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="194" left="619" width="130" height="18" font="5">• Structured behavioral </text>
<text top="212" left="619" width="127" height="17" font="5">interventions that used </text>
<text top="229" left="619" width="118" height="17" font="5">an identical format (4 </text>
<text top="246" left="619" width="130" height="17" font="5">individual and 14 group </text>
<text top="263" left="619" width="117" height="17" font="5">sessions) to facilitate </text>
<text top="281" left="619" width="138" height="17" font="5">adoption of “established” </text>
<text top="298" left="619" width="141" height="17" font="5">dietary recommendations </text>
<text top="315" left="619" width="119" height="17" font="5">for reduction in BP or </text>
<text top="332" left="619" width="120" height="17" font="5">“established” plus the </text>
<text top="350" left="619" width="89" height="17" font="5">DASH diet. The </text>
<text top="367" left="619" width="114" height="17" font="5">“established” dietary </text>
<text top="384" left="619" width="131" height="17" font="5">recommendations used </text>
<text top="401" left="619" width="117" height="17" font="5">in PREMIER were a) </text>
<text top="418" left="619" width="140" height="17" font="5">weight loss in overweight </text>
<text top="436" left="619" width="70" height="17" font="5">participants, </text>
<text top="453" left="619" width="115" height="17" font="5">b) sodium reduction, </text>
<text top="470" left="619" width="104" height="17" font="5">increased physical </text>
<text top="487" left="619" width="134" height="17" font="5">activity, reduced alcohol </text>
<text top="505" left="619" width="132" height="17" font="5">intake in pts consuming </text>
<text top="522" left="619" width="46" height="17" font="5">alcohol. </text>
<text top="539" left="619" width="85" height="18" font="5">• Compared to </text>
<text top="557" left="619" width="135" height="17" font="5">experience in the advice </text>
<text top="574" left="619" width="113" height="17" font="5">only (control) group, </text>
<text top="592" left="619" width="126" height="17" font="5">there was only modest </text>
<text top="609" left="619" width="87" height="17" font="5">achievement of </text>
<text top="626" left="619" width="133" height="17" font="5">intervention goals in the </text>
<text top="643" left="619" width="137" height="17" font="5">“established” group, with </text>
<text top="660" left="619" width="137" height="17" font="5">a MDs of 3.8 kg (8.4 lbs) </text>
<text top="678" left="619" width="117" height="17" font="5">for body weight, 11.6 </text>
<text top="695" left="619" width="118" height="17" font="5">mmol (267 mg)/d) for </text>
<text top="712" left="619" width="141" height="17" font="5">urinary sodium excretion, </text>
<text top="729" left="619" width="121" height="17" font="5">no change in physical </text>
<text top="746" left="619" width="100" height="17" font="5">activity (but better </text>
<text top="764" left="619" width="131" height="17" font="5">fitness), and no change </text>
<text top="177" left="794" width="69" height="17" font="3"><b>1  endpoint </b></text>
<text top="195" left="794" width="125" height="18" font="5">• Compared to control </text>
<text top="213" left="794" width="128" height="17" font="5">(advice only), SBP and </text>
<text top="230" left="794" width="126" height="17" font="5">DBP were significantly </text>
<text top="247" left="794" width="136" height="17" font="5">reduced with both active </text>
<text top="265" left="794" width="125" height="17" font="5">interventions but there </text>
<text top="282" left="794" width="100" height="17" font="5">was no significant </text>
<text top="299" left="794" width="124" height="17" font="5">difference in the effect </text>
<text top="316" left="794" width="141" height="17" font="5">size between the 2 active </text>
<text top="333" left="794" width="138" height="17" font="5">intervention groups. This </text>
<text top="351" left="794" width="115" height="17" font="5">was true for both the </text>
<text top="368" left="794" width="101" height="17" font="5">normotensive and </text>
<text top="385" left="794" width="142" height="17" font="5">hypertensive pts, with the </text>
<text top="402" left="794" width="140" height="17" font="5">effect size being larger in </text>
<text top="420" left="794" width="145" height="17" font="5">the hypertensive group. In </text>
<text top="437" left="794" width="128" height="17" font="5">the normotensives, the </text>
<text top="454" left="794" width="125" height="17" font="5">MD for change in SBP </text>
<text top="471" left="794" width="112" height="17" font="5">was identical for the </text>
<text top="489" left="794" width="145" height="17" font="5">“established” compared to </text>
<text top="506" left="794" width="133" height="17" font="5">“established plus DASH </text>
<text top="523" left="794" width="130" height="17" font="5">Diet” groups: -3.1 (95% </text>
<text top="540" left="794" width="122" height="17" font="5">CI: -5.1– -1.1) mm Hg </text>
<text top="557" left="794" width="106" height="17" font="5">The corresponding </text>
<text top="575" left="794" width="130" height="17" font="5">changes for DBP were -</text>
<text top="592" left="794" width="132" height="17" font="5">1.6 (95% CI: -2.9– -0.2) </text>
<text top="609" left="794" width="112" height="17" font="5">for the “established” </text>
<text top="626" left="794" width="130" height="17" font="5">intervention group and -</text>
<text top="643" left="794" width="132" height="17" font="5">2.0 (95% CI: -3.4– -0.6) </text>
<text top="661" left="794" width="108" height="17" font="5">for the “established </text>
<text top="678" left="794" width="130" height="17" font="5">intervention plus DASH </text>
<text top="695" left="794" width="68" height="17" font="5">Diet) group. </text>
<text top="712" left="794" width="145" height="18" font="5">• Overall, the incidence of </text>
<text top="730" left="794" width="137" height="17" font="5">HTN was lowest and the </text>
<text top="748" left="794" width="112" height="17" font="5">percent with optimal </text>
<text top="765" left="794" width="121" height="17" font="5">BP was highest in the </text>
<text top="176" left="971" width="81" height="17" font="5">● This was an </text>
<text top="194" left="971" width="118" height="17" font="5">interesting trial which </text>
<text top="211" left="971" width="117" height="17" font="5">employed a behavior </text>
<text top="228" left="971" width="112" height="17" font="5">change approach to </text>
<text top="245" left="971" width="123" height="17" font="5">implement both active </text>
<text top="263" left="971" width="77" height="17" font="5">interventions. </text>
<text top="280" left="971" width="136" height="17" font="5">● The investigators goal </text>
<text top="297" left="971" width="117" height="17" font="5">was to determine the </text>
<text top="314" left="971" width="113" height="17" font="5">additive value of the </text>
<text top="332" left="971" width="123" height="17" font="5">DASH Diet in persons </text>
<text top="349" left="971" width="116" height="17" font="5">already following key </text>
<text top="366" left="971" width="67" height="17" font="5">elements of </text>
<text top="383" left="971" width="72" height="17" font="5">conventional </text>
<text top="400" left="971" width="74" height="17" font="5">(established) </text>
<text top="418" left="971" width="119" height="17" font="5">recommendations for </text>
<text top="435" left="971" width="104" height="17" font="5">nonpharmacologic </text>
<text top="452" left="971" width="137" height="17" font="5">intervention to lower BP. </text>
<text top="469" left="971" width="104" height="17" font="5">● The intervention </text>
<text top="487" left="971" width="139" height="17" font="5">approach in this trial was </text>
<text top="504" left="971" width="87" height="17" font="5">less effective in </text>
<text top="521" left="971" width="119" height="17" font="5">achieving weight loss </text>
<text top="538" left="971" width="131" height="17" font="5">and reduction in dietary </text>
<text top="555" left="971" width="135" height="17" font="5">sodium compared to the </text>
<text top="573" left="971" width="81" height="17" font="5">corresponding </text>
<text top="590" left="971" width="134" height="17" font="5">experience in the TOHP </text>
<text top="607" left="971" width="135" height="17" font="5">and TONE trials and the </text>
<text top="624" left="971" width="119" height="17" font="5">DASH Diet effects on </text>
<text top="641" left="971" width="124" height="17" font="5">intermediate variables </text>
<text top="659" left="971" width="98" height="17" font="5">(such as fruit and </text>
<text top="676" left="971" width="134" height="17" font="5">vegetable consumption) </text>
<text top="693" left="971" width="102" height="17" font="5">was less than that </text>
<text top="710" left="971" width="124" height="17" font="5">achieved in the DASH </text>
<text top="727" left="971" width="115" height="17" font="5">Diet feeding studies. </text>
<text top="745" left="971" width="109" height="17" font="5">Despite the modest </text>
<text top="762" left="971" width="137" height="17" font="5">intervention effects, both </text>
</page>
<page number="259" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="21" size="12" family="Times" color="#6f6363"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="619" width="128" height="17" font="5">in alcohol consumption </text>
<text top="108" left="619" width="115" height="17" font="5">(but very low alcohol </text>
<text top="125" left="619" width="144" height="17" font="5">consumption at baseline). </text>
<text top="140" left="619" width="151" height="17" font="5">Weight loss was somewhat </text>
<text top="156" left="619" width="149" height="17" font="5">greater in the “established” </text>
<text top="171" left="619" width="150" height="17" font="5">plus DASH diet group, with </text>
<text top="186" left="619" width="138" height="17" font="5">a MD of 4.8 kg (10.6 lbs) </text>
<text top="201" left="619" width="152" height="17" font="5">for body weight. This group </text>
<text top="216" left="619" width="143" height="17" font="5">also manifested expected </text>
<text top="231" left="619" width="138" height="17" font="5">effects of the DASH diet, </text>
<text top="246" left="619" width="130" height="17" font="5">with significantly higher </text>
<text top="261" left="619" width="124" height="17" font="5">urinary potassium and </text>
<text top="276" left="619" width="113" height="17" font="5">phosphorous levels, </text>
<text top="291" left="619" width="129" height="17" font="5">greater consumption of </text>
<text top="306" left="619" width="120" height="17" font="5">fruits and vegetables, </text>
<text top="321" left="619" width="119" height="17" font="5">dietary calcium, dairy </text>
<text top="337" left="619" width="121" height="17" font="5">products, and a lower </text>
<text top="351" left="619" width="130" height="17" font="5">consumption of total fat </text>
<text top="367" left="619" width="99" height="17" font="5">and saturated fat. </text>
<text top="382" left="619" width="3" height="17" font="3"><b> </b></text>
<text top="397" left="619" width="144" height="17" font="3"><b>Comparator: </b>Advice only<b> </b></text>
<text top="91" left="794" width="137" height="17" font="5">“established plus DASH” </text>
<text top="108" left="794" width="133" height="17" font="5">diet but the incidence of </text>
<text top="125" left="794" width="146" height="17" font="5">HTN was significantly less </text>
<text top="142" left="794" width="114" height="17" font="5">and the percent with </text>
<text top="160" left="794" width="138" height="17" font="5">optimal BP was higher in </text>
<text top="177" left="794" width="130" height="17" font="5">both active intervention </text>
<text top="194" left="794" width="113" height="17" font="5">groups compared to </text>
<text top="211" left="794" width="93" height="17" font="5">advice only. The </text>
<text top="229" left="794" width="138" height="17" font="5">difference between the 2 </text>
<text top="246" left="794" width="143" height="17" font="5">active intervention groups </text>
<text top="263" left="794" width="141" height="17" font="5">was not significant. In the </text>
<text top="280" left="794" width="143" height="17" font="5">normotensives, there was </text>
<text top="297" left="794" width="120" height="17" font="5">a nonsignificant trend </text>
<text top="315" left="794" width="134" height="17" font="5">towards less HTN and a </text>
<text top="332" left="794" width="105" height="17" font="5">significantly higher </text>
<text top="349" left="794" width="145" height="17" font="5">percent with optimal BP in </text>
<text top="366" left="794" width="130" height="17" font="5">both active intervention </text>
<text top="383" left="794" width="113" height="17" font="5">groups compared to </text>
<text top="401" left="794" width="110" height="17" font="5">advice only, with no </text>
<text top="418" left="794" width="133" height="17" font="5">significant difference for </text>
<text top="435" left="794" width="145" height="17" font="5">percent with optimal BP in </text>
<text top="452" left="794" width="133" height="17" font="5">the 2 active intervention </text>
<text top="469" left="794" width="44" height="17" font="5">groups. </text>
<text top="487" left="786" width="3" height="17" font="5"> </text>
<text top="505" left="794" width="137" height="17" font="3"><b>1  Safety endpoint</b>: N/A<b> </b></text>
<text top="91" left="971" width="111" height="17" font="5">SBP and DBP were </text>
<text top="108" left="971" width="115" height="17" font="5">significantly reduced </text>
<text top="125" left="971" width="118" height="17" font="5">with the conventional </text>
<text top="142" left="971" width="139" height="17" font="5">intervention approach (in </text>
<text top="160" left="971" width="124" height="17" font="5">normotensives as well </text>
<text top="177" left="971" width="130" height="17" font="5">as overall) and addition </text>
<text top="194" left="971" width="135" height="17" font="5">of the DASH diet did not </text>
<text top="211" left="971" width="131" height="17" font="5">have a significant effect </text>
<text top="229" left="971" width="127" height="17" font="5">on reduction of SBP or </text>
<text top="246" left="971" width="32" height="17" font="5">DBP. </text>
<text top="263" left="960" width="109" height="18" font="5">• There were some </text>
<text top="281" left="971" width="116" height="17" font="5">nonsignificant trends </text>
<text top="298" left="971" width="115" height="17" font="5">for slightly lower BP, </text>
<text top="315" left="971" width="113" height="17" font="5">less HTN, and more </text>
<text top="332" left="971" width="96" height="17" font="5">optimal BP in the </text>
<text top="349" left="971" width="96" height="17" font="5">“established plus </text>
<text top="366" left="971" width="102" height="17" font="5">DASH Diet” group </text>
<text top="383" left="971" width="72" height="17" font="5">compared to </text>
<text top="400" left="971" width="112" height="17" font="5">“established” group. </text>
<text top="417" left="971" width="124" height="17" font="5">The authors also cited </text>
<text top="434" left="971" width="120" height="17" font="5">use of the DASH Diet </text>
<text top="451" left="971" width="81" height="17" font="5">as a means to </text>
<text top="468" left="971" width="117" height="17" font="5">beneficially influence </text>
<text top="485" left="971" width="105" height="17" font="5">CVD risk factors in </text>
<text top="502" left="971" width="83" height="17" font="5">addition to BP. </text>
<text top="524" left="83" width="95" height="17" font="5">Aburto NJ, et al., </text>
<text top="541" left="83" width="34" height="17" font="5">2013 <b> </b></text>
<text top="557" left="83" width="55" height="17" font="21"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23558163"><b>23558163</b></a></text>
<text top="557" left="137" width="3" height="17" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23558163"><b> </b></a></text>
<text top="524" left="220" width="119" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="541" left="220" width="111" height="17" font="5">of sodium reduction </text>
<text top="558" left="220" width="37" height="17" font="5">on BP </text>
<text top="576" left="212" width="3" height="17" font="5"> </text>
<text top="593" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="610" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="627" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="645" left="212" width="3" height="17" font="5"> </text>
<text top="663" left="220" width="107" height="17" font="3"><b>Size: </b>Overall study </text>
<text top="680" left="220" width="117" height="17" font="5">included 36 trials (49 </text>
<text top="697" left="220" width="77" height="17" font="5">comparisons) </text>
<text top="714" left="220" width="107" height="17" font="5">conducted in 6,736 </text>
<text top="732" left="220" width="111" height="17" font="5">pts. Of these, 3,263 </text>
<text top="749" left="220" width="30" height="17" font="5">were </text>
<text top="766" left="220" width="122" height="17" font="5">nonhypertensive. The </text>
<text top="523" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="541" left="373" width="99" height="18" font="5">•<b> </b>RCT in humans </text>
<text top="559" left="373" width="122" height="18" font="5">•<b> </b>Trial duration ≥4 wk </text>
<text top="577" left="373" width="122" height="18" font="5">•<b> </b>24-h urinary sodium </text>
<text top="596" left="373" width="163" height="17" font="5">≥40 mmol/d less in treatment </text>
<text top="613" left="373" width="147" height="17" font="5">compared to control group </text>
<text top="630" left="373" width="164" height="18" font="5">•<b> </b>No concurrent interventions </text>
<text top="649" left="373" width="86" height="18" font="5">•<b> </b>Not acutely ill </text>
<text top="667" left="365" width="3" height="17" font="5"> </text>
<text top="683" left="373" width="190" height="17" font="3"><b>Exclusion criteria: </b>Lack of above<b> </b></text>
<text top="524" left="619" width="123" height="17" font="3"><b>Intervention: </b>Sodium </text>
<text top="541" left="619" width="54" height="17" font="5">reduction </text>
<text top="559" left="611" width="3" height="17" font="5"> </text>
<text top="575" left="619" width="139" height="17" font="3"><b>Comparator: </b>No sodium </text>
<text top="592" left="619" width="54" height="17" font="5">reduction<b> </b></text>
<text top="524" left="794" width="127" height="17" font="3"><b>1  endpoint: </b>In pooled </text>
<text top="541" left="794" width="111" height="17" font="5">analysis, the overall </text>
<text top="558" left="794" width="141" height="17" font="5">change in SBP was -3.39 </text>
<text top="575" left="794" width="152" height="17" font="5">(95% CI: -4.31– - 2.46) mm </text>
<text top="592" left="794" width="134" height="17" font="5">Hg. In the pts with HTN, </text>
<text top="610" left="794" width="153" height="17" font="5">the change was -4.06 (95% </text>
<text top="627" left="794" width="96" height="17" font="5">CI: -5.15– -2.96). </text>
<text top="644" left="794" width="141" height="17" font="5">In the normotensives, the </text>
<text top="661" left="794" width="132" height="17" font="5">change was -1.38 (95% </text>
<text top="678" left="794" width="89" height="17" font="5">CI: -2.74–0.02). </text>
<text top="696" left="786" width="3" height="17" font="5"> </text>
<text top="714" left="794" width="134" height="17" font="3"><b>Safety endpoint: </b>In the </text>
<text top="732" left="794" width="138" height="17" font="5">small number of relevant </text>
<text top="750" left="794" width="106" height="17" font="5">trials, there was no </text>
<text top="769" left="794" width="148" height="17" font="5">significant effect of sodium </text>
<text top="524" left="971" width="47" height="17" font="5">● Study </text>
<text top="541" left="971" width="106" height="17" font="5">inclusion/exclusion </text>
<text top="558" left="971" width="107" height="17" font="5">criteria designed to </text>
<text top="575" left="971" width="117" height="17" font="5">yield a group of trials </text>
<text top="592" left="971" width="103" height="17" font="5">that would provide </text>
<text top="610" left="971" width="94" height="17" font="5">results that have </text>
<text top="627" left="971" width="115" height="17" font="5">relevance for clinical </text>
<text top="644" left="971" width="106" height="17" font="5">practice and public </text>
<text top="661" left="971" width="123" height="17" font="5">health. In this context, </text>
<text top="678" left="971" width="126" height="17" font="5">reduced sodium intake </text>
<text top="696" left="971" width="133" height="17" font="5">resulted in a statistically </text>
<text top="713" left="971" width="110" height="17" font="5">significant but small </text>
<text top="730" left="971" width="98" height="17" font="5">reduction in SBP. </text>
</page>
<page number="260" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="52" height="17" font="5">results in </text>
<text top="108" left="220" width="119" height="17" font="5">normotensives in this </text>
<text top="125" left="220" width="105" height="17" font="5">table are based on </text>
<text top="142" left="220" width="122" height="17" font="5">experience in 7 RCTs </text>
<text top="158" left="220" width="107" height="17" font="5">conducted in 3,067 </text>
<text top="173" left="220" width="100" height="17" font="5">normotensive pts.<b> </b></text>
<text top="91" left="794" width="131" height="17" font="5">reduction on lipid levels </text>
<text top="110" left="794" width="128" height="17" font="5">(Total cholesterol, LDL-</text>
<text top="128" left="794" width="98" height="17" font="5">cholesterol, HDL- </text>
<text top="146" left="794" width="129" height="17" font="5">cholesterol, triglyceride </text>
<text top="164" left="794" width="120" height="17" font="5">levels; 11 trials) or on </text>
<text top="182" left="794" width="146" height="17" font="5">plasma (7 trials) or urinary </text>
<text top="200" left="794" width="132" height="17" font="5">catecholamine levels (2 </text>
<text top="218" left="794" width="154" height="17" font="5">trials). Experience in 4 trials </text>
<text top="237" left="794" width="119" height="17" font="5">(3 which could not be </text>
<text top="255" left="794" width="114" height="17" font="5">included in the meta-</text>
<text top="273" left="794" width="122" height="17" font="5">analysis) suggested a </text>
<text top="291" left="794" width="145" height="17" font="5">beneficial effect of sodium </text>
<text top="309" left="794" width="153" height="17" font="5">reduction on urinary protein </text>
<text top="327" left="794" width="57" height="17" font="5">excretion.<b> </b></text>
<text top="346" left="83" width="85" height="17" font="5">Graudal NA, et </text>
<text top="363" left="83" width="76" height="17" font="5">al., 2012 (76) </text>
<text top="380" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22068710?dopt=Citation">22068710</a></text>
<text top="380" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22068710?dopt=Citation"> </a></text>
<text top="346" left="220" width="119" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="363" left="220" width="111" height="17" font="5">of sodium reduction </text>
<text top="380" left="220" width="37" height="17" font="5">on BP </text>
<text top="397" left="212" width="3" height="17" font="5"> </text>
<text top="414" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="432" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="449" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="467" left="212" width="3" height="17" font="5"> </text>
<text top="484" left="220" width="107" height="17" font="3"><b>Size: </b>Overall study </text>
<text top="501" left="220" width="122" height="17" font="5">included 167 trials. Of </text>
<text top="519" left="220" width="119" height="17" font="5">these, 71 RCTs were </text>
<text top="536" left="220" width="107" height="17" font="5">conducted in 5,577 </text>
<text top="553" left="220" width="100" height="17" font="5">normotensive pts, </text>
<text top="570" left="220" width="96" height="17" font="5">with the following </text>
<text top="588" left="220" width="85" height="17" font="5">characteristics: </text>
<text top="605" left="220" width="108" height="18" font="5">•<b> </b>Median age: 27 y </text>
<text top="623" left="220" width="55" height="17" font="5">(13–67 y) </text>
<text top="640" left="220" width="77" height="18" font="5">•<b> </b>Median trial </text>
<text top="658" left="220" width="93" height="17" font="5">duration: 7 d (4– </text>
<text top="676" left="220" width="48" height="17" font="5">1,100 d) </text>
<text top="693" left="220" width="106" height="18" font="5">•<b> </b>5,292 Whites (71 </text>
<text top="711" left="220" width="46" height="17" font="5">studies) </text>
<text top="728" left="220" width="88" height="18" font="5">•<b> </b>268 Blacks (7 </text>
<text top="746" left="220" width="46" height="17" font="5">studies) </text>
<text top="763" left="220" width="78" height="17" font="5">215 Asians (3 </text>
<text top="345" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="363" left="373" width="45" height="18" font="5">•<b> </b>RCTs </text>
<text top="381" left="373" width="191" height="18" font="5">•<b> </b>24-h  collections  or  estimates </text>
<text top="400" left="373" width="191" height="17" font="5">from  ≥8  h  collections  of  urinary </text>
<text top="417" left="373" width="96" height="17" font="5">sodium excretion </text>
<text top="434" left="365" width="3" height="17" font="5"> </text>
<text top="451" left="373" width="216" height="17" font="3"><b>Exclusion criteria: </b>Systematic studies </text>
<text top="468" left="373" width="198" height="17" font="5">in unhealthy pts with diseases other </text>
<text top="486" left="373" width="56" height="17" font="5">than HTN<b> </b></text>
<text top="346" left="619" width="123" height="17" font="3"><b>Intervention: </b>Sodium </text>
<text top="363" left="619" width="54" height="17" font="5">reduction </text>
<text top="381" left="611" width="3" height="17" font="5"> </text>
<text top="398" left="619" width="139" height="17" font="3"><b>Comparator: </b>No sodium </text>
<text top="415" left="619" width="54" height="17" font="5">reduction<b> </b></text>
<text top="346" left="794" width="137" height="17" font="3"><b>1  endpoint: </b>The overall </text>
<text top="363" left="794" width="144" height="17" font="5">effect of sodium reduction </text>
<text top="380" left="794" width="107" height="17" font="5">was not presented. </text>
<text top="398" left="786" width="3" height="17" font="5"> </text>
<text top="415" left="794" width="100" height="17" font="5">A forest plot of 71 </text>
<text top="432" left="794" width="122" height="17" font="5">comparisons (from 61 </text>
<text top="450" left="794" width="101" height="17" font="5">trials) in the 4,919 </text>
<text top="467" left="794" width="115" height="17" font="5">normotensive whites </text>
<text top="484" left="794" width="109" height="17" font="5">assigned to sodium </text>
<text top="501" left="794" width="126" height="17" font="5">reduction compared to </text>
<text top="519" left="794" width="112" height="17" font="5">usual sodium intake </text>
<text top="536" left="794" width="141" height="17" font="5">identified a trend towards </text>
<text top="553" left="794" width="130" height="17" font="5">lower SBP in 50 (70%), </text>
<text top="570" left="794" width="137" height="17" font="5">no difference in 8 (11%), </text>
<text top="588" left="794" width="119" height="17" font="5">and higher SBP in 13 </text>
<text top="605" left="794" width="104" height="17" font="5">(19%). In a pooled </text>
<text top="622" left="794" width="94" height="17" font="5">analysis, sodium </text>
<text top="639" left="794" width="126" height="17" font="5">reduction compared to </text>
<text top="656" left="794" width="145" height="17" font="5">usual sodium intake in the </text>
<text top="674" left="794" width="146" height="17" font="5">normotensives yielded the </text>
<text top="691" left="794" width="124" height="17" font="5">following MDs in SBP: </text>
<text top="708" left="794" width="142" height="18" font="5">•<b> </b>Whites: -1.27 (95% CI: -</text>
<text top="727" left="805" width="69" height="17" font="5">1.88– -0.66) </text>
<text top="745" left="794" width="140" height="18" font="5">•<b> </b>Blacks: -4.02 (95% CI: -</text>
<text top="764" left="805" width="69" height="17" font="5">7.37– -0.68) </text>
<text top="346" left="970" width="135" height="17" font="5">● Heterogeneous group </text>
<text top="363" left="970" width="116" height="17" font="5">of trials that included </text>
<text top="380" left="970" width="121" height="17" font="5">many small studies of </text>
<text top="397" left="970" width="129" height="17" font="5">short duration in young </text>
<text top="414" left="970" width="51" height="17" font="5">persons. </text>
<text top="432" left="970" width="108" height="17" font="5">● Overall finding of </text>
<text top="449" left="970" width="99" height="17" font="5">lower BP in those </text>
<text top="466" left="970" width="124" height="17" font="5">assigned to a reduced </text>
<text top="483" left="970" width="136" height="17" font="5">intake of dietary sodium, </text>
<text top="501" left="970" width="103" height="17" font="5">with an apparently </text>
<text top="518" left="970" width="128" height="17" font="5">greater effect in Blacks </text>
<text top="535" left="970" width="137" height="17" font="5">compared to Whites and </text>
<text top="552" left="970" width="44" height="17" font="5">Asians. </text>
<text top="570" left="971" width="89" height="17" font="5">● The hormone </text>
<text top="587" left="971" width="117" height="17" font="5">changes in this meta-</text>
<text top="604" left="971" width="126" height="17" font="5">analysis likely reflect a </text>
<text top="621" left="971" width="132" height="17" font="5">physiologic response to </text>
<text top="638" left="971" width="100" height="17" font="5">sodium reduction, </text>
<text top="656" left="971" width="126" height="17" font="5">especially in studies of </text>
<text top="673" left="971" width="133" height="17" font="5">short duration and rapid </text>
<text top="690" left="971" width="106" height="17" font="5">changes in sodium </text>
<text top="707" left="971" width="133" height="17" font="5">intake. The increases in </text>
<text top="725" left="971" width="113" height="17" font="5">total cholesterol and </text>
<text top="742" left="971" width="128" height="17" font="5">triglyceride levels were </text>
<text top="759" left="971" width="120" height="17" font="5">not noted in the meta-</text>
</page>
<page number="261" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="46" height="17" font="5">studies)<b> </b></text>
<text top="91" left="794" width="141" height="18" font="5">•<b> </b>Asians: -1.27 (95% CI: -</text>
<text top="109" left="805" width="69" height="17" font="5">3.07– -0.54) </text>
<text top="127" left="786" width="3" height="17" font="5"> </text>
<text top="144" left="794" width="12" height="17" font="5">A </text>
<text top="161" left="794" width="81" height="17" font="5">corresponding </text>
<text top="178" left="794" width="81" height="17" font="5">analysis in the </text>
<text top="196" left="794" width="79" height="17" font="5">hypertensives </text>
<text top="213" left="794" width="42" height="17" font="5">yielded </text>
<text top="230" left="794" width="104" height="17" font="5">the normotensives </text>
<text top="248" left="794" width="114" height="17" font="5">yielded the following </text>
<text top="265" left="794" width="73" height="17" font="5">MDs in SBP: </text>
<text top="282" left="794" width="142" height="18" font="5">•<b> </b>Whites: -5.48 (95% CI: -</text>
<text top="301" left="805" width="69" height="17" font="5">6.53– -4.43) </text>
<text top="319" left="794" width="140" height="18" font="5">•<b> </b>Blacks: -6.44 (95% CI: -</text>
<text top="337" left="805" width="69" height="17" font="5">8.85– -4.03) </text>
<text top="354" left="794" width="148" height="18" font="5">•<b> </b>Asians: -10.21 (95% CI: -</text>
<text top="373" left="805" width="76" height="17" font="5">16.98– -3.44) </text>
<text top="390" left="786" width="3" height="17" font="5"> </text>
<text top="407" left="794" width="134" height="17" font="3"><b>Safety endpoint: </b>In the </text>
<text top="424" left="794" width="130" height="17" font="5">relevant trials (all cross-</text>
<text top="441" left="794" width="145" height="17" font="5">over studies and including </text>
<text top="459" left="794" width="113" height="17" font="5">comparisons in both </text>
<text top="476" left="794" width="97" height="17" font="5">hypertensive and </text>
<text top="493" left="794" width="147" height="17" font="5">normotensive participants) </text>
<text top="510" left="794" width="111" height="17" font="5">that provided safety </text>
<text top="528" left="794" width="139" height="17" font="5">endpoint measurements, </text>
<text top="545" left="794" width="147" height="17" font="5">significant increases in the </text>
<text top="562" left="794" width="134" height="17" font="5">standard MD for plasma </text>
<text top="579" left="794" width="130" height="17" font="5">renin activity (70 trials), </text>
<text top="597" left="794" width="126" height="17" font="5">aldosterone (51 trials), </text>
<text top="614" left="794" width="137" height="17" font="5">noradrenaline (31 trials), </text>
<text top="631" left="794" width="143" height="17" font="5">adrenaline (14 trials), and </text>
<text top="648" left="794" width="119" height="17" font="5">weighted MD for total </text>
<text top="665" left="794" width="145" height="17" font="5">cholesterol (24 trials), and </text>
<text top="683" left="794" width="117" height="17" font="5">triglyceride (18 trials) </text>
<text top="700" left="794" width="116" height="17" font="5">levels. There was no </text>
<text top="717" left="794" width="105" height="17" font="5">significant effect of </text>
<text top="734" left="794" width="141" height="17" font="5">sodium reduction on LDL-</text>
<text top="752" left="794" width="84" height="17" font="5">cholesterol (15 </text>
<text top="769" left="794" width="149" height="17" font="5">trials) and HDL-cholesterol </text>
<text top="91" left="971" width="128" height="17" font="5">analyses conducted by </text>
<text top="108" left="971" width="126" height="17" font="5">Aburto et al. and He et </text>
<text top="125" left="971" width="16" height="17" font="5">al. </text>
</page>
<page number="262" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="22" size="12" family="Times" color="#006fc0"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="58" height="17" font="5">(17 trials).<b> </b></text>
<text top="176" left="83" width="91" height="17" font="5">Geleijnse JM, et </text>
<text top="194" left="83" width="76" height="17" font="5">al., 2003 (69) </text>
<text top="211" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12821954">12821954</a></text>
<text top="211" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12821954"> </a></text>
<text top="176" left="220" width="119" height="17" font="3"><b>Aim</b>: Study the effect </text>
<text top="194" left="220" width="73" height="17" font="5">of potassium </text>
<text top="211" left="220" width="111" height="17" font="5">supplementation on </text>
<text top="228" left="220" width="20" height="17" font="5">BP </text>
<text top="246" left="212" width="3" height="17" font="5"> </text>
<text top="263" left="220" width="70" height="17" font="3"><b>Study type</b>: </text>
<text top="281" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="298" left="220" width="120" height="17" font="5">and meta- regression </text>
<text top="315" left="220" width="48" height="17" font="5">analysis </text>
<text top="333" left="212" width="3" height="17" font="5"> </text>
<text top="350" left="220" width="104" height="17" font="3"><b>Size</b>: 27 RCTs; 19 </text>
<text top="368" left="220" width="111" height="17" font="5">in pts with HTN and </text>
<text top="385" left="220" width="85" height="17" font="5">11 RCTs in pts </text>
<text top="402" left="220" width="71" height="17" font="5">without HTN<b> </b></text>
<text top="176" left="373" width="105" height="17" font="3"><b>Inclusion criteria</b>: </text>
<text top="194" left="373" width="88" height="18" font="5">• RCT in adults </text>
<text top="212" left="373" width="127" height="18" font="5">• Published after 1966 </text>
<text top="230" left="373" width="97" height="18" font="5">• Duration ≥2 wk </text>
<text top="249" left="373" width="172" height="18" font="5">• No concomitant interventions </text>
<text top="268" left="365" width="3" height="17" font="5"> </text>
<text top="285" left="373" width="109" height="17" font="3"><b>Exclusion criteria</b>: </text>
<text top="302" left="373" width="58" height="18" font="5">• Disease </text>
<text top="321" left="373" width="120" height="17" font="5">Outlier results (1 trial)<b> </b></text>
<text top="176" left="619" width="77" height="17" font="3"><b>Intervention</b>: </text>
<text top="194" left="619" width="61" height="17" font="5">Potassium </text>
<text top="211" left="619" width="94" height="17" font="5">supplementation </text>
<text top="229" left="611" width="3" height="17" font="5"> </text>
<text top="246" left="619" width="96" height="17" font="3"><b>Comparator</b>: No </text>
<text top="263" left="619" width="59" height="17" font="5">potassium </text>
<text top="281" left="619" width="94" height="17" font="5">supplementation<b> </b></text>
<text top="176" left="794" width="73" height="17" font="3"><b>1  endpoint</b>: </text>
<text top="194" left="794" width="109" height="18" font="5">• Overall change in </text>
<text top="212" left="794" width="121" height="17" font="5">SBP=- 2.42; 95% CI: -</text>
<text top="229" left="794" width="65" height="17" font="5">3.75– -1.08 </text>
<text top="246" left="794" width="91" height="18" font="5">• In the 19 trials </text>
<text top="264" left="794" width="72" height="17" font="5">conducted in </text>
<text top="282" left="794" width="139" height="17" font="5">hypertensives, change in </text>
<text top="299" left="794" width="131" height="17" font="5">SBP was -3.51 mm Hg; </text>
<text top="316" left="794" width="117" height="17" font="5">95% CI: -5.31– -1.72 </text>
<text top="333" left="794" width="144" height="18" font="5">• In the 3 trials conducted </text>
<text top="352" left="794" width="134" height="17" font="5">in persons without HTN, </text>
<text top="369" left="794" width="137" height="17" font="5">change in SBP was 0.97 </text>
<text top="386" left="794" width="128" height="17" font="5">mm Hg; 95% CI: -3.07–</text>
<text top="403" left="794" width="27" height="17" font="5">1.14 </text>
<text top="421" left="786" width="3" height="17" font="5"> </text>
<text top="438" left="794" width="123" height="17" font="3"><b>Safety endpoint</b>: N/A<b> </b></text>
<text top="177" left="971" width="134" height="18" font="5">• Imputation for missing </text>
<text top="195" left="971" width="27" height="17" font="5">data </text>
<text top="212" left="970" width="107" height="17" font="5">● In addition to the </text>
<text top="229" left="970" width="89" height="17" font="5">treatment effect </text>
<text top="247" left="970" width="74" height="17" font="5">difference by </text>
<text top="264" left="970" width="117" height="17" font="5">presence/absence of </text>
<text top="281" left="970" width="130" height="17" font="5">HTN, there was a trend </text>
<text top="298" left="970" width="85" height="17" font="5">toward a larger </text>
<text top="315" left="970" width="133" height="17" font="5">treatment effect in older </text>
<text top="333" left="970" width="118" height="17" font="5">age (≥45 y), and to a </text>
<text top="350" left="970" width="111" height="17" font="5">lesser extent higher </text>
<text top="367" left="970" width="109" height="17" font="5">baseline urinary Na </text>
<text top="384" left="970" width="124" height="17" font="5">(&gt;150 mmol/24 h) and </text>
<text top="401" left="970" width="105" height="17" font="5">greater increase in </text>
<text top="419" left="970" width="132" height="17" font="5">urinary K (&gt;44 mmol/24 </text>
<text top="436" left="970" width="14" height="17" font="5">h) </text>
<text top="456" left="83" width="81" height="17" font="5">Carlson DJ, et </text>
<text top="474" left="83" width="83" height="17" font="5">al., 2014 (100) </text>
<text top="491" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24582191?dopt=Citation">24582191</a></text>
<text top="491" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24582191?dopt=Citation"> </a></text>
<text top="456" left="219" width="86" height="17" font="3"><b>Aim: </b>Study the </text>
<text top="474" left="219" width="95" height="17" font="5">effect of physical </text>
<text top="491" left="219" width="91" height="17" font="5">activity on BP in </text>
<text top="508" left="219" width="72" height="17" font="5">children with </text>
<text top="525" left="219" width="46" height="17" font="5">obesity. </text>
<text top="543" left="212" width="3" height="17" font="5"> </text>
<text top="560" left="219" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="577" left="219" width="102" height="17" font="5">Systematic review </text>
<text top="595" left="219" width="107" height="17" font="5">and meta-analysis. </text>
<text top="612" left="212" width="3" height="17" font="5"> </text>
<text top="629" left="219" width="129" height="17" font="3"><b>Size: </b>9 RCTs (223 pts: </text>
<text top="646" left="219" width="132" height="17" font="5">127 intervention and 96 </text>
<text top="663" left="220" width="94" height="17" font="5">controls): 6 were </text>
<text top="681" left="220" width="73" height="17" font="5">conducted in </text>
<text top="698" left="220" width="83" height="17" font="5">normotensives.</text>
<text top="698" left="303" width="3" height="17" font="22"><i> </i></text>
<text top="456" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="473" left="373" width="83" height="18" font="5">• Adults ≥18 y </text>
<text top="492" left="373" width="187" height="18" font="5">• RCT, including cross-over trials. </text>
<text top="510" left="373" width="97" height="18" font="5">• Duration ≥4 wk </text>
<text top="529" left="373" width="212" height="18" font="5">• Published in a peer reviewed journal </text>
<text top="547" left="373" width="211" height="17" font="5">between January 1, 1966 and July 31, </text>
<text top="564" left="373" width="31" height="17" font="5">2013 </text>
<text top="582" left="365" width="3" height="17" font="5"> </text>
<text top="599" left="373" width="178" height="17" font="3"><b>Exclusion criteria: </b>Studies that </text>
<text top="616" left="373" width="178" height="17" font="5">employed any intervention other </text>
<text top="633" left="373" width="189" height="17" font="5">than pure isometric exercise (e.g., </text>
<text top="651" left="373" width="113" height="17" font="5">dynamic resistance) </text>
<text top="456" left="619" width="107" height="17" font="3"><b>Intervention: </b>Pure </text>
<text top="474" left="619" width="105" height="17" font="5">isometric exercise. </text>
<text top="491" left="611" width="3" height="17" font="5"> </text>
<text top="508" left="619" width="126" height="17" font="3"><b>Comparator: </b>Use of a </text>
<text top="526" left="619" width="111" height="17" font="5">control group was a </text>
<text top="543" left="619" width="107" height="17" font="5">requirement but no </text>
<text top="560" left="619" width="100" height="17" font="5">additional specific </text>
<text top="577" left="619" width="118" height="17" font="5">information provided.<b> </b></text>
<text top="457" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="475" left="794" width="124" height="18" font="5">• In the overall pooled </text>
<text top="493" left="794" width="125" height="17" font="5">analysis (hypertensive </text>
<text top="510" left="794" width="138" height="17" font="5">and normotensive trials), </text>
<text top="527" left="794" width="144" height="17" font="5">mean change in SBP was </text>
<text top="544" left="794" width="82" height="17" font="5">-6.77 (95% CI: </text>
<text top="561" left="794" width="120" height="17" font="5">-7.93– -5.62) mm Hg. </text>
<text top="579" left="794" width="123" height="18" font="5">• In the subgroup of 3 </text>
<text top="597" left="794" width="128" height="17" font="5">trials with hypertensive </text>
<text top="615" left="794" width="57" height="17" font="5">pts (all on </text>
<text top="632" left="794" width="93" height="17" font="5">antihypertensive </text>
<text top="649" left="794" width="125" height="17" font="5">medication), the mean </text>
<text top="666" left="794" width="141" height="17" font="5">change in SBP was -4.31 </text>
<text top="683" left="794" width="125" height="17" font="5">(95% CI: -6.42– -2.21) </text>
<text top="701" left="794" width="46" height="17" font="5">mm Hg. </text>
<text top="718" left="794" width="142" height="17" font="5">In the subgroup of 6 trials </text>
<text top="735" left="794" width="146" height="17" font="5">with normotensive pts, the </text>
<text top="752" left="794" width="148" height="17" font="5">mean change in SBP was -</text>
<text top="769" left="794" width="152" height="17" font="5">7.83 (95% CI: -9.21– -6.45) </text>
<text top="456" left="970" width="120" height="18" font="5">•<b> </b>This study provides </text>
<text top="474" left="970" width="120" height="17" font="5">information regarding </text>
<text top="492" left="970" width="96" height="17" font="5">the effect of pure </text>
<text top="509" left="970" width="102" height="17" font="5">isometric exercise </text>
<text top="526" left="970" width="123" height="17" font="5">interventions on BP in </text>
<text top="543" left="970" width="40" height="17" font="5">adults. </text>
<text top="561" left="971" width="115" height="18" font="5">• The BP reductions </text>
<text top="579" left="971" width="115" height="17" font="5">reported in this meta-</text>
<text top="596" left="971" width="134" height="17" font="5">analysis are surprisingly </text>
<text top="613" left="971" width="145" height="17" font="5">large but the overall effect </text>
<text top="631" left="971" width="143" height="17" font="5">pattern is quite consistent </text>
<text top="648" left="971" width="140" height="17" font="5">with other meta-analyses </text>
<text top="665" left="971" width="119" height="17" font="5">of isometric exercise. </text>
</page>
<page number="263" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="46" height="17" font="5">mm Hg. </text>
<text top="108" left="794" width="3" height="17" font="3"><b> </b></text>
<text top="125" left="794" width="124" height="17" font="3"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="176" left="83" width="104" height="17" font="5">Garcia-Hermosa A, </text>
<text top="194" left="83" width="90" height="17" font="5">et al., 2013 (99) </text>
<text top="211" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23786645?dopt=Citation">23786645</a></text>
<text top="211" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23786645?dopt=Citation"> </a></text>
<text top="176" left="219" width="86" height="17" font="3"><b>Aim: </b>Study the </text>
<text top="194" left="219" width="96" height="17" font="5">effect of exercise </text>
<text top="211" left="219" width="87" height="17" font="5">on BP in obese </text>
<text top="228" left="219" width="50" height="17" font="5">children. </text>
<text top="246" left="212" width="3" height="17" font="5"> </text>
<text top="263" left="219" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="281" left="219" width="102" height="17" font="5">Systematic review </text>
<text top="298" left="219" width="107" height="17" font="5">and meta-analysis. </text>
<text top="315" left="212" width="3" height="17" font="5"> </text>
<text top="332" left="219" width="105" height="17" font="3"><b>Size: </b>9 RCTs (410 </text>
<text top="350" left="219" width="27" height="17" font="5">pts).<b> </b></text>
<text top="176" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="194" left="373" width="161" height="18" font="5">• Children ≤14 y with obesity </text>
<text top="212" left="373" width="39" height="18" font="5">• RCT </text>
<text top="230" left="373" width="97" height="18" font="5">• Duration ≥8 wk </text>
<text top="249" left="373" width="157" height="18" font="5">• 1° outcome: change in BP </text>
<text top="268" left="365" width="3" height="17" font="5"> </text>
<text top="285" left="373" width="182" height="17" font="3"><b>Exclusion criteria: </b>Concomitant </text>
<text top="302" left="373" width="67" height="17" font="5">intervention<b> </b></text>
<text top="176" left="619" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="194" left="619" width="93" height="17" font="5">Physical activity, </text>
<text top="211" left="619" width="102" height="17" font="5">principally aerobic </text>
<text top="228" left="619" width="53" height="17" font="5">exercise. </text>
<text top="246" left="611" width="3" height="17" font="5"> </text>
<text top="263" left="619" width="96" height="17" font="3"><b>Comparator: </b>No </text>
<text top="281" left="619" width="100" height="17" font="5">physical exercise, </text>
<text top="298" left="619" width="125" height="17" font="5">nutrition, education, or </text>
<text top="315" left="619" width="97" height="17" font="5">dietary restriction </text>
<text top="332" left="619" width="67" height="17" font="5">intervention<b> </b></text>
<text top="176" left="794" width="142" height="17" font="3"><b>1   endpoint:  </b>Change  in </text>
<text top="194" left="794" width="142" height="17" font="5">SBP:  In pooled  analysis, </text>
<text top="211" left="794" width="142" height="17" font="5">mean change in SBP was </text>
<text top="228" left="794" width="138" height="17" font="5">-0.4  (95%  CI:  -0.66–  -</text>
<text top="245" left="794" width="35" height="17" font="5">0.24). </text>
<text top="263" left="786" width="3" height="17" font="5"> </text>
<text top="281" left="794" width="124" height="17" font="3"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="177" left="970" width="116" height="18" font="5">•<b> </b>This meta-analysis </text>
<text top="195" left="970" width="126" height="17" font="5">focused specifically on </text>
<text top="212" left="970" width="115" height="17" font="5">the effect of physical </text>
<text top="229" left="970" width="137" height="17" font="5">activity on BP in children </text>
<text top="247" left="970" width="132" height="17" font="5">with obesity. Although it </text>
<text top="264" left="970" width="132" height="17" font="5">is not stated explicitly, it </text>
<text top="281" left="970" width="124" height="17" font="5">seems likely that all of </text>
<text top="298" left="970" width="117" height="17" font="5">the participants were </text>
<text top="315" left="970" width="122" height="17" font="5">normotensive and not </text>
<text top="333" left="970" width="139" height="17" font="5">receiving medication that </text>
<text top="350" left="970" width="128" height="17" font="5">could influence level of </text>
<text top="367" left="970" width="23" height="17" font="5">BP. </text>
<text top="384" left="970" width="102" height="18" font="5">•<b> </b>The findings are </text>
<text top="402" left="970" width="115" height="17" font="5">consistent with other </text>
<text top="420" left="970" width="117" height="17" font="5">meta-analyses of the </text>
<text top="437" left="970" width="95" height="17" font="5">effect of physical </text>
<text top="454" left="970" width="81" height="17" font="5">activity on BP. </text>
<text top="471" left="970" width="78" height="18" font="5">•<b> </b>Only limited </text>
<text top="490" left="970" width="120" height="17" font="5">information regarding </text>
<text top="507" left="970" width="134" height="17" font="5">study details is provided </text>
<text top="524" left="970" width="126" height="17" font="5">in this publication. The </text>
<text top="541" left="970" width="103" height="17" font="5">interventions were </text>
<text top="559" left="970" width="139" height="18" font="5">•<b> </b>heterogeneous in type, </text>
<text top="577" left="970" width="118" height="17" font="5">duration, and quality. </text>
<text top="595" left="83" width="93" height="17" font="5">Rossi AM, et al., </text>
<text top="612" left="83" width="34" height="17" font="5">2013  </text>
<text top="629" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23541664?dopt=Citation">23541664</a></text>
<text top="629" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23541664?dopt=Citation"> </a></text>
<text top="595" left="219" width="115" height="17" font="3"><b>Aim:  </b>Study  the </text>
<text top="612" left="219" width="115" height="17" font="5">effect  of  resistance </text>
<text top="629" left="219" width="86" height="17" font="5">exercise on BP </text>
<text top="647" left="212" width="3" height="17" font="5"> </text>
<text top="664" left="219" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="681" left="219" width="102" height="17" font="5">Systematic review </text>
<text top="699" left="219" width="103" height="17" font="5">and meta-analysis </text>
<text top="716" left="219" width="3" height="17" font="3"><b> </b></text>
<text top="734" left="212" width="3" height="17" font="5"> </text>
<text top="751" left="219" width="98" height="17" font="3"><b>Size: </b>9 RCTs (11 </text>
<text top="768" left="219" width="108" height="17" font="5">intervention groups </text>
<text top="594" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="612" left="373" width="137" height="18" font="5">• RCTs in adults (≥18 y) </text>
<text top="630" left="373" width="137" height="17" font="5">BP-lowering 1° outcome </text>
<text top="647" left="373" width="122" height="18" font="5">• Trial duration ≥4 wk </text>
<text top="666" left="373" width="211" height="18" font="5">• Resistance training only intervention </text>
<text top="685" left="365" width="3" height="17" font="5"> </text>
<text top="701" left="373" width="216" height="17" font="3"><b>Exclusion criteria: </b>Handgrip/isometric </text>
<text top="719" left="373" width="49" height="17" font="5">exercise<b> </b></text>
<text top="595" left="619" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="612" left="619" width="110" height="17" font="5">Dynamic resistance </text>
<text top="629" left="619" width="104" height="17" font="5">training but overall </text>
<text top="646" left="619" width="86" height="17" font="5">reporting of the </text>
<text top="663" left="619" width="96" height="17" font="5">details was poor. </text>
<text top="681" left="619" width="3" height="17" font="3"><b> </b></text>
<text top="698" left="619" width="96" height="17" font="3"><b>Comparator: </b>No </text>
<text top="715" left="619" width="103" height="17" font="5">resistance training </text>
<text top="732" left="619" width="100" height="17" font="5">but not detailed in </text>
<text top="750" left="619" width="59" height="17" font="5">this article<b> </b></text>
<text top="595" left="794" width="115" height="17" font="3"><b>1  endpoint: </b>Pooled </text>
<text top="612" left="794" width="141" height="17" font="5">experience (hypertensive </text>
<text top="629" left="794" width="125" height="17" font="5">and normotensive pts) </text>
<text top="646" left="794" width="98" height="17" font="5">identified a small, </text>
<text top="663" left="794" width="145" height="17" font="5">nonsignificant reduction in </text>
<text top="681" left="794" width="139" height="17" font="5">mean SBP of -1.03 (95% </text>
<text top="698" left="794" width="19" height="17" font="5">CI: </text>
<text top="715" left="794" width="94" height="17" font="5">-3.44–0.39). The </text>
<text top="732" left="794" width="139" height="17" font="5">corresponding finding for </text>
<text top="749" left="794" width="141" height="17" font="5">DBP was -2.19 (95% CI: -</text>
<text top="766" left="794" width="42" height="17" font="5">3.87– - </text>
<text top="595" left="970" width="124" height="18" font="5">•<b> </b>Suggests resistance </text>
<text top="613" left="970" width="118" height="17" font="5">training is effective in </text>
<text top="630" left="970" width="138" height="17" font="5">lowering BP and was the </text>
<text top="647" left="970" width="135" height="17" font="5">basis for recommending </text>
<text top="665" left="970" width="123" height="17" font="5">this intervention in the </text>
<text top="682" left="970" width="85" height="17" font="5">Canadian HTN </text>
<text top="699" left="970" width="109" height="17" font="5">Education Program </text>
<text top="716" left="970" width="105" height="17" font="5">recommendations. </text>
<text top="734" left="970" width="117" height="18" font="5">•<b> </b>The discrepancy in </text>
<text top="752" left="970" width="131" height="17" font="5">effect size between this </text>
<text top="769" left="970" width="134" height="17" font="5">meta-analysis and the 1 </text>
</page>
<page number="264" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="219" width="118" height="17" font="5">and 14 comparisons) </text>
<text top="108" left="219" width="120" height="17" font="5">conducted in 452 pts. </text>
<text top="125" left="219" width="104" height="17" font="5">10 (71%) of the 14 </text>
<text top="142" left="219" width="103" height="17" font="5">comparisons were </text>
<text top="160" left="219" width="73" height="17" font="5">conducted in </text>
<text top="177" left="219" width="79" height="17" font="5">normotensives<b> </b></text>
<text top="90" left="794" width="35" height="17" font="5">0.51). </text>
<text top="108" left="786" width="3" height="17" font="5"> </text>
<text top="125" left="794" width="124" height="17" font="3"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="91" left="970" width="76" height="17" font="5">conducted by </text>
<text top="108" left="970" width="121" height="17" font="5">Cornelisson et al may </text>
<text top="125" left="970" width="119" height="17" font="5">have been due to the </text>
<text top="142" left="970" width="87" height="17" font="5">more restrictive </text>
<text top="160" left="970" width="133" height="17" font="5">requirement by Rossi et </text>
<text top="177" left="970" width="130" height="17" font="5">al that change in BP be </text>
<text top="194" left="970" width="90" height="17" font="5">the 1° outcome. </text>
<text top="210" left="83" width="91" height="17" font="3"><b>TOHP, Phase II </b></text>
<text top="225" left="83" width="76" height="17" font="5">Hypertension </text>
<text top="240" left="83" width="62" height="17" font="5">Prevention </text>
<text top="255" left="83" width="75" height="17" font="5">Collaborative </text>
<text top="272" left="83" width="97" height="17" font="5">Research Group, </text>
<text top="289" left="83" width="31" height="17" font="5">1997 </text>
<text top="306" left="83" width="48" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation">9080920</a></text>
<text top="306" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9080920?dopt=Citation"> </a></text>
<text top="210" left="220" width="120" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="225" left="220" width="115" height="17" font="5">of weight loss on BP </text>
<text top="240" left="220" width="98" height="17" font="5">and prevention of </text>
<text top="257" left="219" width="32" height="17" font="5">HTN. </text>
<text top="274" left="219" width="3" height="17" font="3"><b> </b></text>
<text top="292" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="309" left="220" width="76" height="17" font="5">Randomized, </text>
<text top="326" left="220" width="57" height="17" font="5">controlled </text>
<text top="343" left="220" width="73" height="17" font="5">factorial trial. </text>
<text top="361" left="212" width="3" height="17" font="5"> </text>
<text top="378" left="219" width="103" height="17" font="3"><b>Size: </b>2,382 pts, of </text>
<text top="395" left="219" width="100" height="17" font="5">whom 1,192 were </text>
<text top="413" left="219" width="92" height="17" font="5">randomized to a </text>
<text top="430" left="219" width="64" height="17" font="5">weight loss </text>
<text top="447" left="219" width="91" height="17" font="5">intervention and </text>
<text top="464" left="219" width="64" height="17" font="5">1,190 were </text>
<text top="482" left="219" width="109" height="17" font="5">randomized to a no </text>
<text top="499" left="219" width="64" height="17" font="5">weight loss </text>
<text top="516" left="219" width="70" height="17" font="5">intervention.<b> </b></text>
<text top="212" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="229" left="373" width="212" height="17" font="5">Healthy community-dwelling adults 30–</text>
<text top="246" left="373" width="26" height="17" font="5">54 y </text>
<text top="263" left="373" width="192" height="18" font="5">• BMI between 110% and 165% of </text>
<text top="281" left="373" width="122" height="17" font="5">desirable body weight </text>
<text top="299" left="373" width="138" height="18" font="5">• Not taking BP-lowering </text>
<text top="317" left="373" width="63" height="17" font="5">medication </text>
<text top="334" left="373" width="170" height="18" font="5">• Mean SBP &lt;140 mm Hg and </text>
<text top="352" left="373" width="106" height="17" font="5">DBP 83-89 mm Hg </text>
<text top="370" left="365" width="3" height="17" font="5"> </text>
<text top="387" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="405" left="373" width="143" height="18" font="5">• Taking antihypertensive </text>
<text top="423" left="373" width="63" height="17" font="5">medication </text>
<text top="440" left="373" width="173" height="18" font="5">• Heart disease, renal disease, </text>
<text top="458" left="373" width="191" height="17" font="5">poorly controlled hyperlipidemia or </text>
<text top="476" left="373" width="182" height="17" font="5">DM, DM requiring insulin, special </text>
<text top="493" left="373" width="115" height="17" font="5">dietary requirements </text>
<text top="510" left="373" width="79" height="17" font="5">&gt;14 drinks/wk<b> </b></text>
<text top="210" left="619" width="130" height="17" font="3"><b>Intervention: </b>Behavior </text>
<text top="225" left="619" width="111" height="17" font="5">change intervention </text>
<text top="240" left="619" width="111" height="17" font="5">(combination of diet </text>
<text top="255" left="619" width="116" height="17" font="5">change and physical </text>
<text top="272" left="619" width="145" height="17" font="5">activity) aimed at studying </text>
<text top="289" left="619" width="128" height="17" font="5">the effects of a modest </text>
<text top="306" left="619" width="136" height="17" font="5">reduction in body weight </text>
<text top="324" left="619" width="106" height="17" font="5">during up to 48 mo </text>
<text top="341" left="619" width="113" height="17" font="5">(minimum 36 mo) of </text>
<text top="358" left="619" width="56" height="17" font="5">follow-up. </text>
<text top="376" left="611" width="3" height="17" font="5"> </text>
<text top="393" left="619" width="112" height="17" font="3"><b>Comparator: </b>Usual </text>
<text top="411" left="619" width="62" height="17" font="5">care group<b> </b></text>
<text top="212" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="230" left="794" width="87" height="17" font="5">Change in SBP </text>
<text top="247" left="794" width="138" height="17" font="5">Compared to usual care, </text>
<text top="264" left="794" width="119" height="17" font="5">the weight loss group </text>
<text top="282" left="794" width="139" height="17" font="5">experienced a significant </text>
<text top="299" left="794" width="143" height="17" font="5">mean reduction of -4.5 kg </text>
<text top="316" left="794" width="130" height="17" font="5">in body weight and -3.7 </text>
<text top="333" left="794" width="147" height="17" font="5">(SD: 0.5; p&lt;0.001) mm Hg </text>
<text top="350" left="794" width="138" height="17" font="5">in SBP at 6 mo (-6.0 mm </text>
<text top="368" left="794" width="117" height="17" font="5">Hg in the weight loss </text>
<text top="385" left="794" width="139" height="17" font="5">group and -2.2 mm Hg in </text>
<text top="402" left="794" width="123" height="17" font="5">the usual care group). </text>
<text top="419" left="794" width="143" height="18" font="5">• A progressive reduction </text>
<text top="438" left="794" width="116" height="17" font="5">in the effect sizes for </text>
<text top="455" left="794" width="138" height="17" font="5">body weight and BP was </text>
<text top="472" left="794" width="117" height="17" font="5">noted over time, with </text>
<text top="489" left="794" width="131" height="17" font="5">mean for SBP at 18, 36 </text>
<text top="507" left="794" width="127" height="17" font="5">mo and termination of -</text>
<text top="524" left="794" width="132" height="17" font="5">1.8 (SD: 0.5; p&lt;0.001), -</text>
<text top="541" left="794" width="121" height="17" font="5">1.3 (SD: 0.5; p=0.01), </text>
<text top="558" left="794" width="104" height="17" font="5">and - 1.1 (SD: 0.5; </text>
<text top="575" left="794" width="49" height="17" font="5">p=0.04). </text>
<text top="593" left="786" width="3" height="17" font="5"> </text>
<text top="611" left="794" width="105" height="17" font="5">Prevention of HTN </text>
<text top="628" left="794" width="122" height="18" font="5">• At 6 mo of follow-up </text>
<text top="646" left="794" width="115" height="17" font="5">the incidence of new </text>
<text top="663" left="794" width="115" height="17" font="5">onset HTN was 42% </text>
<text top="680" left="794" width="132" height="17" font="5">lower in the participants </text>
<text top="698" left="794" width="120" height="17" font="5">randomized to weight </text>
<text top="715" left="794" width="117" height="17" font="5">loss compared to the </text>
<text top="732" left="794" width="95" height="17" font="5">usual care group </text>
<text top="749" left="794" width="53" height="17" font="5">(p=0.02). </text>
<text top="767" left="794" width="81" height="18" font="5">• During more </text>
<text top="212" left="960" width="131" height="18" font="5">•<b> </b>Largest trial of weight </text>
<text top="230" left="970" width="141" height="17" font="5">loss in prevention of HTN </text>
<text top="247" left="970" width="120" height="17" font="5">and also provides the </text>
<text top="265" left="970" width="105" height="17" font="5">longest duration of </text>
<text top="282" left="970" width="53" height="17" font="5">follow-up </text>
<text top="299" left="960" width="135" height="18" font="5">•<b> </b>The assumptions for a </text>
<text top="317" left="970" width="116" height="17" font="5">main effects factorial </text>
<text top="335" left="970" width="132" height="17" font="5">analysis (independence </text>
<text top="352" left="970" width="111" height="17" font="5">of the interventions) </text>
<text top="369" left="970" width="133" height="17" font="5">were not demonstrated. </text>
<text top="386" left="970" width="121" height="17" font="5">Given this finding, the </text>
<text top="404" left="970" width="134" height="17" font="5">most reliable analysis of </text>
<text top="421" left="970" width="71" height="17" font="5">this trial was </text>
<text top="438" left="970" width="101" height="17" font="5">comparison of the </text>
<text top="455" left="970" width="106" height="17" font="5">experience in each </text>
<text top="472" left="970" width="102" height="17" font="5">active intervention </text>
<text top="490" left="970" width="113" height="17" font="5">group with the usual </text>
<text top="507" left="970" width="132" height="17" font="5">care group. This results </text>
<text top="524" left="970" width="90" height="17" font="5">in a reduction in </text>
<text top="541" left="970" width="94" height="17" font="5">statistical power. </text>
<text top="558" left="960" width="117" height="18" font="5">•<b> </b>Consistent with the </text>
<text top="577" left="970" width="139" height="17" font="5">pattern in the proceeding </text>
<text top="594" left="970" width="132" height="17" font="5">TOHP I trial weight loss </text>
<text top="611" left="970" width="112" height="17" font="5">reduced BP and the </text>
<text top="628" left="970" width="138" height="17" font="5">incidence of HTN but the </text>
<text top="645" left="970" width="121" height="17" font="5">effect sizes for weight </text>
<text top="663" left="970" width="126" height="17" font="5">loss and BP as well as </text>
<text top="680" left="970" width="82" height="17" font="5">the difficulty of </text>
<text top="697" left="970" width="87" height="17" font="5">maintaining the </text>
<text top="714" left="970" width="115" height="17" font="5">intervention in highly </text>
<text top="732" left="970" width="81" height="17" font="5">motivated and </text>
<text top="749" left="970" width="126" height="17" font="5">extensively counselled </text>
<text top="766" left="970" width="137" height="17" font="5">participants underscores </text>
</page>
<page number="265" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="135" height="17" font="5">prolonged follow-up, the </text>
<text top="108" left="794" width="119" height="17" font="5">effect size decreased </text>
<text top="125" left="794" width="133" height="17" font="5">but remained borderline </text>
<text top="142" left="794" width="137" height="17" font="5">significant after 48 mo of </text>
<text top="160" left="794" width="85" height="17" font="5">follow-up (13% </text>
<text top="177" left="794" width="106" height="17" font="5">reduction; p=0.06). </text>
<text top="194" left="794" width="135" height="17" font="5">Overall, the incidence of </text>
<text top="211" left="794" width="118" height="17" font="5">HTN was reduced by </text>
<text top="229" left="794" width="81" height="17" font="5">21% (p=0.02). </text>
<text top="246" left="786" width="3" height="17" font="5"> </text>
<text top="263" left="794" width="124" height="17" font="3"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="91" left="970" width="136" height="17" font="5">the difficulty of achieving </text>
<text top="108" left="970" width="119" height="17" font="5">and maintaining ideal </text>
<text top="125" left="970" width="102" height="17" font="5">body weight in the </text>
<text top="143" left="960" width="131" height="18" font="5">•<b> </b>general population by </text>
<text top="161" left="970" width="98" height="17" font="5">means of lifestyle </text>
<text top="178" left="970" width="47" height="17" font="5">change. </text>
<text top="281" left="83" width="87" height="17" font="3"><b>TOHP, Phase I </b></text>
<text top="298" left="83" width="31" height="17" font="5">1992 </text>
<text top="314" left="83" width="48" height="17" font="19"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation">1586398</a></text>
<text top="314" left="131" width="3" height="17" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1586398?dopt=Citation"><b> </b></a></text>
<text top="281" left="220" width="119" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="299" left="220" width="115" height="17" font="5">of weight loss on BP </text>
<text top="316" left="220" width="98" height="17" font="5">and prevention of </text>
<text top="333" left="220" width="29" height="17" font="5">HTN </text>
<text top="351" left="212" width="3" height="17" font="5"> </text>
<text top="368" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="385" left="220" width="76" height="17" font="5">Randomized, </text>
<text top="402" left="220" width="57" height="17" font="5">controlled </text>
<text top="420" left="220" width="73" height="17" font="5">factorial trial. </text>
<text top="437" left="212" width="3" height="17" font="5"> </text>
<text top="452" left="220" width="112" height="17" font="3"><b>Size: </b>Overall, 2,182 </text>
<text top="467" left="220" width="109" height="17" font="5">adults, with the 308 </text>
<text top="482" left="220" width="130" height="17" font="5">assigned to weight loss </text>
<text top="498" left="220" width="128" height="17" font="5">compared to 256 usual </text>
<text top="513" left="220" width="74" height="17" font="5">care controls </text>
<text top="281" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="298" left="373" width="80" height="18" font="5">• Community- </text>
<text top="317" left="373" width="131" height="17" font="5">dwelling adults 30–54 y </text>
<text top="334" left="373" width="142" height="18" font="5">• Not on antihypertensive </text>
<text top="352" left="373" width="63" height="17" font="5">medication </text>
<text top="369" left="373" width="117" height="18" font="5">• DBP 80-89 mm Hg </text>
<text top="388" left="373" width="55" height="18" font="5">• Healthy </text>
<text top="407" left="365" width="3" height="17" font="5"> </text>
<text top="424" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="440" left="373" width="75" height="18" font="5">•  Disease </text>
<text top="457" left="373" width="220" height="18" font="5">•  Inability to comply with the protocol<b> </b></text>
<text top="281" left="619" width="130" height="17" font="3"><b>Intervention: </b>Behavior </text>
<text top="299" left="619" width="111" height="17" font="5">change intervention </text>
<text top="316" left="619" width="111" height="17" font="5">(combination of diet </text>
<text top="333" left="619" width="115" height="17" font="5">change and physical </text>
<text top="350" left="619" width="45" height="17" font="5">activity) </text>
<text top="368" left="611" width="3" height="17" font="5"> </text>
<text top="383" left="619" width="140" height="17" font="3"><b>Comparator: </b>Usual care<b> </b></text>
<text top="282" left="794" width="133" height="17" font="3"><b>1  endpoint: </b>Change in </text>
<text top="300" left="794" width="29" height="17" font="5">DBP </text>
<text top="318" left="786" width="3" height="17" font="5"> </text>
<text top="335" left="794" width="133" height="17" font="3"><b>2  endpoint: </b>Change in </text>
<text top="352" left="794" width="28" height="17" font="5">SBP </text>
<text top="370" left="786" width="3" height="17" font="5"> </text>
<text top="388" left="794" width="129" height="17" font="3"><b>Safety endpoint: </b>CVD </text>
<text top="406" left="794" width="126" height="17" font="5">events, symptoms and </text>
<text top="424" left="794" width="127" height="17" font="5">general and well being<b> </b></text>
<text top="281" left="971" width="112" height="18" font="5">•<b> </b>Significantly lower </text>
<text top="300" left="971" width="99" height="17" font="5">DBP (2.3 mm Hg; </text>
<text top="317" left="971" width="122" height="17" font="5">p&lt;0.01) and SBP (2.9 </text>
<text top="334" left="971" width="125" height="17" font="5">mm Hg; p&lt;0.01) in the </text>
<text top="351" left="971" width="99" height="17" font="5">weight loss group </text>
<text top="369" left="971" width="105" height="17" font="5">compared to usual </text>
<text top="386" left="971" width="27" height="17" font="5">care </text>
<text top="403" left="971" width="106" height="18" font="5">•<b> </b>Few CVD events </text>
<text top="421" left="971" width="30" height="18" font="5">•<b> </b>No </text>
<text top="440" left="971" width="70" height="17" font="5">difference in </text>
<text top="457" left="971" width="59" height="17" font="5">symptoms </text>
<text top="474" left="971" width="71" height="18" font="5">•<b> </b>Significant </text>
<text top="492" left="971" width="132" height="17" font="5">improvement in general </text>
<text top="509" left="971" width="82" height="17" font="5">well-being at 6 </text>
<text top="526" left="960" width="121" height="18" font="5">•<b> </b>and 18 mo (p&lt;0.05) </text>
<text top="545" left="83" width="70" height="17" font="5">Xin X, et al., </text>
<text top="562" left="83" width="34" height="17" font="5">2001  </text>
<text top="579" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11711507?dopt=Citation">11711507</a></text>
<text top="579" left="137" width="3" height="17" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11711507?dopt=Citation"><b> </b></a></text>
<text top="545" left="220" width="119" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="562" left="220" width="110" height="17" font="5">of alcohol reduction </text>
<text top="580" left="220" width="37" height="17" font="5">on BP </text>
<text top="597" left="212" width="3" height="17" font="3"><b> </b></text>
<text top="615" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="632" left="220" width="102" height="17" font="5">Systematic review </text>
<text top="649" left="220" width="103" height="17" font="5">and meta-analysis </text>
<text top="666" left="212" width="3" height="17" font="3"><b> </b></text>
<text top="683" left="220" width="32" height="17" font="3"><b>Size: </b></text>
<text top="700" left="220" width="84" height="18" font="5">• 15 RCTs (25 </text>
<text top="719" left="220" width="102" height="17" font="5">comparisons) with </text>
<text top="736" left="220" width="57" height="17" font="5">2,234 pts. </text>
<text top="754" left="220" width="80" height="18" font="5">• 6 trials were </text>
<text top="772" left="220" width="73" height="17" font="5">conducted in </text>
<text top="545" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="562" left="373" width="99" height="18" font="5">• RCT in humans </text>
<text top="581" left="373" width="186" height="18" font="5">• Publication between 1966-1999 </text>
<text top="599" left="373" width="97" height="18" font="5">• Duration ≥1 wk </text>
<text top="617" left="373" width="172" height="18" font="5">• Only pts regularly consuming </text>
<text top="635" left="373" width="43" height="17" font="5">alcohol </text>
<text top="653" left="373" width="166" height="18" font="5">• Only difference between the </text>
<text top="671" left="373" width="212" height="17" font="5">comparison groups was alcohol intake </text>
<text top="689" left="365" width="3" height="17" font="3"><b> </b></text>
<text top="706" left="373" width="193" height="17" font="3"><b>Exclusion criteria: </b>Comparison of </text>
<text top="723" left="373" width="176" height="17" font="5">different doses of alcohol intake<b> </b></text>
<text top="545" left="619" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="562" left="619" width="114" height="17" font="5">Reduction in alcohol </text>
<text top="580" left="619" width="120" height="17" font="5">consumption. In most </text>
<text top="597" left="619" width="130" height="17" font="5">trials this was achieved </text>
<text top="614" left="619" width="111" height="17" font="5">by randomization to </text>
<text top="631" left="619" width="130" height="17" font="5">“light” alcohol but some </text>
<text top="648" left="619" width="123" height="17" font="5">RCT were based on a </text>
<text top="666" left="619" width="127" height="17" font="5">behavioral intervention </text>
<text top="683" left="619" width="122" height="17" font="5">aimed at reducing the </text>
<text top="700" left="619" width="95" height="17" font="5">number of drinks </text>
<text top="717" left="619" width="64" height="17" font="5">consumed. </text>
<text top="735" left="611" width="3" height="17" font="3"><b> </b></text>
<text top="752" left="619" width="112" height="17" font="3"><b>Comparator: </b>Usual </text>
<text top="770" left="619" width="133" height="17" font="5">consumption of alcohol <b> </b></text>
<text top="546" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="563" left="794" width="98" height="18" font="5">• Overall, alcohol </text>
<text top="582" left="794" width="141" height="17" font="5">reduction was associated </text>
<text top="599" left="794" width="93" height="17" font="5">with a significant </text>
<text top="616" left="794" width="143" height="17" font="5">reduction in mean SBP of </text>
<text top="633" left="794" width="125" height="17" font="5">-3.31 (95% CI: -4.10– -</text>
<text top="651" left="794" width="129" height="17" font="5">2.52) and DBP of -2.04 </text>
<text top="668" left="794" width="128" height="17" font="5">(95% CI: -2.58– -1.49). </text>
<text top="685" left="794" width="123" height="18" font="5">• In the subgroup of 7 </text>
<text top="703" left="794" width="120" height="17" font="5">RCTs in persons with </text>
<text top="720" left="794" width="137" height="17" font="5">HTN, the mean changes </text>
<text top="738" left="794" width="123" height="17" font="5">in SBP and DBP were </text>
<text top="755" left="794" width="150" height="17" font="5">-3.9 (95% CI: -5.04– -2.76) </text>
<text top="772" left="794" width="24" height="17" font="5">and </text>
<text top="545" left="971" width="137" height="18" font="5">• This is the most recent </text>
<text top="563" left="971" width="115" height="17" font="5">meta-analysis of this </text>
<text top="581" left="971" width="137" height="17" font="5">topic. Although this meta-</text>
<text top="598" left="971" width="104" height="17" font="5">analysis reports % </text>
<text top="615" left="971" width="109" height="17" font="5">reduction in alcohol </text>
<text top="632" left="971" width="136" height="17" font="5">intake, most trials aimed </text>
<text top="649" left="971" width="130" height="17" font="5">at reducing the number </text>
<text top="667" left="971" width="101" height="17" font="5">of alcoholic drinks </text>
<text top="684" left="971" width="123" height="17" font="5">consumed achieved a </text>
<text top="701" left="971" width="112" height="17" font="5">reduction of about 3 </text>
<text top="718" left="971" width="50" height="17" font="5">drinks/d. </text>
<text top="736" left="971" width="92" height="17" font="5">The intervention </text>
<text top="753" left="971" width="70" height="17" font="5">results were </text>
<text top="770" left="971" width="104" height="17" font="5">consistent with the </text>
</page>
<page number="266" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="111" height="17" font="5">normotensives (269 </text>
<text top="108" left="220" width="113" height="17" font="5">pts with a mean age </text>
<text top="125" left="220" width="106" height="17" font="5">ranging from 26.5– </text>
<text top="142" left="220" width="94" height="17" font="5">45.5 y). Average </text>
<text top="160" left="220" width="87" height="17" font="5">consumption of </text>
<text top="177" left="220" width="105" height="17" font="5">alcohol at baseline </text>
<text top="194" left="220" width="98" height="17" font="5">was not reported. </text>
<text top="211" left="220" width="122" height="17" font="5">Follow-up varied from </text>
<text top="229" left="220" width="49" height="17" font="5">1–18 wk<b> </b></text>
<text top="90" left="794" width="125" height="17" font="5">-2.41 (95% CI: -3.25– -</text>
<text top="108" left="794" width="35" height="17" font="5">1.57). </text>
<text top="125" left="794" width="123" height="18" font="5">• In the subgroup of 6 </text>
<text top="144" left="794" width="131" height="17" font="5">RCTs in normotensives </text>
<text top="161" left="794" width="102" height="17" font="5">the corresponding </text>
<text top="178" left="794" width="143" height="17" font="5">changes in SBP and DBP </text>
<text top="195" left="794" width="113" height="17" font="5">were -3.5 (95% CI: - </text>
<text top="212" left="794" width="125" height="17" font="5">4.61– -2.51) and -1.80 </text>
<text top="230" left="794" width="50" height="17" font="5">(95% CI: </text>
<text top="248" left="794" width="77" height="17" font="5">-3.03– -0.58). </text>
<text top="266" left="794" width="3" height="17" font="3"><b> </b></text>
<text top="284" left="794" width="127" height="18" font="5">• In a meta-regression </text>
<text top="302" left="794" width="92" height="17" font="5">analysis, a dose-</text>
<text top="319" left="794" width="113" height="17" font="5">response was noted </text>
<text top="336" left="794" width="131" height="17" font="5">between % reduction in </text>
<text top="353" left="794" width="139" height="17" font="5">alcohol consumption and </text>
<text top="371" left="794" width="124" height="17" font="5">mean reduction in BP. </text>
<text top="388" left="786" width="3" height="17" font="5"> </text>
<text top="406" left="794" width="137" height="17" font="3"><b>1  Safety endpoint: </b>N/A<b> </b></text>
<text top="91" left="971" width="108" height="17" font="5">relationship alcohol </text>
<text top="108" left="971" width="56" height="17" font="5">and BP in </text>
<text top="125" left="971" width="76" height="17" font="5">observational </text>
<text top="142" left="971" width="85" height="17" font="5">epidemiology – </text>
<text top="160" left="971" width="98" height="17" font="5">about a 1 mm Hg </text>
<text top="177" left="971" width="87" height="17" font="5">higher SBP per </text>
<text top="194" left="971" width="81" height="17" font="5">alcoholic drink </text>
<text top="211" left="971" width="77" height="17" font="5">consumed. In </text>
<text top="229" left="971" width="76" height="17" font="5">observational </text>
<text top="246" left="971" width="86" height="17" font="5">studies, type of </text>
<text top="263" left="971" width="93" height="17" font="5">alcohol does not </text>
<text top="280" left="971" width="109" height="17" font="5">seem to matter and </text>
<text top="297" left="971" width="95" height="17" font="5">at lower levels of </text>
<text top="315" left="971" width="42" height="17" font="5">alcohol </text>
<text top="332" left="971" width="95" height="17" font="5">consumption (&lt;1 </text>
<text top="349" left="971" width="76" height="17" font="5">standard size </text>
<text top="366" left="971" width="102" height="17" font="5">alcoholic drink per </text>
<text top="383" left="971" width="103" height="17" font="5">day in women and </text>
<text top="401" left="971" width="93" height="17" font="5">&lt;2 in men) there </text>
<text top="418" left="971" width="97" height="17" font="5">does not seem to </text>
<text top="435" left="971" width="89" height="17" font="5">be an important </text>
<text top="452" left="971" width="102" height="17" font="5">biological effect of </text>
<text top="469" left="971" width="83" height="17" font="5">alcohol on BP. </text>
<text top="487" left="971" width="101" height="18" font="5">• The relationship </text>
<text top="505" left="971" width="92" height="17" font="5">between alcohol </text>
<text top="522" left="971" width="129" height="17" font="5">consumption and BP is </text>
<text top="539" left="971" width="87" height="17" font="5">predictable and </text>
<text top="557" left="971" width="72" height="17" font="5">consistent in </text>
<text top="574" left="971" width="129" height="17" font="5">observational and RCT </text>
<text top="591" left="971" width="121" height="17" font="5">studies. However, the </text>
<text top="608" left="971" width="116" height="17" font="5">relationship between </text>
<text top="625" left="971" width="139" height="17" font="5">alcohol consumption and </text>
<text top="643" left="971" width="139" height="17" font="5">CVD is more complex as </text>
<text top="660" left="971" width="117" height="17" font="5">alcohol is associated </text>
<text top="677" left="971" width="103" height="17" font="5">with an apparently </text>
<text top="694" left="971" width="135" height="17" font="5">beneficial effect on CVD </text>
<text top="712" left="971" width="128" height="17" font="5">risk, possibly mediated </text>
<text top="729" left="971" width="124" height="17" font="5">by an increase in HDL-</text>
<text top="746" left="971" width="66" height="17" font="5">cholesterol. </text>
<text top="763" left="971" width="110" height="18" font="5">• Pregnant women, </text>
</page>
<page number="267" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="971" width="97" height="17" font="5">pts with HTN and </text>
<text top="108" left="971" width="94" height="17" font="5">those at risk of a </text>
<text top="125" left="971" width="94" height="17" font="5">drinking problem </text>
<text top="142" left="971" width="90" height="17" font="5">should not drink </text>
<text top="160" left="971" width="113" height="17" font="5">alcohol. Established </text>
<text top="177" left="971" width="95" height="17" font="5">light drinkers (&lt;2 </text>
<text top="194" left="971" width="111" height="17" font="5">standard drinks/d in </text>
<text top="211" left="971" width="92" height="17" font="5">men and &lt;1/d in </text>
<text top="229" left="971" width="94" height="17" font="5">women) who are </text>
<text top="246" left="971" width="122" height="18" font="5">•<b> </b>normotensive are in </text>
<text top="264" left="971" width="87" height="17" font="5">a favorable risk </text>
<text top="281" left="971" width="101" height="17" font="5">category for CVD. </text>
<text top="299" left="83" width="83" height="17" font="5">Stewart SH, et </text>
<text top="316" left="83" width="51" height="17" font="5">al., 2008 </text>
<text top="333" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18821872">18821872</a></text>
<text top="333" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18821872"> </a></text>
<text top="299" left="220" width="119" height="17" font="3"><b>Aim: </b>Study the effect </text>
<text top="316" left="220" width="104" height="17" font="5">of reduced alcohol </text>
<text top="333" left="220" width="77" height="17" font="5">intake on BP. </text>
<text top="351" left="212" width="3" height="17" font="5"> </text>
<text top="369" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="386" left="220" width="76" height="17" font="5">Randomized, </text>
<text top="403" left="220" width="103" height="17" font="5">controlled factorial </text>
<text top="420" left="220" width="27" height="17" font="5">trial. </text>
<text top="438" left="212" width="3" height="17" font="5"> </text>
<text top="456" left="220" width="90" height="17" font="3"><b>Size: </b>1,383 pts.<b> </b></text>
<text top="299" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="316" left="373" width="129" height="18" font="5">• Alcohol dependence. </text>
<text top="334" left="373" width="137" height="18" font="5">• 4—21 d of abstinence. </text>
<text top="353" left="373" width="194" height="18" font="5">• Men: &gt;21 drinks/wk; Women &gt;14 </text>
<text top="371" left="373" width="58" height="17" font="5">drinks/wk. </text>
<text top="388" left="373" width="177" height="18" font="5">• At least 2 heavy drinking days </text>
<text top="407" left="373" width="178" height="17" font="5">within a consecutive 30-d period </text>
<text top="424" left="373" width="159" height="17" font="5">during 90 d prior to baseline. </text>
<text top="442" left="365" width="3" height="17" font="5"> </text>
<text top="459" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="476" left="373" width="144" height="18" font="5">• Other substance abuse. </text>
<text top="495" left="373" width="172" height="18" font="5">• Psychiatric disorder requiring </text>
<text top="513" left="373" width="66" height="17" font="5">medication. </text>
<text top="530" left="373" width="151" height="17" font="5">Unstable medical condition<b> </b></text>
<text top="299" left="619" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="316" left="619" width="100" height="17" font="5">Pharmacotherapy </text>
<text top="333" left="619" width="68" height="17" font="5">(naltrexone, </text>
<text top="351" left="619" width="124" height="17" font="5">acamprosate, or both) </text>
<text top="368" left="619" width="86" height="17" font="5">and counseling </text>
<text top="385" left="619" width="121" height="17" font="5">strategies (behavioral </text>
<text top="402" left="619" width="84" height="17" font="5">and/or medical </text>
<text top="420" left="619" width="83" height="17" font="5">management). </text>
<text top="437" left="611" width="3" height="17" font="5"> </text>
<text top="455" left="619" width="129" height="17" font="3"><b>Comparator: </b>Placebo.<b> </b></text>
<text top="299" left="794" width="87" height="17" font="3"><b>Change in BP: </b></text>
<text top="316" left="794" width="107" height="18" font="5">• Based on up to 5 </text>
<text top="334" left="794" width="123" height="17" font="5">repeated measures of </text>
<text top="352" left="794" width="115" height="17" font="5">BP over 16 wk. Data </text>
<text top="369" left="794" width="114" height="17" font="5">modeled to estimate </text>
<text top="386" left="794" width="104" height="17" font="5">change in BP over </text>
<text top="403" left="794" width="30" height="17" font="5">time. </text>
<text top="421" left="786" width="3" height="17" font="5"> </text>
<text top="438" left="794" width="115" height="18" font="5">• For pts with higher </text>
<text top="456" left="794" width="124" height="17" font="5">than average baseline </text>
<text top="473" left="794" width="114" height="17" font="5">SBP (&gt;132 mm Hg), </text>
<text top="490" left="794" width="111" height="17" font="5">SBP declined by an </text>
<text top="508" left="794" width="122" height="17" font="5">average of 12 mm Hg </text>
<text top="525" left="794" width="40" height="17" font="5">(149— </text>
<text top="543" left="794" width="153" height="17" font="5">137) in the intervention arm </text>
<text top="561" left="794" width="147" height="17" font="5">compared to placebo, with </text>
<text top="579" left="794" width="147" height="17" font="5">a corresponding decline in </text>
<text top="597" left="794" width="154" height="17" font="5">DBP of 8 mm Hg. For those </text>
<text top="616" left="794" width="145" height="17" font="5">with a baseline SBP ≤132 </text>
<text top="634" left="794" width="117" height="17" font="5">mm Hg there was no </text>
<text top="652" left="794" width="145" height="17" font="5">change in SBP (120—121 </text>
<text top="670" left="794" width="94" height="17" font="5">mm Hg) or DBP.<b> </b></text>
<text top="299" left="971" width="122" height="18" font="5">•<b> </b>This  trial  was </text>
<text top="317" left="971" width="122" height="17" font="5">designed  to evaluate </text>
<text top="335" left="971" width="73" height="17" font="5">interventions </text>
<text top="335" left="1074" width="18" height="17" font="5">for </text>
<text top="352" left="971" width="122" height="17" font="5">treatment  of  alcohol </text>
<text top="369" left="971" width="75" height="17" font="5">dependence. </text>
<text top="386" left="971" width="30" height="18" font="5">•<b> </b>BP </text>
<text top="404" left="971" width="85" height="17" font="5">measurements </text>
<text top="422" left="971" width="50" height="17" font="5">were not </text>
<text top="439" left="971" width="77" height="17" font="5">standardized. </text>
<text top="456" left="971" width="108" height="18" font="5">• About 20% of the </text>
<text top="474" left="971" width="102" height="17" font="5">observations were </text>
<text top="492" left="971" width="136" height="17" font="5">missing and assumed to </text>
<text top="509" left="971" width="65" height="17" font="5">be random. </text>
<text top="689" left="83" width="100" height="17" font="5">Dickenson HO, et </text>
<text top="706" left="83" width="54" height="17" font="5">al., 2006  </text>
<text top="723" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16508562">16508562</a></text>
<text top="723" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16508562"> </a></text>
<text top="688" left="220" width="66" height="17" font="3"><b>Aim: </b>Study </text>
<text top="706" left="220" width="89" height="17" font="5">effectiveness of </text>
<text top="723" left="220" width="44" height="17" font="5">lifestyle </text>
<text top="740" left="220" width="76" height="17" font="5">interventions, </text>
<text top="757" left="220" width="100" height="17" font="5">including reduced </text>
<text top="688" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="704" left="373" width="128" height="18" font="5">•  Only parallel trials </text>
<text top="723" left="373" width="206" height="18" font="5">• SBP ≥140 mm Hg and/or DBP ≥85 </text>
<text top="741" left="373" width="42" height="17" font="5">mm Hg </text>
<text top="758" left="373" width="95" height="18" font="5">• ≥8 wk duration </text>
<text top="688" left="619" width="127" height="17" font="3"><b>Intervention: </b>Lifestyle </text>
<text top="706" left="619" width="94" height="17" font="5">change aimed at </text>
<text top="723" left="619" width="121" height="17" font="5">reduced consumption </text>
<text top="740" left="619" width="56" height="17" font="5">of alcohol </text>
<text top="757" left="619" width="3" height="17" font="3"><b> </b></text>
<text top="689" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="707" left="794" width="136" height="17" font="3"><b>-</b>Net reduction (95% CI): </text>
<text top="723" left="794" width="122" height="17" font="5">SBP -3.8 (-6.1— -1.4) </text>
<text top="741" left="794" width="3" height="17" font="3"><b> </b></text>
<text top="758" left="794" width="123" height="17" font="5">DBP -3.2 (-5.0— -1.4) </text>
<text top="688" left="971" width="144" height="18" font="5">•<b> </b>Relatively small number </text>
<text top="708" left="981" width="42" height="17" font="5">of trials </text>
<text top="725" left="971" width="54" height="18" font="5">•<b> </b>Limited </text>
<text top="727" left="1053" width="39" height="17" font="5">details </text>
<text top="744" left="971" width="51" height="17" font="5">provided </text>
</page>
<page number="268" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="220" width="100" height="17" font="5">alcohol intake, for </text>
<text top="108" left="220" width="101" height="17" font="5">treatment of HTN. </text>
<text top="126" left="212" width="3" height="17" font="5"> </text>
<text top="143" left="220" width="112" height="17" font="3"><b>Study type: </b>1 of 10 </text>
<text top="160" left="220" width="87" height="17" font="5">meta-analyses. </text>
<text top="178" left="212" width="3" height="17" font="5"> </text>
<text top="195" left="220" width="106" height="17" font="3"><b>Size: </b>4 trials which </text>
<text top="212" left="220" width="106" height="17" font="5">collectively studied </text>
<text top="229" left="220" width="44" height="17" font="5">305 pts<b> </b></text>
<text top="91" left="373" width="81" height="18" font="5">• BP outcome </text>
<text top="110" left="365" width="3" height="17" font="5"> </text>
<text top="127" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="144" left="373" width="144" height="18" font="5">• 2º HTN or renal disease </text>
<text top="162" left="373" width="107" height="18" font="5">• Pregnant women </text>
<text top="180" left="373" width="173" height="17" font="5">Change in BP meds during trial<b> </b></text>
<text top="91" left="619" width="112" height="17" font="3"><b>Comparator: </b>Usual </text>
<text top="108" left="619" width="27" height="17" font="5">care<b> </b></text>
<text top="92" left="786" width="3" height="17" font="5"> </text>
<text top="109" left="794" width="100" height="17" font="3"><b>Safety endpoint: </b></text>
<text top="126" left="794" width="24" height="17" font="5">N/A<b> </b></text>
<text top="247" left="83" width="95" height="17" font="5">Wallace P, et al., </text>
<text top="264" left="83" width="34" height="17" font="5">1988  </text>
<text top="282" left="83" width="48" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3052668">3052668</a></text>
<text top="282" left="131" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/3052668"> </a></text>
<text top="247" left="220" width="66" height="17" font="3"><b>Aim: </b>Study </text>
<text top="264" left="220" width="89" height="17" font="5">effectiveness of </text>
<text top="282" left="220" width="109" height="17" font="5">general practitioner </text>
<text top="299" left="220" width="94" height="17" font="5">advice to reduce </text>
<text top="316" left="220" width="86" height="17" font="5">heavy drinking. </text>
<text top="334" left="212" width="3" height="17" font="5"> </text>
<text top="351" left="220" width="70" height="17" font="3"><b>Study type: </b></text>
<text top="369" left="220" width="39" height="18" font="5">• RCT </text>
<text top="387" left="212" width="3" height="17" font="5"> </text>
<text top="404" left="220" width="92" height="17" font="3"><b>Size: </b>909 adults </text>
<text top="422" left="220" width="103" height="17" font="5">(641 men and 268 </text>
<text top="439" left="220" width="47" height="17" font="5">women)<b> </b></text>
<text top="247" left="373" width="191" height="17" font="3"><b>Inclusion criteria: </b>Heavy drinking </text>
<text top="264" left="373" width="209" height="17" font="5">during wk prior to screening interview. </text>
<text top="282" left="365" width="3" height="17" font="5"> </text>
<text top="299" left="373" width="204" height="17" font="3"><b>Exclusion criteria: </b>None mentioned<b> </b></text>
<text top="247" left="619" width="134" height="17" font="3"><b>Intervention: </b>Physician </text>
<text top="264" left="619" width="115" height="17" font="5">counselling aimed at </text>
<text top="282" left="619" width="134" height="17" font="5">reduced consumption of </text>
<text top="299" left="619" width="46" height="17" font="5">alcohol. </text>
<text top="317" left="611" width="3" height="17" font="5"> </text>
<text top="334" left="619" width="140" height="17" font="3"><b>Comparator: </b>Usual care<b> </b></text>
<text top="247" left="794" width="68" height="17" font="3"><b>Endpoints: </b></text>
<text top="264" left="794" width="102" height="18" font="5">• 1° outcome was </text>
<text top="283" left="794" width="136" height="17" font="5">reduction in percent with </text>
<text top="300" left="794" width="122" height="17" font="5">heavy consumption of </text>
<text top="317" left="794" width="101" height="17" font="5">alcohol (mean net </text>
<text top="334" left="794" width="113" height="17" font="5">change=46%). Liver </text>
<text top="351" left="794" width="122" height="17" font="5">enzymes and BP also </text>
<text top="369" left="794" width="147" height="17" font="5">measured at 6 and 12 mo. </text>
<text top="386" left="794" width="85" height="18" font="5">• Pretreatment </text>
<text top="404" left="794" width="122" height="17" font="5">SBP/DBP=133.5/79.9 </text>
<text top="422" left="794" width="46" height="17" font="5">mm Hg. </text>
<text top="440" left="794" width="140" height="17" font="5">Net reduction SBP=-2.12 </text>
<text top="458" left="794" width="125" height="17" font="5">(95% CI: -4.19– -0.00) </text>
<text top="476" left="794" width="3" height="17" font="3"><b> </b></text>
<text top="495" left="794" width="100" height="17" font="3"><b>Safety endpoint: </b></text>
<text top="513" left="794" width="24" height="17" font="5">N/A<b> </b></text>
<text top="247" left="971" width="132" height="17" font="5">● The goal was to blind </text>
<text top="264" left="971" width="117" height="17" font="5">those conducting the </text>
<text top="282" left="971" width="133" height="17" font="5">outcome assessment to </text>
<text top="299" left="971" width="142" height="17" font="5">treatment assignment but </text>
<text top="316" left="971" width="138" height="17" font="5">by 6 mo assignment was </text>
<text top="333" left="971" width="132" height="17" font="5">known in 20-30% of the </text>
<text top="350" left="971" width="70" height="17" font="5">participants. </text>
<text top="367" left="971" width="142" height="18" font="5">•<b> </b>A reduction in SBP was </text>
<text top="387" left="981" width="124" height="17" font="5">noted despite use of a </text>
<text top="405" left="981" width="114" height="17" font="5">modest intervention. </text>
<text top="531" left="83" width="79" height="17" font="5">Lang T, et al., </text>
<text top="548" left="83" width="31" height="17" font="5">1995 </text>
<text top="566" left="83" width="48" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8596098">8596098</a></text>
<text top="566" left="131" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8596098"> </a></text>
<text top="531" left="220" width="114" height="17" font="3"><b>Aim</b>: Worksite study </text>
<text top="548" left="220" width="104" height="17" font="5">of reduced alcohol </text>
<text top="566" left="220" width="119" height="17" font="5">intake effect on BP in </text>
<text top="583" left="220" width="108" height="17" font="5">heavy drinkers with </text>
<text top="600" left="220" width="32" height="17" font="5">HTN. </text>
<text top="618" left="212" width="3" height="17" font="5"> </text>
<text top="635" left="220" width="99" height="17" font="3"><b>Study type: </b>RCT </text>
<text top="653" left="212" width="3" height="17" font="5"> </text>
<text top="670" left="220" width="72" height="17" font="3"><b>Size: </b>14 site </text>
<text top="688" left="220" width="88" height="17" font="5">physicians; 129 </text>
<text top="705" left="220" width="100" height="17" font="5">adults (95% men)<b> </b></text>
<text top="531" left="373" width="106" height="17" font="3"><b>Inclusion criteria: </b></text>
<text top="548" left="373" width="187" height="18" font="5">• Heavy drinking (documented by </text>
<text top="567" left="373" width="196" height="17" font="5">history and liver enzyme elevation). </text>
<text top="584" left="373" width="100" height="18" font="5">• HTN (SBP/DBP </text>
<text top="602" left="373" width="95" height="17" font="5">&gt;140/90 mm Hg) </text>
<text top="620" left="365" width="3" height="17" font="5"> </text>
<text top="638" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="655" left="373" width="54" height="18" font="5">• 2º HTN </text>
<text top="673" left="373" width="124" height="18" font="5">• Severe liver disease </text>
<text top="692" left="373" width="140" height="17" font="5">Planned move/retirement.<b> </b></text>
<text top="531" left="619" width="134" height="17" font="3"><b>Intervention: </b>Physician </text>
<text top="548" left="619" width="129" height="17" font="5">and worker counselling </text>
<text top="566" left="619" width="98" height="17" font="5">aimed at reduced </text>
<text top="583" left="619" width="133" height="17" font="5">consumption of alcohol. </text>
<text top="601" left="611" width="3" height="17" font="5"> </text>
<text top="618" left="619" width="77" height="17" font="3"><b>Comparator: </b></text>
<text top="635" left="619" width="66" height="17" font="5">Usual care. </text>
<text top="653" left="611" width="3" height="17" font="5"> </text>
<text top="670" left="619" width="114" height="17" font="3"><b>Duration</b>: Follow-up </text>
<text top="688" left="619" width="126" height="17" font="5">visits at 1, 3, 6, and 18 </text>
<text top="705" left="619" width="24" height="17" font="5">mo.<b> </b></text>
<text top="531" left="794" width="68" height="17" font="3"><b>Endpoints: </b></text>
<text top="548" left="794" width="61" height="18" font="5">• Baseline </text>
<text top="567" left="794" width="125" height="17" font="5">SBP/DBP=162.5/98.0. </text>
<text top="584" left="794" width="102" height="17" font="5">Although all of the </text>
<text top="601" left="794" width="127" height="17" font="5">workers had HTN, only </text>
<text top="618" left="794" width="126" height="17" font="5">about 20% were being </text>
<text top="636" left="794" width="67" height="17" font="5">treated with </text>
<text top="653" left="794" width="93" height="17" font="5">antihypertensive </text>
<text top="670" left="794" width="135" height="17" font="5">medications at baseline. </text>
<text top="687" left="794" width="133" height="18" font="5">• At 1 y, the net change </text>
<text top="705" left="794" width="122" height="17" font="5">in SBP=-5.5 (p&lt;0.05). </text>
<text top="723" left="794" width="117" height="17" font="5">When 5 sites with &lt;5 </text>
<text top="740" left="794" width="98" height="17" font="5">workers/site were </text>
<text top="757" left="794" width="97" height="17" font="5">excluded, the net </text>
<text top="531" left="971" width="141" height="17" font="5">● Behavioral intervention </text>
<text top="548" left="971" width="142" height="17" font="5">state of the art for its time </text>
<text top="566" left="971" width="56" height="17" font="5">● Careful </text>
<text top="583" left="971" width="118" height="17" font="5">measurements of BP </text>
<text top="600" left="971" width="109" height="17" font="5">using Hawksley RZ </text>
<text top="617" left="971" width="119" height="17" font="5">sphygmomanometer. </text>
<text top="634" left="971" width="132" height="17" font="5">● Main analyses do not </text>
<text top="652" left="971" width="137" height="17" font="5">seem to have accounted </text>
<text top="669" left="971" width="100" height="17" font="5">for cluster design. </text>
</page>
<page number="269" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="137" height="17" font="5">change in SBP=-7.3 mm </text>
<text top="108" left="794" width="72" height="17" font="5">Hg (p&lt;0.01). </text>
<text top="125" left="794" width="136" height="17" font="5">At 2 y, the net change in </text>
<text top="142" left="794" width="109" height="17" font="5">SBP=-6.6 (p&lt;0.05). </text>
<text top="159" left="794" width="3" height="17" font="3"><b> </b></text>
<text top="178" left="794" width="100" height="17" font="3"><b>Safety endpoint: </b></text>
<text top="195" left="794" width="24" height="17" font="5">N/A<b> </b></text>
<text top="211" left="83" width="100" height="17" font="5">Thompson AM, et </text>
<text top="226" left="83" width="51" height="17" font="5">al., 2011 </text>
<text top="243" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21364140?dopt=Citation">21364140</a></text>
<text top="243" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21364140?dopt=Citation"> </a></text>
<text top="211" left="220" width="119" height="17" font="3"><b>Aim: </b>To evaluate the </text>
<text top="226" left="220" width="47" height="17" font="5">effect of </text>
<text top="241" left="220" width="93" height="17" font="5">antihypertensive </text>
<text top="256" left="220" width="87" height="17" font="5">treatment on 2º </text>
<text top="271" left="220" width="104" height="17" font="5">prevention of CVD </text>
<text top="286" left="220" width="116" height="17" font="5">events and all-cause </text>
<text top="303" left="220" width="111" height="17" font="5">mortality among pts </text>
<text top="320" left="220" width="91" height="17" font="5">without clinically </text>
<text top="337" left="220" width="76" height="17" font="5">defined HTN. </text>
<text top="355" left="212" width="3" height="17" font="5"> </text>
<text top="373" left="220" width="70" height="17" font="3"><b>Study type</b>: </text>
<text top="390" left="220" width="83" height="17" font="5">Meta- analysis </text>
<text top="407" left="220" width="69" height="17" font="5">including 25 </text>
<text top="424" left="220" width="35" height="17" font="5">RCTs </text>
<text top="442" left="212" width="3" height="17" font="5"> </text>
<text top="459" left="220" width="92" height="17" font="3"><b>Size</b>: 64,162 pts </text>
<text top="477" left="220" width="75" height="17" font="5">without HTN.<b> </b></text>
<text top="211" left="373" width="141" height="17" font="3"><b>Inclusion criteria: </b>RCTs </text>
<text top="226" left="373" width="107" height="17" font="5">of antihypertensive </text>
<text top="241" left="373" width="142" height="17" font="5">treatment among pts with </text>
<text top="256" left="373" width="149" height="17" font="5">BP &lt;140/90 mm Hg for the </text>
<text top="273" left="373" width="147" height="17" font="5">prevention of CVD events. </text>
<text top="290" left="373" width="3" height="17" font="3"><b> </b></text>
<text top="308" left="373" width="208" height="17" font="3"><b>Exclusion criteria</b>: CVD events were </text>
<text top="325" left="373" width="175" height="17" font="5">not reported by HTN status that </text>
<text top="342" left="373" width="207" height="17" font="5">included participants with and without </text>
<text top="359" left="373" width="208" height="17" font="5">HTN; study population did not include </text>
<text top="376" left="373" width="181" height="17" font="5">persons with BP in the normal or </text>
<text top="394" left="373" width="168" height="17" font="5">prehypertensive ranges; study </text>
<text top="411" left="373" width="215" height="17" font="5">population did not include persons with </text>
<text top="428" left="373" width="205" height="17" font="5">preexisting CVD or CVD equivalents, </text>
<text top="445" left="373" width="165" height="17" font="5">such as DM; antihypertensive </text>
<text top="462" left="373" width="178" height="17" font="5">medication was not a part of the </text>
<text top="480" left="373" width="206" height="17" font="5">intervention; treatment allocation was </text>
<text top="497" left="373" width="204" height="17" font="5">not random; measure of variance not </text>
<text top="514" left="373" width="186" height="17" font="5">reported; participants were &lt;18 y; </text>
<text top="531" left="373" width="175" height="17" font="5">there were differences between </text>
<text top="548" left="373" width="204" height="17" font="5">intervention and control groups other </text>
<text top="566" left="373" width="179" height="17" font="5">than antihypertensive treatment. </text>
<text top="583" left="373" width="142" height="17" font="5">Preexisting CVD included </text>
<text top="600" left="373" width="32" height="17" font="5">PAD.<b> </b></text>
<text top="211" left="619" width="109" height="17" font="3"><b>Interventions</b>: Any </text>
<text top="226" left="619" width="127" height="17" font="5">antihypertensive agent </text>
<text top="241" left="619" width="130" height="17" font="5">compared with placebo </text>
<text top="258" left="619" width="90" height="17" font="5">or no treatment.<b> </b></text>
<text top="211" left="794" width="137" height="17" font="3"><b>Results</b>: Compared with </text>
<text top="226" left="794" width="122" height="17" font="5">controls, pts receiving </text>
<text top="241" left="794" width="93" height="17" font="5">antihypertensive </text>
<text top="256" left="794" width="69" height="17" font="5">medications </text>
<text top="271" left="794" width="137" height="17" font="5">had a pooled RR of 0.77 </text>
<text top="286" left="794" width="131" height="17" font="5">(95% CI: 0.61, 0.77) for </text>
<text top="303" left="794" width="150" height="17" font="5">stroke: 0.80 (95% CI: 0.69, </text>
<text top="320" left="794" width="148" height="17" font="5">0.93) for MI: 0.71 (95% CI: </text>
<text top="337" left="794" width="140" height="17" font="5">0.65, 0.77) for CHF: 0.85 </text>
<text top="354" left="794" width="131" height="17" font="5">(95% CI: 0.80, 0.90) for </text>
<text top="372" left="794" width="132" height="17" font="5">composite CVD events: </text>
<text top="389" left="794" width="141" height="17" font="5">0.83 (95% CI: 0.69, 0.99) </text>
<text top="406" left="794" width="47" height="17" font="5">for CVD </text>
<text top="423" left="794" width="152" height="17" font="5">mortality and 0.87 (95% CI: </text>
<text top="441" left="794" width="133" height="17" font="5">0.80, 0.95) for all-cause </text>
<text top="458" left="794" width="123" height="17" font="5">mortality from random </text>
<text top="475" left="794" width="144" height="17" font="5">effect models. Results did </text>
<text top="492" left="794" width="145" height="17" font="5">not differ according to trial </text>
<text top="510" left="794" width="96" height="17" font="5">characteristics or </text>
<text top="527" left="794" width="121" height="17" font="5">subgroups defined by </text>
<text top="544" left="794" width="134" height="17" font="5">clinical history, although </text>
<text top="561" left="794" width="145" height="17" font="5">no specific PAD subgroup </text>
<text top="578" left="794" width="73" height="17" font="5">was defined. </text>
<text top="596" left="786" width="3" height="17" font="5"> </text>
<text top="613" left="794" width="150" height="17" font="3"><b>Summary</b>: Among pts with </text>
<text top="630" left="794" width="126" height="17" font="5">clinical history of CVD, </text>
<text top="647" left="794" width="147" height="17" font="5">including PAD, but without </text>
<text top="665" left="794" width="125" height="17" font="5">HTN, antihypertensive </text>
<text top="682" left="794" width="143" height="17" font="5">treatment was associated </text>
<text top="699" left="794" width="149" height="17" font="5">with reduced risk of stroke, </text>
<text top="716" left="794" width="121" height="17" font="5">CHF, composite CVD </text>
<text top="733" left="794" width="116" height="17" font="5">events and all-cause </text>
<text top="751" left="794" width="53" height="17" font="5">mortality.<b> </b></text>
<text top="212" left="971" width="131" height="17" font="3"><b> Study limitations and </b></text>
<text top="230" left="971" width="96" height="17" font="3"><b>adverse events: </b></text>
<text top="247" left="971" width="122" height="18" font="5">• PAD not specifically </text>
<text top="265" left="971" width="118" height="17" font="5">collected at baseline, </text>
<text top="283" left="971" width="104" height="17" font="5">thus cannot detect </text>
<text top="300" left="971" width="91" height="17" font="5">actual incidence </text>
<text top="317" left="971" width="57" height="17" font="5">(however, </text>
<text top="334" left="971" width="81" height="17" font="5">randomization </text>
<text top="351" left="971" width="140" height="17" font="5">● presumably resulted in </text>
<text top="369" left="971" width="141" height="17" font="5">equal number of baseline </text>
<text top="386" left="971" width="107" height="17" font="5">PAD cases in each </text>
<text top="403" left="971" width="39" height="17" font="5">group) </text>
<text top="420" left="971" width="122" height="17" font="5">● Asymptomatic PAD </text>
<text top="438" left="971" width="130" height="17" font="5">likely missed (definition </text>
<text top="455" left="971" width="135" height="17" font="5">used in this study based </text>
<text top="472" left="971" width="132" height="17" font="5">on hospitalization, likely </text>
<text top="489" left="971" width="106" height="17" font="5">only capturing very </text>
<text top="506" left="971" width="80" height="17" font="5">severe cases) </text>
</page>
<page number="270" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="83" width="94" height="17" font="5">Thomopoulos C, </text>
<text top="108" left="83" width="64" height="17" font="5">et al., 2014 </text>
<text top="123" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25259547?dopt=Citation">25259547</a></text>
<text top="123" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25259547?dopt=Citation"> </a></text>
<text top="91" left="220" width="103" height="17" font="3"><b>Aim: </b>Investigating </text>
<text top="108" left="220" width="117" height="17" font="5">whether all grades of </text>
<text top="125" left="220" width="121" height="17" font="5">HTN benefit from BP- </text>
<text top="142" left="220" width="104" height="17" font="5">lowering treatment </text>
<text top="160" left="220" width="100" height="17" font="5">and which are the </text>
<text top="177" left="220" width="103" height="17" font="5">target BP levels to </text>
<text top="194" left="220" width="106" height="17" font="5">maximize outcome </text>
<text top="211" left="220" width="57" height="17" font="5">reduction. </text>
<text top="229" left="212" width="3" height="17" font="5"> </text>
<text top="247" left="220" width="71" height="17" font="3"><b>Study type: </b></text>
<text top="264" left="220" width="96" height="17" font="5">Meta- analysis of </text>
<text top="281" left="220" width="35" height="17" font="5">RCTs </text>
<text top="299" left="212" width="3" height="17" font="5"> </text>
<text top="314" left="220" width="109" height="17" font="3"><b>Size: </b>32 RCTs with </text>
<text top="330" left="220" width="68" height="17" font="5">104,359 pts<b> </b></text>
<text top="91" left="373" width="187" height="17" font="3"><b>Inclusion criteria: </b>Intentional BP-</text>
<text top="108" left="373" width="173" height="17" font="5">lowering comparing active drug </text>
<text top="125" left="373" width="206" height="17" font="5">treatment with placebo, or less active </text>
<text top="142" left="373" width="189" height="17" font="5">treatment (intentional BP-lowering </text>
<text top="160" left="373" width="213" height="17" font="5">trials), or comparison of an active drug </text>
<text top="177" left="373" width="148" height="17" font="5">with placebo over baseline </text>
<text top="194" left="373" width="215" height="17" font="5">antihypertensive treatment, resulting in </text>
<text top="211" left="373" width="210" height="17" font="5">a BP difference of at least 2 mm Hg in </text>
<text top="229" left="373" width="209" height="17" font="5">either SBP or DBP (nonintentional BP-</text>
<text top="246" left="373" width="149" height="17" font="5">lowering trials); enrolling of </text>
<text top="263" left="373" width="211" height="17" font="5">hypertensive individuals only or a high </text>
<text top="280" left="373" width="186" height="17" font="5">proportion (at least 40%) of them. </text>
<text top="298" left="365" width="3" height="17" font="5"> </text>
<text top="314" left="373" width="134" height="17" font="3"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="89" left="619" width="151" height="17" font="3"><b>Intervention/Comparator: </b></text>
<text top="104" left="619" width="136" height="17" font="5">Criteria of eligibility were </text>
<text top="120" left="619" width="129" height="17" font="5">intentional BP-lowering </text>
<text top="135" left="619" width="124" height="17" font="5">comparing active drug </text>
<text top="150" left="619" width="145" height="17" font="5">treatment with placebo, or </text>
<text top="166" left="619" width="116" height="17" font="5">less active treatment </text>
<text top="181" left="619" width="133" height="17" font="5">(intentional BP-lowering </text>
<text top="196" left="619" width="149" height="17" font="5">trials), or comparison of an </text>
<text top="211" left="619" width="135" height="17" font="5">active drug with placebo </text>
<text top="227" left="619" width="76" height="17" font="5">over baseline </text>
<text top="242" left="619" width="152" height="17" font="5">antihypertensive treatment, </text>
<text top="257" left="619" width="150" height="17" font="5">resulting in a BP difference </text>
<text top="273" left="619" width="123" height="17" font="5">of at least 2 mm Hg in </text>
<text top="288" left="619" width="105" height="17" font="5">either SBP or DBP </text>
<text top="303" left="619" width="154" height="17" font="5">(nonintentional BP-lowering </text>
<text top="319" left="619" width="100" height="17" font="5">trials); enrolling of </text>
<text top="334" left="619" width="134" height="17" font="5">hypertensive individuals </text>
<text top="349" left="619" width="154" height="17" font="5">only or a high proportion (at </text>
<text top="364" left="619" width="143" height="17" font="5">least 40%) of them. Other </text>
<text top="380" left="619" width="132" height="17" font="5">inclusion criteria can be </text>
<text top="395" left="619" width="125" height="17" font="5">found in the preceding </text>
<text top="410" left="619" width="149" height="17" font="5">paper. 51 trials were found </text>
<text top="426" left="619" width="151" height="17" font="5">eligible either for assessing </text>
<text top="441" left="619" width="122" height="17" font="5">BP-lowering effects in </text>
<text top="456" left="619" width="150" height="17" font="5">different HTN grades or for </text>
<text top="472" left="619" width="132" height="17" font="5">assessing the effects of </text>
<text top="487" left="619" width="123" height="17" font="5">achieving different BP </text>
<text top="502" left="619" width="35" height="17" font="5">levels<b> </b></text>
<text top="91" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="109" left="794" width="121" height="18" font="5">• As some trials were </text>
<text top="127" left="794" width="119" height="17" font="5">done on low- risk pts, </text>
<text top="145" left="794" width="138" height="17" font="5">others on higher risk pts, </text>
<text top="162" left="794" width="140" height="17" font="5">no evaluation of absolute </text>
<text top="179" left="794" width="27" height="17" font="5">risk- </text>
<text top="196" left="794" width="117" height="17" font="5">reduction was made. </text>
<text top="213" left="794" width="128" height="17" font="5">However, a 2º analysis </text>
<text top="231" left="794" width="137" height="17" font="5">was done including trials </text>
<text top="248" left="794" width="124" height="17" font="5">or trial subgroups with </text>
<text top="265" left="794" width="140" height="17" font="5">mean baseline SBP/DBP </text>
<text top="282" left="794" width="132" height="17" font="5">values in grade 1 range </text>
<text top="299" left="794" width="126" height="17" font="5">and a low-to-moderate </text>
<text top="317" left="794" width="146" height="17" font="5">risk (&lt;5% CV deaths in 10 </text>
<text top="334" left="794" width="121" height="17" font="5">y in controls): FEVER </text>
<text top="351" left="794" width="147" height="17" font="5">stratum with baseline SBP </text>
<text top="368" left="794" width="135" height="17" font="5">below the median (&lt;153 </text>
<text top="386" left="794" width="104" height="17" font="5">mm Hg) (e7); HTN </text>
<text top="403" left="794" width="136" height="17" font="5">Detection and Follow-up </text>
<text top="420" left="794" width="120" height="17" font="5">Program stratum with </text>
<text top="437" left="794" width="139" height="17" font="5">baseline DBP 90–94 mm </text>
<text top="454" left="794" width="118" height="17" font="5">Hg and no CVD (e9); </text>
<text top="472" left="794" width="121" height="17" font="5">OSLO (e17); TOMHS </text>
<text top="489" left="794" width="137" height="17" font="5">(e28) and USPHS (e29). </text>
<text top="506" left="794" width="141" height="17" font="5">Risks of stroke, CHD, the </text>
<text top="523" left="794" width="134" height="17" font="5">composite of stroke and </text>
<text top="541" left="794" width="144" height="17" font="5">CHD, and all-cause death </text>
<text top="558" left="794" width="145" height="17" font="5">were significantly reduced </text>
<text top="575" left="794" width="132" height="17" font="5">by BP-lowering in these </text>
<text top="592" left="794" width="135" height="17" font="5">low-to-moderate risk pts </text>
<text top="609" left="794" width="131" height="17" font="5">(control group: average </text>
<text top="627" left="794" width="142" height="17" font="5">CV mortality 4.5% in10 y) </text>
<text top="644" left="794" width="110" height="17" font="5">with a moderate BP </text>
<text top="661" left="794" width="104" height="17" font="5">elevation (average </text>
<text top="678" left="794" width="132" height="17" font="5">SBP/DBP 145.5/91 mm </text>
<text top="696" left="794" width="121" height="17" font="5">Hg) at randomization. </text>
<text top="713" left="794" width="126" height="17" font="5">Standardized risk ratio </text>
<text top="730" left="794" width="115" height="17" font="5">associated with 10/5 </text>
<text top="747" left="794" width="127" height="17" font="5">reduction in BP: stroke </text>
<text top="764" left="794" width="141" height="17" font="5">0.33 (95% CI: 0.11–0.98) </text>
<text top="90" left="971" width="146" height="17" font="3"><b>Summary</b>: Meta-analyses </text>
<text top="107" left="971" width="100" height="17" font="5">favor BP-lowering </text>
<text top="124" left="971" width="143" height="17" font="5">treatment even in grade 1 </text>
<text top="142" left="971" width="138" height="17" font="5">HTN at low-to- moderate </text>
<text top="158" left="971" width="99" height="17" font="5">risk, and lowering </text>
<text top="176" left="971" width="142" height="17" font="5">SBP/DBP to &lt;140/90 mm </text>
<text top="193" left="971" width="127" height="17" font="5">Hg. Achieving &lt;130/80 </text>
<text top="210" left="971" width="141" height="17" font="5">mm Hg appears safe, but </text>
<text top="227" left="971" width="149" height="17" font="5">only adds further reduction </text>
<text top="244" left="971" width="53" height="17" font="5">in stroke.<b> </b></text>
</page>
<page number="271" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="90" left="794" width="139" height="17" font="5">CHD 0.68 (95% CI: 0.48–</text>
<text top="108" left="794" width="31" height="17" font="5">0.95) </text>
<text top="125" left="794" width="142" height="17" font="5">CVD death 0.57 (95% CI: </text>
<text top="142" left="794" width="34" height="17" font="5">0.32– </text>
<text top="159" left="794" width="152" height="17" font="5">1.02) total death 0.53 (95% </text>
<text top="176" left="794" width="34" height="17" font="5">0.35– </text>
<text top="194" left="794" width="31" height="17" font="5">0.80) </text>
<text top="211" left="794" width="141" height="18" font="5">• Compared outcomes of </text>
<text top="229" left="794" width="130" height="17" font="5">achieved on study SBP </text>
<text top="247" left="794" width="82" height="17" font="5">&lt;130 vs. ≥130 </text>
<text top="264" left="794" width="130" height="17" font="5">Standardized Risk ratio </text>
<text top="281" left="794" width="115" height="17" font="5">associated with 10/5 </text>
<text top="298" left="794" width="127" height="17" font="5">reduction in BP: stroke </text>
<text top="315" left="794" width="140" height="17" font="5">0.68 (95% CI: 0.57, 0.83) </text>
<text top="332" left="794" width="139" height="17" font="5">CHD 0.87 (95% CI: 0.76, </text>
<text top="350" left="794" width="31" height="17" font="5">1.00) </text>
<text top="367" left="794" width="129" height="17" font="5">HF 0.92 (95% CI: 0.47, </text>
<text top="384" left="794" width="31" height="17" font="5">1.77) </text>
<text top="401" left="794" width="139" height="17" font="5">CVD 0.81 (95% CI: 0.67, </text>
<text top="418" left="794" width="31" height="17" font="5">1.00) </text>
<text top="436" left="794" width="142" height="17" font="5">CVD death 0.88 (95% CI: </text>
<text top="453" left="794" width="31" height="17" font="5">0.77, </text>
<text top="470" left="794" width="152" height="17" font="5">1.01) total death 0.88 (95% </text>
<text top="487" left="794" width="19" height="17" font="5">CI: </text>
<text top="504" left="794" width="62" height="17" font="5">0.77, 0.99) </text>
<text top="520" left="794" width="143" height="17" font="5">Outcomes of achieved on </text>
<text top="535" left="794" width="135" height="17" font="5">study SBP  130–139 vs. </text>
<text top="551" left="794" width="135" height="17" font="5">≥140 Standardized Risk </text>
<text top="566" left="794" width="90" height="17" font="5">ratio associated </text>
<text top="581" left="794" width="143" height="17" font="5">with 10/5 reduction in BP: </text>
<text top="596" left="794" width="37" height="17" font="5">stroke </text>
<text top="611" left="794" width="141" height="17" font="5">0.63 (95% CI: 0.52–0.77) </text>
<text top="626" left="794" width="139" height="17" font="5">CHD 0.77 (95% CI: 0.70–</text>
<text top="641" left="794" width="31" height="17" font="5">0.86) </text>
<text top="656" left="794" width="129" height="17" font="5">HF 0.76 (95% CI: 0.47–</text>
<text top="671" left="794" width="31" height="17" font="5">1.25) </text>
<text top="686" left="794" width="139" height="17" font="5">CVD 0.74 (95% CI: 0.62–</text>
<text top="701" left="794" width="31" height="17" font="5">0.88) </text>
<text top="716" left="794" width="142" height="17" font="5">CVD death 0.81 (95% CI: </text>
<text top="731" left="794" width="34" height="17" font="5">0.67– </text>
<text top="746" left="794" width="152" height="17" font="5">0.97) total death 0.87 (95% </text>
<text top="761" left="794" width="19" height="17" font="5">CI: </text>
</page>
<page number="272" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="89" left="794" width="62" height="17" font="5">0.75–1.00) </text>
<text top="104" left="794" width="146" height="18" font="5">• Similar pattern of results </text>
<text top="121" left="805" width="118" height="17" font="5">for on treatment DBP </text>
<text top="177" left="83" width="40" height="17" font="3"><b>MDRD </b></text>
<text top="196" left="83" width="80" height="17" font="5">Klahr S, et al., </text>
<text top="214" left="83" width="31" height="17" font="5">1994 </text>
<text top="232" left="83" width="48" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8114857?dopt=Citation">8114857</a></text>
<text top="232" left="131" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8114857?dopt=Citation"> </a></text>
<text top="176" left="220" width="107" height="17" font="3"><b>Aim: </b>To determine </text>
<text top="194" left="220" width="101" height="17" font="5">whether restricted </text>
<text top="211" left="220" width="92" height="17" font="5">protein intake or </text>
<text top="228" left="220" width="106" height="17" font="5">tighter HTN control </text>
<text top="245" left="220" width="68" height="17" font="5">would delay </text>
<text top="263" left="220" width="111" height="17" font="5">progression of CKD </text>
<text top="281" left="212" width="3" height="17" font="3"><b> </b></text>
<text top="298" left="220" width="70" height="17" font="3"><b>Study type</b>: </text>
<text top="315" left="220" width="72" height="17" font="5">Randomized </text>
<text top="332" left="220" width="111" height="17" font="5">management to low </text>
<text top="349" left="220" width="117" height="17" font="5">or usual BP goal and </text>
<text top="367" left="220" width="121" height="17" font="5">usual, low or very low </text>
<text top="384" left="220" width="77" height="17" font="5">protein intake </text>
<text top="401" left="212" width="3" height="17" font="3"><b> </b></text>
<text top="418" left="220" width="32" height="17" font="3"><b>Size: </b></text>
<text top="436" left="220" width="41" height="18" font="5">• Total </text>
<text top="454" left="220" width="78" height="17" font="5">n=840  Study </text>
<text top="471" left="220" width="10" height="17" font="5">1 </text>
<text top="471" left="260" width="38" height="17" font="5">n=585 </text>
<text top="488" left="220" width="35" height="17" font="5">Study </text>
<text top="488" left="287" width="10" height="17" font="5">2 </text>
<text top="506" left="220" width="38" height="17" font="5">n=255 </text>
<text top="523" left="220" width="127" height="18" font="5">• Mean follow-up 2.2 y </text>
<text top="541" left="220" width="102" height="18" font="5">• Mean MAP, mm </text>
<text top="559" left="220" width="16" height="17" font="5">Hg</text>
<text top="559" left="235" width="29" height="17" font="15"> (SD)</text>
<text top="559" left="264" width="7" height="17" font="5">: </text>
<text top="576" left="220" width="91" height="17" font="5">Study 1: 98 (11) </text>
<text top="593" left="220" width="91" height="17" font="5">Study 2: 98 (11) </text>
<text top="611" left="220" width="100" height="18" font="5">• Mean SBP, mm </text>
<text top="629" left="220" width="16" height="17" font="5">Hg</text>
<text top="629" left="235" width="29" height="17" font="15"> (SD)</text>
<text top="629" left="264" width="7" height="17" font="5">: </text>
<text top="646" left="220" width="98" height="17" font="5">Study 1: 131 (18) </text>
<text top="663" left="220" width="98" height="17" font="5">Study 2: 133 (18) </text>
<text top="681" left="220" width="100" height="18" font="5">• Mean DBP, mm </text>
<text top="699" left="220" width="16" height="17" font="5">Hg</text>
<text top="699" left="235" width="29" height="17" font="15"> (SD)</text>
<text top="699" left="264" width="7" height="17" font="5">: </text>
<text top="716" left="220" width="91" height="17" font="5">Study 1: 81 (10) </text>
<text top="734" left="220" width="91" height="17" font="5">Study 2: 81 (10)<b> </b></text>
<text top="176" left="373" width="219" height="17" font="3"><b>Inclusion criteria: </b>Adults 18–70 y, with </text>
<text top="194" left="373" width="204" height="17" font="5">renal insufficiency (serum Cr 1.2–7.0 </text>
<text top="211" left="373" width="213" height="17" font="5">mg/dL in women and 1.4–7.0 mg/dL in </text>
<text top="228" left="373" width="208" height="17" font="5">men or CrCl &lt;70 mL/min per 1.73 m²) </text>
<text top="245" left="373" width="213" height="17" font="5">and MAP≤125 mm Hg (normotensives </text>
<text top="263" left="373" width="53" height="17" font="5">included) </text>
<text top="281" left="365" width="3" height="17" font="3"><b> </b></text>
<text top="298" left="373" width="110" height="17" font="3"><b>Exclusion criteria: </b></text>
<text top="315" left="373" width="135" height="17" font="5">Pregnancy, body weight </text>
<text top="332" left="373" width="182" height="17" font="5">&lt;80% or &gt;160% of standard, DM </text>
<text top="350" left="373" width="213" height="17" font="5">requiring insulin, urine protein &gt;10 g/d, </text>
<text top="367" left="373" width="188" height="17" font="5">history of renal transplant, chronic </text>
<text top="384" left="373" width="204" height="17" font="5">medical conditions, doubts regarding </text>
<text top="401" left="373" width="69" height="17" font="5">compliance.<b> </b></text>
<text top="176" left="619" width="78" height="17" font="3"><b>Intervention: </b></text>
<text top="194" left="619" width="104" height="18" font="5">• Study 1 included </text>
<text top="212" left="619" width="141" height="17" font="5">subjects with GFR 25–55 </text>
<text top="229" left="619" width="138" height="17" font="5">mL/min 1.73 m² (n=585); </text>
<text top="247" left="619" width="104" height="18" font="5">• Study 2 included </text>
<text top="265" left="619" width="140" height="17" font="5">subjects with GFR 13–24 </text>
<text top="282" left="619" width="135" height="17" font="5">mL/min 1.73 m² (n=255) </text>
<text top="299" left="619" width="142" height="18" font="5">• Low MAP goal ≤92 mm </text>
<text top="317" left="619" width="121" height="17" font="5">Hg for those 18–60 y; </text>
<text top="335" left="619" width="112" height="17" font="5">≤98 for those ≥61 y </text>
<text top="352" left="619" width="142" height="18" font="5">• Usual: MAP goal ≤107 </text>
<text top="370" left="619" width="142" height="17" font="5">mm Hg for those 18–60; </text>
<text top="387" left="619" width="128" height="17" font="5">MAP ≤113 for subjects </text>
<text top="404" left="619" width="25" height="17" font="5">≥61 </text>
<text top="422" left="619" width="66" height="18" font="5">• 2 studies: </text>
<text top="440" left="619" width="138" height="17" font="5">Study 1: above BP goals </text>
<text top="457" left="619" width="136" height="17" font="5">plus usual or low protein </text>
<text top="474" left="619" width="141" height="17" font="5">diet (1.3 or 0.58 g protein </text>
<text top="492" left="619" width="135" height="17" font="5">per kg of body weight/d) </text>
<text top="509" left="619" width="138" height="17" font="5">Study 2: above BP goals </text>
<text top="526" left="619" width="110" height="17" font="5">plus low or very low </text>
<text top="543" left="619" width="137" height="17" font="5">protein diet (0.58 or 0.28 </text>
<text top="561" left="619" width="62" height="17" font="5">g per kg/d) </text>
<text top="576" left="619" width="143" height="17" font="5">Between group difference </text>
<text top="591" left="619" width="113" height="17" font="5">in MAP, mm Hg 4.7; </text>
<text top="607" left="619" width="48" height="17" font="5">p&lt;0.001 </text>
<text top="622" left="619" width="139" height="17" font="3"><b>Comparator: </b>By BP and </text>
<text top="637" left="619" width="110" height="17" font="5">protein intake goals<b> </b></text>
<text top="177" left="794" width="76" height="17" font="3"><b>1° endpoint: </b></text>
<text top="195" left="794" width="131" height="17" font="5">Rate of decline in GFR, </text>
<text top="213" left="794" width="96" height="17" font="5">mL/min (95% CI) </text>
<text top="230" left="794" width="55" height="18" font="5">• Study 1 </text>
<text top="248" left="794" width="32" height="17" font="5">From </text>
<text top="266" left="794" width="63" height="17" font="5">baseline to </text>
<text top="283" left="794" width="60" height="17" font="5">4 mo Low: </text>
<text top="300" left="794" width="52" height="17" font="5">3.4; 95% </text>
<text top="317" left="794" width="64" height="17" font="5">CI: 2.6–4.1 </text>
<text top="334" left="794" width="62" height="17" font="5">Usual: 1.9; </text>
<text top="352" left="794" width="47" height="17" font="5">95% CI: </text>
<text top="369" left="794" width="44" height="17" font="5">1.1–2.7 </text>
<text top="386" left="794" width="48" height="17" font="5">p=0.010 </text>
<text top="403" left="794" width="105" height="17" font="5">4 mo to study end, </text>
<text top="420" left="794" width="145" height="17" font="5">Low: 2.8; 95% CI: 2.2–3.3 </text>
<text top="438" left="794" width="62" height="17" font="5">Usual: 3.9; </text>
<text top="455" left="794" width="47" height="17" font="5">95% CI: </text>
<text top="472" left="794" width="44" height="17" font="5">3.3–4.5 </text>
<text top="490" left="794" width="48" height="17" font="5">p=0.006 </text>
<text top="507" left="794" width="87" height="17" font="5">Baseline to 3 y, </text>
<text top="524" left="794" width="131" height="17" font="5">Low: 10.7; 95% CI: 9.1–</text>
<text top="541" left="794" width="27" height="17" font="5">12.4 </text>
<text top="558" left="794" width="69" height="17" font="5">Usual: 12.3; </text>
<text top="575" left="794" width="78" height="17" font="5">95% CI: 10.6–</text>
<text top="593" left="794" width="69" height="17" font="5">14.0 p=0.18 </text>
<text top="610" left="794" width="55" height="18" font="5">• Study 2 </text>
<text top="628" left="794" width="81" height="17" font="5">From baseline </text>
<text top="646" left="794" width="87" height="17" font="5">to end of study, </text>
<text top="663" left="794" width="81" height="17" font="5">Low: 3.7; 95% </text>
<text top="680" left="794" width="64" height="17" font="5">CI: 3.1–4.3 </text>
<text top="697" left="794" width="62" height="17" font="5">Usual: 4.2; </text>
<text top="714" left="794" width="47" height="17" font="5">95% CI: </text>
<text top="730" left="794" width="44" height="17" font="5">3.6–4.9 </text>
<text top="747" left="794" width="41" height="17" font="5">p=0.28 </text>
<text top="764" left="794" width="90" height="17" font="5">ESRD or death: </text>
<text top="174" left="971" width="73" height="17" font="3"><b>Limitations</b>: </text>
<text top="190" left="971" width="130" height="18" font="5">• Drug therapy was not </text>
<text top="206" left="971" width="71" height="17" font="5">randomized. </text>
<text top="221" left="971" width="130" height="17" font="5">Recommended ACEI ± </text>
<text top="236" left="971" width="124" height="17" font="5">diuretic then CCB and </text>
<text top="251" left="971" width="134" height="17" font="5">others. More subjects in </text>
<text top="266" left="971" width="130" height="17" font="5">the low BP goal groups </text>
<text top="281" left="971" width="124" height="17" font="5">received ACEIs (48%, </text>
<text top="296" left="971" width="103" height="17" font="5">51% also reported </text>
<text top="310" left="971" width="122" height="17" font="5">elsewhere) compared </text>
<text top="325" left="971" width="113" height="17" font="5">to the usual BP goal </text>
<text top="340" left="971" width="124" height="17" font="5">group (28%, 32% also </text>
<text top="355" left="971" width="100" height="17" font="5">reported e/w) (not </text>
<text top="370" left="971" width="127" height="17" font="5">noted in 1° manuscript </text>
<text top="385" left="971" width="83" height="17" font="5">but reported in </text>
<text top="400" left="971" width="108" height="17" font="5">Peterson JC, et al., </text>
<text top="415" left="971" width="102" height="17" font="5">1995 (170)). 1.9% </text>
<text top="430" left="971" width="121" height="17" font="5">study 1, 1.2% study 2 </text>
<text top="445" left="971" width="92" height="17" font="5">lost to follow-up. </text>
<text top="460" left="971" width="109" height="18" font="5">• Rate  of  GFR </text>
<text top="476" left="971" width="108" height="17" font="5">decline was slower </text>
<text top="491" left="971" width="109" height="17" font="5">than  expected  in </text>
<text top="506" left="971" width="108" height="17" font="5">the  control  groups </text>
<text top="521" left="971" width="24" height="17" font="5">and </text>
<text top="521" left="1014" width="25" height="17" font="5">was </text>
<text top="521" left="1059" width="20" height="17" font="5">not </text>
<text top="536" left="971" width="53" height="17" font="5">constant. </text>
<text top="553" left="962" width="3" height="17" font="3"><b> </b></text>
<text top="570" left="971" width="141" height="17" font="3"><b>Summary: </b>No significant </text>
<text top="586" left="971" width="148" height="17" font="5">benefits overall from either </text>
<text top="604" left="971" width="130" height="17" font="5">low protein or lower BP </text>
<text top="620" left="971" width="109" height="17" font="5">target. There was a </text>
<text top="638" left="971" width="118" height="17" font="5">significant interaction </text>
<text top="655" left="971" width="140" height="17" font="5">between baseline urinary </text>
<text top="672" left="971" width="138" height="17" font="5">protein excretion and BP </text>
<text top="689" left="971" width="123" height="17" font="5">interventions (p=0.01) </text>
<text top="706" left="971" width="146" height="17" font="5">indicating that low BP was </text>
<text top="723" left="971" width="141" height="17" font="5">of benefit to subjects with </text>
<text top="740" left="971" width="114" height="17" font="5">&gt;1 g proteinuria with </text>
<text top="757" left="971" width="145" height="17" font="5">slower progression of loss </text>
</page>
<page number="273" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="55" height="18" font="5">• Study 2 </text>
<text top="109" left="794" width="147" height="17" font="5">RR for low vs. usual: 0.85; </text>
<text top="126" left="794" width="81" height="17" font="5">95% CI: 0.60– </text>
<text top="144" left="794" width="63" height="17" font="5">1.22 p=NR<b> </b></text>
<text top="90" left="971" width="43" height="17" font="5">of GFR<b> </b></text>
<text top="176" left="83" width="80" height="17" font="5">Soliman EZ et </text>
<text top="194" left="83" width="51" height="17" font="5">al., 2015 </text>
<text top="212" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26459421?dopt=Citation">26459421</a></text>
<text top="212" left="137" width="3" height="17" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26459421?dopt=Citation"><b> </b></a></text>
<text top="176" left="220" width="100" height="17" font="3"><b>Aim: </b>To compare </text>
<text top="194" left="220" width="53" height="17" font="5">effects of </text>
<text top="211" left="220" width="89" height="17" font="5">combinations of </text>
<text top="228" left="220" width="75" height="17" font="5">standard and </text>
<text top="245" left="220" width="106" height="17" font="5">intensive control of </text>
<text top="263" left="220" width="121" height="17" font="5">BP on the risk of LVH </text>
<text top="280" left="220" width="117" height="17" font="5">in the ACCORD trial. </text>
<text top="298" left="212" width="3" height="17" font="5"> </text>
<text top="315" left="220" width="98" height="17" font="3"><b>Study type</b>: RCT </text>
<text top="332" left="212" width="3" height="17" font="5"> </text>
<text top="350" left="220" width="119" height="17" font="3"><b>Size</b>: 4,331 pts, 4.7 y </text>
<text top="367" left="220" width="53" height="17" font="5">follow-up<b> </b></text>
<text top="176" left="373" width="215" height="17" font="3"><b>Inclusion criteria</b>: DM- 2 with HgbA1c </text>
<text top="194" left="376" width="35" height="17" font="5">7.5%; </text>
<text top="211" left="376" width="151" height="17" font="5">40 y with CVD or  55 y with </text>
<text top="228" left="373" width="129" height="17" font="5">anatomical evidence of </text>
<text top="245" left="373" width="205" height="17" font="5">atherosclerosis, albuminuria, LVH, or </text>
<text top="263" left="373" width="190" height="17" font="5">at least 2 additional risk factors for </text>
<text top="280" left="373" width="33" height="17" font="5">CVD. </text>
<text top="298" left="365" width="3" height="17" font="5"> </text>
<text top="315" left="373" width="196" height="17" font="3"><b>Exclusion criteria</b>: BMI  45, serum </text>
<text top="332" left="373" width="186" height="17" font="5">creatinine &gt;1.5, and other serious </text>
<text top="350" left="373" width="41" height="17" font="5">illness.<b> </b></text>
<text top="176" left="619" width="105" height="17" font="5">Pts were randomly </text>
<text top="193" left="619" width="118" height="17" font="5">assigned to intensive </text>
<text top="211" left="619" width="143" height="17" font="5">therapy SBP&lt;120 mm Hg </text>
<text top="228" left="619" width="110" height="17" font="5">or standard therapy </text>
<text top="245" left="619" width="102" height="17" font="5">SBP&lt;140 mm Hg.<b> </b></text>
<text top="176" left="794" width="128" height="17" font="3"><b>1  outcomes</b>: Nonfatal </text>
<text top="194" left="794" width="143" height="17" font="5">MI, nonfatal stroke, or CV </text>
<text top="211" left="794" width="38" height="17" font="5">death. </text>
<text top="229" left="786" width="3" height="17" font="5"> </text>
<text top="246" left="794" width="126" height="17" font="3"><b>Results</b>: The outcome </text>
<text top="263" left="794" width="87" height="17" font="5">measures were </text>
<text top="281" left="794" width="141" height="17" font="5">electrocardiographic LVH </text>
<text top="298" left="794" width="102" height="17" font="5">defined by Cornell </text>
<text top="315" left="794" width="135" height="17" font="5">voltage (binary variable) </text>
<text top="332" left="794" width="133" height="17" font="5">and mean Cornell index </text>
<text top="350" left="794" width="121" height="17" font="5">(continuous variable). </text>
<text top="367" left="794" width="137" height="17" font="5">The baseline prevalence </text>
<text top="384" left="794" width="130" height="17" font="5">of LVH (5.3% vs. 5.4%; </text>
<text top="401" left="794" width="124" height="17" font="5">p=0.91) and the mean </text>
<text top="418" left="794" width="132" height="17" font="5">Cornell index (1,456 vs. </text>
<text top="436" left="794" width="34" height="17" font="5">1,470 </text>
<text top="453" left="794" width="138" height="17" font="5">µV; p=0.45) were similar </text>
<text top="470" left="794" width="142" height="17" font="5">in the intensive (n=2,154) </text>
<text top="487" left="794" width="132" height="17" font="5">and standard (n=2,177) </text>
<text top="505" left="794" width="107" height="17" font="5">BP- lowering arms, </text>
<text top="522" left="794" width="127" height="17" font="5">respectively. However, </text>
<text top="539" left="794" width="138" height="17" font="5">after median follow-up of </text>
<text top="556" left="794" width="89" height="17" font="5">4.4 y, intensive, </text>
<text top="573" left="794" width="138" height="17" font="5">compared with standard, </text>
<text top="591" left="794" width="94" height="17" font="5">BP lowering was </text>
<text top="608" left="794" width="126" height="17" font="5">associated with a 39% </text>
<text top="625" left="794" width="126" height="17" font="5">lower risk of LVH (OR: </text>
<text top="642" left="794" width="139" height="17" font="5">0.61; 95% CI: 0.43–0.88; </text>
<text top="659" left="794" width="76" height="17" font="5">p=0.008) and </text>
<text top="677" left="794" width="110" height="17" font="5">a significantly lower </text>
<text top="694" left="794" width="126" height="17" font="5">adjusted mean Cornell </text>
<text top="711" left="794" width="124" height="17" font="5">index (1,352 vs. 1,447 </text>
<text top="728" left="794" width="137" height="17" font="5">µV; p&lt;0.001). The lower </text>
<text top="746" left="794" width="126" height="17" font="5">risk of LVH associated </text>
<text top="763" left="794" width="146" height="17" font="5">with intensive BP lowering </text>
<text top="176" left="971" width="139" height="17" font="3"><b>Limitations: </b>2º analysis; </text>
<text top="194" left="971" width="131" height="17" font="5">open-label design; LVH </text>
<text top="211" left="971" width="134" height="17" font="5">defined by EKG and not </text>
<text top="228" left="971" width="133" height="17" font="5">by echo or cardiac MRI; </text>
<text top="245" left="971" width="133" height="17" font="5">results may not apply to </text>
<text top="263" left="971" width="102" height="17" font="5">younger, healthier </text>
<text top="280" left="971" width="55" height="17" font="5">diabetics. </text>
<text top="298" left="962" width="3" height="17" font="5"> </text>
<text top="315" left="971" width="146" height="17" font="3"><b>Conclusions</b>: Targeting a </text>
<text top="332" left="971" width="42" height="17" font="5">SBP of </text>
<text top="349" left="971" width="107" height="17" font="5">&lt;120 mm Hg when </text>
<text top="367" left="971" width="83" height="17" font="5">compared with </text>
<text top="381" left="971" width="132" height="17" font="5">&lt;140 mm Hg in pts with </text>
<text top="396" left="971" width="139" height="17" font="5">HTN and DM produces a </text>
<text top="410" left="971" width="137" height="17" font="5">greater reduction in LVH<b> </b></text>
</page>
<page number="274" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="794" width="115" height="17" font="5">during follow-up was </text>
<text top="108" left="794" width="95" height="17" font="5">because of more </text>
<text top="125" left="794" width="124" height="17" font="5">regression of baseline </text>
<text top="142" left="794" width="122" height="17" font="5">LVH and lower rate of </text>
<text top="160" left="794" width="119" height="17" font="5">developing new LVH, </text>
<text top="177" left="794" width="83" height="17" font="5">compared with </text>
<text top="195" left="794" width="143" height="17" font="5">standard BP lowering. No </text>
<text top="212" left="794" width="150" height="17" font="5">interactions by age, sex, or </text>
<text top="229" left="794" width="115" height="17" font="5">race were observed.<b> </b></text>
<text top="247" left="83" width="57" height="17" font="3"><b>ACCORD </b></text>
<text top="264" left="83" width="83" height="17" font="5">Cushman WC, </text>
<text top="282" left="83" width="68" height="17" font="5">et al., 2010  </text>
<text top="299" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20228401?dopt=Citation">20228401</a></text>
<text top="299" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20228401?dopt=Citation"> </a></text>
<text top="247" left="220" width="89" height="17" font="3"><b>Aim</b>: To assess </text>
<text top="265" left="220" width="92" height="17" font="5">whether therapy </text>
<text top="282" left="220" width="92" height="17" font="5">targeting normal </text>
<text top="299" left="220" width="110" height="17" font="5">SBP (&lt;120 mm Hg) </text>
<text top="316" left="220" width="102" height="17" font="5">reduces major CV </text>
<text top="333" left="220" width="100" height="17" font="5">events in DM-2 at </text>
<text top="351" left="220" width="87" height="17" font="5">high risk for CV </text>
<text top="368" left="220" width="43" height="17" font="5">events. </text>
<text top="386" left="212" width="3" height="17" font="5"> </text>
<text top="403" left="220" width="98" height="17" font="3"><b>Study type</b>: RCT </text>
<text top="421" left="212" width="3" height="17" font="5"> </text>
<text top="438" left="220" width="119" height="17" font="3"><b>Size</b>: 4,733 pts, 4.7 y </text>
<text top="455" left="220" width="53" height="17" font="5">follow-up<b> </b></text>
<text top="247" left="373" width="215" height="17" font="3"><b>Inclusion criteria</b>: DM- 2 with HgbA1c </text>
<text top="265" left="376" width="35" height="17" font="5">7.5%; </text>
<text top="282" left="376" width="151" height="17" font="5">40 y with CVD or  55 y with </text>
<text top="299" left="373" width="129" height="17" font="5">anatomical evidence of </text>
<text top="316" left="373" width="205" height="17" font="5">atherosclerosis, albuminuria, LVH, or </text>
<text top="334" left="373" width="155" height="17" font="5">≥2 additional risk factors for </text>
<text top="351" left="373" width="33" height="17" font="5">CVD. </text>
<text top="368" left="365" width="3" height="17" font="5"> </text>
<text top="386" left="373" width="196" height="17" font="3"><b>Exclusion criteria</b>: BMI  45, serum </text>
<text top="403" left="373" width="186" height="17" font="5">creatinine &gt;1.5, and other serious </text>
<text top="420" left="373" width="41" height="17" font="5">illness.<b> </b></text>
<text top="247" left="619" width="105" height="17" font="5">Pts were randomly </text>
<text top="264" left="619" width="118" height="17" font="5">assigned to intensive </text>
<text top="281" left="619" width="146" height="17" font="5">therapy SBP &lt;120 mm Hg </text>
<text top="299" left="619" width="138" height="17" font="5">or standard therapy SBP </text>
<text top="316" left="619" width="77" height="17" font="5">&lt;140 mm Hg. </text>
<text top="247" left="794" width="128" height="17" font="3"><b>1  outcomes</b>: Nonfatal </text>
<text top="265" left="794" width="143" height="17" font="5">MI, nonfatal stroke, or CV </text>
<text top="282" left="794" width="38" height="17" font="5">death. </text>
<text top="299" left="786" width="3" height="17" font="5"> </text>
<text top="317" left="794" width="147" height="17" font="3"><b>Results</b>: Mean SBP in the </text>
<text top="334" left="794" width="131" height="17" font="5">intensive therapy group </text>
<text top="351" left="794" width="139" height="17" font="5">was 119.3 mm Hg and in </text>
<text top="368" left="794" width="116" height="17" font="5">the standard therapy </text>
<text top="386" left="794" width="141" height="17" font="5">group was 133.5 mm Hg. </text>
<text top="403" left="794" width="132" height="17" font="5">The annual 1° outcome </text>
<text top="420" left="794" width="124" height="17" font="5">1.87% in the intensive </text>
<text top="437" left="794" width="141" height="17" font="5">therapy group and 2.09% </text>
<text top="454" left="794" width="129" height="17" font="5">in the standard therapy </text>
<text top="472" left="794" width="137" height="17" font="5">group HR: 0.88; 95% CI: </text>
<text top="489" left="794" width="68" height="17" font="5">0.073–1.06; </text>
<text top="506" left="794" width="110" height="17" font="5">p=0.20. The annual </text>
<text top="523" left="794" width="130" height="17" font="5">rates of death from any </text>
<text top="541" left="794" width="128" height="17" font="5">cause were 1.28% and </text>
<text top="558" left="794" width="82" height="17" font="5">1.19% in the 2 </text>
<text top="575" left="794" width="141" height="17" font="5">groups, respectively (HR: </text>
<text top="592" left="794" width="139" height="17" font="5">0.59; 95% CI: 0.39–0.89; </text>
<text top="609" left="794" width="141" height="17" font="5">p=0.01). Serious adverse </text>
<text top="627" left="794" width="108" height="17" font="5">events attributed to </text>
<text top="644" left="794" width="93" height="17" font="5">antihypertensive </text>
<text top="661" left="794" width="120" height="17" font="5">treatment occurred in </text>
<text top="678" left="794" width="117" height="17" font="5">3.3% of the intensive </text>
<text top="696" left="794" width="44" height="17" font="5">therapy </text>
<text top="713" left="794" width="124" height="17" font="5">group and 1.3% of the </text>
<text top="730" left="794" width="131" height="17" font="5">standard therapy group </text>
<text top="747" left="794" width="60" height="17" font="5">(p&lt;0.001).<b> </b></text>
<text top="247" left="971" width="122" height="17" font="3"><b>Limitations</b>: This trial </text>
<text top="265" left="971" width="101" height="17" font="5">had an open label </text>
<text top="282" left="971" width="106" height="17" font="5">design. The rate of </text>
<text top="299" left="971" width="120" height="17" font="5">adverse events in the </text>
<text top="316" left="971" width="131" height="17" font="5">standard therapy group </text>
<text top="333" left="971" width="135" height="17" font="5">was less than expected. </text>
<text top="351" left="971" width="137" height="17" font="5">Pts younger than 40 y or </text>
<text top="368" left="971" width="135" height="17" font="5">older than 79 y were not </text>
<text top="385" left="971" width="53" height="17" font="5">included. </text>
<text top="403" left="962" width="3" height="17" font="5"> </text>
<text top="420" left="971" width="121" height="17" font="3"><b>Summary</b>: In pts with </text>
<text top="437" left="971" width="124" height="17" font="5">DM-2 and high risk for </text>
<text top="454" left="971" width="115" height="17" font="5">CV events, targeting </text>
<text top="472" left="971" width="89" height="17" font="5">SBP of &lt;120 as </text>
<text top="489" left="971" width="138" height="17" font="5">compared with &lt;140 mm </text>
<text top="506" left="971" width="121" height="17" font="5">Hg did not reduce the </text>
<text top="523" left="971" width="98" height="17" font="5">rate of composite </text>
<text top="541" left="971" width="115" height="17" font="5">outcome of fatal and </text>
<text top="558" left="971" width="102" height="17" font="5">nonfatal major CV </text>
<text top="575" left="971" width="89" height="17" font="5">events and was </text>
<text top="592" left="971" width="130" height="17" font="5">associated with greater </text>
<text top="609" left="971" width="130" height="17" font="5">risk for adverse events.<b> </b></text>
</page>
<page number="275" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="83" width="93" height="17" font="5">Van Dieren S, et </text>
<text top="108" left="83" width="51" height="17" font="5">al., 2012 </text>
<text top="125" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22677192?dopt=Citation">22677192</a></text>
<text top="125" left="137" width="3" height="17" font="3"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22677192?dopt=Citation"><b> </b></a></text>
<text top="91" left="220" width="90" height="17" font="3"><b>Aim: </b>To assess </text>
<text top="108" left="220" width="76" height="17" font="5">differences in </text>
<text top="125" left="220" width="109" height="17" font="5">treatment effects of </text>
<text top="142" left="220" width="109" height="17" font="5">a fixed combination </text>
<text top="160" left="220" width="81" height="17" font="5">of perindopril– </text>
<text top="177" left="220" width="84" height="17" font="5">indapamide on </text>
<text top="194" left="220" width="74" height="17" font="5">major clinical </text>
<text top="211" left="220" width="115" height="17" font="5">outcomes in pts with </text>
<text top="229" left="220" width="99" height="17" font="5">type 2 DM across </text>
<text top="246" left="220" width="95" height="17" font="5">subgroups of CV </text>
<text top="263" left="220" width="26" height="17" font="5">risk. </text>
<text top="281" left="212" width="3" height="17" font="5"> </text>
<text top="298" left="220" width="99" height="17" font="3"><b>Study type: </b>RCT </text>
<text top="316" left="212" width="3" height="17" font="5"> </text>
<text top="333" left="220" width="93" height="17" font="3"><b>Size: </b>11,140 pts </text>
<text top="351" left="220" width="111" height="17" font="5">with DM-2, from the </text>
<text top="368" left="220" width="86" height="17" font="5">ADVANCE trial<b> </b></text>
<text top="90" left="373" width="174" height="17" font="3"><b>Inclusion criteria: </b>DM-2, aged </text>
<text top="108" left="373" width="161" height="17" font="5">≥55 y, with a history of major </text>
<text top="125" left="373" width="177" height="17" font="5">macrovascular or microvascular </text>
<text top="142" left="373" width="205" height="17" font="5">disease, or at least 1 other risk factor </text>
<text top="160" left="373" width="113" height="17" font="5">for vascular disease </text>
<text top="177" left="365" width="3" height="17" font="5"> </text>
<text top="194" left="373" width="165" height="17" font="3"><b>Exclusion criteria: </b>A definite </text>
<text top="211" left="373" width="197" height="17" font="5">indication for, or contraindication to, </text>
<text top="229" left="373" width="208" height="17" font="5">any of the study treatments, a definite </text>
<text top="246" left="373" width="167" height="17" font="5">indication for long-term insulin </text>
<text top="263" left="373" width="206" height="17" font="5">treatment or were participating in any </text>
<text top="281" left="373" width="98" height="17" font="5">other clinical trial.<b> </b></text>
<text top="90" left="619" width="147" height="17" font="3"><b>Intervention: </b>Perindopril– </text>
<text top="108" left="619" width="134" height="17" font="5">indapamide or matching </text>
<text top="125" left="619" width="46" height="17" font="5">placebo </text>
<text top="92" left="794" width="73" height="17" font="3"><b>1  endpoint: </b></text>
<text top="109" left="794" width="107" height="18" font="5">• The Framingham </text>
<text top="127" left="794" width="119" height="17" font="5">equation was used to </text>
<text top="145" left="794" width="124" height="17" font="5">calculate 5-y CVD risk </text>
<text top="162" left="794" width="139" height="17" font="5">and to divide participants </text>
<text top="179" left="794" width="100" height="17" font="5">into 2 risk groups, </text>
<text top="196" left="794" width="120" height="17" font="5">moderate-to-high risk </text>
<text top="213" left="794" width="133" height="17" font="5">(&lt;25% and no history of </text>
<text top="231" left="794" width="137" height="17" font="5">macrovascular disease), </text>
<text top="248" left="794" width="115" height="17" font="5">very high risk (&gt;25% </text>
<text top="265" left="794" width="92" height="17" font="5">and/or history of </text>
<text top="282" left="794" width="137" height="17" font="5">macrovascular disease). </text>
<text top="299" left="794" width="88" height="17" font="5">Endpoints were </text>
<text top="317" left="794" width="107" height="17" font="5">macrovascular and </text>
<text top="334" left="794" width="122" height="17" font="5">microvascular events.<b> </b></text>
<text top="91" left="971" width="110" height="17" font="3"><b>Summary</b>: Relative </text>
<text top="108" left="971" width="123" height="17" font="5">effects of BP-lowering </text>
<text top="125" left="971" width="93" height="17" font="5">with perindopril– </text>
<text top="142" left="971" width="104" height="17" font="5">indapamide on CV </text>
<text top="160" left="971" width="126" height="17" font="5">outcomes were similar </text>
<text top="177" left="971" width="137" height="17" font="5">across risk groups whilst </text>
<text top="194" left="971" width="135" height="17" font="5">absolute effects trended </text>
<text top="211" left="971" width="134" height="17" font="5">to be greater in the high-</text>
<text top="229" left="971" width="61" height="17" font="5">risk group.<b> </b></text>
<text top="386" left="83" width="95" height="17" font="5">Montgomery AA, </text>
<text top="403" left="83" width="64" height="17" font="5">et al., 2003 </text>
<text top="420" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12923409?dopt=Citation">12923409</a></text>
<text top="420" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12923409?dopt=Citation"> </a></text>
<text top="386" left="220" width="98" height="17" font="3"><b>Aim: </b>To estimate </text>
<text top="403" left="220" width="96" height="17" font="5">the effectiveness </text>
<text top="420" left="220" width="51" height="17" font="5">and cost-</text>
<text top="437" left="220" width="89" height="17" font="5">effectiveness of </text>
<text top="455" left="220" width="69" height="17" font="5">BP-lowering </text>
<text top="472" left="220" width="93" height="17" font="5">treatment over a </text>
<text top="489" left="220" width="46" height="17" font="5">lifetime. </text>
<text top="507" left="212" width="3" height="17" font="5"> </text>
<text top="524" left="220" width="114" height="17" font="3"><b>Study type: </b>Markov </text>
<text top="541" left="220" width="96" height="17" font="5">decision analysis </text>
<text top="559" left="220" width="98" height="17" font="5">model comparing </text>
<text top="576" left="220" width="79" height="17" font="5">treatment and </text>
<text top="593" left="220" width="90" height="17" font="5">nontreatment of </text>
<text top="610" left="220" width="32" height="17" font="5">HTN. </text>
<text top="628" left="212" width="3" height="17" font="5"> </text>
<text top="645" left="220" width="103" height="17" font="3"><b>Size: </b>Hypothetical </text>
<text top="663" left="220" width="79" height="17" font="5">cohorts for 20 </text>
<text top="680" left="220" width="96" height="17" font="5">different strata of </text>
<text top="697" left="220" width="108" height="17" font="5">sex, age (30– 79 y, </text>
<text top="714" left="220" width="109" height="17" font="5">in 10-y bands), and </text>
<text top="732" left="220" width="93" height="17" font="5">CV risk (low and </text>
<text top="749" left="220" width="31" height="17" font="5">high)<b> </b></text>
<text top="386" left="373" width="215" height="17" font="3"><b>Inclusion criteria: </b>We created models </text>
<text top="403" left="373" width="208" height="17" font="5">for 20 different strata of sex, age (age </text>
<text top="420" left="373" width="189" height="17" font="5">30–70 y in 10-y bands), and 2 risk </text>
<text top="437" left="373" width="210" height="17" font="5">profiles (designated as ‘low’ and ‘high’ </text>
<text top="455" left="373" width="183" height="17" font="5">risk). These example risk profiles </text>
<text top="472" left="373" width="214" height="17" font="5">represent the extremes of absolute CV </text>
<text top="489" left="373" width="195" height="17" font="5">risk, based on data from the Health </text>
<text top="506" left="373" width="175" height="17" font="5">Survey for England and using a </text>
<text top="523" left="373" width="167" height="17" font="5">Framingham risk function. We </text>
<text top="541" left="373" width="167" height="17" font="5">recognize that the risk of most </text>
<text top="558" left="373" width="213" height="17" font="5">individuals seen in primary care will be </text>
<text top="575" left="373" width="193" height="17" font="5">somewhere between the examples </text>
<text top="592" left="373" width="191" height="17" font="5">presented here. The data included </text>
<text top="609" left="373" width="210" height="17" font="5">were as follows: age- and sex-specific </text>
<text top="627" left="373" width="217" height="17" font="5">mean SBP of untreated individuals with </text>
<text top="644" left="373" width="214" height="17" font="5">SBP&gt;0.160 mm Hg were used for both </text>
<text top="661" left="373" width="179" height="17" font="5">high-risk and low-risk profiles. In </text>
<text top="678" left="373" width="217" height="17" font="5">addition, low-risk profile was defined as </text>
<text top="696" left="373" width="178" height="17" font="5">nonsmoker, 10th percentile total </text>
<text top="713" left="373" width="174" height="17" font="5">cholesterol 90th percentile HDL </text>
<text top="730" left="373" width="205" height="17" font="5">cholesterol, no DM, and no LVH, and </text>
<text top="747" left="373" width="172" height="17" font="5">high-risk profile was defined as </text>
<text top="764" left="373" width="158" height="17" font="5">smoker, 90th percentile total </text>
<text top="386" left="619" width="137" height="17" font="3"><b>Intervention: </b>Treatment </text>
<text top="403" left="619" width="146" height="17" font="5">and nontreatment of HTN.<b> </b></text>
<text top="387" left="794" width="96" height="17" font="3"><b>1  endpoint: </b>Life </text>
<text top="405" left="794" width="93" height="17" font="5">expectancy, and </text>
<text top="423" left="794" width="96" height="17" font="5">incremental cost: </text>
<text top="442" left="794" width="126" height="17" font="5">effectiveness ratios for </text>
<text top="460" left="794" width="155" height="17" font="5">treatment and nontreatment </text>
<text top="478" left="794" width="57" height="17" font="5">strategies<b> </b></text>
<text top="386" left="971" width="134" height="18" font="5">• Probabilities of clinical </text>
<text top="404" left="971" width="120" height="17" font="5">events were obtained </text>
<text top="421" left="971" width="139" height="17" font="5">from published literature. </text>
<text top="439" left="962" width="3" height="17" font="5"> </text>
<text top="456" left="971" width="63" height="17" font="3"><b>Summary</b>: </text>
<text top="474" left="971" width="136" height="18" font="5">• Incremental  cost  per </text>
<text top="492" left="971" width="136" height="17" font="5">quality-  adjusted  life  y </text>
<text top="509" left="971" width="136" height="17" font="5">among  low-risk  groups </text>
<text top="526" left="971" width="124" height="17" font="5">ranged from £1,030 to </text>
<text top="544" left="971" width="74" height="17" font="5">£3,304. Cost-</text>
<text top="561" left="971" width="132" height="17" font="5">effectiveness results for </text>
<text top="578" left="971" width="95" height="17" font="5">low-risk pts were </text>
<text top="595" left="971" width="130" height="17" font="5">sensitive to the utility of </text>
<text top="613" left="971" width="52" height="17" font="5">receiving </text>
<text top="630" left="971" width="93" height="17" font="5">antihypertensive </text>
<text top="647" left="971" width="132" height="17" font="5">treatment. Treatment of </text>
<text top="664" left="971" width="139" height="17" font="5">high- risk individuals was </text>
<text top="681" left="971" width="118" height="17" font="5">highly cost- effective, </text>
<text top="699" left="971" width="108" height="17" font="5">such that it was the </text>
<text top="716" left="971" width="135" height="17" font="5">dominant strategy in the </text>
<text top="733" left="971" width="122" height="17" font="5">oldest age group, and </text>
<text top="750" left="971" width="127" height="17" font="5">resulted in incremental </text>
<text top="767" left="971" width="96" height="17" font="5">costs per quality- </text>
</page>
<page number="276" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="23" size="12" family="Times" color="#292425"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="373" width="178" height="17" font="5">cholesterol, 10th percentile HDL </text>
<text top="108" left="373" width="147" height="17" font="5">cholesterol, DM, and LVH. </text>
<text top="126" left="365" width="3" height="17" font="5"> </text>
<text top="143" left="373" width="134" height="17" font="3"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="91" left="971" width="123" height="17" font="5">adjusted life y ranging </text>
<text top="108" left="971" width="28" height="17" font="5">from </text>
<text top="125" left="971" width="71" height="17" font="5">£34–£265 in </text>
<text top="142" left="971" width="72" height="17" font="5">younger age </text>
<text top="160" left="971" width="44" height="17" font="5">groups. </text>
<text top="177" left="971" width="125" height="17" font="23">Policy decisions about </text>
<text top="194" left="971" width="96" height="17" font="23">which pts to treat </text>
<text top="211" left="971" width="118" height="17" font="23">depend on whether a </text>
<text top="229" left="971" width="129" height="17" font="23">life-expectancy or cost- </text>
<text top="246" left="971" width="75" height="17" font="23">effectiveness </text>
<text top="263" left="971" width="115" height="17" font="23">perspective is taken. </text>
<text top="280" left="971" width="135" height="17" font="23">Treatment increases life </text>
<text top="297" left="971" width="128" height="17" font="23">expectancy in all strata </text>
<text top="315" left="971" width="137" height="17" font="23">of age, sex, and CV risk. </text>
<text top="332" left="971" width="103" height="17" font="23">However, younger </text>
<text top="349" left="971" width="135" height="17" font="23">individuals stand to gain </text>
<text top="366" left="971" width="116" height="17" font="23">proportionately more </text>
<text top="383" left="971" width="130" height="17" font="23">from BP treatment than </text>
<text top="401" left="971" width="129" height="17" font="23">do the elderly. In terms </text>
<text top="418" left="971" width="122" height="17" font="23">of cost- effectiveness, </text>
<text top="435" left="971" width="96" height="17" font="23">pts at high risk of </text>
<text top="435" left="1067" width="29" height="17" font="5">CVD </text>
<text top="452" left="971" width="97" height="17" font="23">are a highly cost- </text>
<text top="469" left="971" width="129" height="17" font="23">effective group to treat. </text>
<text top="487" left="971" width="116" height="17" font="23">In pts at lower risk of </text>
<text top="504" left="971" width="109" height="17" font="23">CVD, consideration </text>
<text top="521" left="971" width="85" height="17" font="23">should be given</text>
<text top="521" left="1056" width="3" height="17" font="5"> </text>
<text top="538" left="971" width="141" height="17" font="23">to issues of pt preference </text>
<text top="556" left="971" width="50" height="17" font="23">and cost.</text>
<text top="556" left="1020" width="3" height="17" font="3"><b> </b></text>
</page>
<page number="277" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="83" width="83" height="17" font="5">Julius S, et al., </text>
<text top="108" left="83" width="34" height="17" font="5">2006  </text>
<text top="125" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662">16537662</a></text>
<text top="125" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16537662"> </a></text>
<text top="91" left="219" width="111" height="17" font="3"><b>Study type</b>: RCT in </text>
<text top="108" left="219" width="85" height="17" font="5">pre-HTN16 mg </text>
<text top="125" left="219" width="90" height="17" font="5">candesartan vs. </text>
<text top="142" left="219" width="46" height="17" font="5">placebo </text>
<text top="160" left="220" width="75" height="17" font="3"><b>Size</b>: 809 pts<b> </b></text>
<text top="91" left="373" width="55" height="17" font="5">58% men<b> </b></text>
<text top="90" left="619" width="24" height="17" font="5">N/A<b> </b></text>
<text top="91" left="786" width="135" height="17" font="5">During the first 2 y, HTN </text>
<text top="108" left="786" width="143" height="17" font="5">developed in 154 (40.4%) </text>
<text top="125" left="786" width="134" height="17" font="5">pts in the placebo group </text>
<text top="142" left="786" width="126" height="17" font="5">compared with only 53 </text>
<text top="160" left="786" width="127" height="17" font="5">(13.6%) of those in the </text>
<text top="177" left="786" width="138" height="17" font="5">candesartan group, for a </text>
<text top="197" left="786" width="140" height="17" font="5">RR of 66.3% (p&lt;0.0001). </text>
<text top="214" left="786" width="154" height="17" font="5">After 4 y, HTN developed in </text>
<text top="231" left="786" width="150" height="17" font="5">240 (63.0%) in the placebo </text>
<text top="248" left="786" width="150" height="17" font="5">group vs. only 208 (53.2%) </text>
<text top="266" left="786" width="160" height="17" font="5">in the candesartan group RR </text>
<text top="283" left="786" width="105" height="17" font="5">15.6% (p&lt;0.0069). </text>
<text top="91" left="971" width="125" height="18" font="5">• 2/3 of those with pre-</text>
<text top="112" left="971" width="104" height="17" font="5">HTN develop HTN </text>
<text top="131" left="971" width="58" height="17" font="5">within 4 y. </text>
<text top="151" left="971" width="129" height="17" font="5">Candesartan interrupts </text>
<text top="171" left="971" width="126" height="17" font="5">the onset and reduced </text>
<text top="191" left="971" width="55" height="17" font="5">by 15.6% </text>
<text top="321" left="83" width="89" height="17" font="5">Lawes CMM, et </text>
<text top="338" left="83" width="51" height="17" font="5">al., 2002 </text>
<text top="355" left="83" width="55" height="17" font="17"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16222626">16222626</a></text>
<text top="355" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16222626"> </a></text>
<text top="321" left="219" width="113" height="17" font="3"><b>Study type</b>: Review </text>
<text top="338" left="219" width="90" height="17" font="5">of observational </text>
<text top="355" left="219" width="66" height="17" font="5">reports and </text>
<text top="372" left="219" width="68" height="17" font="5">randomized </text>
<text top="390" left="219" width="86" height="17" font="5">controlled trials<b> </b></text>
<text top="321" left="373" width="24" height="17" font="5">N/A </text>
<text top="321" left="619" width="24" height="17" font="5">N/A </text>
<text top="321" left="794" width="124" height="18" font="5">• The relative benefits </text>
<text top="339" left="794" width="130" height="17" font="5">of BP lowering for CHD </text>
<text top="356" left="794" width="122" height="17" font="5">prevention likely to be </text>
<text top="373" left="794" width="108" height="17" font="5">consistent across a </text>
<text top="391" left="794" width="125" height="17" font="5">wide range of different </text>
<text top="408" left="794" width="66" height="17" font="5">populations </text>
<text top="425" left="794" width="76" height="18" font="5">• Likely to be </text>
<text top="443" left="794" width="131" height="17" font="5">considerable benefit for </text>
<text top="461" left="794" width="113" height="17" font="5">BP lowering beyond </text>
<text top="478" left="794" width="120" height="17" font="5">traditional thresholds, </text>
<text top="495" left="794" width="144" height="17" font="5">especially in those at high </text>
<text top="512" left="794" width="69" height="17" font="5">risk for CVD </text>
<text top="529" left="794" width="123" height="18" font="5">• BP lowering is likely </text>
<text top="548" left="794" width="117" height="17" font="5">to be more important </text>
<text top="565" left="794" width="111" height="17" font="5">than choice of initial </text>
<text top="582" left="794" width="34" height="17" font="5">agent </text>
<text top="599" left="794" width="113" height="18" font="5">• A large majority of </text>
<text top="618" left="794" width="122" height="17" font="5">patients being treated </text>
<text top="635" left="794" width="122" height="17" font="5">for hypertension have </text>
<text top="652" left="794" width="92" height="17" font="5">suboptimal BPs. </text>
<text top="669" left="794" width="128" height="17" font="5">Initiatives to lower their </text>
<text top="687" left="794" width="132" height="17" font="5">BP further are essential </text>
<text top="321" left="971" width="109" height="18" font="5">• Strongly supports </text>
<text top="342" left="971" width="116" height="17" font="5">lower BPs during BP </text>
<text top="361" left="971" width="128" height="17" font="5">treatment, especially in </text>
<text top="381" left="971" width="110" height="17" font="5">those at high risk of </text>
<text top="401" left="971" width="29" height="17" font="5">CVD </text>
<text top="705" left="66" width="3" height="17" font="5"> </text>
<text top="744" left="59" width="983" height="21" font="4"><b>Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of High Blood Pressure or Hypertension (Section 4.4.) </b></text>
</page>
<page number="278" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="104" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="199" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="215" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="375" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="569" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="546" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="899" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="926" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="144" left="83" width="65" height="17" font="5">Bress et al, </text>
<text top="161" left="83" width="31" height="17" font="5">2017 </text>
<text top="179" left="83" width="3" height="17" font="5"> </text>
<text top="197" left="83" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29171809">29171809</a></text>
<text top="197" left="137" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29171809"> </a></text>
<text top="143" left="193" width="25" height="17" font="5">Aim </text>
<text top="160" left="193" width="96" height="17" font="5">To determine the </text>
<text top="178" left="193" width="126" height="17" font="5">lifetime health benefits </text>
<text top="195" left="193" width="120" height="17" font="5">and health care costs </text>
<text top="212" left="193" width="87" height="17" font="5">associated with </text>
<text top="229" left="193" width="92" height="17" font="5">intensive control </text>
<text top="247" left="193" width="91" height="17" font="5">versus standard </text>
<text top="264" left="193" width="40" height="17" font="5">control </text>
<text top="281" left="193" width="3" height="17" font="5"> </text>
<text top="298" left="193" width="62" height="17" font="5">Study type </text>
<text top="315" left="193" width="126" height="17" font="5">Microsimulation model </text>
<text top="333" left="193" width="3" height="17" font="5"> </text>
<text top="350" left="193" width="87" height="17" font="5">N=Hypothetical </text>
<text top="367" left="193" width="115" height="17" font="5">population of 10,000 </text>
<text top="384" left="193" width="100" height="17" font="5">patients based on </text>
<text top="401" left="193" width="95" height="17" font="5">characteristics of </text>
<text top="419" left="193" width="80" height="17" font="5">Systolic Blood </text>
<text top="436" left="193" width="120" height="17" font="5">Pressure Intervention </text>
<text top="453" left="193" width="84" height="17" font="5">Trial (SPRINT) </text>
<text top="470" left="193" width="60" height="17" font="5">population </text>
<text top="143" left="335" width="92" height="17" font="5">Inclusion criteria </text>
<text top="160" left="335" width="3" height="17" font="5"> </text>
<text top="178" left="335" width="170" height="17" font="5">SPRINT trial inclusion criteria:  </text>
<text top="195" left="335" width="3" height="17" font="5"> </text>
<text top="212" left="332" width="100" height="18" font="5">•  age ≥50 years </text>
<text top="230" left="332" width="194" height="18" font="5">•  systolic blood pressure 130-180 </text>
<text top="248" left="334" width="185" height="17" font="5">mmHg on 0 or 1 antihypertensive </text>
<text top="266" left="334" width="186" height="17" font="5">medication class, 130-170 mmHg </text>
<text top="283" left="334" width="154" height="17" font="5">on up to 2 classes, 130-160 </text>
<text top="300" left="334" width="170" height="17" font="5">mmHg on up to 3 classes, 130-</text>
<text top="317" left="334" width="173" height="17" font="5">150 mmHg on up to 4 classes;  </text>
<text top="335" left="334" width="3" height="17" font="5"> </text>
<text top="353" left="332" width="181" height="18" font="5">•  presence of one or more high </text>
<text top="371" left="334" width="167" height="17" font="5">CVD risk conditions (including </text>
<text top="389" left="334" width="168" height="17" font="5">history of clinical or subclinical </text>
<text top="406" left="334" width="187" height="17" font="5">cardiovascular disease other than </text>
<text top="423" left="334" width="158" height="17" font="5">stroke, estimated glomerular </text>
<text top="440" left="334" width="120" height="17" font="5">filtration rate of 20-59 </text>
<text top="458" left="334" width="173" height="17" font="5">ml/min/1.73m2, 10-year risk for </text>
<text top="475" left="334" width="178" height="17" font="5">CVD ≥15% calculated using the </text>
<text top="492" left="334" width="191" height="17" font="5">Framingham risk score for general </text>
<text top="509" left="334" width="163" height="17" font="5">clinical practice, and age ≥75 </text>
<text top="526" left="334" width="37" height="17" font="5">years. </text>
<text top="544" left="335" width="3" height="17" font="5"> </text>
<text top="561" left="335" width="174" height="17" font="5">SPRINT trial exclusion criteria:  </text>
<text top="578" left="332" width="69" height="18" font="5">•  Diabetes </text>
<text top="596" left="332" width="118" height="18" font="5">•  a history of stroke </text>
<text top="615" left="332" width="155" height="18" font="5">•  more than 1 gram/day of </text>
<text top="633" left="334" width="62" height="17" font="5">proteinuria </text>
<text top="650" left="332" width="86" height="18" font="5">•  heart failure </text>
<text top="668" left="332" width="78" height="18" font="5">•  on dialysis </text>
<text top="686" left="343" width="145" height="17" font="5">eGFR &lt;20 ml/min/1.73m2 </text>
<text top="144" left="540" width="7" height="17" font="5">1</text>
<text top="143" left="547" width="64" height="18" font="5"> endpoint  </text>
<text top="175" left="540" width="212" height="17" font="7"><i>CVD events (acute MI, acute coronary </i></text>
<text top="192" left="540" width="233" height="17" font="7"><i>syndrome not resulting in MI, stroke, heart </i></text>
<text top="209" left="540" width="41" height="17" font="7"><i>failure) </i></text>
<text top="227" left="540" width="3" height="17" font="7"><i> </i></text>
<text top="245" left="540" width="7" height="17" font="5">2</text>
<text top="244" left="547" width="70" height="18" font="5"> endpoints  </text>
<text top="276" left="540" width="102" height="17" font="7"><i>all cause mortality </i></text>
<text top="293" left="540" width="82" height="17" font="7"><i>CVD mortality’ </i></text>
<text top="310" left="540" width="69" height="17" font="7"><i>serious AEs </i></text>
<text top="327" left="540" width="198" height="17" font="7"><i>Cost (total direct medical costs over </i></text>
<text top="344" left="540" width="164" height="17" font="7"><i>remaining lifetime) and QALY </i></text>
<text top="362" left="540" width="7" height="17" font="7"><i>  </i></text>
<text top="379" left="540" width="218" height="17" font="5">CVD Events: Simulated incidence rates </text>
<text top="396" left="540" width="223" height="17" font="5">were 17.3 events per 1000 person years </text>
<text top="413" left="540" width="213" height="17" font="5">in intensive control group and 22.2 per </text>
<text top="431" left="540" width="210" height="17" font="5">1000 person years in standard control </text>
<text top="448" left="540" width="229" height="17" font="5">group (compared to 16.4 and 21.9 events </text>
<text top="465" left="540" width="232" height="17" font="5">in actual trial).  Predicted hazard ratio was </text>
<text top="482" left="540" width="213" height="17" font="5">0.78 (95% CI 0.70-0.87) and observed </text>
<text top="499" left="540" width="163" height="17" font="5">HR=0.75 (95% CI 0.64-0.89). </text>
<text top="517" left="540" width="3" height="17" font="5"> </text>
<text top="534" left="540" width="207" height="17" font="5">Model predicted that intensive control </text>
<text top="551" left="540" width="213" height="17" font="5">would prevent 170 incident events and </text>
<text top="568" left="540" width="206" height="17" font="5">190 deaths from CVD over remaining </text>
<text top="586" left="540" width="227" height="17" font="5">lifetime of 10,000 patients compared with </text>
<text top="603" left="540" width="107" height="17" font="5">standard treatment </text>
<text top="620" left="540" width="3" height="17" font="5"> </text>
<text top="637" left="540" width="219" height="17" font="5">Intensive control cost $47,000 more per </text>
<text top="654" left="540" width="213" height="17" font="5">QALY gained than standard control. In </text>
<text top="672" left="540" width="195" height="17" font="5">1000 probabilistic simulations, 54% </text>
<text top="689" left="540" width="230" height="17" font="5">probabitliyt that intensive control was cost </text>
<text top="706" left="540" width="232" height="17" font="5">effective at willingness-to-pay threshold of </text>
<text top="723" left="540" width="191" height="17" font="5">$50,000 per QALY and a 79% at a </text>
<text top="741" left="540" width="180" height="17" font="5">threshold of $100,000 per QALY </text>
<text top="758" left="540" width="3" height="17" font="5"> </text>
<text top="143" left="789" width="63" height="17" font="5">Summary:  </text>
<text top="160" left="789" width="3" height="17" font="5"> </text>
<text top="178" left="797" width="312" height="17" font="5">Intensive systolic blood-pressure control in adults at high </text>
<text top="195" left="797" width="329" height="17" font="5">risk for cardiovascular disease was cost-effective and below </text>
<text top="213" left="797" width="282" height="17" font="5">common U.S. willingness-to-pay thresholds in most </text>
<text top="230" left="797" width="283" height="17" font="5">simulations regardless of whether the benefits were </text>
<text top="247" left="797" width="325" height="17" font="5">reduced after 5 years or persisted for the remaining lifetime </text>
<text top="264" left="797" width="75" height="17" font="5">of the patient </text>
</page>
<page number="279" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="104" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="199" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="215" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="375" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="569" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="546" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="899" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="926" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="540" width="235" height="17" font="5">Cost effectiveness of intensive control was </text>
<text top="160" left="540" width="219" height="17" font="5">maximized at approximately 20 years in </text>
<text top="178" left="540" width="224" height="17" font="5">the lifetime best-case scenario and at 10 </text>
<text top="195" left="540" width="204" height="17" font="5">years in the persistence-of-treatment-</text>
<text top="212" left="540" width="90" height="17" font="5">effect scenarios </text>
<text top="229" left="540" width="3" height="17" font="5"> </text>
<text top="247" left="540" width="185" height="17" font="5">Patients 75 and older had a more </text>
<text top="264" left="540" width="196" height="17" font="5">favorable ICER ($26,000 per QALY </text>
<text top="281" left="540" width="51" height="17" font="5">gained).  </text>
<text top="298" left="540" width="3" height="17" font="5"> </text>
<text top="315" left="540" width="188" height="17" font="5">Women had less favorable ICERs </text>
<text top="333" left="540" width="154" height="17" font="5">($77,000 per QALY gained) </text>
<text top="350" left="540" width="3" height="17" font="5"> </text>
<text top="367" left="540" width="206" height="17" font="5">Patients with previous cardiovascular </text>
<text top="384" left="540" width="188" height="17" font="5">disease had less favorable ICERs </text>
<text top="401" left="540" width="154" height="17" font="5">($72,000 per QALY gained) </text>
<text top="419" left="540" width="3" height="17" font="5"> </text>
<text top="436" left="549" width="202" height="17" font="5">The model was most sensitive to the </text>
<text top="454" left="549" width="207" height="17" font="5">HR for cardiovascular disease events </text>
<text top="471" left="549" width="207" height="17" font="5">with intensive control, the risk of CVD </text>
<text top="488" left="549" width="203" height="17" font="5">events with standard control, the risk </text>
<text top="505" left="549" width="176" height="17" font="5">of end-stage renal disease after </text>
<text top="523" left="549" width="193" height="17" font="5">chronic kidney disease, the hazard </text>
<text top="540" left="549" width="209" height="17" font="5">ratio for death from causes other than </text>
<text top="557" left="549" width="205" height="17" font="5">CVD with intensive control during the </text>
<text top="574" left="549" width="194" height="17" font="5">first 5 years, and the risk of chronic </text>
<text top="591" left="549" width="205" height="17" font="5">kidney disease with standard control, </text>
<text top="609" left="549" width="194" height="17" font="5">each of which potentially increased </text>
<text top="626" left="549" width="196" height="17" font="5">the ICER above $50,000 per QALY </text>
<text top="645" left="83" width="74" height="17" font="5">Upadhyay A, </text>
<text top="662" left="83" width="68" height="17" font="5">et al., 2011  </text>
<text top="679" left="75" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21403055?dopt=Citation">21403055</a></text>
<text top="679" left="129" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21403055?dopt=Citation"> </a></text>
<text top="644" left="201" width="109" height="17" font="5">Aim: To summarize </text>
<text top="661" left="201" width="90" height="17" font="5">trials comparing </text>
<text top="678" left="201" width="109" height="17" font="5">lower vs. higher BP </text>
<text top="696" left="201" width="99" height="17" font="5">targets in pts with </text>
<text top="713" left="201" width="83" height="17" font="5">CKD; focus on </text>
<text top="730" left="201" width="95" height="17" font="5">proteinuria as an </text>
<text top="747" left="201" width="80" height="17" font="5">effect modifier </text>
<text top="765" left="193" width="3" height="17" font="5"> </text>
<text top="644" left="343" width="120" height="17" font="5">Inclusion criteria: &gt;50 </text>
<text top="661" left="343" width="134" height="17" font="5">pts/group, 1 y follow-up, </text>
<text top="678" left="343" width="147" height="17" font="5">outcomes of death, kidney </text>
<text top="696" left="343" width="147" height="17" font="5">failure, CV events, change </text>
<text top="713" left="343" width="147" height="17" font="5">in kidney function, number </text>
<text top="730" left="343" width="150" height="17" font="5">of antihypertensive agents, </text>
<text top="747" left="343" width="90" height="17" font="5">adverse events. </text>
<text top="764" left="343" width="185" height="17" font="5">3 trials (MDRD, AASK, REIN-2; 8 </text>
<text top="644" left="549" width="192" height="17" font="5">Results: Overall trials did not show </text>
<text top="662" left="549" width="92" height="17" font="5">that BP target of </text>
<text top="679" left="549" width="192" height="17" font="5">&lt;125/75–130/80 is more beneficial </text>
<text top="696" left="549" width="86" height="17" font="5">than a target of </text>
<text top="713" left="549" width="180" height="17" font="5">&lt;140/90. Lower quality evidence </text>
<text top="731" left="549" width="163" height="17" font="5">suggests a low target may be </text>
<text top="748" left="549" width="154" height="17" font="5">beneficial in subgroups with </text>
<text top="765" left="549" width="62" height="17" font="5">proteinuria </text>
<text top="644" left="797" width="304" height="17" font="5">Limitations: No pts with DM-1 included. Duration (mean </text>
<text top="662" left="797" width="316" height="17" font="5">follow- up 2–4 y) may be too short to detect differences in </text>
<text top="679" left="797" width="321" height="17" font="5">clinically important outcomes. Reporting of adverse events </text>
<text top="696" left="797" width="68" height="17" font="5">not uniform. </text>
<text top="713" left="789" width="3" height="17" font="5"> </text>
<text top="731" left="789" width="319" height="17" font="5">Summary: Available evidence is inconclusive but does not </text>
<text top="748" left="789" width="329" height="17" font="5">prove a BP target &lt;130/80 improves clinical outcomes more </text>
<text top="765" left="789" width="242" height="17" font="5">than a target of &lt;140/90 in adults with CKD. </text>
</page>
<page number="280" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="104" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="199" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="215" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="375" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="569" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="546" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="899" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="926" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="201" width="65" height="17" font="5">Study type: </text>
<text top="160" left="201" width="103" height="17" font="5">Systematic review </text>
<text top="178" left="193" width="3" height="17" font="5"> </text>
<text top="196" left="193" width="65" height="17" font="5">Size: 2,272 </text>
<text top="143" left="335" width="46" height="17" font="5">reports) </text>
<text top="143" left="540" width="79" height="17" font="5">&gt;300–1,000/d </text>
<text top="214" left="83" width="68" height="17" font="5">Jafar TH, et </text>
<text top="233" left="83" width="54" height="17" font="5">al., 2003  </text>
<text top="252" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12965979?dopt=Citation">12965979</a></text>
<text top="252" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12965979?dopt=Citation"> </a></text>
<text top="212" left="201" width="104" height="17" font="5">Aim: To determine </text>
<text top="227" left="201" width="89" height="17" font="5">the levels of BP </text>
<text top="243" left="201" width="96" height="17" font="5">and urine protein </text>
<text top="258" left="201" width="53" height="17" font="5">excretion </text>
<text top="273" left="201" width="87" height="17" font="5">associated with </text>
<text top="288" left="201" width="78" height="17" font="5">lowest risk for </text>
<text top="304" left="201" width="81" height="17" font="5">progression of </text>
<text top="319" left="201" width="67" height="17" font="5">CKD during </text>
<text top="334" left="201" width="93" height="17" font="5">antihypertensive </text>
<text top="350" left="201" width="94" height="17" font="5">therapy with and </text>
<text top="365" left="201" width="84" height="17" font="5">without ACEIs. </text>
<text top="382" left="193" width="3" height="17" font="5"> </text>
<text top="399" left="201" width="82" height="17" font="5">Study type: 11 </text>
<text top="416" left="201" width="93" height="17" font="5">RCTs in pts with </text>
<text top="434" left="201" width="81" height="17" font="5">predominantly </text>
<text top="451" left="201" width="105" height="17" font="5">nondiabetic kidney </text>
<text top="468" left="201" width="46" height="17" font="5">disease </text>
<text top="485" left="193" width="3" height="17" font="5"> </text>
<text top="503" left="201" width="105" height="17" font="5">Size: 1,860 pooled </text>
<text top="520" left="201" width="90" height="17" font="5">in pt level meta- </text>
<text top="537" left="201" width="85" height="17" font="5">analysis; mean </text>
<text top="554" left="201" width="97" height="17" font="5">duration of follow-</text>
<text top="571" left="201" width="17" height="17" font="5">up </text>
<text top="589" left="201" width="30" height="17" font="5">2.2 y </text>
<text top="211" left="343" width="96" height="17" font="5">Inclusion criteria: </text>
<text top="226" left="343" width="167" height="18" font="5">• Pt-level meta-analysis using </text>
<text top="242" left="343" width="151" height="17" font="5">data from the AIPRD Study </text>
<text top="258" left="343" width="147" height="17" font="5">Group database to assess </text>
<text top="273" left="343" width="158" height="17" font="5">relationships among pts with </text>
<text top="288" left="343" width="151" height="17" font="5">nondiabetic kidney disease </text>
<text top="303" left="343" width="158" height="17" font="5">across a wide range of urine </text>
<text top="319" left="343" width="171" height="17" font="5">protein excretion values during </text>
<text top="334" left="343" width="162" height="17" font="5">antihypertensive therapy with </text>
<text top="349" left="343" width="108" height="17" font="5">and without ACEIs. </text>
<text top="365" left="343" width="148" height="18" font="5">• The AIPRD Study Group </text>
<text top="380" left="343" width="157" height="17" font="5">database included 1,860 pts </text>
<text top="395" left="343" width="130" height="17" font="5">with nondiabetic kidney </text>
<text top="410" left="343" width="172" height="17" font="5">disease enrolled in 11 RCTs of </text>
<text top="425" left="343" width="168" height="17" font="5">ACEIs to slow the progression </text>
<text top="440" left="343" width="126" height="17" font="5">of kidney disease. The </text>
<text top="455" left="343" width="111" height="17" font="5">database contained </text>
<text top="470" left="343" width="135" height="17" font="5">information on BP, urine </text>
<text top="485" left="343" width="135" height="17" font="5">protein excretion, serum </text>
<text top="500" left="343" width="170" height="17" font="5">creatinine, and onset of kidney </text>
<text top="515" left="343" width="149" height="17" font="5">failure during 22,610 visits. </text>
<text top="530" left="343" width="154" height="18" font="5">• Included only randomized </text>
<text top="546" left="343" width="142" height="17" font="5">trials (with a minimum 1 y </text>
<text top="561" left="343" width="159" height="17" font="5">follow-up) that compared the </text>
<text top="575" left="343" width="146" height="17" font="5">effects of antihypertensive </text>
<text top="590" left="343" width="165" height="17" font="5">regimens that included ACEIs </text>
<text top="605" left="343" width="153" height="17" font="5">with the effects of regimens </text>
<text top="620" left="343" width="148" height="17" font="5">that did not include ACEIs. </text>
<text top="635" left="343" width="143" height="17" font="5">HTN or decreased kidney </text>
<text top="650" left="343" width="169" height="17" font="5">function was required for entry </text>
<text top="665" left="343" width="84" height="17" font="5">into all studies. </text>
<text top="682" left="335" width="3" height="17" font="5"> </text>
<text top="699" left="343" width="167" height="17" font="5">Exclusion criteria: Common to </text>
<text top="716" left="343" width="134" height="17" font="5">all studies: acute kidney </text>
<text top="734" left="343" width="121" height="17" font="5">failure, treatment with </text>
<text top="751" left="343" width="149" height="17" font="5">immunosuppressive meds, </text>
<text top="768" left="343" width="173" height="17" font="5">clinically significant chronic HF, </text>
<text top="214" left="549" width="182" height="17" font="5">1° endpoint: Progression of CKD </text>
<text top="231" left="549" width="161" height="17" font="5">defined as doubling of serum </text>
<text top="248" left="549" width="194" height="17" font="5">creatinine or onset of kidney failure </text>
<text top="266" left="540" width="3" height="17" font="5"> </text>
<text top="283" left="549" width="134" height="17" font="5">Results: Kidney disease </text>
<text top="301" left="549" width="199" height="17" font="5">progression documented in 311 pts, </text>
<text top="318" left="549" width="104" height="17" font="5">124 (13.2%) in the </text>
<text top="335" left="549" width="195" height="17" font="5">ACEI group and 187 (20.5%) in the </text>
<text top="352" left="549" width="198" height="17" font="5">control group (p=0.001). 176 (9.5%) </text>
<text top="369" left="549" width="99" height="17" font="5">developed kidney </text>
<text top="387" left="549" width="163" height="17" font="5">failure: 70 (7.4%) in the ACEI </text>
<text top="404" left="549" width="203" height="17" font="5">group and 106 (11.6%) in the control </text>
<text top="421" left="549" width="95" height="17" font="5">group (p=0.002). </text>
<text top="439" left="549" width="191" height="17" font="5">SBP of 110–129 mm Hg and urine </text>
<text top="456" left="549" width="172" height="17" font="5">protein excretion &lt;2.0 g/d were </text>
<text top="474" left="549" width="205" height="17" font="5">associated with lowest risk for kidney </text>
<text top="491" left="549" width="204" height="17" font="5">disease progression. ACEI beneficial </text>
<text top="508" left="549" width="184" height="17" font="5">after adjustment for BP and urine </text>
<text top="525" left="549" width="201" height="17" font="5">protein excretion (RR: 0.67; 95% CI: </text>
<text top="542" left="549" width="90" height="17" font="5">0.53–0.84). The </text>
<text top="560" left="549" width="204" height="17" font="5">increased risk for kidney progression </text>
<text top="577" left="549" width="195" height="17" font="5">at higher SBP levels was greater in </text>
<text top="595" left="549" width="198" height="17" font="5">pts with urine protein excretion &gt;1.0 </text>
<text top="612" left="549" width="80" height="17" font="5">g/d (p&lt;0.006). </text>
<text top="214" left="797" width="318" height="17" font="5">Limitations: Studies included were not designed to assess </text>
<text top="231" left="797" width="303" height="17" font="5">the effect of lowering BP and urine protein excretion on </text>
<text top="248" left="797" width="156" height="17" font="5">kidney disease progression. </text>
<text top="266" left="789" width="3" height="17" font="5"> </text>
<text top="283" left="797" width="322" height="17" font="5">Conclusions:  Although  reverse  causation  cannot  be </text>
<text top="301" left="797" width="322" height="17" font="5">excluded  with  certainty,  SBP  goal  between  110  and  129 </text>
<text top="318" left="797" width="322" height="17" font="5">mm Hg may be beneficial in pts with urine protein excretion </text>
<text top="335" left="797" width="52" height="17" font="5">&gt;1.0 g/d. </text>
<text top="353" left="797" width="311" height="17" font="5">SBP &lt;110 mm Hg may be associated with higher risk for </text>
<text top="370" left="797" width="156" height="17" font="5">kidney disease progression. </text>
</page>
<page number="281" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="104" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="199" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="215" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="375" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="569" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="546" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="899" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="926" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="343" width="148" height="17" font="5">obstructive uropathy, renal </text>
<text top="160" left="343" width="173" height="17" font="5">artery stenosis, active systemic </text>
<text top="178" left="343" width="140" height="17" font="5">disease, DM-1, history of </text>
<text top="195" left="343" width="141" height="17" font="5">transplantation, history of </text>
<text top="212" left="343" width="53" height="17" font="5">allergy to </text>
<text top="230" left="83" width="38" height="17" font="5">Emdin </text>
<text top="247" left="83" width="49" height="17" font="5">C, et al., </text>
<text top="264" left="83" width="34" height="17" font="5">2015  </text>
<text top="282" left="83" width="3" height="17" font="5"> </text>
<text top="300" left="83" width="55" height="17" font="17"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25668264?dopt=Citation">25668264</a></text>
<text top="300" left="137" width="3" height="17" font="5"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25668264?dopt=Citation"> </a></text>
<text top="230" left="201" width="88" height="17" font="5">Aim: Determine </text>
<text top="247" left="201" width="71" height="17" font="5">associations </text>
<text top="264" left="201" width="70" height="17" font="5">between BP-</text>
<text top="282" left="201" width="49" height="17" font="5">lowering </text>
<text top="299" left="201" width="79" height="17" font="5">treatment and </text>
<text top="316" left="201" width="68" height="17" font="5">presence of </text>
<text top="333" left="201" width="49" height="17" font="5">vascular </text>
<text top="350" left="201" width="82" height="17" font="5">disease in DM-</text>
<text top="368" left="201" width="10" height="17" font="5">2 </text>
<text top="386" left="193" width="3" height="17" font="5"> </text>
<text top="403" left="201" width="65" height="17" font="5">Study type: </text>
<text top="420" left="201" width="70" height="17" font="5">Large meta- </text>
<text top="437" left="201" width="62" height="17" font="5">analysis of </text>
<text top="455" left="201" width="83" height="17" font="5">40 high quality </text>
<text top="472" left="201" width="87" height="17" font="5">RCTs (1/1966– </text>
<text top="489" left="201" width="114" height="17" font="5">10/2014) judged low </text>
<text top="506" left="201" width="62" height="17" font="5">risk of bias </text>
<text top="524" left="193" width="3" height="17" font="5"> </text>
<text top="541" left="201" width="98" height="17" font="5">Size: 100,354 pts </text>
<text top="559" left="201" width="96" height="17" font="5">with DM; all trials </text>
<text top="576" left="201" width="79" height="17" font="5">&gt;1,000 pt-y of </text>
<text top="593" left="201" width="73" height="17" font="5">follow-up BP-</text>
<text top="610" left="201" width="96" height="17" font="5">lowering drug vs. </text>
<text top="627" left="201" width="102" height="17" font="5">placebo: 26 RCTs </text>
<text top="645" left="193" width="3" height="17" font="5"> </text>
<text top="662" left="201" width="113" height="18" font="5">• More intensive vs. </text>
<text top="680" left="201" width="97" height="17" font="5">less intensive BP </text>
<text top="698" left="201" width="97" height="17" font="5">lowering: 7 RCTs </text>
<text top="713" left="201" width="89" height="17" font="5">BP-lowering vs. </text>
<text top="728" left="201" width="94" height="17" font="5">another drug: 17 </text>
<text top="744" left="201" width="35" height="17" font="5">RCTs </text>
<text top="230" left="343" width="161" height="17" font="5">Inclusion criteria: All RCTs of </text>
<text top="247" left="343" width="138" height="17" font="5">BP-lowering treatment in </text>
<text top="264" left="343" width="152" height="17" font="5">which entire trial population </text>
<text top="282" left="343" width="140" height="17" font="5">had DM-2 or in which the </text>
<text top="299" left="343" width="171" height="17" font="5">results of a DM subgroup were </text>
<text top="316" left="343" width="128" height="17" font="5">obtained. Studies were </text>
<text top="333" left="343" width="144" height="17" font="5">included regardless of the </text>
<text top="350" left="343" width="132" height="17" font="5">presence or absence of </text>
<text top="368" left="343" width="76" height="17" font="5">defined HTN. </text>
<text top="386" left="335" width="3" height="17" font="5"> </text>
<text top="400" left="343" width="133" height="17" font="5">Exclusion criteria: Trials </text>
<text top="414" left="343" width="173" height="17" font="5">conducted predominantly in pts </text>
<text top="428" left="343" width="171" height="17" font="5">with type 1 DM were excluded. </text>
<text top="230" left="540" width="217" height="18" font="5">•  BP-lowering drug vs. placebo: 26 </text>
<text top="249" left="567" width="35" height="17" font="5">RCTs </text>
<text top="266" left="540" width="146" height="18" font="5">•  More intensive vs. less </text>
<text top="284" left="567" width="133" height="17" font="5">intensive BP lowering: 7 </text>
<text top="301" left="567" width="35" height="17" font="5">RCTs </text>
<text top="319" left="540" width="235" height="18" font="5">•  BP-lowering vs. another drug: 17 RCTs </text>
<text top="338" left="540" width="3" height="17" font="5"> </text>
<text top="355" left="549" width="194" height="17" font="5">Results: Baseline BP: A 10-mm Hg </text>
<text top="372" left="549" width="205" height="17" font="5">SBP reduction was associated with a </text>
<text top="389" left="549" width="189" height="17" font="5">significantly lower risk of all-cause </text>
<text top="406" left="549" width="184" height="17" font="5">mortality RR: 0.87 (95% CI: 0.78–</text>
<text top="424" left="549" width="156" height="17" font="5">0.96), CVD events RR: 0.89 </text>
<text top="441" left="549" width="217" height="17" font="5">(95% CI: 0.80–0.98), and stroke events </text>
<text top="458" left="549" width="25" height="17" font="5">RR: </text>
<text top="475" left="549" width="169" height="17" font="5">0.73 (95% CI: 0.64–0.83). The </text>
<text top="493" left="549" width="200" height="17" font="5">associations for HF and renal failure </text>
<text top="510" left="549" width="213" height="17" font="5">were not significant. For microvascular </text>
<text top="527" left="549" width="215" height="17" font="5">events, a 10-mm reduction in SBP was </text>
<text top="544" left="549" width="167" height="17" font="5">associated with a lower risk of </text>
<text top="561" left="549" width="198" height="17" font="5">retinopathy RR: 0.87 (95% CI: 0.76–</text>
<text top="579" left="549" width="206" height="17" font="5">0.99) and albuminuria RR: 0.83 (95% </text>
<text top="596" left="549" width="85" height="17" font="5">CI: 0.79–0.87). </text>
<text top="613" left="540" width="3" height="17" font="5"> </text>
<text top="630" left="549" width="131" height="17" font="5">Stratified by initial SBP: </text>
<text top="647" left="549" width="204" height="17" font="5">Trials stratified by SBP &gt;140 to &lt;140 </text>
<text top="665" left="549" width="147" height="17" font="5">mm Hg showed significant </text>
<text top="682" left="549" width="211" height="17" font="5">interactions for all-cause mortality RR: </text>
<text top="699" left="549" width="160" height="17" font="5">0.73 (95% CI: 0.64–0.84) vs. </text>
<text top="716" left="549" width="226" height="17" font="5">1.07 (95% CI: 0.92–1.26), CVD RR: 0.74 </text>
<text top="733" left="549" width="217" height="17" font="5">(95% CI: 0.65–0.85) vs. RR: 0.96 (95% </text>
<text top="750" left="549" width="19" height="17" font="5">CI: </text>
<text top="768" left="549" width="199" height="17" font="5">0.88–1.05), CHD RR: 0.73 (95% CI: </text>
<text top="230" left="797" width="325" height="17" font="5">Limitations: Reliability of this meta-analysis is limited by the </text>
<text top="247" left="797" width="321" height="17" font="5">scarcity of large trials with achieved SBP levels in the 120–</text>
<text top="264" left="797" width="279" height="17" font="5">130 mm Hg range. The relatively short follow-up of </text>
<text top="282" left="797" width="299" height="17" font="5">included trails may have prevented associations of BP-</text>
<text top="299" left="797" width="297" height="17" font="5">lowering treatment with vascular outcomes from being </text>
<text top="316" left="797" width="315" height="17" font="5">observed, particularly for outcomes such as HF and renal </text>
<text top="333" left="797" width="259" height="17" font="5">failure, which are often a consequence of MI or </text>
<text top="350" left="797" width="142" height="17" font="5">albuminuria, respectively. </text>
<text top="368" left="789" width="3" height="17" font="5"> </text>
<text top="386" left="797" width="59" height="17" font="5">Summary: </text>
<text top="403" left="797" width="315" height="18" font="5">• This large meta-analysis of 40 RCTs provides evidence </text>
<text top="421" left="797" width="324" height="17" font="5">that BP lowering is associated with lower risks of outcomes </text>
<text top="438" left="797" width="305" height="17" font="5">in pts with initial mean SBP  140 mm Hg compared with </text>
<text top="456" left="797" width="330" height="17" font="5">those &lt;140 mm Hg with the exception of stroke, albuminuria </text>
<text top="473" left="797" width="333" height="17" font="5">and retinopathy. When trials were stratified by achieved SBP </text>
<text top="490" left="797" width="320" height="17" font="5">treatment was associated with lower risks only in the &lt;130 </text>
<text top="507" left="797" width="237" height="17" font="5">mm Hg stratum for stroke and albuminuria. </text>
<text top="525" left="797" width="329" height="18" font="5">• This meta-analysis shows that although BP lowering was </text>
<text top="543" left="797" width="329" height="17" font="5">not associated with a lower risk of CVD or CHD events at a </text>
<text top="560" left="797" width="76" height="17" font="5">baseline SBP </text>
<text top="577" left="797" width="280" height="17" font="5">&lt;140 mm Hg, it does observe lower risks of stroke, </text>
<text top="595" left="797" width="240" height="17" font="5">retinopathy and progression of albuminuria. </text>
<text top="612" left="797" width="305" height="17" font="5">This study provides evidence that for individuals at high </text>
<text top="629" left="797" width="324" height="17" font="5">risk for these outcomes (history of cerebrovascular disease </text>
<text top="647" left="797" width="304" height="17" font="5">or mild nonproliferative retinopathy), commencement of </text>
<text top="664" left="797" width="316" height="17" font="5">therapy below an initial SBP of 140 mm Hg and treatment </text>
<text top="681" left="797" width="172" height="17" font="5">to SBP &lt;130 may be indicated. </text>
</page>
<page number="282" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="104" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="199" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="215" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="375" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="569" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="546" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="899" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="926" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="549" width="34" height="17" font="5">0.61– </text>
<text top="160" left="549" width="220" height="17" font="5">0.87) vs. RR: 0.97 (95% CI: 0.86–1.10), </text>
<text top="178" left="549" width="20" height="17" font="5">HF </text>
<text top="195" left="549" width="209" height="17" font="5">RR: 0.75 (95% CI: 0.59–0.94) vs. RR: </text>
<text top="212" left="549" width="27" height="17" font="5">0.97 </text>
<text top="229" left="549" width="204" height="17" font="5">(95% CI: 0.79–1.19) and albuminuria </text>
<text top="246" left="549" width="25" height="17" font="5">RR: </text>
<text top="264" left="549" width="212" height="17" font="5">0.71 (95% CI: 0.63–0.79) vs. RR: 0.86 </text>
<text top="281" left="549" width="32" height="17" font="5">(95% </text>
<text top="298" left="549" width="85" height="17" font="5">CI: 0.81–0.99). </text>
<text top="316" left="540" width="3" height="17" font="5"> </text>
<text top="333" left="549" width="152" height="17" font="5">Stratified by achieved SBP: </text>
<text top="350" left="549" width="193" height="17" font="5">Trials stratified by SBP achieved in </text>
<text top="368" left="549" width="184" height="17" font="5">the treatment group  130 or &lt;130 </text>
<text top="385" left="549" width="200" height="17" font="5">mm Hg and the associations of a 10-</text>
<text top="402" left="549" width="183" height="17" font="5">mm Hg SBP reduction compared </text>
<text top="419" left="549" width="150" height="17" font="5">between the strata showed </text>
<text top="437" left="549" width="195" height="17" font="5">significant interactions for all-cause </text>
<text top="454" left="549" width="184" height="17" font="5">mortality RR: 0.75 (95% CI: 0.65–</text>
<text top="471" left="549" width="51" height="17" font="5">0.86) vs. </text>
<text top="488" left="549" width="205" height="17" font="5">RR: 1.06 (95% CI: 0.90–1.265), CVD </text>
<text top="505" left="549" width="25" height="17" font="5">RR: </text>
<text top="522" left="549" width="212" height="17" font="5">0.74 (95% CI: 0.64–0.85) vs. RR: 0.96 </text>
<text top="540" left="549" width="32" height="17" font="5">(95% </text>
<text top="557" left="549" width="218" height="17" font="5">CI: 0.88–1.05), CHD RR: 0.70 (95% CI: </text>
<text top="574" left="549" width="219" height="17" font="5">0.58– 0.83) vs. RR: 0.97 (95% CI: 0.85–</text>
<text top="591" left="549" width="55" height="17" font="5">1.10), HF </text>
<text top="608" left="549" width="209" height="17" font="5">RR: 0.75 (95% CI: 0.59–0.95) vs. RR: </text>
<text top="625" left="549" width="27" height="17" font="5">1.00 </text>
<text top="642" left="549" width="204" height="17" font="5">(95% CI: 0.81–1.23) and albuminuria </text>
<text top="660" left="549" width="25" height="17" font="5">RR: </text>
<text top="677" left="549" width="212" height="17" font="5">0.71 (95% CI: 0.64–0.79) vs. RR: 0.86 </text>
<text top="694" left="549" width="32" height="17" font="5">(95% </text>
<text top="712" left="549" width="180" height="17" font="5">CI: 0.81–0.90) with higher risk in </text>
<text top="729" left="549" width="129" height="17" font="5">the  130 mm Hg group. </text>
<text top="747" left="540" width="3" height="17" font="5"> </text>
<text top="764" left="549" width="213" height="17" font="5">Stratified by class of medications: Few </text>
</page>
<page number="283" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="104" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="199" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="215" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="375" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="569" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="546" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="899" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="926" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="549" width="181" height="17" font="5">differences were observed in the </text>
<text top="160" left="549" width="185" height="17" font="5">association between BP-lowering </text>
<text top="178" left="549" width="208" height="17" font="5">treatment and outcomes for regimens </text>
<text top="195" left="549" width="160" height="17" font="5">based on different classes of </text>
<text top="212" left="549" width="183" height="17" font="5">medications, except HF, in which </text>
<text top="229" left="549" width="199" height="17" font="5">diuretics were associated with lower </text>
<text top="247" left="549" width="208" height="17" font="5">RR: 0.83 (95% CI: 0.72–0.95) than all </text>
<text top="264" left="549" width="79" height="17" font="5">other classes. </text>
<text top="281" left="549" width="219" height="17" font="5">This was driven largely by the results of </text>
<text top="298" left="549" width="53" height="17" font="5">ALLHAT. </text>
<text top="316" left="66" width="3" height="17" font="5"> </text>
<text top="356" left="66" width="402" height="21" font="4"><b>Data Supplement 15. RCTs of Tobacco Use (Section 4.5.) </b></text>
<text top="386" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="403" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="420" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="386" left="211" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="403" left="216" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="420" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="386" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="386" left="536" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="403" left="553" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="420" left="536" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="438" left="557" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="386" left="727" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="403" left="667" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="420" left="737" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="387" left="935" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="386" left="1000" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="404" left="969" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="422" left="977" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="456" left="75" width="100" height="17" font="5">Carson et al 2012 </text>
<text top="473" left="75" width="25" height="17" font="5">(24) </text>
<text top="490" left="75" width="3" height="17" font="5"> </text>
<text top="507" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22592671">22592671</a></text>
<text top="507" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/22592671"> </a></text>
<text top="456" left="192" width="76" height="17" font="5">Aim of Study: </text>
<text top="473" left="192" width="96" height="17" font="5">To determine the </text>
<text top="490" left="192" width="89" height="17" font="5">effectiveness of </text>
<text top="507" left="192" width="108" height="17" font="5">training health care </text>
<text top="524" left="192" width="109" height="17" font="5">professionals in the </text>
<text top="542" left="192" width="108" height="17" font="5">delivery of smoking </text>
<text top="559" left="192" width="55" height="17" font="5">cessation </text>
<text top="576" left="192" width="114" height="17" font="5">interventions to their </text>
<text top="593" left="192" width="87" height="17" font="5">patients, and to </text>
<text top="610" left="192" width="118" height="17" font="5">assess the additional </text>
<text top="628" left="192" width="97" height="17" font="5">effects of training </text>
<text top="645" left="192" width="111" height="17" font="5">characteristics such </text>
<text top="662" left="192" width="83" height="17" font="5">as intervention </text>
<text top="679" left="192" width="93" height="17" font="5">content, delivery </text>
<text top="697" left="192" width="117" height="17" font="5">method and intensity </text>
<text top="714" left="192" width="3" height="17" font="5"> </text>
<text top="731" left="192" width="92" height="17" font="5">Meta analysis of </text>
<text top="748" left="192" width="35" height="17" font="5">RCTs </text>
<text top="765" left="192" width="3" height="17" font="5"> </text>
<text top="456" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="473" left="324" width="52" height="18" font="5">•  RCTs </text>
<text top="491" left="324" width="172" height="18" font="5">•  Unit of randomization was a </text>
<text top="509" left="325" width="186" height="17" font="5">healthcare practitioner or practice </text>
<text top="527" left="324" width="174" height="18" font="5">•  Reported effects on patients </text>
<text top="545" left="325" width="106" height="17" font="5">who were smokers </text>
<text top="562" left="324" width="195" height="18" font="5">•  Compared a trained group to an </text>
<text top="580" left="325" width="171" height="17" font="5">untrained group and those that </text>
<text top="597" left="325" width="166" height="17" font="5">examined the effectiveness of </text>
<text top="615" left="325" width="184" height="17" font="5">adding prompts and reminders to </text>
<text top="632" left="325" width="47" height="17" font="5">training  </text>
<text top="649" left="326" width="3" height="17" font="5"> </text>
<text top="680" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="710" left="324" width="178" height="18" font="5">•  Studies that used a historical </text>
<text top="728" left="325" width="40" height="17" font="5">control </text>
<text top="456" left="534" width="3" height="17" font="5"> </text>
<text top="457" left="662" width="7" height="17" font="5">1</text>
<text top="456" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="474" left="662" width="231" height="17" font="5">Abstinence from smoking 6+ months after </text>
<text top="491" left="662" width="183" height="17" font="5">the start of the intervention (point </text>
<text top="508" left="662" width="221" height="17" font="5">prevalence and continuous abstinence)  </text>
<text top="526" left="662" width="3" height="17" font="5"> </text>
<text top="543" left="662" width="48" height="17" font="5">Results: </text>
<text top="560" left="662" width="230" height="17" font="5">13/17 included studies found no evidence </text>
<text top="577" left="662" width="194" height="17" font="5">of an effect for continuous smoking </text>
<text top="594" left="662" width="205" height="17" font="5">abstinence following the intervention. </text>
<text top="612" left="662" width="3" height="17" font="5"> </text>
<text top="629" left="662" width="200" height="17" font="5">Meta-analysis of 14 studies for point </text>
<text top="646" left="662" width="227" height="17" font="5">prevalence of smoking (OR 1.36, 95% CI </text>
<text top="663" left="662" width="79" height="17" font="5">1.20 to 1.55).  </text>
<text top="680" left="662" width="3" height="17" font="5"> </text>
<text top="698" left="662" width="189" height="17" font="5">Meta-analysis of eight studies that </text>
<text top="715" left="662" width="200" height="17" font="5">reported continuous abstinence was </text>
<text top="732" left="662" width="221" height="17" font="5">statistically significant (OR 1.60, 95% CI </text>
<text top="749" left="662" width="76" height="17" font="5">1.26 to 2.03). </text>
<text top="766" left="662" width="3" height="17" font="5"> </text>
<text top="457" left="910" width="7" height="17" font="5">2</text>
<text top="456" left="917" width="66" height="18" font="5"> endpoints </text>
<text top="474" left="910" width="188" height="17" font="5">Process measures at patient level </text>
<text top="491" left="910" width="3" height="17" font="5"> </text>
<text top="508" left="910" width="202" height="17" font="5">Number of referrals made (physician </text>
<text top="526" left="910" width="83" height="17" font="5">level outcome) </text>
<text top="543" left="910" width="3" height="17" font="5"> </text>
<text top="560" left="910" width="44" height="17" font="5">Results </text>
<text top="577" left="910" width="189" height="17" font="5">Healthcare professionals who had </text>
<text top="594" left="910" width="199" height="17" font="5">received training were more likely to </text>
<text top="612" left="910" width="223" height="17" font="5">perform tasks of smoking cessation than </text>
<text top="629" left="910" width="199" height="17" font="5">untrained controls, including: asking </text>
<text top="646" left="910" width="194" height="17" font="5">patients to set a quit date ((random </text>
<text top="663" left="910" width="222" height="17" font="5">effects OR 4.98, 95% CI 2.29 to 10.86),  </text>
<text top="680" left="910" width="213" height="17" font="5">make follow-up appointments (random </text>
<text top="698" left="910" width="62" height="17" font="5">effects OR </text>
<text top="715" left="910" width="154" height="17" font="5">3.34, 95% CI 1.51 to 7.37),  </text>
<text top="732" left="910" width="213" height="17" font="5">counselling of smokers (OR 2.28, 95% </text>
<text top="749" left="910" width="95" height="17" font="5">CI 1.58 to 3.27),  </text>
</page>
<page number="284" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="192" width="120" height="17" font="5">N=17 studies (28.531 </text>
<text top="108" left="192" width="113" height="17" font="5">patients at baseline; </text>
<text top="125" left="192" width="71" height="17" font="5">1,434 health </text>
<text top="142" left="192" width="89" height="17" font="5">professionals at </text>
<text top="160" left="192" width="53" height="17" font="5">baseline) </text>
<text top="91" left="662" width="3" height="17" font="5"> </text>
<text top="91" left="910" width="220" height="17" font="5">provision of self-help material (OR 3.52, </text>
<text top="108" left="910" width="221" height="17" font="5">95% CI 1.90 to 6.52) and prescription of </text>
<text top="125" left="910" width="209" height="17" font="5">a quit date (OR 14.18, 95% CI 6.57 to </text>
<text top="142" left="910" width="203" height="17" font="5">30.61). No evidence of an effect was </text>
<text top="160" left="910" width="204" height="17" font="5">observed for the provision of nicotine </text>
<text top="177" left="910" width="227" height="17" font="5">gum/replacement therapy (OR 1.57, 95% </text>
<text top="194" left="910" width="92" height="17" font="5">CI 0.87 to 2.84). </text>
<text top="212" left="75" width="84" height="17" font="5">Patnode, 2015 </text>
<text top="229" left="75" width="3" height="17" font="5"> </text>
<text top="247" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26491759">26491759</a></text>
<text top="247" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26491759"> </a></text>
<text top="212" left="192" width="76" height="17" font="5">Aim of Study: </text>
<text top="229" left="192" width="96" height="17" font="5">To determine the </text>
<text top="247" left="192" width="99" height="17" font="5">effectiveness and </text>
<text top="264" left="192" width="50" height="17" font="5">safety of </text>
<text top="281" left="192" width="99" height="17" font="5">pharmacotherapy </text>
<text top="298" left="192" width="84" height="17" font="5">and behavioral </text>
<text top="315" left="192" width="102" height="17" font="5">tobacco cessation </text>
<text top="333" left="192" width="86" height="17" font="5">interventions in </text>
<text top="350" left="192" width="97" height="17" font="5">adults. Electronic </text>
<text top="367" left="192" width="91" height="17" font="5">nicotine delivery </text>
<text top="384" left="192" width="74" height="17" font="5">systems also </text>
<text top="401" left="192" width="53" height="17" font="5">included. </text>
<text top="419" left="192" width="3" height="17" font="5"> </text>
<text top="436" left="192" width="119" height="17" font="5">Review of systematic </text>
<text top="453" left="192" width="45" height="17" font="5">reviews </text>
<text top="470" left="192" width="3" height="17" font="5"> </text>
<text top="487" left="192" width="47" height="17" font="5">54 SRs: </text>
<text top="505" left="192" width="114" height="17" font="5">Pharmacotherapy: 9 </text>
<text top="522" left="192" width="27" height="17" font="5">SRs </text>
<text top="539" left="192" width="109" height="17" font="5">Behavioral: 33 SRs </text>
<text top="212" left="326" width="3" height="17" font="5"> </text>
<text top="212" left="534" width="3" height="17" font="5"> </text>
<text top="213" left="662" width="7" height="17" font="5">1</text>
<text top="212" left="668" width="60" height="18" font="5"> endpoint </text>
<text top="230" left="662" width="57" height="17" font="5">Quit rates </text>
<text top="248" left="662" width="3" height="17" font="5"> </text>
<text top="265" left="662" width="222" height="17" font="5">One SR included one RCT that reported </text>
<text top="282" left="662" width="176" height="17" font="5">effect of an intensive behavioral </text>
<text top="299" left="662" width="227" height="17" font="5">intervention on health outcomes in males </text>
<text top="317" left="662" width="220" height="17" font="5">at high risk for CV disease. No effect on </text>
<text top="334" left="662" width="221" height="17" font="5">total mortality, CV mortality, lung cancer </text>
<text top="351" left="662" width="228" height="17" font="5">incidence and mortality at 20 years but at </text>
<text top="368" left="662" width="212" height="17" font="5">33 years of follow-up there were fewer </text>
<text top="385" left="662" width="180" height="17" font="5">deaths from respiratory illness in </text>
<text top="403" left="662" width="216" height="17" font="5">intervention group. No other behavioral </text>
<text top="420" left="662" width="206" height="17" font="5">SR included a study that reported CV </text>
<text top="437" left="662" width="154" height="17" font="5">health outcomes.  No SR of </text>
<text top="454" left="662" width="221" height="17" font="5">pharmacotherapy for smoking cessation </text>
<text top="471" left="662" width="167" height="17" font="5">reported CV health outcomes. </text>
<text top="489" left="662" width="3" height="17" font="5"> </text>
<text top="506" left="662" width="223" height="17" font="5">Effect of NRT versus placebo or no NRT </text>
<text top="523" left="662" width="182" height="17" font="5">for smoking cessation: 117 trials, </text>
<text top="540" left="662" width="226" height="17" font="5">n=51,265, RR 1.60, 95% CI 1.53 to 1.68, </text>
<text top="557" left="662" width="225" height="17" font="5">I2=30%; 17.3% quit in intervention group </text>
<text top="575" left="662" width="234" height="17" font="5">versus 10.3% in control group at 6 months </text>
<text top="592" left="662" width="3" height="17" font="5"> </text>
<text top="609" left="662" width="224" height="17" font="5">Effect of bupropion versus placebo or no </text>
<text top="626" left="662" width="232" height="17" font="5">pharmacotherapy: 44 trials, n=13,728, RR </text>
<text top="643" left="662" width="230" height="17" font="5">1.62, 95% CI 1.49 to 1.76, I2-18%; 19.7% </text>
<text top="661" left="662" width="200" height="17" font="5">quit versus 11.5% at 6 to 12 months </text>
<text top="678" left="662" width="3" height="17" font="5"> </text>
<text top="695" left="662" width="228" height="17" font="5">Effect of varenicline versus placebo or no </text>
<text top="712" left="662" width="219" height="17" font="5">varenicline: 14 trials, n=6,166, RR 2.27, </text>
<text top="730" left="662" width="229" height="17" font="5">95% CI 2.02 to 2.55, I2=63% at 6 months </text>
<text top="747" left="662" width="3" height="17" font="5"> </text>
<text top="212" left="910" width="32" height="17" font="5">NRT: </text>
<text top="229" left="910" width="212" height="17" font="5">Any CV event (minor or major) of NRT </text>
<text top="247" left="910" width="219" height="17" font="5">versus placebo: 21 trials, n=11,647, RR </text>
<text top="264" left="910" width="213" height="17" font="5">1.81, 95% CI 1.35 to 2.43, I2=0% (285 </text>
<text top="281" left="910" width="70" height="17" font="5">events total) </text>
<text top="298" left="910" width="3" height="17" font="5"> </text>
<text top="315" left="910" width="222" height="17" font="5">Any major CV event (CV death, nonfatal </text>
<text top="333" left="910" width="191" height="17" font="5">MI, nonfatal stroke) of NRT versus </text>
<text top="350" left="910" width="207" height="17" font="5">placebo:21 trials, n=11,647, RR 1.38, </text>
<text top="367" left="910" width="204" height="17" font="5">95% CI 0.58 to 3.26, I2=0 (19 events </text>
<text top="384" left="910" width="31" height="17" font="5">total) </text>
<text top="401" left="910" width="3" height="17" font="5"> </text>
<text top="419" left="910" width="221" height="17" font="5">All cause mortality: NRT versus placebo </text>
<text top="436" left="910" width="227" height="17" font="5">or usual care: 8 trials, N=2,765, OR 0.74, </text>
<text top="453" left="910" width="215" height="17" font="5">95% CI 0.33 to 1.67, I2=0% (27 events </text>
<text top="470" left="910" width="31" height="17" font="5">total) </text>
<text top="487" left="910" width="3" height="17" font="5"> </text>
<text top="505" left="910" width="63" height="17" font="5">Bupropion: </text>
<text top="522" left="910" width="203" height="17" font="5">All CV adverse events bupropion SR </text>
<text top="539" left="910" width="219" height="17" font="5">versus placebo: 27 trials, n=10,402, RR </text>
<text top="556" left="910" width="210" height="17" font="5">1.03, 95% CI 0.71 to 1.50, I2=0%, (92 </text>
<text top="573" left="910" width="70" height="17" font="5">events total) </text>
<text top="591" left="910" width="3" height="17" font="5"> </text>
<text top="608" left="910" width="220" height="17" font="5">Major CV adverse events bupropion SR </text>
<text top="625" left="910" width="219" height="17" font="5">versus placebo: 27 trials, n=10,402, RR </text>
<text top="642" left="910" width="195" height="17" font="5">0.57, 95% CI 0.31 to 1.04, I2=0 (40 </text>
<text top="660" left="910" width="70" height="17" font="5">events total) </text>
<text top="677" left="910" width="3" height="17" font="5"> </text>
<text top="694" left="910" width="68" height="17" font="5">Varenicline: </text>
<text top="711" left="910" width="226" height="17" font="5">All CV adverse events varenicline versus </text>
<text top="728" left="910" width="203" height="17" font="5">placebo: 18 trials, n=9,072, RR 1.24, </text>
<text top="746" left="910" width="222" height="17" font="5">95% CI 0.85 to 1.81, I2=0% (104 events </text>
<text top="763" left="910" width="31" height="17" font="5">total) </text>
</page>
<page number="285" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="662" width="199" height="17" font="5">Effect of physician advice versus no </text>
<text top="108" left="662" width="229" height="17" font="5">advice or usual care: 28 trials, n=22, 239, </text>
<text top="125" left="662" width="216" height="17" font="5">RR 1.76, 95% CI 1.58 to 1.96, I2=40%; </text>
<text top="142" left="662" width="229" height="17" font="5">8.0% quit in the intervention group versus </text>
<text top="160" left="662" width="208" height="17" font="5">4.8% in the control group at 6 months </text>
<text top="177" left="662" width="3" height="17" font="5"> </text>
<text top="194" left="662" width="227" height="17" font="5">Effect of self-help material with or without </text>
<text top="211" left="662" width="232" height="17" font="5">advice versus no self-help material with or </text>
<text top="229" left="662" width="214" height="17" font="5">without advice: 33 trials, n=29,495, RR </text>
<text top="246" left="662" width="192" height="17" font="5">1.06, 95% CI 0.98 to 1.16, I2=23% </text>
<text top="263" left="662" width="3" height="17" font="5"> </text>
<text top="280" left="662" width="228" height="17" font="5">Effect of multisession helpline counseling </text>
<text top="297" left="662" width="185" height="17" font="5">versus single session or self-help </text>
<text top="315" left="662" width="217" height="17" font="5">materials: 12 trials, n=30,182, RR 1.41, </text>
<text top="332" left="662" width="161" height="17" font="5">95% CI 1.20 to 1.66, I2=71% </text>
<text top="349" left="662" width="3" height="17" font="5"> </text>
<text top="366" left="662" width="229" height="17" font="5">Effect of nonhelpline, proactive telephone </text>
<text top="383" left="662" width="206" height="17" font="5">counseling versus a control: 52 trials, </text>
<text top="401" left="662" width="226" height="17" font="5">n=30,246, RR 1.27, 95% CI 1.20 to 1.36, </text>
<text top="418" left="662" width="113" height="17" font="5">I2=42% at 6 months </text>
<text top="91" left="910" width="3" height="17" font="5"> </text>
<text top="108" left="910" width="196" height="17" font="5">Major CV events varenicline versus </text>
<text top="125" left="910" width="203" height="17" font="5">placebo: 18 trials, n=9,072, RR 1.44, </text>
<text top="142" left="910" width="215" height="17" font="5">95% CI 0.73 to 2.83, I2=o% (35 events </text>
<text top="160" left="910" width="31" height="17" font="5">total) </text>
<text top="177" left="910" width="3" height="17" font="5"> </text>
<text top="194" left="910" width="206" height="17" font="5">In reviews of behavioral interventions </text>
<text top="211" left="910" width="178" height="17" font="5">reporting of adverse events was </text>
<text top="229" left="910" width="200" height="17" font="5">infrequent and limited to trials of ear-</text>
<text top="246" left="910" width="195" height="17" font="5">acupuncture, ear-acupressure, and </text>
<text top="263" left="910" width="87" height="17" font="5">auriculotherapy </text>
<text top="436" left="75" width="57" height="17" font="5">Stead LF, </text>
<text top="453" left="75" width="103" height="17" font="5">Lancaster T, 2016 </text>
<text top="470" left="75" width="3" height="17" font="5"> </text>
<text top="487" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23076944">23076944</a></text>
<text top="487" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23076944"> </a></text>
<text top="436" left="192" width="66" height="17" font="5">Study Aims </text>
<text top="466" left="192" width="113" height="17" font="5">To assess the effect </text>
<text top="484" left="192" width="73" height="17" font="5">of combining </text>
<text top="501" left="192" width="104" height="17" font="5">behavioral support </text>
<text top="518" left="192" width="120" height="17" font="5">and medication to aid </text>
<text top="535" left="192" width="108" height="17" font="5">smoking cessation, </text>
<text top="552" left="192" width="104" height="17" font="5">compared to using </text>
<text top="570" left="192" width="82" height="17" font="5">neither, and to </text>
<text top="587" left="192" width="89" height="17" font="5">identify whether </text>
<text top="604" left="192" width="101" height="17" font="5">there are different </text>
<text top="621" left="192" width="117" height="17" font="5">effects depending on </text>
<text top="638" left="192" width="116" height="17" font="5">characteristics of the </text>
<text top="656" left="192" width="98" height="17" font="5">treatment setting, </text>
<text top="673" left="192" width="70" height="17" font="5">intervention, </text>
<text top="690" left="192" width="120" height="17" font="5">population treated, or </text>
<text top="707" left="192" width="114" height="17" font="5">take-up of treatment </text>
<text top="725" left="192" width="3" height="17" font="5"> </text>
<text top="742" left="192" width="66" height="17" font="5">Study Type </text>
<text top="436" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="453" left="326" width="188" height="17" font="5">Randomized or quasi-randomized </text>
<text top="470" left="326" width="86" height="17" font="5">controlled trials </text>
<text top="487" left="326" width="3" height="17" font="5"> </text>
<text top="505" left="326" width="175" height="17" font="5">Trials that recruited people who </text>
<text top="522" left="326" width="189" height="17" font="5">smoke in any setting except those </text>
<text top="539" left="326" width="192" height="17" font="5">of pregnant women or adolescents </text>
<text top="556" left="326" width="3" height="17" font="5"> </text>
<text top="573" left="326" width="151" height="17" font="5">Interventions for increasing </text>
<text top="591" left="326" width="178" height="17" font="5">smoking cessation that included </text>
<text top="608" left="326" width="149" height="17" font="5">behavioral support and the </text>
<text top="625" left="326" width="176" height="17" font="5">availability of pharmacotherapy, </text>
<text top="642" left="326" width="101" height="17" font="5">regardless of type </text>
<text top="660" left="326" width="3" height="17" font="5"> </text>
<text top="677" left="326" width="178" height="17" font="5">Control group not systematically </text>
<text top="694" left="326" width="141" height="17" font="5">offered pharmacotherapy </text>
<text top="711" left="326" width="3" height="17" font="5"> </text>
<text top="728" left="326" width="183" height="17" font="5">Control group offered usual care, </text>
<text top="746" left="326" width="184" height="17" font="5">self-help materials or brief advice </text>
<text top="436" left="534" width="68" height="17" font="5">Intervention </text>
<text top="453" left="534" width="91" height="17" font="5">interventions for </text>
<text top="470" left="534" width="108" height="17" font="5">increasing smoking </text>
<text top="487" left="534" width="79" height="17" font="5">cessation that </text>
<text top="505" left="534" width="109" height="17" font="5">included behavioral </text>
<text top="522" left="534" width="89" height="17" font="5">support and the </text>
<text top="539" left="534" width="74" height="17" font="5">availability of </text>
<text top="556" left="534" width="102" height="17" font="5">pharmacotherapy, </text>
<text top="573" left="534" width="101" height="17" font="5">regardless of type </text>
<text top="591" left="534" width="116" height="17" font="5">of pharmacotherapy  </text>
<text top="608" left="534" width="3" height="17" font="5"> </text>
<text top="625" left="534" width="70" height="17" font="5">Comparison </text>
<text top="642" left="534" width="102" height="17" font="5">Not systematically </text>
<text top="660" left="534" width="42" height="17" font="5">offered </text>
<text top="677" left="534" width="106" height="17" font="5">pharmacotherapy,  </text>
<text top="694" left="534" width="94" height="17" font="5">Could be offered </text>
<text top="711" left="534" width="113" height="17" font="5">usual care, self-help </text>
<text top="728" left="534" width="95" height="17" font="5">materials or brief </text>
<text top="746" left="534" width="102" height="17" font="5">advice on quitting, </text>
<text top="763" left="534" width="103" height="17" font="5">but support had to </text>
<text top="437" left="662" width="7" height="17" font="5">1</text>
<text top="436" left="668" width="64" height="18" font="5"> endpoint: </text>
<text top="466" left="662" width="219" height="17" font="5">Smoking cessation at the longest follow-</text>
<text top="483" left="662" width="182" height="17" font="5">up using the strictest definition of </text>
<text top="501" left="662" width="63" height="17" font="5">abstinence </text>
<text top="518" left="662" width="3" height="17" font="5"> </text>
<text top="535" left="662" width="44" height="17" font="5">Results </text>
<text top="552" left="662" width="3" height="17" font="5"> </text>
<text top="570" left="662" width="219" height="17" font="7"><i>Smoking cessation at the longest follow-</i></text>
<text top="587" left="662" width="182" height="17" font="7"><i>up using the strictest definition of </i></text>
<text top="604" left="662" width="63" height="17" font="7"><i>abstinence </i></text>
<text top="621" left="662" width="3" height="17" font="7"><i> </i></text>
<text top="638" left="662" width="210" height="17" font="5">NB: Lung Health Study Excluded from </text>
<text top="656" left="662" width="205" height="17" font="5">analyses due to added heterogeneity </text>
<text top="673" left="662" width="3" height="17" font="5"> </text>
<text top="690" left="662" width="166" height="17" font="5">RR=1.83 (95% CI 1.68-1.98), I</text>
<text top="691" left="828" width="4" height="11" font="8">2</text>
<text top="690" left="832" width="42" height="17" font="5">=36%.  </text>
<text top="707" left="662" width="206" height="17" font="5">Possibility of publication or other bias </text>
<text top="724" left="662" width="3" height="17" font="5"> </text>
<text top="742" left="662" width="176" height="17" font="5">High quality evidence (GRADE) </text>
<text top="437" left="910" width="7" height="17" font="5">2</text>
<text top="436" left="917" width="70" height="18" font="5"> endpoints: </text>
<text top="466" left="910" width="225" height="17" font="5">Any other abstinence outcomes reported </text>
<text top="483" left="910" width="3" height="17" font="5"> </text>
<text top="513" left="910" width="114" height="17" font="5">Subgroup Analyses: </text>
<text top="530" left="910" width="42" height="17" font="7"><i>Setting </i></text>
<text top="547" left="910" width="203" height="17" font="5">Healthcare setting RR=1.97 (95% CI </text>
<text top="564" left="910" width="211" height="17" font="5">1.79-2.18) vs. other settings RR=1.53, </text>
<text top="582" left="910" width="99" height="17" font="5">95% CI 1.33-1.75 </text>
<text top="599" left="910" width="3" height="17" font="5"> </text>
<text top="616" left="910" width="96" height="17" font="7"><i>Motivation to quit </i></text>
<text top="633" left="910" width="228" height="17" font="5">Selected for motivation RR=1.90 (95% CI </text>
<text top="650" left="910" width="211" height="17" font="5">1.68-2.15) vs. “not selected” subgroup </text>
<text top="668" left="910" width="222" height="17" font="5">RR=1.60 (95% CI 1.42-1.80). Motivation </text>
<text top="685" left="910" width="224" height="17" font="5">to quit was not an effect modifier in meta </text>
<text top="702" left="910" width="111" height="17" font="5">regression (p=0.09) </text>
<text top="719" left="910" width="3" height="17" font="5"> </text>
<text top="736" left="910" width="49" height="17" font="7"><i>Provider </i></text>
<text top="754" left="910" width="211" height="17" font="5">Speciality care RR=1.81, 95% CI 1.64-</text>
<text top="771" left="910" width="218" height="17" font="5">1.99 vs. counseling linked to usual care </text>
</page>
<page number="286" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="192" width="102" height="17" font="5">Systematic review </text>
<text top="109" left="192" width="103" height="17" font="5">and meta-analysis </text>
<text top="140" left="192" width="76" height="17" font="5">N=53 studies </text>
<text top="171" left="192" width="3" height="17" font="5"> </text>
<text top="91" left="326" width="173" height="17" font="5">on quitting (lower intensity than </text>
<text top="108" left="326" width="71" height="17" font="5">intervention) </text>
<text top="125" left="326" width="3" height="17" font="5"> </text>
<text top="142" left="326" width="97" height="17" font="5">Exclusion criteria </text>
<text top="160" left="326" width="185" height="17" font="5">Trials of interventions in pregnant </text>
<text top="177" left="326" width="136" height="17" font="5">women and adolescents </text>
<text top="194" left="326" width="3" height="17" font="5"> </text>
<text top="211" left="326" width="173" height="17" font="5">Fewer than 20% of participants </text>
<text top="229" left="326" width="134" height="17" font="5">were eligible for or used </text>
<text top="246" left="326" width="99" height="17" font="5">pharmacotherapy </text>
<text top="263" left="326" width="3" height="17" font="5"> </text>
<text top="280" left="326" width="183" height="17" font="5">Trials less than six months follow </text>
<text top="297" left="326" width="153" height="17" font="5">up from start of intervention </text>
<text top="91" left="534" width="85" height="17" font="5">have been of a </text>
<text top="108" left="534" width="108" height="17" font="5">lower intensity than </text>
<text top="125" left="534" width="70" height="17" font="5">that given to </text>
<text top="142" left="534" width="67" height="17" font="5">intervention </text>
<text top="160" left="534" width="70" height="17" font="5">participants. </text>
<text top="91" left="910" width="207" height="17" font="5">RR=2.03 (95% CI 1.70-2.43). In meta </text>
<text top="108" left="910" width="198" height="17" font="5">regression, type of provider was not </text>
<text top="125" left="910" width="188" height="17" font="5">significant effect modifier (p=0.37) </text>
<text top="142" left="910" width="3" height="17" font="5"> </text>
<text top="160" left="910" width="49" height="17" font="7"><i>Intensity </i></text>
<text top="177" left="910" width="228" height="17" font="5">Eight or more sessions RR=2.10 (95% CI </text>
<text top="194" left="910" width="60" height="17" font="5">1.65-2.68) </text>
<text top="315" left="66" width="3" height="17" font="5"> </text>
<text top="355" left="59" width="807" height="21" font="4"><b>Data Supplement 16. Nonrandomized Trials, Observational Studies, and/or Registries of Tobacco Use (Section 4.5.)</b></text>
<text top="358" left="866" width="3" height="17" font="3"><b> </b></text>
<text top="385" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="402" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="420" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="385" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="402" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="385" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="385" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="402" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="385" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="402" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="438" left="75" width="81" height="17" font="5">Lv et al, 2015  </text>
<text top="455" left="75" width="3" height="17" font="5"> </text>
<text top="472" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26188829">26188829</a></text>
<text top="472" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26188829"> </a></text>
<text top="438" left="193" width="65" height="17" font="5">Study type: </text>
<text top="455" left="193" width="75" height="17" font="5">SR and meta </text>
<text top="472" left="193" width="61" height="17" font="5">analysis of </text>
<text top="489" left="193" width="119" height="17" font="5">observational studies </text>
<text top="507" left="193" width="3" height="17" font="5"> </text>
<text top="524" left="193" width="76" height="17" font="5">N=40 studies </text>
<text top="438" left="326" width="52" height="17" font="5">Inclusion </text>
<text top="455" left="324" width="178" height="18" font="5">•  prospective cohort studies or </text>
<text top="473" left="325" width="119" height="17" font="5">case–control studies  </text>
<text top="491" left="324" width="148" height="18" font="5">•  humans aged ≥18 year </text>
<text top="509" left="324" width="167" height="18" font="5">•  exposure was secondhand </text>
<text top="527" left="325" width="185" height="17" font="5">smoke (SHS) or passive smoking </text>
<text top="544" left="325" width="100" height="17" font="5">in never smokers, </text>
<text top="561" left="324" width="190" height="18" font="5">•  For self-reported SHS, detailed </text>
<text top="580" left="325" width="184" height="17" font="5">questionnaire-based descriptions </text>
<text top="597" left="325" width="190" height="17" font="5">confirming the regular exposure to </text>
<text top="614" left="325" width="194" height="17" font="5">another person's tobacco smoke at </text>
<text top="631" left="325" width="174" height="17" font="5">home or out of home should be </text>
<text top="648" left="325" width="59" height="17" font="5">available;  </text>
<text top="666" left="324" width="195" height="18" font="5">•  Collected outcomes of all-cause </text>
<text top="684" left="325" width="180" height="17" font="5">mortality or CVD (including CHD </text>
<text top="701" left="325" width="72" height="17" font="5">and stroke);  </text>
<text top="718" left="324" width="189" height="18" font="5">•  unexposed subjects were used </text>
<text top="737" left="325" width="127" height="17" font="5">as the reference group </text>
<text top="754" left="324" width="185" height="18" font="5">•  quantitative estimates such as </text>
<text top="772" left="325" width="192" height="17" font="5">RR, hazard ratio, or odds ratio and </text>
<text top="439" left="535" width="7" height="17" font="5">1</text>
<text top="438" left="542" width="60" height="18" font="5"> endpoint </text>
<text top="456" left="535" width="103" height="17" font="5">All cause mortality </text>
<text top="473" left="535" width="29" height="17" font="5">CVD </text>
<text top="490" left="535" width="30" height="17" font="5">CHD </text>
<text top="508" left="535" width="39" height="17" font="5">Stroke </text>
<text top="525" left="535" width="3" height="17" font="5"> </text>
<text top="542" left="535" width="233" height="17" font="7"><i>Self-reported SHS exposure and all cause </i></text>
<text top="559" left="535" width="132" height="17" font="7"><i>mortality</i> (n=12 studies) </text>
<text top="577" left="535" width="3" height="17" font="5"> </text>
<text top="594" left="535" width="183" height="17" font="5">RR=1.18, 95% CI 1.10-1.27, with </text>
<text top="611" left="535" width="219" height="17" font="5">significant between study heterogeneity </text>
<text top="628" left="535" width="205" height="17" font="5">(p=0.001) and with some evidence of </text>
<text top="645" left="535" width="88" height="17" font="5">publication bias </text>
<text top="663" left="535" width="3" height="17" font="5"> </text>
<text top="680" left="535" width="201" height="17" font="5">RR females=1.16, 95% CI 1.06-1.27 </text>
<text top="697" left="535" width="191" height="17" font="5">RR males=1.20, 95% CI 1.10-1.31 </text>
<text top="714" left="535" width="3" height="17" font="5"> </text>
<text top="732" left="535" width="223" height="17" font="5">RR &lt;65 years of age=1.28, 95% CI 1.00-</text>
<text top="749" left="535" width="27" height="17" font="5">1.64 </text>
<text top="438" left="786" width="59" height="17" font="5">Summary: </text>
<text top="455" left="786" width="296" height="17" font="5">never smokers exposed to SHS, compared with those </text>
<text top="472" left="786" width="323" height="17" font="5">unexposed, had a significantly increased risk of 18% for all-</text>
<text top="489" left="786" width="313" height="17" font="5">cause mortality, 23% for CVD, 23% for CHD,and 29% for </text>
<text top="507" left="786" width="350" height="17" font="5">stroke. The findings did not change after stratification by gender </text>
<text top="524" left="786" width="42" height="17" font="5">or age. </text>
</page>
<page number="287" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="325" width="150" height="17" font="5">corresponding variance (or </text>
<text top="160" left="325" width="163" height="17" font="5">information to calculate these </text>
<text top="178" left="325" width="141" height="17" font="5">measures) were reported </text>
<text top="195" left="324" width="130" height="18" font="5">•  published in English </text>
<text top="143" left="535" width="223" height="17" font="5">RR 65+ years of age=1.34, 95% CI 1.12-</text>
<text top="160" left="535" width="27" height="17" font="5">1.61 </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="3" height="17" font="7"><i> </i></text>
<text top="212" left="535" width="210" height="17" font="7"><i>Self-reported SHS exposure and CVD </i></text>
<text top="229" left="535" width="82" height="17" font="5">(n=38 studies) </text>
<text top="247" left="535" width="183" height="17" font="5">RR=1.23, 95% CI 1.16-1.31, with </text>
<text top="264" left="535" width="234" height="17" font="5">significant between study heterogeneity (p-</text>
<text top="281" left="535" width="225" height="17" font="5">0.0001). There was evidence suggesting </text>
<text top="298" left="535" width="230" height="17" font="5">publication bias; trim-and-fill method used </text>
<text top="315" left="535" width="232" height="17" font="5">to impute 12 hypothetical studies resulting </text>
<text top="333" left="535" width="168" height="17" font="5">in RR=1.16, 95% CI 1.09-1.23 </text>
<text top="350" left="535" width="3" height="17" font="5"> </text>
<text top="367" left="535" width="201" height="17" font="5">RR females=1.24, 95% CI 1.14-1.35 </text>
<text top="384" left="535" width="191" height="17" font="5">RR males=1.20, 95% CI 1.11-1.30 </text>
<text top="401" left="535" width="3" height="17" font="5"> </text>
<text top="419" left="535" width="223" height="17" font="5">RR &lt;65 years of age=1.30, 95% CI 1.18-</text>
<text top="436" left="535" width="27" height="17" font="5">1.43 </text>
<text top="453" left="535" width="223" height="17" font="5">RR 65+ years of age=1.21, 95% CI 1.01-</text>
<text top="470" left="535" width="27" height="17" font="5">1.44 </text>
<text top="487" left="535" width="3" height="17" font="5"> </text>
<text top="505" left="535" width="228" height="17" font="7"><i>Objectively measured SHS exposure and </i></text>
<text top="522" left="535" width="104" height="17" font="7"><i>CVD </i>(n=4 studies)<i> </i></text>
<text top="539" left="535" width="194" height="17" font="5">RR lowest cotinine vs. cotining &lt;15 </text>
<text top="556" left="535" width="199" height="17" font="5">ng/ml=1.41, 95% CI 1.05-1.88 (after </text>
<text top="573" left="535" width="211" height="17" font="5">exclusion of an outlier study RR=1.65, </text>
<text top="591" left="535" width="103" height="17" font="5">95% CI 1.32-2.05) </text>
<text top="608" left="535" width="3" height="17" font="5"> </text>
<text top="625" left="535" width="214" height="17" font="7"><i>Self-reported SHS exposure and CHD  </i></text>
<text top="642" left="535" width="82" height="17" font="5">(n=30 studies)<i> </i></text>
<text top="660" left="535" width="183" height="17" font="5">RR=1.23, 95% CI 1.14-1.32, with </text>
<text top="677" left="535" width="219" height="17" font="5">significant between study heterogeneity </text>
<text top="694" left="535" width="180" height="17" font="5">(p=0.0001). There was evidence </text>
<text top="711" left="535" width="219" height="17" font="5">suggesting publication bias; trim-and-fill </text>
<text top="728" left="535" width="208" height="17" font="5">method used to impute 9 hypothetical </text>
<text top="746" left="535" width="233" height="17" font="5">studies resulting in RR=1.17, 95% CI 1.08-</text>
<text top="763" left="535" width="27" height="17" font="5">1.25 </text>
</page>
<page number="288" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="3" height="17" font="5"> </text>
<text top="160" left="535" width="201" height="17" font="5">RR females=1.24, 95% CI 1.12-1.38 </text>
<text top="178" left="535" width="191" height="17" font="5">RR males=1.16, 95% CI 1.08-1.26 </text>
<text top="195" left="535" width="3" height="17" font="5"> </text>
<text top="212" left="535" width="223" height="17" font="5">RR &lt;65 years of age=1.29, 95% CI 1.15-</text>
<text top="229" left="535" width="27" height="17" font="5">1.44 </text>
<text top="247" left="535" width="223" height="17" font="5">RR 65+ years of age=1.37, 95% CI 0.99-</text>
<text top="264" left="535" width="27" height="17" font="5">1.89 </text>
<text top="281" left="535" width="3" height="17" font="5"> </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="218" height="17" font="7"><i>Self-reported SHS exposure and stroke</i> </text>
<text top="333" left="535" width="82" height="17" font="5">(n=15 studies) </text>
<text top="350" left="535" width="3" height="17" font="5"> </text>
<text top="367" left="535" width="183" height="17" font="5">RR=1.29, 95% CI 1.15-1.45, with </text>
<text top="384" left="535" width="219" height="17" font="5">significant between study heterogeneity </text>
<text top="401" left="535" width="230" height="17" font="5">(p=0.02) and no publication bias detected </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="436" left="535" width="201" height="17" font="5">RR females=1.21, 95% CI 1.08-1.37 </text>
<text top="453" left="535" width="191" height="17" font="5">RR males=1.44, 95% CI 1.14-1.82 </text>
<text top="470" left="535" width="3" height="17" font="5"> </text>
<text top="487" left="535" width="223" height="17" font="5">RR &lt;65 years of age=1.33, 95% CI 1.06-</text>
<text top="505" left="535" width="27" height="17" font="5">1.68 </text>
<text top="522" left="535" width="223" height="17" font="5">RR 65+ years of age=1.43, 95% CI 1.03-</text>
<text top="539" left="535" width="27" height="17" font="5">1.99 </text>
<text top="556" left="535" width="3" height="17" font="5"> </text>
<text top="574" left="75" width="93" height="17" font="5">Pan, et al., 2015 </text>
<text top="591" left="75" width="3" height="17" font="5"> </text>
<text top="609" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26311724">26311724</a></text>
<text top="609" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26311724"> </a></text>
<text top="574" left="193" width="102" height="17" font="5">Systematic review </text>
<text top="591" left="193" width="107" height="17" font="5">and meta-analyses </text>
<text top="609" left="193" width="80" height="17" font="5">of prospective </text>
<text top="626" left="193" width="101" height="17" font="5">studies in diabetic </text>
<text top="643" left="193" width="46" height="17" font="5">patients </text>
<text top="660" left="193" width="3" height="17" font="5"> </text>
<text top="678" left="193" width="94" height="17" font="5">89 cohorts; most </text>
<text top="695" left="193" width="115" height="17" font="5">studies conducted in </text>
<text top="712" left="193" width="108" height="17" font="5">Europe and the US </text>
<text top="729" left="193" width="3" height="17" font="5"> </text>
<text top="574" left="326" width="92" height="17" font="5">Inclusion criteria </text>
<text top="592" left="326" width="170" height="18" font="5">•  DM1 or DM2; prospective </text>
<text top="610" left="353" width="33" height="17" font="5">study </text>
<text top="627" left="326" width="177" height="18" font="5">•  Mean age NR (mean study </text>
<text top="645" left="353" width="131" height="17" font="5">range 25.4 to 79 years) </text>
<text top="662" left="326" width="175" height="18" font="5">•  Mean % female NR (mean </text>
<text top="681" left="353" width="142" height="17" font="5">study range 0% to 100%) </text>
<text top="698" left="326" width="187" height="18" font="5">•  Mean % current smokers not </text>
<text top="716" left="353" width="155" height="17" font="5">reported (mean study range </text>
<text top="733" left="353" width="88" height="17" font="5">8.0% to 59.3%) </text>
<text top="574" left="535" width="123" height="17" font="5">Cardiovascular death  </text>
<text top="591" left="535" width="198" height="17" font="5">Current smokers vs. never smokers </text>
<text top="609" left="535" width="227" height="17" font="5">RR 1.43 (95% CI 1.18 to 1.73, I2=32%, 8 </text>
<text top="626" left="535" width="46" height="17" font="5">studies) </text>
<text top="643" left="535" width="3" height="17" font="5"> </text>
<text top="660" left="535" width="231" height="17" font="5">All-cause mortality: RR 1.62 (95% CI 1.49 </text>
<text top="678" left="535" width="157" height="17" font="5">to 1.76, I2=51%, 13 studies) </text>
<text top="695" left="535" width="120" height="17" font="5">Cardiovascular death </text>
<text top="712" left="535" width="204" height="17" font="5">Former smokers vs. current smokers </text>
<text top="729" left="535" width="227" height="17" font="5">RR 0.66 (95% CI 0.48 to 0.91, I2=47%, 6 </text>
<text top="746" left="535" width="46" height="17" font="5">studies) </text>
<text top="764" left="535" width="3" height="17" font="5"> </text>
<text top="574" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="289" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="193" width="113" height="17" font="5">Total N not reported </text>
<text top="160" left="193" width="103" height="17" font="5">but N for all-cause </text>
<text top="178" left="193" width="60" height="17" font="5">mortality = </text>
<text top="195" left="193" width="58" height="17" font="5">1,132,700 </text>
<text top="212" left="193" width="3" height="17" font="5"> </text>
<text top="229" left="193" width="108" height="17" font="5">Follow-up duration: </text>
<text top="247" left="193" width="113" height="17" font="5">Overall NR (range 1 </text>
<text top="264" left="193" width="68" height="17" font="5">to 20 years) </text>
<text top="143" left="535" width="231" height="17" font="5">All-cause mortality: RR 0.65 (95% CI 0.61 </text>
<text top="160" left="535" width="157" height="17" font="5">to 0.70, I2=66%, 30 studies) </text>
<text top="178" left="535" width="3" height="17" font="5"> </text>
<text top="195" left="535" width="126" height="17" font="5">Acute coronary events </text>
<text top="212" left="535" width="198" height="17" font="5">Current smokers vs. never smokers </text>
<text top="229" left="535" width="173" height="17" font="5">Risk of coronary heart disease: </text>
<text top="247" left="535" width="3" height="17" font="5"> </text>
<text top="264" left="535" width="234" height="17" font="5">RR 1.47 (95% CI 1.29 to 1.69, I2=61%, 13 </text>
<text top="281" left="535" width="46" height="17" font="5">studies) </text>
<text top="298" left="535" width="3" height="17" font="5"> </text>
<text top="315" left="535" width="126" height="17" font="5">Acute coronary events </text>
<text top="333" left="535" width="204" height="17" font="5">Former smokers vs. current smokers </text>
<text top="350" left="535" width="173" height="17" font="5">Risk of coronary heart disease: </text>
<text top="367" left="535" width="3" height="17" font="5"> </text>
<text top="384" left="535" width="234" height="17" font="5">RR 0.65 (95% CI 0.61 to 0.71, I2=66%, 10 </text>
<text top="401" left="535" width="46" height="17" font="5">studies) </text>
<text top="419" left="535" width="3" height="17" font="5"> </text>
<text top="436" left="535" width="79" height="17" font="5">Stroke events </text>
<text top="453" left="535" width="198" height="17" font="5">Current smokers vs. never smokers </text>
<text top="470" left="535" width="227" height="17" font="5">RR 1.54 (95% CI 1.26 to 1.88, I2=40%, 9 </text>
<text top="487" left="535" width="46" height="17" font="5">studies) </text>
<text top="505" left="535" width="3" height="17" font="5"> </text>
<text top="522" left="535" width="79" height="17" font="5">Stroke events </text>
<text top="539" left="535" width="204" height="17" font="5">Former smokers vs. current smokers </text>
<text top="556" left="535" width="227" height="17" font="5">RR 1.04 (95% CI 0.87 to 1.23, I2=25%, 9 </text>
<text top="575" left="535" width="42" height="17" font="5">studies </text>
<text top="606" left="75" width="101" height="17" font="5">Mons, et al., 2015 </text>
<text top="624" left="75" width="63" height="17" font="5">CHANCES </text>
<text top="641" left="75" width="66" height="17" font="5">Consortium </text>
<text top="658" left="75" width="3" height="17" font="5"> </text>
<text top="675" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25896935">25896935</a></text>
<text top="675" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25896935"> </a></text>
<text top="606" left="193" width="97" height="17" font="5">Meta-analyses of </text>
<text top="625" left="193" width="109" height="17" font="5">prospective studies </text>
<text top="655" left="193" width="106" height="17" font="5">25 cohorts from 23 </text>
<text top="674" left="193" width="53" height="17" font="5">countries </text>
<text top="705" left="193" width="64" height="17" font="5">N=50,3905 </text>
<text top="735" left="193" width="108" height="17" font="5">Follow-up duration: </text>
<text top="754" left="193" width="102" height="17" font="5">Overall NR (range </text>
<text top="606" left="326" width="98" height="17" font="5">Inclusion Criteria: </text>
<text top="624" left="326" width="3" height="17" font="5"> </text>
<text top="641" left="326" width="157" height="18" font="5">•  Aged 60 and above; no </text>
<text top="659" left="353" width="156" height="17" font="5">history of stroke or coronary </text>
<text top="676" left="353" width="40" height="17" font="5">events </text>
<text top="693" left="326" width="132" height="18" font="5">•  Age: 60-69: 86.6% </text>
<text top="712" left="326" width="147" height="18" font="5">•  70 and above: 13.4% </text>
<text top="730" left="326" width="113" height="18" font="5">•  % female: 0.44 </text>
<text top="748" left="326" width="173" height="18" font="5">•  % never smoked: 190,688 </text>
<text top="766" left="353" width="46" height="17" font="5">(40.2%) </text>
<text top="606" left="535" width="236" height="17" font="5">Cardiovascular death: Current smokers vs. </text>
<text top="624" left="535" width="84" height="17" font="5">never smokers </text>
<text top="653" left="535" width="190" height="17" font="5">All: HR 2.07 (95% CI 1.82 to 2.36) </text>
<text top="670" left="535" width="207" height="17" font="5">Men: HR 1.95 (95% CI 1.69 to 2.25)   </text>
<text top="687" left="535" width="218" height="17" font="5">Women: HR 2.22 (95% CI 1.86 to 2.65) </text>
<text top="704" left="535" width="233" height="17" font="5">Age 60-69: HR 2.45 (95% CI 2.22 to 2.69) </text>
<text top="721" left="535" width="222" height="17" font="5">Age 70+: HR 1.70 (95% CI 1.42 to 2.04) </text>
<text top="739" left="535" width="227" height="17" font="5">Smoking &lt; 10 cigs/day: HR 1.87 (95% CI </text>
<text top="756" left="535" width="73" height="17" font="5">1.63 to 2.15) </text>
<text top="606" left="786" width="3" height="17" font="5"> </text>
</page>
<page number="290" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="193" width="95" height="17" font="5">1.6 years to 15.4 </text>
<text top="162" left="193" width="38" height="17" font="5">years) </text>
<text top="143" left="326" width="181" height="18" font="5">•  % former smokers: 255,158 </text>
<text top="161" left="353" width="46" height="17" font="5">(47.4%) </text>
<text top="179" left="326" width="184" height="18" font="5">•  % current smokers: 588,737 </text>
<text top="197" left="353" width="46" height="17" font="5">(12.4%) </text>
<text top="143" left="535" width="234" height="17" font="5">Smoking 10-19 cigs/day: HR 1.94 (95% CI </text>
<text top="160" left="535" width="73" height="17" font="5">1.65 to 2.28) </text>
<text top="178" left="535" width="224" height="17" font="5">Smoking 20+ cigs/day: HR 2.63 (95% CI </text>
<text top="195" left="535" width="73" height="17" font="5">2.28 to 3.04) </text>
<text top="224" left="535" width="235" height="17" font="5">Cardiovascular death: Former smokers vs. </text>
<text top="241" left="535" width="84" height="17" font="5">never smokers </text>
<text top="258" left="535" width="190" height="17" font="5">All: HR 1.37 (95% CI 1.25 to 1.49) </text>
<text top="276" left="535" width="200" height="17" font="5">Men: HR 1.33 (95% CI 1.20 to 1.48) </text>
<text top="293" left="535" width="218" height="17" font="5">Women: HR 1.40 (95% CI 1.25 to 1.57) </text>
<text top="310" left="535" width="233" height="17" font="5">Age 60-69: HR 1.57 (95% CI 1.43 to 1.72) </text>
<text top="327" left="535" width="222" height="17" font="5">Age 70+: HR 1.21 (95% CI 1.08 to 1.36) </text>
<text top="344" left="535" width="223" height="17" font="5">Acute coronary events: Current smokers </text>
<text top="362" left="535" width="103" height="17" font="5">vs. never smokers </text>
<text top="379" left="535" width="190" height="17" font="5">All: HR 1.18 (95% CI 1.06 to 1.32) </text>
<text top="396" left="535" width="200" height="17" font="5">Men: HR 1.18 (95% CI 1.00 to 1.38) </text>
<text top="413" left="535" width="218" height="17" font="5">Women: HR 1.24 (95% CI 1.07 to 1.41) </text>
<text top="431" left="535" width="233" height="17" font="5">Age 60-69: HR 1.25 (95% CI 1.10 to 1.43) </text>
<text top="448" left="535" width="222" height="17" font="5">Age 70+: HR 1.12 (95% CI 0.95 to 1.32) </text>
<text top="465" left="535" width="3" height="17" font="5"> </text>
<text top="482" left="535" width="222" height="17" font="5">Acute coronary events: Former smokers </text>
<text top="499" left="535" width="111" height="17" font="5">vs. current smokers </text>
<text top="517" left="535" width="231" height="17" font="5">Quit &lt; 5 years ago: HR 0.84 (95% CI 0.72 </text>
<text top="534" left="535" width="45" height="17" font="5">to 0.98) </text>
<text top="551" left="535" width="217" height="17" font="5">Quit 5 to 9 years ago: HR 0.86 (95% CI </text>
<text top="568" left="535" width="73" height="17" font="5">0.72 to 1.02) </text>
<text top="586" left="535" width="231" height="17" font="5">Quit 10 to 19 years ago: HR 0.69 (95% CI </text>
<text top="603" left="535" width="73" height="17" font="5">0.58 to 0.82) </text>
<text top="620" left="535" width="235" height="17" font="5">Quit 20+ years ago: HR 0.58 (95% CI 0.46 </text>
<text top="637" left="535" width="45" height="17" font="5">to 0.72) </text>
<text top="654" left="535" width="3" height="17" font="5"> </text>
<text top="672" left="535" width="229" height="17" font="5">Stroke events: Current smokers vs. never </text>
<text top="689" left="535" width="50" height="17" font="5">smokers </text>
<text top="706" left="535" width="190" height="17" font="5">All: HR 1.58 (95% CI 1.40 to 1.78) </text>
<text top="723" left="535" width="200" height="17" font="5">Men: HR 1.44 (95% CI 1.23 to 1.68) </text>
<text top="741" left="535" width="218" height="17" font="5">Women: HR 1.78 (95% CI 1.46 to 2.17) </text>
<text top="758" left="535" width="233" height="17" font="5">Age 60-69: HR 1.68 (95% CI 1.46 to 1.94) </text>
</page>
<page number="291" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="78" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="103" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="81" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="194" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="210" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="368" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="564" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="542" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="898" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="925" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="535" width="222" height="17" font="5">Age 70+: HR 1.49 (95% CI 1.22 to 1.82) </text>
<text top="160" left="535" width="227" height="17" font="5">Smoking &lt; 10 cigs/day: HR 1.43 (95% CI </text>
<text top="178" left="535" width="73" height="17" font="5">1.24 to 1.64) </text>
<text top="195" left="535" width="232" height="17" font="5">Smoking 10 to 19 cigs/day: HR 1.60 (95% </text>
<text top="212" left="535" width="88" height="17" font="5">CI 1.41 to 1.82) </text>
<text top="229" left="535" width="224" height="17" font="5">Smoking 20+ cigs/day: HR 1.91 (95% CI </text>
<text top="247" left="535" width="73" height="17" font="5">1.66 to 2.21) </text>
<text top="264" left="535" width="3" height="17" font="5"> </text>
<text top="281" left="535" width="228" height="17" font="5">Stroke events: Former smokers vs. never </text>
<text top="298" left="535" width="50" height="17" font="5">smokers </text>
<text top="315" left="535" width="190" height="17" font="5">All: HR 1.17 (95% CI 1.07 to 1.26) </text>
<text top="333" left="535" width="200" height="17" font="5">Men: HR 1.08 (95% CI 0.97 to 1.21) </text>
<text top="350" left="535" width="218" height="17" font="5">Women: HR 1.20 (95% CI 1.06 to 1.36) </text>
<text top="367" left="535" width="233" height="17" font="5">Age 60-69: HR 1.22 (95% CI 1.10 to 1.35) </text>
<text top="384" left="535" width="222" height="17" font="5">Age 70+: HR 1.10 (95% CI 0.95 to 1.28) </text>
<text top="401" left="535" width="3" height="17" font="5"> </text>
<text top="419" left="535" width="236" height="17" font="5">Stroke events: Former smokers vs. current </text>
<text top="436" left="535" width="50" height="17" font="5">smokers </text>
<text top="453" left="535" width="231" height="17" font="5">Quit &lt; 5 years ago: HR 0.97 (95% CI 0.79 </text>
<text top="470" left="535" width="45" height="17" font="5">to 1.19) </text>
<text top="487" left="535" width="217" height="17" font="5">Quit 5 to 9 years ago: HR 0.98 (95% CI </text>
<text top="505" left="535" width="73" height="17" font="5">0.74 to 1.31) </text>
<text top="522" left="535" width="231" height="17" font="5">Quit 10 to 19 years ago: HR 0.79 (95% CI </text>
<text top="539" left="535" width="73" height="17" font="5">0.69 to 0.92) </text>
<text top="556" left="535" width="235" height="17" font="5">Quit 20+ years ago: HR 0.67 (95% CI 0.60 </text>
<text top="573" left="535" width="45" height="17" font="5">to 0.76) </text>
<text top="595" left="66" width="4" height="14" font="5"> </text>
<text top="592" left="282" width="3" height="17" font="5"> </text>
</page>
<page number="292" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="24" size="12" family="Times" color="#000000"/>
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="90" left="66" width="396" height="21" font="4"><b>Data Supplement 17. RCTs of Aspirin Use (Section 4.6.)  </b></text>
<text top="121" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="138" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="155" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="121" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="138" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="155" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="121" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="121" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="138" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="155" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="172" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="121" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="138" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="155" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="122" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="121" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="139" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="156" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="190" left="75" width="87" height="17" font="5">Guirguis-Blake, </text>
<text top="207" left="75" width="55" height="17" font="5">2016 and </text>
<text top="224" left="75" width="84" height="17" font="5">Whitlock, 2016 </text>
<text top="242" left="75" width="52" height="17" font="5">USPSTF </text>
<text top="259" left="75" width="3" height="17" font="5"> </text>
<text top="276" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27064410">27064410</a></text>
<text top="276" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27064410"> </a></text>
<text top="190" left="186" width="134" height="17" font="3"><b>Aim: </b>Aspirin for primary </text>
<text top="207" left="186" width="74" height="17" font="5">prevention of </text>
<text top="224" left="186" width="122" height="17" font="5">cardiovascular events </text>
<text top="242" left="186" width="129" height="17" font="3"><b>Study Type:</b> 11 RCTs  </text>
<text top="259" left="186" width="64" height="17" font="5">N=118,445 </text>
<text top="276" left="186" width="124" height="17" font="5">Also included 4 cohort </text>
<text top="293" left="186" width="143" height="17" font="5">studies on major bleeding </text>
<text top="311" left="186" width="22" height="17" font="5">risk </text>
<text top="190" left="346" width="95" height="17" font="24"><i><b>Guirguis-Blake: </b></i></text>
<text top="221" left="346" width="105" height="17" font="3"><b>Inclusion criteria  </b></text>
<text top="251" left="346" width="157" height="17" font="5">randomized, controlled trials </text>
<text top="268" left="346" width="164" height="17" font="5">(RCTs) and controlled clinical </text>
<text top="286" left="346" width="33" height="17" font="5">trials  </text>
<text top="303" left="346" width="3" height="17" font="5"> </text>
<text top="320" left="346" width="182" height="17" font="5">examined the primary prevention </text>
<text top="337" left="346" width="146" height="17" font="5">of CVD with oral aspirin (a </text>
<text top="355" left="346" width="169" height="17" font="5">minimum of 75 mg every other </text>
<text top="372" left="346" width="186" height="17" font="5">day for 1 year or more) compared </text>
<text top="389" left="346" width="162" height="17" font="5">with placebo or no treatment  </text>
<text top="406" left="346" width="3" height="17" font="5"> </text>
<text top="423" left="346" width="132" height="17" font="5">adults aged 40 years or </text>
<text top="441" left="346" width="31" height="17" font="5">older </text>
<text top="471" left="346" width="106" height="17" font="3"><b>Exclusion criteria </b></text>
<text top="502" left="346" width="149" height="17" font="5">excluded interventions that </text>
<text top="520" left="346" width="109" height="17" font="5">included nonaspirin </text>
<text top="539" left="346" width="164" height="17" font="5">antithrombotic medications or </text>
<text top="557" left="346" width="149" height="17" font="5">aspirin as cotreatment with </text>
<text top="576" left="346" width="148" height="17" font="5">another active intervention </text>
<text top="607" left="346" width="59" height="17" font="24"><i><b>Whitlock: </b></i></text>
<text top="637" left="346" width="102" height="17" font="3"><b>Inclusion criteria </b></text>
<text top="668" left="346" width="187" height="17" font="5">trials and large longitudinal cohort </text>
<text top="685" left="346" width="46" height="17" font="5">studies  </text>
<text top="702" left="346" width="160" height="17" font="5">adults with a mean age of 40 </text>
<text top="719" left="346" width="82" height="17" font="5">years or older  </text>
<text top="737" left="346" width="3" height="17" font="5"> </text>
<text top="754" left="346" width="185" height="17" font="5">evaluated regular oral aspirin use </text>
<text top="771" left="346" width="185" height="17" font="5">(≥75 mg at least every other day) </text>
<text top="190" left="547" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="207" left="547" width="78" height="17" font="5">oral aspirin (a </text>
<text top="224" left="547" width="104" height="17" font="5">minimum of 75 mg </text>
<text top="242" left="547" width="116" height="17" font="5">every other day for 1 </text>
<text top="259" left="547" width="81" height="17" font="5">year or more)  </text>
<text top="276" left="547" width="3" height="17" font="5"> </text>
<text top="293" left="547" width="73" height="17" font="3"><b>Comparator </b></text>
<text top="311" left="547" width="78" height="17" font="5">placebo or no </text>
<text top="328" left="547" width="55" height="17" font="5">treatment<b> </b></text>
<text top="190" left="677" width="220" height="17" font="3"><b>Results:</b> Aspirin (any dose) vs. placebo </text>
<text top="207" left="677" width="71" height="17" font="5">or no aspirin </text>
<text top="224" left="677" width="216" height="17" font="5">Nonfatal MI: 10 trials, RR 0.78 (95% CI </text>
<text top="242" left="677" width="121" height="17" font="5">0.71 to 0.87), I2=62% </text>
<text top="259" left="677" width="220" height="17" font="5">Nonfatal stroke: 10 trials, RR 0.95 (95% </text>
<text top="276" left="677" width="137" height="17" font="5">CI 0.85 to 1.06), I2=25% </text>
<text top="293" left="677" width="213" height="17" font="5">CVD mortality: 11 trials, RR 0.94 (95% </text>
<text top="311" left="677" width="141" height="17" font="5">CI 0.86 to 1.03), I2=8.8% </text>
<text top="328" left="677" width="206" height="17" font="5">All-cause mortality: 11 trials, RR 0.94 </text>
<text top="345" left="677" width="120" height="17" font="5">(95% CI 0.89 to 0.99) </text>
<text top="362" left="677" width="3" height="17" font="5"> </text>
<text top="379" left="677" width="220" height="17" font="5">Aspirin &lt;=100 mg/day vs. placebo or no </text>
<text top="397" left="677" width="40" height="17" font="5">aspirin </text>
<text top="414" left="677" width="209" height="17" font="5">Nonfatal MI: 8 trials, RR 0.83 (95% CI </text>
<text top="431" left="677" width="121" height="17" font="5">0.74 to 0.94), I2=54% </text>
<text top="448" left="677" width="213" height="17" font="5">Nonfatal stroke: 7 trials, RR 0.86 (95% </text>
<text top="465" left="677" width="130" height="17" font="5">CI 0.76 to 0.98), I2=0% </text>
<text top="483" left="677" width="222" height="17" font="5">CVD mortality: 8 trials, RR 0.97 (95% CI </text>
<text top="500" left="677" width="121" height="17" font="5">0.85 to 1.10), I2=30% </text>
<text top="517" left="677" width="199" height="17" font="5">All-cause mortality: 8 trials, RR 0.95 </text>
<text top="534" left="677" width="162" height="17" font="5">(95% CI 0.89 to 1.01), I2=0% </text>
<text top="552" left="677" width="3" height="17" font="5"> </text>
<text top="569" left="677" width="209" height="17" font="5">Effects of duration: Benefits appear to </text>
<text top="586" left="677" width="210" height="17" font="5">begin within first 1 to 5 years; no clear </text>
<text top="603" left="677" width="60" height="17" font="5">upper limit </text>
<text top="620" left="677" width="3" height="17" font="5"> </text>
<text top="638" left="677" width="207" height="17" font="5">Formulation: No conclusions possible </text>
<text top="655" left="677" width="3" height="17" font="5"> </text>
<text top="672" left="677" width="63" height="17" font="5">Subgroups </text>
<text top="689" left="677" width="220" height="17" font="5">Age: 3 trials found greater RR reduction </text>
<text top="707" left="677" width="223" height="17" font="5">for MI with older age; no clear difference </text>
<text top="724" left="677" width="212" height="17" font="5">for stroke by age; inconsistent data for </text>
<text top="741" left="677" width="218" height="17" font="5">differences for composite CV outcomes </text>
<text top="758" left="677" width="40" height="17" font="5">by age </text>
<text top="190" left="918" width="24" height="17" font="5">N/A </text>
</page>
<page number="293" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="346" width="148" height="17" font="5">for 1 year or longer for any </text>
<text top="178" left="346" width="156" height="17" font="5">indication compared with no </text>
<text top="195" left="346" width="123" height="17" font="5">treatment or placebo.  </text>
<text top="212" left="346" width="3" height="17" font="5"> </text>
<text top="229" left="345" width="178" height="17" font="5">reported major GI or intracranial </text>
<text top="247" left="345" width="53" height="17" font="5">bleeding. </text>
<text top="160" left="677" width="210" height="17" font="5">Sex: No strong evidence for treatment </text>
<text top="178" left="677" width="179" height="17" font="5">modification for aspirin by sex or </text>
<text top="195" left="677" width="51" height="17" font="5">outcome </text>
<text top="212" left="677" width="199" height="17" font="5">Diabetes: Evidence does not clearly </text>
<text top="229" left="677" width="176" height="17" font="5">support heterogeneity of aspirin </text>
<text top="247" left="677" width="193" height="17" font="5">treatment effect based on diabetes </text>
<text top="264" left="677" width="36" height="17" font="5">status </text>
<text top="282" left="75" width="86" height="17" font="5">Lotrionte, 2016 </text>
<text top="299" left="75" width="3" height="17" font="5"> </text>
<text top="316" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26851562">26851562</a></text>
<text top="316" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26851562"> </a></text>
<text top="282" left="186" width="134" height="17" font="3"><b>Aim:</b> Aspirin for primary </text>
<text top="299" left="186" width="74" height="17" font="5">prevention of </text>
<text top="316" left="186" width="126" height="17" font="5">cardiovascular events, </text>
<text top="333" left="186" width="104" height="17" font="5">focus on dose and </text>
<text top="350" left="186" width="66" height="17" font="5">preparation </text>
<text top="368" left="186" width="129" height="17" font="3"><b>Study Type:</b> 11 RCTs  </text>
<text top="385" left="186" width="64" height="17" font="5">N=104,101 </text>
<text top="282" left="345" width="102" height="17" font="3"><b>Inclusion criteria </b></text>
<text top="312" left="346" width="159" height="17" font="5">Randomized trials in primary </text>
<text top="329" left="346" width="173" height="17" font="5">prevention as recently reported </text>
<text top="346" left="346" width="112" height="17" font="5">by the updated U.S. </text>
<text top="364" left="346" width="177" height="17" font="5">Preventive Services Task Force </text>
<text top="381" left="346" width="178" height="17" font="5">reports (not otherwise specified) </text>
<text top="398" left="346" width="3" height="17" font="5"> </text>
<text top="415" left="346" width="3" height="17" font="5"> </text>
<text top="282" left="547" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="299" left="547" width="114" height="17" font="5">Aspirin with average </text>
<text top="316" left="547" width="110" height="17" font="5">daily doses of &lt;100 </text>
<text top="333" left="547" width="96" height="17" font="5">mg, 100 mg, and </text>
<text top="350" left="547" width="55" height="17" font="5">&gt;100 mg. </text>
<text top="368" left="547" width="86" height="17" font="5">Preparations in </text>
<text top="385" left="547" width="100" height="17" font="5">coated, controlled </text>
<text top="402" left="547" width="116" height="17" font="5">release, non-coated, </text>
<text top="419" left="547" width="70" height="17" font="5">or otherwise </text>
<text top="437" left="547" width="66" height="17" font="5">unspecified </text>
<text top="454" left="547" width="3" height="17" font="3"><b> </b></text>
<text top="471" left="547" width="73" height="17" font="3"><b>Comparator </b></text>
<text top="488" left="547" width="46" height="17" font="5">placebo<b> </b></text>
<text top="282" left="677" width="215" height="17" font="3"><b>Results</b>: Aspirin vs. placebo, OR (95% </text>
<text top="299" left="677" width="20" height="17" font="5">CI) </text>
<text top="316" left="677" width="104" height="17" font="5">All-cause mortality </text>
<text top="333" left="677" width="182" height="17" font="5">&lt;100 mg/day: 0.95 (0.87 to 1.03) </text>
<text top="350" left="677" width="175" height="17" font="5">100 mg/day: 0.92 (0.80 to 1.05) </text>
<text top="368" left="677" width="169" height="17" font="5">&gt;100 mg/day: 0.93 (0.84-1.02) </text>
<text top="385" left="677" width="138" height="17" font="5">Coated: 0.91 (0.77-1.07) </text>
<text top="402" left="677" width="198" height="17" font="5">Controlled release: 1.03 (0.80-1.32) </text>
<text top="419" left="677" width="161" height="17" font="5">Non-coated: 0.94 (0.87-1.02) </text>
<text top="437" left="677" width="226" height="17" font="5">Unspecified formulation: 0.93 (0.84-1.03) </text>
<text top="454" left="677" width="204" height="17" font="5">Major adverse cardiovascular events </text>
<text top="471" left="677" width="169" height="17" font="5">&lt;100 mg/day: 0.86 (0.76-0.97) </text>
<text top="488" left="677" width="162" height="17" font="5">100 mg/day: 1.02 (0.85-1.24) </text>
<text top="505" left="677" width="169" height="17" font="5">&gt;100 mg/day: 0.80 (0.72-0.89) </text>
<text top="523" left="677" width="138" height="17" font="5">Coated: 0.96 (0.75-1.25) </text>
<text top="540" left="677" width="198" height="17" font="5">Controlled release: 0.78 (0.59-1.03) </text>
<text top="557" left="677" width="161" height="17" font="5">Non-coated: 0.94 (0.84-1.05) </text>
<text top="574" left="677" width="226" height="17" font="5">Unspecified formulation: 0.75 (0.66-0.85) </text>
<text top="282" left="918" width="24" height="17" font="5">N/A </text>
<text top="592" left="75" width="87" height="17" font="5">Raju, 2016 and </text>
<text top="609" left="75" width="31" height="17" font="5">2011 </text>
<text top="627" left="75" width="3" height="17" font="5"> </text>
<text top="644" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27126466">27126466</a></text>
<text top="644" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27126466"> </a></text>
<text top="592" left="186" width="112" height="17" font="3"><b>Aim:</b> Updated Meta-</text>
<text top="609" left="186" width="117" height="17" font="5">Analysis of Aspirin in </text>
<text top="627" left="186" width="121" height="17" font="5">Primary Prevention of </text>
<text top="644" left="186" width="133" height="17" font="5">Cardiovascular Disease </text>
<text top="661" left="186" width="93" height="17" font="5">(random effects) </text>
<text top="592" left="346" width="102" height="17" font="3"><b>Inclusion criteria </b></text>
<text top="609" left="346" width="148" height="17" font="5">randomized controlled trial </text>
<text top="627" left="346" width="178" height="17" font="5">included adults without a history </text>
<text top="644" left="346" width="169" height="17" font="5">of symptomatic cardiovascular </text>
<text top="661" left="346" width="146" height="17" font="5">disease (&gt;95% of enrolled </text>
<text top="678" left="346" width="66" height="17" font="5">participants </text>
<text top="696" left="346" width="3" height="17" font="5"> </text>
<text top="713" left="346" width="185" height="17" font="5">compared aspirin (any dose) with </text>
<text top="730" left="346" width="173" height="17" font="5">placebo or no aspirin treatment </text>
<text top="747" left="346" width="113" height="17" font="5">for the prevention of </text>
<text top="764" left="346" width="129" height="17" font="5">cardiovascular disease </text>
<text top="592" left="547" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="609" left="547" width="41" height="17" font="5">Aspirin </text>
<text top="627" left="547" width="3" height="17" font="5"> </text>
<text top="644" left="547" width="73" height="17" font="3"><b>Comparator </b></text>
<text top="661" left="547" width="87" height="17" font="5">Placebo or non-</text>
<text top="678" left="547" width="40" height="17" font="5">aspirin<b> </b></text>
<text top="592" left="677" width="190" height="17" font="3"><b>Results:</b> Aspirin vs. placebo or no </text>
<text top="609" left="677" width="40" height="17" font="5">aspirin </text>
<text top="627" left="677" width="204" height="17" font="5">All-cause mortality (9 trials): RR 0.94 </text>
<text top="644" left="677" width="120" height="17" font="5">(95% CI 0.89 to 1.00) </text>
<text top="661" left="677" width="218" height="17" font="5">CV mortality (9 trials): RR 0.95 (95% CI </text>
<text top="678" left="677" width="73" height="17" font="5">0.84 to 1.07) </text>
<text top="696" left="677" width="226" height="17" font="5">Major CV events (8 trials): RR 0.89 (95% </text>
<text top="713" left="677" width="88" height="17" font="5">CI 0.82 to 0.97) </text>
<text top="730" left="677" width="206" height="17" font="5">MI (9 trials): RR 0.78 (95% CI 0.65 to </text>
<text top="747" left="677" width="31" height="17" font="5">0.94) </text>
<text top="592" left="918" width="24" height="17" font="5">N/A </text>
</page>
<page number="294" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="346" width="3" height="17" font="5"> </text>
<text top="178" left="346" width="150" height="17" font="5">reported at least one of the </text>
<text top="195" left="346" width="164" height="17" font="5">following outcomes: all-cause </text>
<text top="212" left="346" width="136" height="17" font="5">mortality, cardiovascular </text>
<text top="229" left="346" width="173" height="17" font="5">mortality, myocardial infarction, </text>
<text top="247" left="346" width="121" height="17" font="5">stroke, and bleeding.  </text>
<text top="264" left="346" width="3" height="17" font="5"> </text>
<text top="281" left="346" width="106" height="17" font="3"><b>Exclusion criteria </b></text>
<text top="298" left="346" width="157" height="17" font="5">Studies in which aspirin was </text>
<text top="315" left="346" width="135" height="17" font="5">combined with a second </text>
<text top="333" left="346" width="157" height="17" font="5">antithrombotic agent  unless </text>
<text top="350" left="346" width="183" height="17" font="5">there were separate placebo and </text>
<text top="367" left="346" width="179" height="17" font="5">aspirin-only treatment groups, in </text>
<text top="384" left="346" width="166" height="17" font="5">which case only the data from </text>
<text top="401" left="346" width="154" height="17" font="5">these groups were included </text>
<text top="419" left="344" width="21" height="18" font="5">•   </text>
<text top="160" left="677" width="215" height="17" font="5">Stroke (9 trials): RR 0.94 (95% CI 0.84-</text>
<text top="178" left="677" width="31" height="17" font="5">1.06) </text>
<text top="438" left="75" width="76" height="17" font="7"><i>Prevention of </i></text>
<text top="455" left="75" width="83" height="17" font="7"><i>Progression of </i></text>
<text top="472" left="75" width="66" height="17" font="7"><i>Arterial and </i></text>
<text top="489" left="75" width="82" height="17" font="7"><i>Diabetes trial   </i></text>
<text top="507" left="75" width="68" height="17" font="5">Belch, 2008 </text>
<text top="524" left="75" width="3" height="17" font="5"> </text>
<text top="541" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18927173">18927173</a></text>
<text top="541" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18927173"> </a></text>
<text top="438" left="186" width="133" height="17" font="3"><b>Study Type:</b> 2 x 2 RCT </text>
<text top="455" left="186" width="77" height="17" font="5">(antioxidants) </text>
<text top="472" left="186" width="50" height="17" font="5">N=1,276 </text>
<text top="489" left="186" width="70" height="17" font="5">Country: UK </text>
<text top="438" left="344" width="176" height="18" font="5">•  <b>Inclusion Criteria:</b> Men and </text>
<text top="456" left="345" width="186" height="17" font="5">women &gt;=40 years of age, type 1 </text>
<text top="473" left="345" width="125" height="17" font="5">or type 2 diabetes and </text>
<text top="490" left="345" width="187" height="17" font="5">asymptomatic peripheral vascular </text>
<text top="507" left="345" width="162" height="17" font="5">disease (ankle brachial index </text>
<text top="525" left="345" width="46" height="17" font="5">&lt;=0.99) </text>
<text top="438" left="547" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="455" left="547" width="116" height="17" font="5">daily aspirin 100 mg, </text>
<text top="472" left="547" width="103" height="17" font="5">plus antioxidant or </text>
<text top="489" left="547" width="92" height="17" font="5">placebo capsule </text>
<text top="507" left="547" width="94" height="17" font="5">(factorial design) </text>
<text top="524" left="547" width="3" height="17" font="3"><b> </b></text>
<text top="541" left="547" width="73" height="17" font="3"><b>Comparator </b></text>
<text top="558" left="547" width="79" height="17" font="3"><b>Placebo plus </b></text>
<text top="575" left="547" width="77" height="17" font="5">antioxidant or </text>
<text top="593" left="547" width="92" height="17" font="5">placebo capsule<b> </b></text>
<text top="439" left="677" width="7" height="17" font="3"><b>1</b></text>
<text top="438" left="684" width="195" height="18" font="5"><b> endpoint:</b> CV death, nonfatal MI, </text>
<text top="456" left="677" width="172" height="17" font="5">nonfatal stroke, or above ankle </text>
<text top="473" left="677" width="198" height="17" font="5">amputation for critical limb ischemia </text>
<text top="490" left="677" width="3" height="17" font="5"> </text>
<text top="508" left="677" width="185" height="17" font="5">CV Death: Aspirin: 6.7% (43/638) </text>
<text top="525" left="677" width="132" height="17" font="5">Placebo: 5.5% (35/638) </text>
<text top="542" left="677" width="172" height="17" font="5">HR: 1.23 (95% CI 0.79 to 1.93) </text>
<text top="559" left="677" width="3" height="17" font="5"> </text>
<text top="577" left="677" width="202" height="17" font="5">Nonfatal MI: Aspirin: 14.1% (90/638) </text>
<text top="594" left="677" width="139" height="17" font="5">Placebo: 12.9% (82/638) </text>
<text top="611" left="677" width="172" height="17" font="5">RR: 1.10 (95% CI 0.83 to 1.45) </text>
<text top="628" left="677" width="3" height="17" font="5"> </text>
<text top="645" left="677" width="217" height="17" font="5">Nonfatal Stroke: Aspirin: 5.8% (37/638) </text>
<text top="663" left="677" width="132" height="17" font="5">Placebo: 7.8% (50/638) </text>
<text top="680" left="677" width="172" height="17" font="5">RR: 0.74 (95% CI 0.49 to 1.12) </text>
<text top="438" left="918" width="24" height="17" font="5">N/A </text>
<text top="698" left="75" width="59" height="17" font="7"><i>Aspirin for </i></text>
<text top="716" left="75" width="80" height="17" font="7"><i>Asymptomatic </i></text>
<text top="735" left="75" width="87" height="17" font="7"><i>Atherosclerosis </i></text>
<text top="754" left="75" width="23" height="17" font="7"><i>trial </i></text>
<text top="698" left="186" width="102" height="17" font="3"><b>Study Type:</b> RCT </text>
<text top="728" left="186" width="117" height="17" font="5">N=3,350 Country:UK </text>
<text top="698" left="344" width="176" height="18" font="5">•  <b>Inclusion Criteria:</b> Men and </text>
<text top="716" left="345" width="187" height="17" font="5">women 50 to 75 years of age with </text>
<text top="733" left="345" width="187" height="17" font="5">asymptomatic peripheral vascular </text>
<text top="750" left="345" width="162" height="17" font="5">disease (ankle brachial index </text>
<text top="768" left="345" width="42" height="17" font="5">&lt;=0.95 </text>
<text top="698" left="547" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="715" left="547" width="106" height="17" font="5">Once daily 100 mg </text>
<text top="732" left="547" width="84" height="17" font="5">aspirin (enteric </text>
<text top="749" left="547" width="44" height="17" font="5">coated) </text>
<text top="767" left="547" width="3" height="17" font="3"><b> </b></text>
<text top="699" left="677" width="7" height="17" font="3"><b>1</b></text>
<text top="698" left="684" width="195" height="18" font="5"><b> endpoint:</b> CV death, nonfatal MI, </text>
<text top="716" left="677" width="198" height="17" font="5">nonfatal stroke, or revascularization </text>
<text top="733" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="751" left="677" width="196" height="17" font="5">CV Death: Aspirin: 2.1% (35/1,675) </text>
<text top="768" left="677" width="142" height="17" font="5">Placebo: 1.8% (30/1,675) </text>
<text top="698" left="918" width="24" height="17" font="5">N/A </text>
</page>
<page number="295" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="75" width="80" height="17" font="5">Fowkes, 2010 </text>
<text top="178" left="75" width="3" height="17" font="5"> </text>
<text top="195" left="75" width="55" height="17" font="6"><a href="file:///C:/Users/Amalia.gomez-rexrode/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.Outlook/F9LOIJIF/20197530">20197530</a></text>
<text top="195" left="129" width="3" height="17" font="5"><a href="file:///C:/Users/Amalia.gomez-rexrode/AppData/Local/Microsoft/Windows/Temporary%20Internet%20Files/Content.Outlook/F9LOIJIF/20197530"> </a></text>
<text top="160" left="547" width="73" height="17" font="3"><b>Comparator </b></text>
<text top="178" left="547" width="46" height="17" font="5">placebo<b> </b></text>
<text top="160" left="677" width="172" height="17" font="5">RR: 1.17 (95% CI 0.72 to 1.89) </text>
<text top="178" left="677" width="3" height="17" font="5"> </text>
<text top="195" left="677" width="205" height="17" font="5">Nonfatal MI: Aspirin: 5.4% (90/1,675) </text>
<text top="212" left="677" width="142" height="17" font="5">Placebo: 5.1% (86/1,675) </text>
<text top="229" left="677" width="172" height="17" font="5">RR: 1.05 (95% CI 0.78 to 1.40) </text>
<text top="247" left="677" width="3" height="17" font="5"> </text>
<text top="264" left="677" width="222" height="17" font="5">Nonfatal stroke: Aspirin: 2.6% (44/1675) </text>
<text top="281" left="677" width="139" height="17" font="5">Placebo: 3.0% (50/1675) </text>
<text top="298" left="677" width="172" height="17" font="5">RR: 0.88 (95% CI 0.59 to 1.31) </text>
<text top="315" left="677" width="3" height="17" font="5"> </text>
<text top="333" left="677" width="3" height="17" font="5"> </text>
<text top="350" left="75" width="57" height="17" font="7"><i>Japanese </i></text>
<text top="368" left="75" width="46" height="17" font="7"><i>Primary </i></text>
<text top="385" left="75" width="62" height="17" font="7"><i>Prevention </i></text>
<text top="402" left="75" width="42" height="17" font="7"><i>Project </i></text>
<text top="419" left="75" width="68" height="17" font="5">Ikeda, 2014 </text>
<text top="437" left="75" width="3" height="17" font="5"> </text>
<text top="454" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25401325">25401325</a></text>
<text top="454" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25401325"> </a></text>
<text top="351" left="186" width="102" height="17" font="3"><b>Study Type:</b> RCT </text>
<text top="381" left="186" width="57" height="17" font="5">N=14,464 </text>
<text top="412" left="186" width="83" height="17" font="5">Country:Japan </text>
<text top="351" left="344" width="176" height="18" font="5">•  <b>Inclusion Criteria:</b> Men and </text>
<text top="369" left="345" width="187" height="17" font="5">women 60 to 85 years of age with </text>
<text top="386" left="345" width="166" height="17" font="5">hypertension, dyslipidemia, or </text>
<text top="403" left="345" width="95" height="17" font="5">diabetes mellitus </text>
<text top="350" left="547" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="368" left="547" width="92" height="17" font="5">100-mg tablet of </text>
<text top="385" left="547" width="81" height="17" font="5">enteric-coated </text>
<text top="402" left="547" width="98" height="17" font="5">aspirin once daily </text>
<text top="419" left="547" width="3" height="17" font="5"> </text>
<text top="437" left="547" width="73" height="17" font="3"><b>Comparator </b></text>
<text top="454" left="547" width="83" height="17" font="5">No aspirin (not </text>
<text top="471" left="547" width="57" height="17" font="5">placebo – </text>
<text top="488" left="547" width="117" height="17" font="5">participants were not </text>
<text top="505" left="547" width="47" height="17" font="5">blinded)<b> </b></text>
<text top="352" left="677" width="7" height="17" font="3"><b>1</b></text>
<text top="351" left="684" width="209" height="18" font="5"><b> endpoint:</b> CV death, nonfatal MI, or </text>
<text top="369" left="677" width="84" height="17" font="5">nonfatal stroke </text>
<text top="386" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="403" left="677" width="196" height="17" font="5">CV Death: Aspirin: 0.8% (58/7,220) </text>
<text top="420" left="677" width="153" height="17" font="5">No aspirin: 0.8% (57/7,244) </text>
<text top="438" left="677" width="168" height="17" font="5">HR: 1.03 (95% CI 0.71 to 1.48 </text>
<text top="455" left="677" width="3" height="17" font="5"> </text>
<text top="472" left="677" width="205" height="17" font="5">Nonfatal MI: Aspirin: 0.4% (27/7,220) </text>
<text top="489" left="677" width="153" height="17" font="5">No aspirin: 0.6% (47/7,244) </text>
<text top="507" left="677" width="172" height="17" font="5">RR: 0.58 (95% CI 0.36 to 0.92) </text>
<text top="524" left="677" width="3" height="17" font="5"> </text>
<text top="541" left="677" width="202" height="17" font="5">Fatal Stroke: Aspirin: 0.1% (7/7,220) </text>
<text top="558" left="677" width="153" height="17" font="5">No aspirin: 0.2% (12/7,244) </text>
<text top="575" left="677" width="172" height="17" font="5">RR: 0.59 (95% CI 0.23 to 1.49) </text>
<text top="350" left="918" width="24" height="17" font="5">N/A </text>
<text top="593" left="75" width="57" height="17" font="5">Japanese </text>
<text top="611" left="75" width="46" height="17" font="5">Primary </text>
<text top="628" left="75" width="76" height="17" font="5">Prevention of </text>
<text top="645" left="75" width="87" height="17" font="5">Atherosclerosis </text>
<text top="662" left="75" width="87" height="17" font="5">With Aspirin for </text>
<text top="679" left="75" width="52" height="17" font="5">Diabetes </text>
<text top="697" left="75" width="3" height="17" font="5"> </text>
<text top="714" left="75" width="77" height="17" font="5">Ogawa, 2008 </text>
<text top="731" left="75" width="3" height="17" font="5"> </text>
<text top="748" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18997198">18997198</a></text>
<text top="748" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18997198"> </a></text>
<text top="593" left="186" width="29" height="17" font="5">RCT </text>
<text top="611" left="186" width="3" height="17" font="3"><b> </b></text>
<text top="628" left="186" width="50" height="17" font="5">N=2,539 </text>
<text top="645" left="186" width="3" height="17" font="5"> </text>
<text top="662" left="186" width="3" height="17" font="5"> </text>
<text top="593" left="345" width="108" height="17" font="3"><b>Inclusion Criteria: </b></text>
<text top="612" left="344" width="159" height="18" font="5">•  Men and women 30 to 85 </text>
<text top="630" left="345" width="183" height="17" font="5">years of age with type 2 diabetes </text>
<text top="647" left="345" width="45" height="17" font="5">mellitus </text>
<text top="593" left="547" width="83" height="17" font="5">Aspirin dose &amp; </text>
<text top="611" left="547" width="68" height="17" font="5">formulation: </text>
<text top="628" left="547" width="106" height="17" font="5">81 or 100 mg once </text>
<text top="647" left="547" width="93" height="17" font="5">daily, not enteric </text>
<text top="665" left="547" width="40" height="17" font="5">coated </text>
<text top="696" left="547" width="91" height="17" font="5">Comparator: No </text>
<text top="713" left="547" width="40" height="17" font="5">aspirin<b> </b></text>
<text top="593" left="677" width="110" height="17" font="3"><b>Primary Endpoint: </b></text>
<text top="611" left="677" width="200" height="17" font="5">Sudden death; death from coronary, </text>
<text top="628" left="677" width="197" height="17" font="5">cerebrovascular, and aortic causes; </text>
<text top="645" left="677" width="187" height="17" font="5">nonfatal MI; unstable angina; new </text>
<text top="662" left="677" width="214" height="17" font="5">exertional angina; nonfatal stroke; TIA; </text>
<text top="679" left="677" width="226" height="17" font="5">or nonfatal aortic and peripheral vascular </text>
<text top="697" left="677" width="46" height="17" font="5">disease </text>
<text top="714" left="677" width="3" height="17" font="5"> </text>
<text top="731" left="677" width="99" height="17" font="5">Major CV Events: </text>
<text top="748" left="677" width="200" height="17" font="5">Sudden death; death from coronary, </text>
<text top="766" left="677" width="197" height="17" font="5">cerebrovascular, and aortic causes; </text>
<text top="593" left="918" width="100" height="17" font="3"><b>Adverse Events: </b></text>
<text top="611" left="918" width="3" height="17" font="5"> </text>
<text top="628" left="918" width="92" height="17" font="5">Any GI Bleeding </text>
<text top="645" left="918" width="135" height="17" font="5">Aspirin: 1.0% (12/1,262) </text>
<text top="662" left="918" width="146" height="17" font="5">No aspirin: 0.3% (4/1,277) </text>
<text top="679" left="918" width="172" height="17" font="5">RR: 3.04 (95% CI 0.98 to 9.39) </text>
<text top="697" left="918" width="3" height="17" font="5"> </text>
<text top="714" left="918" width="113" height="17" font="5">Serious GI Bleeding </text>
<text top="731" left="918" width="129" height="17" font="5">Aspirin: 0.3% (4/1,262) </text>
<text top="748" left="918" width="136" height="17" font="5">No aspirin: 0% (0/1,277) </text>
<text top="766" left="918" width="169" height="17" font="5">RR: 9.11 (95% CI 0.49 to 169) </text>
</page>
<page number="296" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="187" height="17" font="5">nonfatal MI; unstable angina; new </text>
<text top="178" left="677" width="214" height="17" font="5">exertional angina; nonfatal stroke; TIA; </text>
<text top="195" left="677" width="226" height="17" font="5">or nonfatal aortic and peripheral vascular </text>
<text top="212" left="677" width="46" height="17" font="5">disease </text>
<text top="229" left="677" width="135" height="17" font="5">Aspirin: 5.4% (68/1,262) </text>
<text top="247" left="677" width="153" height="17" font="5">No aspirin: 6.7% (86/1,277) </text>
<text top="264" left="677" width="172" height="17" font="5">HR: 0.80 (95% CI 0.58 to 1.10) </text>
<text top="281" left="677" width="3" height="17" font="5"> </text>
<text top="298" left="677" width="60" height="17" font="5">CV Death: </text>
<text top="315" left="677" width="135" height="17" font="5">Aspirin: 0.08% (1/1,262) </text>
<text top="333" left="677" width="153" height="17" font="5">No aspirin: 0.8% (10/1,277) </text>
<text top="350" left="677" width="172" height="17" font="5">HR: 0.10 (95% CI 0.01 to 0.79) </text>
<text top="367" left="677" width="3" height="17" font="5"> </text>
<text top="384" left="677" width="39" height="17" font="5">Stroke </text>
<text top="401" left="677" width="135" height="17" font="5">Aspirin: 2.2% (28/1,262) </text>
<text top="419" left="677" width="153" height="17" font="5">No aspirin: 2.5% (32/1,277) </text>
<text top="436" left="677" width="172" height="17" font="5">HR: 0.84 (95% CI 0.53 to 1.32) </text>
<text top="453" left="677" width="3" height="17" font="5"> </text>
<text top="470" left="677" width="134" height="17" font="3"><b>Secondary Endpoints: </b></text>
<text top="487" left="677" width="3" height="17" font="5"> </text>
<text top="505" left="677" width="63" height="17" font="5">Adherence </text>
<text top="522" left="677" width="228" height="17" font="5">By end of study 10% in aspirin group had </text>
<text top="539" left="677" width="212" height="17" font="5">stopped aspirin and 0.5% in no aspirin </text>
<text top="556" left="677" width="132" height="17" font="5">group had taken aspirin </text>
<text top="573" left="677" width="3" height="17" font="5"> </text>
<text top="591" left="677" width="107" height="17" font="5">All-Cause Mortality </text>
<text top="608" left="677" width="135" height="17" font="5">Aspirin: 2.7% (34/1,262) </text>
<text top="625" left="677" width="153" height="17" font="5">No aspirin: 3.0% (38/1,277) </text>
<text top="642" left="677" width="172" height="17" font="5">HR: 0.90 (95% CI 0.57 to 1.14) </text>
<text top="660" left="677" width="3" height="17" font="5"> </text>
<text top="677" left="677" width="114" height="17" font="5">Fatal or non-fatal MI </text>
<text top="694" left="677" width="135" height="17" font="5">Aspirin: 1.0% (12/1,262) </text>
<text top="711" left="677" width="146" height="17" font="5">No aspirin: 0.7% (9/1,277) </text>
<text top="728" left="677" width="172" height="17" font="5">RR: 1.35 (95% CI 0.57 to 3.19) </text>
<text top="746" left="677" width="3" height="17" font="5"> </text>
<text top="763" left="677" width="48" height="17" font="5">Fatal MI </text>
</page>
<page number="297" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="118" height="17" font="5">Aspirin: 0% (0/1,262) </text>
<text top="178" left="677" width="146" height="17" font="5">No aspirin: 0.4% (5/1,277) </text>
<text top="195" left="677" width="179" height="17" font="5">RR: 0.09 (95% CI 0.005 to 1.66) </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="70" height="17" font="5">Fatal Stroke </text>
<text top="247" left="677" width="135" height="17" font="5">Aspirin: 0.08% (1/1,262) </text>
<text top="264" left="677" width="146" height="17" font="5">No aspirin: 0.4% (5/1,277) </text>
<text top="281" left="677" width="179" height="17" font="5">HR: 0.20 (95% CI 0.024 to 1.74) </text>
<text top="298" left="677" width="3" height="17" font="5"> </text>
<text top="315" left="677" width="113" height="17" font="5">Hemorrhagic Stroke </text>
<text top="333" left="677" width="129" height="17" font="5">Aspirin: 0.5% (6/1,262) </text>
<text top="350" left="677" width="146" height="17" font="5">No aspirin: 0.5% (7/1,277) </text>
<text top="367" left="677" width="172" height="17" font="5">RR: 0.87 (95% CI 0.29 to 2.57) </text>
<text top="384" left="677" width="3" height="17" font="5"> </text>
<text top="401" left="677" width="91" height="17" font="5">Ischemic Stroke </text>
<text top="419" left="677" width="135" height="17" font="5">Aspirin: 1.7% (22/1,262) </text>
<text top="436" left="677" width="153" height="17" font="5">No aspirin: 2.0% (25/1,277) </text>
<text top="453" left="677" width="172" height="17" font="5">RR: 0.89 (95% CI 0.50 to 1.57) </text>
<text top="471" left="75" width="54" height="17" font="5">Aspirin in </text>
<text top="488" left="75" width="96" height="17" font="5">Reducing Events </text>
<text top="505" left="75" width="74" height="17" font="5">in the Elderly </text>
<text top="523" left="75" width="65" height="17" font="5">(ASPREE)  </text>
<text top="540" left="75" width="3" height="17" font="5"> </text>
<text top="557" left="75" width="72" height="17" font="5">McNeil 2018 </text>
<text top="574" left="75" width="3" height="17" font="5"> </text>
<text top="591" left="75" width="55" height="17" font="6"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30221597">30221597</a></text>
<text top="591" left="129" width="3" height="17" font="5"><a href="https://www.ncbi.nlm.nih.gov/pubmed/30221597"> </a></text>
<text top="471" left="186" width="64" height="17" font="3"><b>Study Aim </b></text>
<text top="488" left="186" width="124" height="17" font="5">effect of aspirin on the </text>
<text top="505" left="186" width="130" height="17" font="5">prespecified secondary </text>
<text top="523" left="186" width="74" height="17" font="5">end points of </text>
<text top="540" left="186" width="128" height="17" font="5">cardiovascular disease </text>
<text top="557" left="186" width="128" height="17" font="5">and major hemorrhage </text>
<text top="574" left="186" width="3" height="17" font="3"><b> </b></text>
<text top="591" left="186" width="70" height="17" font="3"><b>Study Type </b></text>
<text top="609" left="186" width="29" height="17" font="5">RCT </text>
<text top="626" left="186" width="3" height="17" font="5"> </text>
<text top="643" left="186" width="57" height="17" font="3"><b>N=19,114</b> </text>
<text top="471" left="345" width="102" height="17" font="3"><b>Inclusion criteria </b></text>
<text top="502" left="346" width="111" height="17" font="5">community-dwelling </text>
<text top="519" left="346" width="3" height="17" font="5"> </text>
<text top="536" left="346" width="176" height="17" font="5">adults living in Australia and the </text>
<text top="553" left="346" width="81" height="17" font="5">United States  </text>
<text top="570" left="346" width="3" height="17" font="5"> </text>
<text top="588" left="346" width="177" height="17" font="5">70 years of age or older (or ≥65 </text>
<text top="605" left="346" width="174" height="17" font="5">years of age among blacks and </text>
<text top="622" left="346" width="179" height="17" font="5">Hispanics in the United States).  </text>
<text top="639" left="346" width="3" height="17" font="5"> </text>
<text top="656" left="346" width="170" height="17" font="5">Free from overt coronary heart </text>
<text top="674" left="346" width="171" height="17" font="5">disease, overt cerebrovascular </text>
<text top="691" left="346" width="148" height="17" font="5">disease, atrial fibrillation, a </text>
<text top="708" left="346" width="167" height="17" font="5">clinical diagnosis of dementia, </text>
<text top="725" left="346" width="155" height="17" font="5">clinically significant physical </text>
<text top="743" left="346" width="180" height="17" font="5">disability, a high risk of bleeding, </text>
<text top="760" left="346" width="120" height="17" font="5">anemia, and a known </text>
<text top="471" left="547" width="74" height="17" font="3"><b>Intervention </b></text>
<text top="488" left="547" width="99" height="17" font="5">100 mg of enteric-</text>
<text top="505" left="547" width="80" height="17" font="5">coated aspirin </text>
<text top="523" left="547" width="53" height="17" font="5">(n=9525) </text>
<text top="540" left="547" width="3" height="17" font="5"> </text>
<text top="557" left="547" width="73" height="17" font="3"><b>Comparator </b></text>
<text top="574" left="547" width="101" height="17" font="5">Placebo (n=9589)<b> </b></text>
<text top="471" left="677" width="219" height="17" font="3"><b>Primary Endpoint: </b>reported separately<b> </b></text>
<text top="488" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="505" left="677" width="137" height="17" font="3"><b>Secondary Endpoints:  </b></text>
<text top="523" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="540" left="677" width="185" height="17" font="5">Composite of fatal coronary heart </text>
<text top="557" left="677" width="213" height="17" font="5">disease (myocardial infarction, sudden </text>
<text top="574" left="677" width="197" height="17" font="5">cardiac death, or any other death in </text>
<text top="591" left="677" width="177" height="17" font="5">which the underlying cause was </text>
<text top="609" left="677" width="177" height="17" font="5">considered to be coronary heart </text>
<text top="626" left="677" width="220" height="17" font="5">disease), nonfatal myocardial infarction, </text>
<text top="643" left="677" width="224" height="17" font="5">fatal or nonfatal stroke, or hospitalization </text>
<text top="660" left="677" width="90" height="17" font="5">for heart failure. </text>
<text top="678" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="695" left="677" width="184" height="17" font="5">Nonprespecified end point: major </text>
<text top="712" left="677" width="205" height="17" font="5">adverse cardiovascular events was a </text>
<text top="729" left="677" width="182" height="17" font="5">composite of fatal coronary heart </text>
<text top="746" left="677" width="199" height="17" font="5">disease (excluding death from heart </text>
<text top="471" left="918" width="81" height="17" font="3"><b>Conclusions</b>  </text>
<text top="488" left="918" width="180" height="17" font="5">The use of low-dose aspirin as a </text>
<text top="505" left="918" width="196" height="17" font="5">primary prevention strategy in older </text>
<text top="523" left="918" width="211" height="17" font="5">adults resulted in a significantly higher </text>
<text top="540" left="918" width="204" height="17" font="5">risk of major hemorrhage and did not </text>
<text top="557" left="918" width="193" height="17" font="5">result in a significantly lower risk of </text>
<text top="574" left="918" width="202" height="17" font="5">cardiovascular disease than placebo </text>
</page>
<page number="298" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="346" width="175" height="17" font="5">contraindication to or inability to </text>
<text top="178" left="346" width="73" height="17" font="5">take aspirin.  </text>
<text top="195" left="345" width="3" height="17" font="5"> </text>
<text top="213" left="345" width="3" height="17" font="3"><b> </b></text>
<text top="232" left="345" width="106" height="17" font="3"><b>Exclusion criteria </b></text>
<text top="263" left="346" width="140" height="17" font="5">Current regular use of an </text>
<text top="280" left="346" width="154" height="17" font="5">anticoagulant or antiplatelet </text>
<text top="297" left="346" width="161" height="17" font="5">medication other than aspirin </text>
<text top="314" left="346" width="3" height="17" font="5"> </text>
<text top="331" left="346" width="166" height="17" font="5">systolic blood pressure of 180 </text>
<text top="349" left="346" width="161" height="17" font="5">mm Hg or more or a diastolic </text>
<text top="366" left="346" width="180" height="17" font="5">blood pressure of 105 mm Hg or </text>
<text top="383" left="346" width="31" height="17" font="5">more </text>
<text top="400" left="346" width="3" height="17" font="5"> </text>
<text top="418" left="346" width="133" height="17" font="5">medical indication for or </text>
<text top="435" left="346" width="184" height="17" font="5">contraindication to regular aspirin </text>
<text top="452" left="346" width="44" height="17" font="5">therapy </text>
<text top="469" left="346" width="3" height="17" font="5"> </text>
<text top="486" left="344" width="188" height="18" font="5">•  presence of a condition that, in </text>
<text top="505" left="345" width="169" height="17" font="5">the opinion of the primary care </text>
<text top="522" left="345" width="171" height="17" font="5">physician was likely to result in </text>
<text top="539" left="345" width="113" height="17" font="5">death within 5 years </text>
<text top="160" left="677" width="225" height="17" font="5">failure), nonfatal myocardial infarction, or </text>
<text top="178" left="677" width="176" height="17" font="5">fatal or nonfatal ischemic stroke </text>
<text top="195" left="677" width="3" height="17" font="5"> </text>
<text top="212" left="677" width="166" height="17" font="5">Composite major hemorrhage </text>
<text top="229" left="677" width="188" height="17" font="5">(hemorrhagic stroke, symptomatic </text>
<text top="247" left="677" width="224" height="17" font="5">intracranial bleeding, clinically significant </text>
<text top="264" left="677" width="121" height="17" font="5">extracranial bleeding) </text>
<text top="281" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="298" left="677" width="48" height="17" font="3"><b>Results </b></text>
<text top="315" left="677" width="191" height="17" font="7"><i>Cardiovascular disease Aspirin vs. </i></text>
<text top="333" left="677" width="51" height="17" font="7"><i>Placebo  </i></text>
<text top="350" left="677" width="191" height="17" font="5">10.7/1000 person years aspirin vs. </text>
<text top="367" left="677" width="183" height="17" font="5">11.3/1000 person years placebo, </text>
<text top="384" left="677" width="160" height="17" font="5">HR=0.95 (95% CI 0.83-1.08) </text>
<text top="401" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="419" left="677" width="198" height="17" font="7"><i>Major adverse cardiovascular event </i></text>
<text top="436" left="677" width="185" height="17" font="5">7.8/1000 person years aspirin vs. </text>
<text top="453" left="677" width="228" height="17" font="5">8.8/1000 person years placebo. HR=0.89 </text>
<text top="470" left="677" width="107" height="17" font="5">(95% CI 0.77-1.03) </text>
<text top="487" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="505" left="677" width="159" height="17" font="7"><i>Fatal cardiovascular disease </i></text>
<text top="522" left="677" width="185" height="17" font="5">1.8/1000 person years aspirin vs. </text>
<text top="539" left="677" width="228" height="17" font="5">1.9/1000 person years placebo. HR=0.97 </text>
<text top="556" left="677" width="107" height="17" font="5">(95% CI 0.71-1.33) </text>
<text top="573" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="591" left="677" width="170" height="17" font="7"><i>Hospitalization for heart failure </i></text>
<text top="608" left="677" width="226" height="17" font="5">2.1/1000 person years aspirin vs. 1.9 per </text>
<text top="625" left="677" width="225" height="17" font="5">1000 person years for placebo. HR=1.07 </text>
<text top="642" left="677" width="107" height="17" font="5">(95% CI 0.79-1.44) </text>
<text top="660" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="677" left="677" width="208" height="17" font="7"><i>Fatal or nonfatal myocardial infarction </i></text>
<text top="694" left="677" width="185" height="17" font="5">4.0/1000 person years aspirin vs. </text>
<text top="711" left="677" width="228" height="17" font="5">4.3/1000 person years placebo. HR=0.93 </text>
<text top="728" left="677" width="107" height="17" font="5">(95% CI 0.76-1.15) </text>
<text top="746" left="677" width="3" height="17" font="3"><b> </b></text>
<text top="763" left="677" width="181" height="17" font="7"><i>Fatal or nonfatal ischemic stroke </i></text>
</page>
<page number="299" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="178" height="17" font="5">3.5/1000 perso years aspirin vs. </text>
<text top="178" left="677" width="228" height="17" font="5">3.9/1000 person years placebo. HR=0.89 </text>
<text top="195" left="677" width="107" height="17" font="5">(95% CI 0.71-1.11) </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="107" height="17" font="7"><i>Major hemorrhage  </i></text>
<text top="247" left="677" width="178" height="17" font="5">8.6/1000 person year aspirin vs. </text>
<text top="264" left="677" width="208" height="17" font="5">6.2/1000 per years placebo. HR=1.38 </text>
<text top="281" left="677" width="156" height="17" font="5">(95% CI 1.18-1.62) p&lt;0.001 </text>
<text top="298" left="677" width="3" height="17" font="5"> </text>
<text top="315" left="677" width="114" height="17" font="7"><i>Intracranial bleeding </i></text>
<text top="333" left="677" width="25" height="17" font="5">Any </text>
<text top="350" left="677" width="185" height="17" font="5">2.5/1000 person years aspirin vs. </text>
<text top="367" left="677" width="228" height="17" font="5">1.7/1000 person years placebo. HR=1.50 </text>
<text top="384" left="677" width="107" height="17" font="5">(95% CI 1.11-2.02) </text>
<text top="401" left="677" width="3" height="17" font="5"> </text>
<text top="419" left="677" width="111" height="17" font="7"><i>Hemorrhagic stroke </i></text>
<text top="436" left="677" width="185" height="17" font="5">1.0/1000 person years aspirin vs. </text>
<text top="453" left="677" width="228" height="17" font="5">0.8/1000 person years placebo. HR=1.27 </text>
<text top="470" left="677" width="107" height="17" font="5">(95% CI 0.81-2.00) </text>
<text top="487" left="677" width="3" height="17" font="5"> </text>
<text top="505" left="677" width="195" height="17" font="7"><i>Subdural or extradural hemorrhage </i></text>
<text top="522" left="677" width="185" height="17" font="5">0.9/1000 person years aspirin vs. </text>
<text top="539" left="677" width="228" height="17" font="5">0.5/1000 person years placebo. HR=1.79 </text>
<text top="556" left="677" width="107" height="17" font="5">(95% CI 1.06-3.02) </text>
<text top="573" left="677" width="3" height="17" font="5"> </text>
<text top="591" left="677" width="149" height="17" font="7"><i>Subarachnoid hemorrhage </i></text>
<text top="608" left="677" width="185" height="17" font="5">0.4/1000 person years aspirin vs. </text>
<text top="625" left="677" width="228" height="17" font="5">0.3/1000 person years placebo. HR=1.30 </text>
<text top="642" left="677" width="107" height="17" font="5">(95% CI 0.64-2.60) </text>
<text top="660" left="677" width="3" height="17" font="5"> </text>
<text top="677" left="677" width="173" height="17" font="7"><i>Upper gastrointestinal bleeding </i></text>
<text top="694" left="677" width="185" height="17" font="5">2.1/1000 person years aspirin vs. </text>
<text top="711" left="677" width="228" height="17" font="5">1.1/1000 person years placebo. HR=1.87 </text>
<text top="728" left="677" width="107" height="17" font="5">(95% CI 1.32-2.66) </text>
<text top="746" left="677" width="3" height="17" font="5"> </text>
<text top="763" left="677" width="173" height="17" font="7"><i>Lower gastrointestinal bleeding </i></text>
</page>
<page number="300" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="75" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="100" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="78" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="218" width="83" height="17" font="3"><b>Aim of Study; </b></text>
<text top="108" left="223" width="74" height="17" font="3"><b>Study Type; </b></text>
<text top="125" left="217" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="384" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="550" width="111" height="17" font="3"><b>Study Intervention </b></text>
<text top="108" left="567" width="76" height="17" font="3"><b>(# patients) / </b></text>
<text top="125" left="550" width="111" height="17" font="3"><b>Study Comparator </b></text>
<text top="142" left="571" width="69" height="17" font="3"><b>(# patients) </b></text>
<text top="91" left="739" width="105" height="17" font="3"><b>Endpoint Results </b></text>
<text top="108" left="678" width="225" height="17" font="3"><b>(Absolute Event Rates, P value; OR or </b></text>
<text top="125" left="748" width="85" height="17" font="3"><b>RR; &amp; 95% CI) </b></text>
<text top="92" left="939" width="65" height="17" font="3"><b>Relevant  2</b></text>
<text top="91" left="1004" width="114" height="18" font="5"><b> Endpoint (if any); </b></text>
<text top="109" left="974" width="111" height="17" font="3"><b>Study Limitations; </b></text>
<text top="126" left="981" width="96" height="17" font="3"><b>Adverse Events </b></text>
<text top="160" left="677" width="185" height="17" font="5">1.7/1000 person years aspirin vs. </text>
<text top="178" left="677" width="228" height="17" font="5">1.3/1000 person years placebo. HR=1.36 </text>
<text top="195" left="677" width="107" height="17" font="5">(95% CI 0.96-1.94) </text>
<text top="212" left="677" width="3" height="17" font="5"> </text>
<text top="229" left="677" width="133" height="17" font="7"><i>Bleeding at another site </i></text>
<text top="247" left="677" width="185" height="17" font="5">2.4/1000 person years aspirin vs. </text>
<text top="264" left="677" width="228" height="17" font="5">2.1/1000 person years placebo. HR=1.16 </text>
<text top="281" left="677" width="107" height="17" font="5">(95% CI 0.87-1.54) </text>
<text top="298" left="677" width="3" height="17" font="5"> </text>
<text top="315" left="677" width="135" height="17" font="7"><i>Fatal major hemorrhage </i></text>
<text top="333" left="677" width="185" height="17" font="5">0.7/1000 person years aspirin vs. </text>
<text top="350" left="677" width="228" height="17" font="5">0.6/1000 person years placebo. HR=1.18 </text>
<text top="367" left="677" width="107" height="17" font="5">(95% CI 0.68-2.03) </text>
<text top="384" left="677" width="3" height="17" font="5"> </text>
<text top="401" left="677" width="139" height="17" font="7"><i>Fatal hemorrhagic stroke </i></text>
<text top="419" left="677" width="185" height="17" font="5">0.3/1000 person years aspirin vs. </text>
<text top="436" left="677" width="228" height="17" font="5">0.3/1000 person years placebo. HR=1.01 </text>
<text top="453" left="677" width="107" height="17" font="5">(95% CI 0.47-2.17) </text>
<text top="471" left="66" width="3" height="17" font="5"> </text>
<text top="520" left="66" width="797" height="21" font="4"><b>Data Supplement 18. Nonrandomized Trials, Observational Studies, and/or Registries of Aspirin Use (Section 4.6) </b></text>
<text top="544" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="561" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="578" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="544" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="561" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="544" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="544" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="561" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="544" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="561" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="596" left="75" width="114" height="17" font="5">García Rodríguez et </text>
<text top="614" left="75" width="57" height="17" font="5">al, 2016.   </text>
<text top="631" left="75" width="55" height="17" font="21"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27490468"><b>27490468</b></a></text>
<text top="631" left="129" width="3" height="17" font="3"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27490468"><b> </b></a></text>
<text top="596" left="205" width="106" height="17" font="3"><b>Aim</b>: To determine </text>
<text top="614" left="205" width="113" height="17" font="5">the risks of the most </text>
<text top="631" left="205" width="96" height="17" font="5">clinically relevant </text>
<text top="648" left="205" width="100" height="17" font="5">adverse effect, GI </text>
<text top="665" left="205" width="98" height="17" font="5">bleeding, and the </text>
<text top="682" left="205" width="126" height="17" font="5">serious but rare event, </text>
<text top="700" left="205" width="87" height="17" font="5">ICH, in patients </text>
<text top="717" left="205" width="89" height="17" font="5">taking low-dose </text>
<text top="734" left="205" width="110" height="17" font="5">aspirin in real-world </text>
<text top="751" left="205" width="46" height="17" font="5">settings </text>
<text top="768" left="205" width="3" height="17" font="5"> </text>
<text top="597" left="342" width="109" height="17" font="3"><b>Inclusion criteria:</b>  </text>
<text top="615" left="341" width="183" height="18" font="5">•  Men and women age 50–75 y </text>
<text top="633" left="341" width="179" height="18" font="5">•  Published between 1946 and </text>
<text top="651" left="342" width="68" height="17" font="5">March 2015 </text>
<text top="669" left="341" width="66" height="18" font="5">•  Humans </text>
<text top="687" left="341" width="131" height="18" font="5">•  Published in English </text>
<text top="705" left="344" width="3" height="17" font="5"> </text>
<text top="722" left="344" width="114" height="17" font="3"><b>Exclusion criteria:</b>  </text>
<text top="740" left="341" width="190" height="18" font="5">•  Reviews, editorials, comments, </text>
<text top="758" left="342" width="189" height="17" font="5">clinical trials and pediatric studies  </text>
<text top="598" left="546" width="7" height="17" font="3"><b>1</b></text>
<text top="597" left="553" width="210" height="18" font="5"><b> endpoint</b>: incidences of GI bleeding </text>
<text top="615" left="546" width="171" height="17" font="5">and ICH and measures of their </text>
<text top="632" left="546" width="225" height="17" font="5">association (OR, RR, HR, IRR, SIR) with </text>
<text top="649" left="546" width="210" height="17" font="5">low-dose aspirin (75–325 mg per day) </text>
<text top="666" left="546" width="3" height="17" font="5"> </text>
<text top="684" left="546" width="206" height="17" font="5">Overall incidence (as cases per 1000 </text>
<text top="701" left="546" width="207" height="17" font="5">person-years) of GI bleeding with low-</text>
<text top="718" left="546" width="222" height="17" font="5">dose aspirin were reported in two cohort </text>
<text top="735" left="546" width="220" height="17" font="5">studies, one of which involved only men </text>
<text top="752" left="546" width="226" height="17" font="5">(1.39 events per 1000 person-years) and </text>
<text top="597" left="791" width="312" height="17" font="5">Limitations: Significant heterogeneity for most outcomes. </text>
</page>
<page number="301" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="205" width="70" height="17" font="3"><b>Study type</b>: </text>
<text top="160" left="205" width="116" height="17" font="5">Systematic review of </text>
<text top="178" left="205" width="119" height="17" font="5">observational studies </text>
<text top="195" left="205" width="76" height="17" font="5">N=39 studies </text>
<text top="212" left="205" width="3" height="17" font="3"><b> </b></text>
<text top="143" left="341" width="158" height="18" font="5">•  studies using only aspirin </text>
<text top="161" left="342" width="167" height="17" font="5">doses higher than 325 mg per </text>
<text top="179" left="342" width="27" height="17" font="5">day. </text>
<text top="196" left="344" width="3" height="17" font="3"><b> </b></text>
<text top="143" left="546" width="218" height="17" font="5">the other of which involved only women </text>
<text top="160" left="546" width="71" height="17" font="5">(1.67 events </text>
<text top="178" left="546" width="131" height="17" font="5">per 1000 person-years) </text>
<text top="195" left="546" width="3" height="17" font="5"> </text>
<text top="212" left="546" width="191" height="17" font="7"><i>Upper GI Bleeding</i>: Overall pooled </text>
<text top="229" left="546" width="204" height="17" font="5">estimate of the RR  2.3 (95% CI: 2.0–</text>
<text top="247" left="546" width="193" height="17" font="5">2.6), with significant heterogeneity  </text>
<text top="264" left="546" width="8" height="17" font="5">(I</text>
<text top="265" left="554" width="4" height="11" font="8">2</text>
<text top="264" left="558" width="201" height="17" font="5"> = 80.5%).  One study compared the </text>
<text top="281" left="546" width="174" height="17" font="5">RR for UGIB in the primary and </text>
<text top="298" left="546" width="171" height="17" font="5">secondary prevention of CVD:  </text>
<text top="315" left="546" width="129" height="17" font="5">(adjusted RR [95% CI]: </text>
<text top="333" left="546" width="212" height="17" font="5">1.90 [1.59–2.26] and 1.40 [1.14–1.72], </text>
<text top="350" left="546" width="187" height="17" font="5">respectively), though the absolute </text>
<text top="367" left="546" width="211" height="17" font="5">increase in risk of UGIB with low-dose </text>
<text top="384" left="546" width="196" height="17" font="5">aspirin was higher in the secondary </text>
<text top="401" left="546" width="204" height="17" font="5">prevention cohort than in the primary </text>
<text top="419" left="546" width="109" height="17" font="5">prevention cohort.   </text>
<text top="436" left="546" width="3" height="17" font="5"> </text>
<text top="453" left="546" width="204" height="17" font="5">Range of incidence of UGIB with low-</text>
<text top="470" left="546" width="210" height="17" font="5">dose aspirin (n=4 studies)= 0.70–3.64 </text>
<text top="487" left="546" width="163" height="17" font="5">cases per 1000 person-years </text>
<text top="505" left="546" width="3" height="17" font="5"> </text>
<text top="522" left="546" width="180" height="17" font="7"><i>Lower GI bleeding</i>: n=6 studies.  </text>
<text top="539" left="546" width="3" height="17" font="5"> </text>
<text top="556" left="546" width="216" height="17" font="5">Pooled RR=1.8 (95% CI: 1.1–3.0), with </text>
<text top="573" left="546" width="228" height="17" font="5">significant heterogeneity between studies </text>
<text top="591" left="546" width="8" height="17" font="5">(I</text>
<text top="592" left="554" width="4" height="11" font="8">2</text>
<text top="591" left="558" width="60" height="17" font="5"> = 81.1%). </text>
<text top="608" left="546" width="3" height="17" font="5"> </text>
<text top="625" left="546" width="222" height="17" font="5">Three studies reported overall incidence </text>
<text top="642" left="546" width="203" height="17" font="5">of LGIB (range:(0.48–0.74 cases per </text>
<text top="660" left="546" width="114" height="17" font="5">1000 person-years). </text>
<text top="677" left="546" width="3" height="17" font="5"> </text>
<text top="694" left="546" width="3" height="17" font="7"><i> </i></text>
<text top="711" left="546" width="228" height="17" font="7"><i>Intracranial hemorrhage</i>: Pooled RR= 1.4 </text>
<text top="728" left="546" width="183" height="17" font="5">(95% CI 1.2–1.7), with significant </text>
<text top="746" left="546" width="178" height="17" font="5">heterogeneity between studies (I</text>
<text top="747" left="724" width="4" height="11" font="8">2</text>
<text top="746" left="729" width="14" height="17" font="5"> = </text>
<text top="763" left="546" width="46" height="17" font="5">92.0%)  </text>
</page>
<page number="302" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="91" left="84" width="98" height="17" font="3"><b>Study Acronym; </b></text>
<text top="108" left="109" width="48" height="17" font="3"><b>Author; </b></text>
<text top="125" left="87" width="92" height="17" font="3"><b>Year Published </b></text>
<text top="91" left="209" width="118" height="17" font="3"><b>Study Type/Design; </b></text>
<text top="108" left="225" width="86" height="17" font="3"><b>Study Size (N) </b></text>
<text top="91" left="383" width="111" height="17" font="3"><b>Patient Population </b></text>
<text top="91" left="573" width="179" height="17" font="3"><b>Primary Endpoint and Results </b></text>
<text top="108" left="550" width="224" height="17" font="3"><b>(include P value; OR or RR; &amp; 95% CI) </b></text>
<text top="91" left="900" width="130" height="17" font="3"><b>Summary/Conclusion </b></text>
<text top="108" left="928" width="75" height="17" font="3"><b>Comment(s) </b></text>
<text top="143" left="546" width="3" height="17" font="5"> </text>
<text top="160" left="546" width="224" height="17" font="5">N=1 study reported the overall incidence </text>
<text top="178" left="546" width="215" height="17" font="5">of ICH with low dose aspirin (8.0 cases </text>
<text top="195" left="546" width="206" height="17" font="5">per 1000 person-years) in a cohort of </text>
<text top="212" left="546" width="228" height="17" font="5">patients with non-valvular atrial fibrillation </text>
<text top="229" left="546" width="3" height="17" font="5"> </text>
<text top="247" left="546" width="25" height="17" font="7"><i>Age </i></text>
<text top="264" left="546" width="226" height="17" font="5">There was no clear evidence that the RR </text>
<text top="282" left="546" width="181" height="17" font="5">of bleeding with low-dose aspirin </text>
<text top="301" left="546" width="193" height="17" font="5">increases with increasing age (n=8 </text>
<text top="319" left="546" width="50" height="17" font="5">studies) <b> </b></text>
<text top="339" left="66" width="3" height="17" font="5"> </text>
<text top="369" left="66" width="3" height="17" font="5"> </text>
<text top="400" left="66" width="3" height="17" font="5"> </text>
<text top="431" left="66" width="84" height="21" font="4"><b>References </b></text>
<text top="463" left="66" width="16" height="17" font="0">1. </text>
<text top="463" left="120" width="1018" height="17" font="0">Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169:1748-55. </text>
<text top="484" left="66" width="16" height="17" font="0">2. </text>
<text top="484" left="120" width="1023" height="17" font="0">Chen Z, Ernst ME, Ardery G, et al. Physician-pharmacist co-management and 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2013;15:337-</text>
<text top="504" left="66" width="25" height="17" font="0">43. </text>
<text top="524" left="66" width="16" height="17" font="0">3. </text>
<text top="524" left="120" width="1001" height="17" font="0">Fazel MT, Bagalagel A, Lee JK, et al. Impact of Diabetes Care by Pharmacists as Part of Health Care Team in Ambulatory Settings: A Systematic Review </text>
<text top="544" left="66" width="386" height="17" font="0">and Meta-analysis. Ann Pharmacother. 2017;51:890-907. </text>
<text top="564" left="66" width="16" height="17" font="0">4. </text>
<text top="564" left="120" width="965" height="17" font="0">Hirsch JD, Steers N, Adler DS, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a </text>
<text top="584" left="66" width="383" height="17" font="0">randomized, pragmatic trial. Clin Ther. 2014;36:1244-54. </text>
<text top="604" left="66" width="16" height="17" font="0">5. </text>
<text top="604" left="120" width="1005" height="17" font="0">Hunt JS, Siemienczuk J, Pape G, et al. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled </text>
<text top="625" left="66" width="343" height="17" font="0">hypertension. J Gen Intern Med. 2008;23:1966-72. </text>
<text top="645" left="66" width="16" height="17" font="0">6. </text>
<text top="645" left="120" width="1001" height="17" font="0">Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med </text>
<text top="665" left="66" width="152" height="17" font="0">Care. 2010;48:923-33. </text>
<text top="685" left="66" width="16" height="17" font="0">7. </text>
<text top="685" left="120" width="983" height="17" font="0">McLean DL, McAlister FA, Johnson JA, et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure </text>
<text top="705" left="66" width="1003" height="17" font="0">management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. </text>
<text top="725" left="66" width="130" height="17" font="0">2008;168:2355-61. </text>
<text top="745" left="66" width="16" height="17" font="0">8. </text>
<text top="745" left="120" width="970" height="17" font="0">Mills KT, Obst KM, Shen W, et al. Comparative Effectiveness of Implementation Strategies for Blood Pressure Control in Hypertensive Patients: A </text>
<text top="766" left="66" width="495" height="17" font="0">Systematic Review and Meta-analysis. Ann Intern Med. 2018;168:110-20. </text>
</page>
<page number="303" position="absolute" top="0" left="0" height="918" width="1188">
<text top="796" left="66" width="574" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc., </text>
<text top="814" left="66" width="4" height="17" font="0"> </text>
<text top="93" left="66" width="16" height="17" font="0">9. </text>
<text top="93" left="120" width="961" height="17" font="0">Polgreen LA, Han J, Carter BL, et al. Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control. </text>
<text top="113" left="66" width="220" height="17" font="0">Hypertension. 2015;66:1145-51. </text>
<text top="134" left="66" width="25" height="17" font="0">10. </text>
<text top="134" left="120" width="968" height="17" font="0">Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. </text>
<text top="154" left="66" width="105" height="17" font="0">2014;47:86-99. </text>
<text top="174" left="66" width="25" height="17" font="0">11. </text>
<text top="174" left="120" width="971" height="17" font="0">Chen EH, Thom DH, Hessler DM, et al. Using the Teamlet Model to improve chronic care in an academic primary care practice. J Gen Intern Med. </text>
<text top="194" left="66" width="166" height="17" font="0">2010;25 Suppl 4:S610-4. </text>
<text top="214" left="66" width="25" height="17" font="0">12. </text>
<text top="214" left="120" width="987" height="17" font="0">Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. </text>
<text top="234" left="66" width="114" height="17" font="0">2006;113:791-8. </text>
<text top="254" left="66" width="25" height="17" font="0">13. </text>
<text top="254" left="120" width="1027" height="17" font="0">Estruch R, Ros E, Salas-Salvado J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil </text>
<text top="275" left="66" width="252" height="17" font="0">or Nuts. N Engl J Med. 2018;378:e34. </text>
<text top="295" left="66" width="25" height="17" font="0">14. </text>
<text top="295" left="120" width="977" height="17" font="0">Kiage JN, Merrill PD, Robinson CJ, et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke </text>
<text top="315" left="66" width="346" height="17" font="0">(REGARDS) cohort. Am J Clin Nutr. 2013;97:1121-8. </text>
<text top="335" left="66" width="25" height="17" font="0">15. </text>
<text top="335" left="120" width="1000" height="17" font="0">Orrow G, Kinmonth AL, Sanderson S, et al. Effectiveness of physical activity promotion based in primary care: systematic review and meta-analysis of </text>
<text top="355" left="66" width="351" height="17" font="0">randomised controlled trials. BMJ. 2012;344:e1389. </text>
<text top="375" left="66" width="25" height="17" font="0">16. </text>
<text top="375" left="120" width="1007" height="17" font="0">Ekelund U, Steene-Johannessen J, Brown WJ, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with </text>
<text top="395" left="66" width="793" height="17" font="0">mortality? A harmonised meta-analysis of data from more than 1 million men and women. Lancet. 2016;388:1302-10. </text>
<text top="416" left="66" width="25" height="17" font="0">17. </text>
<text top="416" left="120" width="956" height="17" font="0">LeBlanc EL. Draft Evidence Review: Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions. Kaiser </text>
<text top="436" left="66" width="276" height="17" font="0">Permanente Center for Health Research. </text>
<text top="456" left="66" width="25" height="17" font="0">18. </text>
<text top="456" left="120" width="1012" height="17" font="0">Azadbakht L, Fard NR, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 </text>
<text top="476" left="66" width="566" height="17" font="0">diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011;34:55-7. </text>
<text top="496" left="66" width="25" height="17" font="0">19. </text>
<text top="496" left="120" width="1016" height="17" font="0">Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data </text>
<text top="516" left="66" width="522" height="17" font="0">from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. </text>
<text top="537" left="66" width="25" height="17" font="0">20. </text>
<text top="537" left="120" width="1008" height="17" font="0">Perak AM, Ning H, de Ferranti SD, et al. Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia </text>
<text top="557" left="66" width="266" height="17" font="0">Phenotype. Circulation. 2016;134:9-19. </text>
<text top="577" left="66" width="25" height="17" font="0">21. </text>
<text top="577" left="120" width="1018" height="17" font="0">Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J </text>
<text top="597" left="66" width="169" height="17" font="0">Med. 2008;358:2545-59. </text>
<text top="617" left="66" width="25" height="17" font="0">22. </text>
<text top="617" left="120" width="1011" height="17" font="0">Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J </text>
<text top="637" left="66" width="169" height="17" font="0">Med. 1997;336:1117-24. </text>
<text top="657" left="66" width="25" height="17" font="0">23. </text>
<text top="657" left="120" width="1021" height="17" font="0">Neaton JD, Grimm RH, Jr., Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. </text>
<text top="677" left="66" width="168" height="17" font="0">JAMA. 1993;270:713-24. </text>
<text top="698" left="66" width="25" height="17" font="0">24. </text>
<text top="698" left="120" width="933" height="17" font="0">Carson KV, Verbiest ME, Crone MR, et al. Training health professionals in smoking cessation. Cochrane Database Syst Rev. 2012;CD000214. </text>
<text top="730" left="66" width="4" height="17" font="0"> </text>
</page>
</pdf2xml>
